



Australian Government

Department of Health and Ageing

**SCHEDULE OF
PHARMACEUTICAL BENEFITS**

This Schedule is also available on the internet at
www.pbs.gov.au

**EFFECTIVE
1 August 2012 - 31 August 2012
(ALL PREVIOUS EDITIONS CANCELLED)**

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

This Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These arrangements operate under the *National Health Act 1953*. However, at the time of printing, the relevant legislation giving authority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment for the supply of pharmaceutical benefits. The legislation is available from the Federal Register of Legislative Instruments website at <http://www.frli.gov.au>.

The information is not intended to give or replace any legal, medical, dental or optometrical advice. This document is not a legal document and does not constitute legal advice. Neither the information nor this document can be relied upon without first seeking and obtaining independent legal, medical, dental or optometrical advice beforehand. To the extent permitted by law, the Commonwealth of Australia will not be held responsible, nor accept any liability (whether arising out of negligence or otherwise), for any injury, damages, costs, expenses and losses suffered or incurred by a person where such a person has relied on this document or used the information in it as legal, medical, dental or optometrical advice.

CONTENTS

PHARMACEUTICAL BENEFITS.....	6	
SUMMARY OF CHANGES	7	
SECTION 100 – HIGHLY SPECIALISED DRUGS PROGRAM	13	
ADDRESSES — MEDICARE AUSTRALIA	16	
AUTHORITY PRESCRIPTION APPLICATIONS	17	
REQUESTS FOR DRUGS VIA THE SPECIAL ACCESS SCHEME (SAS)	17	
POISONS INFORMATION CENTRES.....	18	
DRUG INFORMATION CENTRES	18	
LIST OF CONTACT OFFICERS FOR RECALLS OF THERAPEUTIC GOODS	19	
INDEX OF MANUFACTURERS' CODES	20	
SECTION 1 — EXPLANATORY NOTES	29	
INTRODUCTION	29	
1. THE SCHEDULE — WHERE TO FIND WHAT	29	
Section 1.....	29	
Section 2.....	29	
Section 3.....	29	
Section 4.....	30	
Repatriation Schedule of Pharmaceutical Benefits	30	
2. PRESCRIBING MEDICINES — INFORMATION FOR PBS PRESCRIBERS	30	
PBS prescribers.....	30	
PBS Prescription forms	30	
Ordering forms	31	
Preparing general PBS prescriptions	31	
Do's and Don't's.....	31	
Writing the PBS prescription	31	
Restrictions	32	
Authority PBS prescriptions.....	32	
Authority required PBS Prescriptions.....	32	
Authority required (STREAMLINED) PBS Prescriptions.....	33	
Writing authority PBS prescriptions	33	
Maximum quantities and repeats.....	34	
Regulation 24.....	34	
Urgent cases	34	
Drugs of addiction.....	34	
Emergency drug supplies	34	
Availability of Methoxyflurane for emergency treatment only	35	
		<i>Improving the capacity of the PBS to meet particular Aboriginal and Torres Strait Islander health needs</i>
		<i>How to prescribe these items?</i>
		<i>Aboriginal and Torres Strait Islander identification</i>
		<i>Asking about Aboriginal and/or Torres Strait Islander identification.....</i>
		<i>Aboriginal and Torres Strait Islander health ...</i>
		<i>Communication and cultural issues.....</i>
		3. SUPPLYING MEDICINES — WHAT PHARMACISTS NEED TO KNOW.....
		<i>Eligible suppliers.....</i>
		<i>Approval conditions for pharmacists.....</i>
		<i>Before supplying pharmaceutical benefits ..</i>
		<i>Supplying pharmaceutical benefits</i>
		<i>Do's and Don'ts.....</i>
		<i>What to do if the Schedule changes</i>
		<i>Suspected forgery.....</i>
		<i>Regulation 24</i>
		<i>Repeat authorisations</i>
		<i>Preparing Repeat Authorisation Forms</i>
		<i>Repeat authorisations for injectables and solvents.....</i>
		<i>Repeat authorisations for deferred supply.....</i>
		<i>Authority PBS prescriptions</i>
		<i>Urgent cases.....</i>
		<i>Receipts</i>
		<i>Emergency drug supplies.....</i>
		4. PATIENT CHARGES.....
		<i>Type of patient</i>
		<i>Establishing entitlement.....</i>
		<i>What to charge</i>
		<i>Patient contribution</i>
		<i>Patient contributions for early supply of some PBS medicines.....</i>
		<i>Special patient contributions, brand premiums and therapeutic group premiums.....</i>
		<i>Solvents</i>
		<i>Increased quantities</i>
		<i>Regulation 24.....</i>
		<i>After hours.....</i>
		<i>Delivery.....</i>
		5. THE SAFETY NET SCHEME
		<i>Safety net thresholds.....</i>
		<i>Safety net cross-over arrangements.....</i>
		<i>Recording PBS prescriptions</i>
		<i>Hospital prescription record forms</i>
		<i>Multi-item prescription forms</i>
		<i>Qualifying PBS prescriptions.....</i>

<i>Lost prescription record forms</i>	<i>44</i>
<i>Retrospective entitlement and patient refunds</i>	<i>44</i>
<i>Applying for a Safety Net Entitlement/Concession Card.....</i>	<i>44</i>
<i>Issuing a Safety Net Entitlement/Concession Card.....</i>	<i>44</i>
<i>Issuing supplementary cards.....</i>	<i>44</i>
<i>Notification to Medicare Australia and claim for payment</i>	<i>45</i>
<i>Lost Safety Net Entitlement/Concession Cards</i>	<i>45</i>
<i>Pharmacy record of issued cards</i>	<i>45</i>
6. MEDICARE AUSTRALIA ENTITLEMENT CHECKS	45
General Patients	45
Concessional Patients.....	45
<i>Entitlement checking procedures.....</i>	<i>45</i>
General Patients.....	45
Concessional Patients.....	45
Step by step.....	45
7. HOW PHARMACISTS CLAIM REIMBURSEMENT: INFORMATION REQUIRED.....	46
<i>PBS Prescription identification</i>	<i>46</i>
<i>Serial numbers</i>	<i>46</i>
Repeat authorisations for authority PBS prescriptions.....	47
Repeat authorisations for deferred supply	47
Injectable item ordered with a solvent	47
<i>Dropper containers</i>	<i>47</i>
<i>Extemporaneously-prepared pharmaceutical benefits not listed in the Standard Formulae List.....</i>	<i>47</i>
PBS prescriptions paid on an average price basis.....	47
Pricing non-pre-priced extemporaneous preparations.....	47
<i>RPBS prescriptions for items not included in either the PBS or RPBS Schedule</i>	<i>47</i>
<i>Payment to Pharmacists for Dispensing Premium-free Substitutable Medicines.....</i>	<i>47</i>
8. HOW PHARMACISTS CLAIM REIMBURSEMENT: DOCUMENTS TO BE SUBMITTED	47
<i>Completing the claim form</i>	<i>48</i>
<i>Lodging claims</i>	<i>48</i>
<i>Reconciliation statements.....</i>	<i>48</i>
9. PRICING PBS PRESCRIPTIONS.....	48
<i>Pricing principles</i>	<i>48</i>
<i>Pricing dates</i>	<i>48</i>
<i>Pricing ready-prepared items.....</i>	<i>49</i>
For maximum quantities	49
For lesser quantities	49
Wastage table percentage	49
<i>Pricing extemporaneously-prepared items .</i>	<i>49</i>
General	49
Pricing of ingredients.....	50
Pricing PBS prescriptions where extra ingredients are added to a formula	50
Containers	50
Special provisions for extemporaneous PBS prescriptions outside the Standard Formulae List	50
10. MISCELLANEOUS	51
<i>References</i>	<i>51</i>
<i>Standards</i>	<i>51</i>
<i>Legislation</i>	<i>51</i>
NURSE PRACTITIONER PBS PRESCRIBING.....	51
MIDWIFE PBS PRESCRIBING	53
THERAPEUTIC INDEX	54
SECTION 2.....	60
SYMBOLS USED IN THE SCHEDULE	61
EMERGENCY DRUG SUPPLIES	63
SPECIAL PHARMACEUTICAL BENEFITS.....	67
GENERAL PHARMACEUTICAL BENEFITS.....	70
PHARMACEUTICAL BENEFITS FOR PALLIATIVE CARE....	520
PHARMACEUTICAL BENEFITS FOR DENTAL USE	537
PHARMACEUTICAL BENEFITS FOR OPTOMETRICAL USE	564
ITEMS AVAILABLE UNDER SPECIAL ARRANGEMENTS (SECTION 100)	572
SECTION 3 – CONTAINER PRICES, FEES, STANDARD PACKS AND PRICES FOR READY PREPARED PHARMACEUTICAL BENEFITS	877
SECTION 4.....	890
DRUG TARIFF	891
CONTAINER PRICES	895
STANDARD FORMULA PREPARATIONS	896
TABLE OF CODES, MAXIMUM QUANTITIES, AND NUMBER OF REPEATS FOR EXTEMPORANEOUSLY PREPARED BENEFITS	899
REPATRIATION SCHEDULE OF PHARMACEUTICAL BENEFITS	900
BENEFICIARIES' ENTITLEMENT CARDS AND ELIGIBILITY FOR REPATRIATION PHARMACEUTICAL BENEFITS.....	901
RPBS EXPLANATORY NOTES	902
<i>Introduction.....</i>	<i>902</i>
The Australian Repatriation System	902
<i>RPBS prescribing provisions.....</i>	<i>902</i>
Prior Approval Arrangements.....	902
Palliative Care Drugs.....	903
Dental Prescribing	903
Prescribing by optometrists.....	903

<i>Provisions governing pricing and payment for</i>	
<i>RPBS benefits</i>	<i>904</i>
Introduction	904
Pricing of Schedule Items	904
Pricing of Non-Schedule Ready Prepared Items	
.....	904
Pricing of Non-Schedule Extemporaneously	
Prepared Items	904
Miscellaneous Pricing Rules	904
<i>General.....</i>	<i>904</i>
Packaging Material, Postage or Freight	904
Payment for Items Supplied at Short Intervals	
.....	904
Receipts for Patient Charges	904
Special Patient Contributions	905

Therapeutic Group Premiums — Authority	
Processing.....	905
DEPARTMENT OF VETERANS' AFFAIRS.....	906
THERAPEUTIC INDEX FOR RPBS	908
SECTION 1	910
SECTION 2	955
GENERIC/PROPRIETARY INDEX.....	958
THERAPEUTIC GROUP PREMIUM POLICY	1042
BRAND PREMIUM POLICY	1044

PHARMACEUTICAL BENEFITS

Fees, Patient Contributions and Safety Net Thresholds

The following fees, patient contributions and safety net thresholds apply as at 1 August 2012 and are included, where applicable, in prices published in the Schedule —

Dispensing Fees:	Ready-prepared	\$6.52
	Dangerous drug fee	\$2.71
	Extemporaneously-prepared	\$8.56
	Allowable additional patient charge*	\$4.04
Additional Fees (for safety net prices):	Ready-prepared	\$1.11
	Extemporaneously-prepared	\$1.45
Patient Co-payments:	General	\$35.40
	Concessional	\$5.80
Safety Net Thresholds:	General	\$1363.30
	Concessional	\$348.00
Safety Net Card Issue Fee:		\$8.88

*The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed price for maximum quantity less than the general patient co-payment. The pharmacist may charge general patients the allowable additional fee but the fee cannot take the cost of the prescription above the general patient co-payment for the medicine. This fee does not count towards the Safety Net threshold.

SUMMARY OF CHANGES

Additions

Addition – Item

1923F	Amino Acid Formula with Vitamins and Minerals without Methionine, Threonine and Valine and low in Isoleucine , Oral liquid 130 mL, 30 (<i>MMA/PA cooler</i>)
1909L	Amino Acid Formula with Vitamins and Minerals without Phenylalanine , Sachets 34 g, 30 (<i>PKU express 20</i>)
1914R	Amino Acid Formula with Vitamins and Minerals without Valine, Leucine and Isoleucine , Sachets 34 g, 30 (<i>MSUD express 20</i>)
2022K	Auranofin , Capsule 3 mg (<i>Ridaura</i>)
2002J	Cefuroxime Axetil , Powder for oral suspension 125 mg (base) per 5 mL, 70 mL (<i>Zinnat</i>) (Dental)
5499K	Cefuroxime Axetil , Powder for oral suspension 125 mg (base) per 5 mL, 70 mL (<i>Zinnat</i>)
1954W	Etanercept , Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL (<i>Enbrel</i>)
1963H	Etanercept , Injections 50 mg in 1 mL single use pre-filled syringes, 4 (<i>Enbrel</i>)
1964J	Etanercept , Injection 50 mg in 1 mL single use auto-injector, 4 (<i>Enbrel</i>)
1976B	Icatibant , Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe (<i>Firazyr</i>)
1952R	Rasagiline , Tablet 1 mg (as mesilate) (<i>Azilect</i>)
1418P	Ticagrelor , Tablet 90 mg (<i>Brilinta</i>)
1938B	Triglycerides—medium Chain, Formula , Compound powder 400 g (<i>Lipistart</i>)

Addition – Brand

8202Q	<i>Spren 100, QA – Aspirin</i> , Tablet 100 mg
8213G	<i>Atorvastatin SCP 10, RZ – Atorvastatin</i> , Tablet 10 mg (as calcium)
9230T	<i>Atorvastatin SCP 10, RZ – Atorvastatin</i> , Tablet 10 mg (as calcium)
8214H	<i>Atorvastatin SCP 20, RZ – Atorvastatin</i> , Tablet 20 mg (as calcium)
9231W	<i>Atorvastatin SCP 20, RZ – Atorvastatin</i> , Tablet 20 mg (as calcium)
8215J	<i>Atorvastatin SCP 40, RZ – Atorvastatin</i> , Tablet 40 mg (as calcium)
9232X	<i>Atorvastatin SCP 40, RZ – Atorvastatin</i> , Tablet 40 mg (as calcium)
8521L	<i>Atorvastatin SCP 80, RZ – Atorvastatin</i> , Tablet 80 mg (as calcium)
9233Y	<i>Atorvastatin SCP 80, RZ – Atorvastatin</i> , Tablet 80 mg (as calcium)
8213G	<i>STADA Atorvastatin, TD – Atorvastatin</i> , Tablet 10 mg (as calcium)
8214H	<i>STADA Atorvastatin, TD – Atorvastatin</i> , Tablet 20 mg (as calcium)
8215J	<i>STADA Atorvastatin, TD – Atorvastatin</i> , Tablet 40 mg (as calcium)
8521L	<i>STADA Atorvastatin, TD – Atorvastatin</i> , Tablet 80 mg (as calcium)
9230T	<i>STADA Atorvastatin, TD – Atorvastatin</i> , Tablet 10 mg (as calcium)
9231W	<i>STADA Atorvastatin, TD – Atorvastatin</i> , Tablet 20 mg (as calcium)
9232X	<i>STADA Atorvastatin, TD – Atorvastatin</i> , Tablet 40 mg (as calcium)
9233Y	<i>STADA Atorvastatin, TD – Atorvastatin</i> , Tablet 80 mg (as calcium)
8315P	<i>Cefepime Sandoz, SZ – Cefepime</i> , Powder for injection 1 g (as hydrochloride) (solvent required)
8316Q	<i>Cefepime Sandoz, SZ – Cefepime</i> , Powder for injection 2 g (as hydrochloride) (solvent required)
8358X	<i>Plavacor 75, MI – Clopidogrel</i> , Tablet 75 mg (as hydrogen sulfate)
9354H	<i>STADA Clopidogrel, TD – Clopidogrel</i> , Tablet 75 mg (as besilate)
8019C	<i>Cyprocur 100, QA – Cyproterone Acetate</i> , Tablet 100 mg

1313D	<i>Diltiazem Sandoz CD, SZ</i> – Diltiazem Hydrochloride , Capsule 240 mg (controlled delivery)
8480H	<i>Diltiazem Sandoz CD, SZ</i> – Diltiazem Hydrochloride , Capsule 360 mg (controlled delivery)
1370D	<i>Enalapril-PS, FZ</i> – Enalapril , Tablet containing enalapril maleate 5 mg
1368B	<i>Enalapril-PS, FZ</i> – Enalapril , Tablet containing enalapril maleate 10 mg
1369C	<i>Enalapril-PS, FZ</i> – Enalapril , Tablet containing enalapril maleate 20 mg
8770N	<i>APO-Galantamine MR, TX</i> – Galantamine Hydrobromide , Capsule 8 mg (base) (prolonged release)
8771P	<i>APO-Galantamine MR, TX</i> – Galantamine Hydrobromide , Capsule 16 mg (base) (prolonged release)
8772Q	<i>APO-Galantamine MR, TX</i> – Galantamine Hydrobromide , Capsule 24 mg (base) (prolonged release)
8770N	<i>Gamine XR, QA</i> – Galantamine Hydrobromide , Capsule 8 mg (base) (prolonged release)
8771P	<i>Gamine XR, QA</i> – Galantamine Hydrobromide , Capsule 16 mg (base) (prolonged release)
8772Q	<i>Gamine XR, QA</i> – Galantamine Hydrobromide , Capsule 24 mg (base) (prolonged release)
1512N	<i>APO- Hydroxychloroquine, TX</i> – Hydroxychloroquine Sulfate , Tablet 200 mg
1512N	<i>Chem mart Hydroxychloroquine, CH</i> – Hydroxychloroquine Sulfate , Tablet 200 mg
1512N	<i>Terry White Chemists Hydroxychloroquine, TW</i> – Hydroxychloroquine Sulfate , Tablet 200 mg
2436F	<i>Indapamide-PS, FZ</i> – Indapamide Hemihydrate , Tablet 2.5 mg
5552F	<i>APO-Latanoprost, TX</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL (Optometrical)
8243W	<i>APO-Latanoprost, TX</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL
5552F	<i>Chem mart Latanoprost, CH</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL (Optometrical)
8243W	<i>Chem mart Latanoprost, CH</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL
5552F	<i>Latanoprost Pfizer, FZ</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL (Optometrical)
8243W	<i>Latanoprost Pfizer, FZ</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL
5552F	<i>Latanoprost Sandoz, SZ</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL (Optometrical)
8243W	<i>Latanoprost Sandoz, SZ</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL
5552F	<i>Terry White Chemists Latanoprost, TW</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL (Optometrical)
8243W	<i>Terry White Chemists Latanoprost, TW</i> – Latanoprost , Eye drops 50 micrograms per mL (0.005%), 2.5 mL
8895E	<i>Latanocom, FZ</i> – Latanoprost with Timolol Maleate , Eye drops 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL
5553G	<i>Latanocom, FZ</i> – Latanoprost with Timolol Maleate , Eye drops 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL (Optometrical)
8245Y	<i>Lezole, WQ</i> – Letrozole , Tablet 2.5 mg
8887R	<i>Melox 7.5, GM</i> – Meloxicam , Capsule 7.5 mg
8888T	<i>Melox 15, GM</i> – Meloxicam , Capsule 15 mg
8561N	<i>Meloxicam-PS, FZ</i> – Meloxicam , Tablet 7.5 mg
8562P	<i>Meloxicam-PS, FZ</i> – Meloxicam , Tablet 15 mg
2430X	<i>Formet Aspen 500, AS</i> – Metformin Hydrochloride , Tablet 500 mg
1801T	<i>Formet Aspen 850, AS</i> – Metformin Hydrochloride , Tablet 850 mg
8855C	<i>Remeron SolTab, FR</i> – Mirtazapine , Tablet 15 mg (orally disintegrating)
8856D	<i>Remeron SolTab, FR</i> – Mirtazapine , Tablet 30 mg (orally disintegrating)
8857E	<i>Remeron SolTab, FR</i> – Mirtazapine , Tablet 45 mg (orally disintegrating)
3010K	<i>Norfloxacin-PS, FZ</i> – Norfloxacin , Tablet 400 mg
1024X	<i>STADA Olanzapine, TD</i> – Olanzapine , Tablet 2.5 mg (as benzoate)
1037N	<i>STADA Olanzapine, TD</i> – Olanzapine , Tablet 5 mg (as benzoate)
1041T	<i>STADA Olanzapine, TD</i> – Olanzapine , Tablet 7.5 mg (as benzoate)
1042W	<i>STADA Olanzapine, TD</i> – Olanzapine , Tablet 10 mg (as benzoate)

8333N *Omeprazole-PS, FZ* – **Omeprazole**, Tablet 20 mg

9151P *Simipex 0.125, QA* – **Pramipexole Hydrochloride**, Tablet 125 micrograms

9152Q *Simipex 0.25, QA* – **Pramipexole Hydrochloride**, Tablet 250 micrograms

9153R *Simipex 1, QA* – **Pramipexole Hydrochloride**, Tablet 1 mg

2833D *Pravastatin-PS, FZ* – **Pravastatin**, Tablet containing pravastatin sodium 10 mg

2834E *Pravastatin-PS, FZ* – **Pravastatin**, Tablet containing pravastatin sodium 20 mg

8197K *Pravastatin-PS, FZ* – **Pravastatin**, Tablet containing pravastatin sodium 40 mg

8829Q *Pravastatin-PS, FZ* – **Pravastatin**, Tablet containing pravastatin sodium 80 mg

9237E *Pravastatin-PS, FZ* – **Pravastatin**, Tablet containing pravastatin sodium 10 mg

9238F *Pravastatin-PS, FZ* – **Pravastatin**, Tablet containing pravastatin sodium 20 mg

9239G *Pravastatin-PS, FZ* – **Pravastatin**, Tablet containing pravastatin sodium 40 mg

9240H *Pravastatin-PS, FZ* – **Pravastatin**, Tablet containing pravastatin sodium 80 mg

8456C *Quetiapine-Synthon, ZT* – **Quetiapine**, Tablet 25 mg (as fumarate)

8457D *Quetiapine-Synthon, ZT* – **Quetiapine**, Tablet 100 mg (as fumarate)

8458E *Quetiapine-Synthon, ZT* – **Quetiapine**, Tablet 200 mg (as fumarate)

8580N *Quetiapine-Synthon, ZT* – **Quetiapine**, Tablet 300 mg (as fumarate)

8456C *STADA Quetiapine, TD* – **Quetiapine**, Tablet 25 mg (as fumarate)

8457D *STADA Quetiapine, TD* – **Quetiapine**, Tablet 100 mg (as fumarate)

8458E *STADA Quetiapine, TD* – **Quetiapine**, Tablet 200 mg (as fumarate)

8580N *STADA Quetiapine, TD* – **Quetiapine**, Tablet 300 mg (as fumarate)

9120B *APO-Ramipril, TX* – **Ramipril**, Capsule 1.25 mg

9120B *Chem mart Ramipril, CH* – **Ramipril**, Capsule 1.25 mg

9120B *Terry White Chemists Ramipril, TW* – **Ramipril**, Capsule 1.25 mg

9121C *APO-Ramipril, TX* – **Ramipril**, Capsule 2.5 mg

9121C *Chem mart Ramipril, CH* – **Ramipril**, Capsule 2.5 mg

9121C *Terry White Chemists Ramipril, TW* – **Ramipril**, Capsule 2.5 mg

9122D *APO-Ramipril, TX* – **Ramipril**, Capsule 5 mg

9122D *Chem mart Ramipril, CH* – **Ramipril**, Capsule 5 mg

9122D *Terry White Chemists Ramipril, TW* – **Ramipril**, Capsule 5 mg

1760P *Roxithromycin-PS, FZ* – **Roxithromycin**, Tablet 150 mg

5260W *Roxithromycin-PS, FZ* – **Roxithromycin**, Tablet 150 mg (**Dental**)

8016X *Roxithromycin-PS, FZ* – **Roxithromycin**, Tablet 300 mg

5261X *Roxithromycin-PS, FZ* – **Roxithromycin**, Tablet 300 mg (**Dental**)

2011W *Simvastatin-DRLA, RZ* – **Simvastatin**, Tablet 10 mg

2012X *Simvastatin-DRLA, RZ* – **Simvastatin**, Tablet 20 mg

8173E *Simvastatin-DRLA, RZ* – **Simvastatin**, Tablet 40 mg

8313M *Simvastatin-DRLA, RZ* – **Simvastatin**, Tablet 80 mg

9242K *Simvastatin-DRLA, RZ* – **Simvastatin**, Tablet 10 mg

9243L *Simvastatin-DRLA, RZ* – **Simvastatin**, Tablet 20 mg

9244M *Simvastatin-DRLA, RZ* – **Simvastatin**, Tablet 40 mg

9245N *Simvastatin-DRLA, RZ* – **Simvastatin**, Tablet 80 mg

8144P *Sumagran Aspen 50, AS* – **Sumatriptan**, Tablet 50 mg (as succinate)

8378Y *Orion Temozolomide, ON* – **Temozolomide**, Capsule 5 mg

8379B	<i>Orion Temozolomide, ON – Temozolomide</i> , Capsule 20 mg
8380C	<i>Orion Temozolomide, ON – Temozolomide</i> , Capsule 100 mg
9362R	<i>Orion Temozolomide, ON – Temozolomide</i> , Capsule 140 mg
8381D	<i>Orion Temozolomide, ON – Temozolomide</i> , Capsule 250 mg
8819E	<i>Orion Temozolomide, ON – Temozolomide</i> , Capsule 5 mg
8820F	<i>Orion Temozolomide, ON – Temozolomide</i> , Capsule 20 mg
8821G	<i>Orion Temozolomide, ON – Temozolomide</i> , Capsule 100 mg
9361Q	<i>Orion Temozolomide, ON – Temozolomide</i> , Capsule 140 mg

Addition – Equivalence Indicator

1512N	<i>Plaquenil, SW – Hydroxychloroquine Sulfate</i> , Tablet 200 mg
8243W	<i>Xalatan, PF – Latanoprost</i> , Eye drops 50 micrograms per mL (0.005%), 2.5 mL
5552F	<i>Xalatan, PF – Latanoprost</i> , Eye drops 50 micrograms per mL (0.005%), 2.5 mL (Optometrical)
8895E	<i>Xalacom, PF – Latanoprost with Timolol Maleate</i> , Eye drops 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL
5553G	<i>Xalacom, PF – Latanoprost with Timolol Maleate</i> , Eye drops 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL (Optometrical)
9151P	<i>Sifrol, BY – Pramipexole Hydrochloride</i> , Tablet 125 micrograms
9152Q	<i>Sifrol, BY – Pramipexole Hydrochloride</i> , Tablet 250 micrograms
9153R	<i>Sifrol, BY – Pramipexole Hydrochloride</i> , Tablet 1 mg

Addition – Note

1382R	Ranibizumab , Solution for intravitreal injection 2.3 mg in 0.23 mL (<i>Lucentis</i>)
-------	--

Deletions

Deletion – Item

1743R	Oestradiol , Transdermal patches 2 mg (releasing approximately 25 micrograms per 24 hours), 8 (<i>Estraderm 25</i>)
-------	--

Deletion – Brand

3318P	<i>Cephbell, BF – Cephalexin</i> , Capsule 500 mg (Dental)
3119E	<i>Cephbell, BF – Cephalexin</i> , Capsule 500 mg
8220P	<i>Citalobell, BF – Citalopram Hydrobromide</i> , Tablet 20 mg (base)
2449X	<i>Mellihexal, SZ – Gliclazide</i> , Tablet 80 mg
8621R	<i>Actonel Once-a-Week, SW – Risedronate Sodium</i> , Tablet 35 mg
8899J	<i>Actonel Combi, SW – Risedronate Sodium and Calcium Carbonate</i> , Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)
8173E	<i>Simvahexal, HX – Simvastatin</i> , Tablet 40 mg
9244M	<i>Simvahexal, HX – Simvastatin</i> , Tablet 40 mg

Deletion – Equivalence Indicator

8899J	<i>Acris Combi, AF – Risedronate Sodium and Calcium Carbonate</i> , Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)
-------	---

Alterations

Alteration – Brand Name

From:

5484P *GA express, VF – Amino Acid Formula with Vitamins and Minerals without Lysine and low in Tryptophan*, Sachets 25 g, 30

To:

5484P *GA express 15, VF– Amino Acid Formula with Vitamins and Minerals without Lysine and low in Tryptophan*, Sachets 25 g, 30

From:

8744F *HCU express, VF – Amino Acid Formula with Vitamins and Minerals without Methionine*, Sachets 25 g, 30

To:

8744F *HCU express 15, VF – Amino Acid Formula with Vitamins and Minerals without Methionine*, Sachets 25 g, 30

From:

3443F *MMA/PA express, VF – Amino Acid Formula with Vitamins and Minerals without Methionine, Threonine and Valine and low in Isoleucine*, Sachets 25 g, 30

To:

3443F *MMA/PA express 15, VF – Amino Acid Formula with Vitamins and Minerals without Methionine, Threonine and Valine and low in Isoleucine*, Sachets 25 g, 30

From:

8591E *PKU express, VF – Amino Acid Formula with Vitamins and Minerals without Phenylalanine*, Sachets 25 g, 30

To:

8591E *PKU express 15, VF – Amino Acid Formula with Vitamins and Minerals without Phenylalanine*, Sachets 25 g, 30

From:

8667E *TYR express, VF –Amino Acid Formula with Vitamins and Minerals without Phenylalanine and Tyrosine*, Sachets 25 g, 30

To:

8667E *TYR express 15, VF – Amino Acid Formula with Vitamins and Minerals without Phenylalanine and Tyrosine*, Sachets 25 g, 30

From:

8632H *MSUD express, VF – Amino Acid Formula with Vitamins and Minerals without Valine, Leucine and Isoleucine*, Sachets 25 g, 30

To:

8632H *MSUD express 15, VF – Amino Acid Formula with Vitamins and Minerals without Valine, Leucine and Isoleucine*, Sachets 25 g, 30

From:

1784X *Max Pharma Pty Ltd, XF – Ceftriaxone*, Powder for injection 1 g

To:

1784X *Max Pharma Ceftriaxone, GQ – Ceftriaxone*, Powder for injection 1 g

Alteration – Maximum Quantity

		From:	To:
8349K	Morphine Sulfate , Capsule 10 mg (containing sustained release pellets) (<i>Kapanol</i>)	20	28
2839K	Morphine Sulfate , Capsule 20 mg (containing sustained release pellets) (<i>Kapanol</i>)	20	28
2840L	Morphine Sulfate , Capsule 50 mg (containing sustained release pellets) (<i>Kapanol</i>)	20	28
2841M	Morphine Sulfate , Capsule 100 mg (containing sustained release pellets) (<i>Kapanol</i>)	20	28

Alteration – Restriction

5457F **Denosumab**, Injection 60 mg in 1 mL pre-filled syringe (*Prolia*)

Alteration – Manufacturer's Code

		From:	To:
5281Y	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
5282B	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
5283C	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
5284D	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
8737W	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
8741C	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
8961P	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe, 6	AB	VE
8962Q	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen, 6	AB	VE
8963R	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
8964T	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
8965W	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
8966X	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9033K	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
9034L	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
9077R	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
9078T	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
9099X	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9100Y	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9101B	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9102C	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9103D	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9104E	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9186L	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe, 6	AB	VE
9187M	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen, 6	AB	VE
9188N	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
9189P	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
9190Q	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9191R	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9425C	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
9426D	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
9427E	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled syringe	AB	VE
9428F	<i>Humira</i> , VE – Adalimumab , Injection 40 mg in 0.8 mL pre-filled pen	AB	VE
8511Y	<i>Alendrobell 70mg</i> , GQ – Alendronate Sodium , Tablet equivalent to 70 mg alendronic acid	BF	GQ
1788D	<i>Max Pharma Ceftriaxone</i> , GQ – Ceftriaxone , Powder for injection 1 g	XF	GQ
1209P	<i>Ciprofloxacin-BW</i> , GQ – Ciprofloxacin , Tablet 500 mg	BF	GQ
1210Q	<i>Ciprofloxacin-BW</i> , GQ – Ciprofloxacin , Tablet 750 mg	BF	GQ
1313D	<i>Diltahexal CD</i> , HX – Diltiazem Hydrochloride , Capsule 240 mg (controlled delivery)	SZ	HX
8480H	<i>Diltahexal CD</i> , HX – Diltiazem Hydrochloride , Capsule 360 mg (controlled delivery)	SZ	HX

		<i>From:</i>	<i>To:</i>
8875D	<i>Lucrin Depot 7.5mg PDS, VE – Leuprorelin Acetate</i> , I.M. injection (modified release), powder for injection 7.5 mg with diluent in pre-filled dual-chamber syringe	AB	VE
8876E	<i>Lucrin Depot 3 Month PDS, VE – Leuprorelin Acetate</i> , I.M. injection (modified release), powder for injection 22.5 mg with diluent in pre-filled dual-chamber syringe	AB	VE
8877F	<i>Lucrin Depot 4 Month PDS, VE – Leuprorelin Acetate</i> , I.M. injection (modified release), powder for injection 30 mg with diluent in pre-filled dual-chamber syringe	AB	VE
8970D	<i>Duodopa, VE – Levodopa with Carbidopa</i> , Intestinal gel 20 mg-5 mg per mL, 100 mL	AB	VE
8561N	<i>Meloxicbell, GQ – Meloxicam</i> , Tablet 7.5 mg	BF	GQ
8562P	<i>Meloxicbell, GQ – Meloxicam</i> , Tablet 15 mg	BF	GQ

SECTION 100 – HIGHLY SPECIALISED DRUGS PROGRAM

Additions

Addition – Item

2008Q	Mannitol , Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers (<i>bronchitol</i>)(Private)
2015C	Mannitol , Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers (<i>bronchitol</i>)(Public)

Addition – Brand

6193Y	<i>Lamivudine RBX, RA – Lamivudine</i> , Tablet 150 mg (Private)
5772T	<i>Lamivudine RBX, RA – Lamivudine</i> , Tablet 150 mg (Public)
6435Q	<i>Lamivudine RBX, RA – Lamivudine</i> , Tablet 300 mg (Private)
5774X	<i>Lamivudine RBX, RA – Lamivudine</i> , Tablet 300 mg (Public)

Addition – Equivalence Indicator

6193Y	<i>3TC, VI – Lamivudine</i> , Tablet 150 mg (Private)
5772T	<i>3TC, VI – Lamivudine</i> , Tablet 150 mg (Public)
6435Q	<i>3TC, VI – Lamivudine</i> , Tablet 300 mg (Private)
5774X	<i>3TC, VI – Lamivudine</i> , Tablet 300 mg (Public)

Addition – Note

6120D	Dornase Alfa , Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL (<i>Pulmozyme</i>)(Private)
5704F	Dornase Alfa , Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL (<i>Pulmozyme</i>)(Public)

Deletions

Deletion – Item

9656F	Tipranavir , Oral liquid 100 mg per mL, 95 mL (<i>Aptivus</i>)(Public)
9676G	Tipranavir , Oral liquid 100 mg per mL, 95 mL (<i>Aptivus</i>)(Private)

Alterations

Alteration – Manufacturer's Code

		<i>From</i>	<i>To</i>
9661L	<i>Humira, VE – Adalimumab</i> , Injection 20 mg in 0.4 mL pre-filled syringe (Public)	AB	VE
9662M	<i>Humira, VE – Adalimumab</i> , Injection 40 mg in 0.8 mL pre-filled syringe (Public)	AB	VE
9663N	<i>Humira, VE – Adalimumab</i> , Injection 40 mg in 0.8 mL pre-filled pen (Public)	AB	VE

		<i>From</i>	<i>To</i>
9678J	<i>Humira, VE – Adalimumab</i> , Injection 20 mg in 0.4 mL pre-filled syringe (Private)	AB	VE
9679K	<i>Humira, VE – Adalimumab</i> , Injection 40 mg in 0.8 mL pre-filled syringe (Private)	AB	VE
9680L	<i>Humira, VE – Adalimumab</i> , Injection 40 mg in 0.8 mL pre-filled pen (Private)	AB	VE
9743T	<i>Duodopa, VE – Levodopa with Carbidopa</i> , Intestinal gel 20 mg-5 mg per mL, 100 mL (Public)	AB	VE
9744W	<i>Duodopa, VE – Levodopa with Carbidopa</i> , Intestinal gel 20 mg-5 mg per mL, 100 mL (Private)	AB	VE
9633B	<i>Kaletra, VE – Lopinavir with Ritonavir</i> , Tablet 100 mg-25 mg (Private)	AB	VE
5790R	<i>Kaletra, VE – Lopinavir with Ritonavir</i> , Tablet 100 mg-25 mg (Public)	AB	VE
6495W	<i>Kaletra, VE – Lopinavir with Ritonavir</i> , Tablet 200 mg-50 mg (Private)	AB	VE
5791T	<i>Kaletra, VE – Lopinavir with Ritonavir</i> , Tablet 200 mg-50 mg (Public)	AB	VE
6341R	<i>Kaletra, VE – Lopinavir with Ritonavir</i> , Oral liquid 400 mg-100 mg per 5 mL, 60 mL (Private)	AB	VE
5789Q	<i>Kaletra, VE – Lopinavir with Ritonavir</i> , Oral liquid 400 mg-100 mg per 5 mL, 60 mL (Public)	AB	VE
6227R	<i>Octreotide MaxRx, GQ – Octreotide</i> , Injection 50 micrograms (as acetate) in 1 mL (Private)	XF	GQ
9508K	<i>Octreotide MaxRx, GQ – Octreotide</i> , Injection 50 micrograms (as acetate) in 1 mL (Public)	XF	GQ
6228T	<i>Octreotide MaxRx, GQ – Octreotide</i> , Injection 100 micrograms (as acetate) in 1 mL (Private)	XF	GQ
9509L	<i>Octreotide MaxRx, GQ – Octreotide</i> , Injection 100 micrograms (as acetate) in 1 mL (Public)	XF	GQ
6229W	<i>Octreotide MaxRx, GQ – Octreotide</i> , Injection 500 micrograms (as acetate) in 1 mL (Private)	XF	GQ
9510M	<i>Octreotide MaxRx, GQ – Octreotide</i> , Injection 500 micrograms (as acetate) in 1 mL (Public)	XF	GQ
9677H	<i>Norvir, VE – Ritonavir</i> , Tablet 100 mg (Private)	AB	VE
9660K	<i>Norvir, VE – Ritonavir</i> , Tablet 100 mg (Public)	AB	VE
6494T	<i>Norvir, VE – Ritonavir</i> , Oral solution 600 mg per 7.5 mL (80 mg per mL), 90 mL (Private)	AB	VE
9542F	<i>Norvir, VE – Ritonavir</i> , Oral solution 600 mg per 7.5 mL (80 mg per mL), 90 mL (Public)	AB	VE

Advance Notices

Advance Notices – Deletion of Item

The following items will be deleted from the Schedule of Pharmaceutical Benefits on 1 September 2012:

Items discontinued by the manufacturer—

9163G	Calcipotriol , Scalp solution 50 micrograms per mL (0.005%), 30 mL (<i>Daivonex</i>)
2920Q	Disodium Etidronate , Tablet 200 mg (<i>Didronel</i>)
8056B	Disodium Etidronate and Calcium Carbonate , Pack containing 28 tablets disodium etidronate 200 mg and 76 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium) (<i>Didrocal</i>)
9193W	Glucose Indicator—blood , Test strips, 25 (<i>On-Call Plus</i>)
9256E	Glucose Indicator—blood , Test strips, 25 (<i>On-Call Plus</i>)
1253Y	Verapamil Hydrochloride , Tablet 160 mg (<i>Isoptin</i>)

Deletion requested by manufacturer—

2530E	Lincomycin , Injection 600 mg in 2 mL (<i>Lincocin</i>)
5144R	Lincomycin , Injection 600 mg in 2 mL (<i>Lincocin</i>) (Dental)

The following items will be deleted from the Schedule of Pharmaceutical Benefits on 1 October 2012:

Items discontinued by the manufacturer—

2244D	Amino Acids—synthetic, Formula , Compound powder 400 g (<i>Neocate Advance Tropical Flavour</i>)
2553J	Amino Acids—synthetic, Formula , Compound powder 400 g (<i>Neocate Advance Tropical Flavour</i>)

The following items will be deleted from the Schedule of Pharmaceutical Benefits on 1 November 2012:

Items discontinued by the manufacturer—

2820K	Betamethasone Valerate , Ointment 200 micrograms (base) per g (0.02%), 100 g (<i>Celestone-M, Antroquoril</i>)
-------	---

- 1060T **Verapamil Hydrochloride**, Injection 5 mg in 2 mL (*Isoptin*)
- 3494X **Verapamil Hydrochloride**, Injection 5 mg in 2 mL (*Isoptin*)(**Emergency Drug Supply**)

Advance Notices – Deletion of Brand

The following brands will be deleted from the Schedule of Pharmaceutical Benefits on 1 September 2012:
Brands discontinued by the manufacturer—

- 1312C *Diltahexal CD, HX* – **Diltiazem Hydrochloride**, Capsule 180 mg (controlled delivery)
- 2013Y *Simvahexal, HX* – **Simvastatin**, Tablet 5 mg
- 2011W *Simvahexal, HX* – **Simvastatin**, Tablet 10 mg
- 2012X *Simvahexal, HX* – **Simvastatin**, Tablet 20 mg
- 9241J *Simvahexal, HX* – **Simvastatin**, Tablet 5 mg
- 9242K *Simvahexal, HX* – **Simvastatin**, Tablet 10 mg
- 9243L *Simvahexal, HX* – **Simvastatin**, Tablet 20 mg
- 1278G *Timoptol, FR* – **Timolol Maleate**, Eye drops 2.5 mg (base) per mL (0.25%), 5 mL
- 5547Y *Timoptol, FR* – **Timolol Maleate**, Eye drops 2.5 mg (base) per mL (0.25%), 5 mL (**Optometrical**)

The following brand will be deleted from the Schedule of Pharmaceutical Benefits on 1 October 2012:
Brand discontinued by the manufacturer—

- 2488Y *Pepcidine, MK* – **Famotidine**, Tablet 40 mg

The following brand will be deleted from the Schedule of Pharmaceutical Benefits on 1 November 2012:
Brand discontinued by the manufacturer—

- 8316Q *Maxipime, BQ* – **Cefepime**, Powder for injection 2 g (as hydrochloride) (solvent required)

Addresses — Medicare Australia

Medicare Australia has responsibility for the operational aspects of the Pharmaceutical Benefits Scheme (PBS). This responsibility covers the processing of pharmaceutical benefit and safety net claims, authority applications and supply of PBS stationery used by medical practitioners, participating dental practitioners and approved pharmacists.

Procedures for ordering prescription forms are set out in the Introduction of this Schedule.

New South Wales and Australian Capital Territory

Pharmaceutical Benefits Branch
130 George Street
Parramatta NSW 2150

General and IME enquiries — Tel: 132 290

Orange Service Centre
189 Anson Street
Orange NSW 2800

General and IME enquiries — Tel: 132 290

Victoria

Pharmaceutical Branch
Level 10
595 Collins Street
Melbourne Vic 3000

General and IME enquiries — Tel: 132 290

Queensland

Pharmaceutical Services Branch
143 Turbot Street
Brisbane Qld 4000

General and IME enquiries — Tel: 132 290

Western Australia

Pharmaceutical Benefits Branch
Level 5, Work Distribution Centre,
(Reception on Level 4)
130 Stirling Street
Northbridge WA 6003

General and IME enquiries — Tel: 132 290

South Australia and Northern Territory

Pharmaceutical Services Branch
209 Greenhill Road
Eastwood SA 5063

General and IME enquiries — Tel: 132 290

Tasmania

Pharmaceutical Branch
199 Collins Street
Hobart Tas 7000

General and IME enquiries — Tel: 132 290

National Program Management

Pharmaceutical Benefits Branch
Medicare Australia
134 Reed Street
Tuggeranong ACT 2900
Telephone — (02) 6124 6333
Website — www.medicareaustralia.gov.au Email — pbs@medicareaustralia.gov.au

Authority Prescription Applications

Authority required benefits fall into two categories – *Authority required* and *Authority required (STREAMLINED)*. The process in which an authority PBS prescription can be prescribed will depend on the type of Authority required benefit.

Prior approval is required for Authority required items as well as all requests for increased quantities and/or repeats for any category of PBS item.

Prior approval is not required for Authority required (STREAMLINED) items except if increased quantities and/or repeats are required (see Explanatory Notes for details).

Mail Applications:

REPLY PAID No. 9857
PBS Authorities Section
Medicare Australia
GPO Box 9857
In your Capital City

Telephone Applications:

Free call 1800 888 333
Australia-wide 24 hour service PBS Authorities Section

For telephone applications please have the following information available:

Patient:

Medicare Number
Surname
First name
Full residential address (including post code)

PBS Authority Prescription Number:

Top right hand side of the handwritten PBS Authority Form

Your Prescriber Number:

Located below your address block on the personalised forms

Drug Information:

PBS item
Quantity required and number of repeats
Daily dose
Disease or purpose information

Requests for Drugs via the Special Access Scheme (SAS)

Requests for individual patient approval to obtain drugs that are available only through the SAS may be directed to a delegate within the Drug Safety and Evaluation Branch, Therapeutic Goods Administration, telephone (02) 6232 8111, facsimile (02) 6232 8112, or by mail to PO Box 100 Woden ACT 2606.

Department of Veterans' Affairs

Details of the approving authority for the Department of Veterans' Affairs are listed at the front of the Repatriation Schedule of Pharmaceutical Benefits.

Telephone Interpreter Service

A 24-hour, seven days a week telephone service is available by contacting 131 450.

The translating service (TIS) can provide immediate assistance over the telephone or arrange for an interpreter to go to a location specified in either city or country areas. The TIS service has access to 2000 professional interpreters, covering over 100 languages and dialects.

Poisons Information Centres

Phone 131 126 from anywhere in Australia — 24 hours — form information and advice on the treatment of poisoning, bites and stings

NSW

The New Children's Hospital
Hawkesbury Road
Westmead NSW 2148
Tel: (02) 9845 3111

VIC

Austin Hospital
Studley Road
Heidelberg VIC 3084
Tel: (03) 9496 4410
www.austin.org.au/poisons

QLD

Pharmacy Department
Royal Children's Hospital
Herston QLD 4029
Tel: 131 126

WA

Sir Charles Gairdner Hospital
Hospital Avenue
Nedlands WA 6009
Tel: 131 126

TAS

Tel: 131 126

NT

Tel: 131 126

ACT

Tel: 131 126

Drug Information Centres

NSW

Drug Information Pharmacist
New South Wales Medicines Information
Centre
PO Box 766
Darlinghurst NSW 2010
Tel: (02) 8382 2136

OR

Drug Information Pharmacist
Hunter Drug Information Service
Newcastle Mater Misericordiae Hospital
Locked Bag 7
Hunter Regional Mail Centre NSW 2310
Tel: (02) 4921 1278
Tel: (02) 4921 1328

VIC

Drug Information Pharmacist
Austin & Repatriation Medical Centre
Studley Road
Heidelberg Vic 3084
Tel: (03) 9496 5668

OR

Drug Information Pharmacist
Drug Information Centre
Southern Health Care Network
Monash Medical Centre
246 Clayton Road
Clayton Vic 3168
Tel: (03) 9594 2361

QLD

Assistant Director of Pharmacy
Queensland Drug Information Ctr
Royal Brisbane Hospital
E Floor, Block 7
Herston Road
Herston Qld 4029
Tel: (07) 3636 7098
(07) 3636 7599

SA

Drug Information Pharmacist
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000
Tel: (08) 8222 5546

OR

Drug Information Pharmacist
Flinders Medical Centre
Bedford Park SA 5042
Tel: (08) 8204 5301

OR

Drug Information Pharmacist
Queen Elizabeth Hospital
Woodville Road
Woodville SA 5011
Tel: (08) 8222 6777

WA

Drug Information Pharmacist
Sir Charles Gairdner Hospital
Hospital Avenue
Nedlands WA 6009
Tel: (08) 9346 2923

TAS

Drug Information Pharmacist
Royal Hobart Hospital
GPO Box 1061L
Hobart Tas 7001
Tel: (03) 6222 8737

NT

Drug Information Pharmacist
Royal Darwin Hospital
PO Box 41326
Casuarina NT 0811
Tel: (08) 8922 8424

ACT

Drug Information Pharmacist
Canberra Hospital
Yamba Drive
Garran ACT 2605
Tel: (02) 6244 3333

List of Contact Officers for Recalls of Therapeutic Goods

For details of consumer level recalls only — telephone 1800 020 512

These officers may be contacted —

- to obtain information about current recalls
- to report suspected problems relating to the quality, safety or efficacy of a therapeutic good

Australian Recall Coordinator

Mr Mick O'Connor

Bh 02 6232 8197

Mobile 0421 583 361

Fax 02 6203 1451

E-mail recalls@tga.gov.au

Australian Capital Territory

Mr Michael Conroy

Bh 02 6207 3974

Mobile 0418 182 375

Fax 02 6205 0997

E-mail pharmaceuticalservices@act.gov.au
MichaelJ.Conroy@act.gov.au

New South Wales

Mr B. Battye

Bh 02 9879 3214

Mobile 0401 712 050

Fax 02 9859 5165

E-mail bruce.battye@doh.health.nsw.gov.au

Ms J. Mackson

Bh 02 9879 3214

Mobile 0411 145 562

Fax 02 9859 5165

E-mail jmack@doh.health.nsw.gov.au

Victoria

Ms M. Smith

Bh 03 9096 5355

Bh 1300 364 545

Mobile 0408 598 663

Fax 1300 360 830

E-mail megan.l.smith@health.vic.gov.au

Mr M. McCrone

Bh 03 9096 5066

Bh 1300 364 545

Mobile 0408 581 312

Fax 1300 360 830

E-mail matthew.mccrone@health.vic.gov.au

Queensland

Mr C.J. Healey

Bh 07 3328 9310

Mobile 0403 053 090

Fax 07 3328 9354

E-mail chris_healey@health.qld.gov.au

Mr A. Hawkins

Bh 07 3328 9310

Mobile 0449 267 625

Fax 07 3328 9354

E-mail andrew_hawkins@health.qld.gov.au

South Australia

Mr S. Morris

Bh 08 8204 1940

Mobile 0431 657 090

Fax 08 8226 9837

E-mail steve.morris@health.sa.gov.au

Ms E. Hender

Bh 0418 747 833

Mobile 0431 657 090

Fax 08 8226 9837

E-mail elizabeth.hender@health.sa.gov.au

Western Australia

Mr Neil Keen

Bh 08 9222 6883

Mobile 0419 944 801

Fax 08 9222 2463

E-mail neil.keen@health.wa.gov.au
poisons@health.wa.gov.au

Tasmania

Ms M. Sharpe

Bh 03 6233 3766

Ah 03 6223 3476

Fax 03 6233 3904

E-mail mary.sharpe@dhhs.tas.gov.au

Mr J. Galloway

Bh 03 6233 2064

Ah 03 6223 7074

Fax 03 6233 3904

E-mail james.galloway@dhhs.tas.gov.au

Northern Territory

Ms Helgi Stone

Bh 08 8922 7035

Mobile 0429 091 636

Fax 08 8922 7200

E-mail Helgi.stone@nt.gov.au

Mr T. DeZilva

Bh 08 8922 7340

Mobile 0400 251 419

Fax 08 8922 7200

E-mail tyronne.dezilva@nt.gov.au

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>
AB	Abbott Australasia Pty Ltd Sir Joseph Banks Corporate Park 32-34 Lord Street Botany NSW 2019 Tel: (02) 9384 9700 Fax: (02) 9384 9800
AC	Alberto Culver Company 14 Loyalty Road North Rocks NSW 2151 Tel: (02) 9630 5099 Fax: (02) 9683 5026
AE	AFT Pharmaceuticals Pty Ltd Level 1, 296 Burns Bay Road Lane Cove NSW 2066 Tel: 1800 097 639 Fax: 1800 097 810
AF	Alphapharm Pty Limited Level 1, 30 The Bond 30-34 Hickson Road Millers Point NSW 2000 Tel: (02) 9298 3999 Fax: (02) 9566 4686
AG	Allergan Australia Pty Ltd Level 4, 810 Pacific Highway Gordon NSW 2072 Tel: 1800 252 224 Fax: (02) 9498 0290
AL	Alphapharm Medical A Division of Alphapharm Pty Limited Level 1, 30 The Bond 30-34 Hickson Road Millers Point NSW 2000 Tel: (02) 9298 3999 Fax: (02) 9566 4686
AN	Amgen Australia Pty Ltd Level 7, 123 Epping Road North Ryde NSW 2113 Tel: (02) 9870 1333 Fax: (02) 9870 1344
AO	Advanced Medical Optics Australia Pty Ltd Level 3, Building 2 20 Bridge Street Pymble NSW 2073 Tel: 1800 266 111 Fax: 1800 266 222
AP	AstraZeneca Pty Ltd Alma Road North Ryde NSW 2113 Tel: (02) 9978 3500 Fax: (02) 9978 3700
AQ	Alcon Laboratories (Australia) Pty Ltd Allambie Grove Park 25 Frenchs Forest Road East Frenchs Forest NSW 2086 Tel: 1800 025 004 Fax: (02) 9452 5209

<i>Code</i>	<i>Manufacturer</i>
AS	Aspen Pharmacare Australia Pty Ltd First Floor, 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540
AT	Actelion Pharmaceuticals Australia Pty Ltd Level 2 West, Suites 48-50 7 Narabang Way Belrose NSW 2085 Tel: (02) 9486 4600 Fax: (02) 9986 1344
AV	Aventis Pharma Division of Sanofi-Aventis Australia Pty Limited Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000
BB	Blackmores Ltd 23 Roseberry Street Balgowlah NSW 2093 Tel: (02) 9951 0111 Fax: (02) 9949 1954
BD	Biogen Idec Australia Pty Ltd Suite 2, Level 4 123 Epping Road North Ryde NSW 2113 Tel: (02) 8875 3900 Fax: (02) 9889 1162
BE	Beiersdorf Australia Limited 4 Khartoum Road North Ryde NSW 2113 Tel: (02) 9888 0977 Fax: (02) 9887 3487
BG	Biochemie Australia A Division of Sandoz Pty Ltd Level 2, 19 Harris Street Pyrmont NSW 2009 Tel: (02) 9566 1500 Fax: (02) 9566 1458
BI	Biotech Pharmaceuticals Pty Ltd 83 Cherry Lane Laverton North Vic 3026 Tel: (03) 9278 7555 Fax: (03) 9369 6730
BK	Becton Dickinson Pty Ltd 80 Rushdale Street Knoxfield Vic 3180 Tel: (03) 9764 2444 Fax: (03) 9764 2550
BN	Bayer Australia Limited 875 Pacific Highway Pymble NSW 2073 Tel: (02) 9391 6000 Fax: (02) 9988 3311

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>	<i>Code</i>	<i>Manufacturer</i>
BQ	Bristol-Myers Squibb Pharmaceuticals A Division of Bristol-Myers Squibb Australia Pty Ltd 556 Princes Highway Noble Park Vic 3174 Tel: (03) 9213 4000 Fax: (03) 9701 1518	CR	Pharmacor Limited 5/36 Campbell Avenue Cromer NSW 2099 Tel: (02) 9981 4470 Fax: (02) 9981 4475
BR	B. Braun Australia Pty Ltd Norwest Business Park 17 Lexington Drive Bella Vista NSW 2153 Tel: (02) 9629 0200 Fax: (02) 9629 0299	CS	CSL Limited 45 Poplar Road Parkville Vic 3052 Tel: (03) 9389 1911 Fax: (03) 9388 2351
BU	Bausch & Lomb Surgical A Division of Bausch & Lomb (Australia) Pty Ltd Level 4, 113 Wicks Road North Ryde NSW 2113 Tel: (02) 9887 1444 Fax: (02) 9888 9642	CT	Coloplast Pty Ltd 33 Gilby Road Mount Waverley Vic 3149 Tel: 1800 673 317 Fax: (03) 9541 1199
BV	B.S.N. 315 Ferntree Gully Road Mount Waverley Vic 3149 Tel: (03) 8540 6777 Fax: 1800 671 000	CU	Care Pharmaceuticals Pty Ltd Suite 303, Level 3, 59-75 Grafton Street Bondi Junction NSW 2022 Tel: 1800 788 870 Fax:
BX	Baxter Healthcare Pty Limited 1 Baxter Drive Old Toongabbie NSW 2146 Tel: (02) 9848 1111 Fax: (02) 9848 1123	CX	Contact Lens Centre Australia Pty Ltd Unit D6, Hallmark Business Park Cnr Westall and Centre Roads Clayton Vic 3168 Tel: (03) 9543 1811 Fax: (03) 9543 8066
BY	Boehringer Ingelheim Pty Limited 78 Waterloo Road North Ryde NSW 2113 Tel: (02) 8875 8800 Fax: (02) 8875 8801	DO	Aurobindo Pharma (Australia) Pty Ltd Unit 3, North Rydelink Business Park 277-283 Lane Cove Road Macquarie Park NSW 2113 Tel: (02) 9805 6000 Fax: (02) 9887 1191
BZ	Boucher & Muir Pty Ltd trading as BNM Group Level 1, 134 Willoughby Road Crows Nest NSW 2065 Tel: (02) 9431 6333 Fax: (02) 9906 7147	DQ	Church & Dwight (Australia) Pty Ltd Unit 1/108 Old Pittwater Road Brookvale NSW 2100 Tel: 1800 222 099 Fax:
CC	ConvaTec A Division of Bristol-Myers Squibb Australia Pty Ltd 606 Hawthorn Road East Brighton Vic 3187 Tel: 1800 335 276 Fax: (03) 9525 0920	EH	Entra Health Systems Pty Ltd 12/60 Castlereagh Street Sydney NSW 2000 Tel: (02) 8005 4745 Fax: (02) 8088 7105
CH	Symbion Pty Ltd, trading as Chemmart Level 3, 484 St Kilda Road Melbourne Vic 3004 Tel: (03) 9918 5555 Fax:	EL	Eli Lilly Australia Pty Limited 112 Wharf Road West Ryde NSW 2114 Tel: (02) 9325 4444 Fax: (02) 9325 4410
CJ	Celgene Pty Ltd Level 7, 607 St Kilda Road Melbourne Vic 3004 Tel: (03) 9539 5500 Fax: (03) 9539 5566	EO	Ego Pharmaceuticals Pty Ltd 21-31 Malcolm Road Braeside Vic 3195 Tel: (03) 9587 1088 Fax: (03) 9580 7647
		FB	Pierre Fabre Medicament Australia Pty Limited Suite 3B, 1 Richardson Place North Ryde NSW 2113 Tel: (02) 8662 9800 Fax: (02) 8662 9888

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>
FK	Invida Australia Pty Ltd Level 8, 67 Albert Avenue Chatswood NSW 2067 Tel: (02) 9080 7200 Fax: (02) 9080 7201
FM	Fawns and McAllan Pty Ltd A member of Aspen Group of Companies First Floor, 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540
FP	Ferring Pharmaceuticals Pty Ltd Suite 2, Level 1, Building 1 Pymble Corporate Centre 20 Bridge Street Pymble NSW 2073 Tel: (02) 9497 2300 Fax: (02) 9497 2399
FR	Charles E. Frosst Division of Merck Sharp & Dohme (Australia) Pty Ltd 54-68 Ferndell Street South Granville NSW 2142 Tel: (02) 9795 9500 Fax: (02) 9795 9595
FZ	Pfizer Established Products Division of Pfizer Australia Pty Ltd 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9850 3111
GA	Galderma Australia Pty Ltd Suite 4, 13B Narabang Way Belrose NSW 2085 Tel: (02) 9479 0600 Fax: (02) 9986 1699
GC	GlaxoSmithKline Consumer Healthcare 82 Hughes Avenue Ermington NSW 2115 Tel: (02) 9684 0888 Fax: (02) 9684 6958
GH	Mercury Pharma (Australia) Pty Ltd Level 1, 134 Willoughby Road Crows Nest NSW 2065 Tel: (02) 9431 6333 Fax: (02) 9906 7147
GI	Gilead Sciences Pty Ltd Level 1, 128 Jolimont Road East Melbourne Vic 3002 Tel: (03) 9272 4400 Fax: (03) 9272 4435
GK	GlaxoSmithKline Australia Pty Ltd Level 4, 436-438 Johnston Street Abbotsford Vic 3067 Tel: (03) 9413 7300 Fax: (03) 8761 2410

<i>Code</i>	<i>Manufacturer</i>
GM	Ascent Pharma Pty Ltd 151-153 Clarendon Street South Melbourne Vic 3205 Tel: 1800 678 302 Fax: (03) 8677 6666
GN	Ascent Pharmaceuticals Limited 151-153 Clarendon Street South Melbourne Vic 3205 Tel: 1800 678 302 Fax: (03) 8677 6666
GQ	Generic Health Pty Ltd Suite 1, Level 1 1175 Toorak Road Camberwell Vic 3124 Tel: (03) 9809 7900 Fax: (03) 9809 7999
GX	GenRx A Division of Apotex Pty Ltd 16 Giffnock Avenue Macquarie Park NSW 2113 Tel: (02) 8877 8333 Fax: (02) 8877 8377
GZ	Genzyme A Division of sanofi-aventis Australia Pty Limited Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000
HA	Hamilton Laboratories Pty Ltd 217 Flinders Street Adelaide SA 5000 Tel: (08) 8223 2957 Fax: (08) 8232 1480
HC	Biotech Healthcare A division of Biotech Pharmaceuticals Pty Ltd 83 Cherry Lane Laverton North Vic 3026 Tel: (03) 9278 7555 Fax: (03) 9369 6730
HE	HealthSense Products Pty Ltd 87 Pitfield Crescent Rowville Vic 3178 Tel: 1300 462 188 Fax:
HH	Hospira Pty Ltd (David Bull Laboratories, Faulding Pharmaceuticals) Level 3, 500 Collins Street Melbourne Vic 3000 Tel: (03) 8744 5200 Fax: (03) 9866 3504
HL	Helex-A Pty Ltd 9/7 Anella Avenue Castle Hill NSW 2154 Tel: (02) 9846 1911 Fax: (02) 9846 1930

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>
HM	Meda Pharmaceuticals Pty Ltd Level 20, Tower A, The Zenith Centre, 821 Pacific Highway Chatswood NSW 2067 Tel: (02) 8448 2080 Fax: (02) 8448 2010
HR	Paul Hartmann Pty Ltd 27-28/11-21 Underwood Road Homebush NSW 2140 Tel: 1800 805 839 Fax: (02) 8762 7100
HX	Hexal Australia A division of Sandoz Pty Ltd Level 2, 19 Harris Street Pyrmont NSW 2009 Tel: (02) 9566 1500 Fax: (02) 9566 1458
IA	iNova Pharmaceuticals (Australia) Pty Limited 9-15 Chilvers Road Thornleigh NSW 2120 Tel: (02) 9875 6333 Fax: (02) 9875 6416
IK	Medtronic Australasia Pty Ltd 97 Waterloo Road North Ryde NSW 2113 Tel: (02) 9857 9000 Fax: (02) 9887 1829
IQ	loquin A Division of Alcon Laboratories (Australia) Pty Ltd Allambie Grove Park 25 Frenchs Forest Road East Frenchs Forest NSW 2086 Tel: 1800 025 004 Fax: (02) 9452 5209
IS	Ipsen Pty Ltd Suite 6, 40 Montclair Avenue Glen Waverley Vic 3150 Tel: (03) 8544 8100 Fax: (03) 9562 5152
IX	Clinect Pty Ltd Level 3, 484 St Kilda Road Melbourne VIC 3004 Tel: (03) 9918 5555 Fax: (03) 9918 5582
JC	Janssen-Cilag Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Tel: (02) 8875 3333 Fax: (02) 8875 3300
JJ	Johnson & Johnson Medical 1-5 Khartoum Road North Ryde NSW 2113 Tel: (02) 9878 9111 Fax: 1800 808 233
JT	Johnson & Johnson Pacific Pty Limited 45 Jones Street Ultimo NSW 2007 Tel: 13 1565 Fax: (02) 8260 8102

<i>Code</i>	<i>Manufacturer</i>
KE	Kendall Australasia Pty Ltd 22 Giffnock Avenue North Ryde NSW 2113 Tel: 1800 252 467 Fax: (02) 9888 7378
KN	Knoll A Division of Abbott Australasia Pty Ltd 32-34 Lord Street Botany NSW 2019 Tel: (02) 9384 9700 Fax: (02) 9384 9800
KP	KwikPen Products of Eli Lilly Australia Pty Limited 112 Wharf Road West Ryde NSW 2114 Tel: (02) 9325 4444 Fax: (02) 9325 4410
KY	Key Pharmaceuticals Pty Ltd 12 Lyonpark Road Macquarie Park NSW 2113 Tel: (02) 8113 6200 Fax: (02) 8113 6222
LB	Life Bioscience Pty Ltd 10 Atherton Road Oakleigh Vic 3166 Tel: 1800 114 610 Fax: (03) 8660 2785
LM	Link Medical Products Pty Ltd Unit 1, 5 Apollo Street Warriewood NSW 2102 Tel: (02) 8401 9777 Fax: (02) 8401 9786
LN	Lennon Healthcare A Division of Aspen Pharmacare Australia Pty Ltd First Floor 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540
LO	LEO Pharma Pty Ltd Level 3, Tower 1 25 Montpelier Road Bowen Hills Qld 4006 Tel: (07) 3250 1200 Fax: (07) 3250 1299
LU	Lundbeck Australia Pty Ltd 1 Innovation Road North Ryde NSW 2113 Tel: (02) 8669 1000 Fax: (02) 8669 1090
LY	Eli Lilly Australia Pty Limited 112 Wharf Road West Ryde NSW 2114 Tel: (02) 9325 4444 Fax: (02) 9325 4410
MD	Macarthur Research Division of Roche Products Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9981 3229

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>
MF	Mundipharma Pty Ltd Level 33, 50 Bridge Street Sydney NSW 2000 Tel: (02) 9231 7200 Fax: (02) 9223 0011
MH	Molnlycke Health Care Pty Ltd Building 1, Ground Floor 14 Aquatic Drive Frenchs Forest NSW 2086 Tel: (02) 9453 1144 Fax: (02) 9453 1155
MI	Meditech Int. Pty Ltd Unit 5, 36 Campbell Avenue Cromer NSW 2099 Tel: (02) 9981 4470 Fax: (02) 9981 4475
MK	Merck Sharp & Dohme (Australia) Pty Ltd 54-68 Ferndell Street South Granville NSW 2142 Tel: (02) 9795 9500 Fax: (02) 9795 9595
MM	3M Pharmaceuticals Australia Pty Ltd 9-15 Chilvers Road Thornleigh NSW 2120 Tel: (02) 9875 6333 Fax: (02) 9875 6416
MQ	Alphapharm Pharmaceuticals Level 1, 30 The Bond 30-34 Hickson Road Millers Point NSW 2000 Tel: (02) 9298 3999 Fax: (02) 9566 4686
MS	Abbott Diabetes Care (A Division of Abbott Australasia Pty Ltd) 666 Doncaster Road Doncaster Vic 3108 Tel: (03) 9843 7100 Fax: (03) 9855 8020
MT	Mentholatum Australasia Pty Ltd 12-16 Janine Street Scoresby Vic 3179 Tel: (03) 9763 0322 Fax: (03) 9763 2699
MW	Biomed Aust Pty Ltd c/- Robinson Legal Level 4, 350 Kent Street Sydney NSW 2000 Tel: (02) 9299 2100 Fax: (02) 9299 2201
NA	National Diagnostic Products 22/39 Herbert Street St Leonards NSW 2065 Tel: (02) 9432 8100 Fax: (02) 9432 1151
NC	Novartis Consumer Health Australasia Pty Ltd 327-333 Police Road Mulgrave Vic 3170 Tel: (03) 9701 2711 Fax: (03) 9701 2911

<i>Code</i>	<i>Manufacturer</i>
NE	Norgine Pty Limited 3/14 Rodborough Road Frenchs Forest NSW 2086 Tel: (02) 9972 7500 Fax: (02) 9972 7522
NF	FlexPen Products of Novo Nordisk Pharmaceuticals Pty Ltd Level 3, 21 Solent Circuit Baulkham Hills NSW 2153 Tel: (02) 8858 3600 Fax: (02) 8858 3799
NH	Nycomed Healthcare Pty Limited 2 Lyon Park Road Macquarie Park North Ryde NSW 2113 Tel: (02) 9859 6900 Fax: (02) 9859 6950
NI	InnoLet Products of Novo Nordisk Pharmaceuticals Pty Ltd Level 3, 21 Solent Circuit Baulkham Hills NSW 2153 Tel: (02) 8858 3600 Fax: (02) 8858 3799
NM	Novartis Medicines A Division of Novartis Pharmaceuticals Australia Pty Ltd 54 Waterloo Road North Ryde NSW 2113 Tel: (02) 9805 3555 Fax: (02) 9887 4551
NO	Novo Nordisk Pharmaceuticals Pty Ltd Level 3, 21 Solent Circuit Baulkham Hills NSW 2153 Tel: (02) 8858 3600 Fax: (02) 8858 3799
NQ	Nycomed Pty Ltd 2 Lyon Park Road Macquarie Park North Ryde NSW 2113 Tel: (02) 9859 6900 Fax: (02) 9859 6950
NT	Nestlé Australia Ltd 60 Bathurst Street Sydney NSW 2000 Tel: (02) 9931 2345 Fax: (02) 9931 2610
NU	Nutricia Australia Pty Limited Talavera Corporate Centre Level 4, Building D 12-24 Talavera Road North Ryde NSW 2113 Tel: (02) 8875 0300 Fax: (02) 8978 4841
NV	Novartis Pharmaceuticals Australia Pty Ltd 54 Waterloo Road North Ryde NSW 2113 Tel: (02) 9805 3555 Fax: (02) 9887 4551

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>
NX	Nipro Australia Pty Ltd Suite 2, 20 Churchill Crescent Cammeray NSW 2062 Tel: 1800 451 737 Fax: (03) 9879 9945
NZ	Nycomed Services Pty Limited 2 Lyon Park Road Macquarie Park North Ryde NSW 2113 Tel: (02) 9859 6900 Fax: (02) 9859 6950
OA	Orphan Australia Pty Ltd A member of Aspen Group of Companies First Floor, 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540
OB	Oral B Laboratories Pty Ltd Level 3, 90 Mount Street North Sydney NSW 2060 Tel: (02) 9957 6499 Fax: (02) 9957 5383
OE	Omegapharm Pty Ltd 21 Queen Street Ormond Vic 3204 Tel: (03) 9483 0070 Fax: (03) 9483 0070
OI	Boian Surgical Pty Ltd 486 King Georges Road Beverly Hills NSW 2209 Tel: (02) 9580 7447 Fax: (02) 9580 7450
OL	Owen Laboratories Division of Galderma Australia Pty Ltd 9 Rodborough Road Frenchs Forest NSW 2086 Tel: 1800 800 765 Fax: (02) 9975 5374
OM	Colgate Oral Care 345 George Street Sydney NSW 2000 Tel: (02) 9229 5600 Fax: (02) 9232 8448
ON	Orion Laboratories Pty Ltd 25-29 Delawney Street Balcatta WA 6021 Tel: (08) 9441 7800 Fax: (08) 9441 7888
OY	Orion Laboratories Pty Ltd 25-29 Delawney Street Balcatta WA 6021 Tel: (08) 9441 7800 Fax: (08) 9441 7888
OZ	Medical Specialties Australia Pty Ltd 54 Gibbes Street Chatswood NSW 2067 Tel: (02) 9417 7955 Fax: (02) 9417 5779

<i>Code</i>	<i>Manufacturer</i>
PE	Pacific EyeCare A Division of Allergan Australia Pty Ltd Level 4, 810 Pacific Highway Gordon NSW 2072 Tel: 1800 252 224 Fax: (02) 9498 0290
PF	Pfizer Pty Limited 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9858 1347
PK	Fresenius Kabi Australia Pty Limited 964 Pacific Highway Pymble NSW 2073 Tel: 1300 732 001 Fax: 1300 304 384
PL	Phebra 332 Burns Bay Road Lane Cove NSW 2066 Tel: (02) 9420 9199 Fax: (02) 9420 9177
PM	PMC Pharma A Division of AstraZeneca Pty Ltd Alma Road North Ryde NSW 2113 Tel: (02) 9978 3500 Fax: (02) 9978 3700
PP	Petrus Pharmaceuticals Pty Ltd Level 3, IBM Building 1060 Hay Street West Perth WA 6005 Tel: (08) 9368 5954 Fax: (08) 9368 6692
PQ	PMIP Pty Ltd Unit 1, 5 Apollo Street Warriewood NSW 2102 Tel: (02) 8401 9777 Fax: (02) 8401 9786
PX	Point of Care Diagnostics Australia Pty Ltd Unit 14, 76 Reserve Road Artarmon NSW 2064 Tel: (02) 9437 1355 Fax: (02) 9437 1399
PY	Procter & Gamble Pharmaceuticals Australia Pty Ltd 99 Phillip Street Parramatta NSW 2150 Tel: (02) 9685 4500 Fax: (02) 9685 4777
PZ	Prohealth Asia Pacific Pty Ltd Suite 108A, 20 Lexington Drive Bella Vista NSW 2153 Tel: 1300 024 784 Fax: 1300 008 463

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>	<i>Code</i>	<i>Manufacturer</i>
QA	Aspen Pharma Pty Ltd First Floor, 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540	SB	Nutricia Australia - Clinical A division of Nutricia Australia Pty Limited Talavera Corporate Centre Level 4, Building D 12-24 Talavera Road North Ryde NSW 2113 Tel: (02) 8875 0300 Fax: (02) 8978 4841
QB	Bionime Australia Pty Ltd Level 7, 60 York Street Sydney NSW 2000 Tel: (02) 9262 6900 Fax: (02) 9262 6922	SE	Servier Laboratories (Aust.) Pty Ltd 8 Cato Street Hawthorn Vic 3122 Tel: (03) 8823 7333 Fax: (03) 9822 9790
QR	Ranbaxy Australia Pty Limited Suite 4.02, Level 4 Building D 12-24 Talavera Road North Ryde NSW 2113 Tel: (02) 9647 1172 Fax: (02) 9647 1172	SG	Merck Serono Australia Pty Ltd Unit 3-4, 25 Frenchs Forest Road East Frenchs Forest NSW 2086 Tel: (02) 8977 4100 Fax: (02) 9975 1516
RA	Ranbaxy Australia Pty Limited Suite 4.02, Level 4 Building D 12-24 Talavera Road North Ryde NSW 2113 Tel: (02) 9647 1172 Fax: (02) 9647 1172	SI	Sigma Company Limited 1408 Centre Road Clayton Vic 3168 Tel: (03) 9542 9987 Fax: (03) 9542 9548
RB	BioRevive Pty Ltd Level 1, 263 Mary Street Richmond Vic 3121 Tel: (03) 8416 0399 Fax: (03) 8416 0345	SJ	Sharpe Laboratories Pty Ltd 12 Hope Street Ermington NSW 2115 Tel: (02) 9858 5622 Fax: (02) 9858 5957
RC	Reckitt Benckiser (Australia) Pty Limited 44 Wharf Road West Ryde NSW 2114 Tel: (02) 9857 2000 Fax: (02) 9857 2004	SN	Smith & Nephew Healthcare 315 Ferntree Gully Road Mount Waverley Vic 3149 Tel: (03) 8540 6777 Fax: 1800 671 000
RD	Roche Diagnostics Australia Pty Ltd 31 Victoria Avenue Castle Hill NSW 2154 Tel: (02) 9899 7999 Fax: (02) 9634 4696	SS	SSL Australia Pty Ltd 225 Beach Road Mordialloc Vic 3195 Tel: 1800 999 155 Fax: (03) 9587 6870
RO	Roche Products Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9971 7401	SW	Sanofi-Aventis Australia Pty Ltd Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000
RX	Ardix A Division of Servier Laboratories (Australia) Pty Ltd 8 Cato Street Hawthorn Vic 3122 Tel: (03) 8823 7333 Fax: (03) 9822 9790	SY	Bayer Australia Ltd 875 Pacific Highway Pymble NSW 2073 Tel: (02) 9391 6000 Fax: (02) 9988 3311
RZ	Dr Reddy's Laboratories (Australia) Pty Ltd Level 1, 181 Bay Street Brighton Vic 3186 Tel: (03) 9595 3812 Fax: (03) 9595 3800	SZ	Sandoz Pty Ltd Level 2, 19 Harris Street Pyrmont NSW 2009 Tel: (02) 9566 1500 Fax: (02) 9566 1458
SA	SciGen (Australia) Pty Ltd Suite 1, 13B Narabang Way Belrose NSW 2085 Tel: (02) 9485 1800 Fax: (02) 9485 1888	TA	Actavis Australia Pty Ltd Upper Ground Floor 183 Melbourne Street North Adelaide SA 5006 Tel: (08) 8267 1545 Fax: (08) 8267 2642

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>
TD	STADA Pharmaceuticals Australia Pty Ltd Suite 1101, 46 Market Street SYDNEY NSW 2000 Tel: (02) 9279 4667 Fax: (02) 9012 0918
TM	Technipro Marketing Pty Ltd Unit 10, 13 Berry Street Clyde NSW 2142 Tel: (02) 9897 5899 Fax: (02) 9897 5799
TS	Specialised Therapeutics Australia Pty Ltd Level 1, 711 High Street Kew East Vic 3102 Tel: 1300 798 820 Fax: 1800 798 829
TW	Symbion Pty Ltd, trading as Terry White Chemists Level 3, 484 St Kilda Road Melbourne Vic 3004 Tel: (03) 9918 5555 Fax:
TX	Apotex Pty Ltd 16 Giffnock Avenue Macquarie Park NSW 2113 Tel: (02) 8877 8333 Fax: (02) 8877 8377
UC	UCB Pharma A Division of UCB Australia Pty Ltd Level 1, 1155 Malvern Road Malvern Vic 3144 Tel: (03) 9828 1800 Fax: (03) 9828 1860
UM	Unomedical Pty Ltd 11-17 Wilmette Place Mona Vale NSW 2103 Tel: (02) 9997 8033 Fax: (02) 9997 3760
VE	AbbVie Pty Ltd 32-34 Lord Street Botany NSW 2019 Tel: (02) 9384 9700 Fax: (02) 9384 9800
VF	VitaFlo Australia Pty Ltd 110 Fyans Street South Geelong Vic 3220 Tel: (03) 5229 8222 Fax: (03) 5229 8225
VI	ViiV Healthcare Pty Ltd Level 4, 436-438 Johnston Street Abbotsford Vic 3067 Tel: (03) 9413 7300 Fax: (03) 8761 2456
VP	Meda Valeant Pharma Australia Pty Ltd Level 7, Suite 7.02 3 Rider Boulevard Rhodes NSW 2138 Tel: (02) 8757 5100 Fax: (02) 9743 4053

<i>Code</i>	<i>Manufacturer</i>
VT	Valeant Pharmaceuticals Australasia Pty Ltd Level 7, Suite 7.02 3 Rider Boulevard Rhodes NSW 2138 Tel: 1800 630 056 Fax: (02) 9743 4053
WA	Winthrop Pharmaceuticals Division of Sanofi-Aventis Australia Pty Limited Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000
WQ	Willow Pharmaceuticals Pty Limited Level 4, 5 Essex Street The Rocks NSW 2000 Tel: (02) 9241 2235 Fax: (02) 9241 2217
XA	Pharmaxis Ltd 20 Rodborough Road Frenchs Forest NSW 2086 Tel: (02) 9454 7200 Fax: (02) 9451 3622
XM	The Medicines Company (Australia) Pty Ltd Suite 1, Level 8, North Tower, 1-5 Railway Street Chatswood NSW 2067 Tel: 1800 755 459 Fax: (02) 9412 4556
XP	Aaxis Pacific Pty Ltd 24-32 Forge Street Blacktown NSW 2148 Tel: (02) 9881 3333 Fax: (02) 9881 3322
XS	Symbion Pty Ltd Level 3, 484 St Kilda Road Melbourne Vic 3004 Tel: (03) 9918 5555 Fax:
YM	Symbion Pty Ltd Level 3, 484 St Kilda Road Melbourne Vic 3004 Tel: (03) 9918 5555 Fax:
YN	Mayne Pharma International Pty Ltd 1538 Main North Road Salisbury SA 5106 Tel: (08) 8209 2666 Fax: (08) 8281 6998
YS	Symbion Pty Ltd Level 3, 484 St Kilda Road Melbourne Vic 3004 Tel: (03) 9918 5555 Fax:

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>
YT	Mayne Products Pty Ltd 1538 Main North Road Salisbury SA 5106 Tel: (08) 8209 2666 Fax: (08) 8281 6998
ZF	Sun Pharmaceutical Industries (Australia) Pty Ltd 1053 Burwood Highway Ferntree Gully Vic 3156 Tel: (03) 9568 6102 Fax: (03) 9568 6610
ZI	Shire Australia Pty Limited Level 9, Avaya House 123 Epping Road North Ryde NSW 2113 Tel: 1800 012 612 Fax: (02) 8875 7977
ZP	Spirit Pharmaceuticals Pty Ltd 117 Harrington Street The Rocks Sydney NSW 2000 Tel: (02) 9251 1088 Fax: (02) 9251 1099
ZT	Synthon A.U. Pty Ltd Suite 511, 460 Pacific Highway St Leonards NSW 2065 Tel: (02) 9966 9900 Fax: (02) 9966 9099

<i>Code</i>	<i>Manufacturer</i>
-------------	---------------------

Section 1 — Explanatory Notes

Introduction

These Explanatory Notes are provided to help PBS prescribers and pharmacists work within the Australian Government's Pharmaceutical Benefits Scheme (PBS).

The PBS is a system of subsidising the cost of most prescription medicines. The subsidies are available to all Australian residents and eligible foreign visitors, i.e., people from countries which have Reciprocal Health Care Agreements with Australia. These countries are the United Kingdom, Ireland, New Zealand, Malta, Italy, Sweden, the Netherlands, Finland, Norway, Belgium and Slovenia.

The aim of the PBS, which has been in operation since 1948, is to provide reliable and affordable access to a wide range of necessary medicines.

The Schedule of Pharmaceutical Benefits referred to throughout as the 'Schedule' – lists all the medicinal products available under the PBS, and explains the uses for which they can be subsidised.

The Schedule is produced monthly by the Australian Department of Health and Ageing (effective on the first day of each month).

It is vital therefore that PBS prescribers and pharmacists remain up to date with information on which medicines are included in or excluded from the Schedule, which PBS prescribers may prescribe certain medicines, whether restrictions apply to the medicines, and how much patients should pay.

Queries relating to the PBS can be made to the Pharmaceutical Benefits Branch of Medicare Australia (telephone 132 290 open 24 hours a day, 7 days a week). Queries relating to the Repatriation Pharmaceutical Benefits Scheme (RPBS) can be made to the State offices of the Department of Veterans' Affairs (DVA) (telephone 1800 552 580).

1. The Schedule — Where to Find What

The Schedule of Pharmaceutical Benefits is divided into sections. At the start of the Schedule, immediately after the table of contents, is a summary of any changes to listed items. This is followed by a list of important information sources, contacts and addresses, then an index of manufacturers' codes.

The last pages of the Schedule provide a generic/proprietary index of PBS and RPBS ready-prepared items.

Section 1

Section 1 is what you are reading, the Explanatory Notes. It outlines the correct way to prescribe and supply pharmaceutical benefits; patient charges; who qualifies for concessions; how the Safety Net system works; and, for pharmacists, how to claim reimbursement for PBS items.

Please note that except where indicated, the term '**prescriber**' is used in this section to cover doctors, dentists, optometrists, midwives and nurse practitioners who are approved to prescribe PBS medicines under the National Health Act 1953.

And except where stated otherwise, the term '**pharmacist**' means a pharmacist approved to supply medicines under the PBS.

Section 2

This section lists ready-prepared items, and includes the form, manner of administration, brand and brand equivalents which may be prescribed, and the maximum quantity and number of repeats for each item.

Emergency drug supplies are also listed at the beginning of this section.

Any medicines that have restrictions on how they can be prescribed are printed in ***bold italics***. Items appearing in more than one therapeutic group are cross-referenced.

The second page of Section 2 explains symbols used throughout the Schedule.

The use of 'NOTE' in this section is used to clarify how some pharmaceutical benefits should be prescribed.

The use of 'CAUTION' is to warn of known adverse reactions from, or precautions to be taken with, a particular pharmaceutical benefit. (The absence of a cautionary note does not imply reactions may not happen.)

Separate lists at the end of Section 2 relate to items that can be prescribed by dentists and optometrists who work within the PBS. These are followed by a list of items that are made available under special arrangements for doctors to prescribe.

Section 3

This section lists container prices, fees related to dispensing, standard packs and prices for ready-prepared preparations.

Section 4

This section deals with extemporaneous preparations. It lists the ingredients which can be used, a table of maximum quantities and number of repeats, container prices, and a list of standard formula preparations and prices (based on formularies in common use and referred to in the Schedule as the Standard Formulae List).

Restrictions applying to the use of a pharmaceutical benefit are indicated against the item.

Repatriation Schedule of Pharmaceutical Benefits

After Section 4, the Schedule provides information about pharmaceutical benefits under the RPBS. These may only be prescribed to DVA beneficiaries holding one of the repatriation health cards (see details under '4. Patient Charges').

2. Prescribing Medicines – Information for PBS Prescribers

PBS prescribers

Pharmaceutical benefits can only be prescribed by doctors, dentists, optometrists, midwives and nurse practitioners who are approved to prescribe PBS medicines under the *National Health Act 1953*.

PBS Prescription forms

Standard PBS prescription forms are available from Medicare Australia for prescribing pharmaceutical benefits.

For doctors:

- *Personalised forms* — are printed with the doctor's name, qualifications, practice address/es, telephone number and prescriber number (which relates to pharmaceutical benefits). They are only provided to doctors who have a Medicare provider number.
- *Non-personalised (blank) forms* — are distributed as an emergency supply (usually when a doctor has temporarily run out of personalised forms).
- *Locum forms* — have the doctor's name, prescriber number and telephone number (if available) and a space to record the practice where the doctor is working.
- *PBS/RPBS Authority Prescription Forms* — can be in personalised, non-personalised or locum format.
- *Computer PBS prescription forms* — are either continuous or single sheet. On the reverse side they list the name, address and telephone number of the practice, and in the case of a sole doctor practice, the doctor's name.

For dentists:

- *Personalised forms* — have the dentist's name, qualifications, practice address/es, telephone number and prescriber number.
- *Non-personalised (blank) forms* — are distributed for emergency supply only.

For optometrists:

- *Personalised forms* — have the optometrist's name, qualifications, practice address/es, telephone number and prescriber number. These forms can be also be used to prescribe authority-required PBS/RPBS items.

For midwives:

- *Personalised forms* — have the midwife's name, qualifications, practice address/es, telephone number and prescriber number.
- *Non-personalised (blank) forms* — are distributed for emergency supply only.

For nurse practitioners:

- *Personalised forms* — have the nurse practitioner's name, qualifications, practice address/es, telephone number and prescriber number.
- *Non-personalised (blank) forms* — are distributed for emergency supply only.

PBS prescription forms for PBS prescribers are supplied free of charge.

The inclusion of the prescriber number on a PBS prescription enables the pharmacist to be sure the prescription is from a legitimate prescriber and satisfies State/Territory legislation. A PBS prescription written by a dentist, an optometrist, a midwife or a nurse practitioner must include the person's approval number as a PBS prescriber.

PBS prescriptions should be provided to the patient in duplicate, as both parts make up a valid PBS prescription. The patient should be reminded to present both the original and the duplicate copy to the pharmacist.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment within a participating public hospital may prescribe PBS subsidised medication. The States of Victoria, Queensland, South Australia and Western Australia, and the Northern Territory have agreed to implement these arrangements.

Ordering forms

Prescribers are asked not to over order. Getting the right amount of forms helps to reduce the cost to taxpayers and helps to reduce paper wastage. Also, the pads may deteriorate if stored over time.

Order forms for standard and authority PBS prescription forms are available from Medicare Australia stationery officers. Contact details are listed in the front of the Schedule. Order forms for computer PBS prescription form stationery are obtained from Medicare Australia (at the address below). Orders should be sent to:

Prescription Pad Order Clerk
Pharmaceutical Branch
Medicare Australia
GPO Box 9826
Sydney NSW 2001
Telephone (02) 9895 3295

Orders for PBS prescription stationery will only be accepted by application in writing and through the channels mentioned above.

Preparing general PBS prescriptions

Do's and Don't's

A PBS prescription is only valid when it is written by a doctor, a dentist, an optometrist, a midwife or a nurse practitioner.

The PBS prescription must be for the treatment of the person named on the PBS prescription. A PBS prescription may only be written for the treatment of one person.

A prescriber cannot write more than one PBS prescription for the same pharmaceutical benefit for the same person on the same day.

Up to **three** pharmaceutical benefit items may be included on a single PBS prescription form except for Authority required, Authority required (STREAMLINED) items and optometrist items. These items must be written on individual forms. Pharmaceutical benefits and non-pharmaceutical benefits should not be listed together on the one PBS prescription form.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment within a participating public hospital may prescribe PBS subsidised medication. The States of Victoria, Queensland, South Australia and Western Australia, and the Northern Territory have agreed to implement these arrangements.

If an item has a particular manner of administration it may not, as a pharmaceutical benefit, be administered in any other way, e.g., an ophthalmic preparation may not be prescribed for topical use.

If an item is restricted, and the use for the patient is different from the use specified in the restriction, it cannot be prescribed as a pharmaceutical benefit. The prescriber should write the prescription as a non-PBS private prescription. If a standard PBS prescription form is used for this purpose the 'PBS/RPBS' text must be clearly struck out. It should also be endorsed 'non-PBS'.

Prescribers must heed State/Territory laws when prescribing drugs listed as narcotic, specified or restricted in the poisons legislation of the particular State or Territory. Legislative requirements in some States/Territories are such that prescribers may be required to prescribe a drug of addiction on a separate PBS prescription. Prescribers must ensure that prescriptions written under the PBS fall within the limits of the prescribing approval granted to the person under State or Territory requirements. It is the prescriber's responsibility to ensure that PBS prescriptions comply with all aspects of his/her prescriber approval. Inclusion of a PBS medicine for prescribing does NOT confer approval for a particular prescriber to prescribe that medicine if it is not authorised to be prescribed in a particular State or Territory.

A prescriber cannot prescribe a narcotic drug for him/herself.

Prescribers are issued with individual PBS prescription pads by Medicare Australia for their own use — these pads should not be used by other prescribers, as this can cause confusion through incorrect pharmacy records.

Doctors should, and dentists and optometrists, midwives and nurse practitioners are required to, include their prescriber number on non-personalised PBS prescriptions.

The following admixtures are not pharmaceutical benefits:

- the admixture of two or more ready-prepared items listed in the Schedule; or
- the admixture of a ready-prepared item and one or more extemporaneous drugs listed in Section 4 of the Schedule; or
- the admixture of a non-pharmaceutical benefit item with a pharmaceutical benefit item.

Writing the PBS prescription

The following rules apply for writing PBS prescriptions:

- they must be written in indelible form (i.e., ink or ball-point pen) in the prescriber's own handwriting (exceptions must be approved by Medicare Australia's Chief Executive Officer) either on the standard PBS prescription, or on paper approximately 18 cm x 12 cm,

or they can be generated by computer on a form approved by Medicare Australia. For patient safety reasons, both the original and the duplicate must be legible;

- they must record the prescriber's name and address (and, in the case of dentists, optometrists, midwives and nurse practitioners, the prescriber number), the patient's name, address and entitlement status, and whether the prescription is under the PBS or RPBS;
- they should completely identify the pharmaceutical benefit by detailing the item, dose, form, strength, quantity and instructions for use;
- they should indicate where brand substitution is not permitted. PBS prescriptions must not be prepared using a computer prescribing program that contains a default which would result in all prescriptions being indicated as Brand Substitution Not Permitted;
- where 'solvent required' is included after the form, the volume and number of ampoules must be specified; and
- they must be signed by the prescriber and dated. Forward or back dating is not permitted.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment within a participating public hospital may prescribe PBS subsidised medication. The States of Victoria, Queensland, South Australia and Western Australia, and the Northern Territory have agreed to implement these arrangements.

Restrictions

Pharmaceutical benefits listed in the Schedule fall into three broad categories:

Unrestricted benefits - have no restrictions on their therapeutic uses;

Restricted benefits - can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and

Authority required benefits - Authority required benefits fall into two categories:

- *Authority required benefits* are restricted benefits that require prior approval from Medicare Australia or the DVA (noted as **Authority required**)
- *Authority required (STREAMLINED) benefits* are restricted benefits that do not require prior approval from Medicare Australia or the DVA but require the recording of a streamlined authority code (noted as **Authority required (STREAMLINED)**).

Authority PBS prescriptions

Authority required benefits fall into two categories - *Authority required* and *Authority required (STREAMLINED)*.

All PBS prescribers (with the exception of dentists) can write authority PBS prescriptions.

Authority PBS prescriptions cannot have retrospective approval.

Authority required PBS Prescriptions

Approval of authority PBS prescriptions by Medicare Australia may be sought by:

- posting an Authority Prescription Form to Medicare Australia - after approval, Medicare Australia will forward both copies of the prescription to the patient or the prescriber (if it is to be sent direct to the patient, the prescriber should mark the box next to the patient's details);
- calling Medicare Australia Authority Freecall service (1800 888 333); or
- using Medicare Australia PBS authorities website at www.medicareaustralia.gov.au/providers.

Approval of authority prescriptions by the DVA may be obtained either by posting an Authority Prescription Form to the DVA, or by using the DVA Authority Freecall service (1800 552 580).

An authority PBS/RPBS prescription is not valid until it has been approved by Medicare Australia or the DVA. Without this approval, a pharmacist must not supply the item as a PBS/RPBS benefit.

Each Authority required PBS/RPBS item must be written on an Authority PBS/RPBS prescription form, one item per form. Authority PBS prescription forms provide for the following:

- the patient/pharmacist copy, which records prescriber, patient, and pharmaceutical benefit item details. Where required a repeat authorisation, which is used for repeat supply, is attached to the pharmacist/patient copy until the last supply is made. The patient/pharmacist copy is then retained by the pharmacist;
- the Medicare Australia/DVA copy which records prescriber, patient, and pharmaceutical benefit item details. After the first dispensing, the Medicare Australia/DVA copy is forwarded to Medicare Australia for processing and payment;
- the prescriber's copy (for computer generated scripts, this is the tear off portion at the base of the script) or Prescriber/Medicare Australia/DVA copy (for handwritten scripts this is the long white copy), is kept by Medicare Australia or the DVA for record purposes when approval is sought in writing. When approval is by telephone or by the authorities website, the prescriber must keep this copy

for 12 months. This copy must record the daily dose, details of the disease, clinical justification for using the item, the patient's age (if the patient is a child) and whether the patient has previously received an authority for this pharmaceutical benefit.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment within a participating public hospital may prescribe PBS subsidised medication. The States of Victoria, Queensland, South Australia and Western Australia, and the Northern Territory have agreed to implement these arrangements.

Authority required (STREAMLINED) PBS Prescriptions

Prior approval is not required from Medicare Australia or DVA to prescribe an Authority required (STREAMLINED) item (except where increased quantities and/or repeats are required). Instead the authority prescription form must include a four digit streamlined authority code.

This code is listed with the corresponding restriction for each Authority required (STREAMLINED) item and the prescriber must write the code on the authority PBS/RPBS prescription form. An authority prescription for an Authority required (STREAMLINED) item is not valid unless the code is included on the prescription form. Without the streamlined authority code, a pharmacist must not supply the item as a PBS benefit.

There are no Authority Required (STREAMLINED) items in the Repatriation Schedule of Pharmaceutical Benefits.

Authority required (STREAMLINED) PBS prescriptions must be written on an Authority PBS/RPBS Prescription Form, this includes:

- the pharmacist/patient copy, which records prescriber, patient, and pharmaceutical benefit item details. The prescription is given directly to the patient to be dispensed at their pharmacy;
- the Medicare Australia/DVA copy which records prescriber, patient, and pharmaceutical benefit item details. After the first dispensing, the Medicare Australia/DVA copy is forwarded to Medicare Australia for processing and payment;
- the prescriber's copy is kept by the prescriber for 12 months. This copy must record the daily dose, details of the disease, clinical justification for using the item, the patient's age (if the patient is a child) and whether the patient has previously received an authority for this pharmaceutical benefit.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment within a participating public hospital may prescribe PBS subsidised medication. The States of Victoria, Queensland, South Australia and Western Australia, and the Northern Territory have agreed to implement these arrangements.

Writing authority PBS prescriptions

The following rules apply:

- only one item may be prescribed per PBS prescription;
- PBS prescriptions must be completed by prescribers in writing, unless otherwise approved by Medicare Australia;
- prescribers should include their name, address, telephone number and **prescriber number** (not provider number);
- prescribers must include the patient's name, address and entitlement status (i.e. whether they are a 'concessional' or 'general patient');
- prescribers must indicate when brand substitution is not permitted. PBS prescriptions must not be prepared using a computer prescribing program that contains a default which would result in all PBS prescriptions being indicated as Brand Substitution Not Permitted;
- in certain circumstances, the prescriber must provide additional information to Medicare Australia with the authority application; and
- the PBS prescription must be signed by the prescriber and dated.

Posted applications which lack necessary information, and therefore cannot be approved, will be returned for correction. If the matter can be clarified via telephone, an Authority to Prescribe Form may be prepared by Medicare Australia or the DVA and sent to the prescriber.

In the case of authority PBS prescriptions approved by telephone, the approval number must be included on the PBS prescription to enable the pharmacist to supply the medication. A prescriber who is granted approval but decides not to continue with the therapy should advise Medicare Australia.

In the case of Authority required (STREAMLINED) prescriptions, the streamlined authority code must be written on the PBS/RPBS prescription form. This enables the pharmacist to supply the medication as a PBS benefit.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment within a participating public hospital may prescribe PBS subsidised medication. The States of Victoria, Queensland, South Australia and Western Australia, and the Northern Territory have agreed to implement these arrangements.

Maximum quantities and repeats

The maximum quantity and number of repeats allowed for PBS items are recommended by the Pharmaceutical Benefits Advisory Committee (PBAC). In the case of RPBS items, the recommendations are made by the Repatriation Pharmaceutical Reference Committee (RPRC).

All PBS prescribers (with the exception of dentists) can prescribe repeats.

PBS prescriptions and repeats can be for any quantity up to the maximum. It is not necessary to prescribe the maximum quantity if a lesser quantity is sufficient for the patient's needs. Please clearly indicate the number of tablets, capsules, etc. required and the number of repeats needed, and **do not use** abbreviations such as 'Max. Qty', 'M.Q.', or 'M.R.'.

If a prescriber feels the maximum quantity or number of repeats should be increased for a particular patient, he or she must complete an Authority PBS Prescription Form (see procedures above under 'Authority PBS Prescriptions'). The provision of increased quantities and repeats on authority PBS prescriptions is intended to provide approximately one month's therapy which may be repeated (if clinically appropriate) to provide 6 months' therapy in total. This situation usually arises where higher than normal dosages are required.

Approval for increased quantities and repeats of Authority required, Authority required (STREAMLINED) and Restricted benefit PBS items will be granted only where the reason for the PBS prescription is consistent with the indications published in the Schedule.

Approval for increased quantities and repeats extends only to the provision of a pharmaceutical benefit for the patient and does not imply approval of any aspects of the patient's care, which are the responsibility of the treating prescriber.

Regulation 24

Under this regulation, original and repeat supplies of pharmaceutical benefits can be supplied at the one time if a medical practitioner, a midwife or a nurse practitioner is first satisfied that certain conditions apply, then endorses the PBS prescription 'Regulation 24'. RPBS prescriptions may be endorsed 'hardship conditions apply'.

The medical practitioner, midwife or nurse practitioner must first be satisfied all the following conditions apply:

- the maximum PBS quantity is insufficient for the patient's treatment; **AND**
- the patient has a chronic illness or lives in a remote area where access to PBS supplies is limited; **AND**
- the patient would suffer great hardship trying to get the pharmaceutical benefit on separate occasions.

Regulation 24 does not apply for supply of pharmaceutical benefits on optometrist prescriptions.

Urgent cases

In urgent cases and where State/Territory law allows, a prescriber may telephone a pharmacist and ask that a PBS prescription be supplied. He/she must then forward the written PBS prescription and duplicate to the pharmacist within **seven days of the date of supply**.

This also applies to 'Authority required' authority PBS prescriptions provided prior approval has been given by Medicare Australia or DVA. The follow-up written PBS prescription must include the approval number provided over the phone by Medicare Australia or DVA.

Drugs of addiction

Prescribers must heed State/Territory laws when prescribing drugs listed as narcotic, specified or restricted and must notify, or receive approval from, the appropriate health authority.

When a PBS/RPBS authority application is for a drug of addiction (other than dexamphetamine sulfate), the following guidelines apply:

- the maximum quantity authorised is generally for one month's therapy (e.g., one week's therapy with three repeats);
- where supply for a longer period is warranted, quantities are usually for up to three months' therapy;
- telephone approvals are limited to one month's therapy.

Prescribers should also state the interval of repeat where repeats are called for, and ensure State/Territory health authorities are notified about ongoing treatment.

Emergency drug supplies

Certain pharmaceutical benefits are provided without charge to prescribers who in turn can supply them free to patients for emergency use.

The Emergency Drug Supply Order Form must be completed in triplicate, signed, and the original and duplicate given to a pharmacist. Each form is valid for the month indicated on the form.

Prescribers may order the maximum quantity of an item provided they do not already have the maximum quantity on hand. The items can only be obtained once a month. Prescribers may also ask for a particular brand of a pharmaceutical benefit. If it is unavailable, they must specify another listed brand, and initial the alteration.

A receipt must be signed by the prescriber, or by an authorised representative, when supplies are received.

Availability of Methoxyflurane for emergency treatment only

A new Emergency Treatment Program (ETP) for medical practitioners has been established to provide for medicines such as Methoxyflurane to be supplied as items for emergency treatment, other than hospital treatment. Unlike other emergency drug supplies, Methoxyflurane, liquid for inhalation 999.9 mg per g, 3 mL (with inhaler) (*Penthrox*[®]) is not available for prescribing as a general pharmaceutical benefit.

Methoxyflurane is therefore PBS-listed as a 'special pharmaceutical product' under section 100AA, only for emergency treatment, other than hospital treatment. As such, the availability of this drug is provided for under special arrangements under section 100 (1) of the *National Health Act 1953*. The legislative instrument can be viewed on the Federal Register of Legislative instruments at www.frli.gov.au.

For the purposes of administration, Methoxyflurane will be listed with other emergency drug supplies, as outlined above, and be managed by Medicare Australia in the same manner as other emergency drug supply items with the same supply and claiming procedures.

Improving the capacity of the PBS to meet particular Aboriginal and Torres Strait Islander health needs

The PBS includes listings to support the treatment of conditions common in Aboriginal and Torres Strait Islander health settings. These listings are specifically for your patients who identify as Aboriginal and/or Torres Strait Islander persons. Some listings will be medicines recently added to the PBS; others may contain specific restrictions for existing PBS items.

A significant proportion of the higher levels of illness experienced by Aboriginal and Torres Strait Islanders may be addressed through better access to appropriate medicines. The PBS aims to provide greater choice in therapeutic options and to address:

- the greater burden of disease experienced by Aboriginal and Torres Strait Islander peoples; and
- morbidity almost exclusively seen in this population.

How to prescribe these items?

These items are available as "Authority PBS prescriptions". You should obtain approval from Medicare Australia before prescribing these items for patients who identify as Aboriginal and/or Torres Strait Islander persons through the Authority Freecall service [1800 888 333], on line or by mail.

All PBS prescribers except dentists can write Authority PBS prescriptions and your patients will be required to pay their normal PBS co-payment.

Special arrangements apply in remote area Aboriginal Health Services for supplying these PBS items.

Aboriginal and Torres Strait Islander identification

Establishing a client's background may have clinical significance and should be part of routine medical history taking. In the case of Aboriginal and Torres Strait Islander people, this is also relevant to establish eligibility for services such as health checks, specific immunisation programs, and the some PBS items.

Improving the level of identification of Aboriginal and Torres Strait Islander people will also assist in developing initiatives to meet particular needs.

For the purposes of these PBS items a person is Aboriginal and/or Torres Strait Islander if the person identifies himself or herself as being an Aboriginal and/or Torres Strait Islander. Clients should be asked to self-identify either verbally or by completing a form.

- Some people may give this information without being asked.
- It is important not to assume that a person is or is not Aboriginal or Torres Strait Islander.

Asking about Aboriginal and/or Torres Strait Islander identification

Practitioners should ensure that each person attending their practice has the opportunity to identify if they are Aboriginal or Torres Strait Islander. An environment which maintains confidentiality and provides an explanation for this question if requested will assist this process.

- The inquiry may be made verbally and recorded by the general practitioner as part of routine medical history taking at first consultation, or by a receptionist or other staff member. An appropriate question to ask is:
"Are you (is this child) of Aboriginal or Torres Strait Islander origin?"
- Alternatively, the question may be included on a client self-history or practice record form, using a standard question such as:
"Are you (is this child) of Aboriginal or Torres Strait Islander origin?"
 - Yes - Aboriginal
 - Yes - Torres Strait Islander
 - Yes - Aboriginal and Torres Strait Islander
 - No

Aboriginal and Torres Strait Islander health

Major causes of excess mortality in Aboriginal and Torres Strait Islander peoples are:

- circulatory conditions (including ischaemic heart disease, hypertension, cerebrovascular disease and rheumatic heart disease);
- external causes (including accident and injury);
- endocrine causes (mainly type two diabetes and its complications); and
- respiratory conditions.

Causes of morbidity vary but include the risk factors and precursors of all of these. They also include infections of the respiratory system, the ears (in particular, chronic suppurative otitis media), the eyes (trachoma in some settings), the skin and the gastrointestinal system. End-stage renal disease is a major cause of hospitalisations, and much early renal disease remains undetected. In some settings, sexually transmissible infections are common.

Living environments affect health and may be compromised by overcrowding, limited access to clean water and sanitation, and poverty. Social and family life may be negatively influenced by an excessive burden of care for family members, by substance use and sometimes by family violence.

Communication and cultural issues

Aboriginal cultures are numerous and diverse in language, customs, non-verbal and verbal communication, geographical locations and experiences. Torres Strait Islanders are a separate people with a distinctly different culture and identity. Aboriginal and Torres Strait Islander people often perceive health differently from other Australians.

For Aboriginal and Torres Strait Islander peoples' health does not just entail the freedom of the individual from sickness but requires support for healthy and interdependent relationships between families, communities, land, sea and spirit. The focus must be on spiritual, cultural, emotional and social well-being as well as physical health

Source: National Aboriginal and Torres Strait Islander Health Council. National Strategic Framework for Aboriginal and Torres Strait Islander Health 2003-2013, Context. Canberra: Commonwealth of Australia; 2004.

To provide effective primary health care to Aboriginal and Torres Strait Islander clients, you need to be aware of the issues surrounding this diversity, and which may have an impact on the delivery of services.

- Aboriginal and Torres Strait Islander people may be reluctant to use mainstream medical services. This may be because of a lack of understanding of the mainstream health system and previous negative experiences within the mainstream health care system.
- Access to adequate health care may be hindered by family obligations (often extended family), lack of transport or money, or geographical isolation.
- English may be the person's second, third or even fourth language. Therefore it may be appropriate to consider the use of an interpreter.
- Aboriginal and Torres Strait Islander people may be reluctant to consult a health care provider of the opposite sex, particularly with regard to women's and men's health issues.

The differences between the cultural and language backgrounds of health service providers and patients, whether urban, rural or remote, may range from minor to extreme.

You should:

- Make efforts to ensure waiting rooms are welcoming to Aboriginal and Torres Strait Islander people, including displaying relevant posters and pamphlets;
- Provide a relaxed setting for the consultation (e.g. sit next to your patient rather than across a desk);
- Allow time at the first consultation to build rapport and trust;
- Ensure the person understands clearly what the service entails and the details of any procedures involved, and possible follow-up or referral requirements;
- Obtain health promotion information appropriate for Aboriginal and Torres Strait Islander patients;
- Allow the patient to have family members present if desired. When inviting family or community members to accompany a patient, ensure the patient fully consents to their attendance and that the community/family members are fully aware of the need for confidentiality;
- Provide gender appropriate staff where possible, for both male and female patients, especially in regard to pap smears, mammograms, sexual health checks, pregnancy checks, antenatal care and postnatal care;
- Encourage all staff in the practice to attend Aboriginal and Torres Strait Islander Cultural Awareness programs, which are widely available;
- Ensure practice staff have awareness of appropriate referral and/or support organisations for Aboriginal and Torres Strait Islander patients; and
- Develop partnerships with local Aboriginal and Torres Strait Islander community organisations.

For more information, pbs-indigenous@health.gov.au

3. Supplying Medicines — What Pharmacists Need to Know

Eligible suppliers

Pharmaceutical benefits are mainly supplied by approved pharmacists – pharmacists who comply with certain conditions. These pharmacists are approved to dispense pharmaceutical benefits from a particular pharmacy.

Other suppliers include approved doctors (usually practising in isolated areas), Friendly Society pharmacies, and approved hospitals. All suppliers are issued with approval numbers by Medicare Australia. They should follow the procedures in these Explanatory Notes.

Unapproved pharmacists *cannot* supply pharmaceutical benefits.

Approval conditions for pharmacists

A pharmacist approved to supply medicines under the PBS:

- can only supply benefits from the pharmacy that he/she is operating;
- will not supply to anyone any pharmaceutical benefit that attracts a Commonwealth contribution for free, or for a price that is less than the relevant patient contribution;
- will clearly advertise that any offer for free or cut-price medicines does not include pharmaceutical benefits which have a Commonwealth contribution;
- will not pay rebates or refunds of patient contributions;
- will publicly display a notice setting out the pharmacy's normal trading hours;
- is obliged to supply pharmaceutical benefits at the pharmacy at any hour if a PBS prescription is marked 'urgent' and initialled by the prescriber;
- will keep adequate stocks for the supply of pharmaceutical benefits;
- may be called on by Medicare Australia to provide details of stocks of pharmaceutical benefits or preparations for pharmaceutical benefits; and
- must keep the duplicates of all old format PBS prescriptions, and the patient/pharmacist copies of all new format PBS prescriptions, with a Commonwealth contribution for at least one year from the date of supply. This includes PBS prescriptions ordering repeats when it is the final supply, and order forms for emergency drug supplies. Please note that some State/Territory laws require these copies to be kept for longer periods.

Before supplying pharmaceutical benefits

Several steps must be taken before a pharmaceutical benefit is supplied.

Firstly, a pharmacist must endorse the PBS prescription and duplicate with his/her name and approved supplier number.

Secondly, a PBS prescription identifying number must be given to the PBS prescription item on both the PBS prescription and duplicate. Any recognised series of numbers may be used.

If more than one item is on a PBS prescription, a separate identifying number should be allocated to each item.

In the case of a repeat authorisation, the same PBS prescription identifying number(s) must be carried through for each item. A pharmacist must also allocate his/her own identifying number on the repeat authorisation. It must be written alongside the date and place of supply.

Supplying pharmaceutical benefits

Do's and Don'ts

Except in urgent cases (see details under '2. Prescribing Medicines ... Urgent cases'), pharmacists are authorised to supply pharmaceutical benefits only after they receive:

- the pharmacist/patient and Medicare Australia or DVA copies of a valid PBS prescription which is not more than 12 months old; or
- the pharmacist/patient and Medicare Australia or DVA copies of an approved authority PBS prescription or an authority to prescribe which is not more than 12 months old; or
- a repeat authorisation attached to a patient/pharmacist PBS prescription not more than 12 months after the date of the original PBS prescription.

A pharmacist must not supply an Authority required (STREAMLINED) item unless the prescriber has written the four digit streamlined authority code on an authority PBS/RPBS prescription.

A pharmaceutical benefit cannot be supplied more times than specified in the PBS prescription.

A pharmacist cannot add to, delete from, or alter a PBS prescription in any other way. However, there may be circumstances where after contacting a prescriber, the pharmacist can clarify the prescriber's intentions and endorse the PBS prescription accordingly.

Once a pharmaceutical benefit has been supplied to a patient, it may not be supplied to that patient again:

- on the same day or within the next 20 days, if it is a benefit (other than an eye preparation) that has five or more repeats allowed in the Schedule; or
- on the same day or within the next four days (e.g., if a pharmaceutical benefit is supplied on a Monday, it cannot be supplied again to that patient until the next Saturday) in the case of other benefits.

Exceptions to this are:

- when a PBS prescription is endorsed with the words 'Regulation 24' or 'hardship conditions apply' (see below under 'Regulation 24'); and
- If a pharmacist believes a repeat supply is needed without delay for the treatment of the person, or a previous supply has been destroyed, lost or stolen. In this case, the pharmacist can provide another supply but must write 'immediate supply necessary' and sign the PBS prescription.

A pharmacist can supply an alternative pharmaceutical benefit without reference to the prescriber, provided that:

- the PBS prescription does not indicate that only the pharmaceutical benefit prescribed is to be supplied (ie substitution is not permitted); and
- the Schedule states that the prescribed benefit and the substitute benefits are equivalent; and
- supply of the substitute benefit does not contravene relevant State/Territory law; and
- the substitute benefit is a listed brand in the Schedule.

Pharmacists must heed State/Territory laws when supplying drugs listed as narcotic, specified or restricted in legislation of the particular State or Territory.

What to do if the Schedule changes

If an item or brand is deleted from the Schedule, it *cannot* be supplied as a pharmaceutical benefit from the date the deletion takes effect – regardless of whether the PBS prescription was written before this date. This includes repeat authorisations. (Special conditions applying to RPBS prescriptions are detailed in the RPBS Explanatory Notes.)

However, if restrictions on the prescribing of a pharmaceutical benefit change, or the maximum quantity or number of repeats is altered in the Schedule, valid PBS prescriptions written before the date of effect of the change *may* still be supplied as pharmaceutical benefits, under the conditions applying at the date of prescribing.

Suspected forgery

Pharmacists should take all reasonable steps to satisfy themselves that all items on a PBS prescription were written by a medical practitioner, a dentist, an optometrist, a midwife or a nurse practitioner.

Regulation 24

This regulation allows pharmacists to supply a pharmaceutical benefit and all of its repeats at the one time.

The PBS prescription must be endorsed by the medical practitioner, midwife or nurse practitioner with the words 'Regulation 24' if it is an item under the PBS, or 'hardship conditions apply' if it is being supplied under the RPBS. (For more information see under '2. Prescribing Medicines ... Regulation 24'). Regulation 24 does not apply for supply of pharmaceutical benefits on optometrist prescriptions.

Repeat authorisations

When a PBS prescription calls for repeat supplies, the pharmacist shall prepare a Repeat Authorisation Form, except when the PBS prescription is marked 'Regulation 24'.

The repeat may be requested on a standard PBS prescription, an authority PBS prescription or an Authority to Prescribe Form, or on an earlier repeat authorisation. In the latter case, it must come with the duplicate PBS prescription, or in the new format, the "patient/pharmacist copy".

Preparing Repeat Authorisation Forms

A Repeat Authorisation Form must show:

- the category of benefit (concession or general) – by placing a cross (x) in the relevant box;
- the patient's name and full address;
- in the case of repeats authorised on authority PBS prescriptions, the authority prescription number;
- details of the original PBS prescription stating the item, form, strength, quantity and directions;
- if substitution has occurred, the name of the brand actually supplied;

- for the first supply, the pharmacy name, address and approval number, the date of the original PBS prescription and the allotted PBS prescription identifying number;
- for subsequent supplies, the pharmacy approval number, and the date and PBS prescription number of the original prescription;
- the number of times the item is to be repeated and the number of times it has been supplied;
- the name and pharmacy approval number of the pharmacist issuing the repeat authorisation; and
- the date of supply.

When a repeat authorisation is prepared for any further repeats or deferred supply, a pharmacist must attach the duplicate copy of an old format PBS prescription, or the patient/pharmacist copy of a new format PBS prescription, and give both to the patient at the time of supply.

Repeat authorisations for injectables and solvents

Where an injectable pharmaceutical benefit requires a solvent, both items should be treated as one pharmaceutical benefit. If repeats are needed, only one repeat authorisation is to be prepared. Details of the injectable and the solvent should appear in the space provided for the 'original prescription transcription'.

Repeat authorisations for deferred supply

When a PBS prescription orders a number of pharmaceutical benefit items, but the patient does not need all of the items at the same time, a separate repeat authorisation for each deferred item must be prepared. The words 'original supply deferred' should be indicated across the relevant item on the original PBS prescription, its duplicate, and on the repeat authorisation.

Deferred items must not be claimed on the original PBS prescription.

The Repeat Authorisation Form when it is used for a deferred supply, is issued in the same way as normal repeat authorisations except that:

- '0' is to be inserted in the space for 'no. of times already dispensed'; and
- if no repeats are ordered, '0' is to be inserted in the space for 'no. of repeats authorised'.

Supplying a benefit on a deferred supply repeat authorisation is to be treated as if it is the first time of supply. If repeats are directed, the normal procedure for repeat authorisations applies. Details of the pharmacy at which the deferred supply was authorised are to be written onto subsequent repeat authorisations.

Authority PBS prescriptions

If a pharmacist is presented with an authority PBS prescription and is not sure if it has been approved, he or she should contact Medicare Australia. Please note that Medicare Australia will not provide clinical information.

If the authority PBS/RPBS prescription is for an Authority required (STREAMLINED) item the pharmacist should ensure that the prescriber has written the four digit streamlined authority code on the prescription, this enables the pharmacist to supply the item as a PBS benefit.

The pharmacist is required to include the four digit streamlined authority code on the claim for the PBS dispensing.

Urgent cases

In urgent cases and where State/Territory law allows, pharmacists can supply a pharmaceutical benefit to a person without a PBS prescription, provided details of the prescription are given by the prescriber via telephone or other means. The prescriber must then forward the written PBS prescription and duplicate to the pharmacist within **seven days of the date of supply**.

Where a pharmaceutical benefit needs prior approval from Medicare Australia or the DVA, the prescriber must obtain approval and then advise the pharmacist of the PBS prescription and approval details. Only an original supply can be provided in this manner, not repeats.

Receipts

A person receiving a pharmaceutical benefit item must sign and date a receipt for it. If the person is not the patient, that person must also endorse the PBS prescription or repeat authorisation with his/her address. A receipt cannot be obtained until supply of the benefit has been made.

If a pharmaceutical benefit has to be sent through the post, by rail, or by other means, and a receipt is not practical, the pharmacist must certify on the PBS prescription or repeat authorisation that the benefit has been supplied, and write the date of supply and details of how it was sent. For example, if a pharmaceutical benefit is mailed to a patient on 1 April 2008, the pharmacist should write: "Certified supplied – mailed to patient 1 April 2008 (name of pharmacist) (signature of pharmacist) (date of certification)".

If an item is supplied in an urgent case, or to a person who cannot read or write, the pharmacist should sign and date a statement on the PBS prescription or repeat authorisation, stating the item has been supplied and the date on which it was supplied, and explaining why there is no receipt. For example, if a pharmaceutical benefit is supplied to a patient with a broken arm on 1 May 2008, the pharmacist should write: "Certified supplied 1 May 2008 – patient has a broken arm and is unable to sign (name of pharmacist) (signature of pharmacist) (date of certification)".

Only the pharmacist approved to supply pharmaceutical benefits can certify supply.

Emergency drug supplies

Pharmacists may supply certain pharmaceutical benefit items free of charge to medical practitioners or other authorised prescribers for emergencies if they receive an Emergency Drug Supply Order Form in duplicate, signed by the medical practitioners or other authorised prescriber.

Pharmacists must be satisfied the form was completed by a medical practitioner or other authorised prescribers and includes the medical practitioner's or other authorised prescriber's name and address. If a pharmacist does not know the medical practitioner or other authorised prescriber, he/she should confirm the medical practitioner's or other authorised prescriber's registration and endorse this on the back of the form.

For more information about emergency supplies see under 2. Prescribing Medicines ... Emergency drug supplies'.

4. Patient Charges

Type of patient

There are two types of PBS beneficiaries, general patients, who hold a Medicare card and concessional patients who hold a Medicare card and one of the following:

- Pensioner Concession Card
- Commonwealth Seniors Health Card
- Health Care Card
- Repatriation Health Card for All Conditions (gold) — concessional patients under RPBS
- Repatriation Health Card for Specific Conditions (white) — only regarded as concessional patients for RPBS prescriptions unless they hold a separate entitlement from Centrelink, otherwise they are general patients
- Repatriation Pharmaceutical Benefits Card (orange) — concessional patients under RPBS
- Safety Net Concession Card or Safety Net Entitlement Card — issued by Medicare Australia.

Concessional patients are recognised by public hospitals in all States and Territories apart from South Australia (where DVA beneficiaries are treated as general patients) and New South Wales (where holders of a white DVA card are treated as general patients).

Under the Reciprocal Health Care Agreements, visitors from participating countries (see the introduction of this section for the list of countries) are treated as general patients and do not have concessional entitlements. To receive pharmaceutical benefits these visitors may need to present a temporary Medicare card or their passport. Pharmacists should contact Medicare Australia if they have enquiries about these arrangements.

Establishing entitlement

PBS prescription forms supplied by Medicare Australia have spaces provided for details of a patient's entitlement status. Anyone can enter this information, which must include:

- a cross (x) in the appropriate box to indicate the level of patient contribution;
- the complete Medicare number (including individual reference number) or complete Veteran file number on the card; and
- if applicable, the complete concession number on the card.

The person who signs the receipt for pharmaceutical benefits also accepts responsibility for the validity of the entitlement information on the PBS prescription.

All PBS prescriptions must have a Medicare or Veteran file number. All concessional PBS prescriptions must have a concession number. However, it is not necessary for the Medicare (Veteran file) or the concession number to be endorsed on the PBS prescription if it is included in the electronic prescription details supplied by a pharmacist who is using the Claims Transmission System.

What to charge

Patient contribution

Under the PBS, the maximum cost for a pharmaceutical benefit item at a pharmacy is \$35.40 for general patients and \$5.80 for concessional patients, plus any applicable special patient contribution, brand premium or therapeutic group premium. General patients who have reached the safety net threshold (see details under '5. The Safety Net Scheme') may receive pharmaceutical benefits at the concessional rate, plus any applicable special patient contribution, brand premium or therapeutic group premium.

Patients who have a Safety Net Entitlement Card (see details under '5. The Safety Net Scheme') may receive PBS items free of charge, except for any applicable special patient contribution, brand premium or therapeutic group premium.

The contribution rate for general patients as outpatients at public hospitals in most of Australia is \$28.30. The exceptions are in Queensland and in hospitals participating in the pharmaceutical reforms where they pay the safety net value of an item listed in the Schedule (see details

under '5. The Safety Net Scheme'), or up to the general co-payment amount for items not listed in the Schedule. The public hospital pharmaceutical reforms enable participating public hospitals to prescribe and supply pharmaceutical medication from the PBS to outpatients and patients upon discharge. A range of chemotherapy drugs is also available for day-admitted and non-admitted chemotherapy patients.

The contribution rate for concessional patients in all public hospitals is equal to the concessional co-payment amount.

The supply of a pharmaceutical benefit or a Repatriation pharmaceutical benefit to a patient is GST-free. Goods and services tax must not be included in the price charged to a patient for the supply of a PBS or RPBS script.

It is the patient's responsibility to pay any charge lawfully imposed by an approved pharmacist or supply may be refused.

The patient contribution rates are adjusted on 1 January each year in line with inflation.

Patient contributions for early supply of some PBS medicines

Prescriptions for some PBS and RPBS pharmaceutical benefits are not eligible for safety net benefits if re-supplied within 20 days of a supply of the same pharmaceutical benefit for the same person. This is known as the 'Safety Net 20 day rule' and came into effect on 1 January 2006.

Where a prescription is subject to the Safety Net 20 day rules:

- the patient contribution does not count towards the Safety Net, and
- after the Safety Net threshold is reached, the usual patient co-payment amount for the corresponding entitlement level (not the Safety Net amount) applies.

For example: The payment for such a prescription for a patient with a Safety Net Entitlement Card would be the concessional co-payment amount — not free. For a general patient with a Safety Net Concession Card, the usual general co-payment amount would apply — not the concessional amount.

The Safety Net 20 day rule does not apply to PBS/RPBS prescriptions originating from hospitals or day hospital facilities.

Special patient contributions, brand premiums and therapeutic group premiums

A special patient contribution is payable for a pharmaceutical benefit when a supplier will not supply it at the benchmark price. Any extra charge for a higher priced benefit is paid by the patient, together with their usual patient contribution. Other than for bleomycin sulfate (available under the 'Efficient Funding of Chemotherapy - Section 100 Arrangements'), exemptions on medical grounds are available, but must be granted by Medicare Australia. For RPBS special patient contribution arrangements see the RPBS Explanatory Notes.

Under the brand premium arrangements, reimbursement to pharmacists is based on the lowest-priced brand. Any extra charge for a higher priced brand is paid by the patient, together with their usual patient contribution.

Under the therapeutic group premium arrangements, reimbursement to pharmacists is based on the lowest priced benefit items within identified therapeutic groups. Any extra charge for a higher priced benefit is paid by the patient, together with their usual patient contribution. Exemptions on medical grounds are available, but must be granted by Medicare Australia.

Special patient contributions, brand premiums and therapeutic group premiums apply to maximum quantities. When a quantity is less than, or — on an authority or 'Regulation 24' PBS prescription — more than, the maximum, the contributions or premiums will be a factor of the maximum quantity, using standard pricing rules.

There are separate arrangements for PBS prescriptions in certain public hospitals. To obtain pharmaceutical benefits under these arrangements a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment in a participating public hospital may prescribe PBS subsidised medication. Victoria, Queensland, South Australia, Western Australia and the Northern Territory have these arrangements.

Solvents

Where a solvent is prescribed as a part of a pharmaceutical benefit, only one patient contribution is charged.

Increased quantities

Where a prescriber has written an authority PBS prescription for a quantity greater than the maximum, the patient contribution should be made for each supply of the increased maximum quantity.

Regulation 24

For 'Regulation 24' PBS prescriptions, a pharmacist should charge the usual patient contribution for the original and for each repeat quantity needed to make up the total supply (plus any applicable special patient contribution, brand premium or therapeutic group premium, for the original and each repeat quantity in the total supply).

After hours

A pharmacist may charge an extra fee if supplying a PBS item outside normal trading hours. This charge is paid by the patient and does not count towards the safety net.

Delivery

A charge can be added for delivering pharmaceutical benefits from the pharmacy. This charge does not count towards the safety net. For RPBS delivery arrangements refer to the RPBS Explanatory Notes.

5. The Safety Net Scheme

The PBS safety net protects patients and their families requiring a large number of PBS or RPBS items. For the purposes of the scheme, the family includes the person:

- the partner or de facto partner;
- children under the age of 16 who are in the care and control of the person; or
- dependent full-time students under the age of 25.

The scheme requires pharmacists, on request by patients, to record the supply of PBS and RPBS items on prescription record forms. When a patient reaches the Safety Net threshold within a calendar year, they qualify to receive PBS or RPBS items at a cheaper price or free of charge for the rest of that year. Any applicable special patient contributions, brand premiums or therapeutic group premiums must still be met by the patient.

The safety net threshold is reached by accumulating eligible patient contributions for PBS prescriptions supplied through community pharmacies and private hospitals and for out-patient medication supplied by public hospitals.

Pharmaceutical benefits (including authority items) can only be counted towards the safety net threshold when prescribed and supplied according to PBS conditions. A medicine supplied by a pharmacist not approved to supply pharmaceutical benefits cannot count towards the safety net.

Prescriptions for some pharmaceutical benefits are not eligible for safety net arrangements if re-supplied within 20 days of supply of the same item for the same person and the patient contribution cannot count towards the safety net (see also details under '4. Patient Charges' and '7. How Pharmacists Claim Reimbursement'). This does not apply to out-patient medications in public hospitals or to any prescriptions originating from a hospital or day hospital facility.

There are separate arrangements for PBS prescriptions in certain public hospitals. To obtain pharmaceutical benefits under these arrangements a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment in a participating public hospital may prescribe PBS subsidised medication. Victoria, Queensland, South Australia, Western Australia and the Northern Territory have these arrangements.

Safety net thresholds

There are two safety net thresholds. The general patient safety net threshold is currently \$1363.30. When a person and/or their family's total applicable co-payments reach this amount, they may apply for a safety net concession card and pay the concessional co-payment amount of \$5.80 plus any applicable premium for pharmaceutical benefits for the rest of that calendar year.

The concessional safety net threshold is \$348.00 (this also applies to gold, white or orange card holders under the RPBS). When a patient and/or their family's total applicable co-payments reach this amount, they may apply for a safety net entitlement card and may receive pharmaceutical benefits free of charge (except for any applicable premium) for the rest of that calendar year.

Brand premiums, therapeutic group premiums and special patient contributions do not count towards the safety net thresholds.

The safety net thresholds are adjusted on 1 January each year in line with inflation.

Safety net cross-over arrangements

Some patients and/or members of their families will change between general patient and concessional patient status during a calendar year. Patients should apply for the safety net card appropriate to their status at the time they apply.

Concessional patients who were previously general patients can apply for a safety net entitlement card when they reach the concessional safety net threshold. In this case, any pharmaceutical benefits previously supplied at the general co-payment rate in that calendar year will be counted at the concessional rate per item.

General patients who were previously concessional patients can apply for a safety net concession card when they reach the general safety net threshold. In this case, any pharmaceutical benefits previously supplied at the concessional rate in that calendar year will be counted at the concessional rate per item.

In the case of families where one parent holds a concession card and other family members are general patients, the family can choose to apply for either a safety net entitlement card or a safety net concession card.

To receive a safety net entitlement card, all pharmaceutical benefits (including general pharmaceutical benefits) are counted at the concessional rate per item until the concessional threshold is reached. To receive a safety net concession card, general pharmaceutical benefits are counted at the general co-payment rate per item and concessional pharmaceutical benefits at the concessional rate per item, until the general safety net threshold is reached.

White DVA card holders may either be general or concessional patients (depending on their Centrelink entitlements). If they are receiving treatment for a specific disability accepted by the DVA, they are also supplied with specified items under the RPBS at the concessional rate per

item. Therefore, these patients are encouraged to maintain a concessional prescription record form, plus a general prescription record form for items not covered under the RPBS.

White card holders may choose at any time to count contributions made at the general level towards the concessional safety net threshold and receive credits equal to the concessional co-payment amount for each pharmaceutical benefit purchased. Alternatively, white card holders can count contributions at the concessional level towards the general safety net, and receive credits equal to the concessional co-payment amount for each pharmaceutical benefit purchased.

Gold or orange DVA card holders may receive all of their prescription items under the RPBS, and only pay the concessional co-payment amount for each item.

Dependants of white, gold or orange card holders are treated separately and may be either general patients or concessional patients. Their prescriptions may be included in the cross-over arrangements.

Recording PBS prescriptions

There are two types of prescription record forms to record PBS prescription items. A blue form, used for items obtained at community pharmacies and available from community pharmacies, Medicare offices and Medicare Australia; and a grey form, used by out-patients who pay for items at public hospital pharmacies and available from hospital out-patient departments or Medicare Australia.

Patients should record their general or concessional status on the prescription record form, enter their Centrelink, DVA and/or Safety Net Concession/Entitlement Card number, and list family members covered. General patients must also record their Medicare number when applying for a safety net concession card.

Details to be entered on the form by the pharmacist are:

- date of supply;
- PBS/RPBS code number of the item (for community pharmacies only);
- the safety net value of the item (for community pharmacies only);
- pharmacist's approval number (for community pharmacies only);
- item identification — medicine code, name of medicine or abbreviation (for public hospitals only);
- hospital charge (for public hospitals only);
- hospital safety net number (for public hospitals only); and
- signature of the authorised person making the entry.

Community pharmacists should record in the 'safety net value' column:

- the patient contribution when it is less than the PBS dispensed price; or
- the safety net value shown in the Schedule, or any lesser amount charged, if the PBS dispensed price is less than or equal to the patient contribution. The pharmacist may discount the price for these items.

Some computer software suppliers provide a special label to record this information on the prescription record forms. Some suppliers also provide a computer printout as a prescription record form.

The patient is responsible for maintenance and storage of their prescription record form. However, it may be kept in the pharmacy. A person (or family) may have more than one prescription record form.

Hospital prescription record forms

Items to be recorded on hospital prescription record forms must be approved by the hospital's pharmaceutical advisory committee and may be listed on a hospital's formulary (a list of pharmaceutical items approved by the committee for the treatment of particular illnesses), or authorised on a patient-by-patient basis.

Multi-item prescription forms

If a patient submits a multi-item PBS prescription form, which would take the total co-payments past the safety net threshold, any items in excess are treated as entitled items once a safety net entitlement/concession card is issued.

Excess items should be treated as 'deferred supply' items.

For example, if a family has a new PBS prescription for three items and the first takes the family up to the threshold, then this item should be supplied at the general rate. If the second item takes the family over the threshold, the pharmacist should then issue a safety net concession card and supply both this and the third item at the concessional rate. This involves the deferral of two items, recording the safety net concession card number, and the subsequent supply of these items.

Qualifying PBS prescriptions

A PBS prescription should be supplied at the concessional rate or free of charge plus any applicable premium, when the safety net value or hospital charge for that PBS prescription takes the total co-payments over the qualifying amount for a safety net entitlement/concession card.

Lost prescription record forms

If a prescription record form has been lost, stolen or destroyed, a pharmacist may prepare a duplicate copy, but is under no obligation to do so.

Retrospective entitlement and patient refunds

Responsibility for claiming entitlements rests with the patient. If items recorded on a prescription record form have exceeded the safety net threshold, the cost of those items in excess of the limit cannot be refunded by a pharmacist.

However, if the patient failed to apply for a safety net entitlement/concession card on reaching the safety net threshold they should write to Medicare Australia and provide copies of pharmacy accounts or a signed statement from the pharmacist giving the date of supply, description and cost of items supplied and paid for. A copy of the relevant prescription record form should also be provided. If these are not available, the patient should give the name of the pharmacy where the card was issued and the number on the card so that Medicare Australia can locate the prescription record form in its records. Cash refunds are not available. Medicare Australia contact details are provided in the 'Addresses — Medicare Australia' part of the Schedule.

If the patient cannot satisfy a pharmacist that they have a current entitlement and is charged the general patient price, the pharmacist should issue the patient with a receipt and a claim form (provided by Medicare Australia). The patient can then obtain a refund via Medicare offices or PBS processing centres. RPBS prescription refunds are paid at DVA State offices.

Medicare Australia can only pay refunds for PBS items supplied through approved pharmacies. Refunds for hospital supplied items should be referred to the relevant hospital or health department. Refunds cannot be made where the patient was charged the general or concessional amount instead of the safety net concessional or safety net entitlement amount as a result of the safety net 20 day rule. Receipts for prescriptions where the safety net 20 day rule has applied must include 'SN20DR' to indicate the reason for the amount charged.

There are separate arrangements for PBS prescriptions in some public hospitals. To obtain pharmaceutical benefits under these arrangements a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical treatment or a midwife providing midwifery treatment or a nurse practitioner providing nurse practitioner treatment in a participating public hospital may prescribe PBS subsidised medication. Victoria, Queensland, South Australia, Western Australia and the Northern Territory have these arrangements.

Applying for a Safety Net Entitlement/Concession Card

Once the safety net threshold has been reached, the person covered by a prescription record form may complete the application and declaration to get a safety net entitlement/concession card. Please note that software packages that produce computer generated applications must be approved by Medicare Australia.

If the card is issued to a dependent child or student, it should be in the name of a parent.

When issuing entitlement/concession cards, pharmacists do not have to check all prescription record form details. However, they should ensure each entry has been signed and that the prescription record form total qualifies the patient for the relevant safety net card.

When appropriate the pharmacist should check that the patient's Medicare card number is on the prescription record form.

Issuing a Safety Net Entitlement/Concession Card

When satisfied that the individual or family is entitled, the pharmacist should issue the next blank safety net entitlement/concession card with the following details:

- the names of family members covered. If there are more than eight family members, a second card should be issued listing the card holder and family members not listed on the first card. The prescription record form has space to record that two cards have been issued, and
- the two-character code to indicate the relationship to the card holder. Applicable codes are:
 - SP - partner;
 - DC - child under 16 years; and
 - DS - dependent full-time student under 25 years.

The pharmacist should be satisfied that only family members are listed on the card. The unused space on the card should be ruled through to prevent extra names being added. The sticky label from the safety net entitlement/concession card, pre-printed with the card number, should be attached to the prescription record form. The pharmacist should sign and stamp each prescription record form with the pharmacy stamp and enter the card issue details on a safety net — claim for payment form.

Issuing supplementary cards

A pharmacist may give a card holder a supplementary card for a partner or dependant only at the time the original card is issued. The duplicate card should be recorded in the additional box on the prescription record form.

Later requests for supplementary cards and requests to add a new family member to the original card are to be referred to Medicare Australia.

Notification to Medicare Australia and claim for payment

Payment for issuing a safety net entitlement/concession card is made after the safety net — claim for payment form is sent to Medicare Australia, no later than one month after a card is issued.

Each form must be accompanied by all supporting documentation (prescription record form and cancelled or void safety net entitlement/concession cards).

Payment will not be made for void cards.

Lost Safety Net Entitlement/Concession Cards

When a card has been lost, damaged, stolen or destroyed, a pharmacist cannot re-issue a person with a replacement card. The original card holder (or partner) must apply to Medicare Australia.

Pharmacy record of issued cards

A record of all cards issued must be kept at the pharmacy from which the pharmacist is approved to supply pharmaceutical benefits. The duplicate ('bookfast') copy in the safety net — claim for payment book is provided for this purpose.

6. Medicare Australia Entitlement Checks

General Patients

Medicare Australia validates a patient's entitlement to pharmaceutical benefits by checking Medicare and/or Veteran file numbers in pharmacist's claims. If a number is not recorded correctly, a patient cannot be identified against Medicare Australia's Pharmaceutical Benefits Entitlement File and entitlement cannot be established.

If the Medicare or Veteran file number provided in the pharmacists' claims is incorrect or the number and the name supplied do not match Medicare Australia records to enable patient identification, an appropriate warning or rejection code will be returned to the pharmacy. These notifications of missing or incorrect Medicare or Veteran file numbers are provided to pharmacists in their reconciliation statement produced after the claim period has been paid by Medicare Australia.

Special numbers are available for use in certain circumstances for eligible people who are unable to provide a Medicare number.

Concessional Patients

Medicare Australia routinely validates a patient's entitlement to free or concessional benefits by checking concessional numbers in pharmacists' claims. If a number is not recorded correctly, a patient cannot be identified against Medicare Australia's Pharmaceutical Benefits Entitlement File and entitlement cannot be established.

When a number is found to be from a card which was incorrect, expired at the time of supply or entitlement was withdrawn, warning or rejection codes will be returned to the pharmacy to assist with validation of concessional entitlement in relation to future claims from the same patient.

Entitlement checking procedures

General Patients

Once a pharmacist has been notified by Medicare Australia of an incorrect Medicare or Veteran file number he/she should correct the number for future claims by:

- updating his/her system to reflect the correct number provided by Medicare Australia (if patient consent to do so has been obtained); or
- speaking to the patient; or
- obtaining patient consent and calling Medicare Australia on the Improved Monitoring of Entitlements (IME) (132 290 — select option 1).

If the patient presents a Medicare card that appears correct, but according to Medicare Australia is not a valid number, or not a valid number for that person, a pharmacist may use a special number. A photocopy of the card, or a form must accompany the use of this number. The form is available on Medicare Australia's website or by calling 132 290.

Concessional Patients

Once a pharmacist has been notified by Medicare Australia of an incorrect concessional entitlement number, he/she should view the entitlement card to confirm the entitlement number, and start and end dates, when the patient next presents a PBS prescription.

Step by step

Pharmacists should take the following steps where concession entitlement does not appear to be valid or current:

- Re-confirm entitlement with the cardholder/customer;

- Contact Medicare Australia on 132 290, with consent, to confirm the cardholder/customer concession status;
- If Medicare Australia advises that the cardholder/customer is concessionally entitled to receive the PBS medicines on that day, supply the prescription as a concessional entitlement;
- If Medicare Australia advises that the cardholder/customer is not concessionally entitled to receive the PBS medicines on that day, supply as a general prescription. Provide the customer with the information sheet "Your entitlement card" which explains entitlement checking to the customer and the steps they can follow if they are concessionally entitled.

7. How Pharmacists Claim Reimbursement: Information Required

Medicare Australia uses a computerised system for pricing PBS prescriptions, repeat authorisations and emergency drug supply orders, and for calculating claims.

The payment system is designed to pay pharmacists correctly for the pharmaceutical benefits they supply. It is essential instructions are followed carefully and that each document includes all relevant information. Accurate and complete data ensures claim payment is not delayed.

PBS Prescription identification

Pharmacists must include certain information on each PBS prescription sent in for claim, as specified below. It is important that this information is entered correctly and in the right place on the PBS prescription. This information will be included in a sticker produced by pharmacy software.

The sticker should be placed on the extreme left front of a PBS prescription, opposite each item being claimed. It must not obscure any details written by the prescriber. Most prescribers use PBS prescriptions, which have space for the sticker. If a sticker is not used, a PBS prescription identification stamp can be used or the information can be written in the same place, and in the same order.

Pharmacists should avoid writing over, or placing the sticker over, the prescriber number pre-printed on PBS/RPBS prescriptions, or the prescriber number box on PBS dental and optometrist, midwife and nurse practitioner prescriptions.

The sticker is not necessary for current repeat authorisation, emergency drug supplies, or for old style authority PBS prescription and authority to prescribe forms, as they have printed spaces for the necessary details. However, it is required for the new format authority PBS prescription forms.

The following information should be entered next to the appropriate letter on the sticker or stamp:

- 'S' — the serial number for the claim
- 'A' —
 - the price claimed for pricing elected PBS prescriptions, exceptional PBS prescriptions and RPBS non-scheduled prescriptions (see under 'Extemporaneously-prepared pharmaceutical benefits not listed in the Standard Formulae List' for explanations of pricing elected PBS prescriptions and exceptional PBS prescriptions); and/or
 - confirmation that the PBS prescription is endorsed 'Regulation 24' or the RPBS prescription is endorsed 'hardship conditions apply'; and/or
 - a claim for a glass dropper bottle where applicable; and/or
 - any clarification of the prescription which will assist Medicare Australia payment processing.
- 'No.' — the PBS prescription identifying number.

Serial numbers

PBS prescription, repeat authorisation, authority PBS prescription, and emergency drug supplies forms submitted in each claim must bear consecutive serial numbers starting with:

- 1 – for emergency drug supplies;
- 1 – for general benefits;
- C1 – for concessional and Safety Net Concession Card benefits;
- E1 – for Safety Net Entitlement Card benefits; and
- R1 – for RPBS benefits.

Each serial number should also be noted on any document kept by the pharmacist for record purposes.

Each emergency drug supply item should be given a serial number, e.g., if there are five items on the first form in the claim, the first item on the second form in the claim will start with the serial number 6.

For prescriptions subject to the Safety Net 20 day rule, the serial number corresponds to the resulting payment category for the pharmaceutical benefit as supplied, not the patient's entitlement category.

Repeat authorisations for authority PBS prescriptions

When a benefit is supplied on a repeat authorisation which needed an authority PBS prescription, the serial number must be prefixed with the letter 'A' for a general benefit; 'AC' for a concessional benefit or a benefit supplied to a Safety Net Concession Card holder; 'AE' for a Safety Net Entitlement Card holder; or 'AR' for a RPBS benefit.

Repeat authorisations for deferred supply

When a benefit is supplied on a repeat authorisation prepared for deferred supply, the serial number must be prefixed with the letter 'D' for a general benefit; 'DC' for a concessional benefit or a benefit supplied to a Safety Net Concession Card holder; 'DE' for a Safety Net Entitlement Card holder; or 'DR' for a RPBS benefit.

Injectable item ordered with a solvent

When both an injectable item and a solvent are to be supplied, only one serial number is used. This number should be placed on the left hand side of the prescription, opposite the injectable item.

Dropper containers

Dispensed prices for extemporaneously-prepared eye drops, ear drops and nasal instillations include the price of a polythene dropper container. However, if a glass dropper container is supplied, payment should be claimed by writing 'glass bottle' in box 'A' of the stamp.

Extemporaneously-prepared pharmaceutical benefits not listed in the Standard Formulae List

When a formula is not listed on the Standard Formulae List, the PBS prescription is paid at an average of 10 g/mL rate for the type of preparation, unless the pharmacist elects otherwise. A pharmacist may price an exceptional PBS prescription, or elect to price all non-pre-priced extemporaneous PBS prescriptions.

PBS prescriptions paid on an average price basis

If the PBS prescription is to be claimed as an exceptional PBS prescription, the pharmacist should write details of the formula supplied on the PBS prescription or repeat authorisation form; price the PBS prescription in accordance with the pricing principles (as detailed in '9. Pricing PBS Prescriptions'); and enter the calculated price on the sticker.

An exceptional PBS prescription is for an extemporaneously-prepared pharmaceutical benefit that is not included in the Standard Formulae List and for which the price of the ingredients (based on basic pricing rules) is twice or more than the recovery price of the ingredients calculated on an average price basis. Further information on pricing PBS prescriptions can be accessed from the book let titled *Explanation of Current Pricing* on the Medicare Australia's website at www.medicareaustralia.gov.au (PBS publications for Health Care Providers).

Pricing non-pre-priced extemporaneous preparations

Pharmacists should notify Medicare Australia when they elect to price non-pre-priced extemporaneous preparations. Each PBS prescription should be priced in accordance with the pricing principles and that price entered on the sticker.

RPBS prescriptions for items not included in either the PBS or RPBS Schedule

When a prescription for a RPBS patient is for an item not included in either the PBS or the RPBS Schedule, the price claimed should be entered on the sticker. Full details on pricing and availability of such items under the RPBS are set out in the RPBS Explanatory Notes.

Payment to Pharmacists for Dispensing Premium-free Substitutable Medicines

Premium Free Dispensing Incentive payments will commence for eligible PBS listed products dispensed from 1 August 2008. Premium Free Dispensing Incentive payments will be available to approved suppliers to dispense a substitutable, premium-free medicine. The payment will be available only for PBS items which attract a Government subsidy. This includes PBS items supplied to DVA entitled consumers.

A number of conditions and criteria apply to receive this payment. Scripts will be assessed for validity and the Premium Free Dispensing Incentive payment will be paid by Medicare Australia. Further information on this payment can be found on the Medicare Australia website at: <http://www.medicareaustralia.gov.au/provider/pbs/pharmacists/reforms.shtml#dispensing>

8. How Pharmacists Claim Reimbursement: Documents to be Submitted

A claim for pharmaceutical benefits consists of:

- the original and duplicate of a completed Claim for Payment Form;
- the original orders for emergency drug supplies in a separate bundle;
- the originals of all old format PBS prescriptions and authority PBS prescriptions, the Medicare Australia/DVA copies of new format PBS prescriptions and authority PBS prescriptions, and all repeat authorisations, separated into four bundles for benefits supplied to the general public; concessional beneficiaries/Safety Net Concession Card holders; Safety Net Entitlement Card holders and RPBS patients.

PBS prescriptions in each bundle should be in serial number order, with serial number 1 at the top of the bundle.

PBS prescriptions subject to the Safety Net 20 day rule are bundled according to the resulting payment category. For prescription forms with multiple PBS items, where the Safety Net 20 day rule would result in different payment categories for different items, dispensing via 'deferred supply' should be used where necessary to allow all items to be included in the correct bundles.

PBS prescriptions in the wrong bundle may be returned to the pharmacist for clarification. If appropriate, they can be resubmitted in the correct bundle in the next claim period.

Completing the claim form

The claimant's name, address of the pharmacy from which the pharmacist is approved to supply pharmaceutical benefits, approval number, and claim period number should be entered on the Claim for Payment Form. These details should match the latest written information held by Medicare Australia, or payments can be delayed while clarification is sought.

The claim period number should state how many claims have been submitted so far in a calendar year, e.g., the sixth claim submitted by an approved pharmacist in 2005 should have a claim period number of 0506.

The first and last serial numbers given to items in each bundle are to be entered on the Claim for Payment Form.

A total claim amount is not required – this will be calculated by Medicare Australia after the PBS prescriptions have been individually priced.

The declaration must be signed by the pharmacist approved to supply pharmaceutical benefits, unless he/she has made arrangements through Medicare Australia for another pharmacist to sign it.

Lodging claims

A claim may be lodged at any time during the month at the relevant Medicare Australia State office. Unless other arrangements have been made with Medicare Australia, the following conditions apply:

- only one claim period can exist and only one claim can be lodged per month;
- the claim period shall cover pharmaceutical benefits supplied during one month; and
- the claim shall be sent within 30 days from when the benefits were supplied.

Claims for pharmaceutical benefits supplied over 18 months earlier may not be accepted for computer processing. Pharmacists with such claims should contact Medicare Australia.

Reconciliation statements

As mentioned earlier, a pharmacist will receive a PBS reconciliation statement after a claim period has been processed. It provides details of each prescription for each brand of each pharmaceutical benefit item supplied in that claim period.

Reasons for non-payment of any item are coded, with the code numbers explained in the statement.

PBS prescriptions and repeat authorisations not accepted for payment will be returned, with the exception of PBS prescriptions with a dispensed price equal to or less than the patient contribution. Any other items on those PBS prescriptions that have been paid will have been cancelled.

If a PBS prescription was not accepted and can be re-submitted, it must be given a new serial number and included in a subsequent claim period.

If a PBS prescription is finally rejected for payment and a pharmacist is not satisfied with the decision, he/she may apply to the Administrative Appeals Tribunal for a review of that decision.

9. Pricing PBS Prescriptions

Pricing principles

The same pricing principles apply to all PBS prescriptions.

For ready-prepared pharmaceutical benefits, payment is made on the basis of the lowest-priced brand.

For a pharmaceutical benefit not listed as a ready-prepared item, and where a formulation title is stated but no formulary specified, payment is made on the basis of precedence given to formularies by State/Territory legislation.

Prices published in the Schedule do not include any component for goods and services tax (GST).

Further information on pricing PBS prescriptions can be accessed from the booklet titled *Explanation of Current Pricing* on the Medicare Australia's website at www.medicareaustralia.gov.au (PBS publications for Health Care Providers).

Pricing dates

Ready-prepared pharmaceutical benefits are priced on the first day of April, August and December for items supplied as from each of those days respectively.

Extemporaneously-prepared pharmaceutical benefits and containers are priced on the first day of May each year for items supplied as from the first day of August that year.

Pricing ready-prepared items

For maximum quantities

The price payable for a pharmaceutical benefit is shown in the Schedule against the item. The price is for the maximum quantity available.

If the prescription is for an injectable item and solvent, the price of each is added together, but only one dispensing fee is payable.

The maximum quantity of some pharmaceutical benefits, such as eye drops and oral suspensions, has been determined as a single pack corresponding to the manufacturer's pack. These packs cannot be broken, so if a PBS prescription calls for less, the maximum quantity should be supplied and claimed from Medicare Australia. Packs not to be broken are indicated by a double dagger (‡) in the Schedule.

For lesser quantities

For items where the standard pack is the same as the maximum quantity, and the pack can be broken, the price payable for a lesser quantity is established as follows:

- an amount equal to the dispensing fee, and if applicable the dangerous drug fee, is deducted from the benefit price as shown in the Schedule;
- to this new amount, a wastage percentage is applied, determined from the Wastage Factor Table;
- then the amount equal to the dispensing fee, dangerous drug fee (if applicable), and appropriate container fee, is added.

In no case shall the price for a broken quantity be more than the dispensed price of the Schedule's maximum quantity.

When a standard pack is not the same as the maximum quantity, the price of the pharmaceutical benefit concerned has an asterisk next to it and the standard pack rate is set out in Section 3 of the Schedule. The price payable for the quantity supplied is established by:

- applying the appropriate wastage table percentage to the standard pack rate;
- then adding an amount equivalent to the dispensing fee, the dangerous drug fee where applicable, and the appropriate container fee.

In no case shall the supply of a broken quantity, which is less than the item's maximum quantity, cost more than the dispensed price for the maximum quantity.

No container fee is payable when the quantity of pharmaceutical benefit supplied is more than the quantity contained in the standard pack.

Wastage table percentage

The following Wastage Factor Table is used to calculate the price payable for quantities supplied from the standard pack.

Wastage Factor Table

Column A - 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100

Column B - 10, 18, 26, 32, 38, 44, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 100

The appropriate wastage table percentage is as follows:

- the percentage of the amount supplied from the amount in the standard pack is determined; and
- where this percentage is the same as a percentage listed in Column A of the table, the percentage used is the figure shown in Column B; or
- where the percentage is not the same as a percentage in Column A, then the nearest upward percentage in Column A applies, and the percentage used is the figure in Column B.

For example, 24 tablets are supplied from a standard pack of 100. Thus 24 per cent of the number contained in the standard pack is supplied. As this percentage does not appear in Column A, the next higher (i.e., 25 per cent) is used. Reading down from 25 per cent to Column B, the wastage table percentage is found to be 38 per cent.

Pricing extemporaneously-prepared items

General

The price payable for supplying the maximum quantity of standard formula preparations is shown in the Standard Formulae List.

The following principles apply in determining prices of all pre-priced extemporaneous formulae on the list.

They also apply when a pharmacist elects to price extemporaneous PBS prescriptions outside the list, including exceptional PBS prescriptions.

The amount payable is the sum of:

- the recovery price of each ingredient as shown in the Drug Tariff;
- the price of the appropriate container as shown in the price section; and

- a dispensing fee as shown in the price section.

Pricing of ingredients

When the quantity dispensed is not specified in the Drug Tariff, the recovery price is as follows:

1. determine the basic pricing unit relative to the quantity dispensed by referring to the following table:

Quantity	Basic Pricing Unit
Up to and including 700 mg	100 mg price rate
Over 700 mg and up to and including 1 g	price as if 1 g
Over 1 g and up to and including 7 g	1 g price rate
Over 7 g and up to and including 10 g	price as if 10 g
Over 10 g and up to and including 80 g	10 g price rate
Over 80 g and up to and including 90 g	price as if 80 g
Over 90 g	100 g price rate

2. find the recovery price of the basic pricing unit by applying the following quantity divisors to the recovery price shown for the ingredient in the Drug Tariff:
 - 100 g price is 500 g price divided by 5, or 1 kg price divided by 10
 - 10 g price is 100 g price plus 12.5 per cent divided by 10
 - 1 g price is 10 g price plus 25 per cent divided by 10
 - 100 mg price is 1 g price plus 25 per cent divided by 10
1. find the recovery price by multiplying the price of the basic pricing unit – as established in 2 – by the fraction that the quantity dispensed bears to the basic pricing unit.

For pricing purposes the quantity is to be taken to the next upward 50 milligrams or 0.05 millilitres.

The minimum recovery price for any ingredient is one cent. In other cases where a fraction of a cent occurs, the price is to be taken to the nearest cent (a half cent being taken up to the next cent).

In no case shall the recovery price for a quantity of an ingredient exceed the recovery price for a greater quantity of that ingredient.

Where liquids are purchased by weight, the recovery price includes the 'Specific Gravity Factor'.

Special pricing provisions apply to drugs marked '(a)' or '(b)' in the Drug Tariff.

For drugs marked '(a)', the pricing rules shown above apply to quantities up to the quantity listed in the Drug Tariff. Greater quantities are priced on a linear basis: the recovery price is ascertained by multiplying the fraction that the quantity dispensed bears to the quantity listed in the Drug Tariff by the price shown for the quantity listed.

Drugs marked '(b)' are packed sterile or are unstable, and all quantities are priced as if whole pack(s) were required. The recovery price is ascertained by multiplying the fraction that the quantity dispensed bears to the quantity listed in the Drug Tariff, taken to the next whole number, by the price shown for the quantity listed.

Pricing PBS prescriptions where extra ingredients are added to a formula

Where the vehicle is liquid and one or more solid ingredients are added, displacement of the liquid by the solid ingredients is disregarded for pricing purposes.

Containers

When a quantity is for more than the container sizes listed in this Schedule, payment will be made as if that quantity had been supplied in the minimum number of containers necessary to supply that quantity.

A double size container is allowed for bulk powders.

Special provisions for extemporaneous PBS prescriptions outside the Standard Formulae List

If a pharmacist elects to price extemporaneous PBS prescriptions outside the Standard Formulae List, there can be no variation for three months. This applies to all extemporaneously-prepared formulae not on the list, and includes both PBS and RPBS prescriptions.

If a pharmacist does not elect to price out these PBS prescriptions, he/she will be paid at an average reimbursement rate.

Under this system, payment is made on the basis of an average 10 g/mL rate applied to the category of preparation concerned, i.e., the price will be determined by multiplying the appropriate 10 g/mL rate by the number of 10 g/mL units supplied and adding container and dispensing fees. For example, an 80 mL mixture would be priced at eight times the average 10 mL rate for mixtures, with container and dispensing fee added.

The average 10 g/mL rate for each type of preparation is calculated monthly. It applies to PBS prescriptions supplied in the following month.

PBS prescriptions ordering a combination of standard formula preparations fall outside the scope of the Standard Formulae List and therefore are subject to this section.

Any variant to a formula included in the list (adding or deleting an ingredient or varying the dose) takes the formula dispensed outside the list.

When an ingredient is added to a standard formula and the recovery price for the standard formula plus additive under the average price system is less than for the standard formula alone, the pharmacist may have the PBS prescription priced as a basic standard formula item.

10. Miscellaneous

References

This Schedule identifies monographs of the British Pharmacopoeia, the British Pharmaceutical Codex, and the Australian Pharmaceutical Formulary and Handbook by the letters BP, BPC and APF respectively. References to all editions of the BPC and to earlier editions of the BP and APF also include the year of publication or the number of the edition.

Standards

Pharmacists can only supply under the PBS medicines which, or whose ingredients, conform to the standards of composition or purity prescribed. These standards are those specified in the *Therapeutic Goods Act 1989*.

Legislation

Copies of the *National Health Act 1953* and the *National Health (Pharmaceutical Benefits) Regulations 1960* are available from Government AusInfo shops in each capital city. The Act and the Regulations may also be accessed through the Attorney-General's Department website at www.comlaw.gov.au.

Nurse practitioner PBS prescribing

MEDICINES WHICH MAY BE PRESCRIBED BY AUTHORISED NURSE PRACTITIONERS

From 1 September 2010, nurse practitioners endorsed to prescribe under state or territory legislation can apply for approval as PBS prescribers (*authorised nurse practitioners*). Information for nurse practitioners to become authorised PBS prescribers is available from Medicare Australia.

The medicines listed for prescribing by authorised nurse practitioners are identified by 'NP' in the PBS Schedule. Nurse practitioners must not write PBS prescriptions for other medicines.

PBS prescribing is limited by a nurse practitioner's scope of practice, and state and territory prescribing rights. Prescribing of PBS medicines is also contingent on a prescriber being an *authorised nurse practitioner* and having collaborative arrangements in place, as required by amendments to the *National Health Act 1953*.

The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for making recommendations to the Minister for Health and Ageing regarding medicines for prescribing by authorised nurse practitioners.

Further to prescribing within collaborative arrangements, certain medicines also have additional conditions for prescribing by nurse practitioners, as recommended by the PBAC. These medicines are identified by the codes 'CTO' for continuation therapy only or 'SCM' for prescribing within a shared care model, as outlined below:

- *Continuing therapy only model*

Where the patient's treatment and prescribing of a medicine has been initiated by a medical practitioner, but prescribing is continued by a nurse practitioner. (This is similar to existing arrangements between specialists and medical practitioners for prescribing certain medicines.)

- *Shared care model*

Where care is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed plan to manage the patient, in a patientcentred model of care. The details surrounding shared care arrangements will depend on the practitioners involved, patient needs and the healthcare context.

Some medicines are included in more than one section of the Schedule, and for more than one prescriber type. For a prescription to be eligible for subsidy, prescribers must ensure that they prescribe under the PBS only those medicines, and in accordance with the restrictions, listed for their prescriber type. Listing details for the same product may differ between sections and different PBS item codes apply for each prescriber type.

Nurse practitioner PBS prescriptions are identifiable by colour, and include the indicator 'NP' on personalised forms and a tick box on non-personalised (blank) forms.

Prescriptions must include the nurse practitioner's PBS prescriber number. For unrestricted and restricted PBS medicines, midwives/nurse practitioners can use the personalised or non-personalised PBS prescriber forms. For authority required and authority required (streamlined)

PBS medicines, midwives/nurse practitioners can use the authority personalised or non-personalised PBS prescriber forms. Nurse practitioner PBS prescriptions may include repeats.

Regulation 24 applies for nurse practitioner prescribing. A nurse practitioner can direct that original and repeat supplies of pharmaceutical benefits be supplied at the one time, if certain conditions are satisfied.

Authority prescriptions: Authority prescriptions for authority required items, or for increased quantities or repeats, require prior approval from Medicare Australia for each prescription. (Refer to Prescribing Medicines — Information for PBS prescribers and Supplying medicines — What Pharmacists Need to Know, for more information on authority prescriptions.)

State and territory requirements: Nurse practitioners may prescribe medicines as private prescriptions according to their state/territory prescribing accreditation. The medicines which can be prescribed differ between states and territories. It is the nurse practitioner's responsibility to ensure adherence to State/Territory law for all prescriptions (PBS and private) and additionally to all PBS requirements for PBS prescriptions.

Midwife PBS prescribing

MEDICINES WHICH MAY BE PRESCRIBED BY AUTHORISED MIDWIVES

From 1 September 2010, midwives endorsed to prescribe under state or territory legislation can apply for approval as PBS prescribers (*authorised midwives*). Information for midwives to become authorised PBS prescribers is available from Medicare Australia.

The medicines listed for prescribing by authorised midwives are identified by 'MW' in the PBS Schedule. Midwives must not write PBS prescriptions for other medicines.

PBS prescribing by midwives is limited by state and territory prescribing rights. It is also contingent on a prescriber being an *authorised midwife* and having collaborative arrangements in place, as required by amendments to the *National Health Act 1953*.

The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for making recommendations to the Minister for Health and Ageing regarding medicines for prescribing by authorised midwives.

Some medicines are included in more than one section of the Schedule, and for more than one prescriber type. For a prescription to be eligible for subsidy, prescribers must ensure that they prescribe under the PBS only those medicines, and in accordance with the restrictions, listed for their prescriber type. Listing details for the same product may differ between sections and different PBS item codes apply for each prescriber type.

Midwife PBS prescriptions are identifiable by colour, and include the indicator 'MW' on personalised forms and a tick box on non-personalised (blank) forms. Prescriptions must include the midwife's PBS prescriber number. For unrestricted and restricted PBS medicines, midwives/nurse practitioners can use the personalised or non-personalised PBS prescriber forms. For authority required and authority required (streamlined) PBS medicines, midwives/nurse practitioners can use the authority personalised or non-personalised PBS prescriber forms. Midwife PBS prescriptions may include repeats.

Regulation 24 applies for midwife prescribing. A midwife can direct that original and repeat supplies of pharmaceutical benefits be supplied at the one time, if certain conditions are satisfied.

Authority prescriptions: Authority prescriptions for authority required items, or for increased quantities or repeats, require prior approval from Medicare Australia for each prescription. (Refer to Prescribing Medicines—Information for PBS prescribers and Supplying Medicines — What Pharmacists Need to Know, for more information on authority prescriptions.)

State and Territory requirements: Midwives may prescribe medicines as private prescriptions according to their state/territory prescribing accreditation. The medicines which can be prescribed differ between states and territories. It is the midwife's responsibility to ensure adherence to state/territory law for all prescriptions (PBS and private) and additionally to all PBS requirements for PBS prescriptions.

Therapeutic Index

<i>Alimentary tract and metabolism</i>	71
Stomatological preparations	71
Stomatological preparations.....	71
Drugs for acid related disorders	71
Antacids	71
Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	71
Drugs for functional gastrointestinal disorders	79
Belladonna and derivatives, plain	79
Propulsives.....	79
Antiemetics and antinauseants	79
Antiemetics and antinauseants	79
Bile and liver Therapy	84
Bile therapy.....	84
Laxatives	84
Laxatives	84
Antidiarrheals, intestinal antiinflammatory/ antiinfective agents.....	86
Intestinal antiinfectives	86
Electrolytes with carbohydrates	87
Antipropulsives.....	87
Intestinal antiinflammatory agents.....	87
Digestives, incl. enzymes	90
Digestives, incl. enzymes	90
Drugs used in diabetes	91
Insulins and analogues.....	91
Blood glucose lowering drugs, excl. insulins.....	93
Vitamins.....	102
Vitamin A and D, incl. combinations of the two	102
Vitamin B ₁ , plain and in combination with vitamin B ₆ and vitamin B ₁₂	102
Mineral supplements.....	103
Calcium	103
Potassium	103
Other mineral supplements.....	103
Anabolic agents for systemic use.....	103
Anabolic steroids	103
<i>Blood and blood forming organs</i>	105
Antithrombotic agents.....	105
Antithrombotic agents.....	105
Antihemorrhagics	113
Antifibrinolytics.....	113
Antianemic preparations	114
Iron preparations	114
Vitamin B ₁₂ and folic acid.....	114
Blood substitutes and perfusion solutions	115
Blood and related products	115
I.V. solutions	115
Other hematological agents	116
Other hematological agents	116
<i>Cardiovascular system</i>	117
Cardiac therapy	117
Cardiac glycosides.....	117
Antiarrhythmics, class I and III.....	117
Cardiac stimulants excl. cardiac glycosides.....	118
Vasodilators used in cardiac diseases.....	119
Antihypertensives.....	120
Antiadrenergic agents, centrally acting	120
Antiadrenergic agents, peripherally acting.....	121
Arteriolar smooth muscle, agents acting on.....	121
Diuretics.....	122

Low-ceiling diuretics, thiazides	122
Low-ceiling diuretics, excl. thiazides	122
High-ceiling diuretics	122
Potassium-sparing agents	123
Diuretics and potassium-sparing agents in combination	124
Peripheral vasodilators	124
Peripheral vasodilators	124
Beta blocking agents	124
Beta blocking agents	124
Calcium channel blockers	129
Selective calcium channel blockers with mainly vascular effects	129
Selective calcium channel blockers with direct cardiac effects	131
Agents acting on the renin-angiotensin system	132
ACE inhibitors, plain	132
ACE inhibitors, combinations	140
Angiotensin II antagonists, plain	142
Angiotensin II antagonists, combinations	144
Lipid modifying agents	149
Lipid modifying agents, plain	149
Lipid modifying agents, combinations	163
Dermatologicals	166
Antifungals for dermatological use	166
Antifungals for topical use	166
Antifungals for systemic use	167
Antipsoriatics	168
Antipsoriatics for topical use	168
Antipsoriatics for systemic use	169
Antibiotics and chemotherapeutics for dermatological use	169
Chemotherapeutics for topical use	169
Corticosteroids, dermatological preparations	169
Corticosteroids, plain	169
Anti-acne preparations	171
Anti-acne preparations for topical use	171
Anti-acne preparations for systemic use	171
Other dermatological preparations	172
Other dermatological preparations	172
Genito urinary system and sex hormones	174
Other gynecologicals	174
Contraceptives for topical use	174
Other gynecologicals	174
Sex hormones and modulators of the genital system	175
Hormonal contraceptives for systemic use	175
Androgens	176
Estrogens	177
Progestogens	178
Progestogens and estrogens in combination	179
Gonadotropins and other ovulation stimulants	180
Antiandrogens	181
Other sex hormones and modulators of the genital system	182
Urologicals	182
Other urologicals, incl. antispasmodics	182
Drugs used in benign prostatic hypertrophy	183
Systemic hormonal preparations, excl. sex hormones and insulins	185
Pituitary and hypothalamic hormones and analogues	185
Anterior pituitary lobe hormones and analogues	185
Posterior pituitary lobe hormones	185
Hypothalamic hormones	186
Corticosteroids for systemic use	186
Corticosteroids for systemic use, plain	186
Thyroid therapy	189
Thyroid preparations	189
Antithyroid preparations	190

Pancreatic hormones.....	190
Glycogenolytic hormones	190
Calcium homeostasis	190
Parathyroid hormones and analogues.....	190
Anti-parathyroid agents.....	191
Antiinfectives for systemic use	193
Antibacterials for systemic use	193
Tetracyclines	193
Beta-lactam antibacterials, penicillins	195
Other beta-lactam antibacterials.....	199
Sulfonamides and trimethoprim.....	204
Macrolides, lincosamides and streptogramins	205
Aminoglycoside antibacterials	207
Quinolone antibacterials	207
Other antibacterials	209
Antimycotics for systemic use	211
Antimycotics for systemic use	211
Antimycobacterials.....	214
Drugs for treatment of tuberculosis	214
Drugs for treatment of lepra	214
Antivirals for systemic use	215
Direct acting antivirals	215
Vaccines.....	220
Bacterial vaccines	220
Antineoplastic and immunomodulating agents.....	222
Antineoplastic agents	222
Alkylating agents.....	222
Antimetabolites	223
Plant alkaloids and other natural products.....	224
Cytotoxic antibiotics and related substances	225
Other antineoplastic agents	225
Endocrine therapy	245
Hormones and related agents	245
Hormone antagonists and related agents	247
Immunostimulants	251
Immunostimulants.....	251
Immunosuppressants	253
Immunosuppressants	253
Musculo-skeletal system.....	391
Antiinflammatory and antirheumatic products	391
Antiinflammatory and antirheumatic products, non-steroids.....	391
Specific antirheumatic agents.....	395
Muscle relaxants.....	396
Muscle relaxants, centrally acting agents	396
Muscle relaxants, directly acting agents.....	396
Antigout preparations	397
Antigout preparations	397
Drugs for treatment of bone diseases	398
Drugs affecting bone structure and mineralization	398
Nervous system	408
Analgesics	408
Opioids.....	408
Other analgesics and antipyretics.....	420
Antimigraine preparations.....	421
Antiepileptics	423
Antiepileptics	423
Anti-Parkinson drugs	433
Anticholinergic agents	433
Dopaminergic agents	433
Psycholeptics	438
Antipsychotics.....	438
Anxiolytics.....	454

Hypnotics and sedatives	456
Psychoanaleptics	457
Antidepressants	457
Psychostimulants, agents used for ADHD and nootropics	467
Anti-dementia drugs	469
Other nervous system drugs	475
Parasympathomimetics	475
Drugs used in addictive disorders	475
Other nervous system drugs	478
Antiparasitic products, insecticides and repellents	479
Antiprotozoals	479
Agents against amoebiasis and other protozoal diseases	479
Antimalarials	479
Anthelmintics	480
Antitrematodals	480
Antinematodal agents	480
Ectoparasitocides, incl. scabicides, insecticides and repellents	481
Ectoparasitocides, incl. scabicides	481
Respiratory system	482
Nasal preparations	482
Decongestants and other nasal preparations for topical use	482
Drugs for obstructive airway diseases	482
Adrenergics, inhalants	482
Other drugs for obstructive airway diseases, inhalants	485
Adrenergics for systemic use	486
Other systemic drugs for obstructive airway diseases	487
Cough and cold preparations	488
Cough suppressants, excl. combinations with expectorants	488
Antihistamines for systemic use	488
Antihistamines for systemic use	488
Sensory organs	489
Ophthalmologicals	489
Antiinfectives	489
Antiinflammatory agents	490
Antiglaucoma preparations and miotics	490
Mydriatics and cycloplegics	493
Decongestants and antiallergics	493
Ocular vascular disorder agents	493
Other ophthalmologicals	495
Otologicals	500
Antiinfectives	500
Corticosteroids and antiinfectives in combination	500
Ophthalmological and otological preparations	500
Antiinfectives	500
Various	501
Allergens	501
Allergens	501
All other therapeutic products	501
All other therapeutic products	501
Diagnostic agents	503
Urine tests	503
Other diagnostic agents	504
General nutrients	506
Other nutrients	506
All other non-therapeutic products	519
All other non-therapeutic products	519
Pharmaceutical Benefits for Palliative Care	520
Alimentary tract and metabolism	521
Stomatological preparations	521

Stomatological preparations.....	521
Drugs for functional gastrointestinal disorders	522
Belladonna and derivatives, plain.....	522
Laxatives	522
Laxatives	522
Musculo-skeletal system.....	527
Antiinflammatory and antirheumatic products	527
Antiinflammatory and antirheumatic products, non-steroids.....	527
Nervous system	531
Analgesics	531
Opioids.....	531
Other analgesics and antipyretics.....	533
Antiepileptics.....	534
Antiepileptics.....	534
Psycholeptics	534
Anxiolytics.....	534
Hypnotics and sedatives	536
Pharmaceutical Benefits for Dental Use.....	537
Alimentary tract and metabolism	538
Stomatological preparations	538
Stomatological preparations.....	538
Drugs for functional gastrointestinal disorders	538
Belladonna and derivatives, plain.....	538
Propulsives.....	538
Antiemetics and antinauseants	538
Antiemetics and antinauseants	538
Antidiarrheals, intestinal antiinflammatory/ antiinfective agents.....	539
Intestinal antiinfectives	539
Blood and blood forming organs.....	540
Blood substitutes and perfusion solutions	540
I.V. solutions	540
Cardiovascular system.....	541
Cardiac therapy	541
Antiarrhythmics, class I and III	541
Cardiac stimulants excl. cardiac glycosides.....	541
Vasodilators used in cardiac diseases.....	541
Dermatologicals.....	542
Corticosteroids, dermatological preparations.....	542
Corticosteroids, plain.....	542
Systemic hormonal preparations, excl. sex hormones and insulins	543
Corticosteroids for systemic use.....	543
Corticosteroids for systemic use, plain	543
Pancreatic hormones.....	543
Glycogenolytic hormones	543
Antiinfectives for systemic use	544
Antibacterials for systemic use.....	544
Tetracyclines.....	544
Beta-lactam antibacterials, penicillins	544
Other beta-lactam antibacterials.....	547
Sulfonamides and trimethoprim.....	550
Macrolides, lincosamides and streptogramins	550
Other antibacterials.....	551
Musculo-skeletal system.....	553
Antiinflammatory and antirheumatic products	553
Antiinflammatory and antirheumatic products, non-steroids.....	553

Nervous system	556
Analgesics	556
Opioids	556
Other analgesics and antipyretics	558
Antiepileptics	559
Antiepileptics	559
Anti-Parkinson drugs	559
Anticholinergic agents	559
Psycholeptics	559
Anxiolytics	559
Hypnotics and sedatives	560
Respiratory system	561
Drugs for obstructive airway diseases	561
Adrenergics for systemic use	561
Sensory organs	562
Ophthalmologicals	562
Antiinfectives	562
Various	563
All other therapeutic products	563
All other therapeutic products	563
All other non-therapeutic products	563
All other non-therapeutic products	563
Pharmaceutical Benefits for Optometrical Use	564
Sensory organs	565
Ophthalmologicals	565
Antiinfectives	565
Antiinflammatory agents	565
Antiglaucoma preparations and miotics	566
Decongestants and antiallergics	568
Other ophthalmologicals	568
Ophthalmological and otological preparations	571
Antiinfectives	571

Section 2

Emergency Drug Supplies

Special Pharmaceutical Benefits

General Pharmaceutical Benefits

Pharmaceutical Benefits for Palliative Care

Pharmaceutical Benefits for Dental Use

Pharmaceutical Benefits for Optometrical Use

Items Available Under Special Arrangements (s.100)

SYMBOLS USED IN THE SCHEDULE

An asterisk (*) against the dispensed price of a benefit indicates that the manufacturer's pack does not coincide with the maximum quantity.

A double dagger (‡) in the maximum quantity column indicates an item for which the maximum quantity has been specially determined to correspond to the manufacturer's pack and the manufacturer's standard pack should be prescribed and supplied. For any item where a maximum quantity greater than 1 is marked with a double dagger (‡), that maximum quantity should be prescribed and supplied.

A gauge sign (#) against the dispensed price of a benefit indicates that the product is not preconstituted and that an extemporaneously-prepared dispensing fee is included in the dispensed price and, where appropriate, an amount for purified water.

Where a STATE is indicated after a manufacturer's code, that brand may be available only in the State indicated. NSW–(N); Vic–(V); Qld–(Q); SA–(S); WA–(W); Tas–(T).

RESTRICTED BENEFITS

All restricted items have separate headings for authority and non-authority items. In each case these items may be prescribed as pharmaceutical benefits only for use for one of the specified indications. Where more than one indication is specified for an Authority required or Restricted pharmaceutical benefit, each indication is separated from the preceding indication by a semi-colon and commences on the next line. In the case of Authority required (STREAMLINED) items, each indication will also include a four digit streamlined authority code. The drug may be prescribed as a pharmaceutical benefit for a patient who qualifies under any of the specified indications.

A straight line is drawn between entries for different forms and strengths of an item to indicate clearly the different restrictions which apply to these various forms and strengths.

The maximum quantity and/or number of repeats in respect of an item shown in the Schedule may be varied by the Chief Executive Officer of Medicare Australia when approving an Authority Prescription or an Authority to Prescribe. The quantity and number of repeats shown on the authority shall be supplied. (See Explanatory Notes). Payment will be made on the basis of the price shown for that item in the Schedule.

CODES FOR INJECTABLE ITEMS WITH ALLOWABLE SOLVENTS

The entry in this schedule of those pharmaceutical benefit injectable items which require a solvent includes the codes of the items with the relevant solvents. For each such item the code is for the injectable with 10mL sodium chloride injection 9 mg per mL (0.9%).

BRAND EQUIVALENCE

'a' located immediately before brand names of a particular strength of an item indicates that the sponsors of these brands have submitted evidence that they have been demonstrated to be bioequivalent or therapeutically equivalent, or that justification for not needing bioequivalence or therapeutic equivalence data has been provided to and accepted by the Therapeutic Goods Administration. It would thus be expected that these brands may be interchanged without differences in clinical effect.

For other brands of an item, i.e., those not indicated as above, it is unknown whether or not they are equivalent. There may be several reasons for this, such as bioequivalence data not being considered necessary when the products were approved for marketing, or that advice or data have not been forthcoming from sponsors. This does not necessarily suggest a lack of safety or efficacy, but in these circumstances caution should be taken if brands are interchanged.

'b' attached to brand names indicates that these brands are also equivalent, but that it is not known if there is equivalence between brands marked 'a' and brands marked 'b'.

BRAND PREMIUM POLICY

The Brand Premium Policy was introduced on 1 December 1990 to increase price competition by allowing pharmaceutical manufacturers to set their own price on multi-branded items listed on the Pharmaceutical Benefits Scheme and to encourage the development of the generic pharmaceutical industry in Australia. The policy does this by increasing prescribers' and patients' consciousness about the price of drugs. In effect, it makes both groups question whether it is necessary for the patient to pay more for the drugs when a cheaper brand is available. The policy also allows companies to establish prices taking into account competition and consumer acceptance.

The policy operates where there is more than one brand of a particular drug available through the Pharmaceutical Benefits Scheme and where the brands are therapeutically interchangeable. Due to this, the policy mainly applies to out of patent drugs.

Basically the policy operates by:

- the Australian Government subsidising a drug to the level of the lowest priced brand (except in those instances where the lowest priced brand has, as part of its price, a therapeutic group premium);
- suppliers of other brands of that drug being able to set a price above the price charged by the supplier(s) of the lowest priced brand(s); and
- the patient paying the brand premium which is the price difference between the lowest price brand and the brand prescribed.

If a prescription is written generically or for the lowest priced brand, and the lowest priced brand is supplied, there is no brand premium payable.

'B' located immediately before an amount in the premium column indicates a brand premium which applies to that particular brand of the item.

If a brand of a drug which is subject to a therapeutic group premium also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'T' and 'B' respectively.

If a brand of a drug which is subject to a special patient contribution also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'S' and 'B' respectively.

THERAPEUTIC GROUP PREMIUM POLICY

The Therapeutic Group Premium Policy was introduced on 1 February 1998 as an extension of the Brand Premium Policy to encourage greater competition between manufacturers of drugs and to make doctors and patients more aware of the costs of medicines.

The Therapeutic Group Premium policy applies within narrowly defined therapeutic sub-groups where the drugs concerned are of similar safety, efficacy and health outcomes.

Basically the policy operates by:

- the Australian Government subsidising drugs within a defined therapeutic sub-group to the level of the lowest priced drug in the sub-group;
- suppliers of other drugs within that sub-group being able to set prices above the price charged by the supplier(s) of the lowest priced drug; and
- the patient paying the therapeutic group premium which is the price difference between the lowest price drug and the drug prescribed.

'T' located immediately before an amount in the premium column indicates a therapeutic group premium which applies to that particular item.

If a brand of a drug which is subject to a therapeutic group premium also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'T' and 'B' respectively.

The success of the Government in controlling prices of products supplied through the Pharmaceutical Benefits Scheme has often been criticised by the pharmaceutical industry. Under both the Brand Premium Policy and the Therapeutic Group Premium Policy, suppliers of multi-branded items and therapeutically similar drugs are able to set their own prices at a level that they think the market will bear. At the same time, the prescriber and the patient can decide whether it is necessary to pay more for a particular brand or drug when a cheaper one is available and is therapeutically interchangeable.

The brand premium or therapeutic group premium does not count toward the patient's safety net.

It should be noted that the brand premium or therapeutic group premium is not a Government charge or revenue. The premium arises from the manufacturer's price and the majority goes to the manufacturer with wholesalers and pharmacists receiving a small percentage.

Emergency Drug Supplies

EMERGENCY DRUG SUPPLIES

Code	Name, Manner of Administration and Form	Max. Qty	Dispensed Price for Max. Qty \$	Proprietary Name and Manufacturer	
3451P NP	ADRENALINE Injection 1 mg in 1 mL (1 in 1,000)	5	20.44	Link Medical Products Pty Ltd	LM
3453R NP	ATROPINE Injection containing atropine sulfate 600 micrograms in 1 mL	10	20.64	Pfizer Australia Pty Ltd	PF
3455W NP	CHLORPROMAZINE HYDROCHLORIDE Injection 50 mg in 2 mL	10	20.58	Largactil	SW
or	or				
3456X NP	HALOPERIDOL Injection 5 mg in 1 mL	10	22.38	Serenace	QA
3457Y NP	BENZTROPINE MESYLATE Injection 2 mg in 2 mL	5	103.69	Cogentin	FK
3458B NP	DIAZEPAM Injection 10 mg in 2 mL	5	12.39	Hospira Pty Limited	HH
3460D NP	DIHYDROERGOTAMINE MESYLATE Injection 1 mg in 1 mL	5	17.16	Dihydergot	NV
3463G NP	DIPHTHERIA and TETANUS VACCINE, ADSORBED, DILUTED FOR ADULT USE Injection 0.5 mL in pre-filled syringe	20	*275.12	ADT Booster	CS
3466K NP	FRUSEMIDE Injection 20 mg in 2 mL	5	9.72	^a Frusemide Sandoz	SZ
				^a Lasix	SW
				^a Frusemide-Claris	AE
3467L NP	GLUCAGON HYDROCHLORIDE Injection set containing 1 mg (1 i.u.) and 1 mL solvent in disposable syringe	1	45.73	GlucaGen Hypokit	NO
3472R NP	DEXAMETHASONE SODIUM PHOSPHATE Injection equivalent to 4 mg dexamethasone phosphate in 1 mL	5	16.32	^a Hospira Pty Limited	HH
				^a Dexmethsone	AS
or	or				
3470P NP	HYDROCORTISONE SODIUM SUCCINATE Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	2	*16.62	Solu-Cortef	PF
or	or				
3471Q NP	HYDROCORTISONE SODIUM SUCCINATE Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	1	15.64	Solu-Cortef	PF
3473T NP	HYOSCINE BUTYLBROMIDE Injection 20 mg in 1 mL	5	24.31	Buscopan	BY
3474W NP	LIGNOCAINE HYDROCHLORIDE Injection 100 mg in 5 mL	5	37.43	Pfizer Australia Pty Ltd	PF
3475X NP	GLYCERYL TRINITRATE Sublingual spray (pump pack) 400 micrograms per dose (200 doses)	‡1	20.23	Nitrolingual Pumpspray	SW
3476Y NP	METOCLOPRAMIDE HYDROCHLORIDE Injection 10 mg in 2 mL	10	13.09	Maxolon	VT
or	or				
3477B NP	PROCHLORPERAZINE Injection containing prochlorperazine mesylate 12.5 mg in 1 mL	10	16.92	Stemetil	SW
3478C NP	CLONAZEPAM Oral liquid 2.5 mg per mL, 10 mL	‡1	10.83	Rivotril	RO

EMERGENCY DRUG SUPPLIES

Code	Name, Manner of Administration and Form	Max. Qty	Dispensed Price for Max. Qty \$	Proprietary Name and Manufacturer	
3479D NP or 3480E NP	MORPHINE SULFATE Injection 15 mg in 1 mL or MORPHINE SULFATE Injection 30 mg in 1 mL	5	14.45	Hospira Pty Limited	HH
3482G NP	NALOXONE HYDROCHLORIDE Injection 2 mg in 5 mL	2	*78.18	Naloxone Min-I-Jet	CS
3484J NP	TRAMADOL HYDROCHLORIDE Injection 100 mg in 2 mL	5	13.20 ^a	Tramal 100	CS
			^a	Tramahexal	SZ
3486L NP or 3485K NP	BENZYL PENICILLIN Powder for injection 600 mg or PROCAINE PENICILLIN Injection 1.5 g	10	*43.02	BenPen	CS
3487M NP	BENZYL PENICILLIN Powder for injection 3 g	5	92.32	Cilicaine	QA
3488N NP	PROMETHAZINE HYDROCHLORIDE Injection 50 mg in 2 mL	1	12.85	BenPen	CS
3489P	METHOXYFLURANE Liquid for inhalation 999.9 mg per g, 3 mL (with inhaler)	10	*22.42	Hospira Pty Limited	HH
3491R NP	TERBUTALINE SULFATE Injection 500 micrograms in 1 mL	1	44.88	Penthrox	NQ
3494X NP	VERAPAMIL HYDROCHLORIDE Injection 5 mg in 2 mL	5	30.69	Bricanyl	AP
3495Y NP	SALBUTAMOL SULFATE Oral pressurised inhalation 100 micrograms (base) per dose (200 doses), CFC-free formulation	5	12.48	Isoptin	AB
3495Y NP	SALBUTAMOL SULFATE Oral pressurised inhalation 100 micrograms (base) per dose (200 doses), CFC-free formulation	‡1	10.22 ^a	Asmol CFC-free	AL
			^a	Airomir	IA
			^a	APO-Salbutamol Inhaler	TX
3495Y NP	SALBUTAMOL SULFATE Oral pressurised inhalation 100 micrograms (base) per dose (200 doses), CFC-free formulation	‡1	11.38 ^a	Ventolin CFC-free	GK
or 3496B NP	or SALBUTAMOL SULFATE Nebuliser solution single dose units 2.5 mg (base) in 2.5 mL, 30	‡1	12.47 ^a	Asmol 2.5 uni-dose	AF
			^a	GenRx Salbutamol	GX
			^a	Butamol 2.5	QA
			^a	Pharmacor Salbutamol 2.5	CR
			^a	Salbutamol Sandoz	SZ
			^a	Salbutamol-GA	GM
3496B NP	SALBUTAMOL SULFATE Nebuliser solution single dose units 2.5 mg (base) in 2.5 mL, 30	‡1	13.14 ^a	Ventolin Nebules	GK

EMERGENCY DRUG SUPPLIES

Code	Name, Manner of Administration and Form	Max. Qty	Dispensed		Proprietary Name and Manufacturer	
			Price for	Max. Qty		
			\$			
3497C NP	SALBUTAMOL SULFATE Nebuliser solution single dose units 5 mg (base) in 2.5 mL, 30	±1	12.80	^a	Asmol 5 uni-dose	AF
				^a	GenRx Salbutamol	GX
				^a	Butamol 5	QA
				^a	Pharmacor Salbutamol 5	CR
				^a	Salbutamol Sandoz	SZ
				^a	Salbutamol-GA	GM
3497C NP	SALBUTAMOL SULFATE Nebuliser solution single dose units 5 mg (base) in 2.5 mL, 30	±1	13.48	^a	Ventolin Nebules	GK

Special Pharmaceutical Benefits

GENERAL PHARMACEUTICAL BENEFITS

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Reimbursement Price for Max. Qty \$	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	----------------	---------	--	--	--	-----------------------------

1888J	Powder for paediatric oral drops	±1	1	^s 0.61	#13.36	#13.97	14.81	Amoxil	GK
NP	100 mg per mL, 20 mL								

Cautionary Remarks

Treatment of infections suspected or proven to be due to a susceptible organism in patients who require a liquid formulation and in whom the syrup formulations are unsuitable.

9714G NP	Powder for paediatric oral drops 100 mg per mL, 20 mL	£1	1	..	#13.97	#13.97	15.42	Amoxil	GK
-------------	--	----	---	----	--------	--------	-------	--------	----

Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics.

No applications for increased maximum quantities and/or repeats will be authorised.

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8298R	Tablet 2.5 mg (as hydrochloride)	4	5	^s 2.78	*26.00	*28.78	27.11	Naramig	GK
-------	----------------------------------	---	---	-------------------	--------	--------	-------	---------	----

Naratriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.

Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where:

- (a) adverse events have occurred with other suitable PBS-listed drugs; or
- (b) drug interactions have occurred with other suitable PBS-listed drugs; or
- (c) drug interactions are expected to occur with other suitable PBS-listed drugs; or
- (d) transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance; or
- (e) transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences.

No applications for increased maximum quantities and/or repeats will be authorised.

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9734H NP	Tablet 2.5 mg (as hydrochloride)	4	5	..	*28.78	*28.78	29.89	Naramig	GK
-------------	----------------------------------	---	---	----	--------	--------	-------	---------	----

Zolmitriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.

SPECIAL PHARMACEUTICAL BENEFITS

The special patient contribution is payable by all patients in addition to the relevant patient contribution for concessional and general patients. Other than for bleomycin sulfate, exemptions on medical grounds are available. For eligible veterans under RPBS provisions, see RPBS EXPLANATORY NOTES, paragraph 32.

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Reimbursement Price for Max. Qty \$	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<u>Authority required</u>								
Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8266C	Tablet 2.5 mg	4	5	\$2.76	*25.94	*28.70	27.05	Zomig
NP								AP

ZOLMITRIPTAN

Caution

Zolmitriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.

Authority required

Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where:

- (a) adverse events have occurred with other suitable PBS-listed drugs; or
- (b) drug interactions have occurred with other suitable PBS-listed drugs; or
- (c) drug interactions are expected to occur with other suitable PBS-listed drugs; or
- (d) transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance; or
- (e) transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9736K NP	Tablet 2.5 mg	4	5	..	*28.70	*28.70	29.81	Zomig	AP
-------------	---------------	---	---	----	--------	--------	-------	-------	----

PHARMACEUTICAL BENEFITS FOR DENTAL USE

AMOXYCILLIN

3310F	Powder for paediatric oral drops 100 mg per mL, 20 mL	£1	..	\$0.61	#13.36	#13.97	14.81	Amoxil	GK
-------	--	----	----	--------	--------	--------	-------	--------	----

General Pharmaceutical Benefits

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Alimentary tract and metabolism

Stomatological preparations

Stomatological preparations

Antiinfectives and antiseptics for local oral treatment

2931G NP	AMPHOTERICIN Lozenge 10 mg	20	1	..	12.13	13.24	Fungilin	QA
-------------	--------------------------------------	----	---	----	-------	-------	----------	----

3033P NP	NYSTATIN Oral suspension 100,000 units per mL, 24 mL	1	1	..	11.24	12.35	Mycostatin	FM
							Nilstat	QA

Other agents for local oral treatment

BENZYDAMINE HYDROCHLORIDE

Restricted benefit

Radiation induced mucositis.

1121B NP	Mouth and throat rinse 22.5 mg per 15 mL, 500 mL	1	1	..	22.36	23.47	Diffiam	IA
-------------	---	---	---	----	-------	-------	---------	----

Drugs for acid related disorders

Antacids

Combinations and complexes of aluminium, calcium and magnesium compounds

2157M NP	ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE Oral suspension 200 mg-200 mg per 5 mL, 500 mL	2	5	..	*17.80	18.91	Mylanta P	JT
-------------	--	---	---	----	--------	-------	-----------	----

2159P NP	ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE Oral suspension 250 mg-120 mg-120 mg per 5 mL, 500 mL	2	5	..	*17.80	18.91	Gastrogel	FM
-------------	---	---	---	----	--------	-------	-----------	----

Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)

H₂-receptor antagonists

Note

The base-priced drugs in this therapeutic group are cimetidine, nizatidine and ranitidine hydrochloride (except ranitidine hydrochloride effervescent tablet 150 mg (base) and syrup 150 mg (base) per 10 mL, 300 mL).

CIMETIDINE

Note

Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug.

1158Y NP	Tablet 400 mg	60	5	..	18.58	19.69	Magicul 400	AF
-------------	---------------	----	---	----	-------	-------	-------------	----

1159B NP	Tablet 800 mg	30	5	..	18.58	19.69	Magicul 800	AF
-------------	---------------	----	---	----	-------	-------	-------------	----

FAMOTIDINE

Note

Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug.

2487X NP	Tablet 20 mg	60	5	..	14.32	15.43	^a Ausfam 20	QA
							^a Chem mart Famotidine	CH
							^a Famotidine Sandoz	SZ

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a GenRx Famotidine GX
							^a Pamacid 20 AF
							^a Pepzan GM
							^a Terry White Chemists Famotidine TW
2488Y NP	Tablet 40 mg	30	5	..	14.32	15.43	^a Ausfam 40 QA
							^a Chem mart Famotidine CH
							^a Famotidine Sandoz SZ
							^a GenRx Famotidine GX
							^a Pamacid 40 AF
							^a Pepzan GM
							^a Terry White Chemists Famotidine TW
				^B 3.84	18.16	15.43	^a Pepcidine MK
NIZATIDINE							
Note							
Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug.							
1504E NP	Capsule 300 mg	30	5	..	18.53	19.64	^a Nizac LN
							^a Tacidine AF
				^B 5.32	23.85	19.64	^a Tazac AS
1505F NP	Capsule 150 mg	60	5	..	18.53	19.64	^a Nizac LN
							^a Tacidine AF
				^B 5.32	23.85	19.64	^a Tazac AS
RANITIDINE HYDROCHLORIDE							
Note							
Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug.							
1937Y NP	Effervescent tablet 150 mg (base)	60	5	^T 3.16	*20.58	18.53	Zantac GK
1977C NP	Tablet 300 mg (base)	30	5	..	17.40	18.51	^a Ausran QA
							^a Chem mart Ranitidine CH
							^a GenRx Ranitidine GX
							^a Rani 2 AF
							^a Ranitidine Sandoz SZ
							^a Terry White Chemists Ranitidine TW
							^a Ulcaid RA
				^B 2.35	19.75	18.51	^a Zantac GK
1978D NP,MW	Tablet 150 mg (base)	60	5	..	17.40	18.51	^a Ausran QA
							^a Chem mart Ranitidine CH
							^a GenRx Ranitidine GX
							^a Rani 2 AF
							^a Ranitidine-PS FZ
							^a Ranitidine Sandoz SZ
							^a Ranoxyl GM
							^a Terry White TW

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							Chemists Ranitidine	
							^a Ulcaid	RA
				^B 2.35	19.75	18.51	^a Zantac	GK
8162N NP	Syrup 150 mg (base) per 10 mL, 300 mL	2	5	^T 2.20	*26.82	25.73	Zantac Syrup	GK

RANITIDINE HYDROCHLORIDE

Note

Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug.

Authority required

Adverse effects occurring with all of the base-priced drugs;

Drug interactions occurring with all of the base-priced drugs;

Drug interactions expected to occur with all of the base-priced drugs;

Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.

8903N NP	Effervescent tablet 150 mg (base)	60	5	..	*20.58	21.69	Zantac	GK
8905Q NP	Syrup 150 mg (base) per 10 mL, 300 mL	2	5	..	*26.82	27.93	Zantac Syrup	GK

Prostaglandins

MISOPROSTOL

Caution

Misoprostol is a prostaglandin analogue. It should not be used in pregnant women.

Authority required (STREAMLINED)

2630

Reduction in the incidence of gastrointestinal complications in patients who have a history of peptic ulcer disease and where NSAID therapy is essential;

2631

Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery. The date and the method by which the ulcer was proven must be documented in the patient's medical records when treatment is initiated;

2632

Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years. The date and the method by which the ulcer was proven must be documented in the patient's medical records when treatment is initiated.

1648R	Tablet 200 micrograms	120	2	..	52.22	35.40	Cytotec	PF
-------	-----------------------	-----	---	----	-------	-------	---------	----

Proton pump inhibitors

ESOMEPRAZOLE MAGNESIUM TRIHYDRATE

Restricted benefit

Initial treatment of gastric ulcer.

Note

Helicobacter pylori eradication therapy should be considered.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8886Q NP	Tablet (enteric coated), equivalent to 20 mg esomeprazole	30	1	..	30.14	31.25	Nexium	AP
-------------	---	----	---	----	-------	-------	--------	----

ESOMEPRAZOLE MAGNESIUM TRIHYDRATE

Restricted benefit

Healing of gastro-oesophageal reflux disease.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8601Q NP	Tablet (enteric coated), equivalent to 40 mg esomeprazole	30	1	..	45.79	35.40	Nexium	AP
-------------	---	----	---	----	-------	-------	--------	----

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE							
<u>Restricted benefit</u>							
Maintenance of healed gastro-oesophageal reflux disease;							
Scleroderma oesophagus;							
Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion.							
<u>Note</u>							
No applications for increased maximum quantities will be authorised.							
8600P <i>NP</i>	Tablet (enteric coated), equivalent to 20 mg esomeprazole	30	5	..	30.14	31.25	Nexium AP
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE							
<u>Authority required</u>							
Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion;							
Scleroderma oesophagus.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
3401B <i>NP</i>	Tablet (enteric coated), equivalent to 40 mg esomeprazole	30	5	..	45.79	35.40	Nexium AP
LANSOPRAZOLE							
<u>Restricted benefit</u>							
Initial treatment of peptic ulcer.							
<u>Note</u>							
Helicobacter pylori eradication therapy should be considered.							
No applications for increased repeats will be authorised.							
<u>Note</u>							
Pharmaceutical benefits that have the form lansoprazole capsule 30 mg and pharmaceutical benefits that have the form lansoprazole tablet 30 mg (orally disintegrating) are equivalent for the purposes of substitution.							
2240X <i>NP</i>	Capsule 30 mg	28	1	..	23.55	24.66 ^a	APO-Lansoprazole TX
						^a	Lanzopran RA
						^a	Zopral AF
9477T <i>NP</i>	Tablet 30 mg (orally disintegrating)	28	1	^b 0.96	24.51	24.66 ^a	Zoton FasTabs PF
LANSOPRAZOLE							
<u>Restricted benefit</u>							
Gastro-oesophageal reflux disease;							
Scleroderma oesophagus.							
8198L <i>NP</i>	Capsule 15 mg	30	5	..	16.71	17.82	Zopral AF
9331D <i>NP</i>	Tablet 15 mg (orally disintegrating)	28	5	..	16.00	17.11	Zoton FasTabs PF
LANSOPRAZOLE							
<u>Restricted benefit</u>							
Gastro-oesophageal reflux disease;							
Scleroderma oesophagus.							

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Note Pharmaceutical benefits that have the form lansoprazole capsule 30 mg and pharmaceutical benefits that have the form lansoprazole tablet 30 mg (orally disintegrating) are equivalent for the purposes of substitution.							
2241Y NP	Capsule 30 mg	28	5	..	23.55	24.66 ^a	APO-Lansoprazole TX
						^a	Lanzopran RA
						^a	Zopral AF
9478W NP	Tablet 30 mg (orally disintegrating)	28	5	^B 0.96	24.51	24.66 ^a	Zoton FasTabs PF
OMEPRAZOLE Restricted benefit Initial treatment of peptic ulcer.							
Note Helicobacter pylori eradication therapy should be considered.							
No applications for increased repeats will be authorised.							
Note Pharmaceutical benefits that have the form omeprazole tablet 20 mg and pharmaceutical benefits that have the form omeprazole tablet 20 mg (as magnesium) are equivalent for the purposes of substitution.							
8331L NP	Tablet 20 mg	30	1	..	20.14	21.25 ^a	APO-Omeprazole TX
						^a	Chem mart CH
						^a	Omeprazole GX
						^a	GenRx Omeprazole SZ
						^a	Meprazol GM
						^a	Omeprazole-GA GQ
						^a	Omeprazole generichealth FZ
						^a	Omeprazole-PS RA
						^a	Omeprazole Ranbaxy WA
						^a	Omeprazole Winthrop ZP
						^a	Ozmep TW
						^a	Terry White Chemists Omeprazole
9109K NP	Tablet 20 mg (as magnesium)	30	1	..	20.14	21.25 ^a	Acimax Tablets AL
						^a	Omepral PM
						^a	Omeprazole SZ
				^B 2.23	22.37	21.25 ^a	Sandoz AP
						^a	Losec Tablets
OMEPRAZOLE Restricted benefit Initial treatment of peptic ulcer.							
Note Helicobacter pylori eradication therapy should be considered.							
No applications for increased repeats will be authorised.							
1326T NP	Capsule 20 mg	30	1	..	20.14	21.25 ^a	APO-Omeprazole TX
						^a	Omeprazole HX
						^a	Sandoz GM
						^a	Omepro-GA QA
						^a	Pemzo

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							^a Pharmacor	CR
							^a Omeprazole 20	
							^a Probitor	SZ
<hr/>								
OMEPRAZOLE								
<u>Restricted benefit</u>								
Gastro-oesophageal reflux disease;								
Scleroderma oesophagus;								
Zollinger-Ellison syndrome.								
<u>Note</u>								
Pharmaceutical benefits that have the form omeprazole tablet 20 mg and pharmaceutical benefits that have the form omeprazole tablet 20 mg (as magnesium) are equivalent for the purposes of substitution.								
8333N NP	Tablet 20 mg	30	5	..	20.14	21.25	^a APO-Omeprazole	TX
							^a Chem mart	CH
							^a Omeprazole	
							^a GenRx Omeprazole	GX
							^a Meprazol	SZ
							^a Omeprazole-GA	GM
							^a Omeprazole	GQ
							^a generichealth	
							^a Omeprazole-PS	FZ
							^a Omeprazole	RA
							^a Ranbaxy	
							^a Omeprazole	WA
							^a Winthrop	
							^a Ozmepr	ZP
							^a Terry White	TW
							^a Chemists	
							^a Omeprazole	
9110L NP	Tablet 20 mg (as magnesium)	30	5	..	20.14	21.25	^a Acimax Tablets	AL
							^a Omepral	PM
							^a Omeprazole	SZ
							^a Sandoz	
				^B 2.23	22.37	21.25	^a Losec Tablets	AP
<hr/>								
OMEPRAZOLE								
<u>Restricted benefit</u>								
Gastro-oesophageal reflux disease;								
Scleroderma oesophagus;								
Zollinger-Ellison syndrome.								
1327W NP	Capsule 20 mg	30	5	..	20.14	21.25	^a APO-Omeprazole	TX
							^a Omeprazole	HX
							^a Sandoz	
							^a Omepro-GA	GM
							^a Pemzo	QA
							^a Pharmacor	CR
							^a Omeprazole 20	
							^a Probitor	SZ
8332M NP	Tablet 10 mg (as magnesium)	30	5	..	16.12	17.23	Losec Tablets	AP

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer
PANTOPRAZOLE SODIUM SESQUIHYDRATE								
<u>Restricted benefit</u>								
Initial treatment of peptic ulcer.								
<u>Note</u>								
Helicobacter pylori eradication therapy should be considered.								
<u>Note</u>								
No applications for increased repeats will be authorised.								
8007K NP	Tablet (enteric coated), equivalent to 40 mg pantoprazole	30	2	..	21.59	22.70	^a	APO-Pantoprazole TX
							^a	Chem mart CH
							^a	Pantoprazole Ozpan RA
							^a	Panthron GN
							^a	Panto NZ
							^a	Pantofast 40 RZ
							^a	Pantoloc NH
							^a	Pantoprazole-GA GM
							^a	Pantoprazole generichealth GQ
							^a	Pantoprazole-PS FZ
							^a	Pantoprazole Sandoz SZ
							^a	Salpraz AF
							^a	Somac NQ
							^a	Sozol QA
							^a	Terry White Chemists TW
							^a	Pantoprazole Torzole 40 TA
9423Y NP	Sachet containing granules 40 mg	30	2	..	30.81	31.92		Somac NQ
PANTOPRAZOLE SODIUM SESQUIHYDRATE								
<u>Restricted benefit</u>								
Gastro-oesophageal reflux disease.								
<u>Restricted benefit</u>								
Scleroderma oesophagus;								
Zollinger-Ellison syndrome.								
8008L NP	Tablet (enteric coated), equivalent to 40 mg pantoprazole	30	5	..	21.59	22.70	^a	APO-Pantoprazole TX
							^a	Chem mart CH
							^a	Pantoprazole Ozpan RA
							^a	Panthron GN
							^a	Panto NZ
							^a	Pantofast 40 RZ
							^a	Pantoloc NH
							^a	Pantoprazole-GA GM
							^a	Pantoprazole generichealth GQ
							^a	Pantoprazole-PS FZ
							^a	Pantoprazole Sandoz SZ
							^a	Salpraz AF
							^a	Somac NQ
							^a	Sozol QA

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8399C NP	Tablet (enteric coated), equivalent to 20 mg pantoprazole	30	5	..	13.87	14.98	^a Terry White Chemists Pantoprazole	TW
							^a Torzole 40	TA
							^a APO-Pantoprazole	TX
							^a Chem mart Pantoprazole	CH
							^a Ozpan	RA
							^a Panto	NZ
							^a Pantofast 20	RZ
							^a Pantoloc	NH
							^a Pantoprazole-GA	GM
							^a Pantoprazole generichealth	GQ
							^a Pantoprazole-PS	FZ
							^a Pantoprazole Sandoz	SZ
							^a Salpraz	AF
							^a Somac	NQ
							^a Terry White Chemists Pantoprazole	TW
9424B NP	Sachet containing granules 40 mg	30	5	..	30.81	31.92	^a Torzole 20	TA
							Somac	NQ

RABEPRAZOLE SODIUM

Restricted benefit

Initial treatment of peptic ulcer.

Note

Helicobacter pylori eradication therapy should be considered.

Note

No applications for increased repeats will be authorised.

8509W NP	Tablet 20 mg (enteric coated)	30	2	..	33.80	34.91	Pariet	JC
-------------	-------------------------------	----	---	----	-------	-------	--------	----

RABEPRAZOLE SODIUM

Restricted benefit

Gastro-oesophageal reflux disease;

Scleroderma oesophagus.

8507R NP	Tablet 10 mg (enteric coated)	28	5	..	33.80	34.91	Pariet	JC
8508T NP	Tablet 20 mg (enteric coated)	30	5	..	33.80	34.91	Pariet	JC

Combinations for eradication of Helicobacter pylori

ESOMEPRAZOLE MAGNESIUM TRIHYDRATE and CLARITHROMYCIN and AMOXYCILLIN

Restricted benefit

Eradication of Helicobacter pylori associated with peptic ulcer disease.

8738X NP	Pack containing 14 tablets (enteric coated) equivalent to 20 mg esomeprazole, 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg	£1	65.37	35.40	Nexium Hp7	AP
-------------	---	----	----	----	-------	-------	------------	----

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
OMEPRAZOLE and CLARITHROMYCIN and AMOXYCILLIN								
<u>Restricted benefit</u>								
Eradication of Helicobacter pylori associated with peptic ulcer disease.								
8272J NP	Pack containing 14 capsules omeprazole 20 mg, 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg	1	58.74	35.40	Probitor Hp7	SZ
<i>Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)</i>								
SODIUM ALGINATE with CALCIUM CARBONATE and SODIUM BICARBONATE								
2014B NP	Oral liquid 1 g-320 mg-534 mg in 20 mL, 500 mL	2	5	..	*14.78	15.89	Gaviscon P	RC
SUCRALFATE								
2055E NP	Tablet equivalent to 1 g anhydrous sucralfate	120	2	..	24.82	25.93 ^a	Ulcyte	AF
				^B 2.06	26.88	25.93 ^a	Carafate	AS

Drugs for functional gastrointestinal disorders

Belladonna and derivatives, plain

Belladonna alkaloids, tertiary amines

ATROPINE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1089H NP	Injection containing atropine sulfate 600 micrograms in 1 mL	10	1	..	20.64	21.75	Pfizer Australia Pty Ltd	PF
-------------	---	----	---	----	-------	-------	-----------------------------	----

Propulsives

Propulsives

DOMPERIDONE

1347X NP	Tablet 10 mg	25	8.99	10.10	Motilium	JC
-------------	--------------	----	----	----	------	-------	----------	----

METOCLOPRAMIDE HYDROCHLORIDE

1206L NP,MW	Injection 10 mg in 2 mL	10	13.09	14.20	Maxolon	VT
1207M NP,MW	Tablet 10 mg	25	8.30	9.41	Pramin	AF
				^B 3.02	11.32	9.41	Maxolon	VT

Antiemetics and antinauseants

Antiemetics and antinauseants

Serotonin (5HT₃) antagonists

GRANISETRON HYDROCHLORIDE

Restricted benefit

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

8728J NP	Tablet 2 mg (base)	2	*59.08	35.40	Kytril	HH
-------------	--------------------	---	----	----	--------	-------	--------	----

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
GRANISETRON HYDROCHLORIDE <u>Authority required (STREAMLINED)</u> 3611 Management of nausea and vomiting associated with radiotherapy being used to treat malignancy.								
8873B NP	Tablet 2 mg (base)	5	1	..	137.94	35.40	Kytril	HH
<hr/>								
GRANISETRON HYDROCHLORIDE <u>Restricted benefit</u> Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration. Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle. <u>Note</u> For item codes 8729K and 1812J, pharmaceutical benefits that have the form concentrated injection 3 mg (base) in 3 mL are equivalent for the purposes of substitution.								
1812J NP	Concentrated injection 3 mg (base) in 3 mL	1	*37.98	35.40	^a Granisetron Kabi	PK
8729K NP	Concentrated injection 3 mg (base) in 3 mL	1	37.95	35.40	^a Kytril	HH
<hr/>								
GRANISETRON HYDROCHLORIDE <u>Authority required (STREAMLINED)</u> 3611 Management of nausea and vomiting associated with radiotherapy being used to treat malignancy. <u>Note</u> For item codes 8730L and 1814L, pharmaceutical benefits that have the form concentrated injection 3 mg (base) in 3 mL are equivalent for the purposes of substitution.								
1814L NP	Concentrated injection 3 mg (base) in 3 mL	1	*37.98	35.40	^a Granisetron Kabi	PK
8730L NP	Concentrated injection 3 mg (base) in 3 mL	1	37.95	35.40	^a Kytril	HH
<hr/>								
ONDANSETRON <u>Restricted benefit</u> Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration. Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.								
8224W NP	Tablet 4 mg (as hydrochloride dihydrate)	4	26.52	27.63	^a APO-Ondansetron	TX
							^a Ondansetron-DRLA	RZ
							^a Ondaz	SZ
							^a Onsetron 4	ZP
							^a Zofran	GK
							^a Zondan	GM
8225X NP	Tablet 8 mg (as hydrochloride dihydrate)	4	37.83	35.40	^a APO-Ondansetron	TX
							^a Ondansetron-DRLA	RZ
							^a Ondaz	SZ
							^a Onsetron 8	ZP
							^a Zofran	GK
							^a Zondan	GM
8226Y NP	I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL	1	8.91	10.02	^a Ondansetron Alphapharm	AF
							^a Ondansetron-Claris	AE

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8227B NP	I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL	1	10.30	11.41	^a Ondaz	SZ
							^a Onsetron	ZP
							^a Zofran	GK
							^a Ondansetron Alphapharm	AF
							^a Ondansetron-Clarix	AE
							^a Ondaz	SZ
							^a Onsetron	ZP
							^a Zofran	GK
9441X NP	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	1	102.06	35.40	Zofran syrup 50 mL	GK

ONDANSETRON

Restricted benefit

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

Note

Pharmaceutical benefits that have the form ondansetron tablet (orally disintegrating) 4 mg and pharmaceutical benefits that have the form ondansetron wafer 4 mg are equivalent for the purposes of substitution.

5470X NP	Tablet (orally disintegrating) 4 mg	4	26.52	27.63	^a Ondansetron ODT- DRLA	RZ
							^a Onsetron ODT 4	WQ
8410P NP	Wafer 4 mg	4	26.52	27.63	^a Ondaz Zydis	SZ
							^a Zofran Zydis	GK

ONDANSETRON

Restricted benefit

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

Note

Pharmaceutical benefits that have the form ondansetron tablet (orally disintegrating) 8 mg and pharmaceutical benefits that have the form ondansetron wafer 8 mg are equivalent for the purposes of substitution.

5471Y NP	Tablet (orally disintegrating) 8 mg	4	37.83	35.40	^a Ondansetron ODT- DRLA	RZ
							^a Onsetron ODT 8	WQ
8411Q NP	Wafer 8 mg	4	37.83	35.40	^a Ondaz Zydis	SZ
							^a Zofran Zydis	GK

ONDANSETRON

Authority required (STREAMLINED)

3611

Management of nausea and vomiting associated with radiotherapy being used to treat malignancy.

1594X NP	Tablet 4 mg (as hydrochloride dihydrate)	10	1	..	54.50	35.40	^a APO-Ondansetron	TX
							^a Ondansetron-DRLA	RZ
							^a Ondansetron Tabs Pfizer	FZ
							^a Ondaz	SZ

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
1595Y NP	Tablet 8 mg (as hydrochloride dihydrate)	10	1	..	81.42	35.40	^a Onsetron 4	ZP
							^a Zilfojim 4	DO
							^a Zofran	GK
							^a Zondan	GM
							^a APO-Ondansetron	TX
							^a Ondansetron-DRLA	RZ
							^a Ondansetron Tabs Pfizer	FZ
							^a Ondaz	SZ
							^a Onsetron 8	ZP
							^a Zilfojim 8	DO
1596B NP	I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL	1	8.91	10.02	^a Zofran	GK
							^a Zondan	GM
							^a Ondansetron	AF
							^a Alphapharm	
							^a Ondansetron-Clarix	AE
1597C NP	I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL	1	10.30	11.41	^a Ondaz	SZ
							^a Onsetron	ZP
							^a Zofran	GK
							^a Ondansetron	AF
							^a Alphapharm	
8233H NP	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	1	1	..	102.06	35.40	^a Ondansetron-Clarix	AE
							^a Ondaz	SZ
							^a Onsetron	ZP
							^a Zofran	GK
							^a Zofran syrup 50 mL	GK

ONDANSETRON

Authority required (STREAMLINED)

3611

Management of nausea and vomiting associated with radiotherapy being used to treat malignancy.

Note

Pharmaceutical benefits that have the form ondansetron tablet (orally disintegrating) 4 mg and pharmaceutical benefits that have the form ondansetron wafer 4 mg are equivalent for the purposes of substitution.

5472B NP	Tablet (orally disintegrating) 4 mg	10	1	..	54.50	35.40	^a Ondansetron ODT-DRLA	RZ
							^a Onsetron ODT 4	WQ
8412R NP	Wafer 4 mg	10	1	..	54.50	35.40	^a Ondaz Zydis	SZ
							^a Zofran Zydis	GK

ONDANSETRON

Authority required (STREAMLINED)

3611

Management of nausea and vomiting associated with radiotherapy being used to treat malignancy.

Note

Pharmaceutical benefits that have the form ondansetron tablet (orally disintegrating) 8 mg and pharmaceutical benefits that have the form ondansetron wafer 8 mg are equivalent for the purposes of substitution.

5473C NP	Tablet (orally disintegrating) 8 mg	10	1	..	81.42	35.40	^a Ondansetron ODT-DRLA	RZ
							^a Onsetron ODT 8	WQ
8413T	Wafer 8 mg	10	1	..	81.42	35.40	^a Ondaz Zydis	SZ

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
NP							

^a Zofran Zydis GK

PALONOSETRON

Restricted benefit

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Note

No applications for increased maximum quantities will be authorised. Palonosetron is not PBS-subsidised for administration with oral 5-HT3 antagonists.

5295Q NP	Injection 250 micrograms (as hydrochloride) in 5 mL	1	47.96	35.40	Aloxi	TS
-------------	---	---	----	----	-------	-------	-------	----

TROPISETRON HYDROCHLORIDE

Restricted benefit

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

2745L NP	Capsule 5 mg (base)	2	50.82	35.40	Navoban	NV
2746M NP	I.V. injection 5 mg (base) in 5 mL	1	29.39	30.50	Navoban	NV

Other antiemetics

APREPITANT

Note

Aprepitant is not PBS-subsidised for nausea and vomiting associated with radiotherapy being used to treat malignancy.

Authority required (STREAMLINED)

3619

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone, where any 1 of the following chemotherapy agents are to be administered:

- (a) altretamine;
- (b) carmustine;
- (c) cisplatin when a single dose constitutes a cycle of chemotherapy;
- (d) cyclophosphamide at a dose of 1500 mg per square metre per day or greater;
- (e) dacarbazine;
- (f) procarbazine when a single dose constitutes a cycle of chemotherapy;
- (g) streptozocin.

No more than 1 pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy;

3620

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5HT3 antagonist and dexamethasone, where cyclophosphamide and an anthracycline are to be co-administered.

No more than 1 pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy;

3621

Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone on day 1, where the patient has had a prior episode of chemotherapy induced nausea or vomiting where any 1 of the following intravenous chemotherapy agents is to be administered:

- (a) arsenic trioxide;
- (b) azacitidine;
- (c) carboplatin;
- (d) cyclophosphamide at a dose of less than 1500 mg per square metre per day;
- (e) cytarabine at a dose of greater than 1 g per square metre per day;
- (f) dactinomycin;
- (g) daunorubicin;
- (h) doxorubicin;
- (i) epirubicin;
- (j) fotemustine;
- (k) idarubicin;
- (l) ifosfamide;
- (m) irinotecan;
- (n) melphalan;
- (o) methotrexate at a dose of 250 mg to 1 g per square metre;

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	(p) oxaliplatin; (q) raltitrexed. No more than one pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy. Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle.							
	Note No applications for increased maximum quantities and/or repeats will be authorised.							
8808N NP	Pack containing 1 capsule 125 mg and 2 capsules 80 mg	1	5	..	138.99	35.40	Emend	MK
PROCHLORPERAZINE								
Caution Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.								
Note As prochlorperazine may be associated with parkinsonism and tardive dyskinesia it should be used for short-term treatment only. However, authorities for increased maximum quantities and/or repeats of prochlorperazine tablets will be granted for the treatment of emesis associated with malignant disease.								
2369Q NP	Injection containing prochlorperazine mesylate 12.5 mg in 1 mL	10	16.92	18.03	Stemetil	SW
2893G NP	Tablet containing prochlorperazine maleate 5 mg	25	8.79	9.90	^a APO-Prochlorperazine	TX
							^a Pharmacor Prozine 5	CR
							^a ProCalm	QA
							^a Prochlorperazine-GA	GM
							^a Prochlorperazine GH	GQ
							^a Prochlorperazine-PS	FZ
							^a Stemetil	AV
				^B 2.57	11.36	9.90	^a Stemetil	SW
2895J NP	Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5	1	2	..	20.03	21.14	Stemetil	SW

Bile and liver Therapy

Bile therapy

Bile acid preparations

URSODEOXYCHOLIC ACID

Authority required (STREAMLINED)

1700

Primary biliary cirrhosis.

Note

Not for use in the treatment of sclerosing cholangitis or cholelithiasis.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8448P NP	Capsule 250 mg	200	2	..	*372.70	35.40	Ursafalk	OA
-------------	----------------	-----	---	----	---------	-------	----------	----

Laxatives

Laxatives

Contact laxatives

BISACODYL

Restricted benefit

Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty	Safety Net		
					\$	\$		
	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities; For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult; Patients receiving palliative care; Terminal malignant neoplasia; Anorectal congenital abnormalities; Megacolon.							
1258F NP	Suppositories 10 mg, 12	3	4	..	*18.43	19.54	Petrus Bisacodyl Suppositories	PP
1259G NP	Tablet 5 mg	200	2	..	14.21	15.32	Bisalax	AS
							Lax-Tab	AE
1260H NP	Suppositories 10 mg, 10	3	5	..	*21.04	22.15	^a Petrus Bisacodyl Suppositories	PP
				^B 1.50	*22.54	22.15	^a Dulcolax	BY

Bulk producers

STERCULIA with FRANGULA BARK

Restricted benefit

Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;

Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;

For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;

Patients receiving palliative care;

Terminal malignant neoplasia;

Anorectal congenital abnormalities;

Megacolon.

1104D NP	Granules 620 mg-80 mg per g (62%-8%), 500 g	£1	1	..	26.47	27.58	Normacol Plus	NE
-------------	---	----	---	----	-------	-------	---------------	----

Osmotically acting laxatives

LACTULOSE

Restricted benefit

Hepatic coma or precoma (chronic porto-systemic encephalopathy);

Constipation in patients with malignant neoplasia.

3064G NP	Mixture 3.34 g per 5 mL, 500 mL	£1	5	..	12.11	13.22	^a Actilax	AF
							^a Genlac	QA
							^a GenRx Lactulose	GX
							^a Lac-Dol	GM
							^a Lactocur	SZ
				^B 1.20	13.31	13.22	^a Duphalac	AB

MACROGOL 3350

Restricted benefit

Constipation in patients with malignant neoplasia;

Chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents;

Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function not responding to other oral therapies;

Patients receiving palliative care.

3416T NP	Powder for oral solution 510 g	£1	5	..	20.65	21.76	^a MediHealth ClearLax	ON
							^a OsmoLax	KY
							^a your pharmacy Clear Laxative	OY
8612G NP	Sachets containing powder for solution 13.125 g with electrolytes, 30	£1	5	..	20.65	21.76	Movicol	NE

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Enemas

BISACODYL

Restricted benefit

Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;

Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;

For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;

Patients receiving palliative care;

Terminal malignant neoplasia;

Anorectal congenital abnormalities;

Megacolon.

1263L NP	Enemas 10 mg in 5 mL, 25	1	2	..	38.04	35.40	Bisalax	AS
-------------	--------------------------	---	---	----	-------	-------	---------	----

SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE

Restricted benefit

Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;

Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;

For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;

Patients receiving palliative care;

Terminal malignant neoplasia;

Anorectal congenital abnormalities;

Megacolon.

2091C NP	Enemas 3.125 g-450 mg-45 mg in 5 mL, 12	2	2	..	*32.38	33.49	^a Micolette	AE
							^a Microlax	JT

Other laxatives

GLYCEROL

Restricted benefit

Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;

Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;

For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;

Patients receiving palliative care;

Terminal malignant neoplasia;

Anorectal congenital abnormalities;

Megacolon.

2555L NP	Suppositories 700 mg (for infants), 12	3	5	..	*19.57	20.68	Petrus Pharmaceuticals Pty Ltd	PP
2556M NP	Suppositories 1.4 g (for children), 12	3	5	..	*19.99	21.10	Petrus Pharmaceuticals Pty Ltd	PP
2557N NP	Suppositories 2.8 g (for adults), 12	3	5	..	*20.50	21.61	Petrus Pharmaceuticals Pty Ltd	PP

Antidiarrheals, intestinal antiinflammatory/ antiinfective agents

Intestinal antiinfectives

Antibiotics

NYSTATIN

1696G NP	Tablet 500,000 units	50	18.08	19.19	Nilstat	QA
1699K	Capsule 500,000 units	50	18.08	19.19	Nilstat	QA

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
NP								

VANCOMYCIN

Authority required

Antibiotic associated pseudomembranous colitis due to Clostridium difficile which is unresponsive to metronidazole;

Antibiotic associated pseudomembranous colitis due to Clostridium difficile where there is intolerance to metronidazole.

Note

Metronidazole has similar efficacy to vancomycin but may have less selective pressure to vancomycin resistant enterococci and is therefore the preferred treatment.

3113W	Capsule 125 mg (125,000 i.u.) vancomycin activity	40	*232.36	35.40	Vancocin	AS
3114X	Capsule 250 mg (250,000 i.u.) vancomycin activity	40	*440.16	35.40	Vancocin	AS

Electrolytes with carbohydrates

Oral rehydration salt formulations

ELECTROLYTE REPLACEMENT (ORAL)

Note

Each sachet contains sodium chloride 470 mg, potassium chloride 300 mg, sodium acid citrate 530 mg and glucose 3.56 g.

3196F	Sachets containing powder for oral solution	1	13.02	14.13	^a O.R.S.	AS
NP	4.9 g, 10						^a Repalyte New Formulation	SW
							^a restore O.R.S.	GM

Antipropulsives

Antipropulsives

DIPHENOXYLATE HYDROCHLORIDE with ATROPINE SULFATE

2501P	Tablet 2.5 mg-25 micrograms	20	8.58	9.69	^a Lofenoxal	HC
NP				^B 1.72	10.30	9.69	^a Lomotil	BI

LOPERAMIDE HYDROCHLORIDE

1571Q	Capsule 2 mg	12	8.56	9.67	^a Gastro-Stop Loperamide	AS
NP				^B 0.89	9.45	9.67	^a Imodium	JT

Intestinal antiinflammatory agents

Corticosteroids acting locally

HYDROCORTISONE ACETATE

Restricted benefit

Proctitis;

Ulcerative colitis.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1502C	Rectal foam 90 mg per applicatorful, 14 applications, aerosol 21.1 g	2	3	..	*37.18	35.40	Colifoam	AS
NP								

PREDNISOLONE SODIUM PHOSPHATE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1920C	Retention enema equivalent to 20 mg	28	3	..	*211.44	35.40	Predsol	QA
-------	-------------------------------------	----	---	----	---------	-------	---------	----

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
NP	prednisolone in 100 mL						

PREDNISOLONE SODIUM PHOSPHATE

Restricted benefit

Proctitis;

Ulcerative colitis.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2554K NP	Suppositories equivalent to 5 mg prednisolone, 10	3	3	..	*41.80	35.40	Predsol	QA
-------------	--	---	---	----	--------	-------	---------	----

Aminosalicylic acid and similar agents

BALSALAZIDE SODIUM

Authority required (STREAMLINED)

1708

Ulcerative colitis where hypersensitivity to sulfonamides exists;

1709

Ulcerative colitis where intolerance to sulfasalazine exists.

Note

Not for the treatment of Crohn disease.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8845M NP	Capsule 750 mg	180	5	..	124.95	35.40	Colazide	PK
-------------	----------------	-----	---	----	--------	-------	----------	----

MESALAZINE

Authority required (STREAMLINED)

1708

Ulcerative colitis where hypersensitivity to sulfonamides exists;

1709

Ulcerative colitis where intolerance to sulfasalazine exists;

2268

Crohn disease where hypersensitivity to sulfonamides exists;

2269

Crohn disease where intolerance to sulfasalazine exists.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1611T NP	Tablet 250 mg (enteric coated)	100	5	..	93.53	35.40	Mesasal	GK
2214M NP	Tablet 500 mg (prolonged release)	200	5	..	*297.54	35.40	Pentasa	FP
2234N NP	Sachet containing prolonged release granules, 1 g per sachet	120	5	..	330.77	35.40	Pentasa	FP
2287J NP	Sachet containing prolonged release granules, 2 g per sachet	60	5	..	312.40	35.40	Pentasa	FP
3413P NP	Tablet 1 g (prolonged release)	120	5	..	*330.78	35.40	Pentasa	FP
8731M NP	Tablet 500 mg (enteric coated)	200	5	..	*297.54	35.40	Salofalk	OA

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
MESALAZINE								
<u>Authority required (STREAMLINED)</u>								
1708								
Ulcerative colitis where hypersensitivity to sulfonamides exists;								
1709								
Ulcerative colitis where intolerance to sulfasalazine exists.								
<u>Note</u>								
Not for the treatment of Crohn disease.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8598M NP	Sachet containing granules, 500 mg per sachet	200	5	..	*297.54	35.40	Salofalk	OA
8599N NP	Sachet containing granules, 1 g per sachet	100	5	..	279.73	35.40	Salofalk	OA
9206M NP	Sachet containing granules, 1.5 g per sachet	60	5	..	245.02	35.40	Salofalk	OA
9353G NP	Tablet 1.2 g (prolonged release)	60	5	..	221.09	35.40	Mezavant	ZI
<hr/>								
MESALAZINE								
<u>Restricted benefit</u>								
Acute episode of mild to moderate ulcerative proctitis.								
<u>Note</u>								
Not for the treatment of Crohn disease.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
5461K NP	Suppository (moulded) 1 g	30	1	..	136.49	35.40	Salofalk	OA
8752P NP	Suppository 1 g	30	1	..	136.49	35.40	Pentasa	FP
<hr/>								
MESALAZINE								
<u>Authority required (STREAMLINED)</u>								
1707								
Acute episode of mild to moderate ulcerative colitis.								
<u>Note</u>								
Not for the treatment of Crohn disease.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
8616L NP	Enemas 2 g in 60 mL, 7	4	1	..	*336.32	35.40	Salofalk	OA
8617M NP	Enemas 4 g in 60 mL, 7	4	1	..	*446.00	35.40	Salofalk	OA
8753Q NP	Enemas 1 g in 100 mL, 7	4	1	..	*336.32	35.40	Pentasa	FP
8768L NP	Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g	4	1	..	*336.32	35.40	Salofalk	OA

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
OLSALAZINE SODIUM								
<u>Authority required (STREAMLINED)</u>								
1708								
Ulcerative colitis where hypersensitivity to sulfonamides exists;								
1709								
Ulcerative colitis where intolerance to sulfasalazine exists.								
<u>Note</u>								
Not for the treatment of Crohn disease.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1728Y NP	Capsule 250 mg	100	5	..	61.51	35.40	Dipentum	UC
8086N NP	Tablet 500 mg	100	5	..	103.39	35.40	Dipentum	UC
SULFASALAZINE								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2093E NP	Tablet 500 mg	200	5	..	*50.38	35.40	Salazopyrin	PF
2096H NP	Tablet 500 mg (enteric coated)	200	5	..	*54.34	35.40 ^a	Pyralin EN	FZ
				^B 1.84	*56.18	35.40 ^a	Salazopyrin-EN	PF
SULFASALAZINE								
<u>Restricted benefit</u>								
For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
9208P	Tablet 500 mg	200	11	..	*50.38	35.40	Salazopyrin	PF
9209Q	Tablet 500 mg (enteric coated)	200	11	..	*54.34	35.40 ^a	Pyralin EN	FZ
				^B 1.84	*56.18	35.40 ^a	Salazopyrin-EN	PF

Digestives, incl. enzymes

Digestives, incl. enzymes Enzyme preparations

PANCREATIC EXTRACT

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

5453B NP	Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g	3	10	..	*141.88	35.40	Creon Micro	AB
8020D NP	Capsule (containing enteric coated minicapsules) providing not less than 10,000 BP units of lipase activity	500	10	..	*183.77	35.40	Creon 10,000	AB
8021E NP	Capsule (containing enteric coated minicapsules) providing not less than 25,000 BP units of lipase activity	200	10	..	*147.84	35.40	Creon 25,000	AB
9412J NP	Capsule (containing enteric coated minicapsules) providing not less than	200	10	..	*230.06	35.40	Creon 40,000	AB

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	40,000 BP units of lipase activity							
PANCREATIC EXTRACT								
<u>Restricted benefit</u>								
For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
5454C	Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g	3	21	..	*141.88	35.40	Creon Micro	AB
9226N	Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity	500	21	..	*183.77	35.40	Creon 10,000	AB
9227P	Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity	200	21	..	*147.84	35.40	Creon 25,000	AB
9413K	Capsule (containing enteric coated minimicrospheres) providing not less than 40,000 BP units of lipase activity	200	21	..	*230.06	35.40	Creon 40,000	AB
PANCRELIPASE								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8366H NP	Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity	200	10	..	*138.00	35.40	Panzytrat 25000	TM
PANCRELIPASE								
<u>Restricted benefit</u>								
For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
9229R	Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity	200	21	..	*138.00	35.40	Panzytrat 25000	TM

Drugs used in diabetes

Insulins and analogues

Insulins and analogues for injection, fast-acting

INSULIN ASPART								
8435Y NP	Injections (human analogue) 100 units per mL, 3 mL, 5	5	1	..	*264.32	35.40	NovoRapid FlexPen	NF
							NovoRapid Penfill 3 mL	NO
8571D NP	Injection (human analogue) 100 units per mL, 10 mL	5	2	..	*159.37	35.40	NovoRapid	NO
INSULIN GLULISINE								
1921D NP	Injections (human analogue) 100 units per mL, 3 mL, 5	5	1	..	*264.32	35.40	Apidra	AV
							Apidra SoloStar	SW
9224L	Injection (human analogue) 100 units per mL,	5	2	..	*159.37	35.40	Apidra	SW

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
NP	10 mL							
INSULIN LISPRO								
8084L NP	Injection (human analogue) 100 units per mL, 10 mL	5	2	..	*159.37	35.40	Humalog	LY
8212F NP	Injections (human analogue) 100 units per mL, 3 mL, 5	5	1	..	*264.32	35.40	Humalog	LY
							Humalog KwikPen	KP
INSULIN NEUTRAL								
1531N NP	Injection (human) 100 units per mL, 10 mL	5	2	..	*133.92	35.40	Actrapid	NO
							Humulin R	LY
1713E NP	Injection (bovine) 100 units per mL, 10 mL	5	2	..	*172.12	35.40	Hypurin Neutral	AS
1762R NP	Injections (human) 100 units per mL, 3 mL, 5	5	1	..	*224.42	35.40	Actrapid Penfill 3 mL	NO
							Humulin R	LY
Insulins and analogues for injection, intermediate-acting								
INSULIN ISOPHANE (N.P.H.)								
1533Q NP	Injection (human) 100 units per mL, 10 mL	5	2	..	*133.92	35.40	Humulin NPH	LY
							Protaphane	NO
1711C NP	Injection (bovine) 100 units per mL, 10 mL	5	2	..	*172.12	35.40	Hypurin Isophane	AS
1761Q NP	Injections (human) 100 units per mL, 3 mL, 5	5	1	..	*224.42	35.40	Humulin NPH	LY
							Protaphane InnoLet	NI
							Protaphane Penfill 3 mL	NO
Insulins and analogues for injection, intermediate-acting combined with fast-acting								
INSULIN ASPART—INSULIN ASPART PROTAMINE SUSPENSION								
8609D NP	Injections (human analogue) 100 units (30 units- 70 units) per mL, 3 mL, 5	5	1	..	*264.32	35.40	NovoMix 30 FlexPen	NF
							NovoMix 30 Penfill 3 mL	NO
INSULIN LISPRO—INSULIN LISPRO PROTAMINE SUSPENSION								
8390N NP	Injections (human analogue) 100 units (25 units- 75 units) per mL, 3 mL, 5	5	1	..	*264.32	35.40	Humalog Mix25	LY
							Humalog Mix25 KwikPen	KP
8874C NP	Injections (human analogue) 100 units (50 units- 50 units) per mL, 3 mL, 5	5	1	..	*264.32	35.40	Humalog Mix50	LY
							Humalog Mix50 KwikPen	KP
INSULIN NEUTRAL—INSULIN ISOPHANE (N.P.H.), (MIXED) (Biphasic Isophane)								
1426C NP	Injection (human) 100 units (30 units-70 units) per mL, 10 mL	5	2	..	*133.92	35.40	Humulin 30/70	LY
1763T NP	Injections (human) 100 units (30 units-70 units) per mL, 3 mL, 5	5	1	..	*224.42	35.40	Humulin 30/70	LY
							Mixtard 30/70 InnoLet	NI
							Mixtard 30/70 Penfill 3 mL	NO
2062M NP	Injections (human) 100 units (50 units-50 units) per mL, 3 mL, 5	5	1	..	*224.42	35.40	Mixtard 50/50 Penfill 3 mL	NO

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Insulins and analogues for injection, long-acting								
INSULIN DETEMIR								
<u>Restricted benefit</u>								
Type 1 diabetes.								
9040T NP	Injections (human analogue) 100 units per mL, 3 mL, 5	5	1	..	*432.82	35.40	Levemir FlexPen	NF
							Levemir Penfill	NO
INSULIN GLARGINE								
9039R NP	Injections (human analogue) 100 units per mL, 3 mL, 5	5	1	..	*432.82	35.40	Lantus	SW
							Lantus SoloStar	AV
Blood glucose lowering drugs, excl. insulins								
Biguanides								
METFORMIN HYDROCHLORIDE								
1801T NP	Tablet 850 mg	60	5	..	11.76	12.87	^a APO-Metformin 850	TX
							^a Chem mart Metformin	CH
							^a Diaformin 850	AF
							^a Formet 850	QA
							^a Formet Aspen 850	AS
							^a GenRx Metformin	GX
							^a Glucobete 850	DO
							^a Metformin 850	CR
							^a Metformin-GA	GM
							^a Metformin generichealth	GQ
							^a Metformin Pfizer	FZ
							^a Metformin Ranbaxy	RA
							^a Metformin Sandoz	SZ
							^a Terry White Chemists Metformin	TW
				^B 0.87	12.63	12.87	^a Glucophage	MQ
				^B 1.41	13.17	12.87	^a Diabex 850	AL
2430X NP	Tablet 500 mg	100	5	..	11.76	12.87	^a APO-Metformin 500	TX
							^a Chem mart Metformin	CH
							^a Diaformin	AF
							^a Formet 500	QA
							^a Formet Aspen 500	AS
							^a GenRx Metformin	GX
							^a Glucobete 500	DO
							^a Metformin 500	CR
							^a Metformin-GA	GM
							^a Metformin generichealth	GQ
							^a Metformin Pfizer	FZ
							^a Metformin Ranbaxy	RA
							^a Metformin Sandoz	SZ
							^a Terry White Chemists	TW

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
3439B NP	Tablet 1 g (extended release)	60	5	^B 0.87	12.63	12.87	^a Metformin Glucophage MQ
				^B 1.41	13.17	12.87	^a Diabex AL
				..	14.92	16.03	Diabex XR 1000 AL
8607B NP	Tablet 1 g	90	5	..	15.67	16.78	^a APO-Metformin 1000 TX
							^a Chem mart Metformin 1000 CH
							^a Diaformin 1000 AF
							^a Formet 1000 QA
							^a Glucobete 1000 DO
							^a Metformin-GA GM
							^a Metformin generichealth 1000 GQ
							^a Metformin Pfizer FZ
							^a Metformin Ranbaxy 1000 RA
							^a Metformin Sandoz SZ
							^a Pharmacor Metformin 1000 CR
							^a Terry White Chemists Metformin 1000 TW
9435N NP	Tablet 500 mg (extended release)	120	5	^B 1.43	17.10	16.78	^a Diabex 1000 AL
				..	14.92	16.03	^a Diabex XR AL
				^a Diaformin XR AF			
							^a Metex XR QA

Sulfonamides, urea derivatives

GLIBENCLAMIDE

Caution

Sulfonylureas may cause hypoglycaemia, particularly in the elderly.

2939Q	Tablet 5 mg	100	5	..	11.49	12.60	^a	Glimef	AF
NP				^B 1.44	12.93	12.60	^a	Daonil	SW

GLICLAZIDE

Caution

Sulfonylureas may cause hypoglycaemia, particularly in the elderly.

2449X NP	Tablet 80 mg	100	5	..	13.26	14.37	^a	Chem mart Gliclazide	CH
							^a	GenRx Gliclazide	GX
							^a	Glyade	AF
							^a	Nidem	QA
							^a	Terry White Chemists Gliclazide	TW
8535F NP	Tablet 30 mg (modified release)	100	5	..	13.45	14.56	^a	APO-Gliclazide MR	TX
							^a	Chem mart Gliclazide MR	CH
							^a	Glyade MR	AF
							^a	Oziclide MR	RA
							^a	Terry White Chemists Gliclazide MR	TW

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
9302N NP	Tablet 60 mg (modified release)	60	5	..	14.85	15.96	Diamicron 60mg MR
GLIMEPIRIDE							
Caution							
Sulfonylureas may cause hypoglycaemia, particularly in the elderly.							
8450R NP	Tablet 1 mg	30	5	..	8.38	9.49	^a APO-Glimepiride TX
							^a Aylide 1 AF
							^a Diapride 1 QA
							^a Dimirel AV
							^a Glimepiride GA 1 GM
							^a Glimepiride Sandoz SZ
							^a Pharmacor CR
				^B 2.81	11.19	9.49	^a Glimepiride 1 Amaryl SW
8451T NP	Tablet 2 mg	30	5	..	10.10	11.21	^a APO-Glimepiride TX
							^a Aylide 2 AF
							^a Diapride 2 QA
							^a Dimirel AV
							^a Glimepiride GA 2 GM
							^a Glimepiride Sandoz SZ
							^a Pharmacor CR
				^B 2.81	12.91	11.21	^a Glimepiride 2 Amaryl SW
8452W NP	Tablet 4 mg	30	5	..	12.12	13.23	^a APO-Glimepiride TX
							^a Aylide 4 AF
							^a Diapride 4 QA
							^a Dimirel AV
							^a Glimepiride GA 4 GM
							^a Glimepiride Sandoz SZ
							^a Pharmacor CR
				^B 2.80	14.92	13.23	^a Glimepiride 4 Amaryl SW
8533D NP	Tablet 3 mg	30	5	..	11.10	12.21	^a APO-Glimepiride TX
							^a Aylide 3 AF
							^a Diapride 3 QA
							^a Dimirel AV
							^a Glimepiride GA 3 GM
							^a Glimepiride Sandoz SZ
							^a Pharmacor CR
				^B 2.80	13.90	12.21	^a Glimepiride 3 Amaryl SW
GLIPIZIDE							
Caution							
Sulfonylureas may cause hypoglycaemia, particularly in the elderly.							
2440K NP	Tablet 5 mg	100	5	..	12.37	13.48	^a Melizide AF
				^B 3.83	16.20	13.48	^a Minidiab PF

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Combinations of oral blood glucose lowering drugs

METFORMIN HYDROCHLORIDE with GLIBENCLAMIDE

Caution

Sulfonylureas may cause hypoglycaemia, particularly in the elderly.

8810Q NP	Tablet 500 mg-2.5 mg	90	5	..	15.58	16.69	Glucovance 500mg/2.5mg	AL
8811R NP	Tablet 500 mg-5 mg	90	5	..	16.70	17.81	Glucovance 500mg/5mg	AL
8838E NP	Tablet 250 mg-1.25 mg	90	5	..	14.57	15.68	Glucovance 250mg/1.25mg	AL

ROSIGLITAZONE with METFORMIN

Note

Rosiglitazone with metformin fixed dose combination tablet is not PBS-subsidised when used in combination with a sulfonylurea (triple oral therapy) or an insulin or a dipeptidyl peptidase 4 inhibitor (gliptin) or a glucagon-like peptide-1.

Authority required

Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

- (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or
- (b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.

9059T NP	Tablet containing 2 mg rosiglitazone (as maleate) with 500 mg metformin hydrochloride	56	5	..	64.05	35.40	Avandamet	GK
9060W NP	Tablet containing 2 mg rosiglitazone (as maleate) with 1 g metformin hydrochloride	56	5	..	66.69	35.40	Avandamet	GK
9061X NP	Tablet containing 4 mg rosiglitazone (as maleate) with 500 mg metformin hydrochloride	56	5	..	93.51	35.40	Avandamet	GK
9062Y NP	Tablet containing 4 mg rosiglitazone (as maleate) with 1 g metformin hydrochloride	56	5	..	96.15	35.40	Avandamet	GK

SITAGLIPTIN with METFORMIN

Note

Sitagliptin with metformin fixed dose combination tablet is not PBS-subsidised for use in combination with a sulfonylurea (triple oral therapy), as initial therapy or in combination with a thiazolidinedione (glitazone) or a glucagon-like peptide-1.

Authority required (STREAMLINED)

3543

Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

- (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or
- (b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Authority required (STREAMLINED)</u>								
3149								
Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and sitagliptin.								
9449H NP	Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 500 mg metformin hydrochloride	56	5	..	93.51	35.40	Janumet	MK
9450J NP	Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 850 mg metformin hydrochloride	56	5	..	95.39	35.40	Janumet	MK
9451K NP	Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 1000 mg metformin hydrochloride	56	5	..	96.15	35.40	Janumet	MK

VILDAGLIPTIN with METFORMIN

Note

Vildagliptin with metformin fixed dose combination tablet is not PBS-subsidised for use in combination with a sulfonylurea (triple oral therapy), as initial therapy or in combination with a thiazolidinedione (glitazone) or a glucagon-like peptide-1.

Authority required (STREAMLINED)

3543

Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

- (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or
- (b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records;

3686

Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and vildagliptin.

5474D NP	Tablet containing 50 mg vildagliptin with 500 mg metformin hydrochloride	60	5	..	96.65	35.40	Galvumet 50/500	NV
5475E NP	Tablet containing 50 mg vildagliptin with 850 mg metformin hydrochloride	60	5	..	98.66	35.40	Galvumet 50/850	NV
5476F NP	Tablet containing 50 mg vildagliptin with 1000 mg metformin hydrochloride	60	5	..	99.48	35.40	Galvumet 50/1000	NV

Alpha glucosidase inhibitors

ACARBOSE

8188Y NP	Tablet 50 mg	90	5	..	34.63	35.40	Glucobay 50	BN
8189B NP	Tablet 100 mg	90	5	..	45.63	35.40	Glucobay 100	BN

Thiazolidinediones

PIOGLITAZONE

Note

Pioglitazone hydrochloride is not PBS-subsidised as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor (gliptin) or a glucagon-like peptide-1.

Authority required (STREAMLINED)

3540

Dual oral combination therapy with metformin or a sulfonylurea

Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	<p>The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p> <p>Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:</p> <p>(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or</p> <p>(b) red cell transfusion within the previous 3 months.</p> <p>A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.</p> <p>Authority required (STREAMLINED)</p> <p>3541</p> <p>Combination therapy with insulin</p> <p>Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated.</p> <p>The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p> <p>Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:</p> <p>(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or</p> <p>(b) red cell transfusion within the previous 3 months.</p> <p>A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.</p> <p>Authority required (STREAMLINED)</p> <p>3542</p> <p>Triple oral combination therapy with metformin and a sulfonylurea</p> <p>Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with maximally tolerated doses of metformin and a sulfonylurea.</p> <p>The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p> <p>Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:</p> <p>(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or</p> <p>(b) red cell transfusion within the previous 3 months.</p> <p>A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.</p>						
8694N NP	Tablet 15 mg (as hydrochloride)	28	5	..	53.10	35.40	<p>^a Acpio 15 QA</p> <p>^a Actos LY</p> <p>^a APOTEX- Pioglitazone TX</p> <p>^a Chem mart Pioglitazone CH</p> <p>^a Pharmacor Pioglitazone 15 CR</p> <p>^a Pioglitazone-GA GM</p> <p>^a Pioglitazone generichealth 15 GQ</p> <p>^a Pioglitazone Sandoz SZ</p> <p>^a Pizaccord RA</p> <p>^a Terry White Chemists Pioglitazone TW</p> <p>^a Vexazone AF</p>
8695P NP	Tablet 30 mg (as hydrochloride)	28	5	..	77.72	35.40	<p>^a Acpio 30 QA</p> <p>^a Actos LY</p>

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
8696Q NP	Tablet 45 mg (as hydrochloride)	28	5	..	99.11	35.40	^a APOTEX- Pioglitazone TX
							^a Chem mart Pioglitazone CH
							^a Pharmacor Pioglitazone 30 CR
							^a Pioglitazone-GA GM
							^a Pioglitazone generichealth 30 GQ
							^a Pioglitazone Sandoz SZ
							^a Pizaccord RA
							^a Terry White Chemists Pioglitazone TW
							^a Vexazone AF
							^a Acpio 45 QA
							^a Actos LY
							^a APOTEX- Pioglitazone TX
							^a Chem mart Pioglitazone CH
							^a Pharmacor Pioglitazone 45 CR
							^a Pioglitazone-GA GM
							^a Pioglitazone generichealth 45 GQ
							^a Pioglitazone Sandoz SZ
							^a Pizaccord RA
							^a Terry White Chemists Pioglitazone TW
							^a Vexazone AF

ROSIGLITAZONE

Note

Rosiglitazone maleate is not PBS-subsidised as monotherapy or in combination with metformin and a sulfonylurea (triple oral therapy) or an insulin or a dipeptidyl peptidase 4 inhibitor (gliptin) or a glucagon-like peptide-1.

Authority required

Dual oral combination therapy with metformin or a sulfonylurea

Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or

(b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.

8689H NP	Tablet 4 mg (as maleate)	28	5	..	61.25	35.40	Avandia	GK
8690J NP	Tablet 8 mg (as maleate)	28	5	..	90.70	35.40	Avandia	GK

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Dipeptidyl peptidase 4 (DPP-4) inhibitors

LINAGLIPTIN

Note

Linagliptin is not PBS-subsidised for use in combination with metformin and a sulfonylurea (triple oral therapy), as monotherapy or in combination with a thiazolidinedione (glitazone) or a glucagon-like peptide-1.

Authority required (STREAMLINED)

3540

Dual oral combination therapy with metformin or a sulfonylurea

Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

- (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or
- (b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.

3387G NP	Tablet 5 mg	30	5	..	96.72	35.40	Trajenta	BY
-------------	-------------	----	---	----	-------	-------	----------	----

SAXAGLIPTIN

Note

Saxagliptin is not PBS-subsidised for use in combination with metformin and a sulfonylurea (triple oral therapy), as monotherapy or in combination with a thiazolidinedione (glitazone) or a glucagon-like peptide-1.

Authority required (STREAMLINED)

3540

Dual oral combination therapy with metformin or a sulfonylurea

Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

- (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or
- (b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.

8983T NP	Tablet 5 mg (as hydrochloride)	28	5	..	90.70	35.40	Onglyza	BQ
-------------	--------------------------------	----	---	----	-------	-------	---------	----

SITAGLIPTIN

Note

Sitagliptin is not PBS-subsidised for use in combination with metformin and a sulfonylurea (triple oral therapy), as monotherapy or in combination with a thiazolidinedione (glitazone) or a glucagon-like peptide-1.

Authority required (STREAMLINED)

3540

Dual oral combination therapy with metformin or a sulfonylurea

Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
<p>Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:</p> <p>(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or</p> <p>(b) red cell transfusion within the previous 3 months.</p> <p>A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.</p>							
9180E NP	Tablet 25 mg (as phosphate monohydrate)	28	5	..	90.70	35.40	Januvia MK
9181F NP	Tablet 50 mg (as phosphate monohydrate)	28	5	..	90.70	35.40	Januvia MK
9182G NP	Tablet 100 mg (as phosphate monohydrate)	28	5	..	90.70	35.40	Januvia MK

VILDAGLIPTIN

Note

Vildagliptin is not PBS-subsidised for use in combination with metformin and a sulfonylurea (triple oral therapy), as monotherapy or in combination with a thiazolidinedione (glitazone) or a glucagon-like peptide-1.

Authority required (STREAMLINED)

3540

Dual oral combination therapy with metformin or a sulfonylurea

Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or

(b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.

3415R NP	Tablet 50 mg	60	5	..	96.71	35.40	Galvus NV
-------------	--------------	----	---	----	-------	-------	-----------

Other blood glucose lowering drugs, excl. insulins

EXENATIDE

Note

Exenatide is not PBS-subsidised as monotherapy or in combination with an insulin, a thiazolidinedione (glitazone) or a dipeptidyl peptidase 4 inhibitor (gliptin).

Authority required (STREAMLINED)

3540

Dual oral combination therapy with metformin or a sulfonylurea

Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or

(b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.

Authority required (STREAMLINED)

3542

Triple oral combination therapy with metformin and a sulfonylurea

Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with maximally tolerated doses of metformin and a sulfonylurea.								
The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.								
Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:								
(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or								
(b) red cell transfusion within the previous 3 months.								
A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records.								
<u>Note</u>								
Special Pricing Arrangements apply.								
3423E NP	Injection solution 5 micrograms per dose in pre-filled pen, 60 doses	1	5	..	176.49	35.40	Byetta 5 microgram	LY
3424F NP	Injection solution 10 micrograms per dose in pre-filled pen, 60 doses	1	5	..	176.49	35.40	Byetta 10 microgram	LY

Vitamins

Vitamin A and D, incl. combinations of the two *Vitamin D and analogues*

CALCITRIOL

Authority required (STREAMLINED)

1165

Hypocalcaemia due to renal disease;

1166

Hypoparathyroidism;

1167

Hypophosphataemic rickets;

1467

Vitamin D-resistant rickets;

2636

Treatment for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

2502Q NP	Capsule 0.25 microgram	100	3	..	37.41	35.40	^a Calciprox	GN
							^a Calcitriol-GA	GM
							^a Calcitriol-PS	FZ
							^a Calcitriol Sandoz	SZ
							^a GenRx Calcitriol	GX
							^a Kosteo	QA
							^a Rocaltrol	RO
							^a Sical	AF

Vitamin B₁, plain and in combination with vitamin B₆ and vitamin B₁₂ *Vitamin B₁, plain*

THIAMINE HYDROCHLORIDE

Authority required (STREAMLINED)

2384

Prophylaxis of thiamine deficiency in an Aboriginal or a Torres Strait Islander person.

1070H NP	Tablet 100 mg	100	2	..	11.60	12.71	Betamin	SW
-------------	---------------	-----	---	----	-------	-------	---------	----

Alimentary tract and metabolism

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer	
Mineral supplements								

Calcium

Calcium

CALCIUM

Authority required (STREAMLINED)

2212

Hyperphosphataemia associated with chronic renal failure.

3116B NP	Tablet (chewable) 500 mg (as carbonate)	240	1	..	*30.56	31.67	Cal-Sup	IA
3117C NP	Tablet 600 mg (as carbonate)	240	1	..	22.30	23.41	Calci-Tab 600	AE

Potassium

Potassium

POTASSIUM CHLORIDE

Note

For item codes 2642C and 1841X, pharmaceutical benefits that have the form tablet 600 mg (sustained release) are equivalent for the purposes of substitution.

1841X NP	Tablet 600 mg (sustained release)	200	1	..	12.99	14.10 ^a	Span-K	AS
2642C NP	Tablet 600 mg (sustained release)	200	1	..	*12.98	14.09 ^a	Duro-K	NM
				^B 2.94	*15.92	14.09 ^a	Slow-K	NV

POTASSIUM CHLORIDE with POTASSIUM BICARBONATE

3012M NP	Effervescent tablet 14 mmol potassium and 8 mmol chloride	60	1	..	15.24	16.35	Chlorvescent	AS
-------------	---	----	---	----	-------	-------	--------------	----

Other mineral supplements

Magnesium

MAGNESIUM

Authority required

Hypomagnesaemia in an Aboriginal or a Torres Strait Islander person;

Chronic renal disease in an Aboriginal or a Torres Strait Islander person.

5146W NP	Tablet 37.4 mg (as aspartate dihydrate)	50	5	..	13.80	14.91	Mag-Sup	PP
-------------	---	----	---	----	-------	-------	---------	----

Anabolic agents for systemic use

Anabolic steroids

Estren derivatives

NANDROLONE DECANOATE

Authority required

Monotherapy for osteoporosis, where other treatment has failed and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval;

Monotherapy for osteoporosis, where other treatment is not tolerated and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval;

Monotherapy for osteoporosis, where other treatment is contraindicated and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval;

Patients receiving PBS-subsidised therapy with this drug for osteoporosis prior to 1 February 2004;

Patients on long-term treatment with corticosteroids.

Note

Monotherapy for the treatment of osteoporosis does not exclude calcium supplementation.

1671Y	Injection 50 mg in 1 mL, disposable syringe	1	7	..	21.30	22.41	Deca-Durabolin	MK
-------	---	---	---	----	-------	-------	----------------	----

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer
					for Max. Qty \$	Recordable Value for Safety Net \$	

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Blood and blood forming organs

Antithrombotic agents

Antithrombotic agents

Vitamin K antagonists

WARFARIN SODIUM

Caution

The listed brands have NOT been shown to be bioequivalent and should not be interchanged.

2209G NP	Tablet 2 mg	50	2	..	12.87	13.98	Coumadin	QA
2211J NP	Tablet 5 mg	50	2	..	14.13	15.24	Coumadin	QA
							Marevan	FM
2843P NP	Tablet 1 mg	50	2	..	12.52	13.63	Coumadin	QA
							Marevan	FM
2844Q NP	Tablet 3 mg	50	2	..	12.79	13.90	Marevan	FM

Heparin group

DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium—porcine mucous)

2816F NP	Injection 5,000 units (anti-Xa) in 0.2 mL single dose pre-filled syringe	20	*108.98	35.40	Fragmin	PF
5445N NP	Injection 12,500 units (anti-Xa) in 0.5 mL single dose pre-filled syringe	10	1	..	125.79	35.40	Fragmin	PF
8269F NP	Injection 10,000 units (anti-Xa) in 1 mL single dose pre-filled syringe	10	1	..	91.09	35.40	Fragmin	PF
8271H NP	Injection 7,500 units (anti-Xa) in 0.75 mL single dose pre-filled syringe	10	1	..	68.48	35.40	Fragmin	PF
8603T NP	Injection 2,500 units (anti-Xa) in 0.2 mL single dose pre-filled syringe	20	*104.84	35.40	Fragmin	PF

DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium—porcine mucous)

Restricted benefit

Haemodialysis.

1229Q NP	Injection 10,000 units (anti-Xa) in 1 mL single dose pre-filled syringe	20	3	..	*175.66	35.40	Fragmin	PF
1296F NP	Injection 12,500 units (anti-Xa) in 0.5 mL single dose pre-filled syringe	20	3	..	*241.38	35.40	Fragmin	PF
8641T NP	Injection 2,500 units (anti-Xa) in 0.2 mL single dose pre-filled syringe	20	3	..	*104.84	35.40	Fragmin	PF
8642W NP	Injection 5,000 units (anti-Xa) in 0.2 mL single dose pre-filled syringe	20	3	..	*108.98	35.40	Fragmin	PF
8643X NP	Injection 7,500 units (anti-Xa) in 0.75 mL single dose pre-filled syringe	20	3	..	*130.44	35.40	Fragmin	PF

DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium—porcine mucous)

Restricted benefit

Management of symptomatic venous thromboembolism in a patient with a solid tumour(s).

Note

No applications for increased maximum quantities will be authorised.

8956J NP	Injection 7,500 units (anti-Xa) in 0.75 mL single dose pre-filled syringe	30	5	..	*192.40	35.40	Fragmin	PF
8957K NP	Injection 10,000 units (anti-Xa) in 1 mL single dose pre-filled syringe	30	5	..	*255.16	35.40	Fragmin	PF
8958L	Injection 12,500 units (anti-Xa) in 0.5 mL single dose pre-filled syringe	30	5	..	*349.81	35.40	Fragmin	PF

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<i>NP</i>	dose pre-filled syringe							
8959M <i>NP</i>	Injection 15,000 units (anti-Xa) in 0.6 mL single dose pre-filled syringe	30	5	..	*414.85	35.40	Fragmin	PF
8960N <i>NP</i>	Injection 18,000 units (anti-Xa) in 0.72 mL single dose pre-filled syringe	30	5	..	*493.69	35.40	Fragmin	PF
ENOXAPARIN SODIUM								
8262W <i>NP</i>	Injection 60 mg (6,000 i.u. anti-Xa) in 0.6 mL pre- filled syringe	10	1	..	79.78	35.40	Clexane	SW
8263X <i>NP</i>	Injection 80 mg (8,000 i.u. anti-Xa) in 0.8 mL pre- filled syringe	10	1	..	90.80	35.40	Clexane	SW
8264Y <i>NP</i>	Injection 100 mg (10,000 i.u. anti-Xa) in 1 mL pre-filled syringe	10	1	..	109.18	35.40	Clexane	SW
8510X <i>NP</i>	Injection 40 mg (4,000 i.u. anti-Xa) in 0.4 mL pre- filled syringe	20	*108.98	35.40	Clexane	SW
8558K <i>NP</i>	Injection 20 mg (2,000 i.u. anti-Xa) in 0.2 mL pre- filled syringe	20	*104.84	35.40	Clexane	SW
9195Y <i>NP</i>	Solution for injection 40 mg (4,000 i.u. anti-Xa) in 0.4 mL	20	*108.98	35.40	Clexane	SW
ENOXAPARIN SODIUM								
<u>Restricted benefit</u>								
Haemodialysis.								
5434B <i>NP</i>	Injection 80 mg (8,000 i.u. anti-Xa) in 0.8 mL pre- filled syringe	20	3	..	*175.08	35.40	Clexane	SW
5435C <i>NP</i>	Injection 100 mg (10,000 i.u. anti-Xa) in 1 mL pre-filled syringe	20	3	..	*211.18	35.40	Clexane	SW
8639Q <i>NP</i>	Injection 40 mg (4,000 i.u. anti-Xa) in 0.4 mL pre- filled syringe	20	3	..	*108.98	35.40	Clexane	SW
8640R <i>NP</i>	Injection 60 mg (6,000 i.u. anti-Xa) in 0.6 mL pre- filled syringe	20	3	..	*153.04	35.40	Clexane	SW
8716R <i>NP</i>	Injection 20 mg (2,000 i.u. anti-Xa) in 0.2 mL pre- filled syringe	20	3	..	*104.84	35.40	Clexane	SW
9196B <i>NP</i>	Solution for injection 40 mg (4,000 i.u. anti-Xa) in 0.4 mL	20	3	..	*108.98	35.40	Clexane	SW
HEPARIN SODIUM								
1076P <i>NP</i>	Injection 35,000 units in 35 mL	12	5	..	*278.68	35.40	Hospira Pty Limited	HH
1463B <i>NP</i>	Injection (preservative-free) 5,000 units in 5 mL	50	5	..	71.62	35.40	Pfizer Australia Pty Ltd	PF
1466E <i>NP</i>	Injection 5,000 units in 0.2 mL	5	5	..	15.58	16.69	Hospira Pty Limited	HH
Platelet aggregation inhibitors excl. heparin								
ABCIXIMAB								
<u>Authority required (STREAMLINED)</u>								
1716								
Patients undergoing percutaneous coronary balloon angioplasty;								
1717								
Patients undergoing percutaneous coronary atherectomy;								
1718								
Patients undergoing percutaneous coronary stent placement.								
8048N	I.V. injection 10 mg in 5 mL	3	*1453.21	35.40	ReoPro	LY
ASPIRIN								
1010E <i>NP</i>	Tablet 300 mg (dispersible)	96	1	..	8.27	9.38	Solprin	RC
8202Q <i>NP</i>	Tablet 100 mg	112	1	..	7.88	8.99 ^a	Mayne Pharma Aspirin	YT

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				^B 1.08	8.96	8.99	^a Spren 100 QA
							^a Astrix YN

CLOPIDOGREL

Authority required (STREAMLINED)

1719

Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin;

1720

Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding;

1721

Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs;

1722

Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin;

1723

Prevention of recurrence of myocardial infarction or unstable angina in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding;

1724

Prevention of recurrence of myocardial infarction or unstable angina in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs.

Note

Not for prophylaxis of DVT or peripheral arterial disease.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

Pharmaceutical benefits that have the forms clopidogrel tablet 75 mg, clopidogrel tablet 75 mg (as besilate) and clopidogrel tablet 75 mg (as hydrogen sulfate) are equivalent for the purposes of substitution.

5436D NP	Tablet 75 mg	28	5	..	50.15	35.40	^a Clopidogrel-DRLA	RZ
8358X NP	Tablet 75 mg (as hydrogen sulfate)	28	5	..	50.15	35.40	^a APO-Clopidogrel	TX
							^a Chem mart	CH
							^a Clopidogrel	
							^a Clopidogrel RBX	RA
							^a Clopidogrel Sandoz	SZ
							^a Clopidogrel	
							^a Winthrop	WA
							^a Iscover	BQ
							^a Pharmacor	CR
							^a Clopidogrel 75	
							^a Piax	AF
							^a Plavacor 75	MI
							^a Plavix	SW
							^a Terry White	
							^a Chemists	TW
							^a Clopidogrel	
9354H NP	Tablet 75 mg (as besilate)	28	5	..	50.15	35.40	^a Clopidogrel Actavis	TA
							^a Clopidogrel-GA	GM
							^a Clopidogrel GH	GQ
							^a Clopidogrel-PS	FZ
							^a Clovix 75	QA
							^a STADA Clopidogrel	TD

Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events.

[illegible]

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
2095G NP	Tablet 250 mg	60	5	..	122.03	35.40	Tilodene AF

TIROFIBAN HYDROCHLORIDE

Authority required (STREAMLINED)

1729

Patients with high risk unstable angina who have new transient or persistent ST-T ischaemic changes and anginal pain lasting longer than 20 minutes;

1730

Patients with high risk unstable angina who have new transient or persistent ST-T ischaemic changes and repetitive episodes of angina at rest or during minimal exercise in the previous 12 hours;

1275

Patients with non-Q-wave myocardial infarction.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8350L NP	Solution concentrate for I.V. infusion 12.5 mg (base) in 50 mL	1	2	..	363.21	35.40	Aggrastat AS
-------------	--	---	---	----	--------	-------	--------------

Enzymes

RETEPLASE (Recombinant plasminogen activator)

Restricted benefit

Treatment of acute myocardial infarction within 6 hours of onset of attack.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8253J NP	Pack containing 2 vials powder for injection 10 units, 2 single use pre-filled syringes with solvent, 2 reconstitution spikes and 2 needles	1	2067.06	35.40	Rapilysin 10 U TA
-------------	---	---	----	----	---------	-------	-------------------

TENECTEPLASE

Restricted benefit

Treatment of acute myocardial infarction within 12 hours of onset of attack.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8526R NP	Powder for injection 40 mg with solvent	1	1960.86	35.40	Metalyse BY
8527T NP	Powder for injection 50 mg with solvent	1	2057.16	35.40	Metalyse BY

Direct thrombin inhibitors

BIVALIRUDIN TRIFLUOROACETATE

Authority required (STREAMLINED)

3075

A patient undergoing percutaneous coronary intervention.

8844L	Powder for I.V. injection 250 mg (base)	1	671.85	35.40	Angiomax XM
-------	---	---	----	----	--------	-------	-------------

DABIGATRAN ETEXILATE

Authority required

Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 20 days supply to complete a course of treatment.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Blood and blood forming organs

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer	
Note								
No applications for increased maximum quantities and/or repeats will be authorised.								
9318K NP	Capsule 75 mg (as mesilate)	20	1	..	*45.64	35.40	Pradaxa	BY
9319L NP	Capsule 110 mg (as mesilate)	20	1	..	*45.64	35.40	Pradaxa	BY

DABIGATRAN ETEXILATE

Authority required

Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days supply to complete a course of treatment.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9320M NP	Capsule 75 mg (as mesilate)	60	120.77	35.40	Pradaxa	BY
9321N NP	Capsule 110 mg (as mesilate)	60	120.77	35.40	Pradaxa	BY

DABIGATRAN ETEXILATE

Authority required

Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 10 days of therapy.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9322P NP	Capsule 75 mg (as mesilate)	20	*45.64	35.40	Pradaxa	BY
9323Q NP	Capsule 110 mg (as mesilate)	20	*45.64	35.40	Pradaxa	BY

Other antithrombotic agents

APIXABAN

Authority required

Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 10 days of therapy;

Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 10 days supply to complete a course of treatment.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

5500L NP	Tablet 2.5 mg	20	101.24	35.40	Eliquis	BQ
-------------	---------------	----	----	----	--------	-------	---------	----

APIXABAN

Authority required

Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 15 days of therapy;

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 15 days supply to complete a course of treatment.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

5054B	Tablet 2.5 mg	30	148.76	35.40	Eliquis	BQ
-------	---------------	----	----	----	--------	-------	---------	----

NP

APIXABAN

Authority required

Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days supply to complete a course of treatment.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

5061J	Tablet 2.5 mg	60	279.99	35.40	Eliquis	BQ
-------	---------------	----	----	----	--------	-------	---------	----

NP

FONDAPARINUX SODIUM

Authority required (STREAMLINED)

2005

Prevention of venous thromboembolic events in patients undergoing major hip surgery;

2006

Prevention of venous thromboembolic events in patients undergoing total knee replacement.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8775W	Injection 2.5 mg in 0.5 mL single dose pre-filled syringe	7	*140.64	35.40	Arixtra	GK
-------	---	---	----	----	---------	-------	---------	----

NP

RIVAROXABAN

Authority required

Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 20 days supply to complete a course of treatment.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9465E	Tablet 10 mg	10	1	..	101.24	35.40	Xarelto	BN
-------	--------------	----	---	----	--------	-------	---------	----

NP

RIVAROXABAN

Authority required

Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days supply to complete a course of treatment.

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Note Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
Note No applications for increased maximum quantities and/or repeats will be authorised.							
9466F NP	Tablet 10 mg	15	1	..	148.76	35.40	Xarelto BN
RIVAROXABAN Authority required Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days of therapy.							
Note Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
Note No applications for increased maximum quantities and/or repeats will be authorised.							
9467G NP	Tablet 10 mg	30	279.99	35.40	Xarelto BN
RIVAROXABAN Authority required Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 10 days of therapy.							
Note Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
Note No applications for increased maximum quantities and/or repeats will be authorised.							
9468H NP	Tablet 10 mg	10	101.24	35.40	Xarelto BN
RIVAROXABAN Authority required Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 15 days of therapy.							
Note Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
Note No applications for increased maximum quantities and/or repeats will be authorised.							
9469J NP	Tablet 10 mg	15	148.76	35.40	Xarelto BN

Antihemorrhagics

Antifibrinolytics

Amino acids

TRANEXAMIC ACID

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
2180R NP	Tablet 500 mg	100	2	..	51.78	35.40	Cyklokapron	PF

Antianemic preparations

Iron preparations

Iron bivalent, oral preparations

FERROUS FUMARATE

8985X NP	Tablet 200 mg (equivalent to 65.7 mg iron)	60	1	..	11.72	12.83	Ferro-tab	AE
-------------	--	----	---	----	-------	-------	-----------	----

FERROUS SULFATE

8815Y NP	Oral liquid 30 mg per mL, 250 mL	±1	2	..	19.45	20.56	Ferro-Liquid	AE
-------------	----------------------------------	----	---	----	-------	-------	--------------	----

Iron trivalent, parenteral preparations

IRON POLYMALTOSE COMPLEX

2593L NP	Injection 100 mg (iron) in 2 mL	5	49.67	35.40	^a Ferrosig	SI
							^a Ferrum H	AS

IRON SUCROSE

Authority required (STREAMLINED)

2070

Iron deficiency anaemia, in combination with either epoetin alfa or darbepoetin alfa, in patients undergoing chronic haemodialysis who have had a documented hypersensitivity reaction to iron polymaltose and in whom continued intravenous iron therapy is appropriate.

8807M NP	Concentrate for solution for infusion 2.7 g (equivalent to 100 mg iron (III)) in 5 mL	5	139.58	35.40	Venofer	AS
-------------	---	---	----	----	--------	-------	---------	----

Iron in combination with folic acid

FERROUS FUMARATE with FOLIC ACID

9011G NP	Tablet 310 mg (equivalent to 100 mg iron)-350 micrograms	60	1	..	12.89	14.00	Ferro-f-tab	AE
-------------	--	----	---	----	-------	-------	-------------	----

Vitamin B₁₂ and folic acid

Vitamin B₁₂ (cyanocobalamin and derivatives)

HYDROXOCOBALAMIN

Restricted benefit

Pernicious anaemia;

Other proven vitamin B₁₂ deficiencies;

Prophylaxis after gastrectomy.

Note

One injection of hydroxocobalamin 1 mg every three months provides appropriate maintenance therapy in vitamin B₁₂ deficiencies.

9048F NP	Injection 1 mg (as chloride) in 1 mL	3	14.94	16.05	^a Hydroxo-B12	AS
							^a Neo-B12	HH

Folic acid and derivatives

FOLIC ACID

2958Q NP	Tablet 500 micrograms	200	*13.88	14.99	Megafof 0.5	AF
-------------	-----------------------	-----	----	----	--------	-------	-------------	----

Blood and blood forming organs

					Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium			Brand Name and Manufacturer	
FOLIC ACID								
Note								
The 5 mg strength tablet should be used in malabsorption states only.								
1437P NP	Tablet 5 mg	200	1	..	*14.12	15.23	Megafol 5	AF

Blood substitutes and perfusion solutions

Blood and related products

Blood substitutes and plasma protein fractions

GELATIN - SUCCINYLATED								
8444K NP	I.V. infusion 20 g per 500 mL, 500 mL	3	*45.85	35.40	Gelofusine	BR
HYDROXYETHYL STARCH 130/0.4								
9487H NP	I.V. infusion 30 g per 500 mL, 500 mL	3	*45.85	35.40	Voluven 6%	PK

I.V. solutions

Solutions for parenteral nutrition

GLUCOSE								
2245E NP	I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L	5	1	..	*22.92	24.03	^a B. Braun Australia Pty Ltd	BR
							^a Baxter Healthcare Pty Ltd	BX
							^a Fresenius Kabi Australia Pty Limited	PK
9444C NP	I.V. infusion 139 mmol (anhydrous) per 500 mL (5%), 500 mL	5	1	..	*17.97	19.08	^a B. Braun Australia Pty Ltd	BR
							^a Fresenius Kabi Australia Pty Limited	PK
9445D NP	I.V. infusion 278 mmol (anhydrous) per 500 mL (10%), 500 mL	5	1	..	*17.97	19.08	Fresenius Kabi Australia Pty Limited	PK
9474P NP	I.V. infusion 69.5 mmol (anhydrous) per 250 mL (5%), 250 mL	5	1	..	*23.77	24.88	^a B. Braun Australia Pty Ltd	BR
							^a Glucose 5% Freeflex	PK

Solutions affecting the electrolyte balance

ELECTROLYTE REPLACEMENT SOLUTION								
3199J NP	I.V. infusion 1 L	2	1	..	*22.06	23.17	Plasma-Lyte 148	BX
SODIUM CHLORIDE								
2260Y NP	I.V. infusion 513 mmol per L (3%), 1 L	2	1	..	*12.22	13.33	Baxter Healthcare Pty Ltd	BX
2264E NP	I.V. infusion 154 mmol per L (0.9%), 1 L	5	1	..	*16.02	17.13	^a B. Braun Australia Pty Ltd	BR
							^a Baxter Healthcare Pty Ltd	BX
							^a Fresenius Kabi Australia Pty Limited	PK
9392H NP	I.V. infusion 77 mmol per 500 mL (0.9%), 500 mL	5	1	..	*13.12	14.23	^a B. Braun Australia Pty Ltd	BR
							^a Fresenius Kabi Australia Pty Limited	PK

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
9473N NP	I.V. infusion 38.5 mmol per 250 mL (0.9%), 250 mL	5	1	..	*16.47	17.58 ^a	B. Braun Australia Pty Ltd	BR
							Sodium Chloride 0.9% Freeflex	PK
SODIUM CHLORIDE COMPOUND								
2266G NP	I.V. infusion 1 L	4	1	..	*30.12	31.23	Baxter Healthcare Pty Ltd	BX
SODIUM CHLORIDE with GLUCOSE								
2278X NP	I.V. infusion 39 mmol-69 mmol (anhydrous) per 500 mL (0.45%-2.5%), 500 mL	5	1	..	*28.87	29.98	Baxter Healthcare Pty Ltd	BX
2279Y NP	I.V. infusion 19 mmol-104 mmol (anhydrous) per 500 mL (0.225%-3.75%), 500 mL	5	1	..	*28.87	29.98	Baxter Healthcare Pty Ltd	BX
2281C NP	I.V. infusion 31 mmol-222 mmol (anhydrous) per L (0.18%-4%), 1 L	5	1	..	*23.62	24.73	Baxter Healthcare Pty Ltd	BX
SODIUM LACTATE COMPOUND								
2286H NP	I.V. infusion 1 L	5	1	..	*15.62	16.73 ^a	B. Braun Australia Pty Ltd	BR
							Baxter Healthcare Pty Ltd	BX
							Fresenius Kabi Australia Pty Limited	PK
9416N NP	I.V. infusion 500 mL	5	1	..	*12.92	14.03 ^a	B. Braun Australia Pty Ltd	BR
							Fresenius Kabi Australia Pty Limited	PK

Other hematological agents

Other hematological agents

Drugs used in hereditary angioedema

ICATIBANT

Authority required

Initial supply for anticipated emergency treatment of an acute attack of hereditary angioedema in a patient with confirmed diagnosis of C1-esterase inhibitor deficiency who has been assessed to be at significant risk of an acute attack of hereditary angioedema by or in consultation with a clinical immunologist, respiratory physician, specialist allergist or general physician experienced in the management of patients with hereditary angioedema.

The name of the specialist consulted must be provided at the time of application for initial supply.

The name of the Approved Pathology Authority and date of the diagnosing pathology test must be included in the authority application;

Continuing supply for anticipated emergency treatment of an acute attack of hereditary angioedema, where the patient has previously been issued with an authority prescription for this drug.

Note

Icatibant should be provided in the framework of a comprehensive hereditary angioedema prophylaxis program and an emergency Action Plan including training in recognition of the symptoms of hereditary angioedema and the self-administration of icatibant. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au)

1976B	Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe	1	1	..	2571.46	35.40	Firazyr	ZI
-------	---	---	---	----	---------	-------	---------	----

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Cardiovascular system

Cardiac therapy

Cardiac glycosides

Digitalis glycosides

DIGOXIN

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1322N NP	Tablet 250 micrograms	100	1	..	10.81	11.92 ^a	Sigmaxin	FM
				^B 2.94	13.75	11.92 ^a	Lanoxin	QA
2605D NP	Tablet 62.5 micrograms	200	1	..	10.52	11.63 ^a	Sigmaxin-PG	FM
				^B 2.95	13.47	11.63 ^a	Lanoxin-PG	QA
3164M NP	Oral solution for children 50 micrograms per mL, 60 mL	2	3	..	*41.22	35.40	Lanoxin	QA

Antiarrhythmics, class I and III

Antiarrhythmics, class IA

DISOPYRAMIDE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2923W NP	Capsule 100 mg	100	5	..	29.23	30.34	Rythmodan	SW
2924X NP	Capsule 150 mg	100	5	..	46.61	35.40	Rythmodan	SW

Antiarrhythmics, class IB

LIGNOCAINE HYDROCHLORIDE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2875H NP	Injection 100 mg in 5 mL	5	37.43	35.40	Pfizer Australia Pty Ltd	PF
2876J NP	Infusion 500 mg in 5 mL	10	29.69	30.80	Xylocard 500	AP

Antiarrhythmics, class IC

FLECAINIDE ACETATE

Caution

Flecainide acetate should be avoided in patients with poor cardiac function.

Restricted benefit

Serious supra-ventricular cardiac arrhythmias;

Serious ventricular cardiac arrhythmias where treatment is initiated in a hospital (in-patient or out-patient).

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1088G NP	Tablet 50 mg	60	5	..	37.85	35.40	Tambacor	IA
1090J NP	Tablet 100 mg	60	5	..	44.79	35.40 ^a	Flecatab	AF

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
							^a Tambocor	IA

Antiarrhythmics, class III

AMIODARONE

Caution

Amiodarone hydrochloride has been reported to cause frequent and potentially serious toxicity. Regular monitoring of hepatic and thyroid function is recommended.

Restricted benefit

Severe cardiac arrhythmias.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2343H NP	Tablet containing amiodarone hydrochloride 200 mg	30	5	..	18.32	19.43	^a Amiodarone Sandoz	SZ
							^a Aratac 200	AF
							^a Chem mart Amiodarone	CH
							^a Cordarone X 200	SW
							^a GenRx Amiodarone	GX
							^a Rithmik 200	QA
							^a Terry White Chemists Amiodarone	TW
2344J NP	Tablet containing amiodarone hydrochloride 100 mg	30	5	..	13.14	14.25	^a Amiodarone Sandoz	SZ
							^a Aratac 100	AF
							^a Cordarone X 100	SW

SOTALOL HYDROCHLORIDE

Restricted benefit

Severe cardiac arrhythmias.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2043M NP	Tablet 160 mg	60	5	..	20.12	21.23	^a Cardol	AF
							^a Chem mart Sotalol	CH
							^a GenRx Sotalol	GX
							^a Solavert	QA
							^a Sotalol Sandoz	SZ
							^a Terry White Chemists Sotalol	TW
8398B NP	Tablet 80 mg	60	5	^B 5.00	25.12	21.23	^a Sotacor	FM
				..	12.87	13.98	^a GenRx Sotalol	GX
							^a Solavert	QA
							^a Sotalol Sandoz	SZ
				^B 4.99	17.86	13.98	^a Sotacor	FM

Cardiac stimulants excl. cardiac glycosides Adrenergic and dopaminergic agents

ADRENALINE

1016L NP	Injection 1 mg in 1 mL (1 in 1,000)	5	1	..	20.44	21.55	Link Medical Products Pty Ltd	LM
-------------	-------------------------------------	---	---	----	-------	-------	----------------------------------	----

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
ADRENALINE								
<u>Authority required</u>								
Initial sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who:								
(a) has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply; or								
(b) has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis;								
Continuing sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug.								
<u>Note</u>								
The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au .)								
<u>Note</u>								
Authority approvals will be limited to a maximum quantity of 2 auto-injectors (Anapen or EpiPen) at any one time.								
No repeats will be issued.								
<u>Caution</u>								
EpiPen and Anapen products have different administration techniques and should not be prescribed to the same patient without training in their use.								
3408J NP	I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector	1	106.10	35.40	Anapen Junior	LM
3409K NP	I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector	1	106.10	35.40	Anapen	LM
8697R NP	I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector	1	106.10	35.40	EpiPen Jr.	AL
8698T NP	I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector	1	106.10	35.40	EpiPen	AL

Vasodilators used in cardiac diseases

Organic nitrates

GLYCERYL TRINITRATE								
1459T NP	Tablets 600 micrograms, 100	1	5	..	14.93	16.04	^a Lycinate	FM
				^B 2.94	17.87	16.04	^a Anginine Stabilised	QA
1515R NP	Transdermal patch releasing approximately 5 mg per 24 hours	30	5	..	27.42	28.53	Transiderm-Nitro 25	NV
1516T NP	Transdermal patch releasing approximately 10 mg per 24 hours	30	5	..	33.91	35.02	Transiderm-Nitro 50	NV
8010N NP	Transdermal patch releasing approximately 5 mg per 24 hours	30	5	..	27.42	28.53	Nitro-Dur 5	MK
8011P NP	Transdermal patch releasing approximately 10 mg per 24 hours	30	5	..	33.91	35.02	Nitro-Dur 10	MK
8026K NP	Transdermal patch releasing approximately 15 mg per 24 hours	30	5	..	33.91	35.02	Nitro-Dur 15	MK
8027L NP	Transdermal patch releasing approximately 5 mg per 24 hours	30	5	..	27.42	28.53	Minitran 5	IA
8028M NP	Transdermal patch releasing approximately 10 mg per 24 hours	30	5	..	33.91	35.02	Minitran 10	IA
8119H NP	Transdermal patch releasing approximately 15 mg per 24 hours	30	5	..	33.91	35.02	Minitran 15	IA

GLYCERYL TRINITRATE

Note

The spray should not be inhaled.

8171C NP	Sublingual spray (pump pack) 400 micrograms per dose (200 doses)	1	5	..	20.23	21.34	Nitrolingual Pumpspray	SW
-------------	--	---	---	----	-------	-------	------------------------	----

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
ISOSORBIDE DINITRATE							
2588F NP	Sublingual tablet 5 mg	200	2	..	*14.66	15.77	Isordil Sublingual QA
ISOSORBIDE MONONITRATE							
1558B NP	Tablet 60 mg (sustained release)	30	5	..	12.02	13.13 ^a	Chem mart Isosorbide Mononitrate CH
						^a Duride	AF
						^a GenRx Isosorbide Mononitrate	GX
						^a Imtrate 60 mg	GM
						^a Isomonit	SZ
						^a Monodur 60 mg	PM
						^a Terry White Chemists Isosorbide Mononitrate	TW
				^B 2.41	14.43	13.13 ^a	Imdur Durule AP
8273K NP	Tablet 120 mg (sustained release)	30	5	..	19.55	20.66 ^a	Monodur 120 mg PM
				^B 2.55	22.10	20.66 ^a	Imdur 120 mg AP

Other vasodilators used in cardiac diseases

NICORANDIL

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8228C NP	Tablets 10 mg, 60	£1	5	..	24.24	25.35	Ikorel	SW
8229D NP	Tablets 20 mg, 60	£1	5	..	31.36	32.47	Ikorel	SW

PERHEXILINE MALEATE

Caution

Regular monitoring of drug serum levels is recommended.

Authority required (STREAMLINED)

1023

Angina not responding to other therapy.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1822X NP	Tablet 100 mg	100	5	..	62.72	35.40	Pexsig	QA
-------------	---------------	-----	---	----	-------	-------	--------	----

Antihypertensives

Antiadrenergic agents, centrally acting

Methyldopa

METHYLDOPA								
1629R NP	Tablet 250 mg	100	5	..	13.97	15.08 ^a	Hydopa	AF
				^B 2.70	16.67	15.08 ^a	Aldomet	AS

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Imidazoline receptor agonists								
CLONIDINE								
3141H NP	Tablet 150 micrograms	100	5	..	37.54	35.40	Catapres	BY
3145M NP	Tablet 100 micrograms	100	5	..	28.98	30.09	Catapres 100	BY
MOXONIDINE								
Restricted benefit								
Hypertension in patients receiving concurrent antihypertensive therapy.								
9019Q NP	Tablet 200 micrograms	30	5	..	19.63	20.74	Physiotens	AB
9020R NP	Tablet 400 micrograms	30	5	..	28.88	29.99	Physiotens	AB
Antiadrenergic agents, peripherally acting								
Alpha-adrenoceptor antagonists								
PRAZOSIN								
1478T NP	Tablet 5 mg (as hydrochloride)	100	5	..	20.67	21.78	^a APO-Prazosin	TX
							^a Chem mart	CH
							^a Prazosin	
							^a Minipress	PF
							^a Terry White	TW
							^a Chemists	
1479W NP	Tablet 1 mg (as hydrochloride)	100	5	..	11.47	12.58	^a APO-Prazosin	TX
							^a Chem mart	CH
							^a Prazosin	
							^a Minipress	PF
							^a Terry White	TW
							^a Chemists	
1480X NP	Tablet 2 mg (as hydrochloride)	100	5	..	14.40	15.51	^a APO-Prazosin	TX
							^a Chem mart	CH
							^a Prazosin	
							^a Minipress	PF
							^a Terry White	TW
							^a Chemists	
							^a Prazosin	

Arteriolar smooth muscle, agents acting on *Hydrazinophthalazine derivatives*

HYDRALAZINE HYDROCHLORIDE								
1639G NP	Tablet 50 mg	200	2	..	*17.52	18.63	Alphapress 50	AF
1640H NP	Tablet 25 mg	200	2	..	*15.60	16.71	Alphapress 25	AF

Pyrimidine derivatives

MINOXIDIL

Authority required (STREAMLINED)

2759

Severe refractory hypertension. Treatment must be initiated by a consultant physician.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
2313R NP	Tablet 10 mg	100	5	..	52.93	35.40	Loniten PF

Diuretics

Low-ceiling diuretics, thiazides

Thiazides, plain

HYDROCHLOROTHIAZIDE

1484D NP	Tablet 25 mg	100	1	..	21.34	22.45	Dithiazide	PL
-------------	--------------	-----	---	----	-------	-------	------------	----

Low-ceiling diuretics, excl. thiazides

Sulfonamides, plain

CHLORTHALIDONE

1585K	Tablet 25 mg	100	1	..	*17.68	18.79	Hygroton 25	LM
-------	--------------	-----	---	----	--------	-------	-------------	----

INDAPAMIDE HEMIHYDRATE

2436F NP	Tablet 2.5 mg	90	1	..	15.35	16.46	^a	Chem mart Indapamide	CH
							^a	Dapa-Tabs	AF
							^a	GenRx Indapamide	GX
							^a	Indapamide-GA	GM
							^a	Indapamide-PS	FZ
							^a	Indapamide Sandoz	SZ
							^a	Insig	QA
							^a	Terry White Chemists Indapamide	TW
				^b 2.04	17.39	16.46	^a	Natrilix	SE
8532C NP	Tablet 1.5 mg (sustained release)	90	1	..	17.34	18.45		Natrilix SR	SE

High-ceiling diuretics

Sulfonamides, plain

FRUSEMIDE

Note

For item codes 2414C and 1810G, pharmaceutical benefits that have the form tablet 20 mg are equivalent for the purposes of substitution.

1810G NP	Tablet 20 mg	100	1	..	*8.60	9.71	^a	Urex-M	FM
				^B 1.92	*10.52	9.71	^a	Lasix-M	SW
2414C NP	Tablet 20 mg	100	1	..	8.60	9.71	^a	Chem mart Frusemide	CH
							^a	Frusemide-PS	FZ
							^a	Frusid	GM
							^a	GenRx Frusemide	GX
							^a	Terry White Chemists Frusemide	TW
<hr/>									
	FRUSEMIDE								
2411X NP	Oral solution 10 mg per mL, 30 mL	‡1	3	..	17.16	18.27		Lasix	SW
2412Y NP	Tablet 40 mg	100	1	..	8.42	9.53	^a	Chem mart Frusemide	CH

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							^a Frusax	GN
							^a Frusemide-PS	FZ
							^a Frusemide Sandoz	SZ
							^a Frusid	GM
							^a GenRx Frusemide	GX
							^a Terry White Chemists Frusemide	TW
							^a Uremide	AF
							Urex	FM
				^B 2.40	10.82	9.53	^a Lasix	SW
2413B NP	Injection 20 mg in 2 mL	5	9.72	10.83	^a Frusemide-Clarix	AE
							^a Frusemide Sandoz	SZ
							^a Lasix	SW
2415D NP	Tablet 500 mg	50	3	..	16.34	17.45	Urex-Forte	FM

Aryloxyacetic acid derivatives

ETHACRYNIC ACID

Restricted benefit

Patients hypersensitive to other oral diuretics.

8748K NP	Tablet 25 mg	200	1	..	*197.40	35.40	Edecrin	FK
-------------	--------------	-----	---	----	---------	-------	---------	----

Potassium-sparing agents

Aldosterone antagonists

EPLERENONE

Caution

Serum electrolytes should be checked regularly.

Authority required (STREAMLINED)

2637

Heart failure with a left ventricular ejection fraction of 40% or less occurring within 3 to 14 days following an acute myocardial infarction. Treatment with eplerenone must be commenced within 14 days of an acute myocardial infarction.

The date of the acute myocardial infarction and the date of initiation of eplerenone treatment must be documented in the patient's medical records when PBS-subsidised treatment is initiated.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8879H NP	Tablet 25 mg	30	5	..	112.87	35.40	Inspra	PF
8880J NP	Tablet 50 mg	30	5	..	112.87	35.40	Inspra	PF

SPIRONOLACTONE

Caution

Appropriate contraceptive measures should be taken by women of child-bearing age in whom spironolactone therapy has been initiated.

Caution

Serum electrolytes should be checked regularly.

2339D NP	Tablet 25 mg	100	5	..	12.29	13.40	^a Spiractin 25	AF
				^B 1.75	14.04	13.40	^a Aldactone	PF
2340E NP	Tablet 100 mg	100	5	..	29.22	30.33	^a Spiractin 100	AF
				^B 2.40	31.62	30.33	^a Aldactone	PF

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Diuretics and potassium-sparing agents in combination								
<i>Low-ceiling diuretics and potassium-sparing agents</i>								
HYDROCHLOROTHIAZIDE with AMILORIDE HYDROCHLORIDE								
<u>Caution</u>								
Serum electrolytes should be checked regularly.								
1486F NP	Tablet 50 mg-5 mg	100	1	..	*13.60	14.71	Moduretic	AS
HYDROCHLOROTHIAZIDE with TRIAMTERENE								
<u>Caution</u>								
Serum electrolytes should be checked regularly.								
1280J NP	Tablet 25 mg-50 mg	100	1	..	12.99	14.10	Hydrene 25/50	AF

Peripheral vasodilators

Peripheral vasodilators

Other peripheral vasodilators

PHENOXYBENZAMINE HYDROCHLORIDE

Restricted benefit

Phaeochromocytoma;

Neurogenic urinary retention.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1166J NP	Capsules 10 mg, 30	3	5	..	*205.00	35.40	Dibenzyliline	GH
1862B NP	Capsule 10 mg	100	5	..	67.46	35.40	Dibenzyliline	GH
9286R NP	Capsules 10 mg, 100	1	5	..	1164.57	35.40	Dibenzyliline	BZ

Beta blocking agents

Beta blocking agents

Beta blocking agents, non-selective

OXPRENOLOL HYDROCHLORIDE

2942W NP	Tablet 20 mg	100	5	..	27.98	29.09	Corbeton 20	AF
2961W NP	Tablet 40 mg	100	5	..	48.34	35.40	Corbeton 40	AF

PINDOLOL

3062E NP	Tablet 5 mg	100	5	..	33.46	34.57	Barbloc 5	AF
3065H NP	Tablet 15 mg	50	5	..	13.44	14.55 ^a	Barbloc 15	AF
				^B 2.57	16.01	14.55 ^a	Visken 15	NV

PROPRANOLOL HYDROCHLORIDE

2565B NP	Tablet 10 mg	100	5	..	10.29	11.40	Deralin 10	AF
				^B 3.14	13.43	11.40	Inderal	AP
2566C NP	Tablet 40 mg	100	5	..	10.66	11.77	Deralin 40	AF

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				^B 3.14	13.80	11.77	Inderal AP
2899N NP	Tablet 160 mg	50	5	..	11.11	12.22	Deralin 160 AF
SOTALOL HYDROCHLORIDE							
<u>Restricted benefit</u>							
Severe cardiac arrhythmias.							
<u>Note</u>							
Shared Care Model:							
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
2043M NP	Tablet 160 mg	60	5	..	20.12	21.23	^a Cardol AF
							^a Chem mart Sotalol CH
							^a GenRx Sotalol GX
							^a Solavert QA
							^a Sotalol Sandoz SZ
							^a Terry White TW
							Chemists Sotalol
				^B 5.00	25.12	21.23	^a Sotacor FM
8398B NP	Tablet 80 mg	60	5	..	12.87	13.98	^a GenRx Sotalol GX
							^a Solavert QA
							^a Sotalol Sandoz SZ
				^B 4.99	17.86	13.98	^a Sotacor FM

Beta blocking agents, selective

ATENOLOL							
1081X NP	Tablet 50 mg	30	5	..	8.91	10.02	^a APO-Atenolol TX
							^a Atenolol-GA GN
							^a Atenolol GQ
							generichealth
							^a Atenolol-PS FZ
							^a Atenolol Sandoz SZ
							^a Chem mart CH
							Atenolol
							^a Noten AF
							^a Tensig QA
							^a Terry White TW
							Chemists
							Atenolol
				^B 2.21	11.12	10.02	^a Tenormin AP

BISOPROLOL FUMARATE

Authority required (STREAMLINED)

3234

Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8604W NP	Tablet 2.5 mg	28	5	..	41.47	35.40	^a APO-Bisoprolol TX
							^a Beprol 2.5 DO
							^a Bicard 2.5 QA

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8605X NP	Tablet 5 mg	28	5	..	49.07	35.40	^a Bicolor	AL
							^a Biso 2.5	WQ
							^a Bisoprolol GH	GQ
							^a Bisoprolol Pfizer	FZ
							^a Bisoprolol Sandoz	SZ
							^a Bispro 2.5	AF
							^a Chem mart	CH
							^a Terry White Chemists	TW
							^a Bisoprolol	
							^a APO-Bisoprolol	TX
							^a Beprol 5	DO
							^a Bicard 5	QA
							^a Bicolor	AL
							^a Biso 5	WQ
							^a Bisoprolol GH	GQ
							^a Bisoprolol Pfizer	FZ
8606Y NP	Tablet 10 mg	28	5	..	58.85	35.40	^a Bisoprolol Sandoz	SZ
							^a Bispro 5	AF
							^a Chem mart	CH
							^a Terry White Chemists	TW
							^a Bisoprolol	
							^a APO-Bisoprolol	TX
							^a Beprol 10	DO
							^a Bicard 10	QA
							^a Bicolor	AL
							^a Biso 10	WQ
							^a Bisoprolol GH	GQ
							^a Bisoprolol Pfizer	FZ
							^a Bisoprolol Sandoz	SZ
							^a Bispro 10	AF
							^a Chem mart	CH
							^a Terry White Chemists	TW
							^a Bisoprolol	

METOPROLOL SUCCINATE

Authority required (STREAMLINED)

3234

Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8732N NP	Tablet 23.75 mg (controlled release)	15	21.14	22.25	Toprol-XL 23.75	AP
8733P NP	Tablet 47.5 mg (controlled release)	30	5	..	72.56	35.40	Toprol-XL 47.5	AP
8734Q NP	Tablet 95 mg (controlled release)	30	5	..	89.06	35.40	Toprol-XL 95	AP
8735R NP	Tablet 190 mg (controlled release)	30	5	..	109.70	35.40	Toprol-XL 190	AP

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer
METOPROLOL TARTRATE								
1324Q NP	Tablet 50 mg	100	5	..	9.92	11.03	^a	Chem mart Metoprolol CH
							^a	GenRx Metoprolol GX
							^a	Metohexal SZ
							^a	Metrol 50 QA
							^a	Minax 50 AF
							^a	Terry White Chemists Metoprolol TW
				^B 2.51	12.43	11.03	^a	Betaloc AP
				^B 2.52	12.44	11.03		Lopresor 50 NV
1325R NP	Tablet 100 mg	60	5	..	10.86	11.97	^a	Chem mart Metoprolol CH
							^a	GenRx Metoprolol GX
							^a	Metohexal SZ
							^a	Metrol 100 QA
							^a	Minax 100 AF
							^a	Terry White Chemists Metoprolol TW
				^B 2.50	13.36	11.97	^a	Betaloc AP
								Lopresor 100 NV

NEBIVOLOL

Authority required (STREAMLINED)

3234

Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9310B NP	Tablet 1.25 mg (as hydrochloride), 28	1	5	..	29.35	30.46		Nebilet CS
9311C NP	Tablet 5 mg (as hydrochloride)	28	5	..	61.04	35.40		Nebilet CS
9312D NP	Tablet 10 mg (as hydrochloride)	28	5	..	68.12	35.40		Nebilet CS
9316H NP	Tablet 1.25 mg (as hydrochloride)	56	5	..	*50.72	35.40		Nebilet CS

Alpha and beta blocking agents

CARVEDILOL

Authority required (STREAMLINED)

3234

Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated;

1735

Patients receiving this drug as a pharmaceutical benefit prior to 1 August 2002.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8255L NP	Tablet 3.125 mg	30	12.91	14.02	^a	APO-Carvedilol TX
							^a	Chem mart Carvedilol 3.125 mg CH

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
8256M NP	Tablet 6.25 mg	60	5	..	36.75	35.40	^a Dilatrend 3.125 RO
							^a GenRx Carvedilol GX
							^a GN-Carvedilol GM
							^a Terry White Chemists Carvedilol 3.125 mg TW
							^a Vedilol 3.125 QA
							^a Volirop 3.125 DO
							^a APO-Carvedilol TX
							^a Carvedilol generichealth GQ
							^a Carvedilol Sandoz SZ
							^a Chem mart Carvedilol 6.25 mg CH
							^a Dicarz AF
							^a Dilatrend 6.25 RO
							^a GenRx Carvedilol GX
							^a GN-Carvedilol GM
							^a Terry White Chemists Carvedilol 6.25 mg TW
8257N NP	Tablet 12.5 mg	60	5	..	43.89	35.40	^a Vedilol 6.25 QA
							^a Volirop 6.25 DO
							^a APO-Carvedilol TX
							^a Carvedilol generichealth GQ
							^a Carvedilol Sandoz SZ
							^a Chem mart Carvedilol 12.5 mg CH
							^a Dicarz AF
							^a Dilatrend 12.5 RO
							^a GenRx Carvedilol GX
							^a GN-Carvedilol GM
							^a Terry White Chemists Carvedilol 12.5 mg TW
							^a Vedilol 12.5 QA
							^a Volirop 12.5 DO
							^a APO-Carvedilol TX
							^a Carvedilol generichealth GQ
8258P NP	Tablet 25 mg	60	5	..	52.10	35.40	^a Carvedilol Sandoz SZ
							^a Chem mart Carvedilol 25 mg CH
							^a Dicarz AF
							^a Dilatrend 25 RO
							^a GenRx Carvedilol GX
							^a GN-Carvedilol GM
							^a Terry White Chemists Carvedilol 25 mg TW
							^a Vedilol 25 QA

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer	
							^a	Volirop 25	DO
LABETALOL HYDROCHLORIDE									
1566K NP	Tablet 100 mg	100	5	..	15.38	16.49	^a	Presolol 100	AF
				^B 3.13	18.51	16.49	^a	Trandate	QA
1567L NP	Tablet 200 mg	100	5	..	21.10	22.21	^a	Presolol 200	AF
				^B 3.14	24.24	22.21	^a	Trandate	QA

Calcium channel blockers

Selective calcium channel blockers with mainly vascular effects *Dihydropyridine derivatives*

AMLODIPINE

Note

Pharmaceutical benefits that have the form amlodipine tablet 5 mg (as besylate) and pharmaceutical benefits that have the form amlodipine tablet 5 mg (as maleate) are equivalent for the purposes of substitution.

1343Q NP	Tablet 5 mg (as maleate)	30	5	..	11.56	12.67	^a	Amlo 5	ZP
2751T NP	Tablet 5 mg (as besylate)	30	5	..	11.56	12.67	^a	Amlodipine-DRLA	RZ
							^a	Amlodipine-GA	GM
							^a	Amlodipine generichealth	GQ
							^a	Amlodipine Pfizer	FZ
							^a	Amlodipine Sandoz	SZ
							^a	APO-Amlodipine	TX
							^a	Auro-Amlodipine 5	DO
							^a	Chem mart Amlodipine	CH
							^a	Nordip	AF
							^a	Norvapine	GN
							^a	Ozlodip	RA
							^a	Pharmacor Amlodipine 5	CR
							^a	Terry White Chemists Amlodipine	TW
				^B 3.75	15.31	12.67	^a	Norvasc	PF

AMLODIPINE

Note

Pharmaceutical benefits that have the form amlodipine tablet 10 mg (as besylate) and pharmaceutical benefits that have the form amlodipine tablet 10 mg (as maleate) are equivalent for the purposes of substitution.

1345T NP	Tablet 10 mg (as maleate)	30	5	..	15.35	16.46	^a	Amlo 10	ZP
2752W NP	Tablet 10 mg (as besylate)	30	5	..	15.35	16.46	^a	Amlodipine-DRLA	RZ
							^a	Amlodipine-GA	GM
							^a	Amlodipine generichealth	GQ
							^a	Amlodipine Pfizer	FZ
							^a	Amlodipine Sandoz	SZ
							^a	APO-Amlodipine	TX
							^a	Auro-Amlodipine 10	DO

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Chem mart CH
							^a Amlodipine AF
							^a Nordip AF
							^a Norvapine GN
							^a Ozlodip RA
							^a Pharmacor CR
							^a Amlodipine 10 TW
							^a Terry White Chemists TW
				^B 5.50	20.85	16.46	^a Amlodipine PF
							^a Norvasc PF
	FELODIPINE						
2361G NP	Tablet 2.5 mg (extended release)	30	5	..	11.71	12.82	^a Felodur ER 2.5 mg AL
				^B 4.06	15.77	12.82	^a Plendil ER AP
2366M NP	Tablet 5 mg (extended release)	30	5	..	13.97	15.08	^a Felodil XR 5 QA
							^a Felodur ER 5 mg AL
				^B 4.07	18.04	15.08	^a Plendil ER AP
2367N NP	Tablet 10 mg (extended release)	30	5	..	20.01	21.12	^a Felodil XR 10 QA
							^a Felodur ER 10 mg AL
				^B 4.08	24.09	21.12	^a Plendil ER AP
	LERCANIDIPINE HYDROCHLORIDE						
8534E NP	Tablet 10 mg	28	5	..	12.76	13.87	^a APO-Lercanidipine TX
							^a Chem mart CH
							^a Lercanidipine GM
							^a Lercadip QA
							^a Lercan QA
							^a Lercanidipine SZ
							^a Sandoz TW
							^a Terry White Chemists TW
							^a Lercanidipine AF
				^B 2.66	15.42	13.87	^a Zircol AB
8679T NP	Tablet 20 mg	28	5	..	16.94	18.05	^a Zanidip TX
							^a APO-Lercanidipine TX
							^a Chem mart CH
							^a Lercanidipine GM
							^a Lercadip QA
							^a Lercan QA
							^a Lercanidipine SZ
							^a Sandoz TW
							^a Terry White Chemists TW
							^a Lercanidipine AF
				^B 2.64	19.58	18.05	^a Zircol AB
	NIFEDIPINE						
1694E NP	Tablet 10 mg	60	5	..	13.75	14.86	^a Adefin 10 AF
				^B 0.95	14.70	14.86	^a Adalat 10 BN
1695F NP	Tablet 20 mg	60	5	..	15.42	16.53	^a Adefin 20 AF

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
1906H NP	Tablet 30 mg (controlled release)	30	5	1.76	17.18	16.53	^a GenRx Nifedipine	GX
							^a Nifehexal	SZ
							^a Adalat 20	BN
				2.03	18.56	17.64	^a Addos XR 30	QA
							^a Adefin XL 30	AF
							^a APO-Nifedipine XR	TX
1907J NP	Tablet 60 mg (controlled release)	30	5	2.03	19.08	20.19	^a Adalat Oros 30	BN
							^a Addos XR 60	QA
							^a Adefin XL 60	AF
				2.24	21.32	20.19	^a APO-Nifedipine XR	TX
							^a Adalat Oros 60	BN
							^a Adalat Oros 20mg	BN
8610E NP	Tablet 20 mg (controlled release)	30	5	..	15.78	16.89		

1312C NP	Capsule 180 mg (controlled delivery)	30	5	..	15.17	16.28	^a	Cardizem CD	SW
							^a	Chem mart Diltiazem CD	CH
							^a	Diltahexal CD	HX
							^a	Diltiazem Sandoz CD	SZ
							^a	GenRx Diltiazem CD	GX
							^a	Terry White Chemists Diltiazem CD	TW

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
1313D <i>NP</i>	Capsule 240 mg (controlled delivery)	30	5	..	18.20	19.31	^a Vasocardol CD AV
							^a Cardizem CD SW
							^a Chem mart CH
							^a Diltiazem CD HX
							^a Diltiazem Sandoz CD SZ
							^a GenRx Diltiazem CD GX
							^a Terry White Chemists Diltiazem CD TW
1335G <i>NP</i>	Tablet 60 mg	90	5	..	14.32	15.43	^a Vasocardol CD AV
							^a Cardizem SW
							^a Chem mart Diltiazem CH
							^a Coras AF
							^a Diltiazem Sandoz SZ
							^a Dilzem 60 mg GM
							^a GenRx Diltiazem GX
8480H <i>NP</i>	Capsule 360 mg (controlled delivery)	30	5	..	21.84	22.95	^a Terry White Chemists Diltiazem TW
							^a Vasocardol AV
							^a Cardizem CD SW
							^a Diltahexal CD HX
							^a Diltiazem Sandoz CD SZ
							^a Vasocardol CD AV

Agents acting on the renin-angiotensin system

ACE inhibitors, plain

ACE inhibitors, plain

Caution

Use of ACE inhibitors during pregnancy is contraindicated since these drugs have been associated with foetal death in utero.

CAPTOPRIL

1147J <i>NP</i>	Tablet 12.5 mg	90	5	..	14.77	15.88	^a Captopril Sandoz SZ
							^a GenRx Captopril GX
							^a Zedace AF
1148K <i>NP</i>	Tablet 25 mg	90	5	..	18.46	19.57	^a Captopril Sandoz SZ
							^a GenRx Captopril GX
							^a Zedace AF
1149L <i>NP</i>	Tablet 50 mg	90	5	^B 6.92	25.38	19.57	^a Capoten QA
				..	30.07	31.18	^a Captopril Sandoz SZ
							^a GenRx Captopril GX
							^a Zedace AF
				^B 5.38	35.45	31.18	^a Capoten QA

CAPTOPRIL

Restricted benefit

For patients unable to take a solid dose form of an ACE inhibitor.

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
8760C NP	Oral solution 5 mg per mL, 95 mL	1	5	..	111.92	35.40	Capoten QA
ENALAPRIL							
1368B NP	Tablet containing enalapril maleate 10 mg	30	5	..	13.86	14.97	^a Acetec AL
							^a Auspril QA
							^a Chem mart CH
							^a Enalapril GM
							^a Enalapril GQ
							^a generichealth FZ
							^a Enalapril-PS SZ
							^a Enalapril Sandoz GX
							^a GenRx Enalapril TW
				^B 4.65	18.51	14.97	^a Renitec MK
1369C NP	Tablet containing enalapril maleate 20 mg	30	5	..	15.86	16.97	^a Acetec AL
							^a Auspril QA
							^a Chem mart CH
							^a Enalapril GM
							^a Enalapril-GA GQ
							^a Enalapril FZ
							^a generichealth SZ
							^a Enalapril-PS GX
							^a Enalapril Sandoz TW
							^a GenRx Enalapril TW
							^a Terry White Chemists Enalapril
				^B 4.66	20.52	16.97	^a Renitec 20 MK
1370D NP	Tablet containing enalapril maleate 5 mg	30	5	..	10.98	12.09	^a Acetec AL
							^a Auspril QA
							^a Chem mart CH
							^a Enalapril GM
							^a Enalapril-GA GQ
							^a Enalapril FZ
							^a generichealth SZ
							^a Enalapril-PS GX
							^a Enalapril Sandoz TW
							^a GenRx Enalapril TW
							^a Terry White Chemists Enalapril
				^B 4.66	15.64	12.09	^a Renitec M MK
FOSINOPRIL SODIUM							
1182F NP	Tablet 10 mg	30	5	..	15.29	16.40	^a Fosipril 10 QA
							^a GenRx Fosinopril GX
							^a Monace 10 AF
							^a Monopril BQ
1183G NP	Tablet 20 mg	30	5	..	19.66	20.77	^a Fosipril 20 QA
							^a GenRx Fosinopril GX

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Monace 20 AF
							^a Monopril BQ
	LISINOPRIL						
2456G NP	Tablet 5 mg	30	5	..	11.98	13.09	^a APO-Lisinopril TX
							^a Chem mart CH
							^a Lisinopril
							^a Fibsol 5 QA
							^a GenRx Lisinopril GX
							^a Lisinopril 5 CR
							^a Lisinopril-DRLA RZ
							^a Lisinopril-GA GN
							^a Lisinopril GQ
							^a generichealth
							^a Lisinopril-PS FZ
							^a Lisinopril Ranbaxy RA
							^a Lisinopril Sandoz SZ
							^a Lisodur AF
							^a Terry White TW
							^a Chemists
							^a Lisinopril
				^B 1.47	13.45	13.09	^a Zestril AP
				^B 3.74	15.72	13.09	^a Prinivil 5 MK
2457H NP	Tablet 10 mg	30	5	..	14.72	15.83	^a APO-Lisinopril TX
							^a Chem mart CH
							^a Lisinopril
							^a Fibsol 10 QA
							^a GenRx Lisinopril GX
							^a Lisinopril 10 CR
							^a Lisinopril-DRLA RZ
							^a Lisinopril-GA GN
							^a Lisinopril GQ
							^a generichealth
							^a Lisinopril-PS FZ
							^a Lisinopril Ranbaxy RA
							^a Lisinopril Sandoz SZ
							^a Lisodur AF
							^a Terry White TW
							^a Chemists
							^a Lisinopril
				^B 1.47	16.19	15.83	^a Zestril AP
				^B 3.76	18.48	15.83	^a Prinivil 10 MK
2458J NP	Tablet 20 mg	30	5	..	16.85	17.96	^a APO-Lisinopril TX
							^a Chem mart CH
							^a Lisinopril
							^a Fibsol 20 QA
							^a GenRx Lisinopril GX
							^a Lisinopril 20 CR
							^a Lisinopril-DRLA RZ
							^a Lisinopril-GA GN
							^a Lisinopril GQ
							^a generichealth
							^a Lisinopril-PS FZ
							^a Lisinopril Ranbaxy RA

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Lisinopril Sandoz SZ
							^a Lisodur AF
							^a Terry White Chemists Lisinopril TW
				^B 1.47	18.32	17.96	^a Zestril AP
				^B 3.75	20.60	17.96	^a Prinivil 20 MK

PERINDOPRIL

Note

Pharmaceutical benefits that have the form perindopril erbumine tablet 2 mg and pharmaceutical benefits that have the form perindopril arginine tablet 2.5 mg are equivalent for the purposes of substitution.

3050M NP	Tablet containing 2 mg perindopril erbumine	30	5	..	11.48	12.59	^a APO-Perindopril TX
							^a Chem mart Perindopril CH
							^a GenRx Perindopril GX
							^a Idaprex 2 SZ
							^a Indopril 2 QA
							^a Ozapace RA
							^a Perindo AF
							^a Perindopril 2 CR
							^a Perindopril-DP GN
							^a Perindopril-GA GM
							^a Perindopril generichealth GQ
							^a Terry White Chemists Perindopril TW
9006B NP	Tablet containing 2.5 mg perindopril arginine	30	5	..	11.48	12.59	^a Coversyl 2.5mg SE

PERINDOPRIL

Note

Pharmaceutical benefits that have the form perindopril erbumine tablet 4 mg and pharmaceutical benefits that have the form perindopril arginine tablet 5 mg are equivalent for the purposes of substitution.

3051N NP	Tablet containing 4 mg perindopril erbumine	30	5	..	15.79	16.90	^a APO-Perindopril TX
							^a Chem mart Perindopril CH
							^a GenRx Perindopril GX
							^a Idaprex 4 SZ
							^a Indopril 4 QA
							^a Ozapace RA
							^a Perindo AF
							^a Perindopril 4 CR
							^a Perindopril-DP GN
							^a Perindopril-GA GM
							^a Perindopril generichealth GQ
							^a Terry White Chemists Perindopril TW
9007C NP	Tablet containing 5 mg perindopril arginine	30	5	..	15.79	16.90	^a Coversyl 5mg SE

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
PERINDOPRIL							
Note							
Pharmaceutical benefits that have the form perindopril erbumine tablet 8 mg and pharmaceutical benefits that have the form perindopril arginine tablet 10 mg are equivalent for the purposes of substitution.							
8704D NP	Tablet containing 8 mg perindopril erbumine	30	5	..	20.72	21.83	^a APO-Perindopril TX
							^a Chem mart CH
							^a Perindopril GX
							^a GenRx Perindopril SZ
							^a Idaprex 8 QA
							^a Indopril 8 RA
							^a Ozapace AF
							^a Perindo CR
							^a Perindopril 8 GN
							^a Perindopril-DP GM
							^a Perindopril-GA GQ
							^a Perindopril generichealth TW
							^a Terry White Chemists Perindopril SE
9008D NP	Tablet containing 10 mg perindopril arginine	30	5	..	20.72	21.83	^a Coversyl 10mg
QUINAPRIL							
1968N NP	Tablet 5 mg (as hydrochloride)	30	5	..	11.94	13.05	^a Acquin 5 QA
							^a Acquin Aspen 5 AS
							^a APO-Quinapril TX
							^a Aquinafil GN
							^a Pharmacor Quinapril 5 CR
							^a Qpril 5 AF
							^a Quinapril generichealth GQ
							^a Quinapril Pfizer FZ
							^a Quinapril Sandoz SZ
				^B 1.95	13.89	13.05	^a Accupril PF
1969P NP	Tablet 10 mg (as hydrochloride)	30	5	..	14.25	15.36	^a Acquin 10 QA
							^a Acquin Aspen 10 AS
							^a APO-Quinapril TX
							^a Aquinafil GN
							^a Pharmacor Quinapril 10 CR
							^a Qpril 10 AF
							^a Quinapril generichealth GQ
							^a Quinapril Pfizer FZ
				^B 1.95	16.20	15.36	^a Accupril PF
1970Q NP	Tablet 20 mg (as hydrochloride)	30	5	..	16.09	17.20	^a Acquin 20 QA
							^a Acquin Aspen 20 AS
							^a APO-Quinapril TX
							^a Aquinafil GN
							^a Pharmacor Quinapril 20 CR
							^a Qpril 20 AF

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Quinapril-GA GM
							^a Quinapril generichealth GQ
							^a Quinapril Pfizer FZ
							^a Quinapril Sandoz SZ
				^B 1.95	18.04	17.20	^a Accupril PF

RAMIPRIL

Note

Pharmaceutical benefits that have the form ramipril tablet 1.25 mg and pharmaceutical benefits that have the form ramipril capsule 1.25 mg are equivalent for the purposes of substitution.

1944H NP	Tablet 1.25 mg	30	5	..	9.60	10.71	^a APO-Ramipril TX
							^a Chem mart Ramipril CH
							^a Prilace 1.25 QA
							^a Ramace 1.25 mg AV
							^a Ramipril Sandoz SZ
							^a Ramipril Tabs Pfizer FZ
							^a Ramipril Winthrop WA
							^a Terry White Chemists Ramipril TW
							^a Tritace 1.25 mg SW
							^a Tryzan Tabs 1.25 AF
							^a Vascalace 1.25 DO
9120B NP	Capsule 1.25 mg	30	5	..	9.60	10.71	^a APO-Ramipril TX
							^a Chem mart Ramipril CH
							^a Pharmacor Ramipril 1.25 CR
							^a Ramipril-GA GM
							^a Ramipril generichealth GQ
							^a Terry White Chemists Ramipril TW
							^a Tryzan Caps 1.25 AF

RAMIPRIL

Note

Pharmaceutical benefits that have the form ramipril tablet 2.5 mg and pharmaceutical benefits that have the form ramipril capsule 2.5 mg are equivalent for the purposes of substitution.

1945J NP	Tablet 2.5 mg	30	5	..	11.02	12.13	^a APO-Ramipril TX
							^a Chem mart Ramipril CH
							^a Prilace 2.5 QA
							^a Ramace 2.5 mg AV
							^a Ramipril Sandoz SZ
							^a Ramipril Tabs Pfizer FZ
							^a Ramipril Winthrop WA
							^a Terry White Chemists Ramipril TW
							^a Tritace 2.5 mg SW

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
9121C NP	Capsule 2.5 mg	30	5	..	11.02	12.13	^a Tryzan Tabs 2.5 AF
							^a Vascalace 2.5 DO
							^a APO-Ramipril TX
							^a Chem mart CH
							^a Ramipril
							^a Pharmacor CR
							^a Ramipril 2.5
							^a Ramipril-GA GM
							^a Ramipril GQ
							^a generichealth
							^a Terry White TW
							^a Chemists
							^a Ramipril
							^a Tryzan Caps 2.5 AF

RAMIPRIL

Note

Pharmaceutical benefits that have the form ramipril tablet 5 mg and pharmaceutical benefits that have the form ramipril capsule 5 mg are equivalent for the purposes of substitution.

1946K NP	Tablet 5 mg	30	5	..	12.17	13.28	^a APO-Ramipril TX
							^a Chem mart CH
							^a Ramipril
							^a Prilace 5 QA
							^a Ramace 5 mg AV
							^a Ramipril Sandoz SZ
							^a Ramipril Tabs Pfizer FZ
							^a Ramipril Winthrop WA
							^a Terry White TW
9122D NP	Capsule 5 mg	30	5	..	12.17	13.28	^a Chemists
							^a Ramipril
							^a Tritace 5 mg SW
							^a Tryzan Tabs 5 AF
							^a Vascalace 5 DO
							^a APO-Ramipril TX
							^a Chem mart CH
							^a Ramipril
							^a Pharmacor CR
							^a Ramipril 5
							^a Ramipril-GA GM
							^a Ramipril GQ
							^a generichealth
							^a Terry White TW
							^a Chemists
							^a Ramipril
							^a Tryzan Caps 5 AF

RAMIPRIL

Note

Pharmaceutical benefits that have the form ramipril tablet 10 mg and pharmaceutical benefits that have the form ramipril capsule 10 mg are equivalent for the purposes of substitution.

1316G NP	Tablet 10 mg	30	5	..	16.50	17.61	^a APO-Ramipril TX
							^a Chem mart CH
							^a Ramipril
							^a Ramipril Sandoz SZ

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8470T NP	Capsule 10 mg	30	5	..	16.50	17.61	^a Ramipril Tabs Pfizer	FZ
							^a Terry White Chemists Ramipril	TW
							^a Tritace	SW
							^a Tryzan Tabs 10	AF
							^a Vascalace 10	DO
							^a APO-Ramipril	TX
							^a Chem mart Ramipril	CH
							^a GenRx Ramipril	GX
							^a Pharmacor Ramipril 10	CR
							^a Prilace 10	QA
							^a Ramace 10 mg	AV
							^a Ramipril-GA	GM
							^a Ramipril generichealth	GQ
							^a Ramipril-PS	FZ
							^a Ramipril Sandoz	SZ
							^a Ramipril Winthrop	WA
							^a Terry White Chemists Ramipril	TW
							^a Tritace 10 mg	SW
							^a Tryzan Caps 10	AF
<hr/>								
8668F NP	RAMIPRIL Pack containing 7 tablets 2.5 mg, 21 tablets 5 mg and 10 capsules 10 mg	±1	15.78	16.89	Tritace Titration Pack	SW
2791X NP	TRANDOLAPRIL Capsule 500 micrograms	28	5	..	8.68	9.79	^a APO-Trandolapril	TX
2792Y NP	Capsule 1 mg	28	5	..	12.25	13.36	^a Dolapril 0.5	QA
							^a Tranalpha	AF
							^a Trandolapril-DP	GN
							^a Trandolapril generichealth	GQ
							^a Gopten	AB
							^a APO-Trandolapril	TX
2793B NP	Capsule 2 mg	28	5	..	13.43	14.54	^a Dolapril 1	QA
							^a Tranalpha	AF
							^a Trandolapril-DP	GN
							^a Trandolapril generichealth	GQ
							^a Gopten	AB
							^a APO-Trandolapril	TX
							^a Dolapril 2	QA
							^a Tranalpha	AF
^a Trandolapril-DP	GN							
^a Trandolapril generichealth	GQ							

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
				^B 3.00	16.43	14.54	^a Gopten	AB
8758Y NP	Capsule 4 mg	28	5	..	19.49	20.60	^a APO-Trandolapril	TX
							^a Dolapril 4	QA
							^a Tranalpha	AF
							^a Trandolapril-DP	GN
							^a Trandolapril generichealth	GQ
				^B 3.00	22.49	20.60	^a Gopten	AB

ACE inhibitors, combinations

ACE inhibitors and diuretics

Caution

Use of ACE inhibitors during pregnancy is contraindicated since these drugs have been associated with foetal death in utero.

ENALAPRIL MALEATE with HYDROCHLOROTHIAZIDE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

8477E NP	Tablet 20 mg-6 mg	30	5	..	27.70	28.81	^a Enalapril/HCT Sandoz	SZ
							^a Renitec Plus 20/6	MK

FOSINOPRIL SODIUM with HYDROCHLOROTHIAZIDE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

8400D NP	Tablet 10 mg-12.5 mg	30	5	..	21.42	22.53	^a APO-Fosinopril HCTZ 10/12.5	TX
							^a Fosinopril/HCTZ-GA 10/12.5	GM
							^a Hyforil	RA
							^a Monoplus 10/12.5	BQ
8401E NP	Tablet 20 mg-12.5 mg	30	5	..	28.40	29.51	^a APO-Fosinopril HCTZ 20/12.5	TX
							^a Fosetic 20/12.5	ZP
							^a Fosinopril/HCTZ-GA 20/12.5	GM
							^a Hyforil	RA
							^a Monoplus 20/12.5	BQ

PERINDOPRIL with INDAPAMIDE HEMIHYDRATE

2190G NP	Tablet containing 2.5 mg perindopril arginine- 0.625 mg indapamide hemihydrate	30	5	..	15.10	16.21	Coversyl Plus LD 2.5mg/0.625mg	SE
-------------	---	----	---	----	-------	-------	-----------------------------------	----

PERINDOPRIL with INDAPAMIDE HEMIHYDRATE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

Note

Pharmaceutical benefits that have the form perindopril with indapamide hemihydrate tablet (containing 4 mg perindopril erbumine-1.25 mg indapamide hemihydrate) and pharmaceutical benefits that have the form perindopril with indapamide hemihydrate tablet (containing 5 mg perindopril arginine-1.25 mg indapamide hemihydrate) are equivalent for the purposes of substitution.

2845R NP	Tablet containing 5 mg perindopril arginine- 1.25 mg indapamide hemihydrate	30	5	..	25.79	26.90	^a Coversyl Plus 5mg/1.25mg	SE
8449Q NP	Tablet containing 4 mg perindopril erbumine- 1.25 mg indapamide hemihydrate	30	5	..	25.79	26.90	^a Chem mart Perindopril/ Indapamide 4/1.25	CH
							^a GenRx Perindopril/ Indapamide	GX

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							4/1.25
						^a	Idaprex Combi SZ
							4/1.25
						^a	Indopril Combi QA
							4/1.25
						^a	Perindo Combi AF
							4/1.25
						^a	Perindopril/ Indapamide GH GQ
							4/1.25
						^a	Terry White Chemists TW
							Perindopril/ Indapamide 4/1.25

QUINAPRIL HYDROCHLORIDE with HYDROCHLOROTHIAZIDE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

8589C NP	Tablet 10 mg (base)-12.5 mg	30	5	..	16.47	17.58	Accuretic 10/12.5mg	PF
8590D NP	Tablet 20 mg (base)-12.5 mg	30	5	..	18.31	19.42	Accuretic 20/12.5mg	PF

ACE inhibitors and calcium channel blockers

Caution

Use of ACE inhibitors during pregnancy is contraindicated since these drugs have been associated with foetal death in utero.

LERCANIDIPINE HYDROCHLORIDE with ENALAPRIL MALEATE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

9144G NP	Tablet 10 mg-10 mg	28	5	..	19.61	20.72	Zan-Extra 10/10	AB
9145H NP	Tablet 10 mg-20 mg	28	5	..	21.48	22.59	Zan-Extra 10/20	AB

PERINDOPRIL with AMLODIPINE

Note

Treatment should not be initiated with this combination.

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination;

Stable coronary heart disease in a patient who is stabilised on treatment with perindopril and amlodipine at the same doses.

9346X NP	Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besylate)	30	5	..	27.21	28.32	^a Coveram	SE
							^a Reaptan 5/5	RX
9347Y NP	Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besylate)	30	5	..	34.55	35.40	^a Coveram	SE
							^a Reaptan 5/10	RX
9348B NP	Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besylate)	30	5	..	33.04	34.15	^a Coveram	SE
							^a Reaptan 10/5	RX
9349C NP	Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besylate)	30	5	..	40.36	35.40	^a Coveram	SE
							^a Reaptan 10/10	RX

RAMIPRIL with FELODIPINE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

2626F NP	Tablet 2.5 mg-2.5 mg (modified release)	30	5	..	16.20	17.31	Triasyn 2.5/2.5	SW
2629J NP	Tablet 5 mg-5 mg (modified release)	30	5	..	19.62	20.73	Triasyn 5.0/5.0	SW

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
TRANDOLAPRIL with VERAPAMIL HYDROCHLORIDE								
Caution								
The myocardial depressant effects of verapamil hydrochloride and of beta-blocking drugs are additive.								
Restricted benefit								
Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.								
2857J NP	Tablet 4 mg-240 mg (sustained release)	28	5	..	28.12	29.23	Tarka 4/240	AB
9387C NP	Tablet 2 mg-180 mg (sustained release)	28	5	..	19.91	21.02	Tarka 2/180	AB
Angiotensin II antagonists, plain								
Angiotensin II antagonists, plain								
CANDESARTAN CILEXETIL								
8295N NP	Tablet 4 mg	30	5	..	9.20	10.31	Atacand	AP
8296P NP	Tablet 8 mg	30	5	T2.95	17.22	15.38	Atacand	AP
8297Q NP	Tablet 16 mg	30	5	T3.26	32.27	30.12	Atacand	AP
8889W NP	Tablet 32 mg	30	5	T2.87	39.66	35.40	Atacand	AP
CANDESARTAN CILEXETIL								
Authority required								
Adverse effects occurring with all of the base-priced drugs;								
Drug interactions occurring with all of the base-priced drugs;								
Drug interactions expected to occur with all of the base-priced drugs;								
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.								
8997M NP	Tablet 8 mg	30	5	..	17.22	18.33	Atacand	AP
8998N NP	Tablet 16 mg	30	5	..	32.27	33.38	Atacand	AP
8999P NP	Tablet 32 mg	30	5	..	39.66	35.40	Atacand	AP
EPROSARTAN MESYLATE								
8397Y NP	Tablet 400 mg (base)	56	5	T3.48	*26.96	24.59	Teveten	AB
8447N NP	Tablet 600 mg (base)	28	5	T2.00	29.73	28.84	Teveten	AB
EPROSARTAN MESYLATE								
Authority required								
Adverse effects occurring with all of the base-priced drugs;								
Drug interactions occurring with all of the base-priced drugs;								
Drug interactions expected to occur with all of the base-priced drugs;								
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.								
5491B NP	Tablet 600 mg (base)	28	5	..	29.73	30.84	Teveten	AB
8951D NP	Tablet 400 mg (base)	56	5	..	*26.96	28.07	Teveten	AB
IRBESARTAN								
8246B NP	Tablet 75 mg	30	5	..	14.56	15.67	^a Avapro	BQ
						^a	Karvea	SW

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8247C NP	Tablet 150 mg	30	5	..	18.00	19.11 ^a	Avapro	BQ
						^a	Karvea	SW
8248D NP	Tablet 300 mg	30	5	..	29.46	30.57 ^a	Avapro	BQ
						^a	Karvea	SW
LOSARTAN								
5452Y NP	Tablet containing losartan potassium 25 mg	30	5	..	14.02	15.13	Cozavan	AF
8203R NP	Tablet containing losartan potassium 50 mg	60	5	..	*27.94	29.05	Cozavan	AF
OLMESARTAN MEDOXOMIL								
2147B NP	Tablet 20 mg	30	5	^T 2.00	19.45	18.56	Olmotec	MK
2148C NP	Tablet 40 mg	30	5	^T 2.00	31.72	30.83	Olmotec	MK
OLMESARTAN MEDOXOMIL								
Authority required								
Adverse effects occurring with all of the base-priced drugs;								
Drug interactions occurring with all of the base-priced drugs;								
Drug interactions expected to occur with all of the base-priced drugs;								
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.								
5492C NP	Tablet 20 mg	30	5	..	19.45	20.56	Olmotec	MK
5493D NP	Tablet 40 mg	30	5	..	31.72	32.83	Olmotec	MK
TELMISARTAN								
8355R NP	Tablet 40 mg	28	5	^T 2.00	16.27	15.38	Micardis	BY
8356T NP	Tablet 80 mg	28	5	^T 1.99	31.00	30.12	Micardis	BY
TELMISARTAN								
Authority required								
Adverse effects occurring with all of the base-priced drugs;								
Drug interactions occurring with all of the base-priced drugs;								
Drug interactions expected to occur with all of the base-priced drugs;								
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.								
5494E NP	Tablet 40 mg	28	5	..	16.27	17.38	Micardis	BY
5495F NP	Tablet 80 mg	28	5	..	31.00	32.11	Micardis	BY
VALSARTAN								
9368C NP	Tablet 40 mg	28	15.52	16.63	Diovan	NV
9369D NP	Tablet 80 mg	28	5	..	19.50	20.61	Diovan	NV
9370E NP	Tablet 160 mg	28	5	..	23.15	24.26	Diovan	NV

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

VALSARTAN

Note

No applications for increased maximum quantities and/or repeats will be authorised for the 320 mg tablet.

9371F NP	Tablet 320 mg	28	5	..	27.73	28.84	Diovan	NV
-------------	---------------	----	---	----	-------	-------	--------	----

Angiotensin II antagonists, combinations

Angiotensin II antagonists and diuretics

CANDESARTAN CILEXETIL with HYDROCHLOROTHIAZIDE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

8504N NP	Tablet 16 mg-12.5 mg	30	5	..	31.23	32.34	Atacand Plus 16/12.5	AP
9314F NP	Tablet 32 mg-12.5 mg	30	5	..	39.01	35.40	Atacand Plus 32/12.5	AP
9315G NP	Tablet 32 mg-25 mg	30	5	..	41.21	35.40	Atacand Plus 32/25	AP

EPROSARTAN MESYLATE with HYDROCHLOROTHIAZIDE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

8624X NP	Tablet 600 mg (base)-12.5 mg	28	5	..	29.80	30.91	Teveten Plus 600/12.5	AB
-------------	------------------------------	----	---	----	-------	-------	--------------------------	----

IRBESARTAN with HYDROCHLOROTHIAZIDE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

2136K NP	Tablet 300 mg-25 mg	30	5	..	33.91	35.02	^a Avapro HCT 300/25	BQ
							^a Karvezide 300/25	SW
8404H NP	Tablet 150 mg-12.5 mg	30	5	..	20.22	21.33	^a Avapro HCT 150/12.5	BQ
							^a Karvezide 150/12.5	SW
8405J NP	Tablet 300 mg-12.5 mg	30	5	..	31.68	32.79	^a Avapro HCT 300/12.5	BQ
							^a Karvezide 300/12.5	SW

OLMESARTAN MEDOXOMIL with HYDROCHLOROTHIAZIDE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

2161R NP	Tablet 20 mg-12.5 mg	30	5	..	19.66	20.77	Olmotec Plus	MK
2166B NP	Tablet 40 mg-12.5 mg	30	5	..	31.94	33.05	Olmotec Plus	MK
2170F NP	Tablet 40 mg-25 mg	30	5	..	34.17	35.28	Olmotec Plus	MK

TELMISARTAN with HYDROCHLOROTHIAZIDE

Restricted benefit

Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.

8622T NP	Tablet 40 mg-12.5 mg	28	5	..	16.34	17.45	Micardis Plus 40/12.5 mg	BY
8623W NP	Tablet 80 mg-12.5 mg	28	5	..	31.08	32.19	Micardis Plus 80/12.5 mg	BY
9381R NP	Tablet 80 mg-25 mg	28	5	..	33.17	34.28	Micardis Plus 80/25 mg	BY

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
VALSARTAN with HYDROCHLOROTHIAZIDE								
<u>Restricted benefit</u>								
Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.								
9372G NP	Tablet 80 mg-12.5 mg	28	5	..	21.57	22.68	Co-Diovan 80/12.5	NV
9373H NP	Tablet 160 mg-12.5 mg	28	5	..	25.22	26.33	Co-Diovan 160/12.5	NV
9374J NP	Tablet 160 mg-25 mg	28	5	..	27.30	28.41	Co-Diovan 160/25	NV
<hr/>								
VALSARTAN with HYDROCHLOROTHIAZIDE								
<u>Restricted benefit</u>								
Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised for the tablets containing 320 mg valsartan.								
9481B NP	Tablet 320 mg-12.5 mg	28	5	..	29.80	30.91	Co-Diovan 320/12.5	NV
9482C NP	Tablet 320 mg-25 mg	28	5	..	31.88	32.99	Co-Diovan 320/25	NV
 Angiotensin II antagonists and calcium channel blockers								
AMLODIPINE with VALSARTAN								
<u>Restricted benefit</u>								
Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.								
5459H NP	Tablet 5 mg (as besylate)-320 mg	28	5	..	32.43	33.54	Exforge 5/320	NV
5460J NP	Tablet 10 mg (as besylate)-320 mg	28	5	..	35.97	35.40	Exforge 10/320	NV
9375K NP	Tablet 5 mg (as besylate)-80 mg	28	5	..	24.21	25.32	Exforge 5/80	NV
9376L NP	Tablet 5 mg (as besylate)-160 mg	28	5	..	27.85	28.96	Exforge 5/160	NV
9377M NP	Tablet 10 mg (as besylate)-160 mg	28	5	..	31.39	32.50	Exforge 10/160	NV
 OLMESARTAN with AMLODIPINE								
<u>Restricted benefit</u>								
Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.								
5292M	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besylate)	30	5	..	22.48	23.59	Sevikar 20/5	MK
5293N	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besylate)	30	5	..	34.75	35.40	Sevikar 40/5	MK
5294P	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besylate)	30	5	..	38.55	35.40	Sevikar 40/10	MK
 TELMISARTAN with AMLODIPINE								
<u>Restricted benefit</u>								
Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.								
8978M NP	Tablet 40 mg-5 mg (as besylate)	28	5	..	18.97	20.08	Twynsta	BY
8979N NP	Tablet 40 mg-10 mg (as besylate)	28	5	..	22.52	23.63	Twynsta	BY
8980P NP	Tablet 80 mg-5 mg (as besylate)	28	5	..	33.72	34.83	Twynsta	BY
8981Q NP	Tablet 80 mg-10 mg (as besylate)	28	5	..	37.26	35.40	Twynsta	BY

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Angiotensin II antagonists, other combinations								
AMLODIPINE with VALSARTAN and HYDROCHLOROTHIAZIDE								
Restricted benefit								
Hypertension in a patient who is not adequately controlled with any two of the drugs in the combination.								
5285E NP	Tablet 5 mg (as besylate)-160 mg-12.5 mg	28	5	..	29.92	31.03	Exforge HCT 5/160/12.5	NV
5286F NP	Tablet 5 mg (as besylate)-160 mg-25 mg	28	5	..	32.00	33.11	Exforge HCT 5/160/25	NV
5287G NP	Tablet 10 mg (as besylate)-160 mg-12.5 mg	28	5	..	33.46	34.57	Exforge HCT 10/160/12.5	NV
5288H NP	Tablet 10 mg (as besylate)-160 mg-25 mg	28	5	..	35.55	35.40	Exforge HCT 10/160/25	NV
5289J NP	Tablet 10 mg (as besylate)-320 mg-25 mg	28	5	..	40.12	35.40	Exforge HCT 10/320/25	NV

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

GENERAL STATEMENT FOR LIPID-LOWERING DRUGS PRESCRIBED AS PHARMACEUTICAL BENEFITS

Use the following criteria to determine patient eligibility for subsidisation under the PBS for the following drugs:

- atorvastatin calcium
- fluvastatin sodium
- pravastatin sodium
- rosuvastatin calcium
- simvastatin
- fenofibrate
- gemfibrozil

By writing a PBS prescription, the prescriber is certifying the patient satisfies the qualifying criteria set out below and the use is in accordance with the registered indications which differ between agents in this class - refer to the current Product Information for details. Note also that patients already established on a particular lipid-lowering drug, where use satisfies the PBS qualifying criteria, but is outside the registered indications for that drug, are not required to switch to another drug in the class to retain PBS eligibility.

Patients in very high risk categories (see below) may commence drug therapy with statins or fibrates immediately (ie simultaneously with an appropriate diet). For all other patients, dietary therapy should be trialled prior to initiation of drug therapy.

Dietary therapy should be continued concurrently with pharmacological therapy and should be reviewed on at least an annual basis.


Patients identified as being in one of the following very high risk categories may commence drug therapy with statins or fibrates at any cholesterol level:

- coronary heart disease which has become symptomatic
- cerebrovascular disease which has become symptomatic
- peripheral vascular disease which has become symptomatic
- diabetes mellitus with microalbuminuria (defined as urinary albumin excretion rate of >20mcg/min or urinary albumin to creatinine ratio of > 2.5 for males, > 3.5 for females)
- diabetes mellitus in Aboriginal or Torres Strait Islander patients
- diabetes mellitus in patients aged 60 years or more
- family history of coronary heart disease which has become symptomatic before the age of 55 years in two or more first degree relatives
- family history of coronary heart disease which has become symptomatic before the age of 45 years in one or more first degree relatives

If your patient is not identified as being in any of the above very high risk categories, then use the flow-chart and table below to determine whether your patient satisfies the following criteria for subsidisation under the PBS. Document how the patient meets each of these steps in the patient record. Lipid levels must be measured at an accredited laboratory.

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	



Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

POST-DIETARY QUALIFYING CRITERIA

Dietary therapy should be continued concurrently with pharmacological therapy and should be reviewed on at least an annual basis.

PATIENT CATEGORY	LIPID LEVELS FOR PBS SUBSIDY
Patients with diabetes mellitus not otherwise included	total cholesterol > 5.5 mmol/L
Aboriginal or Torres Strait Islander patients Patients with hypertension	total cholesterol > 6.5 mmol/L or total cholesterol > 5.5 mmol/L and HDL cholesterol < 1 mmol/L
Patients with HDL cholesterol < 1 mmol/L	total cholesterol > 6.5 mmol/L
Patients with familial hypercholesterolaemia identified by: <ul style="list-style-type: none"> DNA mutation; or tendon xanthomas in the patient or their first or second degree relative Patients with: <ul style="list-style-type: none"> family history of coronary heart disease which has become symptomatic before the age of 60 years in one or more first degree relatives; or family history of coronary heart disease which has become symptomatic before the age of 50 years in one or more second degree relatives 	If aged 18 years or less at treatment initiation: LDL cholesterol > 4 mmol/L If aged more than 18 years at treatment initiation: LDL cholesterol > 5 mmol/L or total cholesterol > 6.5 mmol/L or total cholesterol > 5.5 mmol/L and HDL cholesterol < 1 mmol/L
Patients not eligible under the above: <ul style="list-style-type: none"> men aged 35 to 75 years post-menopausal women aged up to 75 years 	total cholesterol > 7.5 mmol/L or triglyceride > 4 mmol/L
Patients not otherwise included	total cholesterol > 9 mmol/L or triglyceride > 8 mmol/L

Lipid modifying agents

Lipid modifying agents, plain *HMG CoA reductase inhibitors*

ATORVASTATIN

Restricted benefit

For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.

8213G	Tablet 10 mg (as calcium)	30	5	..	37.23	35.40	^a	APO-Atorvastatin	TX
NP								Atorvachol	GM
								Atorvastatin GH	GQ
								Atorvastatin Pfizer	FZ
								Atorvastatin Sandoz	SZ
								Atorvastatin SCP 10	RZ
								Chem mart Atorvastatin	CH
								Lipitor	PF
								Lorstat 10	AF
								STADA Atorvastatin	TD

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
8214H NP	Tablet 20 mg (as calcium)	30	5	..	50.41	35.40	^a Terry White Chemists Atorvastatin
							^a Torvastat 10 QA
							^a Trovas RA
							^a APO-Atorvastatin TX
							^a Atorvachol GM
							^a Atorvastatin GH GQ
							^a Atorvastatin Pfizer FZ
							^a Atorvastatin Sandoz SZ
							^a Atorvastatin SCP 20 RZ
							^a Chem mart Atorvastatin CH
							^a Lipitor PF
							^a Lorstat 20 AF
							^a STADA Atorvastatin TD
							^a Terry White Chemists Atorvastatin
							^a Torvastat 20 QA
8215J NP	Tablet 40 mg (as calcium)	30	5	..	67.54	35.40	^a Trovas RA
							^a APO-Atorvastatin TX
							^a Atorvachol GM
							^a Atorvastatin GH GQ
							^a Atorvastatin Pfizer FZ
							^a Atorvastatin Sandoz SZ
							^a Atorvastatin SCP 40 RZ
							^a Chem mart Atorvastatin CH
							^a Lipitor PF
							^a Lorstat 40 AF
							^a STADA Atorvastatin TD
							^a Terry White Chemists Atorvastatin
							^a Torvastat 40 QA
							^a Trovas RA
							^a APO-Atorvastatin TX
8521L NP	Tablet 80 mg (as calcium)	30	5	..	93.74	35.40	^a Atorvachol GM
							^a Atorvastatin GH GQ
							^a Atorvastatin Pfizer FZ
							^a Atorvastatin Sandoz SZ
							^a Atorvastatin SCP 80 RZ
							^a Chem mart Atorvastatin CH
							^a Lipitor PF
							^a Lorstat 80 AF
							^a STADA Atorvastatin TD
							^a Terry White Chemists Atorvastatin
							^a Torvastat 80 QA

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
							^a Trovas	RA
ATORVASTATIN								
<u>Restricted benefit</u>								
For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
9230T	Tablet 10 mg (as calcium)	30	11	..	37.23	35.40	^a APO-Atorvastatin	TX
							^a Atorvachol	GM
							^a Atorvastatin GH	GQ
							^a Atorvastatin Pfizer	FZ
							^a Atorvastatin	SZ
							Sandoz	
							^a Atorvastatin SCP 10	RZ
							^a Chem mart	CH
							Atorvastatin	
							^a Lipitor	PF
							^a Lorstat 10	AF
							^a STADA Atorvastatin	TD
							^a Terry White	TW
							Chemists	
							Atorvastatin	
							^a Torvastat 10	QA
							^a Trovas	RA
9231W	Tablet 20 mg (as calcium)	30	11	..	50.41	35.40	^a APO-Atorvastatin	TX
							^a Atorvachol	GM
							^a Atorvastatin GH	GQ
							^a Atorvastatin Pfizer	FZ
							^a Atorvastatin	SZ
							Sandoz	
							^a Atorvastatin SCP 20	RZ
							^a Chem mart	CH
							Atorvastatin	
							^a Lipitor	PF
							^a Lorstat 20	AF
							^a STADA Atorvastatin	TD
							^a Terry White	TW
							Chemists	
							Atorvastatin	
							^a Torvastat 20	QA
							^a Trovas	RA
9232X	Tablet 40 mg (as calcium)	30	11	..	67.54	35.40	^a APO-Atorvastatin	TX
							^a Atorvachol	GM
							^a Atorvastatin GH	GQ
							^a Atorvastatin Pfizer	FZ
							^a Atorvastatin	SZ
							Sandoz	
							^a Atorvastatin SCP 40	RZ
							^a Chem mart	CH
							Atorvastatin	
							^a Lipitor	PF
							^a Lorstat 40	AF
							^a STADA Atorvastatin	TD

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							^a Terry White Chemists Atorvastatin	TW
							^a Torvastat 40	QA
							^a Trovas	RA
9233Y	Tablet 80 mg (as calcium)	30	11	..	93.74	35.40	^a APO-Atorvastatin	TX
							^a Atorvachol	GM
							^a Atorvastatin GH	GQ
							^a Atorvastatin Pfizer	FZ
							^a Atorvastatin Sandoz	SZ
							^a Atorvastatin SCP 80	RZ
							^a Chem mart Atorvastatin	CH
							^a Lipitor	PF
							^a Lorstat 80	AF
							^a STADA Atorvastatin	TD
							^a Terry White Chemists Atorvastatin	TW
							^a Torvastat 80	QA
							^a Trovas	RA

FLUVASTATIN

Restricted benefit

For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.

2863Q <i>NP</i>	Tablet (prolonged release) 80 mg (as sodium)	28	5	..	45.52	35.40	Lescol XL	NV
8023G <i>NP</i>	Capsule 20 mg (as sodium)	28	5	..	25.56	26.67	^a Lescol	NV
				^B 3.09	28.65	26.67	^a Vastin	NM
8024H <i>NP</i>	Capsule 40 mg (as sodium)	28	5	..	29.87	30.98	^a Lescol	NV
				^B 3.36	33.23	30.98	^a Vastin	NM

FLUVASTATIN

Restricted benefit

For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9234B	Capsule 20 mg (as sodium)	28	11	..	25.56	26.67	^a Lescol	NV
				^B 3.09	28.65	26.67	^a Vastin	NM
9235C	Capsule 40 mg (as sodium)	28	11	..	29.87	30.98	^a Lescol	NV
				^B 3.36	33.23	30.98	^a Vastin	NM
9236D	Tablet (prolonged release) 80 mg (as sodium)	28	11	..	45.52	35.40	Lescol XL	NV

PRAVASTATIN

Restricted benefit

For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.

2833D <i>NP</i>	Tablet containing pravastatin sodium 10 mg	30	5	..	13.72	14.83	^a APO-Pravastatin	TX
							^a Chem mart Pravastatin	CH
							^a Cholstat 10	AF

[illegible]

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer			
8829Q NP	Tablet containing pravastatin sodium 80 mg	30	5	^B 4.26	28.59	25.44	^a	Pravastatin			
				..	33.91	35.02	^a	Pravachol FM			
							^a	APO-Pravastatin TX			
							^a	Chem mart CH			
							^a	Pravastatin Lipostat 80 QA			
							^a	Pravastatin-GA 80 GM			
							^a	Pravastatin generichealth GQ			
							^a	Pravastatin-PS FZ			
							^a	Pravastatin Sandoz SZ			
							^a	Terry White Chemists TW			
			^B 4.25	38.16	35.02	^a	Pravastatin Pravachol FM				
<hr/>											
PRAVASTATIN											
<u>Restricted benefit</u>											
For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.											
<u>Note</u>											
No applications for increased maximum quantities and/or repeats will be authorised.											
9237E	Tablet containing pravastatin sodium 10 mg	30	11	..	13.72	14.83	^a	APO-Pravastatin TX			
							^a	Chem mart CH			
								Pravastatin			
							^a	Cholstat 10 AF			
							^a	GenRx Pravastatin GX			
							^a	Lipostat 10 QA			
							^a	Pharmacor CR			
							^a	Pravastat 10			
							^a	Pravastatin Actavis 10 TA			
							^a	Pravastatin-GA 10 GM			
9238F	Tablet containing pravastatin sodium 20 mg	30	11	..	17.72	14.83	^a	Pravastatin generichealth GQ			
							..	17.97	19.08	^a	Pravastatin-PS FZ
										^a	Pravastatin Sandoz SZ
										^a	Pravastatin WA
										^a	Winthrop
										^a	Terry White Chemists TW
											Pravastatin
							^B 4.00	17.72	14.83	^a	Pravachol FM
										^a	APO-Pravastatin TX
										^a	Chem mart CH
			^a	Pravastatin							
			^a	Cholstat 20 AF							
			^a	Cholvastin RA							
			^a	GenRx Pravastatin GX							
			^a	Lipostat 20 QA							
			^a	Pharmacor CR							
				Pravastat 20							
			^a	Pravastatin Actavis 20 TA							
			^a	Pravastatin-GA 20 GM							
			^a	Pravastatin generichealth GQ							

PRAVASTATIN

Restricted benefit

For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
9239G	Tablet containing pravastatin sodium 40 mg	30	11	..	24.33	25.44	^a Pravastatin-PS FZ
							^a Pravastatin Sandoz SZ
							^a Pravastatin Winthrop WA
							^a Terry White Chemists TW
							^a Pravastatin FM
							^a Pravachol FM
							^a APO-Pravastatin TX
							^a Chem mart CH
							^a Pravastatin Cholstat 40 AF
							^a Cholvastin RA
							^a GenRx Pravastatin GX
							^a Lipostat 40 QA
							^a Pharmacor CR
							^a Pravastat 40 TA
							^a Pravastatin Actavis 40 TA
							^a Pravastatin-GA 40 GM
							^a Pravastatin generichealth GQ
							^a Pravastatin-PS FZ
							^a Pravastatin Sandoz SZ
							^a Pravastatin Winthrop WA
9240H	Tablet containing pravastatin sodium 80 mg	30	11	..	33.91	35.02	^a Terry White Chemists TW
							^a Pravastatin FM
							^a Pravachol FM
							^a APO-Pravastatin TX
							^a Chem mart CH
							^a Pravastatin Lipostat 80 QA
							^a Pravastatin-GA 80 GM
							^a Pravastatin generichealth GQ
							^a Pravastatin-PS FZ
							^a Pravastatin Sandoz SZ
9245C	Tablet 40 mg (as calcium)	30	5	..	100.66	35.40	^a Crestor AP
							^a Crestor AP

ROSUVASTATIN

Restricted benefit

For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.

9042X NP	Tablet 5 mg (as calcium)	30	5	..	39.55	35.40	Crestor	AP
9043Y NP	Tablet 10 mg (as calcium)	30	5	..	53.16	35.40	Crestor	AP
9044B NP	Tablet 20 mg (as calcium)	30	5	..	72.52	35.40	Crestor	AP
9045C NP	Tablet 40 mg (as calcium)	30	5	..	100.66	35.40	Crestor	AP

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
ROSUVASTATIN								
<u>Restricted benefit</u>								
For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
3402C	Tablet 5 mg (as calcium)	30	11	..	39.55	35.40	Crestor	AP
3403D	Tablet 10 mg (as calcium)	30	11	..	53.16	35.40	Crestor	AP
3404E	Tablet 20 mg (as calcium)	30	11	..	72.52	35.40	Crestor	AP
3405F	Tablet 40 mg (as calcium)	30	11	..	100.66	35.40	Crestor	AP
SIMVASTATIN								
<u>Restricted benefit</u>								
For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.								
2011W NP	Tablet 10 mg	30	5	..	14.37	15.48	^a APO-Simvastatin	TX
							^a Auro-Simvastatin 10	DO
							^a Chem mart Simvastatin	CH
							^a GenRx Simvastatin	GX
							^a Pharmacor Simvastatin 10	MI
							^a Ransim	RA
							^a Simvacor 10	CR
							^a Simvahexal	HX
							^a Simvar 10	QA
							^a Simvastatin-DP	GM
							^a Simvastatin-DRLA	RZ
							^a Simvastatin-GA 10	GN
							^a Simvastatin generichealth	GQ
							^a Simvastatin Pfizer	FZ
							^a Simvastatin Sandoz	SZ
							^a Simvastatin-Spirit 10	ZP
							^a Simvastatin Winthrop	WA
							^a Synthon Simvastatin	ZT
							^a Terry White Chemists Simvastatin	TW
							^a Zimstat	AF
				^B 3.33	17.70	15.48	^a Lipex 10	FR
							^a Zocor	MK
2012X NP	Tablet 20 mg	30	5	..	17.82	18.93	^a APO-Simvastatin	TX
							^a Auro-Simvastatin 20	DO
							^a Chem mart Simvastatin	CH
							^a GenRx Simvastatin	GX
							^a Pharmacor Simvastatin 20	MI
							^a Ransim	RA
							^a Simvacor 20	CR
							^a Simvahexal	HX

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
2013Y NP	Tablet 5 mg	30	5	..	12.20	13.31	^a Simvar 20 QA
							^a Simvastatin-DP GM
							^a Simvastatin-DRLA RZ
							^a Simvastatin-GA 20 GN
							^a Simvastatin generichealth GQ
							^a Simvastatin Pfizer FZ
							^a Simvastatin Sandoz SZ
							^a Simvastatin-Spirit 20 ZP
							^a Simvastatin Winthrop WA
							^a Synthon Simvastatin ZT
							^a Terry White Chemists Simvastatin TW
							^a Zimstat AF
							^a Lipex 20 FR
							^a Zocor MK
8173E NP	Tablet 40 mg	30	5	..	22.78	23.89	^a Simvahexal HX
							^a Simvastatin Sandoz SZ
							^a Zimstat AF
							^a Zocor MK
							^a APO-Simvastatin TX
							^a Auro-Simvastatin 40 DO
							^a Chem mart Simvastatin CH
							^a GenRx Simvastatin GX
							^a Pharmacor Simvastatin 40 MI
							^a Ransim RA
							^a Simvacor 40 CR
							^a Simvar 40 QA
							^a Simvastatin-DP GM
							^a Simvastatin-DRLA RZ
8313M NP	Tablet 80 mg	30	5	..	29.89	31.00	^a Simvastatin-GA 40 GN
							^a Simvastatin generichealth GQ
							^a Simvastatin Pfizer FZ
							^a Simvastatin Sandoz SZ
							^a Simvastatin-Spirit 40 ZP
							^a Simvastatin Winthrop WA
							^a Synthon Simvastatin ZT
							^a Terry White Chemists Simvastatin TW
							^a Zimstat AF
							^a Lipex 40 FR
							^a Zocor MK
							^a APO-Simvastatin TX
							^a Auro-Simvastatin 80 DO

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
						^a	Chem mart Simvastatin CH
						^a	GenRx Simvastatin GX
						^a	Pharmacor Simvastatin 80 MI
						^a	Ransim RA
						^a	Simvacor 80 CR
						^a	Simvar 80 QA
						^a	Simvastatin-DP GM
						^a	Simvastatin-DRLA RZ
						^a	Simvastatin-GA 80 GN
						^a	Simvastatin generichealth GQ
						^a	Simvastatin Pfizer FZ
						^a	Simvastatin Sandoz SZ
						^a	Simvastatin-Spirit 80 ZP
						^a	Simvastatin Winthrop WA
						^a	Synthon ZT
						^a	Simvastatin Terry White Chemists TW
						^a	Simvastatin Zimstat AF
				^B 3.32	33.21	31.00	^a Lipex 80 FR
						^a	Zocor MK

SIMVASTATIN

Restricted benefit

Accessed General:
For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

Note
No applications for increased maximum quantities and/or repeats will be authorised.

9241J	Tablet 5 mg	30	11	..	12.20	13.31	^a	Simvahexal	HX
							^a	Simvastatin Sandoz	SZ
							^a	Zimstat	AF
				^b 3.32	15.52	13.31	^a	Zocor	MK
9242K	Tablet 10 mg	30	11	..	14.37	15.48	^a	APO-Simvastatin	TX
							^a	Auro-Simvastatin 10	DO
							^a	Chem mart Simvastatin	CH
							^a	GenRx Simvastatin	GX
							^a	Pharmacor Simvastatin 10	MI
							^a	Ransim	RA
							^a	Simvacor 10	CR
							^a	Simvahexal	HX
							^a	Simvar 10	QA
							^a	Simvastatin-DP	GM
							^a	Simvastatin-DRLA	RZ
							^a	Simvastatin-GA 10	GN
							^a	Simvastatin generichealth	GQ

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
9243L	Tablet 20 mg	30	11	..	17.82	18.93	^a Simvastatin Pfizer FZ
							^a Simvastatin Sandoz SZ
							^a Simvastatin-Spirit 10 ZP
							^a Simvastatin Winthrop WA
							^a Synthon ZT
							^a Simvastatin Terry White Chemists TW
							^a Simvastatin Zimstat AF
							^a Lipex 10 FR
							^a Zocor MK
							^a APO-Simvastatin TX
							^a Auro-Simvastatin 20 DO
							^a Chem mart Simvastatin CH
							^a GenRx Simvastatin GX
							^a Pharmacor Simvastatin 20 MI
							^a Ransim RA
							^a Simvacor 20 CR
							^a Simvahexal HX
							^a Simvar 20 QA
							^a Simvastatin-DP GM
							^a Simvastatin-DRLA RZ
							^a Simvastatin-GA 20 GN
							^a Simvastatin generichealth GQ
							^a Simvastatin Pfizer FZ
							^a Simvastatin Sandoz SZ
							^a Simvastatin-Spirit 20 ZP
							^a Simvastatin Winthrop WA
							^a Synthon ZT
							^a Simvastatin Terry White Chemists TW
							^a Simvastatin Zimstat AF
							^a Lipex 20 FR
							^a Zocor MK
							^a APO-Simvastatin TX
							^a Auro-Simvastatin 40 DO
							^a Chem mart Simvastatin CH
							^a GenRx Simvastatin GX
							^a Pharmacor Simvastatin 40 MI
							^a Ransim RA
							^a Simvacor 40 CR
							^a Simvar 40 QA
							^a Simvastatin-DP GM
							^a Simvastatin-DRLA RZ
							^a Simvastatin-GA 40 GN
9244M	Tablet 40 mg	30	11	..	22.78	23.89	^a Simvastatin Pfizer FZ
							^a Simvastatin Sandoz SZ
							^a Simvastatin-Spirit 20 ZP
							^a Simvastatin Winthrop WA
							^a Synthon ZT
							^a Simvastatin Terry White Chemists TW
							^a Simvastatin Zimstat AF
							^a Lipex 20 FR
							^a Zocor MK
							^a APO-Simvastatin TX
							^a Auro-Simvastatin 40 DO
							^a Chem mart Simvastatin CH
							^a GenRx Simvastatin GX
							^a Pharmacor Simvastatin 40 MI
							^a Ransim RA
							^a Simvacor 40 CR
							^a Simvar 40 QA
							^a Simvastatin-DP GM
							^a Simvastatin-DRLA RZ
							^a Simvastatin-GA 40 GN
							^a Simvastatin Pfizer FZ
							^a Simvastatin Sandoz SZ
							^a Simvastatin-Spirit 20 ZP
							^a Simvastatin Winthrop WA
							^a Synthon ZT
							^a Simvastatin Terry White Chemists TW
							^a Simvastatin Zimstat AF
							^a Lipex 20 FR
							^a Zocor MK
							^a APO-Simvastatin TX
							^a Auro-Simvastatin 40 DO
							^a Chem mart Simvastatin CH
							^a GenRx Simvastatin GX
							^a Pharmacor Simvastatin 40 MI
							^a Ransim RA
							^a Simvacor 40 CR
							^a Simvar 40 QA
							^a Simvastatin-DP GM
							^a Simvastatin-DRLA RZ
							^a Simvastatin-GA 40 GN

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
9245N	Tablet 80 mg	30	11	..	29.89	31.00	^a Simvastatin generichealth GQ
							^a Simvastatin Pfizer FZ
							^a Simvastatin Sandoz SZ
							^a Simvastatin-Spirit 40 ZP
							^a Simvastatin Winthrop WA
							^a Synthon Simvastatin ZT
							^a Terry White Chemists Simvastatin TW
							^a Zimstat AF
							^B 3.32 26.10 23.89 ^a Lipex 40 FR
							^a Zocor MK
							^a APO-Simvastatin TX
							^a Auro-Simvastatin 80 DO
							^a Chem mart Simvastatin CH
							^a GenRx Simvastatin GX
							^a Pharmacor Simvastatin 80 MI
							^a Ransim RA
							^a Simvacor 80 CR
							^a Simvar 80 QA
							^a Simvastatin-DP GM
							^a Simvastatin-DRLA RZ
							^a Simvastatin-GA 80 GN
							^a Simvastatin generichealth GQ
							^a Simvastatin Pfizer FZ
							^a Simvastatin Sandoz SZ
							^a Simvastatin-Spirit 80 ZP
							^a Simvastatin Winthrop WA
							^a Synthon Simvastatin ZT
							^a Terry White Chemists Simvastatin TW
							^a Zimstat AF
							^B 3.32 33.21 31.00 ^a Lipex 80 FR
							^a Zocor MK

Fibrates

FENOFIBRATE

Note

The risk of serious muscle toxicity is increased if fenofibrate is used concomitantly with HMG CoA reductase inhibitors or other fibrates. Such combination therapy should be used with caution in patients with severe combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and patients monitored closely for chronic signs of muscle toxicity.

Restricted benefit

For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.

9022W NP	Tablet 48 mg	60	5	..	30.15	31.26	Lipidil	AB
9023X NP	Tablet 145 mg	30	5	..	41.85	35.40	Lipidil	AB

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

FENOFIBRATE

Note

The risk of serious muscle toxicity is increased if fenofibrate is used concomitantly with HMG CoA reductase inhibitors or other fibrates. Such combination therapy should be used with caution in patients with severe combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and patients monitored closely for chronic signs of muscle toxicity.

Restricted benefit

For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9246P	Tablet 48 mg	60	11	..	30.15	31.26	Lipidil	AB
9247Q	Tablet 145 mg	30	11	..	41.85	35.40	Lipidil	AB

GEMFIBROZIL

Note

The risk of serious muscle toxicity is increased if gemfibrozil is used concomitantly with HMG CoA reductase inhibitors or other fibrates. Such combination therapy should be used with caution in patients with severe combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and patients monitored closely for chronic signs of muscle toxicity.

Restricted benefit

For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.

1453L NP	Tablet 600 mg	60	5	..	22.14	23.25	^a Ausgem	QA
							^a Chem mart	CH
							^a Gemfibrozil	
							^a Gemhexal	SZ
							^a GenRx Gemfibrozil	GX
							^a Jezil	GN
							^a Lipazil 600 mg	GM
							^a Lipigem	AF
							^a Pharmacor	CR
							^a Gemfibrozil 600	
							^a Terry White Chemists	TW
							^a Gemfibrozil	
				^B 1.98	24.12	23.25	^a Lopid	PF

GEMFIBROZIL

Note

The risk of serious muscle toxicity is increased if gemfibrozil is used concomitantly with HMG CoA reductase inhibitors or other fibrates. Such combination therapy should be used with caution in patients with severe combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and patients monitored closely for chronic signs of muscle toxicity.

Restricted benefit

For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9248R	Tablet 600 mg	60	11	..	22.14	23.25	^a Ausgem	QA
							^a Chem mart	CH
							^a Gemfibrozil	
							^a Gemhexal	SZ
							^a GenRx Gemfibrozil	GX
							^a Jezil	GN
							^a Lipazil 600 mg	GM

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Lipigem AF
							^a Pharmacor CR
							^a Gemfibrozil 600 TW
							^a Terry White Chemists PF
				^B 1.98	24.12	23.25	^a Gemfibrozil Lipid PF

Bile acid sequestrants

2967E NP	CHOLESTYRAMINE Sachets 4.7 g (equivalent to 4 g cholestyramine), 50	2	5	..	*72.04	35.40	Questran Lite QA
-------------	--	---	---	----	--------	-------	------------------

CHOLESTYRAMINE

Restricted benefit

For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9249T	Sachets 4.7 g (equivalent to 4 g cholestyramine), 50	2	11	..	*72.04	35.40	Questran Lite QA
-------	---	---	----	----	--------	-------	------------------

COLESTIPOL HYDROCHLORIDE

1224K NP	Sachets 5 g, 120	£1	5	..	85.14	35.40	Colestid PF
-------------	------------------	----	---	----	-------	-------	-------------

COLESTIPOL HYDROCHLORIDE

Restricted benefit

For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9250W	Sachets 5 g, 120	£1	11	..	85.14	35.40	Colestid PF
-------	------------------	----	----	----	-------	-------	-------------

Other lipid modifying agents

EZETIMIBE

Authority required (STREAMLINED)

Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have:

3724

(a) coronary heart disease; or

3725

(b) diabetes mellitus; or

3726

(c) peripheral vascular disease; or

3727

(d) heterozygous familial hypercholesterolaemia; or

3728

(e) symptomatic cerebrovascular disease; or

3729

(f) family history of coronary heart disease; or

3730

(g) hypertension.

Inadequate control with a statin is defined as follows:

(1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	subsidy (i.e. a patient not in a very high risk category), a cholesterol level in excess of that threshold after at least 3 months of treatment at a maximum tolerated dose of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level (i.e. a very high risk category patient), a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a maximum tolerated dose of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated.						
	<u>Authority required (STREAMLINED)</u>						
	1989 Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) is contraindicated;						
	3731 Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be discontinued or reduced because the patient developed a clinically important product-related adverse event during treatment with a statin. A clinically important product-related adverse event is defined as follows: (i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or (ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.						
	<u>Authority required (STREAMLINED)</u>						
	1991 Homozygous sitosterolaemia;						
	2438 Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs), in combination with an HMG CoA reductase inhibitor (statin).						
	<u>Note</u> Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.						
8757X NP	Tablet 10 mg	30	5	..	71.07	35.40	Ezetrol MK

Lipid modifying agents, combinations

HMG CoA reductase inhibitors in combination with other lipid modifying agents

EZETIMIBE with SIMVASTATIN

Authority required (STREAMLINED)

2431

Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs);

3739

Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be reduced because the patient developed a clinically important product-related adverse event during treatment with a statin.

A clinically important product-related adverse event is defined as follows:

- (i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or
- (ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or
- (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9483D NP	Tablet 10 mg-10 mg	30	5	..	88.89	35.40	Vytorin	MK
9484E NP	Tablet 10 mg-20 mg	30	5	..	96.69	35.40	Vytorin	MK

HMG CoA reductase inhibitors, other combinations

9049G <i>NP</i>	Tablet 5 mg (base)-10 mg (base)	30	5	..	42.10	35.40	^a	Cadatin 5/10	FZ
							^a	Caduet 5/10	PF
9050H <i>NP</i>	Tablet 5 mg (base)-20 mg (base)	30	5	..	54.79	35.40	^a	Cadatin 5/20	FZ
							^a	Caduet 5/20	PF
9051J <i>NP</i>	Tablet 5 mg (base)-40 mg (base)	30	5	..	72.36	35.40	^a	Cadatin 5/40	FZ
							^a	Caduet 5/40	PF
9052K <i>NP</i>	Tablet 5 mg (base)-80 mg (base)	30	5	..	98.56	35.40	^a	Cadatin 5/80	FZ

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
9053L <i>NP</i>	Tablet 10 mg (base)-10 mg (base)	30	5	..	45.40	35.40	^a Caduet 5/80	PF
							^a Cadatin 10/10	FZ
9054M <i>NP</i>	Tablet 10 mg (base)-20 mg (base)	30	5	..	58.30	35.40	^a Caduet 10/10	PF
							^a Cadatin 10/20	FZ
9055N <i>NP</i>	Tablet 10 mg (base)-40 mg (base)	30	5	..	75.99	35.40	^a Caduet 10/20	PF
							^a Cadatin 10/40	FZ
9056P <i>NP</i>	Tablet 10 mg (base)-80 mg (base)	30	5	..	102.19	35.40	^a Caduet 10/40	PF
							^a Cadatin 10/80	FZ
							^a Caduet 10/80	PF

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Dermatologicals

Antifungals for dermatological use

Antifungals for topical use

Antibiotics

NYSTATIN

Authority required (STREAMLINED)

2354

Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.

1698J NP	Cream 100,000 units per g, 15 g	2	3	..	*18.66	19.77	Mycostatin	FM
-------------	---------------------------------	---	---	----	--------	-------	------------	----

Imidazole and triazole derivatives

KETOCONAZOLE

Authority required (STREAMLINED)

2354

Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.

1574W NP	Shampoo 20 mg per g (2%), 60 mL	¥1	1	..	18.41	19.52	Nizoral 2%	JT
9024Y NP	Cream 20 mg per g (2%), 30 g	¥1	2	..	23.22	24.33	Nizoral 2% Cream	JT
9025B NP	Shampoo 10 mg per g (1%), 100 mL	¥1	1	..	17.70	18.81	Nizoral 1%	JT

MICONAZOLE

Authority required (STREAMLINED)

2354

Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.

9031H NP	Tincture 20 mg per mL (2%), 30 mL	¥1	2	..	19.57	20.68	Daktarin	JT
-------------	-----------------------------------	----	---	----	-------	-------	----------	----

MICONAZOLE NITRATE

Authority required (STREAMLINED)

2354

Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.

9026C NP	Cream 20 mg per g (2%), 15 g	2	3	..	*16.00	17.11	Daktarin	JT
9027D NP	Cream 20 mg per g (2%), 30 g	¥1	2	..	14.89	16.00	Daktarin	JT
9028E NP	Cream 20 mg per g (2%), 70 g	¥1	1	..	16.89	18.00	Daktarin	JT
9029F NP	Powder 20 mg per g (2%), 30 g	¥1	2	..	15.66	16.77	Daktarin	JT
9030G NP	Lotion 20 mg per mL (2%), 30 g	¥1	2	..	16.82	17.93	Daktarin	JT

Other antifungals for topical use

TERBINAFINE

Authority required (STREAMLINED)

2354

Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person;

3243

Treatment of a fungal or a yeast infection in a patient aged up to 18 years inclusive.

9160D NP	Cream containing terbinafine hydrochloride 10 mg per g (1%), 15 g	2	3	..	*37.46	35.40	Lamisil	NC
-------------	--	---	---	----	--------	-------	---------	----

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Antifungals for systemic use								
<i>Antifungals for systemic use</i>								
GRISEOFULVIN								
1460W NP	Tablet 125 mg	100	2	..	25.97	27.08	Grisovin	QA
2982Y NP	Tablet 500 mg	28	2	..	27.09	28.20	Grisovin 500	QA
TERBINAFINE								
<u>Authority required</u>								
Treatment of a dermatophyte infection in an Aboriginal or a Torres Strait Islander person where topical treatment has failed;								
Treatment of a dermatophyte infection in a patient aged up to 18 years inclusive where topical treatment and griseofulvin have failed.								
2285G NP	Tablet 250 mg (as hydrochloride)	42	69.30	35.40	^a GenRx Terbinafine	GX
							^a Lamisil (Novartis Pharmaceuticals Australia Pty Limited)	NV
							^a Sebifin 250	RA
							^a Tamsil	QA
							^a Terbihexal	HX
							^a Terbinafine 250	CR
							^a Terbinafine-DRLA	RZ
							^a Terbinafine-GA	GM
							^a Terbinafine Sandoz	SZ
							^a Terbix 250	MI
							^a Tinasil	AF
TERBINAFINE								
<u>Authority required</u>								
Proximal or extensive (greater than 80% nail involvement) onychomycosis due to dermatophyte infection where topical treatment has failed. This infection must be proven by microscopy or culture and confirmed by an Approved Pathology Authority. The date of the pathology report must be provided at the time of application and must not be more than 12 months old.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
2804N NP	Tablet 250 mg (as hydrochloride)	42	1	..	69.30	35.40	^a GenRx Terbinafine	GX
							^a Lamisil (Novartis Pharmaceuticals Australia Pty Limited)	NV
							^a Sebifin 250	RA
							^a Tamsil	QA
							^a Terbihexal	HX
							^a Terbinafine 250	CR
							^a Terbinafine-DRLA	RZ
							^a Terbinafine-GA	GM
							^a Terbinafine Sandoz	SZ
							^a Terbix 250	MI
							^a Tinasil	AF

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Antipsoriatics								
Antipsoriatics for topical use								
Tars								
COAL TAR - PREPARED								
8864M NP	Gel 10 mg per g (1%), 100 mL	‡1	2	..	33.18	34.29	Exorex	GM
Other antipsoriatics for topical use								
CALCIPOTRIOL								
<u>Restricted benefit</u>								
Chronic stable plaque type psoriasis vulgaris.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2080L NP	Cream 50 micrograms per g (0.005%), 30 g	‡1	1	..	28.16	29.27	Daivonex	LO
CALCIPOTRIOL								
<u>Restricted benefit</u>								
Chronic stable plaque type psoriasis vulgaris of the scalp.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
9163G NP	Scalp solution 50 micrograms per mL (0.005%), 30 mL	‡1	1	..	28.16	29.27	Daivonex	LO
CALCIPOTRIOL with BETAMETHASONE DIPROPIONATE								
<u>Restricted benefit</u>								
Chronic stable plaque type psoriasis vulgaris in a patient who is not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
9494Q NP	Ointment 50 micrograms-500 micrograms (base) per g (0.005%-0.05%), 30 g	‡1	1	..	41.99	35.40	Daivobet	LO
CALCIPOTRIOL with BETAMETHASONE DIPROPIONATE								
<u>Restricted benefit</u>								
Chronic stable plaque type psoriasis vulgaris of the scalp in a patient who is not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
5276Q NP	Gel 50 micrograms-500 micrograms (base) per g (0.005%-0.05%), 30 g	‡1	1	..	41.99	35.40	Daivobet 50/500 gel	LO

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Antipsoriatics for systemic use								
<i>Retinoids for treatment of psoriasis</i>								
ACITRETIN								
<u>Caution</u>								
This drug is a potent teratogen—pregnancy should be avoided for at least two years after cessation of therapy.								
<u>Note</u>								
Care must be taken to comply with the provisions of State/Territory law when prescribing acitretin.								
<u>Authority required (STREAMLINED)</u>								
1366								
Severe intractable psoriasis;								
1363								
Severe forms of disorders of keratinisation.								
2019G	Capsule 10 mg	100	2	..	205.87	35.40	Neotigason	TA
2020H	Capsule 25 mg	100	2	..	393.31	35.40	Neotigason	TA

Antibiotics and chemotherapeutics for dermatological use

Chemotherapeutics for topical use

Sulfonamides

SILVER SULFADIAZINE

Restricted benefit

Prevention and treatment of infection in partial or full skin thickness loss due to burns;

Prevention and treatment of infection in partial or full skin thickness loss due to epidermolysis bullosa;

Stasis ulcers.

9479X NP	Cream 10 mg per g (1%), 50 g	‡1	19.25	20.36	Flamazine	SN
-------------	------------------------------	----	----	----	-------	-------	-----------	----

Corticosteroids, dermatological preparations

Corticosteroids, plain

Corticosteroids, weak (group I)

HYDROCORTISONE ACETATE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

2881P NP	Cream 10 mg per g (1%), 50 g	‡1	1	..	8.66	9.77	^a Cortic-DS 1%	FM
				^B 2.70	11.36	9.77	^a Sigmacort	QA
2882Q NP	Topical ointment 10 mg per g (1%), 50 g	‡1	1	..	8.66	9.77	^a Cortic-DS 1%	FM
				^B 2.70	11.36	9.77	^a Sigmacort	QA
2887Y NP	Cream 10 mg per g (1%), 30 g	‡1	1	..	8.99	10.10	^a Cortic-DS 1%	FM
				^B 2.69	11.68	10.10	^a Sigmacort	QA
2888B NP	Topical ointment 10 mg per g (1%), 30 g	‡1	1	..	8.99	10.10	^a Cortic-DS 1%	FM
				^B 2.69	11.68	10.10	^a Sigmacort	QA

Corticosteroids, moderately potent (group II)

TRIAMCINOLONE ACETONIDE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

2117K NP	Cream 200 micrograms per g (0.02%), 100 g	2	*14.50	15.61	^a Tricortone	FM
				^B 3.78	*18.28	15.61	^a Aristocort 0.02%	QA
2118L	Ointment 200 micrograms per g (0.02%), 100 g	2	*14.50	15.61	^a Tricortone	FM

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
NP				^B 3.78	*18.28	15.61 ^a	Aristocort 0.02% QA

Corticosteroids, potent (group III)

BETAMETHASONE DIPROPIONATE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1115Q NP	Cream 500 micrograms (base) per g (0.05%), 15 g	‡1	1	.. ^B 2.45	13.24 15.69	14.35 ^a 14.35 ^a	Eleuphrat Diprosone	FR MK
1119X NP	Ointment 500 micrograms (base) per g (0.05%), 15 g	‡1	1	.. ^B 2.45	13.24 15.69	14.35 ^a 14.35 ^a	Eleuphrat Diprosone	FR MK

BETAMETHASONE VALERATE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

2812B NP	Cream 200 micrograms (base) per g (0.02%), 100 g	2 ^B 2.46 ^B 6.88	*24.32 *26.78 *31.20	25.43 ^a 25.43 ^b 25.43 ^a 25.43 ^b	Antroquoril Cortival 1/5 Celestone-M Betnovate 1/5	FR FM MK QA
2820K NP	Ointment 200 micrograms (base) per g (0.02%), 100 g	2 ^B 2.46	*24.32 *26.78	25.43 ^a 25.43 ^a	Antroquoril Celestone-M	FR MK

BETAMETHASONE VALERATE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2813C NP	Cream 500 micrograms (base) per g (0.05%), 15 g	‡1	1	.. ^B 2.94	8.51 11.45	9.62 ^b 9.62 ^b	Cortival 1/2 Betnovate 1/2	FM QA
2815E NP	Ointment 500 micrograms (base) per g (0.05%), 15 g	‡1	1	.. ^B 2.94	8.51 11.45	9.62 ^b 9.62 ^b	Cortival 1/2 Betnovate 1/2	FM QA

METHYLPREDNISOLONE ACEPONATE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8054X NP	Cream 1 mg per g (0.1%), 15 g	‡1	14.08	15.19	Advantan	CS
8055Y NP	Ointment 1 mg per g (0.1%), 15 g	‡1	14.08	15.19	Advantan	CS
8128T NP	Fatty ointment 1 mg per g (0.1%), 15 g	‡1	14.08	15.19	Advantan	CS

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
METHYLPREDNISOLONE ACEPONATE								
<u>Restricted benefit</u>								
Eczema.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8618N NP	Lotion 1 mg per g (0.1%), 20 g	‡1	14.75	15.86	Advantan	CS
MOMETASONE FUROATE								
<u>Restricted benefit</u>								
Treatment of corticosteroid-responsive dermatoses.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1913Q NP	Cream 1 mg per g (0.1%), 15 g	‡1	14.02	15.13 ^a	Novasone	FR
				^B 2.45	16.47	15.13 ^a	Elocon	MK
1915T NP	Ointment 1 mg per g (0.1%), 15 g	‡1	14.02	15.13 ^a	Novasone	FR
				^B 2.45	16.47	15.13 ^a	Elocon	MK
8043H NP	Lotion 1 mg per g (0.1% w/w), 30 mL	‡1	18.33	19.44 ^a	Novasone	FR
				^B 2.45	20.78	19.44 ^a	Elocon	MK

Anti-acne preparations

Anti-acne preparations for topical use

Retinoids for topical use in acne

ADAPALENE with BENZOYL PEROXIDE

Restricted benefit

Acute treatment, in combination with an oral antibiotic, of severe acne vulgaris.

8954G	Gel 1 mg-25 mg per g (0.1%-2.5%), 30 g	\$1	1	..	37.02	35.40	Epiduo	GA
-------	--	-----	---	----	-------	-------	--------	----

ADAPALENE with BENZOYL PEROXIDE

Restricted benefit

Maintenance treatment of severe acne vulgaris.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8955H NP	Gel 1 mg-25 mg per g (0.1%-2.5%), 30 g	\$1	3	..	37.02	35.40	Epiduo	GA
-------------	--	-----	---	----	-------	-------	--------	----

Anti-acne preparations for systemic use

Retinoids for treatment of acne

ISOTRETINOIN

Caution

This drug causes birth defects. Isotretinoin has been reported to cause other frequent and potentially serious toxicity.

Note

Care must be taken to comply with the provisions of State/Territory law when prescribing isotretinoin.

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Authority required (STREAMLINED)</u>								
1354								
Severe cystic acne not responsive to other therapy.								
2549E	Capsule 40 mg	30	3	..	91.12	35.40	Oratane	GM
2591J	Capsule 10 mg	60	3	..	66.66	35.40	^a APO-Isotretinoin	TX
							^a Oratane	GM
							^a Roaccutane	RO
							^a Rocta 10	QA
2592K	Capsule 20 mg	60	3	..	100.25	35.40	^a APO-Isotretinoin	TX
							^a GenRx Isotretinoin	GX
							^a Oratane	GM
							^a Roaccutane	RO
							^a Rocta 20	QA

Other dermatological preparations

Other dermatological preparations

Agents for dermatitis, excluding corticosteroids

PIMECROLIMUS

Authority required

Treatment of facial or eyelid atopic dermatitis in patients aged at least 3 months with 1 or more of the following contraindications to topical corticosteroids:

- (i) perioral dermatitis;
- (ii) periorbital dermatitis;
- (iii) rosacea;
- (iv) epidermal atrophy;
- (v) dermal atrophy;
- (vi) allergy to topical corticosteroids;
- (vii) cataracts;
- (viii) glaucoma;
- (ix) raised intraocular pressure.

Authority required

Short-term (up to 3 weeks) intermittent treatment of atopic dermatitis of the face or eyelids in patients aged at least 3 months who fail to achieve satisfactory disease control with intermittent topical corticosteroid therapy, and where more than 3 months have passed since the initial diagnosis of atopic dermatitis.

Failure to achieve satisfactory disease control with intermittent topical corticosteroid therapy is manifest by:

- (i) failure of the facial skin to clear despite at least 2 weeks of topical hydrocortisone 1% applied every day; or
- (ii) failure of the facial skin to clear despite at least 1 week of a moderate or potent topical corticosteroid applied every day; or
- (iii) clearing of the facial skin with at least 2 weeks of topical hydrocortisone 1% applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions; or
- (iv) clearing of the facial skin with at least 1 week of a moderate or potent topical corticosteroid applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions.

Note

No applications for increased maximum quantities and/or repeats will be authorised. Only 1 authority application per 6 months, per patient, will be authorised.

8802G	Cream 10 mg per g (1%), 15 g	£1	1	..	33.89	35.00	Elidel	HM
-------	------------------------------	----	---	----	-------	-------	--------	----

Other dermatologicals

DAPSONE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1272Y NP	Tablet 100 mg	100	1	..	113.94	35.40	Link Medical Products Pty Ltd	LM
8801F NP	Tablet 25 mg	100	1	..	100.68	35.40	Link Medical Products Pty Ltd	LM

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
IMIQUIMOD							
<u>Authority required</u>							
Treatment of biopsy confirmed primary (previously untreated) superficial basal cell carcinoma (sBCC) in patients with normal immune function for whom surgical excision, cryotherapy, or curettage with diathermy are inappropriate and topical drug therapy is required.							
The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application.							
<u>Note</u>							
The patient or carer must be able to understand and administer the imiquimod dosing regimen.							
No applications for increased maximum quantities and/or repeats will be authorised.							
Treatment of recurrent (previously treated) lesions will not be authorised.							
2546B	Cream 50 mg per g (5%), 250 mg single use sachets, 12	1	1	..	160.05	35.40	Aldara IA

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Genito urinary system and sex hormones

Other gynecologicals

Contraceptives for topical use

Intrauterine contraceptives

LEVONORGESTREL

Restricted benefit

Contraception;

Idiopathic menorrhagia where oral treatments are ineffective;

Idiopathic menorrhagia where oral treatments are contraindicated.

8633J NP	Intrauterine drug delivery system 52 mg (releasing approximately 20 micrograms per 24 hours)	1	266.32	35.40	Mirena	BN
-------------	--	---	----	----	--------	-------	--------	----

Other gynecologicals

Prolactine inhibitors

BROMOCRIPTINE MESYLATE

Restricted benefit

Prevention of the onset of lactation in the puerperium for medical reasons.

1444B	Tablet 2.5 mg (base)	30	19.02	20.13	^a Kripton 2.5	AF
NP							^a Parlodel	NV

BROMOCRIPTINE MESYLATE

Restricted benefit

Acromegaly;

Parkinson's disease;

Pathological hyperprolactinaemia where surgery is not indicated;

Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;

Pathological hyperprolactinaemia where radiotherapy is not indicated;

Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.

Note

Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.

Note

For item codes 1443Y and 1559C, pharmaceutical benefits that have the form tablet 2.5 mg (base) are equivalent for the purposes of substitution.

1443Y	Tablet 2.5 mg (base)	60	5	..	*31.52	32.63	^a Parlodel	NV
1559C	Tablet 2.5 mg (base)	60	5	..	31.52	32.63	^a Kripton 2.5	AF

BROMOCRIPTINE MESYLATE

Restricted benefit

Acromegaly;

Parkinson's disease;

Pathological hyperprolactinaemia where surgery is not indicated;

Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;

Pathological hyperprolactinaemia where radiotherapy is not indicated;

Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.

Note

Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.

1445C	Capsule 10 mg (base)	100	5	..	148.56	35.40	Kripton 10	AF
-------	----------------------	-----	---	----	--------	-------	------------	----

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
1446D	Capsule 5 mg (base)	60	5	..	48.38	35.40	Kripton 5	AF
CABERGOLINE								
<u>Restricted benefit</u>								
Prevention of the onset of lactation in the puerperium for medical reasons.								
8115D NP	Tablet 500 micrograms	2	23.82	24.93	^a Dostan	GM
							^a Dostinex	PF
CABERGOLINE								
<u>Authority required (STREAMLINED)</u>								
2659								
Pathological hyperprolactinaemia where surgery is not indicated;								
2660								
Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;								
2661								
Pathological hyperprolactinaemia where radiotherapy is not indicated;								
2662								
Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.								
8114C	Tablet 500 micrograms	8	5	..	65.17	35.40	^a Dostan	GM
							^a Dostinex	PF
							^a Tinexa	QA
QUINAGOLIDE HYDROCHLORIDE								
<u>Authority required (STREAMLINED)</u>								
2659								
Pathological hyperprolactinaemia where surgery is not indicated;								
2660								
Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;								
2661								
Pathological hyperprolactinaemia where radiotherapy is not indicated;								
2662								
Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.								
8822H	Tablet 75 micrograms (base)	30	5	..	54.89	35.40	Norprolac	FP
8860H	Pack containing 3 tablets 25 micrograms (base) and 3 tablets 50 micrograms (base)	±1	11.57	12.68	Norprolac	FP

Sex hormones and modulators of the genital system

Hormonal contraceptives for systemic use

Progestogens and estrogens, fixed combinations

LEVONORGESTREL with ETHINYLOESTRADIOL								
1394J NP	Pack containing 21 tablets 150 micrograms- 30 micrograms and 7 inert tablets	4	2	..	17.09	18.20	^b Monofeme 28	FZ
							^a Levlen ED	SY
				^B 13.55	30.64	18.20	^b Nordette 28	PF
				^B 13.59	30.68	18.20	^a Microgynon 30 ED	BN
1456P NP	Pack containing 21 tablets 125 micrograms- 50 micrograms and 7 inert tablets	4	2	..	17.09	18.20	Microgynon 50 ED	BN
NORETHISTERONE with ETHINYLOESTRADIOL								
2774B NP	Pack containing 21 tablets 500 micrograms- 35 micrograms and 7 inert tablets	4	2	..	*16.56	17.67	^a Norimin 28 Day	FZ
				^B 7.68	*24.24	17.67	^a Brevinor	PF

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
2775C NP	Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets	4	2	..	*16.56	17.67 ^a	Norimin-1 28 Day	FZ
				^B 7.68	*24.24	17.67 ^a	Brevinor-1	PF
NORETHISTERONE with MESTRANOL								
3179H NP	Pack containing 21 tablets 1 mg-50 micrograms and 7 inert tablets	4	2	..	*16.56	17.67	Norinyl-1/28	PF
Progestogens and estrogens, sequential preparations								
LEVONORGESTREL with ETHINYLOESTRADIOL								
1392G NP	Pack containing 6 tablets 50 micrograms- 30 micrograms, 5 tablets 75 micrograms- 40 micrograms, 10 tablets 125 micrograms- 30 micrograms and 7 inert tablets	4	2	..	17.09	18.20 ^b	Trifeme 28	FZ
							^a Logynon ED	SY
				^B 13.55	30.64	18.20 ^b	Triphasil 28	PF
				^B 13.59	30.68	18.20 ^a	Triquilar ED	BN
NORETHISTERONE with ETHINYLOESTRADIOL								
2776D NP	Pack containing 12 tablets 500 micrograms- 35 micrograms, 9 tablets 1 mg-35 micrograms and 7 inert tablets	4	2	..	*16.56	17.67	Improvil 28 Day	FZ
Progestogens								
ETONOGESTREL								
8487Q NP,MW	Subcutaneous implant 68 mg	1	216.02	35.40	Implanon NXT	MK
LEVONORGESTREL								
2913H NP,MW	Tablets 30 micrograms, 28	4	2	..	17.42	18.53	Microlut 28	BN
MEDROXYPROGESTERONE ACETATE								
3118D NP	Injection 150 mg in 1 mL	1	1	..	21.39	22.50 ^a	Depo-Ralovera	FZ
				^B 3.20	24.59	22.50 ^a	Depo-Provera	PF
NORETHISTERONE								
1967M NP	Tablets 350 micrograms, 28	4	2	..	*16.56	17.67 ^a	Locilan 28 Day	FZ
							Micronor	JC
				^B 3.88	*20.44	17.67 ^a	Noriday 28 Day	PF

Androgens

3-oxoandrostens (4) derivatives

TESTOSTERONE

Authority required

Androgen deficiency in males with established pituitary or testicular disorders;

Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men);

Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age.

8098F	Subcutaneous implant 100 mg	6	*209.68	35.40	Merck Sharp & Dohme (Australia) Pty Ltd	MK
-------	-----------------------------	---	----	----	---------	-------	--	----

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8099G	Subcutaneous implant 200 mg	3	*209.65	35.40	Merck Sharp & Dohme (Australia) Pty Ltd	MK
8460G	Transdermal patches 12.2 mg (releasing approximately 2.5 mg per 24 hours), 60	¥1	5	..	95.94	35.40	Androderm	HH
8619P	Transdermal patches 24.3 mg (releasing approximately 5 mg per 24 hours), 30	¥1	5	..	95.94	35.40	Androderm	HH
8830R	Transdermal gel 50 mg in 5 g sachet, 30	¥1	5	..	95.22	35.40	Testogel	BN

TESTOSTERONE ENANTHATE

Authority required

Androgen deficiency in males with established pituitary or testicular disorders;

Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men);

Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age.

2114G	Injection 250 mg in 1 mL	3	3	..	33.58	34.69	Primoteston Depot	BN
-------	--------------------------	---	---	----	-------	-------	-------------------	----

TESTOSTERONE UNDECANOATE

Authority required

Androgen deficiency in males with established pituitary or testicular disorders;

Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men);

Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age.

2115H	Capsule 40 mg	60	5	..	37.63	35.40	Andriol Testocaps	MK
9004X	I.M. injection 1,000 mg in 4 mL	1	1	..	147.51	35.40	Reandron 1000	BN

Estrogens

Natural and semisynthetic estrogens, plain

OESTRADIOL

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

Oestradiol should be used in conjunction with an oral progestogen in women with an intact uterus.

8125P NP	Transdermal patches 3.8 mg (releasing approximately 50 micrograms per 24 hours), 4	¥1	5	..	17.19	18.30	Climara 50	BN
8126Q NP	Transdermal patches 7.6 mg (releasing approximately 100 micrograms per 24 hours), 4	¥1	5	..	19.23	20.34	Climara 100	BN
8140K NP	Transdermal patches 1.5 mg (releasing approximately 50 micrograms per 24 hours), 8	¥1	5	..	17.19	18.30	Estraderm MX 50	NV
8286D NP	Transdermal gel 1 mg in 1 g sachet, 28	¥1	5	..	17.19	18.30	Sandrena	AS
8311K NP	Transdermal patches 750 micrograms (releasing approximately 25 micrograms per 24 hours), 8	¥1	5	..	17.19	18.30	Estraderm MX 25	NV
8312L NP	Transdermal patches 3 mg (releasing approximately 100 micrograms per 24 hours), 8	¥1	5	..	19.23	20.34	Estraderm MX 100	NV
8485N NP	Transdermal patches 2 mg (releasing approximately 25 micrograms per 24 hours), 4	¥1	5	..	17.19	18.30	Climara 25	BN
8486P NP	Transdermal patches 5.7 mg (releasing approximately 75 micrograms per 24 hours), 4	¥1	5	..	19.23	20.34	Climara 75	BN
8761D NP	Transdermal patches 390 micrograms (releasing approximately 25 micrograms per 24 hours), 8	¥1	5	..	17.19	18.30	Estradot 25	NV
8762E NP	Transdermal patches 585 micrograms (releasing approximately 37.5 micrograms per 24 hours),	¥1	5	..	17.19	18.30	Estradot 37.5	NV

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	8							
8763F NP	Transdermal patches 780 micrograms (releasing approximately 50 micrograms per 24 hours), 8	¥1	5	..	17.19	18.30	Estradot 50	NV
8764G NP	Transdermal patches 1.17 mg (releasing approximately 75 micrograms per 24 hours), 8	¥1	5	..	19.23	20.34	Estradot 75	NV
8765H NP	Transdermal patches 1.56 mg (releasing approximately 100 micrograms per 24 hours), 8	¥1	5	..	19.23	20.34	Estradot 100	NV

OESTRADIOL

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1742Q NP	Vaginal tablets 25 micrograms, 15	¥1	2	..	26.88	27.99	Vagifem	NO
8274L NP	Tablet 2 mg	56	2	..	13.65	14.76	Zumenon	AB

OESTRADIOL VALERATE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1663M NP	Tablet 1 mg	56	2	..	11.78	12.89	Progynova	BN
1664N NP	Tablet 2 mg	56	2	..	14.00	15.11	Progynova	BN

OESTRIOL

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1771F NP	Pessaries 500 micrograms, 15	¥1	2	..	21.36	22.47	Ovestin Ovula	MK
1781R NP	Vaginal cream 1 mg per g (0.1%), 15 g	¥1	1	..	19.19	20.30	Ovestin	MK

Progestogens

Pregnen (4) derivatives

MEDROXYPROGESTERONE ACETATE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2321E NP	Tablet 10 mg	30	2	..	15.40	16.51	^a Medroxyprogesterone Sandoz	SZ
							^a Ralovera	FZ
				^B 1.95	17.35	16.51	^a Provera	PF
2323G NP	Tablet 5 mg	56	2	..	14.79	15.90	^a Ralovera	FZ
				^B 1.95	16.74	15.90	^a Provera	PF

MEDROXYPROGESTERONE ACETATE

Restricted benefit

Endometriosis.

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
2722G	Tablet 10 mg	100	2	..	30.80	31.91 ^a	Ralovera	FZ
				^B 1.95	32.75	31.91 ^a	Provera	PF

Estren derivatives

NORETHISTERONE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2993M NP	Tablet 5 mg	30	2	..	32.06	33.17	Primolut N	BN
-------------	-------------	----	---	----	-------	-------	------------	----

Progestogens and estrogens in combination

Progestogens and estrogens, combinations

OESTRADIOL with NORETHISTERONE ACETATE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8427M NP	Transdermal patches 620 micrograms-2.7 mg (releasing approximately 50 micrograms- 140 micrograms per 24 hours), 8	£1	5	..	19.23	20.34	Estalis continuous 50/140	NV
8428N NP	Transdermal patches 510 micrograms-4.8 mg (releasing approximately 50 micrograms- 250 micrograms per 24 hours), 8	£1	5	..	19.23	20.34	Estalis continuous 50/250	NV

Progestogens and estrogens, sequential preparations

OESTRADIOL and OESTRADIOL with DYDROGESTERONE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8244X NP	Pack containing 14 tablets oestradiol 2 mg and 14 tablets oestradiol 2 mg with dydrogesterone 10 mg	£1	5	..	18.86	19.97	Femoston 2/10	AB
-------------	---	----	---	----	-------	-------	---------------	----

OESTRADIOL and OESTRADIOL with NORETHISTERONE ACETATE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8425K NP	Pack containing 4 transdermal patches oestradiol 780 micrograms (releasing approximately 50 micrograms per 24 hours) and 4 transdermal patches oestradiol with norethisterone acetate 620 micrograms- 2.7 mg (releasing approximately 50 micrograms-140 micrograms per 24 hours)	£1	5	..	19.23	20.34	Estalis sequi 50/140	NV
8426L NP	Pack containing 4 transdermal patches oestradiol 780 micrograms (releasing approximately 50 micrograms per 24 hours) and 4 transdermal patches oestradiol with norethisterone acetate 510 micrograms- 4.8 mg (releasing approximately 50 micrograms-250 micrograms per 24 hours)	£1	5	..	19.23	20.34	Estalis sequi 50/250	NV

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Gonadotropins and other ovulation stimulants

Gonadotropins

FOLLITROPIN ALFA

Restricted benefit

Anovulatory infertility.

Note

Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.

Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.

Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.

Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.

Restricted benefit

For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given.

8713N	Injection 300 i.u. in 0.5 mL multi-dose cartridge	3	5	..	*563.53	35.40	Gonal-f Pen	SG
8714P	Injection 450 i.u. in 0.75 mL multi-dose cartridge	3	5	..	*842.02	35.40	Gonal-f Pen	SG
8715Q	Injection 900 i.u. in 1.5 mL multi-dose cartridge	2	5	..	*1115.34	35.40	Gonal-f Pen	SG

FOLLITROPIN BETA

Restricted benefit

Anovulatory infertility.

Note

Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.

Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.

Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.

Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.

Restricted benefit

For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given.

8565T	Solution for injection 300 i.u. in 0.36 mL multi-dose cartridge	3	5	..	*563.53	35.40	Puregon 300 IU/0.36 mL	MK
8566W	Solution for injection 600 i.u. in 0.72 mL multi-dose cartridge	2	5	..	*749.18	35.40	Puregon 600 IU/0.72 mL	MK
8871X	Solution for injection 900 i.u. in 1.08 mL multi-dose cartridge	2	5	..	*1115.32	35.40	Puregon 900 IU/1.08 mL	MK

HUMAN CHORIONIC GONADOTROPHIN

Restricted benefit

Anovulatory infertility.

Note

Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.

Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.

Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.

Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.

Restricted benefit

For the treatment of infertility in males due to hypogonadotrophic hypogonadism;

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
	For the treatment of infertility in males associated with isolated luteinising hormone deficiency;						
	For the treatment of males who have combined deficiency of human growth hormone and gonadotrophins and in whom the absence of secondary sexual characteristics indicates a lag in maturation.						
	<u>Restricted benefit</u>						
	For the treatment of boys over the age of 16 years who show clinical evidence of hypogonadism or delayed puberty. Treatment must not extend beyond 6 months.						
1581F	Injection set containing 3 ampoules powder for injection 1,500 units and 3 ampoules solvent 1 mL	1	5	..	53.57	35.40	Pregnyl MK

Ovulation stimulants, synthetic

CLOMIPHENE CITRATE

Note

Care must be taken to comply with the provisions of State/Territory law when prescribing clomiphene citrate.

Restricted benefit

Anovulatory infertility;

Patients undergoing in-vitro fertilisation.

1211R	Tablet 50 mg	10	5	..	34.61	35.40	^a Clomid ^a Serophene	SW SG
-------	--------------	----	---	----	-------	-------	---	----------

Antiandrogens

Antiandrogens, plain preparations

CYPROTERONE ACETATE

Authority required (STREAMLINED)

1230

Moderate to severe androgenisation in non-pregnant women (acne alone is not a sufficient indication of androgenisation).

Caution

This drug should not be used during pregnancy as it may result in feminisation of the male foetus.

1269T	Tablet 50 mg	20	5	..	44.39	35.40	^a Cyprohexal ^a Cyprone ^a Cyprostat ^a GenRx Cyproterone Acetate ^a Procur	SZ AF SY GX GM
				^B 2.50	46.89	35.40	^a Androcur	BN

CYPROTERONE ACETATE

Authority required (STREAMLINED)

1014

Advanced carcinoma of the prostate;

1404

To reduce drive in sexual deviations in males.

1270W	Tablet 50 mg	100	5	..	*167.42	35.40	^a Cyprohexal ^a Cyprone ^a Cyprostat ^a GenRx Cyproterone Acetate ^a Procur	SZ AF SY GX GM
				^B 2.62	*170.04	35.40	^a Androcur	BN
8019C	Tablet 100 mg	50	5	..	136.87	35.40	^a Cyprocur 100 ^a Cyprohexal ^a Cyprostat-100 ^a GenRx Cyproterone Acetate	QA SZ SY GX

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
				^B 1.31	138.18	35.40	^a Procur 100	GM
							^a Androcur-100	BN

Other sex hormones and modulators of the genital system

Antigonadotropins and similar agents

DANAZOL

Caution

Pregnancy must be excluded prior to administration of this drug.

Authority required (STREAMLINED)

1090

Endometriosis, visually proven;

1151

Hereditary angio-oedema;

2639

Short-term treatment (up to 6 months) of intractable primary menorrhagia (Treatment of this indication is limited to 6 months. See Australian Product Information);

2640

Short-term treatment (up to 6 months) of severe benign (fibrocystic) breast disease or mastalgia associated with severe symptomatic benign breast disease in patients refractory to other treatments (Treatment of this indication is limited to 6 months. See Australian Product Information).

1285P	Capsule 100 mg	100	5	..	58.68	35.40	Azol 100	AF
1287R	Capsule 200 mg	100	5	..	87.07	35.40	Azol 200	AF

GESTRINONE

Authority required (STREAMLINED)

3652

Short-term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months' therapy may be prescribed).

8015W	Capsule 2.5 mg	8	5	..	81.91	35.40	Dimetiose	SW
-------	----------------	---	---	----	-------	-------	-----------	----

Selective estrogen receptor modulators

RALOXIFENE HYDROCHLORIDE

Authority required (STREAMLINED)

2647

Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

8363E NP	Tablet 60 mg	28	5	..	57.97	35.40	Evista	LY
-------------	--------------	----	---	----	-------	-------	--------	----

Urologicals

Other urologicals, incl. antispasmodics

Urinary antispasmodics

OXYBUTYNIN

Restricted benefit

Detrusor overactivity in a patient who cannot tolerate oral oxybutynin, or who cannot swallow oral oxybutynin.

9454N NP	Transdermal patches 36 mg (releasing approximately 3.9 mg per 24 hours), 8	±1	5	..	35.33	35.40	Oxytrol	HH
-------------	--	----	---	----	-------	-------	---------	----

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
OXYBUTYNIN HYDROCHLORIDE							
<u>Restricted benefit</u>							
Detrusor overactivity.							
8039D NP	Tablet 5 mg	100	5	..	14.48	15.59 ^a	Ditropan SW
						^a	Oxybutynin Sandoz SZ
						^a	Oxybutynin Winthrop WA
PROPANTHELINE BROMIDE							
<u>Restricted benefit</u>							
Detrusor overactivity.							
1953T NP	Tablet 15 mg	200	5	..	*26.56	27.67	Pro-Banthine QA

Other urologicals

PHENOXYBENZAMINE HYDROCHLORIDE							
<u>Restricted benefit</u>							
Pheochromocytoma;							
Neurogenic urinary retention.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1166J NP	Capsules 10 mg, 30	3	5	..	*205.00	35.40	Dibenylne GH
1862B NP	Capsule 10 mg	100	5	..	67.46	35.40	Dibenylne GH
9286R NP	Capsules 10 mg, 100	±1	5	..	1164.57	35.40	Dibenzylne BZ
SODIUM BICARBONATE							
9470K NP	Capsule 840 mg	100	2	..	14.10	15.21	Sodibic AS

Drugs used in benign prostatic hypertrophy

Alpha-adrenoreceptor antagonists

DUTASTERIDE with TAMSULOSIN							
<u>Authority required (STREAMLINED)</u>							
3687							
Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia where treatment has been initiated by a urologist.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
5490Y NP	Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms	30	5	..	35.39	35.40	Duodart 500ug/400ug GK

Testosterone-5-alpha reductase inhibitors

DUTASTERIDE
Authority required (STREAMLINED)
3667

Treatment, in combination with an alpha-antagonist, of lower urinary tract symptoms due to benign prostatic hyperplasia where treatment is initiated by a urologist.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer
					for Max. Qty \$	Recordable Value for Safety Net \$	
5468T NP	Capsule 500 micrograms	30	5	..	30.53	31.64	Avodart GK

Systemic hormonal preparations, excl. sex hormones and insulins

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Systemic hormonal preparations, excl. sex hormones and insulins

Pituitary and hypothalamic hormones and analogues

Anterior pituitary lobe hormones and analogues

ACTH

2832C	TETRACOSACTRIN							
	Injection 1 mg in 1 mL	5	5	..	*71.37	35.40	Synacthen Depot 1 mg/1 mL	NV

Thyrotropin

THYROTROPIN ALFA

Authority required (STREAMLINED)

3193

Ablation of thyroid remnant tissue, in combination with radioactive iodine, in a post thyroidectomy patient without known metastatic disease.

2700D	Powder for injection 0.9 mg, 2	1	1901.52	35.40	Thyrogen	GZ
-------	--------------------------------	---	----	----	---------	-------	----------	----

Posterior pituitary lobe hormones

Vasopressin and analogues

DESMOPRESSIN ACETATE

Authority required (STREAMLINED)

1678

Cranial diabetes insipidus.

2129C	Intranasal solution 100 micrograms per mL, 2.5 mL	5	5	..	*161.27	35.40	Minirin	FP
8662X	Tablet 200 micrograms	90	5	..	*180.01	35.40	Minirin	FP
8711L	Nasal spray (pump pack) 10 micrograms per actuation, 60 actuations, 6 mL	2	5	..	*161.14	35.40	Minirin Nasal Spray	FP

DESMOPRESSIN ACETATE

Authority required (STREAMLINED)

2641

Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm;

2642

Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated.

Note

Not to be used in preference to enuresis alarms.

Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.

Note

Only one application per six months with no more than twice the maximum quantity will be authorised for the tablets.

8663Y NP	Tablet 200 micrograms	30	5	..	64.35	35.40	Minirin	FP
-------------	-----------------------	----	---	----	-------	-------	---------	----

DESMOPRESSIN ACETATE

Authority required (STREAMLINED)

2641

Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm;

2642

Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated.

Systemic hormonal preparations, excl. sex hormones and insulins

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Note Not to be used in preference to enuresis alarms. Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.								
Note Only one application per six months will be authorised for the wafers. No more than twice the maximum quantity for the 120 micrograms wafers and no applications for increased maximum quantities for the 240 micrograms wafers will be authorised.								
8975J NP	Wafer 240 micrograms (base)	30	5	..	116.04	35.40	Minirin Melt	FP
9398P NP	Wafer 120 micrograms (base)	30	5	..	70.95	35.40	Minirin Melt	FP

DESMOPRESSIN ACETATE

Authority required (STREAMLINED)

2641

Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm;

2642

Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated.

Note

Not to be used in preference to enuresis alarms.

Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.

8712M NP	Nasal spray (pump pack) 10 micrograms per actuation, 60 actuations, 6 mL	£1	5	..	83.83	35.40	Minirin Nasal Spray	FP
-------------	--	----	---	----	-------	-------	---------------------	----

Hypothalamic hormones

Gonadotropin-releasing hormones

NAFARELIN

Authority required

Initial treatment (up to 6 months) of visually proven endometriosis;

Subsequent treatment (up to 6 months) of visually proven endometriosis, where 2 years or more have elapsed since the end of the previous course and where a recent bone density assessment has been made. The date of the assessment must be provided.

2962X	Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses	£1	5	..	95.61	35.40	Synarel	PF
-------	--	----	---	----	-------	-------	---------	----

Corticosteroids for systemic use

Corticosteroids for systemic use, plain

Mineralocorticoids

FLUDROCORTISONE ACETATE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1433K NP	Tablet 100 micrograms	200	1	..	*46.60	35.40	Florinef	QA
-------------	-----------------------	-----	---	----	--------	-------	----------	----

Glucocorticoids

BETAMETHASONE ACETATE with BETAMETHASONE SODIUM PHOSPHATE

Restricted benefit

Alopecia areata;

For local intra-articular or peri-articular infiltration;

Granulomata, dermal;

Keloid;

Lichen planus hypertrophic;

Lichen simplex chronicus;

Systemic hormonal preparations, excl. sex hormones and insulins

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	Lupus erythematosus, chronic discoid; Necrobiosis lipoidica; Uveitis.							
	Note							
	Shared Care Model:							
	For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
2694T NP	Injection 3 mg-3.9 mg (equivalent to 5.7 mg betamethasone) in 1 mL	5	25.10	26.21	Celestone Chronodose	MK
	CORTISONE ACETATE							
	Note							
	Continuing Therapy Only:							
	For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1246N NP	Tablet 5 mg	50	4	..	15.40	16.51	Cortate	AS
1247P NP	Tablet 25 mg	60	4	..	17.84	18.95	Cortate	AS
	DEXAMETHASONE							
	Note							
	Shared Care Model:							
	For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1292B NP	Tablet 500 micrograms	30	4	..	8.94	10.05	Dexamethsone	AS
2507Y NP	Tablet 4 mg	30	4	..	12.50	13.61	Dexamethsone	AS
	DEXAMETHASONE SODIUM PHOSPHATE							
	Note							
	Shared Care Model:							
	For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1291Y NP	Injection equivalent to 8 mg dexamethasone phosphate in 2 mL	5	1	..	24.30	25.41 ^a	Dexamethsone	AS
						^a	Hospira Pty Limited	HH
2509C NP	Injection equivalent to 4 mg dexamethasone phosphate in 1 mL	5	16.32	17.43 ^a	Dexamethsone	AS
						^a	Hospira Pty Limited	HH
	HYDROCORTISONE							
	Note							
	Continuing Therapy Only:							
	For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1499X NP	Tablet 4 mg	50	4	..	23.15	24.26	Hysone 4	AF
1500Y NP	Tablet 20 mg	60	4	..	30.26	31.37	Hysone 20	AF
	HYDROCORTISONE SODIUM SUCCINATE							
1501B NP	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	2	*16.62	17.73	Solu-Cortef	PF
3096Y NP	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	1	15.64	16.75	Solu-Cortef	PF

Systemic hormonal preparations, excl. sex hormones and insulins

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
HYDROCORTISONE SODIUM SUCCINATE								
<u>Restricted benefit</u>								
For use in a hospital.								
1510L NP	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	6	*36.82	35.40	Solu-Cortef	PF
1511M NP	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	6	*58.84	35.40	Solu-Cortef	PF
METHYLPREDNISOLONE								
<u>Note</u>								
Pharmaceutical benefits that have the form methylprednisolone powder for injection 40 mg (as sodium succinate) and pharmaceutical benefits that have the form methylprednisolone powder for injection 40 mg (as sodium succinate) with diluent are equivalent for the purposes of substitution.								
2981X NP	Powder for injection 40 mg (as sodium succinate) with diluent	5	30.57	31.68 ^a	Solu-Medrol	PF
5263B NP	Powder for injection 40 mg (as sodium succinate)	5	30.57	31.68 ^a	Methylpred	AS
METHYLPREDNISOLONE								
<u>Note</u>								
Pharmaceutical benefits that have the form methylprednisolone powder for injection 1 g (as sodium succinate) and pharmaceutical benefits that have the form methylprednisolone powder for injection 1 g (as sodium succinate) with diluent are equivalent for the purposes of substitution.								
5264C NP	Powder for injection 1 g (as sodium succinate)	1	79.79	35.40 ^a	Methylpred	AS
8834Y NP	Powder for injection 1 g (as sodium succinate) with diluent	1	79.79	35.40 ^a	Solu-Medrol	PF
METHYLPREDNISOLONE ACETATE								
<u>Restricted benefit</u>								
For local intra-articular or peri-articular infiltration.								
1928L NP	Injection 40 mg in 1 mL	5	21.48	22.59 ^a	Depo-Nisalone	FZ
				^B 0.96	22.44	22.59 ^a	Depo-Medrol	PF
PREDNISOLONE								
1916W NP	Tablet 25 mg	30	4	..	10.23	11.34	Panafcortelone	AS
							Solone	VT
1917X NP	Tablet 5 mg	60	4	..	8.58	9.69	Panafcortelone	AS
							Solone	VT
3152X NP	Tablet 1 mg	100	4	..	8.43	9.54 ^a	Predsolone	LN
				^B 0.44	8.87	9.54 ^a	Panafcortelone	AS
PREDNISOLONE SODIUM PHOSPHATE								
8285C NP	Oral solution equivalent to 5 mg prednisolone per mL, 30 mL	‡1	5	..	14.80	15.91 ^a	PredMix	LN
				^B 2.36	17.16	15.91 ^a	Redipred	AS
PREDNISONE								
1934T NP	Tablet 1 mg	100	4	..	8.96	10.07 ^a	Predsone	LN
				^B 0.61	9.57	10.07 ^a	Panafcort	AS
1935W NP	Tablet 5 mg	60	4	..	9.28	10.39	Panafcort	AS
							Sone	VT
1936X	Tablet 25 mg	30	4	..	11.51	12.62	Panafcort	AS

Systemic hormonal preparations, excl. sex hormones and insulins

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
NP							Sone VT
	TRIAMCINOLONE ACETONIDE <u>Restricted benefit</u> Alopecia areata; For local intra-articular or peri-articular infiltration; Granulomata, dermal; Keloid; Lichen planus hypertrophic; Lichen simplex chronicus; Lupus erythematosus, chronic discoid; Necrobiosis lipoidica; Psoriasis.						
	<u>Note</u> Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.						
2990J NP	Injection 10 mg in 1 mL	5	25.10	26.21	Kenacort-A10 QA

Thyroid therapy

Thyroid preparations Thyroid hormones

LIOTHYRONINE SODIUM

Authority required (STREAMLINED)

1219

Management of patients with thyroid cancer;

1858

Replacement therapy for hypothyroid patients who have documented intolerance to thyroxine sodium;

1859

Replacement therapy for hypothyroid patients who have documented resistance to thyroxine sodium;

1182

Initiation of thyroid therapy in severely hypothyroid patients.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2318B NP	Tablet 20 micrograms	100	2	..	83.63	35.40	Tertroxin QA
-------------	----------------------	-----	---	----	-------	-------	--------------

THYROXINE SODIUM

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2173J NP	Tablet equivalent to 200 micrograms anhydrous thyroxine sodium	200	1	..	27.11	28.22 ^a	Eutroxig FM
				^B 2.21	29.32	28.22 ^a	Oroxine QA
2174K NP	Tablet equivalent to 50 micrograms anhydrous thyroxine sodium	200	1	..	23.47	24.58 ^a	Eutroxig FM
				^B 2.21	25.68	24.58 ^a	Oroxine QA
2175L NP	Tablet equivalent to 100 micrograms anhydrous thyroxine sodium	200	1	..	24.08	25.19 ^a	Eutroxig FM
				^B 2.21	26.29	25.19 ^a	Oroxine QA

Systemic hormonal preparations, excl. sex hormones and insulins

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
9287T NP	Tablet equivalent to 75 micrograms anhydrous thyroxine sodium	200	1	..	24.12	25.23 ^a	Eutroxsig FM
				^B 2.27	26.39	25.23 ^a	Oroxine QA

Antithyroid preparations *Thiouracils*

PROPYLTHIOURACIL

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1955X NP	Tablet 50 mg	200	2	..	*49.74	35.40	PTU	PL
-------------	--------------	-----	---	----	--------	-------	-----	----

Sulfur-containing imidazole derivatives

CARBIMAZOLE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1153Q NP	Tablet 5 mg	200	2	..	*31.14	32.25	Neo-Mercazole	LM
-------------	-------------	-----	---	----	--------	-------	---------------	----

Pancreatic hormones

Glycogenolytic hormones *Glycogenolytic hormones*

GLUCAGON HYDROCHLORIDE

1449G NP	Injection set containing 1 mg (1 i.u.) and 1 mL solvent in disposable syringe	1	1	..	45.73	35.40	GlucaGen Hypokit	NO
-------------	--	---	---	----	-------	-------	------------------	----

Calcium homeostasis

Parathyroid hormones and analogues *Parathyroid hormones and analogues*

TERIPARATIDE

Authority required

Initial treatment, as the sole PBS-subsidised agent, by a specialist or consultant physician, for severe, established osteoporosis in a patient with a very high risk of fracture who:

- (a) has a bone mineral density (BMD) T-score of -3.0 or less; and
- (b) has had 2 or more fractures due to minimal trauma; and
- (c) has experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

If treatment with anti-resorptive therapy is contraindicated according to the relevant TGA-approved Product Information, details of the contraindication must be provided at the time of application.

If an intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use of one anti-resorptive agent, alternate anti-resorptive agents must be trialled so that the patient achieves the minimum requirement of 12 months continuous therapy. Details of accepted toxicities including severity can be found on the Medicare Australia website at www.medicareaustralia.gov.au and must be provided at the time of application.

Anti-resorptive therapies for osteoporosis and their adequate doses which will be accepted for the purposes of administering this restriction are alendronate sodium 10 mg per day or 70 mg once weekly, risedronate sodium 5 mg per day or 35 mg once weekly or 150 mg once monthly, raloxifene hydrochloride 60 mg per day (women only), denosumab 60 mg once every 6 months, disodium etidronate 200 mg with calcium carbonate 1.25 g per day, strontium ranelate 2 g per day and zoledronic acid 5 mg per annum.

Systemic hormonal preparations, excl. sex hormones and insulins

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
<p>Details of prior anti-resorptive therapy, fracture history including the date(s), site(s), the symptoms associated with the fracture(s) which developed during the course of anti-resorptive therapy and the score of the qualifying BMD measurement must be provided to Medicare Australia at the time of application.</p> <p><u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.</p> <p><u>Authority required</u> Continuing treatment for severe established osteoporosis where the patient has previously been issued with an authority prescription for this drug.</p> <p>Teriparatide must only be used for a lifetime maximum of 18 months therapy (18 pens). Up to a maximum of 18 pens will be reimbursed through the PBS.</p> <p><u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.</p> <p><u>Note</u> Special Pricing Arrangements apply.</p>							
9411H	Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen	1	5	..	438.47	35.40	Forteo LY

Anti-parathyroid agents Calcitonin preparations

SALCATONIN

Note

The maximum quantities for salcatonin shown represent the number of individual ampoules and NOT multiples of the manufacturer's packs. The pack size for both strengths is five ampoules.

Authority required (STREAMLINED)

3256

Symptomatic Paget disease of bone;

1412

Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2995P NP	Injection 50 i.u. in 1 mL	30	5	..	*207.76	35.40	Miacalcic 50	NV
2997R NP	Injection 100 i.u. in 1 mL	15	5	..	*161.23	35.40	Miacalcic 100	NV

Other anti-parathyroid agents

CINACALCET

Authority required (STREAMLINED)

3673

Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has a decrease of at least 30% in iPTH concentrations after 6 months treatment;

3672

Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has iPTH greater than 15 pmol per L and an (adjusted) serum calcium concentration of less than 2.6 mmol per L after 6 months treatment.

Note

During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.

During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability. Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.

Systemic hormonal preparations, excl. sex hormones and insulins

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

Special Pricing Arrangements apply.

9157Y NP	Tablet 30 mg (as hydrochloride)	28	5	..	343.70	35.40	Sensipar	AN
9158B NP	Tablet 60 mg (as hydrochloride)	28	5	..	670.42	35.40	Sensipar	AN
9159C NP	Tablet 90 mg (as hydrochloride)	28	5	..	1002.37	35.40	Sensipar	AN

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Antiinfectives for systemic use

Antibacterials for systemic use

Tetracyclines

Tetracyclines

DOXYCYCLINE

Note

Pharmaceutical benefits that have the form doxycycline tablet 100 mg (as hydrochloride) and pharmaceutical benefits that have the form doxycycline tablet 100 mg (as monohydrate) are equivalent for the purposes of substitution.

2709N NP	Tablet 100 mg (as hydrochloride)	7	1	..	8.46	9.57	^a Doxsig	QA
							^a Doxy-100	GM
							^a Doxylin 100	AF
9105F NP	Tablet 100 mg (as monohydrate)	7	1	..	8.46	9.57	^a Chem mart Doxycycline	CH
							^a Doxyhexal	SZ
							^a GenRx Doxycycline	GX
							^a Terry White Chemists Doxycycline	TW

DOXYCYCLINE

2708M NP	Capsule 100 mg (as hydrochloride)	7	1	..	8.46	9.57	^a Mayne Pharma Doxycycline	YT
				^B 2.86	11.32	9.57	^a Doryx	YN

DOXYCYCLINE

Restricted benefit

Bronchiectasis in patients aged 8 years or older;

Chronic bronchitis in patients aged 8 years or older;

Severe acne.

Note

Pharmaceutical benefits that have the form doxycycline tablet 50 mg (as hydrochloride) and pharmaceutical benefits that have the form doxycycline tablet 50 mg (as monohydrate) are equivalent for the purposes of substitution.

2711Q NP	Tablet 50 mg (as hydrochloride)	25	5	..	9.98	11.09	^a Doxy-50	GM
							^a Doxylin 50	AF
				^B 1.95	11.93	11.09	^a Vibra-Tabs	PF
9106G NP	Tablet 50 mg (as monohydrate)	25	5	..	9.98	11.09	^a Chem mart Doxycycline	CH
							^a Doxyhexal	SZ
							^a Frakas	QA
							^a GenRx Doxycycline	GX
							^a Terry White Chemists Doxycycline	TW

DOXYCYCLINE

Restricted benefit

Bronchiectasis in patients aged 8 years or older;

Chronic bronchitis in patients aged 8 years or older;

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer	
	Severe acne.								
2707L NP	Capsule 50 mg (as hydrochloride)	25	5	..	9.98	11.09	^a	Mayne Pharma Doxycycline	YT
				^B 2.91	12.89	11.09	^a	Doryx	YN
<hr/>									
DOXYCYCLINE									
<u>Restricted benefit</u>									
Pelvic inflammatory disease.									
<u>Note</u>									
Pharmaceutical benefits that have the form doxycycline tablet 100 mg (as hydrochloride) and pharmaceutical benefits that have the form doxycycline tablet 100 mg (as monohydrate) are equivalent for the purposes of substitution.									
2702F NP	Tablet 100 mg (as hydrochloride)	28	*14.28	15.39	^a	Doxsig	QA
							^a	Doxy-100	GM
							^a	Doxylin 100	AF
9107H NP	Tablet 100 mg (as monohydrate)	28	*14.28	15.39	^a	Chem mart Doxycycline	CH
							^a	Doxyhexal	SZ
							^a	GenRx Doxycycline	GX
							^a	Terry White Chemists Doxycycline	TW
<hr/>									
DOXYCYCLINE									
<u>Restricted benefit</u>									
Pelvic inflammatory disease.									
2703G NP	Capsule 100 mg (as hydrochloride)	28	*14.28	15.39	^a	Mayne Pharma Doxycycline	YT
				^B 11.44	*25.72	15.39	^a	Doryx	YN
<hr/>									
DOXYCYCLINE									
<u>Restricted benefit</u>									
Urethritis.									
<u>Note</u>									
Pharmaceutical benefits that have the form doxycycline tablet 100 mg (as hydrochloride) and pharmaceutical benefits that have the form doxycycline tablet 100 mg (as monohydrate) are equivalent for the purposes of substitution.									
1800R NP	Tablet 100 mg (as monohydrate)	21	12.35	13.46	^a	GenRx Doxycycline	GX
2714W NP	Tablet 100 mg (as hydrochloride)	21	*12.34	13.45	^a	Doxsig	QA
							^a	Doxy-100	GM
							^a	Doxylin 100	AF
9108J NP	Tablet 100 mg (as monohydrate)	21	*12.34	13.45	^a	Chem mart Doxycycline	CH
							^a	Doxyhexal	SZ
							^a	Terry White Chemists Doxycycline	TW
<hr/>									
DOXYCYCLINE									
<u>Restricted benefit</u>									
Urethritis.									
2715X	Capsule 100 mg (as hydrochloride)	21	12.32	13.43	^a	Mayne Pharma	YT

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer
NP								
				^B 3.89	16.21	13.43	^a	Doxycycline Doryx YN

MINOCYCLINE

Caution

There are concerns about the incidence of benign intracranial hypertension associated with this drug.

Restricted benefit

Severe acne not responding to other tetracyclines.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

1616C	Tablet 50 mg	60	5	..	15.15	16.26	^a	Akamin 50 AF
NP				^B 1.89	17.04	16.26	^a	Minomycin-50 QA

Beta-lactam antibacterials, penicillins

Penicillins with extended spectrum

AMOXYCILLIN

1884E	Capsule 250 mg	20	1	..	7.83	8.94	^a	Alphamox 250 AF
NP,MW							^a	Amoxycillin-GA GM
							^a	Amoxycillin RA
							^a	Ranbaxy
							^a	Amoxycillin Sandoz SZ
							^a	APO-Amoxycillin TX
							^a	Chem mart CH
							^a	Amoxycillin
							^a	Cilamox QA
							^a	GenRx Amoxycillin GX
							^a	Terry White Chemists TW
							^a	Amoxycillin
				^B 0.88	8.71	8.94	^a	Amoxil GK
1886G	Powder for syrup 125 mg per 5 mL, 100 mL	‡1	1	..	#10.30	11.75	^a	Alphamox 125 AF
NP							^a	Amoxycillin Sandoz SZ
							^a	Bgramin GM
							^a	Chem mart CH
							^a	Amoxycillin
							^a	GenRx Amoxycillin GX
							^a	Ranmoxy RA
							^a	Terry White Chemists TW
							^a	Amoxycillin
				^B 0.89	#11.19	11.75	^a	Amoxil GK
1887H	Powder for syrup 250 mg per 5 mL, 100 mL	‡1	1	..	#10.81	12.26	^a	Alphamox 250 AF
NP							^a	Amoxycillin Sandoz SZ
							^a	Bgramin GM
							^a	Chem mart CH
							^a	Amoxycillin
							^a	Cilamox QA
							^a	GenRx Amoxycillin GX
							^a	Ranmoxy RA
							^a	Terry White Chemists TW
							^a	Amoxycillin
				^B 0.87	#11.68	12.26	^a	Amoxil Forte GK
1889K	Capsule 500 mg	20	1	..	9.13	10.24	^a	Alphamox 500 AF

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
NP,MW							^a Amoxycillin-GA	GM
							^a Amoxycillin generichealth 500	GQ
							^a Amoxycillin Ranbaxy	RA
							^a Amoxycillin Sandoz	SZ
							^a APO-Amoxycillin	TX
							^a Chem mart Amoxycillin	CH
							^a Cilamox	QA
							^a GenRx Amoxycillin	GX
							^a Terry White Chemists Amoxycillin	TW
							^a Amoxil	GK
8705E NP	Powder for oral suspension 500 mg per 5 mL, 100 mL	‡1	1	.. ^B 0.89	#12.67 10.02	14.12 10.24	Maxamox	SZ
<hr/>								
AMOXYCILLIN								
<u>Restricted benefit</u>								
Acute exacerbations of chronic bronchitis.								
8581P NP	Tablet 1 g	14	1	.. ^B 0.73	9.21 9.94	10.32 10.32	^a Amoxycillin Sandoz	BG
							^a Maxamox	SZ
AMPICILLIN								
2390T NP	Powder for injection 500 mg	5	1	..	10.95	12.06	^a Austrapen	LN
							^a Ibimicyn	TS
2977Q NP	Powder for injection 1 g	5	1	..	13.79	14.90	^a Aspen Ampicyn	AS
							^a Austrapen	LN
							^a Ibimicyn	TS
Beta-lactamase sensitive penicillins								
BENZATHINE BENZYL PENICILLIN								
2267H NP	Injection 900 mg in 2.3 mL single use pre-filled syringe	10	293.21	35.40	Bicillin L-A	PF
BENZYL PENICILLIN								
1775K NP,MW	Powder for injection 600 mg	10	1	..	*43.02	35.40	BenPen	CS
2647H NP	Powder for injection 3 g	10	*67.02	35.40	BenPen	CS
PHENOXYMETHYL PENICILLIN								
1787C NP	Tablet 250 mg	50	*11.42	12.53	Abbocillin-VK Filmtab	QA
1789E NP	Capsule 250 mg	50	11.26	12.37	^a Cilicaine VK	FM
							^a Cilopen VK	GM
							LPV	VT
2965C NP	Capsule 500 mg	50	13.57	14.68	^a Cilicaine VK	FM
							^a Cilopen VK	GM

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							LPV	VT
3028J NP	Tablet 500 mg	50	*13.76	14.87	Abbocillin-VK Filmtab	QA
8976K NP	Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL	2	1	..	*#16.89	18.34	Phenoxymethyl- penicillin-AFT	AE
8977L NP	Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL	2	1	..	*#19.45	20.90	Phenoxymethyl- penicillin-AFT	AE
9143F NP	Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL	2	1	..	*21.70	22.81	^a Cilicaine V	FM
				^B 1.90	*23.60	22.81	^a Abbocillin-V	QA

PHENOXYMETHYLPENICILLIN

Restricted benefit

Prophylaxis of recurrent streptococcal infections (including rheumatic fever).

1703P NP	Tablet 250 mg	50	5	..	*11.42	12.53	Abbocillin-VK Filmtab	QA
1705R NP	Capsule 250 mg	50	5	..	11.26	12.37	^a Cilicaine VK	FM
							^a Cilopen VK	GM
							LPV	VT

PROCAINE PENICILLIN

1794K NP	Injection 1.5 g	5	92.32	35.40	Cilicaine	QA
-------------	-----------------	---	----	----	-------	-------	-----------	----

Beta-lactamase resistant penicillins

DICLOXACILLIN

Restricted benefit

Serious staphylococcal infections.

8121K NP,MW	Capsule 250 mg	24	11.29	12.40	^a Dicloxsig	QA
							^a Distaph 250	AF
8122L NP,MW	Capsule 500 mg	24	16.51	17.62	^a Diclocil	BQ
							^a Dicloxsig	QA
							^a Distaph 500	AF

FLUCLOXACILLIN

Caution

Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.

1524F NP	Powder for injection 500 mg	5	12.86	13.97	^a Flubiclox	TS
							^a Flucil	AS
1525G NP	Powder for injection 1 g	5	1	..	16.43	17.54	^a Flubiclox	TS
							^a Flucil	AS
							^a Hospira Pty Limited	HH

FLUCLOXACILLIN

Caution

Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.

Restricted benefit

Serious staphylococcal infections.

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
1526H <i>NP,MW</i>	Capsule 250 mg (as sodium)	24	11.29	12.40	^a Flopen AS
							^a Staphylex 250 AF
1527J <i>NP,MW</i>	Capsule 500 mg (as sodium)	24	16.51	17.62	^a Flopen AS
							^a Staphylex 500 AF
9149M <i>NP</i>	Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL	‡1	#16.18	17.63	Flucil LN
9150N <i>NP</i>	Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL	‡1	#19.71	21.16	Flucil LN

Combinations of penicillins, incl. beta-lactamase inhibitors

AMOXYCILLIN with CLAVULANIC ACID

Caution

Hepatotoxicity has been reported with this drug.

Restricted benefit

Infections where resistance to amoxycillin is suspected;

Infections where resistance to amoxycillin is proven.

1891M <i>NP,MW</i>	Tablet 500 mg-125 mg	10	1	..	10.18	11.29	^a Amoxycillin/ Clavulanic Acid 500/125 generichealth GQ
							^a APO-Amoxycillin/ Clavulanic Acid 500/125 TX
							^a Clamoxyl Duo AL
							^a Curam Duo 500/125 SZ
							^a GA-Amclav 500/125 GM
							^a Moxiclav Duo 500/125 QA
				^B 1.57	11.75	11.29	^a Augmentin Duo GK
1892N <i>NP</i>	Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL	‡1	1	..	#11.38	12.83	^a Clamoxyl AL
							^a Curam SZ
				^B 1.58	#12.96	12.83	^a Augmentin GK
8254K <i>NP</i>	Tablet 875 mg-125 mg	10	1	..	11.73	12.84	^a Amoxycillin/ Clavulanic Acid 875/125 generichealth GQ
							^a Chem mart CH
							^a Amoxycillin and Clavulanic Acid
							^a Clamoxyl Duo forte AL
							^a Clavycillin 875/125 CR
							^a Curam Duo Forte 875/125 SZ
							^a GA-Amclav Forte 875/125 GM
							^a GenRx Amoxycillin and Clavulanic Acid GX
							^a Moxiclav Duo Forte 875/125 QA
							^a Terry White Chemists TW
							^a Amoxycillin and Clavulanic Acid
				^B 1.56	13.29	12.84	^a Augmentin Duo forte GK
8319W <i>NP</i>	Powder for syrup 400 mg-57 mg per 5 mL, 60 mL	‡1	1	..	#12.35	13.80	^a Clamoxyl Duo 400 AL

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				^B 1.58	#13.93	13.80	^a Curam Duo SZ
							^a Augmentin Duo 400 GK

TICARCILLIN with CLAVULANIC ACID

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;

Septicaemia, suspected;

Septicaemia, proven.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2179Q NP	Powder for injection 3 g-100 mg (solvent required) (code 6884H applies to above item with approved solvent)	10	163.42	35.40	Timentin GK
-------------	--	----	----	----	--------	-------	-------------

Other beta-lactam antibacterials

First-generation cephalosporins

CEFALOTIN

2964B NP	Powder for injection 1 g	10	1	..	22.98	24.09	^a Cefalotin Sandoz SZ
							^a Hospira Pty Limited HH
							^a Keflin Neutral AS

CEPHALEXIN

3058Y NP,MW	Capsule 250 mg	20	1	..	8.02	9.13	^a Cefalexin Sandoz SZ
							^a Cephalixin generichealth GQ
							^a Cephalixin-PS FZ
							^a Cephatrust 250 MI
							^a Chem mart Cephalixin CH
							^a Cilex GM
							^a GenRx Cephalixin GX
							^a Ialex LN
							^a Ibilex 250 AF
							^a Pharmacor Cephalixin 250 CR
							^a Rancef RA
							^a Terry White Chemists Cephalixin TW
				^B 3.94	11.96	9.13	^a Keflex AS
3094W NP	Granules for syrup 125 mg per 5 mL, 100 mL	#1	1	..	#10.91	12.36	^a APO-Cephalixin TX
							^a Cefalexin Sandoz SZ
							^a Chem mart Cephalixin CH
							^a Cilex GM
							^a GenRx Cephalixin GX
							^a Ialex LN
							^a Ibilex 125 AF
							^a Terry White Chemists Cephalixin TW

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				^B 4.34	#15.25	12.36	^a Keflex AS
3095X NP	Granules for syrup 250 mg per 5 mL, 100 mL	‡1	1	..	#11.78	13.23	^a APO-Cephalexin TX
							^a Cefalexin Sandoz SZ
							^a Chem mart CH
							^a Cephalexin
							^a Cilex GM
							^a GenRx Cephalexin GX
							^a Ialex LN
							^a Ibilex 250 AF
							^a Terry White Chemists TW
							^a Cephalexin
				^B 5.58	#17.36	13.23	^a Keflex AS
3119E NP,MW	Capsule 500 mg	20	1	..	9.20	10.31	^a Cefalexin Sandoz SZ
							^a Cephalexin GQ
							^a generichealth
							^a Cephalexin-PS FZ
							^a Cephatrust 500 MI
							^a Chem mart CH
							^a Cephalexin
							^a Cilex GM
							^a GenRx Cephalexin GX
							^a Ialex LN
							^a Ibilex 500 AF
							^a Pharmacor CR
							^a Cephalexin 500
							^a Rancef RA
							^a Terry White Chemists TW
							^a Cephalexin
				^B 5.65	14.85	10.31	^a Keflex AS

CEPHAZOLIN

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;

Septicaemia, suspected;

Septicaemia, proven.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1256D NP	Powder for injection 500 mg	10	*39.98	35.40	^a Cefazolin-AFT AE
							^a Hospira Pty Limited HH
9326W NP	Powder for injection 2 g	10	*104.32	35.40	^a Cefazolin Sandoz SZ
							^a Cephalozin Alphapharm AF

CEPHAZOLIN

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;

Septicaemia, suspected;

Septicaemia, proven.

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Note Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
Note For item codes 1257E and 1797N, pharmaceutical benefits that have the form powder for injection 1 g are equivalent for the purposes of substitution.							
1257E NP	Powder for injection 1 g	10	49.72	35.40	^a Cefazolin Sandoz SZ
							^a Cephazolin Alphapharm AF
							^a Kefzol AS
1797N NP	Powder for injection 1 g	10	*49.72	35.40	^a Cefazolin-AFT AE
							^a Hospira Pty Limited HH
CEPHAZOLIN Restricted benefit Cellulitis.							
5477G NP	Powder for injection 500 mg	10	*39.98	35.40	^a Cefazolin-AFT AE
							^a Hospira Pty Limited HH
5479J NP	Powder for injection 2 g	10	*104.32	35.40	^a Cefazolin Sandoz SZ
							^a Cephazolin Alphapharm AF
CEPHAZOLIN Restricted benefit Cellulitis.							
Note For item codes 5478H and 1799Q, pharmaceutical benefits that have the form powder for injection 1 g are equivalent for the purposes of substitution.							
1799Q NP	Powder for injection 1 g	10	*49.72	35.40	^a Cefazolin-AFT AE
							^a Hospira Pty Limited HH
5478H NP	Powder for injection 1 g	10	49.72	35.40	^a Cefazolin Sandoz SZ
							^a Cephazolin Alphapharm AF
							^a Kefzol AS

Second-generation cephalosporins

CEFACTOR

Caution

Serum sickness-like reactions have been reported with this drug, especially in children.

1169M	Tablet 375 mg (sustained release)	10	1	..	11.43	12.54	^a Cefaclor-GA GN
							^a Cefaclor GH GQ
							^a Chem mart CH
							^a Cefaclor CD
							^a GenRx Cefaclor CD GX
							^a Karlor CD LN
							^a Keflor CD AF
							^a Ozcef RA
							^a Terry White Chemists TW

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer		
2460L	Powder for oral suspension 125 mg per 5 mL, 100 mL	1	1	B6.16 ..	17.59 #12.58	12.54 14.03	a	Cefaclor CD	AS
							a	Ceclor CD	QA
							a	Aclor 125	QA
							a	Cefaclor Sandoz	SZ
							a	Chem mart	CH
							a	Cefaclor	CH
							a	GenRx Cefaclor	GX
							a	Keflor	AF
2461M	Powder for oral suspension 250 mg per 5 mL, 75 mL	1	1	B4.83 ..	#17.41 #12.82	14.03 14.27	a	Ozcef	RA
							a	Terry White Chemists	TW
							a	Cefaclor	AS
							a	Ceclor	AS
							a	Aclor 250	QA
							a	Cefaclor Sandoz	SZ
							a	Chem mart	CH
							a	Cefaclor	CH
5499K	Powder for oral suspension 125 mg (base) per 5 mL, 70 mL	1	1	..	#19.54	20.99	a	GenRx Cefaclor	GX
							a	Keflor	AF
							a	Ozcef	RA
							a	Terry White Chemists	TW
							a	Cefaclor	AS
							a	Cefaclor	AS
							a	Cefaclor	AS
							a	Cefaclor	AS
8292K	Tablet 250 mg (base)	14	1	..	18.72	19.83	a	Ceclor	AS
							a	Ceclor	AS
CEFUROXIME AXETIL									
5499K	Powder for oral suspension 125 mg (base) per 5 mL, 70 mL	1	1	..	#19.54	20.99	Zinnat	GK	
8292K	Tablet 250 mg (base)	14	1	..	18.72	19.83	Zinnat	GK	

Third-generation cephalosporins

CEFOTAXIME

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;

Septicaemia, suspected;

Septicaemia, proven.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

For item codes 1085D and 1758M, pharmaceutical benefits that have the form powder for injection 1 g are equivalent for the purposes of substitution.

1085D NP	Powder for injection 1 g	10	*26.42	27.53	a	Cefotaxime Sandoz SZ
1758M NP	Powder for injection 1 g	10	26.54	27.65	a	Hospira Pty Limited HH

CEFOTAXIME

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;

Septicaemia, suspected;

Septicaemia, proven.

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Note</u> Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u> For item codes 1086E and 1759N, pharmaceutical benefits that have the form powder for injection 2 g are equivalent for the purposes of substitution.								
1086E NP	Powder for injection 2 g	10	*43.02	35.40 ^a	Cefotaxime Sandoz	SZ
1759N NP	Powder for injection 2 g	10	43.12	35.40 ^a	Hospira Pty Limited	HH
CEFTRIAXONE <u>Restricted benefit</u> Gonorrhoea.								
9058R NP	Powder for injection 500 mg	1	10.35	11.46	Ceftriaxone ICP	PP
<hr/>								
CEFTRIAXONE <u>Restricted benefit</u> Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent; Septicaemia, suspected; Septicaemia, proven.								
<u>Note</u> Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1783W NP	Powder for injection 500 mg	5	*25.67	26.78	Ceftriaxone ICP	PP
1785Y NP	Powder for injection 2 g	5	*59.62	35.40 ^a	Ceftriaxone-AFT	AE
						^a	Ceftriaxone ICP	PP
						^a	Ceftriaxone Sandoz	SZ
						^a	DBL Ceftriaxone	HH
						^a	Rocephin	RO
<hr/>								
CEFTRIAXONE <u>Restricted benefit</u> Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent; Septicaemia, suspected; Septicaemia, proven.								
<u>Note</u> Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u> For item codes 1784X and 1788D, pharmaceutical benefits that have the form powder for injection 1 g are equivalent for the purposes of substitution.								
1784X NP	Powder for injection 1 g	5	*36.42	35.40 ^a	Ceftriaxone-AFT	AE
						^a	Ceftriaxone ICP	PP
						^a	Ceftriaxone Sandoz	SZ
						^a	DBL Ceftriaxone	HH
						^a	Rocephin	RO

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<hr/>								
CEFTRIAXONE								
<u>Restricted benefit</u>								
Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;								
Septicaemia, suspected;								
Septicaemia, proven.								
<u>Note</u>								
For item codes 1784X and 1788D, pharmaceutical benefits that have the form powder for injection 1 g are equivalent for the purposes of substitution.								
1788D NP	Powder for injection 1 g	5	36.45	35.40 ^a	Max Pharma Ceftriaxone	GQ

Fourth-generation cephalosporins

CEFEPIME								
<u>Authority required</u>								
Treatment of febrile neutropenia.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8315P NP	Powder for injection 1 g (as hydrochloride) (solvent required) (code 7079N applies to above item with approved solvent)	10	*161.72	35.40 ^a	Cefepime Sandoz	SZ
							^a DBL Cefepime	HH
							^a Omegapharm Pty Ltd	OE
8316Q NP	Powder for injection 2 g (as hydrochloride) (solvent required) (code 7085X applies to above item with approved solvent)	10	*293.32	35.40 ^a	Cefepime Sandoz	SZ
							^a DBL Cefepime	HH
							^a Maxipime	BQ
							^a Omegapharm Pty Ltd	OE

Sulfonamides and trimethoprim ***Trimethoprim and derivatives***

TRIMETHOPRIM								
2922T NP	Tablet 300 mg	7	1	..	8.48	9.59 ^a	Alprim	AF
					^B 1.89	10.37	^a Triprim	QA

Combinations of sulfonamides and trimethoprim, incl. derivatives

TRIMETHOPRIM with SULFAMETHOXAZOLE									
<u>Caution</u>									
There is an increased risk of severe adverse reactions with this combination in the elderly.									
2951H <i>NP</i>	Tablet 160 mg-800 mg	10	1	..	9.34	10.45	^a	Bactrim DS	RO
							^a	Resprim Forte	AF
				^B 1.46	10.80	10.45	^a	Septrin Forte	QA
3103H <i>NP</i>	Oral suspension 40 mg-200 mg per 5 mL, 100 mL	±1	1	..	9.03	10.14		Bactrim	RO
				^B 1.79	10.82	10.14		Septrin	QA

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Macrolides, lincosamides and streptogramins								
Macrolides								
AZITHROMYCIN								
<u>Restricted benefit</u>								
Uncomplicated urethritis due to Chlamydia trachomatis;								
Uncomplicated cervicitis due to Chlamydia trachomatis.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
8200N NP	Tablet 500 mg (as dihydrate)	2	21.19	22.30	^a Azithromycin Sandoz ^a Zithromax ^a Zitrocin	SZ PF GM
<hr/>								
AZITHROMYCIN								
<u>Restricted benefit</u>								
Trachoma.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
8201P NP	Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL	#1	#21.27	22.72	Zithromax	PF
8336R NP	Tablet 500 mg (as dihydrate)	2	2	..	21.19	22.30	^a Azithromycin Sandoz ^a Zithromax ^a Zitrocin	SZ PF GM
<hr/>								
CLARITHROMYCIN								
8318T NP	Tablet 250 mg	14	1	..	11.32	12.43	^a APO- Clarithromycin ^a Chem mart Clarithromycin ^a Clarac ^a Clarihexal ^a Clarithro 250 ^a GenRx Clarithromycin ^a Kalixocin ^a Terry White Chemists Clarithromycin	TX CH GM SZ QA GX AF TW
				^B 1.50	12.82	12.43	^a Klacid	AB
<hr/>								
CLARITHROMYCIN								
<u>Restricted benefit</u>								
Bordetella pertussis;								
Atypical mycobacterial infections.								
9192T NP	Powder for oral liquid 250 mg per 5 mL, 50 mL	#1	#30.80	32.25	Klacid	AB
<hr/>								
ERYTHROMYCIN								
1404X NP	Capsule 250 mg	25	1	..	10.79	11.90	^a Mayne Pharma Erythromycin	YT
				^B 2.91	13.70	11.90	^a Eryc	YN

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer	
ERYTHROMYCIN ETHYL SUCCINATE									
2424N NP	Powder for oral liquid 200 mg (base) per 5 mL, 100 mL	‡1	1	..	#14.65	16.10	^a	E-Mycin 200	AF
				^B 2.71	#17.36	16.10	^a	E.E.S. 200	LM
2428T NP	Powder for oral liquid 400 mg (base) per 5 mL, 100 mL	‡1	1	..	#16.16	17.61	^a	E-Mycin 400	AF
				^B 2.73	#18.89	17.61	^a	E.E.S. Granules	LM
2750R NP	Tablet 400 mg (base)	25	1	..	10.79	11.90	^a	E-Mycin	AF
				^B 2.66	13.45	11.90	^a	E.E.S. 400 Filmtab	LM
ERYTHROMYCIN LACTOBIONATE									
1397M NP	Powder for I.V. infusion 1 g (base)	5	*98.72	35.40		Erythrocin-I.V.	LM
ROXITHROMYCIN									
1760P NP	Tablet 150 mg	10	1	..	9.86	10.97	^a	APO-Roxithromycin	TX
							^a	Biaxsig	AV
							^a	Chem mart	CH
							^a	Roxithromycin	
							^a	Roxar 150	QA
							^a	Roximycin	AF
							^a	Roxithromycin-GA	GM
							^a	Roxithromycin-PS	FZ
							^a	Roxithromycin	SZ
							^a	Sandoz	
							^a	Terry White	TW
								Chemists	
				^B 2.61	12.47	10.97	^a	Roxithromycin	
							^a	Rulide	SW
8016X NP	Tablet 300 mg	5	1	..	9.86	10.97	^a	APO-Roxithromycin	TX
							^a	Biaxsig	AV
							^a	Chem mart	CH
							^a	Roxithromycin	
							^a	Roxar 300	QA
							^a	Roximycin	AF
							^a	Roxithromycin-GA	GM
							^a	Roxithromycin-PS	FZ
							^a	Roxithromycin	SZ
							^a	Sandoz	
							^a	Terry White	TW
								Chemists	
				^B 2.61	12.47	10.97	^a	Roxithromycin	
							^a	Rulide	SW
8129W NP	Tablet for oral suspension 50 mg	10	1	..	12.99	14.10		Rulide D	SW

Lincosamides

CLINDAMYCIN

Restricted benefit

Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin.

3138E NP,MW	Capsule 150 mg	24	19.85	20.96	^a	Cleocin	FZ
				^B 1.37	21.22	20.96	^a	Dalacin C	PF

Antiinfectives for systemic use

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer	
LINCOMYCIN								
2530E NP,MW	Injection 600 mg in 2 mL	5	33.84	34.95	Lincocin	PF

Aminoglycoside antibacterials

Other aminoglycosides

GENTAMICIN SULFATE								
2824P NP	Injection 80 mg (base) in 2 mL	10	1	..	19.77	20.88	Pfizer Australia Pty Ltd	PF

TOBRAMYCIN

Authority required (STREAMLINED)

3842

Management of a proven *Pseudomonas aeruginosa* infection in a patient with cystic fibrosis.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Special Pricing Arrangements apply.

5442K	Solution for inhalation 300 mg in 5 mL	56	2	..	2137.46	35.40	Tobi	NV
-------	--	----	---	----	---------	-------	------	----

TOBRAMYCIN SULFATE

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;

Septicaemia, suspected;

Septicaemia, proven.

1356J NP	Injection 80 mg (base) in 2 mL	10	1	..	*65.12	35.40	Hospira Pty Limited	HH
8872Y NP	Injection 80 mg (base) in 2 mL (without preservative)	10	1	..	*65.12	35.40	Pfizer Australia Pty Ltd	PF

TOBRAMYCIN SULFATE

Restricted benefit

Systemic treatment of *Pseudomonas aeruginosa* infection in a patient with cystic fibrosis.

9480Y NP	Injection 500 mg (base) in 5 mL (without preservative)	10	1	..	357.47	35.40	Tobra-Day	PL
-------------	--	----	---	----	--------	-------	-----------	----

Quinolone antibacterials

Fluoroquinolones

CIPROFLOXACIN

Authority required

Respiratory tract infection proven or suspected to be caused by *Pseudomonas aeruginosa* in severely immunocompromised patients;

Bacterial gastroenteritis in severely immunocompromised patients;

Treatment of infections proven to be due to *Pseudomonas aeruginosa* or other gram-negative bacteria resistant to all other oral antimicrobials;

Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials;

Gonorrhoea.

1208N NP	Tablet 250 mg	14	17.33	18.44	^a C-Flox 250	AL
							^a Cifran	RA
							^a Ciprofloxacin-DRLA	RZ
							^a Ciprofloxacin Sandoz	SZ
							^a Ciprol 250	QA
							^a GenRx	GX

NP

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							Ciprofloxacin
				^B 0.79	18.12	18.44	^a Profloxin HX
							^a Ciproxin 250 BN
<hr/>							
CIPROFLOXACIN							
<u>Authority required</u>							
Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients;							
Bacterial gastroenteritis in severely immunocompromised patients;							
Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials;							
Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials.							
1209P NP	Tablet 500 mg	14	27.66	28.77	^a C-Flox 500 AL
							^a Cifran RA
							^a Ciprofloxacin 500 CR
							^a Ciprofloxacin-BW GQ
							^a Ciprofloxacin-DRLA RZ
							^a Ciprofloxacin-GA GM
							^a Ciprofloxacin-PS FZ
							^a Ciprofloxacin SZ
							^a Sandoz
							^a Ciprol 500 QA
							^a GenRx GX
							^a Ciprofloxacin
				^B 0.79	28.45	28.77	^a Loxip 500 DO
							^a Ciproxin 500 BN
1210Q NP	Tablet 750 mg	14	38.38	35.40	^a C-Flox 750 AL
							^a Cifran RA
							^a Ciprofloxacin 750 CR
							^a Ciprofloxacin-BW GQ
							^a Ciprofloxacin-DRLA RZ
							^a Ciprofloxacin-GA GM
							^a Ciprofloxacin-PS FZ
							^a Ciprofloxacin SZ
							^a Sandoz
							^a Ciprol 750 QA
							^a GenRx GX
							^a Ciprofloxacin
				^B 0.78	39.16	35.40	^a Loxip 750 DO
							^a Ciproxin 750 BN
<hr/>							
NORFLOXACIN							
<u>Authority required</u>							
Acute bacterial enterocolitis;							
Complicated urinary tract infection.							
3010K NP	Tablet 400 mg	14	1	..	13.85	14.96	^a Chem mart CH
							^a Norfloxacin
							^a GenRx Norfloxacin GX
							^a Norfloxacin-GA GM
							^a Norfloxacin-PS FZ
							^a Norfloxacin Sandoz SZ
							^a Nufloxib AF

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Roxin QA
							^a Terry White Chemists TW
							Norfloxacina
				^B 3.91	17.76	14.96	^a Noroxin MK

Other antibacterials

Glycopeptide antibacterials

VANCOMYCIN

Restricted benefit

Prophylaxis of endocarditis in patients hypersensitive to penicillin.

2269K	Powder for injection 1 g (as hydrochloride) (1,000,000 i.u. vancomycin activity)	1	16.62	17.73	^a Hospira Pty Limited HH
							^a Vancomycin Alphapharm AF
							^a Vancomycin Sandoz SZ
							^a Vycin IV WQ
3130R	Powder for injection 500 mg (as hydrochloride) (500,000 i.u. vancomycin activity)	2	*16.62	17.73	^a Hospira Pty Limited HH
							^a Vancocin CP AS
							^a Vancomycin Alphapharm AF
							^a Vancomycin Sandoz SZ
							^a Vycin IV WQ

VANCOMYCIN

Restricted benefit

Endophthalmitis;

Use initiated in a hospital for infections where vancomycin is an appropriate antibiotic.

2270L	Powder for injection 1 g (as hydrochloride) (1,000,000 i.u. vancomycin activity)	3	*36.82	35.40	^a Hospira Pty Limited HH
							^a Vancomycin Alphapharm AF
							^a Vancomycin Sandoz SZ
							^a Vycin IV WQ
3131T	Powder for injection 500 mg (as hydrochloride) (500,000 i.u. vancomycin activity)	5	*31.77	32.88	^a Hospira Pty Limited HH
							^a Vancocin CP AS
							^a Vancomycin Alphapharm AF
							^a Vancomycin Sandoz SZ
							^a Vycin IV WQ

Steroid antibacterials

FUSIDIC ACID

Restricted benefit

For use in combination with another antibiotic in the treatment of proven serious staphylococcal infections.

2312Q	Tablet (sodium salt) 250 mg	36	1	..	90.99	35.40	Fucidin CS
-------	-----------------------------	----	---	----	-------	-------	------------

Imidazole derivatives

METRONIDAZOLE

1636D NP	Tablet 200 mg	21	1	..	7.98	9.09	^a Metrogl 200 AF
-------------	---------------	----	---	----	------	------	-----------------------------

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
						^a	Metronide 200	AV
				^B 2.30	10.28	9.09	^a Flagyl	SW
1642K NP	Suppositories 500 mg, 10	‡1	23.26	24.37	Flagyl	SW
<hr/>								
METRONIDAZOLE								
<u>Restricted benefit</u>								
Treatment of anaerobic infections.								
1621H NP	Tablet 400 mg	21	1	..	9.95	11.06	^a Metrogyl 400	AF
				^B 2.30	12.25	11.06	^a Metronide 400	AV
						^a	Flagyl	SW
<hr/>								
METRONIDAZOLE								
<u>Restricted benefit</u>								
Prophylaxis in large bowel surgery;								
Treatment, in a hospital, of acute anaerobic sepsis.								
<u>Note</u>								
For item codes 1638F and 1821W, pharmaceutical benefits that have the form I.V. infusion 500 mg in 100 mL are equivalent for the purposes of substitution.								
1638F NP	I.V. infusion 500 mg in 100 mL	5	1	..	*30.77	31.88	^a Baxter Healthcare Pty Ltd	BX
1821W NP	I.V. infusion 500 mg in 100 mL	5	1	..	*30.89	32.00	^a DBL Metronidazole Intravenous Infusion	HH
<hr/>								
METRONIDAZOLE BENZOATE								
1630T NP	Oral suspension 320 mg per 5 mL (equivalent to 200 mg metronidazole in 5 mL), 100 mL	‡1	18.92	20.03	Flagyl S	SW
<hr/>								
TINIDAZOLE								
1465D NP	Tablet 500 mg	4	10.89	12.00	^a Simplotan	FZ
				^B 2.42	13.31	12.00	^a Fasigyn	PF

Nitrofurantoin derivatives

NITROFURANTOIN

Caution

Nitrofurantoin may cause peripheral neuritis and severe pulmonary reactions.

1692C NP,MW	Capsule 50 mg	30	1	..	20.48	21.59	Macrochantin	PF
1693D NP,MW	Capsule 100 mg	30	1	..	26.36	27.47	Macrochantin	PF

Other antibacterials

HEXAMINE HIPPURATE

3124K NP	Tablet 1 g	100	5	..	43.35	35.40	Hiprex	IA
-------------	------------	-----	---	----	-------	-------	--------	----

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
Antimycotics for systemic use							

Antimycotics for systemic use

Imidazole derivatives

KETOCONAZOLE

Authority required (STREAMLINED)

3606

Symptomatic genital candidiasis recurring after treatment of at least 2 episodes with topical therapy.

Caution

Hepatotoxicity has been reported with ketoconazole.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1573T NP	Tablet 200 mg	10	19.89	21.00	Nizoral	JC
-------------	---------------	----	----	----	-------	-------	---------	----

KETOCONAZOLE

Authority required (STREAMLINED)

3604

Oral candidiasis in severely immunocompromised persons where topical therapy has failed;

3605

Systemic or deep mycoses where other forms of therapy have failed.

Caution

Hepatotoxicity has been reported with ketoconazole.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1572R NP	Tablet 200 mg	30	5	..	42.27	35.40	Nizoral	JC
-------------	---------------	----	---	----	-------	-------	---------	----

Triazole derivatives

FLUCONAZOLE

Authority required (STREAMLINED)

3615

Treatment of cryptococcal meningitis;

3616

Maintenance therapy in patients with cryptococcal meningitis and immunosuppression;

3613

Treatment of oropharyngeal candidiasis in immunosuppressed patients;

3614

Treatment of oesophageal candidiasis in immunosuppressed patients;

3617

Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients;

3618

Treatment of serious and life-threatening candida infections.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1471K NP	Capsule 50 mg	28	5	..	41.51	35.40	^a Diflucan	PF
							^a Dizole 50	AF
							^a Fluconazole Sandoz	SZ
							^a Ozole	RA

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
1472L NP	Capsule 100 mg	28	5	..	71.85	35.40	^a Diflucan	PF
							^a Dizole 100	AF
							^a Fluconazole Sandoz	SZ
							^a Ozole	RA
1473M NP	Solution for I.V. infusion 100 mg in 50 mL	7	*117.33	35.40	^a Diflucan	PF
							^a Fluconazole-Claris	AE
							^a Fluconazole Hexal	HX
							^a Fluconazole Sandoz	SZ
1474N NP	Solution for I.V. infusion 200 mg in 100 mL	7	*214.07	35.40	^a Baxter Healthcare Pty Ltd	BX
							^a Diflucan	PF
							^a Fluconazole-Claris	AE
							^a Fluconazole Hexal	HX
							^a Fluconazole Sandoz	SZ
1475P NP	Capsule 200 mg	28	5	..	133.79	35.40	^a APO-Fluconazole	TX
							^a Diflucan	PF
							^a Dizole 200	AF
							^a Fluconazole Sandoz	SZ
							^a Fluzole 200	QA
							^a Ozole	RA
1757L NP	Solution for I.V. infusion 400 mg in 200 mL	1	53.63	35.40	Baxter Healthcare Pty Ltd	BX

FLUCONAZOLE

Authority required

Treatment of cryptococcal meningitis in a patient unable to take a solid dose form of fluconazole;

Maintenance therapy in a patient with cryptococcal meningitis and immunosuppression unable to take a solid dose form of fluconazole;

Treatment of oropharyngeal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole;

Treatment of oesophageal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole;

Prophylaxis of oropharyngeal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole;

Treatment of serious and life-threatening candida infections in a patient unable to take a solid dose form of fluconazole.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

5446P NP	Powder for oral suspension 50 mg in 5 mL, 35 mL	1	#57.98	35.40	Diflucan	PF
-------------	--	---	----	----	--------	-------	----------	----

ITRACONAZOLE

Authority required (STREAMLINED)

3607

Systemic aspergillosis;

3608

Systemic sporotrichosis;

3609

Systemic histoplasmosis;

3610

Treatment and maintenance therapy in patients with AIDS who have disseminated pulmonary histoplasmosis infection;

3612

Treatment and maintenance therapy in patients with AIDS who have chronic pulmonary histoplasmosis infection;

3613

Treatment of oropharyngeal candidiasis in immunosuppressed patients;

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
3614								
Treatment of oesophageal candidiasis in immunosuppressed patients.								
Note								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8196J NP	Capsule 100 mg	60	5	..	246.89	35.40	Sporanox	JC
POSACONAZOLE								
Authority required								
Treatment of invasive aspergillosis in patients intolerant to, or with disease refractory to, alternative therapy;								
Treatment of fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis and mycetoma in patients intolerant to, or with disease refractory to, alternative therapy.								
Authority required								
Prophylaxis of invasive fungal infections, including both yeasts and moulds, in a patient who is at high risk of developing these infections, defined as follows:								
(1) Neutropenia								
Patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome.								
Treatment should continue until recovery of the neutrophil count to at least 500 cells per cubic millimetre.								
Patients who have had a previous invasive fungal infection should have secondary prophylaxis during subsequent episodes of neutropenia.								
(2) Graft versus host disease (GVHD)								
Patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant.								
No more than 6 months therapy per episode will be PBS-subsidised.								
Note								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
Note								
Application for an increased maximum quantity to allow for up to 1 month's treatment and repeats sufficient for up to 6 months' treatment may be authorised.								
9360P NP	Oral suspension 40 mg per mL, 105 mL	1	733.36	35.40	Noxafil	MK
VORICONAZOLE								
Authority required								
For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients;								
For the treatment and maintenance therapy of serious fungal infections caused by Scedosporium species or Fusarium species;								
For the treatment and maintenance therapy of serious Candida infections where:								
(a) the causative species is not susceptible to fluconazole; or								
(b) treatment with fluconazole has failed; or								
(c) treatment with fluconazole is not tolerated;								
For the treatment and maintenance therapy of other serious invasive mycosis.								
Note								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
9363T NP	Tablet 50 mg	56	2	..	700.97	35.40	Vfend	PF
9364W NP	Tablet 200 mg	56	2	..	2631.18	35.40	Vfend	PF

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
VORICONAZOLE							
<u>Authority required</u>							
For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients;							
For the treatment and maintenance therapy of serious fungal infections caused by <i>Scedosporium</i> species or <i>Fusarium</i> species;							
For the treatment and maintenance therapy of serious <i>Candida</i> infections where:							
(a) the causative species is not susceptible to fluconazole; or							
(b) treatment with fluconazole has failed; or							
(c) treatment with fluconazole is not tolerated;							
For the treatment and maintenance therapy of other serious invasive mycosis.							
<u>Note</u>							
Shared Care Model:							
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
<u>Note</u>							
Application for an increased maximum quantity to allow for up to 1 month's treatment and repeats sufficient for up to 6 months' treatment may be authorised.							
9452L	Powder for oral suspension 40 mg per mL, 70 mL	1	#703.58	35.40	Vfend
NP							PF

Antimycobacterials

Drugs for treatment of tuberculosis

Hydrazides

ISONIAZID

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1554T NP	Tablet 100 mg	100	2	..	21.59	22.70	Fawns and McAllan Proprietary Limited	FM
-------------	---------------	-----	---	----	-------	-------	---	----

Drugs for treatment of lepra

Drugs for treatment of lepra

DAPSONE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1272Y NP	Tablet 100 mg	100	1	..	113.94	35.40	Link Medical Products Pty Ltd	LM
8801F NP	Tablet 25 mg	100	1	..	100.68	35.40	Link Medical Products Pty Ltd	LM

RIFAMPICIN

Authority required

Leprosy in adults.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1982H NP	Capsule 150 mg	100	49.98	35.40	Rimycin 150	AF
1983J NP	Capsule 300 mg	100	71.16	35.40	Rimycin 300	AF

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
RIFAMPICIN								
<u>Restricted benefit</u>								
Prophylaxis of meningococcal disease in close contacts and carriers;								
Prophylactic treatment of contacts of patients with Haemophilus influenzae type B.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1981G NP	Capsule 150 mg	10	44.99	35.40	Rimycin 150	AF
1984K NP	Capsule 300 mg	10	25.25	26.36	Rimycin 300	AF
8025J NP	Syrup 100 mg per 5 mL, 60 mL	‡1	28.67	29.78	Rifadin	SW

Antivirals for systemic use

Direct acting antivirals

Nucleosides and nucleotides excl. reverse transcriptase inhibitors

ACICLOVIR

Authority required (STREAMLINED)

3632

Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment.

Note

Aciclovir 200 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.

No applications for increased maximum quantities and/or repeats will be authorised.

Note

For item codes 1003T and 1555W, pharmaceutical benefits that have the form tablet 200 mg are equivalent for the purposes of substitution.

1003T NP	Tablet 200 mg	50	*66.50	35.40	^a Acihexal	SZ
							^a Acyclo-V 200	AF
							^a Lovir	GM
				^B 4.10	*70.60	35.40	^a Zovirax 200 mg	GK
1555W NP	Tablet 200 mg	50	66.48	35.40	^a GenRx Aciclovir	GX

ACICLOVIR

Authority required (STREAMLINED)

3633

Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.

Note

Aciclovir 200 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.

1007B NP	Tablet 200 mg	90	5	..	116.22	35.40	^a Aciclovir 200	CR
							^a Aciclovir GH	GQ
							^a Acihexal	SZ
							^a Acyclo-V 200	AF
							^a Chem mart Aciclovir	CH
							^a GenRx Aciclovir	GX
							^a Lovir	GM
							^a Ozvir	RA
							^a Terry White Chemists Aciclovir	TW

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				^B 3.06	119.28	35.40 ^a	Zovirax 200 mg GK

ACICLOVIR

Authority required (STREAMLINED)

3622

Treatment of patients with herpes zoster within 72 hours of the onset of the rash;

3631

Herpes zoster ophthalmicus.

Note

Aciclovir is effective only if commenced within 72 hours of onset of rash.

Aciclovir 800 mg is not PBS-subsidised for herpes simplex or chickenpox.

Note

No applications for repeats will be authorised.

1052J NP	Tablet 800 mg	35	139.42	35.40 ^a	Aciclovir 800 CR
						^a	Acihexal SZ
						^a	Acyclo-V 800 AF
						^a	GenRx Aciclovir GX
				^B 1.49	140.91	35.40 ^a	Zovirax 800 mg GK

ACICLOVIR

Authority required (STREAMLINED)

3630

Patients with advanced HIV disease (CD4 cell counts of less than 150 million per litre).

8234J NP	Tablet 800 mg	120	5	..	425.33	35.40 ^a	Acihexal SZ
						^a	Acyclo-V 800 AF

FAMCICLOVIR

Authority required (STREAMLINED)

3624

Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.

Note

Famciclovir 125 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.

8092X NP	Tablet 125 mg	40	1	..	131.98	35.40 ^a	APO-Famciclovir TX
						^a	Ezovir AF
						^a	Famvir NV
						^a	Favic 125 QA

FAMCICLOVIR

Authority required (STREAMLINED)

3624

Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.

Note

Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.

2274Q NP	Tablet 250 mg	20	1	..	131.98	35.40 ^a	APO-Famciclovir TX
						^a	Ezovir AF
						^a	Famciclovir Sandoz SZ

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							^a Famvir	NV
							^a Favic 250	QA
<hr/>								
FAMCICLOVIR								
<u>Authority required (STREAMLINED)</u>								
3622								
Treatment of patients with herpes zoster within 72 hours of the onset of the rash.								
<u>Note</u>								
Famciclovir is effective only if commenced within 72 hours of onset of rash.								
Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.								
<u>Note</u>								
No applications for repeats will be authorised.								
8002E NP	Tablet 250 mg	21	138.26	35.40	^a APO-Famciclovir	TX
							^a Ezovir	AF
							^a Famciclovir Sandoz	SZ
							^a Famvir	NV
							^a Favic 250	QA
<hr/>								
FAMCICLOVIR								
<u>Authority required (STREAMLINED)</u>								
3623								
Suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.								
<u>Note</u>								
Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.								
8217L NP	Tablet 250 mg	56	5	..	343.86	35.40	^a APO-Famciclovir	TX
							^a Ezovir	AF
							^a Famciclovir Sandoz	SZ
							^a Famvir	NV
							^a Favic 250	QA
<hr/>								
FAMCICLOVIR								
<u>Authority required (STREAMLINED)</u>								
3625								
Treatment of immunocompromised patients with herpes zoster within 72 hours of the onset of the rash.								
<u>Note</u>								
Famciclovir is effective only if commenced within 72 hours of onset of rash.								
Famciclovir 500 mg is not PBS-subsidised for chickenpox.								
Famciclovir 500 mg is not PBS-subsidised for herpes zoster, genital herpes or other herpes simplex infections in immunocompetent patients.								
<u>Note</u>								
No applications for repeats will be authorised.								
8897G NP	Tablet 500 mg	30	194.70	35.40	^a APO-Famciclovir	TX
							^a Chem mart Famciclovir	CH
							^a Famvir	NV
							^a Favic 500	QA
							^a Terry White Chemists	TW

FAMCICLOVIR

3626

Authority required (STREAMLINED)

3627

Authority required (STREAMLINED)

3628

3629

Note

Famciclovir 500 mg is not PBS-subsidised for chickenpox.

Famciclovir 500 mg is not PBS-subsidised for herpes zoster, genital herpes or other herpes simplex infections in immunocompetent patients.

VALACICLOVIR

Authority required (STREAMLINED)

3632

Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment.

Note

Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8133C NP	Tablet 500 mg (as hydrochloride)	20	*105.88	35.40	^a	APO-Valaciclovir	TX
							^a	Chem mart	CH
							^a	Valaciclovir	
							^a	Terry White	TW
								Chemists	
							^a	Valaciclovir	
							^a	Vaclovir	AF
							^a	Valaciclovir GA	GN
							^a	Valaciclovir Pfizer	FZ
							^a	Valaciclovir Sandoz	SZ
							^a	Valnir	QA
							^a	Valtrex	GK
							^a	Valvala	NV

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
							^a Zelitrex	GM

VALACICLOVIR

Authority required (STREAMLINED)

3624

Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.

Note

Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.

8134D NP	Tablet 500 mg (as hydrochloride)	30	5	..	155.53	35.40	^a APO-Valaciclovir	TX
							^a Chem mart	CH
							^a Valaciclovir	
							^a Shilova 500	DO
							^a Terry White	TW
							^a Chemists	
							^a Valaciclovir	
							^a Vaclovir	AF
							^a Valaciclovir Actavis	TA
							^a 500	
							^a Valaciclovir GA	GN
							^a Valaciclovir	GQ
							^a generichealth	
							^a Valaciclovir Pfizer	FZ
							^a Valaciclovir RBX	RA
							^a Valaciclovir Sandoz	SZ
							^a Valaciclovir SZ	HX
							^a Valacor 500	QR
							^a Valnir	QA
							^a Valtrex	GK
							^a Valvala	NV
							^a Zelitrex	GM

VALACICLOVIR

Authority required (STREAMLINED)

3623

Suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.

Note

Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.

5480K NP	Tablet 500 mg (as hydrochloride)	30	5	..	155.53	35.40	^a APO-Valaciclovir	TX
							^a Chem mart	CH
							^a Valaciclovir	
							^a Shilova 500	DO
							^a Terry White	TW
							^a Chemists	
							^a Valaciclovir	
							^a Vaclovir	AF
							^a Valaciclovir Actavis	TA
							^a 500	
							^a Valaciclovir GA	GN
							^a Valaciclovir	GQ
							^a generichealth	
							^a Valaciclovir Pfizer	FZ
							^a Valaciclovir RBX	RA

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
						^a	Valaciclovir SZ HX
						^a	Valacor 500 QR
						^a	Valnir QA
						^a	Valtrex GK
						^a	Zelitrex GM

VALACICLOVIR

Authority required (STREAMLINED)

3622

Treatment of patients with herpes zoster within 72 hours of the onset of the rash;

3631

Herpes zoster ophthalmicus.

Note

Valaciclovir is effective only if commenced within 72 hours of onset of rash.

Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.

Note

No applications for repeats will be authorised.

8064K NP	Tablet 500 mg (as hydrochloride)	42	214.16	35.40	^a	APO-Valaciclovir TX
							^a	Chem mart CH
							^a	Valaciclovir
							^a	Terry White TW
							^a	Chemists
							^a	Valaciclovir
							^a	Vaclovir AF
							^a	Valaciclovir Actavis TA
							^a	500
							^a	Valaciclovir GA GN
							^a	Valaciclovir GQ
							^a	generichealth
							^a	Valaciclovir Pfizer FZ
							^a	Valaciclovir RBX RA
							^a	Valaciclovir Sandoz SZ
							^a	Valacor 500 QR
							^a	Valnir QA
							^a	Valtrex GK
							^a	Valvala NV
							^a	Zelitrex GM

Vaccines

Bacterial vaccines

Pneumococcal vaccines

PNEUMOCOCCAL VACCINE, POLYVALENT

Restricted benefit

Splenectomised persons over 2 years of age;

Persons with Hodgkin's disease;

Persons at high risk of pneumococcal infections.

1903E NP	Injection 0.5 mL (23 valent)	1	46.23	35.40	Pneumovax 23 CS
-------------	------------------------------	---	----	----	-------	-------	-----------------

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
<i>Tetanus vaccines</i>							
DIPHTHERIA and TETANUS VACCINE, ADSORBED, DILUTED FOR ADULT USE							
<u>Note</u>							
For immunisation of adults and children aged greater than or equal to 8 years.							
8783G NP	Injection 0.5 mL in pre-filled syringe	5	75.44	35.40	ADT Booster CS

Antineoplastic and immunomodulating agents

Alkylating agents

CHLORAMBUCIL								
1163F	Tablet 2 mg	100	2	..	*138.08	35.40	Leukeran	AS

CYCLOPHOSPHAMIDE								
1266P	Tablet 50 mg	50	2	..	31.39	32.50	Cycloblastin	PF

MELPHALAN								
2547C	Tablet 2 mg	25	1	..	50.98	35.40	Alkeran	AS

	BUSULFAN							
1128J	Tablet 2 mg	100	86.36	35.40	Myleran	AS

CARMUSTINE

Glioblastoma multiforme, suspected or confirmed, at the time of initial surgery.

Carmustine is not PBS-subsidised for use in conjunction with PBS-subsidised temozolomide.

8898H	Implants 7.7 mg, 8	#1	17539.42	35.40	Gliadel	OA
-------	--------------------	----	----	----	----------	-------	---------	----

TEMOZOLOMIDE

Glioblastoma multiforme concomitantly with radiotherapy.

Temozolomide is not PBS-subsidised for use in conjunction with PBS-subsidised carmustine.

No applications for increased repeats will be authorised.

8819E	Capsule 5 mg	15	2	..	*176.20	35.40	a a a a	Astromide Orion Temozolomide Temizole 5	WQ ON QA
8820F	Capsule 20 mg	15	2	..	*478.18	35.40	a a a a	Astromide Orion Temozolomide Temizole 20	WQ ON QA
8821G	Capsule 100 mg	15	2	..	*2019.34	35.40	a a a a	Astromide Orion Temozolomide Temizole 100	WQ ON QA
9361Q	Capsule 140 mg	15	2	..	*2755.84	35.40	a a	Astromide Orion	WQ ON

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Temizole 140 QA
							^a Temodal MK
<hr/>							
TEMOZOLOMIDE							
Authority required							
Recurrence of anaplastic astrocytoma following standard therapy;							
Recurrence of glioblastoma multiforme following standard therapy;							
Glioblastoma multiforme following radiotherapy.							
8378Y	Capsule 5 mg	5	5	..	63.08	35.40	^a Astromide WQ ^a Orion ON Temozolomide
							^a Temizole 5 QA
							^a Temodal MK
8379B	Capsule 20 mg	5	5	..	172.81	35.40	^a Astromide WQ ^a Orion ON Temozolomide
							^a Temizole 20 QA
							^a Temodal MK
8380C	Capsule 100 mg	5	5	..	680.03	35.40	^a Astromide WQ ^a Orion ON Temozolomide
							^a Temizole 100 QA
							^a Temodal MK
8381D	Capsule 250 mg	5	5	..	1567.55	35.40	^a Astromide WQ ^a Orion ON Temozolomide
							^a Temizole 250 QA
							^a Temodal MK
9362R	Capsule 140 mg	5	5	..	935.35	35.40	^a Astromide WQ ^a Orion ON Temozolomide
							^a Temizole 140 QA
							^a Temodal MK

Antimetabolites

Folic acid analogues

METHOTREXATE							
1622J	Tablet 2.5 mg	30	5	..	13.22	14.33	^a Hospira Pty Limited HH ^a Methoblastin PF
2272N	Tablet 10 mg	15	3	..	21.94	23.05	Methoblastin PF
2396D	Injection 5 mg in 2 mL	5	30.29	31.40	Hospira Pty Limited HH

METHOTREXATE

Note

For item codes 2395C and 1818Q, pharmaceutical benefits that have the form injection 50 mg in 2 mL are equivalent for the purposes of substitution.

1818Q	Injection 50 mg in 2 mL	5	5	..	*29.77	30.88	^a Methaccord WQ
2395C	Injection 50 mg in 2 mL	5	5	..	29.74	30.85	^a Hospira Pty Limited HH ^a Pfizer Australia Pty Ltd PF

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

METHOTREXATE

Restricted benefit

For patients requiring doses greater than 20 mg per week.

1623K	Tablet 10 mg	50	2	..	45.38	35.40	Methoblastin	PF
-------	--------------	----	---	----	-------	-------	--------------	----

Purine analogues

FLUDARABINE PHOSPHATE

Authority required

B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.

Stage A progressive disease is defined by at least one of the following: persistent rise in lymphocyte count with doubling time less than 12 months; a downward trend in haemoglobin or platelets, or both; more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present; constitutional symptoms attributable to disease.

The diagnosis of chronic lymphocytic leukaemia (CLL) must have been established based on:
(a) a lymphocytosis, with more than 5,000 million lymphocytes per L in the peripheral blood; and
(b) a clonal population of B-cells (CD5/CD19) documented by flow cytometry.

9184J	Tablet 10 mg	20	5	..	936.80	35.40	Fludara	GZ
-------	--------------	----	---	----	--------	-------	---------	----

MERCAPTOPYRINE

1598D	Tablet 50 mg	100	2	..	*252.04	35.40	Purinethol	AS
-------	--------------	-----	---	----	---------	-------	------------	----

THIOGUANINE

1233X	Tablet 40 mg	25	1	..	198.76	35.40	Lanvis	AS
-------	--------------	----	---	----	--------	-------	--------	----

Pyrimidine analogues

CAPECITABINE

Authority required

Advanced breast cancer after failure of prior therapy which includes a taxane and an anthracycline;

Advanced breast cancer where therapy with a taxane and/or an anthracycline is contraindicated;

Advanced breast cancer in combination with docetaxel after failure of prior anthracycline-containing chemotherapy;

Treatment of advanced or metastatic colorectal cancer;

Adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour either as:

- (a) monotherapy; or
- (b) in combination with oxaliplatin;

Advanced (Stage III or IV) oesophago-gastric cancer, previously untreated, in combination with a cisplatin-based regimen, in a patient with a WHO performance status of 2 or less.

Note

In the adjuvant setting, the recommended treatment duration is 24 weeks.

Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.

Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.

8361C	Tablet 150 mg	60	2	..	124.03	35.40	Xeloda	RO
8362D	Tablet 500 mg	120	2	..	695.27	35.40	Xeloda	RO

Plant alkaloids and other natural products

Vinca alkaloids and analogues

VINORELBINE

Authority required

Locally advanced or metastatic non-small cell lung cancer.

9009E	Capsule 20 mg (as tartrate)	20	2	..	*1973.12	35.40	Navelbine	FB
9010F	Capsule 30 mg (as tartrate)	16	2	..	*2340.12	35.40	Navelbine	FB

Antineoplastic and immunomodulating agents

					Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium			Brand Name and Manufacturer	
<i>Podophyllotoxin derivatives</i>								
ETOPOSIDE								
1389D	Capsule 100 mg	10	390.83	35.40	Vepesid	BQ
1396L	Capsule 50 mg	20	445.04	35.40	Vepesid	BQ

Cytotoxic antibiotics and related substances

Anthracyclines and related substances

IDARUBICIN HYDROCHLORIDE

Restricted benefit

Acute myelogenous leukaemia.

2446R	Capsule 5 mg	3	*267.70	35.40	Zavedos	PF
2448W	Capsule 10 mg	3	*494.59	35.40	Zavedos	PF

Other antineoplastic agents

Protein kinase inhibitors

DASATINIB

Note

Any queries concerning the arrangements to prescribe dasatinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Applications for authority to prescribe dasatinib should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase who has failed an adequate trial of imatinib or nilotinib as first-line treatment.

Failure of an adequate trial of imatinib or nilotinib is defined as:

- (i) Lack of response to initial imatinib or nilotinib therapy, defined as either:
 - failure to achieve a haematological response after a minimum of 3 months therapy with imatinib or nilotinib for patients initially treated in chronic phase; or
 - failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib or nilotinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or
 - failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib or nilotinib; OR
- (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib or nilotinib therapy; OR
- (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing imatinib or nilotinib therapy; OR
- (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib or nilotinib for any phase of chronic myeloid leukaemia.

Accelerated phase is defined by the presence of 1 or more of the following:

- (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or
- (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or
- (3) Peripheral basophils greater than or equal to 20%; or
- (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or
- (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR

Blast crisis is defined as either:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

- (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or
(2) Extramedullary involvement other than spleen and liver; OR

(v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib or nilotinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia.

Patients should be commenced on a dose of dasatinib of at least 100 mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% within 18 months and thereafter at 12 monthly intervals.

Applications for authorisation must be in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Chronic Myeloid Leukaemia - Second and Third Line - Supporting Information Form; and
- (c) a signed patient acknowledgement; and
- (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 0.1% on the international scale. (The date of the relevant pathology report needs to be provided); and
- (e) where there has been a loss of response to imatinib or nilotinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement.

Authority required

Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18 months and thereafter at 12 monthly intervals.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Chronic Myeloid Leukaemia - Second and Third Line - Application Form for continuing treatment; and
- (3) demonstration of continued response to treatment as evidenced by either:
 - (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided; or
 - (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided.

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of tyrosine kinase inhibitors (TKI) agents for all phases of chronic myeloid leukaemia. Where the term TKI agent appears in the following notes and restrictions it refers to dasatinib or nilotinib. Imatinib mesylate is not approved for use in second or third line treatment.

Patients are eligible for PBS-subsidised treatment with only one of dasatinib or nilotinib at any one time and must not be receiving concomitant interferon alfa therapy. Eligible patients may only swap between these agents if they have not failed prior PBS-subsidised treatment with that agent.

Nilotinib is not approved for patients in blast crisis.

1. Initial second line treatment

From 1 April 2012, under the PBS, a patient will be able to be prescribed either dasatinib or nilotinib within the initial 18 month treatment period as second-line therapy, as long as only one agent is approved at a time and providing the patient did not fail that drug as first-line therapy.

During the initial 18 month treatment period, switching between approved second-line agents may only occur for reasons of intolerance, not failure of response.

2. Initial third line treatment

Third-line treatment with a TKI can only be approved when imatinib is used for first-line treatment. Patients will only be approved for PBS-subsidised treatment with one third-line agent.

From 1 April 2012, under the PBS, a patient will be able to be prescribed either dasatinib or nilotinib providing the patient did not fail that drug as first or second line therapy and for nilotinib the patient is not in blast crisis.

3. Continuing treatment for second and third line treatment

All continuing applications are to be written and must include a pathology report demonstrating the patient has responded to PBS-subsidised treatment as follows:

- (i) within 18 months of the commencement of treatment, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and
- (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.

During second line continuing treatment beyond the initial 18 month treatment period, switching between approved second line TKI agents may only occur for reason of intolerance. Where there is failure of response, switching may only occur through application for prescription of a third line agent.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
<p>4. Authority approval requirements.</p> <p>Response criteria to initial treatment with dasatinib or nilotinib:</p> <p>For the purposes of assessing response to PBS-subsidised treatment with dasatinib or nilotinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted within 18 months of the commencement of treatment with dasatinib or nilotinib (patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% is demonstrable by 18 months are eligible to receive continuing treatment with that agent).</p> <p>5. Definitions of response.</p> <p>A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.</p> <p>A peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.</p> <p>6. Definitions of loss of response.</p> <p>Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing tyrosine kinase inhibitor (TKI) therapy.</p> <p>Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing tyrosine kinase inhibitor therapy.</p>								
2478K	Tablet 20 mg	60	5	..	3095.55	35.40	Sprycel	BQ
2482P	Tablet 50 mg	60	5	..	5003.90	35.40	Sprycel	BQ
2485T	Tablet 70 mg	60	5	..	6160.29	35.40	Sprycel	BQ
9342Q	Tablet 100 mg	30	5	..	5003.90	35.40	Sprycel	BQ

DASATINIB

Note

Any queries concerning the arrangements to prescribe dasatinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Applications for authority to prescribe dasatinib should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.

Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.

Patients should be commenced on a dose of dasatinib of at least 100 mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to dasatinib therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and
- (4) a signed patient acknowledgement form.

Authority required

Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.

Applications for authorisation must be in writing and must include:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty	Safety Net		
					\$	\$		
	<p>(1) a completed authority prescription form; and</p> <p>(2) demonstration of continued response to treatment as evidenced by either:</p> <p>(a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or</p> <p>(b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided.</p> <p>Note</p> <p>The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of tyrosine kinase inhibitors (TKI) agents for the chronic phase of chronic myeloid leukaemia. Where the term TKI agent appears in the following notes and restrictions it refers to imatinib mesylate, dasatinib or nilotinib.</p> <p>Patients are eligible for PBS-subsidised treatment with only one TKI agent at any one time and must not be receiving concomitant interferon alfa therapy. Eligible patients may only swap between TKI agents if they have not failed prior PBS-subsidised treatment with that agent.</p> <p>1. Initial treatment - imatinib mesylate, dasatinib and nilotinib</p> <p>From 1 April 2012, under the PBS, a patient will be able to be prescribed any of imatinib mesylate, dasatinib or nilotinib within the initial 18 month treatment period, as long as only one agent is used at a time and providing the patient has not failed to respond to any one of these TKIs.</p> <p>During the initial 18 month treatment period, switching between approved first-line agents may only occur for reasons of intolerance, not failure of response.</p> <p>2. Continuing treatment with imatinib mesylate - first-line</p> <p>First continuing applications are to be written and must include a pathology report demonstrating the patient has responded to the initial course of treatment.</p> <p>Second and subsequent authority applications for continuing therapy with imatinib mesylate may be made on the telephone by contacting Medicare Australia on 1800 700 720 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Patients must maintain a major cytogenetic response or have a peripheral blood BCR-ABL of less than 1% to receive continuing therapy.</p> <p>3. Continuing treatment with dasatinib or nilotinib - first-line</p> <p>All continuing applications are to be written and must include a pathology report demonstrating the patient has responded to PBS-subsidised treatment as follows:</p> <p>(i) within 18 months of the commencement of treatment, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and</p> <p>(ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.</p> <p>4. For imatinib mesylate, dasatinib and nilotinib</p> <p>During continuing therapy beyond the initial 18 month treatment period, switching between approved first-line agents may only occur for reason of intolerance. Where there is failure of response, switching may only occur through application for prescription of second-line agents.</p> <p>Where a patient has previously received PBS-subsidised treatment with imatinib mesylate, dasatinib or nilotinib no approval will be granted for PBS-subsidised re-treatment in the chronic phase of chronic myeloid leukaemia, where that patient has at any time failed to meet the response criteria whilst on that TKI agent.</p> <p>5. Authority approval requirements.</p> <p>Response criteria to initial treatment with imatinib mesylate, dasatinib or nilotinib:</p> <p>For the purposes of assessing response to PBS-subsidised treatment with imatinib mesylate, dasatinib or nilotinib either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted within 18 months of the commencement of treatment with imatinib mesylate, dasatinib or nilotinib (patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% is demonstrable by 18 months are eligible to receive continuing treatment with that agent).</p> <p>6. Definitions of response.</p> <p>A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.</p> <p>A peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.</p> <p>7. Definitions of loss of response.</p> <p>Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing tyrosine kinase inhibitor (TKI) therapy.</p> <p>Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing tyrosine kinase inhibitor therapy.</p>							
1354G	Tablet 20 mg	60	5	..	3095.55	35.40	Sprycel BQ	

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
1381Q	Tablet 50 mg	60	5	..	5003.90	35.40	Sprycel BQ
1415L	Tablet 70 mg	60	5	..	6160.29	35.40	Sprycel BQ
1416M	Tablet 100 mg	30	5	..	5003.90	35.40	Sprycel BQ

DASATINIB

Note

Any queries concerning the arrangements to prescribe dasatinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Applications for authority to prescribe dasatinib should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.

Failure of treatment is defined as either:

- (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;
- (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;
- (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.

Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.

The first authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and
- (c) a signed patient acknowledgement; and
- (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided.

Authority required

Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1 December 2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.

Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.

The first authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and
- (c) a signed patient acknowledgement; and
- (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided.

Authority required

Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.

Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
<u>Note</u> Dasatinib will only be subsidised for patients with acute lymphoblastic leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate and who are not appropriate for an allogeneic haemopoietic stem cell transplant.							
<u>Note</u> No applications for increased repeats will be authorised.							
9125G	Tablet 20 mg	60	2	..	3095.55	35.40	Sprycel BQ
9126H	Tablet 50 mg	60	2	..	5003.90	35.40	Sprycel BQ
9127J	Tablet 70 mg	60	2	..	6160.29	35.40	Sprycel BQ
9343R	Tablet 100 mg	30	2	..	5003.90	35.40	Sprycel BQ

ERLOTINIB

Authority required

Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer with a WHO performance status of 3 or less, after prior treatment with platinum-based chemotherapy, where:

- (1) (a) disease progression has occurred following treatment with docetaxel or pemetrexed; or
- (b) treatment with docetaxel and pemetrexed is either contraindicated or cannot be tolerated; and
- (2) further cytotoxic chemotherapy is not appropriate.

Authority required

Continuing PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer who has previously been issued with an authority prescription for this drug and who does not have progressive disease.

Note

Special Pricing Arrangements apply.

9166K	Tablet 25 mg (as hydrochloride)	30	3	..	794.29	35.40	Tarceva RO
9167L	Tablet 100 mg (as hydrochloride)	30	3	..	2703.44	35.40	Tarceva RO
9168M	Tablet 150 mg (as hydrochloride)	30	3	..	3309.76	35.40	Tarceva RO

GEFITINIB

Authority required

Initial PBS-subsidised treatment, as monotherapy, of locally advanced or metastatic non-small cell lung cancer in patients with a WHO performance status of 2 or less, where:

- (1) disease progression has occurred following treatment with at least 1 chemotherapy agent; and
- (2) there is evidence that the patient has an activating mutation(s) of the epidermal growth factor receptor (EGFR) gene in tumour material.

Authority required

Continuing PBS-subsidised treatment, as monotherapy, of locally advanced or metastatic non-small cell lung cancer in patients with a WHO performance status of 2 or less, where the patient has previously been issued with an authority prescription for gefitinib.

8769M	Tablet 250 mg	30	3	..	3851.46	35.40	Iressa AP
-------	---------------	----	---	----	---------	-------	-----------

IMATINIB

Note

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

For the following diseases, written authority is required at initiation and for continuation:

Dermatofibrosarcoma protuberans;
Hypereosinophilic syndrome;
Chronic eosinophilic leukaemia;
Myelodysplastic or myeloproliferative disorder;
Aggressive systemic mastocytosis with eosinophilia.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Authority required

Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.

Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.

Patients should be commenced on a dose of imatinib mesylate of 400 mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to imatinib mesylate therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and
- (4) a signed patient acknowledgement form.

Authority required

Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with imatinib mesylate for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.

First continuing applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) demonstration of a response to treatment as evidenced by either:
 - (a) major cytogenetic response [see Note explaining requirements]; or
 - (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements].

Second and subsequent authority applications for continuing therapy with imatinib mesylate may be made on the telephone by contacting Medicare Australia on 1800 700 720 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Patients must maintain a major cytogenetic response or have a peripheral blood BCR-ABL of less than 1% to receive continuing therapy.

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of tyrosine kinase inhibitors (TKI) agents for the chronic phase of chronic myeloid leukaemia. Where the term TKI agent appears in the following notes and restrictions it refers to imatinib mesylate, dasatinib or nilotinib.

Patients are eligible for PBS-subsidised treatment with only one TKI agent at any one time and must not be receiving concomitant interferon alfa therapy. Eligible patients may only swap between TKI agents if they have not failed prior PBS-subsidised treatment with that agent.

1. Initial treatment - imatinib mesylate, dasatinib and nilotinib

From 1 April 2012, under the PBS, a patient will be able to be prescribed any of imatinib mesylate, dasatinib or nilotinib within the initial 18 month treatment period, as long as only one agent is used at a time and providing the patient has not failed to respond to any one of these TKIs.

During the initial 18 month treatment period, switching between approved first-line agents may only occur for reasons of intolerance, not failure of response.

2. Continuing treatment with imatinib mesylate - first-line

First continuing applications are to be written and must include a pathology report demonstrating the patient has responded to the initial course of treatment.

Second and subsequent authority applications for continuing therapy with imatinib mesylate may be made on the telephone by contacting Medicare Australia on 1800 700 720 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Patients must maintain a major cytogenetic response or have a peripheral blood BCR-ABL of less than 1% to receive continuing therapy.

3. Continuing treatment with dasatinib or nilotinib - first-line

All continuing applications are to be written and must include a pathology report demonstrating the patient has responded to PBS-subsidised treatment as follows:

- (i) within 18 months of the commencement of treatment, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and
- (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.

4. For imatinib mesylate, dasatinib and nilotinib

During continuing therapy beyond the initial 18 month treatment period, switching between approved first-line agents may only occur for reason of intolerance. Where there is failure of response, switching may only occur through application for prescription of second-line agents.

Where a patient has previously received PBS-subsidised treatment with imatinib mesylate, dasatinib or nilotinib no approval will be granted for PBS-

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	subsidised re-treatment in the chronic phase of chronic myeloid leukaemia, where that patient has at any time failed to meet the response criteria whilst on that TKI agent.						
	<p>5. Authority approval requirements.</p> <p>Response criteria to initial treatment with imatinib mesylate, dasatinib or nilotinib:</p> <p>For the purposes of assessing response to PBS-subsidised treatment with imatinib mesylate, dasatinib or nilotinib either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted within 18 months of the commencement of treatment with imatinib mesylate, dasatinib or nilotinib (patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% is demonstrable by 18 months are eligible to receive continuing treatment with that agent).</p> <p>6. Definitions of response.</p> <p>A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.</p> <p>A peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.</p> <p>7. Definitions of loss of response.</p> <p>Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing tyrosine kinase inhibitor (TKI) therapy.</p> <p>Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing tyrosine kinase inhibitor therapy.</p>						
9113P	Tablet 100 mg (as mesylate)	60	5	..	2005.08	35.40	Glivec NV
9114Q	Tablet 400 mg (as mesylate)	30	5	..	3863.70	35.40	Glivec NV

IMATINIB

Note

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

For the following diseases, written authority is required at initiation and for continuation:

Dermatofibrosarcoma protuberans;
Hypereosinophilic syndrome;
Chronic eosinophilic leukaemia;
Myelodysplastic or myeloproliferative disorder;
Aggressive systemic mastocytosis with eosinophilia.

Authority required

Treatment of patients in the accelerated phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to the accelerated phase is defined by the presence of 1 or more of the following:

- (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or
- (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or
- (3) Peripheral basophils greater than or equal to 20%; or
- (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or
- (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).

Applications for authorisation must be in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
(c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criteria (1), (2), (3) and (5) above, or details of the dates of assessments in the case of progressive splenomegaly.							
<u>Authority required</u>							
Treatment of patients in the blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to myeloid blast crisis is defined as either:							
(1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or							
(2) Extramedullary involvement other than spleen and liver.							
Applications for authorisation must be in writing and must include:							
(a) a completed authority prescription form; and							
(b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and							
(c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criterion (1) above, or details of the date of assessment in the case of extramedullary involvement.							
<u>Authority required</u>							
Continuing treatment of patients with chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, where the patient has previously received PBS-subsidised treatment with imatinib mesylate of:							
(i) the accelerated phase of chronic myeloid leukaemia; or							
(ii) the blast phase of chronic myeloid leukaemia.							
<u>Note</u>							
No applications for increased repeats will be authorised.							
9115R	Tablet 100 mg (as mesylate)	60	2	..	2005.08	35.40	Glivec NV
9116T	Tablet 400 mg (as mesylate)	30	2	..	3863.70	35.40	Glivec NV

IMATINIB

Note

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

For the following diseases, written authority is required at initiation and for continuation:

Dermatofibrosarcoma protuberans;
Hypereosinophilic syndrome;
Chronic eosinophilic leukaemia;
Myelodysplastic or myeloproliferative disorder;
Aggressive systemic mastocytosis with eosinophilia.

Authority required

Initial treatment in combination with chemotherapy as induction or consolidation of a newly diagnosed patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.

The first authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and
- (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and
- (d) a signed patient acknowledgement.

Authority required

Initial treatment of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript BCR-ABL who was previously treated with imatinib mesylate under the Imatinib Compassionate Program and who meets all the PBS criteria.

The first authority application must be made in writing and must include:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	(a) a completed authority prescription form; and (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and (d) a signed patient acknowledgement.						
	<u>Authority required</u> Continuing treatment in combination with chemotherapy as maintenance of first complete remission of patients with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.						
	Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).						
	Imatinib mesylate is available with a lifetime maximum of 24 months for continuing treatment with imatinib mesylate therapy for patients with acute lymphoblastic leukaemia reimbursed through the PBS.						
	Any queries concerning the arrangements to prescribe imatinib mesylate beyond 24 months may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).						
	<u>Note</u> Allogeneic stem cell transplantation is the preferred therapy for eligible patients achieving a complete remission of Philadelphia positive acute lymphoblastic leukaemia.						
	<u>Note</u> No applications for increased repeats will be authorised.						
9123E	Tablet 100 mg (as mesylate)	60	2	..	2005.08	35.40	Glivec NV
9124F	Tablet 400 mg (as mesylate)	30	2	..	3863.70	35.40	Glivec NV

IMATINIB

Note

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

Medicare Australia
 Prior Written Approval of Specialised Drugs
 Reply Paid 9826
 GPO Box 9826
 HOBART TAS 7001

For the following diseases, written authority is required at initiation and for continuation:

Dermatofibrosarcoma protuberans;
 Hypereosinophilic syndrome;
 Chronic eosinophilic leukaemia;
 Myelodysplastic or myeloproliferative disorder;
 Aggressive systemic mastocytosis with eosinophilia.

Authority required

Initial PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans.

Maximum dose: 800 mg per day.

- (1) Where the application for authority to prescribe is being sought on the basis of unresectable tumour, written evidence in support of that claim must be provided; and
- (2) Where the application for authority to prescribe is being sought on the basis of locally recurrent disease, the site of the local recurrence must be specified; and
- (3) Where the application for authority to prescribe is being sought on the basis of metastatic disease, the site(s) of metastatic disease must be provided.

Applications for authorisation for initial treatment must be made in writing and must include:

- (a) a completed authority prescription form; and

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
	(b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and (c) a signed patient acknowledgement.							
	<u>Authority required</u> Continuing PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans who has previously been issued with an authority prescription for imatinib and who has demonstrated a response, but whose disease remains unresectable.							
	Maximum dose: 800 mg per day.							
	Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and (c) a statement that the disease has not progressed on imatinib therapy.							
	<u>Note</u> No applications for increased repeats will be authorised.							
9172R	Tablet 100 mg (as mesylate)	60	2	..	2005.08	35.40	Glivec	NV
9173T	Tablet 400 mg (as mesylate)	30	2	..	3863.70	35.40	Glivec	NV

IMATINIB

Note

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

For the following diseases, written authority is required at initiation and for continuation:

Dermatofibrosarcoma protuberans;
Hypereosinophilic syndrome;
Chronic eosinophilic leukaemia;
Myelodysplastic or myeloproliferative disorder;
Aggressive systemic mastocytosis with eosinophilia.

Authority required

Initial PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia requiring treatment and confirmed to carry the FIP1L1-PDGFR fusion gene.

Maximum dose: 400 mg per day.

Applications for authorisation for initial treatment must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and
- (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFR fusion gene; and
- (d) a copy of the full blood examination report confirming the presence of hypereosinophilic syndrome or chronic eosinophilic leukaemia; and
- (e) details of organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and
- (f) a signed patient acknowledgement.

Authority required

Continuing PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia who has previously been issued with an authority prescription for imatinib and who has achieved and maintained a complete haematological response.

Maximum dose: 400 mg per day.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and
- (c) a copy of the full blood examination report which demonstrates a complete haematological response, with a normal eosinophil count; and
- (d) a statement that the disease has not progressed on imatinib therapy.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
Note							
No applications for increased repeats will be authorised.							
9174W	Tablet 100 mg (as mesylate)	60	2	..	2005.08	35.40	Glivec NV
9175X	Tablet 400 mg (as mesylate)	30	2	..	3863.70	35.40	Glivec NV

IMATINIB

Note

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

For the following diseases, written authority is required at initiation and for continuation:

Dermatofibrosarcoma protuberans;
Hypereosinophilic syndrome;
Chronic eosinophilic leukaemia;
Myelodysplastic or myeloproliferative disorder;
Aggressive systemic mastocytosis with eosinophilia.

Authority required

Initial PBS-subsidised treatment of a patient with a myelodysplastic or myeloproliferative disorder where:

- (1) there is confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement either by standard karyotyping, or FISH or PDGFRB fusion gene transcript; and
- (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:
 - cytarabine;
 - etoposide;
 - hydroxyurea.

Maximum dose: 400 mg per day.

Applications for authorisation for initial treatment must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and
- (c) a copy of the pathology report confirming the platelet-derived growth factor receptor (PDGFR) gene re-arrangement; and
- (d) a copy of the bone marrow biopsy report which demonstrates the presence of a myelodysplastic or myeloproliferative disorder; and
- (e) details of the prior therapy trialled and the response; and
- (f) a signed patient acknowledgement.

Authority required

Continuing PBS-subsidised treatment of a patient with a PDGFRB fusion gene-positive myelodysplastic or myeloproliferative disorder who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.

Maximum dose: 400 mg per day.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and
- (c) a copy of the full blood examination report which demonstrates a complete haematological response; and
- (d) a statement that the disease has not progressed on imatinib therapy.

Note

No applications for increased repeats will be authorised.

9176Y	Tablet 100 mg (as mesylate)	60	2	..	2005.08	35.40	Glivec	NV
9177B	Tablet 400 mg (as mesylate)	30	2	..	3863.70	35.40	Glivec	NV

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
IMATINIB							
<u>Note</u>							
Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).							
Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au .							
Written applications for authority to prescribe imatinib mesylate should be forwarded to:							
Medicare Australia Prior Written Approval of Specialised Drugs Reply Paid 9826 GPO Box 9826 HOBART TAS 7001							
For the following diseases, written authority is required at initiation and for continuation: Dermatofibrosarcoma protuberans; Hypereosinophilic syndrome; Chronic eosinophilic leukaemia; Myelodysplastic or myeloproliferative disorder; Aggressive systemic mastocytosis with eosinophilia.							
<u>Authority required</u>							
Initial PBS-subsidised treatment of a patient with aggressive systemic mastocytosis with eosinophilia where:							
(1) there is confirmed evidence of the FIP1L1-PDGFR fusion gene; and							
(2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:							
— corticosteroids;							
— hydroxyurea.							
Maximum dose: 400 mg per day.							
Applications for authorisation for initial treatment must be made in writing and must include:							
(a) a completed authority prescription form; and							
(b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and							
(c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFR fusion gene; and							
(d) a copy of the bone marrow biopsy report and/or other tissue biopsy report confirming the diagnosis of aggressive systemic mastocytosis and a copy of the full blood examination report demonstrating eosinophilia; and							
(e) details of symptomatic organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and							
(f) details of prior treatment trialled and the response; and							
(g) a signed patient acknowledgement.							
<u>Authority required</u>							
Continuing PBS-subsidised treatment of a patient with aggressive systemic mastocytosis confirmed to carry the FIP1L1-PDGFR fusion gene, who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.							
Maximum dose: 400 mg per day.							
Applications for authorisation must be made in writing and must include:							
(a) a completed authority prescription form; and							
(b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and							
(c) a copy of the full blood examination report which demonstrates a complete haematological response; and							
(d) a statement that the disease has not progressed on imatinib therapy.							
<u>Note</u>							
No applications for increased repeats will be authorised.							
9178C	Tablet 100 mg (as mesylate)	60	2	..	2005.08	35.40	Glivec NV
9179D	Tablet 400 mg (as mesylate)	30	2	..	3863.70	35.40	Glivec NV

IMATINIB

Note

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

For the following diseases, written authority is required at initiation and for continuation:

Dermatofibrosarcoma protuberans;
Hypereosinophilic syndrome;
Chronic eosinophilic leukaemia;
Myelodysplastic or myeloproliferative disorder;
Aggressive systemic mastocytosis with eosinophilia.

Authority required

Initial PBS-subsidised treatment, for up to 3 months, of a patient with a metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining.

Patients must commence treatment at a dose not exceeding 400 mg per day for at least 3 months. Authority prescriptions for a higher dose will not be approved during this initial 3 month treatment period.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Metastatic or Unresectable Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and
 - (ii) a copy of the most recent (within 2 months of the application) computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour(s), including whether or not there is evidence of metastatic disease; and
 - (iii) where the application for authority to prescribe is being sought on the basis of an unresectable tumour, written evidence in support of that claim must be provided.

Authority required

Continuing PBS-subsidised treatment, at a dose of up to 600 mg per day, of a patient with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for this drug.

Applications for continuing treatment may be made by telephone (1800 700 270, hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.

Note

Patients with metastatic/unresectable disease who achieve a response to treatment at an imatinib dose of 400 mg per day should be continued at this dose and assessed for response at regular intervals. Patients who fail to achieve a response to 400 mg per day may have their dose increased to 600 mg per day. Authority applications for doses higher than 600 mg per day will not be approved.

A response to treatment is defined as a decrease from baseline in the sum of the products of the perpendicular diameters of all measurable lesions of 50% or greater. (Response definition based on the Southwest Oncology Group standard criteria, see Demetri et al. N Engl J Med 2002; 347: 472-80.)

Note

No applications for increased repeats will be authorised.

9111M	Tablet 100 mg (as mesylate)	60	2	..	2005.08	35.40	Glivec	NV
9112N	Tablet 400 mg (as mesylate)	30	2	..	3863.70	35.40	Glivec	NV

IMATINIB

Note

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
	GPO Box 9826 HOBART TAS 7001						
	<p>For the following diseases, written authority is required at initiation and for continuation:</p> <p>Dermatofibrosarcoma protuberans; Hypereosinophilic syndrome; Chronic eosinophilic leukaemia; Myelodysplastic or myeloproliferative disorder; Aggressive systemic mastocytosis with eosinophilia.</p> <p>Authority required</p> <p>Adjuvant treatment of a patient at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST) which has been histologically confirmed by the detection of CD117 on immunohistochemical staining, at a dose not exceeding 400 mg per day for a period of 12 months.</p> <p>High risk of recurrence is defined as: Primary GIST greater than 5 cm with a mitotic count of greater than 5/50 high power fields (HPF); or Primary GIST greater than 10 cm with any mitotic rate; or Primary GIST with a mitotic count of greater than 10/50 HPF. (Prognosis definition based on the Australian and New Zealand consensus approach to best practice management, see Zalcberg et al. Asia-Pacific Journal of Clinical Oncology 2008: 4.4: 188-98.)</p> <p>Applications for authorisation must be in writing and must include:</p> <p>(1) a completed authority prescription form; and (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following: (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and (ii) a copy of the pathology report must include the size and mitotic rate of the tumour, and the date of tumour resection must be documented, which must not be more than 3 months prior to the date of this application.</p> <p>Authority required</p> <p>Initial treatment of a patient who was receiving adjuvant imatinib mesylate for gastrointestinal stromal tumour (GIST) prior to 1 September 2011 and who meets the PBS eligibility criteria for adjuvant treatment with imatinib mesylate of a patient at high risk of recurrence following complete resection of primary GIST. The patient is eligible to receive sufficient imatinib at a dose of 400 mg per day to complete 12 months of combined PBS-subsidised and non-PBS-subsidised therapy.</p> <p>Applications for authorisation must be in writing and must include:</p> <p>(1) a completed authority prescription form; and (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following: (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and (ii) a copy of the pathology report must include the size and mitotic rate of the tumour, and the date of tumour resection must be documented.</p>						
5443L	Tablet 100 mg (as mesylate)	60	5	..	2005.08	35.40	Glivec NV
5444M	Tablet 400 mg (as mesylate)	30	5	..	3863.70	35.40	Glivec NV

LAPATINIB

Note

Any queries concerning the arrangements to prescribe lapatinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Lapatinib should not be used in patients with a left ventricular ejection fraction (LVEF) of less than 45% or with symptomatic heart failure. Cardiac function must be tested by a suitable method including, for example, ECHO or MUGA, prior to seeking the initial authority approval and then at 3 monthly intervals during treatment.

Lapatinib is not PBS-subsidised when used in combination with Commonwealth-subsidised trastuzumab.

If disease progression occurs, the prescribing doctor must contact Medicare Australia within one week on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) and lapatinib treatment must be ceased immediately.

Authority required

Initial treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer (equivalent to Stage IIIC or Stage IV) who has received prior therapy with a taxane, for at least 3 cycles, and whose disease has progressed despite treatment with trastuzumab for metastatic disease.

Authority applications for initial treatment must be made in writing and must include:

- (a) a completed authority prescription form;

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	(b) a pathology report demonstrating HER2 positivity has been demonstrated by in situ hybridisation (ISH); (c) date of last treatment with a taxane and total number of cycles; (d) a signed patient acknowledgment; (e) dates of treatment with trastuzumab; and (f) date of demonstration of progression whilst on treatment with trastuzumab.						
	<u>Note</u> Treatment with trastuzumab for metastatic disease is defined as trastuzumab administered alone or in combination with chemotherapy for at least 6 weeks at standard doses.						
	If treatment with a taxane is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.						
	If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].						
	<u>Authority required</u> Continuing treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer who has previously received treatment with PBS-subsidised lapatinib and who does not have progressive disease.						
	Authority applications must be made in writing and must include: (a) a completed authority prescription form; and (b) a statement from the prescribing doctor that the disease has not progressed.						
	<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.						
9148L	Tablet 250 mg (as ditosylate monohydrate)	140	2	..	*3387.56	35.40	Tykerb GK

NILOTINIB

Note

Any queries concerning the arrangements to prescribe nilotinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Applications for authority to prescribe nilotinib should be forwarded to:

Medicare Australia
 Prior Written Approval of Specialised Drugs
 Reply Paid 9826
 GPO Box 9826
 HOBART TAS 7001.

Authority required

Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in chronic or accelerated phase who has failed an adequate trial of imatinib or dasatinib as first-line treatment.

Failure of an adequate trial of imatinib or dasatinib is defined as:

(i) Lack of response to initial imatinib or dasatinib therapy, defined as either:

- failure to achieve a haematological response after a minimum of 3 months therapy with imatinib or dasatinib for patients initially treated in chronic phase; or
- failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib or dasatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or
- failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib or dasatinib; OR

(ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib or dasatinib therapy; OR

(iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing imatinib or dasatinib therapy; OR

(iv) Development of accelerated phase in a patient previously prescribed imatinib or dasatinib for the chronic phase of chronic myeloid leukaemia.

Accelerated phase is defined by the presence of 1 or more of the following:

- (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or
- (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

than 30%; or
 (3) Peripheral basophils greater than or equal to 20%; or
 (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or
 (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR

(v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib or dasatinib therapy in patients with accelerated phase chronic myeloid leukaemia, provided that blast crisis has been excluded on bone marrow biopsy.

Patients should be commenced on a dose of nilotinib of 400 mg twice daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to nilotinib therapy or a peripheral blood BCR-ABL level of less than 1% within 18 months and thereafter at 12 monthly intervals.

Applications for authorisation must be in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Chronic Myeloid Leukaemia - Second and Third Line - Supporting Information Form; and
- (c) a signed patient acknowledgement; and
- (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 0.1% on the international scale. (The date of the relevant pathology report needs to be provided); and
- (e) where there has been a loss of response to imatinib or dasatinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement.

Authority required

Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with nilotinib for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18 months and thereafter at 12 monthly intervals.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Chronic Myeloid Leukaemia - Second and Third Line - Application Form for continuing treatment; and
- (3) demonstration of continued response to treatment as evidenced by either:
 - (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided; or
 - (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided.

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of tyrosine kinase inhibitors (TKI) agents for all phases of chronic myeloid leukaemia. Where the term TKI agent appears in the following notes and restrictions it refers to dasatinib or nilotinib. Imatinib mesylate is not approved for use in second or third line treatment.

Patients are eligible for PBS-subsidised treatment with only one of dasatinib or nilotinib at any one time and must not be receiving concomitant interferon alfa therapy. Eligible patients may only swap between these agents if they have not failed prior PBS-subsidised treatment with that agent.

Nilotinib is not approved for patients in blast crisis.

1. Initial second line treatment

From 1 April 2012, under the PBS, a patient will be able to be prescribed either dasatinib or nilotinib within the initial 18 month treatment period as second-line therapy, as long as only one agent is approved at a time and providing the patient did not fail that drug as first-line therapy.

During the initial 18 month treatment period, switching between approved second-line agents may only occur for reasons of intolerance, not failure of response.

2. Initial third line treatment

Third-line treatment with a TKI can only be approved when imatinib is used for first-line treatment. Patients will only be approved for PBS-subsidised treatment with one third-line agent.

From 1 April 2012, under the PBS, a patient will be able to be prescribed either dasatinib or nilotinib providing the patient did not fail that drug as first or second line therapy and for nilotinib the patient is not in blast crisis.

3. Continuing treatment for second and third line treatment

All continuing applications are to be written and must include a pathology report demonstrating the patient has responded to PBS-subsidised treatment as follows:

- (i) within 18 months of the commencement of treatment, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and
- (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	During second line continuing treatment beyond the initial 18 month treatment period, switching between approved second line TKI agents may only occur for reason of intolerance. Where there is failure of response, switching may only occur through application for prescription of a third line agent.						
	<p>4. Authority approval requirements.</p> <p>Response criteria to initial treatment with dasatinib or nilotinib:</p> <p>For the purposes of assessing response to PBS-subsidised treatment with dasatinib or nilotinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted within 18 months of the commencement of treatment with dasatinib or nilotinib (patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% is demonstrable by 18 months are eligible to receive continuing treatment with that agent).</p> <p>5. Definitions of response.</p> <p>A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.</p> <p>A peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.</p> <p>6. Definitions of loss of response.</p> <p>Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing tyrosine kinase inhibitor (TKI) therapy.</p> <p>Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing tyrosine kinase inhibitor therapy.</p>						
9171Q	Capsule 200 mg (as hydrochloride monohydrate)	120	5	..	5872.24	35.40	Tasigna NV

NILOTINIB

Note

Any queries concerning the arrangements to prescribe nilotinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Applications for authority to prescribe nilotinib should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.

Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.

Patients should be commenced on a dose of nilotinib of 300 mg twice daily. Continuing therapy is dependent on patients demonstrating a response to nilotinib therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and
- (4) a signed patient acknowledgement form.

Authority required

Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with nilotinib for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.

Applications for authorisation must be in writing and must include:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer	
					for Max. Qty \$	Recordable Value for Safety Net \$		
	<p>(1) a completed authority prescription form; and</p> <p>(2) demonstration of continued response to treatment as evidenced by either:</p> <p>(a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or</p> <p>(b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided.</p> <p>Note</p> <p>The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of tyrosine kinase inhibitors (TKI) agents for the chronic phase of chronic myeloid leukaemia. Where the term TKI agent appears in the following notes and restrictions it refers to imatinib mesylate, dasatinib or nilotinib.</p> <p>Patients are eligible for PBS-subsidised treatment with only one TKI agent at any one time and must not be receiving concomitant interferon alfa therapy. Eligible patients may only swap between TKI agents if they have not failed prior PBS-subsidised treatment with that agent.</p> <p>1. Initial treatment - imatinib mesylate, dasatinib and nilotinib</p> <p>From 1 April 2012, under the PBS, a patient will be able to be prescribed any of imatinib mesylate, dasatinib or nilotinib within the initial 18 month treatment period, as long as only one agent is used at a time and providing the patient has not failed to respond to any one of these TKIs.</p> <p>During the initial 18 month treatment period, switching between approved first-line agents may only occur for reasons of intolerance, not failure of response.</p> <p>2. Continuing treatment with imatinib mesylate - first-line</p> <p>First continuing applications are to be written and must include a pathology report demonstrating the patient has responded to the initial course of treatment.</p> <p>Second and subsequent authority applications for continuing therapy with imatinib mesylate may be made on the telephone by contacting Medicare Australia on 1800 700 720 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Patients must maintain a major cytogenetic response or have a peripheral blood BCR-ABL of less than 1% to receive continuing therapy.</p> <p>3. Continuing treatment with dasatinib or nilotinib - first-line</p> <p>All continuing applications are to be written and must include a pathology report demonstrating the patient has responded to PBS-subsidised treatment as follows:</p> <p>(i) within 18 months of the commencement of treatment, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and</p> <p>(ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.</p> <p>4. For imatinib mesylate, dasatinib and nilotinib</p> <p>During continuing therapy beyond the initial 18 month treatment period, switching between approved first-line agents may only occur for reason of intolerance. Where there is failure of response, switching may only occur through application for prescription of second-line agents.</p> <p>Where a patient has previously received PBS-subsidised treatment with imatinib mesylate, dasatinib or nilotinib no approval will be granted for PBS-subsidised re-treatment in the chronic phase of chronic myeloid leukaemia, where that patient has at any time failed to meet the response criteria whilst on that TKI agent.</p> <p>5. Authority approval requirements.</p> <p>Response criteria to initial treatment with imatinib mesylate, dasatinib or nilotinib:</p> <p>For the purposes of assessing response to PBS-subsidised treatment with imatinib mesylate, dasatinib or nilotinib either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted within 18 months of the commencement of treatment with imatinib mesylate, dasatinib or nilotinib (patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% is demonstrable by 18 months are eligible to receive continuing treatment with that agent).</p> <p>6. Definitions of response.</p> <p>A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.</p> <p>A peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.</p> <p>7. Definitions of loss of response.</p> <p>Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing tyrosine kinase inhibitor (TKI) therapy.</p> <p>Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing tyrosine kinase inhibitor therapy.</p>							
1309X	Capsule 150 mg (as hydrochloride monohydrate)	120	5	..	4467.97	35.40	Tasigna NV	

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
SORAFENIB							
<u>Authority required</u>							
Initial treatment, as the sole PBS-subsidised agent, of advanced (BCLC Stage C) hepatocellular carcinoma in a patient with a WHO performance status of 2 or less and Child Pugh class A;							
Continuing treatment, as the sole PBS-subsidised agent, of advanced hepatocellular carcinoma in a patient who has previously been treated with PBS-subsidised sorafenib and who does not have progressive disease.							
<u>Note</u>							
Sorafenib is not PBS-subsidised for adjunctive treatment after resection, ablation or chemoembolization.							
Sorafenib is not PBS-subsidised for maintenance therapy after disease progression.							
No applications for increased maximum quantities and/or repeats will be authorised.							
<u>Note</u>							
Special Pricing Arrangements apply.							
9380Q	Tablet 200 mg (as tosylate)	120	2	..	*6457.18	35.40	Nexavar BN

SUNITINIB

Authority required

Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Special Pricing Arrangements apply.

9417P	Capsule 12.5 mg (as malate)	28	1	..	1834.30	35.40	Sutent	PF
9418Q	Capsule 25 mg (as malate)	28	1	..	3521.86	35.40	Sutent	PF
9419R	Capsule 50 mg (as malate)	28	1	..	6897.54	35.40	Sutent	PF

SUNITINIB

Authority required

Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for sunitinib and who has stable or responding disease according to RECIST criteria.

Note

RECIST Criteria is defined as follows:

Complete response (CR) is disappearance of all target lesions.

Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions.

Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions.

Stable disease (SD) is small changes that do not meet above criteria.

Authority required

Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who was receiving treatment with sunitinib prior to 1 May 2009.

Note

Special Pricing Arrangements apply.

9420T	Capsule 12.5 mg (as malate)	28	3	..	1834.30	35.40	Sutent	PF
9421W	Capsule 25 mg (as malate)	28	3	..	3521.86	35.40	Sutent	PF
9422X	Capsule 50 mg (as malate)	28	3	..	6897.54	35.40	Sutent	PF

SUNITINIB

Authority required

Initial PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance.

Applications for authorisation must be in writing and must include:

(1) a completed authority prescription form; and

(2) a completed Sunitinib Malate (Sutent) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

(3) a signed patient acknowledgement.

Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.

Note

Any queries concerning the arrangements to prescribe sunitinib malate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Any queries concerning patients who are enrolled on the Sunitinib Compassionate Program may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe sunitinib malate should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

Sunitinib malate is not PBS-subsidised for the treatment of patients with resectable malignant gastrointestinal stromal tumours.

Authority required

Continuing PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for sunitinib and who does not have progressive disease.

Applications for continuing treatment may be made by telephone (1800 700 270, hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients who have failed to respond or who are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.

Patients who have progressive disease on sunitinib are no longer eligible for PBS-subsidised sunitinib.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Special Pricing Arrangements apply.

9488J	Capsule 12.5 mg (as malate)	28	1	..	1834.30	35.40	Sutent	PF
9489K	Capsule 25 mg (as malate)	28	1	..	3521.86	35.40	Sutent	PF
9490L	Capsule 50 mg (as malate)	28	1	..	6897.54	35.40	Sutent	PF

Other antineoplastic agents

HYDROXYUREA								
3093T	Capsule 500 mg	100	76.56	35.40	Hydrea	BQ

Endocrine therapy

Hormones and related agents

Progestogens

MEDROXYPROGESTERONE ACETATE

Restricted benefit

Hormone-dependent advanced breast cancer.

2728N	Tablet 500 mg	30	2	..	125.97	35.40	Provera	PF
-------	---------------	----	---	----	--------	-------	---------	----

MEDROXYPROGESTERONE ACETATE

Restricted benefit

Hormone-dependent breast cancer;

Endometrial cancer.

2316X	Tablet 200 mg	60	2	..	101.89	35.40	Provera	PF
-------	---------------	----	---	----	--------	-------	---------	----

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
2725K	Tablet 100 mg	100	2	..	90.48	35.40	Provera	PF
2727M	Tablet 250 mg	60	2	..	125.75	35.40	Provera	PF

MEGESTROL ACETATE

Restricted benefit

Hormone-dependent advanced breast cancer.

2734X	Tablet 160 mg	30	2	..	83.49	35.40	Megace	QA
-------	---------------	----	---	----	-------	-------	--------	----

Gonadotropin releasing hormone analogues

GOSERELIN ACETATE

Authority required

Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate;

Hormone-dependent locally advanced (equivalent to stage III) or metastatic (equivalent to stage IV) breast cancer in pre-menopausal women;

Short-term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months' therapy will be authorised);

Hormone-dependent breast cancer as an alternative to adjuvant chemotherapy in peri- or pre-menopausal women.

1454M	Subcutaneous implant 3.6 mg (base) in pre-filled injection syringe	1	5	..	333.10	35.40	Zoladex Implant	AP
-------	--	---	---	----	--------	-------	-----------------	----

GOSERELIN ACETATE

Authority required (STREAMLINED)

3229

Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.

8093Y	Subcutaneous implant (long acting) 10.8 mg (base) in pre-filled injection syringe	1	1	..	1108.86	35.40	Zoladex 10.8 Implant	AP
-------	---	---	---	----	---------	-------	----------------------	----

GOSERELIN ACETATE and BICALUTAMIDE

Authority required (STREAMLINED)

3239

Metastatic (equivalent to stage D) prostatic carcinoma in patients for whom a combination of an antiandrogen and a GnRH (LH-RH) agonist is required.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9064C	Pack containing 1 subcutaneous implant goserelin 3.6 mg in pre-filled injection syringe and 28 tablets bicalutamide 50 mg	£1	5	..	477.47	35.40	ZolaCos CP 3.6/50	AP
9065D	Pack containing 1 subcutaneous implant goserelin 10.8 mg in pre-filled injection syringe and 28 tablets bicalutamide 50 mg	£1	1248.39	35.40	ZolaCos CP 10.8/50(28)	AP
9066E	Pack containing 1 subcutaneous implant goserelin 10.8 mg in pre-filled injection syringe and 84 tablets bicalutamide 50 mg	£1	1	..	1527.47	35.40	ZolaCos CP 10.8/50(84)	AP

LEUPRORELIN ACETATE

Authority required (STREAMLINED)

3229

Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.

8707G	Suspension for subcutaneous injection (modified release), 7.5 mg injection set	1	5	..	420.30	35.40	Eligard 1 month	HH
8708H	Suspension for subcutaneous injection (modified release), 22.5 mg injection set	1	1	..	1108.86	35.40	Eligard 3 month	HH
8709J	Suspension for subcutaneous injection (modified release), 30 mg injection set	1	1	..	1451.43	35.40	Eligard 4 month	HH
8859G	Suspension for subcutaneous injection (modified release), 45 mg injection set	1	2124.08	35.40	Eligard 6 month	HH
8875D	I.M. injection (modified release), powder for injection 7.5 mg with diluent in pre-filled dual-chamber syringe	1	5	..	420.30	35.40	Lucrin Depot 7.5mg PDS	VE

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8876E	I.M. injection (modified release), powder for injection 22.5 mg with diluent in pre-filled dual-chamber syringe	1	1	..	1108.86	35.40	Lucrin Depot	VE
							3 Month PDS	
8877F	I.M. injection (modified release), powder for injection 30 mg with diluent in pre-filled dual-chamber syringe	1	1	..	1451.43	35.40	Lucrin Depot	VE
							4 Month PDS	

TRIPTORELIN

Authority required (STREAMLINED)

3229

Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.

5297T	Powder for I.M. injection (prolonged release) 22.5 mg (as embonate) with solvent, syringe and needles	1	2124.08	35.40	Diphereline	IS
9378N	Powder for I.M. injection (prolonged release) 3.75 mg (as embonate) with solvent, syringe and needles	1	5	..	420.30	35.40	Diphereline	IS
9379P	Powder for I.M. injection (prolonged release) 11.25 mg (as embonate) with solvent, syringe and needles	1	1	..	1108.86	35.40	Diphereline	IS

Hormone antagonists and related agents

Anti-estrogens

TAMOXIFEN CITRATE

Restricted benefit

Treatment of hormone-dependent breast cancer.

Note

This drug is not PBS-subsidised for primary prevention of breast cancer.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2109B NP	Tablet 10 mg (base)	60	5	..	37.36	35.40	Genox 10	AF
-------------	---------------------	----	---	----	-------	-------	----------	----

TAMOXIFEN CITRATE

Restricted benefit

Treatment of hormone-dependent breast cancer.

Note

This drug is not PBS-subsidised for primary prevention of breast cancer.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

For item codes 2110C and 1880Y, pharmaceutical benefits that have the form tablet 20 mg (base) are equivalent for the purposes of substitution.

1880Y NP	Tablet 20 mg (base)	60	5	^B 3.62	*61.30	35.40	^a Nolvadex-D	AP
2110C NP	Tablet 20 mg (base)	60	5	..	57.65	35.40	^a Genox 20	AF
							^a GenRx Tamoxifen	GX
							^a Tamosin	QA
							^a Tamoxen 20 mg	GM
							^a Tamoxifen Sandoz	SZ

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

TOREMIFENE CITRATE

Restricted benefit

Treatment of hormone-dependent metastatic breast cancer in post-menopausal patients.

Note

This drug is not PBS-subsidised for primary prevention of breast cancer.

8216K	Tablet 60 mg (base)	30	5	..	73.84	35.40	Fareston	MK
-------	---------------------	----	---	----	-------	-------	----------	----

Anti-androgens

BICALUTAMIDE

Authority required (STREAMLINED)

3674

Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) analogue therapy.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8094B NP	Tablet 50 mg	28	5	..	151.74	35.40	^a	APO-Bicalutamide	TX
							^a	Bicalutamide-GA	GM
							^a	Bicalutamide	RA
							^a	Ranbaxy	
							^a	Calutex	QA
							^a	Cosamide	AF
							^a	Cosudex	SZ

CYPROTERONE ACETATE

Authority required (STREAMLINED)

1014

Advanced carcinoma of the prostate;

1404

To reduce drive in sexual deviations in males.

1270W	Tablet 50 mg	100	5	..	*167.42	35.40	^a	Cyprohexal	SZ	
							^a	Cyprone	AF	
							^a	Cyprostat	SY	
							^a	GenRx Cyproterone Acetate	GX	
							^a	Procur	GM	
8019C	Tablet 100 mg	50	5	..	^B 2.62	*170.04	35.40	^a	Androcur	BN
					136.87	35.40	^a	Cyprocur 100	QA	
							^a	Cyprohexal	SZ	
							^a	Cyprostat-100	SY	
							^a	GenRx Cyproterone Acetate	GX	
							^a	Procur 100	GM	
						^B 1.31	138.18	35.40	^a	Androcur-100

FLUTAMIDE

Authority required (STREAMLINED)

3674

Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) analogue therapy.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<u>Note</u>							
Shared Care Model:							
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1417N	Tablet 250 mg	100	5	..	201.79	35.40	^a Eulexin MK
NP						^a Flutamin	AF

NILUTAMIDE

Authority required (STREAMLINED)

3675

Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in combination with GnRH (LH-RH) analogue therapy;

3300

Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in conjunction with surgical orchidectomy.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8131Y NP	Tablet 150 mg	30	5	..	236.66	35.40	Anandron	SW
-------------	---------------	----	---	----	--------	-------	----------	----

Aromatase inhibitors

ANASTROZOLE

Restricted benefit

Treatment of hormone-dependent breast cancer in post-menopausal women.

Note

This drug is not PBS-subsidised for primary prevention of breast cancer.

This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8179L NP	Tablet 1 mg	30	5	..	152.48	35.40	^a Anastrol	QA
							^a Anastrozole-DRLA	RZ
							^a Anastrozole-GA	GM
							^a Anastrozole GH	GQ
							^a Anastrozole-PS	FZ
							^a Anastrozole RBX	RA
							^a Anastrozole Sandoz	SZ
							^a Anastrozole Synthon	ZT
							^a Anzole	WQ
							^a APO-Anastrozole	TX
							^a Arianna	AF
							^a Arimidex	AP
							^a Chem mart Anastrozole	CH
							^a Terry White Chemists Anastrozole	TW

EXEMESTANE

Restricted benefit

Treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate;

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Treatment of hormone-dependent early breast cancer in post-menopausal women following a minimum of 2 years' treatment with tamoxifen citrate.

Note

This drug is not PBS-subsidised for primary prevention of breast cancer.

This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years, i.e. a patient who has received 2 years of tamoxifen therapy may only receive 3 years of PBS-subsidised treatment with exemestane.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8506Q NP	Tablet 25 mg	30	5	..	152.48	35.40	^a	APO-Exemestane	TX
							^a	Aromasin	PF
							^a	Exaccord	RA
							^a	Exemestane Pfizer	FZ
							^a	Exemestane Sandoz	SZ

LETROZOLE

Restricted benefit

Treatment of hormone-dependent advanced breast cancer in post-menopausal women;

Treatment of hormone-dependent early breast cancer in post-menopausal women;

Extended adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women commencing within 6 months of ceasing treatment with tamoxifen citrate.

Note

This drug is not PBS-subsidised for primary prevention of breast cancer.

This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years.

This drug is not PBS-subsidised for extended adjuvant early breast cancer treatment where the total duration of letrozole (or any other aromatase inhibitor) treatment extends beyond 5 years.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8245Y NP	Tablet 2.5 mg	30	5	..	152.48	35.40	^a	APO-Letrozole	TX
							^a	Chem mart	CH
							^a	Letrozole	
							^a	Femara 2.5 mg	NV
							^a	Femolet	AF
							^a	Fera	QA
							^a	Letara	FZ
							^a	Letrozole Actavis	TA
							^a	Letrozole-DRLA	RZ
							^a	Letrozole-GA	GM
							^a	Letrozole generichealth	GQ
							^a	Letrozole RBX	RA
							^a	Letrozole Sandoz	SZ
							^a	Letrozole-Synthon	ZT
							^a	Lezole	WQ
							^a	Terry White Chemists Letrozole	TW

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<i>Other hormone antagonists and related agents</i>							
DEGARELIX <u>Authority required (STREAMLINED)</u> 3229 Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.							
5455D	Powder for injection 80 mg (as acetate), injection set	1	5	..	420.30	35.40	Firmagon 80mg FP
<hr/>							
DEGARELIX <u>Authority required (STREAMLINED)</u> 3229 Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.							
<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised for the 120 mg powder for injection.							
5456E	Powder for injection 120 mg (as acetate), 2, injection set	1	438.82	35.40	Firmagon 120mg FP

Immunostimulants

Immunostimulants

Interferons

INTERFERON ALFA-2a

Caution

Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required

Hairy cell leukaemia;

Myeloproliferative disease with excessive thrombocytosis.

8180M	Injection 3,000,000 i.u. in 0.5 mL single dose pre-filled syringe	15	4	..	*506.32	35.40	Roferon-A	RO
-------	---	----	---	----	---------	-------	-----------	----

INTERFERON ALFA-2a

Caution

Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required

Myeloproliferative disease with excessive thrombocytosis.

8551C	Injection 4,500,000 i.u. in 0.5 mL single dose pre-filled syringe	5	4	..	*264.82	35.40	Roferon-A	RO
8552D	Injection 6,000,000 i.u. in 0.5 mL single dose pre-filled syringe	5	4	..	*344.82	35.40	Roferon-A	RO
8553E	Injection 9,000,000 i.u. in 0.5 mL single dose pre-filled syringe	5	4	..	*506.22	35.40	Roferon-A	RO

INTERFERON ALFA-2a

Caution

Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy.

8181N	Injection 3,000,000 i.u. in 0.5 mL single dose pre-filled syringe	15	5	..	*506.32	35.40	Roferon-A	RO
8182P	Injection 4,500,000 i.u. in 0.5 mL single dose pre-filled syringe	5	5	..	*264.82	35.40	Roferon-A	RO

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8183Q	Injection 6,000,000 i.u. in 0.5 mL single dose pre-filled syringe	5	5	..	*344.82	35.40	Roferon-A	RO
8184R	Injection 9,000,000 i.u. in 0.5 mL single dose pre-filled syringe	5	5	..	*506.22	35.40	Roferon-A	RO

INTERFERON ALFA-2b

Caution

Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required

Hairy cell leukaemia.

8572E	Solution for injection 18,000,000 i.u. in 1.2 mL multi-dose injection pen	3	4	..	*606.13	35.40	Intron A Redipen	MK
-------	---	---	---	----	---------	-------	------------------	----

INTERFERON ALFA-2b

Caution

Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required

Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy;

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy.

8348J	Solution for injection 18,000,000 i.u. in 1.2 mL multi-dose injection pen	3	5	..	*606.13	35.40	Intron A Redipen	MK
8476D	Solution for injection 30,000,000 i.u. in 1.2 mL multi-dose injection pen	3	5	..	*1005.85	35.40	Intron A Redipen	MK

INTERFERON BETA-1a

Authority required

Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule;

Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule.

8289G	Injection set comprising 1 vial powder for injection 30 micrograms (6,000,000 i.u.) with diluent	4	5	..	1056.87	35.40	Avonex	BD
8403G	Injection 44 micrograms (12,000,000 i.u.) in 0.5 mL single dose pre-filled syringe	12	5	..	1056.87	35.40	Rebif 44	SG
8805K	Injection 30 micrograms (6,000,000 i.u.) in 0.5 mL single dose pre-filled syringe	4	5	..	1056.87	35.40	Avonex	BD
8968B	Injection 44 micrograms (12,000,000 i.u.) in 0.5 mL single dose autoinjector	12	5	..	1056.87	35.40	Rebif 44	SG
9332E	Solution for injection 132 micrograms in 1.5 mL multidose cartridge	4	5	..	1056.87	35.40	Rebif 44	SG

INTERFERON BETA-1b

Authority required

Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule;

Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8101J	Injection set including 1 vial powder for injection 8,000,000 i.u. (250 micrograms) and solvent	15	5	..	1180.26	35.40	Betaferon	BN

Other immunostimulants

BCG IMMUNOTHERAPEUTIC (Bacillus Calmette-Guérin/ Connaught strain)

Restricted benefit

Treatment of carcinoma in situ of the urinary bladder.

1140B	Powder for intravesical administration containing 6.6 to 19.2 x 10 ⁸ CFU	3	1	..	*459.97	35.40	ImmuCyst	SW
-------	---	---	---	----	---------	-------	----------	----

BCG-TICE (Bacillus Calmette-Guérin/ Tice strain)

Restricted benefit

Primary and relapsing superficial urothelial carcinoma of the bladder.

1131M	Vial containing powder for intravesical administration approximately 5 x 10 ⁸ CFU	3	1	..	556.49	35.40	OncoTICE	MK
-------	--	---	---	----	--------	-------	----------	----

GLATIRAMER ACETATE

Authority required

Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule;

Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule.

8726G	Injection 20 mg in 1 mL single dose pre-filled syringe	28	5	..	1092.75	35.40	Copaxone	CS
-------	--	----	---	----	---------	-------	----------	----

Immunosuppressants

Immunosuppressants

Selective immunosuppressants

ABATACEPT

Note

Any queries concerning the arrangements to prescribe abatacept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe abatacept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer
					for Max. Qty \$	Recordable Value for Safety Net \$	

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
(3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application. One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription must be written for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats.

Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application. The prescription must be written with a maximum quantity of 4 and up to 3 repeats.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with abatacept.

Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with abatacept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised abatacept treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application. One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription must be written for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats.

Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application. The prescription must be written with a maximum quantity of 4 and up to 3 repeats.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised abatacept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised abatacept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.							
<u>Note</u> Special Pricing Arrangements apply.							
1220F	Injection 125 mg in 1 mL single dose pre-filled syringe	4	3	..	1754.01	35.40	Orencia BQ

ABATACEPT

Note

Any queries concerning the arrangements to prescribe abatacept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe abatacept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

(iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with abatacept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with abatacept.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;
AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with abatacept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with abatacept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty	Safety Net		
	\$	\$						
Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.								
Note								
No applications for increased maximum quantities and/or repeats will be authorised.								
Note								
Special Pricing Arrangements apply.								
1221G	Injection 125 mg in 1 mL single dose pre-filled syringe	4	5	..	1754.01	35.40	Orencia	BQ
EVEROLIMUS								
Caution								
Careful monitoring of patients is mandatory.								
Authority required								
Maintenance therapy, following initiation and stabilisation of treatment with everolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with:								
(a) renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application;								
(b) cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.								
8840G	Tablet 0.25 mg	60	3	..	282.89	35.40	Certican	NV
8841H	Tablet 0.5 mg	60	3	..	543.93	35.40	Certican	NV
8842J	Tablet 0.75 mg	120	3	..	*1578.72	35.40	Certican	NV
9352F	Tablet 1 mg	120	3	..	*2068.86	35.40	Certican	NV
FINGOLIMOD								
Authority required								
Initial treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule;								
Continuing treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in a patient previously issued with an authority prescription for this drug who does not show continuing progression of disability while on treatment with this drug and who has demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule.								
Note								
Special Pricing Arrangements apply.								
5262Y	Capsule 500 micrograms (as hydrochloride)	28	5	..	2313.08	35.40	Gilenya	NV
LEFLUNOMIDE								
Caution								
Leflunomide is a category X drug and must not be given to pregnant women. Pregnancy should be avoided for two years after cessation of therapy, unless special wash-out procedures are carried out.								
Authority required (STREAMLINED)								
2643								
Initial treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate. Treatment must be initiated by a physician;								
2681								
Initial treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate. Treatment must be initiated by a physician.								
Note								
No applications for increased maximum quantities and/or repeats will be authorised.								
8373Q	Pack containing 3 tablets leflunomide 100 mg and 30 tablets leflunomide 20 mg	1	175.74	35.40	Arava	SW

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
LEFLUNOMIDE							
<u>Caution</u>							
Leflunomide is a category X drug and must not be given to pregnant women. Pregnancy should be avoided for two years after cessation of therapy, unless special wash-out procedures are carried out.							
<u>Authority required (STREAMLINED)</u>							
2644							
Treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate. Treatment must be initiated by a physician.							
8374R	Tablet 10 mg	30	5	..	76.90	35.40	^a APO-Leflunomide TX ^a Arabloc AV ^a Arava SW ^a Lunava 10 ZP
8375T	Tablet 20 mg	30	5	..	113.67	35.40	^a APO-Leflunomide TX ^a Arabloc AV ^a Arava SW ^a Lunava 20 ZP
<hr/>							
LEFLUNOMIDE							
<u>Caution</u>							
Leflunomide is a category X drug and must not be given to pregnant women. Pregnancy should be avoided for two years after cessation of therapy, unless special wash-out procedures are carried out.							
<u>Authority required (STREAMLINED)</u>							
2682							
Treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate. Treatment must be initiated by a physician.							
5449T	Tablet 10 mg	30	5	..	76.90	35.40	^a Arabloc AV ^a Arava SW
5450W	Tablet 20 mg	30	5	..	113.67	35.40	^a Arabloc AV ^a Arava SW
<hr/>							
MYCOPHENOLATE MOFETIL							
<u>Caution</u>							
Careful monitoring of patients is mandatory.							
<u>Authority required</u>							
Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with:							
(a) renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application;							
(b) cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.							
<u>Note</u>							
For item codes 8649F and 1836P, pharmaceutical benefits that have the form capsule 250 mg are equivalent for the purposes of substitution.							
1836P	Capsule 250 mg	300	3	..	*528.52	35.40	^a Ceptolate AF
8649F	Capsule 250 mg	300	3	..	*528.46	35.40	^a APO- TX ^a Mycophenolate ^a CellCept RO ^a Imulate QA ^a Mycophenolate SZ ^a Sandoz ^a Pharmacor CR ^a Mycophenolate 250

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
MYCOPHENOLATE MOFETIL								
<u>Caution</u> Careful monitoring of patients is mandatory.								
<u>Authority required</u> Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with: (a) renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application; (b) cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.								
8650G	Tablet 500 mg	150	3	..	*528.46	35.40	^a APO- Mycophenolate ^a CellCept ^a Ceptolate ^a Imulate ^a Mycophenolate Sandoz ^a Pharmacor Mycophenolate 500 CellCept	TX RO AF QA SZ CR
8651H	Powder for oral suspension 1 g per 5 mL, 165 mL	‡1	3	..	#290.03	35.40	CellCept	RO
MYCOPHENOLATE SODIUM								
<u>Caution</u> Careful monitoring of patients is mandatory.								
<u>Authority required</u> Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate sodium and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.								
8652J	Tablet (enteric coated) 180 mg (mycophenolic acid)	120	3	..	225.28	35.40	Myfortic	NV
8653K	Tablet (enteric coated) 360 mg (mycophenolic acid)	120	3	..	426.03	35.40	Myfortic	NV
SIROLIMUS								
<u>Caution</u> Careful monitoring of patients is mandatory.								
<u>Authority required</u> Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.								
8724E	Tablet 1 mg	100	3	..	815.35	35.40	Rapamune	PF
8725F	Oral solution 1 mg per mL, 60 mL	‡1	3	..	529.84	35.40	Rapamune	PF
8833X	Tablet 2 mg	100	3	..	1583.79	35.40	Rapamune	PF
8984W	Tablet 0.5 mg	100	3	..	413.39	35.40	Rapamune	PF

Tumor necrosis factor alpha (TNF-alpha) inhibitors

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with adalimumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised. Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.								
<u>Note</u> Special Pricing Arrangements apply.								
8737W	Injection 40 mg in 0.8 mL pre-filled syringe	2	3	..	1774.46	35.40	Humira	VE
9099X	Injection 40 mg in 0.8 mL pre-filled pen	2	3	..	1774.46	35.40	Humira	VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

(iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or

(iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	subcutaneous formulation.						

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with adalimumab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with adalimumab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
	for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.							
	Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.							
	<u>Note</u>							
	No applications for increased maximum quantities and/or repeats will be authorised.							
	Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.							
	<u>Note</u>							
	Special Pricing Arrangements apply.							
8741C	Injection 40 mg in 0.8 mL pre-filled syringe	2	5	..	1774.46	35.40	Humira	VE
9100Y	Injection 40 mg in 0.8 mL pre-filled pen	2	5	..	1774.46	35.40	Humira	VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialed it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

Authority required

Initial 1

Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have severe active psoriatic arthritis; and
- (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and
- (3) have failed to achieve an adequate response to:
 - (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and
 - (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or
 - (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) an active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Initial 2

Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have a documented history of severe active psoriatic arthritis; and
- (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and
- (3) have not failed treatment with adalimumab during the current Treatment Cycle.

Applications for patients who have received PBS-subsidised treatment with adalimumab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

adalimumab treatment, within the timeframes specified below.

A maximum of 16 weeks treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.

9033K	Injection 40 mg in 0.8 mL pre-filled syringe	2	3	..	1774.46	35.40	Humira	VE
9101B	Injection 40 mg in 0.8 mL pre-filled pen	2	3	..	1774.46	35.40	Humira	VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].						

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:

- (1) who have a documented history of severe active psoriatic arthritis; and
- (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with adalimumab; and
- (3) who, at the time of application, demonstrate an adequate response to treatment with adalimumab.

An adequate response to treatment with adalimumab is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.

Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.

9034L	Injection 40 mg in 0.8 mL pre-filled syringe	2	5	..	1774.46	35.40	Humira	VE
-------	--	---	---	----	---------	-------	--------	----

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
9102C	Injection 40 mg in 0.8 mL pre-filled pen	2	5	..	1774.46	35.40	Humira VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept, golimumab and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept, golimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 4 TNF-alfa antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial PBS-subsidised TNF-alfa antagonists without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and 18 weeks of treatment for infliximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.

A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with golimumab.

A patient who commenced treatment with golimumab for active ankylosing spondylitis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with golimumab will be assessed under the continuing treatment restriction.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patients)

Initial PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND

(a) who has at least 2 of the following:

- (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or
- (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or
- (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND

(b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.

The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.

If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.

If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.

The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:

- (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND
- (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.

The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.

Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:
 - (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and
 - (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and
 - (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and
 - (iv) a signed patient acknowledgment form.

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Authority required

Initial 2 (change or re-commencement for all patients)

Initial PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with adalimumab in the current treatment cycle.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
	Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.							
	Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.							
	Authority applications must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].							
	A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.							
	Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.							
	Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.							
	Note No applications for increased maximum quantities and/or repeats will be authorised. Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.							
9077R	Injection 40 mg in 0.8 mL pre-filled syringe	2	3	..	1774.46	35.40	Humira	VE
9103D	Injection 40 mg in 0.8 mL pre-filled pen	2	3	..	1774.46	35.40	Humira	VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept, golimumab and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept, golimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 4 TNF-alfa antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial PBS-subsidised TNF-alfa antagonists without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and 18 weeks of treatment for infliximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.

A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI,

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with golimumab.

A patient who commenced treatment with golimumab for active ankylosing spondylitis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with golimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Continuing treatment for all patients

Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:

- (a) has demonstrated an adequate response to treatment with adalimumab; and
- (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with adalimumab.

An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:

- (a) an ESR measurement no greater than 25 mm per hour; or
- (b) a CRP measurement no greater than 10 mg per L; or
- (c) an ESR or CRP measurement reduced by at least 20% from baseline.

Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].

All measurements provided must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.

All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with adalimumab. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
9078T	Injection 40 mg in 0.8 mL pre-filled syringe	2	5	..	1774.46	35.40	Humira VE
9104E	Injection 40 mg in 0.8 mL pre-filled pen	2	5	..	1774.46	35.40	Humira VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alpha antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alpha antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alpha antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alpha antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alpha antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alpha antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alpha antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alpha antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alpha antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alpha antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alpha antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alpha antagonist therapy after 1 August 2008.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alpha antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alpha antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alpha antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patients)

Initial treatment of Crohn disease in a patient assessed by CDAI.

Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and
- (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (c) has failed to achieve an adequate response to prior systemic therapy including:
 - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
 - (ii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

The most recent CDAI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) two completed authority prescription forms; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and
 - (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and
 - (iii) the signed patient acknowledgement.

A maximum of 16 weeks treatment will be authorised under this criterion.

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Authority required

Initial 2

Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.

Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and
- (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) two completed authority prescription forms; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and
 - (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Authority required

Initial 1

Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.

Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:

- (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and
- (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and
- (c) has evidence of intestinal inflammation; and
- (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (e) has failed to achieve an adequate response to prior systemic drug therapy including:
 - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
 - (ii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

(a) have evidence of intestinal inflammation, including:

(i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR

(ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR

(iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;

AND/OR

(b) be assessed clinically as being in a high faecal output state;

AND/OR

(c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.

Applications for authorisation must be made in writing and must include:

(a) two completed authority prescription forms; and

(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:

(i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and

(ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and

(iii) date of the most recent clinical assessment; and

(iv) the signed patient acknowledgement.

All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.

A maximum of 16 weeks treatment will be authorised under this criterion.

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Authority required

Initial 2

Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.

Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:

(a) has a documented history of severe refractory Crohn disease; and

(b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and

(c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) two completed authority prescription forms; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and
 - (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.

A maximum of 16 weeks of treatment will be approved under this criterion.

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Authority required

Initial 1

Initial treatment of Crohn disease in a patient with extensive small intestine disease.

Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and
- (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and
- (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) has failed to achieve an adequate response to prior systemic therapy including:
 - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
 - (ii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;
- AND/OR
- (b) have evidence of active intestinal inflammation, including:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
	(i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR						
	(ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR						
	(iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;						
	AND/OR						
	(c) be assessed clinically as being in a high faecal output state;						
	AND/OR						
	(d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.						

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.

Applications for authorisation must be made in writing and must include:

- (a) two completed authority prescription forms; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and
 - (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or
 - (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and
 - (iii) date of the most recent clinical assessment; and
 - (iv) the signed patient acknowledgement.

All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.

A maximum of 16 weeks treatment of adalimumab will be authorised under this criterion.

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9186L	Injection 40 mg in 0.8 mL pre-filled syringe, 6	1	5036.46	35.40	Humira	VE
9187M	Injection 40 mg in 0.8 mL pre-filled pen, 6	1	5036.46	35.40	Humira	VE
9188N	Injection 40 mg in 0.8 mL pre-filled syringe	2	2	..	1774.46	35.40	Humira	VE
9190Q	Injection 40 mg in 0.8 mL pre-filled pen	2	2	..	1774.46	35.40	Humira	VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 3 (grandfather)

Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with adalimumab.

Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:

- has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9 November 2007; and
- had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with adalimumab. Where a

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and
(c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
(d) has demonstrated or sustained an adequate response to treatment with adalimumab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and
 - (ii) the signed patient acknowledgement.

The current CDAI assessment must be no more than 1 month old at the time of application. The baseline CDAI assessment must be from immediately prior to commencing treatment with adalimumab.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.

A maximum of 24 weeks treatment will be approved under this criterion.

Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

Authority required

Continuing treatment of Crohn disease in a patient assessed by CDAI.

Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) has demonstrated or sustained an adequate response to treatment with adalimumab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.

The CDAI assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with adalimumab, a CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.

Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

A maximum of 24 weeks treatment will be authorised under this criterion.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.

Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and
- (b) has demonstrated or sustained an adequate response to treatment with adalimumab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to adalimumab treatment is defined as:

- (a) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
 - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or
- (b) reversal of high faecal output state; or
- (c) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.

The patient's assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.

Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

A maximum of 24 weeks of treatment will be authorised under this criterion.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment of Crohn disease in a patient with extensive small intestine disease.

Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50 cm of the small intestine; and
- (b) has demonstrated or sustained an adequate response to treatment with adalimumab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to adalimumab treatment is defined as:

- (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or
- (b) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
 - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

- (c) reversal of high faecal output state; or
(d) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or
 - (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or
 - (iii) the date of clinical assessment.

All assessments must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.

Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

A maximum of 24 weeks treatment will be authorised under this criterion.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial 3

Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with adalimumab.

Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9 November 2007; and
- (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; or
- (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) has demonstrated or sustained an adequate response to treatment with adalimumab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.

An adequate response to adalimumab treatment is defined as:

- (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or
- (b) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
 - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or
- (c) reversal of high faecal output state; or
- (d) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or
 - (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	(3) the date of clinical assessment(s); and (ii) the signed patient acknowledgement.						
	The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with adalimumab. Where a baseline assessment is not available, please call Medicare Australia on 1800 700 270 to discuss.						
	The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.						
	Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.						
	Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.						
	Patients who fail to demonstrate or sustain a response to treatment with adalimumab for Crohn disease as specified in the criteria for continuing treatment with adalimumab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.						
	A maximum of 24 weeks treatment will be authorised under this criterion. Where fewer than 5 repeats are requested at the time of this application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).						
	Patients may qualify for PBS-subsidised treatment under this restriction once only.						
	Note No applications for increased maximum quantities and/or repeats will be authorised.						
9189P	Injection 40 mg in 0.8 mL pre-filled syringe	2	5	..	1774.46	35.40	Humira VE
9191R	Injection 40 mg in 0.8 mL pre-filled pen	2	5	..	1774.46	35.40	Humira VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.

From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.

There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made in the following situations:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).

All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.

(2) Assessment of response to initial treatment.

When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

(3) Application for continuing treatment.

Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.

For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

(4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.

Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

(5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

Authority required

Initial treatment [Initial 1, Whole body (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
 - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or
 - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or
 - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer
					for Max. Qty \$	Recordable Value for Safety Net \$	

Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Authority required

Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.

Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Initial treatment [Initial 1, Face, hand, foot (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	(ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.						

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:
 - (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or
 - (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.

Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Authority required

Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

Antineoplastic and immunomodulating agents

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer
A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.							

Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Special Pricing Arrangements apply.

9425C	Injection 40 mg in 0.8 mL pre-filled syringe	2	4	..	1774.46	35.40	Humira	VE
9426D	Injection 40 mg in 0.8 mL pre-filled pen	2	4	..	1774.46	35.40	Humira	VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.

From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.

There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made in the following situations:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).

All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.

(2) Assessment of response to initial treatment.

When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

(3) Application for continuing treatment.

Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.

For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

(4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.

Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

(5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

Authority required

Continuing treatment (Whole body)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis; and
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and
- (c) who have demonstrated an adequate response to their most recent course of treatment with adalimumab.

An adequate response to treatment is defined as:

A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.

The most recent PASI assessment must be no more than 1 month old at the time of application.

Approval will be based on the PASI assessment of response to the most recent course of treatment with adalimumab.

A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.

Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
	Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.							
	Authority required							
	Continuing treatment (Face, hand, foot)							
	Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:							
	(a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and							
	(b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and							
	(c) who have demonstrated an adequate response to treatment with adalimumab.							
	An adequate response to adalimumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:							
	(i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or							
	(ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.							
	This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.							
	Applications for authorisation must be made in writing and must include:							
	(a) a completed authority prescription form; and							
	(b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:							
	(i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].							
	The most recent PASI assessment must be no more than 1 month old at the time of application.							
	A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.							
	Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.							
	A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.							
	It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.							
	The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.							
	Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.							
	Note							
	No applications for increased maximum quantities and/or repeats will be authorised.							
	Note							
	Special Pricing Arrangements apply.							
9427E	Injection 40 mg in 0.8 mL pre-filled syringe	2	5	..	1774.46	35.40	Humira	VE
9428F	Injection 40 mg in 0.8 mL pre-filled pen	2	5	..	1774.46	35.40	Humira	VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH A HISTORY OF JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient over 18 years who has a history of juvenile idiopathic arthritis with onset prior to the age of 18 years. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any one time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 5 year break in PBS-subsidised bDMARD therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment.

A patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count and ESR/CRP) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patient or patient recommencing after a break of more than 12 months).

Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:

- (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND
- (b) has received no PBS-subsidised treatment with a bDMARD for this condition in the previous 12 months; and
- (c) has failed to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	— hydroxychloroquine at a dose of at least 200 mg daily; and/or — leflunomide at a dose of at least 10 mg daily; and/or — sulfasalazine at a dose of at least 2 g daily.						

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg per day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialed, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) an active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
<p>If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle.</p> <p><u>Authority required</u></p> <p>Initial 2 (change or re-commencement after break of less than 12 months).</p> <p>Initial PBS-subsidised treatment with adalimumab by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:</p> <p>(a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND</p> <p>(b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and</p> <p>(c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p> <p>The authority application must be made in writing and must include:</p> <p>(a) a completed authority prescription form; and</p> <p>(b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p> <p>Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p> <p>A maximum of 16 weeks of treatment will be authorised under this restriction.</p> <p>Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p> <p>Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p> <p>Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p> <p>Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p> <p>If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle.</p>							
5281Y	Injection 40 mg in 0.8 mL pre-filled syringe	2	3	..	1774.46	35.40	Humira VE
5282B	Injection 40 mg in 0.8 mL pre-filled pen	2	3	..	1774.46	35.40	Humira VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH A HISTORY OF JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient over 18 years who has a history of juvenile idiopathic arthritis with onset prior to the age of 18 years. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any one time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 5 year break in PBS-subsidised bDMARD therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment.

A patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count and ESR/CRP) or the prior non-bDMARD therapy requirements, except if the patient has

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

Authority required

Initial 3 ('grandfather' patients).

Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:

- (a) has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and
- (b) was receiving treatment with adalimumab prior to 1 March 2010; and
- (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and
- (d) is receiving treatment with adalimumab at the time of application.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 24 weeks of treatment with adalimumab will be approved under this criterion.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

The same indices of disease severity used to establish baseline at the commencement of treatment with a bDMARD must be used for assessment of all continuing applications.

The assessment of the patient's response to a continuing course of therapy must be made within 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled in order to ensure continuity of treatment for those patients who meet the continuation criterion.

A patient may qualify for PBS-subsidised treatment under this restriction once only.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<u>Authority required</u>							
Continuing treatment.							
Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older:							
(a) who has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and							
(b) who has demonstrated an adequate response to treatment with adalimumab; and							
(c) whose most recent course of PBS-subsidised bDMARD treatment was with adalimumab.							
An adequate response to treatment is defined as:							
an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;							
AND either of the following:							
(i) an active joint count of fewer than 10 active (swollen and tender) joints; or							
(ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or							
(iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:							
— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or							
— shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).							
The authority application must be made in writing and must include:							
(1) a completed authority prescription form; and							
(2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].							
A maximum of 24 weeks of treatment will be approved under this restriction.							
Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).							
All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.							
If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle.							
5283C	Injection 40 mg in 0.8 mL pre-filled syringe	2	5	..	1774.46	35.40	Humira VE
5284D	Injection 40 mg in 0.8 mL pre-filled pen	2	5	..	1774.46	35.40	Humira VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF COMPLEX REFRACTORY FISTULISING CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for patients with complex refractory fistulising Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 April 2011, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 April 2011 is considered to be in their first cycle as of 1 April 2011.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 April 2011.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 April 2011, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for complex refractory fistulising Crohn disease prior to 4 November 2010 or infliximab prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1

Initial treatment of complex refractory FISTULISING CROHN DISEASE.

Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and
- (b) has an externally draining enterocutaneous or rectovaginal fistula; and
- (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

Authority applications must be made in writing and must include:

- (a) two completed authority prescription forms; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and
 - (ii) a signed patient acknowledgement.

The most recent fistula assessment must be no more than 1 month old at the time of application.

A maximum of 16 weeks treatment will be authorised under this criterion.

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would

Antineoplastic and immunomodulating agents

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer
	otherwise extend the initial treatment period.						

An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.

This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Authority required

Initial 2

Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.

Initial PBS-subsidised treatment with adalimumab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:

- (a) has a documented history of complex refractory fistulising Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and
- (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the time frames specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) two completed authority prescription forms; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and
 - details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.

The most recent fistula assessment must be no more than 1 month old at the time of application.

A maximum of 16 weeks treatment will be authorised under this criterion.

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.

This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8961P	Injection 40 mg in 0.8 mL pre-filled syringe, 6	1	5036.46	35.40	Humira	VE
8962Q	Injection 40 mg in 0.8 mL pre-filled pen, 6	1	5036.46	35.40	Humira	VE

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
8963R	Injection 40 mg in 0.8 mL pre-filled syringe	2	2	..	1774.46	35.40	Humira VE
8965W	Injection 40 mg in 0.8 mL pre-filled pen	2	2	..	1774.46	35.40	Humira VE

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF COMPLEX REFRACTORY FISTULISING CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for patients with complex refractory fistulising Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 April 2011, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 April 2011 is considered to be in their first cycle as of 1 April 2011.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 April 2011.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 April 2011, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
	submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.						

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for complex refractory fistulising Crohn disease prior to 4 November 2010 or infliximab prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Authority required

Initial 3 (grandfather)

Initial PBS-subsidised treatment of complex refractory FISTULISING CROHN DISEASE in a patient who has previously received non-PBS-subsidised therapy with adalimumab.

Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who satisfies the following criteria:

- (a) has a documented history of complex refractory fistulising Crohn disease and was receiving treatment with adalimumab prior to 4 November 2010; and
- (b) had a draining enterocutaneous or rectovaginal fistula(e) prior to commencing treatment with adalimumab; and
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) is receiving treatment with adalimumab at the time of application; and
- (e) has demonstrated or sustained an adequate response to treatment with adalimumab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to adalimumab treatment is defined as:

- (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or
- (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current and baseline Fistula Assessment form including the date of assessment of the patient's condition; and
 - (ii) a signed patient acknowledgement.

The current fistula assessment must be no more than 1 month old at the time of application.

The baseline fistula assessment must be from immediately prior to commencing treatment with adalimumab.

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.

A maximum of 24 weeks treatment will be approved under this criterion.

Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

Authority required

Continuing treatment of complex refractory FISTULISING CROHN DISEASE.

Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of complex refractory fistulising Crohn disease; and
- (b) has demonstrated or sustained an adequate response to treatment with adalimumab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response is defined as:

- (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or
- (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes a completed Fistula Assessment form including the date of the assessment of the patient's condition.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

The fistula assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.

Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

A maximum of 24 weeks treatment will be authorised under this criterion.

Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8964T	Injection 40 mg in 0.8 mL pre-filled syringe	2	5	..	1774.46	35.40	Humira	VE
8966X	Injection 40 mg in 0.8 mL pre-filled pen	2	5	..	1774.46	35.40	Humira	VE

CERTOLIZUMAB PEGOL

Note

Any queries concerning the arrangements to prescribe certolizumab pegol may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe certolizumab pegol should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with certolizumab pegol, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	— hydroxychloroquine at a dose of at least 200 mg daily; and/or — leflunomide at a dose of at least 10 mg daily; and/or — sulfasalazine at a dose of at least 2 g daily.						

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 18 to 20 weeks of treatment depending on the dosage regimen will be authorised under this restriction.

Where fewer than 5 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 18 or 20 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with certolizumab pegol.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Patients who fail to demonstrate a response to treatment with certolizumab pegol under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with certolizumab pegol, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with certolizumab pegol and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised certolizumab pegol treatment, within the timeframes specified below.

A maximum of 18 to 20 weeks of treatment depending on the dosage regimen will be authorised under this restriction.

Where fewer than 5 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 18 or 20 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised certolizumab pegol treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised certolizumab pegol treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with certolizumab pegol under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with certolizumab pegol, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with certolizumab pegol; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with certolizumab pegol.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with certolizumab pegol must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with certolizumab pegol, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
Patients who fail to demonstrate a response to treatment with certolizumab pegol under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.							
<u>Note</u>							
Special Pricing Arrangements apply.							
3425G	Injection 200 mg in 1 mL single use pre-filled syringe	2	5	..	1708.74	35.40	Cimzia UC

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.

Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with etanercept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Special Pricing Arrangements apply.

8637N	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	3	..	*1829.10	35.40	Enbrel	PF
9089J	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	3	..	1774.47	35.40	Enbrel	PF
9459W	Injection 50 mg in 1 mL single use auto-injector, 4	1	3	..	1774.47	35.40	Enbrel	PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF- α antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains

Antineoplastic and immunomodulating agents

						Dispensed Price for	Maximum Recordable Value for
	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Max. Qty \$	Safety Net \$	Brand Name and Manufacturer
Code							
	eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.						

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with etanercept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with etanercept.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<p>AND either of the following:</p> <p>(i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p> <p>(ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p> <p>— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p> <p>— shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p> <p>The authority application must be made in writing and must include:</p> <p>(1) a completed authority prescription form; and</p> <p>(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p> <p>A maximum of 24 weeks of treatment will be approved under this restriction.</p> <p>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p> <p>All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p> <p>Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p> <p><u>Note</u></p> <p>No applications for increased maximum quantities and/or repeats will be authorised.</p> <p><u>Note</u></p> <p>Special Pricing Arrangements apply.</p>							
8638P	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	5	..	*1829.10	35.40	Enbrel PF
9090K	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	5	..	1774.47	35.40	Enbrel PF
9460X	Injection 50 mg in 1 mL single use auto-injector, 4	1	5	..	1774.47	35.40	Enbrel PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

Authority required

Initial 1

Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have severe active psoriatic arthritis; and
- (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and
- (3) have failed to achieve an adequate response to:
 - (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and
 - (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or
 - (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) an active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks treatment will be authorised under this restriction.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Initial 2

Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have a documented history of severe active psoriatic arthritis; and
- (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and
- (3) have not failed treatment with etanercept during the current Treatment Cycle.

Applications for patients who have received PBS-subsidised treatment with etanercept within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.

A maximum of 16 weeks treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9035M	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	3	..	*1829.10	35.40	Enbrel	PF
9087G	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	3	..	1774.47	35.40	Enbrel	PF
9457R	Injection 50 mg in 1 mL single use auto-injector, 4	1	3	..	1774.47	35.40	Enbrel	PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:

- (1) who have a documented history of severe active psoriatic arthritis; and
- (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with etanercept; and
- (3) who, at the time of application, demonstrate an adequate response to treatment with etanercept.

An adequate response to treatment with etanercept is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
(2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].							

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.

Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9036N	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	5	..	*1829.10	35.40	Enbrel	PF
9088H	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	5	..	1774.47	35.40	Enbrel	PF
9458T	Injection 50 mg in 1 mL single use auto-injector, 4	1	5	..	1774.47	35.40	Enbrel	PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept, golimumab and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alpha antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept, golimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 4 TNF-alfa antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial PBS-subsidised TNF-alfa antagonists without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
	first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.						

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and 18 weeks of treatment for infliximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.

A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

response according to these revised baseline measurements.

For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with golimumab.

A patient who commenced treatment with golimumab for active ankylosing spondylitis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with golimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patients)

Initial PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND

(a) who has at least 2 of the following:

- (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or
- (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or
- (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND

(b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.

The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.

If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.

If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.

The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:

- (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND
- (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.

The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.

Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:

- (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and
- (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and
- (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and
- (iv) a signed patient acknowledgment form.

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Authority required

Initial 2 (change or re-commencement for all patients)

Initial PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with etanercept in the current treatment cycle.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].

A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8778B	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	3	..	*1829.10	35.40	Enbrel	PF
9085E	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	3	..	1774.47	35.40	Enbrel	PF
9455P	Injection 50 mg in 1 mL single use auto-injector, 4	1	3	..	1774.47	35.40	Enbrel	PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept, golimumab and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept, golimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 4 TNF-alfa antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial PBS-subsidised TNF-alfa antagonists without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and 18 weeks of treatment for infliximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.

A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with golimumab.

A patient who commenced treatment with golimumab for active ankylosing spondylitis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with golimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Continuing treatment for all patients

Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:

- (a) has demonstrated an adequate response to treatment with etanercept; and
- (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept.

An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:

- (a) an ESR measurement no greater than 25 mm per hour; or
- (b) a CRP measurement no greater than 10 mg per L; or
- (c) an ESR or CRP measurement reduced by at least 20% from baseline.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<p>Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p> <p>Authority applications must be made in writing and must include:</p> <p>(a) a completed authority prescription form; and</p> <p>(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p> <p>All measurements provided must be no more than 1 month old at the time of application.</p> <p>A maximum of 24 weeks of treatment with etanercept will be authorised under this criterion.</p> <p>Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p> <p>All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with etanercept. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p> <p>Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.</p> <p><u>Note</u></p> <p>No applications for increased maximum quantities and/or repeats will be authorised.</p>							
8779C	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	5	..	*1829.10	35.40	Enbrel PF
9086F	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	5	..	1774.47	35.40	Enbrel PF
9456Q	Injection 50 mg in 1 mL single use auto-injector, 4	1	5	..	1774.47	35.40	Enbrel PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.

From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.

There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made in the following situations:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).

All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.

(2) Assessment of response to initial treatment.

When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

(3) Application for continuing treatment.

Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.

For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

(4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.

Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

(5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

Authority required

Initial treatment [Initial 1, Whole body (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
 - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or
 - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or
 - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)];
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

Antineoplastic and immunomodulating agents

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer
A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.							

Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.

Authority required

Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Initial treatment [Initial 1, Face, hand, foot (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
	(i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.						

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:
 - (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or
 - (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Authority required

Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]]; and
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Special Pricing Arrangements apply.

9037P	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	3	..	*1829.10	35.40	Enbrel	PF
9091L	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	3	..	1774.47	35.40	Enbrel	PF
9461Y	Injection 50 mg in 1 mL single use auto-injector, 4	1	3	..	1774.47	35.40	Enbrel	PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.

From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.

There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made in the following situations:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).

All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.

(2) Assessment of response to initial treatment.

When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

(3) Application for continuing treatment.

Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.

For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

(4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.

Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

(5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

Authority required

Continuing treatment (Whole body)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis; and
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and
- (c) who have demonstrated an adequate response to their most recent course of treatment with etanercept.

An adequate response to treatment is defined as:

A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
- (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.

The most recent PASI assessment must be no more than 1 month old at the time of application.

Approval will be based on the PASI assessment of response to the most recent course of treatment with etanercept.

A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.

Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
Australia on 1800 700 270 to discuss.							

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Continuing treatment (Face, hand, foot)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and
- (c) who have demonstrated an adequate response to treatment with etanercept.

An adequate response to etanercept treatment is defined as the plaque or plaques assessed prior to biological treatment showing:

- (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or
- (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

The most recent PASI assessment must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.

Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.

The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Special Pricing Arrangements apply.

9429G	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	5	..	*1829.10	35.40	Enbrel	PF
9431J	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	5	..	1774.47	35.40	Enbrel	PF
9462B	Injection 50 mg in 1 mL single use auto-injector, 4	1	5	..	1774.47	35.40	Enbrel	PF

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH A HISTORY OF JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient over 18 years who has a history of juvenile idiopathic arthritis with onset prior to the age of 18 years. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any one time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 5 year break in PBS-subsidised bDMARD therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment.

A patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count and ESR/CRP) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patient or patient recommencing after a break of more than 12 months).

Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:

- (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND
- (b) has received no PBS-subsidised treatment with a bDMARD for this condition in the previous 12 months; and

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

(c) has failed to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:

- hydroxychloroquine at a dose of at least 200 mg daily; or
- leflunomide at a dose of at least 10 mg daily; or
- sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg per day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialed, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) an active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
	maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).							
	Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.							
	Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.							
	If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle.							
	Authority required							
	Initial 2 (change or re-commencement after break of less than 12 months).							
	Initial PBS-subsidised treatment with etanercept by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:							
	(a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND							
	(b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and							
	(c) has not failed PBS-subsidised therapy with etanercept for this condition more than once in the current treatment cycle.							
	The authority application must be made in writing and must include:							
	(a) a completed authority prescription form; and							
	(b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].							
	Applications for a patient who has received PBS-subsidised treatment with etanercept in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.							
	A maximum of 16 weeks of treatment will be authorised under this restriction.							
	Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with etanercept may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).							
	Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.							
	Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.							
	Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.							
	If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle.							
3445H	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	3	..	*1829.10	35.40	Enbrel	PF
3446J	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	3	..	1774.47	35.40	Enbrel	PF
3447K	Injection 50 mg in 1 mL single use auto-injector, 4	1	3	..	1774.47	35.40	Enbrel	PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH A HISTORY OF JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient over 18 years who has a history of juvenile idiopathic arthritis with onset prior to the age of 18 years. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any one time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 5 year break in PBS-subsidised bDMARD therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment.

A patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count and ESR/CRP) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

Authority required

Continuing treatment.

Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older:

- (a) who has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and
- (b) who has demonstrated an adequate response to treatment with etanercept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with etanercept.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;
AND either of the following:

- (i) an active joint count of fewer than 10 active (swollen and tender) joints; or
- (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or
- (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<p>The authority application must be made in writing and must include:</p> <p>(1) a completed authority prescription form; and</p> <p>(2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p> <p>A maximum of 24 weeks of treatment will be approved under this restriction.</p> <p>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p> <p>All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p> <p>If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle.</p>							
3448L	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	5	..	*1829.10	35.40	Enbrel PF
3449M	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	5	..	1774.47	35.40	Enbrel PF
3450N	Injection 50 mg in 1 mL single use auto-injector, 4	1	5	..	1774.47	35.40	Enbrel PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS UNDER 18 YEARS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of etanercept for patients under 18 years with severe chronic plaque psoriasis.

Applications under this restriction will be limited to provide patients with a maximum of 24 weeks of therapy. A maximum of 16 weeks treatment with etanercept will be authorised for the primary application. The balance, a further 8 weeks treatment, will be authorised if the submitted Psoriasis Area and Severity Index (PASI) assessment demonstrates an adequate response to treatment.

A patient may fail to respond to PBS-subsidised etanercept twice under this restriction. Once a patient has failed to respond to treatment 2 times, they must have, at a minimum, a 12 month break. The length of a treatment break is measured from the date the most recent treatment was stopped to the date of the first application for initial treatment.

There are separate restrictions for treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made for patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy.

(2) Applications for approval for re-treatment.

Applications for re-treatment with etanercept should be made in the following situations:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

- (i) a patient who has received prior PBS-subsidised etanercept and experiences a disease flare, and wishes to start a second or subsequent treatment course with etanercept following a break of less than 12 months in PBS-subsidised therapy; or
- (ii) a patient who has received and failed to respond to prior PBS-subsidised etanercept and wishes to start a second or subsequent treatment course following a break of less than 12 months in PBS-subsidised therapy.

Patients are eligible for re-treatment due to disease flare if there is a 50% or greater change in the patients PASI score or the patient has a current PASI score of greater than 15, compared to the most recent response assessment following cessation of the most recent 24 weeks of PBS-subsidised etanercept.

(3) Assessment of response to treatment.

When prescribing treatment with etanercept, a PASI assessment must be conducted after at least 12 weeks of treatment.

This assessment must be submitted to Medicare Australia within 1 month of the completion of 12 weeks of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

A prescription for a further 8 weeks of treatment should be submitted with the PASI assessment. This will complete 24 weeks of treatment for eligible patients.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for etanercept. However, prescribers may provide new baseline measurements any time that an initial or re-treatment authority is submitted and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of gaining approval for the remainder of 24 weeks treatment.

(5) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment course with etanercept following a break in PBS-subsidised etanercept therapy of at least 12 months, must requalify for treatment under the initial treatment restriction. The PASI assessments must not be older than 1 month at the time of application.

Authority required

Initial treatment [Whole body (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist of a patient under 18 years who:

- (a) has severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and
- (b) has not received any prior PBS-subsidised treatment with etanercept for this condition; and
- (c) whose parent or authorised guardian has signed a patient acknowledgement; and
- (d) has failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 3 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
 - (ii) methotrexate at a dose of at least 10 mg or 10 mg per square metre weekly (whichever is lowest) for at least 6 weeks; and/or
 - (iii) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and

Antineoplastic and immunomodulating agents

						Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer	
(iii) the parent or authorised guardian signed patient and prescriber acknowledgements.								

A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction. A maximum of 16 weeks treatment with etanercept will be authorised for the primary application. The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.

Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.

An adequate response to treatment is defined as:

A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, when compared with the pre-etanercept treatment baseline value.

Authority required

Re-Treatment [Whole body (Received prior etanercept under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for a patient under 18 years who has:

- (a) a documented history of severe chronic plaque psoriasis; and
- (b) received prior PBS-subsidised treatment with etanercept for this condition; and
- (c) not failed PBS-subsidised therapy with etanercept for the treatment of this condition more than once in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of prior etanercept treatment, including date.

A total maximum of 24 weeks of treatment with etanercept will be authorised under this restriction. A maximum of 16 weeks treatment with etanercept will be authorised for the primary application. The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.

Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.

Authority required

Initial treatment [Face, hand, foot (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist of a patient under 18 years who:

- (a) has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- (b) has not received any prior PBS-subsidised treatment with etanercept for this condition; and
- (c) whose parent or authorised guardian has signed a patient acknowledgement; and
- (d) has failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 3 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	(ii) methotrexate at a dose of at least 10 mg or 10 mg per square metre weekly (whichever is lowest) for at least 6 weeks; and/or						
	(iii) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.						

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:
 - (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or
 - (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the parent or authorised guardian signed patient and prescriber acknowledgements.

A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction. A maximum of 16 weeks treatment with etanercept will be authorised for the primary application. The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.

Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.

An adequate response to treatment is defined as:

A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, when compared with the pre-etanercept treatment baseline value.

Authority required

Re-Treatment [Face, hand, foot (Received prior etanercept under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for a patient under 18 years who has:

- (a) a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
- (b) received prior PBS-subsidised treatment with etanercept for this condition; and
- (c) not failed PBS-subsidised therapy with etanercept for the treatment of this condition more than once in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]]; and
 - (ii) details of prior etanercept treatment, including date.

A total maximum of 24 weeks of treatment with etanercept will be authorised under this restriction. A maximum of 16 weeks treatment with etanercept will be authorised for the primary application. The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

PASI assessment shows an adequate demonstrated response to treatment.

Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Special Pricing Arrangements apply.

1954W	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	2	3	..	*1829.10	35.40	Enbrel	PF
1963H	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	3	..	1774.47	35.40	Enbrel	PF
1964J	Injection 50 mg in 1 mL single use auto-injector, 4	1	3	..	1774.47	35.40	Enbrel	PF

GOLIMUMAB

Note

Any queries concerning the arrangements to prescribe golimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe golimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer
					for Max. Qty \$	Recordable Value for Safety Net \$	

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
	— sulfasalazine at a dose of at least 2 g daily.				\$	\$	

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with golimumab.

Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with golimumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised golimumab treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised golimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

3426H	Injection 50 mg in 0.5 mL single use pre-filled syringe	1	3	..	1777.39	35.40	Simponi	JC
3427J	Injection 50 mg in 0.5 mL single use pre-filled pen	1	3	..	1777.39	35.40	Simponi	JC

GOLIMUMAB

Note

Any queries concerning the arrangements to prescribe golimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe golimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with golimumab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with golimumab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with golimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

3428K	Injection 50 mg in 0.5 mL single use pre-filled syringe	1	5	..	1777.39	35.40	Simponi	JC
3429L	Injection 50 mg in 0.5 mL single use pre-filled pen	1	5	..	1777.39	35.40	Simponi	JC

GOLIMUMAB

Note

Any queries concerning the arrangements to prescribe golimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe golimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes,

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

Authority required

Initial 1

Initial PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have severe active psoriatic arthritis; and
- (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and
- (3) have failed to achieve an adequate response to:
 - (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and
 - (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or
 - (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) an active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.								
The authority application must be made in writing and must include:								
(1) a completed authority prescription form; and								
(2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and								
(3) a signed patient acknowledgement.								
A maximum of 16 weeks treatment will be authorised under this restriction.								
Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).								
The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.								
Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.								
<u>Authority required</u>								
Initial 2								
Initial PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:								
(1) have a documented history of severe active psoriatic arthritis; and								
(2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and								
(3) have not failed treatment with golimumab during the current Treatment Cycle.								
Applications for patients who have received PBS-subsidised treatment with golimumab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised golimumab treatment, within the timeframes specified below.								
A maximum of 16 weeks treatment will be authorised under this restriction.								
Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).								
Where the most recent course of PBS-subsidised golimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.								
Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.								
The authority application must be made in writing and must include:								
(1) a completed authority prescription form; and								
(2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].								
Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised. Applications for treatment with golimumab where the dosing frequency exceeds 50 mg every 4 weeks will not be approved.								
3430M	Injection 50 mg in 0.5 mL single use pre-filled syringe	1	3	..	1777.39	35.40	Simponi	JC
3431N	Injection 50 mg in 0.5 mL single use pre-filled pen	1	3	..	1777.39	35.40	Simponi	JC

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

GOLIMUMAB

Note

Any queries concerning the arrangements to prescribe golimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe golimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialed it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

Authority required

Initial 3 — grandfather golimumab patients

Initial PBS-subsidised supply for continuing treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have a documented history of severe active psoriatic arthritis; and
- (2) were receiving treatment with golimumab prior to 1 March 2010; and
- (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with golimumab; and
- (4) are receiving treatment with golimumab at the time of application.

The authority application must be made in writing and must include:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
	(1) a completed authority prescription form; and (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and (3) a signed patient acknowledgement.							
	A maximum of 24 weeks of treatment with golimumab will be authorised under this restriction.							
	Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).							
	Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.							
	Patients may qualify for PBS-subsidised treatment under this restriction once only.							
	Authority required							
	Continuing treatment							
	Continuing PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:							
	(1) who have a documented history of severe active psoriatic arthritis; and (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with golimumab; and (3) who, at the time of application, demonstrate an adequate response to treatment with golimumab.							
	An adequate response to treatment with golimumab is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%: — elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or — shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).							
	The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].							
	A maximum of 24 weeks of treatment will be approved under this restriction.							
	Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).							
	All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with golimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.							
	Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.							
	Note							
	No applications for increased maximum quantities and/or repeats will be authorised. Applications for treatment with golimumab where the dosing frequency exceeds 50 mg every 4 weeks will not be approved.							
3432P	Injection 50 mg in 0.5 mL single use pre-filled syringe	1	5	..	1777.39	35.40	Simponi	JC
3433Q	Injection 50 mg in 0.5 mL single use pre-filled pen	1	5	..	1777.39	35.40	Simponi	JC

GOLIMUMAB

Note

Any queries concerning the arrangements to prescribe golimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe golimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept, golimumab and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept, golimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 4 TNF-alfa antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial PBS-subsidised TNF-alfa antagonists without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and 18 weeks of treatment for infliximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.

A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with golimumab.

A patient who commenced treatment with golimumab for active ankylosing spondylitis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with golimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patients)

Initial PBS-subsidised treatment with golimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND

(a) who has at least 2 of the following:

(i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

(ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or

(iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND

(b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.

The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.

If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.

If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.

The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:

- (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND
- (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.

The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.

Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:
 - (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and
 - (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and
 - (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and
 - (iv) a signed patient acknowledgment form.

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A maximum of 16 weeks of treatment with golimumab will be approved under this criterion.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Authority required

Initial 2 (change or re-commencement for all patients)

Initial PBS-subsidised treatment with golimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with golimumab in the current treatment cycle.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Authority applications must be made in writing and must include:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	(a) a completed authority prescription form; and (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].						
	A maximum of 16 weeks of treatment with golimumab will be approved under this criterion.						
	Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.						
	Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.						
	Note No applications for increased maximum quantities and/or repeats will be authorised. Applications for treatment with golimumab where the dosing frequency exceeds 50 mg every 4 weeks will not be approved.						
3434R	Injection 50 mg in 0.5 mL single use pre-filled syringe	1	3	..	1777.39	35.40	Simponi JC
3435T	Injection 50 mg in 0.5 mL single use pre-filled pen	1	3	..	1777.39	35.40	Simponi JC

GOLIMUMAB

Note

Any queries concerning the arrangements to prescribe golimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe golimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept, golimumab and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept, golimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 4 TNF-alfa antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial PBS-subsidised TNF-alfa antagonists without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and 18 weeks of treatment for infliximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.

A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with golimumab.

A patient who commenced treatment with golimumab for active ankylosing spondylitis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with golimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial ('grandfather' patients)

Initial PBS-subsidised supply for continuing treatment with golimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who was receiving treatment with golimumab prior to 1 March 2010; and

- (a) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with golimumab; and
- (b) is receiving treatment with golimumab at the time of application.

The BASDAI assessment and ESR and/or CRP measurements provided must be no more than 1 month old at the time of application. Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the following:
 - (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and
 - (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and
 - (iii) a signed patient acknowledgment form.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of the course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is due in order to ensure continuity of treatment for those patients who meet the continuation criteria. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Patients may only qualify for PBS-subsidised treatment under this criterion once.

Authority required

Continuing treatment for all patients

Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:

- (a) has demonstrated an adequate response to treatment with golimumab; and
- (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with golimumab.

An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

- (a) an ESR measurement no greater than 25 mm per hour; or
 (b) a CRP measurement no greater than 10 mg per L; or
 (c) an ESR or CRP measurement reduced by at least 20% from baseline.

Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
 (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].

All measurements provided must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.

All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with golimumab. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Note

No applications for increased maximum quantities and/or repeats will be authorised. Applications for treatment with golimumab where the dosing frequency exceeds 50 mg every 4 weeks will not be approved.

3436W	Injection 50 mg in 0.5 mL single use pre-filled syringe	1	5	..	1777.39	35.40	Simponi	JC
3437X	Injection 50 mg in 0.5 mL single use pre-filled pen	1	5	..	1777.39	35.40	Simponi	JC

Interleukin inhibitors

USTEKINUMAB

Note

Any queries concerning the arrangements to prescribe ustekinumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe ustekinumab should be forwarded to:

Medicare Australia
 Prior Written Approval of Specialised Drugs
 Reply Paid 9826
 GPO Box 9826
 HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.

From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.

There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made in the following situations:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).

All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.

(2) Assessment of response to initial treatment.

When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

(3) Application for continuing treatment.

Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.

For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

(4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
	agent.						

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.

Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

(5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

Authority required

Initial treatment [Initial 1, Whole body (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
 - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or
 - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or
 - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection. Up to a maximum of 2 repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.

Note

No applications for increased repeats will be authorised.

Authority required

Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with ustekinumab for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised ustekinumab treatment within this Treatment Cycle and who wish to re-commence ustekinumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised ustekinumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection. Up to a maximum of 2 repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Note

No applications for increased repeats will be authorised.

Authority required

Initial treatment [Initial 1, Face, hand, foot (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
 - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or
 - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or
 - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:
 - (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or
 - (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection. Up to a maximum of 2 repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Note

No applications for increased repeats will be authorised.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Authority required

Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with ustekinumab for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised ustekinumab treatment within this Treatment Cycle and who wish to re-commence ustekinumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised ustekinumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection. Up to a maximum of 2 repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased repeats will be authorised.

Note

Special Pricing Arrangements apply.

9304Q	Injection 45 mg in 0.5 mL	1	2	..	4601.52	35.40	Stelara	JC
-------	---------------------------	---	---	----	---------	-------	---------	----

USTEKINUMAB

Note

Any queries concerning the arrangements to prescribe ustekinumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe ustekinumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.

From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.

There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made in the following situations:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).

All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.

(2) Assessment of response to initial treatment.

When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

(3) Application for continuing treatment.

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.

For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

(4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.

Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

(5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

Authority required

Continuing treatment (Whole body)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis; and
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with ustekinumab; and
- (c) who have demonstrated an adequate response to their most recent course of treatment with ustekinumab.

An adequate response to treatment is defined as:

A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with ustekinumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
(i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.							

The most recent PASI assessment must be no more than 1 month old at the time of application.

Approval will be based on the PASI assessment of response to the most recent course of treatment with ustekinumab.

A maximum of 24 weeks of treatment with ustekinumab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection. Up to a maximum of 1 repeat will be authorised.

Where fewer than 1 repeat is requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased repeats will be authorised.

Authority required

Continuing treatment (Face, hand, foot)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with ustekinumab; and
- (c) who have demonstrated an adequate response to treatment with ustekinumab.

An adequate response to ustekinumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:

- (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or
- (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with ustekinumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

The most recent PASI assessment must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with ustekinumab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection. Up to a maximum of 1 repeat will be authorised.

Where fewer than 1 repeat is requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.							
It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.							
The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.							
Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.							
<u>Note</u> No applications for increased repeats will be authorised.							
<u>Note</u> Special Pricing Arrangements apply.							
9305R	Injection 45 mg in 0.5 mL	1	1	..	4601.52	35.40	Stelara JC

Calcineurin inhibitors

CYCLOSPORIN

Caution

Careful monitoring of patients is mandatory.

Authority required

Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of:

(a) patients with organ or tissue transplants. Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.

The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application;

(b) patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate. Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient. The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application;

(c) patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life. Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient. The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application;

(d) patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired. Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient. The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application;

(e) patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate. Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient. The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application;

Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate;

Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life;

Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.

8657P	Capsule 10 mg	120	3	..	*94.52	35.40	Neoral 10	NV
8658Q	Capsule 25 mg	60	3	..	*97.34	35.40	^a Cicloral	SZ
							^a Neoral 25	NV
8659R	Capsule 50 mg	60	3	..	*195.48	35.40	^a Cicloral	SZ
							^a Neoral 50	NV
8660T	Capsule 100 mg	60	3	..	*374.54	35.40	^a Cicloral	SZ
							^a Neoral 100	NV
8661W	Oral liquid 100 mg per mL, 50 mL	2	3	..	*712.76	35.40	Neoral	NV

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
TACROLIMUS							
<u>Caution</u>							
Careful monitoring of patients is mandatory.							
<u>Authority required</u>							
Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants. Therapy must remain under the supervision and direction of the transplant unit reviewing the patient. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.							
5299X	Capsule 0.5 mg (once daily prolonged release)	30	3	..	64.69	35.40	Prograf XL JC
5300Y	Capsule 1 mg (once daily prolonged release)	60	3	..	236.01	35.40	Prograf XL JC
5451X	Capsule 5 mg (once daily prolonged release)	30	3	..	556.42	35.40	Prograf XL JC
8646C	Capsule 0.5 mg	100	3	..	200.40	35.40	^a Prograf JC
						^a Tacrolimus Sandoz	SZ
8647D	Capsule 1 mg	100	3	..	377.01	35.40	^a Prograf JC
						^a Tacrolimus Sandoz	SZ
8648E	Capsule 5 mg	50	3	..	922.54	35.40	^a Prograf JC
						^a Tacrolimus Sandoz	SZ

Other immunosuppressants

AZATHIOPRINE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2687K NP	Tablet 50 mg	100	5	..	48.16	35.40	^a Azamun	GM
							^a Azapin	QA
							^a Azathioprine Sandoz	SZ
							^a GenRx	GX
							^a Azathioprine	AS
							^a Imuran	AF
2688L NP	Tablet 25 mg	100	5	..	31.61	32.72	^a Azathioprine	SZ
							^a Sandoz	AS

METHOTREXATE

1622J	Tablet 2.5 mg	30	5	..	13.22	14.33	^a Hospira Pty Limited	HH
							^a Methoblastin	PF
2272N	Tablet 10 mg	15	3	..	21.94	23.05	Methoblastin	PF

METHOTREXATE

Restricted benefit

For patients requiring doses greater than 20 mg per week.

1623K	Tablet 10 mg	50	2	..	45.38	35.40	Methoblastin	PF
-------	--------------	----	---	----	-------	-------	--------------	----

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Musculo-skeletal system

Antiinflammatory and antirheumatic products

Antiinflammatory and antirheumatic products, non-steroids

Acetic acid derivatives and related substances

1302M NP,MW	DICLOFENAC SODIUM Suppository 100 mg	40	3	..	*25.02	26.13	Voltaren 100	NV
<hr/>								
1299J NP	DICLOFENAC SODIUM <u>Restricted benefit</u> Chronic arthropathies (including osteoarthritis) with an inflammatory component; Bone pain due to malignant disease.	100	3	..	*12.84	13.95	^a APO-Diclofenac	TX
							^a Chem mart Diclofenac	CH
							^a Clonac 25	QA
							^a Diclofenac-GA	GM
							^a Diclofenac Sandoz	SZ
							^a Fenac 25	AF
							^a Terry White Chemists Diclofenac	TW
				^B 2.32	*15.16	13.95	^a Voltaren 25	NV
1300K NP	Tablet 50 mg (enteric coated)	50	3	..	10.92	12.03	^a APO-Diclofenac	TX
							^a Chem mart Diclofenac	CH
							^a Clonac 50	QA
							^a Diclofenac-GA	GM
							^a Diclofenac Sandoz	SZ
							^a Fenac	AF
							^a Terry White Chemists Diclofenac	TW
				^B 2.34	13.26	12.03	^a Voltaren 50	NV
2757D NP	INDOMETHACIN Suppository 100 mg	40	3	..	*22.60	23.71	Indocid	AS
<hr/>								
2454E NP	INDOMETHACIN <u>Restricted benefit</u> Chronic arthropathies (including osteoarthritis) with an inflammatory component; Bone pain due to malignant disease.	100	3	..	*12.52	13.63	^a Arthrexin	AF
				^B 2.02	*14.54	13.63	^a Indocid	AS

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Oxicams							
MELOXICAM							
Note							
The use of meloxicam for the treatment of the following conditions is not subsidised through the PBS:							
(a) acute pain;							
(b) soft tissue injury;							
(c) arthrosis without an inflammatory component.							
Restricted benefit							
Symptomatic treatment of osteoarthritis;							
Symptomatic treatment of rheumatoid arthritis.							
Note							
Pharmaceutical benefits that have the form meloxicam tablet 7.5 mg and pharmaceutical benefits that have the form meloxicam capsule 7.5 mg are equivalent for the purposes of substitution.							
8561N NP	Tablet 7.5 mg	30	3	..	14.95	16.06	^a Chem mart Meloxicam 7.5 mg ^a GenRx Meloxicam GX ^a Meloxibell GQ ^a Meloxicam-GA GM ^a Meloxicam-PS FZ ^a Meloxicam Ranbaxy RA ^a Meloxicam Sandoz SZ ^a Movalis 7.5 QA ^a Moxicam 7.5 AF ^a Pharmacor Meloxicam 7.5 CR ^a Terry White Chemists Meloxicam 7.5 mg TW
8887R NP	Capsule 7.5 mg	30	3	^B 1.35 ..	16.30 14.95	16.06 16.06	^a Mobic BY ^a APO-Meloxicam TX ^a Chem mart Meloxicam CH ^a Melox 7.5 GM ^a Mobic BY ^a Movalis 7.5 QA ^a Terry White Chemists Meloxicam TW
MELOXICAM							
Note							
The use of meloxicam for the treatment of the following conditions is not subsidised through the PBS:							
(a) acute pain;							
(b) soft tissue injury;							
(c) arthrosis without an inflammatory component.							
Restricted benefit							
Symptomatic treatment of osteoarthritis;							
Symptomatic treatment of rheumatoid arthritis.							
Note							
Pharmaceutical benefits that have the form meloxicam tablet 15 mg and pharmaceutical benefits that have the form meloxicam capsule 15 mg are equivalent for the purposes of substitution.							
8562P NP	Tablet 15 mg	30	3	..	18.83	19.94	^a Chem mart Meloxicam CH

Musculo-skeletal system

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer	
8888T NP	Capsule 15 mg	30	3	..	18.83	19.94	15 mg	
							^a GenRx Meloxicam GX	
							^a Meloxicibell GQ	
							^a Meloxicam-GA GM	
							^a Meloxicam-PS FZ	
							^a Meloxicam RA	
							Ranbaxy	
							^a Meloxicam Sandoz SZ	
							^a Movalis 15 QA	
							^a Moxicam 15 AF	
							^a Pharmacor CR	
							Meloxicam 15	
							^a Terry White Chemists TW	
							Meloxicam	
							15 mg	
1895R NP	Dispersible tablet 10 mg	50	3	..	12.30	13.41	^a Mobic BY	
							^a APO-Meloxicam TX	
							^a Chem mart CH	
							Meloxicam	
							^a Melox 15 GM	
							^a Mobic BY	
							^a Movalis 15 QA	
							^a Terry White Chemists TW	
							Meloxicam	
PIROXICAM								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component.								
1895R NP	Dispersible tablet 10 mg	50	3	..	12.30	13.41	Mobilis D-10 AF	
1896T NP	Dispersible tablet 20 mg	25	3	..	12.02	13.13	^a Mobilis D-20 AF	
1897W NP	Capsule 10 mg	50	3	..	12.30	13.41	^B 2.95	
							^a Feldene-D PF	
							^a Chem mart CH	
							Piroxicam	
							^a GenRx Piroxicam GX	
1898X NP	Capsule 20 mg	25	3	..	12.02	13.13	^a Mobilis 10 AF	
							^a Terry White Chemists TW	
							Piroxicam	
							^B 2.52	
							14.82	
							13.41	
							^a Feldene PF	
							^a Chem mart CH	
Piroxicam								
							^a GenRx Piroxicam GX	
							^a Mobilis 20 AF	
							^a Terry White Chemists TW	
							Piroxicam	
							^B 2.49	
							^a Feldene PF	

Propionic acid derivatives

IBUPROFEN								
3192B NP,MW	Tablet 400 mg	30	9.29	10.40	Brufen	AB

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
IBUPROFEN								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component;								
Bone pain due to malignant disease.								
3190X NP	Tablet 400 mg	90	3	..	*14.83	15.94	Brufen	AB
KETOPROFEN								
1588N NP	Suppository 100 mg	40	3	..	*25.40	26.51	Orudis	SW
KETOPROFEN								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component.								
1590Q NP	Capsule 200 mg (sustained release)	28	3	..	19.20	20.31	^a Oruvail SR	AV
				^B 2.21	21.41	20.31	^a Orudis SR 200	SW
NAPROXEN								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component;								
Bone pain due to malignant disease.								
1614Y NP	Tablet 750 mg (sustained release)	28	3	..	12.18	13.29	^a Proxen SR 750	MD
				^B 1.22	13.40	13.29	^a Naprosyn SR750	RO
1615B NP	Tablet 1 g (sustained release)	28	3	..	14.06	15.17	^a Proxen SR 1000	MD
				^B 1.29	15.35	15.17	^a Naprosyn SR1000	RO
1659H NP	Tablet 500 mg	50	3	..	12.68	13.79	^a Inza 500	AF
				^B 1.30	13.98	13.79	^a Naprosyn	RO
1674D NP	Tablet 250 mg	100	3	..	*13.44	14.55	^a Inza 250	AF
				^B 2.24	*15.68	14.55	^a Naprosyn	RO
NAPROXEN SODIUM								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component;								
Bone pain due to malignant disease.								
<u>Note</u>								
Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.								
1795L NP	Tablet 550 mg	50	3	..	12.87	13.98	^a Crysanal	MD
				^B 2.17	15.04	13.98	^a Anaprox 550	RO
TIAPROFENIC ACID								
<u>Caution</u>								
Cystitis and other urinary disorders have been reported with this drug.								
<u>Note</u>								
The recommended maximum dose is 600 mg per day.								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component.								
2103Q NP	Tablet 300 mg	60	3	..	17.68	18.79	Surgam	SW

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Fenamates

MEFENAMIC ACID

Restricted benefit

Dysmenorrhoea;

Menorrhagia.

1824B NP	Capsule 250 mg	50	2	..	18.26	19.37	Ponstan	PF
-------------	----------------	----	---	----	-------	-------	---------	----

Coxibs

CELECOXIB

Note

The use of celecoxib for the treatment of the following conditions is not subsidised through the PBS:

(a) acute pain;

(b) soft tissue injury;

(c) arthrosis without an inflammatory component.

Restricted benefit

Symptomatic treatment of osteoarthritis;

Symptomatic treatment of rheumatoid arthritis.

8439E NP	Capsule 100 mg	60	3	..	32.41	33.52	Celebrex	PF
8440F NP	Capsule 200 mg	30	3	..	32.41	33.52	Celebrex	PF

Specific antirheumatic agents

Quinolines

HYDROXYCHLOROQUINE SULFATE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1512N NP	Tablet 200 mg	100	1	..	32.69	33.80	^a APO-Hydroxychloroquine	TX
							^a Chem mart Hydroxychloroquine	CH
							^a Plaquenil	SW
							^a Terry White Chemists Hydroxychloroquine	TW

Gold preparations

AURANOFIN

Caution

Regular blood and urine checks are essential.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1095P NP	Tablet 3 mg	60	5	..	63.65	35.40	Ridaura	GH
2022K NP	Capsule 3 mg	60	5	..	779.09	35.40	Ridaura	BZ

SODIUM AUROTHIOMALATE

Caution

Regular blood and urine checks are essential.

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2016D NP	Injection 10 mg	10	67.13	35.40	Myocrisin	SW
2017E NP	Injection 20 mg	10	1	..	102.77	35.40	Myocrisin	SW
2018F NP	Injection 50 mg	10	1	..	152.57	35.40	Myocrisin	SW

Penicillamine and similar agents

PENICILLAMINE

Caution

Regular blood and urine checks are essential.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2721F NP	Tablet 125 mg	100	1	..	31.73	32.84	D-Penamine	AL
2838J NP	Tablet 250 mg	100	1	..	53.39	35.40	D-Penamine	AL

Muscle relaxants

Muscle relaxants, centrally acting agents

Other centrally acting agents

BACLOFEN

2729P NP	Tablet 10 mg	100	5	..	23.32	24.43	^a Chem mart Baclofen	CH
							^a Clofen 10	AF
							^a GenRx Baclofen	GX
							^a Stelax 10	QA
							^a Terry White Chemists Baclofen	TW
				^B 1.50	24.82	24.43	^a Lioresal 10	NV
2730Q NP	Tablet 25 mg	100	5	..	42.97	35.40	^a Chem mart Baclofen	CH
							^a Clofen 25	AF
							^a GenRx Baclofen	GX
							^a Stelax 25	QA
							^a Terry White Chemists Baclofen	TW
				^B 1.29	44.26	35.40	^a Lioresal 25	NV

Muscle relaxants, directly acting agents

Dantrolene and derivatives

DANTROLENE SODIUM

Restricted benefit

Treatment of chronic spasticity.

1779P NP	Capsule 25 mg	100	2	..	72.14	35.40	Dantrium	PF
1780Q NP	Capsule 50 mg	100	2	..	81.91	35.40	Dantrium	PF

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Antigout preparations							

Antigout preparations

Preparations inhibiting uric acid production

ALLOPURINOL

Note

The dose should be adjusted in accordance with renal function.

Note

For item codes 2600W and 1557Y, pharmaceutical benefits that have the form tablet 100 mg are equivalent for the purposes of substitution.

1557Y NP	Tablet 100 mg	200	2	..	*12.96	14.07	^a	Progout 100	AF
2600W NP	Tablet 100 mg	200	2	..	12.96	14.07	^a	Allopurinol Sandoz	SZ
							^a	Allosig	FM
							^a	Chem mart	CH
							^a	Allopurinol	
							^a	GenRx Allopurinol	GX
							^a	Terry White	TW
							^a	Chemists	
				^B 2.85	15.81	14.07	^a	Allopurinol	
							^a	Zyloprim	QA

ALLOPURINOL

Note

The dose should be adjusted in accordance with renal function.

2604C NP	Tablet 300 mg	60	2	..	10.33	11.44	^a	Allopurinol Sandoz	SZ
							^a	Allosig	FM
							^a	Chem mart	CH
							^a	Allopurinol	
							^a	GenRx Allopurinol	GX
							^a	Progout 300	AF
							^a	Terry White	TW
							^a	Chemists	
				^B 2.85	13.18	11.44	^a	Allopurinol	
							^a	Zyloprim	QA

Preparations increasing uric acid excretion

PROBENECID

1940D NP	Tablet 500 mg	100	5	..	75.79	35.40		Pro-Cid	PL
-------------	---------------	-----	---	----	-------	-------	--	---------	----

Preparations with no effect on uric acid metabolism

COLCHICINE

3410L NP	Tablet 500 micrograms	30	5	..	11.10	12.21	^a	Lengout	LN
				^B 0.85	11.95	12.21	^a	Colgout	AS

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
Drugs for treatment of bone diseases							

Drugs affecting bone structure and mineralization

Bisphosphonates

ALENDRONATE SODIUM

Authority required (STREAMLINED)

3070

Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.

The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

3933

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.

The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

2646

Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

8511Y NP	Tablet equivalent to 70 mg alendronic acid	4	5	..	27.62	28.73	^a	Adronat	AF
							^a	Alendrobell 70mg	GQ
							^a	Alendronate-GA	GM
							^a	Alendronate Sandoz	SZ
							^a	Alendro Once Weekly	QA
							^a	APO-Alendronate	TX
							^a	Chem mart Alendronate 70mg	CH
							^a	Densate 70	DO
							^a	Ossmax 70mg	RA
							^a	Terry White Chemists Alendronate 70mg	TW
							^B 2.50	30.12	28.73

ALENDRONATE SODIUM

Authority required (STREAMLINED)

3256

Symptomatic Paget disease of bone.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8090T NP	Tablet equivalent to 40 mg alendronic acid	30	5	..	73.17	35.40		Fosamax 40 mg	MK
-------------	--	----	---	----	-------	-------	--	---------------	----

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
DISODIUM ETIDRONATE							
<u>Authority required (STREAMLINED)</u>							
3257							
Symptomatic Paget disease of bone when calcitonin has been found to be unsatisfactory due to lack of efficacy;							
3258							
Symptomatic Paget disease of bone when calcitonin has been found to be unsatisfactory due to unacceptable side effects;							
1153							
Heterotopic ossification.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
2920Q NP	Tablet 200 mg	60	5	..	115.27	35.40	Didronel PF
DISODIUM PAMIDRONATE							
<u>Authority required (STREAMLINED)</u>							
3256							
Symptomatic Paget disease of bone.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
<u>Note</u>							
Pharmaceutical benefits that have the form disodium pamidronate powder for I.V. infusion 15 mg (after reconstitution) and pharmaceutical benefits that have the form disodium pamidronate concentrated injection 15 mg are equivalent for the purposes of substitution.							
8208B NP	Injection set containing 4 vials powder for I.V. infusion 15 mg and 4 ampoules solvent 5 mL	1	250.22	35.40 ^a	Aredia 15 mg NV
8461H NP	Concentrated injection 15 mg in 5 mL	4	*250.24	35.40 ^a	Pamisol HH
DISODIUM PAMIDRONATE							
<u>Authority required (STREAMLINED)</u>							
3256							
Symptomatic Paget disease of bone.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
<u>Note</u>							
Pharmaceutical benefits that have the form disodium pamidronate powder for I.V. infusion 30 mg (after reconstitution) and pharmaceutical benefits that have the form disodium pamidronate concentrated injection 30 mg are equivalent for the purposes of substitution.							
8209C NP	Injection set containing 2 vials powder for I.V. infusion 30 mg and 2 ampoules solvent 10 mL	1	250.22	35.40 ^a	Aredia 30 mg NV
8462J NP	Concentrated injection 30 mg in 10 mL	2	*250.22	35.40 ^a	Pamisol HH
DISODIUM PAMIDRONATE							
<u>Authority required (STREAMLINED)</u>							
3256							
Symptomatic Paget disease of bone.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
8463K NP	Concentrated injection 60 mg in 10 mL	1	250.20	35.40	Pamisol HH

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
IBANDRONIC ACID								
<u>Restricted benefit</u>								
Bone metastases from breast cancer.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
9357L NP	Tablet 50 mg (as ibandronate sodium monohydrate)	28	2	..	342.44	35.40	Bondronat	HH
RISEDRONATE SODIUM								
<u>Authority required (STREAMLINED)</u>								
3070								
Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.								
The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.								
<u>Authority required (STREAMLINED)</u>								
2645								
Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.								
The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.								
<u>Authority required (STREAMLINED)</u>								
2646								
Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.								
A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.								
<u>Note</u>								
Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.								
8481J NP	Tablet 5 mg	28	5	..	46.65	35.40	Actonel	SW
8621R NP	Tablet 35 mg	4	5	..	46.65	35.40	^a Acris Once-a-Week	AF
							^a APO-Risedronate	TX
							^a Chem mart	CH
							^a Risedronate	
							^a Risedronate-GA	GM
							^a Risedronate	SZ
							^a Sandoz	
							^a Risedro once a week	QA
							^a Terry White Chemists	TW
							^a Risedronate	
8972F NP	Tablet 35 mg (enteric coated)	4	5	..	46.65	35.40	Actonel EC	SW
9391G NP	Tablet 150 mg	1	5	..	49.63	35.40	Actonel Once-a-Month	SW

RISEDRONATE SODIUM

Authority required (STREAMLINED)

3256

Symptomatic Paget disease of bone.

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
9288W	Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL	1	589.27	35.40	Aclasta NV

ZOLEDRONIC ACID

Authority required

Symptomatic Paget disease of bone.

Only 1 treatment each year per patient will be PBS-subsidised.

9350D	Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL	1	589.27	35.40	Aclasta NV
-------	--	---	----	----	--------	-------	------------

Bisphosphonates, combinations

ALENDRONATE SODIUM with COLECALCIFEROL

Authority required (STREAMLINED)

3070

Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.

The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

3933

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.

The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

2646

Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

Note

Fosamax Plus provides a supplemental intake of vitamin D. The amount of colecalciferol present in Fosamax Plus is not sufficient to use as the sole treatment for correction of vitamin D deficiency.

9012H NP	Tablet equivalent to 70 mg alendronic acid with 70 micrograms colecalciferol	4	5	..	45.26	35.40	Fosamax Plus MK
-------------	--	---	---	----	-------	-------	-----------------

ALENDRONATE SODIUM with COLECALCIFEROL

Authority required (STREAMLINED)

3070

Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.

The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

3933

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.

The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Authority required (STREAMLINED)</u>								
2646								
Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.								
A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.								
<u>Note</u>								
Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.								
9183H	Tablet equivalent to 70 mg alendronic acid with	4	5	..	45.26	35.40 ^a	Dronalen Plus	GM
NP	140 micrograms colecalciferol			B2.50	47.76	35.40 ^a	Fosamax Plus 70	MK
							mg/140 mcg	

ALENDRONATE SODIUM with COLECALCIFEROL and CALCIUM CARBONATE

Authority required (STREAMLINED)

3070

Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.

The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

3933

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.

The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

2646

Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

9351E NP	Pack containing 4 tablets containing the equivalent of 70 mg alendronic acid with 140 micrograms colecalciferol and 48 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)	£1	5	..	45.26	35.40 ^a	Dronalen Plus D-Cal FR
							^a Fosamax Plus D-Cal MK

DISODIUM ETIDRONATE and CALCIUM CARBONATE

Authority required (STREAMLINED)

2646

Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8056B NP	Pack containing 28 tablets disodium etidronate 200 mg and 76 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)	£1	1	..	70.79	35.40	Didrocal	PF

RISEDRONATE SODIUM and CALCIUM CARBONATE

Authority required (STREAMLINED)

3070

Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.

The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

2645

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.

The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

2646

Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

8899J NP	Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)	£1	5	..	46.65	35.40	Acris Combi	AF
8973G NP	Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)	£1	5	..	46.65	35.40	Actonel EC Combi	SW

RISEDRONATE SODIUM and CALCIUM CARBONATE with COLECALCIFEROL

Authority required (STREAMLINED)

3070

Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.

The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

2645

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.

The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

2646

Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

8974H	Pack containing 4 enteric coated tablets	£1	5	..	46.65	35.40	Actonel EC Combi	SW
-------	--	----	---	----	-------	-------	------------------	----

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
NP	risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g (equivalent to 1 g calcium) with colecalciferol 22 micrograms						D	
9147K NP	Pack containing 4 tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g (equivalent to 1 g calcium) with colecalciferol 22 micrograms	1	5	..	46.65	35.40	Actonel Combi D	SW

Other drugs affecting bone structure and mineralization

CALCITRIOL

Authority required (STREAMLINED)

1165

Hypocalcaemia due to renal disease;

1166

Hypoparathyroidism;

1167

Hypophosphataemic rickets;

1467

Vitamin D-resistant rickets;

2636

Treatment for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

2502Q NP	Capsule 0.25 microgram	100	3	..	37.41	35.40	^a Calciprox	GN
							^a Calcitriol-GA	GM
							^a Calcitriol-PS	FZ
							^a Calcitriol Sandoz	SZ
							^a GenRx Calcitriol	GX
							^a Kosteo	QA
							^a Rocaltrol	RO
							^a Sical	AF

DENOSUMAB

Authority required

Bone metastases from breast cancer;

Bone metastases from castration-resistant prostate cancer.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

5110Y NP	Injection 120 mg in 1.7 mL	1	5	..	532.07	35.40	Xgeva	AN
-------------	----------------------------	---	---	----	--------	-------	-------	----

DENOSUMAB

Authority required (STREAMLINED)

4054

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a woman aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.

The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated;

3987

Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in a woman with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
	A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.						
	<u>Note</u> Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.						
	<u>Note</u> Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.						
5457F NP	Injection 60 mg in 1 mL pre-filled syringe	1	298.79	35.40	Prolia AN

RALOXIFENE HYDROCHLORIDE

Authority required (STREAMLINED)

2647

Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

8363E NP	Tablet 60 mg	28	5	..	57.97	35.40	Evista LY
-------------	--------------	----	---	----	-------	-------	-----------

STRONTIUM RANELATE

Authority required (STREAMLINED)

2758

Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a woman aged 70 years or older with a bone mineral density (BMD) T-score of -3.0 or less.

The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.

Authority required (STREAMLINED)

2647

Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Note

Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.

3036T NP	Sachet containing granules for oral suspension 2 g	28	5	..	53.44	35.40	Protos 2 g SE
-------------	---	----	---	----	-------	-------	---------------

TERIPARATIDE

Authority required

Initial treatment, as the sole PBS-subsidised agent, by a specialist or consultant physician, for severe, established osteoporosis in a patient with a very high risk of fracture who:

- (a) has a bone mineral density (BMD) T-score of -3.0 or less; and
- (b) has had 2 or more fractures due to minimal trauma; and
- (c) has experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	If treatment with anti-resorptive therapy is contraindicated according to the relevant TGA-approved Product Information, details of the contraindication must be provided at the time of application.						
	If an intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use of one anti-resorptive agent, alternate anti-resorptive agents must be trialled so that the patient achieves the minimum requirement of 12 months continuous therapy. Details of accepted toxicities including severity can be found on the Medicare Australia website at www.medicareaustralia.gov.au and must be provided at the time of application.						
	Anti-resorptive therapies for osteoporosis and their adequate doses which will be accepted for the purposes of administering this restriction are alendronate sodium 10 mg per day or 70 mg once weekly, risedronate sodium 5 mg per day or 35 mg once weekly or 150 mg once monthly, raloxifene hydrochloride 60 mg per day (women only), denosumab 60 mg once every 6 months, disodium etidronate 200 mg with calcium carbonate 1.25 g per day, strontium ranelate 2 g per day and zoledronic acid 5 mg per annum.						
	Details of prior anti-resorptive therapy, fracture history including the date(s), site(s), the symptoms associated with the fracture(s) which developed during the course of anti-resorptive therapy and the score of the qualifying BMD measurement must be provided to Medicare Australia at the time of application.						
	<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.						
	<u>Authority required</u> Continuing treatment for severe established osteoporosis where the patient has previously been issued with an authority prescription for this drug.						
	Teriparatide must only be used for a lifetime maximum of 18 months therapy (18 pens). Up to a maximum of 18 pens will be reimbursed through the PBS.						
	<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.						
	<u>Note</u> Special Pricing Arrangements apply.						
9411H	Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen	1	5	..	438.47	35.40	Forteo LY

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Nervous system

Analgesics

Opioids

Natural opium alkaloids

1214X NP	CODEINE PHOSPHATE Tablet 30 mg	20	16.97	18.08	Fawns and McAllan Proprietary Limited	FM
-------------	--	----	----	----	-------	-------	---	----

CODEINE PHOSPHATE with PARACETAMOL

Note

Authorities for increased maximum quantities and/or repeats will not be granted except as detailed under the 'Authority required' listing of codeine phosphate with paracetamol below.

1215Y NP	Tablet 30 mg-500 mg	20	7.58	8.69	^a APO- Paracetamol/Code ine 500/30	TX
							^a Codalgin Forte	FM
							^a Codapane Forte	AL
							^a Comfarol Forte	SZ
							^a Prodeine Forte	AV
					^B 2.80	10.38	^a Panadeine Forte	SW

CODEINE PHOSPHATE with PARACETAMOL

Authority required

Severe disabling pain not responding to non-narcotic analgesics.

Note

Each authority approval will be limited to no more than 240 tablets per month for no more than 6 months.

8785J NP	Tablet 30 mg-500 mg	60	*9.70	10.81	^a APO- Paracetamol/Code ine 500/30	TX
							^a Codalgin Forte	FM
							^a Codapane Forte	AL
							^a Comfarol Forte	SZ
							^a Prodeine Forte	AV
					^B 8.40	*18.10	^a Panadeine Forte	SW

HYDROMORPHONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

8420E NP	Injection 2 mg in 1 mL	5	22.94	24.05	Dilaudid	MF
8421F NP	Injection 10 mg in 1 mL	5	29.07	30.18	Dilaudid-HP	MF
8422G NP	Injection 50 mg in 5 mL	5	52.10	35.40	Dilaudid-HP	MF
8423H NP	Injection 500 mg in 50 mL	1	75.51	35.40	Dilaudid-HP	MF

HYDROMORPHONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Restricted benefit</u>								
Chronic severe disabling pain not responding to non-narcotic analgesics.								
<u>Note</u>								
Authorities for increased maximum quantities and/or repeats will be granted only for:								
(i) chronic severe disabling pain associated with proven malignant neoplasia; or								
(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or								
(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or								
(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.								
9299K NP	Tablet 4 mg (modified release)	14	31.05	32.16	Jurnista	JC
9406C NP	Tablet 8 mg (modified release)	14	36.51	35.40	Jurnista	JC
9407D NP	Tablet 16 mg (modified release)	14	52.92	35.40	Jurnista	JC
9408E NP	Tablet 32 mg (modified release)	14	88.80	35.40	Jurnista	JC
9409F NP	Tablet 64 mg (modified release)	14	149.48	35.40	Jurnista	JC

HYDROMORPHONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

(i) severe disabling pain associated with proven malignant neoplasia; or

(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or

(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or

(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

8424J NP	Oral liquid 1 mg per mL, 473 mL	1	63.80	35.40	Dilaudid MF
8541M NP	Tablet 2 mg	20	17.20	18.31	Dilaudid MF
8542N NP	Tablet 4 mg	20	19.95	21.06	Dilaudid MF
8543P NP	Tablet 8 mg	20	30.13	31.24	Dilaudid MF

MORPHINE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Note</u>								
Authorities for increased maximum quantities and/or repeats will be granted only for:								
(i) severe disabling pain associated with proven malignant neoplasia; or								
(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or								
(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or								
(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.								
2122Q NP	Oral solution 2 mg per mL, 200 mL	1	20.43	21.54	Ordine 2	MF
2123R NP	Oral solution 5 mg per mL, 200 mL	1	22.83	23.94	Ordine 5	MF
2124T NP	Oral solution 10 mg per mL, 200 mL	1	26.96	28.07	Ordine 10	MF

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

1644M NP,MW	Injection 10 mg in 1 mL	5	14.09	15.20	Hospira Pty Limited	HH
1645N NP,MW	Injection 15 mg in 1 mL	5	14.45	15.56	Hospira Pty Limited	HH
1647Q NP	Injection 30 mg in 1 mL	5	15.87	16.98	Hospira Pty Limited	HH

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain due to cancer not responding to non-narcotic analgesics.

8669G NP	Tablet 10 mg	20	14.41	15.52	Sevredol	MF
8670H NP	Tablet 20 mg	20	15.36	16.47	Sevredol	MF

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

(i) severe disabling pain associated with proven malignant neoplasia; or

(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or

(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or

(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
prescription for treatment beyond 12 months has previously been issued for this patient.								
1646P NP	Tablet 30 mg	20	14.13	15.24	Anamorph	FM
<hr/>								
MORPHINE SULFATE								
Caution								
The risk of drug dependence is high.								
Restricted benefit								
Chronic severe disabling pain not responding to non-narcotic analgesics.								
Note								
Authorities for increased maximum quantities and/or repeats will be granted only for:								
(i) chronic severe disabling pain associated with proven malignant neoplasia; or								
(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or								
(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or								
(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.								
1653B NP	Tablet 10 mg (controlled release)	28	20.14	21.25	^a APOTEX- MORPHINE MR	TX
							^a Momex SR 10	QA
							^a MS Contin	MF
1654C NP	Tablet 30 mg (controlled release)	28	35.99	35.40	^a APOTEX- MORPHINE MR	TX
							^a Momex SR 30	QA
							^a MS Contin	MF
1655D NP	Tablet 60 mg (controlled release)	28	54.58	35.40	^a APOTEX- MORPHINE MR	TX
							^a Momex SR 60	QA
							^a MS Contin	MF
1656E NP	Tablet 100 mg (controlled release)	28	72.61	35.40	^a APOTEX- MORPHINE MR	TX
							^a Momex SR 100	QA
							^a MS Contin	MF
2839K NP	Capsule 20 mg (containing sustained release pellets)	28	25.11	26.22	Kapanol	GK
2840L NP	Capsule 50 mg (containing sustained release pellets)	28	43.41	35.40	Kapanol	GK
2841M NP	Capsule 100 mg (containing sustained release pellets)	28	70.57	35.40	Kapanol	GK
8035X NP	Tablet 5 mg (controlled release)	28	17.69	18.80	MS Contin	MF
8146R NP	Sachet containing controlled release granules for oral suspension, 30 mg per sachet	28	62.17	35.40	MS Contin Suspension 30 mg	MF
8305D NP	Sachet containing controlled release granules for oral suspension, 60 mg per sachet	28	69.97	35.40	MS Contin Suspension 60 mg	MF
8306E NP	Sachet containing controlled release granules for oral suspension, 100 mg per sachet	28	86.47	35.40	MS Contin Suspension 100 mg	MF
8349K NP	Capsule 10 mg (containing sustained release pellets)	28	20.13	21.24	Kapanol	GK
8489T NP	Tablet 15 mg (controlled release)	28	24.33	25.44	MS Contin	MF

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8490W NP	Sachet containing controlled release granules for oral suspension, 20 mg per sachet	28	60.39	35.40	MS Contin Suspension 20 mg	MF
8491X NP	Capsule 30 mg (controlled release)	14	24.32	25.43	MS Mono	MF
8492Y NP	Capsule 60 mg (controlled release)	14	35.97	35.40	MS Mono	MF
8493B NP	Capsule 90 mg (controlled release)	14	41.52	35.40	MS Mono	MF
8494C NP	Capsule 120 mg (controlled release)	14	54.57	35.40	MS Mono	MF

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Authority required

Chronic severe disabling pain due to cancer.

8453X NP	Tablet 200 mg (controlled release)	28	121.96	35.40	MS Contin	MF
8454Y NP	Sachet containing controlled release granules for oral suspension, 200 mg per sachet	28	163.85	35.40	MS Contin Suspension 200 mg	MF

MORPHINE TARTRATE

Caution

The risk of drug dependence is high.

1607N NP	Injection 120 mg in 1.5 mL	5	30.77	31.88	Hospira Pty Limited	HH
-------------	----------------------------	---	----	----	-------	-------	---------------------	----

OXYCODONE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

(i) severe disabling pain associated with proven malignant neoplasia; or

(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or

(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or

(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

2481N NP	Suppository 30 mg	12	43.76	35.40	Proladone	PL
-------------	-------------------	----	----	----	-------	-------	-----------	----

OXYCODONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

(i) severe disabling pain associated with proven malignant neoplasia; or

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or						
	(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or						
	(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.						
2622B NP	Tablet 5 mg	20	12.40	13.51	Endone QA
8464L NP	Capsule 5 mg	20	12.40	13.51	OxyNorm MF
8501K NP	Capsule 10 mg	20	15.52	16.63	OxyNorm MF
8502L NP	Capsule 20 mg	20	20.25	21.36	OxyNorm MF
8644Y NP	Oral solution 5 mg per 5 mL, 250 mL	1	20.82	21.93	OxyNorm Liquid 5mg/5mL MF

OXYCODONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

(i) chronic severe disabling pain associated with proven malignant neoplasia; or

(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or

(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or

(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

8385H NP	Tablet 10 mg (controlled release)	28	27.19	28.30	OxyContin MF
8386J NP	Tablet 20 mg (controlled release)	28	41.07	35.40	OxyContin MF
8387K NP	Tablet 40 mg (controlled release)	28	62.70	35.40	OxyContin MF
8388L NP	Tablet 80 mg (controlled release)	28	96.82	35.40	OxyContin MF
8681X NP	Tablet 5 mg (controlled release)	28	26.10	27.21	OxyContin MF
9399Q NP	Tablet 15 mg (controlled release)	28	35.57	35.40	OxyContin MF
9400R NP	Tablet 30 mg (controlled release)	28	52.79	35.40	OxyContin MF

OXYCODONE HYDROCHLORIDE with NALOXONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Note							
Authorities for increased maximum quantities and/or repeats will be granted only for:							
(i) chronic severe disabling pain associated with proven malignant neoplasia; or							
(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or							
(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or							
(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.							
Note							
Shared Care Model:							
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
8000C NP	Tablet 5 mg-2.5 mg (controlled release)	28	29.47	30.58	Targin 5/2.5mg MF
8934F NP	Tablet 10 mg-5 mg (controlled release)	28	30.77	31.88	Targin 10/5mg MF
8935G NP	Tablet 20 mg-10 mg (controlled release)	28	46.95	35.40	Targin 20/10mg MF
8936H NP	Tablet 40 mg-20 mg (controlled release)	28	73.38	35.40	Targin 40/20mg MF

Phenylpiperidine derivatives

FENTANYL

Caution

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

(i) chronic severe disabling pain associated with proven malignant neoplasia; or

(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or

(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or

(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

Note

Fentanyl transdermal patches are not recommended in opioid naive patients with non-cancer pain, because of a high incidence of adverse events in these patients. Patients with cancer pain may be initiated on the lowest strength patch (12 micrograms per hour).

Pharmaceutical benefits that have the forms fentanyl transdermal patch 2.063 mg, fentanyl transdermal patch 1.28 mg and fentanyl transdermal patch 2.1 mg (all releasing approximately 12 micrograms per hour) are equivalent for the purposes of substitution.

5265D NP	Transdermal patch 1.28 mg (releasing approximately 12 micrograms per hour)	5	41.63	35.40 ^a	Denpax	AF
5437E NP	Transdermal patch 2.063 mg (releasing approximately 12 micrograms per hour)	5	41.63	35.40 ^a	Fenpatch 12	ZP
8878G NP	Transdermal patch 2.1 mg (releasing approximately 12 micrograms per hour)	5	41.63	35.40 ^a	Durogesic 12	JC
						^a	Fentanyl Sandoz	SZ

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
FENTANYL							
<u>Caution</u>							
The risk of drug dependence is high.							
<u>Restricted benefit</u>							
Chronic severe disabling pain not responding to non-narcotic analgesics.							
<u>Note</u>							
Authorities for increased maximum quantities and/or repeats will be granted only for:							
(i) chronic severe disabling pain associated with proven malignant neoplasia; or							
(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or							
(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or							
(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.							
<u>Note</u>							
Fentanyl transdermal patches are not recommended in opioid naive patients with non-cancer pain, because of a high incidence of adverse events in these patients. Patients with cancer pain may be initiated on the lowest strength patch (12 micrograms per hour).							
Pharmaceutical benefits that have the forms fentanyl transdermal patch 4.125 mg, fentanyl transdermal patch 2.55 mg and fentanyl transdermal patch 4.2 mg (all releasing approximately 25 micrograms per hour) are equivalent for the purposes of substitution.							
5277R NP	Transdermal patch 2.55 mg (releasing approximately 25 micrograms per hour)	5	49.56	35.40 ^a	Denpax AF
5438F NP	Transdermal patch 4.125 mg (releasing approximately 25 micrograms per hour)	5	49.56	35.40 ^a	Fenpatch 25 ZP
8891Y NP	Transdermal patch 4.2 mg (releasing approximately 25 micrograms per hour)	5	49.56	35.40 ^a	Durogesic 25 JC
						^a	Fentanyl Sandoz SZ
FENTANYL							
<u>Caution</u>							
The risk of drug dependence is high.							
<u>Restricted benefit</u>							
Chronic severe disabling pain not responding to non-narcotic analgesics.							
<u>Note</u>							
Authorities for increased maximum quantities and/or repeats will be granted only for:							
(i) chronic severe disabling pain associated with proven malignant neoplasia; or							
(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or							
(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or							
(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.							
<u>Note</u>							
Fentanyl transdermal patches are not recommended in opioid naive patients with non-cancer pain, because of a high incidence of adverse events in these patients. Patients with cancer pain may be initiated on the lowest strength patch (12 micrograms per hour).							
Pharmaceutical benefits that have the forms fentanyl transdermal patch 8.25 mg, fentanyl transdermal patch 5.10 mg and fentanyl transdermal patch 8.4 mg (all releasing approximately 50 micrograms per hour) are equivalent for the purposes of substitution.							
5278T NP	Transdermal patch 5.10 mg (releasing approximately 50 micrograms per hour)	5	81.68	35.40 ^a	Denpax AF

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
5439G NP	Transdermal patch 8.25 mg (releasing approximately 50 micrograms per hour)	5	81.68	35.40 ^a	Fenpatch 50	ZP
8892B NP	Transdermal patch 8.4 mg (releasing approximately 50 micrograms per hour)	5	81.68	35.40 ^a	Durogesic 50	JC
						^a	Fentanyl Sandoz	SZ

FENTANYL

Caution

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

- (i) chronic severe disabling pain associated with proven malignant neoplasia; or
- (ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or
- (iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or
- (iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

Note

Fentanyl transdermal patches are not recommended in opioid naive patients with non-cancer pain, because of a high incidence of adverse events in these patients. Patients with cancer pain may be initiated on the lowest strength patch (12 micrograms per hour).

Pharmaceutical benefits that have the forms fentanyl transdermal patch 12.375 mg, fentanyl transdermal patch 7.65 mg and fentanyl transdermal patch 12.6 mg (all releasing approximately 75 micrograms per hour) are equivalent for the purposes of substitution.

5279W NP	Transdermal patch 7.65 mg (releasing approximately 75 micrograms per hour)	5	108.47	35.40 ^a	Denpax	AF
5440H NP	Transdermal patch 12.375 mg (releasing approximately 75 micrograms per hour)	5	108.47	35.40 ^a	Fenpatch 75	ZP
8893C NP	Transdermal patch 12.6 mg (releasing approximately 75 micrograms per hour)	5	108.47	35.40 ^a	Durogesic 75	JC
						^a	Fentanyl Sandoz	SZ

FENTANYL

Caution

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

- (i) chronic severe disabling pain associated with proven malignant neoplasia; or
- (ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or
- (iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or
- (iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Note							
Fentanyl transdermal patches are not recommended in opioid naive patients with non-cancer pain, because of a high incidence of adverse events in these patients. Patients with cancer pain may be initiated on the lowest strength patch (12 micrograms per hour).							
Pharmaceutical benefits that have the forms fentanyl transdermal patch 16.5 mg, fentanyl transdermal patch 10.20 mg and fentanyl transdermal patch 16.8 mg (all releasing approximately 100 micrograms per hour) are equivalent for the purposes of substitution.							
5280X NP	Transdermal patch 10.20 mg (releasing approximately 100 micrograms per hour)	5	132.40	35.40 ^a	Denpax AF
5441J NP	Transdermal patch 16.5 mg (releasing approximately 100 micrograms per hour)	5	132.40	35.40 ^a	Fenpatch 100 ZP
8894D NP	Transdermal patch 16.8 mg (releasing approximately 100 micrograms per hour)	5	132.40	35.40 ^a	Durogesic 100 JC
						^a	Fentanyl Sandoz SZ

Diphenylpropylamine derivatives

METHADONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

- (i) severe disabling pain associated with proven malignant neoplasia; or
- (ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or
- (iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or
- (iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1606M NP	Injection 10 mg in 1 mL	5	49.41	35.40	Physeptone QA
1609Q NP	Tablet 10 mg	20	15.33	16.44	Physeptone QA

Oripavine derivatives

BUPRENORPHINE

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for:

- (i) chronic severe disabling pain associated with proven malignant neoplasia; or
- (ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or
- (iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or
- (iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Caution</u>								
The risk of drug dependence is high.								
8865N NP	Transdermal patch 5 mg (releasing approximately 5 micrograms per hour)	2	26.80	27.91	Norspan	MF
8866P NP	Transdermal patch 10 mg (releasing approximately 10 micrograms per hour)	2	40.87	35.40	Norspan	MF
8867Q NP	Transdermal patch 20 mg (releasing approximately 20 micrograms per hour)	2	56.18	35.40	Norspan	MF

Other opioids

TRAMADOL HYDROCHLORIDE

Restricted benefit

For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8455B NP	Capsule 50 mg	20	8.49	9.60	^a APO-Tramadol	TX
							^a Chem mart	CH
							^a GA Tramadol 50mg	GM
							^a GenRx Tramadol	GX
							^a Lodam 50	ZP
							^a Terry White Chemists	TW
							^a Tramadol Sandoz	SZ
							^a Tramedo	AF
							^a Zydol	QA
				^B 2.41	10.90	9.60	^a Tramal	CS

TRAMADOL HYDROCHLORIDE

Restricted benefit

For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8611F NP	Capsule 50 mg	20	2	..	8.49	9.60	^a APO-Tramadol	TX
							^a Chem mart	CH
							^a GA Tramadol 50mg	GM
							^a GenRx Tramadol	GX
							^a Lodam 50	ZP
							^a Terry White Chemists	TW
							^a Tramadol Sandoz	SZ
							^a Tramedo	AF
							^a Zydol	QA
				^B 2.41	10.90	9.60	^a Tramal	CS

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
TRAMADOL HYDROCHLORIDE							
<u>Restricted benefit</u>							
For pain where aspirin and/or paracetamol alone are inappropriate or have failed.							
<u>Note</u>							
Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.							
2527B NP	Tablet 50 mg (twice daily sustained release)	20	10.26	11.37	Tramal SR 50 CS
8523N NP	Tablet 100 mg (twice daily sustained release)	20	11.86	12.97	^a APO-Tramadol SR TX
							^a Chem mart CH
							^a Tramadol SR
							^a GA Tramadol SR GM
							^a 100mg
							^a Lodam SR 100 ZP
							^a Terry White TW
							^a Chemists
							^a Tramadol SR
							^a Tramadol Sandoz SZ
							^a SR
							^a Tramedo SR 100 AF
							^a Zydol SR 100 QA
				^B 4.50	16.36	12.97	^a Tramal SR 100 CS
8524P NP	Tablet 150 mg (twice daily sustained release)	20	13.72	14.83	^a APO-Tramadol SR TX
							^a Chem mart CH
							^a Tramadol SR
							^a GA Tramadol SR GM
							^a 150mg
							^a Lodam SR 150 ZP
							^a Terry White TW
							^a Chemists
							^a Tramadol SR
							^a Tramadol Sandoz SZ
							^a SR
							^a Tramedo SR 150 AF
							^a Zydol SR 150 QA
				^B 5.37	19.09	14.83	^a Tramal SR 150 CS
8525Q NP	Tablet 200 mg (twice daily sustained release)	20	15.28	16.39	^a APO-Tramadol SR TX
							^a Chem mart CH
							^a Tramadol SR
							^a GA Tramadol SR GM
							^a 200mg
							^a Lodam SR 200 ZP
							^a Terry White TW
							^a Chemists
							^a Tramadol SR
							^a Tramadol Sandoz SZ
							^a SR
							^a Tramedo SR 200 AF
							^a Zydol SR 200 QA
				^B 6.09	21.37	16.39	^a Tramal SR 200 CS
8843K NP	Oral drops 100 mg per mL, 10 mL	±1	13.81	14.92	Tramal CS
9199E NP	Tablet 100 mg (once a day extended release)	10	11.51	12.62	Durotram XR IA
9200F NP	Tablet 200 mg (once a day extended release)	10	13.65	14.76	Durotram XR IA
9201G NP	Tablet 300 mg (once a day extended release)	10	16.12	17.23	Durotram XR IA

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
TRAMADOL HYDROCHLORIDE								
<u>Restricted benefit</u>								
Short-term treatment of acute pain.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
8582Q NP	Injection 100 mg in 2 mL	5	13.20	14.31	^a Tramahexal	SZ
							^a Tramal 100	CS
Other analgesics and antipyretics								
<i>Salicylic acid and derivatives</i>								
ASPIRIN								
1010E NP	Tablet 300 mg (dispersible)	96	1	..	8.27	9.38	Solprin	RC
<i>Anilides</i>								
PARACETAMOL								
1746X NP	Tablet 500 mg	100	1	..	8.42	9.53	^a APO-Paracetamol	TX
							^a Chem mart Paracetamol	XS
							^a Febridol	GM
							^a Generic Health Pty Ltd	GQ
							^a Panamax	SW
							^a Paracetamol Sandoz	SZ
							^a Paralgin	FM
							^a Pharmacy Choice Paracetamol	YM
							^a Terry White Chemists Paracetamol	YS
1747Y NP	Oral liquid 120 mg per 5 mL, 100 mL	‡1	2	..	9.48	10.59	Panamax	SW
1770E NP	Oral liquid 240 mg per 5 mL, 200 mL	‡1	2	..	10.78	11.89	Panamax 240 Elixir	SW
PARACETAMOL								
<u>Restricted benefit</u>								
Chronic arthropathies.								
8784H NP	Tablet 500 mg	300	4	..	*12.22	13.33	^a APO-Paracetamol	TX
							^a Chem mart Paracetamol	XS
							^a Febridol	GM
							^a Generic Health Pty Ltd	GQ
							^a Panamax	SW
							^a Paracetamol Sandoz	SZ
							^a Paralgin	FM
							^a Pharmacy Choice Paracetamol	YM
							^a Terry White Chemists Paracetamol	YS

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

PARACETAMOL

Restricted benefit

Relief of persistent pain associated with osteoarthritis.

8814X NP	Tablet 665 mg (modified release)	192	5	..	*16.74	17.85	Panadol Osteo	GC
-------------	----------------------------------	-----	---	----	--------	-------	---------------	----

Antimigraine preparations

Ergot alkaloids

DIHYDROERGOTAMINE MESYLATE

1323P	Injection 1 mg in 1 mL	5	17.16	18.27	Dihydergot	NV
-------	------------------------	---	----	----	-------	-------	------------	----

METHYSERGIDE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2826R NP	Tablet 1 mg	100	2	..	*45.06	35.40	Deseril	LM
-------------	-------------	-----	---	----	--------	-------	---------	----

Selective 5HT₁-receptor agonists

ELETRIPTAN

Caution

Eletriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.

Authority required (STREAMLINED)

3233

Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

5290K NP	Tablet 40 mg (as hydrobromide)	4	5	..	24.85	25.96	Relpax	PF
5291L NP	Tablet 80 mg (as hydrobromide)	4	5	..	24.85	25.96	Relpax	PF

RIZATRIPTAN

Caution

Rizatriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.

Authority required (STREAMLINED)

3233

Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9313E NP	Wafer 10 mg (as benzoate)	4	5	..	*25.22	26.33	Maxalt	MK
-------------	---------------------------	---	---	----	--------	-------	--------	----

SUMATRIPTAN

Caution

Sumatriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Authority required (STREAMLINED)</u>								
3233								
Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
Pharmaceutical benefits that have the form sumatriptan tablet 50 mg (as succinate) and pharmaceutical benefits that have the form sumatriptan tablet (fast disintegrating) 50 mg (as succinate) are equivalent for the purposes of substitution.								
1849H NP	Tablet 50 mg (as succinate)	4	5	..	24.48	25.59	^a Pharmacor Sumatriptan 50 ^a Sumatriptan-GA ^a Sumatriptan generichealth	CR GM GQ
8144P NP	Tablet 50 mg (as succinate)	4	5	..	*24.48	25.59	^a APO-Sumatriptan ^a Chem mart Sumatriptan ^a Sumagran 50 ^a Sumagran Aspen 50 ^a Sumatab ^a Terry White Chemists Sumatriptan	TX CH QA AS AF TW
8885P NP	Tablet (fast disintegrating) 50 mg (as succinate)	4	5	..	^B 1.84 *26.32 *24.48	25.59	^a Imigran ^a Imigran FDT	GK GK

SUMATRIPTAN

Caution

Sumatriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.

Authority required (STREAMLINED)

3233

Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8341B NP	Nasal spray 20 mg in 0.1 mL single dose unit	2	5	..	19.35	20.46	Imigran	GK
-------------	--	---	---	----	-------	-------	---------	----

Other antimigraine preparations

CYPROHEPTADINE HYDROCHLORIDE

Restricted benefit

Prevention of migraine.

Note

Cyproheptadine hydrochloride is not PBS-subsidised for use in hay fever or atopy.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
1798P NP	Tablet 4 mg	100	2	..	14.29	15.40	Periactin	AS

PIZOTIFEN MALATE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

3074T NP	Tablet 500 micrograms (base)	100	2	..	21.85	22.96	Sandomigran 0.5	NV
-------------	------------------------------	-----	---	----	-------	-------	-----------------	----

Antiepileptics

Antiepileptics

Barbiturates and derivatives

PHENOBARBITONE

Restricted benefit

Epilepsy.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1850J NP	Tablet 30 mg	200	4	..	16.70	17.81	Aspen Pharma Pty Ltd	QA
-------------	--------------	-----	---	----	-------	-------	----------------------	----

PHENOBARBITONE SODIUM

Restricted benefit

Epilepsy.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1853M NP	Injection 200 mg in 1 mL	5	39.12	35.40	Fawns and McAllan Proprietary Limited	FM
-------------	--------------------------	---	----	----	-------	-------	---------------------------------------	----

PRIMIDONE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1939C NP	Tablet 250 mg	200	2	..	83.59	35.40	Mysoline	LM
-------------	---------------	-----	---	----	-------	-------	----------	----

Hydantoin derivatives

PHENYTOIN

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1249R NP	Tablet 50 mg	200	2	..	43.66	35.40	Dilantin Infatabs	PF
2692Q NP	Paediatric oral suspension 30 mg per 5 mL, 500 mL	1	3	..	26.50	27.61	Dilantin	PF

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
PHENYTOIN SODIUM							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1873N NP	Capsule 30 mg	200	2	..	29.28	30.39	Dilantin Sodium PF
1874P NP	Capsule 100 mg	200	2	..	30.22	31.33	Dilantin Sodium PF

Succinimide derivatives

ETHOSUXIMIDE								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1413J NP	Capsule 250 mg	200	2	..	54.20	35.40	Zarontin	PF
1414K NP	Paediatric syrup 250 mg per 5 mL, 200 mL	‡1	5	..	25.39	26.50	Zarontin	PF

Benzodiazepine derivatives

CLONAZEPAM								
<u>Authority required</u>								
Neurologically proven epilepsy.								
<u>Caution</u>								
Abuse of clonazepam has been reported. Refer to the current product information.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1805B NP	Tablet 500 micrograms	200	2	..	*19.60	20.71 ^a	Paxam 0.5	AF
				^B 3.42	*23.02	20.71 ^a	Rivotril	RO
1806C NP	Tablet 2 mg	200	2	..	*31.16	32.27 ^a	Paxam 2	AF
				^B 3.86	*35.02	32.27 ^a	Rivotril	RO
1808E NP	Oral liquid 2.5 mg per mL, 10 mL	2	*15.14	16.25	Rivotril	RO

CLONAZEPAM

Restricted benefit

Epilepsy.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1807D NP	Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)	5	18.68	19.79	Rivotril	RO
-------------	---	---	----	----	-------	-------	----------	----

NITRAZEPAM

Authority required

Myoclonic epilepsy;

Malignant neoplasia (late stage);

For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal;

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.							
	<u>Note</u>							
	Continuing Therapy Only:							
	For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
2732T	Tablet 5 mg	50	5	..	*9.32	10.43 ^a	Alodorm	AF
NP				^B 2.90	*12.22	10.43 ^a	Mogadon	VT

Carboxamide derivatives

CARBAMAZEPINE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

For item codes 2422L and 1708X, pharmaceutical benefits that have the form tablet 100 mg are equivalent for the purposes of substitution.

1708X	Tablet 100 mg	200	2	..	18.61	19.72	^a Carbamazepine	SZ
NP							Sandoz	
2422L	Tablet 100 mg	200	2	^B 2.96	*21.56	19.71	^a Tegretol 100	NV
NP								

CARBAMAZEPINE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

For item codes 2419H and 1706T, pharmaceutical benefits that have the form tablet 200 mg are equivalent for the purposes of substitution.

1706T	Tablet 200 mg	200	2	^B 2.96	*32.06	30.21	^a Tegretol 200	NV
NP								
2419H	Tablet 200 mg	200	2	..	29.12	30.23	^a Carbamazepine	SZ
NP							^a Sandoz	
							^a Teril	AF

CARBAMAZEPINE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2426Q	Tablet 200 mg (controlled release)	200	2	..	29.58	30.69	Tegretol CR 200	NV
NP								
2427R	Oral suspension 100 mg per 5 mL, 300 mL	£1	5	..	21.45	22.56	Tegretol Liquid	NV
NP								
2431Y	Tablet 400 mg (controlled release)	200	2	..	49.12	35.40	Tegretol CR 400	NV
NP								

OXCARBAZEPINE

Authority required (STREAMLINED)

1587

Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8584T NP	Tablet 150 mg	100	5	..	72.37	35.40	Trileptal	NV
8585W NP	Tablet 300 mg	100	5	..	115.18	35.40	Trileptal	NV
8586X NP	Tablet 600 mg	100	5	..	188.08	35.40	Trileptal	NV
8588B NP	Oral suspension 60 mg per mL, 250 mL	2	5	..	*138.22	35.40	Trileptal	NV

Fatty acid derivatives

SODIUM VALPROATE

Caution

There are reports of fatal hepatotoxicity, particularly in children.

There is increasing evidence of dose-related teratogenesis from this drug.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2289L NP	Tablet 200 mg (enteric coated)	200	2	..	*30.02	31.13	^a Sodium Valproate Sandoz	SZ
							^a Valprease 200	QA
							^a Valpro 200	AF
							^a Valproate Winthrop EC 200	WA
				^B 2.00	*32.02	31.13	^a Epilim EC	SW
2290M NP	Tablet 500 mg (enteric coated)	200	2	..	*51.48	35.40	^a Sodium Valproate Sandoz	SZ
							^a Valprease 500	QA
							^a Valpro 500	AF
							^a Valproate Winthrop EC 500	WA
				^B 2.00	*53.48	35.40	^a Epilim EC	SW
2293Q NP	Oral liquid 200 mg per 5 mL, 300 mL	2	2	..	*35.02	35.40	Epilim Liquid	SW
2294R NP	Crushable tablet 100 mg	200	2	..	*32.10	33.21	Epilim	SW
2295T NP	Syrup 200 mg per 5 mL, 300 mL	2	2	..	*35.02	35.40	Epilim Syrup	SW

TIAGABINE HYDROCHLORIDE

Authority required (STREAMLINED)

2664

Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8221Q NP	Tablet 5 mg (base)	100	5	..	*72.74	35.40	Gabitril	OA
8222R NP	Tablet 10 mg (base)	100	5	..	*138.94	35.40	Gabitril	OA
8223T NP	Tablet 15 mg (base)	100	5	..	*196.98	35.40	Gabitril	OA

VIGABATRIN

Caution

Visual field defects have been reported with this drug.

Authority required (STREAMLINED)

1426

Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Note								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2667J NP	Tablet 500 mg	100	5	..	101.03	35.40	Sabril	SW
2668K NP	Oral powder, sachet 500 mg	60	5	..	67.80	35.40	Sabril	SW
Other antiepileptics								
GABAPENTIN								
Authority required (STREAMLINED)								
2664								
Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.								
Note								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1834M NP	Capsule 300 mg	100	5	..	45.19	35.40	^a DBL Gabapentin	HH
							^a Gabapentin 300	CR
							^a Gabapentin-GA	GM
							^a Gabapentin Sandoz	SZ
							^a Gabatine 300	QA
							^a Gantin	GN
							^a GenRx Gabapentin	GX
							^a Nupentin 300	AF
				^B 1.95	47.14	35.40	^a Neurontin	PF
1835N NP	Capsule 400 mg	100	5	..	57.78	35.40	^a DBL Gabapentin	HH
							^a Gabapentin 400	CR
							^a Gabapentin Sandoz	SZ
							^a Gabatine 400	QA
							^a Gantin	GN
							^a GenRx Gabapentin	GX
							^a Nupentin 400	AF
				^B 1.95	59.73	35.40	^a Neurontin	PF
8389M NP	Tablet 800 mg	100	5	..	115.00	35.40	^a Gabaran	RA
							^a Gabatine 800	QA
							^a Gantin	GN
							^a GenRx Gabapentin	GX
							^a Nupentin Tabs	AF
							^a Pharmacor Gabapentin 800	CR
				^B 1.95	116.95	35.40	^a Neurontin	PF
8505P NP	Capsule 100 mg	100	5	..	18.28	19.39	^a APO-Gabapentin	TX
							^a DBL Gabapentin	HH
							^a Gabatine 100	QA
							^a Nupentin 100	AF
				^B 1.95	20.23	19.39	^a Neurontin	PF
8559L NP	Tablet 600 mg	100	5	..	87.89	35.40	^a Gabaran	RA
							^a Gabatine 600	QA
							^a GenRx Gabapentin	GX

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							^a Nupentin Tabs	AF
							^a Pharmacor Gabapentin 600	CR
				^B 1.96	89.85	35.40	^a Neurontin	PF

LACOSAMIDE

Authority required

Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.

A patient must have trialled and failed to achieve satisfactory seizure control with:

- (i) at least one first-line anti-epileptic agent; and
- (ii) at least two second-line adjunctive anti-epileptic agents;

Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide.

Note

No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9333F NP	Tablet 50 mg	14	1	..	30.31	31.42	Vimpat	UC
9334G NP	Tablets 100 mg, 14	1	1	..	52.39	35.40	Vimpat	UC
9335H NP	Tablet 100 mg	56	5	..	188.55	35.40	Vimpat	UC
9336J NP	Tablets 150 mg, 14	1	1	..	74.79	35.40	Vimpat	UC
9337K NP	Tablet 150 mg	56	5	..	272.74	35.40	Vimpat	UC
9338L NP	Tablet 200 mg	56	5	..	355.48	35.40	Vimpat	UC

LAMOTRIGINE

Authority required (STREAMLINED)

1426

Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2848X NP	Tablet 25 mg	56	5	..	23.78	24.89	^a APO-Lamotrigine	TX
							^a GenRx Lamotrigine	GX
							^a Lamidus	RA
							^a Lamogine	AF
							^a Lamotrigine-GA	GN
							^a Lamotrigine generichealth	GQ
							^a Lamotrigine-PS	FZ
							^a Lamotrigine Sandoz	SZ
							^a Lamotrust 25	MI
							^a Seaze 25	QA
							^a Torlemo DT 25	TA
				^B 1.86	25.64	24.89	^a Lamictal	GK
2849Y NP	Tablet 50 mg	56	5	..	35.30	35.40	^a APO-Lamotrigine	TX
							^a GenRx Lamotrigine	GX

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
8655M NP	Tablet 500 mg	60	5	..	75.26	35.40	Levetiracetam
							^a Kepcet GM
							^a Keppra UC
							^a Kerron 250 DO
							^a Kevtam AF
							^a Levecetam 250 RZ
							^a Levetiracetam generichealth GQ
							^a Levetiracetam SZ SZ
							^a Levitaccord RA
							^a Levitam 250 QA
							^a Terry White Chemists TW
							Levetiracetam
							^a APO-Levetiracetam TX
							^a Chem mart CH
							Levetiracetam
							^a Kepcet GM
							^a Keppra UC
							^a Kerron 500 DO
							^a Kevtam AF
							^a Levecetam 500 RZ
8656N NP	Tablet 1 g	60	5	..	121.05	35.40	^a Levetiracetam generichealth GQ
							^a Levetiracetam SZ SZ
							^a Levitaccord RA
							^a Levitam 500 QA
							^a Terry White Chemists TW
							Levetiracetam
							^a APO-Levetiracetam TX
							^a Chem mart CH
							Levetiracetam
							^a Kepcet GM
							^a Keppra UC
							^a Kerron 1000 DO
							^a Kevtam AF
							^a Levecetam 1000 RZ
							^a Levetiracetam generichealth GQ
							^a Levetiracetam SZ SZ
							^a Levitaccord RA
							^a Levitam 1000 QA
							^a Terry White Chemists TW
							Levetiracetam

LEVETIRACETAM

Authority required (STREAMLINED)

3291

Treatment of partial epileptic seizures, which are not controlled satisfactorily by other anti-epileptic drugs in a patient unable to take a solid dose form of levetiracetam.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Note Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
9169N NP	Oral solution 100 mg per mL, 300 mL	\$1	5	..	111.52	35.40	Keppra	UC
SULTHIAME Note Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2099L NP	Tablet 50 mg	200	2	..	82.57	35.40	Ospolot	PL
2100M NP	Tablet 200 mg	200	2	..	206.09	35.40	Ospolot	PL
TOPIRAMATE Authority required (STREAMLINED) 2797 Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs.								
Authority required (STREAMLINED) 2799 Prophylaxis of migraine in a patient who has experienced an average of 3 or more migraines per month over a period of at least 6 months, and who: (a) has a contraindication to beta-blockers, as described in the relevant TGA-approved Product Information; OR (b) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with a beta-blocker; AND (c) has a contraindication to pizotifen because the weight gain associated with this drug poses an unacceptable risk; OR (d) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with pizotifen.								
Details of the contraindication and/or intolerance(s) must be documented in the patient's medical records when treatment is initiated.								
Note Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8163P NP	Tablet 25 mg	60	5	..	36.57	35.40	^a APO-Topiramate	TX
							^a Epiramax 25	QA
							^a RBX Topiramate	RA
							^a Tamate	AF
							^a Topamax	JC
							^a Topiramate-GA	GM
							^a Topiramate Sandoz	SZ
8164Q NP	Tablet 50 mg	60	5	..	53.91	35.40	^a APO-Topiramate	TX
							^a Epiramax 50	QA
							^a RBX Topiramate	RA
							^a Tamate	AF
							^a Topamax	JC
							^a Topiramate-GA	GM
							^a Topiramate Sandoz	SZ

TOPIRAMATE
Authority required (STREAMLINED)
2797

Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Note Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
8165R NP	Tablet 100 mg	60	5	..	80.74	35.40	^a APO-Topiramate TX ^a Epiramax 100 QA ^a RBX Topiramate RA ^a Tamate AF ^a Topamax JC ^a Topiramate-GA GM ^a Topiramate Sandoz SZ
8166T NP	Tablet 200 mg	60	5	..	131.19	35.40	^a APO-Topiramate TX ^a Epiramax 200 QA ^a RBX Topiramate RA ^a Tamate AF ^a Topamax JC ^a Topiramate-GA GM ^a Topiramate Sandoz SZ

TOPIRAMATE

Authority required (STREAMLINED)

2798

Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs in patients unable to take a solid dose form of topiramate.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8371N NP	Capsule 15 mg	60	5	..	28.38	29.49	Topamax Sprinkle JC
8372P NP	Capsule 25 mg	60	5	..	36.08	35.40	Topamax Sprinkle JC
8520K NP	Capsule 50 mg	60	5	..	53.86	35.40	Topamax Sprinkle JC

ZONISAMIDE

Authority required (STREAMLINED)

2664

Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9388D NP	Capsule 25 mg	56	5	..	22.90	24.01	Zonegran SA
9389E NP	Capsule 50 mg	56	5	..	33.82	34.93	Zonegran SA
9390F NP	Capsule 100 mg	112	5	..	*93.56	35.40	Zonegran SA

Nervous system

					Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium			Brand Name and Manufacturer	
Anti-Parkinson drugs								

Anticholinergic agents

Tertiary amines

BENZHEXOL HYDROCHLORIDE

1109J NP	Tablet 2 mg	200	2	..	15.42	16.53	Artane	QA
1110K NP	Tablet 5 mg	200	1	..	22.11	23.22	Artane	QA

BIPERIDEN HYDROCHLORIDE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2544X NP	Tablet 2 mg	200	2	..	*20.98	22.09	Akineton	LM
-------------	-------------	-----	---	----	--------	-------	----------	----

Ethers of tropine or tropine derivatives

BENZTROPINE MESYLATE

2362H NP	Tablet 2 mg	60	2	..	12.86	13.97	Benztrop	PL
3038X NP	Injection 2 mg in 2 mL	5	103.69	35.40	Cogentin	FK

Dopaminergic agents

Dopa and dopa derivatives

LEVODOPA with BENSERAZIDE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2225D NP	Capsule 100 mg-25 mg	100	5	..	39.02	35.40	Madopar 125	RO
2226E NP	Capsule 200 mg-50 mg	100	5	..	50.11	35.40	Madopar	RO
2227F NP	Capsule 50 mg-12.5 mg	100	5	..	23.10	24.21	Madopar 62.5	RO
2228G NP	Tablet 200 mg-50 mg	100	5	..	50.11	35.40	Madopar	RO
2229H NP	Tablet 100 mg-25 mg	100	5	..	39.02	35.40	Madopar 125	RO
2231K NP	Capsule 100 mg-25 mg (sustained release)	100	5	..	42.10	35.40	Madopar HBS	RO
8218M NP	Dispersible tablet 50 mg-12.5 mg	100	5	..	23.10	24.21	Madopar Rapid 62.5	RO
8219N NP	Dispersible tablet 100 mg-25 mg	100	5	..	39.02	35.40	Madopar Rapid 125	RO

LEVODOPA with CARBIDOPA

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1242J NP	Tablet 100 mg-25 mg	100	5	..	38.39	35.40	^a Kinson	AF
				^B 5.19	43.58	35.40	^a Sinemet 100/25	MK
1245M NP	Tablet 250 mg-25 mg	100	5	..	45.19	35.40	^a Levo/Carbidopa Sandoz	SZ
				^B 2.92	48.11	35.40	^a Sinemet	MK

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<hr/>								
LEVODOPA with CARBIDOPA								
<u>Authority required (STREAMLINED)</u>								
1257								
Parkinson's disease where fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1255C NP	Tablet 200 mg-50 mg (modified release)	100	5	..	67.97	35.40	Sinemet CR	MK
<hr/>								
LEVODOPA with CARBIDOPA								
<u>Authority required</u>								
Maintenance therapy following treatment which was commenced in a hospital-based movement disorder clinic, of a patient with advanced Parkinson disease with severe disabling motor fluctuations not adequately controlled by oral therapy.								
<u>Note</u>								
Patients should have adequate cognitive function to manage administration with a portable continuous infusion pump.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8970D NP	Intestinal gel 20 mg-5 mg per mL, 100 mL	56	5	..	*11682.44	35.40	Duodopa	VE
<hr/>								
LEVODOPA with CARBIDOPA and ENTACAPONE								
<u>Authority required (STREAMLINED)</u>								
3305								
Parkinson disease in patients being treated with levodopa—decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect;								
3306								
Parkinson disease in patients stabilised on concomitant treatment with levodopa—decarboxylase inhibitor combinations and entacapone.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8797B NP	Tablet 50 mg-12.5 mg-200 mg	200	4	..	*311.98	35.40	Stalevo	NV
8798C NP	Tablet 100 mg-25 mg-200 mg	200	4	..	*342.02	35.40	Stalevo	NV
8799D NP	Tablet 150 mg-37.5 mg-200 mg	200	4	..	*372.06	35.40	Stalevo	NV
9292C NP	Tablet 200 mg-50 mg-200 mg	200	4	..	*399.72	35.40	Stalevo	NV
9344T NP	Tablet 75 mg-18.75 mg-200 mg	200	4	..	*325.22	35.40	Stalevo	NV
9345W NP	Tablet 125 mg-31.25 mg-200 mg	200	4	..	*354.06	35.40	Stalevo	NV
<hr/>								

Adamantane derivatives

AMANTADINE HYDROCHLORIDE

Restricted benefit

Parkinson's disease which is not drug induced.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
3016R NP	Capsule 100 mg	100	5	..	44.40	35.40	Symmetrel 100 NV

Dopamine agonists

BROMOCRIPTINE MESYLATE

Restricted benefit

Acromegaly;

Parkinson's disease;

Pathological hyperprolactinaemia where surgery is not indicated;

Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;

Pathological hyperprolactinaemia where radiotherapy is not indicated;

Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.

Note

Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.

Note

For item codes 1443Y and 1559C, pharmaceutical benefits that have the form tablet 2.5 mg (base) are equivalent for the purposes of substitution.

1443Y	Tablet 2.5 mg (base)	60	5	..	*31.52	32.63 ^a	Parlodel	NV
1559C	Tablet 2.5 mg (base)	60	5	..	31.52	32.63 ^a	Kripton 2.5	AF

BROMOCRIPTINE MESYLATE

Restricted benefit

Acromegaly;

Parkinson's disease;

Pathological hyperprolactinaemia where surgery is not indicated;

Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;

Pathological hyperprolactinaemia where radiotherapy is not indicated;

Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.

Note

Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.

1445C	Capsule 10 mg (base)	100	5	..	148.56	35.40	Kripton 10	AF
1446D	Capsule 5 mg (base)	60	5	..	48.38	35.40	Kripton 5	AF

CABERGOLINE

Restricted benefit

Parkinson's disease.

Note

Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8393R NP	Tablet 1 mg	30	5	..	59.88	35.40 ^a	Bergoline 1	QA
						^a	Cabaser	PF
						^a	Cobasol	GM
8394T NP	Tablet 2 mg	30	5	..	78.04	35.40 ^a	Bergoline 2	QA
						^a	Cabaser	PF
						^a	Cobasol	GM

PERGOLIDE MESYLATE

Restricted benefit

Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Note</u>								
Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.								
<u>Note</u>								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2808T NP	Tablet 50 micrograms (base)	100	53.03	35.40	Permax	AS
2809W NP	Tablet 250 micrograms (base)	100	5	..	66.28	35.40	Permax	AS
2810X NP	Tablet 1 mg (base)	100	5	..	241.79	35.40	Permax	AS

PRAMIPEXOLE HYDROCHLORIDE

Caution

Episodes of sudden onset of sleep without warning, during activity, have been reported with this drug.

Note

Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.

Restricted benefit

Parkinson disease.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9151P NP	Tablet 125 micrograms	30	10.99	12.10	^a Sifrol	BY
							^a Simipex 0.125	QA
9152Q NP	Tablet 250 micrograms	100	5	..	35.83	35.40	^a Sifrol	BY
							^a Simipex 0.25	QA
9153R NP	Tablet 1 mg	100	5	..	128.92	35.40	^a Sifrol	BY
							^a Simipex 1	QA

PRAMIPEXOLE HYDROCHLORIDE

Caution

Episodes of sudden onset of sleep without warning, during activity, have been reported with this drug.

Note

Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.

Restricted benefit

Treatment of severe primary Restless Legs Syndrome in a patient who manifests all 4 diagnostic criteria below and whose baseline International Restless Legs Syndrome Rating Scale (IRLSRS) score is greater than or equal to 21 points prior to initiation of pramipexole.

The date and IRLSRS score must be documented in the patient's medical records at the time pramipexole treatment is initiated.

The diagnostic criteria for Restless Legs Syndrome are:

- An urge to move the legs usually accompanied or caused by unpleasant sensations in the legs; and
- The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting; and
- The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues; and
- The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur during the evening or night.

Pramipexole is not PBS-subsidised for Restless Legs Syndrome secondary to other causes.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
9393J NP	Tablet 125 micrograms	30	2	..	10.99	12.10	Sifrol	BY
9394K NP	Tablet 250 micrograms	100	2	..	35.83	35.40	Sifrol	BY

PRAMIPEXOLE HYDROCHLORIDE

Caution

Episodes of sudden onset of sleep without warning, during activity, have been reported with this drug.

Note

Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.

Restricted benefit

Parkinson disease.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be approved for extended release pramipexole formulations.

3418X NP	Tablet 0.375 mg (extended release)	30	5	..	19.94	21.05	Sifrol ER	BY
3419Y NP	Tablet 0.75 mg (extended release)	30	5	..	32.91	34.02	Sifrol ER	BY
3420B NP	Tablet 1.5 mg (extended release)	30	5	..	57.00	35.40	Sifrol ER	BY
3421C NP	Tablet 3 mg (extended release)	30	5	..	116.67	35.40	Sifrol ER	BY
3422D NP	Tablet 4.5 mg (extended release)	30	5	..	171.76	35.40	Sifrol ER	BY
5143Q NP	Tablet 2.25 mg (extended release)	30	5	..	82.24	35.40	Sifrol ER	BY
5145T NP	Tablet 3.75 mg (extended release)	30	5	..	141.92	35.40	Sifrol ER	BY

Monoamine oxidase type B inhibitors

RASAGILINE

Authority required (STREAMLINED)

4053

Parkinson disease.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

1952R NP	Tablet 1 mg (as mesilate)	30	5	..	121.69	35.40	Azilect	LU
-------------	---------------------------	----	---	----	--------	-------	---------	----

SELEGILINE HYDROCHLORIDE

Restricted benefit

Late stage Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1973W NP	Tablet 5 mg	100	5	..	53.06	35.40 ^a	Eldepryl	AS
						^a	Selgene	AF

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Other dopaminergic agents

ENTACAPONE

Authority required (STREAMLINED)

2067

Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8367J NP	Tablet 200 mg	200	4	..	*281.92	35.40	Comtan	NV
-------------	---------------	-----	---	----	---------	-------	--------	----

Psycholeptics

Antipsychotics

Phenothiazine with aliphatic side-chain

CHLORPROMAZINE HYDROCHLORIDE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1195X NP	Injection 50 mg in 2 mL	10	20.58	21.69	Largactil	SW
1196Y NP	Tablet 10 mg	100	5	..	10.59	11.70	Largactil	SW
1197B NP	Tablet 25 mg	100	5	..	11.19	12.30	Largactil	SW
1199D NP	Tablet 100 mg	100	5	..	17.54	18.65	Largactil	SW
1201F NP	Mixture 25 mg per 5 mL, 100 mL	1	5	..	12.67	13.78	Largactil	SW

Phenothiazine with piperazine structure

FLUPHENAZINE DECANOATE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1001Q NP	Injection 50 mg in 2 mL	5	37.75	35.40	Modecate	BQ
1046C NP	Injection 12.5 mg in 0.5 mL	5	19.32	20.43	Modecate	BQ
3098C NP	Injection 25 mg in 1 mL	5	26.48	27.59	Modecate	BQ

TRIFLUOPERAZINE HYDROCHLORIDE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2185B NP	Tablet 1 mg (base)	100	5	..	13.41	14.52	Stelazine	GH
2186C NP	Tablet 5 mg (base)	100	5	..	13.96	15.07	Stelazine	GH
2386N NP	Tablet 2 mg (base)	100	5	..	13.58	14.69	Stelazine	GH

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Phenothiazines with piperidine structure

PERICYAZINE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

3052P NP	Tablet 2.5 mg	100	5	..	10.51	11.62	Neulactil	SW
3053Q NP	Tablet 10 mg	100	5	..	14.56	15.67	Neulactil	SW

Butyrophenone derivatives

HALOPERIDOL

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2761H NP	Tablet 500 micrograms	100	5	..	10.66	11.77	Serenace	QA
2763K NP	Oral liquid 2 mg per mL, 100 mL	£1	5	..	20.55	21.66	Serenace	QA
2767P NP	Tablet 1.5 mg	100	5	..	11.01	12.12	Serenace	QA
2768Q NP	Injection 5 mg in 1 mL	10	22.38	23.49	Serenace	QA
2770T NP	Tablet 5 mg	50	5	..	10.78	11.89	Serenace	QA

HALOPERIDOL DECANOATE

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2765M NP	I.M. injection equivalent to 50 mg haloperidol in 1 mL	5	26.77	27.88	Haldol decanoate	JC
2766N NP	I.M. injection equivalent to 150 mg haloperidol in 3 mL	5	46.33	35.40	Haldol decanoate	JC

Indole derivatives

ZIPRASIDONE HYDROCHLORIDE

Authority required (STREAMLINED)

1589

Schizophrenia.

Authority required (STREAMLINED)

3084

Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9070J NP	Capsule 20 mg (base)	60	5	..	90.71	35.40	Zeldox	PF
9071K NP	Capsule 40 mg (base)	60	5	..	175.21	35.40	Zeldox	PF
9072L NP	Capsule 60 mg (base)	60	5	..	253.73	35.40	Zeldox	PF
9073M NP	Capsule 80 mg (base)	60	5	..	330.53	35.40	Zeldox	PF

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<i>Thioxanthene derivatives</i>								
FLUPENTHIXOL DECANOATE								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2255Q NP	Oily I.M. injection 20 mg in 1 mL	5	20.61	21.72	Fluanxol Depot	LU
2257T NP	Oily I.M. injection 100 mg in 1 mL	5	48.37	35.40	Fluanxol Concentrated Depot	LU
ZUCLOPENTHIXOL DECANOATE								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8097E NP	Oily I.M. injection 200 mg in 1 mL	5	27.34	28.45	Clopixol Depot	LU
<i>Diazepines, oxazepines, thiazepines and oxepines</i>								
ASENAPINE								
<u>Authority required (STREAMLINED)</u>								
1589								
Schizophrenia;								
3935								
Treatment, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder;								
3936								
Maintenance treatment, as monotherapy, of bipolar I disorder.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
5140M NP	Sublingual wafer 5 mg (as maleate)	60	5	..	157.17	35.40	Saphris	LU
5141N NP	Sublingual wafer 10 mg (as maleate)	60	5	..	252.82	35.40	Saphris	LU
OLANZAPINE								
<u>Authority required (STREAMLINED)</u>								
1589								
Schizophrenia;								
2044								
Maintenance treatment of bipolar I disorder.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
Pharmaceutical benefits that have the form olanzapine tablet 2.5 mg and pharmaceutical benefits that have the form olanzapine tablet 2.5 mg (as benzoate) are equivalent for the purposes of substitution.								
1024X NP	Tablet 2.5 mg (as benzoate)	28	5	..	46.83	35.40	^a Olanzapine generichealth 2.5	GQ
							^a Olanzapine- Synthon	ZT
							^a STADA Olanzapine	TD
8170B NP	Tablet 2.5 mg	28	5	..	46.83	35.40	^a APO-Olanzapine	TX

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Chem mart CH
							^a Olanzapine
							^a Lanzek EL
							^a Olanzapine-DRLA RZ
							^a Olanzapine-GA GM
							^a Olanzapine-PS FZ
							^a Olanzapine RBX RA
							^a Olanzapine Sandoz SZ
							^a Ozin 2.5 DO
							^a Pharmacor CR
							^a Olanzapine 2.5
							^a Terry White TW
							^a Chemists
							^a Olanzapine
							^a Zylap 2.5 QA
							^a Zypine AF
							^a Zyprexa LY

OLANZAPINE

Authority required (STREAMLINED)

1589

Schizophrenia;

2044

Maintenance treatment of bipolar I disorder.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

Pharmaceutical benefits that have the form olanzapine tablet 5 mg and pharmaceutical benefits that have the form olanzapine tablet 5 mg (as benzoate) are equivalent for the purposes of substitution.

1037N NP	Tablet 5 mg (as benzoate)	28	5	..	84.51	35.40	^a Olanzapine generichealth 5	GQ
							^a Olanzapine- Synthon	ZT
							^a STADA Olanzapine	TD
8185T NP	Tablet 5 mg	28	5	..	84.51	35.40	^a APO-Olanzapine	TX
							^a Chem mart	CH
							^a Olanzapine	
							^a Lanzek	EL
							^a Olanzapine-DRLA	RZ
							^a Olanzapine-GA	GM
							^a Olanzapine-PS	FZ
							^a Olanzapine RBX	RA
							^a Olanzapine Sandoz	SZ
							^a Ozin 5	DO
							^a Pharmacor	CR
							^a Olanzapine 5	
							^a Terry White	TW
							^a Chemists	
							^a Olanzapine	
							^a Zylap 5	QA
							^a Zypine	AF
							^a Zyprexa	LY

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
OLANZAPINE								
<u>Authority required (STREAMLINED)</u>								
1589								
Schizophrenia;								
2044								
Maintenance treatment of bipolar I disorder.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
Pharmaceutical benefits that have the form olanzapine tablet 7.5 mg and pharmaceutical benefits that have the form olanzapine tablet 7.5 mg (as benzoate) are equivalent for the purposes of substitution.								
1041T NP	Tablet 7.5 mg (as benzoate)	28	5	..	124.70	35.40	^a Olanzapine generichealth 7.5 ^a Olanzapine- Synthon ^a STADA Olanzapine	GQ ZT TD
8186W NP	Tablet 7.5 mg	28	5	..	124.70	35.40	^a APO-Olanzapine ^a Chem mart Olanzapine ^a Lanzek ^a Olanzapine-DRLA ^a Olanzapine-GA ^a Olanzapine-PS ^a Olanzapine RBX ^a Olanzapine Sandoz ^a Ozin 7.5 ^a Pharmacor Olanzapine 7.5 ^a Terry White Chemists Olanzapine ^a Zylap 7.5 ^a Zypine ^a Zyprexa	TX CH EL RZ GM FZ RA SZ DO CR TW QA AF LY
<hr/>								
OLANZAPINE								
<u>Authority required (STREAMLINED)</u>								
1589								
Schizophrenia;								
2044								
Maintenance treatment of bipolar I disorder.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
Pharmaceutical benefits that have the form olanzapine tablet 10 mg and pharmaceutical benefits that have the form olanzapine tablet 10 mg (as benzoate) are equivalent for the purposes of substitution.								
1042W NP	Tablet 10 mg (as benzoate)	28	5	..	164.10	35.40	^a Olanzapine generichealth 10 ^a Olanzapine- Synthon ^a STADA Olanzapine	GQ ZT TD
8187X	Tablet 10 mg	28	5	..	164.10	35.40	^a APO-Olanzapine	TX

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer		
NP							a	Chem mart Olanzapine	CH
							a	Lanzek	EL
							a	Olanzapine-DRLA	RZ
							a	Olanzapine-GA	GM
							a	Olanzapine-PS	FZ
							a	Olanzapine RBX	RA
							a	Olanzapine Sandoz	SZ
							a	Ozin 10	DO
							a	Pharmacor Olanzapine 10	CR
							a	Terry White Chemists Olanzapine	TW
							a	Zylap 10	QA
							a	Zypine	AF
							a	Zyprexa	LY
<hr/>									
OLANZAPINE									
<u>Authority required (STREAMLINED)</u>									
1589									
Schizophrenia;									
2044									
Maintenance treatment of bipolar I disorder.									
<u>Note</u>									
Shared Care Model:									
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.									
<u>Note</u>									
Pharmaceutical benefits that have the form olanzapine tablet 5 mg (orally disintegrating) and pharmaceutical benefits that have the form olanzapine wafer 5 mg are equivalent for the purposes of substitution.									
3381Y	Tablet 5 mg (orally disintegrating)	28	5	..	84.51	35.40	a	APO-Olanzapine	TX
NP								ODT	
							a	Chem mart	CH
								Olanzapine ODT	
							a	Olanzapine-GA	GM
								ODT	
							a	Olanzapine ODT-	RZ
								DRLA	
							a	Olanzapine ODT	GQ
								generichealth 5	
							a	Olanzapine Sandoz	SZ
								ODT 5	
							a	PS Olanzapine ODT	FZ
							a	Terry White	TW
								Chemists	
								Olanzapine ODT	
							a	Zylap ODT 5	QA
8433W	Wafer 5 mg	28	5	..	84.51	35.40	a	Lanzek Zydis	EL
NP									
							a	Zypine ODT	AF
							a	Zyprexa Zydis	LY

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
OLANZAPINE							
<u>Authority required (STREAMLINED)</u>							
1589							
Schizophrenia;							
2044							
Maintenance treatment of bipolar I disorder.							
<u>Note</u>							
Shared Care Model:							
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
<u>Note</u>							
Pharmaceutical benefits that have the form olanzapine tablet 10 mg (orally disintegrating) and pharmaceutical benefits that have the form olanzapine wafer 10 mg are equivalent for the purposes of substitution.							
3382B NP	Tablet 10 mg (orally disintegrating)	28	5	..	164.10	35.40	^a APO-Olanzapine ODT TX ^a Chem mart CH ^a Olanzapine ODT Olanzapine-GA GM ^a Olanzapine ODT-DRLA RZ ^a Olanzapine ODT generichealth 10 GQ ^a Olanzapine Sandoz ODT 10 SZ ^a PS Olanzapine ODT FZ ^a Terry White Chemists Olanzapine ODT TW ^a Zylap ODT 10 QA
8434X NP	Wafer 10 mg	28	5	..	164.10	35.40	^a Lanzek Zydis EL ^a Zypine ODT AF ^a Zyprexa Zydis LY
OLANZAPINE							
<u>Authority required (STREAMLINED)</u>							
1589							
Schizophrenia;							
2044							
Maintenance treatment of bipolar I disorder.							
<u>Note</u>							
Shared Care Model:							
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
<u>Note</u>							
Pharmaceutical benefits that have the form olanzapine tablet 15 mg (orally disintegrating) and pharmaceutical benefits that have the form olanzapine wafer 15 mg are equivalent for the purposes of substitution.							
3384D NP	Tablet 15 mg (orally disintegrating)	28	5	..	239.39	35.40	^a APO-Olanzapine ODT TX ^a Chem mart CH ^a Terry White Chemists Olanzapine ODT TW ^a Zyprexa Zydis LY
8952E NP	Wafer 15 mg	28	5	..	239.39	35.40	^a Zyprexa Zydis LY

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
OLANZAPINE								
<u>Authority required (STREAMLINED)</u>								
1589								
Schizophrenia;								
2044								
Maintenance treatment of bipolar I disorder.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
Pharmaceutical benefits that have the form olanzapine tablet 20 mg (orally disintegrating) and pharmaceutical benefits that have the form olanzapine wafer 20 mg are equivalent for the purposes of substitution.								
3385E NP	Tablet 20 mg (orally disintegrating)	28	5	..	311.00	35.40	^a APO-Olanzapine ODT	TX
							^a Chem mart Olanzapine ODT	CH
							^a Terry White Chemists Olanzapine ODT	TW
8953F NP	Wafer 20 mg	28	5	..	311.00	35.40	^a Zyprexa Zydis	LY
<hr/>								
OLANZAPINE								
<u>Authority required (STREAMLINED)</u>								
1589								
Schizophrenia.								
<u>Caution</u>								
Monitor for post-injection syndrome for at least three hours after each injection.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
Special Pricing Arrangements apply.								
9294E NP	Powder for injection 210 mg (as pamoate monohydrate) with diluent	2	5	..	*499.88	35.40	Zyprexa Relprevv	LY
9295F NP	Powder for injection 300 mg (as pamoate monohydrate) with diluent	2	5	..	*809.36	35.40	Zyprexa Relprevv	LY
9303P NP	Powder for injection 405 mg (as pamoate monohydrate) with diluent	1	5	..	499.88	35.40	Zyprexa Relprevv	LY
QUETIAPINE								
<u>Authority required (STREAMLINED)</u>								
1589								
Schizophrenia;								
2765								
Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder;								
2044								
Maintenance treatment of bipolar I disorder.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
5458G NP	Tablet (modified release) 150 mg (as fumarate)	60	5	..	118.28	35.40	Seroquel XR	AP
8456C NP	Tablet 25 mg (as fumarate)	60	5	..	46.92	35.40	^a APO-Quetiapine	TX
							^a Chem mart Quetiapine	CH

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
8457D NP	Tablet 100 mg (as fumarate)	90	5	..	118.28	35.40	^a Delucon 25 DO
							^a Quetiaccord WQ
							^a Quetiapine Actavis 25 TA
							^a Quetiapine-DRLA RZ
							^a Quetiapine GH 25 GQ
							^a Quetiapine Pfizer FZ
							^a Quetiapine RBX RA
							^a Quetiapine Sandoz SZ
							^a Quetiapine-Synthon ZT
							^a Quipine GM
							^a Sequase PM
							^a Seronia 25 QA
							^a Seroquel AP
							^a STADA Quetiapine TD
							^a Syquet AF
							^a Terry White Chemists Quetiapine TW
							^a APO-Quetiapine TX
							^a Chem mart Quetiapine CH
							^a Delucon 100 DO
							^a Quetiaccord WQ
8458E NP	Tablet 200 mg (as fumarate)	60	5	..	158.79	35.40	^a Quetiapine Actavis 100 TA
							^a Quetiapine-DRLA RZ
							^a Quetiapine GH 100 GQ
							^a Quetiapine Pfizer FZ
							^a Quetiapine RBX RA
							^a Quetiapine Sandoz SZ
							^a Quetiapine-Synthon ZT
							^a Quipine GM
							^a Sequase PM
							^a Seronia 100 QA
							^a Seroquel AP
							^a STADA Quetiapine TD
							^a Syquet AF
							^a Terry White Chemists Quetiapine TW
							^a APO-Quetiapine TX
							^a Chem mart Quetiapine CH
							^a Delucon 200 DO
							^a Quetiaccord WQ
							^a Quetiapine Actavis 200 TA
							^a Quetiapine-DRLA RZ
							^a Quetiapine GH 200 GQ
							^a Quetiapine Pfizer FZ
							^a Quetiapine RBX RA
							^a Quetiapine Sandoz SZ

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Quetiapine- Synthon ZT
							^a Quipine GM
							^a Sequase PM
							^a Seronia 200 QA
							^a Seroquel AP
							^a STADA Quetiapine TD
							^a Syquet AF
							^a Terry White Chemists Quetiapine TW
8580N NP	Tablet 300 mg (as fumarate)	60	5	..	227.64	35.40	^a APO-Quetiapine TX
							^a Chem mart Quetiapine CH
							^a Delucon 300 DO
							^a Quetiaccord WQ
							^a Quetiapine Actavis 300 TA
							^a Quetiapine-DRLA RZ
							^a Quetiapine GH 300 GQ
							^a Quetiapine Pfizer FZ
							^a Quetiapine RBX RA
							^a Quetiapine Sandoz SZ
							^a Quetiapine- Synthon ZT
							^a Quipine GM
							^a Sequase PM
							^a Seronia 300 QA
							^a Seroquel AP
							^a STADA Quetiapine TD
							^a Syquet AF
							^a Terry White Chemists Quetiapine TW
9202H NP	Tablet (modified release) 50 mg (as fumarate)	60	5	..	85.50	35.40	Seroquel XR AP
9203J NP	Tablet (modified release) 200 mg (as fumarate)	60	5	..	158.79	35.40	Seroquel XR AP
9204K NP	Tablet (modified release) 300 mg (as fumarate)	60	5	..	227.64	35.40	Seroquel XR AP
9205L NP	Tablet (modified release) 400 mg (as fumarate)	60	5	..	301.38	35.40	Seroquel XR AP

Benzamides

AMISULPRIDE

Authority required (STREAMLINED)

1589

Schizophrenia.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8594H NP	Tablet 100 mg	30	5	..	27.94	29.05	^a Amisulpride 100 Winthrop WA
							^a Amisulpride Sandoz SZ
							^a APO-Amisulpride TX
							^a Solian 100 SW

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8595J <i>NP</i>	Tablet 200 mg	60	5	..	94.80	35.40	^a Sulprix	AF
							^a Amisulpride 200 Winthrop	WA
							^a Amisulpride Sandoz	SZ
							^a APO-Amisulpride	TX
							^a Solian 200	SW
8596K <i>NP</i>	Tablet 400 mg	60	5	..	166.60	35.40	^a Sulprix	AF
							^a Amipride 400	QA
							^a Amisulpride 400 Winthrop	WA
							^a Amisulpride Sandoz	SZ
							^a APO-Amisulpride	TX
8736T <i>NP</i>	Oral solution 100 mg per mL, 60 mL	2	5	..	*148.84	35.40	^a Solian 400	SW
							^a Sulprix	AF
							Solian Solution	SW

Lithium

LITHIUM CARBONATE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

3059B <i>NP</i>	Tablet 250 mg	200	2	..	16.99	18.10	Lithicarb	AS
8290H <i>NP</i>	Tablet 450 mg (slow release)	200	2	..	*34.40	35.40	Quilonum SR	GK

Other antipsychotics

ARIPRAZOLE

Authority required (STREAMLINED)

1589

Schizophrenia.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8717T <i>NP</i>	Tablet 10 mg	30	5	..	152.35	35.40	Abilify	BQ
8718W <i>NP</i>	Tablet 15 mg	30	5	..	212.66	35.40	Abilify	BQ
8719X <i>NP</i>	Tablet 20 mg	30	5	..	253.53	35.40	Abilify	BQ
8720Y <i>NP</i>	Tablet 30 mg	30	5	..	303.59	35.40	Abilify	BQ

PALIPERIDONE

Authority required (STREAMLINED)

1589

Schizophrenia.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

Special Pricing Arrangements apply to 3 mg and 6 mg strengths.

9140C <i>NP</i>	Tablet 3 mg (prolonged release)	28	5	..	161.17	35.40	Invega	JC
--------------------	---------------------------------	----	---	----	--------	-------	--------	----

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
9141D NP	Tablet 6 mg (prolonged release)	28	5	..	169.78	35.40	Invega	JC

PALIPERIDONE

Authority required (STREAMLINED)

1589

Schizophrenia.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

5100K NP	I.M. injection (modified release) 25 mg (as palmitate) in pre-filled syringe	1	5	..	149.73	35.40	Invega Sustenna	JC
5102M NP	I.M. injection (modified release) 50 mg (as palmitate) in pre-filled syringe	1	5	..	284.90	35.40	Invega Sustenna	JC
5103N NP	I.M. injection (modified release) 75 mg (as palmitate) in pre-filled syringe	1	5	..	363.24	35.40	Invega Sustenna	JC
5107T NP	I.M. injection (modified release) 100 mg (as palmitate) in pre-filled syringe	1	5	..	440.79	35.40	Invega Sustenna	JC
5109X NP	I.M. injection (modified release) 150 mg (as palmitate) in pre-filled syringe	1	5	..	440.79	35.40	Invega Sustenna	JC
9142E NP	Tablet 9 mg (prolonged release)	28	5	..	226.11	35.40	Invega	JC

RISPERIDONE

Authority required (STREAMLINED)

2061

Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful.

Caution

In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.

Authority required (STREAMLINED)

3083

Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.

Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.

Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.

The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

For item codes 8787L and 1842Y, pharmaceutical benefits that have the form tablet 0.5 mg are equivalent for the purposes of substitution.

8787L NP	Tablet 0.5 mg	60	2	..	26.69	27.80	^a Ozidal	RA
							^a Resdone 0.5	CR
							^a Rispa	QA
							^a Risperidone Actavis 0.5	TA
							^a Risperidone-DRLA	RZ
							^a Risperidone-GA	GM

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							^a Risperidone Pfizer	FZ
							^a Risperidone Sandoz	SZ
							^a Rixadone	AF

RISPERIDONE

Authority required (STREAMLINED)

2061

Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful.

Caution

In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.

Authority required (STREAMLINED)

3083

Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.

Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.

Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.

The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders.

Note

For item codes 8787L and 1842Y, pharmaceutical benefits that have the form tablet 0.5 mg are equivalent for the purposes of substitution.

1842Y NP	Tablet 0.5 mg	60	2	..	*26.71	27.82	^a APO-Risperidone	TX
							^a Risperdal	JC

RISPERIDONE

Authority required (STREAMLINED)

2061

Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful.

Caution

In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.

Authority required (STREAMLINED)

3083

Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.

Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.

Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.

The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8788M NP	Tablet 0.5 mg (orally disintegrating)	56	2	..	*29.10	30.21	Risperdal Quicklet	JC
8789N NP	Tablet 1 mg	60	2	..	44.87	35.40	^a APO-Risperidone	TX
							^a Ozidal	RA
							^a Resdone 1	CR
							^a Rispa	QA
							^a Risperdal	JC
							^a Risperidone Actavis 1	TA
							^a Risperidone-DRLA	RZ
							^a Risperidone-GA	GM
							^a Risperidone generichealth	GQ
							^a Risperidone Pfizer	FZ
							^a Risperidone Sandoz	SZ
							^a Rixadone	AF
8790P NP	Tablet 1 mg (orally disintegrating)	56	2	..	*50.30	35.40	Risperdal Quicklet	JC
9293D NP	Oral solution 1 mg per mL, 100 mL	‡1	2	..	118.13	35.40	Risperdal	JC

RISPERIDONE

Authority required (STREAMLINED)

1589

Schizophrenia.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

For item codes 8869T and 1846E, pharmaceutical benefits that have the form tablet 0.5 mg are equivalent for the purposes of substitution.

1846E NP	Tablet 0.5 mg	60	5	..	*26.71	27.82	^a APO-Risperidone	TX
							^a Risperdal	JC
8869T NP	Tablet 0.5 mg	60	5	..	26.69	27.80	^a Ozidal	RA
							^a Resdone 0.5	CR
							^a Rispa	QA
							^a Risperidone Actavis 0.5	TA
							^a Risperidone-DRLA	RZ
							^a Risperidone-GA	GM
							^a Risperidone Pfizer	FZ
							^a Risperidone Sandoz	SZ
							^a Rixadone	AF

RISPERIDONE

Authority required (STREAMLINED)

1589

Schizophrenia.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
8870W NP	Tablet 0.5 mg (orally disintegrating)	56	5	..	*29.10	30.21	Risperdal Quicklet JC

RISPERIDONE

Authority required (STREAMLINED)

1589

Schizophrenia.

Authority required (STREAMLINED)

2272

Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

3169T NP	Tablet 1 mg	60	5	..	44.87	35.40	^a APO-Risperidone TX
							^a Ozidal RA
							^a Resdone 1 CR
							^a Rispa QA
							^a Risperdal JC
							^a Risperidone Actavis 1 TA
							^a Risperidone-DRLA RZ
							^a Risperidone-GA GM
							^a Risperidone generichealth GQ
							^a Risperidone Pfizer FZ
							^a Risperidone Sandoz SZ
							^a Rixadone AF
3170W NP	Tablet 2 mg	60	5	..	91.67	35.40	^a APO-Risperidone TX
							^a Ozidal RA
							^a Resdone 2 CR
							^a Rispa QA
							^a Risperdal JC
							^a Risperidone Actavis 2 TA
							^a Risperidone-DRLA RZ
							^a Risperidone-GA GM
							^a Risperidone generichealth GQ
							^a Risperidone Pfizer FZ
							^a Risperidone Sandoz SZ
							^a Rixadone AF
3171X NP	Tablet 3 mg	60	5	..	137.84	35.40	^a APO-Risperidone TX
							^a Ozidal RA
							^a Resdone 3 CR
							^a Rispa QA
							^a Risperdal JC
							^a Risperidone Actavis 3 TA
							^a Risperidone-DRLA RZ
							^a Risperidone-GA GM
							^a Risperidone generichealth GQ

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
3172Y NP	Tablet 4 mg	60	5	..	183.79	35.40	^a Risperidone Pfizer FZ
							^a Risperidone Sandoz SZ
							^a Rixadone AF
							^a APO-Risperidone TX
							^a Ozidal RA
							^a Resdone 4 CR
							^a Rispa QA
							^a Risperdal JC
							^a Risperidone Actavis 4 TA
							^a Risperidone-DRLA RZ
							^a Risperidone-GA GM
							^a Risperidone generichealth GQ
							^a Risperidone Pfizer FZ
							^a Risperidone Sandoz SZ
							^a Rixadone AF
8100H NP	Oral solution 1 mg per mL, 100 mL	1	5	..	118.13	35.40	Risperdal JC
8792R NP	Tablet 1 mg (orally disintegrating)	56	5	..	*50.30	35.40	Risperdal Quicklet JC
8794W NP	Tablet 2 mg (orally disintegrating)	56	5	..	*93.34	35.40	Risperdal Quicklet JC
9075P NP	Tablet 3 mg (orally disintegrating)	56	5	..	*135.52	35.40	Risperdal Quicklet JC
9076Q NP	Tablet 4 mg (orally disintegrating)	56	5	..	*178.42	35.40	Risperdal Quicklet JC

RISPERIDONE

Authority required (STREAMLINED)

3083

Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.

Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.

Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.

The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9079W NP	Tablet 2 mg	60	2	..	91.67	35.40	^a APO-Risperidone TX
							^a Ozidal RA
							^a Resdone 2 CR
							^a Rispa QA
							^a Risperdal JC
							^a Risperidone Actavis 2 TA
							^a Risperidone-DRLA RZ
							^a Risperidone-GA GM
							^a Risperidone GQ

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
9080X NP	Tablet 2 mg (orally disintegrating)	56	2	..	*93.34	35.40	generichealth	
							^a Risperidone Pfizer	FZ
							^a Risperidone Sandoz	SZ
							^a Rixadone	AF
							Risperdal Quicklet	JC

RISPERIDONE

Authority required (STREAMLINED)

1589

Schizophrenia;

3841

Maintenance treatment, in combination with lithium or sodium valproate, of treatment refractory bipolar I disorder.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8780D NP	Powder for I.M. injection 25 mg (modified release) with 2 mL diluent in pre-filled syringe	2	5	..	*277.20	35.40	Risperdal Consta	JC
8781E NP	Powder for I.M. injection 37.5 mg (modified release) with 2 mL diluent in pre-filled syringe	2	5	..	*353.54	35.40	Risperdal Consta	JC
8782F NP	Powder for I.M. injection 50 mg (modified release) with 2 mL diluent in pre-filled syringe	2	5	..	*429.08	35.40	Risperdal Consta	JC

Anxiolytics

Benzodiazepine derivatives

ALPRAZOLAM

Authority required

Panic disorder where other treatments have failed or are inappropriate.

2130D NP	Tablet 250 micrograms	50	8.98	10.09	^a Alprax 0.25	QA
							^a Alprazolam Sandoz	SZ
							^a Kalma 0.25	AF
					^B 1.96	10.94	^a Xanax	PF
2131E NP	Tablet 500 micrograms	50	10.50	11.61	^a Alprax 0.5	QA
							^a Alprazolam Sandoz	SZ
							^a Kalma 0.5	AF
					^B 1.95	12.45	^a Xanax	PF
2132F NP	Tablet 1 mg	50	2	..	13.45	14.56	^a Alprax 1	QA
							^a Alprazolam Sandoz	SZ
							^a Chem mart Alprazolam	CH
							^a GenRx Alprazolam	GX
							^a Kalma 1	AF
							^a Ralozam	GM
							^a Terry White Chemists Alprazolam	TW
					^B 1.95	15.40	^a Xanax	PF
8118G NP	Tablet 2 mg	50	2	..	17.26	18.37	^a Alprax 2	QA
							^a Alprazolam Sandoz	SZ
							^a Chem mart Alprazolam	CH
							^a GenRx Alprazolam	GX

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							^a Kalma 2	AF
							^a Ralozam	GM
							^a Terry White Chemists	TW
				^B 1.96	19.22	18.37	^a Alprazolam Xanax Tri-Score	PF

DIAZEPAM

Note

Authorities for increased maximum quantities and/or repeats for the oral forms of diazepam will be granted only for

(i) the treatment of disabling spasticity; or

(ii) malignant neoplasia (late stage); or

(iii) use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal; or

(iv) use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.

Up to six months' treatment (i.e. one month's treatment with five repeats) may be requested.

2558P NP	Injection 10 mg in 2 mL	5	12.39	13.50	Hospira Pty Limited	HH
3161J NP	Tablet 2 mg	50	7.82	8.93	^a Antenex 2	AF
							^a APO-Diazepam	TX
							^a Ranzepam	RA
							^a Valpam 2	QA
				^B 0.82	8.64	8.93	^a Valium	RO
3162K NP	Tablet 5 mg	50	7.95	9.06	^a Antenex 5	AF
							^a APO-Diazepam	TX
							^a Diazepam-GA	GM
							^a Ranzepam	RA
							^a Valpam 5	QA
				^B 0.85	8.80	9.06	^a Valium	RO

OXAZEPAM

Note

Authorities for increased maximum quantities and/or repeats will not be granted except as detailed under the 'Authority required' listing of oxazepam below.

3132W NP	Tablet 15 mg	25	7.75	8.86	^a Alepam 15	AF
				^B 2.69	10.44	8.86	^a Serepax	QA
3133X NP	Tablet 30 mg	25	7.75	8.86	^a Alepam 30	AF
							^a APO-Oxazepam	TX
							^a Murelax	FM
				^B 2.69	10.44	8.86	^a Serepax	QA

OXAZEPAM

Authority required

Malignant neoplasia (late stage);

For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal;

Nervous system

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net			
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$		Brand Name and Manufacturer	
	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.								
3134Y NP	Tablet 15 mg	50	5	..	*8.98	10.09	^a	Alepam 15	AF
				^B 5.38	*14.36	10.09	^a	Serepax	QA
3135B NP	Tablet 30 mg	50	5	..	*8.98	10.09	^a	Alepam 30	AF
							^a	APO-Oxazepam	TX
							^a	Murelax	FM
				^B 5.38	*14.36	10.09	^a	Serepax	QA

Other anxiolytics

CLOMIPRAMINE HYDROCHLORIDE

Restricted benefit

Cataplexy associated with narcolepsy;

Obsessive-compulsive disorder;

Phobic disorders in adults.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1561E NP	Tablet 25 mg	50	2	..	15.19	16.30 ^a	Chem mart Clomipramine CH
						^a	GenRx GX
						^a	Clomipramine AF
						^a	Placil TW
						^a	Terry White Chemists Clomipramine
				^B 3.06	18.25	16.30 ^a	Anafranil 25 NV

Hypnotics and sedatives

Benzodiazepine derivatives

NITRAZEPAM

Note

Authorities for increased maximum quantities and/or repeats will not be granted except as detailed under the 'Authority required' listing of nitrazepam below.

2723H NP	Tablet 5 mg	25	7.92	9.03 ^a	Alodorm AF
				^B 1.45	9.37	9.03 ^a	Mogadon VT

NITRAZEPAM

Authority required

Myoclonic epilepsy;

Malignant neoplasia (late stage);

For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal;

For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2732T NP	Tablet 5 mg	50	5	..	*9.32	10.43 ^a	Alodorm AF
-------------	-------------	----	---	----	-------	--------------------	------------

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
				^B 2.90	*12.22	10.43	^a Mogadon	VT

TEMAZEPAM

Note

Authorities for increased maximum quantities and/or repeats will not be granted except as detailed under the 'Authority required' listing of temazepam below.

2089Y NP	Tablet 10 mg	25	7.56	8.67	^a APO-Temazepam	TX
							^a Temaze	AF
							^a Temtabs	FM
				^B 2.05	9.61	8.67	^a Normison	QA

TEMAZEPAM

Authority required

Malignant neoplasia (late stage);

For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal;

For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2088X NP	Tablet 10 mg	50	5	..	*8.60	9.71	^a APO-Temazepam	TX
							^a Temaze	AF
							^a Temtabs	FM
				^B 4.10	*12.70	9.71	^a Normison	QA

Psychoanaleptics

Antidepressants

Non-selective monoamine reuptake inhibitors

AMITRIPTYLINE HYDROCHLORIDE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2417F NP	Tablet 10 mg	50	2	..	8.54	9.65	Endep 10	AF
2418G NP	Tablet 25 mg	50	2	..	8.66	9.77	Endep 25	AF
2429W NP	Tablet 50 mg	50	2	..	8.99	10.10	Endep 50	AF

CLOMIPRAMINE HYDROCHLORIDE

Restricted benefit

Cataplexy associated with narcolepsy;

Obsessive-compulsive disorder;

Phobic disorders in adults.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
1561E NP	Tablet 25 mg	50	2	..	15.19	16.30	^a Chem mart	CH
							^a Clomipramine	
							^a GenRx	GX
							^a Clomipramine	
							^a Placil	AF
							^a Terry White	TW
							^a Chemists	
				^B 3.06	18.25	16.30	^a Clomipramine	
							^a Anafranil 25	NV

DOTHIEPIN HYDROCHLORIDE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1357K NP	Capsule 25 mg	50	2	..	9.48	10.59	Dothep 25	AF
1358L NP	Tablet 75 mg	30	2	..	9.48	10.59	Dothep 75	AF

DOXEPIN HYDROCHLORIDE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1011F NP	Capsule 10 mg (base)	50	2	..	9.07	10.18	Deptran 10	AF
				^B 1.95	11.02	10.18	Sinequan	PF
1012G NP	Tablet 50 mg (base)	50	2	..	9.81	10.92	Deptran 50	AF
1013H NP	Capsule 25 mg (base)	50	2	..	9.50	10.61	Deptran 25	AF
				^B 1.95	11.45	10.61	Sinequan	PF

IMIPRAMINE HYDROCHLORIDE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2420J NP	Tablet 10 mg	50	2	..	8.64	9.75	^a Tolerade 10	PQ
				^B 2.79	11.43	9.75	^a Tofranil 10	LM
2421K NP	Tablet 25 mg	50	2	..	12.53	13.64	^a Tolerade 25	PQ
				^B 2.79	15.32	13.64	^a Tofranil 25	LM

NORTRIPTYLINE HYDROCHLORIDE

Restricted benefit

Major depression where other antidepressant therapy has failed;

Major depression where other antidepressant therapy is contraindicated.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2522R NP	Tablet 10 mg (base)	50	2	..	13.42	14.53	Allegron	AS
2523T NP	Tablet 25 mg (base)	50	2	..	15.20	16.31	Allegron	AS

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<i>Selective serotonin reuptake inhibitors</i>							
CITALOPRAM HYDROBROMIDE							
<u>Restricted benefit</u>							
Major depressive disorders.							
8220P NP	Tablet 20 mg (base)	28	5	..	13.56	14.67	^a A-Citalopram TA
							^a APO-Citalopram TX
							^a Auro-Citalopram 20 DO
							^a Celapram AF
							^a Celica RA
							^a Chem mart CH
							Citalopram
							^a Ciazil GM
							^a Citalopram 20 CR
							^a Citalopram-GA GN
							^a Citalopram GQ
							generichealth
							^a Citalopram Pfizer FZ
							^a Citalopram Sandoz SZ
							^a GenRx Citalopram GX
							^a Pharmacor MI
							Citalo 20
							^a Talam QA
							^a Terry White TW
							Chemists
							Citalopram
				^B 4.45	18.01	14.67	^a Cipramil LU
8702B NP	Tablet 10 mg (base)	28	5	..	11.15	12.26	Celapram AF
8703C NP	Tablet 40 mg (base)	28	5	..	18.42	19.53	^a APO-Citalopram TX
							^a Auro-Citalopram 40 DO
							^a Celapram AF
							^a Citalopram Pfizer FZ
							^a Citalopram Sandoz SZ
							^a GenRx Citalopram GX
ESCITALOPRAM							
<u>Restricted benefit</u>							
Major depressive disorders.							
8700X NP	Tablet 10 mg (as oxalate)	28	5	..	15.75	16.86	^a APO-Escitalopram TX
							^a Chem mart CH
							Escitalopram
							^a Escicor 10 MI
							^a Escitalopram-DRLA RZ
							^a Escitalopram GA GN
							^a Escitalopram GQ
							generichealth
							^a Esipram GM
							^a Esitalo SZ
							^a Lexam 10 QA
							^a LoxaLate AF
							^a Pharmacor CR
							Escitalopram 10
							^a Terry White TW
							Chemists

Nervous system

					Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium			Brand Name and Manufacturer	
8701Y NP	Tablet 20 mg (as oxalate)	28	5	^B 2.97	18.72	16.86	^a	Escitalopram
				..	15.84	16.95	^a	Lexapro LU
							^a	APO-Escitalopram TX
							^a	Chem mart CH
							^a	Escitalopram MI
							^a	Escicor 20 RZ
							^a	Escitalopram-DRLA GN
							^a	Escitalopram GA GQ
							^a	Escitalopram generichealth GM
							^a	Esipram SZ
							^a	Esitalo QA
							^a	Lexam 20 AF
							^a	LoxaLate CR
							^a	Pharmacor Escitalopram 20 TW
			^a	Terry White Chemists Escitalopram				
			^B 4.33	20.17	16.95	^a	Lexapro LU	

ESCITALOPRAM

Restricted benefit

Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and:

(a) for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared; or

(b) who has been assessed by a psychiatrist;

Continuing PBS-subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1 March 2008.

Restricted benefit

Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and:

(a) for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared; or

(b) who has been assessed by a psychiatrist;

Continuing PBS-subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1 March 2008.

9432K NP	Tablet 10 mg (as oxalate)	28	5	..	15.75	16.86	^a Esipram	GM
				^B 2.97	18.72	16.86	^a Lexapro	LU
9433L NP	Tablet 20 mg (as oxalate)	28	5	..	15.84	16.95	^a Esipram	GM
				^B 4.33	20.17	16.95	^a Lexapro	LU

ESCITALOPRAM

Restricted benefit

Major depressive disorders.

Restricted benefit

Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and:

(a) for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared; or

(b) who has been assessed by a psychiatrist;

Continuing PBS-subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1 November 2008.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<u>Restricted benefit</u>							
Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and:							
(a) for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared; or							
(b) who has been assessed by a psychiatrist;							
Continuing PBS-subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1 November 2008.							
8849R NP	Oral solution 10 mg (as oxalate) per mL, 28 mL	1	5	..	34.40	35.40	Lexapro LU
FLUOXETINE							
<u>Restricted benefit</u>							
Major depressive disorders;							
Obsessive-compulsive disorder.							
1434L NP	Capsule 20 mg (as hydrochloride)	28	5	..	17.64	18.75	^a Auscap QA
							^a Chem mart CH
							^a Fluoxetine 20 CR
							^a Fluoxetine-GA GM
							^a Fluoxetine generichealth GQ
							^a Fluoxetine-PS FZ
							^a Fluoxetine RBX RA
							^a Fluoxetine Sandoz SZ
							^a GenRx Fluoxetine GX
							^a Lovan AL
							^a Terry White Chemists Fluoxetine TW
							^a Zactin AF
				^B 3.53	21.17	18.75	^a Prozac 20 LY
8270G NP	Tablet, dispersible, 20 mg (as hydrochloride)	28	5	..	17.64	18.75	^a Lovan 20 Tab AL
							^a Zactin Tablet AF
				^B 3.53	21.17	18.75	^a Prozac Tab LY
FLUVOXAMINE							
<u>Restricted benefit</u>							
Major depressive disorders;							
Obsessive-compulsive disorder.							
8174F NP	Tablet containing fluvoxamine maleate 100 mg	30	5	..	22.94	24.05	^a APO-Fluvoxamine TX
							^a Faverin 100 QA
							^a Fluvoxamine GA GM
							^a Movox 100 AF
							^a Voxam SZ
				^B 2.30	25.24	24.05	^a Luvox AB
8512B NP	Tablet containing fluvoxamine maleate 50 mg	30	5	..	17.35	18.46	^a APO-Fluvoxamine TX
							^a Faverin 50 QA
							^a Fluvoxamine GA GM
							^a Movox 50 AL
							^a Voxam SZ
				^B 2.30	19.65	18.46	^a Luvox AB

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
PAROXETINE							
<u>Restricted benefit</u>							
Major depressive disorders;							
Obsessive-compulsive disorder;							
Panic disorder.							
<u>Note</u>							
Pharmaceutical benefits that have the form paroxetine tablet 20 mg (as hydrochloride) and pharmaceutical benefits that have the form paroxetine tablet 20 mg (as mesilate) are equivalent for the purposes of substitution.							
2242B NP	Tablet 20 mg (as hydrochloride)	30	5	..	17.20	18.31	^a Chem mart CH
							^a Paroxetine QA
							^a Extine 20 GX
							^a GenRx Paroxetine CR
							^a Paroxetine 20 GN
							^a Paroxetine-GA SZ
							^a Paroxetine Sandoz AF
							^a Paxtine DO
							^a Roxet 20 TW
							^a Terry White Chemists Paroxetine
				^B 0.80	18.00	18.31	^a Aropax GK
9197C NP	Tablet 20 mg (as mesilate)	30	5	..	17.20	18.31	^a Paroxetine GQ
							^a generichealth ZT
							^a Paroxetine Synthon MI
							^a Pharmacor Paroxo 20
SERTRALINE							
<u>Restricted benefit</u>							
Major depressive disorders.							
2236Q NP	Tablet 50 mg (as hydrochloride)	30	5	..	16.01	17.12	^a Auro-Sertraline 50 DO
							^a Chem mart CH
							^a Sertraline AF
							^a Eleva 50 GX
							^a GenRx Sertraline QA
							^a Sertra 50 MI
							^a Sertracor 50 CR
							^a Sertraline 50 RZ
							^a Sertraline-DRLA GM
							^a Sertraline-GA GQ
							^a Sertraline generichealth
							^a Sertraline Pfizer FZ
							^a Sertraline Sandoz SZ
							^a Setrona RA
							^a Terry White Chemists Sertraline
							^a Xydep 50 GN
				^B 1.95	17.96	17.12	^a Zoloft PF
2237R NP	Tablet 100 mg (as hydrochloride)	30	5	..	16.01	17.12	^a Auro-Sertraline 100 DO
							^a Chem mart CH
							^a Sertraline AF
							^a Eleva 100 GX
							^a GenRx Sertraline

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Sertra 100 QA
							^a Sertracor 100 MI
							^a Sertraline 100 CR
							^a Sertraline-DRLA RZ
							^a Sertraline-GA GM
							^a Sertraline GQ
							^a generichealth
							^a Sertraline Pfizer FZ
							^a Sertraline Sandoz SZ
							^a Setrona RA
							^a Terry White TW
							^a Chemists Sertraline
				^B 1.95	17.96	17.12	^a Xydep 100 GN
							^a Zoloft PF
<hr/>							
SERTRALINE							
<u>Restricted benefit</u>							
Obsessive-compulsive disorder;							
Panic disorder where other treatments have failed or are inappropriate.							
8836C NP	Tablet 50 mg (as hydrochloride)	30	5	..	16.01	17.12	^a Auro-Sertraline 50 DO
							^a Eleva 50 AF
							^a Sertraline Pfizer FZ
							^a Xydep 50 GN
				^B 1.95	17.96	17.12	^a Zoloft PF
8837D NP	Tablet 100 mg (as hydrochloride)	30	5	..	16.01	17.12	^a Auro-Sertraline 100 DO
							^a Eleva 100 AF
							^a Sertraline Pfizer FZ
							^a Xydep 100 GN
				^B 1.95	17.96	17.12	^a Zoloft PF

Monoamine oxidase inhibitors, non-selective

PHENELZINE SULFATE

Caution

This drug is an irreversible monoamine oxidase inhibitor.

Restricted benefit

Depression where all other anti-depressant therapy has failed or is inappropriate.

2856H	Tablet 15 mg (base)	100	1	..	100.20	35.40	Nardil	LM
-------	---------------------	-----	---	----	--------	-------	--------	----

TRANLYCPROMINE SULFATE

Caution

This drug is an irreversible monoamine oxidase inhibitor.

2444P	Tablet 10 mg (base)	50	2	..	33.65	34.76	Parnate	GH
-------	---------------------	----	---	----	-------	-------	---------	----

Monoamine oxidase type A inhibitors

MOCLOBEMIDE

Restricted benefit

Major depressive disorders.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
Note Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1900B NP	Tablet 150 mg	60	5	..	16.00	17.11	^a Amira 150 AF ^a Chem mart Moclobemide CH ^a Clobemix GM ^a GenRx Moclobemide GX ^a Moclobemide-PS FZ ^a Moclobemide Sandoz SZ ^a Mohexal HX ^a Terry White Chemists Moclobemide TW
8003F NP	Tablet 300 mg	60	5	^B 0.55 ..	16.55 24.77	17.11 25.88	^a Aurorix VP ^a Amira 300 AF ^a Chem mart Moclobemide CH ^a Clobemix GM ^a GenRx Moclobemide GX ^a Moclobemide-PS FZ ^a Moclobemide Sandoz SZ ^a Terry White Chemists Moclobemide TW ^B 1.10 ^a Aurorix 300 mg VP

Other antidepressants

DESVENLAFAXINE SUCCINATE

Restricted benefit

Major depressive disorders.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9366Y NP	Tablet 50 mg (base) (extended release)	28	5	..	43.41	35.40	Pristiq PF
9367B NP	Tablet 100 mg (base) (extended release)	28	5	..	50.52	35.40	Pristiq PF

DULOXETINE HYDROCHLORIDE

Restricted benefit

Major depressive disorders.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9155W NP	Capsule 30 mg (base)	28	38.32	35.40	Cymbalta LY
9156X NP	Capsule 60 mg (base)	28	5	..	50.52	35.40	Cymbalta LY

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
LITHIUM CARBONATE							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
3059B NP	Tablet 250 mg	200	2	..	16.99	18.10	Lithicarb AS
8290H NP	Tablet 450 mg (slow release)	200	2	..	*34.40	35.40	Quilonum SR GK
MIANSERIN HYDROCHLORIDE							
<u>Caution</u>							
Neutropenia and agranulocytosis are more frequent in the elderly, especially in the early months of therapy.							
<u>Restricted benefit</u>							
Severe depression.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1627P NP	Tablet 10 mg	50	5	..	15.48	16.59 ^a	Lumin 10 AF
				^B 3.30	18.78	16.59 ^a	Tolvon MK
1628Q NP	Tablet 20 mg	50	5	..	25.44	26.55 ^a	Lumin 20 AF
				^B 3.30	28.74	26.55 ^a	Tolvon MK
MIRTAZAPINE							
<u>Restricted benefit</u>							
Major depressive disorders.							
<u>Note</u>							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
8513C NP	Tablet 30 mg	30	5	..	21.31	22.42 ^a	Aurozapine 30 DO
						^a	Axit 30 AF
						^a	Chem mart CH
						^a	Mirtazapine GenRx Mirtazapine GX
						^a	Mirtazapine-DP GM
						^a	Mirtazapine GH GQ
						^a	Mirtazapine Sandoz SZ
						^a	Mirtazon QA
						^a	Terry White Chemists TW
						^a	Mirtazapine
				^B 3.50	24.81	22.42 ^a	Avanza MK
8855C NP	Tablet 15 mg (orally disintegrating)	30	5	..	23.52	24.63 ^a	Avanza SolTab MK
						^a	Milivin OD 15 DO
						^a	Remeron SolTab FR
8856D NP	Tablet 30 mg (orally disintegrating)	30	5	..	29.20	30.31 ^a	Avanza SolTab MK
						^a	Milivin OD 30 DO
						^a	Remeron SolTab FR
8857E NP	Tablet 45 mg (orally disintegrating)	30	5	..	40.70	35.40 ^a	Avanza SolTab MK
						^a	Milivin OD 45 DO

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer				
8883M NP	Tablet 45 mg	30	5	..	31.19	32.30	^a Remeron SolTab	FR			
							^a APO-Mirtazapine	TX			
							^a Aurozapine 45	DO			
							^a Axit 45	AF			
							^a Chem mart Mirtazapine	CH			
							^a Mirtazapine GH	GQ			
							^a Mirtazapine Sandoz	SZ			
							^a Mirtazon	QA			
							^a Terry White Chemists Mirtazapine	TW			
9365X NP	Tablet 15 mg	30	5	..	16.38	17.49	^B 3.51	34.70	32.30	^a Avanza	MK
							^a Axit 15	AF			
REBOXETINE MESILATE <u>Restricted benefit</u> Major depressive disorders. <u>Note</u> Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.											
8583R NP	Tablet 4 mg (base)	60	5	..	38.86	35.40	Edronax	PF			
VENLAFAXINE HYDROCHLORIDE <u>Restricted benefit</u> Major depressive disorders. <u>Note</u> Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.											
8301X NP	Capsule 75 mg (base) (modified release)	28	5	..	37.81	35.40	^a Altven	FZ			
							^a APO-Venlafaxine XR	TX			
							^a Chem mart Venlafaxine XR	CH			
							^a Efexor-XR	PF			
							^a Elaxine SR 75	ZP			
							^a Enlafax-XR	AF			
							^a Terry White Chemists Venlafaxine XR	TW			
							^a Venlafaxine generichealth XR	GQ			
							^a Venlafaxine Sandoz XR	SZ			
							^a Venla RBX	RA			
							^a Venlexor XR	GM			
8302Y NP	Capsule 150 mg (base) (modified release)	28	5	..	44.20	35.40	^a Altven	FZ			
							^a APO-Venlafaxine XR	TX			
							^a Chem mart Venlafaxine XR	CH			
							^a Efexor-XR	PF			

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8868R NP	Capsule 37.5 mg (base) (modified release)	28	24.25	25.36	^a Elaxine SR 150	ZP
							^a Enlax-XR	AF
							^a Terry White Chemists	TW
							^a Venlafaxine XR	GQ
							^a generichealth XR	SZ
							^a Venlafaxine Sandoz XR	RA
							^a Venla RBX	GM
							^a Venlexor XR	FZ
							^a Altven	PF
							^a Efexor-XR	ZP
							^a Elaxine SR 37.5	RA
							^a Venla RBX	

Psychostimulants, agents used for ADHD and nootropics

Centrally acting sympathomimetics

ATOMOXETINE HYDROCHLORIDE

Authority required

Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where:

(a) treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:

- (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or
- (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or
- (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV; or

(b) treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal; or

(c) treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:

- (1) Adverse effects on growth and weight; and/or
- (2) Adverse effects on sleep including insomnia; and/or
- (3) Adverse effects on appetite including anorexia.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Authority required

Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9092M	Capsule 10 mg (base)	56	5	..	*221.28	35.40	Strattera	LY
9093N	Capsule 18 mg (base)	56	5	..	*221.28	35.40	Strattera	LY
9094P	Capsule 25 mg (base)	56	5	..	*221.28	35.40	Strattera	LY
9095Q	Capsule 40 mg (base)	56	5	..	*221.28	35.40	Strattera	LY
9096R	Capsule 60 mg (base)	56	5	..	*221.28	35.40	Strattera	LY
9289X	Capsule 80 mg (base)	28	5	..	147.21	35.40	Strattera	LY
9290Y	Capsule 100 mg (base)	28	5	..	147.21	35.40	Strattera	LY

DEXAMPHETAMINE SULFATE

Note

Care must be taken to comply with the provisions of State/Territory law when prescribing dexamphetamine.

Authority required

Use in attention deficit hyperactivity disorder, in accordance with State/Territory law;

Narcolepsy.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Note								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
1165H NP	Tablet 5 mg	100	5	..	18.29	19.40	Aspen Pharma Pty Ltd	QA
METHYLPHENIDATE HYDROCHLORIDE								
Note								
Care must be taken to comply with the provisions of State/Territory law when prescribing methylphenidate hydrochloride.								
Authority required								
Use in attention deficit hyperactivity disorder, in accordance with State/Territory law.								
Note								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
8839F NP	Tablet 10 mg	100	5	..	16.99	18.10	Ritalin 10	NV
METHYLPHENIDATE HYDROCHLORIDE								
Note								
Care must be taken to comply with the provisions of State/Territory law when prescribing methylphenidate hydrochloride.								
Authority required								
Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours.								
Note								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2172H NP	Tablet 27 mg (extended release)	30	5	..	55.56	35.40	Concerta	JC
2387P NP	Tablet 18 mg (extended release)	30	5	..	51.42	35.40	Concerta	JC
2388Q NP	Tablet 36 mg (extended release)	30	5	..	59.80	35.40	Concerta	JC
2432B NP	Tablet 54 mg (extended release)	30	5	..	69.86	35.40	Concerta	JC
METHYLPHENIDATE HYDROCHLORIDE								
Note								
Care must be taken to comply with the provisions of State/Territory law when prescribing methylphenidate hydrochloride.								
Authority required								
Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours.								
Note								
Continuing Therapy Only:								
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2276T NP	Capsule 20 mg (modified release)	30	5	..	44.67	35.40	Ritalin LA	NV
2280B NP	Capsule 30 mg (modified release)	30	5	..	52.13	35.40	Ritalin LA	NV
2283E NP	Capsule 40 mg (modified release)	30	5	..	54.66	35.40	Ritalin LA	NV
3440C NP	Capsule 10 mg (modified release)	30	5	..	34.14	35.25	Ritalin LA	NV

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
MODAFINIL							
<u>Note</u>							
Modafinil is not PBS-subsidised when used in combination with PBS-subsidised dexamphetamine sulfate.							
<u>Note</u>							
Any queries concerning the arrangements to prescribe modafinil may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).							
Written applications for authority to prescribe modafinil should be forwarded to:							
Medicare Australia Prior Written Approval of Specialised Drugs Reply Paid 9826 GPO Box 9826 HOBART TAS 7001							
Further prescribing information is on the Medicare Australia website at www.medicareaustralia.gov.au .							
<u>Authority required</u>							
Initial treatment, by a qualified sleep medicine practitioner or neurologist, of patients with narcolepsy where:							
(i) therapy with dexamphetamine sulfate poses an unacceptable medical risk; or							
(ii) intolerance to dexamphetamine sulfate of a severity necessitating treatment withdrawal develops.							
The presence of any 1 of the following indicates treatment with dexamphetamine sulfate poses an unacceptable medical risk:							
(a) a psychiatric disorder;							
(b) a cardiovascular disorder;							
(c) a history of substance abuse;							
(d) glaucoma;							
(e) any other absolute contraindication to dexamphetamine sulfate as specified in the TGA-approved Product Information.							
Patients must meet the following definition of narcolepsy:							
Excessive daytime sleepiness, recurrent naps or lapses into sleep occurring almost daily for at least 3 months and:							
(i) a definite history of cataplexy;							
or							
a mean sleep latency less than or equal to 10 minutes on a Multiple Sleep Latency Test (MSLT). The MSLT must be preceded by nocturnal polysomnography. Sleep prior to the MSLT must be at least 6 hours in duration;							
or							
an electroencephalographic (EEG) recording showing the pathologically rapid development of REM sleep; and							
(ii) absence of any medical or psychiatric disorder that could otherwise account for the hypersomnia.							
The authority application must be made in writing and must include the following:							
(a) a completed authority prescription form; and							
(b) a completed Modafinil (Modavigil) PBS Authority Application for Use in the Treatment of Narcolepsy - Supporting Information Form [www.medicareaustralia.gov.au]; and							
(c) details of the contraindication or intolerance to dexamphetamine sulfate; and							
(d) either:							
(i) the result and date of the polysomnography test and MSLT conducted by, or under the supervision of, a qualified sleep medicine practitioner; or							
(ii) the result and date of the EEG, conducted by, or under the supervision of, a neurologist.							
The polysomnography, MSLT or EEG test reports must be provided with the authority application.							
<u>Authority required</u>							
Continuing treatment of narcolepsy, where the patient has previously been issued with an authority prescription for this drug.							
8816B	Tablet 100 mg	120	5	..	*347.08	35.40	Modavigil CS

Anti-dementia drugs

Anticholinesterases

DONEPEZIL HYDROCHLORIDE

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 10 or more.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.

If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

supply.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;

CONTINUING TREATMENT — (S)MMSE or ADAS-Cog improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:

(a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);

(b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).

The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale. The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.

Patients who qualify under this criterion are from 1 or more of the following groups:

- (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;
- (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;
- (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;
- (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;
- (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;
- (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;

CONTINUING TREATMENT — Clinician assessed improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.

The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8495D NP	Tablet 5 mg	28	5	..	155.55	35.40	Aricept	PF
8496E NP	Tablet 10 mg	28	5	..	155.55	35.40	Aricept	PF

GALANTAMINE HYDROBROMIDE

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 10 or more.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.

If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;

CONTINUING TREATMENT — (S)MMSE or ADAS-Cog improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:

- (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);
- (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).

The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale. The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.

Patients who qualify under this criterion are from 1 or more of the following groups:

- (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;
- (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;
- (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;
- (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;
- (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;
- (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;

CONTINUING TREATMENT — Clinician assessed improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.

The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8770N NP	Capsule 8 mg (base) (prolonged release)	28	5	..	94.47	35.40	^a	APO-Galantamine	TX
								MR	
							^a	Galantyl	AF
							^a	Gamine XR	QA
							^a	Reminyl	JC

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8771P NP	Capsule 16 mg (base) (prolonged release)	28	5	..	114.11	35.40	^a APO-Galantamine MR	TX
							^a Galantyl	AF
							^a Gamine XR	QA
							^a Reminyl	JC
8772Q NP	Capsule 24 mg (base) (prolonged release)	28	5	..	134.74	35.40	^a APO-Galantamine MR	TX
							^a Galantyl	AF
							^a Gamine XR	QA
							^a Reminyl	JC

RIVASTIGMINE

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 10 or more. Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.

If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;

CONTINUING TREATMENT — (S)MMSE or ADAS-Cog improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:

- (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);
- (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).

The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale. The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.

Patients who qualify under this criterion are from 1 or more of the following groups:

- (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;
- (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;
- (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;
- (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;
- (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;
- (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
<p>CONTINUING TREATMENT — Clinician assessed improvement.</p> <p>Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p> <p>The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p> <p>Subsequent applications for continuing treatment can be made by telephone.</p> <p><u>Note</u> Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.</p>							
9161E NP	Transdermal patch 9 mg (releasing approximately 4.6 mg per 24 hours)	30	5	..	166.19	35.40	Exelon Patch 5 NV
9162F NP	Transdermal patch 18 mg (releasing approximately 9.5 mg per 24 hours)	30	5	..	166.19	35.40	Exelon Patch 10 NV

RIVASTIGMINE HYDROGEN TARTRATE

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 10 or more. Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.

If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;

CONTINUING TREATMENT — (S)MMSE or ADAS-Cog improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:

- (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);
- (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).

The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale. The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.

Patients who qualify under this criterion are from 1 or more of the following groups:

- (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	(2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate; (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test; (4) Intellectual (developmental or acquired) disability, eg Down's syndrome; (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test; (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;						
	CONTINUING TREATMENT — Clinician assessed improvement. Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.						
	The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.						
	Subsequent applications for continuing treatment can be made by telephone.						
	<u>Note</u> Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.						
8497F NP	Capsule 1.5 mg (base)	56	5	..	155.55	35.40	Exelon NV
8498G NP	Capsule 3 mg (base)	56	5	..	155.55	35.40	Exelon NV
8499H NP	Capsule 4.5 mg (base)	56	5	..	155.55	35.40	Exelon NV
8500J NP	Capsule 6 mg (base)	56	5	..	155.55	35.40	Exelon NV
8563Q NP	Oral solution 2 mg (base) per mL, 120 mL	£1	5	..	155.55	35.40	Exelon NV

Other anti-dementia drugs

MEMANTINE HYDROCHLORIDE

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 10 to 14.

Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 to 14.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment. For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;

CONTINUING TREATMENT — (S)MMSE improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).

The initial authority application for continuing treatment must include the relevant result from the (S)MMSE and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

Authority required

INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.

Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 to 14 for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).

Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale. The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.							
<p>Patients who qualify under this criterion are from 1 or more of the following groups:</p> <p>(1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;</p> <p>(2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;</p> <p>(3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;</p> <p>(4) Intellectual (developmental or acquired) disability, eg Down's syndrome;</p> <p>(5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;</p> <p>(6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;</p> <p>CONTINUING TREATMENT — Clinician assessed improvement.</p> <p>Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p> <p>The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p> <p>Subsequent applications for continuing treatment can be made by telephone.</p>							
Note							
Continuing Therapy Only:							
For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
1956Y NP	Tablet 10 mg	56	5	..	107.05	35.40 ^a	APO-Memantine TX
						^a Ebixa	LU
						^a Memanxa	QA
9306T NP	Tablet 20 mg	28	5	..	107.05	35.40	Ebixa LU

Other nervous system drugs

Parasympathomimetics

Anticholinesterases

PYRIDOSTIGMINE BROMIDE

1959D	Tablet 60 mg	150	5	..	71.42	35.40	Mestinon	VT
2608G	Tablet 180 mg (modified release)	100	5	..	*149.32	35.40	Mestinon	VT
2724J	Tablet 10 mg	100	5	..	*23.10	24.21	Timespan Mestinon	VT

Choline esters

BETHANECHOL CHLORIDE

1062X NP	Tablet 10 mg	100	2	..	21.13	22.24	Uro-Carb	YN
-------------	--------------	-----	---	----	-------	-------	----------	----

Drugs used in addictive disorders

Drugs used in nicotine dependence

BUPROPION HYDROCHLORIDE

Note

Only one course of PBS-subsidised bupropion hydrochloride will be authorised per 12 months. The period between commencing a course of bupropion hydrochloride and varenicline tartrate must be at least 6 months. A course of treatment with bupropion hydrochloride is 9 weeks. No increased maximum quantities or repeats will be authorised. Clinical review is recommended within 2 to 3 weeks of the original prescription being requested.

Authority required

Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and:

- (a) who has entered a comprehensive support and counselling program; or
- (b) who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.

Details of the program must be specified in the authority application.

8465M NP	Tablet 150 mg (sustained release)	30	73.19	35.40 ^a	Prexaton	GM
-------------	-----------------------------------	----	----	----	-------	--------------------	----------	----

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
				^B 0.80	73.99	35.40 ^a	Zyban GK

BUPROPION HYDROCHLORIDE

Note

Only one course of PBS-subsidised bupropion hydrochloride will be authorised per 12 months. The period between commencing a course of bupropion hydrochloride and varenicline tartrate must be at least 6 months. A course of treatment with bupropion hydrochloride is 9 weeks. No increased maximum quantities or repeats will be authorised. Clinical review is recommended within 2 to 3 weeks of the original prescription being requested.

Authority required

Completion of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program.

8710K NP	Tablet 150 mg (sustained release)	90	159.09	35.40 ^a	Prexaton	GM
				^B 0.81	159.90	35.40 ^a	Zyban	GK

NICOTINE

Authority required

Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy.

Note

Only 2 courses of PBS-subsidised nicotine replacement therapy will be authorised per year.

No applications for increased maximum quantities and/or repeats will be authorised.

Benefit is improved if used in conjunction with a comprehensive support and counselling program.

Authority required

Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.

Details of the program must be specified in the initial authority application;

Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.

Details of the program must be specified in the initial authority application.

Note

A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised.

5465P NP	Transdermal patch releasing approximately 21 mg per 24 hours	28	2	..	55.32	35.40	Nicabate P	GC
9198D NP	Transdermal patch releasing approximately 15 mg per 16 hours	28	2	..	55.32	35.40	Nicorette Patch	JT

NICOTINE

Authority required

Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.

Details of the program must be specified in the initial authority application;

Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.

Details of the program must be specified in the initial authority application.

Note

No applications for increased maximum quantities will be authorised.

Applications for increased repeats, up to a maximum of 2, may be authorised.

A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year.

3414Q NP	Transdermal patch releasing approximately 21 mg per 24 hours	28	55.32	35.40	Nicotinell Step 1	NC
5572G NP	Transdermal patch releasing approximately 14 mg per 24 hours	28	55.32	35.40	Nicotinell Step 2	NC
5573H NP	Transdermal patch releasing approximately 7 mg per 24 hours	28	55.32	35.40	Nicotinell Step 3	NC

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
NICOTINE							
<u>Authority required</u>							
Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy.							
<u>Note</u>							
Only 2 courses of PBS-subsidised nicotine replacement therapy will be authorised per year.							
No applications for increased maximum quantities and/or repeats will be authorised.							
Benefit is improved if used in conjunction with a comprehensive support and counselling program.							
5571F NP	Transdermal patch releasing approximately 21 mg per 24 hours	28	2	..	55.32	35.40	Nicotinell Step 1 NC
VARENICLINE							
<u>Note</u>							
A course of treatment with varenicline tartrate is 12 weeks or up to 24 weeks, if initial treatment of 12 weeks has been successful. Only one course of 12 or up to 24 weeks of PBS-subsidised varenicline tartrate will be authorised per year. The period between commencing varenicline tartrate and bupropion hydrochloride must be at least 6 months. No increased maximum quantities or repeats will be authorised. Clinical review is recommended within 2 to 3 weeks of the initial prescription being requested.							
<u>Authority required</u>							
Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and:							
(a) who has entered a comprehensive support and counselling program; or							
(b) who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.							
Details of the program must be specified in the authority application.							
9128K NP	Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack	‡1	103.22	35.40	Champix PF
VARENICLINE							
<u>Note</u>							
A course of treatment with varenicline tartrate is 12 weeks or up to 24 weeks, if initial treatment of 12 weeks has been successful. Only one course of 12 or up to 24 weeks of PBS-subsidised varenicline tartrate will be authorised per year. The period between commencing varenicline tartrate and bupropion hydrochloride must be at least 6 months. No increased maximum quantities or repeats will be authorised. Clinical review is recommended within 2 to 3 weeks of the initial prescription being requested.							
<u>Authority required</u>							
Continuation of short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program.							
9129L NP	Tablet 1 mg (as tartrate)	112	*231.80	35.40	Champix PF
VARENICLINE							
<u>Note</u>							
A course of treatment with varenicline tartrate is 12 weeks or up to 24 weeks, if initial treatment of 12 weeks has been successful. Only one course of 12 or up to 24 weeks of PBS-subsidised varenicline tartrate will be authorised per year. The period between commencing varenicline tartrate and bupropion hydrochloride must be at least 6 months. No increased maximum quantities or repeats will be authorised. Clinical review is recommended within 2 to 3 weeks of the initial prescription being requested.							
<u>Authority required</u>							
Completion of short-term sole PBS-subsidised therapy as an aid to achieving long-term abstinence after completion of an initial 12-week PBS-subsidised course in a patient who has ceased smoking, and who is enrolled in a comprehensive support and counselling program.							
5469W NP	Tablet 1 mg (as tartrate)	56	2	..	120.52	35.40	Champix PF

Drugs used in alcohol dependence

ACAMPROSATE CALCIUM

Authority required (STREAMLINED)

2665

For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
8357W NP	Tablet 333 mg (enteric coated)	180	1	..	166.68	35.40	Campral	AF
NALTREXONE HYDROCHLORIDE								
<u>Caution</u>								
Naltrexone hydrochloride is contraindicated in patients receiving opioid drugs.								
<u>Authority required</u>								
For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
8370M NP	Tablet 50 mg	30	1	..	135.77	35.40	^a Naltrexone generichealth	GQ
						^a	ReVia	BO

Other nervous system drugs

Other nervous system drugs

RILUZOLE

Authority required

Initial treatment of amyotrophic lateral sclerosis, as diagnosed by a neurologist, in patients with disease duration of 5 years or less and who have at least 60 percent of predicted forced vital capacity within 2 months prior to commencing riluzole therapy and who:

- (1) are ambulatory, and
 - (a) have not undergone tracheostomy, and
 - (b) have not experienced respiratory failure; OR
- (2) are not ambulatory, and
 - (a) have not undergone tracheostomy, and
 - (b) have not experienced respiratory failure, and
 - (c) are either able to use upper limbs or able to swallow.

The date of diagnosis and the date and results of spirometry (in terms of percent of predicted forced vital capacity) must be supplied with the initial authority application.

Authority required

Continuing treatment of amyotrophic lateral sclerosis in patients who have previously been issued with an authority prescription for this drug and who:

- (1) are ambulatory, and
 - (a) have not undergone tracheostomy, and
 - (b) have not experienced respiratory failure; OR
- (2) are not ambulatory, and
 - (a) have not undergone tracheostomy, and
 - (b) have not experienced respiratory failure, and
 - (c) are either able to use upper limbs or able to swallow.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8664B NP	Tablet 50 mg	56	5	..	662.10	35.40	Rilutek	SW
-------------	--------------	----	---	----	--------	-------	---------	----

TETRABENAZINE

Authority required (STREAMLINED)

1161

Hyperkinetic extrapyramidal disorders.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1330B NP	Tablet 25 mg	112	5	..	337.65	35.40	Orphan Australia Pty Ltd	OA
-------------	--------------	-----	---	----	--------	-------	-----------------------------	----

Antiparasitic products, insecticides and repellents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Antiparasitic products, insecticides and repellents

Antiprotozoals

Agents against amoebiasis and other protozoal diseases

Nitroimidazole derivatives

1636D NP	METRONIDAZOLE Tablet 200 mg	21	1	..	7.98	9.09	^a	Metrogyl 200	AF
							^a	Metronide 200	AV
				^B 2.30	10.28	9.09	^a	Flagyl	SW
1642K NP	Suppositories 500 mg, 10	1	23.26	24.37		Flagyl	SW
1621H NP	METRONIDAZOLE <u>Restricted benefit</u> Treatment of anaerobic infections.								
	Tablet 400 mg	21	1	..	9.95	11.06	^a	Metrogyl 400	AF
							^a	Metronide 400	AV
				^B 2.30	12.25	11.06	^a	Flagyl	SW
1630T NP	METRONIDAZOLE BENZOATE Oral suspension 320 mg per 5 mL (equivalent to 200 mg metronidazole in 5 mL), 100 mL	1	18.92	20.03		Flagyl S	SW
1465D NP	TINIDAZOLE Tablet 500 mg	4	10.89	12.00	^a	Simplotan	FZ
				^B 2.42	13.31	12.00	^a	Fasigyn	PF

Other agents against amoebiasis and other protozoal diseases

ATOVAQUONE

Authority required (STREAMLINED)

1433

Treatment of mild to moderate *Pneumocystis carinii* pneumonia in adult patients who are intolerant of trimethoprim/sulfamethoxazole therapy.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

8300W NP	Oral suspension 750 mg per 5 mL, 210 mL	1	1034.67	35.40		Wellvone	GK
1966L NP	PYRIMETHAMINE Tablet 25 mg	50	16.47	17.58		Daraprim	GK

Antimalarials

Biguanides

ATOVAQUONE with PROGUANIL HYDROCHLORIDE

Authority required

Treatment of suspected or confirmed *Plasmodium falciparum* malaria in a patient aged 3 years or older where quinine containing regimens are inappropriate.

Antiparasitic products, insecticides and repellents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
<u>Note</u> Atovaquone with proguanil hydrochloride is not PBS-subsidised for the prophylaxis of malaria.							
<u>Note</u> Shared Care Model: For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
9439T NP	Tablet 250 mg-100 mg	12	67.10	35.40	Malarone GK

Methanolquinolines

QUININE SULFATE

Caution

Severe thrombocytopenia has been reported with this drug.

Authority required (STREAMLINED)

2142

Malaria.

1975Y NP	Tablet 300 mg	50	2	..	14.24	15.35	Quinate AS
-------------	---------------	----	---	----	-------	-------	------------

Artemisinin and derivatives, combinations

ARTEMETHER with LUMEFANTRINE

Authority required

Treatment of suspected or confirmed malaria due to Plasmodium falciparum.

Note

Artemether with lumefantrine is not PBS-subsidised for prophylaxis of malaria.

9498X	Tablet 20 mg-120 mg	24	97.00	35.40	Riamet NV
-------	---------------------	----	----	----	-------	-------	-----------

ARTEMETHER with LUMEFANTRINE

Authority required

Treatment of suspected or confirmed malaria due to Plasmodium falciparum in a patient unable to swallow a solid dosage form of artemether with lumefantrine.

Note

Artemether with lumefantrine is not PBS-subsidised for prophylaxis of malaria.

5296R	Tablet (dispersible) 20 mg-120 mg	18	97.00	35.40	Riamet 20mg/120mg Dispersible NV
-------	-----------------------------------	----	----	----	-------	-------	--

Anthelmintics

Antitrepatodals

Quinoline derivatives and related substances

PRAZIQUANTEL

Authority required (STREAMLINED)

3147

Schistosomiasis.

9447F NP	Tablet 600 mg	8	40.95	35.40	Biltricide BN
-------------	---------------	---	----	----	-------	-------	---------------

Antinematodal agents

Benzimidazole derivatives

ALBENDAZOLE

Authority required (STREAMLINED)

2446

Treatment of whipworm infestation in an Aboriginal or a Torres Strait Islander person;

Antiparasitic products, insecticides and repellents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	1388 Strongyloidiasis;							
	3241 Treatment of hookworm infestation.							
9047E NP	Tablet 200 mg	6	33.20	34.31	Zentel	GK
<hr/>								
	ALBENDAZOLE <u>Authority required (STREAMLINED)</u> 1525 Treatment of tapeworm infestation.							
8503M NP	Tablet 200 mg	6	1	..	33.20	34.31	Zentel	GK
<hr/>								
	ALBENDAZOLE <u>Authority required (STREAMLINED)</u> 1496 For the treatment of hydatid disease in conjunction with surgery or when a surgical cure cannot be achieved or where surgery cannot be used.							
8459F	Tablet 400 mg	60	2	..	185.35	35.40	Eskazole	GK
Tetrahydropyrimidine derivatives								
	PYRANTEL EMBONATE							
3047J NP	Tablet 125 mg (base)	6	14.70	15.81	Anthel 125	AF
3048K NP	Tablet 250 mg (base)	6	22.87	23.98	Anthel 250	AF
Avermectines								
	IVERMECTIN <u>Authority required (STREAMLINED)</u> 1242 Onchocerciasis;							
	1388 Strongyloidiasis.							
8359Y NP	Tablet 3 mg	4	31.41	32.52	Stromectol	MK

Ectoparasiticides, incl. scabicides, insecticides and repellents

Ectoparasiticides, incl. scabicides

Pyrethrines, incl. synthetic compounds

PERMETHRIN								
3054R NP	Cream 50 mg per g (5%), 30 g	£1	1	..	16.87	17.98	Lyclear	JT

Respiratory system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Respiratory system

Nasal preparations

Decongestants and other nasal preparations for topical use

Other nasal preparations

MUPIROCIN

Authority required (STREAMLINED)

3136

Nasal colonisation with Staphylococcus aureus in an Aboriginal or a Torres Strait Islander person.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9440W NP	Nasal ointment 20 mg (as calcium) per g (2%), 3 g	¥1	20.73	21.84	Bactroban	GK
-------------	--	----	----	----	-------	-------	-----------	----

Drugs for obstructive airway diseases

Adrenergics, inhalants

Selective beta-2-adrenoceptor agonists

EFORMOTEROL FUMARATE DIHYDRATE

Restricted benefit

Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids;

Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids.

8136F NP	Capsule containing powder for oral inhalation 12 micrograms (for use in Foradile Aerolizer)	60	5	..	37.43	35.40	Foradile	NV
8239P NP	Powder for oral inhalation in breath actuated device 6 micrograms per dose (60 doses)	¥1	5	..	26.48	27.59	Oxis Turbuhaler	AP
8240Q NP	Powder for oral inhalation in breath actuated device 12 micrograms per dose (60 doses)	¥1	5	..	36.54	35.40	Oxis Turbuhaler	AP

INDACATEROL

Restricted benefit

Chronic obstructive pulmonary disease.

Note

Indacaterol is not PBS-subsidised for the treatment of asthma.

5134F NP	Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler)	30	5	..	73.54	35.40	Onbrez	NV
5137J NP	Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler)	30	5	..	73.54	35.40	Onbrez	NV

SALBUTAMOL SULFATE

1099W NP	Capsule containing powder for oral inhalation 200 micrograms (base) (for use in Ventolin Rotahaler)	200	5	..	*16.16	17.27	Ventolin Rotacaps	GK
8288F NP	Oral pressurised inhalation 100 micrograms (base) per dose (200 doses), CFC-free formulation	2	5	..	*13.92	15.03	^a Airomir	IA
							^a APO-Salbutamol Inhaler	TX
							^a Asmol CFC-free	AL
				^B 2.32	*16.24	15.03	^a Ventolin CFC-free	GK

Respiratory system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
SALBUTAMOL SULFATE								
<u>Restricted benefit</u>								
Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug.								
8354Q NP	Oral pressurised inhalation in breath actuated device 100 micrograms (base) per dose (200 doses), CFC-free formulation	2	5	..	*38.70	35.40	Airomir Autohaler	IA
<hr/>								
SALBUTAMOL SULFATE								
<u>Restricted benefit</u>								
Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer;								
Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer.								
2000G NP	Nebuliser solution single dose units 2.5 mg (base) in 2.5 mL, 30	2	5	..	*18.42	19.53	^a Asmol 2.5 uni-dose	AF
							^a Butamol 2.5	QA
							^a GenRx Salbutamol	GX
							^a Pharmacor Salbutamol 2.5	CR
							^a Salbutamol-GA	GM
							^a Salbutamol Sandoz	SZ
				^B 1.34	*19.76	19.53	^a Ventolin Nebules	GK
2001H NP	Nebuliser solution single dose units 5 mg (base) in 2.5 mL, 30	2	5	..	*19.08	20.19	^a Asmol 5 uni-dose	AF
							^a Butamol 5	QA
							^a GenRx Salbutamol	GX
							^a Pharmacor Salbutamol 5	CR
							^a Salbutamol-GA	GM
							^a Salbutamol Sandoz	SZ
				^B 1.36	*20.44	20.19	^a Ventolin Nebules	GK
2003K NP	Nebuliser solution 5 mg (base) per mL (0.5%), 30 mL	2	2	..	*19.08	20.19	Pfizer Australia Pty Ltd	PF
SALMETEROL XINAFOATE								
<u>Restricted benefit</u>								
Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids;								
Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids.								
8141L NP	Powder for oral inhalation in breath actuated device 50 micrograms (base) per dose (60 doses)	‡1	5	..	37.43	35.40	Serevent Accuhaler	GK
TERBUTALINE SULFATE								
1252X NP	Powder for oral inhalation in breath actuated device 500 micrograms per dose (200 doses)	‡1	5	..	17.93	19.04	Bricanyl Turbuhaler	AP

Adrenergics and other drugs for obstructive airway diseases

BUDESONIDE with EFORMOTEROL FUMARATE DIHYDRATE

Restricted benefit

Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide;

Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide;

For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with oral corticosteroids;

For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with inhaled corticosteroids;

Respiratory system

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer	
For maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and a long-acting beta-2 agonist.								
8625Y NP	Powder for oral inhalation in breath actuated device 200 micrograms-6 micrograms per dose (120 doses)	¥1	5	..	58.87	35.40	Symbicort Turbuhaler 200/6	AP
8796Y NP	Powder for oral inhalation in breath actuated device 100 micrograms-6 micrograms per dose (120 doses)	¥1	5	..	54.57	35.40	Symbicort Turbuhaler 100/6	AP

BUDESONIDE with EFORMOTEROL FUMARATE DIHYDRATE

Restricted benefit

Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide;

Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide.

Note

Symbicort 400/12 is not recommended nor PBS-subsidised for use as 'maintenance and reliever' therapy.

Restricted benefit

Symptomatic treatment of chronic obstructive pulmonary disease (COPD), where the FEV1 is less than 50% predicted normal and there is a history of repeated exacerbations with significant symptoms despite regular beta-2 agonist bronchodilator therapy.

Note

Budesonide with eformoterol fumarate dihydrate is not indicated for the initiation of bronchodilator therapy in COPD.

8750M NP	Powder for oral inhalation in breath actuated devices 400 micrograms-12 micrograms per dose (60 doses), 2	1	5	..	90.65	35.40	Symbicort Turbuhaler 400/12	AP
-------------	---	---	---	----	-------	-------	-----------------------------	----

FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE

Restricted benefit

Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate;

Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate.

8430Q NP	Powder for oral inhalation in breath actuated device 100 micrograms-50 micrograms (base) per dose (60 doses)	¥1	5	..	47.30	35.40	Seretide Accuhaler 100/50	GK
8431R NP	Powder for oral inhalation in breath actuated device 250 micrograms-50 micrograms (base) per dose (60 doses)	¥1	5	..	59.41	35.40	Seretide Accuhaler 250/50	GK
8517G NP	Oral pressurised inhalation 50 micrograms-25 micrograms (base) per dose (120 doses), CFC-free formulation	¥1	5	..	47.30	35.40	Seretide MDI 50/25	GK
8518H NP	Oral pressurised inhalation 125 micrograms-25 micrograms (base) per dose (120 doses), CFC-free formulation	¥1	5	..	59.41	35.40	Seretide MDI 125/25	GK

FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE

Restricted benefit

Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate;

Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate;

Symptomatic treatment of chronic obstructive pulmonary disease (COPD), where the FEV1 is less than 50% predicted normal and there is a history of repeated exacerbations with significant symptoms despite regular beta-2 agonist bronchodilator therapy.

Note

Seretide is not indicated for the initiation of bronchodilator therapy in COPD.

8432T NP	Powder for oral inhalation in breath actuated device 500 micrograms-50 micrograms (base) per dose (60 doses)	¥1	5	..	78.54	35.40	Seretide Accuhaler 500/50	GK
-------------	--	----	---	----	-------	-------	---------------------------	----

Respiratory system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8519J NP	Oral pressurised inhalation 250 micrograms- 25 micrograms (base) per dose (120 doses), CFC-free formulation	#1	5	..	78.54	35.40	Seretide MDI	GK
							250/25	

Other drugs for obstructive airway diseases, inhalants

Glucocorticoids

BECLOMETHASONE DIPROPIONATE

8406K NP	Oral pressurised inhalation 50 micrograms per dose (200 doses), CFC-free formulation	#1	5	..	19.39	20.50	Qvar 50	IA
8407L NP	Oral pressurised inhalation 100 micrograms per dose (200 doses), CFC-free formulation	#1	5	..	33.56	34.67	Qvar 100	IA

BECLOMETHASONE DIPROPIONATE

Restricted benefit

Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug.

8408M NP	Oral pressurised inhalation in breath actuated device 50 micrograms per dose (200 doses), CFC-free formulation	#1	5	..	27.97	29.08	Qvar 50 Autohaler	IA
8409N NP	Oral pressurised inhalation in breath actuated device 100 micrograms per dose (200 doses), CFC-free formulation	#1	5	..	39.23	35.40	Qvar 100 Autohaler	IA

BUDESONIDE

2070Y NP	Powder for oral inhalation in breath actuated device 100 micrograms per dose (200 doses)	#1	5	..	23.44	24.55	Pulmicort Turbuhaler	AP
2071B NP	Powder for oral inhalation in breath actuated device 200 micrograms per dose (200 doses)	#1	5	..	31.18	32.29	Pulmicort Turbuhaler	AP
2072C NP	Powder for oral inhalation in breath actuated device 400 micrograms per dose (200 doses)	#1	5	..	45.94	35.40	Pulmicort Turbuhaler	AP

BUDESONIDE

Authority required (STREAMLINED)

1351

Severe chronic asthma in patients who require long-term steroid therapy and who are unable to use other forms of inhaled steroid therapy.

2065Q NP	Nebuliser suspension single dose units 500 micrograms in 2 mL, 30	#1	5	..	37.96	35.40	Pulmicort Respules	AP
2066R NP	Nebuliser suspension single dose units 1 mg in 2 mL, 30	#1	5	..	49.10	35.40	Pulmicort Respules	AP

CICLESONIDE

8853Y NP	Oral pressurised inhalation 80 micrograms per dose (120 doses), CFC-free formulation	#1	5	..	26.25	27.36	Alvesco 80	NQ
8854B NP	Oral pressurised inhalation 160 micrograms per dose (120 doses), CFC-free formulation	#1	5	..	42.35	35.40	Alvesco 160	NQ

FLUTICASONE PROPIONATE

8147T NP	Powder for oral inhalation in breath actuated device 100 micrograms per dose (60 doses)	#1	5	..	17.19	18.30	Flixotide Junior Accuhaler	GK
8148W NP	Powder for oral inhalation in breath actuated device 250 micrograms per dose (60 doses)	#1	5	..	30.76	31.87	Flixotide Accuhaler	GK
8149X NP	Powder for oral inhalation in breath actuated device 500 micrograms per dose (60 doses)	#1	1	..	49.82	35.40	Flixotide Accuhaler	GK
8345F NP	Oral pressurised inhalation 125 micrograms per dose (120 doses), CFC-free formulation	#1	5	..	30.76	31.87	Flixotide	GK
8346G NP	Oral pressurised inhalation 250 micrograms per dose (120 doses), CFC-free formulation	#1	1	..	49.82	35.40	Flixotide	GK
8516F NP	Oral pressurised inhalation 50 micrograms per dose (120 doses), CFC-free formulation	#1	5	..	17.19	18.30	Flixotide Junior	GK

Respiratory system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Anticholinergics

8671J NP	IPRATROPIUM BROMIDE							
	Oral pressurised inhalation 21 micrograms per dose (200 doses), CFC-free formulation	2	5	..	*33.94	35.05	Atrovent	BY

IPRATROPIUM BROMIDE**Restricted benefit**

Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer;

Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer.

1542E NP	Nebuliser solution single dose units 250 micrograms (anhydrous) in 1 mL, 30	2	5	..	*35.84	35.40	^a	Aeron 250	QA
							^a	APO-Ipratropium	TX
							^a	Ipratrin	AF
							^a	Ipravent	PF
8238N NP	Nebuliser solution single dose units 500 micrograms (anhydrous) in 1 mL, 30	2	5	B0.68	*36.52	35.40	^a	Atrovent	BY
							^a	Aeron 500	QA
							^a	APO-Ipratropium	TX
				..	*41.16	35.40	^a	Ipratrin Adult	AF
							^a	Ipravent	PF
							^a	Atrovent Adult	BY
				B0.58	*41.74	35.40	^a		

TIOTROPIUM BROMIDE MONOHYDRATE**Restricted benefit**

Chronic obstructive pulmonary disease.

8626B NP	Capsule containing powder for oral inhalation 18 micrograms (base) (for use in HandiHaler)	30	5	..	73.54	35.40	Spiriva	BY
-------------	---	----	---	----	-------	-------	---------	----

Antiallergic agents, excl. corticosteroids**NEDOCROMIL SODIUM**

8365G NP	Oral pressurised inhalation 2 mg per dose (112 doses), CFC-free formulation	¥1	5	..	37.79	35.40	Tilade CFC-Free	SW
-------------	---	----	---	----	-------	-------	-----------------	----

SODIUM CROMOGLYCATE

2878L NP	Capsule containing powder for oral inhalation 20 mg (for use in Intal Spinhaler or Intal Haleromatic)	100	5	..	31.51	32.62	Intal Spincaps	GM
8334P NP	Oral pressurised inhalation 5 mg per dose (112 doses), CFC-free formulation	¥1	5	..	35.94	35.40	Intal Forte CFC-Free	SW
8767K NP	Oral pressurised inhalation 1 mg per dose (200 doses), CFC-free formulation	¥1	5	..	30.39	31.50	Intal CFC-Free	SW

Adrenergics for systemic use**Alpha- and beta-adrenoceptor agonists****ADRENALINE**

1016L NP	Injection 1 mg in 1 mL (1 in 1,000)	5	1	..	20.44	21.55	Link Medical Products Pty Ltd	LM
-------------	-------------------------------------	---	---	----	-------	-------	-------------------------------	----

ADRENALINE**Authority required**

Initial sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who:

(a) has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply; or

(b) has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis;

Respiratory system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Continuing sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug.								
<u>Note</u>								
The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au .)								
<u>Note</u>								
Authority approvals will be limited to a maximum quantity of 2 auto-injectors (Anapen or EpiPen) at any one time.								
No repeats will be issued.								
<u>Caution</u>								
EpiPen and Anapen products have different administration techniques and should not be prescribed to the same patient without training in their use.								
3408J NP	I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector	1	106.10	35.40	Anapen Junior	LM
3409K NP	I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector	1	106.10	35.40	Anapen	LM
8697R NP	I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector	1	106.10	35.40	EpiPen Jr.	AL
8698T NP	I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector	1	106.10	35.40	EpiPen	AL

Selective beta-2-adrenoceptor agonists

SALBUTAMOL SULFATE								
1103C NP	Syrup 2 mg (base) per 5 mL, 150 mL	2	5	..	*22.30	23.41	Ventolin	GK
TERBUTALINE SULFATE								
1034K NP	Injection 500 micrograms in 1 mL	5	30.69	31.80	Bricanyl	AP

Other systemic drugs for obstructive airway diseases

Xanthines

THEOPHYLLINE

Caution

Because of variable effects of food on absorption of sustained release theophylline preparations, patients stabilised on one brand should not be changed to another without appropriate monitoring.

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

2614N NP	Syrup 133.3 mg per 25 mL, 500 mL	±1	5	..	12.41	13.52	Nuelin	IA
2634P NP	Tablet 250 mg (sustained release)	100	5	..	13.42	14.53	Nuelin-SR 250	IA
8230E NP	Tablet 200 mg (sustained release)	100	5	..	12.26	13.37	Nuelin-SR 200	IA
8231F NP	Tablet 300 mg (sustained release)	100	5	..	14.80	15.91	Nuelin-SR 300	IA

Leukotriene receptor antagonists

MONTELUKAST SODIUM

Authority required (STREAMLINED)

2617

First-line preventer medication, as the single preventer agent for children aged 2 to 5 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium.

Note

Montelukast sodium is not PBS-subsidised for use in a child aged 2 to 5 years with moderate to severe asthma. It is not intended as an alternative for a child aged 2 to 5 years who requires a corticosteroid as a preventer medication.

Respiratory system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	Montelukast sodium is not subsidised in a child aged 2 to 5 years for use in combination with other preventer medications. PBS subsidy for montelukast sodium will therefore cease for a child aged 2 to 5 years who requires a preventer medication in addition to montelukast sodium.						
	<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.						
8627C NP	Chewable tablet 4 mg (base)	28	5	..	48.03	35.40	Singulair MK
<hr/>							
MONTELUKAST SODIUM							
<u>Authority required (STREAMLINED)</u>							
2618 First-line preventer medication, as the single preventer agent for children aged 6 to 14 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium.							
<u>Authority required (STREAMLINED)</u>							
3217 Prevention of exercise-induced asthma, as an alternative to adding salmeterol xinafoate or eformoterol fumarate, in a child aged 6 to 14 years whose asthma is otherwise well controlled while receiving optimal dose inhaled corticosteroid, but who requires short-acting beta-2 agonist 3 or more times per week for prevention or relief of residual exercise-related symptoms.							
<u>Note</u> Montelukast sodium is not PBS-subsidised for use in a patient aged 15 years or older, or for use in addition to a long-acting beta-agonist in any age group, or for use as a single second line preventer, as an alternative to corticosteroids, in a child aged 6 to 14 years with moderate to severe asthma.							
<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.							
8628D NP	Chewable tablet 5 mg (base)	28	5	..	45.81	35.40	Singulair MK

Cough and cold preparations

Cough suppressants, excl. combinations with expectorants

Opium alkaloids and derivatives

CODEINE PHOSPHATE							
1214X NP	Tablet 30 mg	20	16.97	18.08	Fawns and McAllan Proprietary Limited FM

Antihistamines for systemic use

Antihistamines for systemic use

Phenothiazine derivatives

PROMETHAZINE HYDROCHLORIDE							
1948M NP	Injection 50 mg in 2 mL	10	*22.42	23.53	Hospira Pty Limited HH

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Sensory organs

Ophthalmologicals

Antiinfectives

Antibiotics

AZITHROMYCIN

Restricted benefit

Trachoma.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

8201P NP	Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL	±1	#21.27	22.72	Zithromax	PF
8336R NP	Tablet 500 mg (as dihydrate)	2	2	..	21.19	22.30	^a Azithromycin Sandoz	SZ
							^a Zithromax	PF
							^a Zitrocin	GM

CHLORAMPHENICOL

1171P NP,MW	Eye ointment 10 mg per g (1%), 4 g	±1	9.86	10.97	Chloromycetin	PF
2360F NP,MW	Eye drops 5 mg per mL (0.5%), 10 mL	±1	2	..	11.10	12.21	Chlorsig	QA
							Chloromycetin	PF
							Chlorsig	QA

GENTAMICIN SULFATE

Restricted benefit

Invasive ocular infection;

Perioperative use in ophthalmic surgery;

Suspected pseudomonal eye infection.

1441W	Eye drops 3 mg (base) per mL (0.3%), 5 mL	±1	2	..	18.39	19.50	Genoptic	AG
-------	---	----	---	----	-------	-------	----------	----

TOBRAMYCIN

Restricted benefit

Invasive ocular infection;

Perioperative use in ophthalmic surgery;

Suspected pseudomonal eye infection.

2328M	Eye drops 3 mg per mL (0.3%), 5 mL	±1	2	..	19.38	20.49	Tobrex	AQ
2329N	Eye ointment 3 mg per g (0.3%), 3.5 g	±1	22.48	23.59	Tobrex	AQ

Antivirals

ACICLOVIR

Restricted benefit

Herpes simplex keratitis.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1002R NP	Eye ointment 30 mg per g (3%), 4.5 g	±1	33.73	34.84	Zovirax	GK
-------------	--------------------------------------	----	----	----	-------	-------	---------	----

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Other antiinfectives								
	CIPROFLOXACIN <u>Authority required</u> Bacterial keratitis.							
1217C	Eye drops 3 mg per mL (0.3%), 5 mL	2 B 2.06	*28.58 *30.64	29.69 ^a 29.69 ^a	CiloQuin Ciloxan	IQ AQ
	OFLOXACIN <u>Authority required</u> Bacterial keratitis.							
8383F	Eye drops 3 mg per mL (0.3%), 5 mL	2	*32.24	33.35	Ocuflox	AG
Antiinflammatory agents								
Corticosteroids, plain								
1288T NP	DEXAMETHASONE Eye drops 1 mg per mL (0.1%), 5 mL	‡1	2	..	10.71	11.82	Maxidex	AQ
1204J NP	FLUOROMETHOLONE Eye drops 1 mg per mL (0.1%), 5 mL	‡1	5	..	10.71	11.82	Flucon FML Liquifilm	AQ AG
1438Q NP	FLUOROMETHOLONE ACETATE Eye drops 1 mg per mL (0.1%), 5 mL	‡1	2	..	10.71	11.82	Flarex	AQ
2441L NP	HYDROCORTISONE ACETATE Eye ointment 10 mg per g (1%), 5 g	‡1	12.79	13.90	Hycor	QA
Corticosteroids and mydriatics in combination								
	PREDNISOLONE ACETATE with PHENYLEPHRINE HYDROCHLORIDE <u>Restricted benefit</u> Corneal grafts; Uveitis.							
3112T NP	Eye drops 10 mg-1.2 mg per mL (1%-0.12%), 10 mL	‡1	2	..	23.83	24.94	Prednefrin Forte	AG
Antiinflammatory agents, non-steroids								
8699W NP	FLURBIPROFEN SODIUM Eye drops 300 micrograms per mL (0.03%), single dose units 0.4 mL, 5	1	16.92	18.03	Ocufen	AG
Antiglaucoma preparations and miotics								
Sympathomimetics in glaucoma therapy								
	APRACLONIDINE HYDROCHLORIDE <u>Restricted benefit</u> Short-term reduction of intra-ocular pressure in patients already on maximally tolerated anti-glaucoma therapy.							
8083K	Eye drops 5 mg (base) per mL (0.5%), 10 mL	‡1	2	..	41.87	35.40	Iopidine 0.5%	AQ
5298W	BRIMONIDINE TARTRATE Eye drops 1.5 mg per mL (0.15%), 5 mL	‡1	5	..	20.24	21.35	Alphagan P 1.5	AG

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
8351M	Eye drops 2 mg per mL (0.2%), 5 mL	‡1	5	..	20.24	21.35 ^a	Enidin PE
				^B 1.63	21.87	21.35 ^a	Alphagan AG

BRIMONIDINE TARTRATE with TIMOLOL MALEATE

Restricted benefit

Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;

Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.

8826M	Eye drops 2 mg-5 mg (base) per mL (0.2%-0.5%), 5 mL	‡1	5	..	26.13	27.24	Combigan	AG
-------	--	----	---	----	-------	-------	----------	----

Parasympathomimetics

PILOCARPINE HYDROCHLORIDE

2595N	Eye drops 10 mg per mL (1%), 15 mL	‡1	5	..	12.63	13.74	Isopto Carpine	AQ
2596P	Eye drops 20 mg per mL (2%), 15 mL	‡1	5	..	13.88	14.99	Isopto Carpine	AQ
2598R	Eye drops 40 mg per mL (4%), 15 mL	‡1	5	..	16.73	17.84	Isopto Carpine	AQ

Carbonic anhydrase inhibitors

ACETAZOLAMIDE

Note

Continuing Therapy Only:

For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

1004W NP	Tablet 250 mg	100	3	..	23.89	25.00	Diamox	QA
-------------	---------------	-----	---	----	-------	-------	--------	----

BRINZOLAMIDE

8483L	Eye drops 10 mg per mL (1%), 5 mL	‡1	5	..	22.87	23.98 ^a	BrinzoQuin	IQ
				^B 1.18	24.05	23.98 ^a	Azopt	AQ

BRINZOLAMIDE with TIMOLOL MALEATE

Restricted benefit

Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;

Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.

3438Y	Eye drops 10 mg-5 mg (base) per mL (1%-0.5%), 5 mL	‡1	5	..	26.98	28.09	Azarga	AQ
-------	---	----	---	----	-------	-------	--------	----

DORZOLAMIDE HYDROCHLORIDE

8488R	Eye drops 20 mg (base) per mL (2%), 5 mL	‡1	5	..	21.39	22.50	Trusopt	MK
-------	--	----	---	----	-------	-------	---------	----

DORZOLAMIDE HYDROCHLORIDE with TIMOLOL MALEATE

Restricted benefit

Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;

Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.

8567X	Eye drops 20 mg (base)-5 mg (base) per mL (2%- 0.5%), 5 mL	‡1	5	..	27.28	28.39	Cosopt	MK
-------	---	----	---	----	-------	-------	--------	----

Beta blocking agents

BETAXOLOL HYDROCHLORIDE

2811Y	Eye drops, suspension, 2.5 mg (base) per mL (0.25%), 5 mL	‡1	5	..	14.87	15.98	Betoptic S	AQ
2825Q	Eye drops, solution, 5 mg (base) per mL (0.5%), 5 mL	‡1	5	..	14.87	15.98 ^a	BetoQuin	IQ
				^B 2.09	16.96	15.98 ^a	Betoptic	AQ

Sensory organs

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net			
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer		
TIMOLOL MALEATE									
1278G	Eye drops 2.5 mg (base) per mL (0.25%), 5 mL	1	5	.. ^B 3.03	11.64 14.67	12.75 12.75	^a ^a	Tenopt Timoptol	QA FR
1279H	Eye drops 5 mg (base) per mL (0.5%), 5 mL	1	5	.. ^B 3.03	12.41 15.44	13.52 13.52	^a ^a	Tenopt Timoptol	QA FR
1925H	Eye drops (gellan gum solution) 2.5 mg (base) per mL (0.25%), 2.5 mL	1	5	..	11.64	12.75		Timoptol XE	MK
1926J	Eye drops (gellan gum solution) 5 mg (base) per mL (0.5%), 2.5 mL	1	5	..	12.41	13.52		Timoptol XE	MK
8803H	Eye gel 1 mg (base) per g (0.1%), 5 g	1	5	..	12.97	14.08		Nyogel	NV

Prostaglandin analogues

BIMATOPROST								
8620Q	Eye drops 300 micrograms per mL (0.03%), 3 mL	1	5	..	42.24	35.40	Lumigan	AG

BIMATOPROST with TIMOLOL MALEATE

Restricted benefit

Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;

Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.

9464D	Eye drops 300 micrograms-5 mg (base) per mL (0.03%-0.5%), 3 mL	1	5	..	46.69	35.40	Ganfort 0.3/5	AG
-------	---	---	---	----	-------	-------	---------------	----

LATANOPROST

8243W	Eye drops 50 micrograms per mL (0.005%), 2.5 mL	1	5	..	36.67	35.40	^a APO-Latanoprost	TX
							^a Chem mart	CH
							^a Latanoprost	
							^a Latanoprost Pfizer	FZ
							^a Latanoprost Sandoz	SZ
							^a Terry White Chemists	TW
							^a Latanoprost	
							^a Xalatan	PF

LATANOPROST with TIMOLOL MALEATE

Restricted benefit

Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;

Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.

8895E	Eye drops 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL	1	5	..	40.97	35.40	^a Latanocom	FZ
							^a Xalacom	PF

TRAVOPROST

8597L	Eye drops 40 micrograms per mL (0.004%), 2.5 mL	1	5	..	42.24	35.40	Travatan	AQ
-------	--	---	---	----	-------	-------	----------	----

TRAVOPROST with TIMOLOL MALEATE

Restricted benefit

Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;

Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.

9057Q	Eye drops 40 micrograms-5 mg (base) per mL (0.004%-0.5%), 2.5 mL	1	5	..	46.69	35.40	Duotrav	AQ
-------	---	---	---	----	-------	-------	---------	----

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Mydriatics and cycloplegics								
Anticholinergics								
ATROPINE								
1093M NP	Eye drops containing atropine sulfate 10 mg per mL (1%), 15 mL	†1	2	..	21.87	22.98	Atropt	QA
HOMATROPINE HYDROBROMIDE								
2541R NP	Eye drops 20 mg per mL (2%), 15 mL	†1	2	..	18.91	20.02	Isopto Homatropine	AQ
Decongestants and antiallergics								
Other antiallergics								
SODIUM CROMOGLYCATE								
<u>Restricted benefit</u>								
Vernal kerato-conjunctivitis.								
1127H NP	Eye drops 20 mg per mL (2%), 10 mL	†1	5	..	14.31	15.42	^a Cromolux	AE
							^a Opticrom	SW
Ocular vascular disorder agents								
Antineovascularisation agents								
RANIBIZUMAB								
<u>Authority required</u>								
Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography.								
Where a fluorescein angiogram cannot be performed due to a contraindication as listed in the TGA-approved product information, details of the contraindication must be provided. A copy of the report of an alternative method of diagnosis must be included in the application, for example, optical coherence tomography (OCT) or red free photography.								
Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.								
The first authority application for each eye must be made in writing, and must include:								
(a) a completed authority prescription form; and								
(b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and								
(c) a copy of the fluorescein angiogram or alternative method of diagnosis where applicable.								
Written applications for authority to prescribe ranibizumab should be forwarded to:								
Medicare Australia Prior Written Approval of Specialised Drugs Reply Paid 9826 GPO Box 9826 HOBART TAS 7001								
Alternatively, the first authority application may be faxed to Medicare Australia on 1300 093 177 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Medicare Australia will then contact the prescriber by telephone. The original documentation must be posted to the above address after approval has been gained.								
<u>Authority required</u>								
Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD) where the patient has previously been granted an authority prescription for the same eye.								
Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia. Authority applications for continuing treatment in the same eye may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).								
<u>Note</u>								
Special Pricing Arrangements apply.								
1382R	Solution for intravitreal injection 2.3 mg in 0.23 mL	1	2	..	1976.46	35.40	Lucentis	NV

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

VERTEPORFIN

Authority required

Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography, in a patient with a baseline visual acuity equal to or better than 6/60 (20/200).

Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.

The first authority application for each eye must be made in writing, and must include:

- (a) a completed authority prescription form; and
- (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and
- (c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).

Written applications for authority to prescribe verteporfin should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

Alternatively, the first authority application may be faxed to Medicare Australia on 1300 093 177 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Medicare Australia will then contact the prescriber by telephone. The original documentation must be posted to the above address after approval has been gained.

No more than 15 treatments (1 initial and 14 continuing) per eye will be authorised.

Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin. Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The reason treatment is abandoned must be provided. Where such notification has been made, the treatment so affected will not count towards the maximum.

Authority required

Initial PBS-subsidised treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration where the patient has been authorised by the Angiogram Review Panel to receive treatment with verteporfin in the same eye under the MBS Visudyne Therapy Program.

Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.

The first authority application for each eye must be made in writing, and must include:

- (a) a completed authority prescription form; and
- (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au], which includes the date of review by the Angiogram Review Panel and the number of treatments administered in that eye under the MBS Visudyne Therapy Program; and
- (c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).

Written applications for authority to prescribe verteporfin should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

Alternatively, the first authority application may be faxed to Medicare Australia on 1300 093 177 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Medicare Australia will then contact the prescriber by telephone. The original documentation must be posted to the above address after approval has been gained.

A patient is eligible for a total of 15 subsidised treatments per eye. This maximum includes treatments administered under the MBS Visudyne Therapy Program and the PBS.

Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin. Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The reason treatment is abandoned must be provided. Where such notification has been made, the treatment so affected will not count towards the maximum.

Authority required

Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration where the patient has previously been granted an authority prescription for the same eye.

A patient is eligible for a total of 15 subsidised treatments per eye. This maximum includes treatments administered under the MBS Visudyne

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	Therapy Program and the PBS.						

Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin. Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The reason treatment is abandoned must be provided. Where such notification has been made, the treatment so affected will not count towards the maximum.

Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia. Authority applications for continuing treatment in the same eye may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

1349B	Powder for I.V. infusion 15 mg	1	2246.46	35.40	Visudyne	NV
-------	--------------------------------	---	----	----	---------	-------	----------	----

Other ophthalmologicals

Other ophthalmologicals

CARBOMER

Restricted benefit

Severe dry eye syndrome, including Sjogren's syndrome.

8384G NP	Eye gel 2 mg per g (0.2%), 10 g	1	5	..	10.37	11.48	GelTears	BU
						^a	PAA	IQ
				^B 1.50	11.87	11.48	^a Viscotears	AQ

CARBOMER

Restricted benefit

For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9210R	Eye gel 2 mg per g (0.2%), 10 g	1	11	..	10.37	11.48	GelTears	BU
						^a	PAA	IQ
				^B 1.50	11.87	11.48	^a Viscotears	AQ

CARBOMER

Authority required (STREAMLINED)

1359

Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.

8578L NP	Eye gel 2 mg per g (0.2%), single dose units 0.6 mL, 30	3	5	..	*36.19	35.40	Viscotears Gel PF	AQ
-------------	--	---	---	----	--------	-------	-------------------	----

CARBOMER 974

Authority required (STREAMLINED)

1359

Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.

8514D NP	Ocular lubricating gel 3 mg per g (0.3%), single dose units 0.5 g, 30	3	5	..	*36.16	35.40	Poly Gel	AQ
-------------	--	---	---	----	--------	-------	----------	----

CARMELLOSE SODIUM

Restricted benefit

Severe dry eye syndrome, including Sjogren's syndrome.

8548X NP	Eye drops 5 mg per mL (0.5%), 15 mL	1	5	..	10.69	11.80	Refresh Tears Plus	AG
8593G NP	Eye drops 10 mg per mL (1%), 15 mL	1	5	..	10.69	11.80	Refresh Liquigel	AG

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
CARMELLOSE SODIUM								
<u>Restricted benefit</u>								
For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
9211T	Eye drops 5 mg per mL (0.5%), 15 mL	1	11	..	10.69	11.80	Refresh Tears Plus	AG
9212W	Eye drops 10 mg per mL (1%), 15 mL	1	11	..	10.69	11.80	Refresh Liquigel	AG
<hr/>								
CARMELLOSE SODIUM								
<u>Authority required (STREAMLINED)</u>								
1359								
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.								
2324H	Eye drops 10 mg per mL (1%), single dose units	3	5	..	*36.16	35.40	Celluvisc	AG
NP	0.4 mL, 30							
2338C	Eye drops 5 mg per mL (0.5%), single dose units	3	5	..	*36.16	35.40	Cellufresh	AG
NP	0.4 mL, 30							
8823J	Eye drops 2.5 mg per mL (0.25%), single dose	4	5	..	*40.52	35.40	TheraTears	CX
NP	units 0.6 mL, 24							
8824K	Ocular lubricating gel 10 mg per mL (1%), single	3	5	..	*34.18	35.29	TheraTears	CX
NP	dose units 0.6 mL, 28							
<hr/>								
CARMELLOSE SODIUM with GLYCERIN								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
<u>Note</u>								
The in-use shelf life of Optive is 6 months from the date of opening.								
9355J	Eye drops 5 mg-9 mg per mL (0.5%-0.9%), 15 mL	1	3	..	10.69	11.80	Optive	AG
NP								
<hr/>								
CARMELLOSE SODIUM with GLYCERIN								
<u>Restricted benefit</u>								
For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
<u>Note</u>								
The in-use shelf life of Optive is 6 months from the date of opening.								
9356K	Eye drops 5 mg-9 mg per mL (0.5%-0.9%), 15 mL	1	7	..	10.69	11.80	Optive	AG
<hr/>								
CARMELLOSE SODIUM with GLYCERIN								
<u>Authority required (STREAMLINED)</u>								
1359								
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.								
9307W	Eye drops 5 mg-9 mg per mL (0.5%-0.9%), single	3	5	..	*36.16	35.40	Optive	AG
NP	dose units 0.4 mL, 30							
<hr/>								
HYPROMELLOSE								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
2956N	Eye drops 5 mg per mL (0.5%), 15 mL	1	5	..	10.37	11.48	Methopt	QA
NP								
8287E	Eye drops 3 mg per mL (0.3%), 15 mL (contains	1	5	..	10.37	11.48	^a In a Wink	IQ
NP	sodium perborate as preservative)						Moisturising	

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				^B 1.95	12.32	11.48 ^a	Genteal AQ

HYPROMELLOSE

Restricted benefit

For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9213X	Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative)	1	11	..	10.37	11.48 ^a	In a Wink Moisturising	IQ
				^B 1.95	12.32	11.48 ^a	Genteal	AQ
9214Y	Eye drops 5 mg per mL (0.5%), 15 mL	1	11	..	10.37	11.48	Methopt	QA

HYPROMELLOSE with CARBOMER 980

Restricted benefit

Severe dry eye syndrome, including Sjogren's syndrome.

8564R NP	Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g	1	5	..	10.37	11.48 ^a	HPMC PAA	IQ
				^B 1.95	12.32	11.48 ^a	Genteal gel	AQ

HYPROMELLOSE with CARBOMER 980

Restricted benefit

For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9215B	Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g	1	11	..	10.37	11.48 ^a	HPMC PAA	IQ
				^B 1.95	12.32	11.48 ^a	Genteal gel	AQ

HYPROMELLOSE with DEXTRAN

Restricted benefit

Severe dry eye syndrome, including Sjogren's syndrome.

1509K NP	Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL	1	5	..	10.59	11.70 ^a	Poly-Tears	IQ
				^B 2.04	12.63	11.70 ^a	Tears Naturale	AQ

HYPROMELLOSE with DEXTRAN

Restricted benefit

For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9216C	Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL	1	11	..	10.59	11.70 ^a	Poly-Tears	IQ
				^B 2.04	12.63	11.70 ^a	Tears Naturale	AQ

HYPROMELLOSE with DEXTRAN

Authority required (STREAMLINED)

1359

Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8299T NP	Eye drops 3 mg-1 mg per mL (0.3%-0.1%), single dose units 0.4 mL, 28	3	5	..	*35.17	35.40	Bion Tears	AQ
PARAFFIN								
1750D NP	Pack containing 2 tubes compound eye ointment 3.5 g	1	5	..	20.70	21.81	Poly Visc	IQ
							^a Ircal	PE
				^B 2.12	22.82	21.81	^a Lacri-Lube	AG
1754H NP	Compound eye ointment 3.5 g	2	5	..	*21.34	22.45	^a Poly Visc	IQ
				^B 2.54	*23.88	22.45	^a Duratears	AQ

PARAFFIN

Restricted benefit

For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9217D	Compound eye ointment 3.5 g	2	11	..	*21.34	22.45	^a Poly Visc	IQ
				^B 2.54	*23.88	22.45	^a Duratears	AQ
9218E	Pack containing 2 tubes compound eye ointment 3.5 g	1	11	..	20.70	21.81	Poly Visc	IQ
							^a Ircal	PE
				^B 2.12	22.82	21.81	^a Lacri-Lube	AG

POLYETHYLENE GLYCOL 400

Restricted benefit

Severe dry eye syndrome, including Sjogren's syndrome.

Note

The in-use shelf life of Blink Intensive Tears multi-dose formulation is 45 days from the date of opening.

9491M NP	Eye drops 2.5 mg per mL (0.25%), 15 mL	1	5	..	10.69	11.80	Blink Intensive Tears	AO
-------------	--	---	---	----	-------	-------	-----------------------	----

POLYETHYLENE GLYCOL 400

Restricted benefit

For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Note

The in-use shelf life of Blink Intensive Tears multi-dose formulation is 45 days from the date of opening.

9492N	Eye drops 2.5 mg per mL (0.25%), 15 mL	1	11	..	10.69	11.80	Blink Intensive Tears	AO
-------	--	---	----	----	-------	-------	-----------------------	----

POLYETHYLENE GLYCOL 400

Authority required (STREAMLINED)

1359

Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.

9493P NP	Eye drops 2.5 mg per mL (0.25%), single dose units 0.4 mL, 20	5	5	..	*39.47	35.40	Blink Intensive Tears	AO
-------------	---	---	---	----	--------	-------	-----------------------	----

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
8676P NP	Eye drops 4 mg-3 mg per mL (0.4%-0.3%), 15 mL	1	5	..	10.69	11.80	Systane	AQ
<hr/>								
POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL								
<u>Restricted benefit</u>								
For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
9219F	Eye drops 4 mg-3 mg per mL (0.4%-0.3%), 15 mL	1	11	..	10.69	11.80	Systane	AQ
<hr/>								
POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL								
<u>Authority required (STREAMLINED)</u>								
1359								
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.								
9170P NP	Eye drops 4 mg-3 mg per mL (0.4%-0.3%), single dose units 0.8 mL, 28	2	5	..	*34.18	35.29	Systane	AQ
<hr/>								
POLYVINYL ALCOHOL								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
2681D NP	Eye drops 30 mg per mL (3%), 15 mL	1	5	..	10.37	11.48	^a PVA Forte	PE
				^B 5.59	15.96	11.48	^a Liquifilm Forte	AG
2682E NP	Eye drops 14 mg per mL (1.4%), 15 mL	1	5	..	10.37	11.48	^a PVA Tears	PE
				^B 1.60	11.97	11.48	^a Liquifilm Tears	AG
8831T NP	Eye drops 14 mg per mL (1.4%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	1	5	..	10.37	11.48	Vistil	AE
8832W NP	Eye drops 30 mg per mL (3%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	1	5	..	10.37	11.48	Vistil Forte	AE
<hr/>								
POLYVINYL ALCOHOL								
<u>Restricted benefit</u>								
For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
9220G	Eye drops 14 mg per mL (1.4%), 15 mL	1	11	..	10.37	11.48	^a PVA Tears	PE
				^B 1.60	11.97	11.48	^a Liquifilm Tears	AG
9221H	Eye drops 14 mg per mL (1.4%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	1	11	..	10.37	11.48	Vistil	AE
9222J	Eye drops 30 mg per mL (3%), 15 mL	1	11	..	10.37	11.48	^a PVA Forte	PE
				^B 5.59	15.96	11.48	^a Liquifilm Forte	AG
9223K	Eye drops 30 mg per mL (3%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	1	11	..	10.37	11.48	Vistil Forte	AE

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
SOY LECITHIN								
<u>Authority required (STREAMLINED)</u>								
1359								
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.								
9448G NP	Eye spray 10 mg per mL (1%), 10 mL	2	5	..	*36.16	35.40	tearsagain	RB

Otologicals

Antiinfectives

Antiinfectives

CHLORAMPHENICOL								
1172Q NP	Ear drops (aqueous) 5 mg per mL (0.5%), 5 mL	1	2	..	11.15	12.26	Chloromycetin	PF
CIPROFLOXACIN								
<u>Authority required</u>								
Treatment of chronic suppurative otitis media in an Aboriginal or a Torres Strait Islander person aged 1 month or older;								
Treatment of chronic suppurative otitis media in a patient less than 18 years of age with perforation of the tympanic membrane;								
Treatment of chronic suppurative otitis media in a patient less than 18 years of age with a grommet in situ.								
2480M NP	Ear drops 3 mg per mL (0.3%), 5 mL	1	1	..	19.38	20.49	Ciloxan	AQ
NEOMYCIN UNDECENOATE with BACITRACIN ZINC								
2296W NP	Ear ointment 12 mg (3.5 mg base)-400 units per g, 10 g	1	8.76	9.87	Nemdyn	HA

Corticosteroids and antiinfectives in combination

Corticosteroids and antiinfectives in combination

DEXAMETHASONE with FRAMYCETIN SULFATE and GRAMICIDIN								
2781J NP	Ear drops 500 micrograms-5 mg-50 micrograms per mL, 8 mL	1	2	..	9.49	10.60	^a Otodex	AV
				^B 1.91	11.40	10.60	^a Sofradex	SW
TRIAMCINOLONE ACETONIDE with NEOMYCIN SULFATE, GRAMICIDIN and NYSTATIN								
2971J NP	Ear drops 1 mg-2.5 mg (base)- 250 micrograms-100,000 units per g (0.1%-0.25%-0.025%-100,000 units per g), 7.5 mL	1	2	..	11.19	12.30	^a Otocomb Otic	FM
				^B 1.95	13.14	12.30	^a Kenacomb Otic	QA
2974M NP	Ear ointment 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g (0.1%-0.25%-0.025%-100,000 units per g), 5 g	1	2	..	8.28	9.39	^a Otocomb Otic	FM
				^B 1.95	10.23	9.39	^a Kenacomb Otic	QA

Ophthalmological and otological preparations

Antiinfectives

Antiinfectives

FRAMYCETIN SULFATE								
1440T NP,MW	Eye and ear drops 5 mg per mL (0.5%), 8 mL	1	2	..	10.21	11.32	Soframycin	SW

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Various

Allergens

Allergens

Allergen extracts

INSECT ALLERGEN EXTRACT—HONEY BEE VENOM							
2886X	Injection set containing 550 micrograms	1	238.48	35.40	Albey Bee Venom HL
INSECT ALLERGEN EXTRACT—PAPER WASP VENOM							
Note							
Paper wasp venom is not European wasp venom.							
2918N	Injection set containing 550 micrograms	1	238.48	35.40	Albey Paper Wasp Venom HL
INSECT ALLERGEN EXTRACT—YELLOW JACKET VENOM							
2883R	Injection set containing 550 micrograms	1	238.48	35.40	Albey Yellow Jacket Venom HL

All other therapeutic products

All other therapeutic products

Antidotes

NALOXONE HYDROCHLORIDE							
1753G NP	Injection 2 mg in 5 mL	1	43.59	35.40	Naloxone Min-I-Jet CS

Drugs for treatment of hyperkalemia and hyperphosphatemia

LANTHANUM

Authority required (STREAMLINED)

3546

Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy;

3547

Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.

Note

Not to be used in combination with sevelamer.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

9403X NP	Tablet, chewable, 500 mg (as carbonate hydrate)	90	5	..	305.97	35.40	Fosrenol	ZI
9404Y NP	Tablet, chewable, 750 mg (as carbonate hydrate)	90	5	..	449.52	35.40	Fosrenol	ZI
9405B NP	Tablet, chewable, 1000 mg (as carbonate hydrate)	90	5	..	504.13	35.40	Fosrenol	ZI

SEVELAMER HYDROCHLORIDE

Authority required (STREAMLINED)

3548

Maintenance therapy, following initiation and stabilisation of treatment with sevelamer hydrochloride, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy;

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
3549							
Maintenance therapy, following initiation and stabilisation of treatment with sevelamer hydrochloride, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.							
<u>Note</u>							
Not to be used in combination with lanthanum.							
<u>Note</u>							
Shared Care Model:							
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.							
2142R NP	Tablet 800 mg	180	5	..	357.83	35.40	Renagel GZ

Detoxifying agents for antineoplastic treatment

CALCIUM FOLINATE

Note

For item codes 8740B, 1575X and 1610R, pharmaceutical benefits that have the form injection equivalent to 50 mg folinic acid in 5 mL are equivalent for the purposes of substitution.

1575X	Injection equivalent to 50 mg folinic acid in 5 mL	5	5	..	146.20	35.40	^a	Calcium Folate Ebewe	SZ
1610R	Injection equivalent to 50 mg folinic acid in 5 mL	5	5	..	*146.23	35.40	^a	Leucovorin Calcium (Pfizer Australia Pty Ltd)	PF
8740B	Injection equivalent to 50 mg folinic acid in 5 mL	5	5	..	*146.17	35.40	^a	Leucovorin Calcium (Hospira Pty Limited)	HH

CALCIUM FOLINATE

Note

For item codes 8812T and 1704Q, pharmaceutical benefits that have the form injection equivalent to 100 mg folinic acid in 10 mL are equivalent for the purposes of substitution.

1704Q	Injection equivalent to 100 mg folinic acid in 10 mL	10	1	..	258.88	35.40	^a	Leucovorin Calcium (Pfizer Australia Pty Ltd)	PF
8812T	Injection equivalent to 100 mg folinic acid in 10 mL	10	1	..	*258.82	35.40	^a	Calcium Folate Ebewe	SZ

CALCIUM FOLINATE

8969C	Injection equivalent to 1000 mg folinic acid in 100 mL	1	1	..	258.82	35.40		Calcium Folate Ebewe	SZ
9041W	Injection equivalent to 300 mg folinic acid in 30 mL	4	1	..	*298.60	35.40	^a	Calcium Folate Ebewe	SZ
							^a	Leucovorin Calcium (Hospira Pty Limited)	HH

CALCIUM FOLINATE

Restricted benefit

Antidote to folic acid antagonists.

2308L	Tablet equivalent to 15 mg folinic acid	10	96.41	35.40		Leucovorin Calcium (Hospira Pty Limited)	HH
-------	---	----	----	----	-------	-------	--	--	----

MESNA

Restricted benefit

Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide.

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
8078E	Solution for I.V. injection 400 mg in 4 mL	15	5	..	103.38	35.40	Uromitexan	BX
8079F	Solution for I.V. injection 1 g in 10 mL	15	5	..	223.91	35.40	Uromitexan	BX

Drugs for treatment of hypercalcemia

SODIUM ACID PHOSPHATE

Authority required (STREAMLINED)

1099

Familial hypophosphataemia;

1157

Hypercalcaemia;

1167

Hypophosphataemic rickets;

1467

Vitamin D-resistant rickets.

2946C NP	Compound effervescent tablet containing elemental phosphorus 500 mg, sodium 469 mg (20.4 mmol), potassium 123 mg (3.1 mmol)	100	5	..	81.73	35.40	Phosphate Sandoz	NV
-------------	---	-----	---	----	-------	-------	------------------	----

Other therapeutic products

POLY-L-LACTIC ACID

Note

Authority applications to prescribe poly-l-lactic acid may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial PBS-subsidised treatment, for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection.

Accreditation following completion of injection administration training with Sanofi-Aventis is required to prescribe poly-l-lactic acid under the PBS. Patients must be referred from the HIV physician to the accredited injector.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9475Q	Powder for injection 150 mg	2	4	..	*446.56	35.40	Sculptra	SW
-------	-----------------------------	---	---	----	---------	-------	----------	----

POLY-L-LACTIC ACID

Note

Authority applications to prescribe poly-l-lactic acid may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Maintenance PBS-subsidised treatment, for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection.

Accreditation following completion of injection administration training with Sanofi-Aventis is required to prescribe poly-l-lactic acid under the PBS. Patients must be referred from the HIV physician to the accredited injector.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Maintenance treatment is limited to one re-treatment (maximum 2 vials) every 2 years.

9476R	Powder for injection 150 mg	2	*446.56	35.40	Sculptra	SW
-------	-----------------------------	---	----	----	---------	-------	----------	----

Diagnostic agents

Urine tests

GLUCOSE and KETONE INDICATOR—URINE

3106L NP	Test strips, 50	2	2	..	*17.40	18.51	Keto-Diabur- Test 5000	RD
3107M NP	Test strips, 50	2	2	..	*17.52	18.63	Keto-Diastix	BN

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

GLUCOSE and KETONE INDICATOR—URINE

Restricted benefit

For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9254C	Test strips, 50	2	4	..	*17.40	18.51	Keto-Diabur- Test 5000	RD
9255D	Test strips, 50	2	4	..	*17.52	18.63	Keto-Diastix	BN

GLUCOSE INDICATOR—URINE

3104J NP	Test strips, 50	2	2	..	*19.92	21.03	Diastix	BN
-------------	-----------------	---	---	----	--------	-------	---------	----

GLUCOSE INDICATOR—URINE

Restricted benefit

For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9253B	Test strips, 50	2	4	..	*19.92	21.03	Diastix	BN
-------	-----------------	---	---	----	--------	-------	---------	----

Other diagnostic agents

Tests for diabetes

GLUCOSE INDICATOR—BLOOD

1503D NP	Test strips, 100	1	5	..	53.26	35.40	Contour	IK
1519Y NP	Test strips, 100	1	5	..	53.26	35.40	BGStar	SW
2263D NP	Test strips, 50	2	5	..	*53.28	35.40	Optium Omega	MS
2860M NP	Test strips, 50	2	5	..	*53.28	35.40	Betachek G5	NA
2890D NP	Test strips, 50	2	5	..	*53.28	35.40	Betachek	NA
2914J NP	Test strips, 50	2	5	..	*46.00	35.40	Glucoflex-R	NA
2979T NP	Test strips, 100	1	5	..	53.26	35.40	Accu-Chek Performa	RD
3406G NP	Test strips, 50	2	5	..	*53.28	35.40	CareSens N	LB
3411M NP	Test strips, 100	1	5	..	53.26	35.40	Accu-Chek Advantage/Sens or Comfort	RD
3441D NP	Test strips, 50	2	5	..	*53.28	35.40	OneTouch Verio	JJ
5043K NP	Test strips, 50	2	5	..	*53.28	35.40	Accu-Chek Aviva	RD
5266E NP	Test strips, 50	2	5	..	*53.28	35.40	TRUEresult	NX
5267F NP	Test strips, 50	2	5	..	*53.28	35.40	TRUEbalance	NX
8190C NP	Test strips, 100	1	5	..	53.26	35.40	Accu-Chek Active	RD
8522M NP	Test strips, 100	1	5	..	53.26	35.40	FreeStyle Optium	MS
8723D NP	Test strips, 50	2	5	..	*53.28	35.40	Omnitest EZ	BR
8739Y	Test strips, 50	2	5	..	*53.28	35.40	Accu-Chek Go	RD

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
NP								
8749L	Test strips, 50	2	5	..	*53.28	35.40	GlucoOz	OZ
NP								
8759B	Test strips, 50	2	5	..	*53.28	35.40	CareSens	LB
NP								
8795X	Test strips, 50	2	5	..	*53.28	35.40	SensoCard	PX
NP								
8806L	Test strips, 51	2	5	..	*53.28	35.40	Accu-Chek Integra	RD
NP								
8825L	Test strips, 50	2	5	..	*53.28	35.40	TrueTrack	NX
NP								
9013J	Test strips, 50	2	5	..	*53.28	35.40	Glucocard 01 Sensor	OZ
NP								
9154T	Test strips, 100	1	5	..	53.26	35.40	FreeStyle Lite	MS
NP								
9193W	Test strips, 25	4	5	..	*53.28	35.40	On-Call Plus	PZ
NP								
9298J	Test strips, 50	2	5	..	*53.28	35.40	Bionime Rightest	QB
NP								
9324R	Test strips, 50	2	5	..	*53.28	35.40	AgaMatrix Jazz	HE
NP								
9471L	Test strips, 50	2	5	..	*53.28	35.40	MyGlucoHealth	EH
NP								
9485F	Test strips, 50	2	5	..	*53.28	35.40	Lifeline Attest	OI
NP								

GLUCOSE INDICATOR—BLOOD

Restricted benefit

For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

1518X	Test strips, 100	1	11	..	53.26	35.40	Contour	IK
1520B	Test strips, 100	1	11	..	53.26	35.40	BGStar	SW
3407H	Test strips, 50	2	11	..	*53.28	35.40	CareSens N	LB
3412N	Test strips, 100	1	11	..	53.26	35.40	Accu-Chek Advantage/Sens or Comfort	RD
3442E	Test strips, 50	2	11	..	*53.28	35.40	OneTouch Verio	JJ
5053Y	Test strips, 50	2	11	..	*53.28	35.40	Accu-Chek Aviva	RD
5268G	Test strips, 50	2	11	..	*53.28	35.40	TRUEresult	NX
5269H	Test strips, 50	2	11	..	*53.28	35.40	TRUEbalance	NX
9256E	Test strips, 25	4	11	..	*53.28	35.40	On-Call Plus	PZ
9257F	Test strips, 100	1	11	..	53.26	35.40	Accu-Chek Performa	RD
9261K	Test strips, 50	2	11	..	*53.28	35.40	Glucocard 01 Sensor	OZ
9263M	Test strips, 50	2	11	..	*53.28	35.40	GlucoOz	OZ
9265P	Test strips, 50	2	11	..	*53.28	35.40	Omnitest EZ	BR
9267R	Test strips, 50	2	11	..	*53.28	35.40	Optium Omega	MS
9268T	Test strips, 50	2	11	..	*53.28	35.40	TrueTrack	NX
9269W	Test strips, 100	1	11	..	53.26	35.40	FreeStyle Lite	MS
9270X	Test strips, 100	1	11	..	53.26	35.40	FreeStyle Optium	MS
9273C	Test strips, 100	1	11	..	53.26	35.40	Accu-Chek Active	RD
9274D	Test strips, 50	2	11	..	*53.28	35.40	Accu-Chek Go	RD
9275E	Test strips, 51	2	11	..	*53.28	35.40	Accu-Chek Integra	RD
9276F	Test strips, 50	2	11	..	*53.28	35.40	Betachek	NA
9277G	Test strips, 50	2	11	..	*53.28	35.40	Betachek G5	NA

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
9278H	Test strips, 50	2	11	..	*53.28	35.40	CareSens	LB
9279J	Test strips, 50	2	11	..	*46.00	35.40	Glucoflex-R	NA
9281L	Test strips, 50	2	11	..	*53.28	35.40	SensoCard	PX
9297H	Test strips, 50	2	11	..	*53.28	35.40	Bionime Rightest	QB
9325T	Test strips, 50	2	11	..	*53.28	35.40	AgaMatrix Jazz	HE
9472M	Test strips, 50	2	11	..	*53.28	35.40	MyGlucoHealth	EH
9486G	Test strips, 50	2	11	..	*53.28	35.40	Lifeline Attest	OI

GLUCOSE INDICATOR—BLOOD

Restricted benefit

For use in patients on insulin therapy.

9300L NP	Test strips, 100	‡1	5	..	53.26	35.40	Accu-Chek Mobile	RD
-------------	------------------	----	---	----	-------	-------	------------------	----

GLUCOSE INDICATOR—BLOOD

Restricted benefit

For use in patients on insulin therapy who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

9301M	Test strips, 100	‡1	11	..	53.26	35.40	Accu-Chek Mobile	RD
-------	------------------	----	----	----	-------	-------	------------------	----

General nutrients

Other nutrients

TRIGLYCERIDES, MEDIUM CHAIN

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Authority required

Chylous ascites;

Chylothorax;

Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders;

Hyperlipoproteinaemia type 1;

Intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect, requiring a ketogenic diet;

Long chain fatty acid oxidation disorders.

3128P NP	Oil 500 mL	2	5	..	*52.48	35.40	MCT Oil	SB
9327X NP	Emulsion 250 mL	8	5	..	*214.52	35.40	Liquigen	SB

Fat/carbohydrates/proteins/minerals/vitamins, combinations

AMINO ACIDS—SYNTHETIC, FORMULA

Authority required

Initial treatment for up to 3 months, by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who requires an amino acid based formula as a component of a dietary elimination programme. Treatment with oral steroids should not be commenced during the period of initial treatment.

Eosinophilic oesophagitis is demonstrated by the following criteria:

- (i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and
- (ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and
- (iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.

The date of birth of the patient must be included in the authority.

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<u>Authority required</u>								
Continuing treatment by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who has responded to an initial course of PBS-subsidised treatment. Response to initial treatment is demonstrated by oesophageal biopsy specimens obtained by endoscopy, where the most densely involved oesophageal biopsy had 5 or less eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies. The response criteria will not be deemed to have been met if oral steroids were commenced during initial treatment.								
<u>Note</u>								
Authorities for increased maximum quantities, up to a maximum of 52, may be authorised.								
1521C NP	Compound powder 400 g	12	5	..	*531.76	35.40	Neocate Advance Vanilla	SB
2250K NP	Compound powder 400 g	12	5	..	*531.76	35.40	EleCare	AB

AMINO ACIDS—SYNTHETIC, FORMULA

Authority required

Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24 months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application;

Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24 months. The name of the specialist and the date of birth of the patient must be included in the authority application;

Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24 months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

1180D NP	Compound powder 400 g	8	5	..	*361.24	35.40	Neocate Advance Vanilla	SB
2244D NP	Compound powder 400 g	8	5	..	*361.24	35.40	Neocate Advance Tropical Flavour	SB
8574G NP	Compound powder 400 g	8	5	..	*361.24	35.40	EleCare	AB
8754R NP	Compound powder 400 g	8	5	..	*361.24	35.40	Neocate Advance	SB

AMINO ACIDS—SYNTHETIC, FORMULA

Authority required

Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24 months. Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction. The name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24 months. The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24 months. The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. Then name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24 months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12 months. The name of the specialist and the date of birth of the patient must be included in the authority application;

Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed;

Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition.

Note

Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.

1192R	Compound powder 400 g	8	5	..	*361.24	35.40	Neocate Advance	SB
-------	-----------------------	---	---	----	---------	-------	-----------------	----

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
NP							Vanilla	
2553J	Compound powder 400 g	8	5	..	*361.24	35.40	Neocate Advance	SB
NP							Tropical Flavour	
8575H	Compound powder 400 g	8	5	..	*361.24	35.40	EleCare	AB
NP								
8755T	Compound powder 400 g	8	5	..	*361.24	35.40	Neocate Advance	SB
NP								

AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS

Authority required

Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24 months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application;

Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24 months. The name of the specialist and the date of birth of the patient must be included in the authority application;

Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24 months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

2246F	Compound powder 400 g	8	5	..	*367.96	35.40	Neocate LCP	SB
NP								
9339M	Compound powder 400 g	8	5	..	*367.96	35.40	EleCare LCP	AB
NP								

AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS

Authority required

Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24 months. Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction. The name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24 months. The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24 months. The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. Then name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24 months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12 months. The name of the specialist and the date of birth of the patient must be included in the authority application;

Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed;

Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition.

Note

Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.

2560R	Compound powder 400 g	8	5	..	*367.96	35.40	Neocate LCP	SB
NP								
9340N	Compound powder 400 g	8	5	..	*367.96	35.40	EleCare LCP	AB
NP								

AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS and MEDIUM CHAIN TRIGLYCERIDES

Authority required

Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24 months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	
	strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application;						
	Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24 months. The name of the specialist and the date of birth of the patient must be included in the authority application;						
	Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24 months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application.						
	<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.						
5466Q NP	Compound powder 400 g	8	5	..	*367.96	35.40	Neocate Gold SB

AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS and MEDIUM CHAIN TRIGLYCERIDES

Authority required

Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24 months. Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction. The name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24 months. The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24 months. The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. Then name of the specialist and the date of birth of the patient must be included in the authority application;

Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24 months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12 months. The name of the specialist and the date of birth of the patient must be included in the authority application;

Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed;

Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition.

Note

Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.

5467R NP	Compound powder 400 g	8	5	..	*367.96	35.40	Neocate Gold SB
-------------	-----------------------	---	---	----	---------	-------	-----------------

AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS and MEDIUM CHAIN TRIGLYCERIDES

Authority required

Initial treatment for up to 3 months, by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who requires an amino acid based formula as a component of a dietary elimination programme. Treatment with oral steroids should not be commenced during the period of initial treatment.

Eosinophilic oesophagitis is demonstrated by the following criteria:

- (i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and
- (ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and
- (iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.

The date of birth of the patient must be included in the authority.

Authority required

Continuing treatment by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who has responded to an initial course of PBS-subsidised treatment. Response to initial treatment is demonstrated by oesophageal biopsy specimens obtained by endoscopy, where the most densely involved oesophageal biopsy had 5 or less eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies. The response criteria will not be deemed to have been met if oral steroids were commenced during initial treatment.

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Note

Authorities for increased maximum quantities, up to a maximum of 52, may be authorised.

1545H NP	Compound powder 400 g	12	5	..	*542.32	35.40	Neocate Gold	SB
-------------	-----------------------	----	---	----	---------	-------	--------------	----

PROTEIN HYDROLYSATE FORMULA with MEDIUM CHAIN TRIGLYCERIDES

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Authority required

Initial treatment by, or in consultation with, a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child up to the age of 24 months. The child should have failed to respond to a strict soy-based cows' milk protein free diet. The date of birth of the patient must be included in the authority application;

Continuing treatment by, or in consultation with, a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child up to the age of 24 months, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides. The date of birth of the patient must be included in the authority application;

Treatment by a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child aged over 24 months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application.

Authority required

Biliary atresia;

Chronic liver failure with fat malabsorption;

Chylous ascites;

Chyllothorax;

Cystic fibrosis;

Enterokinase deficiency;

Proven fat malabsorption;

Severe diarrhoea of greater than 2 weeks' duration in an infant aged less than 4 months. The date of birth of the patient must be included in the authority application;

Severe intestinal malabsorption including short bowel syndrome.

2676W NP	Compound powder 400 g	8	5	..	*172.04	35.40	Alfaré	NT
-------------	-----------------------	---	---	----	---------	-------	--------	----

PROTEIN HYDROLYSATE FORMULA with MEDIUM CHAIN TRIGLYCERIDES

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Authority required

Initial treatment by, or in consultation with, a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child up to the age of 24 months. The child should have failed to respond to a strict soy-based cows' milk protein free diet. The date of birth of the patient must be included in the authority application;

Continuing treatment by, or in consultation with, a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child up to the age of 24 months, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides. The date of birth of the patient must be included in the authority application;

Treatment by a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child aged over 24 months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application.

Authority required

Biliary atresia;

Chronic liver failure with fat malabsorption;

Chylous ascites;

Cystic fibrosis;

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	Enterokinase deficiency; Proven fat malabsorption; Severe diarrhoea of greater than 2 weeks' duration in an infant aged less than 4 months. The date of birth of the patient must be included in the authority application; Severe intestinal malabsorption including short bowel syndrome.							
8259Q NP	Compound powder 450 g	8	5	..	*109.96	35.40	Karicare Aptamil Pepti-Junior Gold	NU

TRIGLYCERIDES—MEDIUM CHAIN, FORMULA

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Restricted benefit

Chylous ascites;

Chylothorax;

Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders;

Hyperlipoproteinaemia type 1;

Long chain fatty acid oxidation disorders.

Note

Not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.

1938B NP	Compound powder 400 g	8	5	..	*442.92	35.40	Lipistart	VF
8478F NP	Compound powder 400 g	8	5	..	*421.40	35.40	Monogen	SB

TRIGLYCERIDES—MEDIUM CHAIN, FORMULA

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Restricted benefit

Chylous ascites;

Chylothorax;

Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders.

Note

Caprilon is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet, long chain fatty acid oxidation disorders or hyperlipoproteinaemia type 1.

8629E NP	Compound powder 420 g	8	5	..	*467.56	35.40	Caprilon	SB
-------------	-----------------------	---	---	----	---------	-------	----------	----

Carbohydrates

AMYLOPECTIN, MODIFIED LONG CHAIN

Restricted benefit

Glycogen storage disease.

9386B NP	Sachets 60 g, 30	4	5	..	*752.40	35.40	Glycosade	VF
-------------	------------------	---	---	----	---------	-------	-----------	----

Milk substitutes

MILK POWDER—LACTOSE FREE FORMULA

Authority required

Acute lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application.

Note

No applications for increased maximum quantities and/or repeats will be authorised. No more than 1 application per patient will be authorised.

2350Q NP	Lactose-predigested powder infant formula 900 g	5	*89.02	35.40	Karicare Aptamil De-Lact	NU
8282X NP	Infant formula powder 900 g	5	*112.97	35.40	S-26 LF	PF

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
MILK POWDER—LACTOSE FREE FORMULA								
<u>Authority required</u>								
Proven chronic lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:								
(a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or								
(b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or								
(c) hydrogen breath test.								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
2349P NP	Lactose-predigested powder infant formula 900 g	5	5	..	*89.02	35.40	Karicare Aptamil De-Lact	NU
8283Y NP	Infant formula powder 900 g	5	5	..	*112.97	35.40	S-26 LF	PF

MILK POWDER—LACTOSE MODIFIED

Authority required

Acute lactose intolerance in children aged 1 year and over. The date of birth of the patient must be included in the authority application.

Note

No applications for increased maximum quantities and/or repeats will be authorised. No more than 1 application per patient will be authorised.

2358D NP	Lactose-predigested powder 900 g	3	1	..	*72.91	35.40	Digestelact	SJ
-------------	----------------------------------	---	---	----	--------	-------	-------------	----

MILK POWDER—LACTOSE MODIFIED

Authority required

Proven chronic lactose intolerance in children aged 1 year and over who are significantly malnourished. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:

(a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or

(b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or

(c) hydrogen breath test.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

2357C NP	Lactose-predigested powder 900 g	3	10	..	*72.91	35.40	Digestelact	SJ
-------------	----------------------------------	---	----	----	--------	-------	-------------	----

MILK POWDER—SYNTHETIC

Note

No applications for increased maximum quantities and/or repeats will be authorised.

Authority required

Hypercalcaemia in children under the age of 4 years.

3092R NP	Low calcium compound powder 400 g	8	5	..	*381.48	35.40	Locasol	SB
-------------	-----------------------------------	---	---	----	---------	-------	---------	----

Other combinations of nutrients

AMINO ACID FORMULA with FAT, CARBOHYDRATE, VITAMINS, MINERALS, and TRACE ELEMENTS, without METHIONINE and supplemented with DOCOSAHEXANOIC ACID

Restricted benefit

Pyridoxine non-responsive homocystinuria.

3417W NP	Oral liquid 125 mL, 36	4	5	..	*2508.08	35.40	HCU Anamix junior LQ	SB
-------------	------------------------	---	---	----	----------	-------	----------------------	----

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
AMINO ACID FORMULA with FAT, CARBOHYDRATE, VITAMINS, MINERALS and TRACE ELEMENTS without PHENYLALANINE and TYROSINE, and supplemented with DOCOSAHEXANOIC ACID								
<u>Restricted benefit</u>								
Tyrosinaemia.								
9330C NP	Oral liquid 125 mL, 36	4	5	..	*2508.08	35.40	TYR Anamix junior LQ	SB
AMINO ACID FORMULA without PHENYLALANINE								
<u>Restricted benefit</u>								
Phenylketonuria.								
2347M NP	Sachets containing powder 20 g, 30	7	5	..	*1463.01	35.40	Phlexy-10 Drink Mix	SB
8554F NP	Capsules 500 mg, 200	16	5	..	*1276.44	35.40	Phlexy-10	SB
8678R NP	Tablets 1 g, 75	24	5	..	*1427.08	35.40	Phlexy-10	SB
AMINO ACID FORMULA with VITAMINS, MINERALS and LONG CHAIN POLYUNSATURATED FATTY ACIDS without PHENYLALANINE								
<u>Restricted benefit</u>								
Phenylketonuria.								
8479G NP	Infant formula, powder 400 g	8	5	..	*703.72	35.40	PKU Anamix infant	SB
AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPHAN								
<u>Restricted benefit</u>								
A child aged from 6 months up to 10 years with proven glutaric aciduria type 1.								
9438R NP	Sachets 24 g, 30	4	5	..	*2114.48	35.40	GA gel	VF
AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPHAN								
<u>Restricted benefit</u>								
An infant or young child with proven glutaric aciduria type 1.								
2650L NP	Infant formula, powder 400 g	8	5	..	*769.40	35.40	GA1 Anamix infant	SB
AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPHAN								
<u>Restricted benefit</u>								
A child aged less than 9 years with proven glutaric aciduria type 1.								
2646G NP	Powder 500 g	8	5	..	*1784.84	35.40	XLYS, LOW TRY Maxamaid	SB
AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPHAN								
<u>Restricted benefit</u>								
A patient aged 3 years or older with proven glutaric aciduria type 1.								
5484P NP	Sachets 25 g, 30	4	5	..	*3154.52	35.40	GA express 15	VF
AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE								
<u>Restricted benefit</u>								
For infants and very young children with pyridoxine non-responsive homocystinuria.								
8417B NP	Infant formula, powder 400 g	8	5	..	*769.40	35.40	HCU Anamix infant	SB

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE								
<u>Restricted benefit</u>								
Pyridoxine non-responsive homocystinuria.								
1548L NP	Oral liquid 125 mL, 30	3	5	..	*3098.44	35.40	HCU Lophlex LQ 20	SB
8328H NP	Powder 500 g	8	5	..	*1784.84	35.40	XMET Maxamaid	SB
8416Y NP	Powder 500 g	8	5	..	*2704.84	35.40	XMET Maxamum	SB
8677Q NP	Sachets 24 g, 30	4	5	..	*2114.48	35.40	HCU gel	VF
8744F NP	Sachets 25 g, 30	4	5	..	*3098.48	35.40	HCU express 15	VF
9133Q NP	Oral liquid 130 mL, 30	4	5	..	*3098.48	35.40	HCU Cooler	VF
AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE, THREONINE and VALINE and low in ISOLEUCINE								
<u>Restricted benefit</u>								
Methylmalonic acidemia;								
Propionic acidemia.								
1923F NP	Oral liquid 130 mL, 30	4	5	..	*3098.48	35.40	MMA/PA cooler	VF
3443F NP	Sachets 25 g, 30	4	5	..	*3098.48	35.40	MMA/PA express 15	VF
3444G NP	Sachets 24 g, 30	4	5	..	*2114.48	35.40	MMA/PA gel	VF
8058D NP	Infant formula, powder 400 g	8	5	..	*769.40	35.40	MMA/PA Anamix infant	SB
8059E NP	Powder 500 g	8	5	..	*1784.84	35.40	XMTVI Maxamaid	SB
8061G NP	Powder 500 g	8	5	..	*2704.84	35.40	XMTVI Maxamum	SB
AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE								
<u>Restricted benefit</u>								
Phenylketonuria.								
1411G NP	Sachets 18.2 g, 60	3	5	..	*1640.17	35.40	add-ins	SB
1909L NP	Sachets 34 g, 30	4	5	..	*2054.12	35.40	PKU express 20	VF
2382J NP	Oral liquid 87 mL, 30	4	5	..	*1034.88	35.40	PKU Cooler 10	VF
2474F NP	Oral liquid 174 mL, 30	4	5	..	*2054.12	35.40	PKU Cooler 20	VF
2738D NP	Powder 500 g	8	5	..	*884.12	35.40	XP Maxamaid	SB
2739E NP	Powder 500 g	8	5	..	*1352.52	35.40	XP Maxamum	SB
5483N NP	Oral gel 85 g, 30	4	5	..	*1058.72	35.40	PKU squeezeie	VF
8545R NP	Powder 400 g	8	5	..	*848.68	35.40	Phenex-2	AB
8555G NP	Sachets 24 g, 30	4	5	..	*1058.72	35.40	PKU gel	VF
8591E NP	Sachets 25 g, 30	4	5	..	*1549.24	35.40	PKU express 15	VF
8613H NP	Sachets 29 g, 30	4	5	..	*892.20	35.40	PKU Anamix Junior	SB
8727H NP	Sachets 50 g, 30	3	5	..	*1512.16	35.40	XP Maxamum	SB
8746H NP	Oral liquid 250 mL	90	5	..	*1313.37	35.40	Easiphen	SB
8804J NP	Sachets 27.8 g, 30	3	5	..	*1549.54	35.40	Lophlex	SB
8846N	Oral liquid 130 mL, 30	4	5	..	*1548.44	35.40	PKU Cooler 15	VF

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<i>NP</i> 9021T	Oral liquid 125 mL, 30	3	5	..	*1549.54	35.40	PKU Lophlex LQ 20	SB
<i>NP</i> 9396M	Oral liquid 125 mL, 36	4	5	..	*1269.96	35.40	PKU Anamix Junior LQ	SB
<i>NP</i> 9397N	Oral liquid 62.5 mL, 60	2	5	..	*1059.46	35.40	PKU Lophlex LQ 10	SB

AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE

Restricted benefit

Tyrosinaemia.

<i>NP</i> 1547K	Oral liquid 125 mL, 30	3	5	..	*3098.44	35.40	TYR Lophlex LQ 20	SB
<i>NP</i> 3078B	Powder 500 g	8	5	..	*2704.84	35.40	XPhen, Tyr Maxamum	SB
<i>NP</i> 8445L	Infant formula, powder 400 g	8	5	..	*769.40	35.40	TYR Anamix infant	SB
<i>NP</i> 8446M	Powder 500 g	8	5	..	*1784.84	35.40	XPhen, Tyr Maxamaid	SB
<i>NP</i> 8631G	Sachets 24 g, 30	4	5	..	*2114.48	35.40	TYR gel	VF
<i>NP</i> 8667E	Sachets 25 g, 30	4	5	..	*3098.48	35.40	TYR express 15	VF
<i>NP</i> 9132P	Oral liquid 130 mL, 30	4	5	..	*3098.48	35.40	TYR Cooler	VF
<i>NP</i> 9395L	Sachets 29 g, 30	4	5	..	*1800.56	35.40	TYR Anamix Junior	SB

AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEUCINE

Restricted benefit

Maple syrup urine disease.

<i>NP</i> 1546J	Oral liquid 125 mL, 30	3	5	..	*3098.44	35.40	MSUD Lophlex LQ 20	SB
<i>NP</i> 1914R	Sachets 34 g, 30	4	5	..	*4094.24	35.40	MSUD express 20	VF
<i>NP</i> 2375B	Oral liquid 130 mL, 30	4	5	..	*3098.48	35.40	MSUD Cooler	VF
<i>NP</i> 2380G	Infant formula, powder 400 g	8	5	..	*769.40	35.40	MSUD Anamix infant	SB
<i>NP</i> 8057C	Powder 500 g	8	5	..	*2704.84	35.40	MSUD Maxamum	SB
<i>NP</i> 8260R	Powder 500 g	8	5	..	*1784.84	35.40	MSUD Maxamaid	SB
<i>NP</i> 8310J	Powder 500 g	4	5	..	*2672.08	35.40	MSUD AID III	SB
<i>NP</i> 8592F	Sachets 24 g, 30	4	5	..	*2114.48	35.40	MSUD gel	VF
<i>NP</i> 8632H	Sachets 25 g, 30	4	5	..	*3098.48	35.40	MSUD express 15	VF
<i>NP</i> 8745G	Sachets 29 g, 30	4	5	..	*1800.56	35.40	MSUD Anamix Junior	SB

AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEUCINE with FAT, CARBOHYDRATE and TRACE ELEMENTS and supplemented with DOCOSAHEXANOIC ACID

Restricted benefit

Maple syrup urine disease.

<i>NP</i> 9499Y	Oral liquid 125 mL, 36	4	5	..	*2508.08	35.40	MSUD Anamix Junior LQ	SB
--------------------	------------------------	---	---	----	----------	-------	--------------------------	----

ARGININE with CARBOHYDRATE

Restricted benefit

Urea cycle disorders.

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	Note Arginine with carbohydrate is not indicated for the treatment of arginase deficiency and other inborn errors of protein metabolism.							
5482M NP	Sachets 4 g containing 2 g arginine, 30	4	5	..	*770.92	35.40	Arginine 2000 Amino Acid Supplement	VF
9437Q NP	Sachets 4 g containing 500 mg arginine, 30	4	5	..	*516.12	35.40	Arginine Amino Acid Supplement	VF
CARBOHYDRATE, FAT, VITAMINS, MINERALS and TRACE ELEMENTS								
	Restricted benefit Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae.							
8369L NP	Powder 400 g	8	5	..	*318.28	35.40	Energivit	SB
CITRULLINE with CARBOHYDRATE								
	Restricted benefit Urea cycle disorders in order to prevent low plasma arginine or citrulline levels.							
	Note Citrulline with carbohydrate is not indicated for the treatment of arginase deficiency and other inborn errors of protein metabolism.							
5481L NP	Sachets 4 g containing 1 g citrulline, 30	4	5	..	*516.12	35.40	Citrulline 1000 Amino Acid Supplement	VF
CYSTINE with CARBOHYDRATE								
	Restricted benefit Pyridoxine non-responsive homocystinuria.							
9164H NP	Sachets 4 g containing 500 mg cystine, 30	4	5	..	*516.12	35.40	Cystine Amino Acid Supplement	VF
ESSENTIAL AMINO ACIDS FORMULA								
	Restricted benefit Gyrate atrophy of the choroid and retina; Urea cycle disorders.							
9329B NP	Powder 200 g	6	5	..	*1200.64	35.40	Essential Amino Acid Mix	SB
ESSENTIAL AMINO ACIDS FORMULA with MINERALS and VITAMIN C								
	Restricted benefit Gyrate atrophy of the choroid and retina; Urea cycle disorders.							
2027Q NP	Powder 400 g	5	5	..	*634.27	35.40	Dialamine	SB
ESSENTIAL AMINO ACIDS FORMULA with VITAMINS and MINERALS								
	Restricted benefit Gyrate atrophy of the choroid and retina; Urea cycle disorders.							
9385Y NP	Sachets 12.5 g, 50	4	5	..	*1516.60	35.40	EAA Supplement	VF
HIGH FAT FORMULA with VITAMINS, MINERALS and TRACE ELEMENTS and low in PROTEIN and CARBOHYDRATE								
	Restricted benefit Patients with intractable seizures requiring treatment with a ketogenic diet; Glucose transport protein defects; Pyruvate dehydrogenase deficiency.							

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Note KetoCal should only be used under strict supervision of a dietician, together with a metabolic physician and/or neurologist.								
Note Authorities for increased maximum quantities, up to a maximum of 48, may be authorised.								
9446E NP	Powder 300 g	24	5	..	*1037.56	35.40	KetoCal	SB
ISOLEUCINE with CARBOHYDRATE Restricted benefit Maple syrup urine disease.								
9134R NP	Sachets 4 g containing 50 mg isoleucine, 30	4	5	..	*516.12	35.40	Isoleucine Amino Acid Supplement	VF
9436P NP	Sachets 4 g containing 1 g isoleucine, 30	4	5	..	*567.08	35.40	Isoleucine 1000 Amino Acid Supplement	VF
MILK PROTEIN and FAT FORMULA with VITAMINS and MINERALS—CARBOHYDRATE FREE Restricted benefit Patients with intractable seizures requiring treatment with a ketogenic diet; Glucose transport protein defects; Pyruvate dehydrogenase deficiency; Infants and young children with glucose-galactose intolerance and multiple monosaccharide intolerance.								
8630F NP	Powder 225 g	24	5	..	*648.52	35.40	Carbohydrate Free Mixture	SB
PHENYLALANINE with CARBOHYDRATE Restricted benefit Tyrosinaemia.								
9384X NP	Sachets 4 g containing 50 mg phenylalanine, 30	4	5	..	*516.12	35.40	Phenylalanine Amino Acid Supplement	VF
SOY PROTEIN and FAT FORMULA with VITAMINS and MINERALS—CARBOHYDRATE FREE Restricted benefit Patients with intractable seizures requiring treatment with a ketogenic diet; Glucose transport protein defects; Pyruvate dehydrogenase deficiency; Infants and young children with glucose-galactose intolerance and multiple monosaccharide intolerance.								
8577K NP	Liquid 384 mL	120	5	..	*670.12	35.40	RCF	AB
TRIGLYCERIDES, LONG CHAIN with GLUCOSE POLYMER Restricted benefit Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae.								
9308X NP	Oral liquid 250 mL, 18	6	5	..	*339.88	35.40	ProZero	VF
9309Y NP	Oral liquid 1 L, 6	4	5	..	*304.12	35.40	ProZero	VF
TRIGLYCERIDES, MEDIUM CHAIN and LONG CHAIN with GLUCOSE POLYMER Restricted benefit Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae.								
3136C NP	Compound powder 400 g	8	5	..	*295.64	35.40	Duocal	SB

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
TRIGLYCERIDES—MEDIUM CHAIN, FORMULA								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
<u>Authority required</u>								
Chylous ascites;								
Chylothorax;								
Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders;								
Hyperlipoproteinaemia type 1;								
Long chain fatty acid oxidation disorders.								
<u>Note</u>								
MCT Pro-Cal is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.								
9383W NP	Sachets 16 g, 30	4	5	..	*253.72	35.40	MCT Pro-Cal	VF
TYROSINE with CARBOHYDRATE								
<u>Restricted benefit</u>								
Phenylketonuria.								
9165J NP	Sachets 4 g containing 1 g tyrosine, 30	4	5	..	*516.12	35.40	Tyrosine Amino Acid Supplement	VF
VALINE with CARBOHYDRATE								
<u>Restricted benefit</u>								
Maple syrup urine disease.								
9135T NP	Sachets 4 g containing 50 mg valine, 30	4	5	..	*516.12	35.40	Valine Amino Acid Supplement	VF
9434M NP	Sachets 4 g containing 1 g valine, 30	4	5	..	*567.08	35.40	Valine 1000 Amino Acid Supplement	VF
VITAMINS, MINERALS and TRACE ELEMENTS with CARBOHYDRATE								
<u>Authority required</u>								
Infants and children whose vitamin and mineral intake is insufficient due to a specific diagnosis requiring a highly restrictive therapeutic diet, and whose vitamin, mineral and trace element needs cannot be adequately met with other proprietary vitamin and mineral preparations.								
<u>Note</u>								
Paediatric Seravit should only be used under strict supervision of a dietitian and a paediatrician.								
9328Y NP	Powder 200 g	6	5	..	*390.52	35.40	Paediatric Seravit	SB
WHEY PROTEIN FORMULA supplemented with AMINO ACIDS, LONG CHAIN POLYUNSATURATED FATTY ACIDS, VITAMINS and MINERALS, and low in PROTEIN, PHOSPHATE, POTASSIUM and LACTOSE								
<u>Authority required</u>								
Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus diet, or a low protein, a low phosphorus and a low potassium diet.								
9382T NP	Sachets 100 g, 10	9	5	..	*1485.67	35.40	RenaStart	VF
WHEY PROTEIN FORMULA supplemented with AMINO ACIDS, VITAMINS and MINERALS, and low in PROTEIN, PHOSPHATE, POTASSIUM and LACTOSE								
<u>Authority required</u>								
Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus diet, or a low protein, a low phosphorus and a low potassium diet.								
8587Y NP	Powder 400 g	16	5	..	*1066.04	35.40	Kindergen	SB

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
All other non-therapeutic products							

All other non-therapeutic products
Solvents and diluting agents, incl. irrigating solutions

SODIUM CHLORIDE							
2026P NP	Injection 9 mg per mL (0.9%), 10 mL	5	1	..	8.22	9.33	Pfizer Australia Pty Ltd PF

Pharmaceutical Benefits for Palliative Care

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR
PATIENTS RECEIVING PALLIATIVE CARE**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		

Alimentary tract and metabolism

Stomatological preparations

Stomatological preparations

Other agents for local oral treatment

BENZYDAMINE HYDROCHLORIDE

Authority required (STREAMLINED)

3634

Initial supply, for up to 4 months, for a palliative care patient where a painful mouth is a problem.

5385K NP	Mouth and throat rinse 22.5 mg per 15 mL, 500 mL	£1	3	..	22.36	23.47	Diffiam	IA
-------------	---	----	---	----	-------	-------	---------	----

BENZYDAMINE HYDROCHLORIDE

Authority required (STREAMLINED)

3635

Continuing supply for a palliative care patient where a painful mouth is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5386L NP	Mouth and throat rinse 22.5 mg per 15 mL, 500 mL	£1	22.36	23.47	Diffiam	IA
-------------	---	----	----	----	-------	-------	---------	----

CARMELLOSE SODIUM

Authority required (STREAMLINED)

3636

Initial supply, for up to 4 months, for a palliative care patient where dry mouth is a symptom.

5333Q NP	Mouth spray 10 mg per mL, 25 mL	£1	3	..	10.89	12.00	Aquae	VT
5334R NP	Mouth spray 10 mg per mL, 100 mL	£1	3	..	12.56	13.67	Aquae	VT

CARMELLOSE SODIUM

Authority required (STREAMLINED)

3637

Continuing supply for a palliative care patient where dry mouth is a symptom.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5335T NP	Mouth spray 10 mg per mL, 25 mL	£1	10.89	12.00	Aquae	VT
5336W NP	Mouth spray 10 mg per mL, 100 mL	£1	12.56	13.67	Aquae	VT

HYPROMELLOSE

Authority required (STREAMLINED)

3636

Initial supply, for up to 4 months, for a palliative care patient where dry mouth is a symptom.

5421H NP	Oral gel 20 mg per g, 100 g	£1	3	..	12.75	13.86	Aquae Gel	VT
-------------	-----------------------------	----	---	----	-------	-------	-----------	----

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
HYPROMELLOSE							
<u>Authority required (STREAMLINED)</u>							
3637							
Continuing supply for a palliative care patient where dry mouth is a symptom.							
<u>Note</u>							
Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.							
5422J NP	Oral gel 20 mg per g, 100 g	\$1	12.75	13.86	Aquae Gel VT

Drugs for functional gastrointestinal disorders

Belladonna and derivatives, plain

Belladonna alkaloids semisynthetic, quaternary ammonium compounds

HYOSCINE BUTYLBROMIDE

Authority required (STREAMLINED)

3638

Initial supply, for up to 4 months, for a palliative care patient where colicky pain is a symptom.

5317W NP	Injection 20 mg in 1 mL	30	3	..	*108.64	35.40	Buscopan	BY
-------------	-------------------------	----	---	----	---------	-------	----------	----

HYOSCINE BUTYLBROMIDE

Authority required (STREAMLINED)

3639

Continuing supply for a palliative care patient where colicky pain is a symptom.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5318X NP	Injection 20 mg in 1 mL	30	*108.64	35.40	Buscopan	BY
-------------	-------------------------	----	----	----	---------	-------	----------	----

Laxatives

Laxatives

Contact laxatives

BISACODYL

Authority required (STREAMLINED)

3642

Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem.

5301B NP	Tablet 5 mg	200	3	..	14.21	15.32	Bisalax	AS
							Lax-Tab	AE
5303D NP	Suppositories 10 mg, 10	3	3	..	*21.04	22.15	^a Petrus Bisacodyl Suppositories	PP
				^B 1.50	*22.54	22.15	^a Dulcolax	BY
5304E NP	Suppositories 10 mg, 12	3	3	..	*18.43	19.54	Petrus Bisacodyl Suppositories	PP

BISACODYL

Authority required (STREAMLINED)

3643

Continuing supply for a palliative care patient where constipation is a problem.

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
	Note Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.						
5305F NP	Tablet 5 mg	200	14.21	15.32	Bisalax AS
							Lax-Tab AE
5307H NP	Suppositories 10 mg, 10	3	*21.04	22.15 ^a	Petrus Bisacodyl Suppositories PP
				^B 1.50	*22.54	22.15 ^a	Dulcolax BY
5308J NP	Suppositories 10 mg, 12	3	*18.43	19.54	Petrus Bisacodyl Suppositories PP

Bulk producers

STERCULIA with FRANGULA BARK

Authority required (STREAMLINED)

3642

Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem.

5322D NP	Granules 620 mg-80 mg per g (62%-8%), 500 g	±1	3	..	26.47	27.58	Normacol Plus	NE
-------------	---	----	---	----	-------	-------	---------------	----

STERCULIA with FRANGULA BARK

Authority required (STREAMLINED)

3643

Continuing supply for a palliative care patient where constipation is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5324F NP	Granules 620 mg-80 mg per g (62%-8%), 500 g	±1	26.47	27.58	Normacol Plus	NE
-------------	---	----	----	----	-------	-------	---------------	----

Osmotically acting laxatives

LACTULOSE

Authority required (STREAMLINED)

3642

Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem.

5387M NP	Mixture 3.34 g per 5 mL, 500 mL	3	3	..	*23.29	24.40	^a Actilax	AF
							^a Genlac	QA
							^a GenRx Lactulose	GX
							^a Lac-Dol	GM
							^a Lactocur	SZ
				^B 3.60	*26.89	24.40	^a Duphalac	AB

LACTULOSE

Authority required (STREAMLINED)

3643

Continuing supply for a palliative care patient where constipation is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5388N NP	Mixture 3.34 g per 5 mL, 500 mL	3	*23.29	24.40	^a Actilax	AF
							^a Genlac	QA
							^a GenRx Lactulose	GX

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

						Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer		
							^a	Lac-Dol	GM
							^a	Lactocur	SZ
				^B 3.60	*26.89	24.40	^a	Duphalac	AB

MACROGOL 3350

Authority required (STREAMLINED)

3642

Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem.

5389P NP	Sachets containing powder for solution 13.125 g with electrolytes, 30	2	3	..	*34.78	35.40		Movicol	NE
5426N NP	Powder for oral solution 510 g	2	3	..	*34.78	35.40	^a	MediHealth ClearLax	ON
							^a	OsmoLax	KY
							^a	your pharmacy Clear Laxative	OY

MACROGOL 3350

Authority required (STREAMLINED)

3643

Continuing supply for a palliative care patient where constipation is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5390Q NP	Sachets containing powder for solution 13.125 g with electrolytes, 30	2	*34.78	35.40		Movicol	NE
5427P NP	Powder for oral solution 510 g	2	*34.78	35.40	^a	MediHealth ClearLax	ON
							^a	OsmoLax	KY
							^a	your pharmacy Clear Laxative	OY

Enemas

BISACODYL

Authority required (STREAMLINED)

3642

Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem.

5302C NP	Enemas 10 mg in 5 mL, 25	£1	3	..	38.04	35.40		Bisalax	AS
-------------	--------------------------	----	---	----	-------	-------	--	---------	----

BISACODYL

Authority required (STREAMLINED)

3643

Continuing supply for a palliative care patient where constipation is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5306G NP	Enemas 10 mg in 5 mL, 25	£1	38.04	35.40		Bisalax	AS
-------------	--------------------------	----	----	----	-------	-------	--	---------	----

SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE

Authority required (STREAMLINED)

3642

Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem.

5331N NP	Enemas 3.125 g-450 mg-45 mg in 5 mL, 12	2	3	..	*32.38	33.49	^a	Micolette	AE
-------------	---	---	---	----	--------	-------	--------------	-----------	----

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
						^a	Microlax	JT

SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE

Authority required (STREAMLINED)

3643

Continuing supply for a palliative care patient where constipation is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5332P NP	Enemas 3.125 g-450 mg-45 mg in 5 mL, 12	2	*32.38	33.49	^a	Micolette	AE
							^a	Microlax	JT

Peripheral opioid receptor antagonists

METHYLNALTREXONE

Authority required

Initial supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has failed to respond to laxatives.

Note

No applications for repeats will be authorised.

Note

Special Pricing Arrangements apply.

5423K NP	Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL	3	*130.69	35.40		Relistor	LM
-------------	---	---	----	----	---------	-------	--	----------	----

METHYLNALTREXONE

Authority required

Continuing supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has demonstrated a response to methylnaltrexone.

Note

For first continuing supply, applications for increased repeats may be authorised.

Where consultation with a palliative care specialist or service has occurred, applications for increased repeats may be authorised.

Note

Special Pricing Arrangements apply.

5424L NP	Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL	7	287.94	35.40		Relistor	LM
-------------	---	---	----	----	--------	-------	--	----------	----

Other laxatives

GLYCEROL

Authority required (STREAMLINED)

3642

Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem.

5311M NP	Suppositories 700 mg (for infants), 12	3	3	..	*19.57	20.68		Petrus Pharmaceuticals Pty Ltd	PP
5312N NP	Suppositories 1.4 g (for children), 12	3	3	..	*19.99	21.10		Petrus Pharmaceuticals Pty Ltd	PP
5313P NP	Suppositories 2.8 g (for adults), 12	3	3	..	*20.50	21.61		Petrus Pharmaceuticals Pty Ltd	PP

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
GLYCEROL								
<u>Authority required (STREAMLINED)</u>								
3643								
Continuing supply for a palliative care patient where constipation is a problem.								
<u>Note</u>								
Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.								
5314Q NP	Suppositories 700 mg (for infants), 12	3	*19.57	20.68	Petrus Pharmaceuticals Pty Ltd	PP
5315R NP	Suppositories 1.4 g (for children), 12	3	*19.99	21.10	Petrus Pharmaceuticals Pty Ltd	PP
5316T NP	Suppositories 2.8 g (for adults), 12	3	*20.50	21.61	Petrus Pharmaceuticals Pty Ltd	PP

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR
PATIENTS RECEIVING PALLIATIVE CARE**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Musculo-skeletal system

Antiinflammatory and antirheumatic products

Antiinflammatory and antirheumatic products, non-steroids

Acetic acid derivatives and related substances

DICLOFENAC SODIUM

Authority required (STREAMLINED)

3645

Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem.

5361E NP	Tablet 25 mg (enteric coated)	100	3	..	*12.84	13.95	^a	APO-Diclofenac	TX							
							^a	Chem mart Diclofenac	CH							
							^a	Clonac 25	QA							
							^a	Diclofenac-GA	GM							
							^a	Diclofenac Sandoz	SZ							
							^a	Fenac 25	AF							
							^a	Terry White Chemists Diclofenac	TW							
							^a	Voltaren 25	NV							
							5362F NP	Tablet 50 mg (enteric coated)	50	3	..	10.92	12.03	^a	APO-Diclofenac	TX
														^a	Chem mart Diclofenac	CH
^a	Clonac 50	QA														
^a	Diclofenac-GA	GM														
^a	Diclofenac Sandoz	SZ														
^a	Fenac	AF														
^a	Terry White Chemists Diclofenac	TW														
^a	Voltaren 50	NV														
				^B 2.32	*15.16	13.95								^a	Voltaren 25	NV
				^B 2.34	13.26	12.03								^a	Voltaren 50	NV

DICLOFENAC SODIUM

Authority required

Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem.

5363G NP	Suppository 100 mg	40	3	..	*25.02	26.13		Voltaren 100	NV
-------------	--------------------	----	---	----	--------	-------	--	--------------	----

DICLOFENAC SODIUM

Authority required (STREAMLINED)

3646

Continuing supply for a palliative care patient where severe pain is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5364H NP	Tablet 25 mg (enteric coated)	100	*12.84	13.95	^a	APO-Diclofenac	TX
							^a	Chem mart	CH
							^a	Diclofenac	
							^a	Clonac 25	QA
							^a	Diclofenac-GA	GM

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR
PATIENTS RECEIVING PALLIATIVE CARE**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
5365J NP	Tablet 50 mg (enteric coated)	50	10.92	12.03	^a Diclofenac Sandoz	SZ
							^a Fenac 25	AF
							^a Terry White Chemists	TW
							^a Diclofenac	
							^a Voltaren 25	NV
							^a APO-Diclofenac	TX
							^a Chem mart	CH
							^a Diclofenac	
							^a Clonac 50	QA
							^a Diclofenac-GA	GM
							^a Diclofenac Sandoz	SZ
							^a Fenac	AF
							^a Terry White Chemists	TW
							^a Diclofenac	
							^a Voltaren 50	NV

DICLOFENAC SODIUM

Authority required

Continuing supply for a palliative care patient where severe pain is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5366K NP	Suppository 100 mg	40	*25.02	26.13	Voltaren 100	NV
-------------	--------------------	----	----	----	--------	-------	--------------	----

INDOMETHACIN

Authority required (STREAMLINED)

3645

Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem.

5377B NP	Capsule 25 mg	100	3	..	*12.52	13.63	^a Arthrexin	AF
				^B 2.02	*14.54	13.63	^a Indocid	AS

INDOMETHACIN

Authority required

Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem.

5378C NP	Suppository 100 mg	40	3	..	*22.60	23.71	Indocid	AS
-------------	--------------------	----	---	----	--------	-------	---------	----

INDOMETHACIN

Authority required (STREAMLINED)

3646

Continuing supply for a palliative care patient where severe pain is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5379D NP	Capsule 25 mg	100	*12.52	13.63	^a Arthrexin	AF
				^B 2.02	*14.54	13.63	^a Indocid	AS

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer		
<hr/>									
INDOMETHACIN									
<u>Authority required</u>									
Continuing supply for a palliative care patient where severe pain is a problem.									
<u>Note</u>									
Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.									
5380E NP	Suppository 100 mg	40	*22.60	23.71	Indocid	AS	
<hr/>									
Propionic acid derivatives									
IBUPROFEN									
<u>Authority required</u>									
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem.									
5368M NP	Tablet 400 mg	90	3	..	*14.83	15.94	Brufen	AB	
<hr/>									
IBUPROFEN									
<u>Authority required</u>									
Continuing supply for a palliative care patient where severe pain is a problem.									
<u>Note</u>									
Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.									
5370P NP	Tablet 400 mg	90	*14.83	15.94	Brufen	AB	
<hr/>									
NAPROXEN									
<u>Authority required (STREAMLINED)</u>									
3645									
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem.									
5345H NP	Tablet 250 mg	100	3	..	*13.44	14.55	^a Inza 250	AF	
5346J NP	Tablet 500 mg	50	3		^B 2.24	*15.68	14.55	^a Naprosyn	RO
				..	12.68	13.79	^a Inza 500	AF	
5347K NP	Tablet 750 mg (sustained release)	28	3		^B 1.30	13.98	13.79	^a Naprosyn	RO
				..	12.18	13.29	^a Proxen SR 750	MD	
5348L NP	Tablet 1 g (sustained release)	28	3		^B 1.22	13.40	13.29	^a Naprosyn SR750	RO
				..	14.06	15.17	^a Proxen SR 1000	MD	
					^B 1.29	15.35	15.17	^a Naprosyn SR1000	RO
<hr/>									
NAPROXEN									
<u>Authority required (STREAMLINED)</u>									
3646									
Continuing supply for a palliative care patient where severe pain is a problem.									
<u>Note</u>									
Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.									
5349M NP	Tablet 250 mg	100	*13.44	14.55	^a Inza 250	AF	
5350N	Tablet 500 mg	50	..		^B 2.24	*15.68	14.55	^a Naprosyn	RO
				..	12.68	13.79	^a Inza 500	AF	

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR
PATIENTS RECEIVING PALLIATIVE CARE**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer
<i>NP</i>				^B 1.30	13.98	13.79	^a	Naprosyn RO
5351P <i>NP</i>	Tablet 750 mg (sustained release)	28	12.18	13.29	^a	Proxen SR 750 MD
				^B 1.22	13.40	13.29	^a	Naprosyn SR750 RO
5352Q <i>NP</i>	Tablet 1 g (sustained release)	28	14.06	15.17	^a	Proxen SR 1000 MD
				^B 1.29	15.35	15.17	^a	Naprosyn SR1000 RO

NAPROXEN SODIUM**Authority required (STREAMLINED)****3645**

Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem.

Note

Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.

5353R <i>NP</i>	Tablet 550 mg	50	3	..	12.87	13.98	^a	Crysanal MD
				^B 2.17	15.04	13.98	^a	Anaprox 550 RO

NAPROXEN SODIUM**Authority required (STREAMLINED)****3646**

Continuing supply for a palliative care patient where severe pain is a problem.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

Note

Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.

5354T <i>NP</i>	Tablet 550 mg	50	12.87	13.98	^a	Crysanal MD
				^B 2.17	15.04	13.98	^a	Anaprox 550 RO

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Nervous system

Analgesics

Opioids

Natural opium alkaloids

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Authority required

Initial supply, for up to 3 months, for a palliative care patient with severe disabling pain not responding to non-narcotic analgesics.

Note

Telephone approvals are limited to 1 month's therapy.

5393W NP	Tablet 10 mg	20	2	..	14.41	15.52	Sevredol	MF
5394X NP	Tablet 20 mg	20	2	..	15.36	16.47	Sevredol	MF

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Authority required

Continuing supply for a palliative care patient with severe disabling pain not responding to non-narcotic analgesics.

Note

Where consultation with a palliative care specialist or service has occurred, applications for increased repeats for up to 3 months' supply may be authorised.

Telephone approvals are limited to 1 month's therapy.

5395Y NP	Tablet 10 mg	20	14.41	15.52	Sevredol	MF
5396B NP	Tablet 20 mg	20	15.36	16.47	Sevredol	MF

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Authority required

Initial supply, for up to 3 months, for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Telephone approvals are limited to 1 month's therapy.

5391R NP	Tablet 200 mg (controlled release)	28	2	..	121.96	35.40	MS Contin	MF
-------------	------------------------------------	----	---	----	--------	-------	-----------	----

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Authority required

Continuing supply for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Where consultation with a palliative care specialist or service has occurred, applications for increased repeats for up to 3 months' supply may be authorised.

Telephone approvals are limited to 1 month's therapy.

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
5392T NP	Tablet 200 mg (controlled release)	28	121.96	35.40	MS Contin	MF

Phenylpiperidine derivatives

FENTANYL

Caution

The risk of drug dependence is high.

Authority required

Initial supply for dose titration for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects.

Note

No applications for increased repeats will be authorised.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

Special Pricing Arrangements apply.

5401G NP	Lozenge 200 micrograms (as citrate)	9	115.69	35.40	Actiq	OA
5402H NP	Lozenge 400 micrograms (as citrate)	9	115.69	35.40	Actiq	OA
5403J NP	Lozenge 600 micrograms (as citrate)	9	115.69	35.40	Actiq	OA
5404K NP	Lozenge 800 micrograms (as citrate)	9	115.69	35.40	Actiq	OA
5405L NP	Lozenge 1200 micrograms (as citrate)	9	115.69	35.40	Actiq	OA
5406M NP	Lozenge 1600 micrograms (as citrate)	9	115.69	35.40	Actiq	OA

FENTANYL

Caution

The risk of drug dependence is high.

Authority required

Continuing supply for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects.

Note

For first continuing supply, applications for increased repeats for up to 3 months' supply may be authorised.

Where consultation with a palliative care specialist or service has occurred, applications for increased repeats for up to 3 months' supply may be authorised.

Telephone approvals are limited to 1 month's therapy.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

Special Pricing Arrangements apply.

5407N NP	Lozenge 200 micrograms (as citrate)	60	*680.23	35.40	Actiq	OA
5408P NP	Lozenge 400 micrograms (as citrate)	60	*680.23	35.40	Actiq	OA
5409Q NP	Lozenge 600 micrograms (as citrate)	60	*680.23	35.40	Actiq	OA
5410R NP	Lozenge 800 micrograms (as citrate)	60	*680.23	35.40	Actiq	OA
5411T NP	Lozenge 1200 micrograms (as citrate)	60	*680.23	35.40	Actiq	OA
5412W	Lozenge 1600 micrograms (as citrate)	60	*680.23	35.40	Actiq	OA

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Diphenylpropylamine derivatives

METHADONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Authority required

Initial supply, for up to 3 months, for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Telephone approvals are limited to 1 month's therapy.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

5399E NP	Oral liquid 25 mg per 5 mL, 200 mL	1	2	..	19.02	20.13	Sigma Methadone Syrup	QA
-------------	------------------------------------	---	---	----	-------	-------	-----------------------	----

METHADONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Authority required

Continuing supply for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Where consultation with a palliative care specialist or service has occurred, applications for increased repeats for up to 3 months' supply may be authorised.

Telephone approvals are limited to 1 month's therapy.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

5400F NP	Oral liquid 25 mg per 5 mL, 200 mL	1	19.02	20.13	Sigma Methadone Syrup	QA
-------------	------------------------------------	---	----	----	-------	-------	-----------------------	----

Other analgesics and antipyretics

Anilides

PARACETAMOL

Authority required (STREAMLINED)

3649

Initial supply, for up to 4 months, for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated.

5319Y NP	Suppositories 500 mg, 24	4	3	..	*84.56	35.40	Panadol	GC
5343F NP	Tablet 665 mg (modified release)	192	3	..	*16.74	17.85	Panadol Osteo	GC

PARACETAMOL

Authority required (STREAMLINED)

3650

Continuing supply for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated.

Note

Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred.

5320B NP	Suppositories 500 mg, 24	4	*84.56	35.40	Panadol	GC
5344G NP	Tablet 665 mg (modified release)	192	*16.74	17.85	Panadol Osteo	GC

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for		Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$		

Antiepileptics

Antiepileptics

Benzodiazepine derivatives

CLONAZEPAM

Authority required

Initial supply, for up to 4 months, for a palliative care patient for the prevention of epilepsy.

Note

No applications for increased repeats will be authorised.

5337X NP	Tablet 500 micrograms	100	3	..	13.06	14.17	^a	Paxam 0.5	AF
				^B 1.71	14.77	14.17	^a	Rivotril	RO
5338Y NP	Tablet 2 mg	100	3	..	18.84	19.95	^a	Paxam 2	AF
				^B 1.93	20.77	19.95	^a	Rivotril	RO
5339B NP	Oral liquid 2.5 mg per mL, 10 mL	2	3	..	*15.14	16.25		Rivotril	RO

CLONAZEPAM

Authority required

Continuing supply for a palliative care patient for the prevention of epilepsy.

Note

Where consultation with a palliative care specialist or service has occurred, applications for increased repeats may be authorised.

5340C NP	Tablet 500 micrograms	100	13.06	14.17	^a	Paxam 0.5	AF
				^B 1.71	14.77	14.17	^a	Rivotril	RO
5341D NP	Tablet 2 mg	100	18.84	19.95	^a	Paxam 2	AF
				^B 1.93	20.77	19.95	^a	Rivotril	RO
5342E NP	Oral liquid 2.5 mg per mL, 10 mL	2	*15.14	16.25		Rivotril	RO

Psycholeptics

Anxiolytics

Benzodiazepine derivatives

DIAZEPAM

Authority required

Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem.

Note

No applications for increased repeats will be authorised.

5355W NP	Tablet 2 mg	50	3	..	7.82	8.93	^a	Antenex 2	AF
								APO-Diazepam	TX
								Ranzepam	RA
								Valpam 2	QA
								Valium	RO
5356X NP	Tablet 5 mg	50	3	..	7.95	9.06	^a	Antenex 5	AF
								APO-Diazepam	TX
								Diazepam-GA	GM
								Ranzepam	RA
								Valpam 5	QA
				^B 0.85	8.80	9.06	^a	Valium	RO

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR
PATIENTS RECEIVING PALLIATIVE CARE**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer
<hr/>								
DIAZEPAM								
<u>Authority required</u>								
Continuing supply for a palliative care patient where anxiety is a problem.								
<u>Note</u>								
Where consultation with a palliative care specialist or service has occurred, applications for increased repeats may be authorised.								
5357Y NP	Tablet 2 mg	50	7.82	8.93	^a	Antenex 2 AF
							^a	APO-Diazepam TX
							^a	Ranzepam RA
							^a	Valpam 2 QA
				^B 0.82	8.64	8.93	^a	Valium RO
5358B NP	Tablet 5 mg	50	7.95	9.06	^a	Antenex 5 AF
							^a	APO-Diazepam TX
							^a	Diazepam-GA GM
							^a	Ranzepam RA
							^a	Valpam 5 QA
				^B 0.85	8.80	9.06	^a	Valium RO
<hr/>								
OXAZEPAM								
<u>Authority required</u>								
Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem.								
<u>Note</u>								
No applications for increased repeats will be authorised.								
5371Q NP	Tablet 15 mg	50	3	..	*8.98	10.09	^a	Alepam 15 AF
				^B 5.38	*14.36	10.09	^a	Serepax QA
5372R NP	Tablet 30 mg	50	3	..	*8.98	10.09	^a	Alepam 30 AF
							^a	APO-Oxazepam TX
							^a	Murelax FM
				^B 5.38	*14.36	10.09	^a	Serepax QA
<hr/>								
OXAZEPAM								
<u>Authority required</u>								
Continuing supply for a palliative care patient where anxiety is a problem.								
<u>Note</u>								
Where consultation with a palliative care specialist or service has occurred, applications for increased repeats may be authorised.								
5373T NP	Tablet 15 mg	50	*8.98	10.09	^a	Alepam 15 AF
				^B 5.38	*14.36	10.09	^a	Serepax QA
5374W NP	Tablet 30 mg	50	*8.98	10.09	^a	Alepam 30 AF
							^a	APO-Oxazepam TX
							^a	Murelax FM
				^B 5.38	*14.36	10.09	^a	Serepax QA

PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer	
Hypnotics and sedatives									
<i>Benzodiazepine derivatives</i>									
NITRAZEPAM									
<u>Authority required</u>									
Initial supply, for up to 4 months, for a palliative care patient where insomnia is a problem.									
<u>Note</u>									
No applications for increased repeats will be authorised.									
5359C NP	Tablet 5 mg	50	3	..	*9.32	10.43	^a	Alodorm	AF
				^B 2.90	*12.22	10.43	^a	Mogadon	VT
NITRAZEPAM									
<u>Authority required</u>									
Continuing supply for a palliative care patient where insomnia is a problem.									
<u>Note</u>									
Where consultation with a palliative care specialist or service has occurred, applications for increased repeats may be authorised.									
5360D NP	Tablet 5 mg	50	*9.32	10.43	^a	Alodorm	AF
				^B 2.90	*12.22	10.43	^a	Mogadon	VT
TEMAZEPAM									
<u>Authority required</u>									
Initial supply, for up to 4 months, for a palliative care patient where insomnia is a problem.									
<u>Note</u>									
No applications for increased repeats will be authorised.									
5375X NP	Tablet 10 mg	50	3	..	*8.60	9.71	^a	APO-Temazepam	TX
							^a	Temaze	AF
							^a	Temtabs	FM
				^B 4.10	*12.70	9.71	^a	Normison	QA
TEMAZEPAM									
<u>Authority required</u>									
Continuing supply for a palliative care patient where insomnia is a problem.									
<u>Note</u>									
Where consultation with a palliative care specialist or service has occurred, applications for increased repeats may be authorised.									
5376Y NP	Tablet 10 mg	50	*8.60	9.71	^a	APO-Temazepam	TX
							^a	Temaze	AF
							^a	Temtabs	FM
				^B 4.10	*12.70	9.71	^a	Normison	QA

Pharmaceutical Benefits for Dental Use

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		

Alimentary tract and metabolism

Stomatological preparations

Stomatological preparations

Antiinfectives and antiseptics for local oral treatment

AMPHOTERICIN								
3306B	Lozenge 10 mg	20	12.13	13.24	Fungilin	QA
NYSTATIN								
3343Y	Oral suspension 100,000 units per mL, 24 mL	¥1	11.24	12.35	Mycostatin	FM
							Nilstat	QA

Other agents for local oral treatment

BENZYDAMINE HYDROCHLORIDE								
<u>Restricted benefit</u>								
Radiation induced mucositis.								
5032W	Mouth and throat rinse 22.5 mg per 15 mL, 500 mL	¥1	22.36	23.47	Difflam	IA

Drugs for functional gastrointestinal disorders

Belladonna and derivatives, plain

Belladonna alkaloids, tertiary amines

ATROPINE								
5022H	Injection containing atropine sulfate 600 micrograms in 1 mL	10	20.64	21.75	Pfizer Australia Pty Ltd	PF

Propulsives

Propulsives

METOCLOPRAMIDE HYDROCHLORIDE								
5151D	Tablet 10 mg	25	8.30	9.41	Pramin	AF
				^B 3.02	11.32	9.41	Maxolon	VT
5153F	Injection 10 mg in 2 mL	10	13.09	14.20	Maxolon	VT

Antiemetics and antinauseants

Antiemetics and antinauseants

Other antiemetics

PROCHLORPERAZINE								
<u>Caution</u>								
Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.								
5205Y	Tablet containing prochlorperazine maleate 5 mg	25	8.79	9.90	^a APO-Prochlorperazine	TX
							^a Pharmacor Prozine 5	CR
							^a ProCalm	QA
							^a Prochlorperazine-GA	GM
							^a Prochlorperazine GH	GQ
							^a Prochlorperazine-PS	FZ

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
							^a Stemzine	AV
				^B 2.57	11.36	9.90	^a Stemetil	SW
5206B	Injection containing prochlorperazine mesylate 12.5 mg in 1 mL	10	16.92	18.03	Stemetil	SW
5208D	Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5	1	20.03	21.14	Stemetil	SW
PROMETHAZINE HYDROCHLORIDE								
3374N	Injection 50 mg in 2 mL	10	*22.42	23.53	Hospira Pty Limited	HH

Antidiarrheals, intestinal antiinflammatory/ antiinfective agents

Intestinal antiinfectives

Antibiotics

NYSTATIN

3342X	Tablet 500,000 units	50	18.08	19.19	Nilstat	QA
3345C	Capsule 500,000 units	50	18.08	19.19	Nilstat	QA

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable		Brand Name and Manufacturer
					Max. Qty \$	Value for Safety Net \$		

Blood and blood forming organs

Blood substitutes and perfusion solutions

I.V. solutions

Solutions for parenteral nutrition

GLUCOSE

5005K	I.V. infusion 139 mmol (anhydrous) per 500 mL (5%), 500 mL	5	*17.97	19.08	^a	B. Braun Australia Pty Ltd	BR
							^a	Fresenius Kabi Australia Pty Limited	PK
5106R	I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L	5	*22.92	24.03	^a	B. Braun Australia Pty Ltd	BR
							^a	Baxter Healthcare Pty Ltd	BX
							^a	Fresenius Kabi Australia Pty Limited	PK

Solutions affecting the electrolyte balance

SODIUM CHLORIDE

5021G	I.V. infusion 77 mmol per 500 mL (0.9%), 500 mL	5	*13.12	14.23	^a	B. Braun Australia Pty Ltd	BR
							^a	Fresenius Kabi Australia Pty Limited	PK
5212H	I.V. infusion 154 mmol per L (0.9%), 1 L	5	*16.02	17.13	^a	B. Braun Australia Pty Ltd	BR
							^a	Baxter Healthcare Pty Ltd	BX
							^a	Fresenius Kabi Australia Pty Limited	PK
5213J	I.V. infusion 513 mmol per L (3%), 1 L	2	*12.22	13.33		Baxter Healthcare Pty Ltd	BX

SODIUM CHLORIDE with GLUCOSE

5214K	I.V. infusion 31 mmol-222 mmol (anhydrous) per L (0.18%-4%), 1 L	5	*23.62	24.73		Baxter Healthcare Pty Ltd	BX
5215L	I.V. infusion 19 mmol-104 mmol (anhydrous) per 500 mL (0.225%-3.75%), 500 mL	5	*28.87	29.98		Baxter Healthcare Pty Ltd	BX
5216M	I.V. infusion 39 mmol-69 mmol (anhydrous) per 500 mL (0.45%-2.5%), 500 mL	5	*28.87	29.98		Baxter Healthcare Pty Ltd	BX

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Cardiovascular system

Cardiac therapy

Antiarrhythmics, class I and III

Antiarrhythmics, class IB

LIGNOCAINE HYDROCHLORIDE

5142P	Injection 100 mg in 5 mL	5	37.43	35.40	Pfizer Australia Pty Ltd	PF
-------	--------------------------	---	----	----	-------	-------	--------------------------	----

Cardiac stimulants excl. cardiac glycosides

Adrenergic and dopaminergic agents

ADRENALINE

5004J	Injection 1 mg in 1 mL (1 in 1,000)	5	20.44	21.55	Link Medical Products Pty Ltd	LM
-------	-------------------------------------	---	----	----	-------	-------	-------------------------------	----

Vasodilators used in cardiac diseases

Organic nitrates

GLYCERYL TRINITRATE

5108W	Tablets 600 micrograms, 100	±1	14.93	16.04 ^a	Lycinate	FM
				^B 2.94	17.87	16.04 ^a	Anginine Stabilised	QA

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Dermatologicals

Corticosteroids, dermatological preparations

Corticosteroids, plain

Corticosteroids, weak (group I)

HYDROCORTISONE ACETATE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

5111B	Cream 10 mg per g (1%), 30 g	‡1	8.99	10.10	^a	Cortic-DS 1%	FM
				^B 2.69	11.68	10.10	^a	Sigmacort	QA
5112C	Topical ointment 10 mg per g (1%), 30 g	‡1	8.99	10.10	^a	Cortic-DS 1%	FM
				^B 2.69	11.68	10.10	^a	Sigmacort	QA
5113D	Cream 10 mg per g (1%), 50 g	‡1	8.66	9.77	^a	Cortic-DS 1%	FM
				^B 2.70	11.36	9.77	^a	Sigmacort	QA
5114E	Topical ointment 10 mg per g (1%), 50 g	‡1	8.66	9.77	^a	Cortic-DS 1%	FM
				^B 2.70	11.36	9.77	^a	Sigmacort	QA

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Systemic hormonal preparations, excl. sex hormones and insulins

Corticosteroids for systemic use

Corticosteroids for systemic use, plain *Glucocorticoids*

BETAMETHASONE ACETATE with BETAMETHASONE SODIUM PHOSPHATE

Restricted benefit

For local intra-articular or peri-articular infiltration;

Keloid;

Lichen planus hypertrophic.

5034Y	Injection 3 mg-3.9 mg (equivalent to 5.7 mg betamethasone) in 1 mL	5	25.10	26.21	Celestone Chronodose	MK
-------	--	---	----	----	-------	-------	----------------------	----

HYDROCORTISONE SODIUM SUCCINATE

Restricted benefit

For use in a hospital.

5118J	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	6	*36.82	35.40	Solu-Cortef	PF
5119K	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	6	*58.84	35.40	Solu-Cortef	PF

METHYLPREDNISOLONE ACETATE

Restricted benefit

For local intra-articular or peri-articular infiltration.

5148Y	Injection 40 mg in 1 mL	5	21.48	22.59	^a Depo-Nisolone	FZ
				^B 0.96	22.44	22.59	^a Depo-Medrol	PF

TRIAMCINOLONE ACETONIDE

Restricted benefit

For local intra-articular or peri-articular infiltration;

Keloid;

Lichen planus hypertrophic.

5233K	Injection 10 mg in 1 mL	5	25.10	26.21	Kenacort-A10	QA
-------	-------------------------	---	----	----	-------	-------	--------------	----

Pancreatic hormones

Glycogenolytic hormones *Glycogenolytic hormones*

GLUCAGON HYDROCHLORIDE

5105Q	Injection set containing 1 mg (1 i.u.) and 1 mL solvent in disposable syringe	1	45.73	35.40	GlucaGen Hypokit	NO
-------	---	---	----	----	-------	-------	------------------	----

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Antiinfectives for systemic use

Antibacterials for systemic use

Tetracyclines

Tetracyclines

DOXYCYCLINE

Note

Pharmaceutical benefits that have the form doxycycline tablet 100 mg (as hydrochloride) and pharmaceutical benefits that have the form doxycycline tablet 100 mg (as monohydrate) are equivalent for the purposes of substitution.

3321T	Tablet 100 mg (as hydrochloride)	7	8.46	9.57	^a Doxsig	QA
							^a Doxy-100	GM
							^a Doxilyn 100	AF
5082L	Tablet 100 mg (as monohydrate)	7	8.46	9.57	^a Chem mart	CH
							^a Doxycycline	
							^a Doxyhexal	SZ
							^a GenRx Doxycycline	GX
							^a Terry White	TW
							Chemists	
							Doxycycline	

DOXYCYCLINE

3322W	Capsule 100 mg (as hydrochloride)	7	8.46	9.57	^a Mayne Pharma	YT
							^a Doxycycline	
				^B 2.86	11.32	9.57	^a Doryx	YN

Beta-lactam antibacterials, penicillins

Penicillins with extended spectrum

AMOXYCILLIN

3300Q	Capsule 500 mg	20	9.13	10.24	^a Alphamox 500	AF
							^a Amoxycillin-GA	GM
							^a Amoxycillin	GQ
							generichealth	
							500	
							^a Amoxycillin	RA
							^a Ranbaxy	
							^a Amoxycillin Sandoz	SZ
							^a APO-Amoxycillin	TX
							^a Chem mart	CH
							^a Amoxycillin	
							^a Cilamox	QA
							^a GenRx Amoxycillin	GX
							^a Terry White	TW
							Chemists	
							Amoxycillin	
				^B 0.89	10.02	10.24	^a Amoxil	GK
3301R	Capsule 250 mg	20	7.83	8.94	^a Alphamox 250	AF
							^a Amoxycillin-GA	GM
							^a Amoxycillin	RA
							^a Ranbaxy	
							^a Amoxycillin Sandoz	SZ
							^a APO-Amoxycillin	TX
							^a Chem mart	CH
							^a Amoxycillin	
							^a Cilamox	QA

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
3302T	Powder for syrup 125 mg per 5 mL, 100 mL	#1	#10.30	11.75	^a GenRx Amoxycillin GX
							^a Terry White Chemists TW
							Amoxycillin
							^B 0.88
							8.71
							8.94
							^a Amoxil GK
							^a Alphamox 125 AF
3393N	Powder for syrup 250 mg per 5 mL, 100 mL	#1	#10.81	12.26	^a Amoxycillin Sandoz SZ
							^a Bgramin GM
							^a Chem mart CH
							Amoxycillin
							^a GenRx Amoxycillin GX
							^a Ranmoxy RA
							^a Terry White Chemists TW
							Amoxycillin
5225B	Powder for oral suspension 500 mg per 5 mL, 100 mL	#1	#12.67	14.12	^a Amoxil GK
							^B 0.89
							#11.19
							11.75
							^a Alphamox 250 AF
							^a Amoxycillin Sandoz SZ
							^a Bgramin GM
							^a Chem mart CH
3313J	Powder for injection 500 mg	5	10.95	12.06	^a Amoxycillin
							^a Cilamox QA
							^a GenRx Amoxycillin GX
							^a Ranmoxy RA
							^a Terry White Chemists TW
							Amoxycillin
							^a Amoxil Forte GK
							Maxamox SZ
3314K	Powder for injection 1 g	5	13.79	14.90	^a Austrapen LN
							^a Ibimicyn TS
							^a Aspen Ampicyn AS
							^a Austrapen LN
							^a Ibimicyn TS
Beta-lactamase sensitive penicillins							
5027N	Injection 900 mg in 2.3 mL single use pre-filled syringe	10	293.21	35.40	Bicillin L-A PF
3398W	Powder for injection 600 mg	10	*43.02	35.40	BenPen CS
3399X	Powder for injection 3 g	10	*67.02	35.40	BenPen CS
PHENOXYMETHYLPENICILLIN							
3360W	Tablet 250 mg	50	*11.42	12.53	Abbocillin-VK Filmstab QA
3361X	Tablet 500 mg	50	*13.76	14.87	Abbocillin-VK Filmstab QA
3363B	Capsule 250 mg	50	11.26	12.37	^a Cilicaine VK FM
							^a Cilopen VK GM
3364C	Capsule 500 mg	50	13.57	14.68	LPV VT
							^a Cilicaine VK FM

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							^a Cilopen VK	GM
							LPV	VT
5012T	Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL	2	*21.70	22.81	^a Cilicaine V	FM
				^B 1.90	*23.60	22.81	^a Abbocillin-V	QA
5024K	Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL	2	*#16.89	18.34	Phenoxymethyl- penicillin-AFT	AE
5029Q	Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL	2	*#19.45	20.90	Phenoxymethyl- penicillin-AFT	AE
PROCAINE PENICILLIN								
3371K	Injection 1.5 g	5	92.32	35.40	Cilicaine	QA

Beta-lactamase resistant penicillins

DICLOXACILLIN

Restricted benefit

Serious staphylococcal infections.

5096F	Capsule 250 mg	24	11.29	12.40	^a Dicloxsig	QA
							^a Distaph 250	AF
5097G	Capsule 500 mg	24	16.51	17.62	^a Diclocil	BQ
							^a Dicloxsig	QA
							^a Distaph 500	AF

FLUCLOXACILLIN

Caution

Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.

5094D	Powder for injection 500 mg	5	12.86	13.97	^a Flubiclox	TS
							^a Flucil	AS
5095E	Powder for injection 1 g	5	16.43	17.54	^a Flubiclox	TS
							^a Flucil	AS
							^a Hospira Pty Limited	HH

FLUCLOXACILLIN

Caution

Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.

Restricted benefit

Serious staphylococcal infections.

5090X	Capsule 250 mg (as sodium)	24	11.29	12.40	^a Flopen	AS
							^a Staphylex 250	AF
5091Y	Capsule 500 mg (as sodium)	24	16.51	17.62	^a Flopen	AS
							^a Staphylex 500	AF
5257Q	Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL	‡1	#16.18	17.63	Flucil	LN
5258R	Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL	‡1	#19.71	21.16	Flucil	LN

Combinations of penicillins, incl. beta-lactamase inhibitors

AMOXYCILLIN with CLAVULANIC ACID

Caution

Hepatotoxicity has been reported with this drug.

Restricted benefit

Infections where resistance to amoxycillin is suspected;

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

					Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$			
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium				Brand Name and Manufacturer	
	Infections where resistance to amoxycillin is proven.								
5006L	Tablet 875 mg-125 mg	10	11.73	12.84	^a	Amoxycillin/ Clavulanic Acid 875/125 generichealth	GQ
							^a	Chem mart	CH
							^a	Amoxycillin and Clavulanic Acid	
							^a	Clamoxyl Duo forte	AL
							^a	Clavycillin 875/125	CR
							^a	Curam Duo Forte 875/125	SZ
							^a	GA-Amclav Forte 875/125	GM
							^a	GenRx Amoxycillin and Clavulanic Acid	GX
							^a	Moxiclav Duo Forte 875/125	QA
							^a	Terry White Chemists	TW
				^B 1.56	13.29	12.84	^a	Amoxycillin and Clavulanic Acid	
							^a	Augmentin Duo forte	GK
5008N	Tablet 500 mg-125 mg	10	10.18	11.29	^a	Amoxycillin/ Clavulanic Acid 500/125 generichealth	GQ
							^a	APO-Amoxycillin/ Clavulanic Acid 500/125	TX
							^a	Clamoxyl Duo	AL
							^a	Curam Duo 500/125	SZ
							^a	GA-Amclav 500/125	GM
							^a	Moxiclav Duo 500/125	QA
				^B 1.57	11.75	11.29	^a	Augmentin Duo	GK
5009P	Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL	‡1	#11.38	12.83	^a	Clamoxyl	AL
							^a	Curam	SZ
				^B 1.58	#12.96	12.83	^a	Augmentin	GK
5011R	Powder for syrup 400 mg-57 mg per 5 mL, 60 mL	‡1	#12.35	13.80	^a	Clamoxyl Duo 400	AL
							^a	Curam Duo	SZ
				^B 1.58	#13.93	13.80	^a	Augmentin Duo 400	GK

TICARCILLIN with CLAVULANIC ACID

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.

5230G	Powder for injection 3 g-100 mg (solvent required) (code 7043Q applies to above item with approved solvent)	10	163.42	35.40		Timentin	GK
-------	--	----	----	----	--------	-------	--	----------	----

Other beta-lactam antibacterials
First-generation cephalosporins

CEFALOTIN

3376Q	Powder for injection 1 g	10	22.98	24.09	^a	Cefalotin Sandoz	SZ
-------	--------------------------	----	----	----	-------	-------	--------------	------------------	----

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer	
					\$	\$		
							^a Hospira Pty Limited	HH
							^a Keflin Neutral	AS
CEPHALEXIN								
3317N	Capsule 250 mg	20	8.02	9.13	^a Cefalexin Sandoz	SZ
							^a Cephalixin generichealth	GQ
							^a Cephalixin-PS	FZ
							^a Cephatrust 250	MI
							^a Chem mart Cephalixin	CH
							^a Cilex	GM
							^a GenRx Cephalixin	GX
							^a Ialex	LN
							^a Ibilex 250	AF
							^a Pharmacor Cephalixin 250	CR
							^a Rancef	RA
							^a Terry White Chemists Cephalixin	TW
				^B 3.94	11.96	9.13	^a Keflex	AS
3318P	Capsule 500 mg	20	9.20	10.31	^a Cefalexin Sandoz	SZ
							^a Cephalixin generichealth	GQ
							^a Cephalixin-PS	FZ
							^a Cephatrust 500	MI
							^a Chem mart Cephalixin	CH
							^a Cilex	GM
							^a GenRx Cephalixin	GX
							^a Ialex	LN
							^a Ibilex 500	AF
							^a Pharmacor Cephalixin 500	CR
							^a Rancef	RA
							^a Terry White Chemists Cephalixin	TW
				^B 5.65	14.85	10.31	^a Keflex	AS
3319Q	Granules for syrup 125 mg per 5 mL, 100 mL	‡1	#10.91	12.36	^a APO-Cephalixin	TX
							^a Cefalexin Sandoz	SZ
							^a Chem mart Cephalixin	CH
							^a Cilex	GM
							^a GenRx Cephalixin	GX
							^a Ialex	LN
							^a Ibilex 125	AF
							^a Terry White Chemists Cephalixin	TW
				^B 4.34	#15.25	12.36	^a Keflex	AS
3320R	Granules for syrup 250 mg per 5 mL, 100 mL	‡1	#11.78	13.23	^a APO-Cephalixin	TX
							^a Cefalexin Sandoz	SZ
							^a Chem mart Cephalixin	CH
							^a Cilex	GM

2002J	Powder for oral suspension 125 mg (base) per 5 mL, 70 mL	\$1	\$19.54	20.99	Zinnat	GK
5052X	Tablet 250 mg (base)	14	18.72	19.83	Zinnat	GK

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		

Third-generation cephalosporins

CEFOTAXIME

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.

Note

For item codes 5048Q and 1768C, pharmaceutical benefits that have the form powder for injection 1 g are equivalent for the purposes of substitution.

1768C	Powder for injection 1 g	10	26.54	27.65	^a	Hospira Pty Limited	HH
5048Q	Powder for injection 1 g	10	*26.42	27.53	^a	Cefotaxime Sandoz	SZ

CEFOTAXIME

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.

Note

For item codes 5049R and 1769D, pharmaceutical benefits that have the form powder for injection 2 g are equivalent for the purposes of substitution.

1769D	Powder for injection 2 g	10	43.12	35.40	^a	Hospira Pty Limited	HH
5049R	Powder for injection 2 g	10	*43.02	35.40	^a	Cefotaxime Sandoz	SZ

Sulfonamides and trimethoprim

Combinations of sulfonamides and trimethoprim, incl. derivatives

TRIMETHOPRIM with SULFAMETHOXAZOLE

Caution

There is an increased risk of severe adverse reactions with this combination in the elderly.

3390K	Tablet 160 mg-800 mg	10	9.34	10.45	^a	Bactrim DS	RO
				..	10.80	10.45	^a	Resprim Forte	AF
				^B 1.46	10.80	10.45	^a	Septin Forte	QA
3391L	Oral suspension 40 mg-200 mg per 5 mL, 100 mL	‡1	9.03	10.14		Bactrim	RO
				^B 1.79	10.82	10.14		Septin	QA

Macrolides, lincosamides and streptogramins

Macrolides

ERYTHROMYCIN

3325B	Capsule 250 mg	25	10.79	11.90	^a	Mayne Pharma	YT
				^B 2.91	13.70	11.90	^a	Erythromycin Eryc	YN

ERYTHROMYCIN ETHYL SUCCINATE

3334L	Powder for oral liquid 200 mg (base) per 5 mL, 100 mL	‡1	#14.65	16.10	^a	E-Mycin 200	AF
				^B 2.71	#17.36	16.10	^a	E.E.S. 200	LM
3336N	Tablet 400 mg (base)	25	10.79	11.90	^a	E-Mycin	AF
				^B 2.66	13.45	11.90	^a	E.E.S. 400 Filmtab	LM
3337P	Powder for oral liquid 400 mg (base) per 5 mL, 100 mL	‡1	#16.16	17.61	^a	E-Mycin 400	AF
				^B 2.73	#18.89	17.61	^a	E.E.S. Granules	LM

ERYTHROMYCIN LACTOBIONATE

5088T	Powder for I.V. infusion 1 g (base)	5	*98.72	35.40		Erythrocin-I.V.	LM
-------	-------------------------------------	---	----	----	--------	-------	--	-----------------	----

ROXITHROMYCIN

5259T	Tablet for oral suspension 50 mg	10	12.99	14.10		Rulide D	SW
-------	----------------------------------	----	----	----	-------	-------	--	----------	----

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for		Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$		
5260W	Tablet 150 mg	10	9.86	10.97	^a	APO-Roxithromycin TX
							^a	Biaxsig AV
							^a	Chem mart CH
							^a	Roxithromycin
							^a	Roxar 150 QA
							^a	Roximycin AF
							^a	Roxithromycin-GA GM
							^a	Roxithromycin-PS FZ
							^a	Roxithromycin SZ
							^a	Sandoz
							^a	Terry White TW
							^a	Chemists
							^a	Roxithromycin
				^B 2.61	12.47	10.97	^a	Rulide SW
5261X	Tablet 300 mg	5	9.86	10.97	^a	APO-Roxithromycin TX
							^a	Biaxsig AV
							^a	Chem mart CH
							^a	Roxithromycin
							^a	Roxar 300 QA
							^a	Roximycin AF
							^a	Roxithromycin-GA GM
							^a	Roxithromycin-PS FZ
							^a	Roxithromycin SZ
							^a	Sandoz
							^a	Terry White TW
							^a	Chemists
							^a	Roxithromycin
				^B 2.61	12.47	10.97	^a	Rulide SW

Lincosamides

CLINDAMYCIN

Restricted benefit

Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin.

5057E	Capsule 150 mg	24	19.85	20.96	^a	Cleocin FZ
				^B 1.37	21.22	20.96	^a	Dalacin C PF

LINCOMYCIN

5144R	Injection 600 mg in 2 mL	5	33.84	34.95		Lincocin PF
-------	--------------------------	---	----	----	-------	-------	--	-------------

Other antibacterials

Glycopeptide antibacterials

VANCOMYCIN

Restricted benefit

Prophylaxis of endocarditis in patients hypersensitive to penicillin.

3323X	Powder for injection 500 mg (as hydrochloride) (500,000 i.u. vancomycin activity)	2	*16.62	17.73	^a	Hospira Pty Limited HH
							^a	Vancocin CP AS
							^a	Vancomycin AF
							^a	Alphapharm
							^a	Vancomycin SZ
							^a	Sandoz
							^a	Vycin IV WQ
5083M	Powder for injection 1 g (as hydrochloride) (1,000,000 i.u. vancomycin activity)	1	16.62	17.73	^a	Hospira Pty Limited HH
							^a	Vancomycin AF
							^a	Alphapharm
							^a	Vancomycin SZ

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer	
							^a	Sandoz Vycin IV	WQ
Imidazole derivatives									
METRONIDAZOLE									
3339R	Tablet 200 mg	21	7.98	9.09	^a	Metrogyl 200	AF
							^a	Metronide 200	AV
				^B 2.30	10.28	9.09	^a	Flagyl	SW
5157K	Suppositories 500 mg, 10	‡1	23.26	24.37		Flagyl	SW
<hr/>									
METRONIDAZOLE									
<u>Restricted benefit</u>									
Treatment of anaerobic infections.									
5155H	Tablet 400 mg	21	9.95	11.06	^a	Metrogyl 400	AF
							^a	Metronide 400	AV
				^B 2.30	12.25	11.06	^a	Flagyl	SW
<hr/>									
METRONIDAZOLE									
<u>Restricted benefit</u>									
Treatment, in a hospital, of acute anaerobic sepsis.									
<u>Note</u>									
For item codes 5154G and 1832K, pharmaceutical benefits that have the form I.V. infusion 500 mg in 100 mL are equivalent for the purposes of substitution.									
1832K	I.V. infusion 500 mg in 100 mL	5	*30.89	32.00	^a	DBL Metronidazole Intravenous Infusion	HH
5154G	I.V. infusion 500 mg in 100 mL	5	*30.77	31.88	^a	Baxter Healthcare Pty Ltd	BX
METRONIDAZOLE BENZOATE									
3341W	Oral suspension 320 mg per 5 mL (equivalent to 200 mg metronidazole in 5 mL), 100 mL	‡1	18.92	20.03		Flagyl S	SW

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Musculo-skeletal system

Antiinflammatory and antirheumatic products

Antiinflammatory and antirheumatic products, non-steroids

Acetic acid derivatives and related substances

DICLOFENAC SODIUM								
5079H	Suppository 100 mg	40	*25.02	26.13	Voltaren 100	NV
<hr/>								
DICLOFENAC SODIUM								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component;								
Bone pain due to malignant disease.								
5076E	Tablet 25 mg (enteric coated)	100	*12.84	13.95	^a APO-Diclofenac	TX
							^a Chem mart	CH
							^a Diclofenac	
							^a Clonac 25	QA
							^a Diclofenac-GA	GM
							^a Diclofenac Sandoz	SZ
							^a Fenac 25	AF
							^a Terry White	TW
							^a Chemists	
				^B 2.32	*15.16	13.95	^a Diclofenac	
							^a Voltaren 25	NV
5077F	Tablet 50 mg (enteric coated)	50	10.92	12.03	^a APO-Diclofenac	TX
							^a Chem mart	CH
							^a Diclofenac	
							^a Clonac 50	QA
							^a Diclofenac-GA	GM
							^a Diclofenac Sandoz	SZ
							^a Fenac	AF
							^a Terry White	TW
							^a Chemists	
				^B 2.34	13.26	12.03	^a Diclofenac	
							^a Voltaren 50	NV
<hr/>								
INDOMETHACIN								
5128X	Suppository 100 mg	40	*22.60	23.71	Indocid	AS
<hr/>								
INDOMETHACIN								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component;								
Bone pain due to malignant disease.								
5126T	Capsule 25 mg	100	*12.52	13.63	^a Arthrexin	AF
				^B 2.02	*14.54	13.63	^a Indocid	AS

Oxicams

PIROXICAM

Restricted benefit

Chronic arthropathies (including osteoarthritis) with an inflammatory component.

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum		Brand Name and Manufacturer	
					Max. Qty	Recordable			
					\$	Value for			
						Safety Net			
5201R	Dispersible tablet 10 mg	50	12.30	13.41		Mobilis D-10	AF
5202T	Dispersible tablet 20 mg	25	12.02	13.13	^a	Mobilis D-20	AF
				^B 2.95	14.97	13.13	^a	Feldene-D	PF
5203W	Capsule 10 mg	50	12.30	13.41	^a	Chem mart	CH
							^a	Piroxicam	
							^a	GenRx Piroxicam	GX
							^a	Mobilis 10	AF
							^a	Terry White	TW
								Chemists	
				^B 2.52	14.82	13.41	^a	Piroxicam	
							^a	Feldene	PF
5204X	Capsule 20 mg	25	12.02	13.13	^a	Chem mart	CH
							^a	Piroxicam	
							^a	GenRx Piroxicam	GX
							^a	Mobilis 20	AF
							^a	Terry White	TW
								Chemists	
				^B 2.49	14.51	13.13	^a	Piroxicam	
							^a	Feldene	PF
Propionic acid derivatives									
IBUPROFEN									
5124Q	Tablet 400 mg	30	9.29	10.40		Brufen	AB
<hr/>									
IBUPROFEN									
<u>Restricted benefit</u>									
Chronic arthropathies (including osteoarthritis) with an inflammatory component;									
Bone pain due to malignant disease.									
5123P	Tablet 400 mg	90	*14.83	15.94		Brufen	AB
<hr/>									
KETOPROFEN									
5139L	Suppository 100 mg	40	*25.40	26.51		Orudis	SW
<hr/>									
KETOPROFEN									
<u>Restricted benefit</u>									
Chronic arthropathies (including osteoarthritis) with an inflammatory component.									
5136H	Capsule 200 mg (sustained release)	28	19.20	20.31	^a	Oruvail SR	AV
				^B 2.21	21.41	20.31	^a	Orudis SR 200	SW
<hr/>									
NAPROXEN									
<u>Restricted benefit</u>									
Chronic arthropathies (including osteoarthritis) with an inflammatory component;									
Bone pain due to malignant disease.									
5176K	Tablet 250 mg	100	*13.44	14.55	^a	Inza 250	AF
				^B 2.24	*15.68	14.55	^a	Naprosyn	RO
5177L	Tablet 500 mg	50	12.68	13.79	^a	Inza 500	AF
				^B 1.30	13.98	13.79	^a	Naprosyn	RO
5178M	Tablet 750 mg (sustained release)	28	12.18	13.29	^a	Proxen SR 750	MD
				^B 1.22	13.40	13.29	^a	Naprosyn SR750	RO
5179N	Tablet 1 g (sustained release)	28	14.06	15.17	^a	Proxen SR 1000	MD
				^B 1.29	15.35	15.17	^a	Naprosyn SR1000	RO

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
5186Y	NAPROXEN SODIUM							
	<u>Restricted benefit</u>							
	Chronic arthropathies (including osteoarthritis) with an inflammatory component;							
	Bone pain due to malignant disease.							
	<u>Note</u>							
	Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.							
	Tablet 550 mg	50	12.87	13.98 ^a	Crysanal	MD
				^B 2.17	15.04	13.98 ^a	Anaprox 550	RO

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		

Nervous system

Analgesics

Opioids

Natural opium alkaloids

CODEINE PHOSPHATE

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5063L	Tablet 30 mg	20	16.97	18.08	Fawns and McAllan Proprietary Limited	FM
-------	--------------	----	----	----	-------	-------	---	----

CODEINE PHOSPHATE with PARACETAMOL

3316M	Tablet 30 mg-500 mg	20	7.58	8.69 ^a	APO- Paracetamol/Code ine 500/30	TX
						^a	Codalgin Forte	FM
						^a	Codapane Forte	AL
						^a	Comfarol Forte	SZ
						^a	Prodeine Forte	AV
				^B 2.80	10.38	8.69 ^a	Panadeine Forte	SW

HYDROMORPHONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5115F	Tablet 2 mg	20	17.20	18.31	Dilaudid	MF
5116G	Tablet 4 mg	20	19.95	21.06	Dilaudid	MF
5117H	Tablet 8 mg	20	30.13	31.24	Dilaudid	MF
5132D	Oral liquid 1 mg per mL, 473 mL	1	63.80	35.40	Dilaudid	MF

MORPHINE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5237P	Oral solution 2 mg per mL, 200 mL	1	20.43	21.54	Ordine 2	MF
5238Q	Oral solution 5 mg per mL, 200 mL	1	22.83	23.94	Ordine 5	MF
5239R	Oral solution 10 mg per mL, 200 mL	1	26.96	28.07	Ordine 10	MF

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5168B	Injection 10 mg in 1 mL	5	14.09	15.20	Hospira Pty Limited	HH
-------	-------------------------	---	----	----	-------	-------	---------------------	----

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
5169C	Injection 15 mg in 1 mL	5	14.45	15.56	Hospira Pty Limited	HH
5170D	Injection 30 mg in 1 mL	5	15.87	16.98	Hospira Pty Limited	HH

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5163R	Tablet 30 mg	20	14.13	15.24	Anamorph	FM
-------	--------------	----	----	----	-------	-------	----------	----

OXYCODONE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5194J	Suppository 30 mg	12	43.76	35.40	Proladone	PL
-------	-------------------	----	----	----	-------	-------	-----------	----

OXYCODONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5190E	Oral solution 5 mg per 5 mL, 250 mL	1	20.82	21.93	OxyNorm Liquid 5mg/5mL	MF
5191F	Capsule 5 mg	20	12.40	13.51	OxyNorm	MF
5195K	Tablet 5 mg	20	12.40	13.51	Endone	QA
5197M	Capsule 10 mg	20	15.52	16.63	OxyNorm	MF

Other opioids

TRAMADOL HYDROCHLORIDE

Restricted benefit

For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed;

For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed.

5232J	Capsule 50 mg	20	8.49	9.60	^a APO-Tramadol	TX
							^a Chem mart	CH
							^a Tramadol	
							^a GA Tramadol 50mg	GM
							^a GenRx Tramadol	GX
							^a Lodam 50	ZP
							^a Terry White Chemists	TW
							^a Tramadol	
							^a Tramadol Sandoz	SZ
							^a Tramedo	AF
							^a Zydol	QA
				^B 2.41	10.90	9.60	^a Tramal	CS

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
<hr/>								
TRAMADOL HYDROCHLORIDE								
<u>Restricted benefit</u>								
For pain where aspirin and/or paracetamol alone are inappropriate or have failed.								
5150C	Oral drops 100 mg per mL, 10 mL	‡1	13.81	14.92	Tramal	CS
<hr/>								
TRAMADOL HYDROCHLORIDE								
<u>Restricted benefit</u>								
Short-term treatment of acute pain.								
5231H	Injection 100 mg in 2 mL	5	13.20	14.31	^a Tramahexal ^a Tramal 100	SZ CS
 Other analgesics and antipyretics								
<i>Salicylic acid and derivatives</i>								
ASPIRIN								
5018D	Tablet 300 mg (dispersible)	96	8.27	9.38	Solprin	RC
 <i>Anilides</i>								
PARACETAMOL								
3348F	Oral liquid 120 mg per 5 mL, 100 mL	‡1	9.48	10.59	Panamax	SW
3349G	Oral liquid 240 mg per 5 mL, 200 mL	‡1	10.78	11.89	Panamax 240 Elixir	SW
5196L	Tablet 500 mg	100	8.42	9.53	^a APO-Paracetamol ^a Chem mart Paracetamol ^a Febridol ^a Generic Health Pty Ltd ^a Panamax ^a Paracetamol Sandoz ^a Paralgin ^a Pharmacy Choice Paracetamol ^a Terry White Chemists Paracetamol	TX XS GM GQ SW SZ FM YM YS
<hr/>								
PARACETAMOL								
<u>Restricted benefit</u>								
Chronic arthropathies.								
5224Y	Tablet 500 mg	300	*12.22	13.33	^a APO-Paracetamol ^a Chem mart Paracetamol ^a Febridol ^a Generic Health Pty Ltd ^a Panamax ^a Paracetamol Sandoz ^a Paralgin ^a Pharmacy Choice Paracetamol ^a Terry White	TX XS GM GQ SW SZ FM YM YS

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
							Chemists	Paracetamol

Antiepileptics

Antiepileptics

Carboxamide derivatives

CARBAMAZEPINE

Note

For item codes 5039F and 1755J, pharmaceutical benefits that have the form tablet 100 mg are equivalent for the purposes of substitution.

1755J	Tablet 100 mg	200	18.61	19.72	^a	Carbamazepine Sandoz	SZ
5039F	Tablet 100 mg	200	..	^B 2.96	*21.56	19.71	^a	Tegretol 100	NV

CARBAMAZEPINE

Note

For item codes 5040G and 1724R, pharmaceutical benefits that have the form tablet 200 mg are equivalent for the purposes of substitution.

1724R	Tablet 200 mg	200	..	^B 2.96	*32.06	30.21	^a	Tegretol 200	NV
5040G	Tablet 200 mg	200	29.12	30.23	^a	Carbamazepine Sandoz	SZ
							^a	Teril	AF

CARBAMAZEPINE

5037D	Tablet 400 mg (controlled release)	200	49.12	35.40		Tegretol CR 400	NV
5038E	Tablet 200 mg (controlled release)	200	29.58	30.69		Tegretol CR 200	NV
5041H	Oral suspension 100 mg per 5 mL, 300 mL	£1	21.45	22.56		Tegretol Liquid	NV

Anti-Parkinson drugs

Anticholinergic agents

Ethers of tropine or tropine derivatives

BENZTROPINE MESYLATE

5031T	Injection 2 mg in 2 mL	5	103.69	35.40		Cogentin	FK
-------	------------------------	---	----	----	--------	-------	--	----------	----

Psycholeptics

Anxiolytics

Benzodiazepine derivatives

DIAZEPAM

5071X	Tablet 2 mg	50	7.82	8.93	^a	Antenex 2	AF
							^a	APO-Diazepam	TX
							^a	Ranzepam	RA
							^a	Valpam 2	QA
				^B 0.82	8.64	8.93	^a	Valium	RO
5072Y	Tablet 5 mg	50	7.95	9.06	^a	Antenex 5	AF
							^a	APO-Diazepam	TX
							^a	Diazepam-GA	GM
							^a	Ranzepam	RA
							^a	Valpam 5	QA
				^B 0.85	8.80	9.06	^a	Valium	RO

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for		Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$			
5073B	Injection 10 mg in 2 mL	5	12.39	13.50		Hospira Pty Limited	HH
OXAZEPAM									
5192G	Tablet 15 mg	25	7.75	8.86	^a	Alepam 15	AF
				^B 2.69	10.44	8.86	^a	Serepax	QA
5193H	Tablet 30 mg	25	7.75	8.86	^a	Alepam 30	AF
							^a	APO-Oxazepam	TX
							^a	Murelax	FM
				^B 2.69	10.44	8.86	^a	Serepax	QA
Hypnotics and sedatives									
<i>Benzodiazepine derivatives</i>									
NITRAZEPAM									
5189D	Tablet 5 mg	25	7.92	9.03	^a	Alodorm	AF
				^B 1.45	9.37	9.03	^a	Mogadon	VT
TEMAZEPAM									
5221T	Tablet 10 mg	25	7.56	8.67	^a	APO-Temazepam	TX
							^a	Temaze	AF
							^a	Temtabs	FM
				^B 2.05	9.61	8.67	^a	Normison	QA

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable	Brand Name and Manufacturer
					Max. Qty \$	Value for Safety Net \$	

Respiratory system

Drugs for obstructive airway diseases

Adrenergics for systemic use

Alpha- and beta-adrenoceptor agonists

ADRENALINE

5004J	Injection 1 mg in 1 mL (1 in 1,000)	5	20.44	21.55	Link Medical Products Pty Ltd	LM
-------	-------------------------------------	---	----	----	-------	-------	----------------------------------	----

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Sensory organs

Ophthalmologicals

Antiinfectives

Antibiotics

CHLORAMPHENICOL

5055C	Eye drops 5 mg per mL (0.5%), 10 mL	#1	11.10	12.21	Chloromycetin Chlorsig	PF QA
-------	-------------------------------------	----	----	----	-------	-------	---------------------------	----------

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable	Brand Name and Manufacturer
					Max. Qty \$	Value for Safety Net \$	

Various

All other therapeutic products

All other therapeutic products

Antidotes

NALOXONE HYDROCHLORIDE

5175J	Injection 2 mg in 5 mL	1	43.59	35.40	Naloxone Min-I-Jet	CS
-------	------------------------	---	----	----	-------	-------	--------------------	----

All other non-therapeutic products

All other non-therapeutic products

Solvents and diluting agents, incl. irrigating solutions

SODIUM CHLORIDE

5211G	Injection 9 mg per mL (0.9%), 10 mL	5	8.22	9.33	Pfizer Australia Pty Ltd	PF
-------	-------------------------------------	---	----	----	------	------	-----------------------------	----

Pharmaceutical Benefits for Optometrical Use

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		

Sensory organs

Ophthalmologicals

Antiinfectives

Antibiotics

CHLORAMPHENICOL

5511C	Eye ointment 10 mg per g (1%), 4 g	£1	9.86	10.97	Chloromycetin	PF
							Chlorsig	QA
5512D	Eye drops 5 mg per mL (0.5%), 10 mL	£1	2	..	11.10	12.21	Chloromycetin	PF
							Chlorsig	QA

GENTAMICIN SULFATE

Restricted benefit

Perioperative use in ophthalmic surgery;

Suspected pseudomonal eye infection.

5566Y	Eye drops 3 mg (base) per mL (0.3%), 5 mL	£1	2	..	18.39	19.50	Genoptic	AG
-------	---	----	---	----	-------	-------	----------	----

TOBRAMYCIN

Restricted benefit

Perioperative use in ophthalmic surgery;

Suspected pseudomonal eye infection.

5569D	Eye drops 3 mg per mL (0.3%), 5 mL	£1	2	..	19.38	20.49	Tobrex	AQ
5570E	Eye ointment 3 mg per g (0.3%), 3.5 g	£1	22.48	23.59	Tobrex	AQ

Antivirals

ACICLOVIR

Restricted benefit

Herpes simplex keratitis.

5501M	Eye ointment 30 mg per g (3%), 4.5 g	£1	33.73	34.84	Zovirax	GK
-------	--------------------------------------	----	----	----	-------	-------	---------	----

Other antiinfectives

CIPROFLOXACIN

Authority required

Bacterial keratitis under the supervision and direction of an ophthalmologist.

5564W	Eye drops 3 mg per mL (0.3%), 5 mL	2	*28.58	29.69	^a CiloQuin	IQ
				^B 2.06	*30.64	29.69	^a Ciloxan	AQ

OFLOXACIN

Authority required

Bacterial keratitis under the supervision and direction of an ophthalmologist.

5567B	Eye drops 3 mg per mL (0.3%), 5 mL	2	*32.24	33.35	Ocuflox	AG
-------	------------------------------------	---	----	----	--------	-------	---------	----

Antiinflammatory agents

Corticosteroids, plain

DEXAMETHASONE

Note

No applications for increased maximum quantities and/or repeats will be authorised.

5565X	Eye drops 1 mg per mL (0.1%), 5 mL	£1	10.71	11.82	Maxidex	AQ
-------	------------------------------------	----	----	----	-------	-------	---------	----

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
FLUOROMETHOLONE								
<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.								
5513E	Eye drops 1 mg per mL (0.1%), 5 mL	£1	10.71	11.82	Flucon	AQ
							FML Liquifilm	AG
FLUOROMETHOLONE ACETATE								
<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.								
5533F	Eye drops 1 mg per mL (0.1%), 5 mL	£1	10.71	11.82	Flarex	AQ
HYDROCORTISONE ACETATE								
<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.								
5516H	Eye ointment 10 mg per g (1%), 5 g	£1	12.79	13.90	Hycor	QA
<i>Corticosteroids and mydriatics in combination</i>								
PREDNISOLONE ACETATE with PHENYLEPHRINE HYDROCHLORIDE								
<u>Restricted benefit</u> Uveitis.								
<u>Note</u> No applications for increased maximum quantities and/or repeats will be authorised.								
5568C	Eye drops 10 mg-1.2 mg per mL (1%-0.12%), 10 mL	£1	23.83	24.94	Prednefrin Forte	AG
<i>Antiinflammatory agents, non-steroids</i>								
FLURBIPROFEN SODIUM								
5514F	Eye drops 300 micrograms per mL (0.03%), single dose units 0.4 mL, 5	1	16.92	18.03	Ocufen	AG
Antiglaucoma preparations and miotics								
<i>Sympathomimetics in glaucoma therapy</i>								
BRIMONIDINE TARTRATE								
5534G	Eye drops 2 mg per mL (0.2%), 5 mL	£1	5	.. ^B 1.63	20.24 21.87	21.35 ^a 21.35 ^a	Enidin Alphagan	PE AG
5563T	Eye drops 1.5 mg per mL (0.15%), 5 mL	£1	5	..	20.24	21.35	Alphagan P 1.5	AG
BRIMONIDINE TARTRATE with TIMOLOL MALEATE								
<u>Restricted benefit</u> Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy; Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.								
5535H	Eye drops 2 mg-5 mg (base) per mL (0.2%-0.5%), 5 mL	£1	5	..	26.13	27.24	Combigan	AG
<i>Parasympathomimetics</i>								
PILOCARPINE HYDROCHLORIDE								
5536J	Eye drops 10 mg per mL (1%), 15 mL	£1	5	..	12.63	13.74	Isopto Carpine	AQ
5537K	Eye drops 20 mg per mL (2%), 15 mL	£1	5	..	13.88	14.99	Isopto Carpine	AQ
5538L	Eye drops 40 mg per mL (4%), 15 mL	£1	5	..	16.73	17.84	Isopto Carpine	AQ

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer	
Carbonic anhydrase inhibitors									
BRINZOLAMIDE									
5540N	Eye drops 10 mg per mL (1%), 5 mL	1	5	.. ^B 1.18	22.87 24.05	23.98 ^a 23.98 ^a		BrinzoQuin Azopt	IQ AQ
BRINZOLAMIDE with TIMOLOL MALEATE									
<u>Restricted benefit</u>									
Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;									
Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.									
5562R	Eye drops 10 mg-5 mg (base) per mL (1%-0.5%), 5 mL	1	5	..	26.98	28.09		Azarga	AQ
DORZOLAMIDE HYDROCHLORIDE									
5541P	Eye drops 20 mg (base) per mL (2%), 5 mL	1	5	..	21.39	22.50		Trusopt	MK
DORZOLAMIDE HYDROCHLORIDE with TIMOLOL MALEATE									
<u>Restricted benefit</u>									
Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;									
Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.									
5542Q	Eye drops 20 mg (base)-5 mg (base) per mL (2%- 0.5%), 5 mL	1	5	..	27.28	28.39		Cosopt	MK
Beta blocking agents									
BETAXOLOL HYDROCHLORIDE									
5543R	Eye drops, suspension, 2.5 mg (base) per mL (0.25%), 5 mL	1	5	..	14.87	15.98		Betoptic S	AQ
5544T	Eye drops, solution, 5 mg (base) per mL (0.5%), 5 mL	1	5	.. ^B 2.09	14.87 16.96	15.98 ^a 15.98 ^a		BetoQuin Betoptic	IQ AQ
TIMOLOL MALEATE									
5546X	Eye gel 1 mg (base) per g (0.1%), 5 g	1	5	..	12.97	14.08		Nyogel	NV
5547Y	Eye drops 2.5 mg (base) per mL (0.25%), 5 mL	1	5	.. ^B 3.03	11.64 14.67	12.75 ^a 12.75 ^a		Tenopt Timoptol	QA FR
5548B	Eye drops 5 mg (base) per mL (0.5%), 5 mL	1	5	.. ^B 3.03	12.41 15.44	13.52 ^a 13.52 ^a		Tenopt Timoptol	QA FR
5549C	Eye drops (gellan gum solution) 2.5 mg (base) per mL (0.25%), 2.5 mL	1	5	..	11.64	12.75		Timoptol XE	MK
5550D	Eye drops (gellan gum solution) 5 mg (base) per mL (0.5%), 2.5 mL	1	5	..	12.41	13.52		Timoptol XE	MK
Prostaglandin analogues									
BIMATOPROST									
5551E	Eye drops 300 micrograms per mL (0.03%), 3 mL	1	5	..	42.24	35.40		Lumigan	AG
BIMATOPROST with TIMOLOL MALEATE									
<u>Restricted benefit</u>									
Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;									
Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.									
5558M	Eye drops 300 micrograms-5 mg (base) per mL (0.03%-0.5%), 3 mL	1	5	..	46.69	35.40		Ganfort 0.3/5	AG

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
LATANOPROST								
5552F	Eye drops 50 micrograms per mL (0.005%), 2.5 mL	1	5	..	36.67	35.40	^a APO-Latanoprost	TX
							^a Chem mart	CH
							^a Latanoprost	FZ
							^a Latanoprost	SZ
							^a Sandoz	
							^a Terry White	TW
							^a Chemists	
							^a Latanoprost	
							^a Xalatan	PF
LATANOPROST with TIMOLOL MALEATE								
<u>Restricted benefit</u>								
Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;								
Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.								
5553G	Eye drops 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL	1	5	..	40.97	35.40	^a Latanocom	FZ
							^a Xalacom	PF
TRAVOPROST								
5554H	Eye drops 40 micrograms per mL (0.004%), 2.5 mL	1	5	..	42.24	35.40	Travatan	AQ
TRAVOPROST with TIMOLOL MALEATE								
<u>Restricted benefit</u>								
Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy;								
Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy.								
5555J	Eye drops 40 micrograms-5 mg (base) per mL (0.004%-0.5%), 2.5 mL	1	5	..	46.69	35.40	Duotrav	AQ
Decongestants and antiallergics								
<i>Other antiallergics</i>								
SODIUM CROMOGLYCAT								
<u>Restricted benefit</u>								
Vernal kerato-conjunctivitis.								
5529B	Eye drops 20 mg per mL (2%), 10 mL	1	5	..	14.31	15.42	^a Cromolux	AE
							^a Opticrom	SW
Other ophthalmologicals								
<i>Other ophthalmologicals</i>								
CARBOMER								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
5503P	Eye gel 2 mg per g (0.2%), 10 g	1	5	..	10.37	11.48	GelTears	BU
							^a PAA	IQ
				^B 1.50	11.87	11.48	^a Viscotears	AQ
CARBOMER								
<u>Authority required</u>								
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.								
5504Q	Eye gel 2 mg per g (0.2%), single dose units	3	5	..	*36.19	35.40	Viscotears Gel PF	AQ

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
	0.6 mL, 30							
CARBOMER 974								
<u>Authority required</u>								
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.								
5502N	Ocular lubricating gel 3 mg per g (0.3%), single dose units 0.5 g, 30	3	5	..	*36.16	35.40	Poly Gel	AQ
CARMELLOSE SODIUM								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
5507W	Eye drops 5 mg per mL (0.5%), 15 mL	#1	5	..	10.69	11.80	Refresh Tears Plus	AG
5508X	Eye drops 10 mg per mL (1%), 15 mL	#1	5	..	10.69	11.80	Refresh Liquigel	AG
CARMELLOSE SODIUM								
<u>Authority required</u>								
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.								
5505R	Eye drops 10 mg per mL (1%), single dose units 0.4 mL, 30	3	5	..	*36.16	35.40	Celluvisc	AG
5506T	Eye drops 5 mg per mL (0.5%), single dose units 0.4 mL, 30	3	5	..	*36.16	35.40	Cellufresh	AG
5509Y	Eye drops 2.5 mg per mL (0.25%), single dose units 0.6 mL, 24	4	5	..	*40.52	35.40	TheraTears	CX
5510B	Ocular lubricating gel 10 mg per mL (1%), single dose units 0.6 mL, 28	3	5	..	*34.18	35.29	TheraTears	CX
CARMELLOSE SODIUM with GLYCERIN								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
<u>Note</u>								
The in-use shelf life of Optive is 6 months from the date of opening.								
5556K	Eye drops 5 mg-9 mg per mL (0.5%-0.9%), 15 mL	#1	3	..	10.69	11.80	Optive	AG
CARMELLOSE SODIUM with GLYCERIN								
<u>Authority required</u>								
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.								
5561Q	Eye drops 5 mg-9 mg per mL (0.5%-0.9%), single dose units 0.4 mL, 30	3	5	..	*36.16	35.40	Optive	AG
HYPROMELLOSE								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
5517J	Eye drops 5 mg per mL (0.5%), 15 mL	#1	5	..	10.37	11.48	Methopt	QA
5518K	Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative)	#1	5	..	10.37	11.48	^a In a Wink	IQ
				^B 1.95	12.32	11.48	^a Moisturising Gental	AQ
HYPROMELLOSE with CARBOMER 980								
<u>Restricted benefit</u>								
Severe dry eye syndrome, including Sjogren's syndrome.								
5519L	Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g	#1	5	..	10.37	11.48	^a HPMC PAA	IQ
				^B 1.95	12.32	11.48	^a Gental gel	AQ

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer	
HYPROMELLOSE with DEXTRAN									
<u>Restricted benefit</u>									
Severe dry eye syndrome, including Sjogren's syndrome.									
5520M	Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL	‡1	5	.. B2.04	10.59 12.63	11.70 11.70	a a	Poly-Tears Tears Naturale	IQ AQ
<hr/>									
HYPROMELLOSE with DEXTRAN									
<u>Authority required</u>									
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.									
5521N	Eye drops 3 mg-1 mg per mL (0.3%-0.1%), single dose units 0.4 mL, 28	3	5	..	*35.17	35.40		Bion Tears	AQ
<hr/>									
PARAFFIN									
5522P	Pack containing 2 tubes compound eye ointment 3.5 g	‡1	5	.. B2.12	20.70 22.82	21.81 21.81		Poly Visc Ircal	IQ PE
5523Q	Compound eye ointment 3.5 g	2	5	.. B2.54	*21.34 *23.88	22.45 22.45	a a	Lacri-Lube Poly Visc Duratears	AG IQ AQ
<hr/>									
POLYETHYLENE GLYCOL 400									
<u>Restricted benefit</u>									
Severe dry eye syndrome, including Sjogren's syndrome.									
<u>Note</u>									
The in-use shelf life of Blink Intensive Tears multi-dose formulation is 45 days from the date of opening.									
5559N	Eye drops 2.5 mg per mL (0.25%), 15 mL	‡1	5	..	10.69	11.80		Blink Intensive Tears	AO
<hr/>									
POLYETHYLENE GLYCOL 400									
<u>Authority required</u>									
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.									
5560P	Eye drops 2.5 mg per mL (0.25%), single dose units 0.4 mL, 20	5	5	..	*39.47	35.40		Blink Intensive Tears	AO
<hr/>									
POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL									
<u>Restricted benefit</u>									
Severe dry eye syndrome, including Sjogren's syndrome.									
5524R	Eye drops 4 mg-3 mg per mL (0.4%-0.3%), 15 mL	‡1	5	..	10.69	11.80		Systane	AQ
<hr/>									
POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL									
<u>Authority required</u>									
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.									
5532E	Eye drops 4 mg-3 mg per mL (0.4%-0.3%), single dose units 0.8 mL, 28	2	5	..	*34.18	35.29		Systane	AQ
<hr/>									
POLYVINYL ALCOHOL									
<u>Restricted benefit</u>									
Severe dry eye syndrome, including Sjogren's syndrome.									
5525T	Eye drops 30 mg per mL (3%), 15 mL	‡1	5	.. B5.59	10.37 15.96	11.48 11.48	a a	PVA Forte Liquifilm Forte	PE AG

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for		Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$		
5526W	Eye drops 14 mg per mL (1.4%), 15 mL	‡1	5	..	10.37	11.48	^a	PVA Tears PE
				^B 1.60	11.97	11.48	^a	Liquifilm Tears AG
5527X	Eye drops 14 mg per mL (1.4%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	‡1	5	..	10.37	11.48		Vistil AE
5528Y	Eye drops 30 mg per mL (3%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	‡1	5	..	10.37	11.48		Vistil Forte AE

SOY LECITHIN

Authority required

Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.

5545W	Eye spray 10 mg per mL (1%), 10 mL	2	5	..	*36.16	35.40		tearsagain RB
-------	------------------------------------	---	---	----	--------	-------	--	---------------

Ophthalmological and otological preparations

Antiinfectives

Antiinfectives

FRAMYCETIN SULFATE

5557L	Eye and ear drops 5 mg per mL (0.5%), 8 mL	‡1	2	..	10.21	11.32		Soframycin SW
-------	--	----	---	----	-------	-------	--	---------------

Items Available under Special Arrangements (Section 100)

Section 100 – Items Available under Special Arrangement

In addition to the drugs and medicinal preparations available under normal PBS arrangements listed in this Schedule, a number of drugs are also available as pharmaceutical benefits but are distributed under alternative arrangements where these are considered more appropriate.

These alternative arrangements are provided for under section 100 of the National Health Act 1953. Several programs exist for the provision of drugs as pharmaceutical benefits in this way and this section lists those drugs which are available under the following programs:

- **Highly Specialised Drugs Program**
- **Botulinum Toxin Program**
- **Human Growth Hormone Program**
- **IVF/GIFT Program**
- **Opiate Dependence Treatment Program**

Complete details concerning the availability of drugs as benefits under these programs may be obtained by telephoning the relevant contact number(s) shown in each section, or in certain cases, by referring to the telephone number provided for individual drugs listings.

Section 100 – Highly Specialised Drugs Program

The Australian Government provides funding for certain specialised medications under the Highly Specialised Drugs Program. Highly Specialised Drugs are medicines for the treatment of chronic conditions which, because of their clinical use or other special features, are restricted to supply through public and private hospitals having access to appropriate specialist facilities. To prescribe these drugs as pharmaceutical benefit items, medical practitioners are required to be affiliated with these specialist hospital units. A general practitioner or non-specialist hospital doctor may only prescribe Highly Specialised Drugs to provide maintenance therapy under the guidance of the treating specialist.

Benefits are available for the listed clinical indications only. There is no facility for individual patient approval for indications outside those listed.

To gain access to a Commonwealth funded drug under this program, a patient must attend a participating hospital and be a day admitted patient, a non-admitted patient or a patient on discharge, be under appropriate specialist medical care, meet the specific medical criteria and be an Australian resident in Australia (or other eligible person).

A patient will be required to pay a contribution for each supply of a highly specialised drug at a similar rate to the Pharmaceutical Benefits Scheme. Commonwealth subsidy is not available for hospital in-patients.

Reciprocal Health Care Agreement – Where a patient is entitled to be treated as an eligible person as a visitor from a country with which Australia has entered into a Reciprocal Health Care Agreement, the supply will be limited to the original prescription only. Repeat prescriptions for these patients are not permitted.

Private Hospitals – **In addition to the above requirements**, for Highly Specialised Drugs prescribed through private hospitals, claiming and approval of authority prescriptions is administered by Medicare Australia. Highly Specialised Drugs are authority required items. Medical practitioners must seek approval to prescribe these items as pharmaceutical benefits prior to their dispensing under the PBS. Approval of authority prescriptions by Medicare Australia may be obtained either by posting an Authority Prescription Form to Medicare Australia, or by using Medicare Australia's Authority Freecall service (1800 888 333). **Prescribers must quote the provider number of the hospital when applying.** Not more than two months' supply (one month's supply in the case of Clozapine), with provision for up to 5 repeats, will be authorised. Prescriptions for Highly Specialised Drugs can be dispensed by an approved private hospital's dispensary or by a community pharmacy.

The remuneration rates for Highly Specialised Drugs prescribed through private hospitals comprise the normal PBS ready- prepared dispensing fee plus a mark-up ascertained as follows:

- 10% for drugs with a price ex-manufacturer of less than \$40;
- \$4 for drugs with a price ex-manufacturer of between \$40 and \$100;
- 4% for drugs with a price ex-manufacturer of between \$100.01 and \$1000;
- \$40 for drugs with a price ex-manufacturer of greater than \$1000.

Public Hospitals – For Highly Specialised Drugs prescribed through public hospitals, claiming and access to the program is administered by the States/Territories Health Departments. Prescriptions for Highly Specialised Drugs can be dispensed by public hospital pharmacies.

If you would like further information about the Highly Specialised Drugs Program, please contact your pharmacy, Medicare Australia (Ph: 132 290) or the Australian Government adviser, the Highly Specialised Drugs Working Party Secretariat (Ph: (02) 6289 2331).

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

Blood and blood forming organs

Antihemorrhagics

Vitamin K and other hemostatics

Other systemic hemostatics

ELTROMBOPAG

Note

Eltrombopag is not PBS-subsidised as an alternative to splenectomy.

Any queries concerning the arrangements to prescribe eltrombopag may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe eltrombopag should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

Further prescribing information is on the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:

(1) Splenectomised and:

(a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and

(b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;

OR

(2) Not splenectomised and:

(a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2 mg/kg/day of prednisone for at least 4-6 weeks; and

(b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and

(c) in whom splenectomy is contraindicated for medical reasons.

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:

(a) a platelet count of less than or equal to 20,000 million per L;

OR

(b) a platelet count of 20-30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.

The authority application must be made in writing and must include:

(1) a completed authority prescription form,

(2) a signed patient acknowledgement,

(3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],

(4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and

(5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.

The full blood count must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.

Note

Patients will be able to trial either eltrombopag and/or romiplostim within the initial 24 weeks treatment period. Patients who fail to demonstrate a response to treatment with either eltrombopag and/or romiplostim under the initial restriction will not be eligible to receive further PBS-subsidised treatment with either of these drugs.

No applications for increased repeats will be authorised.

Authority required

Initial (grandfather patients)

Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with eltrombopag prior to 1 November 2011 and in

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

whom the criteria for initial treatment can be demonstrated to have been met at the time eltrombopag was commenced.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form,
- (2) a signed patient acknowledgement,
- (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and
- (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.

A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.

Note

No applications for increased repeats will be authorised.

Authority required

Continuing therapy or re-initiation after a break in therapy

First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with eltrombopag during the initial period of PBS-subsidised treatment.

For the purposes of this restriction, a sustained platelet response is defined as:

- (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised eltrombopag,

AND either of the following:

- (b) a platelet count greater than or equal to 50,000 million per L on at least four (4) occasions, each at least one week apart;

OR

- (c) a platelet count greater than 30,000 million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.

Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:

- (1) a completed authority prescription form, and
- (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and
- (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).

The most recent platelet count must be no more than one month old at the time of application.

A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone.

Note

No applications for increased repeats will be authorised.

Authority required

Second and subsequent applications for continuing therapy

Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with eltrombopag and who continues to display a response to treatment with eltrombopag.

For the purposes of this restriction, a continuing response to treatment with eltrombopag is defined as:

- (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with eltrombopag,

AND either of the following:

- (b) a platelet count greater than or equal to 50,000 million per L

OR

- (c) a platelet count greater than 30,000 million per L and which is double the baseline platelet count.

Platelet counts must be no more than 1 month old at the time of application.

Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

No applications for increased repeats will be authorised.

5827Q	Tablet 25 mg (as olamine)	28	5	..	1558.52	Revolade	GK
5828R	Tablet 50 mg (as olamine)	28	5	..	3070.52	Revolade	GK

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

ROMIPLOSTIM

Note

Romiplostim is not PBS-subsidised as an alternative to splenectomy.

Any queries concerning the arrangements to prescribe romiplostim may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe romiplostim should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

Further prescribing information is on the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:

(1) Splenectomised and:

(a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and

(b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;

OR

(2) Not splenectomised and:

(a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2 mg/kg/day of prednisone for at least 4-6 weeks; and

(b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and

(c) in whom splenectomy is contraindicated for medical reasons.

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:

(a) a platelet count of less than or equal to 20,000 million per L;

OR

(b) a platelet count of 20-30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.

The authority application must be made in writing and must include:

(1) a completed authority prescription form,

(2) a signed patient acknowledgement,

(3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],

(4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and

(5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.

The full blood count must be no more than 1 month old at the time of application.

At the time of the written authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1 microgram/kg. Up to 1 repeat may be requested with the initial written application.

Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The dose (microgram/kg/week) must be provided at the time of application.

Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.

Authority approval will not be given for doses of higher than 10 micrograms/kg/week.

Note

Patients will be able to trial either eltrombopag and/or romiplostim within the initial 24 weeks treatment period. Patients who fail to demonstrate a response to treatment with either eltrombopag and/or romiplostim under the initial restriction will not be eligible to receive further PBS-subsidised treatment with either of these drugs.

Authority required

Initial (grandfather patients)

Initial PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with romiplostim prior to 1 April 2011 and in

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

whom the criteria for initial treatment can be demonstrated to have been met at the time romiplostim was commenced.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form,
- (2) a signed patient acknowledgement,
- (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and
- (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.

For patients whose dose of romiplostim had been stable for at least 4 weeks at the time of the initial application for PBS-subsidy, the medical practitioner should request sufficient number of vials based on the weight of the patient and dose (microgram/kg/week) to provide up to 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.

Where the patient is in the titration phase of treatment with romiplostim, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1 microgram/kg. Up to 1 repeat may be requested with the initial written application.

Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The dose (microgram/kg/week) must be provided at the time of application.

Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.

Authority approval will not be given for doses of higher than 10 micrograms/kg/week.

Authority required

Continuing therapy or re-initiation after a break in therapy

First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with romiplostim during the initial period of PBS-subsidised treatment.

For the purposes of this restriction, a sustained platelet response is defined as:

- (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised romiplostim,

AND either of the following:

- (b) a platelet count greater than or equal to 50,000 million per L on at least four (4) occasions, each at least one week apart;

OR

- (c) a platelet count greater than 30,000 million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.

Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:

- (1) a completed authority prescription form, and
- (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and
- (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).

The most recent platelet count must be no more than one month old at the time of application.

The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone.

Authority approval will not be given for doses of higher than 10 micrograms/kg/week.

Authority required

Second and subsequent applications for continuing therapy

Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with romiplostim and who continues to display a response to treatment with romiplostim.

For the purposes of this restriction, a continuing response to treatment with romiplostim is defined as:

- (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with romiplostim,

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
AND either of the following: (b) a platelet count greater than or equal to 50,000 million per L OR (c) a platelet count greater than 30,000 million per L and which is double the baseline platelet count. Platelet counts must be no more than 1 month old at the time of application. Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised. Authority approval will not be given for doses of higher than 10 micrograms/kg/week. <u>Note</u> Special Pricing Arrangements apply.						
9697J	Powder for injection 375 micrograms (250 micrograms in 0.5 mL when reconstituted)	1	1023.12	Nplate AN
9699L	Powder for injection 625 micrograms (500 micrograms in 1 mL when reconstituted)	1	2001.52	Nplate AN

Antianemic preparations

Other antianemic preparations *Other antianemic preparations*

DARBEPOETIN ALFA

Authority required

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

6320P	Injection 10 micrograms in 0.4 mL pre-filled syringe	8	5	..	*376.84	Aranesp	AN
6321Q	Injection 20 micrograms in 0.5 mL pre-filled syringe	8	5	..	*703.96	Aranesp	AN
6322R	Injection 30 micrograms in 0.3 mL pre-filled syringe	8	5	..	*960.68	Aranesp	AN
6323T	Injection 40 micrograms in 0.4 mL pre-filled syringe	8	5	..	*1160.12	Aranesp	AN
6324W	Injection 50 micrograms in 0.5 mL pre-filled syringe	8	5	..	*1423.30	Aranesp	AN
6325X	Injection 60 micrograms in 0.3 mL pre-filled syringe	8	5	..	*1663.18	Aranesp	AN
6326Y	Injection 100 micrograms in 0.5 mL pre-filled syringe	8	5	..	*2667.02	Aranesp	AN
6365B	Injection 150 micrograms in 0.3 mL pre-filled syringe	8	5	..	*3951.02	Aranesp	AN
6438W	Injection 80 micrograms in 0.4 mL pre-filled syringe	8	5	..	*2174.52	Aranesp	AN
6488L	Injection 20 micrograms in 0.5 mL pre-filled injection pen	8	5	..	*703.96	Aranesp SureClick	AN
6489M	Injection 40 micrograms in 0.4 mL pre-filled injection pen	8	5	..	*1160.12	Aranesp SureClick	AN
6490N	Injection 60 micrograms in 0.3 mL pre-filled injection pen	8	5	..	*1663.16	Aranesp SureClick	AN
6491P	Injection 80 micrograms in 0.4 mL pre-filled injection pen	8	5	..	*2174.52	Aranesp SureClick	AN
6492Q	Injection 100 micrograms in 0.5 mL pre-filled injection pen	8	5	..	*2667.00	Aranesp SureClick	AN
6493R	Injection 150 micrograms in 0.3 mL pre-filled injection pen	8	5	..	*3951.00	Aranesp SureClick	AN

EPOETIN ALFA

Authority required

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

6204M	Injection 2,000 units in 0.5 mL pre-filled syringe	12	5	..	*544.00	Eprex 2000	JC
6205N	Injection 3,000 units in 0.3 mL pre-filled syringe	12	5	..	*700.10	Eprex 3000	JC
6206P	Injection 4,000 units in 0.4 mL pre-filled syringe	12	5	..	*889.80	Eprex 4000	JC
6207Q	Injection 10,000 units in 1 mL pre-filled syringe	12	5	..	*2016.82	Eprex 10000	JC
6251B	Injection 1,000 units in 0.5 mL pre-filled syringe	12	5	..	*297.00	Eprex 1000	JC
6302Q	Injection 5,000 units in 0.5 mL pre-filled syringe	12	5	..	*1103.86	Eprex 5000	JC

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer	
					Max. Qty \$		
6303R	Injection 6,000 units in 0.6 mL pre-filled syringe	12	5	..	*1301.66	Eprex 6000	JC
6305W	Injection 8,000 units in 0.8 mL pre-filled syringe	12	5	..	*1674.44	Eprex 8000	JC
6339P	Injection 40,000 units in 1 mL pre-filled syringe	2	5	..	*1300.52	Eprex 40,000	JC
6434P	Injection 20,000 units in 0.5 mL pre-filled syringe	12	5	..	*3922.52	Eprex 20,000	JC

EPOETIN BETA

Authority required

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

6480C	Injection 2,000 units in 0.3 mL pre-filled syringe	12	5	..	*544.00	NeoRecormon	RO
6481D	Injection 3,000 units in 0.3 mL pre-filled syringe	12	5	..	*700.10	NeoRecormon	RO
6482E	Injection 4,000 units in 0.3 mL pre-filled syringe	12	5	..	*889.80	NeoRecormon	RO
6483F	Injection 5,000 units in 0.3 mL pre-filled syringe	12	5	..	*1103.88	NeoRecormon	RO
6484G	Injection 6,000 units in 0.3 mL pre-filled syringe	12	5	..	*1301.66	NeoRecormon	RO
6485H	Injection 10,000 units in 0.6 mL pre-filled syringe	12	5	..	*2016.82	NeoRecormon	RO
6486J	Injection 20,000 units in 0.6 mL pre-filled syringe	12	5	..	*3922.52	NeoRecormon	RO

EPOETIN LAMBDA

Note

Epoetin lambda should only be administered by the intravenous route.

Authority required

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

9588P	Injection 5,000 units in 0.5 mL pre-filled syringe	12	5	..	*1048.22	Novicrit	NV
9590R	Injection 6,000 units in 0.6 mL pre-filled syringe	12	5	..	*1235.60	Novicrit	NV
9593X	Injection 8,000 units in 0.8 mL pre-filled syringe	12	5	..	*1588.76	Novicrit	NV
9595B	Injection 10,000 units in 1 mL pre-filled syringe	12	5	..	*1913.12	Novicrit	NV
9685R	Injection 1,000 units in 0.5 mL pre-filled syringe	12	5	..	*281.70	Novicrit	NV
9686T	Injection 2,000 units in 1 mL pre-filled syringe	12	5	..	*515.70	Novicrit	NV
9687W	Injection 3,000 units in 0.3 mL pre-filled syringe	12	5	..	*663.60	Novicrit	NV
9688X	Injection 4,000 units in 0.4 mL pre-filled syringe	12	5	..	*843.30	Novicrit	NV

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

Authority required

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

9574X	Injection 30 micrograms in 0.3 mL pre-filled syringe	2	5	..	*390.46	Mircera	RO
9575Y	Injection 50 micrograms in 0.3 mL pre-filled syringe	2	5	..	*646.44	Mircera	RO
9576B	Injection 75 micrograms in 0.3 mL pre-filled syringe	2	5	..	*938.38	Mircera	RO
9577C	Injection 100 micrograms in 0.3 mL pre-filled syringe	2	5	..	*1205.34	Mircera	RO
9578D	Injection 120 micrograms in 0.3 mL pre-filled syringe	2	5	..	*1388.16	Mircera	RO
9579E	Injection 200 micrograms in 0.3 mL pre-filled syringe	2	5	..	*1970.82	Mircera	RO
9580F	Injection 360 micrograms in 0.6 mL pre-filled syringe	2	5	..	*3373.04	Mircera	RO

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Cardiovascular system

Antihypertensives

Other antihypertensives

Other antihypertensives

AMBRISENTAN

Caution

Ambrisentan is a category X drug and must not be given to pregnant women. Pregnancy must be avoided during treatment and for at least 3 months following cessation of treatment with this drug.

Note

Any queries concerning the arrangements to prescribe ambrisentan may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

(a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND

(b) iloprost trometamol, of:

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND

— drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND

(c) epoprostenol sodium, of:

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND

(d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND

(e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND

(f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (c) WHO Functional Class IV primary pulmonary hypertension; OR
- (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial treatment with ambrisentan of patients with one of the following:

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised ambrisentan after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with ambrisentan; OR
- (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than ambrisentan.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with ambrisentan of patients who have received approval for initial PBS-subsidised treatment with ambrisentan and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of ambrisentan treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised. Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

Special Pricing Arrangements apply.

9648T	Tablet 5 mg	30	4081.52	Volibris	GK
9649W	Tablet 10 mg	30	4081.52	Volibris	GK

BOSENTAN MONOHYDRATE

Caution

Bosentan monohydrate is a category X drug and must not be given to pregnant women. Pregnancy must be avoided during treatment and for at least 3 months following cessation of treatment with this drug.

Note

Any queries concerning the arrangements to prescribe bosentan monohydrate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(b) iloprost trometamol, of:

- primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
- primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
- drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND

(c) epoprostenol sodium, of:

- primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
- primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND

(d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND

(e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND

(f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (c) WHO Functional Class IV primary pulmonary hypertension; OR
- (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR

(e) WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Applications for authorisation must be in writing and must include:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
 (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 (i) RHC composite assessment; and
 (ii) ECHO composite assessment; and
 (iii) 6MWT; and
 (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial treatment with bosentan monohydrate of patients with one of the following:

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR
 (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than bosentan monohydrate.

Applications for authorisation must be in writing and must include:

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
 (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
 (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
 (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
 (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 (i) RHC composite assessment; and
 (ii) ECHO composite assessment; and
 (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Cessation of treatment (all patients)

Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to connective tissue disease or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.

Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) [see Note on authority approval requirements].

Approval will only be granted for the 62.5 mg tablet strength. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.

Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month.

Note

Special Pricing Arrangements apply.

6429J	Tablet 62.5 mg (base)	60	4081.52	Tracleer	AT
6430K	Tablet 125 mg (base)	60	4081.52	Tracleer	AT

EPOPROSTENOL SODIUM

Note

Any queries concerning the arrangements to prescribe epoprostenol sodium may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

(a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND

(b) iloprost trometamol, of:

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND

— drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND

(c) epoprostenol sodium, of:

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND

(d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND

(e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND

(f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with epoprostenol sodium of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class IV primary pulmonary hypertension; OR
- (b) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial PBS-subsidised treatment with epoprostenol sodium of patients with one of the following:

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR
- (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR
- (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and
- (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
<p>The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months) except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p> <p>The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p>						
5036C	Powder for I.V. infusion 500 micrograms (base) infusion administration set	1	50.10	Flolan Kit GK
5042J	Powder for I.V. infusion 1.5 mg (base) infusion administration set	1	89.75	Flolan Kit GK

ILOPROST TROMETAMOL

Note

Any queries concerning the arrangements to prescribe iloprost trometamol may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 - drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND
- (c) epoprostenol sodium, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
- (e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
- (f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

(including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with iloprost and who have been assessed by a physician from a designated hospital to have:

WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class IV primary pulmonary hypertension; OR
- (c) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR
- (d) WHO Functional Class IV drug-induced pulmonary arterial hypertension.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial PBS-subsidised treatment with iloprost trometamol of patients with one of the following:

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised iloprost trometamol after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with iloprost trometamol; OR
- (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than iloprost trometamol; OR
- (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and
- (5) for WHO Functional Class III patients, where this is the first application for iloprost trometamol, assessment details of the PBS-subsidised PAH

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

agent they have failed to respond to.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with iloprost trometamol of patients who have received approval for initial PBS-subsidised treatment with iloprost trometamol, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of iloprost trometamol treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

Special Pricing Arrangements apply.

6456T	Solution for inhalation 20 micrograms (base) in 2 mL	30	1122.52	Ventavis	BN
-------	--	----	----	----	---------	----------	----

SILDENAFIL CITRATE

Note

Any queries concerning the arrangements to prescribe sildenafil citrate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 — primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 — drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND
 (c) epoprostenol sodium, of:
 — primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 — primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
 (e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
 (f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial PBS-subsidised treatment with sildenafil citrate of patients with one of the following:

(a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised sildenafil citrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with sildenafil citrate; OR

(b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than sildenafil citrate.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with sildenafil citrate of patients who have received approval for initial PBS-subsidised treatment with sildenafil citrate, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of sildenafil citrate treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

9605M	Tablet 20 mg (base)	90	940.89	Revatio	PF
-------	---------------------	----	----	----	--------	---------	----

TADALAFIL

Note

Any queries concerning the arrangements to prescribe tadalafil may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 - drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND
- (c) epoprostenol sodium, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
- (e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
- (f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

(RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with tadalafil of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with tadalafil of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO;

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial treatment with tadalafil of patients with one of the following:

- (a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised tadalafil after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with tadalafil; OR
- (b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than tadalafil.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with tadalafil of patients who have received approval for initial PBS-subsidised treatment with tadalafil, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of tadalafil treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	
The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised. Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).						
1304P	Tablet 20 mg	56	878.59	Adcirca LY

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Systemic hormonal preparations, excl. sex hormones and insulins

Pituitary and hypothalamic hormones and analogues

Hypothalamic hormones

Somatostatin and analogues

LANREOTIDE ACETATE

Authority required

Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND

- (a) after failure of other therapy including dopamine agonists; or
- (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or
- (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.

In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (6 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.

Treatment must cease if IGF1 is not lower after 3 months treatment.

6332G	Powder for suspension for injection 30 mg (base) with diluent ampoule	2	11	..	*1546.52	Somatuline LA	IS
-------	---	---	----	----	----------	---------------	----

LANREOTIDE ACETATE

Authority required

Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND

- (a) after failure of other therapy including dopamine agonists; or
- (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or
- (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.

In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.

Treatment must cease if IGF1 is not lower after 3 months treatment;

Functional carcinoid tumour causing intractable symptoms. The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.

Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

6423C	Injection 60 mg (base) in single dose pre-filled syringe	2	11	..	*2736.52	Somatuline Autogel	IS
6424D	Injection 90 mg (base) in single dose pre-filled syringe	2	11	..	*3626.52	Somatuline Autogel	IS
6425E	Injection 120 mg (base) in single dose pre-filled syringe	2	11	..	*4526.52	Somatuline Autogel	IS

OCTREOTIDE

Authority required

Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND

- (a) after failure of other therapy including dopamine agonists; or
- (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or
- (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.

In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.

Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100 micrograms 3 times daily;

Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms. The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.

Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

6227R	Injection 50 micrograms (as acetate) in 1 mL	90	11	..	*650.38 ^a	Hospira Pty Limited	HH
-------	--	----	----	----	----------------------	---------------------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	
6228T	Injection 100 micrograms (as acetate) in 1 mL	90	11	..	*1282.90	^a Octreotide MaxRx GQ
						^a Sandostatin 0.05 NV
						^a Hospira Pty Limited HH
						^a Octreotide MaxRx GQ
6229W	Injection 500 micrograms (as acetate) in 1 mL	90	11	..	*6241.00	^a Sandostatin 0.1 NV
						^a Hospira Pty Limited HH
						^a Octreotide MaxRx GQ
						^a Sandostatin 0.5 NV

OCTREOTIDE

Authority required

Acromegaly in a patient controlled on Sandostatin subcutaneous injections.

In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.

Treatment must cease if IGF1 is not lower after 3 months of treatment;

Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.

Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

6426F	Injection (modified release) 10 mg (as acetate), vial and diluent syringe	1	11	..	1353.38	Sandostatin LAR	NV
6427G	Injection (modified release) 20 mg (as acetate), vial and diluent syringe	1	11	..	1786.33	Sandostatin LAR	NV
6428H	Injection (modified release) 30 mg (as acetate), vial and diluent syringe	1	11	..	2223.98	Sandostatin LAR	NV

Calcium homeostasis

Anti-parathyroid agents

Other anti-parathyroid agents

CINACALCET

Authority required

Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50 pmol per L, not responding to conventional therapy.

Note

During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.

During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability. Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.

"Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.

Authority required

Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15 pmol per L and less than 50 pmol per L AND an (adjusted) serum calcium concentration at least 2.6 mmol per L, not responding to conventional treatment.

Note

During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.

During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability. Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

"Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.

Note

Special Pricing Arrangements apply.

9625N	Tablet 30 mg (as hydrochloride)	56	5	..	*623.98	Sensipar	AN
9626P	Tablet 60 mg (as hydrochloride)	56	5	..	*1233.96	Sensipar	AN
9627Q	Tablet 90 mg (as hydrochloride)	56	5	..	*1827.68	Sensipar	AN

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Antiinfectives for systemic use

Antibacterials for systemic use

Macrolides, lincosamides and streptogramins

Macrolides

AZITHROMYCIN

Authority required

Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre.

6221K	Tablet 600 mg (as dihydrate)	16	5	..	*125.04	Zithromax	PF
-------	------------------------------	----	---	----	---------	-----------	----

CLARITHROMYCIN

Authority required

Treatment of Mycobacterium avium complex infections.

6151R	Tablet 250 mg	100	2	..	37.00	Klacid	AB
6152T	Tablet 500 mg	100	2	..	65.84	Klacid	AB

Antimycobacterials

Drugs for treatment of tuberculosis

Antibiotics

RIFABUTIN

Authority required

Treatment of Mycobacterium avium complex infections in HIV-positive patients;

Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre.

6195C	Capsule 150 mg	120	5	..	*618.04	Mycobutin	PF
-------	----------------	-----	---	----	---------	-----------	----

Antivirals for systemic use

Direct acting antivirals

Nucleosides and nucleotides excl. reverse transcriptase inhibitors

CIDOFOVIR

Authority required

Treatment of cytomegalovirus retinitis in patients with AIDS.

6247T	Solution for I.V. infusion 375 mg (anhydrous) in 5 mL single use vial	4	3	..	*3646.52	Vistide	GI
-------	---	---	---	----	----------	---------	----

GANCICLOVIR

Authority required

Cytomegalovirus retinitis in severely immunocompromised patients;

Prophylaxis of cytomegalovirus disease in bone marrow transplant patients at risk of cytomegalovirus disease;

Prophylaxis of cytomegalovirus disease in solid organ transplant patients at risk of cytomegalovirus disease.

6136Y	Powder for I.V. infusion 500 mg (as sodium)	10	1	..	*588.92	Cymevene	RO
-------	---	----	---	----	---------	----------	----

VALACICLOVIR

Authority required

Prophylaxis of cytomegalovirus (CMV) infection and disease following renal transplantation in patients at risk of CMV disease.

6280M	Tablet 500 mg (as hydrochloride)	500	2	..	*2162.42	^a APO-Valaciclovir	TX
						^a Valaciclovir RBX	RA
						^a Valtrex	GK
						^a Valvala	NV

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

^a Zelitrex GM

VALGANCICLOVIR HYDROCHLORIDE

Authority required

Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome;

Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease.

6357N	Tablet 450 mg (base)	120	5	..	*4538.12	Valcyte	RO
9675F	Powder for oral solution 50 mg (base) per mL, 100 mL	11	5	..	*#4623.96	Valcyte	RO

Phosphonic acid derivatives

FOSCARNET SODIUM

Authority required

Treatment of cytomegalovirus retinitis in patients with AIDS;

Treatment of aciclovir-resistant herpes simplex virus infection in immunocompromised patients with HIV infection.

6134W	I.V. infusion 24 mg per mL, 250 mL	6	1	..	1224.02	Foscavir	IX
-------	------------------------------------	---	---	----	---------	----------	----

Protease inhibitors

ATAZANAVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6451M	Capsule 150 mg (as sulfate)	120	5	..	*1090.34	Reyataz	BQ
6452N	Capsule 200 mg (as sulfate)	120	5	..	*1438.28	Reyataz	BQ
9614B	Capsule 300 mg (as sulfate)	60	5	..	*1090.34	Reyataz	BQ
9646Q	Capsule 100 mg (as sulfate)	120	5	..	*730.24	Reyataz	BQ

DARUNAVIR

Authority required

Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance, and who has not demonstrated darunavir resistance associated mutations detected on resistance testing.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

5823L	Tablet 400 mg (as ethanolate)	120	5	..	*1444.80	Prezista	JC
-------	-------------------------------	-----	---	----	----------	----------	----

DARUNAVIR

Authority required

Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir twice daily in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

5000E	Tablet 600 mg (as ethanolate)	120	5	..	*2143.94	Prezista	JC
9581G	Tablet 150 mg (as ethanolate)	240	5	..	1095.23	Prezista	JC

FOSAMPRENAVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer	
					Price for Max. Qty \$		
6453P	Tablet 700 mg (as calcium)	120	5	..	*795.18	Telzir	VI
6454Q	Oral liquid 50 mg (as calcium) per mL, 225 mL	8	5	..	*851.48	Telzir	VI

INDINAVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6202K	Capsule 400 mg (as sulfate)	360	5	..	*952.92	Crixivan 400 mg	MK
-------	-----------------------------	-----	---	----	---------	-----------------	----

RITONAVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6494T	Oral solution 600 mg per 7.5 mL (80 mg per mL), 90 mL	10	5	..	*952.92	Norvir	VE
9677H	Tablet 100 mg	720	5	..	*1028.68	Norvir	VE

SAQUINAVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6498B	Tablet 500 mg (as mesylate)	240	5	..	*1057.64	Invirase	RO
-------	-----------------------------	-----	---	----	----------	----------	----

TIPRANAVIR

Authority required

Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 200 mg ritonavir twice daily in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

Note

Special Pricing Arrangements apply.

9610T	Capsule 250 mg	240	5	..	*2188.52	Aptivus	BY
-------	----------------	-----	---	----	----------	---------	----

Nucleoside and nucleotide reverse transcriptase inhibitors

ABACAVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6264Q	Tablet 300 mg (as sulfate)	120	5	..	*593.08	Ziagen	VI
6265R	Oral solution 20 mg (as sulfate) per mL, 240 mL	8	5	..	*689.96	Ziagen	VI

ADEFOVIR DIPIVOXIL

Authority required

Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:

(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;

Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.

6450L	Tablet 10 mg	60	5	..	*1296.52	Hepsera	GI
-------	--------------	----	---	----	----------	---------	----

DIDANOSINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6298L	Capsule 125 mg (containing enteric coated beadlets)	60	5	..	*298.62	Videx EC	BQ
6299M	Capsule 200 mg (containing enteric coated beadlets)	60	5	..	*346.40	Videx EC	BQ
6300N	Capsule 250 mg (containing enteric coated beadlets)	60	5	..	*431.34	Videx EC	BQ
6301P	Capsule 400 mg (containing enteric coated beadlets)	60	5	..	*686.24	Videx EC	BQ

EMTRICITABINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6137B	Capsule 200 mg	60	5	..	*593.08	Emtriva	GI
-------	----------------	----	---	----	---------	---------	----

ENTECAVIR MONOHYDRATE

Authority required

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:

(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;

(2) Evidence of chronic liver injury as determined by:

- (a) Confirmed elevated serum ALT; or
- (b) Liver biopsy;

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

PBS-subsidised entecavir monohydrate must be used as monotherapy.

9602J	Tablet 0.5 mg	60	5	..	*805.86	Baraclude	BQ
-------	---------------	----	---	----	---------	-----------	----

ENTECAVIR MONOHYDRATE

Authority required

Chronic hepatitis B in a patient without cirrhosis who has failed lamivudine and who satisfies all of the following criteria:

(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or

(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;

Chronic hepatitis B in a patient with cirrhosis who has failed lamivudine and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Note

PBS-subsidised entecavir monohydrate must be used as monotherapy.

9603K	Tablet 1 mg	60	5	..	*1296.52	Baraclude	BQ
-------	-------------	----	---	----	----------	-----------	----

LAMIVUDINE

Authority required

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:

(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;

(2) Evidence of chronic liver injury as determined by:

(a) Confirmed elevated serum ALT; or

(b) Liver biopsy;

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

6257H	Tablet 100 mg	56	5	..	*267.50	Zeffix	GK
6271C	Oral solution 5 mg per mL, 240 mL	5	5	..	*311.87	Zeffix	GK

LAMIVUDINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6193Y	Tablet 150 mg	120	5	..	*499.26	^a 3TC	VI
						^a Lamivudine RBX	RA
6194B	Oral solution 10 mg per mL, 240 mL	8	5	..	*610.92	3TC	VI
6435Q	Tablet 300 mg	60	5	..	*499.26	^a 3TC	VI
						^a Lamivudine RBX	RA

STAVUDINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6186N	Capsule 20 mg	120	5	..	*588.92	Zerit	BQ
6189R	Capsule 30 mg	120	5	..	*700.58	Zerit	BQ
6190T	Capsule 40 mg	120	5	..	*931.92	Zerit	BQ

TELBIVUDINE

Authority required

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:

(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;

(2) Evidence of chronic liver injury as determined by:

(a) Confirmed elevated serum ALT; or

(b) Liver biopsy;

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer	
					Max. Qty \$		
9630W	Tablet 600 mg	56	5	..	*528.36	Sebivo	NV

TENOFOVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

Authority required

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:

- (1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;
- (2) Evidence of chronic liver injury as determined by:
 - (a) Confirmed elevated serum ALT; or
 - (b) Liver biopsy;

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.

Authority required

Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:

- (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
- (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;

Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.

6358P	Tablet containing tenofovir disoproxil fumarate 300 mg	60	5	..	*1011.36	Viread	GI
-------	--	----	---	----	----------	--------	----

ZIDOVUDINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6153W	Capsule 100 mg	400	5	..	*861.24	Retrovir	GK
6154X	Capsule 250 mg	240	5	..	*1279.28	Retrovir	GK
6155Y	Syrup 10 mg per mL, 200 mL	15	5	..	*706.72	Retrovir	GK

Non-nucleoside reverse transcriptase inhibitors

EFAVIRENZ

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6356M	Tablet 600 mg	60	5	..	*571.40	Stocrin	MK
6372J	Oral solution 30 mg per mL, 180 mL	7	5	..	*599.63	Stocrin	MK
9618F	Tablet 200 mg	180	5	..	*571.40	Stocrin	MK

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

ETRAVIRINE

Authority required

Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

5062K	Tablet 200 mg	120	5	..	*1279.52	Intelence	JC
-------	---------------	-----	---	----	----------	-----------	----

NEVIRAPINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6215D	Tablet 200 mg	120	5	..	*571.40	Viramune	BY
9571R	Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL	10	5	..	*1396.52	Viramune	BY

NEVIRAPINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient who has been stabilised on nevirapine immediate release with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

1129K	Tablet 400 mg (extended release)	60	5	..	*571.40	Viramune XR	BY
-------	----------------------------------	----	---	----	---------	-------------	----

RILPIVIRINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

1170N	Tablet 25 mg (as hydrochloride)	60	5	..	*571.40	Edurant	JC
-------	---------------------------------	----	---	----	---------	---------	----

Antivirals for treatment of HIV infections, combinations

ABACAVIR with LAMIVUDINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection.

6458X	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	60	5	..	*1084.30	Kivexa	VI
-------	---	----	---	----	----------	--------	----

ABACAVIR with LAMIVUDINE and ZIDOVUDINE

Authority required

Initial treatment of HIV infection in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection.

6327B	Tablet containing abacavir 300 mg (as sulfate) with lamivudine 150 mg and zidovudine 300 mg	120	5	..	*1661.18	Trizivir	VI
-------	---	-----	---	----	----------	----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
------	---	-------------	----------------	---------------	--	-----------------------------

LAMIVUDINE with ZIDOVUDINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6234D	Tablet 150 mg-300 mg	120	5	..	*1113.48	Combivir	VI
-------	----------------------	-----	---	----	----------	----------	----

LOPINAVIR with RITONAVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6341B	Oral liquid 400 mg-100 mg per 5 mL, 60 mL	10	5	..	*1336.52	Kaletra	VF
-------	---	----	---	----	----------	---------	----

6495W	Tablet 200 mg-50 mg	240	5	..	*1416.52	Kaletra	VF
-------	---------------------	-----	---	----	----------	---------	----

9633B	Tablet 100 mg-25 mg	120	5	..	*362.72	Kaletra	VF
-------	---------------------	-----	---	----	---------	---------	----

TENOFOVIR with EMTRICITABINE

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

6468K	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	60	5	..	*1576.72	Truvada	GI
-------	--	----	---	----	----------	---------	----

TENOFOVIR with EMTRICITABINE and EFAVIRENZ

Authority required

Initial treatment of HIV infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease:

Continuing treatment of HIV infection where the patient has previously received PBS-subsidised therapy for HIV infection.

9650X	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg and efavirenz 600 mg	60	5	..	*2119.88	Atripla	GI
-------	---	----	---	----	----------	---------	----

TENOFOVIR with EMTRICITABINE and RILPIVIRINE

Authority required

Initial treatment of HIV infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease:

Continuing treatment of HIV infection where the patient has previously received PBS-subsidised therapy for HIV infection.

1490K	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg and rilpivirine 25 mg (as hydrochloride)	60	5	..	*2119.88	Eviplera	GI
-------	---	----	---	----	----------	----------	----

Other antivirals

ENFUVIRTIDE

Authority required

Ramiprity requirement

Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

6455R	Pack containing 60 vials powder for injection 90 mg with 60 vials water for injections 1.1 mL (with syringes and swabs)	2	5	..	*4472.52	Fuzeon	RO
-------	---	---	---	----	----------	--------	----

MARAVIROC

Authority required

Treatment, in addition to optimised background therapy in combination with other antiretroviral agents, of an antiretroviral experienced patient infected with only CCR5-tropic HIV-1, who, after each of at least three different antiretroviral regimens that have included one drug from at least 3

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance. A tropism assay to determine CCR5 only strain status is required prior to initiation. Individuals with CXCR4 tropism demonstrated at any time point are not eligible.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

9572T	Tablet 150 mg	120	5	..	*1881.92	Celsentri	VI
9573W	Tablet 300 mg	120	5	..	*1881.92	Celsentri	VI

RALTEGRAVIR

Authority required

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

9629T	Tablet 400 mg (as potassium)	120	5	..	*1377.62	Isentress	MK
-------	------------------------------	-----	---	----	----------	-----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Antineoplastic and immunomodulating agents

Antineoplastic agents

Antimetabolites

Pyrimidine analogues

AZACITIDINE

Note

Any queries concerning the arrangements to prescribe azacitidine may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe azacitidine should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Initial PBS-subsidised treatment of a patient with:

- (1) Myelodysplastic syndrome classified as Intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS); OR
- (2) Chronic Myelomonocytic Leukaemia (10% to 29% marrow blasts without Myeloproliferative Disorder); OR
- (3) Acute Myeloid Leukaemia with 20 to 30% marrow blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) Classification.

Classification of a patient as Intermediate-2 requires a score of 1.5 to 2.0 on the IPSS, achieved with the possible combinations:

1. 11% to 30% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 0 to 1 cytopenias; OR
2. 11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 0 to 1 cytopenias; OR
3. 11% to 20% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR
4. 5% to 10% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR
5. 5% to 10% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias; OR
6. less than 5% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), and 2 to 3 cytopenias.

Classification of a patient as high risk requires a score of 2.5 or more on the IPSS, achieved with the possible combinations:

1. 21% to 30% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR
2. 21% to 30% marrow blasts with intermediate (other abnormalities) or poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR
3. 11% to 20% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR
4. 11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias.

The first authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Azacitidine PBS Authority Application - Supporting Information Form; and
- (c) a copy of the bone marrow biopsy report demonstrating that the patient has myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia; and
- (d) a copy of the full blood examination report; and
- (e) for myelodysplastic syndrome, a copy of the pathology report detailing the cytogenetics demonstrating intermediate-2 or high risk disease according to the International Prognostic Scoring System (IPSS); and
- (f) a signed patient acknowledgment form.

No more than three cycles will be authorised.

Note

Special Pricing Arrangements apply.

6100C	Powder for injection 100 mg	14	2	..	*7746.56	Vidaza	CJ
-------	-----------------------------	----	---	----	----------	--------	----

AZACITIDINE

Note

Any queries concerning the arrangements to prescribe azacitidine may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe azacitidine should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Continuing treatment of a patient with:

- (1) Myelodysplastic syndrome classified as Intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS); OR
- (2) Chronic Myelomonocytic Leukaemia (10% to 29% marrow blasts without Myeloproliferative Disorder); OR
- (3) Acute Myeloid Leukaemia with 20 to 30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) Classification; who has previously been issued with an authority prescription for azacitidine and does not have progressive disease.

Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Up to six cycles will be authorised.

Note

Special Pricing Arrangements apply.

6138C	Powder for injection 100 mg	14	5	..	*7746.56	Vidaza	CJ
-------	-----------------------------	----	---	----	----------	--------	----

Cytotoxic antibiotics and related substances

Anthracyclines and related substances

DOXORUBICIN HYDROCHLORIDE, PEGYLATED LIPOSOMAL

Authority required

Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive mucocutaneous involvement;

Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive visceral involvement.

6249X	Suspension for I.V. infusion 20 mg in 10 mL	4	5	..	*2538.48	Caelyx	JC
						Lipodox	ZF

Immunostimulants

Immunostimulants

Colony stimulating factors

FILGRASTIM

Authority required

For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia;

Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy;

Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation;

A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation;

A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation;

A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;

A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;

A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	
<p>drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;</p> <p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;</p> <p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage);</p> <p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months));</p> <p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months));</p> <p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned.</p>							
<u>Authority required</u>							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia;							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide);							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours;							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours;							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma;							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen);							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease;							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma;							
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP).							
1082Y	Injection 300 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*2562.06	TevaGrastim	AS
1113N	Injection 480 micrograms in 0.8 mL single use pre-filled syringe	20	11	..	*4079.10	TevaGrastim	AS
5830W	Injection 120 micrograms in 0.2 mL single use pre-filled syringe	20	11	..	*1052.74	Nivestim	HH
6126K	Injection 300 micrograms in 1 mL	20	11	..	*2562.06	Neupogen	AN
6127L	Injection 480 micrograms in 1.6 mL	20	11	..	*4079.10	Neupogen	AN
6291D	Injection 300 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*2562.06	Neupogen	AN
6292E	Injection 480 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*4079.10	Neupogen	AN
9693E	Injection 300 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*2562.06	Nivestim	HH
9695G	Injection 480 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*4079.10	Nivestim	HH

LENOGRASTIM

Authority required

Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy;

Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors;

Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation;

Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
<p>Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned.</p> <p><u>Authority required</u></p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia;</p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma;</p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours;</p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours;</p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma;</p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade);</p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma;</p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin's disease;</p> <p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma.</p>						
6337M	Powder for injection 13,400,000 i.u. (105 micrograms)	20	11	..	*1071.52	Granocyte 13 HH
6338N	Powder for injection 33,600,000 i.u. (263 micrograms)	20	11	..	*2613.72	Granocyte 34 HH

PEGFILGRASTIM

Authority required

For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia;

A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;

A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;

A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;

A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;

A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned.

Authority required

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia;

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide);

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours;

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours;

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma;

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen);

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease;

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma;

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP).

6363X	Injection 6 mg in 0.6 mL single use pre-filled syringe	1	11	..	1971.52	Neulasta	AN
-------	--	---	----	----	---------	----------	----

Interferons

INTERFERON ALFA-2a

Caution

Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required

Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase;

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:

- (1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
- (2) Evidence of chronic liver injury as determined by:
 - (a) Confirmed elevated serum ALT; or
 - (b) Liver biopsy;

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

6210W	Injection 3,000,000 i.u. in 0.5 mL single dose pre-filled syringe	30	5	..	*936.22	Roferon-A	RO
6211X	Injection 4,500,000 i.u. in 0.5 mL single dose pre-filled syringe	30	5	..	*1387.42	Roferon-A	RO
6212Y	Injection 6,000,000 i.u. in 0.5 mL single dose pre-filled syringe	30	5	..	*1833.82	Roferon-A	RO
6213B	Injection 9,000,000 i.u. in 0.5 mL single dose pre-filled syringe	30	5	..	*2727.82	Roferon-A	RO

INTERFERON ALFA-2b

Caution

Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required

Adjuvantive therapy of malignant melanoma following surgery in patients with nodal involvement;

Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase;

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:

- (1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;
- (2) Evidence of chronic liver injury as determined by:
 - (a) Confirmed elevated serum ALT; or
 - (b) Liver biopsy;

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

6218G	Solution for injection 18,000,000 i.u. in 3 mL single dose vial	15	5	..	*2727.67	Intron A	MK
6219H	Solution for injection 25,000,000 i.u. in 2.5 mL single dose vial	15	5	..	*3770.32	Intron A	MK
6246R	Solution for injection 10,000,000 i.u. in 1 mL single dose vial	15	5	..	*1536.01	Intron A	MK
6253D	Solution for injection 18,000,000 i.u. in 1.2 mL multi-dose injection pen	2	5	..	*378.30	Intron A Redipen	MK
6254E	Solution for injection 30,000,000 i.u. in 1.2 mL multi-dose injection pen	2	5	..	*626.16	Intron A Redipen	MK
6255F	Solution for injection 60,000,000 i.u. in 1.2 mL multi-dose injection pen	2	5	..	*1238.12	Intron A Redipen	MK

INTERFERON GAMMA-1b

Authority required

Treatment of chronic granulomatous disease in patients with frequent and severe infections despite adequate prophylaxis with antimicrobial agents.

6148N	Injection 2,000,000 i.u. in 0.5 mL	12	11	..	*2768.32	Imukin	BY
-------	------------------------------------	----	----	----	----------	--------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

PEGINTERFERON ALFA-2a

Caution

Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who satisfies all of the following criteria:

(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;

(2) Evidence of chronic liver injury as determined by:

(a) Confirmed elevated serum ALT; or

(b) Liver biopsy;

(3) Has received no prior peginterferon alfa therapy for the treatment of hepatitis B;

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Treatment is limited to 1 course of treatment for a duration of up to 48 weeks;

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:

(1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);

(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.

The treatment course is limited to up to 48 weeks.

Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

(a) a nurse educator/counsellor for patients; and

(b) 24 hour access by patients to medical advice; and

(c) an established liver clinic; and

(d) facilities for safe liver biopsy.

6439X	Injection 135 micrograms in 0.5 mL single use pre-filled syringe	8	5	..	*2378.32	Pegasys	RO
6449K	Injection 180 micrograms in 0.5 mL single use pre-filled syringe	8	5	..	*2746.98	Pegasys	RO

RIBAVIRIN and PEGINTERFERON ALFA-2a

Caution

Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Caution

Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.

Authority required

Patients naive to interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:

(1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);

(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.

Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).

Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

Authority required

Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

The treatment course is limited to 48 weeks. Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

6392K	Pack containing 168 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 135 micrograms	2	5	..	*3119.36	Pegasys RBV	RO
6394M	Pack containing 112 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	2	5	..	*3131.80	Pegasys RBV	RO
6395N	Pack containing 140 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	2	5	..	*3292.34	Pegasys RBV	RO
6396P	Pack containing 168 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	2	5	..	*3452.88	Pegasys RBV	RO

RIBAVIRIN and PEGINTERFERON ALFA-2b

Caution

Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Caution

Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.

Authority required

Patients naive to interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients weighing at least 27 kg who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.

Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).

Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer	
<p>HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12.</p> <p>Note Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:</p> <p>(a) a nurse educator/counsellor for patients; and (b) 24 hour access by patients to medical advice; and (c) an established liver clinic; and (d) facilities for safe liver biopsy.</p> <p>Authority required Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p> <p>Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:</p> <p>(1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive); (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.</p> <p>The treatment course is limited to 48 weeks. Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12.</p> <p>Note Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:</p> <p>(a) a nurse educator/counsellor for patients; and (b) 24 hour access by patients to medical advice; and (c) an established liver clinic; and (d) facilities for safe liver biopsy.</p>							
6400W	Pack containing 112 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 50 micrograms with diluent	2	5	..	*2166.26	Pegatron	MK
6401X	Pack containing 84 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 80 micrograms with diluent	2	5	..	*2469.24	Pegatron	MK
6405D	Pack containing 112 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 100 micrograms with diluent	2	5	..	*3146.14	Pegatron	MK

RIBAVIRIN and PEGINTERFERON ALFA-2b

Caution

Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Caution

Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.

Authority required

Patients naive to interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.

Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).

Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

Authority required

Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

The treatment course is limited to 48 weeks. Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

6402Y	Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 80 micrograms with diluent	2	5	..	*2754.18	Pegatron	MK
6407F	Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 120 micrograms with diluent	2	5	..	*3538.10	Pegatron	MK
6409H	Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent	2	5	..	*4126.04	Pegatron	MK
6410J	Pack containing 168 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent	2	5	..	*4126.04	Pegatron	MK
9634C	Pack containing 196 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent	2	5	..	*4411.00	Pegatron	MK

Immunosuppressants

Immunosuppressants

Selective immunosuppressants

ABATACEPT

Note

Any queries concerning the arrangements to prescribe abatacept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe abatacept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.

Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with abatacept.

Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with abatacept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised abatacept treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.

Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised abatacept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised abatacept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with abatacept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with abatacept.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 5 repeats may be authorised.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with abatacept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with abatacept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

9621J	Powder for I.V. infusion 250 mg	1	531.13	Orencia	BQ
-------	---------------------------------	---	----	----	--------	---------	----

EVEROLIMUS

Caution

Careful monitoring of patients is mandatory.

Authority required

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required;

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

6459Y	Tablet 0.25 mg	120	5	..	*506.34	Certican	NV
6460B	Tablet 0.5 mg	120	5	..	*1006.16	Certican	NV
6461C	Tablet 0.75 mg	240	5	..	*2930.12	Certican	NV
9582H	Tablet 1 mg	240	5	..	*3891.32	Certican	NV

MYCOPHENOLATE MOFETIL

Caution

Careful monitoring of patients is mandatory.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
<u>Authority required</u>						
Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required;						
Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required.						
<u>Note</u>						
For item codes 6208R and 1837Q, pharmaceutical benefits that have the form capsule 250 mg are equivalent for the purposes of substitution.						
1837Q	Capsule 250 mg	600	5	..	*977.44	^a Ceptolate AF
6208R	Capsule 250 mg	600	5	..	*977.38	^a APO- TX
						^a Mycophenolate
						^a CellCept RO
						^a Imulate QA
						^a Mycophenolate SZ
						^a Sandoz
						^a Pharmacor CR
						Mycophenolate 250

MYCOPHENOLATE MOFETIL

Caution

Careful monitoring of patients is mandatory.

Authority required

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required;

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

6209T	Tablet 500 mg	300	5	..	*977.38	^a	APO- TX
						^a	Mycophenolate
						^a	CellCept RO
						^a	Ceptolate AF
						^a	Imulate QA
						^a	Mycophenolate SZ
						^a	Sandoz
						^a	Pharmacor CR
							Mycophenolate 500
6364Y	Powder for oral suspension 1 g per 5 mL, 165 mL	2	5	..	*#517.71		CellCept RO

MYCOPHENOLATE SODIUM

Caution

Careful monitoring of patients is mandatory.

Authority required

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

6369F	Tablet (enteric coated) 180 mg (mycophenolic acid)	240	5	..	*394.90		Myfortic NV
6370G	Tablet (enteric coated) 360 mg (mycophenolic acid)	240	5	..	*783.26		Myfortic NV

NATALIZUMAB

Caution

Progressive multifocal leukoencephalopathy has been reported with this drug.

Note

Neurologists prescribing natalizumab under the PBS listing must be registered with the Tysabri Australian Prescribing Program.

Authority required

Initial treatment, as monotherapy, by a neurologist, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient 18 years of age or older, who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient.

Authority required

Continuing treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in a patient previously issued with an authority prescription for this drug who does not show continuing progression of disability while on treatment with this drug, and who has demonstrated compliance with, and an ability to tolerate, this therapy.

Note

Special Pricing Arrangements apply.

9624M	Solution concentrate for I.V. infusion 300 mg in 15 mL	1	5	..	2084.98	Tysabri	BD
-------	--	---	---	----	---------	---------	----

SIROLIMUS

Caution

Careful monitoring of patients is mandatory.

Authority required

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

6436R	Tablet 1 mg	200	5	..	*1493.18	Rapamune	PF
6437T	Oral solution 1 mg per mL, 60 mL	2	5	..	*979.96	Rapamune	PF
6457W	Tablet 2 mg	200	5	..	*2939.86	Rapamune	PF
9748C	Tablet 0.5 mg	200	5	..	*758.80	Rapamune	PF

Tumor necrosis factor alpha (TNF-alpha) inhibitors

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS WITH SEVERE ACTIVE JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient who has severe active juvenile idiopathic arthritis. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any 1 time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 12 month break in PBS-subsidised biological therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

(6) Withdrawal of treatment after sustained remission.

Withdrawal of treatment with bDMARDs should be considered in a patient who has achieved and sustained complete remission of disease for 12 months. A demonstration of response to the current treatment should be submitted to Medicare Australia at the time treatment is ceased.

Authority required

Initial 1 (new patient or patient recommencing after a break of more than 12 months).

Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:

- (a) who has severe active juvenile idiopathic arthritis; AND
- (b) whose parent or authorised guardian has signed a patient acknowledgement; AND
- (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND
- (d) who has demonstrated either:

- (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or
- (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:
 - oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or
 - oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months. (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)

Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.

Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.

If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

- (a) an active joint count of at least 20 active (swollen and tender) joints; OR
- (b) at least 4 active joints from the following list:
 - (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) an acknowledgement signed by a parent or authorised guardian.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 2 (change or re-commencement after break of less than 12 months).

Initial PBS-subsidised treatment with adalimumab by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:

- (a) has a documented history of severe active juvenile idiopathic arthritis; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and
- (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 3 ('grandfather' patients).

Initial PBS-subsidised supply for continuing treatment with adalimumab, by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:

- (a) has a documented history of severe active juvenile idiopathic arthritis; and
- (b) was receiving treatment with adalimumab prior to 1 March 2010; and

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and
(d) is receiving treatment with adalimumab at the time of application.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) an acknowledgement signed by a parent or authorised guardian.

A maximum of 24 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

The assessment of the patient's response to this initial course of PBS-subsidised therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.

A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A patient may only qualify for PBS-subsidised treatment under this restriction once.

Authority required

Continuing treatment.

Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:

- (a) who has a documented history of severe active juvenile idiopathic arthritis; and
- (b) who has demonstrated an adequate response to treatment with adalimumab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.

An adequate response to treatment is defined as:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

9678J	Injection 20 mg in 0.4 mL pre-filled syringe	2	1676.52	Humira	VE
-------	--	---	----	----	---------	--------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	
9679K	Injection 40 mg in 0.8 mL pre-filled syringe	2	1676.52	Humira VE
9680L	Injection 40 mg in 0.8 mL pre-filled pen	2	1676.52	Humira VE

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS WITH SEVERE ACTIVE JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient who has severe active juvenile idiopathic arthritis. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any 1 time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 12 month break in PBS-subsidised biological therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

(6) Withdrawal of treatment after sustained remission.

Withdrawal of treatment with bDMARDs should be considered in a patient who has achieved and sustained complete remission of disease for 12 months. A demonstration of response to the current treatment should be submitted to Medicare Australia at the time treatment is ceased.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Authority required

Initial 1 (new patient or patient recommencing after a break of more than 12 months).

Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:

- (a) who has severe active juvenile idiopathic arthritis; AND
- (b) whose parent or authorised guardian has signed a patient acknowledgement; AND
- (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND
- (d) who has demonstrated either:

- (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or

- (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:

- oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or

- oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months. (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)

Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.

Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.

If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

- (a) an active joint count of at least 20 active (swollen and tender) joints; OR
- (b) at least 4 active joints from the following list:
 - (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) an acknowledgement signed by a parent or authorised guardian.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 2 (change or re-commencement after break of less than 12 months).

Initial PBS-subsidised treatment with etanercept by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:

- (a) has a documented history of severe active juvenile idiopathic arthritis; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and
- (c) has not failed PBS-subsidised therapy with etanercept for this condition more than once in the current treatment cycle.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for a patient who has received PBS-subsidised treatment with etanercept in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with etanercept may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

Authority required

Continuing treatment.

Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:

- (a) who has a documented history of severe active juvenile idiopathic arthritis; and
- (b) who has demonstrated an adequate response to treatment with etanercept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.

An adequate response to treatment is defined as:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

6367D	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	1	854.12	Enbrel	PF
-------	--	---	----	----	--------	--------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS WITH SEVERE ACTIVE JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient who has severe active juvenile idiopathic arthritis. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any 1 time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 12 month break in PBS-subsidised biological therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

(6) Withdrawal of treatment after sustained remission.

Withdrawal of treatment with bDMARDs should be considered in a patient who has achieved and sustained complete remission of disease for 12 months. A demonstration of response to the current treatment should be submitted to Medicare Australia at the time treatment is ceased.

Authority required

Continuing treatment.

Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre,

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

of a patient 18 years or older:

- (a) who has a documented history of severe active juvenile idiopathic arthritis; and
- (b) who has demonstrated an adequate response to treatment with etanercept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.

An adequate response to treatment is defined as:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.

Where a patient with severe active juvenile idiopathic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50 mg may be prescribed.

9615C	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	1676.53	Enbrel	PF
9641K	Injection 50 mg in 1 mL single use auto-injector, 4	1	1676.53	Enbrel	PF

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept, golimumab and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept, golimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 4 TNF-alfa antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial PBS-subsidised TNF-alfa antagonists without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and 18 weeks of treatment for infliximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.

A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with golimumab.

A patient who commenced treatment with golimumab for active ankylosing spondylitis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with golimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patients)

Initial PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND

(a) who has at least 2 of the following:

- (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or
- (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or
- (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND

(b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.

The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.

If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.

If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.

The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

- (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND
 (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.

The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.

Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:
 - (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and
 - (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and
 - (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and
 - (iv) a signed patient acknowledgment form.

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.

At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Authority required

Initial 2 (change or re-commencement for all patients)

Initial PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with infliximab in the current treatment cycle.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].

A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.

At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Authority required

Continuing treatment for all patients

Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

- (a) has demonstrated an adequate response to treatment with infliximab; and
(b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with infliximab.

An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:

- (a) an ESR measurement no greater than 25 mm per hour; or
(b) a CRP measurement no greater than 10 mg per L; or
(c) an ESR or CRP measurement reduced by at least 20% from baseline.

Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].

All measurements provided must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with infliximab will be authorised under this criterion.

At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.

All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with infliximab. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

6448J	Powder for I.V. infusion 100 mg	1	788.29	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF- α antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF- α antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

- (1) a completed authority prescription form; and
 (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 (3) a signed patient acknowledgement.

A maximum of 22 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
 (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
 (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with infliximab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.

A maximum of 22 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
 (b) who have demonstrated an adequate response to treatment with infliximab; and
 (c) whose most recent course of PBS-subsidised bDMARD treatment was with infliximab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 2 repeats may be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

6397Q	Powder for I.V. infusion 100 mg	1	788.29	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; or
(iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

Authority required

Initial 1

Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have severe active psoriatic arthritis; and
- (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and
- (3) have failed to achieve an adequate response to:
 - (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and
 - (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or
 - (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) an active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 22 weeks treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient,

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Initial 2

Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have a documented history of severe active psoriatic arthritis; and
- (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and
- (3) have not failed treatment with infliximab during the current Treatment Cycle.

Applications for patients who have received PBS-subsidised treatment with infliximab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.

A maximum of 22 weeks treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:

- (1) who have a documented history of severe active psoriatic arthritis; and
- (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with infliximab; and
- (3) who, at the time of application, demonstrate an adequate response to treatment with infliximab.

An adequate response to treatment with infliximab is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats may be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

(Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	
6496X	Powder for I.V. infusion 100 mg	1	788.29	Remicade JC

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patients)

Initial treatment of Crohn disease in a patient assessed by CDAI.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and
- (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (c) has failed to achieve an adequate response to prior systemic therapy including:
 - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
 - (ii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

The most recent CDAI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and
 - (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and
 - (iii) the signed patient acknowledgement.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial 2

Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and
- (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and
 - (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Continuing treatment of Crohn disease in a patient assessed by CDAI.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.

The CDAI assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, a CDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial 1

Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:

- (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and
- (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and
- (c) has evidence of intestinal inflammation; and
- (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (e) has failed to achieve an adequate response to prior systemic drug therapy including:
 - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
 - (ii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) have evidence of intestinal inflammation, including:
 - (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR
 - (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR
 - (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;
- AND/OR
- (b) be assessed clinically as being in a high faecal output state;
- AND/OR
- (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and
 - (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and
 - (iii) date of the most recent clinical assessment; and
 - (iv) the signed patient acknowledgement.

All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial 2

Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and
- (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and
 - (ii). details of prior TNF alfa antagonist treatment including details of date and duration of treatment.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as:

- (a) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
 - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or
- (b) reversal of high faecal output state; or
- (c) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.

The patient's assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial 1

Initial treatment of Crohn disease in a patient with extensive small intestine disease.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and

(b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and

(c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and

(d) has failed to achieve an adequate response to prior systemic therapy including:

(i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and

(ii) immunosuppressive therapy including:

- azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
- 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
- methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220; AND/OR
- (b) have evidence of active intestinal inflammation, including:
 - (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR
 - (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR
 - (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;
- AND/OR
- (c) be assessed clinically as being in a high faecal output state; AND/OR
- (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and
 - (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or
 - (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and
 - (iii) date of the most recent clinical assessment; and
 - (iv) the signed patient acknowledgement.

All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Continuing treatment of Crohn disease in a patient with extensive small intestine disease.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50 cm of the small intestine; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as:

- (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or
- (b) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
 - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or
- (c) reversal of high faecal output state; or
- (d) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or
 - (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or
 - (iii) the date of clinical assessment.

All assessments must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial 3 (grandfather)

Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with infliximab.

Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7 March 2007; and
- (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and
 - (ii) the signed patient acknowledgement.

The current CDAI assessment must be no more than 1 month old at the time of application. The baseline CDAI assessment must be from immediately prior to commencing treatment with infliximab.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

Authority required

Initial 3

Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with infliximab.

Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7 March 2007; and
- (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; or
- (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) has demonstrated or sustained an adequate response to treatment with infliximab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.

An adequate response to infliximab treatment is defined as:

- (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or
- (b) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
 - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or
- (c) reversal of high faecal output state; or

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

(d) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or
 - (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or
 - (3) the date of clinical assessment(s); and
 - (ii) the signed patient acknowledgement.

The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with infliximab. Where a baseline assessment is not available, please call Medicare Australia on 1800 700 270 to discuss.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

9613Y	Powder for I.V. infusion 100 mg	1	788.29	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

evidence of intestinal inflammation submitted with the first authority application for a TNF- α antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF- α antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial treatment of Crohn disease in a paediatric patient.

Initial PBS-subsidised treatment by a gastroenterologist, paediatrician or consultant physician as specified in the NOTE below, of a patient aged 6 to 17 years inclusive with moderate to severe refractory Crohn disease who satisfies the following criteria:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and
- (b) whose parent or authorised guardian has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (c) has failed to achieve an adequate response to 2 of the following 3 conventional prior therapies including:
 - (i) a tapered course of steroids, starting at a dose of at least 1 mg per kg or 40 mg (whichever is the lesser) prednisolone (or equivalent), over a 6 week period;
 - (ii) an 8 week course of enteral nutrition;
 - (iii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 10 mg per square metre weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) severity of disease activity which results in a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30 as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) The most recent PCDAI assessment must be no more than 1 month old at the time of application.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

Applications for authorisation must be made in writing and must include:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

- (a) a completed authority prescription form; and
 (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient's condition; and
 (ii) details of previous systemic drug therapy [dosage, date of commencement and duration of therapy], or dates of enteral nutrition; and
 (iii) the signed patient acknowledgement.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A PCDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Continuing treatment of Crohn disease in a patient initiated on PBS-subsidised treatment as a paediatric patient.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of moderate to severe refractory Crohn disease; and
 (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
 (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 (i) the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition.

The PCDAI assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, a PCDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to receive PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial PBS-subsidised treatment of Crohn disease in a paediatric patient who has previously received non-PBS-subsidised therapy with infliximab.

Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient aged 6 to 17 years inclusive who:

- (a) has a documented history of moderate to severe refractory Crohn disease and was receiving treatment with infliximab prior to 4 July 2007; and
- (b) had a Paediatric Crohn Disease Activity Index (PCDAI) Score of greater than 30 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and
- (c) whose parent or authorised guardian has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and baseline Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition; and
 - (ii) the signed patient acknowledgement.

The current PCDAI assessment must be no more than 1 month old at the time of application. The baseline PCDAI assessment must be from immediately prior to commencing treatment with infliximab.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

9612X	Powder for I.V. infusion 100 mg	1	788.29	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF COMPLEX REFRACTORY FISTULISING CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for patients with complex refractory fistulising Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 April 2011, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 April 2011 is considered to be in their first cycle as of 1 April 2011.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 April 2011.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 April 2011, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for complex refractory fistulising Crohn disease prior to 4 November 2010 or infliximab prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1

Initial treatment of complex refractory FISTULISING CROHN DISEASE.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and
- (b) has an externally draining enterocutaneous or rectovaginal fistula; and
- (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and
 - (ii) a signed patient acknowledgement.

The most recent fistula assessment must be no more than 1 month old at the time of application.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6 will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

An assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial 2

Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.

Initial PBS-subsidised treatment with infliximab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:

- (a) has a documented history of complex refractory fistulising Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and
- (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and
 - (ii) details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.

The most recent fistula assessment must be no more than 1 month old at the time of application.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 3 doses of infliximab

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

An assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial 3 (grandfather)

Initial PBS-subsidised treatment of complex refractory FISTULISING CROHN DISEASE in a patient who has previously received non-PBS-subsidised therapy with infliximab.

Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who satisfies the following criteria:

- (a) has a documented history of complex refractory fistulising Crohn disease and was receiving treatment with infliximab prior to 1 March 2010; and
- (b) had a draining enterocutaneous or rectovaginal fistula(e) prior to commencing treatment with infliximab; and
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) is receiving treatment with infliximab at the time of application; and
- (e) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as:

- (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or
- (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current and baseline Fistula Assessment form including the date of assessment of the patient's condition; and
 - (ii) a signed patient acknowledgement.

The current fistula assessment must be no more than 1 month old at the time of application.

The baseline fistula assessment must be from immediately prior to commencing treatment with infliximab.

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

Authority required

Continuing treatment of complex refractory FISTULISING CROHN DISEASE.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of complex refractory fistulising Crohn disease; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response is defined as:

- (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or
- (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes a completed Fistula Assessment form including the date of the assessment of the patient's condition.

The fistula assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

9674E	Powder for I.V. infusion 100 mg	1	788.29	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.

From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.

There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made in the following situations:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).

All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.

(2) Assessment of response to initial treatment.

When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

(3) Application for continuing treatment.

Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.

For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

(4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.

Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

(5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

Authority required

Initial treatment [Initial 1, Whole body (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
 - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or
 - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or
 - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]]; and
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to recommence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Continuing treatment (Whole body)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis; and
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and
- (c) who have demonstrated an adequate response to their most recent course of treatment with infliximab.

An adequate response to treatment is defined as:

A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.

The most recent PASI assessment must be no more than 1 month old at the time of application.

Approval will be based on the PASI assessment of response to the most recent course of treatment with infliximab.

A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Initial treatment [Initial 1, Face, hand, foot (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
 - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or
 - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

(iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:
 - (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or
 - (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]]; and
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Authority required

Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]]; and
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

treatment.

A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Continuing treatment (Face, hand, foot)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and
- (c) who have demonstrated an adequate response to treatment with infliximab.

An adequate response to infliximab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:

- (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or
- (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

The most recent PASI assessment must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased repeats will be authorised.

9617E	Powder for I.V. infusion 100 mg	1	788.29	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

Interleukin inhibitors

TOCILIZUMAB

Note

Any queries concerning the arrangements to prescribe tocilizumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe tocilizumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form(s); and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.

Up to a maximum of 3 repeats of each strength may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form(s); and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats of each strength may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with tocilizumab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form(s); and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats of each strength may be authorised.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

9671B	Concentrate for injection 80 mg in 4 mL	1	200.88	Actemra	RO
9672C	Concentrate for injection 200 mg in 10 mL	1	492.41	Actemra	RO
9673D	Concentrate for injection 400 mg in 20 mL	1	978.30	Actemra	RO

TOCILIZUMAB

Note

Any queries concerning the arrangements to prescribe tocilizumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe tocilizumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS WITH SEVERE ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of tocilizumab for a patient who has severe active systemic juvenile idiopathic arthritis (sJIA).

From 1 May 2012, a patient receiving PBS-subsidised tocilizumab therapy is considered to be in a treatment cycle. Under these arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with PBS-subsidised tocilizumab while they continue to show a response to therapy, and
- fail to respond, or to sustain a response, to PBS-subsidised tocilizumab twice.

Once a patient has either failed or ceased to respond to 2 courses of treatment, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 12 month break in PBS-subsidised tocilizumab therapy before they are eligible to receive further PBS-subsidised tocilizumab therapy. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised tocilizumab treatment was stopped to the date of the first application for initial treatment with tocilizumab under the new treatment cycle.

A patient who was receiving PBS-subsidised tocilizumab treatment immediately prior to 1 May 2012 is considered to be in their first cycle as of 1 May 2012. A patient who has had a break in tocilizumab treatment of at least 12 months immediately prior to making a new application, on or after 1 May 2012, will commence a new treatment cycle.

A patient who has failed their first course of tocilizumab in a treatment cycle and who has a break in therapy of less than 12 months may commence a second course of treatment within the same treatment cycle.

A patient who has failed their first course of tocilizumab in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle.

(1) How to prescribe PBS-subsidised tocilizumab therapy after 1 May 2012.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised tocilizumab treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with tocilizumab following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(iii) a patient has received the first course of PBS-subsidised (initial or continuing) tocilizumab therapy in a treatment cycle and is deemed to have failed to respond or sustain a response and the treating physician wishes to trial a second course (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab for that course.

For second and subsequent courses of PBS-subsidised tocilizumab, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with tocilizumab, a patient may qualify to receive up to 24 weeks of continuing treatment with tocilizumab providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted tocilizumab supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.

(2) Treatment cycle.

Once initial treatment with PBS-subsidised tocilizumab is approved, a patient deemed to have failed to respond to the first course of treatment may have a second course without having to requalify with respect to the indices of disease severity (joint count, fever and/or CRP level and platelet count) or the prior therapy requirements, except if the patient has had a break in therapy of more than 12 months.

To ensure a patient receives the maximum treatment opportunities allowed under these arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the relevant baseline measurements of the joint count, fever and/or CRP level and platelet count submitted with the first authority application for tocilizumab.

Where a patient is deemed to have failed to respond or to sustain a response to the first course of therapy in a treatment cycle, prescribers may provide new baseline measurements for the second course of treatment within that cycle. Medicare Australia will assess response according to these revised baseline measurements. If new baseline measurements are not submitted with the initial application for the second course of treatment, then those submitted with the first course will be used by Medicare Australia to assess response to the second course.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised tocilizumab therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with tocilizumab.

A patient who commenced treatment with tocilizumab for severe active systemic juvenile idiopathic arthritis prior to 1 November 2011 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with tocilizumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with tocilizumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

(6) Withdrawal of treatment after sustained remission.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Withdrawal of treatment with tocilizumab should be considered in a patient who has achieved and sustained complete remission of disease for 12 months. A demonstration of response to the current treatment should be submitted to Medicare Australia at the time treatment is ceased.

Authority required

Initial 1 (new and recommencing patients after a break of more than 12 months)

Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:

- (a) has been diagnosed with systemic juvenile idiopathic arthritis; AND
- (b) has polyarticular course disease and either:
 - (i) failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):
 - oral or parenteral methotrexate at a dose of at least 15 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or
 - (ii) severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR
 - (c) has refractory systemic symptoms, demonstrated by:
 - an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5 mg per kg per day following a minimum of 2 months of therapy; AND
 - (d) has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.

(1) The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:

- (a) in a patient with polyarticular course disease:
 - (i) an active joint count of at least 20 active (swollen and tender) joints; OR
 - (ii) at least 4 active joints from the following list:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).
- (b) in a patient with refractory systemic symptoms:
 - (i) an active joint count of at least 2 active joints; AND
 - (ii) persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR
 - (iii) a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).

(2) Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.

Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.

If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.

The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the date of assessment of severe active systemic juvenile idiopathic arthritis;
 - (ii) details of prior treatment including dose and duration of treatment;
 - (iii) pathology reports detailing CRP and platelet count where appropriate; and
- (3) a signed patient or authorised guardian acknowledgement form.

The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.

If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle. A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)

Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:

- (a) has a documented history of systemic juvenile idiopathic arthritis; AND
- (b) has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND
- (c) has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) pathology reports detailing CRP and platelet count where appropriate.

Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.

If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle. A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 3 ('grandfather' patients)

Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:

- (a) has a documented history of systemic juvenile idiopathic arthritis; and
- (b) was receiving treatment with tocilizumab prior 1 November 2011; and
- (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and
- (d) is receiving treatment with tocilizumab at the time of application.

To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) pathology reports detailing CRP and platelet count where appropriate; and
 - (3) a signed patient or authorised guardian acknowledgement form.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.

The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab. (See NOTE (3) above for definition of baseline measurements to determine response.)

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.

Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one months supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

A patient may only qualify for PBS-subsidised treatment under this restriction once.

Authority required

Continuing treatment

Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:

- (a) has a documented history of systemic juvenile idiopathic arthritis; AND
- (b) has demonstrated an adequate response to treatment with tocilizumab.

An adequate response to treatment is defined as:

- (a) in a patient with polyarticular course disease:
 - (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
 - (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).
- (b) in a patient with refractory systemic symptoms:
 - (i) absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR
 - (ii) a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR
 - (iii) a reduction in the dose of corticosteroid by at least 30% from baseline.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) baseline and current pathology reports detailing CRP and platelet count where appropriate.

The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.

Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Monday to Friday).

If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle. A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle.

Note

Special Pricing Arrangements apply.

1419Q	Concentrate for injection 80 mg in 4 mL	1	200.88	Actemra	RO
1423X	Concentrate for injection 200 mg in 10 mL	1	492.41	Actemra	RO
1464C	Concentrate for injection 400 mg in 20 mL	1	978.30	Actemra	RO

Calcineurin inhibitors

CYCLOSPORIN

Caution

Careful monitoring of patients is mandatory.

Authority required

For use by organ or tissue transplant recipients.

6109M	Solution concentrate for I.V. infusion 50 mg in 1 mL	10	64.62	Sandimmun	NV
-------	--	----	----	----	-------	-----------	----

CYCLOSPORIN

Caution

Careful monitoring of patients is mandatory.

Authority required

Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit.

Management includes initiation, stabilisation and review of therapy as required;

Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate;

Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life;

Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired;

Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.

6125J	Oral liquid 100 mg per mL, 50 mL	4	5	..	*1309.68	Neoral	NV
6232B	Capsule 10 mg	120	5	..	*84.92	Neoral 10	NV
6352H	Capsule 25 mg	120	5	..	*166.24	^a Cicloral	SZ
						^a Neoral 25	NV
6353J	Capsule 50 mg	120	5	..	*338.84	^a Cicloral	SZ
						^a Neoral 50	NV
6354K	Capsule 100 mg	120	5	..	*683.64	^a Cicloral	SZ
						^a Neoral 100	NV

TACROLIMUS

Caution

Careful monitoring of patients is mandatory.

Authority required

Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit.

Management includes initiation, stabilisation and review of therapy as required.

6216E	Capsule 1 mg	200	5	..	*688.42	^a Prograf	JC
						^a Tacrolimus Sandoz	SZ
6217F	Capsule 5 mg	100	5	..	*1684.90	^a Prograf	JC
						^a Tacrolimus Sandoz	SZ
6328C	Capsule 0.5 mg	200	5	..	*347.48	^a Prograf	JC

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	
					^a	Tacrolimus Sandoz SZ
9681M	Capsule 0.5 mg (once daily prolonged release)	60	5	..	*108.88	Prograf XL JC
9682N	Capsule 1 mg (once daily prolonged release)	120	5	..	*415.66	Prograf XL JC
9683P	Capsule 5 mg (once daily prolonged release)	60	5	..	*1029.40	Prograf XL JC

Other immunosuppressants

LENALIDOMIDE

Note

Any queries concerning the arrangements to prescribe lenalidomide may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Any queries concerning patients who are enrolled on the Lenalidomide Compassionate program may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). These patients must demonstrate they met initial criteria prior to commencing treatment on the compassionate program and also demonstrate they do not have progressive disease. Baseline and current pathology reports must be submitted with the initial application.

Applications for authority to prescribe lenalidomide should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant. The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100 mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.

If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein and less than 200 mg per 24 hour Bence-Jones proteinuria.

Thalidomide treatment failure is defined as:

- (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or
- (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.

Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.

Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.

Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:

- (1) less than a 25% reduction in serum or urine M protein; or
- (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.

Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

(2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.

To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:

- (a) the level of serum monoclonal protein; or
- (b) Bence-Jones proteinuria — the results of 24-hour urinary light chain M protein excretion; or
- (c) the serum level of free kappa and lambda light chains; or
- (d) bone marrow aspirate or trephine; or
- (e) if present, the size and location of lytic bone lesions (not including compression fractures); or
- (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or
- (g) if present, the level of hypercalcaemia, corrected for albumin concentration.

As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10 g per L and urinary Bence-Jones protein undetectable or less than 200 mg per 24 hours) must be provided; and

(3) duration of thalidomide and daily dose prescribed; and

(4) a signed patient acknowledgment.

Note

Patients receiving lenalidomide under the PBS listing must be registered in the i-access risk management program.

Authority required

Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

Patients receiving lenalidomide under the PBS listing must be registered in the i-access risk management program.

Note

Special Pricing Arrangements apply.

9642L	Capsule 5 mg	21	5438.90	Revlimid	CJ
9643M	Capsule 10 mg	21	5689.85	Revlimid	CJ
9644N	Capsule 15 mg	21	6628.13	Revlimid	CJ
9645P	Capsule 25 mg	21	6980.72	Revlimid	CJ

RITUXIMAB

Note

Any queries concerning the arrangements to prescribe rituximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe rituximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist; and
- (c) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (d) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of two infusions will be authorised under this restriction.

Assessment of a patient's response to an initial course of treatment must be made at least 12 weeks after the first infusion so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date it was conducted.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with rituximab.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.

Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Patients who fail to demonstrate a response to rituximab treatment and who qualify to trial an alternate bDMARD according to the interchangeability arrangements for bDMARDs for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist; and
- (c) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with rituximab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised rituximab treatment, within the timeframes specified below.

A maximum of two infusions will be authorised under this restriction.

Where the most recent course of PBS-subsidised rituximab treatment was approved under either of the initial 1 or 2 treatment restrictions patients must be assessed for response at least 12 weeks after the first infusion. This assessment must be provided to Medicare Australia no later than 4 weeks from the date of assessment.

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.

Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Patients who fail to demonstrate a response to rituximab treatment and who qualify to trial an alternate bDMARD according to the interchangeability arrangements for bDMARDs for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with rituximab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with rituximab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of two infusions will be authorised under this restriction.

Patients may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.

Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

9611W	Solution for I.V. infusion 500 mg in 50 mL	1	2310.09	Mabthera	RO
-------	--	---	----	----	---------	----------	----

THALIDOMIDE

Caution

Thalidomide is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and for 1 month after cessation of treatment.

Authority required

Multiple myeloma.

Note

Patients receiving thalidomide under the PBS listing must be registered in the i-access risk management program.

6469L	Capsule 50 mg	112	*1726.52	Thalomid	CJ
9684Q	Capsule 100 mg	56	*1726.52	Thalomid	CJ

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Musculo-skeletal system

Muscle relaxants

Muscle relaxants, centrally acting agents

Other centrally acting agents

BACLOFEN

Authority required

Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity of cerebral origin;

Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to multiple sclerosis;

Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord injury;

Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord disease.

6284R	Intrathecal injection 10 mg in 5 mL	10	*1530.22		Lioresal Intrathecal	NV
-------	-------------------------------------	----	----	----	----------	--	----------------------	----

Drugs for treatment of bone diseases

Drugs affecting bone structure and mineralization

Bisphosphonates

DISODIUM PAMIDRONATE

Authority required

Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.

Note

Pharmaceutical benefits that have the form disodium pamidronate powder for I.V. infusion 15 mg (after reconstitution) and pharmaceutical benefits that have the form disodium pamidronate concentrated injection 15 mg are equivalent for the purposes of substitution.

6286W	Concentrated injection 15 mg in 5 mL	4	2	..	*224.84	^a	Pamisol	HH
6290C	Injection set containing 4 vials powder for I.V. infusion 15 mg and 4 ampoules solvent 5 mL	1	2	..	224.83	^a	Aredia 15 mg	NV

DISODIUM PAMIDRONATE

Authority required

Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.

Note

Pharmaceutical benefits that have the form disodium pamidronate powder for I.V. infusion 30 mg (after reconstitution) and pharmaceutical benefits that have the form disodium pamidronate concentrated injection 30 mg are equivalent for the purposes of substitution.

6279L	Injection set containing 2 vials powder for I.V. infusion 30 mg and 2 ampoules solvent 10 mL	1	2	..	224.83	^a	Aredia 30 mg	NV
6287X	Concentrated injection 30 mg in 10 mL	2	2	..	*224.84	^a	Pamisol	HH

DISODIUM PAMIDRONATE

Authority required

Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.

6288Y	Concentrated injection 60 mg in 10 mL	1	2	..	224.82		Pamisol	HH
-------	---------------------------------------	---	---	----	--------	--	---------	----

DISODIUM PAMIDRONATE

Authority required

Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
<u>Authority required</u>						
Multiple myeloma;						
Bone metastases from breast cancer.						
<u>Note</u>						
Pharmaceutical benefits that have the form disodium pamidronate powder for I.V. infusion 90 mg (after reconstitution) and pharmaceutical benefits that have the form disodium pamidronate concentrated injection 90 mg are equivalent for the purposes of substitution.						
6223M	Injection set containing 1 vial powder for I.V. infusion 90 mg and 1 ampoule solvent 10 mL	1	11	..	333.96 ^a	Aredia 90 mg NV
6289B	Concentrated injection 90 mg in 10 mL	1	11	..	333.96 ^a	Pamisol HH
IBANDRONIC ACID						
<u>Authority required</u>						
Bone metastases from breast cancer.						
9619G	Concentrated injection for I.V. infusion 6 mg (as ibandronate sodium monohydrate) in 6 mL	1	11	..	361.53	Bondronat HH
ZOLEDRONIC ACID						
<u>Authority required</u>						
Multiple myeloma;						
Bone metastases from breast cancer;						
Bone metastases from castration-resistant prostate cancer;						
Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.						
<u>Note</u>						
Special Pricing Arrangements apply.						
6371H	Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL	1	11	..	474.52	Zometa NV

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Nervous system

Anti-Parkinson drugs

Dopaminergic agents

Dopa and dopa derivatives

LEVODOPA with CARBIDOPA

Authority required

Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy.

Treatment must be commenced in a hospital-based movement disorder clinic.

Note

Patients should have adequate cognitive function to manage administration with a portable continuous infusion pump.

A positive clinical response to Duodopa administered via a temporary nasoduodenal tube should be confirmed before a permanent percutaneous endoscopic gastrostomy (PEG) tube is inserted.

9744W	Intestinal gel 20 mg-5 mg per mL, 100 mL	56	5	..	*11582.52	Duodopa	VE
-------	--	----	---	----	-----------	---------	----

Dopamine agonists

APOMORPHINE HYDROCHLORIDE

Authority required

Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy.

9607P	Injection 20 mg in 2 mL	5	88.38	Apomine	HH
9640J	Injection 50 mg in 5 mL	5	208.96	Apomine	HH
9647R	Solution for subcutaneous infusion 50 mg in 10 mL pre-filled syringe	5	208.96	Apomine PFS	HH

Psycholeptics

Antipsychotics

Diazepines, oxazepines, thiazepines and oxepines

CLOZAPINE

Authority required

Schizophrenia in patients who are non-responsive to other neuroleptic agents;

Schizophrenia in patients who are intolerant of other neuroleptic agents.

6101D	Tablet 25 mg	100	60.51	^a Clopine 25	HH
						^a Clozaril 25	NV
6102E	Tablet 100 mg	100	201.48	^a Clopine 100	HH
						^a Clozaril 100	NV
6417R	Tablet 50 mg	100	110.51	Clopine 50	HH
6418T	Tablet 200 mg	100	396.46	Clopine 200	HH
9632Y	Oral liquid 50 mg per mL, 100 mL	1	146.92	Clopine Suspension	HH

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Respiratory system

Drugs for obstructive airway diseases

Other systemic drugs for obstructive airway diseases

Other systemic drugs for obstructive airway diseases

OMALIZUMAB

Note

Any queries concerning the arrangements to prescribe omalizumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe omalizumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH UNCONTROLLED SEVERE ALLERGIC ASTHMA

Patients are eligible to commence an 'omalizumab treatment cycle' (initial treatment course with or without continuing treatment course/s) if they satisfy the eligibility criteria as detailed under the initial treatment restriction.

Once a patient has either failed to achieve or maintain a response to omalizumab, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 6 month break in PBS-subsidised omalizumab therapy before they are eligible to commence the next cycle. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised omalizumab treatment is stopped to the date of the first application for initial treatment with omalizumab under the new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised omalizumab therapy.

(a) Initial treatment.

Applications for initial treatment should be made where a patient has received no prior PBS-subsidised omalizumab treatment in this treatment cycle and wishes to commence such therapy.

Initial treatment authorisations will be limited to provide for a maximum of 28 weeks of therapy with omalizumab.

A patient must be assessed for response to a course of Initial PBS-subsidised treatment following a minimum of 24 weeks of therapy with omalizumab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date of assessment.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with omalizumab.

For second and subsequent courses of PBS-subsidised omalizumab treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of the initial treatment course with omalizumab, a patient may qualify to receive up to a further 24 weeks of continuing treatment with omalizumab providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing omalizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted omalizumab supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with omalizumab.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(2) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the Asthma Control Questionnaire (ACQ; 5 item version) and oral corticosteroid dose, submitted with the Initial authority application for omalizumab. However, prescribers may provide new baseline measurements when a new Initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

(3) Re-commencement of treatment after a 6 month break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised omalizumab therapy of at least 6 months, must re-qualify for initial treatment with respect to the indices of disease severity (oral corticosteroid dose, Asthma Control Questionnaire (ACQ-5) score, and relevant exacerbation history). Patients must have received optimised standard therapy, at adequate doses and for the minimum period specified, immediately prior to the time the new baseline assessments are performed.

(4) Patients 'grandfathered' onto PBS-subsidised treatment with omalizumab.

A patient who commenced treatment with omalizumab for uncontrolled severe allergic asthma prior to 1 November 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the Initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with omalizumab will be authorised under this criterion.

Following completion of the Initial PBS-subsidised course, further applications for treatment with omalizumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle (initial treatment course with or without continuing treatment course/s). For the second and subsequent cycles, a 'Grandfathered' patient must re-qualify for Initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 6 month break in PBS-subsidised therapy' above for further details.

(5) Monitoring of patients.

Anaphylaxis and anaphylactoid reactions have been reported following first or subsequent administration of omalizumab (see Product Information). Patients should be monitored post-injection, and medications for the treatment of anaphylactic reactions should be available for immediate use following administration of omalizumab. Patients should be informed that such reactions are possible and prompt medical attention should be sought if allergic reactions occur.

Authority required

Initial treatment of uncontrolled severe allergic asthma

Initial PBS-subsidised treatment with omalizumab by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient aged 12 years or older with uncontrolled severe allergic asthma who has been under the care of this physician for at least 12 months, and satisfies the following criteria:

(a) has a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by standard clinical features, including:

- (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or
- (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or
- (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; and

(b) duration of asthma of at least 1 year; and

(c) FEV1 less than or equal to 80% predicted, documented on 3 or more occasions in the previous 12 months; and

(d) past or current evidence of atopy, documented by skin prick testing or RAST; and

(e) total serum human immunoglobulin E (IgE) greater than or equal to 76 IU/mL; and

(f) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and

(g) has failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented (see NOTE). Optimised asthma therapy includes:

- (i) adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or formoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated, AND
- (ii) oral corticosteroids (at least 10 mg per day prednisolone (or equivalent)) for at least 6 weeks, unless contraindicated or not tolerated.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	
					\$	\$	

If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application. Details of the accepted toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement of treatment with optimised asthma therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The initial IgE assessment must be no more than 12 months old at the time of application. A re-assessment of free IgE can only be made at least 12 months after the last dose of omalizumab. For patients re-commencing omalizumab within 12 months of the last dose the previous pre-omalizumab IgE level should be used.

The IgE pathology report must be provided with the authority application.

The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:

- (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND
- (b) while on oral corticosteroids and in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes the following:
 - (i) details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and
 - (ii) details of severe exacerbation/s experienced while on oral corticosteroids (date and treatment); and
 - (iii) the signed patient acknowledgement; and
- (c) a completed Asthma Control Questionnaire (ACQ-5) calculation sheet including the date of assessment of the patient's symptoms. (For copies of the ACQ please contact Novartis Medical Information on 1800 671 203 or medinfo.phauno@novartis.com)

At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.

Where fewer than the required number of repeats to complete 28 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 28 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.

The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, must be made at around 24 to 26 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 24 to 26 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.

A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased.

Note

Formal assessment and correction of inhaler technique should be performed in accordance with the National Asthma Council (NAC) Information Paper for Health Professionals on Inhaler Technique (available at www.medicareaustralia.gov.au or www.nationalasthma.org.au); the assessment and adherence to correct technique should be documented in the patient's medical records. Patients can obtain support with inhaler technique through their local Asthma Foundation (1800 645 130).

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with omalizumab, by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient who:

- (a) has a documented history of severe allergic asthma; and
- (b) has demonstrated or sustained an adequate response to treatment with omalizumab.

An adequate response to omalizumab treatment is defined as:

- (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline, OR
- (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes details of maintenance oral corticosteroid dose; and
- (c) a completed Asthma Control Questionnaire (ACQ-5) calculation sheet including the date of assessment of the patient's symptoms. (For copies of the ACQ please contact Novartis Medical Information on 1800 671 203 or medinfo.phauno@novartis.com)

All applications for continuing treatment with omalizumab must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment, and the assessment of oral corticosteroid dose, must be made at around 20 to 22 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.

The first assessment should, where possible, be completed by the same physician who initiated treatment with omalizumab. If the same physician cannot assess the patient please call Medicare Australia on 1800 700 270.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 20 to 22 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.

Patients are eligible to receive continuing courses of omalizumab treatment of up to 24 weeks providing they continue to demonstrate an adequate response to treatment.

At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for a continuing course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information), sufficient for 24 weeks of therapy.

Where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased.

Authority required

Initial PBS-subsidised treatment of severe allergic asthma in a patient who has previously received non-PBS-subsidised therapy with omalizumab (grandfather patients)

Initial PBS-subsidised supply for continuing treatment with omalizumab by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient aged 12 years or older with severe allergic asthma who satisfies the following criteria:

- (a) has a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by standard clinical features, including:
 - (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or
 - (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or
 - (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; and
- (b) duration of asthma of at least 1 year; and
- (c) past or current evidence of atopy, documented by skin prick testing or RAST; and
- (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment for grandfathered patients; and
- (e) prior to omalizumab therapy had failed to achieve adequate control with optimised asthma therapy. Optimised asthma therapy includes:
 - (i) adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or formoterol 12 micrograms bd) for at least 12 months, and
 - (ii) may have included maintenance dose oral corticosteroids; and

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(f) has demonstrated an adequate response to treatment with omalizumab.

A review of the patient's records should be conducted to extract pre- and post-omalizumab data on symptoms, quality of life, medication doses, exacerbations and hospitalisations. Examples of parameters to establish response include:

- (i) a reduction in Asthma Control Questionnaire (ACQ-5) score of at least 0.5;
- (ii) an improvement of at least 0.5 in the Asthma Quality of Life Questionnaire (AQLQ or mini-AQLQ);
- (iii) maintenance oral corticosteroid dose reduced by at least 25% from baseline; and/or
- (iv) a reduction in the number of hospitalisations or severe exacerbations requiring use of systemic corticosteroids, compared to the 12 months prior to commencement of omalizumab.

Where baseline assessments are not available, please call Medicare Australia on 1800 700 270 to discuss.

If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application. Details of the accepted contraindications and toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement of treatment with optimised asthma therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes the following:
 - (i) details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and
 - (ii) details of pre- and post-omalizumab data on symptoms, quality of life, medication doses, exacerbations and hospitalisations; and
 - (iii) the signed patient acknowledgement.

At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.

Where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 24 weeks.

An assessment of the patient's continued response to this course of PBS-subsidised treatment must be made at around 20 to 22 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. The same parameters used to establish response to non-PBS-subsidised therapy with omalizumab should be used for the assessment.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 20 to 22 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.

Patients are eligible to receive continuing courses of omalizumab treatment of up to 24 weeks providing they continue to demonstrate an adequate response to treatment.

Patients may qualify for PBS-subsidised treatment under this restriction once only.

A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased.

Note

Special Pricing Arrangements apply.

9746Y	Powder for injection 150 mg with diluent	1	448.52	Xolair	NV
-------	--	---	----	----	--------	--------	----

Cough and cold preparations

Expectorants, excl. combinations with cough suppressants

Mucolytics

DORNASE ALFA

Authority required

Use by cystic fibrosis patients who satisfy all of the following criteria:

- (1) are 5 years of age or older;

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

- (2) have a FVC greater than 40% predicted for age, gender and height;
- (3) have evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);
- (4) are participating in a 4 week trial as detailed below or have achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) after a 4 week trial.

In order for patients to be eligible for participation in the HSD program, the following conditions must be met:

- (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of dornase alfa under the HSD program is limited to such physicians. If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;
- (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;
- (3) Prior to dornase alfa therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;
- (4) Initial therapy is limited to 4 weeks' treatment with dornase alfa at a dose of 2.5 mg daily;
- (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) are eligible for continued subsidy under the HSD program at a dose of 2.5 mg daily;
- (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 2.5 mg daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;
- (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that dornase alfa treatment is continuing to produce worthwhile benefits. (Dornase alfa therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;
- (8) Other aspects of treatment, such as physiotherapy, must be continued;
- (9) Where there is documented evidence that a patient already receiving dornase alfa therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period).

Note

Dornase alfa is not PBS-subsidised for use in combination with PBS-subsidised mannitol.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

Authority required

Treatment of cystic fibrosis in a patient less than 5 years of age who has:

- (1) A severe clinical course with frequent respiratory exacerbations or chronic respiratory symptoms (including chronic or recurrent cough, wheeze or tachypnoea) requiring frequent hospital admissions more frequently than 3 times per year; or
- (2) Significant bronchiectasis on chest high resolution computed tomography scan; or
- (3) Severe cystic fibrosis bronchiolitis with persistent wheeze non-responsive to conventional medicines; or
- (4) Severe physiological deficit measure by forced oscillation technique or multiple breath nitrogen washout and failure to respond to conventional therapy.

In order for the patient to be eligible for participation in the HSD program, the following conditions must be met:

- (1) The patient must be assessed at a cystic fibrosis clinic/centre which is under the supervision of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis, and the prescribing of dornase alfa under the HSD program is limited to such physicians. If attendance at such a unit is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;
- (2) Following an initial 6 months therapy, a comprehensive assessment must be undertaken and documented involving the patient, the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team to establish agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use. Further reassessments are to be undertaken and documented yearly.

Note

Dornase alfa is not PBS-subsidised for use in combination with PBS-subsidised mannitol.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

Authority required

Grandfather — continuing for patients five years or older

Continuation of treatment of cystic fibrosis in a patient 5 years of age or older, who initiated treatment with dornase alfa at an age of less than 5 years and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use.

Note

Dornase alfa is not PBS-subsidised for use in combination with PBS-subsidised mannitol.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Authority required

Grandfather — for patients less than five years of age who initiated dornase alfa prior to listing

Treatment of cystic fibrosis in a patient less than 5 years of age who initiated treatment with dornase alfa prior to 1 November 2009 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use.

Note

Dornase alfa is not PBS-subsidised for use in combination with PBS-subsidised mannitol.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

6120D	Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL	60	5	..	*2406.52	Pulmozyme	RO
-------	--	----	---	----	----------	-----------	----

MANNITOL

Authority required

Treatment of cystic fibrosis in a patient who satisfies all of the following criteria:

- (1) Prior to mannitol therapy, the patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved PI mannitol initiation dose assessment. If the patient has a negative hyperresponsiveness test they may be eligible for PBS subsidised treatment with mannitol;
- (2) Is 6 years of age or older;
- (3) Has a FEV1 greater than 30% predicted for age, gender and height;
- (4) Is intolerant or inadequately responsive to dornase alfa;
- (5) Has evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);
- (6) Is participating in a 4 week trial, as detailed below, or has achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to mannitol treatment) after a 4 week trial.

In order for patients to be eligible for participation in the HSD program, the following conditions must be met:

- (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of mannitol therapy under the HSD program is limited to such physicians. If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;
- (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;
- (3) Prior to mannitol therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;
- (4) Initial therapy is limited to 4 weeks' treatment with mannitol at a dose of 400 mg twice daily;
- (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to mannitol treatment) are eligible for continued subsidy under the HSD program at a dose of 400mg twice daily;
- (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 400 mg twice daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;
- (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that mannitol powder for inhalation treatment is continuing to produce worthwhile benefits. (Mannitol therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;
- (8) Other aspects of treatment, such as physiotherapy, must be continued;
- (9) Where there is documented evidence that a patient already receiving mannitol therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period).

Note

Mannitol is not PBS-subsidised for use in combination with PBS-subsidised dornase alfa.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

Authority required

Grandfather — for patients who initiated mannitol treatment prior to 1 August 2012

Continuation of treatment of cystic fibrosis in a patient 6 years of age or older, who initiated treatment with mannitol prior to 1 August 2012 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis team, documents agreement that mannitol treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with mannitol should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Note

Mannitol is not PBS-subsidised for use in combination with PBS-subsidised dornase alfa.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

2008Q	Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers	4	5	..	*1782.52	bronchitol	XA
-------	---	---	---	----	----------	------------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Sensory organs

Ophthalmologicals

Antiinfectives
Antivirals

GANCICLOVIR
Authority required
Cytomegalovirus retinitis in severely immunocompromised patients.

6256G	Intravitreal implant 4.5 mg	1	6046.52	Vitrasert	BU
-------	-----------------------------	---	----	----	---------	-----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Various

All other therapeutic products

All other therapeutic products

Iron chelating agents

DEFERASIROX

Authority required

Chronic iron overload in patients with disorders of erythropoiesis.

Note

Special Pricing Arrangements apply.

6499C	Tablet 125 mg (dispersible)	168	5	..	*1448.02	Exjade	NV
6500D	Tablet 250 mg (dispersible)	168	5	..	*2849.44	Exjade	NV
9600G	Tablet 500 mg (dispersible)	168	5	..	*5652.34	Exjade	NV

DEFERIPRONE

Authority required

Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy;

Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective.

6416Q	Tablet 500 mg	600	5	..	*2749.90	Ferriprox	OA
9638G	Oral solution 100 mg per mL, 250 mL	5	5	..	*1172.92	Ferriprox	OA

DEFERRIOXAMINE MESYLATE

Authority required

Disorders of erythropoiesis associated with treatment-related chronic iron overload.

6113R	Powder for injection 500 mg	400	5	..	*3772.12	^a Hospira Pty Limited	HH
				^B 308.80	*4080.92	^a Desferal 500 mg	NV
6270B	Powder for injection 2 g	60	5	..	*2281.72	^a Hospira Pty Limited	HH
				^B 22.80	*2304.52	^a Desferal 2 g	NV

Drugs for treatment of hyperkalemia and hyperphosphatemia

LANTHANUM

Authority required

Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy.

Management includes initiation, stabilisation and review of therapy as required;

Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.

Management includes initiation, stabilisation and review of therapy as required.

Note

Not to be used in combination with sevelamer.

9635D	Tablet, chewable, 500 mg (as carbonate hydrate)	180	5	..	*551.00	Fosrenol	ZI
9636E	Tablet, chewable, 750 mg (as carbonate hydrate)	180	5	..	*828.70	Fosrenol	ZI
9637F	Tablet, chewable, 1000 mg (as carbonate hydrate)	180	5	..	*932.14	Fosrenol	ZI

SEVELAMER HYDROCHLORIDE

Authority required

Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy.

Management includes initiation, stabilisation and review of therapy as required;

Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.

Management includes initiation, stabilisation and review of therapy as required.

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Note

Not to be used in combination with lanthanum.

9620H	Tablet 800 mg	360	5	..	*651.32	Renagel	GZ
-------	---------------	-----	---	----	---------	---------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	Max. Qty	

Blood and blood forming organs

Antihemorrhagics

Vitamin K and other hemostatics

Other systemic hemostatics

ELTROMBOPAG

Note

Eltrombopag is not PBS-subsidised as an alternative to splenectomy.

Any queries concerning the arrangements to prescribe eltrombopag may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe eltrombopag should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

Further prescribing information is on the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:

(1) Splenectomised and:

(a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and

(b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;

OR

(2) Not splenectomised and:

(a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2 mg/kg/day of prednisone for at least 4-6 weeks; and

(b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and

(c) in whom splenectomy is contraindicated for medical reasons.

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:

(a) a platelet count of less than or equal to 20,000 million per L;

OR

(b) a platelet count of 20-30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.

The authority application must be made in writing and must include:

(1) a completed authority prescription form,

(2) a signed patient acknowledgement,

(3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],

(4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and

(5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.

The full blood count must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.

Note

Patients will be able to trial either eltrombopag and/or romiplostim within the initial 24 weeks treatment period. Patients who fail to demonstrate a response to treatment with either eltrombopag and/or romiplostim under the initial restriction will not be eligible to receive further PBS-subsidised treatment with either of these drugs.

No applications for increased repeats will be authorised.

Authority required

Initial (grandfather patients)

Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with eltrombopag prior to 1 November 2011 and in

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

whom the criteria for initial treatment can be demonstrated to have been met at the time eltrombopag was commenced.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form,
- (2) a signed patient acknowledgement,
- (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and
- (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.

A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.

Note

No applications for increased repeats will be authorised.

Authority required

Continuing therapy or re-initiation after a break in therapy

First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with eltrombopag during the initial period of PBS-subsidised treatment.

For the purposes of this restriction, a sustained platelet response is defined as:

- (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised eltrombopag,

AND either of the following:

- (b) a platelet count greater than or equal to 50,000 million per L on at least four (4) occasions, each at least one week apart;

OR

- (c) a platelet count greater than 30,000 million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.

Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:

- (1) a completed authority prescription form, and
- (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and
- (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).

The most recent platelet count must be no more than one month old at the time of application.

A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone.

Note

No applications for increased repeats will be authorised.

Authority required

Second and subsequent applications for continuing therapy

Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with eltrombopag and who continues to display a response to treatment with eltrombopag.

For the purposes of this restriction, a continuing response to treatment with eltrombopag is defined as:

- (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with eltrombopag,

AND either of the following:

- (b) a platelet count greater than or equal to 50,000 million per L

OR

- (c) a platelet count greater than 30,000 million per L and which is double the baseline platelet count.

Platelet counts must be no more than 1 month old at the time of application.

Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

No applications for increased repeats will be authorised.

5825N	Tablet 25 mg (as olamine)	28	5	..	1512.00	Revolade	GK
5826P	Tablet 50 mg (as olamine)	28	5	..	3024.00	Revolade	GK

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

ROMIPLOSTIM

Note

Romiplostim is not PBS-subsidised as an alternative to splenectomy.

Any queries concerning the arrangements to prescribe romiplostim may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe romiplostim should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

Further prescribing information is on the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:

(1) Splenectomised and:

(a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and

(b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;

OR

(2) Not splenectomised and:

(a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2 mg/kg/day of prednisone for at least 4-6 weeks; and

(b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and

(c) in whom splenectomy is contraindicated for medical reasons.

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:

(a) a platelet count of less than or equal to 20,000 million per L;

OR

(b) a platelet count of 20-30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.

The authority application must be made in writing and must include:

(1) a completed authority prescription form,

(2) a signed patient acknowledgement,

(3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],

(4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and

(5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.

The full blood count must be no more than 1 month old at the time of application.

At the time of the written authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1 microgram/kg. Up to 1 repeat may be requested with the initial written application.

Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The dose (microgram/kg/week) must be provided at the time of application.

Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.

Authority approval will not be given for doses of higher than 10 micrograms/kg/week.

Note

Patients will be able to trial either eltrombopag and/or romiplostim within the initial 24 weeks treatment period. Patients who fail to demonstrate a response to treatment with either eltrombopag and/or romiplostim under the initial restriction will not be eligible to receive further PBS-subsidised treatment with either of these drugs.

Authority required

Initial (grandfather patients)

Initial PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with romiplostim prior to 1 April 2011 and in

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

whom the criteria for initial treatment can be demonstrated to have been met at the time romiplostim was commenced.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form,
- (2) a signed patient acknowledgement,
- (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and
- (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.

For patients whose dose of romiplostim had been stable for at least 4 weeks at the time of the initial application for PBS-subsidy, the medical practitioner should request sufficient number of vials based on the weight of the patient and dose (microgram/kg/week) to provide up to 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.

Where the patient is in the titration phase of treatment with romiplostim, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1 microgram/kg. Up to 1 repeat may be requested with the initial written application.

Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The dose (microgram/kg/week) must be provided at the time of application.

Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.

Authority approval will not be given for doses of higher than 10 micrograms/kg/week.

Authority required

Continuing therapy or re-initiation after a break in therapy

First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with romiplostim during the initial period of PBS-subsidised treatment.

For the purposes of this restriction, a sustained platelet response is defined as:

- (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised romiplostim,

AND either of the following:

- (b) a platelet count greater than or equal to 50,000 million per L on at least four (4) occasions, each at least one week apart;

OR

- (c) a platelet count greater than 30,000 million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.

Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:

- (1) a completed authority prescription form, and
- (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and
- (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).

The most recent platelet count must be no more than one month old at the time of application.

The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone.

Authority approval will not be given for doses of higher than 10 micrograms/kg/week.

Authority required

Second and subsequent applications for continuing therapy

Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with romiplostim and who continues to display a response to treatment with romiplostim.

For the purposes of this restriction, a continuing response to treatment with romiplostim is defined as:

- (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with romiplostim,

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

AND either of the following:

(b) a platelet count greater than or equal to 50,000 million per L

OR

(c) a platelet count greater than 30,000 million per L and which is double the baseline platelet count.

Platelet counts must be no more than 1 month old at the time of application.

Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.

Authority approval will not be given for doses of higher than 10 micrograms/kg/week.

Note

Special Pricing Arrangements apply.

9696H	Powder for injection 375 micrograms (250 micrograms in 0.5 mL when reconstituted)	1	977.50	Nplate	AN
9698K	Powder for injection 625 micrograms (500 micrograms in 1 mL when reconstituted)	1	1955.00	Nplate	AN

Antianemic preparations

Other antianemic preparations

Other antianemic preparations

DARBEPOETIN ALFA

Authority required (STREAMLINED)

3334

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

5637Q	Injection 10 micrograms in 0.4 mL pre-filled syringe	8	5	..	*356.08	Aranesp	AN
5638R	Injection 20 micrograms in 0.5 mL pre-filled syringe	8	5	..	*670.62	Aranesp	AN
5639T	Injection 30 micrograms in 0.3 mL pre-filled syringe	8	5	..	*917.46	Aranesp	AN
5640W	Injection 40 micrograms in 0.4 mL pre-filled syringe	8	5	..	*1113.60	Aranesp	AN
5641X	Injection 50 micrograms in 0.5 mL pre-filled syringe	8	5	..	*1376.78	Aranesp	AN
5642Y	Injection 60 micrograms in 0.3 mL pre-filled syringe	8	5	..	*1616.66	Aranesp	AN
5643B	Injection 150 micrograms in 0.3 mL pre-filled syringe	8	5	..	*3904.50	Aranesp	AN
5644C	Injection 80 micrograms in 0.4 mL pre-filled syringe	8	5	..	*2128.00	Aranesp	AN
5645D	Injection 20 micrograms in 0.5 mL pre-filled injection pen	8	5	..	*670.64	Aranesp SureClick	AN
5646E	Injection 40 micrograms in 0.4 mL pre-filled injection pen	8	5	..	*1113.60	Aranesp SureClick	AN
5647F	Injection 60 micrograms in 0.3 mL pre-filled injection pen	8	5	..	*1616.64	Aranesp SureClick	AN
5648G	Injection 80 micrograms in 0.4 mL pre-filled injection pen	8	5	..	*2128.00	Aranesp SureClick	AN
5649H	Injection 100 micrograms in 0.5 mL pre-filled injection pen	8	5	..	*2620.48	Aranesp SureClick	AN
5650J	Injection 150 micrograms in 0.3 mL pre-filled injection pen	8	5	..	*3904.48	Aranesp SureClick	AN
5651K	Injection 100 micrograms in 0.5 mL pre-filled syringe	8	5	..	*2620.50	Aranesp	AN

EPOETIN ALFA

Authority required (STREAMLINED)

3334

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

5713Q	Injection 20,000 units in 0.5 mL pre-filled syringe	12	5	..	*3876.00	Eprex 20,000	JC
5714R	Injection 1,000 units in 0.5 mL pre-filled syringe	12	5	..	*279.30	Eprex 1000	JC
5715T	Injection 5,000 units in 0.5 mL pre-filled syringe	12	5	..	*1057.34	Eprex 5000	JC
5716W	Injection 6,000 units in 0.6 mL pre-filled syringe	12	5	..	*1255.14	Eprex 6000	JC
5717X	Injection 8,000 units in 0.8 mL pre-filled syringe	12	5	..	*1627.92	Eprex 8000	JC

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer	
					Max. Qty \$		
5718Y	Injection 40,000 units in 1 mL pre-filled syringe	2	5	..	*1254.00	Eprex 40,000	JC
5719B	Injection 2,000 units in 0.5 mL pre-filled syringe	12	5	..	*516.80	Eprex 2000	JC
5720C	Injection 3,000 units in 0.3 mL pre-filled syringe	12	5	..	*666.90	Eprex 3000	JC
5721D	Injection 4,000 units in 0.4 mL pre-filled syringe	12	5	..	*849.30	Eprex 4000	JC
5722E	Injection 10,000 units in 1 mL pre-filled syringe	12	5	..	*1970.30	Eprex 10000	JC

EPOETIN BETA

Authority required (STREAMLINED)

3334

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

5724G	Injection 2,000 units in 0.3 mL pre-filled syringe	12	5	..	*516.80	NeoRecormon	RO
5725H	Injection 3,000 units in 0.3 mL pre-filled syringe	12	5	..	*666.90	NeoRecormon	RO
5726J	Injection 4,000 units in 0.3 mL pre-filled syringe	12	5	..	*849.30	NeoRecormon	RO
5727K	Injection 5,000 units in 0.3 mL pre-filled syringe	12	5	..	*1057.36	NeoRecormon	RO
5728L	Injection 6,000 units in 0.3 mL pre-filled syringe	12	5	..	*1255.14	NeoRecormon	RO
5729M	Injection 10,000 units in 0.6 mL pre-filled syringe	12	5	..	*1970.30	NeoRecormon	RO
5730N	Injection 20,000 units in 0.6 mL pre-filled syringe	12	5	..	*3876.00	NeoRecormon	RO

EPOETIN LAMBDA

Note

Epoetin lambda should only be administered by the intravenous route.

Authority required (STREAMLINED)

3334

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

9587N	Injection 4,000 units in 0.4 mL pre-filled syringe	12	5	..	*804.60	Novicrit	NV
9589Q	Injection 5,000 units in 0.5 mL pre-filled syringe	12	5	..	*1001.70	Novicrit	NV
9591T	Injection 6,000 units in 0.6 mL pre-filled syringe	12	5	..	*1189.08	Novicrit	NV
9594Y	Injection 8,000 units in 0.8 mL pre-filled syringe	12	5	..	*1542.24	Novicrit	NV
9596C	Injection 10,000 units in 1 mL pre-filled syringe	12	5	..	*1866.60	Novicrit	NV
9668W	Injection 1,000 units in 0.5 mL pre-filled syringe	12	5	..	*264.60	Novicrit	NV
9669X	Injection 2,000 units in 1 mL pre-filled syringe	12	5	..	*489.60	Novicrit	NV
9670Y	Injection 3,000 units in 0.3 mL pre-filled syringe	12	5	..	*631.80	Novicrit	NV

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

Authority required (STREAMLINED)

3334

Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.

5794Y	Injection 30 micrograms in 0.3 mL pre-filled syringe	2	5	..	*369.18	Mircera	RO
5795B	Injection 50 micrograms in 0.3 mL pre-filled syringe	2	5	..	*615.30	Mircera	RO
5796C	Injection 75 micrograms in 0.3 mL pre-filled syringe	2	5	..	*896.02	Mircera	RO
5797D	Injection 100 micrograms in 0.3 mL pre-filled syringe	2	5	..	*1158.82	Mircera	RO
5798E	Injection 120 micrograms in 0.3 mL pre-filled syringe	2	5	..	*1341.64	Mircera	RO
5799F	Injection 200 micrograms in 0.3 mL pre-filled syringe	2	5	..	*1924.30	Mircera	RO
5800G	Injection 360 micrograms in 0.6 mL pre-filled syringe	2	5	..	*3326.52	Mircera	RO

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Cardiovascular system

Antihypertensives

Other antihypertensives

Other antihypertensives

AMBRISENTAN

Caution

Ambrisentan is a category X drug and must not be given to pregnant women. Pregnancy must be avoided during treatment and for at least 3 months following cessation of treatment with this drug.

Note

Any queries concerning the arrangements to prescribe ambrisentan may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 - drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND
- (c) epoprostenol sodium, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
- (e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
- (f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (c) WHO Functional Class IV primary pulmonary hypertension; OR
- (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial treatment with ambrisentan of patients with one of the following:

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised ambrisentan after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with ambrisentan; OR
- (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than ambrisentan.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with ambrisentan of patients who have received approval for initial PBS-subsidised treatment with ambrisentan and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of ambrisentan treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised. Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

Special Pricing Arrangements apply.

5607D	Tablet 5 mg	30	4035.00	Volibris	GK
5608E	Tablet 10 mg	30	4035.00	Volibris	GK

BOSENTAN MONOHYDRATE

Caution

Bosentan monohydrate is a category X drug and must not be given to pregnant women. Pregnancy must be avoided during treatment and for at least 3 months following cessation of treatment with this drug.

Note

Any queries concerning the arrangements to prescribe bosentan monohydrate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(b) iloprost trometamol, of:

- primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
- primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
- drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND

(c) epoprostenol sodium, of:

- primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
- primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND

(d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND

(e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND

(f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (c) WHO Functional Class IV primary pulmonary hypertension; OR
- (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR

(e) WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Applications for authorisation must be in writing and must include:

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
 (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 (i) RHC composite assessment; and
 (ii) ECHO composite assessment; and
 (iii) 6MWT; and
 (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial treatment with bosentan monohydrate of patients with one of the following:

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR
 (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than bosentan monohydrate.

Applications for authorisation must be in writing and must include:

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
 (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
 (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
 (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
 (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 (i) RHC composite assessment; and
 (ii) ECHO composite assessment; and
 (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Cessation of treatment (all patients)

Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to connective tissue disease or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.

Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) [see Note on authority approval requirements].

Approval will only be granted for the 62.5 mg tablet strength. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.

Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month.

Note

Special Pricing Arrangements apply.

5618Q	Tablet 62.5 mg (base)	60	4035.00	Tracleer	AT
5619R	Tablet 125 mg (base)	60	4035.00	Tracleer	AT

EPOPROSTENOL SODIUM

Note

Any queries concerning the arrangements to prescribe epoprostenol sodium may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

(a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND

(b) iloprost trometamol, of:

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND

— drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND

(c) epoprostenol sodium, of:

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND

— primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND

(d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND

(e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND

(f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with epoprostenol sodium of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class IV primary pulmonary hypertension; OR
- (b) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial PBS-subsidised treatment with epoprostenol sodium of patients with one of the following:

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR
- (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR
- (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and
- (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer	
<p>The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months) except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p> <p>The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p>							
5030R	Powder for I.V. infusion 500 micrograms (base) infusion administration set	1	39.62	Flolan Kit	GK
5035B	Powder for I.V. infusion 1.5 mg (base) infusion administration set	1	79.23	Flolan Kit	GK

ILOPROST TROMETAMOL

Note

Any queries concerning the arrangements to prescribe iloprost trometamol may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 - drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND
- (c) epoprostenol sodium, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
- (e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
- (f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with iloprost and who have been assessed by a physician from a designated hospital to have:

WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class IV primary pulmonary hypertension; OR
- (c) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR
- (d) WHO Functional Class IV drug-induced pulmonary arterial hypertension.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial PBS-subsidised treatment with iloprost trometamol of patients with one of the following:

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised iloprost trometamol after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with iloprost trometamol; OR
- (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than iloprost trometamol; OR
- (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and
- (5) for WHO Functional Class III patients, where this is the first application for iloprost trometamol, assessment details of the PBS-subsidised PAH

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

agent they have failed to respond to.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with iloprost trometamol of patients who have received approval for initial PBS-subsidised treatment with iloprost trometamol, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of iloprost trometamol treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

Special Pricing Arrangements apply.

5751Q	Solution for inhalation 20 micrograms (base) in 2 mL	30	1076.00	Ventavis	BN
-------	--	----	----	----	---------	----------	----

SILDENAFIL CITRATE

Note

Any queries concerning the arrangements to prescribe sildenafil citrate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 — primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 — drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND
 (c) epoprostenol sodium, of:
 — primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 — primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
 (e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
 (f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial PBS-subsidised treatment with sildenafil citrate of patients with one of the following:

(a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised sildenafil citrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with sildenafil citrate; OR

(b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than sildenafil citrate.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with sildenafil citrate of patients who have received approval for initial PBS-subsidised treatment with sildenafil citrate, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of sildenafil citrate treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

9547L	Tablet 20 mg (base)	90	898.43	Revatio	PF
-------	---------------------	----	----	----	--------	---------	----

TADALAFIL

Note

Any queries concerning the arrangements to prescribe tadalafil may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 - drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND
- (c) epoprostenol sodium, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
- (e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
- (f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent. All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with a PAH agent should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.

(c) Swapping between PAH agents.

For eligible patients, applications to swap between these 6 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.

It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.

To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.

(d) Cessation of treatment — bosentan patients only.

Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the time where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.

For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.

7. Re-treatment with a PAH agent.

Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with that agent under any circumstances.

8. Further information.

A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at www.medicareaustralia.gov.au.

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with tadalafil of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Authority required

Initial (new patients)

Application for initial PBS-subsidised treatment with tadalafil of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO;

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT; and
- (3) a signed patient acknowledgment form.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial (change or re-commencement for all patients)

Application for initial treatment with tadalafil of patients with one of the following:

- (a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised tadalafil after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with tadalafil; OR
- (b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than tadalafil.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and
- (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Continuing treatment (all patients)

Continuing PBS-subsidised treatment with tadalafil of patients who have received approval for initial PBS-subsidised treatment with tadalafil, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of tadalafil treatment [see Note for definition of response].

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
 - (i) RHC composite assessment; and
 - (ii) ECHO composite assessment; and
 - (iii) 6MWT.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised. Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

1308W	Tablet 20 mg	56	838.53	Adcirca	LY
-------	--------------	----	----	----	--------	---------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Systemic hormonal preparations, excl. sex hormones and insulins

Pituitary and hypothalamic hormones and analogues

Hypothalamic hormones

Somatostatin and analogues

LANREOTIDE ACETATE

Authority required (STREAMLINED)

3387

Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND

- (a) after failure of other therapy including dopamine agonists; or
- (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or
- (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.

In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (6 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.

Treatment must cease if IGF1 is not lower after 3 months treatment.

5776B	Powder for suspension for injection 30 mg (base) with diluent ampoule	2	11	..	*1500.00	Somatuline LA	IS
-------	---	---	----	----	----------	---------------	----

LANREOTIDE ACETATE

Authority required (STREAMLINED)

3388

Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND

- (a) after failure of other therapy including dopamine agonists; or
- (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or
- (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.

In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.

Treatment must cease if IGF1 is not lower after 3 months treatment;

3389

Functional carcinoid tumour causing intractable symptoms. The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.

Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

5777C	Injection 60 mg (base) in single dose pre-filled syringe	2	11	..	*2690.00	Somatuline Autogel	IS
5778D	Injection 90 mg (base) in single dose pre-filled syringe	2	11	..	*3580.00	Somatuline Autogel	IS
5779E	Injection 120 mg (base) in single dose pre-filled syringe	2	11	..	*4480.00	Somatuline Autogel	IS

OCTREOTIDE

Authority required (STREAMLINED)

3407

Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND

- (a) after failure of other therapy including dopamine agonists; or
- (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or
- (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.

In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.

Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100 micrograms 3 times daily;

3408

Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms. The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

					Dispensed Price for Max. Qty			
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	\$	Brand Name and Manufacturer		
	Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.							
9508K	Injection 50 micrograms (as acetate) in 1 mL	90	11	..	*619.02	^a	Hospira Pty Limited	HH
						^a	Octreotide MaxRx	GQ
						^a	Sandostatin 0.05	NV
9509L	Injection 100 micrograms (as acetate) in 1 mL	90	11	..	*1236.42	^a	Hospira Pty Limited	HH
						^a	Octreotide MaxRx	GQ
						^a	Sandostatin 0.1	NV
9510M	Injection 500 micrograms (as acetate) in 1 mL	90	11	..	*6194.52	^a	Hospira Pty Limited	HH
						^a	Octreotide MaxRx	GQ
						^a	Sandostatin 0.5	NV

OCTREOTIDE

Authority required (STREAMLINED)

3409

Acromegaly in a patient controlled on Sandostatin subcutaneous injections.

In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.

Treatment must cease if IGF1 is not lower after 3 months of treatment;

3410

Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.

Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

9511N	Injection (modified release) 10 mg (as acetate), vial and diluent syringe	1	11	..	1306.86	Sandostatin LAR	NV
9512P	Injection (modified release) 20 mg (as acetate), vial and diluent syringe	1	11	..	1739.81	Sandostatin LAR	NV
9513Q	Injection (modified release) 30 mg (as acetate), vial and diluent syringe	1	11	..	2177.46	Sandostatin LAR	NV

Calcium homeostasis

Anti-parathyroid agents

Other anti-parathyroid agents

CINACALCET

Authority required (STREAMLINED)

3323

Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50 pmol per L, not responding to conventional therapy.

Note

During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.

During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability. Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.

"Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.

Authority required (STREAMLINED)

3324

Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15 pmol per L and less than 50 pmol per L AND an (adjusted) serum calcium concentration at least 2.6 mmol per L, not responding to conventional treatment.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

Note

During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.

During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability. Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.

"Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.

Note

Special Pricing Arrangements apply.

5621W	Tablet 30 mg (as hydrochloride)	56	5	..	*593.72	Sensipar	AN
5622X	Tablet 60 mg (as hydrochloride)	56	5	..	*1187.44	Sensipar	AN
5623Y	Tablet 90 mg (as hydrochloride)	56	5	..	*1781.16	Sensipar	AN

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer	
------	---	-------------	----------------	---------------	--	-----------------------------	--

Antiinfectives for systemic use

Antibacterials for systemic use

Macrolides, lincosamides and streptogramins

Macrolides

AZITHROMYCIN

Authority required (STREAMLINED)

3317

Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre.

5616N	Tablet 600 mg (as dihydrate)	16	5	..	*113.96	Zithromax	PF
-------	------------------------------	----	---	----	---------	-----------	----

CLARITHROMYCIN

Authority required (STREAMLINED)

3325

Treatment of Mycobacterium avium complex infections.

5624B	Tablet 500 mg	100	2	..	55.32	Klacid	AB
5625C	Tablet 250 mg	100	2	..	27.71	Klacid	AB

Antimycobacterials

Drugs for treatment of tuberculosis

Antibiotics

RIFABUTIN

Authority required (STREAMLINED)

3415

Treatment of Mycobacterium avium complex infections in HIV-positive patients;

3317

Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre.

9541E	Capsule 150 mg	120	5	..	*588.00	Mycobutin	PF
-------	----------------	-----	---	----	---------	-----------	----

Antivirals for systemic use

Direct acting antivirals

Nucleosides and nucleotides excl. reverse transcriptase inhibitors

CIDOFOVIR

Authority required (STREAMLINED)

3322

Treatment of cytomegalovirus retinitis in patients with AIDS.

5620T	Solution for I.V. infusion 375 mg (anhydrous) in 5 mL single use vial	4	3	..	*3600.00	Vistide	GI
-------	---	---	---	----	----------	---------	----

GANCICLOVIR

Authority required (STREAMLINED)

3379

Cytomegalovirus retinitis in severely immunocompromised patients;

3380

Prophylaxis of cytomegalovirus disease in bone marrow transplant patients at risk of cytomegalovirus disease;

3381

Prophylaxis of cytomegalovirus disease in solid organ transplant patients at risk of cytomegalovirus disease.

5749N	Powder for I.V. infusion 500 mg (as sodium)	10	1	..	*560.00	Cymevene	RO
-------	---	----	---	----	---------	----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
VALACICLOVIR						
<u>Authority required (STREAMLINED)</u>						
3419						
Prophylaxis of cytomegalovirus (CMV) infection and disease following renal transplantation in patients at risk of CMV disease.						
9568N	Tablet 500 mg (as hydrochloride)	500	2	..	*2115.90	<div><div><div><div>^a APO-Valaciclovir</div><div>^a Valaciclovir RBX</div><div>^a Valtrex</div><div>^a Valvala</div><div>^a Zelitrex</div></div><div><div>TX</div><div>RA</div><div>GK</div><div>NV</div><div>GM</div></div></div></div>

VALGANCICLOVIR HYDROCHLORIDE

Authority required (STREAMLINED)

3420

Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome;

3421

Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease.

9569P	Tablet 450 mg (base)	120	5	..	*4491.60	Valcyte	RO
9655E	Powder for oral solution 50 mg (base) per mL, 100 mL	11	5	..	*4574.79	Valcyte	RO

Phosphonic acid derivatives

FOSCARNET SODIUM

Authority required (STREAMLINED)

3322

Treatment of cytomegalovirus retinitis in patients with AIDS;

3378

Treatment of aciclovir-resistant herpes simplex virus infection in immunocompromised patients with HIV infection.

5747L	I.V. infusion 24 mg per mL, 250 mL	6	1	..	1177.50	Foscavir	IX
-------	------------------------------------	---	---	----	---------	----------	----

Protease inhibitors

ATAZANAVIR

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

5612J	Capsule 300 mg (as sulfate)	60	5	..	*1043.82	Reyataz	BQ
5613K	Capsule 150 mg (as sulfate)	120	5	..	*1043.82	Reyataz	BQ
5614L	Capsule 200 mg (as sulfate)	120	5	..	*1391.76	Reyataz	BQ
5615M	Capsule 100 mg (as sulfate)	120	5	..	*695.88	Reyataz	BQ

DARUNAVIR

Authority required (STREAMLINED)

3941

Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance, and who has not demonstrated darunavir resistance associated mutations detected on resistance testing.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

5821J	Tablet 400 mg (as ethanolate)	120	5	..	*1398.28	Prezista	JC
-------	-------------------------------	-----	---	----	----------	----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer	
					Price for Max. Qty \$		
DARUNAVIR							
<u>Authority required (STREAMLINED)</u>							
3595							
Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir twice daily in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance.							
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.							
3392M	Tablet 600 mg (as ethanolate)	120	5	..	*2097.42	Prezista	JC
5653M	Tablet 150 mg (as ethanolate)	240	5	..	1048.71	Prezista	JC
FOSAMPRENAVIR							
<u>Authority required (STREAMLINED)</u>							
3588							
Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;							
3589							
Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.							
5745J	Oral liquid 50 mg (as calcium) per mL, 225 mL	8	5	..	*812.48	Telzir	VI
5746K	Tablet 700 mg (as calcium)	120	5	..	*758.32	Telzir	VI
INDINAVIR							
<u>Authority required (STREAMLINED)</u>							
3588							
Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;							
3589							
Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.							
5752R	Capsule 400 mg (as sulfate)	360	5	..	*910.00	Crixivan 400 mg	MK
RITONAVIR							
<u>Authority required (STREAMLINED)</u>							
3588							
Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;							
3589							
Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.							
9542F	Oral solution 600 mg per 7.5 mL (80 mg per mL), 90 mL	10	5	..	*910.00	Norvir	VE
9660K	Tablet 100 mg	720	5	..	*982.80	Norvir	VE
SAQUINAVIR							
<u>Authority required (STREAMLINED)</u>							
3588							
Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;							
3589							
Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.							
9545J	Tablet 500 mg (as mesylate)	240	5	..	*1011.12	Invirase	RO

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

TIPRANAVIR

Authority required (STREAMLINED)

3601

Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 200 mg ritonavir twice daily in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance. Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

Note

Special Pricing Arrangements apply.

9567M	Capsule 250 mg	240	5	..	*2142.00	Aptivus	BY
-------	----------------	-----	---	----	----------	---------	----

Nucleoside and nucleotide reverse transcriptase inhibitors

ABACAVIR

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

5601T	Tablet 300 mg (as sulfate)	120	5	..	*564.00	Ziagen	VI
5602W	Oral solution 20 mg (as sulfate) per mL, 240 mL	8	5	..	*657.12	Ziagen	VI

ADEFOVIR DIPIVOXIL

Authority required (STREAMLINED)

3973

Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:

- (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
- (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;

3974

Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.

5606C	Tablet 10 mg	60	5	..	*1250.00	Hepsera	GI
-------	--------------	----	---	----	----------	---------	----

DIDANOSINE

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

5663C	Capsule 125 mg (containing enteric coated beadlets)	60	5	..	*280.86	Videx EC	BQ
5664D	Capsule 200 mg (containing enteric coated beadlets)	60	5	..	*326.80	Videx EC	BQ
5665E	Capsule 250 mg (containing enteric coated beadlets)	60	5	..	*408.48	Videx EC	BQ
5666F	Capsule 400 mg (containing enteric coated beadlets)	60	5	..	*653.58	Videx EC	BQ

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

EMTRICITABINE

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

5709L	Capsule 200 mg	60	5	..	*564.00	Emtriva	GI
-------	----------------	----	---	----	---------	---------	----

ENTECAVIR MONOHYDRATE

Authority required (STREAMLINED)

3961

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:

(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;

(2) Evidence of chronic liver injury as determined by:

(a) Confirmed elevated serum ALT; or

(b) Liver biopsy;

3962

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

PBS-subsidised entecavir monohydrate must be used as monotherapy.

5711N	Tablet 0.5 mg	60	5	..	*768.60	Baraclude	BQ
-------	---------------	----	---	----	---------	-----------	----

ENTECAVIR MONOHYDRATE

Authority required (STREAMLINED)

3964

Chronic hepatitis B in a patient without cirrhosis who has failed lamivudine and who satisfies all of the following criteria:

(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or

(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;

3966

Chronic hepatitis B in a patient with cirrhosis who has failed lamivudine and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

PBS-subsidised entecavir monohydrate must be used as monotherapy.

5712P	Tablet 1 mg	60	5	..	*1250.00	Baraclude	BQ
-------	-------------	----	---	----	----------	-----------	----

LAMIVUDINE

Authority required (STREAMLINED)

3961

Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:

(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;

(2) Evidence of chronic liver injury as determined by:

(a) Confirmed elevated serum ALT; or

(b) Liver biopsy;

3962

Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer	
5770Q	Tablet 100 mg	56	5	..	*250.94	Zeffix	GK
5771R	Oral solution 5 mg per mL, 240 mL	5	5	..	*293.60	Zeffix	GK

LAMIVUDINE

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

5772T	Tablet 150 mg	120	5	..	*473.78	^a 3TC ^a Lamivudine RBX	VI RA
5773W	Oral solution 10 mg per mL, 240 mL	8	5	..	*581.12	3TC	VI
5774X	Tablet 300 mg	60	5	..	*473.78	^a 3TC ^a Lamivudine RBX	VI RA

STAVUDINE

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

9553T	Capsule 20 mg	120	5	..	*560.00	Zerit	BQ
9554W	Capsule 30 mg	120	5	..	*667.36	Zerit	BQ
9556Y	Capsule 40 mg	120	5	..	*889.80	Zerit	BQ

TELBIVUDINE

Authority required (STREAMLINED)

3969

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:

(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;

(2) Evidence of chronic liver injury as determined by:

(a) Confirmed elevated serum ALT; or

(b) Liver biopsy;

3970

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

9562G	Tablet 600 mg	56	5	..	*501.76	Sebivo	NV
-------	---------------	----	---	----	---------	--------	----

TENOFOVIR

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Authority required (STREAMLINED)

3969

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:

- (1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;
- (2) Evidence of chronic liver injury as determined by:
 - (a) Confirmed elevated serum ALT; or
 - (b) Liver biopsy;

3970

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.

Authority required (STREAMLINED)

3973

Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:

- (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
- (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;

3974

Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Note

Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.

9563H	Tablet containing tenofovir disoproxil fumarate 300 mg	60	5	..	*966.20	Viread	GI
-------	--	----	---	----	---------	--------	----

ZIDOVUDINE

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

9570Q	Syrup 10 mg per mL, 200 mL	15	5	..	*673.20	Retrovir	GK
9651Y	Capsule 100 mg	400	5	..	*821.84	Retrovir	GK
9652B	Capsule 250 mg	240	5	..	*1232.76	Retrovir	GK

Non-nucleoside reverse transcriptase inhibitors

EFAVIRENZ

Authority required (STREAMLINED)

3588

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

5706H	Tablet 600 mg	60	5	..	*543.16	Stocrin	MK
5707J	Oral solution 30 mg per mL, 180 mL	7	5	..	*570.29	Stocrin	MK
5708K	Tablet 200 mg	180	5	..	*543.16	Stocrin	MK

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer	
ETRAVIRINE							
<u>Authority required (STREAMLINED)</u>							
3597							
Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.							
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.							
5084N	Tablet 200 mg	120	5	..	*1233.00	Intelence	JC
NEVIRAPINE							
<u>Authority required (STREAMLINED)</u>							
3588							
Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;							
3589							
Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.							
9506H	Tablet 200 mg	120	5	..	*543.16	Viramune	BY
9507J	Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL	10	5	..	*1350.00	Viramune	BY
NEVIRAPINE							
<u>Authority required (STREAMLINED)</u>							
3995							
Initial treatment of HIV infection in combination with other antiretroviral agents in a patient who has been stabilised on nevirapine immediate release with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;							
3589							
Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.							
1132N	Tablet 400 mg (extended release)	60	5	..	*543.16	Viramune XR	BY
RILPIVIRINE							
<u>Authority required (STREAMLINED)</u>							
3588							
Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;							
3589							
Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.							
1173R	Tablet 25 mg (as hydrochloride)	60	5	..	*543.16	Edurant	JC
Antivirals for treatment of HIV infections, combinations							
ABACAVIR with LAMIVUDINE							
<u>Authority required (STREAMLINED)</u>							
3592							
Initial treatment of HIV infection in combination with other antiretroviral agents in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;							
3593							
Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection.							
5603X	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	60	5	..	*1037.78	Kivexa	VI

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer	
					Max. Qty \$		

3986

Continuing treatment of HIV infection where the patient has previously received PBS-subsidised therapy for HIV infection.

1491L	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg and rilpivirine 25 mg (as hydrochloride)	60	5	..	*2073.36	Eviplera	GI
-------	---	----	---	----	----------	----------	----

Other antirvirals**ENFUVIRTIDE****Authority required (STREAMLINED)****3597**

Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

5710M	Pack containing 60 vials powder for injection 90 mg with 60 vials water for injections 1.1 mL (with syringes and swabs)	2	5	..	*4426.00	Fuzeon	RO
-------	---	---	---	----	----------	--------	----

MARAVIROC**Authority required (STREAMLINED)****3599**

Treatment, in addition to optimised background therapy in combination with other antiretroviral agents, of an antiretroviral experienced patient infected with only CCR5-tropic HIV-1, who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance. A tropism assay to determine CCR5 only strain status is required prior to initiation. Individuals with CXCR4 tropism demonstrated at any time point are not eligible.

Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.

5792W	Tablet 150 mg	120	5	..	*1835.40	Celsentri	VI
5793X	Tablet 300 mg	120	5	..	*1835.40	Celsentri	VI

RALTEGRAVIR**Authority required (STREAMLINED)****3588**

Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease;

3589

Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection.

9523F	Tablet 400 mg (as potassium)	120	5	..	*1331.10	Isentress	MK
-------	------------------------------	-----	---	----	----------	-----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Antineoplastic and immunomodulating agents

Antineoplastic agents

Antimetabolites

Pyrimidine analogues

AZACITIDINE

Note

Any queries concerning the arrangements to prescribe azacitidine may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe azacitidine should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Initial PBS-subsidised treatment of a patient with:

- (1) Myelodysplastic syndrome classified as Intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS); OR
- (2) Chronic Myelomonocytic Leukaemia (10% to 29% marrow blasts without Myeloproliferative Disorder); OR
- (3) Acute Myeloid Leukaemia with 20 to 30% marrow blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) Classification.

Classification of a patient as Intermediate-2 requires a score of 1.5 to 2.0 on the IPSS, achieved with the possible combinations:

1. 11% to 30% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 0 to 1 cytopenias; OR
2. 11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 0 to 1 cytopenias; OR
3. 11% to 20% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR
4. 5% to 10% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR
5. 5% to 10% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias; OR
6. less than 5% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), and 2 to 3 cytopenias.

Classification of a patient as high risk requires a score of 2.5 or more on the IPSS, achieved with the possible combinations:

1. 21% to 30% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR
2. 21% to 30% marrow blasts with intermediate (other abnormalities) or poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR
3. 11% to 20% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR
4. 11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias.

The first authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Azacitidine PBS Authority Application - Supporting Information Form; and
- (c) a copy of the bone marrow biopsy report demonstrating that the patient has myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia; and
- (d) a copy of the full blood examination report; and
- (e) for myelodysplastic syndrome, a copy of the pathology report detailing the cytogenetics demonstrating intermediate-2 or high risk disease according to the International Prognostic Scoring System (IPSS); and
- (f) a signed patient acknowledgment form.

No more than three cycles will be authorised.

Note

Special Pricing Arrangements apply.

9597D	Powder for injection 100 mg	14	2	..	*7700.00	Vidaza	CJ
-------	-----------------------------	----	---	----	----------	--------	----

AZACITIDINE

Note

Any queries concerning the arrangements to prescribe azacitidine may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe azacitidine should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Continuing treatment of a patient with:

- (1) Myelodysplastic syndrome classified as Intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS); OR
- (2) Chronic Myelomonocytic Leukaemia (10% to 29% marrow blasts without Myeloproliferative Disorder); OR
- (3) Acute Myeloid Leukaemia with 20 to 30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) Classification; who has previously been issued with an authority prescription for azacitidine and does not have progressive disease.

Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Up to six cycles will be authorised.

Note

Special Pricing Arrangements apply.

9598E	Powder for injection 100 mg	14	5	..	*7700.00	Vidaza	CJ
-------	-----------------------------	----	---	----	----------	--------	----

Cytotoxic antibiotics and related substances

Anthracyclines and related substances

DOXORUBICIN HYDROCHLORIDE, PEGYLATED LIPOSOMAL

Authority required (STREAMLINED)

3348

Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive mucocutaneous involvement;

3349

Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive visceral involvement.

5705G	Suspension for I.V. infusion 20 mg in 10 mL	4	5	..	*2491.96	Caelyx	JC
						Lipodox	ZF

Immunostimulants

Immunostimulants

Colony stimulating factors

FILGRASTIM

Authority required (STREAMLINED)

3357

For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia;

3358

Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy;

3359

Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation;

3360

A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation;

3361

A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation;

3362

A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer	
					Price for Max. Qty \$		
	therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;						
	3363 A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;						
	3364 A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;						
	3365 A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;						
	3366 A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage);						
	3367 A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months));						
	3368 A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months));						
	3369 A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned.						
	<u>Authority required (STREAMLINED)</u>						
	3370 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia;						
	3371 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide);						
	3372 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours;						
	3373 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours;						
	3374 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma;						
	3375 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen);						
	3376 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease;						
	3377 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma;						
	3834 A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP).						
1123D	Injection 300 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*2515.54	TevaGrastim	AS
1126G	Injection 480 micrograms in 0.8 mL single use pre-filled syringe	20	11	..	*4032.58	TevaGrastim	AS

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer	
					\$		
5741E	Injection 300 micrograms in 1 mL	20	11	..	*2515.54	Neupogen	AN
5742F	Injection 300 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*2515.54	Neupogen	AN
5743G	Injection 480 micrograms in 1.6 mL	20	11	..	*4032.58	Neupogen	AN
5744H	Injection 480 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*4032.58	Neupogen	AN
5829T	Injection 120 micrograms in 0.2 mL single use pre-filled syringe	20	11	..	*1006.22	Nivestim	HH
9692D	Injection 300 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*2515.54	Nivestim	HH
9694F	Injection 480 micrograms in 0.5 mL single use pre-filled syringe	20	11	..	*4032.58	Nivestim	HH

LENOGRASTIM

Authority required (STREAMLINED)

3392

Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy;

3393

Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors;

3394

Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation;

3395

Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;

3396

Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned.

Authority required (STREAMLINED)

3397

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia;

3398

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma;

3399

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours;

3400

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours;

3401

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma;

3402

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade);

3403

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma;

3404

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin's disease;

3405

Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma.

5787N	Powder for injection 13,400,000 i.u. (105 micrograms)	20	11	..	*1025.00	Granocyte 13	HH
5788P	Powder for injection 33,600,000 i.u. (263 micrograms)	20	11	..	*2567.20	Granocyte 34	HH

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	
PEGFILGRASTIM						
<u>Authority required (STREAMLINED)</u>						
3357						
For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia;						
3362						
A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;						
3363						
A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;						
3364						
A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;						
3365						
A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;						
3369						
A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned.						
<u>Authority required (STREAMLINED)</u>						
3370						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia;						
3371						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide);						
3372						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours;						
3373						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours;						
3374						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma;						
3375						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen);						
3376						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease;						
3377						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma;						
3834						
A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP).						
9514R	Injection 6 mg in 0.6 mL single use pre-filled syringe	1	11	..	1925.00	Neulasta AN

Interferons

INTERFERON ALFA-2a

Caution

Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer	
<u>Authority required (STREAMLINED)</u>							
3382							
Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase;							
3961							
Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:							
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;							
(2) Evidence of chronic liver injury as determined by:							
(a) Confirmed elevated serum ALT; or							
(b) Liver biopsy;							
3962							
Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.							
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.							
5759D	Injection 3,000,000 i.u. in 0.5 mL single dose pre-filled syringe	30	5	..	*894.00	Roferon-A	RO
5760E	Injection 4,500,000 i.u. in 0.5 mL single dose pre-filled syringe	30	5	..	*1341.00	Roferon-A	RO
5761F	Injection 6,000,000 i.u. in 0.5 mL single dose pre-filled syringe	30	5	..	*1787.40	Roferon-A	RO
5762G	Injection 9,000,000 i.u. in 0.5 mL single dose pre-filled syringe	30	5	..	*2681.40	Roferon-A	RO
INTERFERON ALFA-2b							
<u>Caution</u>							
Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.							
<u>Authority required (STREAMLINED)</u>							
3384							
Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement;							
3382							
Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase;							
3961							
Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:							
(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;							
(2) Evidence of chronic liver injury as determined by:							
(a) Confirmed elevated serum ALT; or							
(b) Liver biopsy;							
3962							
Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.							
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.							
5763H	Solution for injection 18,000,000 i.u. in 1.2 mL multi-dose injection pen	2	5	..	*357.48	Intron A Redipen	MK
5764J	Solution for injection 30,000,000 i.u. in 1.2 mL multi-dose injection pen	2	5	..	*595.80	Intron A Redipen	MK
5765K	Solution for injection 60,000,000 i.u. in 1.2 mL multi-dose injection pen	2	5	..	*1191.60	Intron A Redipen	MK
5766L	Solution for injection 18,000,000 i.u. in 3 mL single dose vial	15	5	..	*2681.10	Intron A	MK
5767M	Solution for injection 25,000,000 i.u. in 2.5 mL single dose vial	15	5	..	*3723.75	Intron A	MK
5768N	Solution for injection 10,000,000 i.u. in 1 mL single dose vial	15	5	..	*1489.50	Intron A	MK
INTERFERON GAMMA-1b							
<u>Authority required (STREAMLINED)</u>							
3385							
Treatment of chronic granulomatous disease in patients with frequent and severe infections despite adequate prophylaxis with antimicrobial agent							
5769P	Injection 2,000,000 i.u. in 0.5 mL	12	11	..	*2721.80	Imukin	BY

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

PEGINTERFERON ALFA-2a

Caution

Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Authority required (STREAMLINED)

3977

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who satisfies all of the following criteria:

(1) Elevated HBV DNA levels - greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;

(2) Evidence of chronic liver injury as determined by:

(a) Confirmed elevated serum ALT; or

(b) Liver biopsy;

(3) Has received no prior peginterferon alfa therapy for the treatment of hepatitis B;

3978

Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who has detectable HBV DNA.

Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.

Treatment is limited to 1 course of treatment for a duration of up to 48 weeks;

3412

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:

(1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);

(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.

The treatment course is limited to up to 48 weeks.

Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

(a) a nurse educator/counsellor for patients; and

(b) 24 hour access by patients to medical advice; and

(c) an established liver clinic; and

(d) facilities for safe liver biopsy.

9515T	Injection 135 micrograms in 0.5 mL single use pre-filled syringe	8	5	..	*2331.80	Pegasys	RO
9516W	Injection 180 micrograms in 0.5 mL single use pre-filled syringe	8	5	..	*2700.46	Pegasys	RO

RIBAVIRIN and PEGINTERFERON ALFA-2a

Caution

Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Caution

Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.

Authority required (STREAMLINED)

3413

Patients naive to interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:

(1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);

(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.

Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

Authority required (STREAMLINED)

3414

Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

The treatment course is limited to 48 weeks. Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

9524G	Pack containing 168 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 135 micrograms	2	5	..	*3072.84	Pegasys RBV	RO
9525H	Pack containing 112 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	2	5	..	*3085.28	Pegasys RBV	RO
9526J	Pack containing 140 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	2	5	..	*3245.82	Pegasys RBV	RO
9527K	Pack containing 168 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	2	5	..	*3406.36	Pegasys RBV	RO

RIBAVIRIN and PEGINTERFERON ALFA-2b

Caution

Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Caution

Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.

Authority required (STREAMLINED)

3949

Patients naive to interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients weighing at least 27 kg who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.

Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

likelihood of early viral response by week 12).

Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

Authority required (STREAMLINED)

3414

Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

The treatment course is limited to 48 weeks. Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

9529M	Pack containing 112 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 50 micrograms with diluent	2	5	..	*2119.74	Pegatron	MK
9530N	Pack containing 84 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 80 micrograms with diluent	2	5	..	*2422.72	Pegatron	MK
9534T	Pack containing 112 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 100 micrograms with diluent	2	5	..	*3099.62	Pegatron	MK

RIBAVIRIN and PEGINTERFERON ALFA-2b

Caution

Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.

Caution

Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.

Authority required (STREAMLINED)

3413

Patients naive to interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).

Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

Authority required (STREAMLINED)

3414

Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)

Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.

The treatment course is limited to 48 weeks. Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12.

Note

Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:

- (a) a nurse educator/counsellor for patients; and
- (b) 24 hour access by patients to medical advice; and
- (c) an established liver clinic; and
- (d) facilities for safe liver biopsy.

9531P	Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 80 micrograms with diluent	2	5	..	*2707.66	Pegatron	MK
9536X	Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 120 micrograms with diluent	2	5	..	*3491.58	Pegatron	MK
9538B	Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent	2	5	..	*4079.52	Pegatron	MK
9539C	Pack containing 168 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent	2	5	..	*4079.52	Pegatron	MK
9540D	Pack containing 196 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent	2	5	..	*4364.48	Pegatron	MK

Immunosuppressants

Immunosuppressants

Selective immunosuppressants

ABATACEPT

Note

Any queries concerning the arrangements to prescribe abatacept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe abatacept should be forwarded to:

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

AND either

(i) a total active joint count of at least 20 active (swollen and tender) joints; or

(ii) at least 4 active joints from the following list of major joints:

— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or

— shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

(1) a completed authority prescription form; and

(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and

(3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.

Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with abatacept.

Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

(a) have a documented history of severe active rheumatoid arthritis; and

(b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

(1) a completed authority prescription form; and

(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with abatacept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised abatacept treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.

Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised abatacept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised abatacept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with abatacept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with abatacept.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 5 repeats may be authorised.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with abatacept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with abatacept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

5605B	Powder for I.V. infusion 250 mg	1	504.43	Orencia	BQ
-------	---------------------------------	---	----	----	--------	---------	----

EVEROLIMUS

Caution

Careful monitoring of patients is mandatory.

Authority required (STREAMLINED)

3355

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required;

3356

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

5737Y	Tablet 1 mg	240	5	..	*3844.80	Certican	NV
5738B	Tablet 0.25 mg	120	5	..	*480.60	Certican	NV
5739C	Tablet 0.5 mg	120	5	..	*961.20	Certican	NV

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer	
					Price for Max. Qty \$		
5740D	Tablet 0.75 mg	240	5	..	*2883.60	Certican	NV

MYCOPHENOLATE MOFETIL

Caution

Careful monitoring of patients is mandatory.

Authority required (STREAMLINED)

3355

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required;

3356

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

Note

For item codes 9501C and 1839T, pharmaceutical benefits that have the form capsule 250 mg are equivalent for the purposes of substitution.

1839T	Capsule 250 mg	600	5	..	*933.60	^a Ceptolate	AF
9501C	Capsule 250 mg	600	5	..	*933.54	^a APO- Mycophenolate CellCept	TX RO
						^a Imulate	QA
						^a Mycophenolate Sandoz	SZ
						^a Pharmacor Mycophenolate 250	CR

MYCOPHENOLATE MOFETIL

Caution

Careful monitoring of patients is mandatory.

Authority required (STREAMLINED)

3355

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required;

3356

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

9500B	Powder for oral suspension 1 g per 5 mL, 165 mL	2	5	..	*489.02	CellCept	RO
9502D	Tablet 500 mg	300	5	..	*933.54	^a APO- Mycophenolate CellCept	TX RO
						^a Ceptolate	AF
						^a Imulate	QA
						^a Mycophenolate Sandoz	SZ
						^a Pharmacor Mycophenolate 500	CR

MYCOPHENOLATE SODIUM

Caution

Careful monitoring of patients is mandatory.

Authority required (STREAMLINED)

3355

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

9503E	Tablet (enteric coated) 180 mg (mycophenolic acid)	240	5	..	*373.44	Myfortic	NV
9504F	Tablet (enteric coated) 360 mg (mycophenolic acid)	240	5	..	*746.86	Myfortic	NV

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

NATALIZUMAB

Caution

Progressive multifocal leukoencephalopathy has been reported with this drug.

Note

Neurologists prescribing natalizumab under the PBS listing must be registered with the Tysabri Australian Prescribing Program.

Authority required (STREAMLINED)

3425

Treatment, as monotherapy, by a neurologist, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient 18 years of age or older, who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years.

The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the patient's medical notes, unless written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient is included in the patient's medical notes.

Natalizumab must be ceased if there is continuing progression of disability while on treatment with natalizumab. For continued treatment the patient must demonstrate compliance with, and an ability to tolerate, natalizumab.

Note

Special Pricing Arrangements apply.

9505G	Solution concentrate for I.V. infusion 300 mg in 15 mL	1	5	..	2038.46	Tysabri	BD
-------	--	---	---	----	---------	---------	----

SIROLIMUS

Caution

Careful monitoring of patients is mandatory.

Authority required (STREAMLINED)

3355

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required.

9548M	Tablet 2 mg	200	5	..	*2893.34	Rapamune	PF
9549N	Tablet 1 mg	200	5	..	*1446.66	Rapamune	PF
9550P	Oral solution 1 mg per mL, 60 mL	2	5	..	*936.00	Rapamune	PF
9747B	Tablet 0.5 mg	200	5	..	*723.34	Rapamune	PF

Tumor necrosis factor alpha (TNF-alpha) inhibitors

ADALIMUMAB

Note

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS WITH SEVERE ACTIVE JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient who has severe active juvenile idiopathic arthritis. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any 1 time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

— continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

— fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 12 month break in PBS-subsidised biological therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

(6) Withdrawal of treatment after sustained remission.

Withdrawal of treatment with bDMARDs should be considered in a patient who has achieved and sustained complete remission of disease for 12 months. A demonstration of response to the current treatment should be submitted to Medicare Australia at the time treatment is ceased.

Authority required

Initial 1 (new patient or patient recommencing after a break of more than 12 months).

Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:

- (a) who has severe active juvenile idiopathic arthritis; AND
- (b) whose parent or authorised guardian has signed a patient acknowledgement; AND
- (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND
- (d) who has demonstrated either:
 - (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or
 - (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:
 - oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or
 - oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months. (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)

Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.

Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.

If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

- (a) an active joint count of at least 20 active (swollen and tender) joints; OR
- (b) at least 4 active joints from the following list:
 - (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) an acknowledgement signed by a parent or authorised guardian.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 2 (change or re-commencement after break of less than 12 months).

Initial PBS-subsidised treatment with adalimumab by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:

- (a) has a documented history of severe active juvenile idiopathic arthritis; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and
- (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 3 ('grandfather' patients).

Initial PBS-subsidised supply for continuing treatment with adalimumab, by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:

- (a) has a documented history of severe active juvenile idiopathic arthritis; and
- (b) was receiving treatment with adalimumab prior to 1 March 2010; and
- (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and
- (d) is receiving treatment with adalimumab at the time of application.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) an acknowledgement signed by a parent or authorised guardian.

A maximum of 24 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

The assessment of the patient's response to this initial course of PBS-subsidised therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.

A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A patient may only qualify for PBS-subsidised treatment under this restriction once.

Authority required

Continuing treatment.

Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:

- (a) who has a documented history of severe active juvenile idiopathic arthritis; and
- (b) who has demonstrated an adequate response to treatment with adalimumab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.

An adequate response to treatment is defined as:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	
<p>All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p> <p>If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.</p>						
9661L	Injection 20 mg in 0.4 mL pre-filled syringe	2	1630.00	Humira VE
9662M	Injection 40 mg in 0.8 mL pre-filled syringe	2	1630.00	Humira VE
9663N	Injection 40 mg in 0.8 mL pre-filled pen	2	1630.00	Humira VE

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS WITH SEVERE ACTIVE JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient who has severe active juvenile idiopathic arthritis. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any 1 time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 12 month break in PBS-subsidised biological therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

details are under 'Swapping therapy' below]; or

(iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

(6) Withdrawal of treatment after sustained remission.

Withdrawal of treatment with bDMARDs should be considered in a patient who has achieved and sustained complete remission of disease for 12 months. A demonstration of response to the current treatment should be submitted to Medicare Australia at the time treatment is ceased.

Authority required

Initial 1 (new patient or patient recommencing after a break of more than 12 months).

Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:

- (a) who has severe active juvenile idiopathic arthritis; AND
- (b) whose parent or authorised guardian has signed a patient acknowledgement; AND
- (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND
- (d) who has demonstrated either:

(i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or

(ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:

— oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or

— oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months. (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)

Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.

Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.

If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

- (a) an active joint count of at least 20 active (swollen and tender) joints; OR
- (b) at least 4 active joints from the following list:
 - (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) an acknowledgement signed by a parent or authorised guardian.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Authority required

Initial 2 (change or re-commencement after break of less than 12 months).

Initial PBS-subsidised treatment with etanercept by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:

- (a) has a documented history of severe active juvenile idiopathic arthritis; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and
- (c) has not failed PBS-subsidised therapy with etanercept for this condition more than once in the current treatment cycle.

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for a patient who has received PBS-subsidised treatment with etanercept in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with etanercept may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.

Authority required

Continuing treatment.

Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:

- (a) who has a documented history of severe active juvenile idiopathic arthritis; and
- (b) who has demonstrated an adequate response to treatment with etanercept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.

An adequate response to treatment is defined as:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	
initial treatment course.						
If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle. A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle.						
5734T	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	1	815.00	Enbrel PF

ETANERCEPT

Note

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS WITH SEVERE ACTIVE JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and etanercept for a patient who has severe active juvenile idiopathic arthritis. Where the term bDMARD appears in the following NOTES and restrictions, it refers to adalimumab and etanercept only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 bDMARDs at any 1 time.

From 1 November 2010, a patient receiving PBS-subsidised bDMARD therapy is considered to be in a treatment cycle where they may swap to the alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy, and
- fail to respond, or to sustain a response to one PBS-subsidised bDMARD twice and the other PBS-subsidised bDMARD once only.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 12 month break in PBS-subsidised biological therapy before they are eligible to receive further PBS-subsidised bDMARD therapy. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment was stopped to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.

A patient who was receiving PBS-subsidised bDMARD treatment immediately prior to 1 November 2010 is considered to be in their first cycle as of 1 November 2010. A patient who has had a break in bDMARD treatment of at least 12 months immediately prior to making a new application, on or after 1 November 2010, will commence a new treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of less than 12 months may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of a bDMARD in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 November 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 12 months in PBS-subsidised therapy with that agent (Initial 2).

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to the alternate bDMARD without having to requalify with respect to the indices of disease severity (joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 12 months.

A patient may trial the alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug twice within the current treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count submitted with the first authority application for a bDMARD. However, prescribers may provide a new baseline measurement any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to the revised baseline measurement.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.

A patient who commenced treatment with adalimumab for severe active juvenile idiopathic arthritis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(6) Withdrawal of treatment after sustained remission.

Withdrawal of treatment with bDMARDs should be considered in a patient who has achieved and sustained complete remission of disease for 12 months. A demonstration of response to the current treatment should be submitted to Medicare Australia at the time treatment is ceased.

Authority required

Continuing treatment.

Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient 18 years or older:

- (a) who has a documented history of severe active juvenile idiopathic arthritis; and
- (b) who has demonstrated an adequate response to treatment with etanercept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.

An adequate response to treatment is defined as:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.

Where a patient with severe active juvenile idiopathic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50 mg may be prescribed.

5733R	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	1630.01	Enbrel	PF
5735W	Injection 50 mg in 1 mL single use auto-injector, 4	1	1630.01	Enbrel	PF

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept, golimumab and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

following NOTES and restrictions, it refers to adalimumab, etanercept, golimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 4 TNF-alfa antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial PBS-subsidised TNF-alfa antagonists without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and 18 weeks of treatment for infliximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for		Brand Name and Manufacturer
					Max. Qty	\$	

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.

A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with golimumab.

A patient who commenced treatment with golimumab for active ankylosing spondylitis prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with golimumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patients)

Initial PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND

(a) who has at least 2 of the following:

- (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or
- (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or
- (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND

(b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.

The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.

If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.

The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:

- (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND
- (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.

The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.

Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:
 - (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and
 - (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and
 - (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and
 - (iv) a signed patient acknowledgment form.

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.

At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Authority required

Initial 2 (change or re-commencement for all patients)

Initial PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with infliximab in the current treatment cycle.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].

A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.

At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

maximum of 18 weeks of treatment may be requested by telephone.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

Authority required

Continuing treatment for all patients

Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:

- (a) has demonstrated an adequate response to treatment with infliximab; and
- (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with infliximab.

An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:

- (a) an ESR measurement no greater than 25 mm per hour; or
- (b) a CRP measurement no greater than 10 mg per L; or
- (c) an ESR or CRP measurement reduced by at least 20% from baseline.

Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].

All measurements provided must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with infliximab will be authorised under this criterion.

At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.

All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with infliximab. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.

5753T	Powder for I.V. infusion 100 mg	1	751.70	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 22 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with infliximab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.

A maximum of 22 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

- (a) who have a documented history of severe active rheumatoid arthritis; and
 (b) who have demonstrated an adequate response to treatment with infliximab; and
 (c) whose most recent course of PBS-subsidised bDMARD treatment was with infliximab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

AND either of the following:

(i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or

(ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:

— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or

— shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

(1) a completed authority prescription form; and

(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 2 repeats may be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

5757B	Powder for I.V. infusion 100 mg	1	751.70	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
 Prior Written Approval of Specialised Drugs
 Reply Paid 9826
 GPO Box 9826
 HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

(1) Initial treatment.

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialed it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

Authority required

Initial 1

Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have severe active psoriatic arthritis; and
- (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and
- (3) have failed to achieve an adequate response to:
 - (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and
 - (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or
 - (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:

an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) an active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website]

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

website (www.medicareaustralia.gov.au); and
(3) a signed patient acknowledgement.

A maximum of 22 weeks treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Initial 2

Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have a documented history of severe active psoriatic arthritis; and
- (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and
- (3) have not failed treatment with infliximab during the current Treatment Cycle.

Applications for patients who have received PBS-subsidised treatment with infliximab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.

A maximum of 22 weeks treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:

- (1) who have a documented history of severe active psoriatic arthritis; and
- (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with infliximab; and
- (3) who, at the time of application, demonstrate an adequate response to treatment with infliximab.

An adequate response to treatment with infliximab is defined as:

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats may be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.

Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept, golimumab and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, golimumab and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2010.

- (1) Initial treatment.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Applications for initial treatment should be made where:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).

All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.

Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

Grandfather patients — golimumab only.

Applications for patients who commenced treatment with golimumab prior to 1 March 2010 may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.

Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.

(2) Continuing treatment.

Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.

(3) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.

Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.

Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; or
- (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.

(4) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.

5756Y	Powder for I.V. infusion 100 mg	1	751.70	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

(iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1 (new patients)

Initial treatment of Crohn disease in a patient assessed by CDAI.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and
- (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (c) has failed to achieve an adequate response to prior systemic therapy including:
 - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
 - (ii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

The most recent CDAI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and
 - (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and
 - (iii) the signed patient acknowledgement.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial 2

Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and
- (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and
 - (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Continuing treatment of Crohn disease in a patient assessed by CDAI.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.

The CDAI assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, a CDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial 1

Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:

- (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and
- (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and
- (c) has evidence of intestinal inflammation; and
- (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (e) has failed to achieve an adequate response to prior systemic drug therapy including:
 - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
 - (ii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) have evidence of intestinal inflammation, including:
 - (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR
 - (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR
 - (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;
- AND/OR
- (b) be assessed clinically as being in a high faecal output state;
- AND/OR

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and
 - (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and
 - (iii) date of the most recent clinical assessment; and
 - (iv) the signed patient acknowledgement.

All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial 2

Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and
- (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and
 - (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as:

- (a) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
 - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or
- (b) reversal of high faecal output state; or
- (c) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.

The patient's assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Authority required

Initial 1

Initial treatment of Crohn disease in a patient with extensive small intestine disease.

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and
- (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and
- (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) has failed to achieve an adequate response to prior systemic therapy including:
 - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
 - (ii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220; AND/OR
- (b) have evidence of active intestinal inflammation, including:
 - (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR
 - (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR
 - (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery; AND/OR
- (c) be assessed clinically as being in a high faecal output state; AND/OR
- (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and
 - (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or
 - (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and
 - (iii) date of the most recent clinical assessment; and
 - (iv) the signed patient acknowledgement.

All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Continuing treatment of Crohn disease in a patient with extensive small intestine disease.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50 cm of the small intestine; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as:

- (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or
- (b) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
 - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or
 - (c) reversal of high faecal output state; or
 - (d) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or
 - (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or
 - (iii) the date of clinical assessment.

All assessments must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial 3 (grandfather)

Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with infliximab.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7 March 2007; and
- (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and
 - (ii) the signed patient acknowledgement.

The current CDAI assessment must be no more than 1 month old at the time of application. The baseline CDAI assessment must be from immediately prior to commencing treatment with infliximab.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

Authority required

Initial 3

Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with infliximab.

Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7 March 2007; and
- (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; or
- (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) has demonstrated or sustained an adequate response to treatment with infliximab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

An adequate response to infliximab treatment is defined as:

- (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or
- (b) improvement of intestinal inflammation as demonstrated by:
 - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR
 - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR
- (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or
- (c) reversal of high faecal output state; or
- (d) avoidance of the need for surgery or total parenteral nutrition (TPN).

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or
 - (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or
 - (3) the date of clinical assessment(s); and
 - (ii) the signed patient acknowledgement.

The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with infliximab. Where a baseline assessment is not available, please call Medicare Australia on 1800 700 270 to discuss.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alpha antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alpha antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alpha antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alpha antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alpha antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alpha antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alpha antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alpha antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alpha antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alpha antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

5754W	Powder for I.V. infusion 100 mg	1	751.70	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.

A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial treatment of Crohn disease in a paediatric patient.

Initial PBS-subsidised treatment by a gastroenterologist, paediatrician or consultant physician as specified in the NOTE below, of a patient aged 6 to 17 years inclusive with moderate to severe refractory Crohn disease who satisfies the following criteria:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and
- (b) whose parent or authorised guardian has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (c) has failed to achieve an adequate response to 2 of the following 3 conventional prior therapies including:
 - (i) a tapered course of steroids, starting at a dose of at least 1 mg per kg or 40 mg (whichever is the lesser) prednisolone (or equivalent), over a 6 week period;
 - (ii) an 8 week course of enteral nutrition;
 - (iii) immunosuppressive therapy including:
 - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
 - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
 - methotrexate at a dose of at least 10 mg per square metre weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

- (a) severity of disease activity which results in a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30 as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) The most recent PCDAI assessment must be no more than 1 month old at the time of application.

All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient's condition; and
 - (ii) details of previous systemic drug therapy [dosage, date of commencement and duration of therapy], or dates of enteral nutrition; and
 - (iii) the signed patient acknowledgement.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A PCDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Continuing treatment of Crohn disease in a patient initiated on PBS-subsidised treatment as a paediatric patient.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of moderate to severe refractory Crohn disease; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition.

The PCDAI assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, a PCDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

treatment with infliximab, will not be eligible to receive PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority required

Initial PBS-subsidised treatment of Crohn disease in a paediatric patient who has previously received non-PBS-subsidised therapy with infliximab.

Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient aged 6 to 17 years inclusive who:

- (a) has a documented history of moderate to severe refractory Crohn disease and was receiving treatment with infliximab prior to 4 July 2007; and
- (b) had a Paediatric Crohn Disease Activity Index (PCDAI) Score of greater than 30 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and
- (c) whose parent or authorised guardian has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and baseline Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition; and
 - (ii) the signed patient acknowledgement.

The current PCDAI assessment must be no more than 1 month old at the time of application. The baseline PCDAI assessment must be from immediately prior to commencing treatment with infliximab.

The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

5755X	Powder for I.V. infusion 100 mg	1	751.70	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

Note

TREATMENT OF COMPLEX REFRACTORY FISTULISING CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for patients with complex refractory fistulising Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 April 2011, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 April 2011 is considered to be in their first cycle as of 1 April 2011.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 April 2011.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.

From 1 April 2011, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

For second and subsequent courses of PBS-subsidised TNF- α antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific TNF- α antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF- α antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF- α antagonist supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF- α antagonist.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised TNF- α antagonist is approved, a patient may swap if eligible to the alternate TNF- α antagonist within the same treatment cycle.

A patient may trial the alternate TNF- α antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF- α antagonist at the time of the application. However, they cannot swap to a particular TNF- α antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, an application for a patient who wishes to swap to the alternate TNF- α antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF- α antagonist the patient is ceasing.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements submitted with the first authority application for a TNF- α antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF- α antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.

A patient who commenced treatment with adalimumab for complex refractory fistulising Crohn disease prior to 4 November 2010 or infliximab prior to 1 March 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

Authority required

Initial 1

Initial treatment of complex refractory FISTULISING CROHN DISEASE.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and
- (b) has an externally draining enterocutaneous or rectovaginal fistula; and
- (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and
 - (ii) a signed patient acknowledgement.

The most recent fistula assessment must be no more than 1 month old at the time of application.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6 will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

An assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial 2

Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.

Initial PBS-subsidised treatment with infliximab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:

- (a) has a documented history of complex refractory fistulising Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and
- (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(ii) details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.

The most recent fistula assessment must be no more than 1 month old at the time of application.

A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

An assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.

This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial 3 (grandfather)

Initial PBS-subsidised treatment of complex refractory FISTULISING CROHN DISEASE in a patient who has previously received non-PBS-subsidised therapy with infliximab.

Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who satisfies the following criteria:

- (a) has a documented history of complex refractory fistulising Crohn disease and was receiving treatment with infliximab prior to 1 March 2010; and
- (b) had a draining enterocutaneous or rectovaginal fistula(e) prior to commencing treatment with infliximab; and
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (d) is receiving treatment with infliximab at the time of application; and
- (e) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response to infliximab treatment is defined as:

- (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or
- (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) a completed current and baseline Fistula Assessment form including the date of assessment of the patient's condition; and
 - (ii) a signed patient acknowledgement.

The current fistula assessment must be no more than 1 month old at the time of application.

The baseline fistula assessment must be from immediately prior to commencing treatment with infliximab.

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max. Qty	\$	

Friday).

Patients may qualify for PBS-subsidised treatment under this restriction once only.

Authority required

Continuing treatment of complex refractory FISTULISING CROHN DISEASE.

Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:

- (a) has a documented history of complex refractory fistulising Crohn disease; and
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

An adequate response is defined as:

- (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or
- (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.

Authority applications must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes a completed Fistula Assessment form including the date of the assessment of the patient's condition.

The fistula assessment must be no more than 1 month old at the time of application.

If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.

Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.

Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

9654D	Powder for I.V. infusion 100 mg	1	751.70	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe infliximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001

;

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.

From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.

There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.

(1) Application for approval for initial treatment.

Applications for a course of initial treatment should be made in the following situations:

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).

All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.

(2) Assessment of response to initial treatment.

When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

(3) Application for continuing treatment.

Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.

For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

(4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.

Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

(5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

Authority required

Initial treatment [Initial 1, Whole body (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
 - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
 - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or
 - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or
 - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

- (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)];
 - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and
 - (iii) the signed patient and prescriber acknowledgements.

A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Authority required

Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have a documented history of severe chronic plaque psoriasis; and
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)];
 - (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Continuing treatment (Whole body)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis; and
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and
- (c) who have demonstrated an adequate response to their most recent course of treatment with infliximab.

An adequate response to treatment is defined as:

A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.

The most recent PASI assessment must be no more than 1 month old at the time of application.

Approval will be based on the PASI assessment of response to the most recent course of treatment with infliximab.

A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised.

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Initial treatment [Initial 1, Face, hand, foot (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

months from the time of initial diagnosis; and

(b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and

(c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and

(d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:

(i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or

(ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or

(iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or

(iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).

The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:

(a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:

(i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or

(ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.

(b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.

(c) The most recent PASI assessment must be no more than 1 month old at the time of application.

Applications for authorisation must be made in writing and must include:

(a) a completed authority prescription form; and

(b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:

(i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and

(ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and

(iii) the signed patient and prescriber acknowledgements.

A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.

A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Authority required

Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]

Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

(a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and

(b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and

(c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.

Applications for authorisation must be made in writing and must include:

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

- (a) a completed authority prescription form; and
 (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
 (ii) details of prior biological treatment, including dosage, date and duration of treatment.

Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.

A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.

A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Authority required

Continuing treatment (Face, hand, foot)

Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:

- (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and
 (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and
 (c) who have demonstrated an adequate response to treatment with infliximab.

An adequate response to infliximab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:

- (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or
 (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.

This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
 (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

The most recent PASI assessment must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.

A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.

It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.

The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.

Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

Note

No applications for increased repeats will be authorised.

5758C	Powder for I.V. infusion 100 mg	1	751.70	Remicade	JC
-------	---------------------------------	---	----	----	--------	----------	----

Interleukin inhibitors

TOCILIZUMAB

Note

Any queries concerning the arrangements to prescribe tocilizumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe tocilizumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (new patient or patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form(s); and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.

Up to a maximum of 3 repeats of each strength may be authorised.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.

Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form(s); and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats of each strength may be authorised.

Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with tocilizumab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(1) a completed authority prescription form(s); and

(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of 24 weeks of treatment will be approved under this restriction.

At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats of each strength may be authorised.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.

Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

9657G	Concentrate for injection 80 mg in 4 mL	1	186.88	Actemra	RO
9658H	Concentrate for injection 200 mg in 10 mL	1	467.20	Actemra	RO
9659J	Concentrate for injection 400 mg in 20 mL	1	934.40	Actemra	RO

TOCILIZUMAB

Note

Any queries concerning the arrangements to prescribe tocilizumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe tocilizumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF PATIENTS WITH SEVERE ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of tocilizumab for a patient who has severe active systemic juvenile idiopathic arthritis (sJIA).

From 1 May 2012, a patient receiving PBS-subsidised tocilizumab therapy is considered to be in a treatment cycle. Under these arrangements, within a single treatment cycle, a patient may:

- continue to receive long-term treatment with PBS-subsidised tocilizumab while they continue to show a response to therapy, and
- fail to respond, or to sustain a response, to PBS-subsidised tocilizumab twice.

Once a patient has either failed or ceased to respond to 2 courses of treatment, they are deemed to have completed a single treatment cycle and they must have, at a minimum, a 12 month break in PBS-subsidised tocilizumab therapy before they are eligible to receive further PBS-subsidised tocilizumab therapy. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised tocilizumab treatment was stopped to the date of the first application for initial treatment with tocilizumab under the new treatment cycle.

A patient who was receiving PBS-subsidised tocilizumab treatment immediately prior to 1 May 2012 is considered to be in their first cycle as of 1 May 2012. A patient who has had a break in tocilizumab treatment of at least 12 months immediately prior to making a new application, on or after 1 May 2012, will commence a new treatment cycle.

A patient who has failed their first course of tocilizumab in a treatment cycle and who has a break in therapy of less than 12 months may commence a second course of treatment within the same treatment cycle.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

A patient who has failed their first course of tocilizumab in a treatment cycle and who has a break in therapy of more than 12 months must commence a new treatment cycle.

(1) How to prescribe PBS-subsidised tocilizumab therapy after 1 May 2012.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised tocilizumab treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient wishes to re-commence treatment with tocilizumab following a break in PBS-subsidised therapy of more than 12 months (Initial 1); or
- (iii) a patient has received the first course of PBS-subsidised (initial or continuing) tocilizumab therapy in a treatment cycle and is deemed to have failed to respond or sustain a response and the treating physician wishes to trial a second course (Initial 2).

Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy.

A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab for that course.

For second and subsequent courses of PBS-subsidised tocilizumab, it is recommended that a patient is reviewed in the 4 weeks prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of an initial treatment course with tocilizumab, a patient may qualify to receive up to 24 weeks of continuing treatment with tocilizumab providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted tocilizumab supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.

(2) Treatment cycle.

Once initial treatment with PBS-subsidised tocilizumab is approved, a patient deemed to have failed to respond to the first course of treatment may have a second course without having to requalify with respect to the indices of disease severity (joint count, fever and/or CRP level and platelet count) or the prior therapy requirements, except if the patient has had a break in therapy of more than 12 months.

To ensure a patient receives the maximum treatment opportunities allowed under these arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the relevant baseline measurements of the joint count, fever and/or CRP level and platelet count submitted with the first authority application for tocilizumab.

Where a patient is deemed to have failed to respond or to sustain a response to the first course of therapy in a treatment cycle, prescribers may provide new baseline measurements for the second course of treatment within that cycle. Medicare Australia will assess response according to these revised baseline measurements. If new baseline measurements are not submitted with the initial application for the second course of treatment, then those submitted with the first course will be used by Medicare Australia to assess response to the second course.

(4) Re-commencement of treatment after a 12 month break in PBS-subsidised therapy.

A patient who wishes to start a second or subsequent treatment cycle following a break in PBS-subsidised tocilizumab therapy of at least 12 months, must requalify for treatment under the Initial 1 treatment restriction.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with tocilizumab.

A patient who commenced treatment with tocilizumab for severe active systemic juvenile idiopathic arthritis prior to 1 November 2011 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with tocilizumab will be

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty	Brand Name and Manufacturer
					\$	

authorised under this criterion.

Following completion of the initial PBS-subsidised course, further applications for treatment with tocilizumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must qualify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 12 month break in PBS-subsidised therapy' above for further details.

(6) Withdrawal of treatment after sustained remission.

Withdrawal of treatment with tocilizumab should be considered in a patient who has achieved and sustained complete remission of disease for 12 months. A demonstration of response to the current treatment should be submitted to Medicare Australia at the time treatment is ceased.

Authority required

Initial 1 (new and recommencing patients after a break of more than 12 months)

Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:

- (a) has been diagnosed with systemic juvenile idiopathic arthritis; AND
- (b) has polyarticular course disease and either:
 - (i) failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):
 - oral or parenteral methotrexate at a dose of at least 15 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or
 - (ii) severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR
 - (c) has refractory systemic symptoms, demonstrated by:
 - an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5 mg per kg per day following a minimum of 2 months of therapy; AND
 - (d) has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.

(1) The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:

- (a) in a patient with polyarticular course disease:
 - (i) an active joint count of at least 20 active (swollen and tender) joints; OR
 - (ii) at least 4 active joints from the following list:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).
- (b) in a patient with refractory systemic symptoms:
 - (i) an active joint count of at least 2 active joints; AND
 - (ii) persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR
 - (iii) a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).

(2) Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.

Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.

If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.

The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) the date of assessment of severe active systemic juvenile idiopathic arthritis;
 - (ii) details of prior treatment including dose and duration of treatment;
 - (iii) pathology reports detailing CRP and platelet count where appropriate; and
- (3) a signed patient or authorised guardian acknowledgement form.

The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.

If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle. A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)

Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:

- (a) has a documented history of systemic juvenile idiopathic arthritis; AND
- (b) has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND
- (c) has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) pathology reports detailing CRP and platelet count where appropriate.

Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.

A maximum of 16 weeks of treatment will be authorised under this restriction.

At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised.

Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.

If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle. A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle.

Authority required

Initial 3 ('grandfather' patients)

Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:

- (a) has a documented history of systemic juvenile idiopathic arthritis; and
- (b) was receiving treatment with tocilizumab prior 1 November 2011; and
- (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and
- (d) is receiving treatment with tocilizumab at the time of application.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) pathology reports detailing CRP and platelet count where appropriate; and
 - (3) a signed patient or authorised guardian acknowledgement form.

The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.

The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab. (See NOTE (3) above for definition of baseline measurements to determine response.)

An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.

Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.

Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one months supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

A patient may only qualify for PBS-subsidised treatment under this restriction once.

Authority required

Continuing treatment

Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:

- (a) has a documented history of systemic juvenile idiopathic arthritis; AND
- (b) has demonstrated an adequate response to treatment with tocilizumab.

An adequate response to treatment is defined as:

- (a) in a patient with polyarticular course disease:
 - (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
 - (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).
- (b) in a patient with refractory systemic symptoms:
 - (i) absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR
 - (ii) a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR
 - (iii) a reduction in the dose of corticosteroid by at least 30% from baseline.

The authority application must be made in writing and must include:

- (1) completed authority prescription form(s); and
- (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:
 - (i) baseline and current pathology reports detailing CRP and platelet count where appropriate.

The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.

Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.

Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

ceased.

Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats will be authorised.

Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle. A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle.

Note

Special Pricing Arrangements apply.

1476Q	Concentrate for injection 80 mg in 4 mL	1	186.88	Actemra	RO
1481Y	Concentrate for injection 200 mg in 10 mL	1	467.20	Actemra	RO
1482B	Concentrate for injection 400 mg in 20 mL	1	934.40	Actemra	RO

Calcineurin inhibitors

CYCLOSPORIN

Caution

Careful monitoring of patients is mandatory.

Authority required (STREAMLINED)

3328

Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required;

3329

Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate;

3330

Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life;

3331

Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired;

3332

Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.

5632K	Capsule 10 mg	120	5	..	*74.40	Neoral 10	NV
5633L	Oral liquid 100 mg per mL, 50 mL	4	5	..	*1263.16	Neoral	NV
5634M	Capsule 25 mg	120	5	..	*153.56	^a Cicloral	SZ
						^a Neoral 25	NV
5635N	Capsule 50 mg	120	5	..	*319.52	^a Cicloral	SZ
						^a Neoral 50	NV
5636P	Capsule 100 mg	120	5	..	*651.08	^a Cicloral	SZ
						^a Neoral 100	NV

CYCLOSPORIN

Caution

Careful monitoring of patients is mandatory.

Authority required (STREAMLINED)

3333

For use by organ or tissue transplant recipients.

5631J	Solution concentrate for I.V. infusion 50 mg in 1 mL	10	54.10	Sandimmun	NV
-------	--	----	----	----	-------	-----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer	
TACROLIMUS							
<u>Caution</u>							
Careful monitoring of patients is mandatory.							
<u>Authority required (STREAMLINED)</u>							
3328							
Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit.							
Management includes initiation, stabilisation and review of therapy as required.							
9558C	Capsule 0.5 mg	200	5	..	*327.84	^a Prograf ^a Tacrolimus Sandoz	JC SZ
9560E	Capsule 1 mg	200	5	..	*655.68	^a Prograf ^a Tacrolimus Sandoz	JC SZ
9561F	Capsule 5 mg	100	5	..	*1638.38	^a Prograf ^a Tacrolimus Sandoz	JC SZ
9664P	Capsule 0.5 mg (once daily prolonged release)	60	5	..	*98.36	Prograf XL	JC
9665Q	Capsule 1 mg (once daily prolonged release)	120	5	..	*393.40	Prograf XL	JC
9666R	Capsule 5 mg (once daily prolonged release)	60	5	..	*983.54	Prograf XL	JC

Other immunosuppressants

LENALIDOMIDE

Note

Any queries concerning the arrangements to prescribe lenalidomide may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Any queries concerning patients who are enrolled on the Lenalidomide Compassionate program may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). These patients must demonstrate they met initial criteria prior to commencing treatment on the compassionate program and also demonstrate they do not have progressive disease. Baseline and current pathology reports must be submitted with the initial application.

Applications for authority to prescribe lenalidomide should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001.

Authority required

Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant. The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100 mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.

If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein and less than 200 mg per 24 hour Bence-Jones proteinuria.

Thalidomide treatment failure is defined as:

- (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or
- (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.

Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.

Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:

- (1) less than a 25% reduction in serum or urine M protein; or
- (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.

Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.

To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:

- (a) the level of serum monoclonal protein; or
- (b) Bence-Jones proteinuria — the results of 24-hour urinary light chain M protein excretion; or
- (c) the serum level of free kappa and lambda light chains; or
- (d) bone marrow aspirate or trephine; or
- (e) if present, the size and location of lytic bone lesions (not including compression fractures); or
- (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or
- (g) if present, the level of hypercalcaemia, corrected for albumin concentration.

As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10 g per L and urinary Bence-Jones protein undetectable or less than 200 mg per 24 hours) must be provided; and

- (3) duration of thalidomide and daily dose prescribed; and
- (4) a signed patient acknowledgment.

Note

Patients receiving lenalidomide under the PBS listing must be registered in the i-access risk management program.

Authority required

Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Note

Patients receiving lenalidomide under the PBS listing must be registered in the i-access risk management program.

Note

Special Pricing Arrangements apply.

5783J	Capsule 5 mg	21	5392.38	Revlimid	CJ
5784K	Capsule 10 mg	21	5643.33	Revlimid	CJ
5785L	Capsule 15 mg	21	6581.61	Revlimid	CJ
5786M	Capsule 25 mg	21	6934.20	Revlimid	CJ

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

RITUXIMAB

Note

Any queries concerning the arrangements to prescribe rituximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Further prescribing information (including Authority Application Forms) is on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe rituximab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised abatacept, golimumab, infliximab and rituximab must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are eligible to receive PBS-subsidised adalimumab, certolizumab pegol, etanercept and tocilizumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:

- a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,
- a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and
- once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.

For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact Medicare Australia on 1800 700 270.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction.

The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.

(a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or
- (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).

Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab and tocilizumab, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

Abatacept patients:

Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.

Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

(b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

(2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.

Abatacept patients:

Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

Note

(3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.

Authority required

Initial 1 (patient re-commencing after a break of more than 24 months)

Initial PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist; and
- (c) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and
- (d) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be:
 - hydroxychloroquine at a dose of at least 200 mg daily; or
 - leflunomide at a dose of at least 10 mg daily; or
 - sulfasalazine at a dose of at least 2 g daily.

If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:

- hydroxychloroquine at a dose of at least 200 mg daily; and/or
- leflunomide at a dose of at least 10 mg daily; and/or
- sulfasalazine at a dose of at least 2 g daily.

The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au]. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.

If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:

- azathioprine at a dose of at least 1 mg/kg per day; and/or
- cyclosporin at a dose of at least 2 mg/kg/day; and/or
- sodium aurothiomalate at a dose of 50 mg weekly.

The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or
- (ii) at least 4 active joints from the following list of major joints:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.

If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.

Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and
- (3) a signed patient acknowledgement.

A maximum of two infusions will be authorised under this restriction.

Assessment of a patient's response to an initial course of treatment must be made at least 12 weeks after the first infusion so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date it was conducted.

Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with rituximab.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.

Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Patients who fail to demonstrate a response to rituximab treatment and who qualify to trial an alternate bDMARD according to the interchangeability arrangements for bDMARDs for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.

Authority required

Initial 2 (change or re-commencement after break of less than 24 months)

Initial course of PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist; and
- (c) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

Applications for patients who have received PBS-subsidised treatment with rituximab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised rituximab treatment, within the timeframes specified below.

A maximum of two infusions will be authorised under this restriction.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Where the most recent course of PBS-subsidised rituximab treatment was approved under either of the initial 1 or 2 treatment restrictions patients must be assessed for response at least 12 weeks after the first infusion. This assessment must be provided to Medicare Australia no later than 4 weeks from the date of assessment.

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.

Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Patients who fail to demonstrate a response to rituximab treatment and who qualify to trial an alternate bDMARD according to the interchangeability arrangements for bDMARDs for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with rituximab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment was with rituximab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
 - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
 - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].

A maximum of two infusions will be authorised under this restriction.

Patients may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.

A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.

Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.

Note

Special Pricing Arrangements apply.

9544H	Solution for I.V. infusion 500 mg in 50 mL	1	2263.57	Mabthera	RO
-------	--	---	----	----	---------	----------	----

THALIDOMIDE

Caution

Thalidomide is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and for 1 month after cessation of treatment.

Authority required (STREAMLINED)

3342

Multiple myeloma.

Note

Patients receiving thalidomide under the PBS listing must be registered in the i-access risk management program.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer	
					Max. Qty \$		
9566L	Capsule 50 mg	112	*1680.00	Thalomid	CJ
9667T	Capsule 100 mg	56	*1680.00	Thalomid	CJ

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Musculo-skeletal system

Muscle relaxants

Muscle relaxants, centrally acting agents

Other centrally acting agents

BACLOFEN

Authority required (STREAMLINED)

3318

Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity of cerebral origin;

3319

Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to multiple sclerosis;

3320

Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord injury;

3321

Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord disease.

5617P	Intrathecal injection 10 mg in 5 mL	10	*1483.70	Lioresal Intrathecal	NV
-------	-------------------------------------	----	----	----	----------	----------------------	----

Drugs for treatment of bone diseases

Drugs affecting bone structure and mineralization

Bisphosphonates

DISODIUM PAMIDRONATE

Authority required (STREAMLINED)

3341

Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.

Note

Pharmaceutical benefits that have the form disodium pamidronate powder for I.V. infusion 15 mg (after reconstitution) and pharmaceutical benefits that have the form disodium pamidronate concentrated injection 15 mg are equivalent for the purposes of substitution.

5667G	Concentrated injection 15 mg in 5 mL	4	2	..	*209.92 ^a	Pamisol	HH
5701C	Injection set containing 4 vials powder for I.V. infusion 15 mg and 4 ampoules solvent 5 mL	1	2	..	209.91 ^a	Aredia 15 mg	NV

DISODIUM PAMIDRONATE

Authority required (STREAMLINED)

3341

Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.

Note

Pharmaceutical benefits that have the form disodium pamidronate powder for I.V. infusion 30 mg (after reconstitution) and pharmaceutical benefits that have the form disodium pamidronate concentrated injection 30 mg are equivalent for the purposes of substitution.

5668H	Concentrated injection 30 mg in 10 mL	2	2	..	*209.92 ^a	Pamisol	HH
5702D	Injection set containing 2 vials powder for I.V. infusion 30 mg and 2 ampoules solvent 10 mL	1	2	..	209.91 ^a	Aredia 30 mg	NV

DISODIUM PAMIDRONATE

Authority required (STREAMLINED)

3341

Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.

5669J	Concentrated injection 60 mg in 10 mL	1	2	..	209.90	Pamisol	HH
-------	---------------------------------------	---	---	----	--------	---------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
DISODIUM PAMIDRONATE <u>Authority required (STREAMLINED)</u> 3341 Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy. <u>Authority required (STREAMLINED)</u> 3342 Multiple myeloma; 3343 Bone metastases from breast cancer. <u>Note</u> Pharmaceutical benefits that have the form disodium pamidronate powder for I.V. infusion 90 mg (after reconstitution) and pharmaceutical benefits that have the form disodium pamidronate concentrated injection 90 mg are equivalent for the purposes of substitution.						
5670K	Concentrated injection 90 mg in 10 mL	1	11	..	314.85 ^a	Pamisol HH
5703E	Injection set containing 1 vial powder for I.V. infusion 90 mg and 1 ampoule solvent 10 mL	1	11	..	314.85 ^a	Aredia 90 mg NV
IBANDRONIC ACID <u>Authority required (STREAMLINED)</u> 3343 Bone metastases from breast cancer.						
5750P	Concentrated injection for I.V. infusion 6 mg (as ibandronate sodium monohydrate) in 6 mL	1	11	..	341.36	Bondronat HH
ZOLEDRONIC ACID <u>Authority required (STREAMLINED)</u> 3342 Multiple myeloma; 3343 Bone metastases from breast cancer; 4052 Bone metastases from castration-resistant prostate cancer; 3341 Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy. <u>Note</u> Special Pricing Arrangements apply.						
9653C	Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL	1	11	..	450.00	Zometa NV

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Nervous system

Anti-Parkinson drugs

Dopaminergic agents

Dopa and dopa derivatives

LEVODOPA with CARBIDOPA

Authority required (STREAMLINED)

3704

Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy.

Treatment must be commenced in a hospital-based movement disorder clinic.

Note

Patients should have adequate cognitive function to manage administration with a portable continuous infusion pump.

A positive clinical response to Duodopa administered via a temporary nasoduodenal tube should be confirmed before a permanent percutaneous endoscopic gastrostomy (PEG) tube is inserted.

9743T	Intestinal gel 20 mg-5 mg per mL, 100 mL	56	5	..	*11536.00	Duodopa	VE
-------	--	----	---	----	-----------	---------	----

Dopamine agonists

APOMORPHINE HYDROCHLORIDE

Authority required (STREAMLINED)

3314

Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy.

5609F	Injection 20 mg in 2 mL	5	77.86	Apomine	HH
5610G	Injection 50 mg in 5 mL	5	194.65	Apomine	HH
5611H	Solution for subcutaneous infusion 50 mg in 10 mL pre-filled syringe	5	194.65	Apomine PFS	HH

Psycholeptics

Antipsychotics

Diazepines, oxazepines, thiazepines and oxepines

CLOZAPINE

Authority required (STREAMLINED)

3326

Schizophrenia in patients who are non-responsive to other neuroleptic agents;

3327

Schizophrenia in patients who are intolerant of other neuroleptic agents.

5626D	Tablet 50 mg	100	99.99	Clopine 50	HH
5627E	Tablet 200 mg	100	374.94	Clopine 200	HH
5628F	Tablet 25 mg	100	49.99	^a Clopine 25	HH
						^a Clozaril 25	NV
5629G	Tablet 100 mg	100	187.46	^a Clopine 100	HH
						^a Clozaril 100	NV
5630H	Oral liquid 50 mg per mL, 100 mL	1	135.00	Clopine Suspension	HH

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Respiratory system

Drugs for obstructive airway diseases

Other systemic drugs for obstructive airway diseases

Other systemic drugs for obstructive airway diseases

OMALIZUMAB

Note

Any queries concerning the arrangements to prescribe omalizumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.

Written applications for authority to prescribe omalizumab should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs
Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH UNCONTROLLED SEVERE ALLERGIC ASTHMA

Patients are eligible to commence an 'omalizumab treatment cycle' (initial treatment course with or without continuing treatment course/s) if they satisfy the eligibility criteria as detailed under the initial treatment restriction.

Once a patient has either failed to achieve or maintain a response to omalizumab, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 6 month break in PBS-subsidised omalizumab therapy before they are eligible to commence the next cycle. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised omalizumab treatment is stopped to the date of the first application for initial treatment with omalizumab under the new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised omalizumab therapy.

(a) Initial treatment.

Applications for initial treatment should be made where a patient has received no prior PBS-subsidised omalizumab treatment in this treatment cycle and wishes to commence such therapy.

Initial treatment authorisations will be limited to provide for a maximum of 28 weeks of therapy with omalizumab.

A patient must be assessed for response to a course of Initial PBS-subsidised treatment following a minimum of 24 weeks of therapy with omalizumab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date of assessment.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with omalizumab.

For second and subsequent courses of PBS-subsidised omalizumab treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

(b) Continuing treatment.

Following the completion of the initial treatment course with omalizumab, a patient may qualify to receive up to a further 24 weeks of continuing treatment with omalizumab providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing omalizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted omalizumab supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with omalizumab.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(2) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the Asthma Control Questionnaire (ACQ; 5 item version) and oral corticosteroid dose, submitted with the Initial authority application for omalizumab. However, prescribers may provide new baseline measurements when a new Initial treatment authority application is submitted and Medicare Australia will assess response according to these revised baseline measurements.

(3) Re-commencement of treatment after a 6 month break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised omalizumab therapy of at least 6 months, must re-qualify for initial treatment with respect to the indices of disease severity (oral corticosteroid dose, Asthma Control Questionnaire (ACQ-5) score, and relevant exacerbation history). Patients must have received optimised standard therapy, at adequate doses and for the minimum period specified, immediately prior to the time the new baseline assessments are performed.

(4) Patients 'grandfathered' onto PBS-subsidised treatment with omalizumab.

A patient who commenced treatment with omalizumab for uncontrolled severe allergic asthma prior to 1 November 2010 and who continues to receive treatment at the time of application, may qualify for treatment under the Initial 'grandfather' treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with omalizumab will be authorised under this criterion.

Following completion of the Initial PBS-subsidised course, further applications for treatment with omalizumab will be assessed under the continuing treatment restriction.

'Grandfather' arrangements will only apply for the first treatment cycle (initial treatment course with or without continuing treatment course/s). For the second and subsequent cycles, a 'Grandfathered' patient must re-qualify for Initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 6 month break in PBS-subsidised therapy' above for further details.

(5) Monitoring of patients.

Anaphylaxis and anaphylactoid reactions have been reported following first or subsequent administration of omalizumab (see Product Information). Patients should be monitored post-injection, and medications for the treatment of anaphylactic reactions should be available for immediate use following administration of omalizumab. Patients should be informed that such reactions are possible and prompt medical attention should be sought if allergic reactions occur.

Authority required

Initial treatment of uncontrolled severe allergic asthma

Initial PBS-subsidised treatment with omalizumab by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient aged 12 years or older with uncontrolled severe allergic asthma who has been under the care of this physician for at least 12 months, and satisfies the following criteria:

(a) has a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by standard clinical features, including:

- (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or
- (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or
- (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; and

(b) duration of asthma of at least 1 year; and

(c) FEV1 less than or equal to 80% predicted, documented on 3 or more occasions in the previous 12 months; and

(d) past or current evidence of atopy, documented by skin prick testing or RAST; and

(e) total serum human immunoglobulin E (IgE) greater than or equal to 76 IU/mL; and

(f) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and

(g) has failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented (see NOTE). Optimised asthma therapy includes:

- (i) adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or formoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated, AND
- (ii) oral corticosteroids (at least 10 mg per day prednisolone (or equivalent)) for at least 6 weeks, unless contraindicated or not tolerated.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application. Details of the accepted toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement of treatment with optimised asthma therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The initial IgE assessment must be no more than 12 months old at the time of application. A re-assessment of free IgE can only be made at least 12 months after the last dose of omalizumab. For patients re-commencing omalizumab within 12 months of the last dose the previous pre-omalizumab IgE level should be used.

The IgE pathology report must be provided with the authority application.

The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:

- (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND
- (b) while on oral corticosteroids and in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes the following:
 - (i) details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and
 - (ii) details of severe exacerbation/s experienced while on oral corticosteroids (date and treatment); and
 - (iii) the signed patient acknowledgement; and
- (c) a completed Asthma Control Questionnaire (ACQ-5) calculation sheet including the date of assessment of the patient's symptoms. (For copies of the ACQ please contact Novartis Medical Information on 1800 671 203 or medinfo.phauno@novartis.com)

At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.

Where fewer than the required number of repeats to complete 28 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 28 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.

The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, must be made at around 24 to 26 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 24 to 26 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.

A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased.

Note

Formal assessment and correction of inhaler technique should be performed in accordance with the National Asthma Council (NAC) Information Paper for Health Professionals on Inhaler Technique (available at www.medicareaustralia.gov.au or www.nationalasthma.org.au); the assessment and adherence to correct technique should be documented in the patient's medical records. Patients can obtain support with inhaler technique through their local Asthma Foundation (1800 645 130).

Authority required

Continuing treatment

Continuing PBS-subsidised treatment with omalizumab, by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient who:

- (a) has a documented history of severe allergic asthma; and
- (b) has demonstrated or sustained an adequate response to treatment with omalizumab.

An adequate response to omalizumab treatment is defined as:

- (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline, OR
- (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes details of maintenance oral corticosteroid dose; and
- (c) a completed Asthma Control Questionnaire (ACQ-5) calculation sheet including the date of assessment of the patient's symptoms. (For copies of the ACQ please contact Novartis Medical Information on 1800 671 203 or medinfo.phauno@novartis.com)

All applications for continuing treatment with omalizumab must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment, and the assessment of oral corticosteroid dose, must be made at around 20 to 22 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.

The first assessment should, where possible, be completed by the same physician who initiated treatment with omalizumab. If the same physician cannot assess the patient please call Medicare Australia on 1800 700 270.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 20 to 22 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.

Patients are eligible to receive continuing courses of omalizumab treatment of up to 24 weeks providing they continue to demonstrate an adequate response to treatment.

At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for a continuing course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information), sufficient for 24 weeks of therapy.

Where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased.

Authority required

Initial PBS-subsidised treatment of severe allergic asthma in a patient who has previously received non-PBS-subsidised therapy with omalizumab (grandfather patients)

Initial PBS-subsidised supply for continuing treatment with omalizumab by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient aged 12 years or older with severe allergic asthma who satisfies the following criteria:

- (a) has a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by standard clinical features, including:
 - (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or
 - (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or
 - (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; and
- (b) duration of asthma of at least 1 year; and
- (c) past or current evidence of atopy, documented by skin prick testing or RAST; and
- (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment for grandfathered patients; and
- (e) prior to omalizumab therapy had failed to achieve adequate control with optimised asthma therapy. Optimised asthma therapy includes:
 - (i) adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or formoterol 12 micrograms bd) for at least 12 months, and
 - (ii) may have included maintenance dose oral corticosteroids; and

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

(f) has demonstrated an adequate response to treatment with omalizumab.

A review of the patient's records should be conducted to extract pre- and post-omalizumab data on symptoms, quality of life, medication doses, exacerbations and hospitalisations. Examples of parameters to establish response include:

- (i) a reduction in Asthma Control Questionnaire (ACQ-5) score of at least 0.5;
- (ii) an improvement of at least 0.5 in the Asthma Quality of Life Questionnaire (AQLQ or mini-AQLQ);
- (iii) maintenance oral corticosteroid dose reduced by at least 25% from baseline; and/or
- (iv) a reduction in the number of hospitalisations or severe exacerbations requiring use of systemic corticosteroids, compared to the 12 months prior to commencement of omalizumab.

Where baseline assessments are not available, please call Medicare Australia on 1800 700 270 to discuss.

If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application. Details of the accepted contraindications and toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement of treatment with optimised asthma therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

The authority application must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes the following:
 - (i) details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and
 - (ii) details of pre- and post-omalizumab data on symptoms, quality of life, medication doses, exacerbations and hospitalisations; and
 - (iii) the signed patient acknowledgement.

At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.

Where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 24 weeks.

An assessment of the patient's continued response to this course of PBS-subsidised treatment must be made at around 20 to 22 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. The same parameters used to establish response to non-PBS-subsidised therapy with omalizumab should be used for the assessment.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 20 to 22 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.

Patients are eligible to receive continuing courses of omalizumab treatment of up to 24 weeks providing they continue to demonstrate an adequate response to treatment.

Patients may qualify for PBS-subsidised treatment under this restriction once only.

A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased.

Note

Special Pricing Arrangements apply.

9745X	Powder for injection 150 mg with diluent	1	425.00	Xolair	NV
-------	--	---	----	----	--------	--------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Cough and cold preparations

Expectorants, excl. combinations with cough suppressants

Mucolytics

DORNASE ALFA

Authority required (STREAMLINED)

3344

Use by cystic fibrosis patients who satisfy all of the following criteria:

- (1) are 5 years of age or older;
- (2) have a FVC greater than 40% predicted for age, gender and height;
- (3) have evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);
- (4) are participating in a 4 week trial as detailed below or have achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) after a 4 week trial.

In order for patients to be eligible for participation in the HSD program, the following conditions must be met:

- (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of dornase alfa under the HSD program is limited to such physicians. If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;
- (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;
- (3) Prior to dornase alfa therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;
- (4) Initial therapy is limited to 4 weeks' treatment with dornase alfa at a dose of 2.5 mg daily;
- (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) are eligible for continued subsidy under the HSD program at a dose of 2.5 mg daily;
- (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 2.5 mg daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;
- (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that dornase alfa treatment is continuing to produce worthwhile benefits. (Dornase alfa therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;
- (8) Other aspects of treatment, such as physiotherapy, must be continued;
- (9) Where there is documented evidence that a patient already receiving dornase alfa therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period).

Note

Dornase alfa is not PBS-subsidised for use in combination with PBS-subsidised mannitol.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

Authority required (STREAMLINED)

3345

Treatment of cystic fibrosis in a patient less than 5 years of age who has:

- (1) A severe clinical course with frequent respiratory exacerbations or chronic respiratory symptoms (including chronic or recurrent cough, wheeze or tachypnoea) requiring frequent hospital admissions more frequently than 3 times per year; or
- (2) Significant bronchiectasis on chest high resolution computed tomography scan; or
- (3) Severe cystic fibrosis bronchiolitis with persistent wheeze non-responsive to conventional medicines; or
- (4) Severe physiological deficit measure by forced oscillation technique or multiple breath nitrogen washout and failure to respond to conventional therapy.

In order for the patient to be eligible for participation in the HSD program, the following conditions must be met:

- (1) The patient must be assessed at a cystic fibrosis clinic/centre which is under the supervision of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis, and the prescribing of dornase alfa under the HSD program is limited to such physicians. If attendance at such a unit is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;
- (2) Following an initial 6 months therapy, a comprehensive assessment must be undertaken and documented involving the patient, the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team to establish agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use. Further reassessments are to be undertaken and documented yearly.

Note

Dornase alfa is not PBS-subsidised for use in combination with PBS-subsidised mannitol.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Authority required (STREAMLINED)

3346

Grandfather — continuing for patients five years or older

Continuation of treatment of cystic fibrosis in a patient 5 years of age or older, who initiated treatment with dornase alfa at an age of less than 5 years and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use.

Note

Dornase alfa is not PBS-subsidised for use in combination with PBS-subsidised mannitol.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

Authority required (STREAMLINED)

3347

Grandfather — for patients less than five years of age who initiated dornase alfa prior to listing

Treatment of cystic fibrosis in a patient less than 5 years of age who initiated treatment with dornase alfa prior to 1 November 2009 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use.

Note

Dornase alfa is not PBS-subsidised for use in combination with PBS-subsidised mannitol.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

5704F	Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL	60	5	..	*2360.00	Pulmozyme	RO
-------	--	----	---	----	----------	-----------	----

MANNITOL

Authority required (STREAMLINED)

4063

Treatment of cystic fibrosis in a patient who satisfies all of the following criteria:

- (1) Prior to mannitol therapy, the patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved PI mannitol initiation dose assessment. If the patient has a negative hyperresponsiveness test they may be eligible for PBS subsidised treatment with mannitol;
- (2) Is 6 years of age or older;
- (3) Has a FEV1 greater than 30% predicted for age, gender and height;
- (4) Is intolerant or inadequately responsive to dornase alfa;
- (5) Has evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);
- (6) Is participating in a 4 week trial, as detailed below, or has achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to mannitol treatment) after a 4 week trial.

In order for patients to be eligible for participation in the HSD program, the following conditions must be met:

- (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of mannitol therapy under the HSD program is limited to such physicians. If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;
- (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;
- (3) Prior to mannitol therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;
- (4) Initial therapy is limited to 4 weeks' treatment with mannitol at a dose of 400 mg twice daily;
- (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to mannitol treatment) are eligible for continued subsidy under the HSD program at a dose of 400mg twice daily;
- (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 400 mg twice daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;
- (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that mannitol powder for inhalation treatment is continuing to produce worthwhile benefits. (Mannitol therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;
- (8) Other aspects of treatment, such as physiotherapy, must be continued;
- (9) Where there is documented evidence that a patient already receiving mannitol therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period).

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for	Brand Name and Manufacturer
					Max. Qty \$	

Note

Mannitol is not PBS-subsidised for use in combination with PBS-subsidised dornase alfa.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

Authority required (STREAMLINED)

4064

Grandfather — for patients who initiated mannitol treatment prior to 1 August 2012

Continuation of treatment of cystic fibrosis in a patient 6 years of age or older, who initiated treatment with mannitol prior to 1 August 2012 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis team, documents agreement that mannitol treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with mannitol should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use.

Note

Mannitol is not PBS-subsidised for use in combination with PBS-subsidised dornase alfa.

It is highly desirable that all patients be included in the national cystic fibrosis patient database.

2015C	Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers	4	5	..	*1736.00	bronchitol	XA
-------	---	---	---	----	----------	------------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Sensory organs

Ophthalmologicals

Antiinfectives

Antivirals

GANCICLOVIR

Authority required (STREAMLINED)

3379

Cytomegalovirus retinitis in severely immunocompromised patients.

5748M	Intravitreal implant 4.5 mg	1	6000.00	Vitrasert	BU
-------	-----------------------------	---	----	----	---------	-----------	----

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed	Brand Name and Manufacturer
					Price for Max. Qty \$	

Various

All other therapeutic products

All other therapeutic products

Iron chelating agents

DEFERASIROX

Authority required (STREAMLINED)

3828

Chronic iron overload in patients with disorders of erythropoiesis.

Note

Special Pricing Arrangements apply.

5654N	Tablet 125 mg (dispersible)	168	5	..	*1401.48	Exjade	NV
5655P	Tablet 250 mg (dispersible)	168	5	..	*2802.90	Exjade	NV
5656Q	Tablet 500 mg (dispersible)	168	5	..	*5605.80	Exjade	NV

DEFERIPRONE

Authority required (STREAMLINED)

3338

Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy;

3339

Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective.

5657R	Tablet 500 mg	600	5	..	*2703.36	Ferriprox	OA
5658T	Oral solution 100 mg per mL, 250 mL	5	5	..	*1126.40	Ferriprox	OA

DEFERRIOXAMINE MESYLATE

Authority required (STREAMLINED)

3340

Disorders of erythropoiesis associated with treatment-related chronic iron overload.

5661Y	Powder for injection 2 g	60	5	..	*2235.00	^a Hospira Pty Limited	HH
				^b 22.80	*2257.80	^a Desferal 2 g	NV
5662B	Powder for injection 500 mg	400	5	..	*3725.60	^a Hospira Pty Limited	HH
				^b 308.80	*4034.40	^a Desferal 500 mg	NV

Drugs for treatment of hyperkalemia and hyperphosphatemia

LANTHANUM

Authority required (STREAMLINED)

3390

Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy.

Management includes initiation, stabilisation and review of therapy as required;

3391

Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.

Management includes initiation, stabilisation and review of therapy as required.

Note

Not to be used in combination with sevelamer.

5780F	Tablet, chewable, 500 mg (as carbonate hydrate)	180	5	..	*523.54	Fosrenol	ZI
5781G	Tablet, chewable, 750 mg (as carbonate hydrate)	180	5	..	*790.56	Fosrenol	ZI
5782H	Tablet, chewable, 1000 mg (as carbonate hydrate)	180	5	..	*890.02	Fosrenol	ZI

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer
SEVELAMER HYDROCHLORIDE						
<u>Authority required (STREAMLINED)</u>						
3390						
Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy.						
Management includes initiation, stabilisation and review of therapy as required;						
3391						
Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.						
Management includes initiation, stabilisation and review of therapy as required.						
<u>Note</u>						
Not to be used in combination with lanthanum.						
9546K	Tablet 800 mg	360	5	..	*620.00	Renagel GZ

SECTION 100 (BOTULINUM TOXIN PROGRAM)

Code	Name, Restriction, Manner of Administration and Form	Pack Size	Price ex manufacture		Brand Name and Manufacturer
			r	\$	

BOTULINUM TOXIN TYPE A PURIFIED NEUROTOXIN COMPLEX

Note

Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.

Criteria for availability

Treatment of blepharospasm or hemifacial spasm in a patient 12 years or older;

Treatment of dynamic equinus foot deformity due to spasticity in an ambulant paediatric cerebral palsy patient aged from 2 to 17 years inclusive;

Continuing PBS-subsidised treatment of dynamic equinus foot deformity due to spasticity in an ambulant cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with botulinum toxin type A purified neurotoxin complex as a paediatric patient;

Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care.

Criteria for availability

Treatment of moderate to severe spasticity of the upper limb in a cerebral palsy patient aged from 2 to 17 years inclusive;

Continuing PBS-subsidised treatment of moderate to severe spasticity of the upper limb in a cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with botulinum toxin type A purified neurotoxin complex as a paediatric patient.

Note

Contact Medicare Australia before commencing PBS-subsidised treatment in cerebral palsy patients who have been treated for moderate to severe spasticity of the upper limb with non-PBS-subsidised botulinum toxin prior to the age of 18.

Criteria for availability

Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a stroke, as second line therapy when standard management has failed (e.g. physiotherapy and/or oral spasticity agents) or as an adjunct to physical therapy.

Maximum number of treatments to be authorised is 4 (total Botox and Dysport) per upper limb per lifetime. Treatment should not be initiated until 3 months post-stroke in patients who do not have established severe contracture. Treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments.

The date of the stroke must be provided.

Contraindications to treatment include established severe contracture and known sensitivity to botulinum toxin.

Criteria for availability

Treatment of severe primary axillary hyperhidrosis in a patient 12 years or older who has failed or is intolerant to topical aluminium chloride hexahydrate after one to two months of treatment.

Maximum number of treatments per year is 3, with no less than 4 months to elapse between treatments.

Note

The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.

6103F	Lyophilised powder for injection 100 units	1	415.50	Botox	AG
-------	--	---	--------	-------	----

CLOSTRIDIUM BOTULINUM TYPE A TOXIN—HAEMAGGLUTININ COMPLEX

Note

Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.

Criteria for availability

Treatment of dynamic equinus foot deformity due to spasticity in an ambulant paediatric cerebral palsy patient aged from 2 to 17 years inclusive;

Continuing PBS-subsidised treatment of dynamic equinus foot deformity due to spasticity in an ambulant cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with clostridium botulinum type A toxin-haemagglutinin complex as a paediatric patient;

Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care;

Treatment of blepharospasm or hemifacial spasm in an adult.

Criteria for availability

Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a stroke, as second line therapy when standard management has failed (e.g. physiotherapy and/or oral spasticity agents) or as an adjunct to physical therapy.

Maximum number of treatments to be authorised is 4 (total Botox and Dysport) per upper limb per lifetime. Treatment should not be initiated until 3 months post-stroke in patients who do not have established severe contracture. Treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments.

The date of the stroke must be provided.

Contraindications to treatment include established severe contracture and known sensitivity to botulinum toxin.

Note

The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.

1152P	Lyophilised powder for I.M. injection 300 units	1	361.52	Dysport	IS
6293F	Lyophilised powder for I.M. injection 500 units	1	644.81	Dysport	IS

SECTION 100 (BOTULINUM TOXIN PROGRAM)

Code	Name, Restriction, Manner of Administration and Form	Pack Size	Price ex manufacturer		Brand Name and Manufacturer
				\$	

SECTION 100 (HUMAN GROWTH HORMONE)

Code	Name, Restriction, Manner of Administration and Form	Pack Size	Price ex manufacturer		Brand Name and Manufacturer
			\$		

SOMATROPIN (Recombinant human growth hormone)

Criteria for availability

Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.

The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:

- (i) short stature and slow growth;
- (ii) short stature associated with biochemical growth hormone deficiency;
- (iii) growth retardation secondary to intracranial lesion or cranial irradiation;
- (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;
- (v) short stature associated with Turner Syndrome;
- (vi) short stature due to short stature homeobox (SHOX) gene disorders;
- (vii) short stature associated with chronic renal insufficiency;
- (viii) biochemical growth hormone deficiency and precocious puberty;
- (ix) Prader-Willi syndrome.

Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines.

Note

Growth hormone (Somatropin) for adults is currently not subsidised through the Pharmaceutical Benefits Scheme.

These guidelines may be obtained from the Department of Health and Ageing's internet site at <http://www.health.gov.au/hGH>, or from:

Growth Hormone Program
Access and Systems Branch
Department of Health and Ageing
GPO Box 9848
CANBERRA ACT 2601
Contact telephone number (02) 6289 7274

Note

Special Pricing Arrangements apply.

5818F	Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)	1	315.50	Norditropin FlexPro	NO
5819G	Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)	1	631.00	Norditropin FlexPro	NO
5820H	Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)	1	946.50	Norditropin FlexPro	NO
6465G	Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)	1	315.50	Norditropin NordiFlex	NO
6466H	Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)	1	631.00	Norditropin NordiFlex	NO
6467J	Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)	1	946.50	Norditropin NordiFlex	NO

SOMATROPIN (Recombinant human growth hormone)

Criteria for availability

Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.

The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:

- (i) short stature and slow growth;
- (ii) short stature associated with biochemical growth hormone deficiency;
- (iii) growth retardation secondary to intracranial lesion or cranial irradiation;
- (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;
- (v) short stature associated with Turner Syndrome;
- (vi) short stature due to short stature homeobox (SHOX) gene disorders;
- (vii) short stature associated with chronic renal insufficiency;
- (viii) biochemical growth hormone deficiency and precocious puberty;
- (ix) Prader-Willi syndrome.

Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines.

SECTION 100 (HUMAN GROWTH HORMONE)

Code	Name, Restriction, Manner of Administration and Form	Pack Size	Price ex manufacturer \$	Brand Name and Manufacturer	
<u>Note</u> Growth hormone (Somatropin) for adults is currently not subsidised through the Pharmaceutical Benefits Scheme. These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH , or from: Growth Hormone Program Access and Systems Branch Department of Health and Ageing GPO Box 9848 CANBERRA ACT 2601 Contact telephone number (02) 6289 7274					
3388H	Solution for injection 20 mg (60 i.u.) in 2.5 mL cartridge (with preservative)	1	990.00	Saizen	SG
5822K	Solution for injection 6 mg (18 i.u.) in 1.03 mL cartridge (with preservative)	1	297.00	Saizen	SG
5824M	Solution for injection 12 mg (36 i.u.) in 1.5 mL cartridge (with preservative)	1	594.00	Saizen	SG
6169Q	Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative)	1	297.00	Humatrope	LY
6170R	Injection 36 i.u. (12 mg) cartridge with 3.15 mL diluent (with preservative)	1	594.00	Humatrope	LY
6266T	Injection 4 mg (12 i.u.) vial with diluent (with preservative)	1	198.00	Zomacton	FP
6295H	Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)	1	247.50	Norditropin SimpleXx	NO
6296J	Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)	1	495.00	Norditropin SimpleXx	NO
6297K	Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)	1	742.50	Norditropin SimpleXx	NO
6310D	Injection 10 mg (30 i.u.) vial with diluent (with preservative)	1	495.00	Zomacton	FP
6311E	Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)	1	495.00	Omnitrope	SZ
6312F	Injection 12 mg (36 i.u.) in 1 mL cartridge (with preservative)	1	594.00	Genotropin	PF
6313G	Injection 0.8 mg (2.4 i.u.) with diluent in single use syringe (without preservative)	7	277.20	Genotropin MiniQuick	PF
6314H	Injection 1 mg (3 i.u.) with diluent in single use syringe (without preservative)	7	346.50	Genotropin MiniQuick	PF
6315J	Injection 1.2 mg (3.6 i.u.) with diluent in single use syringe (without preservative)	7	415.80	Genotropin MiniQuick	PF
6316K	Injection 1.4 mg (4.2 i.u.) with diluent in single use syringe (without preservative)	7	485.10	Genotropin MiniQuick	PF
6317L	Injection 1.6 mg (4.8 i.u.) with diluent in single use syringe (without preservative)	7	554.40	Genotropin MiniQuick	PF
6318M	Injection 1.8 mg (5.4 i.u.) with diluent in single use syringe (without preservative)	7	623.70	Genotropin MiniQuick	PF
6319N	Injection 2 mg (6 i.u.) with diluent in single use syringe (without preservative)	7	693.00	Genotropin MiniQuick	PF
6329D	Injection 8 mg (24 i.u.) vial with 1.37 mL diluent cartridge (with preservative) (for use with one.click auto-injector)	1	396.00	Saizen 8 mg click.easy	SG
6330E	Injection 5 mg (15 i.u.) in 1 mL cartridge (with preservative)	1	247.50	Genotropin	PF
6345Y	Injection 72 i.u. (24 mg) cartridge with 3.15 mL diluent (with preservative)	1	1188.00	Humatrope	LY
6476W	Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)	1	247.50	Omnitrope	SZ
9585L	Powder for injection 5 mg (15 i.u.) with diluent in pre-filled pen (with preservative)	1	247.50	Genotropin GoQuick	PF
9586M	Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative)	1	594.00	Genotropin GoQuick	PF
9604L	Solution for injection 10 mg (30 i.u.) in 2 mL cartridge (with preservative)	1	495.00	NutropinAq	IS
9628R	Injection 0.6 mg (1.8 i.u.) with diluent in single use syringe (without preservative)	7	207.90	Genotropin MiniQuick	PF

SECTION 100 (IVF/GIFT TREATMENT)

Code	Name, Restriction, Manner of Administration and Form	Pack Size	Price ex	Brand Name and Manufacturer
			manufacturer \$	

CETRORELIX

Criteria for availability

For the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.

Note

Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.

9599F	Powder for injection 250 micrograms (as acetate) with diluent	1	46.08	Cetrotide	SG
-------	---	---	-------	-----------	----

CHORIOGONADOTROPIN ALFA

Criteria for availability

Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.

Note

Supply of this item is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.

Note

Special Pricing Arrangements apply.

6182J	Solution for injection 250 micrograms in 0.5 mL pre-filled pen	1	54.80	Ovidrel	SG
9631X	Solution for injection 250 micrograms in 0.5 mL pre-filled syringe	1	54.80	Ovidrel	SG

CORIFOLLITROPIN ALFA

Criteria for availability

A patient who is receiving treatment as described in items 13200, 13201 or 13202 of the Medicare Benefits Schedule and who:

- (i) Has an antral follicle count of 20 or less; and
- (ii) Weighs 90 kg or less; and
- (iii) Is undergoing a gonadotrophin releasing hormone antagonist cycle.

Note

Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.

5816D	Solution for injection 100 micrograms in 0.5 mL single dose pre-filled syringe	1	410.14	Elonva	MK
5817E	Solution for injection 150 micrograms in 0.5 mL single dose pre-filled syringe	1	621.24	Elonva	MK

FOLLITROPIN ALFA

Criteria for availability

Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.

Note

Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.

6431L	Injection 300 i.u. in 0.5 mL multi-dose cartridge	1	144.00	Gonal-f Pen	SG
6432M	Injection 450 i.u. in 0.75 mL multi-dose cartridge	1	216.00	Gonal-f Pen	SG
6433N	Injection 900 i.u. in 1.5 mL multi-dose cartridge	1	432.00	Gonal-f Pen	SG

FOLLITROPIN BETA

Criteria for availability

Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.

Note

Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.

6335K	Solution for injection 300 i.u. in 0.36 mL multi-dose cartridge	1	144.04	Puregon 300 IU/0.36 mL	MK
6336L	Solution for injection 600 i.u. in 0.72 mL multi-dose cartridge	1	288.09	Puregon 600 IU/0.72 mL	MK
6464F	Solution for injection 900 i.u. in 1.08 mL multi-dose cartridge	1	432.11	Puregon 900 IU/1.08 mL	MK

SECTION 100 (IVF/GIFT TREATMENT)

Code	Name, Restriction, Manner of Administration and Form	Pack Size	Price ex manufacturer \$	Brand Name and Manufacturer	
GANIRELIX					
<u>Criteria for availability</u>					
For the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.					
<u>Note</u>					
Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.					
9583J	Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe	1	46.08	Orgalutran	MK
9584K	Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe	5	230.40	Orgalutran	MK
HUMAN CHORIONIC GONADOTROPHIN					
<u>Criteria for availability</u>					
Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.					
<u>Note</u>					
Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.					
6178E	Injection set containing 3 ampoules powder for injection 1,500 units and 3 ampoules solvent 1 mL	1	39.57	Pregnyl	MK
6181H	Powder for injection 5,000 units with solvent	1	11.49	Pregnyl	MK
NAFARELIN					
<u>Criteria for availability</u>					
For the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.					
<u>Note</u>					
Supply of this item is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.					
5815C	Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses	1	75.33	Synarel	PF
PROGESTERONE					
<u>Criteria for availability</u>					
For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement.					
<u>Note</u>					
Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.					
<u>Note</u>					
Special Pricing Arrangements apply.					
6366C	Vaginal gel (prolonged release) 90 mg in single dose pre-filled applicator	15	148.50	Crinone 8%	SG
<hr/>					
PROGESTERONE					
<u>Criteria for availability</u>					
For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement.					
<u>Note</u>					
Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.					
9608Q	Pessary 100 mg	15	50.40	Orion Laboratories Pty Ltd	ON
9609R	Pessary 200 mg	15	55.60	Orion Laboratories Pty Ltd	ON

SECTION 100 (OPIATE DEPENDENCE TREATMENT PROGRAM)

Code	Name, Restriction, Manner of Administration and Form	Pack Size	Price ex manufacturer		Brand Name and Manufacturer
			\$		

BUPRENORPHINE

Criteria for availability

Treatment of opiate dependence, including maintenance and detoxification (withdrawal), within a framework of medical, social and psychological treatment.

Note

Treatment must be in accordance with the law of the relevant State or Territory.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

6307Y NP	Tablet (sublingual) 400 micrograms (as hydrochloride)	7	6.16	Subutex	RC
6308B NP	Tablet (sublingual) 2 mg (as hydrochloride)	7	10.50	Subutex	RC
6309C NP	Tablet (sublingual) 8 mg (as hydrochloride)	7	30.10	Subutex	RC

BUPRENORPHINE with NALOXONE

Caution

Buprenorphine with naloxone soluble film and buprenorphine with naloxone sublingual tablet do not meet all the criteria for bioequivalence. Patients being switched between sublingual tablets and soluble films may therefore require a dosage adjustment.

Criteria for availability

Treatment of opiate dependence within a framework of medical, social and psychological treatment.

Note

Treatment must be in accordance with the law of the relevant State or Territory.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

6470M NP	Tablet (sublingual) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride)	28	46.20	Suboxone	RC
6471N NP	Tablet (sublingual) 8 mg (as hydrochloride)-2 mg (as hydrochloride)	28	132.44	Suboxone	RC
9749D NP	Film (soluble) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride)	28	46.20	Suboxone Film 2/0.5	RC
9750E NP	Film (soluble) 8 mg (as hydrochloride)-2 mg (as hydrochloride)	28	132.44	Suboxone Film 8/2	RC

METHADONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Criteria for availability

Treatment of opiate dependence in accordance with the law of the relevant State or Territory.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

6171T NP	Oral liquid 25 mg per 5 mL, 200 mL	1	7.91	^a Biodone Forte	MW
				^a Sigma Methadone Syrup	QA
6172W NP	Oral liquid 25 mg per 5 mL, 1 L	1	33.20	^a Biodone Forte	MW
				^a Sigma Methadone Syrup	QA

Section 3 – Container Prices, Fees, Standard Packs and Prices for Ready Prepared Pharmaceutical Benefits

CONTAINER PRICES FOR QUANTITIES OF READY PREPARED BENEFITS LESS THAN THE STANDARD PACK:

Injectables	150 mL vial	\$0.81
Other Items	25 mL vial	\$0.32
(The 25 mL is the most commonly used size)		

FEES:

Dispensing Fee for Ready Prepared Benefits	\$6.52
Dangerous Drug Fee	\$2.71
Additional Fee for Agreed Price Ready Prepared Benefits	\$1.11

NOTE -

Standard packs and prices (including mark-up, but without dispensing fee and dangerous drug fee) are for items against the price of which an asterisk () is shown in Section 2 of the Schedule.*

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$	Manufacturer
8048N	ABCIXIMAB	10 mg in 5 mL	1@ 482.23	LY
1003T	ACICLOVIR	200 mg	25@ 29.99	AF, SZ, GM
1557Y	ALLOPURINOL	100 mg	100@ 3.22	AF
2157M	ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE	200 mg-200 mg per 5 mL, 500 mL	1@ 5.64	JT
2159P	ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE	250 mg-120 mg-120 mg per 5 mL, 500 mL	1@ 5.64	FM
3417W	AMINO ACID FORMULA with FAT, CARBOHYDRATE, VITAMINS, MINERALS, and TRACE ELEMENTS, without METHIONINE and supplemented with DOCOSAHEXANOIC ACID	125 mL, 36	1@ 625.39	SB
9330C	AMINO ACID FORMULA with FAT, CARBOHYDRATE, VITAMINS, MINERALS and TRACE ELEMENTS without PHENYLALANINE and TYROSINE, and supplemented with DOCOSAHEXANOIC ACID	125 mL, 36	1@ 625.39	SB
2347M	AMINO ACID FORMULA without PHENYLALANINE	20 g, 30	1@ 208.07	SB
8554F		500 mg, 200	1@ 79.37	SB
8678R		1 g, 75	1@ 59.19	SB
8479G	AMINO ACID FORMULA with VITAMINS, MINERALS and LONG CHAIN POLYUNSATURATED FATTY ACIDS without PHENYLALANINE	400 g	1@ 87.15	SB
2646G	AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPHAN	500 g	1@ 222.29	SB
2650L		400 g	1@ 95.36	SB
5484P		25 g, 30	1@ 787.00	VF
9438R		24 g, 30	1@ 526.99	VF
1548L	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE	125 mL, 30	1@ 1030.64	SB
8328H		500 g	1@ 222.29	SB
8416Y		500 g	1@ 337.29	SB
8417B		400 g	1@ 95.36	SB
8677Q		24 g, 30	1@ 526.99	VF
8744F		25 g, 30	1@ 772.99	VF
9133Q		130 mL, 30	1@ 772.99	VF
1923F	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE, THREONINE and VALINE and low in ISOLEUCINE	130 mL, 30	1@ 772.99	VF
3443F		25 g, 30	1@ 772.99	VF
3444G		24 g, 30	1@ 526.99	VF
8058D		400 g	1@ 95.36	SB
8059E		500 g	1@ 222.29	SB
8061G		500 g	1@ 337.29	SB
1411G	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	18.2 g, 60	1@ 544.55	SB
1909L		34 g, 30	1@ 511.90	VF
2382J		87 mL, 30	1@ 257.09	VF
2474F		174 mL, 30	1@ 511.90	VF
2738D		500 g	1@ 109.70	SB
2739E		500 g	1@ 168.25	SB
5483N		85 g, 30	1@ 263.05	VF
8545R		400 g	1@ 105.27	AB
8555G		24 g, 30	1@ 263.05	VF
8591E		25 g, 30	1@ 385.68	VF
8613H		29 g, 30	1@ 221.42	SB
8727H		50 g, 30	1@ 501.88	SB

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$	Manufacturer
8746H		250 mL	18@ 261.37	SB
8804J		27.8 g, 30	1@ 514.34	SB
8846N		130 mL, 30	1@ 385.48	VF
9021T		125 mL, 30	1@ 514.34	SB
9396M		125 mL, 36	1@ 315.86	SB
9397N		62.5 mL, 60	1@ 526.47	SB
1547K	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE	125 mL, 30	1@ 1030.64	SB
3078B		500 g	1@ 337.29	SB
8445L		400 g	1@ 95.36	SB
8446M		500 g	1@ 222.29	SB
8631G		24 g, 30	1@ 526.99	VF
8667E		25 g, 30	1@ 772.99	VF
9132P		130 mL, 30	1@ 772.99	VF
9395L		29 g, 30	1@ 448.51	SB
1546J	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEUCINE	125 mL, 30	1@ 1030.64	SB
1914R		34 g, 30	1@ 1021.93	VF
2375B		130 mL, 30	1@ 772.99	VF
2380G		400 g	1@ 95.36	SB
8057C		500 g	1@ 337.29	SB
8260R		500 g	1@ 222.29	SB
8310J		500 g	1@ 666.39	SB
8592F		24 g, 30	1@ 526.99	VF
8632H		25 g, 30	1@ 772.99	VF
8745G		29 g, 30	1@ 448.51	SB
9499Y	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEUCINE with FAT, CARBOHYDRATE and TRACE ELEMENTS and supplemented with DOCOSAHEXANOIC ACID	125 mL, 36	1@ 625.39	SB
1180D	AMINO ACIDS—SYNTHETIC, FORMULA	400 g	1@ 44.34	SB
1192R		400 g	1@ 44.34	SB
1521C		400 g	1@ 43.77	SB
2244D		400 g	1@ 44.34	SB
2250K		400 g	1@ 43.77	AB
2553J		400 g	1@ 44.34	SB
8574G		400 g	1@ 44.34	AB
8575H		400 g	1@ 44.34	AB
8754R		400 g	1@ 44.34	SB
8755T		400 g	1@ 44.34	SB
2246F	AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS	400 g	1@ 45.18	SB
2560R		400 g	1@ 45.18	SB
9339M		400 g	1@ 45.18	AB
9340N		400 g	1@ 45.18	AB
1545H	AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS and MEDIUM CHAIN TRIGLYCERIDES	400 g	1@ 44.65	SB
5466Q		400 g	1@ 45.18	SB
5467R		400 g	1@ 45.18	SB
8736T	AMISULPRIDE	100 mg per mL, 60 mL	1@ 71.16	SW
9386B	AMYLOPECTIN, MODIFIED LONG CHAIN	60 g, 30	1@ 186.47	VF
5482M	ARGININE with CARBOHYDRATE	4 g containing 2 g arginine, 30	1@ 191.10	VF
9437Q		4 g containing 500 mg arginine, 30	1@ 127.40	VF
9092M	ATOMOXETINE HYDROCHLORIDE	10 mg (base)	28@ 107.38	LY
9093N		18 mg (base)	28@ 107.38	LY
9094P		25 mg (base)	28@ 107.38	LY
9095Q		40 mg (base)	28@ 107.38	LY

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$		Manufacturer
9096R		60 mg (base)	28@	107.38	LY
1140B	BCG IMMUNOTHERAPEUTIC (Bacillus Calmette-Guérin/ Connaught strain)	6.6 to 19.2 x 10 ⁸ CFU	1@	151.15	SW
1775K	BENZYL PENICILLIN	600 mg	1@	3.65	CS
2647H		3 g	1@	6.05	CS
3398W		600 mg	1@	3.65	CS
3399X		3 g	1@	6.05	CS
2812B	BETAMETHASONE VALERATE	200 mcg (base) per g, 100 g	1@	12.34	QA
2820K		200 mcg (base) per g, 100 g	1@	10.13	MK
2544X	BIPERIDEN HYDROCHLORIDE	2 mg	100@	7.23	LM
1258F	BISACODYL	10 mg, 12	1@	3.97	PP
1260H		10 mg, 10	1@	5.34	BY
5303D		10 mg, 10	1@	5.34	BY
5304E		10 mg, 12	1@	3.97	PP
5307H		10 mg, 10	1@	5.34	BY
5308J		10 mg, 12	1@	3.97	PP
1443Y	BROMOCRIPTINE MESYLATE	2.5 mg (base)	30@	12.50	NV
3116B	CALCIUM	500 mg	60@	6.01	IA
1610R	CALCIUM FOLINATE	equiv. to 50 mg folic acid in 5 mL	10@	221.67	PF
8740B		equiv. to 50 mg folic acid in 5 mL	1@	27.93	HH
8812T		equiv. to 100 mg folic acid in 10 mL	1@	25.23	SZ
9041W		equiv. to 300 mg folic acid in 30 mL	1@	73.02	HH, SZ
1706T	CARBAMAZEPINE	200 mg	100@	12.77	NV
2422L		100 mg	100@	7.52	NV
1724R		200 mg	100@	12.77	NV
5039F		100 mg	100@	7.52	NV
1153Q	CARBIMAZOLE	5 mg	100@	12.31	LM
8369L	CARBOHYDRATE, FAT, VITAMINS, MINERALS and TRACE ELEMENTS	400 g	1@	38.97	SB
8578L	CARBOMER	2 mg per g, 0.6 mL, 30	1@	9.89	AQ
5504Q		2 mg per g, 0.6 mL, 30	1@	9.89	AQ
8514D	CARBOMER 974	3 mg per g, 0.5 g, 30	1@	9.88	AQ
5502N		3 mg per g, 0.5 g, 30	1@	9.88	AQ
2324H	CARMELLOSE SODIUM	10 mg per mL, 0.4 mL, 30	1@	9.88	AG
2338C		5 mg per mL, 0.4 mL, 30	1@	9.88	AG
8823J		2.5 mg per mL, 0.6 mL, 24	1@	8.50	CX
8824K		10 mg per mL, 0.6 mL, 28	1@	9.22	CX
5505R		10 mg per mL, 0.4 mL, 30	1@	9.88	AG
5506T		5 mg per mL, 0.4 mL, 30	1@	9.88	AG
5509Y		2.5 mg per mL, 0.6 mL, 24	1@	8.50	CX
5510B		10 mg per mL, 0.6 mL, 28	1@	9.22	CX
9307W	CARMELLOSE SODIUM with GLYCERIN	5 mg-9 mg per mL, 0.4 mL, 30	1@	9.88	AG
5561Q		5 mg-9 mg per mL, 0.4 mL, 30	1@	9.88	AG
8315P	CEFEPIME	1 g	1@	15.52	OE, HH, SZ
8316Q		2 g	1@	28.68	BQ, OE, HH, SZ
1085D	CEFOTAXIME	1 g	1@	1.99	SZ
1086E		2 g	1@	3.65	SZ
5048Q		1 g	1@	1.99	SZ
5049R		2 g	1@	3.65	SZ
1783W	CEFTRIAXONE	500 mg	1@	3.83	PP
1784X		1 g	1@	5.98	RO, HH, SZ, PP, AE
1785Y		2 g	1@	10.62	RO, HH, SZ, PP, AE
1256D	CEPHAZOLIN	500 mg	5@	16.73	HH, AE
1797N		1 g	5@	21.60	HH, AE
1799Q		1 g	5@	21.60	HH, AE
5477G		500 mg	5@	16.73	HH, AE
5479J		2 g	1@	9.78	SZ, AF
9326W		2 g	1@	9.78	SZ, AF
1163F	CHLORAMBUCIL	2 mg	25@	32.89	AS
1585K	CHLORTHALIDONE	25 mg	50@	5.58	LM
2967E	CHOLESTYRAMINE	4.7 g (equiv. to 4 g cholestyramine)	1@	32.76	QA
9249T		4.7 g (equiv. to 4 g cholestyramine)	1@	32.76	QA
1217C	CIPROFLOXACIN	3 mg per mL, 5 mL	1@	12.06	AQ
5564W		3 mg per mL, 5 mL	1@	12.06	AQ

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$		Manufacturer
5481L	CITRULLINE with CARBOHYDRATE	4 g containing 1 g citrulline, 30	1@	127.40	VF
1805B	CLONAZEPAM	500 mcg	100@	6.54	AF
1806C		2 mg	100@	12.32	AF
1808E		2.5 mg per mL, 10 mL	1@	4.31	RO
5339B		2.5 mg per mL, 10 mL	1@	4.31	RO
5342E		2.5 mg per mL, 10 mL	1@	4.31	RO
8785J	CODEINE PHOSPHATE with PARACETAMOL	30 mg-500 mg	20@	1.06	FM, AV, AL, SZ, TX
8657P	CYCLOSPORIN	10 mg	60@	44.00	NV
8658Q		25 mg	30@	45.41	NV, SZ
8659R		50 mg	30@	94.48	NV, SZ
8660T		100 mg	30@	184.01	NV, SZ
8661W		100 mg per mL, 50 mL	1@	353.12	NV
1270W	CYPROTERONE ACETATE	50 mg	50@	80.45	AF, GM, SY, GX, SZ
9164H	CYSTINE with CARBOHYDRATE	4 g containing 500 mg cystine, 30	1@	127.40	VF
9318K	DABIGATRAN ETEXILATE	75 mg (as mesilate)	10@	19.56	BY
9319L		110 mg (as mesilate)	10@	19.56	BY
9322P		75 mg (as mesilate)	10@	19.56	BY
9323Q		110 mg (as mesilate)	10@	19.56	BY
1229Q	DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium—porcine mucous)	10,000 units (anti-Xa) in 1 mL	10@	84.57	PF
1296F		12,500 units (anti-Xa) in 0.5 mL	10@	117.43	PF
2816F		5,000 units (anti-Xa) in 0.2 mL	10@	51.23	PF
8603T		2,500 units (anti-Xa) in 0.2 mL	10@	49.16	PF
8641T		2,500 units (anti-Xa) in 0.2 mL	10@	49.16	PF
8642W		5,000 units (anti-Xa) in 0.2 mL	10@	51.23	PF
8643X		7,500 units (anti-Xa) in 0.75 mL	10@	61.96	PF
8956J		7,500 units (anti-Xa) in 0.75 mL	10@	61.96	PF
8957K		10,000 units (anti-Xa) in 1 mL	10@	82.88	PF
8958L		12,500 units (anti-Xa) in 0.5 mL	10@	114.43	PF
8959M		15,000 units (anti-Xa) in 0.6 mL	10@	136.11	PF
8960N		18,000 units (anti-Xa) in 0.72 mL	10@	162.39	PF
2129C	DESMOPRESSIN ACETATE	100 mcg per mL, 2.5 mL	1@	30.95	FP
8662X		200 mcg	30@	57.83	FP
8711L		10 mcg per actuation, 60 actuations, 6 mL	1@	77.31	FP
1299J	DICLOFENAC SODIUM	25 mg (e.c.)	50@	3.16	SZ, CH, TW, AF, QA, GM, TX
1302M		100 mg	20@	9.25	NV
5076E		25 mg (e.c.)	50@	3.16	SZ, CH, TW, AF, QA, GM, TX
5079H		100 mg	20@	9.25	NV
5361E		25 mg (e.c.)	50@	3.16	SZ, CH, TW, AF, QA, GM, TX
5363G		100 mg	20@	9.25	NV
5364H		25 mg (e.c.)	50@	3.16	SZ, CH, TW, AF, QA, GM, TX
5366K		100 mg	20@	9.25	NV
3164M	DIGOXIN	50 mcg per mL, 60 mL	1@	17.35	QA
8461H	DISODIUM PAMIDRONATE	15 mg in 5 mL	1@	60.93	HH
8462J		30 mg in 10 mL	1@	121.85	HH
2702F	DOXYCYCLINE	100 mg (as hydrochloride)	7@	1.94	GM, QA, AF
2703G		100 mg (as hydrochloride)	7@	1.94	YT
2714W		100 mg (as hydrochloride)	7@	1.94	GM, QA, AF
9107H		100 mg (as monohydrate)	7@	1.94	SZ, CH, TW, GX
9108J		100 mg (as monohydrate)	7@	1.94	SZ, CH, TW
3199J	ELECTROLYTE REPLACEMENT SOLUTION	1 L	1@	7.77	BX
5434B	ENOXAPARIN SODIUM	80 mg (8,000 i.u. anti-Xa) in 0.8 mL	10@	84.28	SW
5435C		100 mg (10,000 i.u. anti-Xa) in 1 mL	10@	102.33	SW
8510X		40 mg (4,000 i.u. anti-Xa) in 0.4 mL	10@	51.23	SW
8558K		20 mg (2,000 i.u. anti-Xa) in 0.2 mL	10@	49.16	SW
8639Q		40 mg (4,000 i.u. anti-Xa) in 0.4 mL	10@	51.23	SW
8640R		60 mg (6,000 i.u. anti-Xa) in 0.6 mL	10@	73.26	SW

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$		Manufacturer
8716R		20 mg (2,000 i.u. anti-Xa) in 0.2 mL	10@	49.16	SW
9195Y		40 mg (4,000 i.u. anti-Xa) in 0.4 mL	10@	51.23	SW
9196B		40 mg (4,000 i.u. anti-Xa) in 0.4 mL	10@	51.23	SW
8367J	ENTACAPONE	200 mg	100@	137.70	NV
8397Y	EPROSARTAN MESYLATE	400 mg (base)	28@	8.48	AB
8951D		400 mg (base)	28@	10.22	AB
8683B	EPTIFIBATIDE ACETATE	20 mg (base) in 10 mL	1@	128.06	MK
8684C		75 mg (base) in 100 mL	1@	337.98	MK
1397M	ERYTHROMYCIN LACTOBIONATE	1 g (base)	1@	18.44	LM
5088T		1 g (base)	1@	18.44	LM
9329B	ESSENTIAL AMINO ACIDS FORMULA	200 g	1@	199.02	SB
2027Q	ESSENTIAL AMINO ACIDS FORMULA	400 g	1@	125.55	SB
	with MINERALS and VITAMIN C				
9385Y	ESSENTIAL AMINO ACIDS FORMULA with VITAMINS and MINERALS	12.5 g, 50	1@	377.52	VF
1954W	ETANERCEPT	25 mg and 1 mL solvent, 4	1@	911.29	PF
3445H		25 mg and 1 mL solvent, 4	1@	911.29	PF
3448L		25 mg and 1 mL solvent, 4	1@	911.29	PF
8637N		25 mg and 1 mL solvent, 4	1@	911.29	PF
8638P		25 mg and 1 mL solvent, 4	1@	911.29	PF
8778B		25 mg and 1 mL solvent, 4	1@	911.29	PF
8779C		25 mg and 1 mL solvent, 4	1@	911.29	PF
9035M		25 mg and 1 mL solvent, 4	1@	911.29	PF
9036N		25 mg and 1 mL solvent, 4	1@	911.29	PF
9037P		25 mg and 1 mL solvent, 4	1@	911.29	PF
9429G		25 mg and 1 mL solvent, 4	1@	911.29	PF
8748K	ETHACRYNIC ACID	25 mg	100@	95.44	FK
8842J	EVEROLIMUS	0.75 mg	60@	786.10	NV
9352F		1 mg	60@	1031.17	NV
5407N	FENTANYL		30@	335.50	OA
5408P			30@	335.50	OA
5409Q			30@	335.50	OA
5410R			30@	335.50	OA
5411T			30@	335.50	OA
5412W			30@	335.50	OA
1473M	FLUCONAZOLE	100 mg in 50 mL	1@	15.83	PF, HX, SZ, AE
1474N		200 mg in 100 mL	1@	29.65	PF, HX, SZ, AE, BX
1433K	FLUDROCORTISONE ACETATE	100 mcg	100@	20.04	QA
1437P	FOLIC ACID	5 mg	100@	3.80	AF
2958Q		500 mcg	100@	3.68	AF
8713N	FOLLITROPIN ALFA	300 i.u.	1@	185.67	SG
8714P		450 i.u.	1@	278.50	SG
8715Q		900 i.u.	1@	554.41	SG
8565T	FOLLITROPIN BETA	300 i.u. in 0.36 mL	1@	185.67	MK
8566W		600 i.u. in 0.72 mL	1@	371.33	MK
8871X		900 i.u. in 1.08 mL	1@	554.40	MK
8775W	FONDAPARINUX SODIUM	2.5 mg in 0.5 mL	2@	37.05	GK
1810G	FRUSEMIDE	20 mg	50@	2.00	SW
8444K	GELATIN - SUCCINYLATED	20 g per 500 mL, 500 mL	1@	13.11	BR
2245E	GLUCOSE	278 mmol per L, 1 L	1@	3.28	BR, PK, BX
9444C		139 mmol per 500 mL, 500 mL	1@	2.29	BR, PK
9445D		278 mmol per 500 mL, 500 mL	1@	2.29	PK
9474P		69.5 mmol per 250 mL, 250 mL	1@	3.45	BR, PK
5005K		139 mmol per 500 mL, 500 mL	1@	2.29	BR, PK
5106R		278 mmol per L, 1 L	1@	3.28	BR, PK, BX
3106L	GLUCOSE and KETONE INDICATOR— URINE	Test strips, 50	1@	5.44	RD
3107M		Test strips, 50	1@	5.50	BN
9254C		Test strips, 50	1@	5.44	RD
9255D		Test strips, 50	1@	5.50	BN
2263D	GLUCOSE INDICATOR—BLOOD	Test strips, 50	1@	23.38	MS
2860M		Test strips, 50	1@	23.38	NA
2890D		Test strips, 50	1@	23.38	NA
2914J		Test strips, 50	1@	19.74	NA

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$		Manufacturer
3406G		Test strips, 50	1@	23.38	LB
3407H		Test strips, 50	1@	23.38	LB
3441D		Test strips, 50	1@	23.38	JJ
3442E		Test strips, 50	1@	23.38	JJ
5043K		Test Strips, 50	1@	23.38	RD
5053Y		Test strips, 50	1@	23.38	RD
5266E		Test strips, 50	1@	23.38	NX
5267F		Test strips, 50	1@	23.38	NX
5268G		Test strips, 50	1@	23.38	NX
5269H		Test strips, 50	1@	23.38	NX
8723D		Test strips, 50	1@	23.38	BR
8739Y		Test strips, 50	1@	23.38	RD
8749L		Test strips, 50	1@	23.38	OZ
8759B		Test strips, 50	1@	23.38	LB
8795X		Test strips, 50	1@	23.38	PX
8806L		Test strips, 51	1@	23.38	RD
8825L		Test strips, 50	1@	23.38	NX
9013J		Test strips, 50	1@	23.38	OZ
9193W		Test strips, 25	1@	11.69	PZ
9256E		Test strips, 25	1@	11.69	PZ
9261K		Test strips, 50	1@	23.38	OZ
9263M		Test strips, 50	1@	23.38	OZ
9265P		Test strips, 50	1@	23.38	BR
9267R		Test strips, 50	1@	23.38	MS
9268T		Test strips, 50	1@	23.38	NX
9274D		Test strips, 50	1@	23.38	RD
9275E		Test strips, 51	1@	23.38	RD
9276F		Test strips, 50	1@	23.38	NA
9277G		Test strips, 50	1@	23.38	NA
9278H		Test strips, 50	1@	23.38	LB
9279J		Test strips, 50	1@	19.74	NA
9281L		Test strips, 50	1@	23.38	PX
9297H		Test strips, 50	1@	23.38	QB
9298J		Test strips, 50	1@	23.38	QB
9324R		Test strips, 50	1@	23.38	HE
9325T		Test strips, 50	1@	23.38	HE
9471L		Test strips, 50	1@	23.38	EH
9472M		Test strips, 50	1@	23.38	EH
9485F		Test strips, 50	1@	23.38	OI
9486G		Test strips, 50	1@	23.38	OI
3104J	GLUCOSE INDICATOR—URINE	Test strips, 50	1@	6.70	BN
9253B		Test strips, 50	1@	6.70	BN
2555L	GLYCEROL	700 mg, 12	1@	4.35	PP
2556M		1.4 g, 12	1@	4.49	PP
2557N		2.8 g, 12	1@	4.66	PP
5311M		700 mg, 12	1@	4.35	PP
5312N		1.4 g, 12	1@	4.49	PP
5313P		2.8 g, 12	1@	4.66	PP
5314Q		700 mg, 12	1@	4.35	PP
5315R		1.4 g, 12	1@	4.49	PP
5316T		2.8 g, 12	1@	4.66	PP
1812J	GRANISETRON HYDROCHLORIDE	3 mg (base) in 3 mL	5@	91.62	PK
1814L		3 mg (base) in 3 mL	5@	91.62	PK
8728J		2 mg (base)	1@	26.28	HH
1076P	HEPARIN SODIUM	35,000 units in 35 mL	1@	22.68	HH
9446E	HIGH FAT FORMULA with VITAMINS, MINERALS and TRACE ELEMENTS and low in PROTEIN and CARBOHYDRATE	300 g	1@	42.96	SB
1639G	HYDRALAZINE HYDROCHLORIDE	50 mg	100@	5.50	AF
1640H		25 mg	100@	4.54	AF
1486F	HYDROCHLOROTHIAZIDE with AMILORIDE HYDROCHLORIDE	50 mg-5 mg	50@	3.54	AS
1502C	HYDROCORTISONE ACETATE	21.1 g	1@	15.33	AS
1501B	HYDROCORTISONE SODIUM SUCCINATE	100 mg with 2 mL solvent	1@	5.05	PF

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$	Manufacturer
1510L		100 mg with 2 mL solvent	1@ 5.05	PF
1511M		250 mg with 2 mL solvent	1@ 8.72	PF
5118J		100 mg with 2 mL solvent	1@ 5.05	PF
5119K		250 mg with 2 mL solvent	1@ 8.72	PF
9487H	HYDROXYETHYL STARCH 130/0.4	30 g per 500 mL, 500 mL	1@ 13.11	PK
5317W	HYOSCINE BUTYLBROMIDE	20 mg in 1 mL	5@ 17.02	BY
5318X		20 mg in 1 mL	5@ 17.02	BY
8299T	HYPROMELLOSE with DEXTRAN	3 mg-1 mg per mL, 0.4 mL, 28	1@ 9.55	AQ
5521N		3 mg-1 mg per mL, 0.4 mL, 28	1@ 9.55	AQ
3190X	IBUPROFEN	400 mg	30@ 2.77	AB
5123P		400 mg	30@ 2.77	AB
5368M		400 mg	30@ 2.77	AB
5370P		400 mg	30@ 2.77	AB
2446R	IDARUBICIN HYDROCHLORIDE	5 mg	1@ 87.06	PF
2448W		10 mg	1@ 162.69	PF
2454E	INDOMETHACIN	25 mg	50@ 3.00	AF
2757D		100 mg	20@ 8.04	AS
5126T		25 mg	50@ 3.00	AF
5128X		100 mg	20@ 8.04	AS
5377B		25 mg	50@ 3.00	AF
5378C		100 mg	20@ 8.04	AS
5379D		25 mg	50@ 3.00	AF
5380E		100 mg	20@ 8.04	AS
8435Y	INSULIN ASPART	100 units per mL, 3 mL, 5	1@ 51.56	NO, NF
8571D		100 units per mL, 10 mL	1@ 30.57	NO
8609D	INSULIN ASPART—INSULIN ASPART PROTAMINE SUSPENSION	100 units (30 units-70 units) per mL, 3 mL, 5	1@ 51.56	NF, NO
9040T	INSULIN DETEMIR	100 units per mL, 3 mL, 5	1@ 85.26	NF, NO
9039R	INSULIN GLARGINE	100 units per mL, 3 mL, 5	1@ 85.26	SW, AV
1921D	INSULIN GLULISINE	100 units per mL, 3 mL, 5	1@ 51.56	AV, SW
9224L		100 units per mL, 10 mL	1@ 30.57	SW
1533Q	INSULIN ISOPHANE (N.P.H.)	100 units per mL, 10 mL	1@ 25.48	LY, NO
1711C		100 units per mL, 10 mL	1@ 33.12	AS
1761Q		100 units per mL, 3 mL, 5	1@ 43.58	NO, NI, LY
8084L	INSULIN LISPRO	100 units per mL, 10 mL	1@ 30.57	LY
8212F		100 units per mL, 3 mL, 5	1@ 51.56	LY, KP
8390N	INSULIN LISPRO—INSULIN LISPRO PROTAMINE SUSPENSION	100 units (25 units-75 units) per mL, 3 mL, 5	1@ 51.56	LY, KP
8874C		100 units (50 units-50 units) per mL, 3 mL, 5	1@ 51.56	LY, KP
1531N	INSULIN NEUTRAL	100 units per mL, 10 mL	1@ 25.48	NO, LY
1713E		100 units per mL, 10 mL	1@ 33.12	AS
1762R		100 units per mL, 3 mL, 5	1@ 43.58	NO, LY
1426C	INSULIN NEUTRAL—INSULIN ISOPHANE (N.P.H.), (MIXED) (Biphasic Isophane)	100 units (30 units-70 units) per mL, 10 mL	1@ 25.48	LY
1763T		100 units (30 units-70 units) per mL, 3 mL, 5	1@ 43.58	LY, NO, NI
2062M		100 units (50 units-50 units) per mL, 3 mL, 5	1@ 43.58	NO
8180M	INTERFERON ALFA-2a	3,000,000 i.u. in 0.5 mL	1@ 33.32	RO
8181N		3,000,000 i.u. in 0.5 mL	1@ 33.32	RO
8182P		4,500,000 i.u. in 0.5 mL	1@ 51.66	RO
8183Q		6,000,000 i.u. in 0.5 mL	1@ 67.66	RO
8184R		9,000,000 i.u. in 0.5 mL	1@ 99.94	RO
8551C		4,500,000 i.u. in 0.5 mL	1@ 51.66	RO
8552D		6,000,000 i.u. in 0.5 mL	1@ 67.66	RO
8553E		9,000,000 i.u. in 0.5 mL	1@ 99.94	RO
8348J	INTERFERON ALFA-2b	18,000,000 i.u. in 1.2 mL	1@ 199.87	MK
8476D		30,000,000 i.u. in 1.2 mL	1@ 333.11	MK
8572E		18,000,000 i.u. in 1.2 mL	1@ 199.87	MK
1542E	IPRATROPIUM BROMIDE	250 mcg (anhydrous) in 1 mL, 30	1@ 14.66	AF, PF, QA, TX
8238N		500 mcg (anhydrous) in 1 mL, 30	1@ 17.32	AF, PF, QA, TX
8671J		21 mcg per dose (200 doses)	1@ 13.71	BY
9134R	ISOLEUCINE with CARBOHYDRATE	4 g containing 50 mg isoleucine, 30	1@ 127.40	VF

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$	Manufacturer
9436P		4 g containing 1 g isoleucine, 30	1@ 140.14	VF
2588F	ISOSORBIDE DINITRATE	5 mg	100@ 4.07	QA
1588N	KETOPROFEN	100 mg	20@ 9.44	SW
5139L		100 mg	20@ 9.44	SW
5387M	LACTULOSE	3.34 g per 5 mL, 500 mL	1@ 5.59	AF, GM, QA, GX, SZ
5388N		3.34 g per 5 mL, 500 mL	1@ 5.59	AF, GM, QA, GX, SZ
9148L	LAPATINIB	250 mg (as ditosylate monohydrate)	70@ 1690.52	GK
8970D	LEVODOPA with CARBIDOPA	20 mg-5 mg per mL, 100 mL	7@ 1459.49	VE
8797B	LEVODOPA with CARBIDOPA and ENTACAPONE	50 mg-12.5 mg-200 mg	100@ 152.73	NV
8798C		100 mg-25 mg-200 mg	100@ 167.75	NV
8799D		150 mg-37.5 mg-200 mg	100@ 182.77	NV
9292C		200 mg-50 mg-200 mg	100@ 196.60	NV
9344T		75 mg-18.75 mg-200 mg	100@ 159.35	NV
9345W		125 mg-31.25 mg-200 mg	100@ 173.77	NV
8290H	LITHIUM CARBONATE	450 mg (s.r.)	100@ 13.94	GK
8203R	LOSARTAN	50 mg	30@ 10.71	AF
5389P	MACROGOL 3350	13.125 g, 30	1@ 14.13	NE
5390Q		13.125 g, 30	1@ 14.13	NE
5426N		510 g	1@ 14.13	KY, ON, OY
5427P		510 g	1@ 14.13	KY, ON, OY
1598D	MERCAPTOPYRINE	50 mg	25@ 61.38	AS
2214M	MESALAZINE	500 mg (p.r.)	100@ 145.51	FP
3413P		1 g (p.r.)	60@ 162.13	FP
8598M		500 mg	100@ 145.51	OA
8616L		2 g in 60 mL, 7	1@ 82.45	OA
8617M		4 g in 60 mL, 7	1@ 109.87	OA
8731M		500 mg (e.c.)	100@ 145.51	OA
8753Q		1 g in 100 mL, 7	1@ 82.45	FP
8768L		80 g	1@ 82.45	OA
1818Q	METHOTREXATE	50 mg in 2 mL	1@ 4.65	WQ
5423K	METHYLNALTREXONE	12 mg in 0.6 mL	1@ 41.39	LM
2826R	METHYSERGIDE	1 mg	50@ 19.27	LM
1638F	METRONIDAZOLE	500 mg in 100 mL	1@ 4.85	BX
1821W		500 mg in 100 mL	10@ 37.54	HH
1832K		500 mg in 100 mL	10@ 37.54	HH
5154G		500 mg in 100 mL	1@ 4.85	BX
9026C	MICONAZOLE NITRATE	20 mg per g, 15 g	1@ 4.74	JT
2349P	MILK POWDER—LACTOSE FREE FORMULA	900 g	1@ 16.50	NU
2350Q		900 g	1@ 16.50	NU
8282X		900 g	1@ 21.29	PF
8283Y		900 g	1@ 21.29	PF
2357C	MILK POWDER—LACTOSE MODIFIED	900 g	1@ 22.13	SJ
2358D		900 g	1@ 22.13	SJ
3092R	MILK POWDER—SYNTHETIC	400 g	1@ 46.87	SB
8630F	MILK PROTEIN and FAT FORMULA with VITAMINS and MINERALS— CARBOHYDRATE FREE	225 g	1@ 26.75	SB
8816B	MODAFINIL	100 mg	60@ 170.28	CS
1836P	MYCOPHENOLATE MOFETIL	250 mg	50@ 87.00	AF
8649F		250 mg	100@ 173.98	RO, QA, TX, SZ, CR
8650G		500 mg	50@ 173.98	RO, QA, TX, SZ, AF, CR
1674D	NAPROXEN	250 mg	50@ 3.46	AF
5176K		250 mg	50@ 3.46	AF
5345H		250 mg	50@ 3.46	AF
5349M		250 mg	50@ 3.46	AF
8298R	NARATRIPTAN	2.5 mg (as hydrochloride)	2@ 9.74	GK
9734H		2.5 mg (as hydrochloride)	2@ 11.13	GK
9316H	NEBIVOLOL	1.25 mg (as hydrochloride)	28@ 22.10	CS
2732T	NITRAZEPAM	5 mg	25@ 1.40	AF
5359C		5 mg	25@ 1.40	AF
5360D		5 mg	25@ 1.40	AF

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$		Manufacturer
1967M	NORETHISTERONE	350 mcg	1@	2.51	FZ, JC
2774B	NORETHISTERONE with ETHINYLOESTRADIOL	Tablet-Pack	1@	2.51	FZ
2775C		Tablet-Pack	1@	2.51	FZ
2776D		Tablet-Pack	1@	2.51	FZ
3179H	NORETHISTERONE with MESTRANOL	Tablet-Pack	1@	2.51	PF
1698J	NYSTATIN	100,000 units per g, 15 g	1@	6.07	FM
8383F	OFLOXACIN	3 mg per mL, 5 mL	1@	12.86	AG
5567B		3 mg per mL, 5 mL	1@	12.86	AG
9294E	OLANZAPINE	210 mg	1@	246.68	LY
9295F		300 mg	1@	401.42	LY
3134Y	OXAZEPAM	15 mg	25@	1.23	AF
3135B		30 mg	25@	1.23	TX, FM, AF
5371Q		15 mg	25@	1.23	AF
5372R		30 mg	25@	1.23	TX, FM, AF
5373T		15 mg	25@	1.23	AF
5374W		30 mg	25@	1.23	TX, FM, AF
8588B	OXCARBAZEPINE	60 mg per mL, 250 mL	1@	65.85	NV
5453B	PANCREATIC EXTRACT	20 g	1@	45.12	AB
5454C		20 g	1@	45.12	AB
8020D		not less than 10,000 BP units lipase activity	100@	35.45	AB
8021E		not less than 25,000 BP units lipase activity	100@	70.66	AB
9226N		not less than 10,000 BP units lipase activity	100@	35.45	AB
9227P		not less than 25,000 BP units lipase activity	100@	70.66	AB
9412J		not less than 40,000 BP units lipase activity	100@	111.77	AB
9413K		not less than 40,000 BP units lipase activity	100@	111.77	AB
8366H	PANCRELIPASE	not less than 25,000 BP units lipase activity	100@	65.74	TM
9229R		not less than 25,000 BP units lipase activity	100@	65.74	TM
8784H	PARACETAMOL	500 mg	100@	1.90	GM, YS, XS, SZ, YM, TX, GQ, SW, FM
8814X		665 mg (m.r.)	96@	5.11	GC
5224Y		500 mg	100@	1.90	GM, YS, XS, SZ, YM, TX, GQ, SW, FM
5319Y		500 mg, 24	1@	19.51	GC
5320B		500 mg, 24	1@	19.51	GC
5343F		665 mg (m.r.)	96@	5.11	GC
5344G		665 mg (m.r.)	96@	5.11	GC
1754H	PARAFFIN	3.5 g	1@	7.41	IQ
9217D		3.5 g	1@	7.41	IQ
5523Q		3.5 g	1@	7.41	IQ
1166J	PHENOXYBENZAMINE HYDROCHLORIDE	10 mg, 30	1@	66.16	GH
1703P	PHENOXYMETHYLPENICILLIN	250 mg	25@	2.45	QA
1787C		250 mg	25@	2.45	QA
3028J		500 mg	25@	3.62	QA
8976K		125 mg per 5 mL, 100 mL	1@	3.88	AE
8977L		250 mg per 5 mL, 100 mL	1@	5.16	AE
9143F		150 mg per 5 mL, 100 mL	1@	8.54	QA
3360W		250 mg	25@	2.45	QA
3361X		500 mg	25@	3.62	QA
5012T		150 mg per 5 mL, 100 mL	1@	8.54	QA
5024K		125 mg per 5 mL, 100 mL	1@	3.88	AE
5029Q		250 mg per 5 mL, 100 mL	1@	5.16	AE
9384X	PHENYLALANINE with CARBOHYDRATE	4 g containing 50 mg phenylalanine, 30	1@	127.40	VF
9493P	POLYETHYLENE GLYCOL 400	2.5 mg per mL, single dose units 0.4 mL, 20	1@	6.59	AO
5560P		2.5 mg per mL, single dose units 0.4 mL,	1@	6.59	AO

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$		Manufacturer
		20			
9170P	POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL	4 mg-3 mg per mL, single dose units 0.8 mL, 28	1@	13.83	AQ
5532E		4 mg-3 mg per mL, single dose units 0.8 mL, 28	1@	13.83	AQ
9475Q	POLY-L-LACTIC ACID	150 mg	1@	220.02	SW
9476R		150 mg	1@	220.02	SW
2642C	POTASSIUM CHLORIDE	600 mg	100@	3.23	NM
1920C	PREDNISOLONE SODIUM PHOSPHATE	equiv. to 20 mg prednisolone in 100 mL	7@	51.23	QA
2554K		equiv. to 5 mg prednisolone, 10	1@	11.76	QA
1948M	PROMETHAZINE HYDROCHLORIDE	50 mg in 2 mL	5@	7.95	HH
3374N		50 mg in 2 mL	5@	7.95	HH
1953T	PROPANTHELINE BROMIDE	15 mg	100@	10.02	QA
1955X	PROPYLTHIOURACIL	50 mg	100@	21.61	PL
2676W	PROTEIN HYDROLYSATE FORMULA with MEDIUM CHAIN TRIGLYCERIDES	400 g	1@	20.69	NT
8259Q		450 g	1@	12.93	NU
2608G	PYRIDOSTIGMINE BROMIDE	180 mg (m.r.)	50@	71.40	VT
2724J		10 mg	50@	8.29	VT
1937Y	RANITIDINE HYDROCHLORIDE	150 mg (base), effervescent	30@	5.45	GK
8162N		150 mg (base) per 10 mL, 300 mL	1@	9.05	GK
8903N		150 mg (base), effervescent	30@	7.03	GK
8905Q		150 mg (base) per 10 mL, 300 mL	1@	10.15	GK
1842Y	RISPERIDONE	0.5 mg	20@	6.73	JC, TX
1846E		0.5 mg	20@	6.73	JC, TX
8780D		25 mg	1@	135.34	JC
8781E		37.5 mg	1@	173.51	JC
8782F		50 mg	1@	211.28	JC
8788M		0.5 mg (orally disintegrating)	28@	11.29	JC
8790P		1 mg (orally disintegrating)	28@	21.89	JC
8792R		1 mg (orally disintegrating)	28@	21.89	JC
8794W		2 mg (orally disintegrating)	28@	43.41	JC
8870W		0.5 mg (orally disintegrating)	28@	11.29	JC
9075P		3 mg (orally disintegrating)	28@	64.50	JC
9076Q		4 mg (orally disintegrating)	28@	85.95	JC
9080X		2 mg (orally disintegrating)	28@	43.41	JC
9313E	RIZATRIPTAN	10 mg (as benzoate)	2@	9.35	MK
1099W	SALBUTAMOL SULFATE	200 mcg (base)	100@	4.82	GK
1103C		2 mg (base) per 5 mL, 150 mL	1@	7.89	GK
2000G		2.5 mg (base) in 2.5 mL, 30	1@	5.95	AF, GX, QA, CR, SZ, GM
2001H		5 mg (base) in 2.5 mL, 30	1@	6.28	AF, GX, QA, CR, SZ, GM
2003K		5 mg (base) per mL, 30 mL	1@	6.28	PF
8288F		100 mcg (base) per dose (200 doses)	1@	3.70	AL, IA, TX
8354Q		100 mcg (base) per dose (200 doses)	1@	16.09	IA
2995P	SALCATONIN	50 i.u. in 1 mL	5@	33.54	NV
2997R		100 i.u. in 1 mL	5@	51.57	NV
2014B	SODIUM ALGINATE with CALCIUM CARBONATE and SODIUM BICARBONATE	1 g-320 mg-534 mg in 20 mL, 500 mL	1@	4.13	RC
2260Y	SODIUM CHLORIDE	513 mmol per L, 1 L	1@	2.85	BX
2264E		154 mmol per L, 1 L	1@	1.90	BR, PK, BX
9392H		77 mmol per 500 mL, 500 mL	1@	1.32	BR, PK
9473N		38.5 mmol per 250 mL, 250 mL	1@	1.99	BR, PK
5021G		77 mmol per 500 mL, 500 mL	1@	1.32	BR, PK
5212H		154 mmol per L, 1 L	1@	1.90	BR, PK, BX
5213J		513 mmol per L, 1 L	1@	2.85	BX
2266G	SODIUM CHLORIDE COMPOUND	1 L	1@	5.90	BX
2278X	SODIUM CHLORIDE with GLUCOSE	39 mmol-69 mmol per 500 mL, 500 mL	1@	4.47	BX
2279Y		19 mmol-104 mmol per 500 mL, 500 mL	1@	4.47	BX
2281C		31 mmol-222 mmol per L, 1 L	1@	3.42	BX
5214K		31 mmol-222 mmol per L, 1 L	1@	3.42	BX
5215L		19 mmol-104 mmol per 500 mL, 500 mL	1@	4.47	BX

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$		Manufacturer
5216M		39 mmol-69 mmol per 500 mL, 500 mL	1@	4.47	BX
2286H	SODIUM LACTATE COMPOUND	1 L	1@	1.82	BR, PK, BX
9416N		500 mL	1@	1.28	BR, PK
2289L	SODIUM VALPROATE	200 mg (e.c.)	100@	11.75	AF, WA, SZ, QA
2290M		500 mg (e.c.)	100@	22.48	AF, WA, SZ, QA
2293Q		200 mg per 5 mL, 300 mL	1@	14.25	SW
2294R		100 mg	100@	12.79	SW
2295T		200 mg per 5 mL, 300 mL	1@	14.25	SW
9380Q	SORAFENIB	200 mg (as tosylate)	60@	3225.33	BN
2091C	SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE	3.125 g-450 mg-45 mg in 5 mL, 12	1@	12.93	JT, AE
5331N		3.125 g-450 mg-45 mg in 5 mL, 12	1@	12.93	JT, AE
5332P		3.125 g-450 mg-45 mg in 5 mL, 12	1@	12.93	JT, AE
9448G	SOY LECITHIN	10 mg per mL, 10 mL	1@	14.82	RB
5545W		10 mg per mL, 10 mL	1@	14.82	RB
8577K	SOY PROTEIN and FAT FORMULA with VITAMINS and MINERALS— CARBOHYDRATE FREE	384 mL	1@	5.53	AB
2093E	SULFASALAZINE	500 mg	100@	21.93	PF
2096H		500 mg (e.c.)	100@	23.91	FZ
9208P		500 mg	100@	21.93	PF
9209Q		500 mg (e.c.)	100@	23.91	FZ
8144P	SUMATRIPTAN	50 mg (as succinate)	2@	9.90	GK
8885P		50 mg (as succinate) (fast disintegrating)	2@	8.98	GK
1880Y	TAMOXIFEN CITRATE	20 mg (base)	30@	27.39	AP
2088X	TEMAZEPAM	10 mg	25@	1.04	FM, AF, TX
5375X		10 mg	25@	1.04	FM, AF, TX
5376Y		10 mg	25@	1.04	FM, AF, TX
8819E	TEMOZOLOMIDE	5 mg	5@	56.56	MK, QA, WQ, ON
8820F		20 mg	5@	157.22	MK, QA, WQ, ON
8821G		100 mg	5@	670.94	MK, QA, WQ, ON
9361Q		140 mg	5@	916.44	MK, QA, WQ, ON
9160D	TERBINAFINE	10 mg per g, 15 g	1@	15.47	NC
8098F	TESTOSTERONE	100 mg	1@	33.86	MK
8099G		200 mg	1@	67.71	MK
2832C	TETRACOSACTRIN	1 mg in 1 mL	1@	12.97	NV
8221Q	TIAGABINE HYDROCHLORIDE	5 mg (base)	50@	33.11	OA
8222R		10 mg (base)	50@	66.21	OA
8223T		15 mg (base)	50@	95.23	OA
1356J	TOBRAMYCIN SULFATE	80 mg (base) in 2 mL	5@	29.30	HH
8872Y		80 mg (base) in 2 mL (without preservative)	5@	29.30	PF
2117K	TRIAMCINOLONE ACETONIDE	200 mcg per g, 100 g	1@	3.99	FM
2118L		200 mcg per g, 100 g	1@	3.99	FM
9308X	TRIGLYCERIDES, LONG CHAIN with GLUCOSE POLYMER	250 mL, 18	1@	55.56	VF
9309Y		1 L, 6	1@	74.40	VF
3128P	TRIGLYCERIDES, MEDIUM CHAIN	500 mL	1@	22.98	SB
9327X		250 mL	1@	26.00	SB
3136C	TRIGLYCERIDES, MEDIUM CHAIN and LONG CHAIN with GLUCOSE POLYMER	400 g	1@	36.14	SB
1938B	TRIGLYCERIDES—MEDIUM CHAIN, FORMULA	400 g	1@	54.55	VF
8478F		400 g	1@	51.86	SB
8629E		420 g	1@	57.63	SB
9383W		16 g, 30	1@	61.80	VF
9165J	TYROSINE with CARBOHYDRATE	4 g containing 1 g tyrosine, 30	1@	127.40	VF
8448P	URSODEOXYCHOLIC ACID	250 mg	100@	183.09	OA
8133C	VALACICLOVIR	500 mg (as hydrochloride)	10@	49.68	GK, GM, QA, TX, CH, TW, GN, AF, SZ, NV, FZ
9135T	VALINE with CARBOHYDRATE	4 g containing 50 mg valine, 30	1@	127.40	VF
9434M		4 g containing 1 g valine, 30	1@	140.14	VF
2270L	VANCOMYCIN	1 g	1@	10.10	HH, SZ, AF, WQ

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$		Manufacturer
3113W		125 mg	20@	112.92	AS
3114X		250 mg	20@	216.82	AS
3130R		500 mg	1@	5.05	HH, AS, SZ, AF, WQ
3131T		500 mg	1@	5.05	HH, AS, SZ, AF, WQ
3323X		500 mg	1@	5.05	HH, AS, SZ, AF, WQ
9129L	VARENICLINE	1 mg (as tartrate)	56@	112.64	PF
9009E	VINORELBINE	20 mg (as tartrate)	1@	98.33	FB
9010F		30 mg (as tartrate)	1@	145.85	FB
9328Y	VITAMINS, MINERALS and TRACE ELEMENTS with CARBOHYDRATE	200 g	1@	64.00	SB
9382T	WHEY PROTEIN FORMULA supplemented with AMINO ACIDS, LONG CHAIN POLYUNSATURATED FATTY ACIDS, VITAMINS and MINERALS, and low in PROTEIN, PHOSPHATE, POTASSIUM and LACTOSE	100 g, 10	1@	164.35	VF
8587Y	WHEY PROTEIN FORMULA supplemented with AMINO ACIDS, VITAMINS and MINERALS, and low in PROTEIN, PHOSPHATE, POTASSIUM and LACTOSE	400 g	1@	66.22	SB
8266C	ZOLMITRIPTAN	2.5 mg	2@	9.71	AP
9736K		2.5 mg	2@	11.09	AP
9390F	ZONISAMIDE	100 mg	56@	43.52	SA

Section 4

Drug Tariff

Container Prices

Standard Formulae Preparations

**Table of Codes, Maximum Quantities, and Number of
Repeats for Extemporaneously Prepared
Pharmaceutical Benefits**

Drug Tariff

Drug	Standard	Recovery Prices			
		0.1 g/mL	1 g/mL	10 g/mL	100 g/mL
		\$	\$	\$	\$
Acacia Mucilage (by weight)	APF 15	0.01	0.08	0.61	5.42
Acacia, powdered	BP	0.02	0.13	1.06	9.45
Acetic Acid (6 per cent)	BP	0.01	0.02	0.13	1.20
Acetic Acid (33 per cent)	BP	0.01	0.06	0.45	3.99
Acetone (use as additive only)	BP	0.01	0.10	0.78	6.97
Alum	BP	0.02	0.18	1.42	12.60
Aluminium Acetate Solution	BP	0.02	0.16	1.30	11.51
Anise Water Concentrated 1 in 40 (use as additive only)	BP	0.01	0.07	0.52	4.64
Aqueous Cream (for use only as a base combined with active ingredients)	APF	0.01	0.03	0.20	1.79
Ascorbic Acid (for use only as an ingredient of ferrous sulfate mixtures)	BP	0.13	1.03	8.25	73.37
Aspirin	BP	0.06	0.49	3.88	34.50
Belladonna Tincture	BP	0.08	0.62	4.92	43.70
Benzocaine	BP	0.06	0.51	4.08	36.25
Benzoic Acid	BP	0.04	0.33	2.62	23.31
Benzoic Acid Compound Ointment	APF	0.01	0.11	0.92	8.16
Benzoic Acid Solution	BP	0.01	0.10	0.80	7.12
Benzoin Compound Tincture	BP	0.03	0.25	1.96	17.40
Boric Acid (use as additive only)	BP	0.01	0.05	0.39	3.45
Boric Acid, Olive Oil and Zinc Oxide Ointment	QHF	0.01	0.08	0.65	5.75
Calcium Hydroxide	BP	0.08	0.67	5.34	47.50
Calcium Hydroxide Solution	BP	0.01	0.02	0.14	1.24
Castor Oil (use as additive only)	BP	0.01	0.10	0.78	6.95
Cetomacrogol Aqueous Cream (for use only as a base combined with active ingredients)	APF	0.01	0.03	0.23	2.09
Cetrimide Aqueous Cream (for use only as a base combined with active ingredients)	APF	0.02	0.13	1.04	9.22
Chlorhexidine Acetate (use as additive only)	BP	0.64	5.13	41.03	364.70
Chlorhexidine Aqueous Cream (for use only as a base combined with active ingredients)	APF	0.03	0.21	1.68	14.96
Chloroform (use as additive only)	BP	0.07	0.59	4.69	41.67

Drug	Standard	Recovery Prices			
		0.1 g/mL	1 g/mL	10 g/mL	100 g/mL
		\$	\$	\$	\$
Chloroform Spirit	BP	0.01	0.07	0.56	4.94
Chloroform Water Concentrated 1 in 40	APF 15	0.01	0.09	0.69	6.13
Citric Acid Monohydrate	BP	0.02	0.13	1.03	9.15
Coal Tar	BP	0.12	0.98	7.83	69.60
Coal Tar Solution	BP	0.02	0.13	1.04	9.24
Cocaine Hydrochloride	BP	6.09	48.74	389.90	3465.77
Coconut Oil	BP	0.01	0.10	0.80	7.16
Codeine Linctus	APF	0.01	0.07	0.58	5.15
Codeine Phosphate (may only be prescribed in linctuses, mixtures or mixtures for children)	BP	2.34	18.75	150.00	1333.33
Collodion Flexible	BP	0.15	1.23	9.86	87.60
Dithranol	BP	4.07	32.54	260.35	2314.20
Emulsifying Ointment (for use only as a base combined with active ingredients)	BP	0.01	0.08	0.67	5.98
Ephedrine Hydrochloride (may only be prescribed in nasal instillations)	BP	0.93	7.43	59.40	528.00
Ethanol (90 per cent) (use as additive only)	BP	0.01	0.03	0.24	2.12
Ethanol (96 per cent) (use as additive only)	BP	0.01	0.04	0.28	2.48
Ether Solvent (use as additive only)	BP	0.15	1.16	9.26	82.35
Eucalyptus Oil (use as additive only)	BP	0.02	0.13	1.06	9.43
Ferrous Sulfate	BP	0.11	0.91	7.31	65.00
Formaldehyde Solution	BP	0.10	0.80	6.39	56.79
Gentian Alkaline Mixture	APF	0.01	0.07	0.59	5.28
Glycerol	BP	0.01	0.06	0.50	4.46
Honey Purified (use as additive only)	BP 1993	0.01	0.02	0.15	1.35
Hydroxybenzoate Compound Solution	APF	0.07	0.58	4.60	40.92
Iodine	BP	0.23	1.81	14.50	128.89
Iodine Alcoholic Solution	BP	0.02	0.13	1.07	9.48
Iodine Aqueous Oral Solution	BP	0.03	0.27	2.19	19.50
Kaolin Mixture	BPC 1968	0.01	0.10	0.81	7.19
Kaolin and Opium Mixture	APF 14	0.01	0.09	0.69	6.10
Lactic Acid	BP	0.06	0.51	4.07	36.21
Lavender Spike Oil	BPC 1968	0.10	0.80	6.43	57.14
Liquorice Liquid Extract	BP	0.03	0.25	1.99	17.70
Magnesium Carbonate Light	BP	0.03	0.23	1.83	16.27
Magnesium Sulfate (may only be prescribed for other than oral	BP	0.01	0.02	0.12	1.09

Drug	Standard	Recovery Prices			
		0.1 g/mL	1 g/mL	10 g/mL	100 g/mL
		\$	\$	\$	\$
use)					
Magnesium Trisilicate	BP	0.04	0.30	2.41	21.41
Menthol, Racemic or Levomenthol	BP	0.25	1.99	15.88	141.17
Methyl Hydroxybenzoate	BP	0.30	2.40	19.22	170.84
Methyl Hydroxybenzoate Solution	APF	0.03	0.26	2.06	18.32
Methylated Industrial Spirit (use as additive only)	BP	0.01	0.03	0.24	2.11
Olive Oil (use as additive only)	BP	0.01	0.10	0.79	7.03
Paraffin Hard	BP	0.01	0.17	1.37	12.16
Paraffin Liquid (may only be prescribed for other than oral use)	BP	0.01	0.03	0.25	2.20
Paraffin Light Liquid	BP	0.02	0.15	1.20	10.69
Paraffin Soft White	BP	0.01	0.04	0.35	3.15
Paraffin Soft Yellow	BP	0.01	0.06	0.50	4.49
Peppermint Oil (use as additive only)	BP	0.14	1.11	8.91	79.24
Peppermint Water Concentrated 1 in 40 (use as additive only)	APF 16	0.04	0.28	2.21	19.65
Phenobarbitone Sodium (may only be prescribed for the treatment of epilepsy)	BP	10.67	85.38	683.00	6071.11
Phenol Liquefied (not available for ear drops)	BP	0.17	1.37	10.94	97.20
Podophyllum Resin	BP	0.95	7.61	60.90	541.33
Potassium Citrate	BP	0.02	0.13	1.05	9.03
Potassium Iodide	BP	0.07	0.53	4.26	37.83
Potassium Permanganate	BP	0.05	0.41	3.29	29.27
Propyl Hydroxybenzoate	BP	0.25	2.02	16.12	143.29
Propylene Glycol	BP	0.01	0.09	0.71	6.31
Red Syrup	APF 15	0.02	0.13	1.07	9.50
Resorcinol	BP	0.32	2.57	20.52	182.40
Salicylic Acid	BP	0.03	0.23	1.80	15.98
Salicylic Acid Ointment	APF	0.02	0.12	0.96	8.57
Salicylic Acid Ointment	BP	0.02	0.12	0.96	8.57
Simple Ointment (white) (for use only as a base combined with active ingredients)	BP	0.02	0.16	1.26	11.16
Simple Ointment (yellow) (for use only as a base combined with active ingredients)	BP	0.02	0.16	1.26	11.16
Sodium Bicarbonate	BP	0.01	0.08	0.65	5.81
Sodium Chloride	BP	0.02	0.13	1.03	9.12

Drug	Standard	Recovery Prices			
		0.1 g/mL	1 g/mL	10 g/mL	100 g/mL
		\$	\$	\$	\$
Sodium Chloride Solution	BP	0.01	0.01	0.08	0.70
Sodium Citrate	BP	0.02	0.15	1.19	10.60
Sodium Thiosulfate (use as additive only)	BP	0.03	0.21	1.67	14.87
Starch	BP	0.02	0.14	1.11	9.89
Sulfur Ointment (for use only as a base combined with active ingredients)	BP 1980	0.02	0.16	1.27	11.28
Sulfur Precipitated	BP 1980	0.02	0.16	1.24	10.99
Syrup	BP	0.01	0.03	0.23	2.07
Talc Purified, sterilised	BP	0.02	0.19	1.52	13.55
Thymol	BP	0.23	1.81	14.50	128.89
Thymol Compound Mouth Wash	APF 15	0.01	0.11	0.86	7.65
Tragacanth Compound Powder	BP 1980	0.07	0.58	4.64	41.27
Tragacanth Mucilage	APF 13	0.01	0.04	0.29	2.57
Tragacanth Mucilage	BPC 1973	0.01	0.03	0.23	2.02
Tragacanth, powdered	BP	0.12	0.95	7.59	67.50
Trichloroacetic Acid	BP 1980	0.35	2.83	22.63	201.12
Triethanolamine	BP	0.05	0.41	3.26	29.00
Water For Injections, sterilised (b) (extemporaneously prepared eye drops and eye lotions)	BP	—	—	11.37	11.37
Water Purified	BP	0.01	0.01	0.06	0.57
Wool Alcohols Ointment (white) (for use only as a base combined with active ingredients)	BP	0.02	0.14	1.12	9.95
Wool Alcohols Ointment (yellow) (for use only as a base combined with active ingredients)	BP	0.02	0.14	1.12	9.95
Wool Fat	BP	0.02	0.12	0.97	8.64
Wool Fat Hydrous	BP	0.02	0.13	1.05	9.36
Zinc Compound Paste	BP	0.03	0.24	1.90	16.85
Zinc Cream (for use only as a base combined with active ingredients)	BP	0.01	0.08	0.62	5.55
Zinc Oxide	BP	0.02	0.13	1.06	9.43
Zinc and Salicylic Acid Paste	BP	0.02	0.16	1.31	11.62
Zinc Sulfate	BP	0.03	0.21	1.67	14.87

Container Prices

Container Prices	
	\$
DISPENSING BOTTLES –	
25mL	0.61
50mL	0.58
100mL	0.75
200mL	0.98
500mL	1.34
POISON BOTTLES –	
25mL	0.66
50mL	0.74
100mL	0.77
200mL	1.14
500mL	1.34
SCREW CAP JARS –	
25g	0.83
50g	0.90
100g	1.04
200g	0.89
500g	1.29
DROPPER CONTAINERS –	
15mL polythene	0.84
15mL glass	0.86
Dispensing Fee for Extemporaneously Prepared Benefits	8.56
Additional Fee for Agreed Price	1.45
Extemporaneously Prepared Benefits	

Standard Formula Preparations

The following list is not intended to indicate in any way which particular formula an approved pharmacist should use in filling a prescription.

The prices shown in the column 'Dispensed Price for Max. Qty' are for the ingredients, the container and the dispensing fee. The prices shown in the column 'Maximum Recordable Value for Safety Net' are for the ingredients, the container and the dispensing fee and, where applicable, the additional fee for agreed price benefits.

KEY TO REFERENCES:

APF	Australian Pharmaceutical Formulary
BP	British Pharmacopoeia
BPC	British Pharmaceutical Codex
QHF	Queensland Hospital Formulary

Standard Formula Preparations

Code	Item	Reference	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net
			\$	\$
	CREAMS (Maximum Quantity 100 g and 1 Repeat)			
7502W	Salicylic Acid and Sulfur Aqueous	APF	12.07	13.52
	DUSTING POWDERS (Maximum Quantity 100 g and 1 Repeat)			
7458M	Zinc, Starch and Talc	APF 15 & BPC 1973	22.50	23.95
	EAR DROPS (Maximum Quantity 15 mL and 2 Repeats)			
7642F	Aluminium Acetate	APF	10.76	12.21
7643G	Aluminium Acetate	BP	11.34	12.79
7314Y	Sodium Bicarbonate	APF & BP	9.83	11.28
7313X	Spirit	APF	9.70	11.15
	INHALATIONS (Maximum Quantity 50 mL and 1 Repeat)			
7484X	Benzoin and Menthol	APF	21.08	22.53
7308P	Menthol	APF	12.48	13.93
7310R	Menthol and Eucalyptus	BP 1980	13.04	14.49
	LINCTUSES CONTAINING CODEINE PHOSPHATE (Maximum Quantity 100 mL and 0 Repeats)			
7530H	Codeine	APF	14.46	15.91
	LOTIONS (Maximum Quantity 200 mL and 2 Repeats)			
7709R	Aluminium Acetate Aqueous	APF	12.09	13.54
	MIXTURES, OTHER (Maximum Quantity 200 mL and 4 Repeats)			
7604F	Gentian Alkaline	APF	20.09	21.54
7348R	Kaolin	BPC 1968	23.92	25.37
7301G	Kaolin and Opium	APF 14	21.73	23.18
7342K	Magnesium Trisilicate	BPC 1968	16.93	18.38
7343L	Magnesium Trisilicate and Belladonna	BPC 1968	21.72	23.17
	MOUTH WASHES (Maximum Quantity 200 mL and 1 Repeat)			
7457L	Thymol Compound	APF 15	25.00	26.45
	OINTMENTS (Maximum Quantity 100 g and 1 Repeat)			
7914M	Benzoic Acid Compound	APF	17.76	19.21
7914M	Benzoic Acid Compound (extemporaneous formula)	BP	17.76	19.21
7902X	Boric Acid, Olive Oil and Zinc Oxide	QHF	15.35	16.80

Code	Item	Reference	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net
			\$	\$
7926E	Salicylic Acid	APF	18.17	19.62
7928G	Salicylic Acid (extemporaneous formula)	BP	18.17	19.62
	PAINTS (Maximum Quantity 25 mL and 1 Repeat)			
7567G	Podophyllin Compound	APF 16 & BP	42.66	44.11
7568H	Salicylic Acid	APF	34.42	35.87
	PASTES, OTHER (Maximum Quantity 100 g and 1 Repeat)			
7558T	Zinc	APF	26.45	27.90
7558T	Zinc Compound (extemporaneous formula)	BP	26.45	27.90
	POWDER FOR INTERNAL USE (Maximum Quantity 100 g and 2 Repeats)			
7545D	Magnesium Trisilicate	BP	30.86	32.31
—CONTAINER RATES ARE INCLUDED—				

**Table of Codes, Maximum Quantities, and Number of Repeats
for Extemporaneously Prepared Benefits**

Code	Preparation	Maximum Quantity	Number of Repeats
13Q	Creams	100 g	1
48M	Dusting Powders	100 g	1
15T	Ear Drops	15 mL	2
19B	Eye Drops containing Cocaine Hydrochloride	15 mL	..
22E	Eye Drops, Other	15 mL	5
23F	Eye Lotions	200 mL	2
29M	Inhalations	50 mL	1
64J	Linctuses containing Codeine Phosphate	100 mL	..
34T	Linctuses, Other	100 mL	2
39C	Lotions	200 mL	2
65K	Mixtures containing Codeine Phosphate	200 mL	..
40D	Mixtures, Other	200 mL	4
66L	Mixtures for Children containing Codeine Phosphate	100 mL	..
41E	Mixtures for Children, Other	100 mL	4
30N	Mouth Washes	200 mL	1
42F	Nasal Instillations	15 mL	2
43G	Ointments, Waxes	100 g	1
44H	Paints	25 mL	1
63H	Pastes containing Cocaine Hydrochloride	25 g	..
45J	Pastes, Other	100 g	1
49N	Powders for Internal Use	100 g	2
52R	Solutions	200 mL	2

Special Note: Purified Water BP is the minimum requirement for water in all PBS extemporaneous preparations.



Australian Government

Department of Health and Ageing

REPATRIATION SCHEDULE OF PHARMACEUTICAL BENEFITS

1 August 2012

The benefits listed in this Schedule may only be prescribed to Department of Veterans' Affairs beneficiaries holding a:

- Repatriation Health Card For All Conditions (gold); or
- Repatriation Health Card For Specific Conditions (white); or
- Repatriation Pharmaceutical Benefits Card (orange);

BENEFICIARIES' ENTITLEMENT CARDS AND ELIGIBILITY FOR REPATRIATION PHARMACEUTICAL BENEFITS

<p>Gold card</p> <p>This card is issued to those veterans of Australia's defence force, their widows/widowers and dependants entitled to treatment for all medical conditions.</p>	 <p>The image shows a sample Gold Repatriation Health Card. It is a yellowish-gold card with the Australian Government logo at the top left. The text reads: "Repatriation Health Card For All Conditions Within Australia". A large red "SAMPLE" watermark is diagonally across the center. Below the watermark, it says "File No." and "Card expires or on recall".</p>
<p>White card</p> <p>A White Card is issued to Australian veterans or mariners under the Veterans' Entitlements Act 1986 with:</p> <ul style="list-style-type: none"> • an accepted war or service-caused injury or disease; • malignant cancer (neoplasia) whether war-caused or not; • pulmonary tuberculosis whether war-caused or not; • post-traumatic stress disorder whether war-caused or not; or • anxiety and/or depression whether war-caused or not. 	 <p>The image shows a sample White Repatriation Health Card. It is a white card with the Australian Government logo at the top left. The text reads: "Repatriation Health Card - For Specific Conditions". A large red "SAMPLE" watermark is diagonally across the center. Below the watermark, it says "File No." and "Card expires or on recall".</p>
<p>Orange card</p> <p>Orange Repatriation pharmaceutical benefits cards are issued to Commonwealth and allied veterans and mariners who:</p> <ul style="list-style-type: none"> • have qualifying service from World War I or II and • are aged 70 or over and • have been resident in Australia for 10 years or more. 	 <p>The image shows a sample Orange Repatriation Pharmaceutical Benefits Card. It is an orange card with the Australian Government logo at the top left. The text reads: "Repatriation Pharmaceutical Benefits Card". A large red "SAMPLE" watermark is diagonally across the center. Below the watermark, it says "File No." and "Card expires or on recall". At the bottom left, it says "PHARMACEUTICALS ONLY".</p>

For more information go to the Department of Veterans' Affairs website:
http://www.dva.gov.au/service_providers/treatment_cards/Pages/index.aspx

RPBS Explanatory Notes

Introduction

The Australian Repatriation System

- The Australian Repatriation system is based primarily on the principle of compensation to veterans and eligible dependants for injury or death related to war service. In certain cases, treatment is also provided for accepted injuries or conditions that are not service-related or have occurred as a result of other than war service.
- Through the *Veterans' Entitlements Act 1986* the Department of Veterans' Affairs provides programs of compensation, income support and treatment for eligible veterans and their dependants. One of the defined benefits for eligible veterans is the Repatriation Pharmaceutical Benefits Scheme. This range of medications and dressings is more comprehensive than is available through the Pharmaceutical Benefits Scheme.

RPBS prescribing provisions

- Unless otherwise stated, Repatriation Pharmaceutical Benefits Scheme (RPBS) prescriptions must conform with the requirements of Pharmaceutical Benefits Scheme (PBS) prescriptions, as detailed in Section 1 – Explanatory Notes in the *Schedule of Pharmaceutical Benefits* book. The prescriber shall ensure that a prescription contains the following details:
 - the category of benefit, i.e., RPBS, by placing a cross in the relevant box;
 - the patient's full name and address;
 - the prescription date;
 - the DVA file number of the patient as evidence of entitlement;
 - in the case of authority prescriptions, the Authority approval number or the four digit streamlined authority code;
 - the item, form, strength, quantity and directions;
 - the number of repeats, if applicable;
 - indicate when brand substitution is not permitted; and
 - the name, signature, the prescriber number and address of the prescriber.

Prior Approval Arrangements

- The prior approval of the Department is required to prescribe the following:
 - 'Authority required' items (excluding 'Authority required (STREAMLINED)' items) listed in either the PBS or RPBS Schedule;
 - increased quantities and/or repeats of items listed in either the PBS or RPBS Schedule;
 - items listed under section 100 of the *National Health Act 1953*; and
 - other items not listed in either Schedule (non-Schedule items).
- The above items are to be prescribed on the common PBS/RPBS authority prescription form in accordance with the directions stated in the Explanatory Notes in the *Schedule of Pharmaceutical Benefits* (See also information regarding dental prescribing and prescribing by optometrists under the RPBS in these Notes.)
- All Authority required prescriptions and requests for non-Schedule items must receive prior approval from the Department. This can be achieved by either:
 - using the Department's national free call number 1800 552 580; or
 - by mailing the written authority prescription to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) at the reply paid address shown at the end of these RPBS Explanatory Notes.
- Prior approval is not required from DVA to prescribe an Authority required (STREAMLINED) item (except where increased quantities and/or repeats are required). Instead the authority prescription form must include a four digit streamlined authority code.
- Some requests for prior approval (including some non-Schedule items) need to be referred by VAPAC to the Repatriation Pharmaceutical Reference Committee for consideration. In such cases a VAPAC pharmacist will advise the prescriber to submit a request in writing that provides the following information:
 - A current clinical report on the patient's condition (such as age, co-morbidities, renal, liver failure) and clinical reports including pathology, biochemistry, diagnostic and other investigations if appropriate.
 - Details of past and current therapy for the condition. Include details of PBS, RPBS and non-Schedule items utilised, and the results of those therapies.
 - Details of the proposed treatment regimen. Include intended dose and duration of treatment and objective measures of response.

- When the proposed use of the item is outside the TGA-approved indications for use in Australia, provide copies of articles from peer reviewed publications supporting the proposed treatment.
- Signed, informed patient consent where the item is to be used for a non-TGA-approved indication.
- For items without Australian marketing approval, a copy of the TGA Special Access Scheme approval to prescribe the drug.
- Requests for prior approval to prescribe a non-Schedule (PBS or RPBS) item that is of the same therapeutic class (ATC level 3) as an item that is listed on the Schedule, will not be approved unless unequivocal clinical evidence is presented to demonstrate that the requested item is essential for effective treatment of the nominated patient.
- A pharmacist should not supply an item prescribed on an RPBS Authority Prescription Form unless the form has been approved and stamped by VAPAC, or has been endorsed by the prescriber with a telephone Authority approval number provided by VAPAC. Medicare Australia will not accept RPBS Authority prescriptions that have not been approved by the Department of Veterans' Affairs for payment.

Palliative Care Drugs

The following medications may be available, or made available in increased quantities or doses under prior approval arrangements for use only in the palliative care of terminal disease:

- clonazepam
- cyclizine
- dexamethasone
- disodium pamidronate
- fentanyl
- glycopyrrolate
- hyoscine butylbromide
- hyoscine hydrobromide
- ketamine
- midazolam
- octreotide
- For further information telephone VAPAC on 1800 552 580.

Dental Prescribing

- Under Department of Veterans' Affairs arrangements, financial responsibility for pharmaceutical benefits prescribed by a Local Dental Officer (LDO) is limited to treatment to which holders of the following cards are entitled:
 - a Gold Repatriation Health Card – For All Conditions; or
 - a White Repatriation Health Card – For Specific Conditions; or
 - an Orange Repatriation Pharmaceutical Benefits Card.
- Where possible the LDO shall prescribe in accordance with the provisions governing dental prescribing under the Pharmaceutical Benefits Scheme (PBS).
- Prescriptions for PBS Dental Schedule items for Gold, White and Orange Card holders are to be dispensed at the PBS concessional rate. Claims for payment by the dispensing pharmacist are to be included with other Repatriation prescriptions. The card holder is required to meet the cost of any applicable brand premium.
- When a non-PBS Dental Schedule item is prescribed for an eligible card holder, the LDO's private prescription form should be used. The dispensing pharmacist may charge the patient the full cost of the prescription. The patient may claim a refund for the full cost of a non-Schedule item from the Department if an itemised receipt (not a cash register receipt) and a copy of the prescription are provided.

Prescribing by optometrists

- Optometrists approved as 'PBS prescribers' may write RPBS prescriptions as outlined in Section 1 for medicines listed in Section 2 of the PBS Schedule as pharmaceutical benefits for optometrical use.
- Medicines in the optometrist list include non-Authority and Authority required items. Procedures for obtaining VAPAC approval to prescribe 'Authority required' optometrist items or increased quantities and/or repeats of optometrist items under the RPBS are the same as indicated under prior approval arrangements above.
- The list of medicines for prescribing by optometrists under the RPBS is the same as applies under the PBS. There are no optometrist listings in the RPBS Schedule for prescribing for veterans only. There is no provision for optometrist prescribers to request approval to prescribe items that are not included in the PBS optometrist list (non-Schedule items).

- Optometrist PBS/RPBS prescription forms are for use for prescribing non-Authority or Authority required optometrist items under the RPBS with one item per form only.

Provisions governing pricing and payment for RPBS benefits

Introduction

- Unless otherwise stated, the pricing and payment principles and arrangements for approved pharmacists supplying pharmaceutical benefits under the RPBS will be the same as those arrangements applying under the PBS.
- Where a pharmaceutical benefit that is not listed on the PBS or RPBS Schedule is dispensed on an RPBS Authority prescription, a pharmacist will price the benefit and enter the serial number, prescription identifying number and price on the sticker or stamp imprint affixed to the prescription.

Pricing of Schedule Items

- Items supplied under the RPBS from the PBS Schedule, both ready-prepared and extemporaneously-prepared, will be paid on the same basis as benefits supplied under the PBS. Items supplied under the RPBS from the Repatriation Schedule, including wound dressings, will be paid on the basis of the price as given in the Repatriation Pharmaceutical Benefits section (Section 1 – RPBS Schedule, Drugs, Medicines and Dressings) of the *Schedule of Pharmaceutical Benefits*.

Pricing of Non-Schedule Ready Prepared Items

- Non-Schedule ready-prepared items are to be priced on the basis of the invoiced, GST-exclusive wholesale price to pharmacists plus the appropriate PBS mark-up and the PBS dispensing fee. Where the item price to pharmacists is greater than \$100.00, a copy of the invoice pertaining to the supply of that item is to be submitted together with the appropriate copy of the authority prescription as part of the claim for payment.

Pricing of Non-Schedule Extemporaneously Prepared Items

- When an ingredient drug is not listed in the PBS Drug Tariff, the recovery price will be based on the invoiced wholesale price to pharmacists, increased by a mark-up of 100%, calculated in accordance with the directions contained in the pricing instructions for pricing of PBS extemporaneously-prepared benefits in this Schedule. The price paid by the pharmacist for the commercial pack from which the ingredient is used shall be endorsed on the prescription form.

Miscellaneous Pricing Rules

- The price to pharmacists used as the basis of pricing will be the invoiced, GST-exclusive price from the wholesaler.
- If multiple quantities of a manufacturer's original pack are supplied, the PBS mark-up is applied to the price to pharmacist of each pack and then totalled. The PBS dispensing fee, and the PBS dangerous drug fee if applicable, are then added to the total of the marked-up prices.
- When the quantity prescribed corresponds with the quantity of a manufacturer's original pack, in no circumstances will the price payable for one pack exceed that payable for multiples or combinations of packs to supply the quantity prescribed.
- The list of ingredient drugs and prices included in the PBS Drug Tariff are common to both the PBS and RPBS. Certain restrictions apply regarding the prescribing and dispensing of some of these ingredient drugs as pharmaceutical benefits, e.g., use as additive only.
- For items prescribed generically, including non-Schedule and wound dressings, the pharmacist should indicate on the prescription the quantity and brand supplied. If prescriptions are not endorsed, the Department will pay the lowest priced acceptable product available.

General

Packaging Material, Postage or Freight

- Payment to a pharmacist for the costs of packaging materials, postage or freight required to supply a pharmaceutical benefit is to be paid by the patient, who may then claim reimbursement from the Department through the provision of a pharmacist's itemised receipt.

Payment for Items Supplied at Short Intervals

- For all items dispensed at specific short intervals of time, the Department will pay a separate PBS dispensing fee for each occasion that the drug is supplied and which is acknowledged on receipt by the patient or agent.
- The price payable on the items supplied will be based on the individual dose quantity supplied. Where applicable, a PBS dangerous drug fee and a minimum container charge will be payable for each supply.

Receipts for Patient Charges

- Where a charge is paid by a patient in any of the circumstances of paragraphs 13 or 24, the pharmacist is required to provide a printed receipt to the patient with the details of the items or services provided, the amount paid, date of supply and the patient's name and address. The patient may apply for reimbursement from the Department.

Special Patient Contributions

- The Special Patient Contribution for items listed as Special Pharmaceutical Benefits in the PBS Schedule is not payable by veterans entitled to pharmaceutical benefits under the RPBS. Eligible veterans receiving Special Pharmaceutical Benefits under the RPBS are required to pay only the concessional patient contribution and any applicable brand premium. If a Safety Net Entitlement card is held, the veteran should receive a Special Pharmaceutical Benefit free of charge, subject to any brand premium applicable. Medicare Australia will reimburse the dispensing pharmacist the total dispensed price, less the concessional patient contribution and/or brand premium if applicable.

Therapeutic Group Premiums — Authority Processing

Items attracting a therapeutic group premium are dual listed. Dispensing pharmacists are therefore required to select the appropriate code for those items that are dual listed as authority and non-authority items, in order to correctly charge the patient and claim from Medicare Australia. Those authority prescriptions that grant exemption from a therapeutic group premium will have the letters 'TPX' at the beginning of the telephone Authority approval number, or, in the case of a written approval, will be stamped with the words "This prescription does not attract a therapeutic group premium".

DEPARTMENT OF VETERANS' AFFAIRS

Authority Prescription Applications

Applications for authority to prescribe under the Repatriation Pharmaceutical Benefits Scheme (RPBS) should be sent to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) using the free postal service:

REPLY PAID 9998
VAPAC (Veterans' Affairs Pharmaceutical Advisory Centre)
Department of Veterans' Affairs
GPO Box 9998
BRISBANE QLD 4001

For RPBS enquiries and telephone approvals 24 hours a day the Freecall number is:

1800 552 580

Departmental pharmacists answer applications for prior approval for non-Schedule items and Authority application calls.

REPATRIATION PHARMACEUTICAL BENEFITS

Alterations

Alteration – Brand Name

From:

4422R *Metamucil Regular, PY – Psyllium Hydrophilic Mucilloid*, Oral powder (non-flavoured) 336 g

To:

4422R *Metamucil Natural Granular, PY – Psyllium Hydrophilic Mucilloid*, Oral powder (non-flavoured) 336 g

From:

4419N *Metamucil Smooth Texture Orange, PY – Psyllium Hydrophilic Mucilloid*, Oral powder (orange-flavoured, sugar-free) 283 g

To:

4419N *MetamucilOrangeSmooth, PY – Psyllium Hydrophilic Mucilloid*, Oral powder (orange-flavoured, sugar-free) 283 g

Alteration – Item Description

From:

4948K **Dressing—hydroactive (debridement)**, Dressings 5.5 cm, 8 (*TenderWet Active Cavity*)

To:

4948K **Dressing—hydroactive (debridement)**, Dressings 5.5 cm, 10 (*TenderWet Active Cavity*)

From:

4949L **Dressing—hydroactive (debridement)**, Dressings 4 cm, 8 (*TenderWet 24 Active*)

To:

4949L **Dressing—hydroactive (debridement)**, Dressings 4 cm, 10 (*TenderWet 24 Active*)

From:

4950M **Dressing—hydroactive (debridement)**, Dressings 7.5 cm x 7.5 cm, 8 (*TenderWet 24 Active*)

To:

4950M **Dressing—hydroactive (debridement)**, Dressings 7.5 cm x 7.5 cm, 10 (*TenderWet 24 Active*)

Therapeutic Index for RPBS

Alimentary tract and metabolism	911
Stomatological preparations	911
Stomatological preparations.....	911
Drugs for acid related disorders	911
Antacids	911
Drugs for functional gastrointestinal disorders	911
Drugs for functional bowel disorders	911
Belladonna and derivatives, plain	911
Laxatives	911
Laxatives	911
Antiobesity preparations, excl. diet products.....	912
Antiobesity preparations, excl. diet products.....	912
Vitamins.....	913
Vitamin B ₁ , plain and in combination with vitamin B ₆ and vitamin B ₁₂	913
Vitamin B-complex, incl. combinations	913
Mineral supplements.....	913
Calcium	913
Other mineral supplements.....	913
Blood and blood forming organs.....	914
Antithrombotic agents.....	914
Antithrombotic agents.....	914
Blood substitutes and perfusion solutions	914
Irrigating solutions.....	914
Cardiovascular system.....	915
Vasoprotectives.....	915
Agents for treatment of hemorrhoids and anal fissures for topical use.....	915
Dermatologicals.....	916
Antifungals for dermatological use.....	916
Antifungals for topical use	916
Antifungals for systemic use.....	917
Emollients and protectives	917
Emollients and protectives	917
Protectives against UV-radiation	917
Antipruritics, incl. antihistamines, anesthetics, etc.	918
Antipruritics, incl. antihistamines, anesthetics, etc.	918
Antipsoriatics.....	918
Antipsoriatics for topical use	918
Antibiotics and chemotherapeutics for dermatological use.....	918
Antibiotics for topical use	918
Chemotherapeutics for topical use.....	918
Corticosteroids, dermatological preparations	919
Corticosteroids, plain.....	919
Corticosteroids, combinations with antibiotics	919
Antiseptics and disinfectants.....	919
Antiseptics and disinfectants.....	919
Other dermatological preparations	919
Other dermatological preparations	919
Genito urinary system and sex hormones.....	921
Gynecological antiinfectives and antiseptics	921
Antiinfectives and antiseptics, excl. comb. with corticosteroids	921
Other gynecologicals	921
Other gynecologicals	921
Urologicals.....	921
Other urologicals, incl. antispasmodics	921
Drugs used in benign prostatic hypertrophy	925
Antiinfectives for systemic use.....	926

Antibacterials for systemic use	926
Macrolides, lincosamides and streptogramins	926
Antineoplastic and immunomodulating agents.....	927
Antineoplastic agents	927
Antimetabolites	927
Immunosuppressants	927
Immunosuppressants	927
Musculo-skeletal system.....	929
Antiinflammatory and antirheumatic products	929
Antiinflammatory and antirheumatic products, non-steroids	929
Topical products for joint and muscular pain	929
Topical products for joint and muscular pain	929
Drugs for treatment of bone diseases	929
Drugs affecting bone structure and mineralization	929
Nervous system	931
Analgesics	931
Opioids.....	931
Other analgesics and antipyretics.....	931
Psycholeptics	932
Anxiolytics.....	932
Hypnotics and sedatives	932
Other nervous system drugs.....	933
Drugs used in addictive disorders	933
Antiparasitic products, insecticides and repellents	934
Anthelmintics.....	934
Antinematodal agents	934
Respiratory system.....	935
Nasal preparations.....	935
Decongestants and other nasal preparations for topical use	935
Nasal decongestants for systemic use	935
Cough and cold preparations.....	935
Expectorants, excl. combinations with cough suppressants.....	935
Cough suppressants, excl. combinations with expectorants	936
Antihistamines for systemic use	936
Antihistamines for systemic use	936
Sensory organs.....	937
Ophthalmologicals.....	937
Decongestants and antiallergics	937
Otologicals	937
Other otologicals	937
Various	938
All other therapeutic products	938
All other therapeutic products	938
All other non-therapeutic products.....	941
All other non-therapeutic products	941

Section 1

Drugs, Medicines and Dressings

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Alimentary tract and metabolism

Stomatological preparations

Stomatological preparations

Antiinfectives and antiseptics for local oral treatment

CHLORHEXIDINE GLUCONATE

4161B	Mouth wash 2 mg per mL (0.2%), 250 mL	‡1	11.99	5.80	Plaqacide	OB
4204G	Mouth wash 2 mg per mL (0.2%), 300 mL	‡1	15.38	5.80	Savacol Mouth and Throat Rinse	OM

Other agents for local oral treatment

CARMELLOSE SODIUM

4568K	Mouth spray 10 mg per mL, 25 mL	‡1	1	..	10.89	5.80	Aquae	VT
4569L	Mouth spray 10 mg per mL, 100 mL	‡1	12.56	5.80	Aquae	VT

Drugs for acid related disorders

Antacids

Calcium compounds

CALCIUM CARBONATE with GLYCINE

Note

For patients with chronic renal failure.

4055K	Tablet 420 mg-180 mg	200	5	..	*23.28	5.80	Titralac	MM
-------	----------------------	-----	---	----	--------	------	----------	----

Combinations and complexes of aluminium, calcium and magnesium compounds

ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE and SIMETHICONE

4118R	Oral suspension 400 mg-400 mg-30 mg per 5 mL, 500 mL	2	5	..	*22.74	5.80	Mylanta Double Strength	JT
4453J	Tablet 400 mg-400 mg-40 mg	200	5	..	*46.22	5.80	Mylanta Double Strength	JT

Drugs for functional gastrointestinal disorders

Drugs for functional bowel disorders

Synthetic anticholinergics, esters with tertiary amino group

MEBEVERINE HYDROCHLORIDE

4328T	Tablet 135 mg	90	27.01	5.80	^a Colese	AF
				..	32.19	5.80	^a Colofac	AB

Belladonna and derivatives, plain

Belladonna alkaloids semisynthetic, quaternary ammonium compounds

HYOSCINE BUTYLBROMIDE

4279F	Injection 20 mg in 1 mL	5	24.31	5.80	Buscopan	BY
-------	-------------------------	---	----	----	-------	------	----------	----

Laxatives

Laxatives

Softeners, emollients

DOCUSATE SODIUM

4200C	Tablet 50 mg	100	2	..	14.41	5.80	Coloxyl 50	FM
-------	--------------	-----	---	----	-------	------	------------	----

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Contact laxatives								
DOCUSATE SODIUM with SENNA								
4028B	Tablet 50 mg-8 mg	100	2	..	14.51	5.80	Soflax	GM
4198Y	Tablet 50 mg-8 mg	90	2	..	16.80	5.80	Coloxyl with Senna	FM
SENNA STANDARDISED								
4455L	Tablet 7.5 mg	100	1	..	13.96	5.80	Senokot	RC
Bulk producers								
ISPAGHULA HUSK								
4285M	Sachets 3.5 g, 30	£1	1	..	17.74	5.80	Fybogel	RC
PSYLLIUM HYDROPHILIC MUCILLOID								
4419N	Oral powder (orange-flavoured, sugar-free) 283 g	£1	1	..	21.77	5.80	Metamucil Orange Smooth	PY
4422R	Oral powder (non-flavoured) 336 g	£1	1	..	21.77	5.80	Fibre Health Natural Granular	PP
							Metamucil Natural Granular	PY
PSYLLIUM HYDROPHILIC MUCILLOID with HIGH AMYLOSE MAIZE STARCH								
4416K	Oral powder 2.7 g-0.7 g per 7.5 g, 440 g	£1	1	..	21.37	5.80	Nucolox	QA
STERCULIA with FRANGULA BARK								
4558X	Granules 620 mg-80 mg per g (62%-8%), 500 g	£1	1	..	26.47	5.80	Normacol Plus	NE
Enemas								
SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE								
4462W	Enemas 3.125 g-450 mg-45 mg in 5 mL, 4	£1	12.20	5.80	Micolette Microlax	AE JT
Other laxatives								
GLYCEROL								
<u>Restricted benefit</u>								
Short-term use when oral laxative therapy has failed or is inappropriate.								
4246L	Suppositories 2.8 g (for adults), 12	3	*20.50	5.80	Petrus Pharmaceuticals Pty Ltd	PP

Antibesity preparations, excl. diet products

Antibesity preparations, excl. diet products

Peripherally acting antiobesity products

ORLISTAT

Authority required

For the treatment of obese patients.

Total treatment will not exceed 12 months from initial application.

Patients are eligible for 1 continuous treatment in a lifetime.

The patient must be receiving, or enrolled to receive, professional dietetic and weight management advice (where this is available).

Initial treatment for patients who meet the following criteria to qualify:

(a) Body Mass Index (BMI) greater than or equal to 35 with no known co-morbidities; or

(b) BMI greater than or equal to 30 with 1 or more of the following co-morbidities:

(i) diabetes;

(ii) ischaemic heart disease;

Alimentary tract and metabolism

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	(iii) psychiatric conditions; (iv) hypertension. The prescriber must provide the following: (a) initial body weight; and (b) BMI.						
	Continuing treatment for patients who have previously been issued with an authority prescription for orlistat. After 3 months and up to 6 months following commencement of orlistat treatment, patient's initial body weight must have been reduced by 2.5 kg or 2.5% (whichever is the lesser).						
	Continuing treatment for patients who have previously been issued with an authority prescription for orlistat. After 6 months and up to 12 months following commencement of orlistat treatment, patient's initial body weight must have been reduced by 5 kg or 5% (whichever is the lesser).						
	Note The patient should be ideally enrolled in an exercise program and be receiving supplemental vitamins.						
4570M	Capsule 120 mg	84	2	..	140.26	5.80	Xenical RO

Vitamins

Vitamin B₁, plain and in combination with vitamin B₆ and vitamin B₁₂

Vitamin B₁, plain

	THIAMINE HYDROCHLORIDE							
4043T	Tablet 100 mg	100	2	..	11.60	5.80	Betamin	SW

Vitamin B-complex, incl. combinations

Vitamin B-complex, plain

	VITAMIN B GROUP COMPLEX							
4493L	Oral liquid 200 mL	±1	2	..	13.44	5.80	Accomin Adult Tonic	PF

Mineral supplements

Calcium

Calcium

CALCIUM

Restricted benefit

Hypocalcaemia;

Osteoporosis;

Proven calcium malabsorption.

4082W	Tablet 600 mg (as carbonate)	120	1	..	14.41	5.80	CAL-600	PP
4333C	Tablet (chewable) 500 mg (as carbonate)	120	1	..	*18.54	5.80	Cal-Sup	IA

CALCIUM

Restricted benefit

Hyperphosphataemia in chronic renal failure.

4094L	Tablet (chewable) 500 mg (as carbonate)	240	1	..	*30.56	5.80	Cal-Sup	IA
4142B	Tablet 600 mg (as carbonate)	240	1	..	*22.30	5.80	CAL-600	PP

Other mineral supplements

Magnesium

MAGNESIUM

Restricted benefit

Patients with documented hypomagnesaemia.

4321K	Tablet 37.4 mg (as aspartate dihydrate)	50	13.80	5.80	Mag-Sup	PP
				..	14.49	5.80	Magmin	BB

Blood and blood forming organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Blood and blood forming organs

Antithrombotic agents

Antithrombotic agents

Platelet aggregation inhibitors excl. heparin

ASPIRIN

4076M	Tablet 100 mg (with glycine)	90	1	..	15.77	5.80	Cardiprin 100	RC
-------	------------------------------	----	---	----	-------	------	---------------	----

ASPIRIN

Note

The enteric coated preparations are for patients with a significant risk of gastrointestinal bleeding.

4077N	Tablet 100 mg (enteric coated)	84	1	..	13.81	5.80	Cartia	GC
4078P	Capsule 100 mg (containing enteric coated pellets)	84	1	..	14.72	5.80	Astrix	YN

CLOPIDOGREL

Authority required

For use in patients pre- and post-angioplasty.

4179Y	Tablet 75 mg (as hydrogen sulfate)	28	3	..	50.15	5.80	Iscover ^a Plavix ^a	BQ SW
-------	------------------------------------	----	---	----	-------	------	---	----------

Blood substitutes and perfusion solutions

Irrigating solutions

Salt solutions

SODIUM CHLORIDE

4460R	Irrigation solution 9 mg per mL (0.9%), 500 mL	±1	2	..	10.43	5.80	Baxter Healthcare Pty Ltd	BX
4461T	Irrigation solution 9 mg per mL (0.9%), 1 L	±1	2	..	10.75	5.80	Baxter Healthcare Pty Ltd	BX

Cardiovascular system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Cardiovascular system

Vasoprotectives

Agents for treatment of hemorrhoids and anal fissures for topical use

Corticosteroids

HYDROCORTISONE with CINCHOCAINE HYDROCHLORIDE

Caution

Long-term use may lead to skin atrophy.

4036K	Ointment 5 mg-5 mg per g (0.5%-0.5%), 30 g	‡1	22.63	5.80	Proctosedyl	SW
4038M	Suppositories 5 mg-5 mg, 12	‡1	21.34	5.80	Proctosedyl	SW

Other agents for treatment of hemorrhoids and anal fissures for topical use

ZINC OXIDE

4039N	Compound ointment 50 g	‡1	1	..	14.54	5.80	Anusol	JT
4040P	Compound suppositories, 12	‡1	1	..	13.45	5.80	Anusol	JT

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Dermatologicals

Antifungals for dermatological use

Antifungals for topical use

Antibiotics

NYSTATIN								
4001N	Cream 100,000 units per g, 15 g	‡1	1	..	12.59	5.80	Mycostatin	FM

Imidazole and triazole derivatives

CLOTRIMAZOLE								
4004R	Cream 10 mg per g (1%), 20 g	‡1	1	..	8.94	5.80	Clonea	AF

KETOCONAZOLE

Restricted benefit

Severe seborrhoeic dermatitis.

4007X	Shampoo 20 mg per g (2%), 100 mL	‡1	19.47	5.80	Sebizole	GM
4008Y	Shampoo 20 mg per g (2%), 60 mL	‡1	18.41	5.80	Nizoral 2%	JT

MICONAZOLE

4341L	Tincture 20 mg per mL (2%), 30 mL	‡1	1	..	19.57	5.80	Daktarin	JT
-------	-----------------------------------	----	---	----	-------	------	----------	----

MICONAZOLE NITRATE

3400Y	Cream 40 g (2% miconazole)	‡1	1	..	13.78	5.80	Resolve Thrush	EO
4454K	Cream 20 mg per g (2%), 30 g	‡1	1	..	14.89	5.80	Daktarin	JT

Other antifungals for topical use

AMOROLFINE HYDROCHLORIDE

Restricted benefit

Onychomycosis.

4010C	Nail treatment kit containing nail lacquer 50 mg (base) per mL (5%), 5 mL, 60 isopropyl alcohol cleaning pads, 10 spatulas and 30 nail files	‡1	1	..	96.24	5.80	Loceryl	GA
-------	--	----	---	----	-------	------	---------	----

CICLOPIROX OLAMINE

Restricted benefit

Severe seborrhoeic dermatitis.

4106D	Shampoo 15 mg per g (1.5%), 60 mL	‡1	16.66	5.80	Stieprox Liquid	GK
-------	-----------------------------------	----	----	----	-------	------	-----------------	----

TERBINAFINE

Restricted benefit

Tinea pedis.

4463X	Gel 10 mg per g (1%), 15 g	‡1	23.45	5.80	Lamisil DermGel	NC
4473K	Cream containing terbinafine hydrochloride 10 mg per g (1%), 15 g	‡1	1	..	21.99	5.80	Lamisil	NC

TOLNAFTATE

4481W	Spray aerosol 0.7 mg per g (0.07%), 100 g	‡1	15.19	5.80	Tinaderm	MK
-------	---	----	----	----	-------	------	----------	----

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Antifungals for systemic use <i>Antifungals for systemic use</i>								
TERBINAFINE <u>Authority required</u> Onychomycosis due to dermatophyte infection proven by microscopy or culture and confirmed by an approved pathology provider.								
4011D	Tablet 250 mg (as hydrochloride)	42	1	..	69.30	5.80 ^a	Lamisil (Novartis Pharmaceuticals Australia Pty Limited) ^a Tamsil ^a Terbinafine-DP ^a Terbinafine Sandoz ^a Tinasil	NV QA GN SZ AF

Emollients and protectives

Emollients and protectives

Silicone products

DIMETHICONE with GLYCEROL

Restricted benefit

For colostomy and ileostomy use;

For use by paraplegic and quadriplegic patients;

For use with surgical appliances.

4551M	Cream 150 mg-20 mg per g (15%-2%), 500 g	‡1	26.51	5.80	Silic 15	EO
4556T	Cream 150 mg-20 mg per g (15%-2%), 75 g	‡1	12.63	5.80	Silic 15	EO

Soft paraffin and fat products

WOOL ALCOHOLS

4041Q	Ointment 100 g	‡1	1	..	14.28	5.80	Eucerin	BE
-------	----------------	----	---	----	-------	------	---------	----

Carbamide products

UREA

4042R	Cream 100 mg per g (10%), 100 g	‡1	2	..	12.29	5.80	Aquacare H.P.	AG
				..	12.55	5.80	Urederm	VT
				..	12.87	5.80	Calmurid	OL

Other emollients and protectives

CARMELLOSE SODIUM with PECTIN and GELATIN

4518T	Paste 167 mg-167 mg-167 mg per g (16.7%-16.7%- 16.7%), 5 g	‡1	11.95	5.80	Orabase	QA
-------	--	----	----	----	-------	------	---------	----

SKIN EMOLLIENT

4107E	Lotion 500 mL	‡1	2	..	17.45	5.80	Alpha Keri Lotion	MT
4122Y	Bath oil 500 mL	‡1	2	..	17.45	5.80	Alpha Keri Bath Oil	MT
				..	19.86	5.80	QV Bath Oil	EO
				..	19.95	5.80	Hamilton Skin Therapy Oil	VT

Protectives against UV-radiation

Protectives against UV-radiation for topical use

SUNSCREENS

4307Q	Cream 75 g	‡1	2	..	17.12	5.80	Sunsense Sensitive	EO
-------	------------	----	---	----	-------	------	--------------------	----

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
4543D	Solid stick 4.5 g	¥1	2	..	12.40	5.80	SPF 30+ Hamilton Solastick	VT
4544E	Cream 100 g	¥1	2	..	16.17	5.80	Hamilton Sunscreen Family Sunscreen Cream SPF 15	VT
4546G	Lotion (non-alcoholic) 125 mL	¥1	2	..	16.08	5.80	Aquasun Lotion SPF 18	PF
				..	16.17	5.80	Hamilton Sunscreen Family Sunscreen Milk SPF 15	VT
				..	17.09	5.80	SunSense Ultra SPF 30+	EO

Antipruritics, incl. antihistamines, anesthetics, etc.

Antipruritics, incl. antihistamines, anesthetics, etc.

Anesthetics for topical use

LIGNOCAINE HYDROCHLORIDE with CARBOXYMETHYLCELLULOSE

4308R	Mucilage 20 mg-25 mg per mL (2%-2.5%), 200 mL	¥1	79.45	5.80	Xylocaine Viscous	AP
-------	--	----	----	----	-------	------	-------------------	----

Other antipruritics

PINE TAR with TRIETHANOLAMINE LAURYL SULFATE

Note

For patients who have failed to respond to simple moisturising agents.

4408B	Solution 23 mg-60 mg per mL (2.3%-6%), 500 mL	¥1	2	..	23.02	5.80	Pinetarsol	EO
-------	---	----	---	----	-------	------	------------	----

Antipsoriatics

Antipsoriatics for topical use

Tars

ALLANTOIN with SULFUR, PHENOL, COAL TAR SOLUTION and MENTHOL

4505D	Gel 25 mg-5 mg-5 mg-0.05 mL-7.5 mg per g (2.5%-0.5%-0.5%-5%-0.75%), 30 g	¥1	2	..	16.12	5.80	Egopsoryl-TA	EO
-------	---	----	---	----	-------	------	--------------	----

Antibiotics and chemotherapeutics for dermatological use

Antibiotics for topical use

Other antibiotics for topical use

MUPIROCIN

Restricted benefit

For the topical treatment of secondarily infected traumatic skin lesions.

4348W	Cream 20 mg (as calcium) per g (2%), 15 g	¥1	16.38	5.80	Bactroban	GK
4350Y	Ointment 20 mg per g (2%), 15 g	¥1	16.38	5.80	Bactroban	GK

Chemotherapeutics for topical use

Antivirals

PODOPHYLLOTOXIN

Authority required

For the treatment of ano-genital warts.

4390C	Cream 1.5 mg per g (0.15%), 5 g	¥1	52.76	5.80	Wartec Cream	GK
-------	---------------------------------	----	----	----	-------	------	--------------	----

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
4566H	Paint 5 mg per mL (0.5%), 3.5 mL (with 30 swabs)	¥1	39.85	5.80	Condyline Paint	NQ

Corticosteroids, dermatological preparations

Corticosteroids, plain

Corticosteroids, potent (group III)

BETAMETHASONE VALERATE

4131K	Cream 1 mg (base) per g (0.1%), 30 g	¥1	2	..	22.53	5.80	Betnovate	QA
4132L	Ointment 1 mg (base) per g (0.1%), 30 g	¥1	2	..	22.53	5.80	Betnovate	QA

MOMETASONE FUROATE

Note

Application to large areas of skin for longer than four weeks is not recommended.

4342M	Cream 1 mg per g (0.1%), 50 g	¥1	30.88	5.80	Elocon	MK
4343N	Ointment 1 mg per g (0.1%), 50 g	¥1	30.88	5.80	Elocon	MK

Corticosteroids, combinations with antibiotics

Corticosteroids, moderately potent, combinations with antibiotics

TRIAMCINOLONE ACETONIDE with NEOMYCIN SULFATE, GRAMICIDIN and NYSTATIN

Caution

For the short-term treatment of localised infective eczema only.

4482X	Ointment 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g (0.1%-0.25% (base)-0.025%- 100,000 units in 1 g), 15 g	¥1	19.19	5.80	Kenacomb	QA
-------	---	----	----	----	-------	------	----------	----

Antiseptics and disinfectants

Antiseptics and disinfectants

Iodine products

POVIDONE-IODINE

4411E	Solution 100 mg per mL (10%), 100 mL	¥1	22.21	5.80	Betadine Antiseptic Liquid	SW
-------	--------------------------------------	----	----	----	-------	------	----------------------------	----

Other dermatological preparations

Other dermatological preparations

Antihidrotics

DIPHEMANIL METHYLSULFATE

4191N	Dusting powder 20 mg per g (2%), 50 g	¥1	1	..	17.84	5.80	Prantal	MK
-------	---------------------------------------	----	---	----	-------	------	---------	----

Medicated shampoos

PINE TAR with CADE OIL, COAL TAR SOLUTION, ARACHIS OIL EXTRACT OF CRUDE COAL TAR and OLEYL ALCOHOL

4405W	Scalp cleanser 3 mg-3 mg-1 mg-3 mg-10 mg per mL (0.3%-0.3%-0.1%-0.3%-1%), 300 mL	¥1	2	..	21.13	5.80	Polytar	GK
-------	--	----	---	----	-------	------	---------	----

SALICYLIC ACID with COAL TAR SOLUTION

4560B	Scalp cleanser 20 mg-50 mg per mL (2%-5%), 200 mL	¥1	2	..	20.48	5.80	Ionil-T	GA
-------	---	----	---	----	-------	------	---------	----

SALICYLIC ACID with COAL TAR SOLUTION and PINE TAR

4447C	Scalp cleanser 20 mg-10 mg-10 mg per mL (2%-1%-1%), 250 mL	¥1	2	..	18.94	5.80	Sebitar	EO
-------	--	----	---	----	-------	------	---------	----

Dermatologicals

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
SELENIUM SULFIDE								
4452H	Shampoo 25 mg per mL (2.5%), 125 mL	‡1	14.24	5.80	Selsun	DQ
Wart and anti-corn preparations								
SALICYLIC ACID								
4389B	Gel 270 mg per g (27%), 15 g	‡1	19.64	5.80	Duofilm Gel	GK
SALICYLIC ACID with LACTIC ACID								
4386W	Liquid 167 mg-167 mg per g (16.7%-16.7%), 15 mL	‡1	18.25	5.80	Duofilm Solution	GK
Other dermatologicals								
ALLANTOIN with GLYCEROL and ICHTHAMMOL								
Note								
For patients who have failed to respond to simple moisturising agents.								
4280G	Ointment 5 mg-10 mg-10 mg per g (0.5%-1%- 1%), 50 g	‡1	2	..	18.20	5.80	Egoderm Ointment	EO
4281H	Cream 5 mg-10 mg-10 mg per g (0.5%-1%-1%), 50 g	‡1	2	..	18.20	5.80	Egoderm Cream	EO
CATIONIC CONDITIONER with PANTHENOL								
Note								
To be used in conjunction with the scalp cleanser salicylic acid with coal tar solution and pine tar (code 4447C).								
4510J	Cream 200 g	‡1	2	..	14.35	5.80	SebiRinse	EO
DICLOFENAC SODIUM								
Authority required								
For the management of actinic keratoses in patients where other standard treatments are inappropriate, and topical drug therapy is required as field treatment for clinically visible and subclinical lesions.								
Note								
Maximum quantity of four tubes (original + 3 repeats) in 12 months.								
4046Y	Gel 30 mg per g (3%), 25 g	‡1	3	..	58.29	5.80	Solaraze 3% Gel	CS
IMIQUIMOD								
Authority required								
Primary treatment of histopathologically confirmed superficial basal cell carcinoma where other standard treatments are inappropriate and topical drug therapy is required.								
4559Y	Cream 50 mg per g (5%), 250 mg single use sachets, 12	1	1	..	160.05	5.80	Aldara	IA
<hr/>								
IMIQUIMOD								
Authority required								
Treatment of solar keratosis on the face and scalp in patients where other standard treatments are inappropriate and topical drug therapy is required as field treatment for clinically visible and subclinical lesions.								
4134N	Cream 50 mg per g (5%), 250 mg single use sachets, 12	1	1	..	160.05	5.80	Aldara	IA
SKIN CLEANSER								
4549K	Lotion 500 mL	‡1	2	..	20.84	5.80	Hamilton Skin Therapy Wash	VT
ZINC OXIDE with STARCH and CHLORPHENESIN								
4497Q	Dusting powder 100 g	‡1	1	..	12.36	5.80	Z.S.C.	QA

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Genito urinary system and sex hormones

Gynecological antiinfectives and antiseptics

Antiinfectives and antiseptics, excl. comb. with corticosteroids

Antibiotics

NYSTATIN								
4013F	Vaginal cream 100,000 units per dose, 15 doses, 75 g	‡1	1	..	13.89	5.80	Nilstat	QA

Imidazole derivatives

CLOTRIMAZOLE								
4016J	Vaginal cream 50 mg per 5 g (1%), 35 g	‡1	15.18	5.80	APO-Clotrimazole 6 Day Cream	TX
4017K	Vaginal cream 100 mg per 5 g (2%), 20 g	‡1	15.18	5.80	APO-Clotrimazole 3 Day Cream	TX

Other gynecologicals

Other gynecologicals

RICINOLEIC ACID with ACETIC ACID and HYDROXYQUINOLINE SULFATE								
4434J	Vaginal jelly 7 mg-9.4 mg-250 micrograms per g (0.7%-0.94%-0.025%), 100 g	‡1	33.00	5.80	Aci-Jel	CU

Urologicals

Other urologicals, incl. antispasmodics

Drugs used in erectile dysfunction

ALPROSTADIL

Authority required

Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.

Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats.

4579B	Intracavernosal injection 10 micrograms with diluent in single use syringe	6	3	..	*82.72	5.80	Caverject Impulse	PF
4580C	Intracavernosal injection 20 micrograms with diluent in single use syringe	6	3	..	*103.72	5.80	Caverject Impulse	PF

SILDENAFIL CITRATE

Authority required

Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.

Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats.

4584G	Tablet 25 mg (base)	4	5	..	60.78	5.80	Viagra	PF
4585H	Tablet 50 mg (base)	4	5	..	75.59	5.80	Viagra	PF
4586J	Tablet 100 mg (base)	4	5	..	81.22	5.80	Viagra	PF

TADALAFIL

Note

Any queries concerning the arrangements to prescribe tadalafil may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe PAH agents should be forwarded to:

Medicare Australia
Prior Written Approval of Specialised Drugs

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Reply Paid 9826
GPO Box 9826
HOBART TAS 7001;

Note

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of agents for primary pulmonary hypertension and pulmonary arterial hypertension. Where the term PAH agents appears in the following notes and restrictions it refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan and tadalafil.

Patients are eligible for PBS-subsidised treatment with only 1 of the above PAH agents at any 1 time. Eligible patients may only swap between PAH agents if they have not failed prior PBS-subsidised treatment with that agent.

PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of that predicted.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment of patients with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
 - drug-induced pulmonary arterial hypertension, in patients with disease of WHO Functional Class III and IV severity; AND
- (c) epoprostenol sodium, of:
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity and who have failed to respond to prior PBS-subsidised treatment with an alternate PAH agent; AND
 - primary pulmonary hypertension, or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class IV severity; AND
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
- (e) ambrisentan, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
- (f) tadalafil, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

From 1 April 2012, patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment with 1 of these 6 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.

2. Definition of WHO Functional Class III or IV disease severity.

(a) WHO Functional Class III disease severity is defined as follows:

Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.

(b) WHO Functional Class IV disease severity is defined as follows:

Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

3. Designated hospitals.

Refer to the Medicare Australia website at www.medicareaustralia.gov.au for a list of designated hospitals.

4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

(a) Initiation of treatment.

The first written application for PBS-subsidised treatment with the first PAH agent should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.

Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments;
- (2) RHC composite assessment plus 6MWT;
- (3) RHC composite assessment only.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:

- (1) ECHO composite assessment plus 6MWT;
- (2) ECHO composite assessment only.

Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application.

(b) Continuation of treatment.

The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:

- (1) RHC plus ECHO composite assessments plus 6MWT;
- (2) RHC plus ECHO composite assessments;
- (3) RHC composite assessment plus 6MWT;
- (4) ECHO composite assessment plus 6MWT;
- (5) RHC composite assessment only;
- (6) ECHO composite assessment only.

The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.

Note

5. Definition of response to a PAH agent or prior vasodilator treatment.

For patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.

6. Authority approval requirements.

(a) Initiation of PBS-subsidised treatment with a PAH agent, where the patient has not received prior PBS-subsidised treatment with that agent.

All applications for initial treatment must be made in writing, must include a completed authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.

Bosentan only:

Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.

(b) Continuation of treatment.

Written applications for continuing treatment for patients who have demonstrated an adequate response to their current treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6

Genito urinary system and sex hormones

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Drugs used in benign prostatic hypertrophy								
<i>Alpha-adrenoreceptor antagonists</i>								
ALFUZOSIN HYDROCHLORIDE								
<u>Authority required</u>								
Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated.								
4277D	Tablet 10 mg	30	5	..	63.46	5.80	Xatral SR	SW
TAMSULOSIN HYDROCHLORIDE								
<u>Authority required</u>								
Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated.								
4070F	Tablet 400 micrograms (prolonged release)	30	5	..	63.46	5.80	Flomaxtra	CS
TERAZOSIN HYDROCHLORIDE								
<u>Authority required</u>								
Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated.								
4396J	Starter pack containing 7 tablets 1 mg and 7 tablets 2 mg	1	20.15	5.80	Hytrin	AB
4397K	Tablet 2 mg	28	5	..	41.79	5.80	Hytrin	AB
4398L	Tablet 5 mg	28	5	..	58.29	5.80	Hytrin	AB
4399M	Tablet 10 mg	28	5	..	86.16	5.80	Hytrin	AB
<i>Testosterone-5-alpha reductase inhibitors</i>								
FINASTERIDE								
<u>Authority required</u>								
Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated.								
4233T	Tablet 5 mg	30	5	..	102.22	5.80 ^a	Finasta	SZ
				..	111.79	5.80 ^a	Proscar	MK
4303L	Tablet 5 mg	28	5	..	91.37	5.80	Finpro	RZ

Antiinfectives for systemic use

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Antiinfectives for systemic use

Antibacterials for systemic use

Macrolides, lincosamides and streptogramins

Macrolides

AZITHROMYCIN

Restricted benefit

Upper and lower respiratory tract infections.

4115N	Tablet 500 mg (as dihydrate)	3	31.61	5.80	Zedd 500 Zithromax	QA PF
-------	------------------------------	---	----	----	-------	------	-----------------------	----------

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net	Brand Name and Manufacturer
					\$	\$	

Antineoplastic and immunomodulating agents

Antineoplastic agents

Antimetabolites

Pyrimidine analogues

FLUOROURACIL							
4222F	Cream 50 mg per g (5%), 20 g	‡1	55.41	5.80	Efudix VT

Immunosuppressants

Immunosuppressants

Tumor necrosis factor alpha (TNF-alpha) inhibitors

INFLIXIMAB

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) on 1800 552 580.

Written applications for authority to prescribe infliximab should be forwarded to:

Reply Paid 9998
Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC)
Department of Veterans' Affairs
GPO Box 9998
BRISBANE QLD 4001.

Authority required

Initial treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Initial treatment may be prescribed by rheumatologists or consultant physicians for the reduction of signs and symptoms and prevention of structural joint damage in adult patients with active rheumatoid arthritis who satisfy all of the following criteria:

- (1) (a) Proven raised erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP); and
- (1) (b) Proven erosive rheumatoid arthritis without end-stage disease;
- (2) Failure of an adequate trial of methotrexate and 2 other disease modifying anti-rheumatic drugs (such as sulfasalazine, hydroxychloroquine, leflunomide or cyclosporin) — unless these drugs were contraindicated or intolerance had developed;
- (3) No history of active tuberculosis requiring treatment in the last 3 years;
- (4) No history of opportunistic infection in the last 2 months;
- (5) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form).

Authority required

Continuing treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Continuing treatment may be prescribed by rheumatologists or consultant physicians, following initial therapy of 3 doses, in patients who satisfy the following criteria:

- (1) There is improvement in ESR and/or CRP; and
- (2) An ACR20 (American College of Rheumatology) response is achieved by 14 weeks after the commencement of therapy.

Applications for authorisation must be in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form).

Note

Any queries concerning the arrangements to prescribe infliximab may be directed to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) on 1800 552 580.

Written applications for authority to prescribe infliximab should be forwarded to:

Reply Paid 9998
Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC)
Department of Veterans' Affairs

Antineoplastic and immunomodulating agents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer
					for Max. Qty \$	Recordable Value for Safety Net \$	
	GPO Box 9998 BRISBANE QLD 4001.						
4284L	Powder for I.V. infusion 100 mg	1	2	..	847.08	5.80	Remicade JC

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Musculo-skeletal system

Antiinflammatory and antirheumatic products

Antiinflammatory and antirheumatic products, non-steroids

Acetic acid derivatives and related substances

DICLOFENAC SODIUM with MISOPROSTOL

Authority required

Patients requiring an NSAID in whom a risk of upper gastrointestinal complications is high or with a history of peptic ulcer disease.

4190M	Tablet 50 mg-200 micrograms	60	2	..	37.88	5.80	Arthrotec 50	PF
-------	-----------------------------	----	---	----	-------	------	--------------	----

Topical products for joint and muscular pain

Topical products for joint and muscular pain

Preparations with salicylic acid derivatives

METHYL SALICYLATE

4022Q	Compound cream APF, 100 g	£1	1	..	14.12	5.80	Gold Cross	BI
4023R	Ointment BP, 100 g	£1	1	..	12.27	5.80	Gold Cross	BI
4026X	Liniment APF, 100 mL	£1	1	..	10.04	5.80	Gold Cross	BI

Drugs for treatment of bone diseases

Drugs affecting bone structure and mineralization

Bisphosphonates

RISEDRONATE SODIUM

Authority required

For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0).

4443W	Tablet 5 mg	28	5	..	46.65	5.80	Actonel	SW
4444X	Tablet 35 mg	4	5	..	46.65	5.80	^a Actonel Once-a-Week	SW
							^a APO-Risedronate	TX
							^a Chem mart Risedronate	CH
							^a Risedro once a week	QA
							^a Terry White Chemists Risedronate	TW

Bisphosphonates, combinations

RISEDRONATE SODIUM and CALCIUM CARBONATE

Authority required

For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0).

4059P	Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)	£1	5	..	46.65	5.80	Actonel Combi	SW
-------	---	----	---	----	-------	------	---------------	----

RISEDRONATE SODIUM and CALCIUM CARBONATE with COLECALCIFEROL

Authority required

For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day.

Musculo-skeletal system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty	Safety Net	
					\$	\$	
	Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density T-score of less than -1.0).						
4380M	Pack containing 4 tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g (equivalent to 1 g calcium) with colecalciferol 22 micrograms	1	5	..	46.65	5.80	Actonel Combi D SW

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Nervous system

Analgesics

Opioids

Natural opium alkaloids

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Authorities for increased maximum quantities and/or repeats will be granted only for

(i) chronic severe disabling pain associated with proven malignant neoplasia; or

(ii) chronic severe disabling pain where treatment has been initiated by a specialist with appropriate expertise in pain management.

4349X	Tablet 200 mg (controlled release)	28	121.96	5.80	MS Contin	MF
-------	------------------------------------	----	----	----	--------	------	-----------	----

Other analgesics and antipyretics

Salicylic acid and derivatives

CODEINE PHOSPHATE with ASPIRIN

4061R	Tablet soluble 8 mg-300 mg	50	2	..	13.67	5.80	Aspalgin	FM
4286N	Tablet 8 mg-300 mg	40	2	..	14.28	5.80	Aspalgin 40	QA

Anilides

CODEINE PHOSPHATE with PARACETAMOL

4170L	Tablet 15 mg-500 mg	20	2	..	9.83	5.80	Prodeine 15	SW
4171M	Tablet 8 mg-500 mg	50	2	..	12.96	5.80	Codalgin	FM
4275B	Tablet 8 mg-500 mg	40	2	..	10.79	5.80	Panamax Co. 40	SW

Other analgesics and antipyretics

GABAPENTIN

Authority required

To be approved for the treatment of refractory neuropathic pain not controlled by other drugs.

4591P	Capsule 100 mg	100	5	..	18.28	5.80	^a Gabatine 100	QA
							^a Nupentin 100	AF
							^a Neurontin	PF
4592Q	Capsule 300 mg	100	5	..	45.19	5.80	^a DBL Gabapentin	HH
							^a Gabatine 300	QA
							^a Gantin	GN
							^a GenRx Gabapentin	GX
							^a Nupentin 300	AF
4593R	Capsule 400 mg	100	5	..	57.78	5.80	^a Neurontin	PF
							^a DBL Gabapentin	HH
							^a Gabatine 400	QA
							^a Gantin	GN
							^a GenRx Gabapentin	GX
4594T	Tablet 600 mg	100	5	..	59.73	5.80	^a Nupentin 400	AF
							^a Neurontin	PF
							^a Gabatine 600	QA
				..	89.85	5.80	Neurontin	PF

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
4595W	Tablet 800 mg	100	5	..	115.00	5.80 ^a	Gabatine 800	QA
				..	116.95	5.80 ^a	Gantin	GN
				..		5.80 ^a	Neurontin	PF

PREGABALIN

Authority required

For the treatment of refractory neuropathic pain not controlled by other drugs.

4320J	Capsule 25 mg	56	5	..	42.75	5.80	Lyrica	PF
4322L	Capsule 75 mg	56	5	..	85.06	5.80	Lyrica	PF
4323M	Capsule 150 mg	56	5	..	124.34	5.80	Lyrica	PF
4324N	Capsule 300 mg	56	5	..	183.24	5.80	Lyrica	PF

Psycholeptics

Anxiolytics

Benzodiazepine derivatives

BROMAZEPAM

Authority required

Patients with terminal disease;

Patients with refractory phobic or anxiety states.

Note

For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.

4150K	Tablet 3 mg	60	*29.58	5.80	Lexotan	RO
4151L	Tablet 6 mg	60	*36.20	5.80	Lexotan	RO

Azaspirodecanedione derivatives

BUSPIRONE HYDROCHLORIDE

Authority required

For the short-term treatment of anxiety.

4144D	Tablet 5 mg	50	38.09	5.80	Buspar	QA
4145E	Tablet 10 mg	50	54.94	5.80	Buspar	QA

Hypnotics and sedatives

Benzodiazepine derivatives

FLUNITRAZEPAM

Authority required

Patients with terminal disease;

Patients with refractory phobic or anxiety states.

Note

For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.

4216X	Tablet 1 mg	30	13.83	5.80	Hypnodorm	AF
-------	-------------	----	----	----	-------	------	-----------	----

Benzodiazepine related drugs

ZOPICLONE

Restricted benefit

For the short-term treatment of insomnia.

4522B	Tablet 7.5 mg	30	21.86	5.80 ^a	Imrest	AF
				..	25.02	5.80 ^a	Imovane	SW

Nervous system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	
Other nervous system drugs							

Drugs used in addictive disorders

Drugs used in nicotine dependence

NICOTINE

Authority required

Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program.

Note

Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.

4571N	Transdermal patches releasing approximately 7 mg per 24 hours, 7	2	*51.48	5.80	QuitX	AF
4572P	Transdermal patches releasing approximately 14 mg per 24 hours, 7	2	*54.66	5.80	QuitX	AF
				..	*68.84	5.80	Nicabate CQ 14	GC
4573Q	Transdermal patches releasing approximately 21 mg per 24 hours, 7	2	2	..	*57.78	5.80	QuitX	AF
				..	*68.84	5.80	Nicabate CQ 21	GC
4576W	Transdermal patches releasing approximately 5 mg per 16 hours, 7	2	*50.92	5.80	Nicorette Patch	JT
4577X	Transdermal patches releasing approximately 10 mg per 16 hours, 7	2	*54.88	5.80	Nicorette Patch	JT
4578Y	Transdermal patches releasing approximately 15 mg per 16 hours, 7	2	2	..	*60.06	5.80	Nicorette Patch	JT

Antiparasitic products, insecticides and repellents

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer
					for Max. Qty \$	Recordable Value for Safety Net \$	

Antiparasitic products, insecticides and repellents

Anthelmintics

Antinematodal agents
Benzimidazole derivatives

MEBENDAZOLE							
4325P	Tablet 100 mg	6	15.02	5.80	Vermox BI

Respiratory system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Respiratory system

Nasal preparations

Decongestants and other nasal preparations for topical use

Sympathomimetics, plain

OXYMETAZOLINE HYDROCHLORIDE								
4378K	Nasal spray 500 micrograms per mL (0.05%), 15 mL	‡1	17.25	5.80	Drixine	MK
4379L	Nasal spray 500 micrograms per mL (0.05%), 18 mL	‡1	16.86	5.80	Logicin Rapid Relief	QA

Antiallergic agents, excl. corticosteroids

LEVOCABASTINE HYDROCHLORIDE								
4311X	Nasal spray 500 micrograms per mL (0.05%), 10 mL (100 doses)	‡1	2	..	18.34	5.80	Livostin	JT
SODIUM CROMOGLYCATE								
4468E	Nasal spray metered dose pump 20 mg per mL (2%), 26 mL	‡1	5	..	23.01	5.80	Rynacrom	SW

Corticosteroids

BUDESONIDE

Restricted benefit

Severe intractable rhinitis.

4092J	Aqueous nasal spray (pump pack) 64 micrograms per dose (120 doses)	‡1	31.83	5.80	Budamax Aqueous	PM
-------	---	----	----	----	-------	------	-----------------	----

Other nasal preparations

IPRATROPIUM BROMIDE

Restricted benefit

Severe intractable rhinorrhoea, associated with perennial rhinitis, unresponsive to insufflated nasal steroids.

4089F	Aqueous nasal spray (pump pack) 21 micrograms (anhydrous) per dose (180 doses)	‡1	5	..	23.69	5.80	Atrovent Nasal Aqueous	BY
4090G	Aqueous nasal spray (pump pack) 42 micrograms (anhydrous) per dose (180 doses)	‡1	5	..	30.57	5.80	Atrovent Nasal Forte	BY

Nasal decongestants for systemic use

Sympathomimetics

PSEUDOEPHEDRINE HYDROCHLORIDE								
4029C	Tablet 60 mg	12	11.12	5.80	Logicin Sinus	QA

Cough and cold preparations

Expectorants, excl. combinations with cough suppressants

Expectorants

SENEGA and AMMONIA								
4074K	Mixture 200 mL	‡1	4	..	9.28	5.80	Gold Cross	BI

Respiratory system

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer	
					Max. Qty \$	Safety Net \$		
Cough suppressants, excl. combinations with expectorants								
Opium alkaloids and derivatives								
PHOLCODINE								
4071G	Linctus 1 mg per mL (0.1%), 100 mL	‡1	2	..	9.12	5.80	Gold Cross	BI
				..	14.71	5.80	Duro-Tuss	IA

Antihistamines for systemic use

Antihistamines for systemic use

Piperazine derivatives

CETIRIZINE HYDROCHLORIDE								
4175R	Tablet 10 mg	30	29.75	5.80	^a Alzene	AF
				..	32.97	5.80	Zilarex	SZ
				..	39.55	5.80	^a Zyrtec	JT

Other antihistamines for systemic use

FEXOFENADINE HYDROCHLORIDE								
4237B	Tablet 60 mg	60	*55.09	5.80	Telfast	SW
4238C	Tablet 120 mg	30	29.52	5.80	^a Xergic	AF
				..	34.81	5.80	^a Fexal	SZ
				..	47.23	5.80	^a Telfast 120	SW
LORATADINE								
4313B	Tablet 10 mg	30	33.09	5.80	^a Allereze	AF
				..	43.75	5.80	^a Lorano	SZ
				..	46.02	5.80	^a Claratyne	MK

Sensory organs

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Sensory organs

Ophthalmologicals

Decongestants and antiallergics

Sympathomimetics used as decongestants

4032F	ANTAZOLINE with NAPHAZOLINE Eye drops 5 mg (phosphate)-500 micrograms (hydrochloride) per mL (0.5%-0.05%), 15 mL	‡1	1	..	14.90	5.80	Albalon-A	AG
-------	---	----	---	----	-------	------	-----------	----

4035J	NAPHAZOLINE HYDROCHLORIDE Eye drops 1 mg per mL (0.1%), 15 mL	‡1	1	..	15.19	5.80	Albalon Liquifilm	AG
-------	---	----	---	----	-------	------	-------------------	----

Other antiallergics

4310W	LEVOCABASTINE HYDROCHLORIDE Eye drops 500 micrograms per mL (0.05%), 4 mL (120 doses)	‡1	1	..	18.34	5.80	Livostin	JT
-------	--	----	---	----	-------	------	----------	----

Otologicals

Other otologicals

Indifferent preparations

4176T	CARBAMIDE PEROXIDE Ear drops 65 mg per mL (6.5%), 12 mL	‡1	16.18	5.80	Ear Clear for Ear Wax Removal	KY
-------	---	----	----	----	-------	------	----------------------------------	----

4180B	DICHLOROBENZENE with CHLORBUTOL and TURPENTINE OIL Ear drops 20 mg-50 mg-0.1 mL per mL (2%-5%- 10%), 10 mL	‡1	14.18	5.80	Cerumol	AC
-------	---	----	----	----	-------	------	---------	----

4199B	DOCUSATE SODIUM Ear drops 5 mg per mL (0.5%), 10 mL	‡1	14.57	5.80	Waxsol	NE
-------	---	----	----	----	-------	------	--------	----

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

Various

All other therapeutic products

All other therapeutic products
Drugs for treatment of hyperkalemia and hyperphosphatemia

SODIUM POLYSTYRENE SULFONATE							
4470G	Oral powder 454 g	±1	2	..	71.22	5.80	Resonium-A SW

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

REPATRIATION PHARMACEUTICAL BENEFITS SCHEME (RPBS) WOUND ASSESSMENT AND DRESSING IDENTIFICATION

It is essential to define the aetiology of the wound before selecting a dressing. Recommendations are based on wound type, colour of wound base, depth of wound, and amount of exudate.

This wound chart adheres to the MOIST WOUND concept of healing and wound dressings are described below as ABSORBING or MOISTURE DONATING.

Most wound healing products are designed to remain in situ for several days, with the exception of those for infected wounds which should be changed daily. The quantities and repeats listed in the Repatriation Schedule are considered to be adequate to manage the treatment of a wound for two weeks to one month, when an assessment of the wound's healing process should be undertaken.

DRESSINGS

PINK EPITHELIALISING WOUND

Aim: To protect and promote epithelialisation. Epithelialising wounds normally are superficial and only produce a light exudate.

(A) Covering	• Film;	• Gauze—Paraffin;
	• Film Island	• Non-adherent
(B) Absorbing	• Foam (Light Exudate);	• Hydrocolloid (Superficial Wound—Light Exudate)
	• Hydroactive (Superficial Wound—Light Exudate)	

RED GRANULATING WOUND

Aims: (1) to protect the granulating tissue; (2) to encourage epithelialisation; (3) to absorb excess exudate.

LIGHT EXUDATE:	Superficial	Cavity
(A) Absorbing	• Foam (Light Exudate);	• Hydrocolloid (Cavity Wound)
	• Hydroactive (Superficial Wound—Light Exudate);	
	• Hydrocolloid (Superficial Wound—Light Exudate)	
(B) Moisture donating	• Hydrogel—Amorphous;	• Hydrogel—Amorphous
	• Hydrogel—Sheet	
HIGH EXUDATE:	Superficial	Cavity
(A) Absorbing	• Alginate (Superficial Wound);	• Alginate (Cavity Wound);
	• Foam—Heavy Exudate;	• Foam—Moderate Exudate (see “cavity conforming” product);
	• Hydroactive (Superficial Wound—Moderate Exudate);	• Hydroactive (Cavity Wound);
	• Hydrocolloid (Superficial Wound—Moderate/High Exudate)	• Hydrocolloid (Cavity Wound)
(B) Moisture donating	NOT APPROPRIATE	

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for	Maximum Recordable Value for	Brand Name and Manufacturer
					Max. Qty \$	Safety Net \$	

YELLOW SLOUGHY WOUND

Aims: (1) to remove slough; (2) to encourage granulation; (3) to absorb excess exudate.

LIGHT EXUDATE:	Superficial	Cavity
(A) Absorbing	<ul style="list-style-type: none"> • Cadexomer Iodine; • Foam—Light Exudate; • Foam with Charcoal; • Hydroactive (Superficial Wound—Moderate Exudate); • Hydrocolloid (Superficial Wound—Moderate Exudate) 	<ul style="list-style-type: none"> • Cadexomer Iodine; • Hydrocolloid (Cavity Wound)

(B) Moisture Donating	<ul style="list-style-type: none"> • Hydrogel—Amorphous; • Hydrogel—Sheet 	<ul style="list-style-type: none"> • Hydrogel—Amorphous
-----------------------	---	--

HIGH EXUDATE:	Superficial	Cavity
(A) Absorbing	<ul style="list-style-type: none"> • Alginate (Superficial Wound); • Cadexomer Iodine; • Foam—Heavy Exudate; • Hydroactive (Superficial Wound—Moderate/High Exudate); • Hydrocolloid (Superficial Wound—Moderate/High Exudate) 	<ul style="list-style-type: none"> • Alginate (Cavity Wound); • Cadexomer Iodine; • Hydrocolloid (Cavity Wound)

(B) Moisture donating	NOT APPROPRIATE
-----------------------	-----------------

BLACK NECROTIC WOUND

Aim: To remove eschar by — (1) sharp debridement, e.g., scissor/scalpel and/or (2) rehydration and autolytic debridement. (These wounds usually produce a LIGHT EXUDATE.)

DRY / LIGHT EXUDATE:	Superficial	Cavity
(A) Absorbing	<ul style="list-style-type: none"> • Hydroactive (Superficial Wound—Light Exudate); • Hydrocolloid (Superficial Wound—Light/Moderate Exudate) 	<ul style="list-style-type: none"> • Hydrocolloid (Cavity Wound)
(B) Moisture donating	<ul style="list-style-type: none"> • Hydrogel—Amorphous; • Hydrogel—Sheet 	<ul style="list-style-type: none"> • Hydrogel—Amorphous; • Hydrogel—Sheet

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

INFECTED WOUNDS

Aims: (1) to clear the infection with systemic antibiotics; (2) to absorb excess exudate; (3) to remove slough if present; (4) to decrease bacterial burden - by applying a Silver dressing or Cadexomer Iodine dressing.

MALODOROUS WOUNDS

Aims: (1) to clear infection if present; (2) to remove slough if present; (3) to clear colonising odour-producing bacteria in slough — by applying metronidazole gel, a Silver dressing or a Cadexomer Iodine dressing; (4) to absorb excess exudate.

Products: Activated Charcoal; Alginate with Charcoal; Foam with Charcoal; Silver dressing; Cadexomer Iodine dressing.

MINOR SKIN TRAUMA

Aims: (1) to stop bleeding; (2) to prevent infection; (3) to minimise the surface defect; (4) to promote epithelialisation.

ORDERING HARTMANN PRODUCTS

Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.

ORDERING COLOPLAST PRODUCTS

Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.

ORDERING MOLNLYCKE HEALTHCARE PRODUCTS

Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.

All other non-therapeutic products

All other non-therapeutic products

LUBRICATING GEL

4306P	Tube 100 g	1	12.74	5.80	Lubri-Gel	PP
-------	------------	---	----	----	-------	------	-----------	----

Other non-therapeutic auxiliary products

BANDAGE—ABSORBENT WOOL

4653X	Bandage 10 cm x 3 m	6	20.42	5.80	Surepress 650948	CC
-------	---------------------	---	----	----	-------	------	------------------	----

BANDAGE—CALICO

4717G	Bandage, triangular, large	‡1	13.59	5.80	Handy 36361414	BV
-------	----------------------------	----	----	----	-------	------	----------------	----

BANDAGE—COMPRESSION

Note

Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.

4654Y	Bandage, short stretch, 8 cm x 2.6 m	5	*77.87	5.80	Comprilan 01027-00	BV
4656C	Bandage, high stretch, 7.5 cm x 3.5 m	5	*68.47	5.80	Setopress 3504	SS
4657D	Bandage, high stretch, 10 cm x 3.5 m	5	*78.67	5.80	Setopress 3505	SS
4736G	Bandage, high stretch, 7.5 cm x 3 m	5	*94.42	5.80	Tensopress 71723-01	BV
4748X	Bandage, high stretch, 10 cm x 3 m	5	*73.02	5.80	Surepress 650947	CC
				..	*126.72	5.80	Tensopress 71723-00	BV

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
BANDAGE—COMPRESSION								
<u>Note</u> Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.								
<u>Note</u> Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4598B	Bandage, four layer	5	*152.72	5.80	Profore Lite 66050415	SN
4658E	Bandage, four layer	5	*224.52	5.80	Profore 66050016	SN
<hr/>								
BANDAGE—COMPRESSION								
<u>Note</u> Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.								
<u>Restricted benefit</u> Initial treatment of venous ulcers.								
<u>Note</u> Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4938X	Bandage, two layer, 18 cm-22 cm (red)	1	51.02	5.80	ProGuide 66000780	SN
4939Y	Bandage, two layer, 22 cm-28 cm (yellow)	1	51.02	5.80	ProGuide 66000781	SN
4940B	Bandage, two layer, 28 cm-32 cm (green)	1	51.02	5.80	ProGuide 66000782	SN
<hr/>								
BANDAGE—COMPRESSION								
<u>Note</u> Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.								
<u>Restricted benefit</u> Initial treatment of venous ulcers.								
<u>Restricted benefit</u> Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated.								
<u>Note</u> Bandage can be left in situ for up to 7 days as per manufacturer's instructions.								
4050E	Bandage, two layer	1	42.78	5.80	Coban 2	MM
<hr/>								
BANDAGE—COMPRESSION								
<u>Note</u> Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.								
<u>Restricted benefit</u> Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated.								
<u>Note</u> Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4941C	Bandage, two layer, 18 cm-22 cm (red)	4	*182.52	5.80	ProGuide 66000780	SN
4942D	Bandage, two layer, 22 cm-28 cm (yellow)	4	*182.52	5.80	ProGuide 66000781	SN
4943E	Bandage, two layer, 28 cm-32 cm (green)	4	*182.52	5.80	ProGuide 66000782	SN

Various

					Dispensed Price for Max. Qty	Maximum Recordable Value for Safety Net		
Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	\$	\$	Brand Name and Manufacturer	
BANDAGE—RETENTION—COHESIVE—HEAVY								
4660G	Bandage 10 cm x 2 m	2	*19.46	5.80	Coban 1584	MM
4811F	Bandage 5 cm x 1.3 m	2	*14.12	5.80	Peg 7420	BK
4812G	Bandage 7.5 cm x 1.3 m	2	*17.40	5.80	Peg 7422	BK
4813H	Bandage 10 cm x 1.3 m	2	*21.14	5.80	Peg 7423	BK
4814J	Bandage 15 cm x 1.3 m	2	*28.28	5.80	Peg 7425	BK
BANDAGE—RETENTION—COHESIVE—LIGHT								
4662J	Bandage 10 cm x 4 m	2	*17.24	5.80	Handygauze Cohesive 8635	BV
4718H	Bandages 2.5 cm x 4 m, 2	‡1	12.62	5.80	Handygauze Cohesive 8631	BV
4719J	Bandage 6 cm x 4 m	2	*14.80	5.80	Handygauze Cohesive 8633	BV
BANDAGE—RETENTION—COTTON CREPE								
4727T	Bandage 5 cm x 2.3 m	2	*17.54	5.80	Telfa 8252F	KE
				..	*18.38	5.80	Tensocrepe 36300501	BV
4728W	Bandage 7.5 cm x 2.3 m	2	*22.32	5.80	Telfa 8253F	KE
				..	*22.50	5.80	Tensocrepe 36307501	BV
4729X	Bandage 10 cm x 2.3 m	2	*25.48	5.80	Telfa 8254F	KE
				..	*27.92	5.80	Tensocrepe 36301001	BV
BANDAGE—TUBULAR								
4663K	Bandage, straight, size C	‡1	15.48	5.80	Elastoplast 2225	BE
4664L	Bandage, straight, size D	‡1	15.48	5.80	Elastoplast 2226	BE
4665M	Bandage, straight, size E	‡1	15.48	5.80	Elastoplast 2227	BE
4855M	Bandage 6.25 cm x 1 m	‡1	18.27	5.80	Tubigrip B 1520	SS
4856N	Bandage 6.75 cm x 1 m	‡1	18.27	5.80	Tubigrip C 1545	SS
4857P	Bandage 7.5 cm x 1 m	‡1	18.27	5.80	Tubigrip D 1546	SS
4858Q	Bandage 8.75 cm x 1 m	‡1	18.27	5.80	Tubigrip E 1547	SS
4859R	Bandage 10 cm x 1 m	‡1	18.27	5.80	Tubigrip F 1548	SS
BANDAGE—TUBULAR (FINGER)								
4726R	Refill	‡1	13.83	5.80	Tubegauz 0501658	SS
4798M	Complete pack including applicator	‡1	17.87	5.80	Tubegauz 0501633	SS
BANDAGE—TUBULAR (LIGHTWEIGHT)								
4671W	Bandage, small limb size (red), 10 m	‡1	28.46	5.80	Tubifast 2434	SS
4672X	Bandage, medium limb size (green), 10 m	‡1	32.12	5.80	Tubifast 2436	SS
4673Y	Bandage, large limb size (blue), 10 m	‡1	35.68	5.80	Tubifast 2438	SS
BANDAGE—TUBULAR (LONG STOCKING)								
4674B	Bandage, small size	2	*40.28	5.80	Tubigrip 1482	SS
4675C	Bandage, XX/large size	2	*40.28	5.80	Tubigrip 1486	SS
4797L	Bandage, medium size	2	*40.28	5.80	Tubigrip 1483	SS
4799N	Bandage, large size	2	*40.28	5.80	Tubigrip 1484	SS
BANDAGE—TUBULAR (SHORT STOCKING)								
4661H	Bandage, small B/C size	2	*30.54	5.80	Tubigrip 1479	SS

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
4815K	Bandage, medium C/D size	2	*30.54	5.80	Tubigrip 1480	SS
4816L	Bandage, large D/E size	2	*30.54	5.80	Tubigrip 1481	SS

BANDAGE—ZINC PASTE

Note

Used as an adjunct in the management of leg ulceration and associated eczema and skin conditions.

4668Q	Bandage 7.5 cm x 6 m	2	*29.30	5.80	Zincaband 3604	SS
4669R	Bandage 7.5 cm x 6 m	2	3	..	*29.76	5.80	Steripaste 3610	XP
4670T	Bandage 10 cm x 9.1 m	2	3	..	*28.88	5.80	Flexidress 650941	CC

BANDAGE—ZINC PASTE

Note

Used as an adjunct in the management of leg ulceration and associated eczema and skin conditions.

Note

Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.

4750B	Bandage 7.5 cm x 6 m	2	3	..	*73.96	5.80	Viscopaste 4948	SN
4760M	Bandages 80 cm (stockings), 4	1	3	..	85.27	5.80	ZipZoc 66051550	SN

COTTON WOOL ROLL

4701K	Roll 100 g	1	2	..	10.61	5.80	JJ 02013	JJ
-------	------------	---	---	----	-------	------	----------	----

DRESSING—ACTIVATED CHARCOAL (MALODOROUS WOUND)

4681J	Dressing 10.5 cm x 10.5 cm	10	*101.02	5.80	Actisorb Plus MAC031	JJ
4742N	Dressings 10 cm x 10 cm, 10	1	79.08	5.80	CarboFLEX 403202	CC
4743P	Dressings 15 cm x 20 cm, 5	1	89.97	5.80	CarboFLEX 403204	CC

DRESSING—ALGINATE (CAVITY WOUND)

Note

This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.

1905G	Rope 2 g	10	*115.36	5.80	Kaltostat 168117	CC
4832H	Rope 2 g	10	*109.22	5.80	Sorbsan 1411	UM

DRESSING—ALGINATE (CAVITY WOUND)

Note

This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.

Note

Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.

4682K	Ropes 2 g (40 cm), 6	2	*137.82	5.80	Comfeel SeaSorb Filler 3740	CT
-------	----------------------	---	----	----	---------	------	--------------------------------	----

DRESSING—ALGINATE (SUPERFICIAL WOUND)

Note

This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.

Note

Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
4684M	Dressing 5 cm x 5 cm	10	1	..	*47.02	5.80	Comfeel SeaSorb Dressing 3705	CT
4831G	Dressing 10 cm x 10 cm	10	1	..	*84.52	5.80	Sorbsan 1410	UM
				..	*90.22	5.80	Comfeel SeaSorb Dressing 3710	CT

DRESSING—ALGINATE (SUPERFICIAL WOUND)

Note

This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.

4683L	Dressings 7.5 cm x 12 cm, 10	‡1	1	..	91.18	5.80	Kaltostat 168212	CC
-------	------------------------------	----	---	----	-------	------	------------------	----

DRESSING—ALGINATE (SUPERFICIAL WOUND)

Note

This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.

Note

Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.

4691X	Dressings 15 cm x 20 cm, 10	‡1	1	..	236.17	5.80	Algisite M 66000521	SN
4699H	Dressings 5 cm x 5 cm, 10	‡1	1	..	49.50	5.80	Kaltostat 168210	CC
				..	51.38	5.80	Algisite M 66000519	SN
4700J	Dressings 10 cm x 10 cm, 10	‡1	1	..	98.52	5.80	Algisite M 66000520	SN

DRESSING—FILM

4686P	Dressings 6 cm x 7 cm, 8	‡1	15.74	5.80	Nexcare Tegaderm Transparent H1624	MM
4687Q	Dressings 10 cm x 12 cm, 4	‡1	19.75	5.80	Nexcare Tegaderm Transparent H1626	MM
4688R	Dressing 15 cm x 20 cm	6	*30.76	5.80	Tegaderm Transparent 1628	MM

DRESSING—FILM

Note

Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.

4893M	Dressings 10 cm x 12 cm, 10	‡1	32.59	5.80	Op-Site Flexigrid 4629	SN
-------	-----------------------------	----	----	----	-------	------	---------------------------	----

DRESSING—FILM ISLAND

4689T	Dressing 5 cm x 7 cm	10	*16.32	5.80	Tegaderm Transparent Island 3582	MM
4690W	Dressing 9 cm x 10 cm	10	*27.82	5.80	Tegaderm Transparent Island 3586	MM

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
DRESSING—FILM ISLAND							
Note Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.							
4898T	Dressings 5 cm x 7.2 cm, 5	2	*29.02	5.80	Cutifilm Plus 36361370 SN
4899W	Dressings 8 cm x 10 cm, 5	2	*45.60	5.80	Cutifilm Plus 36361371 SN
DRESSING—FOAM—HEAVY EXUDATE							
Note This dressing should remain in place until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound.							
Note Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.							
4795J	Dressings 10 cm x 10 cm, 10	±1	1	..	75.16	5.80	Lyof foam Extra 603088 XP
				..	126.77	5.80	Allevyn 66007637 SN
DRESSING—FOAM—HEAVY EXUDATE							
Note This dressing should remain in place until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound.							
4880W	Dressings 20 cm x 15 cm, 10	±1	1	..	189.21	5.80	Lyof foam Extra 603090 XP
DRESSING—FOAM—MODERATE EXUDATE							
Note This dressing should remain in place until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound.							
Note Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.							
4590N	Dressings 12.5 cm x 12.5 cm, 10	±1	123.33	5.80	Allevyn Adhesive 66000044 SN
4694C	Dressing, cavity, conforming, 20 g	1	1	..	88.83	5.80	Cavicare 4563 SN
DRESSING—FOAM—MODERATE EXUDATE							
Note This dressing should remain in place until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound.							
4878R	Dressings 20 cm x 15 cm, 10	±1	1	..	101.96	5.80	Lyof foam Flat 603095 XP
4890J	Dressings 7.5 cm x 7.5 cm, 10	±1	1	..	42.94	5.80	Lyof foam Flat 603092 XP
4891K	Dressings 10 cm x 10 cm, 10	±1	1	..	49.58	5.80	Lyof foam Flat 603093 XP
DRESSING—FOAM—SILVER							
Authority required For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings.							

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Note Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4252T	Dressings, adhesive, 7.5 cm x 7.5 cm, 10	¥1	134.99	5.80	Allevyn Ag Adhesive 66800073	SN
4255Y	Dressings, adhesive, 10 cm x 10 cm, 10	¥1	200.68	5.80	Allevyn Ag Adhesive 66800075	SN
4258D	Dressings, adhesive, 12.5 cm x 12.5 cm, 10	¥1	245.15	5.80	Allevyn Ag Adhesive 66800078	SN
4259E	Dressings, non-adhesive, 10 cm x 10 cm, 10	¥1	204.52	5.80	Allevyn Ag Non- Adhesive 66800086	SN
4263J	Dressings 7.5 cm x 7.5 cm, 10	¥1	134.99	5.80	Allevyn Ag Gentle 66800460	SN
4266M	Dressings 10 cm x 10 cm, 10	¥1	200.68	5.80	Allevyn Ag Gentle 66800461	SN
4270R	Dressings 12.5 cm x 12.5 cm, 10	¥1	245.15	5.80	Allevyn Ag Gentle 66800462	SN
DRESSING—FOAM with CHARCOAL (MALODOROUS WOUND)								
Note This dressing should remain in place on wounds with odour until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound.								
4892L	Dressings 10 cm x 10 cm, 10	2	*174.16	5.80	Lyof foam C 603025	SS
DRESSING—FOAM with SILICONE—HEAVY EXUDATE								
Note Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.								
4642H	Dressings 7.5 cm x 7.5 cm, 5	¥1	30.87	5.80	Mepilex Border 295200	MH
4643J	Dressings 10 cm x 10 cm, 5	¥1	42.78	5.80	Mepilex Border 295300	MH
DRESSING—FOAM with SILICONE—HEAVY EXUDATE								
Note Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4196W	Dressings 10 cm x 10 cm, 10	¥1	72.91	5.80	Allevyn Gentle 66800248	SN
4207K	Dressings 7.5 cm x 7.5 cm, 10	¥1	51.25	5.80	Allevyn Gentle Border 66800269	SN
4230P	Dressings 10 cm x 10 cm, 10	¥1	72.91	5.80	Allevyn Gentle Border 66800270	SN
DRESSING—FOAM with SILICONE—LIGHT EXUDATE								
Note Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.								
4644K	Dressings 6 cm x 8.5 cm, 5	¥1	28.16	5.80	Mepilex Lite	MH

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
4645L	Dressings 10 cm x 10 cm, 5	‡1	38.31	5.80	284000 Mepilex Lite 284100	MH
DRESSING—FOAM with SILICONE—MODERATE EXUDATE								
Note								
Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.								
4626L	Dressings 10 cm x 10 cm, 5	‡1	42.78	5.80	Mepilex 294100	MH
DRESSING—GAUZE (ABSORBENT PAD)								
4707R	Pads 5 cm x 5 cm, 100	‡1	13.98	5.80	Handy 71117-05	BV
4708T	Pads 10 cm x 10 cm, 100	‡1	27.50	5.80	Handy 71117-06	BV
DRESSING—GAUZE—EYE PAD								
4768Y	Pads, 12	‡1	12.93	5.80	Curity 4112	KE
DRESSING—GAUZE—PARAFFIN								
Note								
Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4759L	Dressings 10 cm x 10 cm, 10	‡1	20.03	5.80	Jelonet 7404	SN
DRESSING—GAUZE—PARAFFIN with CHLORHEXIDINE ACETATE								
Note								
Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4845B	Dressings 10 cm x 10 cm, 10	‡1	2	..	27.13	5.80	Bactigras 7457	SN
DRESSING—HYDROACTIVE (CAVITY WOUND)								
Note								
Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4918W	Dressings 5 cm x 6 cm, 10	‡1	1	..	88.60	5.80	Allevyn Plus Cavity 66047571	SN
4919X	Dressings 10 cm x 10 cm, 5	2	1	..	*187.04	5.80	Allevyn Plus Cavity 66047573	SN
DRESSING—HYDROACTIVE (DEBRIDEMENT)								
Note								
Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.								
4948K	Dressings 5.5 cm, 10	‡1	68.76	5.80	TenderWet Active Cavity	HR
4949L	Dressings 4 cm, 10	‡1	68.00	5.80	TenderWet 24 Active	HR
4950M	Dressings 7.5 cm x 7.5 cm, 10	‡1	92.29	5.80	TenderWet 24 Active	HR
DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—HIGH EXUDATE)								
4692Y	Dressings (foam alternative) 10 cm x 10 cm, 10	‡1	55.00	5.80	CombiDERM 651031	CC

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
4693B	Dressings (foam alternative) 15 cm x 18 cm, 5	‡1	71.82	5.80	CombiDERM 651027	CC
4695D	Dressings, island, 11 cm x 11 cm, 10	‡1	111.34	5.80	Tielle MTL101E	JJ
4696E	Dressings, island, 18 cm x 18 cm, 5	‡1	135.94	5.80	Tielle MT2442	JJ

DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—HIGH EXUDATE)

Note

Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.

4927H	Non-adhesive waterproof semi-permeable absorbent foam pads 10 cm x 10 cm, 10	‡1	1	..	88.03	5.80	Biatain Non-adhesive 3410	CT
4928J	Non-adhesive waterproof semi-permeable absorbent foam pads 15 cm x 15 cm, 5	‡1	2	..	86.55	5.80	Biatain Non-adhesive 3413	CT
4929K	Adhesive waterproof semi-permeable absorbent foam pads 12 cm x 12 cm, 10	‡1	1	..	97.05	5.80	Biatain Adhesive 3420	CT
4930L	Adhesive waterproof semi-permeable absorbent foam pads 18 cm x 18 cm, 5	‡1	2	..	93.92	5.80	Biatain Adhesive 3423	CT

DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—LIGHT EXUDATE)

Note

Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.

4905E	Dressings 5 cm x 6 cm, 10	‡1	1	..	59.29	5.80	Allevyn Thin 66047576	SN
4906F	Dressings 10 cm x 10 cm, 5	2	1	..	*108.42	5.80	Allevyn Thin 66047578	SN

DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—MODERATE EXUDATE)

Note

Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.

4885D	Dressings 5 cm x 6 cm, 10	‡1	1	..	47.99	5.80	Cutinova Hydro 66047441	SN
4886E	Dressings 10 cm x 10 cm, 5	2	1	..	*79.54	5.80	Cutinova Hydro 66047443	SN

DRESSING—HYDROCOLLOID (CAVITY WOUND)

Note

This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.

4896Q	Paste 30 g	10	*145.22	5.80	DuoDERM Paste H7930	CC
-------	------------	----	----	----	---------	------	------------------------	----

DRESSING—HYDROCOLLOID (CAVITY WOUND)

Note

This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.

Note

Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.

4895P	Paste 50 g	2	3	..	*43.32	5.80	Comfeel Paste 4701	CT
-------	------------	---	---	----	--------	------	-----------------------	----

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—LIGHT EXUDATE)								
<u>Note</u> This dressing should be applied to a thickness of 3 mm to 5 mm. It should be covered with a hydrocolloid dressing and may be left in place for up to 7 days.								
<u>Note</u> Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.								
4888G	Dressings 5 cm x 7 cm, 10	‡1	1	..	41.82	5.80	Comfeel Plus Transparent 3530	CT
4889H	Dressings 9 cm x 14 cm, 10	‡1	1	..	84.62	5.80	Comfeel Plus Transparent 3536	CT
4924E	Dressings 10 cm x 10 cm, 10	‡1	1	..	69.88	5.80	Comfeel Plus Transparent 3533	CT
<hr/>								
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—LIGHT EXUDATE)								
<u>Note</u> This dressing should be applied to a thickness of 3 mm to 5 mm. It should be covered with a hydrocolloid dressing and may be left in place for up to 7 days.								
4907G	Dressings 10 cm x 10 cm, 10	‡1	1	..	71.82	5.80	DuoDERM Extra Thin H7955	CC
<hr/>								
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—LIGHT EXUDATE)								
<u>Note</u> This dressing should be applied to a thickness of 3 mm to 5 mm. It should be covered with a hydrocolloid dressing and may be left in place for up to 7 days.								
<u>Note</u> Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.								
4947J	Dressings 10 cm x 10 cm, 10	‡1	1	..	48.25	5.80	Hydrocoll Thin 900758	HR
<hr/>								
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—MODERATE EXUDATE)								
<u>Note</u> This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.								
4897R	Dressings 10 cm x 10 cm, 5	2	1	..	*81.50	5.80	DuoDERM CGF H7660	CC
4920Y	Dressings 20 cm x 20 cm, 5	2	1	..	*222.42	5.80	DuoDERM CGF H7662	CC
<hr/>								
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—MODERATE EXUDATE)								
<u>Note</u> This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.								
<u>Note</u> Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4921B	Dressings 10 cm x 10 cm, 10	‡1	1	..	80.40	5.80	Repicare Ultra 66000434	SN

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—MODERATE EXUDATE)								
Note								
This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.								
Note								
Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.								
4945G	Dressings 10 cm x 10 cm, 10	‡1	1	..	48.25	5.80	Hydrocoll 900744	HR
4946H	Dressings 15 cm x 15 cm, 10	‡1	1	..	90.01	5.80	Hydrocoll 900936	HR
<hr/>								
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—MODERATE EXUDATE)								
Note								
This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.								
Note								
Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.								
4678F	Butterfly shape 7 cm	5	*55.27	5.80	Comfeel Plus Pressure Relieving 3350	CT
4679G	Round 10 cm	5	*59.72	5.80	Comfeel Plus Pressure Relieving 3353	CT
4923D	Dressings with alginate 10 cm x 10 cm, 10	‡1	1	..	82.09	5.80	Comfeel Plus Ulcer Dressing 3110	CT
DRESSING—HYDROFIBRE (ALTERNATE TO ALGINATES)								
4649Q	Dressings 10 cm x 10 cm, 10	‡1	1	..	101.08	5.80	Aquacel 177902	CC
4698G	Ropes 2 g (30 cm), 5	‡1	1	..	83.81	5.80	Aquacel 177904	CC
4922C	Dressings 15 cm x 15 cm, 5	2	1	..	*208.80	5.80	Aquacel 177903	CC
DRESSING—HYDROGEL—AMORPHOUS								
Note								
This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.								
Note								
Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.								
4912M	Tubes 15 g, 10	‡1	1	..	64.58	5.80	DuoDERM Gel H7990	CC
				..	72.19	5.80	Comfeel Purilon Gel 3900	CT
<hr/>								
DRESSING—HYDROGEL—AMORPHOUS								
Note								
This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.								
4913N	Tubes 30 g, 3	3	1	..	*97.21	5.80	DuoDERM Gel H7987	CC
4914P	Tube 50 g	3	3	..	*33.22	5.80	Solugel 10336	JJ

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
DRESSING—HYDROGEL—AMORPHOUS								
Note								
This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.								
Note								
Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4599C	Tube 50 g	3	3	..	*30.61	5.80	SoloSite Gel 36361338	SN
4894N	Tube 25 g	4	3	..	*62.28	5.80	Intrasite Gel 7313	SN
DRESSING—HYDROGEL—SHEET								
Note								
This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.								
4911L	Dressings 9.5 cm x 10.2 cm, 5	2	*83.30	5.80	Nu-Gel 2497	JJ
DRESSING—HYDROGEL—SHEET								
Note								
This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.								
Note								
Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.								
4806Y	Dressings 10 cm x 10 cm, 5	2	*53.38	5.80	Aquaclear 900796	HR
DRESSING—NON-ADHERENT								
Note								
Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4819P	Dressings 5 cm x 5 cm, 5	2	*15.90	5.80	Cutilin Non-Stick Wound Pad 36361374	SN
4860T	Dressings 5 cm x 5 cm, 5	2	*16.58	5.80	Melolin 36361357	SN
4861W	Dressings 10 cm x 10 cm, 10	1	33.80	5.80	Melolin 66974933	SN
4862X	Dressings 10 cm x 10 cm, 5	2	*25.50	5.80	Cutilin Non-Stick Wound Pad 36361375	SN
DRESSING—NON-ADHERENT								
4755G	Dressings 5 cm x 7.5 cm, 10	1	11.12	5.80	Telfa 1970C	KE
4758K	Dressings 7.5 cm x 10 cm, 6	1	11.33	5.80	Telfa 2140C	KE
4844Y	Dressings, self-adhesive, 7.5 cm x 10 cm, 6	1	2	..	12.12	5.80	Telfa 7650C	KE
DRESSING—NON-ADHERENT								
Note								
Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.								
4944F	Dressings 7.5 cm x 10 cm, 10	1	15.34	5.80	Atrauman 499513	HR

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
DRESSING—NON-ADHERENT								
Note Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.								
4243H	Dressings, non-woven, with silicone 5 cm x 7.5 cm, 10	¥1	63.72	5.80	Mepitel 290510	MH
4244J	Dressings, non-woven, with silicone 7.5 cm x 10 cm, 10	¥1	107.72	5.80	Mepitel 290710	MH
DRESSING—TULLE NON-GAUZE—PARAFFIN								
4909J	Dressing 7.6 cm x 7.6 cm	10	1	..	*15.82	5.80	Adaptic 2012	JJ
DRESSING with CADEXOMER IODINE								
Note Suitable for yellow sloughy infected and malodorous wounds.								
Note Smith & Nephew products are distributed via the three major wholesalers, API, Sigma & Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.								
4931M	Sachets 3 g, 7	¥1	2	..	67.47	5.80	Iodosorb Powder 66051070	SN
4932N	Tubes 10 g, 4	¥1	2	..	108.67	5.80	Iodosorb Ointment 66051240	SN
4933P	Tubes 20 g, 2	¥1	2	..	107.65	5.80	Iodosorb Ointment 66051230	SN
4935R	Sheets 5 g (6 cm x 4 cm), 5	¥1	2	..	102.72	5.80	Iodosorb 66051330	SN
4936T	Sachets 10 g (8 cm x 6 cm), 3	¥1	2	..	148.45	5.80	Iodosorb 66051340	SN
4937W	Sheets 17 g (10 cm x 8 cm), 2	¥1	156.46	5.80	Iodosorb 66051360	SN
DRESSING with SILVER								
Authority required For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings.								
Note Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.								
4646M	Hydroactive dressings non-adhesive 10 cm x 10 cm, 5	¥1	175.99	5.80	Biatain Ag 9622	CT
4647N	Hydroactive dressings adhesive 12.5 cm x 12.5 cm, 5	¥1	191.39	5.80	Biatain Ag 9632	CT
DRESSING with SILVER								
Authority required For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings.								
Note Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.								
4648P	Tulle dressings 10 cm x 10 cm, 3	¥1	43.88	5.80	Atrauman Ag 499572	HR
GAUZE and COTTON TISSUE (COMBINE ROLL)								
4761N	Wrapped pack 10 cm x 10 m	¥1	17.31	5.80	JJ 12010	JJ
4767X	Wrapped pack 9 cm x 10 m	¥1	15.49	5.80	BSN 2902165	BV

Various

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
TAPES—NON-WOVEN RETENTION (POLYACRYLATE)								
4915Q	Roll 2.5 cm x 9.1 m	‡1	12.97	5.80	Medipore 2961	MM
TAPES—NON-WOVEN RETENTION (POLYACRYLATE)								
Note								
Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.								
4917T	Roll 2.5 cm x 10 m	‡1	11.14	5.80	Mefix 310250	MH
TAPES—PLASTER ADHESIVE (WITH SILICONE)								
Note								
Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.								
4239D	Roll 2 cm x 3 m	‡1	21.47	5.80	Mepitac 298300	MH
4240E	Roll 4 cm x 1.5 m	‡1	21.47	5.80	Mepitac 298400	MH
TAPES—PLASTER ADHESIVE ELASTIC								
4780N	Roll 2.5 cm x 2.5 m	‡1	12.86	5.80	Leukoplast 01071-00	BV
4781P	Roll 5 cm x 2.5 m	‡1	18.66	5.80	Leukoplast 01072-00	BV
4782Q	Roll 7.5 cm x 2.5 m	‡1	22.23	5.80	Leukoplast 01073-00	BV
TAPES—PLASTER ADHESIVE HYPOALLERGENIC								
4783R	Roll 1.25 cm x 5 m	‡1	10.44	5.80	Leukopor 2471	BV
4785W	Roll 1.25 cm x 5 m	‡1	10.72	5.80	Leukosilk 1021	BV
4787Y	Roll 2.5 cm x 5 m	‡1	13.34	5.80	Leukosilk 1022	BV
4788B	Stretch roll 5 cm x 5 m	‡1	17.31	5.80	Leukoflex 1124	BV
4789C	Roll 5 cm x 5 m	‡1	17.15	5.80	Leukosilk 1024	BV
4790D	Roll 5 cm x 5 m	‡1	16.31	5.80	Leukopor 2474	BV
4794H	Roll 2.5 cm x 5 m	‡1	12.83	5.80	Leukopor 2472	BV
4848E	Roll (dispenser) 1.9 cm x 5.4 m	‡1	11.15	5.80	Nexcare Durable Cloth First Aid Tape 799	MM
4849F	Roll (dispenser) 1.9 cm x 7.3 m	‡1	11.15	5.80	Nexcare Gentle Paper First Aid Tape 789	MM

Section 2

Standard Packs and Prices

NOTE—

Standard packs and prices (including mark-up, but without dispensing fee and dangerous drug fee) are for items against the price of which an asterisk () is shown in Section 1 of the Schedule.*

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$	Manufacturer
4579B	ALPROSTADIL	10 mcg	2@ 25.40	PF
4580C		20 mcg	2@ 32.40	PF
4118R	ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE and SIMETHICONE	400 mg-400 mg-30 mg per 5 mL, 500 mL	1@ 8.11	JT
4453J		400 mg-400 mg-40 mg	100@ 19.85	JT
4598B	BANDAGE—COMPRESSION	Four layer	1@ 29.24	SN
4654Y		8 cm x 2.6 m	1@ 14.27	BV
4656C		7.5 cm x 3.5 m	1@ 12.39	SS
4657D		10 cm x 3.5 m	1@ 14.43	SS
4658E		Four layer	1@ 43.60	SN
4736G		7.5 cm x 3 m	1@ 17.58	BV
4748X		10 cm x 3 m	1@ 24.04	BV
4941C		Two layer, 18 cm-22 cm	1@ 44.00	SN
4942D		Two layer, 22 cm-28 cm	1@ 44.00	SN
4943E		Two layer, 28 cm-32 cm	1@ 44.00	SN
4660G	BANDAGE—RETENTION—COHESIVE— HEAVY	10 cm x 2 m	1@ 6.47	MM
4811F		5 cm x 1.3 m	1@ 3.80	BK
4812G		7.5 cm x 1.3 m	1@ 5.44	BK
4813H		10 cm x 1.3 m	1@ 7.31	BK
4814J		15 cm x 1.3 m	1@ 10.88	BK
4662J	BANDAGE—RETENTION—COHESIVE— LIGHT	10 cm x 4 m	1@ 5.36	BV
4719J		6 cm x 4 m	1@ 4.14	BV
4727T	BANDAGE—RETENTION—COTTON CREPE	5 cm x 2.3 m	1@ 5.93	BV
4728W		7.5 cm x 2.3 m	1@ 7.99	BV
4729X		10 cm x 2.3 m	1@ 10.70	BV
4674B	BANDAGE—TUBULAR (LONG STOCKING)	Small	1@ 16.88	SS
4675C		XX/large	1@ 16.88	SS
4797L		Medium	1@ 16.88	SS
4799N		Large	1@ 16.88	SS
4661H	BANDAGE—TUBULAR (SHORT STOCKING)	Small B/C	1@ 12.01	SS
4815K		Medium C/D	1@ 12.01	SS
4816L		Large D/E	1@ 12.01	SS
4668Q	BANDAGE—ZINC PASTE	7.5 cm x 6 m	1@ 11.39	SS
4669R		7.5 cm x 6 m	1@ 11.62	XP
4670T		10 cm x 9.1 m	1@ 11.18	CC
4750B		7.5 cm x 6 m	1@ 33.72	SN
4150K	BROMAZEPAM	3 mg	30@ 11.53	RO
4151L		6 mg	30@ 14.84	RO
4094L	CALCIUM	500 mg	60@ 6.01	IA
4142B		600 mg	120@ 7.89	PP
4333C		500 mg	60@ 6.01	IA
4055K	CALCIUM CARBONATE with GLYCINE	420 mg-180 mg	100@ 8.38	MM
4681J	DRESSING—ACTIVATED CHARCOAL (MALODOROUS WOUND)	10.5 cm x 10.5 cm	1@ 9.45	JJ
1905G	DRESSING—ALGINATE (CAVITY WOUND)	2 g	5@ 54.42	CC
4682K		2 g (40 cm), 6	1@ 65.65	CT
4832H		2 g	1@ 10.27	UM
4684M	DRESSING—ALGINATE (SUPERFICIAL WOUND)	5 cm x 5 cm	1@ 4.05	CT
4831G		10 cm x 10 cm	1@ 7.80	UM
4688R	DRESSING—FILM	15 cm x 20 cm	1@ 4.04	MM
4689T	DRESSING—FILM ISLAND	5 cm x 7 cm	1@ 0.98	MM
4690W		9 cm x 10 cm	1@ 2.13	MM
4898T		5 cm x 7.2 cm, 5	1@ 11.25	SN
4899W		8 cm x 10 cm, 5	1@ 19.54	SN
4892L	DRESSING—FOAM with CHARCOAL (MALODOROUS WOUND)	10 cm x 10 cm, 10	1@ 83.82	SS

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

Code	Name	Form/Strength	Pack and Price \$	Manufacturer
4919X	DRESSING—HYDROACTIVE (CAVITY WOUND)	10 cm x 10 cm, 5	1@ 90.26	SN
4906F	DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—LIGHT EXUDATE)	10 cm x 10 cm, 5	1@ 50.95	SN
4886E	DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—MODERATE EXUDATE)	10 cm x 10 cm, 5	1@ 36.51	SN
4895P	DRESSING—HYDROCOLLOID (CAVITY WOUND)	50 g	1@ 18.40	CT
4896Q		30 g	1@ 13.87	CC
4678F	DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—MODERATE EXUDATE)	7 cm	1@ 9.75	CT
4679G		10 cm	1@ 10.64	CT
4897R		10 cm x 10 cm, 5	1@ 37.49	CC
4920Y		20 cm x 20 cm, 5	1@ 107.95	CC
4922C	DRESSING—HYDROFIBRE (ALTERNATE TO ALGINATES)	15 cm x 15 cm, 5	1@ 101.14	CC
4599C	DRESSING—HYDROGEL—AMORPHOUS	50 g	1@ 8.03	SN
4894N		25 g	1@ 13.94	SN
4913N		30 g, 3	1@ 30.23	CC
4914P		50 g	1@ 8.90	JJ
4806Y	DRESSING—HYDROGEL—SHEET	10 cm x 10 cm, 5	1@ 23.43	HR
4911L		9.5 cm x 10.2 cm, 5	1@ 38.39	JJ
4819P	DRESSING—NON-ADHERENT	5 cm x 5 cm, 5	1@ 4.69	SN
4860T		5 cm x 5 cm, 5	1@ 5.03	SN
4862X		10 cm x 10 cm, 5	1@ 9.49	SN
4909J	DRESSING—TULLE NON-GAUZE—PARAFFIN	7.6 cm x 7.6 cm	1@ 0.93	JJ
4237B	FEXOFENADINE HYDROCHLORIDE	60 mg	20@ 16.19	SW
4246L	GLYCEROL	2.8 g, 12	1@ 4.66	PP
4571N	NICOTINE	Approx. 7 mg per 24 hours, 7	1@ 22.48	AF
4572P		Approx. 14 mg per 24 hours, 7	1@ 31.16	GC
4573Q		Approx. 21 mg per 24 hours, 7	1@ 31.16	GC
4576W		Approx. 5 mg per 16 hours, 7	1@ 22.20	JT
4577X		Approx. 10 mg per 16 hours, 7	1@ 24.18	JT
4578Y		Approx. 15 mg per 16 hours, 7	1@ 26.77	JT

GENERIC/PROPRIETARY INDEX

GENERIC/PROPRIETARY INDEX

3

3TC (VI)	
.Section 100	615, 762

A

ABACAVIR	
.Section 100	613, 760
ABACAVIR with LAMIVUDINE	
.Section 100	617, 764
ABACAVIR with LAMIVUDINE and ZIDOVUDINE	
.Section 100	617, 765
ABATACEPT	
.Antineoplastic and immunomodulating agents ...	253, 258
.Section 100	628, 776
Abbacillin-V (QA)	
.Antiinfectives for systemic use	197
.Dental.....	546
Abbacillin-VK Filmstab (QA)	
.Antiinfectives for systemic use	196, 197
.Dental.....	545
ABCIXIMAB	
.Blood and blood forming organs.....	106
Abilify (BQ)	
.Nervous system.....	448
ACAMPROSATE CALCIUM	
.Nervous system.....	477
ACARBOSE	
.Alimentary tract and metabolism	97
Accomin Adult Tonic (PF)	
.Repatriation Schedule.....	913
Accu-Chek Active (RD)	
.Various	504, 505
Accu-Chek Advantage/Sensor Comfort (RD)	
.Various	504, 505
Accu-Chek Aviva (RD)	
.Various	504, 505
Accu-Chek Go (RD)	
.Various	504, 505
Accu-Chek Integra (RD)	
.Various	505
Accu-Chek Mobile (RD)	
.Various	506
Accu-Chek Performa (RD)	
.Various	504, 505
Accupril (PF)	
.Cardiovascular system	136, 137
Accuretic 10/12.5mg (PF)	
.Cardiovascular system	141
Accuretic 20/12.5mg (PF)	
.Cardiovascular system	141

ACETAZOLAMIDE	
.Sensory organs.....	491
Acetec (AL)	
.Cardiovascular system	133
ACICLOVIR	
.Antiinfectives for systemic use.....	215, 216
.Optometrical.....	565
.Sensory organs.....	489
Aciclovir 200 (CR)	
.Antiinfectives for systemic use.....	215
Aciclovir 800 (CR)	
.Antiinfectives for systemic use.....	216
Aciclovir GH (GQ)	
.Antiinfectives for systemic use.....	215
Acihexal (SZ)	
.Antiinfectives for systemic use.....	215, 216
Aci-Jel (CU)	
.Repatriation Schedule	921
Acimax Tablets (AL)	
.Alimentary tract and metabolism	75, 76
A-Citalopram (TA)	
.Nervous system.....	459
ACITRETIN	
.Dermatologicals	169
Aclasta (NV)	
.Musculo-skeletal system	402
Aclor 125 (QA)	
.Antiinfectives for systemic use.....	202
.Dental.....	549
Aclor 250 (QA)	
.Antiinfectives for systemic use.....	202
.Dental.....	549
Acpio 15 (QA)	
.Alimentary tract and metabolism	98
Acpio 30 (QA)	
.Alimentary tract and metabolism	98
Acpio 45 (QA)	
.Alimentary tract and metabolism	99
Acquin 10 (QA)	
.Cardiovascular system	136
Acquin 20 (QA)	
.Cardiovascular system	136
Acquin 5 (QA)	
.Cardiovascular system	136
Acquin Aspen 10 (AS)	
.Cardiovascular system	136
Acquin Aspen 20 (AS)	
.Cardiovascular system	136
Acquin Aspen 5 (AS)	
.Cardiovascular system	136
Acris Combi (AF)	
.Musculo-skeletal system	404
Acris Once-a-Week (AF)	

GENERIC/PROPRIETARY INDEX

.Musculo-skeletal system.....	400	<i>Adaptic 2012 (JJ)</i>	
<i>Actemra (RO)</i>		.Repatriation Schedule	953
.Section 100	694, 699, 842, 847	<i>Adcirca (LY)</i>	
<i>Actilax (AF)</i>		.Section 100.....	607, 753
.Alimentary tract and metabolism	85	<i>add-ins (SB)</i>	
.Palliative Care	523	.Various	514
<i>Actiq (OA)</i>		<i>Addos XR 30 (QA)</i>	
.Palliative Care	532	.Cardiovascular system	131
<i>Actisorb Plus MAC031 (JJ)</i>		<i>Addos XR 60 (QA)</i>	
.Repatriation Schedule.....	944	.Cardiovascular system	131
<i>Actonel (SW)</i>		<i>Adefin 10 (AF)</i>	
.Musculo-skeletal system.....	400, 401	.Cardiovascular system	130
.Repatriation Schedule.....	929	<i>Adefin 20 (AF)</i>	
<i>Actonel Combi (SW)</i>		.Cardiovascular system	130
.Repatriation Schedule	929	<i>Adefin XL 30 (AF)</i>	
<i>Actonel Combi D (SW)</i>		.Cardiovascular system	131
.Musculo-skeletal system.....	405	<i>Adefin XL 60 (AF)</i>	
.Repatriation Schedule.....	930	.Cardiovascular system	131
<i>Actonel EC (SW)</i>		ADEFOVIR DIPIVOXIL	
.Musculo-skeletal system.....	400	.Section 100.....	613, 760
<i>Actonel EC Combi (SW)</i>		ADRENALINE	
.Musculo-skeletal system.....	404	.Cardiovascular system	118, 119
<i>Actonel EC Combi D (SW)</i>		.Dental.....	541, 561
.Musculo-skeletal system.....	404	.Respiratory system.....	486
<i>Actonel Once-a-Month (SW)</i>		<i>Adronat (AF)</i>	
.Musculo-skeletal system.....	400	.Musculo-skeletal system.....	398
<i>Actonel Once-a-Week (SW)</i>		<i>ADT Booster (CS)</i>	
.Repatriation Schedule.....	929	.Antiinfectives for systemic use.....	221
<i>Actos (LY)</i>		.Emergency Drug Supplies.....	64
.Alimentary tract and metabolism	98, 99	<i>Advantan (CS)</i>	
<i>Actrapid (NO)</i>		.Dermatologicals	170, 171
.Alimentary tract and metabolism	92	<i>Aeron 250 (QA)</i>	
<i>Actrapid Penfill 3 mL (NO)</i>		.Respiratory system.....	486
.Alimentary tract and metabolism	92	<i>Aeron 500 (QA)</i>	
<i>Acyclo-V 200 (AF)</i>		.Respiratory system.....	486
.Antiinfectives for systemic use	215	<i>AgaMatrix Jazz (HE)</i>	
<i>Acyclo-V 800 (AF)</i>		.Various	505, 506
.Antiinfectives for systemic use	216	<i>Aggrastat (AS)</i>	
<i>Adalat 10 (BN)</i>		.Blood and blood forming organs.....	110
.Cardiovascular system	130	<i>Airomir (IA)</i>	
<i>Adalat 20 (BN)</i>		.Emergency Drug Supplies.....	65
.Cardiovascular system	131	.Respiratory system.....	482
<i>Adalat Oros 20mg (BN)</i>		<i>Airomir Autohaler (IA)</i>	
.Cardiovascular system	131	.Respiratory system.....	483
<i>Adalat Oros 30 (BN)</i>		<i>Akamin 50 (AF)</i>	
.Cardiovascular system	131	.Antiinfectives for systemic use.....	195
<i>Adalat Oros 60 (BN)</i>		<i>Akineton (LM)</i>	
.Cardiovascular system	131	.Nervous system.....	433
ADALIMUMAB		<i>Albalon Liquifilm (AG)</i>	
.Antineoplastic and immunomodulating agents ...	263, 268, 271, 274, 277, 280, 283, 289, 295, 300, 303, 307, 310, 314	.Repatriation Schedule	937
.Section 100	635, 783	<i>Albalon-A (AG)</i>	
ADAPALENE with BENZOYL PEROXIDE		.Repatriation Schedule	937
.Dermatologicals	171	ALBENDAZOLE	
		.Antiparasitic products, insecticides and repellents	480, 481

GENERIC/PROPRIETARY INDEX

<i>Albey Bee Venom (HL)</i>		<i>Allereze (AF)</i>	
.Various	501	.Repatriation Schedule	936
<i>Albey Paper Wasp Venom (HL)</i>		<i>Allewyn 66007637 (SN)</i>	
.Various	501	.Repatriation Schedule	946
<i>Albey Yellow Jacket Venom (HL)</i>		<i>Allewyn Adhesive 66000044 (SN)</i>	
.Various	501	.Repatriation Schedule	946
<i>Aldactone (PF)</i>		<i>Allewyn Ag Adhesive 66800073 (SN)</i>	
.Cardiovascular system	123	.Repatriation Schedule	947
<i>Aldara (IA)</i>		<i>Allewyn Ag Adhesive 66800075 (SN)</i>	
.Dermatologicals	173	.Repatriation Schedule	947
.Repatriation Schedule	920	<i>Allewyn Ag Adhesive 66800078 (SN)</i>	
<i>Aldomet (AS)</i>		.Repatriation Schedule	947
.Cardiovascular system	120	<i>Allewyn Ag Gentle 66800460 (SN)</i>	
<i>Alendro Once Weekly (QA)</i>		.Repatriation Schedule	947
.Musculo-skeletal system	398	<i>Allewyn Ag Gentle 66800461 (SN)</i>	
<i>Alendrobell 70mg (GQ)</i>		.Repatriation Schedule	947
.Musculo-skeletal system	398	<i>Allewyn Ag Gentle 66800462 (SN)</i>	
<i>Alendronate Sandoz (SZ)</i>		.Repatriation Schedule	947
.Musculo-skeletal system	398	<i>Allewyn Ag Non-Adhesive 66800086 (SN)</i>	
ALENDRONATE SODIUM		.Repatriation Schedule	947
.Musculo-skeletal system	398	<i>Allewyn Gentle 66800248 (SN)</i>	
ALENDRONATE SODIUM with COLECALCIFEROL		.Repatriation Schedule	947
.Musculo-skeletal system	402	<i>Allewyn Gentle Border 66800269 (SN)</i>	
ALENDRONATE SODIUM with COLECALCIFEROL and		.Repatriation Schedule	947
CALCIUM CARBONATE		<i>Allewyn Gentle Border 66800270 (SN)</i>	
.Musculo-skeletal system	403	.Repatriation Schedule	947
<i>Alendronate-GA (GM)</i>		<i>Allewyn Plus Cavity 66047571 (SN)</i>	
.Musculo-skeletal system	398	.Repatriation Schedule	948
<i>Alepam 15 (AF)</i>		<i>Allewyn Plus Cavity 66047573 (SN)</i>	
.Dental	560	.Repatriation Schedule	948
.Nervous system	455, 456	<i>Allewyn Thin 66047576 (SN)</i>	
.Palliative Care	535	.Repatriation Schedule	949
<i>Alepam 30 (AF)</i>		<i>Allewyn Thin 66047578 (SN)</i>	
.Dental	560	.Repatriation Schedule	949
.Nervous system	455, 456	ALLOPURINOL	
.Palliative Care	535	.Musculo-skeletal system	397
<i>Alfaré (NT)</i>		<i>Allopurinol Sandoz (SZ)</i>	
.Various	510	.Musculo-skeletal system	397
ALFUZOSIN HYDROCHLORIDE		<i>Allosig (FM)</i>	
.Repatriation Schedule	925	.Musculo-skeletal system	397
<i>Algisite M 66000519 (SN)</i>		<i>Alodorm (AF)</i>	
.Repatriation Schedule	945	.Dental	560
<i>Algisite M 66000520 (SN)</i>		.Nervous system	425, 456
.Repatriation Schedule	945	.Palliative Care	536
<i>Algisite M 66000521 (SN)</i>		<i>Aloxi (TS)</i>	
.Repatriation Schedule	945	.Alimentary tract and metabolism	83
<i>Alkeran (AS)</i>		<i>Alpha Keri Bath Oil (MT)</i>	
.Antineoplastic and immunomodulating agents	222	.Repatriation Schedule	917
ALLANTOIN with GLYCEROL and ICHTHAMMOL		<i>Alpha Keri Lotion (MT)</i>	
.Repatriation Schedule	920	.Repatriation Schedule	917
ALLANTOIN with SULFUR, PHENOL, COAL TAR SOLUTION		<i>Alphagan (AG)</i>	
and MENTHOL		.Optometrical	566
.Repatriation Schedule	918	.Sensory organs	491
<i>Allegron (AS)</i>		<i>Alphagan P 1.5 (AG)</i>	
.Nervous system	458	.Optometrical	566

GENERIC/PROPRIETARY INDEX

.Sensory organs.....	490	PHENYLALANINE and TYROSINE, and supplemented with DOCOSAHEXANOIC ACID	
<i>Alphamox 125 (AF)</i>		.Various	513
.Antiinfectives for systemic use	195	AMINO ACID FORMULA with FAT, CARBOHYDRATE, VITAMINS, MINERALS, and TRACE ELEMENTS, without METHIONINE and supplemented with DOCOSAHEXANOIC ACID	
.Dental.....	545	.Various	512
<i>Alphamox 250 (AF)</i>		AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPHAN	
.Antiinfectives for systemic use	195	.Various	513
.Dental.....	544, 545	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE	
<i>Alphamox 500 (AF)</i>		.Various	513, 514
.Antiinfectives for systemic use	195	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE, THREONINE and VALINE and low in ISOLEUCINE	
.Dental.....	544	.Various	514
<i>Alphapress 25 (AF)</i>		AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	
.Cardiovascular system	121	.Various	514
<i>Alphapress 50 (AF)</i>		AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE	
.Cardiovascular system	121	.Various	515
<i>Alprax 0.25 (QA)</i>		AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEUCINE	
.Nervous system.....	454	.Various	515
<i>Alprax 0.5 (QA)</i>		AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEUCINE with FAT, CARBOHYDRATE and TRACE ELEMENTS and supplemented with DOCOSAHEXANOIC ACID	
.Nervous system.....	454	.Various	515
<i>Alprax 1 (QA)</i>		AMINO ACID FORMULA with VITAMINS, MINERALS and LONG CHAIN POLYUNSATURATED FATTY ACIDS without PHENYLALANINE	
.Nervous system.....	454	.Various	513
<i>Alprax 2 (QA)</i>		AMINO ACID FORMULA without PHENYLALANINE	
.Nervous system.....	454	.Various	513
ALPRAZOLAM		AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS	
.Nervous system.....	454	.Various	508
<i>Alprazolam Sandoz (SZ)</i>		AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY ACIDS and MEDIUM CHAIN TRIGLYCERIDES	
.Nervous system.....	454	.Various	508, 509
<i>Alprim (AF)</i>		AMINO ACIDS—SYNTHETIC, FORMULA	
.Antiinfectives for systemic use	204	.Various	506, 507
ALPROSTADIL		AMIODARONE	
.Repatriation Schedule.....	921	.Cardiovascular system	118
<i>Altven (FZ)</i>		<i>Amiodarone Sandoz (SZ)</i>	
.Nervous system.....	466, 467	.Cardiovascular system	118
ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE		<i>Amipride 400 (QA)</i>	
.Alimentary tract and metabolism	71	.Nervous system.....	448
ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE and SIMETHICONE		<i>Amira 150 (AF)</i>	
.Repatriation Schedule.....	911	.Nervous system.....	464
ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE			
.Alimentary tract and metabolism	71		
<i>Alvesco 160 (NQ)</i>			
.Respiratory system	485		
<i>Alvesco 80 (NQ)</i>			
.Respiratory system	485		
<i>Alzene (AF)</i>			
.Repatriation Schedule.....	936		
AMANTADINE HYDROCHLORIDE			
.Nervous system.....	434		
<i>Amaryl (SW)</i>			
.Alimentary tract and metabolism	95		
AMBRISENTAN			
.Section 100	581, 727		
AMINO ACID FORMULA with FAT, CARBOHYDRATE, VITAMINS, MINERALS and TRACE ELEMENTS without			

GENERIC/PROPRIETARY INDEX

<i>Amira 300 (AF)</i>		<i>.Antiinfectives for systemic use.....</i>	195, 196
<i>.Nervous system.....</i>	464	<i>.Dental.....</i>	544
AMISULPRIDE		<i>Amoxycillin Sandoz (BG)</i>	
<i>.Nervous system.....</i>	447	<i>.Antiinfectives for systemic use.....</i>	196
<i>Amisulpride 100 Winthrop (WA)</i>		<i>Amoxycillin Sandoz (SZ)</i>	
<i>.Nervous system.....</i>	447	<i>.Antiinfectives for systemic use.....</i>	195, 196
<i>Amisulpride 200 Winthrop (WA)</i>		<i>.Dental.....</i>	544, 545
<i>.Nervous system.....</i>	448	AMOXYCILLIN with CLAVULANIC ACID	
<i>Amisulpride 400 Winthrop (WA)</i>		<i>.Antiinfectives for systemic use.....</i>	198
<i>.Nervous system.....</i>	448	<i>.Dental.....</i>	546
<i>Amisulpride Sandoz (SZ)</i>		<i>Amoxycillin/ Clavulanic Acid 500/125 generichealth (GQ)</i>	
<i>.Nervous system.....</i>	447, 448	<i>.Antiinfectives for systemic use.....</i>	198
AMITRIPTYLINE HYDROCHLORIDE		<i>.Dental.....</i>	547
<i>.Nervous system.....</i>	457	<i>Amoxycillin/ Clavulanic Acid 875/125 generichealth (GQ)</i>	
<i>Amlo 10 (ZP)</i>		<i>.Antiinfectives for systemic use.....</i>	198
<i>.Cardiovascular system</i>	129	<i>.Dental.....</i>	547
<i>Amlo 5 (ZP)</i>		<i>Amoxycillin-GA (GM)</i>	
<i>.Cardiovascular system</i>	129	<i>.Antiinfectives for systemic use.....</i>	195, 196
AMLODIPINE		<i>.Dental.....</i>	544
<i>.Cardiovascular system</i>	129	AMPHOTERICIN	
AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM		<i>.Alimentary tract and metabolism</i>	71
<i>.Cardiovascular system</i>	164	<i>.Dental.....</i>	538
<i>Amlodipine generichealth (GQ)</i>		AMPICILLIN	
<i>.Cardiovascular system</i>	129	<i>.Antiinfectives for systemic use.....</i>	196
<i>Amlodipine Pfizer (FZ)</i>		<i>.Dental.....</i>	545
<i>.Cardiovascular system</i>	129	AMYLOPECTIN, MODIFIED LONG CHAIN	
<i>Amlodipine Sandoz (SZ)</i>		<i>.Various</i>	511
<i>.Cardiovascular system</i>	129	<i>Anafranil 25 (NV)</i>	
AMLODIPINE with VALSARTAN		<i>.Nervous system.....</i>	456, 458
<i>.Cardiovascular system</i>	145	<i>Anamorph (FM)</i>	
AMLODIPINE with VALSARTAN and		<i>.Dental.....</i>	557
HYDROCHLOROTHIAZIDE		<i>.Nervous system.....</i>	411
<i>.Cardiovascular system</i>	146	<i>Anandron (SW)</i>	
<i>Amlodipine-DRLA (RZ)</i>		<i>.Antineoplastic and immunomodulating agents</i>	249
<i>.Cardiovascular system</i>	129	<i>Anapen (LM)</i>	
<i>Amlodipine-GA (GM)</i>		<i>.Cardiovascular system</i>	119
<i>.Cardiovascular system</i>	129	<i>.Respiratory system.....</i>	487
AMOROLFINE HYDROCHLORIDE		<i>Anapen Junior (LM)</i>	
<i>.Repatriation Schedule.....</i>	916	<i>.Cardiovascular system</i>	119
<i>Amoxil (GK)</i>		<i>.Respiratory system.....</i>	487
<i>.Special Pharmaceutical Benefits</i>	68, 69	<i>Anaprox 550 (RO)</i>	
<i>.Antiinfectives for systemic use</i>	195, 196	<i>.Dental.....</i>	555
<i>.Dental.....</i>	544, 545	<i>.Musculo-skeletal system</i>	394
<i>.Special Pharmaceutical Benefits</i>	68	<i>.Palliative Care.....</i>	530
<i>Amoxil Forte (GK)</i>		<i>Anastrol (QA)</i>	
<i>.Antiinfectives for systemic use</i>	195	<i>.Antineoplastic and immunomodulating agents</i>	249
<i>.Dental.....</i>	545	ANASTROZOLE	
AMOXYCILLIN		<i>.Antineoplastic and immunomodulating agents</i>	249
<i>.Special Pharmaceutical Benefits</i>	68, 69	<i>Anastrozole GH (GQ)</i>	
<i>.Antiinfectives for systemic use</i>	195, 196	<i>.Antineoplastic and immunomodulating agents</i>	249
<i>.Dental.....</i>	544	<i>Anastrozole RBX (RA)</i>	
<i>Amoxycillin generichealth 500 (GQ)</i>		<i>.Antineoplastic and immunomodulating agents</i>	249
<i>.Antiinfectives for systemic use</i>	196	<i>Anastrozole Sandoz (SZ)</i>	
<i>.Dental.....</i>	544	<i>.Antineoplastic and immunomodulating agents</i>	249
<i>Amoxycillin Ranbaxy (RA)</i>		<i>Anastrozole Synthon (ZT)</i>	

GENERIC/PROPRIETARY INDEX

.Antineoplastic and immunomodulating agents 249	.Blood and blood forming organs..... 111, 112
<i>Anastrozole-DRLA (RZ)</i>	<i>APO- Hydroxychloroquine (TX)</i>
.Antineoplastic and immunomodulating agents 249	.Musculo-skeletal system..... 395
<i>Anastrozole-GA (GM)</i>	<i>APO- Paracetamol/Codeine 500/30 (TX)</i>
.Antineoplastic and immunomodulating agents 249	.Dental..... 556
<i>Anastrozole-PS (FZ)</i>	.Nervous system..... 408
.Antineoplastic and immunomodulating agents 249	<i>APO-Alendronate (TX)</i>
<i>Andriol Testocaps (MK)</i>	.Musculo-skeletal system..... 398
.Genito urinary system and sex hormones 177	<i>APO-Amisulpride (TX)</i>
<i>Androcur (BN)</i>	.Nervous system..... 447, 448
.Antineoplastic and immunomodulating agents 248	<i>APO-Amlodipine (TX)</i>
.Genito urinary system and sex hormones 181	.Cardiovascular system 129
<i>Androcur-100 (BN)</i>	<i>APO-Amoxycillin (TX)</i>
.Antineoplastic and immunomodulating agents 248	.Antiinfectives for systemic use..... 195, 196
.Genito urinary system and sex hormones 182	.Dental..... 544
<i>Androderm (HH)</i>	<i>APO-Amoxycillin/ Clavulanic Acid 500/125 (TX)</i>
.Genito urinary system and sex hormones 177	.Antiinfectives for systemic use..... 198
<i>Anginine Stabilised (QA)</i>	.Dental..... 547
.Cardiovascular system 119	<i>APO-Anastrozole (TX)</i>
.Dental..... 541	.Antineoplastic and immunomodulating agents 249
<i>Angiomax (XM)</i>	<i>APO-Atenolol (TX)</i>
.Blood and blood forming organs..... 110	.Cardiovascular system 125
<i>Anpec 40 (AF)</i>	<i>APO-Atorvastatin (TX)</i>
.Cardiovascular system 131	.Cardiovascular system 149, 150, 151, 152
<i>Anpec 80 (AF)</i>	<i>APO-Bicalutamide (TX)</i>
.Cardiovascular system 131	.Antineoplastic and immunomodulating agents 248
ANTAZOLINE with NAPHAZOLINE	<i>APO-Bisoprolol (TX)</i>
.Repatriation Schedule..... 937	.Cardiovascular system 125, 126
<i>Antenex 2 (AF)</i>	<i>APO-Carvedilol (TX)</i>
.Dental..... 559	.Cardiovascular system 127, 128
.Nervous system..... 455	<i>APO-Cephalexin (TX)</i>
.Palliative Care 534, 535	.Antiinfectives for systemic use..... 199, 200
<i>Antenex 5 (AF)</i>	.Dental..... 548
.Dental..... 559	<i>APO-Citalopram (TX)</i>
.Nervous system..... 455	.Nervous system..... 459
.Palliative Care 534, 535	<i>APO-Clarithromycin (TX)</i>
<i>Anthel 125 (AF)</i>	.Antiinfectives for systemic use..... 205
.Antiparasitic products, insecticides and repellents	<i>APO-Clopidogrel (TX)</i>
..... 481	.Blood and blood forming organs..... 107
<i>Anthel 250 (AF)</i>	<i>APO-Clotrimazole 3 Day Cream (TX)</i>
.Antiparasitic products, insecticides and repellents	.Repatriation Schedule 921
..... 481	<i>APO-Clotrimazole 6 Day Cream (TX)</i>
<i>Antroquoril (FR)</i>	.Repatriation Schedule 921
.Dermatologicals 170	<i>APO-Diazepam (TX)</i>
<i>Anusol (JT)</i>	.Dental..... 559
.Repatriation Schedule..... 915	.Nervous system..... 455
<i>Anzole (WQ)</i>	.Palliative Care..... 534, 535
.Antineoplastic and immunomodulating agents 249	<i>APO-Diclofenac (TX)</i>
<i>Apidra (AV)</i>	.Dental..... 553
.Alimentary tract and metabolism 91	.Musculo-skeletal system..... 391
<i>Apidra (SW)</i>	.Palliative Care..... 527, 528
.Alimentary tract and metabolism 91	<i>APO-Escitalopram (TX)</i>
<i>Apidra SoloStar (SW)</i>	.Nervous system..... 459, 460
.Alimentary tract and metabolism 91	<i>APO-Exemestane (TX)</i>
APIXABAN	.Antineoplastic and immunomodulating agents 250

GENERIC/PROPRIETARY INDEX

<i>APO-Famciclovir (TX)</i>		
.Anti-infectives for systemic use	216, 217, 218	
<i>APO-Fluconazole (TX)</i>		
.Anti-infectives for systemic use	212	
<i>APO-Fluvoxamine (TX)</i>		
.Nervous system.....	461	
<i>APO-Fosinopril HCTZ 10/12.5 (TX)</i>		
.Cardiovascular system	140	
<i>APO-Fosinopril HCTZ 20/12.5 (TX)</i>		
.Cardiovascular system	140	
<i>APO-Gabapentin (TX)</i>		
.Nervous system.....	427	
<i>APO-Galantamine MR (TX)</i>		
.Nervous system.....	471, 472	
<i>APO-Gliclazide MR (TX)</i>		
.Alimentary tract and metabolism	94	
<i>APO-Glimepiride (TX)</i>		
.Alimentary tract and metabolism	95	
<i>APO-Ipratropium (TX)</i>		
.Respiratory system	486	
<i>APO-Isotretinoin (TX)</i>		
.Dermatologicals	172	
<i>APO-Lamotrigine (TX)</i>		
.Nervous system.....	428, 429	
<i>APO-Lansoprazole (TX)</i>		
.Alimentary tract and metabolism	74, 75	
<i>APO-Latanoprost (TX)</i>		
.Optomical.....	568	
.Sensory organs.....	492	
<i>APO-Leflunomide (TX)</i>		
.Antineoplastic and immunomodulating agents	262	
<i>APO-Lercanidipine (TX)</i>		
.Cardiovascular system	130	
<i>APO-Letrozole (TX)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>APO-Levetiracetam (TX)</i>		
.Nervous system.....	429, 430	
<i>APO-Lisinopril (TX)</i>		
.Cardiovascular system	134	
<i>APO-Meloxicam (TX)</i>		
.Musculo-skeletal system.....	392, 393	
<i>APO-Memantine (TX)</i>		
.Nervous system.....	475	
<i>APO-Metformin 1000 (TX)</i>		
.Alimentary tract and metabolism	94	
<i>APO-Metformin 500 (TX)</i>		
.Alimentary tract and metabolism	93	
<i>APO-Metformin 850 (TX)</i>		
.Alimentary tract and metabolism	93	
<i>Apomine (HH)</i>		
.Section 100	709, 858	
<i>Apomine PFS (HH)</i>		
.Section 100	709, 858	
<i>APO-Mirtazapine (TX)</i>		
.Nervous system.....	466	
<i>APO-MORPHINE HYDROCHLORIDE</i>		
.Section 100.....	709, 858	
<i>APO-Mycophenolate (TX)</i>		
.Antineoplastic and immunomodulating agents ...	262, 263	
.Section 100.....	634, 782	
<i>APO-Nifedipine XR (TX)</i>		
.Cardiovascular system	131	
<i>APO-Olanzapine (TX)</i>		
.Nervous system.....	440, 441, 442	
<i>APO-Olanzapine ODT (TX)</i>		
.Nervous system.....	443, 444, 445	
<i>APO-Omeprazole (TX)</i>		
.Alimentary tract and metabolism	75, 76	
<i>APO-Ondansetron (TX)</i>		
.Alimentary tract and metabolism	80, 81, 82	
<i>APO-Oxazepam (TX)</i>		
.Dental.....	560	
.Nervous system.....	455, 456	
.Palliative Care.....	535	
<i>APO-Pantoprazole (TX)</i>		
.Alimentary tract and metabolism	77, 78	
<i>APO-Paracetamol (TX)</i>		
.Dental.....	558	
.Nervous system.....	420	
<i>APO-Perindopril (TX)</i>		
.Cardiovascular system	135, 136	
<i>APO-Pravastatin (TX)</i>		
.Cardiovascular system	152, 153, 154, 155	
<i>APO-Prazosin (TX)</i>		
.Cardiovascular system	121	
<i>APO-Prochlorperazine (TX)</i>		
.Alimentary tract and metabolism	84	
.Dental.....	538	
<i>APO-Quetiapine (TX)</i>		
.Nervous system.....	445, 446, 447	
<i>APO-Quinapril (TX)</i>		
.Cardiovascular system	136	
<i>APO-Ramipril (TX)</i>		
.Cardiovascular system	137, 138, 139	
<i>APO-Risedronate (TX)</i>		
.Musculo-skeletal system	400	
.Repatriation Schedule	929	
<i>APO-Risperidone (TX)</i>		
.Nervous system.....	450, 451, 452, 453	
<i>APO-Roxithromycin (TX)</i>		
.Anti-infectives for systemic use.....	206	
.Dental.....	551	
<i>APO-Salbutamol Inhaler (TX)</i>		
.Emergency Drug Supplies.....	65	
.Respiratory system.....	482	
<i>APO-Simvastatin (TX)</i>		
.Cardiovascular system	156, 157, 158, 159, 160	
<i>APO-Sumatriptan (TX)</i>		
.Nervous system.....	422	

GENERIC/PROPRIETARY INDEX

<i>APO-Temazepam (TX)</i>		<i>Aratac 200 (AF)</i>	
.Dental.....	560	.Cardiovascular system	118
.Nervous system.....	457	<i>Arava (SW)</i>	
.Palliative Care	536	.Antineoplastic and immunomodulating agents ...	261,
<i>APOTEX-MORPHINE MR (TX)</i>		262	
.Nervous system.....	411	<i>Aredia 15 mg (NV)</i>	
<i>APOTEX-Pioglitazone (TX)</i>		.Musculo-skeletal system	399
.Alimentary tract and metabolism	98, 99	.Section 100.....	707, 856
<i>APO-Topiramate (TX)</i>		<i>Aredia 30 mg (NV)</i>	
.Nervous system.....	431, 432	.Musculo-skeletal system	399
<i>APO-Tramadol (TX)</i>		.Section 100.....	707, 856
.Dental.....	557	<i>Aredia 90 mg (NV)</i>	
.Nervous system.....	418	.Section 100.....	708, 857
<i>APO-Tramadol SR (TX)</i>		<i>Arginine 2000 Amino Acid Supplement (VF)</i>	
.Nervous system.....	419	.Various	516
<i>APO-Trandolapril (TX)</i>		<i>Arginine Amino Acid Supplement (VF)</i>	
.Cardiovascular system	139, 140	.Various	516
<i>APO-Valaciclovir (TX)</i>		ARGININE with CARBOHYDRATE	
.Antiinfectives for systemic use	218, 219, 220	.Various	515
.Section 100	611, 758	<i>Arianna (AF)</i>	
<i>APO-Venlafaxine XR (TX)</i>		.Antineoplastic and immunomodulating agents	249
.Nervous system.....	466	<i>Aricept (PF)</i>	
APRACLOPIDINE HYDROCHLORIDE		.Nervous system.....	470
.Sensory organs.....	490	<i>Arimidex (AP)</i>	
APREPITANT		.Antineoplastic and immunomodulating agents	249
.Alimentary tract and metabolism	83	ARIPRAZOLE	
<i>Aptivus (BY)</i>		.Nervous system.....	448
.Section 100	613, 760	<i>Aristocort 0.02% (QA)</i>	
<i>Aquacare H.P. (AG)</i>		.Dermatologicals	169, 170
.Repatriation Schedule.....	917	<i>Arixtra (GK)</i>	
<i>Aquacel 177902 (CC)</i>		.Blood and blood forming organs.....	112
.Repatriation Schedule.....	951	<i>Aromasin (PF)</i>	
<i>Aquacel 177903 (CC)</i>		.Antineoplastic and immunomodulating agents	250
.Repatriation Schedule.....	951	<i>Aropax (GK)</i>	
<i>Aquacel 177904 (CC)</i>		.Nervous system.....	462
.Repatriation Schedule.....	951	<i>Artane (QA)</i>	
<i>Aquaclear 900796 (HR)</i>		.Nervous system.....	433
.Repatriation Schedule.....	952	ARTEMETHER with LUMEFANTRINE	
<i>Aquae (VT)</i>		.Antiparasitic products, insecticides and repellents	
.Palliative Care	521	480
.Repatriation Schedule.....	911	<i>Arthrexin (AF)</i>	
<i>Aquae Gel (VT)</i>		.Dental.....	553
.Palliative Care	521, 522	.Musculo-skeletal system	391
<i>Aquasun Lotion SPF 18 (PF)</i>		.Palliative Care	528
.Repatriation Schedule.....	918	<i>Arthrotec 50 (PF)</i>	
<i>Aquinafil (GN)</i>		.Repatriation Schedule	929
.Cardiovascular system	136	<i>Asasantin SR (BY)</i>	
<i>Arabloc (AV)</i>		.Blood and blood forming organs.....	109
.Antineoplastic and immunomodulating agents	262	ASENAPINE	
<i>Aranesp (AN)</i>		.Nervous system.....	440
.Section 100	579, 725	<i>Asmol 2.5 uni-dose (AF)</i>	
<i>Aranesp SureClick (AN)</i>		.Emergency Drug Supplies.....	65
.Section 100	579, 725	.Respiratory system.....	483
<i>Aratac 100 (AF)</i>		<i>Asmol 5 uni-dose (AF)</i>	
.Cardiovascular system	118	.Emergency Drug Supplies.....	66

GENERIC/PROPRIETARY INDEX

.Respiratory system	483	.Cardiovascular system	149, 150, 151, 152
<i>Asmol CFC-free (AL)</i>		<i>Atorvastatin SCP 10 (RZ)</i>	
.Emergency Drug Supplies	65	.Cardiovascular system	149, 151
.Respiratory system	482	<i>Atorvastatin SCP 20 (RZ)</i>	
<i>Aspalgin (FM)</i>		.Cardiovascular system	150, 151
.Repatriation Schedule	931	<i>Atorvastatin SCP 40 (RZ)</i>	
<i>Aspalgin 40 (QA)</i>		.Cardiovascular system	150, 151
.Repatriation Schedule	931	<i>Atorvastatin SCP 80 (RZ)</i>	
<i>Aspen Ampicyn (AS)</i>		.Cardiovascular system	150, 152
.Antiinfectives for systemic use	196	ATOVAQUONE	
.Dental.....	545	.Antiparasitic products, insecticides and repellents	
<i>Aspen Pharma Pty Ltd (QA)</i>		479
.Nervous system.....	423, 468	ATOVAQUONE with PROGUANIL HYDROCHLORIDE	
ASPIRIN		.Antiparasitic products, insecticides and repellents	
.Blood and blood forming organs.....	106	479
.Dental.....	558	<i>Atrauman 499513 (HR)</i>	
.Nervous system.....	420	.Repatriation Schedule	952
.Repatriation Schedule	914	<i>Atrauman Ag 499572 (HR)</i>	
<i>Astrix (YN)</i>		.Repatriation Schedule	953
.Blood and blood forming organs.....	107	<i>Atripla (GI)</i>	
.Repatriation Schedule	914	.Section 100.....	618, 765
<i>Astromide (WQ)</i>		ATROPINE	
.Antineoplastic and immunomodulating agents ...	222, 223	.Alimentary tract and metabolism	79
<i>Atacand (AP)</i>		.Dental.....	538
.Cardiovascular system	142	.Sensory organs	493
<i>Atacand Plus 16/12.5 (AP)</i>		<i>Atropt (QA)</i>	
.Cardiovascular system	144	.Sensory organs	493
<i>Atacand Plus 32/12.5 (AP)</i>		<i>Atrovent (BY)</i>	
.Cardiovascular system	144	.Respiratory system.....	486
<i>Atacand Plus 32/25 (AP)</i>		<i>Atrovent Adult (BY)</i>	
.Cardiovascular system	144	.Respiratory system.....	486
ATAZANAVIR		<i>Atrovent Nasal Aqueous (BY)</i>	
.Section 100	612, 758	.Repatriation Schedule	935
ATENOLOL		<i>Atrovent Nasal Forte (BY)</i>	
.Cardiovascular system	125	.Repatriation Schedule	935
<i>Atenolol generichealth (GQ)</i>		<i>Augmentin (GK)</i>	
.Cardiovascular system	125	.Antiinfectives for systemic use.....	198
<i>Atenolol Sandoz (SZ)</i>		.Dental.....	547
.Cardiovascular system	125	<i>Augmentin Duo (GK)</i>	
<i>Atenolol-GA (GN)</i>		.Antiinfectives for systemic use.....	198
.Cardiovascular system	125	.Dental.....	547
<i>Atenolol-PS (FZ)</i>		<i>Augmentin Duo 400 (GK)</i>	
.Cardiovascular system	125	.Antiinfectives for systemic use.....	199
ATOMOXETINE HYDROCHLORIDE		.Dental.....	547
.Nervous system.....	467	<i>Augmentin Duo forte (GK)</i>	
<i>Atorvachol (GM)</i>		.Antiinfectives for systemic use.....	198
.Cardiovascular system	149, 150, 151, 152	.Dental.....	547
ATORVASTATIN		AURANOFIN	
.Cardiovascular system	149, 151	.Musculo-skeletal system	395
<i>Atorvastatin GH (GQ)</i>		<i>Auro-Amlodipine 10 (DO)</i>	
.Cardiovascular system	149, 150, 151, 152	.Cardiovascular system	129
<i>Atorvastatin Pfizer (FZ)</i>		<i>Auro-Amlodipine 5 (DO)</i>	
.Cardiovascular system	149, 150, 151, 152	.Cardiovascular system	129
<i>Atorvastatin Sandoz (SZ)</i>		<i>Auro-Citalopram 20 (DO)</i>	
		.Nervous system.....	459

GENERIC/PROPRIETARY INDEX

<i>Auro-Citalopram 40 (DO)</i>		
.Nervous system.....	459	
<i>Aurorix (VP)</i>		
.Nervous system.....	464	
<i>Aurorix 300 mg (VP)</i>		
.Nervous system.....	464	
<i>Auro-Sertraline 100 (DO)</i>		
.Nervous system.....	462, 463	
<i>Auro-Sertraline 50 (DO)</i>		
.Nervous system.....	462, 463	
<i>Auro-Simvastatin 10 (DO)</i>		
.Cardiovascular system	156, 158	
<i>Auro-Simvastatin 20 (DO)</i>		
.Cardiovascular system	156, 159	
<i>Auro-Simvastatin 40 (DO)</i>		
.Cardiovascular system	157, 159	
<i>Auro-Simvastatin 80 (DO)</i>		
.Cardiovascular system	157, 160	
<i>Aurozapine 30 (DO)</i>		
.Nervous system.....	465	
<i>Aurozapine 45 (DO)</i>		
.Nervous system.....	466	
<i>Auscap (QA)</i>		
.Nervous system.....	461	
<i>Ausfam 20 (QA)</i>		
.Alimentary tract and metabolism	71	
<i>Ausfam 40 (QA)</i>		
.Alimentary tract and metabolism	72	
<i>Ausgem (QA)</i>		
.Cardiovascular system	161	
<i>Auspril (QA)</i>		
.Cardiovascular system	133	
<i>Ausran (QA)</i>		
.Alimentary tract and metabolism	72	
<i>Austrapen (LN)</i>		
.Anti-infectives for systemic use	196	
.Dental.....	545	
<i>Avandamet (GK)</i>		
.Alimentary tract and metabolism	96	
<i>Avandia (GK)</i>		
.Alimentary tract and metabolism	99	
<i>Avanza (MK)</i>		
.Nervous system.....	465, 466	
<i>Avanza SolTab (MK)</i>		
.Nervous system.....	465	
<i>Avapro (BQ)</i>		
.Cardiovascular system	142, 143	
<i>Avapro HCT 150/12.5 (BQ)</i>		
.Cardiovascular system	144	
<i>Avapro HCT 300/12.5 (BQ)</i>		
.Cardiovascular system	144	
<i>Avapro HCT 300/25 (BQ)</i>		
.Cardiovascular system	144	
<i>Avodart (GK)</i>		
.Genito urinary system and sex hormones	184	
<i>Avonex (BD)</i>		
.Antineoplastic and immunomodulating agents	252	
<i>Axit 15 (AF)</i>		
.Nervous system.....	466	
<i>Axit 30 (AF)</i>		
.Nervous system.....	465	
<i>Axit 45 (AF)</i>		
.Nervous system.....	466	
<i>Aylide 1 (AF)</i>		
.Alimentary tract and metabolism	95	
<i>Aylide 2 (AF)</i>		
.Alimentary tract and metabolism	95	
<i>Aylide 3 (AF)</i>		
.Alimentary tract and metabolism	95	
<i>Aylide 4 (AF)</i>		
.Alimentary tract and metabolism	95	
AZACITIDINE		
.Section 100.....	620, 767	
<i>Azamun (GM)</i>		
.Antineoplastic and immunomodulating agents	390	
<i>Azapin (QA)</i>		
.Antineoplastic and immunomodulating agents	390	
<i>Azarga (AQ)</i>		
.Optometrical.....	567	
.Sensory organs.....	491	
AZATHIOPRINE		
.Antineoplastic and immunomodulating agents	390	
<i>Azathioprine Sandoz (SZ)</i>		
.Antineoplastic and immunomodulating agents	390	
<i>Azilect (LU)</i>		
.Nervous system.....	437	
AZITHROMYCIN		
.Anti-infectives for systemic use.....	205	
.Repatriation Schedule	926	
.Section 100.....	611, 757	
.Sensory organs.....	489	
<i>Azithromycin Sandoz (SZ)</i>		
.Anti-infectives for systemic use.....	205	
.Sensory organs.....	489	
<i>Azol 100 (AF)</i>		
.Genito urinary system and sex hormones.....	182	
<i>Azol 200 (AF)</i>		
.Genito urinary system and sex hormones.....	182	
<i>Azopt (AQ)</i>		
.Optometrical.....	567	
.Sensory organs.....	491	
B		
<i>B. Braun Australia Pty Ltd (BR)</i>		
.Blood and blood forming organs.....	115, 116	
.Dental.....	540	
BACLOFEN		
.Musculo-skeletal system	396	
.Section 100.....	707, 856	

GENERIC/PROPRIETARY INDEX

<i>Bactigras 7457 (SN)</i>		
.Repatriation Schedule	948	
<i>Bactrim (RO)</i>		
.Antiinfectives for systemic use	204	
.Dental.....	550	
<i>Bactrim DS (RO)</i>		
.Antiinfectives for systemic use	204	
.Dental.....	550	
<i>Bactroban (GK)</i>		
.Repatriation Schedule.....	918	
.Respiratory system	482	
BALSALAZIDE SODIUM		
.Alimentary tract and metabolism	88	
BANDAGE—ABSORBENT WOOL		
.Repatriation Schedule	941	
BANDAGE—CALICO		
.Repatriation Schedule	941	
BANDAGE—COMPRESSION		
.Repatriation Schedule.....	941, 942	
BANDAGE—RETENTION—COHESIVE—HEAVY		
.Repatriation Schedule.....	943	
BANDAGE—RETENTION—COHESIVE—LIGHT		
.Repatriation Schedule.....	943	
BANDAGE—RETENTION—COTTON CREPE		
.Repatriation Schedule	943	
BANDAGE—TUBULAR		
.Repatriation Schedule.....	943	
BANDAGE—TUBULAR (FINGER)		
.Repatriation Schedule.....	943	
BANDAGE—TUBULAR (LIGHTWEIGHT)		
.Repatriation Schedule.....	943	
BANDAGE—TUBULAR (LONG STOCKING)		
.Repatriation Schedule	943	
BANDAGE—TUBULAR (SHORT STOCKING)		
.Repatriation Schedule	943	
BANDAGE—ZINC PASTE		
.Repatriation Schedule.....	944	
<i>Baraclude (BQ)</i>		
.Section 100	614, 615, 761	
<i>Barbloc 15 (AF)</i>		
.Cardiovascular system	124	
<i>Barbloc 5 (AF)</i>		
.Cardiovascular system	124	
<i>Baxter Healthcare Pty Ltd (BX)</i>		
.Antiinfectives for systemic use	210, 212	
.Blood and blood forming organs.....	115, 116	
.Dental.....	540, 552	
.Repatriation Schedule.....	914	
BCG IMMUNOTHERAPEUTIC (Bacillus Calmette-Guérin/ Connaught strain)		
.Antineoplastic and immunomodulating agents	253	
BCG-TICE (Bacillus Calmette-Guérin/ Tice strain)		
.Antineoplastic and immunomodulating agents	253	
BECLOMETHASONE DIPROPIONATE		
.Respiratory system	485	
<i>BenPen (CS)</i>		
.Antiinfectives for systemic use.....	196	
.Dental.....	545	
.Emergency Drug Supplies.....	65	
BENZATHINE BENZYL PENICILLIN		
.Antiinfectives for systemic use.....	196	
.Dental.....	545	
BENZHEXOL HYDROCHLORIDE		
.Nervous system.....	433	
<i>Benztrop (PL)</i>		
.Nervous system.....	433	
BENZTROPINE MESYLATE		
.Dental.....	559	
.Nervous system.....	433	
BENZYDAMINE HYDROCHLORIDE		
.Alimentary tract and metabolism	71	
.Dental.....	538	
.Palliative Care.....	521	
BENZYL PENICILLIN		
.Antiinfectives for systemic use.....	196	
.Dental.....	545	
<i>Beprol 10 (DO)</i>		
.Cardiovascular system	126	
<i>Beprol 2.5 (DO)</i>		
.Cardiovascular system	125	
<i>Beprol 5 (DO)</i>		
.Cardiovascular system	126	
<i>Bergoline 1 (QA)</i>		
.Nervous system.....	435	
<i>Bergoline 2 (QA)</i>		
.Nervous system.....	435	
<i>Betachek (NA)</i>		
.Various	504, 505	
<i>Betachek G5 (NA)</i>		
.Various	504, 505	
<i>Betadine Antiseptic Liquid (SW)</i>		
.Repatriation Schedule	919	
<i>Betaferon (BN)</i>		
.Antineoplastic and immunomodulating agents	253	
<i>Betaloc (AP)</i>		
.Cardiovascular system	127	
BETAMETHASONE ACETATE with BETAMETHASONE SODIUM PHOSPHATE		
.Dental.....	543	
.Systemic hormonal preparations, excl. sex hormones and insulins	186	
BETAMETHASONE DIPROPIONATE		
.Dermatologicals	170	
BETAMETHASONE VALERATE		
.Dermatologicals	170	
.Repatriation Schedule	919	
<i>Betamin (SW)</i>		
.Alimentary tract and metabolism	102	
.Repatriation Schedule	913	
BETAXOLOL HYDROCHLORIDE		

GENERIC/PROPRIETARY INDEX

.Optometrical.....	567	.Cardiovascular system	126
.Sensory organs.....	491	<i>Biltricide (BN)</i>	
BETHANECHOL CHLORIDE		.Antiparasitic products, insecticides and repellents	
.Nervous system.....	475	480
<i>Betnovate (QA)</i>		BIMATOPROST	
.Repatriation Schedule.....	919	.Optometrical.....	567
<i>Betnovate 1/2 (QA)</i>		.Sensory organs.....	492
.Dermatologicals	170	BIMATOPROST with TIMOLOL MALEATE	
<i>Betnovate 1/5 (QA)</i>		.Optometrical.....	567
.Dermatologicals	170	.Sensory organs.....	492
<i>Betoptic (AQ)</i>		<i>Biodone Forte (MW)</i>	
.Optometrical.....	567	.Section 100.....	876
.Sensory organs.....	491	<i>Bion Tears (AQ)</i>	
<i>Betoptic S (AQ)</i>		.Optometrical.....	570
.Optometrical.....	567	.Sensory organs.....	498
.Sensory organs.....	491	<i>Bionime Rightest (QB)</i>	
<i>BetoQuin (IQ)</i>		.Various	505, 506
.Optometrical.....	567	BIPERIDEN HYDROCHLORIDE	
.Sensory organs.....	491	.Nervous system.....	433
<i>Bgramin (GM)</i>		BISACODYL	
.Antimicrobials for systemic use	195	.Alimentary tract and metabolism	84, 86
.Dental.....	545	.Palliative Care.....	522, 524
<i>BGStar (SW)</i>		<i>Bisalax (AS)</i>	
.Various	504, 505	.Alimentary tract and metabolism	85, 86
<i>Biatain Adhesive 3420 (CT)</i>		.Palliative Care.....	522, 523, 524
.Repatriation Schedule.....	949	<i>Biso 10 (WQ)</i>	
<i>Biatain Adhesive 3423 (CT)</i>		.Cardiovascular system	126
.Repatriation Schedule.....	949	<i>Biso 2.5 (WQ)</i>	
<i>Biatain Ag 9622 (CT)</i>		.Cardiovascular system	126
.Repatriation Schedule.....	953	<i>Biso 5 (WQ)</i>	
<i>Biatain Ag 9632 (CT)</i>		.Cardiovascular system	126
.Repatriation Schedule.....	953	BISOPROLOL FUMARATE	
<i>Biatain Non-adhesive 3410 (CT)</i>		.Cardiovascular system	125
.Repatriation Schedule.....	949	<i>Bisoprolol GH (GQ)</i>	
<i>Biatain Non-adhesive 3413 (CT)</i>		.Cardiovascular system	126
.Repatriation Schedule.....	949	<i>Bisoprolol Pfizer (FZ)</i>	
<i>Biaxsig (AV)</i>		.Cardiovascular system	126
.Antimicrobials for systemic use	206	<i>Bisoprolol Sandoz (SZ)</i>	
.Dental.....	551	.Cardiovascular system	126
BICALUTAMIDE		<i>Bispro 10 (AF)</i>	
.Antineoplastic and immunomodulating agents	248	.Cardiovascular system	126
<i>Bicalutamide Ranbaxy (RA)</i>		<i>Bispro 2.5 (AF)</i>	
.Antineoplastic and immunomodulating agents	248	.Cardiovascular system	126
<i>Bicalutamide-GA (GM)</i>		<i>Bispro 5 (AF)</i>	
.Antineoplastic and immunomodulating agents	248	.Cardiovascular system	126
<i>Bicard 10 (QA)</i>		BIVALIRUDIN TRIFLUOROACETATE	
.Cardiovascular system	126	.Blood and blood forming organs.....	110
<i>Bicard 2.5 (QA)</i>		<i>Blink Intensive Tears (AO)</i>	
.Cardiovascular system	125	.Optometrical.....	570
<i>Bicard 5 (QA)</i>		.Sensory organs.....	498
.Cardiovascular system	126	<i>Bondronat (HH)</i>	
<i>Bicillin L-A (PF)</i>		.Musculo-skeletal system	400
.Antimicrobials for systemic use	196	.Section 100.....	708, 857
.Dental.....	545	<i>Bonefos (BN)</i>	
<i>Bicor (AL)</i>		.Musculo-skeletal system	401

GENERIC/PROPRIETARY INDEX

<i>Bonefos 800 mg (BN)</i>		
.Musculo-skeletal system.....	401	
BOSENTAN MONOHYDRATE		
.Section 100	585, 731	
<i>Botox (AG)</i>		
.Section 100	870	
BOTULINUM TOXIN TYPE A PURIFIED NEUROTOXIN COMPLEX		
.Section 100	870	
<i>Brevinor (PF)</i>		
.Genito urinary system and sex hormones	175	
<i>Brevinor-1 (PF)</i>		
.Genito urinary system and sex hormones	176	
<i>Bricanyl (AP)</i>		
.Emergency Drug Supplies	65	
.Respiratory system	487	
<i>Bricanyl Turbuhaler (AP)</i>		
.Respiratory system	483	
<i>Brilinta (AP)</i>		
.Blood and blood forming organs.....	109	
BRIMONIDINE TARTRATE		
.Optometrical.....	566	
.Sensory organs.....	490	
BRIMONIDINE TARTRATE with TIMOLOL MALEATE		
.Optometrical.....	566	
.Sensory organs.....	491	
BRINZOLAMIDE		
.Optometrical.....	567	
.Sensory organs.....	491	
BRINZOLAMIDE with TIMOLOL MALEATE		
.Optometrical.....	567	
.Sensory organs.....	491	
<i>BrinzoQuin (IQ)</i>		
.Optometrical.....	567	
.Sensory organs.....	491	
BROMAZEPAM		
.Repatriation Schedule.....	932	
BROMOCRIPTINE MESYLATE		
.Genito urinary system and sex hormones	174	
.Nervous system.....	435	
<i>bronchitol (XA)</i>		
.Section 100	717, 866	
<i>Brufen (AB)</i>		
.Dental.....	554	
.Musculo-skeletal system.....	393, 394	
.Palliative Care	529	
<i>BSN 2902165 (BV)</i>		
.Repatriation Schedule.....	953	
<i>Budamax Aqueous (PM)</i>		
.Repatriation Schedule.....	935	
BUDESONIDE		
.Repatriation Schedule.....	935	
.Respiratory system	485	
BUDESONIDE with EFORMOTEROL FUMARATE DIHYDRATE		
.Respiratory system.....	483, 484	
BUPRENORPHINE		
.Nervous system.....	417	
.Section 100.....	876	
BUPRENORPHINE with NALOXONE		
.Section 100.....	876	
BUPROPION HYDROCHLORIDE		
.Nervous system.....	475, 476	
<i>Buscopan (BY)</i>		
.Emergency Drug Supplies.....	64	
.Palliative Care.....	522	
.Repatriation Schedule	911	
<i>Buspar (QA)</i>		
.Repatriation Schedule	932	
BUSPIRONE HYDROCHLORIDE		
.Repatriation Schedule	932	
BUSULFAN		
.Antineoplastic and immunomodulating agents	222	
<i>Butamol 2.5 (QA)</i>		
.Emergency Drug Supplies.....	65	
.Respiratory system.....	483	
<i>Butamol 5 (QA)</i>		
.Emergency Drug Supplies.....	66	
.Respiratory system.....	483	
<i>Byetta 10 microgram (LY)</i>		
.Alimentary tract and metabolism	102	
<i>Byetta 5 microgram (LY)</i>		
.Alimentary tract and metabolism	102	
C		
<i>Cabaser (PF)</i>		
.Nervous system.....	435	
CABERGOLINE		
.Genito urinary system and sex hormones.....	175	
.Nervous system.....	435	
<i>Cadatin 10/10 (FZ)</i>		
.Cardiovascular system	165	
<i>Cadatin 10/20 (FZ)</i>		
.Cardiovascular system	165	
<i>Cadatin 10/40 (FZ)</i>		
.Cardiovascular system	165	
<i>Cadatin 10/80 (FZ)</i>		
.Cardiovascular system	165	
<i>Cadatin 5/10 (FZ)</i>		
.Cardiovascular system	164	
<i>Cadatin 5/20 (FZ)</i>		
.Cardiovascular system	164	
<i>Cadatin 5/40 (FZ)</i>		
.Cardiovascular system	164	
<i>Cadatin 5/80 (FZ)</i>		
.Cardiovascular system	164	
<i>Caduet 10/10 (PF)</i>		
.Cardiovascular system	165	
<i>Caduet 10/20 (PF)</i>		

GENERIC/PROPRIETARY INDEX

.Cardiovascular system	165	.Nervous system.....	478
<i>Caduet 10/40 (PF)</i>		CANDESARTAN CILEXETIL	
.Cardiovascular system	165	.Cardiovascular system	142
<i>Caduet 10/80 (PF)</i>		CANDESARTAN CILEXETIL with HYDROCHLOROTHIAZIDE	
.Cardiovascular system	165	.Cardiovascular system	144
<i>Caduet 5/10 (PF)</i>		CAPECITABINE	
.Cardiovascular system	164	.Antineoplastic and immunomodulating agents	224
<i>Caduet 5/20 (PF)</i>		<i>Capoten (QA)</i>	
.Cardiovascular system	164	.Cardiovascular system	132, 133
<i>Caduet 5/40 (PF)</i>		<i>Caprilon (SB)</i>	
.Cardiovascular system	164	.Various	511
<i>Caduet 5/80 (PF)</i>		CAPTOPRIL	
.Cardiovascular system	165	.Cardiovascular system	132
<i>Caelyx (JC)</i>		<i>Captopril Sandoz (SZ)</i>	
.Section 100	621, 768	.Cardiovascular system	132
<i>CAL-600 (PP)</i>		<i>Carafate (AS)</i>	
.Repatriation Schedule.....	913	.Alimentary tract and metabolism	79
CALCIPOTRIOL		CARBAMAZEPINE	
.Dermatologicals	168	.Dental.....	559
CALCIPOTRIOL with BETAMETHASONE DIPROPIONATE		.Nervous system.....	425
.Dermatologicals	168	<i>Carbamazepine Sandoz (SZ)</i>	
<i>Calciprox (GN)</i>		.Dental.....	559
.Alimentary tract and metabolism	102	.Nervous system.....	425
.Musculo-skeletal system.....	405	CARBAMIDE PEROXIDE	
<i>Calci-Tab 600 (AE)</i>		.Repatriation Schedule	937
.Alimentary tract and metabolism	103	CARBIMAZOLE	
CALCITRIOL		.Systemic hormonal preparations, excl. sex hormones and insulins	190
.Alimentary tract and metabolism	102	<i>CarboFLEX 403202 (CC)</i>	
.Musculo-skeletal system.....	405	.Repatriation Schedule	944
<i>Calcitriol Sandoz (SZ)</i>		<i>CarboFLEX 403204 (CC)</i>	
.Alimentary tract and metabolism	102	.Repatriation Schedule	944
.Musculo-skeletal system.....	405	<i>Carbohydrate Free Mixture (SB)</i>	
<i>Calcitriol-GA (GM)</i>		.Various	517
.Alimentary tract and metabolism	102	CARBOHYDRATE, FAT, VITAMINS, MINERALS and TRACE ELEMENTS	
.Musculo-skeletal system.....	405	.Various	516
<i>Calcitriol-PS (FZ)</i>		CARBOMER	
.Alimentary tract and metabolism	102	.Optometrical.....	568
.Musculo-skeletal system.....	405	.Sensory organs.....	495
CALCIUM		CARBOMER 974	
.Alimentary tract and metabolism	103	.Optometrical.....	569
.Repatriation Schedule.....	913	.Sensory organs.....	495
CALCIUM CARBONATE with GLYCINE		<i>Cardiprin 100 (RC)</i>	
.Repatriation Schedule.....	911	.Repatriation Schedule	914
CALCIUM FOLINATE		<i>Cardizem (SW)</i>	
.Various	502	.Cardiovascular system	132
<i>Calcium Folate Ebewe (SZ)</i>		<i>Cardizem CD (SW)</i>	
.Various	502	.Cardiovascular system	131, 132
<i>Calmurid (OL)</i>		<i>Cardol (AF)</i>	
.Repatriation Schedule.....	917	.Cardiovascular system	118, 125
<i>Cal-Sup (IA)</i>		<i>CareSens (LB)</i>	
.Alimentary tract and metabolism	103	.Various	505, 506
.Repatriation Schedule.....	913	<i>CareSens N (LB)</i>	
<i>Calutex (QA)</i>		.Various	504, 505
.Antineoplastic and immunomodulating agents	248		
<i>Campral (AF)</i>			

GENERIC/PROPRIETARY INDEX

CARMELLOSE SODIUM		
.Optometrical.....	569	
.Palliative Care	521	
.Repatriation Schedule	911	
.Sensory organs.....	495, 496	
CARMELLOSE SODIUM with GLYCERIN		
.Optometrical.....	569	
.Sensory organs.....	496	
CARMELLOSE SODIUM with PECTIN and GELATIN		
.Repatriation Schedule.....	917	
CARMUSTINE		
.Antineoplastic and immunomodulating agents	222	
<i>Cartia (GC)</i>		
.Repatriation Schedule	914	
CARVEDILOL		
.Cardiovascular system	127	
<i>Carvedilol generichealth (GQ)</i>		
.Cardiovascular system	128	
<i>Carvedilol Sandoz (SZ)</i>		
.Cardiovascular system	128	
<i>Catapres (BY)</i>		
.Cardiovascular system	121	
<i>Catapres 100 (BY)</i>		
.Cardiovascular system	121	
CATIONIC CONDITIONER with PANTHENOL		
.Repatriation Schedule.....	920	
<i>Caverject Impulse (PF)</i>		
.Repatriation Schedule.....	921	
<i>Cavicare 4563 (SN)</i>		
.Repatriation Schedule.....	946	
<i>Ceclor (AS)</i>		
.Anti-infectives for systemic use	202	
.Dental.....	549	
<i>Ceclor CD (AS)</i>		
.Anti-infectives for systemic use	202	
.Dental.....	549	
CEFACLOR		
.Anti-infectives for systemic use	201	
.Dental.....	549	
<i>Cefaclor GH (GQ)</i>		
.Anti-infectives for systemic use	201	
.Dental.....	549	
<i>Cefaclor Sandoz (SZ)</i>		
.Anti-infectives for systemic use	202	
.Dental.....	549	
<i>Cefaclor-GA (GN)</i>		
.Anti-infectives for systemic use	201	
.Dental.....	549	
<i>Cefalexin Sandoz (SZ)</i>		
.Anti-infectives for systemic use	199, 200	
.Dental.....	548	
CEFALOTIN		
.Anti-infectives for systemic use	199	
.Dental.....	547	
<i>Cefalotin Sandoz (SZ)</i>		
.Anti-infectives for systemic use.....	199	
.Dental.....	547	
<i>Cefazolin Sandoz (SZ)</i>		
.Anti-infectives for systemic use.....	200, 201	
<i>Cefazolin-AFT (AE)</i>		
.Anti-infectives for systemic use.....	200, 201	
CEFEPIME		
.Anti-infectives for systemic use.....	204	
<i>Cefepime Sandoz (SZ)</i>		
.Anti-infectives for systemic use.....	204	
CEFOTAXIME		
.Anti-infectives for systemic use.....	202	
.Dental.....	550	
<i>Cefotaxime Sandoz (SZ)</i>		
.Anti-infectives for systemic use.....	202, 203	
.Dental.....	550	
CEFTRIAXONE		
.Anti-infectives for systemic use.....	203, 204	
<i>Ceftriaxone ICP (PP)</i>		
.Anti-infectives for systemic use.....	203	
<i>Ceftriaxone Sandoz (SZ)</i>		
.Anti-infectives for systemic use.....	203	
<i>Ceftriaxone-AFT (AE)</i>		
.Anti-infectives for systemic use.....	203	
CEFUROXIME AXETIL		
.Anti-infectives for systemic use.....	202	
.Dental.....	549	
<i>Celapram (AF)</i>		
.Nervous system.....	459	
<i>Celebrex (PF)</i>		
.Musculo-skeletal system	395	
CELECOXIB		
.Musculo-skeletal system	395	
<i>Celestone Chronodose (MK)</i>		
.Dental.....	543	
.Systemic hormonal preparations, excl. sex hormones and insulins	187	
<i>Celestone-M (MK)</i>		
.Dermatologicals	170	
<i>Celica (RA)</i>		
.Nervous system.....	459	
<i>CellCept (RO)</i>		
.Antineoplastic and immunomodulating agents ...	262,	
263		
.Section 100.....	634, 782	
<i>Cellufresh (AG)</i>		
.Optometrical.....	569	
.Sensory organs.....	496	
<i>Celluvisc (AG)</i>		
.Optometrical.....	569	
.Sensory organs.....	496	
<i>Celsentri (VI)</i>		
.Section 100.....	619, 766	
CEPHALEXIN		
.Anti-infectives for systemic use.....	199	

GENERIC/PROPRIETARY INDEX

.Dental.....	548	.Antiinfectives for systemic use.....	195, 196
<i>Cephalexin generichealth (GQ)</i>		.Dental.....	544, 545
.Antiinfectives for systemic use	199, 200	<i>Chem mart Amoxycillin and Clavulanic Acid (CH)</i>	
.Dental.....	548	.Antiinfectives for systemic use.....	198
<i>Cephalexin-PS (FZ)</i>		.Dental.....	547
.Antiinfectives for systemic use	199, 200	<i>Chem mart Anastrozole (CH)</i>	
.Dental.....	548	.Antineoplastic and immunomodulating agents	249
<i>Cephadrust 250 (MI)</i>		<i>Chem mart Atenolol (CH)</i>	
.Antiinfectives for systemic use	199	.Cardiovascular system	125
.Dental.....	548	<i>Chem mart Atorvastatin (CH)</i>	
<i>Cephadrust 500 (MI)</i>		.Cardiovascular system	149, 150, 151, 152
.Antiinfectives for systemic use	200	<i>Chem mart Baclofen (CH)</i>	
.Dental.....	548	.Musculo-skeletal system.....	396
CEPHAZOLIN		<i>Chem mart Bisoprolol (CH)</i>	
.Antiinfectives for systemic use	200, 201	.Cardiovascular system	126
<i>Cephazolin Alphapharm (AF)</i>		<i>Chem mart Carvedilol 12.5 mg (CH)</i>	
.Antiinfectives for systemic use	200, 201	.Cardiovascular system	128
<i>Ceptolate (AF)</i>		<i>Chem mart Carvedilol 25 mg (CH)</i>	
.Antineoplastic and immunomodulating agents ...	262, 263	.Cardiovascular system	128
.Section 100	634, 782	<i>Chem mart Carvedilol 3.125 mg (CH)</i>	
<i>Certican (NV)</i>		.Cardiovascular system	127
.Antineoplastic and immunomodulating agents	261	<i>Chem mart Carvedilol 6.25 mg (CH)</i>	
.Section 100	633, 781, 782	.Cardiovascular system	128
CERTOLIZUMAB PEGOL		<i>Chem mart Cefaclor (CH)</i>	
.Antineoplastic and immunomodulating agents	317	.Antiinfectives for systemic use.....	202
<i>Cerumol (AC)</i>		.Dental.....	549
.Repatriation Schedule.....	937	<i>Chem mart Cefaclor CD (CH)</i>	
CETIRIZINE HYDROCHLORIDE		.Antiinfectives for systemic use.....	201
.Repatriation Schedule.....	936	.Dental.....	549
CETRORELIX		<i>Chem mart Cephalexin (CH)</i>	
.Section 100	874	.Antiinfectives for systemic use.....	199, 200
<i>Cetrotide (SG)</i>		.Dental.....	548
.Section 100	874	<i>Chem mart Citalopram (CH)</i>	
<i>C-Flox 250 (AL)</i>		.Nervous system.....	459
.Antiinfectives for systemic use	207	<i>Chem mart Clarithromycin (CH)</i>	
<i>C-Flox 500 (AL)</i>		.Antiinfectives for systemic use.....	205
.Antiinfectives for systemic use	208	<i>Chem mart Clomipramine (CH)</i>	
<i>C-Flox 750 (AL)</i>		.Nervous system.....	456, 458
.Antiinfectives for systemic use	208	<i>Chem mart Clopidogrel (CH)</i>	
<i>Champix (PF)</i>		.Blood and blood forming organs.....	107
.Nervous system.....	477	<i>Chem mart Diclofenac (CH)</i>	
<i>Chem mart Aciclovir (CH)</i>		.Dental.....	553
.Antiinfectives for systemic use	215	.Musculo-skeletal system.....	391
<i>Chem mart Alendronate 70mg (CH)</i>		.Palliative Care.....	527, 528
.Musculo-skeletal system.....	398	<i>Chem mart Diltiazem (CH)</i>	
<i>Chem mart Allopurinol (CH)</i>		.Cardiovascular system	132
.Musculo-skeletal system.....	397	<i>Chem mart Diltiazem CD (CH)</i>	
<i>Chem mart Alprazolam (CH)</i>		.Cardiovascular system	131, 132
.Nervous system.....	454	<i>Chem mart Doxycycline (CH)</i>	
<i>Chem mart Amiodarone (CH)</i>		.Antiinfectives for systemic use.....	193, 194
.Cardiovascular system	118	.Dental.....	544
<i>Chem mart Amlodipine (CH)</i>		<i>Chem mart Enalapril (CH)</i>	
.Cardiovascular system	129, 130	.Cardiovascular system	133
<i>Chem mart Amoxycillin (CH)</i>		<i>Chem mart Escitalopram (CH)</i>	
		.Nervous system.....	459, 460

GENERIC/PROPRIETARY INDEX

<i>Chem mart Famciclovir (CH)</i>		<i>Chem mart Pantoprazole (CH)</i>	
.Antiinfectives for systemic use	217, 218	.Alimentary tract and metabolism	77, 78
<i>Chem mart Famotidine (CH)</i>		<i>Chem mart Paracetamol (XS)</i>	
.Alimentary tract and metabolism	71, 72	.Dental.....	558
<i>Chem mart Fluoxetine (CH)</i>		.Nervous system.....	420
.Nervous system.....	461	<i>Chem mart Paroxetine (CH)</i>	
<i>Chem mart Frusemide (CH)</i>		.Nervous system.....	462
.Cardiovascular system	122	<i>Chem mart Perindopril (CH)</i>	
<i>Chem mart Gemfibrozil (CH)</i>		.Cardiovascular system	135, 136
.Cardiovascular system	161	<i>Chem mart Perindopril/ Indapamide 4/1.25 (CH)</i>	
<i>Chem mart Gliclazide (CH)</i>		.Cardiovascular system	140
.Alimentary tract and metabolism	94	<i>Chem mart Pioglitazone (CH)</i>	
<i>Chem mart Gliclazide MR (CH)</i>		.Alimentary tract and metabolism	98, 99
.Alimentary tract and metabolism	94	<i>Chem mart Piroxicam (CH)</i>	
<i>Chem mart Hydroxychloroquine (CH)</i>		.Dental.....	554
.Musculo-skeletal system.....	395	.Musculo-skeletal system.....	393
<i>Chem mart Indapamide (CH)</i>		<i>Chem mart Pravastatin (CH)</i>	
.Cardiovascular system	122	.Cardiovascular system	152, 153, 154, 155
<i>Chem mart Isosorbide Mononitrate (CH)</i>		<i>Chem mart Prazosin (CH)</i>	
.Cardiovascular system	120	.Cardiovascular system	121
<i>Chem mart Latanoprost (CH)</i>		<i>Chem mart Quetiapine (CH)</i>	
.Optometrical.....	568	.Nervous system.....	445, 446, 447
.Sensory organs.....	492	<i>Chem mart Ramipril (CH)</i>	
<i>Chem mart Lercanidipine (CH)</i>		.Cardiovascular system	137, 138, 139
.Cardiovascular system	130	<i>Chem mart Ranitidine (CH)</i>	
<i>Chem mart Letrozole (CH)</i>		.Alimentary tract and metabolism	72
.Antineoplastic and immunomodulating agents	250	<i>Chem mart Risedronate (CH)</i>	
<i>Chem mart Levetiracetam (CH)</i>		.Musculo-skeletal system.....	400
.Nervous system.....	429, 430	.Repatriation Schedule.....	929
<i>Chem mart Lisinopril (CH)</i>		<i>Chem mart Roxithromycin (CH)</i>	
.Cardiovascular system	134	.Antiinfectives for systemic use.....	206
<i>Chem mart Meloxicam (CH)</i>		.Dental.....	551
.Musculo-skeletal system.....	392, 393	<i>Chem mart Sertraline (CH)</i>	
<i>Chem mart Meloxicam 15 mg (CH)</i>		.Nervous system.....	462
.Musculo-skeletal system.....	392	<i>Chem mart Simvastatin (CH)</i>	
<i>Chem mart Meloxicam 7.5 mg (CH)</i>		.Cardiovascular system	156, 157, 158, 159, 160
.Musculo-skeletal system.....	392	<i>Chem mart Sotalol (CH)</i>	
<i>Chem mart Metformin (CH)</i>		.Cardiovascular system	118, 125
.Alimentary tract and metabolism	93	<i>Chem mart Sumatriptan (CH)</i>	
<i>Chem mart Metformin 1000 (CH)</i>		.Nervous system.....	422
.Alimentary tract and metabolism	94	<i>Chem mart Tramadol (CH)</i>	
<i>Chem mart Metoprolol (CH)</i>		.Dental.....	557
.Cardiovascular system	127	.Nervous system.....	418
<i>Chem mart Mirtazapine (CH)</i>		<i>Chem mart Tramadol SR (CH)</i>	
.Nervous system.....	465, 466	.Nervous system.....	419
<i>Chem mart Moclobemide (CH)</i>		<i>Chem mart Valaciclovir (CH)</i>	
.Nervous system.....	464	.Antiinfectives for systemic use.....	218, 219, 220
<i>Chem mart Norfloxacin (CH)</i>		<i>Chem mart Venlafaxine XR (CH)</i>	
.Antiinfectives for systemic use	208	.Nervous system.....	466
<i>Chem mart Olanzapine (CH)</i>		CHLORAMBUCIL	
.Nervous system.....	441, 442, 443	.Antineoplastic and immunomodulating agents	222
<i>Chem mart Olanzapine ODT (CH)</i>		CHLORAMPHENICOL	
.Nervous system.....	443, 444, 445	.Dental.....	562
<i>Chem mart Omeprazole (CH)</i>		.Optometrical.....	565
.Alimentary tract and metabolism	75, 76	.Sensory organs.....	489, 500

GENERIC/PROPRIETARY INDEX

CHLORHEXIDINE GLUCONATE	
.Repatriation Schedule	911
<i>Chloromycetin (PF)</i>	
.Dental.....	562
.Optometical.....	565
.Sensory organs.....	489, 500
CHLORPROMAZINE HYDROCHLORIDE	
.Nervous system.....	438
<i>Chlorsig (QA)</i>	
.Dental.....	562
.Optometical.....	565
.Sensory organs.....	489
CHLORTHALIDONE	
.Cardiovascular system	122
<i>Chlorvescent (AS)</i>	
.Alimentary tract and metabolism	103
CHOLESTYRAMINE	
.Cardiovascular system	162
<i>Cholstat 10 (AF)</i>	
.Cardiovascular system	152, 154
<i>Cholstat 20 (AF)</i>	
.Cardiovascular system	153, 154
<i>Cholstat 40 (AF)</i>	
.Cardiovascular system	153, 155
<i>Cholvastin (RA)</i>	
.Cardiovascular system	153, 154, 155
CHORIOGONADOTROPIN ALFA	
.Section 100	874
<i>Cialis (LY)</i>	
.Repatriation Schedule.....	924
<i>Ciazil (GM)</i>	
.Nervous system.....	459
CICLESONIDE	
.Respiratory system	485
CICLOPIROX OLAMINE	
.Repatriation Schedule.....	916
<i>Cicloral (SZ)</i>	
.Antineoplastic and immunomodulating agents	389
.Section 100	699, 847
CIDOFOVIR	
.Section 100	611, 757
<i>Cifran (RA)</i>	
.Antiinfectives for systemic use	207, 208
<i>Cilamox (QA)</i>	
.Antiinfectives for systemic use	195, 196
.Dental.....	544, 545
<i>Cilex (GM)</i>	
.Antiinfectives for systemic use	199, 200
.Dental.....	548
<i>Cilicaine (QA)</i>	
.Antiinfectives for systemic use	197
.Dental.....	546
.Emergency Drug Supplies	65
<i>Cilicaine V (FM)</i>	
.Antiinfectives for systemic use	197
.Dental.....	546
<i>Cilicaine VK (FM)</i>	
.Antiinfectives for systemic use.....	196, 197
.Dental.....	545
<i>Cilopen VK (GM)</i>	
.Antiinfectives for systemic use.....	196, 197
.Dental.....	545, 546
<i>CiloQuin (IQ)</i>	
.Optometical.....	565
.Sensory organs.....	490
<i>Ciloxan (AQ)</i>	
.Optometical.....	565
.Sensory organs.....	490, 500
CIMETIDINE	
.Alimentary tract and metabolism	71
<i>Cimzia (UC)</i>	
.Antineoplastic and immunomodulating agents	322
CINACALCET	
.Section 100.....	609, 755
.Systemic hormonal preparations, excl. sex hormones and insulins	191
<i>Cipramil (LU)</i>	
.Nervous system.....	459
CIPROFLOXACIN	
.Antiinfectives for systemic use.....	207, 208
.Optometical.....	565
.Sensory organs.....	490, 500
<i>Ciprofloxacin 500 (CR)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciprofloxacin 750 (CR)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciprofloxacin Sandoz (SZ)</i>	
.Antiinfectives for systemic use.....	207, 208
<i>Ciprofloxacin-BW (GQ)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciprofloxacin-DRLA (RZ)</i>	
.Antiinfectives for systemic use.....	207, 208
<i>Ciprofloxacin-GA (GM)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciprofloxacin-PS (FZ)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciprol 250 (QA)</i>	
.Antiinfectives for systemic use.....	207
<i>Ciprol 500 (QA)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciprol 750 (QA)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciproxin 250 (BN)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciproxin 500 (BN)</i>	
.Antiinfectives for systemic use.....	208
<i>Ciproxin 750 (BN)</i>	
.Antiinfectives for systemic use.....	208
<i>Citalopram 20 (CR)</i>	
.Nervous system.....	459

GENERIC/PROPRIETARY INDEX

<i>Citalopram generichealth (GQ)</i>		
.Nervous system.....	459	
CITALOPRAM HYDROBROMIDE		
.Nervous system.....	459	
<i>Citalopram Pfizer (FZ)</i>		
.Nervous system.....	459	
<i>Citalopram Sandoz (SZ)</i>		
.Nervous system.....	459	
<i>Citalopram-GA (GN)</i>		
.Nervous system.....	459	
<i>Citrulline 1000 Amino Acid Supplement (VF)</i>		
.Various	516	
CITRULLINE with CARBOHYDRATE		
.Various	516	
<i>Clamoxyl (AL)</i>		
.Antiinfectives for systemic use	198	
.Dental.....	547	
<i>Clamoxyl Duo (AL)</i>		
.Antiinfectives for systemic use	198	
.Dental.....	547	
<i>Clamoxyl Duo 400 (AL)</i>		
.Antiinfectives for systemic use	198	
.Dental.....	547	
<i>Clamoxyl Duo forte (AL)</i>		
.Antiinfectives for systemic use	198	
.Dental.....	547	
<i>Clarac (GM)</i>		
.Antiinfectives for systemic use	205	
<i>Claratyne (MK)</i>		
.Repatriation Schedule.....	936	
<i>Clarithexal (SZ)</i>		
.Antiinfectives for systemic use	205	
<i>Clarithro 250 (QA)</i>		
.Antiinfectives for systemic use	205	
CLARITHROMYCIN		
.Antiinfectives for systemic use	205	
.Section 100	611, 757	
<i>Clavycillin 875/125 (CR)</i>		
.Antiinfectives for systemic use	198	
.Dental.....	547	
<i>Cleocin (FZ)</i>		
.Antiinfectives for systemic use	206	
.Dental.....	551	
<i>Clexane (SW)</i>		
.Blood and blood forming organs.....	106	
<i>Climara 100 (BN)</i>		
.Genito urinary system and sex hormones	177	
<i>Climara 25 (BN)</i>		
.Genito urinary system and sex hormones	177	
<i>Climara 50 (BN)</i>		
.Genito urinary system and sex hormones	177	
<i>Climara 75 (BN)</i>		
.Genito urinary system and sex hormones	177	
CLINDAMYCIN		
.Antiinfectives for systemic use	206	
.Dental.....	551	
<i>Clobemix (GM)</i>		
.Nervous system.....	464	
<i>Clofen 10 (AF)</i>		
.Musculo-skeletal system.....	396	
<i>Clofen 25 (AF)</i>		
.Musculo-skeletal system.....	396	
<i>Clomid (SW)</i>		
.Genito urinary system and sex hormones.....	181	
CLOMIPHENE CITRATE		
.Genito urinary system and sex hormones.....	181	
CLOMIPRAMINE HYDROCHLORIDE		
.Nervous system.....	456, 457	
<i>Clonac 25 (QA)</i>		
.Dental.....	553	
.Musculo-skeletal system.....	391	
.Palliative Care.....	527	
<i>Clonac 50 (QA)</i>		
.Dental.....	553	
.Musculo-skeletal system.....	391	
.Palliative Care.....	527, 528	
CLONAZEPAM		
.Nervous system.....	424	
.Palliative Care.....	534	
<i>Clonea (AF)</i>		
.Repatriation Schedule	916	
CLONIDINE		
.Cardiovascular system	121	
CLOPIDOGREL		
.Blood and blood forming organs.....	107, 108	
.Repatriation Schedule	914	
<i>Clopidogrel Actavis (TA)</i>		
.Blood and blood forming organs.....	107	
<i>Clopidogrel GH (GQ)</i>		
.Blood and blood forming organs.....	107	
<i>Clopidogrel RBX (RA)</i>		
.Blood and blood forming organs.....	107	
<i>Clopidogrel Sandoz (SZ)</i>		
.Blood and blood forming organs.....	107	
<i>Clopidogrel Winthrop (WA)</i>		
.Blood and blood forming organs.....	107, 108	
<i>Clopidogrel Winthrop plus aspirin (WA)</i>		
.Blood and blood forming organs.....	108	
CLOPIDOGREL with ASPIRIN		
.Blood and blood forming organs.....	108	
<i>Clopidogrel-DRLA (RZ)</i>		
.Blood and blood forming organs.....	107	
<i>Clopidogrel-GA (GM)</i>		
.Blood and blood forming organs.....	107	
<i>Clopidogrel-PS (FZ)</i>		
.Blood and blood forming organs.....	107	
<i>Clopine 100 (HH)</i>		
.Section 100.....	709, 858	
<i>Clopine 200 (HH)</i>		
.Section 100.....	709, 858	

GENERIC/PROPRIETARY INDEX

<i>Clopine 25 (HH)</i>		
.Section 100	709, 858	
<i>Clopine 50 (HH)</i>		
.Section 100	709, 858	
<i>Clopine Suspension (HH)</i>		
.Section 100	709, 858	
<i>Clopixol Depot (LU)</i>		
.Nervous system.....	440	
CLOSTRIDIUM BOTULINUM TYPE A TOXIN— HAEMAGGLUTININ COMPLEX		
.Section 100	870	
CLOTTRIMAZOLE		
.Repatriation Schedule.....	916, 921	
<i>Clovix 75 (QA)</i>		
.Blood and blood forming organs.....	107	
CLOZAPINE		
.Section 100	709, 858	
<i>Clozaril 100 (NV)</i>		
.Section 100	709, 858	
<i>Clozaril 25 (NV)</i>		
.Section 100	709, 858	
COAL TAR - PREPARED		
.Dermatologicals	168	
<i>Coban 1584 (MM)</i>		
.Repatriation Schedule.....	943	
<i>Coban 2 (MM)</i>		
.Repatriation Schedule.....	942	
<i>Cobasol (GM)</i>		
.Nervous system.....	435	
<i>Codalgin (FM)</i>		
.Repatriation Schedule.....	931	
<i>Codalgin Forte (FM)</i>		
.Dental.....	556	
.Nervous system.....	408	
<i>Codapane Forte (AL)</i>		
.Dental.....	556	
.Nervous system.....	408	
CODEINE PHOSPHATE		
.Dental.....	556	
.Nervous system.....	408	
.Respiratory system	488	
CODEINE PHOSPHATE with ASPIRIN		
.Repatriation Schedule.....	931	
CODEINE PHOSPHATE with PARACETAMOL		
.Dental.....	556	
.Nervous system.....	408	
.Repatriation Schedule.....	931	
<i>Co-Diovan 160/12.5 (NV)</i>		
.Cardiovascular system	145	
<i>Co-Diovan 160/25 (NV)</i>		
.Cardiovascular system	145	
<i>Co-Diovan 320/12.5 (NV)</i>		
.Cardiovascular system	145	
<i>Co-Diovan 320/25 (NV)</i>		
.Cardiovascular system	145	
<i>Co-Diovan 80/12.5 (NV)</i>		
.Cardiovascular system	145	
<i>Cogentin (FK)</i>		
.Dental.....	559	
.Emergency Drug Supplies.....	64	
.Nervous system.....	433	
<i>Colazide (PK)</i>		
.Alimentary tract and metabolism	88	
COLCHICINE		
.Musculo-skeletal system.....	397	
<i>Colese (AF)</i>		
.Repatriation Schedule	911	
<i>Colestid (PF)</i>		
.Cardiovascular system	162	
COLESTIPOL HYDROCHLORIDE		
.Cardiovascular system	162	
<i>Colgout (AS)</i>		
.Musculo-skeletal system.....	397	
<i>Colifoam (AS)</i>		
.Alimentary tract and metabolism	87	
<i>Colofac (AB)</i>		
.Repatriation Schedule	911	
<i>Coloxyl 50 (FM)</i>		
.Repatriation Schedule	911	
<i>Coloxyl with Senna (FM)</i>		
.Repatriation Schedule	912	
<i>CombiDERM 651027 (CC)</i>		
.Repatriation Schedule.....	949	
<i>CombiDERM 651031 (CC)</i>		
.Repatriation Schedule.....	948	
<i>Combigan (AG)</i>		
.Optometrical.....	566	
.Sensory organs.....	491	
<i>Combivir (VI)</i>		
.Section 100.....	618, 765	
<i>Comfarol Forte (SZ)</i>		
.Dental.....	556	
.Nervous system.....	408	
<i>Comfeel Paste 4701 (CT)</i>		
.Repatriation Schedule.....	949	
<i>Comfeel Plus Pressure Relieving 3350 (CT)</i>		
.Repatriation Schedule	951	
<i>Comfeel Plus Pressure Relieving 3353 (CT)</i>		
.Repatriation Schedule	951	
<i>Comfeel Plus Transparent 3530 (CT)</i>		
.Repatriation Schedule	950	
<i>Comfeel Plus Transparent 3533 (CT)</i>		
.Repatriation Schedule.....	950	
<i>Comfeel Plus Transparent 3536 (CT)</i>		
.Repatriation Schedule.....	950	
<i>Comfeel Plus Ulcer Dressing 3110 (CT)</i>		
.Repatriation Schedule	951	
<i>Comfeel Purilon Gel 3900 (CT)</i>		
.Repatriation Schedule	951	
<i>Comfeel SeaSorb Dressing 3705 (CT)</i>		

GENERIC/PROPRIETARY INDEX

.Repatriation Schedule.....	945	COTTON WOOL ROLL	
<i>Comfeel SeaSorb Dressing 3710 (CT)</i>		.Repatriation Schedule.....	944
.Repatriation Schedule.....	945	<i>Coumadin (QA)</i>	
<i>Comfeel SeaSorb Filler 3740 (CT)</i>		.Blood and blood forming organs.....	105
.Repatriation Schedule.....	944	<i>Coveram (SE)</i>	
<i>Comprilan 01027-00 (BV)</i>		.Cardiovascular system	141
.Repatriation Schedule.....	941	<i>Coversyl 10mg (SE)</i>	
<i>Comtan (NV)</i>		.Cardiovascular system	136
.Nervous system.....	438	<i>Coversyl 2.5mg (SE)</i>	
<i>Concerta (JC)</i>		.Cardiovascular system	135
.Nervous system.....	468	<i>Coversyl 5mg (SE)</i>	
<i>Condyline Paint (NQ)</i>		.Cardiovascular system	135
.Repatriation Schedule.....	919	<i>Coversyl Plus 5mg/1.25mg (SE)</i>	
<i>Contour (IK)</i>		.Cardiovascular system	140
.Various	504, 505	<i>Coversyl Plus LD 2.5mg/0.625mg (SE)</i>	
<i>Copaxone (CS)</i>		.Cardiovascular system	140
.Antineoplastic and immunomodulating agents	253	<i>Cozavan (AF)</i>	
<i>CoPlavix (SW)</i>		.Cardiovascular system	143
.Blood and blood forming organs.....	108	<i>Creon 10,000 (AB)</i>	
<i>Coras (AF)</i>		.Alimentary tract and metabolism	90, 91
.Cardiovascular system	132	<i>Creon 25,000 (AB)</i>	
<i>Corbeton 20 (AF)</i>		.Alimentary tract and metabolism	90, 91
.Cardiovascular system	124	<i>Creon 40,000 (AB)</i>	
<i>Corbeton 40 (AF)</i>		.Alimentary tract and metabolism	90, 91
.Cardiovascular system	124	<i>Creon Micro (AB)</i>	
<i>Cordarone X 100 (SW)</i>		.Alimentary tract and metabolism	90, 91
.Cardiovascular system	118	<i>Crestor (AP)</i>	
<i>Cordarone X 200 (SW)</i>		.Cardiovascular system	155, 156
.Cardiovascular system	118	<i>Crinone 8% (SG)</i>	
<i>Cordilox 180 SR (KN)</i>		.Section 100.....	875
.Cardiovascular system	131	<i>Crixivan 400 mg (MK)</i>	
<i>Cordilox SR (KN)</i>		.Section 100.....	613, 759
.Cardiovascular system	131	<i>Cromolux (AE)</i>	
CORIFOLLITROPIN ALFA		.Optometrical.....	568
.Section 100	874	.Sensory organs.....	493
<i>Cortate (AS)</i>		<i>Crysanal (MD)</i>	
.Systemic hormonal preparations, excl. sex hormones		.Dental.....	555
and insulins	187	.Musculo-skeletal system	394
<i>Cortic-DS 1% (FM)</i>		.Palliative Care.....	530
.Dental.....	542	<i>Curam (SZ)</i>	
.Dermatologicals	169	.Antiinfectives for systemic use.....	198
CORTISONE ACETATE		.Dental.....	547
.Systemic hormonal preparations, excl. sex hormones		<i>Curam Duo (SZ)</i>	
and insulins	187	.Antiinfectives for systemic use.....	199
<i>Cortival 1/2 (FM)</i>		.Dental.....	547
.Dermatologicals	170	<i>Curam Duo 500/125 (SZ)</i>	
<i>Cortival 1/5 (FM)</i>		.Antiinfectives for systemic use.....	198
.Dermatologicals	170	.Dental.....	547
<i>Cosamide (AF)</i>		<i>Curam Duo Forte 875/125 (SZ)</i>	
.Antineoplastic and immunomodulating agents	248	.Antiinfectives for systemic use.....	198
<i>Cosopt (MK)</i>		.Dental.....	547
.Optometrical.....	567	<i>Curity 4112 (KE)</i>	
.Sensory organs.....	491	.Repatriation Schedule.....	948
<i>Cosudex (SZ)</i>		<i>Cutifilm Plus 36361370 (SN)</i>	
.Antineoplastic and immunomodulating agents	248	.Repatriation Schedule.....	946

GENERIC/PROPRIETARY INDEX

<i>Cutifilm Plus 36361371 (SN)</i>		
.Repatriation Schedule	946	
<i>Cutilin Non-Stick Wound Pad 36361374 (SN)</i>		
.Repatriation Schedule	952	
<i>Cutilin Non-Stick Wound Pad 36361375 (SN)</i>		
.Repatriation Schedule	952	
<i>Cutinova Hydro 66047441 (SN)</i>		
.Repatriation Schedule	949	
<i>Cutinova Hydro 66047443 (SN)</i>		
.Repatriation Schedule	949	
<i>Cycloblastin (PF)</i>		
.Antineoplastic and immunomodulating agents	222	
CYCLOPHOSPHAMIDE		
.Antineoplastic and immunomodulating agents	222	
CYCLOSPORIN		
.Antineoplastic and immunomodulating agents	389	
.Section 100	699, 847	
<i>Cyklokapron (PF)</i>		
.Blood and blood forming organs.....	114	
<i>Cymbalta (LY)</i>		
.Nervous system.....	464	
<i>Cymevene (RO)</i>		
.Section 100	611, 757	
<i>Cyprocur 100 (QA)</i>		
.Antineoplastic and immunomodulating agents	248	
.Genito urinary system and sex hormones	181	
CYPROHEPTADINE HYDROCHLORIDE		
.Nervous system.....	422	
<i>Cyprohexal (SZ)</i>		
.Antineoplastic and immunomodulating agents	248	
.Genito urinary system and sex hormones	181	
<i>Cyprone (AF)</i>		
.Antineoplastic and immunomodulating agents	248	
.Genito urinary system and sex hormones	181	
<i>Cyprostat (SY)</i>		
.Antineoplastic and immunomodulating agents	248	
.Genito urinary system and sex hormones	181	
<i>Cyprostat-100 (SY)</i>		
.Antineoplastic and immunomodulating agents	248	
.Genito urinary system and sex hormones	181	
CYPROTERONE ACETATE		
.Antineoplastic and immunomodulating agents	248	
.Genito urinary system and sex hormones	181	
<i>Cystine Amino Acid Supplement (VF)</i>		
.Various	516	
CYSTINE with CARBOHYDRATE		
.Various	516	
<i>Cytotec (PF)</i>		
.Alimentary tract and metabolism	73	
D		
DABIGATRAN ETEXILATE		
.Blood and blood forming organs.....	110, 111	
<i>Daivobet (LO)</i>		
.Dermatologicals	168	
<i>Daivobet 50/500 gel (LO)</i>		
.Dermatologicals	168	
<i>Daivonex (LO)</i>		
.Dermatologicals	168	
<i>Daktarin (JT)</i>		
.Dermatologicals	166	
.Repatriation Schedule	916	
<i>Dalacin C (PF)</i>		
.Antiinfectives for systemic use.....	206	
.Dental.....	551	
DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium—porcine mucous)		
.Blood and blood forming organs.....	105	
DANAZOL		
.Genito urinary system and sex hormones.....	182	
<i>Dantrium (PF)</i>		
.Musculo-skeletal system	396	
DANTROLENE SODIUM		
.Musculo-skeletal system	396	
<i>Daonil (SW)</i>		
.Alimentary tract and metabolism	94	
<i>Dapa-Tabs (AF)</i>		
.Cardiovascular system	122	
DAPSONE		
.Antiinfectives for systemic use.....	214	
.Dermatologicals	172	
<i>Daraprim (GK)</i>		
.Antiparasitic products, insecticides and repellents	479	
DARBEPOETIN ALFA		
.Section 100.....	579, 725	
DARUNAVIR		
.Section 100.....	612, 758, 759	
DASATINIB		
.Antineoplastic and immunomodulating agents ...	225, 227, 229	
<i>DBL Cefepime (HH)</i>		
.Antiinfectives for systemic use.....	204	
<i>DBL Ceftriaxone (HH)</i>		
.Antiinfectives for systemic use.....	203	
<i>DBL Gabapentin (HH)</i>		
.Nervous system.....	427	
.Repatriation Schedule	931	
<i>DBL Metronidazole Intravenous Infusion (HH)</i>		
.Antiinfectives for systemic use.....	210	
.Dental.....	552	
<i>Deca-Durabolin (MK)</i>		
.Alimentary tract and metabolism	103	
DEFERASIROX		
.Section 100.....	719, 868	
DEFERIPRONE		
.Section 100.....	719, 868	
DEGARELIX		
.Antineoplastic and immunomodulating agents	251	

GENERIC/PROPRIETARY INDEX

<i>Delucon 100 (DO)</i>		
.Nervous system.....	446	
<i>Delucon 200 (DO)</i>		
.Nervous system.....	446	
<i>Delucon 25 (DO)</i>		
.Nervous system.....	446	
<i>Delucon 300 (DO)</i>		
.Nervous system.....	447	
DENOSUMAB		
.Musculo-skeletal system.....	405	
<i>Depnax (AF)</i>		
.Nervous system.....	414, 415, 416, 417	
<i>Densate 70 (DO)</i>		
.Musculo-skeletal system.....	398	
<i>Depo-Medrol (PF)</i>		
.Dental.....	543	
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
<i>Depo-Nisolone (FZ)</i>		
.Dental.....	543	
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
<i>Depo-Provera (PF)</i>		
.Genito urinary system and sex hormones	176	
<i>Depo-Ralovera (FZ)</i>		
.Genito urinary system and sex hormones	176	
<i>Deptran 10 (AF)</i>		
.Nervous system.....	458	
<i>Deptran 25 (AF)</i>		
.Nervous system.....	458	
<i>Deptran 50 (AF)</i>		
.Nervous system.....	458	
<i>Deralin 10 (AF)</i>		
.Cardiovascular system	124	
<i>Deralin 160 (AF)</i>		
.Cardiovascular system	125	
<i>Deralin 40 (AF)</i>		
.Cardiovascular system	124	
<i>Deseril (LM)</i>		
.Nervous system.....	421	
<i>Desferal 2 g (NV)</i>		
.Section 100	719, 868	
<i>Desferal 500 mg (NV)</i>		
.Section 100	719, 868	
DESFERIOXAMINE MESYLATE		
.Section 100	719, 868	
DESMOPRESSIN ACETATE		
.Systemic hormonal preparations, excl. sex hormones and insulins	185, 186	
DESVENLAFAXINE SUCCINATE		
.Nervous system.....	464	
DEXAMETHASONE		
.Optometrical.....	565	
.Sensory organs.....	490	
.Systemic hormonal preparations, excl. sex hormones and insulins	187	
DEXAMETHASONE SODIUM PHOSPHATE		
.Systemic hormonal preparations, excl. sex hormones and insulins	187	
DEXAMETHASONE with FRAMYCETIN SULFATE and GRAMICIDIN		
.Sensory organs	500	
DEXAMPHETAMINE SULFATE		
.Nervous system.....	467	
<i>Dexmethsone (AS)</i>		
.Emergency Drug Supplies.....	64	
.Systemic hormonal preparations, excl. sex hormones and insulins	187	
<i>Diabex (AL)</i>		
.Alimentary tract and metabolism	94	
<i>Diabex 1000 (AL)</i>		
.Alimentary tract and metabolism	94	
<i>Diabex 850 (AL)</i>		
.Alimentary tract and metabolism	93	
<i>Diabex XR (AL)</i>		
.Alimentary tract and metabolism	94	
<i>Diabex XR 1000 (AL)</i>		
.Alimentary tract and metabolism	94	
<i>Diaformin (AF)</i>		
.Alimentary tract and metabolism	93	
<i>Diaformin 1000 (AF)</i>		
.Alimentary tract and metabolism	94	
<i>Diaformin 850 (AF)</i>		
.Alimentary tract and metabolism	93	
<i>Diaformin XR (AF)</i>		
.Alimentary tract and metabolism	94	
<i>Dialamine (SB)</i>		
.Various	516	
<i>Diamicon 60mg MR (SE)</i>		
.Alimentary tract and metabolism	95	
<i>Diamox (QA)</i>		
.Sensory organs.....	491	
<i>Diapride 1 (QA)</i>		
.Alimentary tract and metabolism	95	
<i>Diapride 2 (QA)</i>		
.Alimentary tract and metabolism	95	
<i>Diapride 3 (QA)</i>		
.Alimentary tract and metabolism	95	
<i>Diapride 4 (QA)</i>		
.Alimentary tract and metabolism	95	
<i>Diastix (BN)</i>		
.Various	504	
DIAZEPAM		
.Dental.....	559	
.Nervous system.....	455	
.Palliative Care.....	534, 535	
<i>Diazepam-GA (GM)</i>		
.Dental.....	559	
.Nervous system.....	455	

GENERIC/PROPRIETARY INDEX

.Palliative Care	534, 535	DIHYDROERGOTAMINE MESYLATE	
<i>Dibenyline (GH)</i>		.Nervous system	421
.Cardiovascular system	124	<i>Dilantin (PF)</i>	
.Genito urinary system and sex hormones	183	.Nervous system	423
<i>Dibenzylamine (BZ)</i>		<i>Dilantin Infatabs (PF)</i>	
.Cardiovascular system	124	.Nervous system	423
.Genito urinary system and sex hormones	183	<i>Dilantin Sodium (PF)</i>	
<i>Dicarz (AF)</i>		.Nervous system	424
.Cardiovascular system	128	<i>Dilatrend 12.5 (RO)</i>	
DICHLOROBENZENE with CHLOR BUTOL and TURPENTINE OIL		.Cardiovascular system	128
.Repatriation Schedule	937	<i>Dilatrend 25 (RO)</i>	
<i>Dicloclil (BQ)</i>		.Cardiovascular system	128
.Anti-infectives for systemic use	197	<i>Dilatrend 3.125 (RO)</i>	
.Dental	546	.Cardiovascular system	128
<i>Diclofenac Sandoz (SZ)</i>		<i>Dilatrend 6.25 (RO)</i>	
.Dental	553	.Cardiovascular system	128
.Musculo-skeletal system	391	<i>Dilaudid (MF)</i>	
.Palliative Care	527, 528	.Dental	556
DICLOFENAC SODIUM		.Nervous system	408, 409
.Dental	553	<i>Dilaudid-HP (MF)</i>	
.Musculo-skeletal system	391	.Nervous system	408
.Palliative Care	527, 528	<i>Diltahexal CD (HX)</i>	
.Repatriation Schedule	920	.Cardiovascular system	131, 132
DICLOFENAC SODIUM with MISOPROSTOL		DILTIAZEM HYDROCHLORIDE	
.Repatriation Schedule	929	.Cardiovascular system	131
<i>Diclofenac-GA (GM)</i>		<i>Diltiazem Sandoz (SZ)</i>	
.Dental	553	.Cardiovascular system	132
.Musculo-skeletal system	391	<i>Diltiazem Sandoz CD (SZ)</i>	
.Palliative Care	527, 528	.Cardiovascular system	131, 132
DICLOXACILLIN		<i>Dilzem 60 mg (GM)</i>	
.Anti-infectives for systemic use	197	.Cardiovascular system	132
.Dental	546	DIMETHICONE with GLYCEROL	
<i>Dicloxsig (QA)</i>		.Repatriation Schedule	917
.Anti-infectives for systemic use	197	<i>Dimetrioze (SW)</i>	
.Dental	546	.Genito urinary system and sex hormones	182
DIDANOSINE		<i>Dimirel (AV)</i>	
.Section 100	614, 760	.Alimentary tract and metabolism	95
<i>Didrocal (PF)</i>		<i>Diovan (NV)</i>	
.Musculo-skeletal system	404	.Cardiovascular system	143, 144
<i>Didronel (PF)</i>		<i>Dipentum (UC)</i>	
.Musculo-skeletal system	399	.Alimentary tract and metabolism	90
<i>Diffiam (IA)</i>		DIPHEMANIL METHYLSULFATE	
.Alimentary tract and metabolism	71	.Repatriation Schedule	919
.Dental	538	DIPHENOXYLATE HYDROCHLORIDE with ATROPINE SULFATE	
.Palliative Care	521	.Alimentary tract and metabolism	87
<i>Diflucan (PF)</i>		<i>Diphereline (IS)</i>	
.Anti-infectives for systemic use	211, 212	.Antineoplastic and immunomodulating agents	247
<i>Digestelact (SJ)</i>		DIPHThERIA and TETANUS VACCINE, ADSORBED, DILUTED FOR ADULT USE	
.Various	512	.Anti-infectives for systemic use	221
DIGOXIN		<i>Diprosone (MK)</i>	
.Cardiovascular system	117	.Dermatologicals	170
<i>Dihydroergot (NV)</i>		DIPYRIDAMOLE	
.Emergency Drug Supplies	64	.Blood and blood forming organs	108
.Nervous system	421		

GENERIC/PROPRIETARY INDEX

DIPYRIDAMOLE with ASPIRIN		
.Blood and blood forming organs.....	108	
DISODIUM ETIDRONATE		
.Musculo-skeletal system.....	399	
DISODIUM ETIDRONATE and CALCIUM CARBONATE		
.Musculo-skeletal system.....	403	
DISODIUM PAMIDRONATE		
.Musculo-skeletal system.....	399	
.Section 100	707, 856, 857	
DISOPYRAMIDE		
.Cardiovascular system	117	
<i>Distaph 250 (AF)</i>		
.Anti-infectives for systemic use	197	
.Dental.....	546	
<i>Distaph 500 (AF)</i>		
.Anti-infectives for systemic use	197	
.Dental.....	546	
<i>Dithiazide (PL)</i>		
.Cardiovascular system	122	
<i>Ditropan (SW)</i>		
.Genito urinary system and sex hormones	183	
<i>Dizole 100 (AF)</i>		
.Anti-infectives for systemic use	212	
<i>Dizole 200 (AF)</i>		
.Anti-infectives for systemic use	212	
<i>Dizole 50 (AF)</i>		
.Anti-infectives for systemic use	211	
DOCUSATE SODIUM		
.Repatriation Schedule.....	911, 937	
DOCUSATE SODIUM with SENNA		
.Repatriation Schedule.....	912	
<i>Dolapril 0.5 (QA)</i>		
.Cardiovascular system	139	
<i>Dolapril 1 (QA)</i>		
.Cardiovascular system	139	
<i>Dolapril 2 (QA)</i>		
.Cardiovascular system	139	
<i>Dolapril 4 (QA)</i>		
.Cardiovascular system	140	
DOMPERIDONE		
.Alimentary tract and metabolism	79	
DONEPEZIL HYDROCHLORIDE		
.Nervous system.....	469	
DORNASE ALFA		
.Section 100	714, 864	
<i>Doryx (YN)</i>		
.Anti-infectives for systemic use	193, 194, 195	
.Dental.....	544	
DORZOLAMIDE HYDROCHLORIDE		
.Optomical.....	567	
.Sensory organs.....	491	
DORZOLAMIDE HYDROCHLORIDE with TIMOLOL MALEATE		
.Optomical.....	567	
.Sensory organs.....	491	
<i>Dostan (GM)</i>		
.Genito urinary system and sex hormones.....	175	
<i>Dostinex (PF)</i>		
.Genito urinary system and sex hormones.....	175	
<i>Dothep 25 (AF)</i>		
.Nervous system.....	458	
<i>Dothep 75 (AF)</i>		
.Nervous system.....	458	
DOTHIEPIN HYDROCHLORIDE		
.Nervous system.....	458	
DOXEPIN HYDROCHLORIDE		
.Nervous system.....	458	
DOXORUBICIN HYDROCHLORIDE, PEGYLATED LIPOSOMAL		
.Section 100.....	621, 768	
<i>Doxsig (QA)</i>		
.Anti-infectives for systemic use.....	193, 194	
.Dental.....	544	
<i>Doxy-100 (GM)</i>		
.Anti-infectives for systemic use.....	193, 194	
.Dental.....	544	
<i>Doxy-50 (GM)</i>		
.Anti-infectives for systemic use.....	193	
DOXYCYCLINE		
.Anti-infectives for systemic use.....	193, 194	
.Dental.....	544	
<i>Doxyhexal (SZ)</i>		
.Anti-infectives for systemic use.....	193, 194	
.Dental.....	544	
<i>Doxylin 100 (AF)</i>		
.Anti-infectives for systemic use.....	193, 194	
.Dental.....	544	
<i>Doxylin 50 (AF)</i>		
.Anti-infectives for systemic use.....	193	
<i>D-Penamine (AL)</i>		
.Musculo-skeletal system	396	
DRESSING with CADEXOMER IODINE		
.Repatriation Schedule.....	953	
DRESSING with SILVER		
.Repatriation Schedule.....	953	
DRESSING—ACTIVATED CHARCOAL (MALODOROUS WOUND)		
.Repatriation Schedule	944	
DRESSING—ALGINATE (CAVITY WOUND)		
.Repatriation Schedule	944	
DRESSING—ALGINATE (SUPERFICIAL WOUND)		
.Repatriation Schedule	944, 945	
DRESSING—FILM		
.Repatriation Schedule.....	945	
DRESSING—FILM ISLAND		
.Repatriation Schedule	945, 946	
DRESSING—FOAM with CHARCOAL (MALODOROUS WOUND)		
.Repatriation Schedule	947	
DRESSING—FOAM with SILICONE—HEAVY EXUDATE		

GENERIC/PROPRIETARY INDEX

.Repatriation Schedule.....	947	.Musculo-skeletal system.....	403
DRESSING—FOAM with SILICONE—LIGHT EXUDATE		<i>Dronalen Plus D-Cal (FR)</i>	
.Repatriation Schedule.....	947	.Musculo-skeletal system.....	403
DRESSING—FOAM with SILICONE—MODERATE EXUDATE		<i>Dulcolax (BY)</i>	
.Repatriation Schedule.....	948	.Alimentary tract and metabolism	85
DRESSING—FOAM—HEAVY EXUDATE		.Palliative Care.....	522, 523
.Repatriation Schedule.....	946	DULOXETINE HYDROCHLORIDE	
DRESSING—FOAM—MODERATE EXUDATE		.Nervous system.....	464
.Repatriation Schedule.....	946	<i>Duocal (SB)</i>	
DRESSING—FOAM—SILVER		.Various	517
.Repatriation Schedule.....	946	<i>DuoCover (BQ)</i>	
DRESSING—GAUZE (ABSORBENT PAD)		.Blood and blood forming organs.....	108
.Repatriation Schedule.....	948	<i>Duodart 500ug/400ug (GK)</i>	
DRESSING—GAUZE—EYE PAD		.Genito urinary system and sex hormones.....	183
.Repatriation Schedule.....	948	<i>DuoDERM CGF H7660 (CC)</i>	
DRESSING—GAUZE—PARAFFIN		.Repatriation Schedule	950
.Repatriation Schedule.....	948	<i>DuoDERM CGF H7662 (CC)</i>	
DRESSING—GAUZE—PARAFFIN with CHLORHEXIDINE ACETATE		.Repatriation Schedule	950
.Repatriation Schedule.....	948	<i>DuoDERM Extra Thin H7955 (CC)</i>	
DRESSING—HYDROACTIVE (CAVITY WOUND)		.Repatriation Schedule	950
.Repatriation Schedule.....	948	<i>DuoDERM Gel H7987 (CC)</i>	
DRESSING—HYDROACTIVE (DEBRIDEMENT)		.Repatriation Schedule	951
.Repatriation Schedule.....	948	<i>DuoDERM Gel H7990 (CC)</i>	
DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—HIGH EXUDATE)		.Repatriation Schedule	951
.Repatriation Schedule.....	948, 949	<i>DuoDERM Paste H7930 (CC)</i>	
DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—LIGHT EXUDATE)		.Repatriation Schedule	949
.Repatriation Schedule.....	949	<i>Duodopa (VE)</i>	
DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—MODERATE EXUDATE)		.Nervous system.....	434
.Repatriation Schedule.....	949	.Section 100.....	709, 858
DRESSING—HYDROCOLLOID (CAVITY WOUND)		<i>Duofilm Gel (GK)</i>	
.Repatriation Schedule.....	949	.Repatriation Schedule	920
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—LIGHT EXUDATE)		<i>Duofilm Solution (GK)</i>	
.Repatriation Schedule.....	950	.Repatriation Schedule	920
DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—MODERATE EXUDATE)		<i>Duotrav (AQ)</i>	
.Repatriation Schedule.....	950, 951	.Optometrical.....	568
DRESSING—HYDROFIBRE (ALTERNATE TO ALGINATES)		.Sensory organs.....	492
.Repatriation Schedule.....	951	<i>Duphalac (AB)</i>	
DRESSING—HYDROGEL—AMORPHOUS		.Alimentary tract and metabolism	85
.Repatriation Schedule.....	951, 952	.Palliative Care.....	523, 524
DRESSING—HYDROGEL—SHEET		<i>Duratears (AQ)</i>	
.Repatriation Schedule.....	952	.Optometrical.....	570
DRESSING—NON-ADHERENT		.Sensory organs.....	498
.Repatriation Schedule.....	952, 953	<i>Duride (AF)</i>	
DRESSING—TULLE NON-GAUZE—PARAFFIN		.Cardiovascular system	120
.Repatriation Schedule.....	953	<i>Durogesic 100 (JC)</i>	
<i>Drixine (MK)</i>		.Nervous system.....	417
.Repatriation Schedule.....	935	<i>Durogesic 12 (JC)</i>	
<i>Dronalen Plus (GM)</i>		.Nervous system.....	414
		<i>Durogesic 25 (JC)</i>	
		.Nervous system.....	415
		<i>Durogesic 50 (JC)</i>	
		.Nervous system.....	416
		<i>Durogesic 75 (JC)</i>	
		.Nervous system.....	416
		<i>Duro-K (NM)</i>	

GENERIC/PROPRIETARY INDEX

.Alimentary tract and metabolism	103
<i>Durotram XR (IA)</i>	
.Nervous system.....	419
<i>Duro-Tuss (IA)</i>	
.Repatriation Schedule	936
DUTASTERIDE	
.Genito urinary system and sex hormones	183
DUTASTERIDE with TAMSULOSIN	
.Genito urinary system and sex hormones	183
<i>Dysport (IS)</i>	
.Section 100	870

E

<i>E.E.S. 200 (LM)</i>	
.Antiinfectives for systemic use	206
.Dental.....	550
<i>E.E.S. 400 Filmtab (LM)</i>	
.Antiinfectives for systemic use	206
.Dental.....	550
<i>E.E.S. Granules (LM)</i>	
.Antiinfectives for systemic use	206
.Dental.....	550
<i>EAA Supplement (VF)</i>	
.Various	516
<i>Ear Clear for Ear Wax Removal (KY)</i>	
.Repatriation Schedule	937
<i>Easiphen (SB)</i>	
.Various	514
<i>Ebixa (LU)</i>	
.Nervous system.....	475
<i>Edecrin (FK)</i>	
.Cardiovascular system	123
<i>Edronax (PF)</i>	
.Nervous system.....	466
<i>Edurant (JC)</i>	
.Section 100	617, 764
EFAVIRENZ	
.Section 100	616, 763
<i>Efexor-XR (PF)</i>	
.Nervous system.....	466, 467
<i>Effient (LY)</i>	
.Blood and blood forming organs.....	109
EFORMOTEROL FUMARATE DIHYDRATE	
.Respiratory system	482
<i>Efudix (VT)</i>	
.Repatriation Schedule	927
<i>Egoderm Cream (EO)</i>	
.Repatriation Schedule	920
<i>Egoderm Ointment (EO)</i>	
.Repatriation Schedule	920
<i>Egopsoryl-TA (EO)</i>	
.Repatriation Schedule.....	918
<i>Elastoplast 2225 (BE)</i>	
.Repatriation Schedule.....	943

<i>Elastoplast 2226 (BE)</i>	
.Repatriation Schedule	943
<i>Elastoplast 2227 (BE)</i>	
.Repatriation Schedule	943
<i>Elaxine SR 150 (ZP)</i>	
.Nervous system.....	467
<i>Elaxine SR 37.5 (ZP)</i>	
.Nervous system.....	467
<i>Elaxine SR 75 (ZP)</i>	
.Nervous system.....	466
<i>Eldepryl (AS)</i>	
.Nervous system.....	437
<i>EleCare (AB)</i>	
.Various	507, 508
<i>EleCare LCP (AB)</i>	
.Various	508
ELECTROLYTE REPLACEMENT (ORAL)	
.Alimentary tract and metabolism	87
ELECTROLYTE REPLACEMENT SOLUTION	
.Blood and blood forming organs.....	115
ELETRIPTAN	
.Nervous system.....	421
<i>Eleuphrat (FR)</i>	
.Dermatologicals	170
<i>Eleva 100 (AF)</i>	
.Nervous system.....	462, 463
<i>Eleva 50 (AF)</i>	
.Nervous system.....	462, 463
<i>Elidel (HM)</i>	
.Dermatologicals	172
<i>Eligard 1 month (HH)</i>	
.Antineoplastic and immunomodulating agents	246
<i>Eligard 3 month (HH)</i>	
.Antineoplastic and immunomodulating agents	246
<i>Eligard 4 month (HH)</i>	
.Antineoplastic and immunomodulating agents	246
<i>Eligard 6 month (HH)</i>	
.Antineoplastic and immunomodulating agents	246
<i>Elquis (BQ)</i>	
.Blood and blood forming organs.....	111, 112
<i>Elocon (MK)</i>	
.Dermatologicals	171
.Repatriation Schedule	919
<i>Elonva (MK)</i>	
.Section 100.....	874
ELTROMBOPAG	
.Section 100.....	575, 721
<i>Emend (MK)</i>	
.Alimentary tract and metabolism	84
EMTRICITABINE	
.Section 100.....	614, 761
<i>Emtriva (GI)</i>	
.Section 100.....	614, 761
<i>E-Mycin (AF)</i>	
.Antiinfectives for systemic use.....	206

GENERIC/PROPRIETARY INDEX

.Dental.....	550	<i>Epilim Liquid (SW)</i>	
<i>E-Mycin 200 (AF)</i>		.Nervous system.....	426
.Antiinfectives for systemic use	206	<i>Epilim Syrup (SW)</i>	
.Dental.....	550	.Nervous system.....	426
<i>E-Mycin 400 (AF)</i>		<i>EpiPen (AL)</i>	
.Antiinfectives for systemic use	206	.Cardiovascular system	119
.Dental.....	550	.Respiratory system.....	487
ENALAPRIL		<i>EpiPen Jr. (AL)</i>	
.Cardiovascular system	133	.Cardiovascular system	119
<i>Enalapril generichealth (GQ)</i>		.Respiratory system.....	487
.Cardiovascular system	133	<i>Epiramax 100 (QA)</i>	
ENALAPRIL MALEATE with HYDROCHLOROTHIAZIDE		.Nervous system.....	432
.Cardiovascular system	140	<i>Epiramax 200 (QA)</i>	
<i>Enalapril Sandoz (SZ)</i>		.Nervous system.....	432
.Cardiovascular system	133	<i>Epiramax 25 (QA)</i>	
<i>Enalapril/HCT Sandoz (SZ)</i>		.Nervous system.....	431
.Cardiovascular system	140	<i>Epiramax 50 (QA)</i>	
<i>Enalapril-GA (GM)</i>		.Nervous system.....	431
.Cardiovascular system	133	EPLERENONE	
<i>Enalapril-PS (FZ)</i>		.Cardiovascular system	123
.Cardiovascular system	133	EPOETIN ALFA	
<i>Enbrel (PF)</i>		.Section 100.....	579, 725
.Antineoplastic and immunomodulating agents ...	326,	EPOETIN BETA	
329, 332, 335, 338, 341, 346, 349, 353, 356, 360		.Section 100.....	580, 726
.Section 100	643, 646, 792, 794	EPOETIN LAMBDA	
<i>Endep 10 (AF)</i>		.Section 100.....	580, 726
.Nervous system.....	457	EPOPROSTENOL SODIUM	
<i>Endep 25 (AF)</i>		.Section 100.....	590, 736
.Nervous system.....	457	<i>Eprex 1000 (JC)</i>	
<i>Endep 50 (AF)</i>		.Section 100.....	579, 725
.Nervous system.....	457	<i>Eprex 10000 (JC)</i>	
<i>Endone (QA)</i>		.Section 100.....	579, 726
.Dental.....	557	<i>Eprex 20,000 (JC)</i>	
.Nervous system.....	413	.Section 100.....	580, 725
<i>Energivit (SB)</i>		<i>Eprex 2000 (JC)</i>	
.Various	516	.Section 100.....	579, 726
ENFUVIRTIDE		<i>Eprex 3000 (JC)</i>	
.Section 100	618, 766	.Section 100.....	579, 726
<i>Enidin (PE)</i>		<i>Eprex 40,000 (JC)</i>	
.Optometrical.....	566	.Section 100.....	580, 726
.Sensory organs.....	491	<i>Eprex 4000 (JC)</i>	
<i>Enlax-XR (AF)</i>		.Section 100.....	579, 726
.Nervous system.....	466, 467	<i>Eprex 5000 (JC)</i>	
ENOXAPARIN SODIUM		.Section 100.....	579, 725
.Blood and blood forming organs.....	106	<i>Eprex 6000 (JC)</i>	
ENTACAPONE		.Section 100.....	580, 725
.Nervous system.....	438	<i>Eprex 8000 (JC)</i>	
ENTECAVIR MONOHYDRATE		.Section 100.....	580, 725
.Section 100	614, 761	EPROSARTAN MESYLATE	
<i>Epiduo (GA)</i>		.Cardiovascular system	142
.Dermatologicals	171	EPROSARTAN MESYLATE with HYDROCHLOROTHIAZIDE	
<i>Epilim (SW)</i>		.Cardiovascular system	144
.Nervous system.....	426	EPTIFIBATIDE ACETATE	
<i>Epilim EC (SW)</i>		.Blood and blood forming organs.....	109
.Nervous system.....	426	ERLOTINIB	

GENERIC/PROPRIETARY INDEX

.Antineoplastic and immunomodulating agents	230
<i>Eryc (YN)</i>	
.Antiinfectives for systemic use	205
.Dental.....	550
<i>Erythrocine-I.V. (LM)</i>	
.Antiinfectives for systemic use	206
.Dental.....	550
ERYTHROMYCIN	
.Antiinfectives for systemic use	205
.Dental.....	550
ERYTHROMYCIN ETHYL SUCCINATE	
.Antiinfectives for systemic use	206
.Dental.....	550
ERYTHROMYCIN LACTOBIONATE	
.Antiinfectives for systemic use	206
.Dental.....	550
<i>Escicor 10 (MI)</i>	
.Nervous system.....	459
<i>Escicor 20 (MI)</i>	
.Nervous system.....	460
ESCITALOPRAM	
.Nervous system.....	459, 460
<i>Escitalopram GA (GN)</i>	
.Nervous system.....	459, 460
<i>Escitalopram generichealth (GQ)</i>	
.Nervous system.....	459, 460
<i>Escitalopram-DRLA (RZ)</i>	
.Nervous system.....	459, 460
<i>Esipram (GM)</i>	
.Nervous system.....	459, 460
<i>Esitalo (SZ)</i>	
.Nervous system.....	459, 460
<i>Eskazole (GK)</i>	
.Antiparasitic products, insecticides and repellents	481
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE	
.Alimentary tract and metabolism	73, 74
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE and CLARITHROMYCIN and AMOXYCILLIN	
.Alimentary tract and metabolism	78
<i>Essential Amino Acid Mix (SB)</i>	
.Various	516
ESSENTIAL AMINO ACIDS FORMULA	
.Various	516
ESSENTIAL AMINO ACIDS FORMULA with MINERALS and VITAMIN C	
.Various	516
ESSENTIAL AMINO ACIDS FORMULA with VITAMINS and MINERALS	
.Various	516
<i>Estalis continuous 50/140 (NV)</i>	
.Genito urinary system and sex hormones	179
<i>Estalis continuous 50/250 (NV)</i>	
.Genito urinary system and sex hormones	179
<i>Estalis sequi 50/140 (NV)</i>	
.Genito urinary system and sex hormones.....	179
<i>Estalis sequi 50/250 (NV)</i>	
.Genito urinary system and sex hormones.....	179
<i>Estraderm MX 100 (NV)</i>	
.Genito urinary system and sex hormones.....	177
<i>Estraderm MX 25 (NV)</i>	
.Genito urinary system and sex hormones.....	177
<i>Estraderm MX 50 (NV)</i>	
.Genito urinary system and sex hormones.....	177
<i>Estradot 100 (NV)</i>	
.Genito urinary system and sex hormones.....	178
<i>Estradot 25 (NV)</i>	
.Genito urinary system and sex hormones.....	177
<i>Estradot 37.5 (NV)</i>	
.Genito urinary system and sex hormones.....	177
<i>Estradot 50 (NV)</i>	
.Genito urinary system and sex hormones.....	178
<i>Estradot 75 (NV)</i>	
.Genito urinary system and sex hormones.....	178
ETANERCEPT	
.Antineoplastic and immunomodulating agents ...	322, 326, 329, 332, 335, 338, 341, 346, 350, 353, 356
.Section 100.....	640, 644, 788, 792
ETHACRYNIC ACID	
.Cardiovascular system	123
ETHOSUXIMIDE	
.Nervous system.....	424
ETONOGESTREL	
.Genito urinary system and sex hormones.....	176
ETOPOSIDE	
.Antineoplastic and immunomodulating agents	225
ETRAVIRINE	
.Section 100.....	617, 764
<i>Eucerin (BE)</i>	
.Repatriation Schedule	917
<i>Eulexin (MK)</i>	
.Antineoplastic and immunomodulating agents	249
<i>Eutroxsig (FM)</i>	
.Systemic hormonal preparations, excl. sex hormones and insulins	189, 190
EVEROLIMUS	
.Antineoplastic and immunomodulating agents	261
.Section 100.....	633, 781
<i>Eviplera (GI)</i>	
.Section 100.....	618, 766
<i>Evista (LY)</i>	
.Genito urinary system and sex hormones.....	182
.Musculo-skeletal system	406
<i>Exaccord (RA)</i>	
.Antineoplastic and immunomodulating agents	250
<i>Exelon (NV)</i>	
.Nervous system.....	474
<i>Exelon Patch 10 (NV)</i>	
.Nervous system.....	473
<i>Exelon Patch 5 (NV)</i>	

GENERIC/PROPRIETARY INDEX

.Nervous system.....	473	.Antiinfectives for systemic use.....	216, 217, 218
EXEMESTANE		<i>Fareston (MK)</i>	
.Antineoplastic and immunomodulating agents	249	.Antineoplastic and immunomodulating agents	248
<i>Exemestane Pfizer (FZ)</i>		<i>Fasigyn (PF)</i>	
.Antineoplastic and immunomodulating agents	250	.Antiinfectives for systemic use.....	210
<i>Exemestane Sandoz (SZ)</i>		.Antiparasitic products, insecticides and repellents	
.Antineoplastic and immunomodulating agents	250	479
EXENATIDE		<i>Faverin 100 (QA)</i>	
.Alimentary tract and metabolism	101	.Nervous system.....	461
<i>Exforge 10/160 (NV)</i>		<i>Faverin 50 (QA)</i>	
.Cardiovascular system	145	.Nervous system.....	461
<i>Exforge 10/320 (NV)</i>		<i>Favic 125 (QA)</i>	
.Cardiovascular system	145	.Antiinfectives for systemic use.....	216
<i>Exforge 5/160 (NV)</i>		<i>Favic 250 (QA)</i>	
.Cardiovascular system	145	.Antiinfectives for systemic use.....	217
<i>Exforge 5/320 (NV)</i>		<i>Favic 500 (QA)</i>	
.Cardiovascular system	145	.Antiinfectives for systemic use.....	217, 218
<i>Exforge 5/80 (NV)</i>		<i>Fawns and McAllan Proprietary Limited (FM)</i>	
.Cardiovascular system	145	.Antiinfectives for systemic use.....	214
<i>Exforge HCT 10/160/12.5 (NV)</i>		.Dental.....	556
.Cardiovascular system	146	.Nervous system.....	408, 423
<i>Exforge HCT 10/160/25 (NV)</i>		.Respiratory system.....	488
.Cardiovascular system	146	<i>Febridol (GM)</i>	
<i>Exforge HCT 10/320/25 (NV)</i>		.Dental.....	558
.Cardiovascular system	146	.Nervous system.....	420
<i>Exforge HCT 5/160/12.5 (NV)</i>		<i>Feldene (PF)</i>	
.Cardiovascular system	146	.Dental.....	554
<i>Exforge HCT 5/160/25 (NV)</i>		.Musculo-skeletal system	393
.Cardiovascular system	146	<i>Feldene-D (PF)</i>	
<i>Exjade (NV)</i>		.Dental.....	554
.Section 100	719, 868	.Musculo-skeletal system	393
<i>Exorex (GM)</i>		<i>Felodil XR 10 (QA)</i>	
.Dermatologicals	168	.Cardiovascular system	130
<i>Extine 20 (QA)</i>		<i>Felodil XR 5 (QA)</i>	
.Nervous system.....	462	.Cardiovascular system	130
EZETIMIBE		FELODIPINE	
.Cardiovascular system	162	.Cardiovascular system	130
EZETIMIBE with SIMVASTATIN		<i>Felodur ER 10 mg (AL)</i>	
.Cardiovascular system	163, 164	.Cardiovascular system	130
<i>Ezetrol (MK)</i>		<i>Felodur ER 2.5 mg (AL)</i>	
.Cardiovascular system	163	.Cardiovascular system	130
<i>Ezovir (AF)</i>		<i>Felodur ER 5 mg (AL)</i>	
.Antiinfectives for systemic use	216, 217, 218	.Cardiovascular system	130
F			
FAMCICLOVIR		<i>Femara 2.5 mg (NV)</i>	
.Antiinfectives for systemic use	216, 217, 218	.Antineoplastic and immunomodulating agents	250
<i>Famciclovir Sandoz (SZ)</i>		<i>Femolet (AF)</i>	
.Antiinfectives for systemic use	216, 217	.Antineoplastic and immunomodulating agents	250
FAMOTIDINE		<i>Femoston 2/10 (AB)</i>	
.Alimentary tract and metabolism	71	.Genito urinary system and sex hormones.....	179
<i>Famotidine Sandoz (SZ)</i>		<i>Fenac (AF)</i>	
.Alimentary tract and metabolism	71, 72	.Dental.....	553
<i>Famvir (NV)</i>		.Musculo-skeletal system	391
		.Palliative Care.....	527, 528
		<i>Fenac 25 (AF)</i>	
		.Dental.....	553

GENERIC/PROPRIETARY INDEX

.Musculo-skeletal system.....	391	FINASTERIDE	
.Palliative Care	527, 528	.Repatriation Schedule	925
FENOFIBRATE		FINGOLIMOD	
.Cardiovascular system	160, 161	.Antineoplastic and immunomodulating agents	261
<i>Fenpatch 100 (ZP)</i>		<i>Finpro (RZ)</i>	
.Nervous system.....	417	.Repatriation Schedule	925
<i>Fenpatch 12 (ZP)</i>		<i>Firazyr (ZI)</i>	
.Nervous system.....	414	.Blood and blood forming organs.....	116
<i>Fenpatch 25 (ZP)</i>		<i>Firmagon 120mg (FP)</i>	
.Nervous system.....	415	.Antineoplastic and immunomodulating agents	251
<i>Fenpatch 50 (ZP)</i>		<i>Firmagon 80mg (FP)</i>	
.Nervous system.....	416	.Antineoplastic and immunomodulating agents	251
<i>Fenpatch 75 (ZP)</i>		<i>Flagyl (SW)</i>	
.Nervous system.....	416	.Anti-infectives for systemic use.....	210
FENTANYL		.Antiparasitic products, insecticides and repellents	
.Nervous system.....	414, 415, 416	479
.Palliative Care	532	.Dental.....	552
<i>Fentanyl Sandoz (SZ)</i>		<i>Flagyl S (SW)</i>	
.Nervous system.....	414, 415, 416, 417	.Anti-infectives for systemic use.....	210
<i>Fera (QA)</i>		.Antiparasitic products, insecticides and repellents	
.Antineoplastic and immunomodulating agents	250	479
<i>Ferriprox (OA)</i>		.Dental.....	552
.Section 100	719, 868	<i>Flamazine (SN)</i>	
<i>Ferro-f-tab (AE)</i>		.Dermatologicals	169
.Blood and blood forming organs.....	114	<i>Flarex (AQ)</i>	
<i>Ferro-Liquid (AE)</i>		.Optometrical.....	566
.Blood and blood forming organs.....	114	.Sensory organs	490
<i>Ferrosig (SI)</i>		FLECAINIDE ACETATE	
.Blood and blood forming organs.....	114	.Cardiovascular system	117
<i>Ferro-tab (AE)</i>		<i>Flecatab (AF)</i>	
.Blood and blood forming organs.....	114	.Cardiovascular system	117
FERROUS FUMARATE		<i>Flexidress 650941 (CC)</i>	
.Blood and blood forming organs.....	114	.Repatriation Schedule	944
FERROUS FUMARATE with FOLIC ACID		<i>Flixotide (GK)</i>	
.Blood and blood forming organs.....	114	.Respiratory system.....	485
FERROUS SULFATE		<i>Flixotide Accuhaler (GK)</i>	
.Blood and blood forming organs.....	114	.Respiratory system.....	485
<i>Ferrum H (AS)</i>		<i>Flixotide Junior (GK)</i>	
.Blood and blood forming organs.....	114	.Respiratory system.....	485
<i>Fexal (SZ)</i>		<i>Flixotide Junior Accuhaler (GK)</i>	
.Repatriation Schedule	936	.Respiratory system.....	485
FEXOFENADINE HYDROCHLORIDE		<i>Flolan Kit (GK)</i>	
.Repatriation Schedule	936	.Section 100.....	594, 740
<i>Fibre Health Natural Granular (PP)</i>		<i>Flomaxtra (CS)</i>	
.Repatriation Schedule	912	.Repatriation Schedule	925
<i>Fibsol 10 (QA)</i>		<i>Flopen (AS)</i>	
.Cardiovascular system	134	.Anti-infectives for systemic use.....	198
<i>Fibsol 20 (QA)</i>		.Dental.....	546
.Cardiovascular system	134	<i>Florinef (QA)</i>	
<i>Fibsol 5 (QA)</i>		.Systemic hormonal preparations, excl. sex hormones	
.Cardiovascular system	134	and insulins	186
FILGRASTIM		<i>Fluanxol Concentrated Depot (LU)</i>	
.Section 100	621, 768	.Nervous system.....	440
<i>Finasta (SZ)</i>		<i>Fluanxol Depot (LU)</i>	
.Repatriation Schedule	925	.Nervous system.....	440

GENERIC/PROPRIETARY INDEX

<i>Flubiclox (TS)</i>		.Nervous system.....440
.Antiinfectives for systemic use	197	
.Dental.....	546	
<i>Flucil (AS)</i>		FLUPHENAZINE DECANOATE
.Antiinfectives for systemic use	197	.Nervous system.....438
.Dental.....	546	
<i>Flucil (LN)</i>		FLURBIPROFEN SODIUM
.Antiinfectives for systemic use	198	.Optometrical.....566
.Dental.....	546	.Sensory organs.....490
FLUCLOXACILLIN		FLUTAMIDE
.Antiinfectives for systemic use	197	.Antineoplastic and immunomodulating agents248
.Dental.....	546	<i>Flutamin (AF)</i>
<i>Flucon (AQ)</i>		.Antineoplastic and immunomodulating agents249
.Optometrical.....	566	FLUTICASONE PROPIONATE
.Sensory organs.....	490	.Respiratory system.....485
FLUCONAZOLE		FLUTICASONE PROPIONATE with SALMETEROL
.Antiinfectives for systemic use	211, 212	XINAFOATE
<i>Fluconazole Hexal (HX)</i>		.Respiratory system.....484
.Antiinfectives for systemic use	212	FLUVASTATIN
<i>Fluconazole Sandoz (SZ)</i>		.Cardiovascular system152
.Antiinfectives for systemic use	211, 212	FLUVOXAMINE
<i>Fluconazole-Clarix (AE)</i>		.Nervous system.....461
.Antiinfectives for systemic use	212	<i>Fluvoxamine GA (GM)</i>
<i>Fludara (GZ)</i>		.Nervous system.....461
.Antineoplastic and immunomodulating agents	224	<i>Fluzole 200 (QA)</i>
FLUDARABINE PHOSPHATE		.Antiinfectives for systemic use.....212
.Antineoplastic and immunomodulating agents	224	<i>FML Liquifilm (AG)</i>
FLUDROCORTISONE ACETATE		.Optometrical.....566
.Systemic hormonal preparations, excl. sex hormones		.Sensory organs.....490
and insulins	186	FOLIC ACID
FLUNITRAZEPAM		.Blood and blood forming organs.....114, 115
.Repatriation Schedule.....	932	FOLLITROPIN ALFA
FLUOROMETHOLONE		.Genito urinary system and sex hormones.....180
.Optometrical.....	566	.Section 100.....874
.Sensory organs.....	490	FOLLITROPIN BETA
FLUOROMETHOLONE ACETATE		.Genito urinary system and sex hormones.....180
.Optometrical.....	566	.Section 100.....874
.Sensory organs.....	490	FONDAPARINUX SODIUM
FLUOROURACIL		.Blood and blood forming organs.....112
.Repatriation Schedule.....	927	<i>Foradile (NV)</i>
FLUOXETINE		.Respiratory system.....482
.Nervous system.....	461	<i>Formet 1000 (QA)</i>
<i>Fluoxetine 20 (CR)</i>		.Alimentary tract and metabolism94
.Nervous system.....	461	<i>Formet 500 (QA)</i>
<i>Fluoxetine generichealth (GQ)</i>		.Alimentary tract and metabolism93
.Nervous system.....	461	<i>Formet 850 (QA)</i>
<i>Fluoxetine RBX (RA)</i>		.Alimentary tract and metabolism93
.Nervous system.....	461	<i>Formet Aspen 500 (AS)</i>
<i>Fluoxetine Sandoz (SZ)</i>		.Alimentary tract and metabolism93
.Nervous system.....	461	<i>Formet Aspen 850 (AS)</i>
<i>Fluoxetine-GA (GM)</i>		.Alimentary tract and metabolism93
.Nervous system.....	461	<i>Forteo (LY)</i>
<i>Fluoxetine-PS (FZ)</i>		.Musculo-skeletal system407
.Nervous system.....	461	.Systemic hormonal preparations, excl. sex hormones
FLUPENTHIXOL DECANOATE		and insulins191
		<i>Fosamax 40 mg (MK)</i>
		.Musculo-skeletal system398
		<i>Fosamax Once Weekly (MK)</i>

GENERIC/PROPRIETARY INDEX

.Musculo-skeletal system.....	398
<i>Fosamax Plus (MK)</i>	
.Musculo-skeletal system.....	402
<i>Fosamax Plus 70 mg/140 mcg (MK)</i>	
.Musculo-skeletal system.....	403
<i>Fosamax Plus D-Cal (MK)</i>	
.Musculo-skeletal system.....	403
FOSAMPRENAVIR	
.Section 100	612, 759
FOSCARNET SODIUM	
.Section 100	612, 758
<i>Foscavir (IX)</i>	
.Section 100	612, 758
<i>Fosetic 20/12.5 (ZP)</i>	
.Cardiovascular system	140
FOSINOPRIL SODIUM	
.Cardiovascular system	133
FOSINOPRIL SODIUM with HYDROCHLOROTHIAZIDE	
.Cardiovascular system	140
<i>Fosinopril/HCTZ-GA 10/12.5 (GM)</i>	
.Cardiovascular system	140
<i>Fosinopril/HCTZ-GA 20/12.5 (GM)</i>	
.Cardiovascular system	140
<i>Fosipril 10 (QA)</i>	
.Cardiovascular system	133
<i>Fosipril 20 (QA)</i>	
.Cardiovascular system	133
<i>Fosrenol (ZI)</i>	
.Section 100	719, 868
.Various	501
<i>Fragmin (PF)</i>	
.Blood and blood forming organs.....	105, 106
<i>Frakas (QA)</i>	
.Antiinfectives for systemic use	193
FRAMYCETIN SULFATE	
.Optometrical.....	571
.Sensory organs.....	500
<i>FreeStyle Lite (MS)</i>	
.Various	505
<i>FreeStyle Optium (MS)</i>	
.Various	504, 505
<i>Fresenius Kabi Australia Pty Limited (PK)</i>	
.Blood and blood forming organs.....	115, 116
.Dental.....	540
<i>Frusax (GN)</i>	
.Cardiovascular system	123
FRUSEMIDE	
.Cardiovascular system	122
<i>Frusamide Sandoz (SZ)</i>	
.Cardiovascular system	123
.Emergency Drug Supplies	64
<i>Frusamide-Claris (AE)</i>	
.Cardiovascular system	123
.Emergency Drug Supplies	64
<i>Frusamide-PS (FZ)</i>	

.Cardiovascular system	122, 123
<i>Frusid (GM)</i>	
.Cardiovascular system	122, 123
<i>Fucidin (CS)</i>	
.Antiinfectives for systemic use.....	209
<i>Fungilin (QA)</i>	
.Alimentary tract and metabolism	71
.Dental.....	538
FUSIDIC ACID	
.Antiinfectives for systemic use.....	209
<i>Fuzeon (RO)</i>	
.Section 100.....	618, 766
<i>Fybogel (RC)</i>	
.Repatriation Schedule	912

G

<i>GA express 15 (VF)</i>	
.Various	513
<i>GA gel (VF)</i>	
.Various	513
<i>GA Tramadol 50mg (GM)</i>	
.Dental.....	557
.Nervous system.....	418
<i>GA Tramadol SR 100mg (GM)</i>	
.Nervous system.....	419
<i>GA Tramadol SR 150mg (GM)</i>	
.Nervous system.....	419
<i>GA Tramadol SR 200mg (GM)</i>	
.Nervous system.....	419
<i>GA1 Anamix infant (SB)</i>	
.Various	513
<i>GA-Amclav 500/125 (GM)</i>	
.Antiinfectives for systemic use.....	198
.Dental.....	547
<i>GA-Amclav Forte 875/125 (GM)</i>	
.Antiinfectives for systemic use.....	198
.Dental.....	547
GABAPENTIN	
.Nervous system.....	427
.Repatriation Schedule	931
<i>Gabapentin 300 (CR)</i>	
.Nervous system.....	427
<i>Gabapentin 400 (CR)</i>	
.Nervous system.....	427
<i>Gabapentin Sandoz (SZ)</i>	
.Nervous system.....	427
<i>Gabapentin-GA (GM)</i>	
.Nervous system.....	427
<i>Gabaran (RA)</i>	
.Nervous system.....	427
<i>Gabatine 100 (QA)</i>	
.Nervous system.....	427
.Repatriation Schedule	931
<i>Gabatine 300 (QA)</i>	

GENERIC/PROPRIETARY INDEX

.Nervous system.....	427	.Cardiovascular system	161
.Repatriation Schedule.....	931	<i>Gemhexal (SZ)</i>	
<i>Gabatine 400 (QA)</i>		.Cardiovascular system	161
.Nervous system.....	427	<i>Generic Health Pty Ltd (GQ)</i>	
.Repatriation Schedule.....	931	.Dental.....	558
<i>Gabatine 600 (QA)</i>		.Nervous system.....	420
.Nervous system.....	427	<i>Genlac (QA)</i>	
.Repatriation Schedule.....	931	.Alimentary tract and metabolism	85
<i>Gabatine 800 (QA)</i>		.Palliative Care.....	523
.Nervous system.....	427	<i>Genoptic (AG)</i>	
.Repatriation Schedule.....	932	.Optometrical	565
<i>Gabitril (OA)</i>		.Sensory organs.....	489
.Nervous system.....	426	<i>Genotropin (PF)</i>	
GALANTAMINE HYDROBROMIDE		.Section 100.....	873
.Nervous system.....	470	<i>Genotropin GoQuick (PF)</i>	
<i>Galantyl (AF)</i>		.Section 100.....	873
.Nervous system.....	471, 472	<i>Genotropin MiniQuick (PF)</i>	
<i>Galvumet 50/1000 (NV)</i>		.Section 100.....	873
.Alimentary tract and metabolism	97	<i>Genox 10 (AF)</i>	
<i>Galvumet 50/500 (NV)</i>		.Antineoplastic and immunomodulating agents	247
.Alimentary tract and metabolism	97	<i>Genox 20 (AF)</i>	
<i>Galvumet 50/850 (NV)</i>		.Antineoplastic and immunomodulating agents	247
.Alimentary tract and metabolism	97	<i>GenRx Aciclovir (GX)</i>	
<i>Galvus (NV)</i>		.Antiinfectives for systemic use.....	215, 216
.Alimentary tract and metabolism	101	<i>GenRx Allopurinol (GX)</i>	
<i>Gamine XR (QA)</i>		.Musculo-skeletal system	397
.Nervous system.....	471, 472	<i>GenRx Alprazolam (GX)</i>	
GANCICLOVIR		.Nervous system.....	454
.Section 100	611, 718, 757, 867	<i>GenRx Amiodarone (GX)</i>	
<i>Ganfort 0.3/5 (AG)</i>		.Cardiovascular system	118
.Optometrical.....	567	<i>GenRx Amoxycillin (GX)</i>	
.Sensory organs.....	492	.Antiinfectives for systemic use.....	195, 196
GANIRELIX		.Dental.....	544, 545
.Section 100	875	<i>GenRx Amoxycillin and Clavulanic Acid (GX)</i>	
<i>Gantin (GN)</i>		.Antiinfectives for systemic use.....	198
.Nervous system.....	427	.Dental.....	547
.Repatriation Schedule.....	931, 932	<i>GenRx Azathioprine (GX)</i>	
<i>Gastrogel (FM)</i>		.Antineoplastic and immunomodulating agents	390
.Alimentary tract and metabolism	71	<i>GenRx Baclofen (GX)</i>	
<i>Gastro-Stop Loperamide (AS)</i>		.Musculo-skeletal system	396
.Alimentary tract and metabolism	87	<i>GenRx Calcitriol (GX)</i>	
GAUZE and COTTON TISSUE (COMBINE ROLL)		.Alimentary tract and metabolism	102
.Repatriation Schedule.....	953	.Musculo-skeletal system	405
<i>Gaviscon P (RC)</i>		<i>GenRx Captopril (GX)</i>	
.Alimentary tract and metabolism	79	.Cardiovascular system	132
GEFITINIB		<i>GenRx Carvedilol (GX)</i>	
.Antineoplastic and immunomodulating agents	230	.Cardiovascular system	128
GELATIN - SUCCINYLATED		<i>GenRx Cefaclor (GX)</i>	
.Blood and blood forming organs.....	115	.Antiinfectives for systemic use.....	202
<i>Gelofusine (BR)</i>		.Dental.....	549
.Blood and blood forming organs.....	115	<i>GenRx Cefaclor CD (GX)</i>	
<i>GelTears (BU)</i>		.Antiinfectives for systemic use.....	201
.Optometrical.....	568	.Dental.....	549
.Sensory organs.....	495	<i>GenRx Cephalexin (GX)</i>	
GEMFIBROZIL		.Antiinfectives for systemic use.....	199, 200

GENERIC/PROPRIETARY INDEX

.Dental.....	548, 549	<i>GenRx Mirtazapine (GX)</i>	
<i>GenRx Ciprofloxacin (GX)</i>		.Nervous system.....	465
.Antiinfectives for systemic use	207, 208	<i>GenRx Moclobemide (GX)</i>	
<i>GenRx Citalopram (GX)</i>		.Nervous system.....	464
.Nervous system.....	459	<i>GenRx Nifedipine (GX)</i>	
<i>GenRx Clarithromycin (GX)</i>		.Cardiovascular system	131
.Antiinfectives for systemic use	205	<i>GenRx Norfloxacin (GX)</i>	
<i>GenRx Clomipramine (GX)</i>		.Antiinfectives for systemic use.....	208
.Nervous system.....	456, 458	<i>GenRx Omeprazole (GX)</i>	
<i>GenRx Cyproterone Acetate (GX)</i>		.Alimentary tract and metabolism	75, 76
.Antineoplastic and immunomodulating agents	248	<i>GenRx Paroxetine (GX)</i>	
.Genito urinary system and sex hormones	181	.Nervous system.....	462
<i>GenRx Diltiazem (GX)</i>		<i>GenRx Perindopril (GX)</i>	
.Cardiovascular system	132	.Cardiovascular system	135, 136
<i>GenRx Diltiazem CD (GX)</i>		<i>GenRx Perindopril/ Indapamide 4/1.25 (GX)</i>	
.Cardiovascular system	131, 132	.Cardiovascular system	140
<i>GenRx Doxycycline (GX)</i>		<i>GenRx Piroxicam (GX)</i>	
.Antiinfectives for systemic use	193, 194	.Dental.....	554
.Dental.....	544	.Musculo-skeletal system	393
<i>GenRx Enalapril (GX)</i>		<i>GenRx Pravastatin (GX)</i>	
.Cardiovascular system	133	.Cardiovascular system	153, 154, 155
<i>GenRx Famotidine (GX)</i>		<i>GenRx Ramipril (GX)</i>	
.Alimentary tract and metabolism	72	.Cardiovascular system	139
<i>GenRx Fluoxetine (GX)</i>		<i>GenRx Ranitidine (GX)</i>	
.Nervous system.....	461	.Alimentary tract and metabolism	72
<i>GenRx Fosinopril (GX)</i>		<i>GenRx Salbutamol (GX)</i>	
.Cardiovascular system	133	.Emergency Drug Supplies.....	65, 66
<i>GenRx Frusemide (GX)</i>		.Respiratory system.....	483
.Cardiovascular system	122, 123	<i>GenRx Sertraline (GX)</i>	
<i>GenRx Gabapentin (GX)</i>		.Nervous system.....	462
.Nervous system.....	427	<i>GenRx Simvastatin (GX)</i>	
.Repatriation Schedule.....	931	.Cardiovascular system	156, 157, 158, 159, 160
<i>GenRx Gemfibrozil (GX)</i>		<i>GenRx Sotalol (GX)</i>	
.Cardiovascular system	161	.Cardiovascular system	118, 125
<i>GenRx Gliclazide (GX)</i>		<i>GenRx Tamoxifen (GX)</i>	
.Alimentary tract and metabolism	94	.Antineoplastic and immunomodulating agents	247
<i>GenRx Indapamide (GX)</i>		<i>GenRx Terbinafine (GX)</i>	
.Cardiovascular system	122	.Dermatologicals	167
<i>GenRx Isosorbide Mononitrate (GX)</i>		<i>GenRx Tramadol (GX)</i>	
.Cardiovascular system	120	.Dental.....	557
<i>GenRx Isotretinoin (GX)</i>		.Nervous system.....	418
.Dermatologicals	172	GENTAMICIN SULFATE	
<i>GenRx Lactulose (GX)</i>		.Antiinfectives for systemic use.....	207
.Alimentary tract and metabolism	85	.Optometrical.....	565
.Palliative Care	523	.Sensory organs.....	489
<i>GenRx Lamotrigine (GX)</i>		<i>Genteal (AQ)</i>	
.Nervous system.....	428, 429	.Optometrical.....	569
<i>GenRx Lisinopril (GX)</i>		.Sensory organs.....	497
.Cardiovascular system	134	<i>Genteal gel (AQ)</i>	
<i>GenRx Meloxicam (GX)</i>		.Optometrical.....	569
.Musculo-skeletal system.....	392, 393	.Sensory organs.....	497
<i>GenRx Metformin (GX)</i>		GESTRINONE	
.Alimentary tract and metabolism	93	.Genito urinary system and sex hormones.....	182
<i>GenRx Metoprolol (GX)</i>		<i>Gilenya (NV)</i>	
.Cardiovascular system	127	.Antineoplastic and immunomodulating agents	261

GENERIC/PROPRIETARY INDEX

GLATIRAMER ACETATE	
.Antineoplastic and immunomodulating agents	253
<i>Glidel (OA)</i>	
.Antineoplastic and immunomodulating agents	222
GLIBENCLAMIDE	
.Alimentary tract and metabolism	94
GLICLAZIDE	
.Alimentary tract and metabolism	94
<i>Glimel (AF)</i>	
.Alimentary tract and metabolism	94
GLIMEPIRIDE	
.Alimentary tract and metabolism	95
<i>Glimepiride GA 1 (GM)</i>	
.Alimentary tract and metabolism	95
<i>Glimepiride GA 2 (GM)</i>	
.Alimentary tract and metabolism	95
<i>Glimepiride GA 3 (GM)</i>	
.Alimentary tract and metabolism	95
<i>Glimepiride GA 4 (GM)</i>	
.Alimentary tract and metabolism	95
<i>Glimepiride Sandoz (SZ)</i>	
.Alimentary tract and metabolism	95
GLIPIZIDE	
.Alimentary tract and metabolism	95
<i>Glivec (NV)</i>	
.Antineoplastic and immunomodulating agents ...	232, 233, 234, 235, 236, 237, 238, 239
<i>GlucaGen Hypokit (NO)</i>	
.Dental.....	543
.Emergency Drug Supplies	64
.Systemic hormonal preparations, excl. sex hormones and insulins	190
GLUCAGON HYDROCHLORIDE	
.Dental.....	543
.Systemic hormonal preparations, excl. sex hormones and insulins	190
<i>Glucobay 100 (BN)</i>	
.Alimentary tract and metabolism	97
<i>Glucobay 50 (BN)</i>	
.Alimentary tract and metabolism	97
<i>Glucobete 1000 (DO)</i>	
.Alimentary tract and metabolism	94
<i>Glucobete 500 (DO)</i>	
.Alimentary tract and metabolism	93
<i>Glucobete 850 (DO)</i>	
.Alimentary tract and metabolism	93
<i>Glucocard 01 Sensor (OZ)</i>	
.Various	505
<i>Glucoflex-R (NA)</i>	
.Various	504, 506
<i>GlucoOz (OZ)</i>	
.Various	505
<i>Glucophage (MQ)</i>	
.Alimentary tract and metabolism	93, 94
GLUCOSE	
.Blood and blood forming organs.....	115
.Dental.....	540
<i>Glucose 5% Freeflex (PK)</i>	
.Blood and blood forming organs.....	115
GLUCOSE and KETONE INDICATOR—URINE	
.Various	503, 504
GLUCOSE INDICATOR—BLOOD	
.Various	504, 505, 506
GLUCOSE INDICATOR—URINE	
.Various	504
<i>Glucovance 250mg/1.25mg (AL)</i>	
.Alimentary tract and metabolism	96
<i>Glucovance 500mg/2.5mg (AL)</i>	
.Alimentary tract and metabolism	96
<i>Glucovance 500mg/5mg (AL)</i>	
.Alimentary tract and metabolism	96
<i>Glyade (AF)</i>	
.Alimentary tract and metabolism	94
<i>Glyade MR (AF)</i>	
.Alimentary tract and metabolism	94
GLYCEROL	
.Alimentary tract and metabolism	86
.Palliative Care.....	525, 526
.Repatriation Schedule	912
GLYCERYL TRINITRATE	
.Cardiovascular system	119
.Dental.....	541
<i>Glycosade (VF)</i>	
.Various	511
<i>GN-Carvedilol (GM)</i>	
.Cardiovascular system	128
<i>Gold Cross (BI)</i>	
.Repatriation Schedule	929, 935, 936
GOLIMUMAB	
.Antineoplastic and immunomodulating agents ...	360, 364, 367, 371, 373, 377
<i>Gonal-f Pen (SG)</i>	
.Genito urinary system and sex hormones.....	180
.Section 100.....	874
<i>Gopten (AB)</i>	
.Cardiovascular system	139, 140
GOSERELIN ACETATE	
.Antineoplastic and immunomodulating agents	246
GOSERELIN ACETATE and BICALUTAMIDE	
.Antineoplastic and immunomodulating agents	246
GRANISETRON HYDROCHLORIDE	
.Alimentary tract and metabolism	79, 80
<i>Granisetron Kabi (PK)</i>	
.Alimentary tract and metabolism	80
<i>Granocyte 13 (HH)</i>	
.Section 100.....	623, 770
<i>Granocyte 34 (HH)</i>	
.Section 100.....	623, 770
GRISEOFULVIN	
.Dermatologicals	167

GENERIC/PROPRIETARY INDEX

<i>Grisovin (QA)</i>	
.Dermatologicals	167
<i>Grisovin 500 (QA)</i>	
.Dermatologicals	167

H

<i>Haldol decanoate (JC)</i>	
.Nervous system.....	439
HALOPERIDOL	
.Nervous system.....	439
HALOPERIDOL DECANOATE	
.Nervous system.....	439
<i>Hamilton Skin Therapy Oil (VT)</i>	
.Repatriation Schedule.....	917
<i>Hamilton Skin Therapy Wash (VT)</i>	
.Repatriation Schedule.....	920
<i>Hamilton Solastick 30+ (VT)</i>	
.Repatriation Schedule.....	918
<i>Hamilton Sunscreen Family Sunscreen Cream SPF 15 (VT)</i>	
.Repatriation Schedule.....	918
<i>Hamilton Sunscreen Family Sunscreen Milk SPF 15 (VT)</i>	
.Repatriation Schedule.....	918
<i>Handy 36361414 (BV)</i>	
.Repatriation Schedule.....	941
<i>Handy 71117-05 (BV)</i>	
.Repatriation Schedule.....	948
<i>Handy 71117-06 (BV)</i>	
.Repatriation Schedule.....	948
<i>Handygauze Cohesive 8631 (BV)</i>	
.Repatriation Schedule.....	943
<i>Handygauze Cohesive 8633 (BV)</i>	
.Repatriation Schedule.....	943
<i>Handygauze Cohesive 8635 (BV)</i>	
.Repatriation Schedule.....	943
<i>HCU Anamix infant (SB)</i>	
.Various	513
<i>HCU Anamix junior LQ (SB)</i>	
.Various	512
<i>HCU Cooler (VF)</i>	
.Various	514
<i>HCU express 15 (VF)</i>	
.Various	514
<i>HCU gel (VF)</i>	
.Various	514
<i>HCU Lophlex LQ 20 (SB)</i>	
.Various	514
HEPARIN SODIUM	
.Blood and blood forming organs.....	106
<i>Hepsera (GI)</i>	
.Section 100	614, 760
HEXAMINE HIPPURATE	
.Antifectives for systemic use	210

HIGH FAT FORMULA with VITAMINS, MINERALS and TRACE ELEMENTS and low in PROTEIN and CARBOHYDRATE	
.Various	516
<i>Hiprex (IA)</i>	
.Antifectives for systemic use.....	210
HOMATROPINE HYDROBROMIDE	
.Sensory organs	493
<i>Hospira Pty Limited (HH)</i>	
.Antifectives for systemic use.....	197, 199, 200, 201, 202, 203, 207, 209
.Antineoplastic and immunomodulating agents ...	223, 390
.Blood and blood forming organs.....	106
.Dental.....	539, 546, 548, 550, 551, 556, 557, 560
.Emergency Drug Supplies.....	64, 65
.Nervous system.....	410, 412, 455
.Respiratory system.....	488
.Section 100.....	608, 609, 719, 755, 868
.Systemic hormonal preparations, excl. sex hormones and insulins	187
<i>HPMC PAA (IQ)</i>	
.Optometrical.....	569
.Sensory organs.....	497
<i>Humalog (LY)</i>	
.Alimentary tract and metabolism	92
<i>Humalog KwikPen (KP)</i>	
.Alimentary tract and metabolism	92
<i>Humalog Mix25 (LY)</i>	
.Alimentary tract and metabolism	92
<i>Humalog Mix25 KwikPen (KP)</i>	
.Alimentary tract and metabolism	92
<i>Humalog Mix50 (LY)</i>	
.Alimentary tract and metabolism	92
<i>Humalog Mix50 KwikPen (KP)</i>	
.Alimentary tract and metabolism	92
HUMAN CHORIONIC GONADOTROPHIN	
.Genito urinary system and sex hormones.....	180
.Section 100.....	875
<i>Humatrope (LY)</i>	
.Section 100.....	873
<i>Humira (VE)</i>	
.Antineoplastic and immunomodulating agents ...	268, 271, 274, 276, 277, 280, 283, 289, 295, 300, 303, 307, 310, 313, 314, 317
.Section 100.....	639, 640, 788
<i>Humulin 30/70 (LY)</i>	
.Alimentary tract and metabolism	92
<i>Humulin NPH (LY)</i>	
.Alimentary tract and metabolism	92
<i>Humulin R (LY)</i>	
.Alimentary tract and metabolism	92
<i>Hycor (QA)</i>	
.Optometrical.....	566
.Sensory organs.....	490

GENERIC/PROPRIETARY INDEX

<i>Hydopa (AF)</i>		
.Cardiovascular system	120	
HYDRALAZINE HYDROCHLORIDE		
.Cardiovascular system	121	
<i>Hydrea (BQ)</i>		
.Antineoplastic and immunomodulating agents	245	
<i>Hydrene 25/50 (AF)</i>		
.Cardiovascular system	124	
HYDROCHLOROTHIAZIDE		
.Cardiovascular system	122	
HYDROCHLOROTHIAZIDE with AMILORIDE		
HYDROCHLORIDE		
.Cardiovascular system	124	
HYDROCHLOROTHIAZIDE with TRIAMTERENE		
.Cardiovascular system	124	
<i>Hydrocoll 900744 (HR)</i>		
.Repatriation Schedule	951	
<i>Hydrocoll 900936 (HR)</i>		
.Repatriation Schedule	951	
<i>Hydrocoll Thin 900758 (HR)</i>		
.Repatriation Schedule	950	
HYDROCORTISONE		
.Systemic hormonal preparations, excl. sex hormones and insulins	187	
HYDROCORTISONE ACETATE		
.Alimentary tract and metabolism	87	
.Dental.....	542	
.Dermatologicals	169	
.Optomterical.....	566	
.Sensory organs.....	490	
HYDROCORTISONE SODIUM SUCCINATE		
.Dental.....	543	
.Systemic hormonal preparations, excl. sex hormones and insulins	187, 188	
HYDROCORTISONE with CINCHOCAINE HYDROCHLORIDE		
.Repatriation Schedule	915	
HYDROMORPHONE HYDROCHLORIDE		
.Dental.....	556	
.Nervous system.....	408, 409	
<i>Hydroxo-B12 (AS)</i>		
.Blood and blood forming organs.....	114	
HYDROXOCOBALAMIN		
.Blood and blood forming organs.....	114	
HYDROXYCHLOROQUINE SULFATE		
.Musculo-skeletal system.....	395	
HYDROXYETHYL STARCH 130/0.4		
.Blood and blood forming organs.....	115	
HYDROXYUREA		
.Antineoplastic and immunomodulating agents	245	
<i>Hyforil (RA)</i>		
.Cardiovascular system	140	
<i>Hygroton 25 (LM)</i>		
.Cardiovascular system	122	
HYOSCINE BUTYLBROMIDE		
.Palliative Care	522	
.Repatriation Schedule	911	
<i>Hypnodorm (AF)</i>		
.Repatriation Schedule	932	
HYPROMELLOSE		
.Optomterical.....	569	
.Palliative Care.....	521, 522	
.Sensory organs	496, 497	
HYPROMELLOSE with CARBOMER 980		
.Optomterical.....	569	
.Sensory organs	497	
HYPROMELLOSE with DEXTRAN		
.Optomterical.....	570	
.Sensory organs	497	
<i>Hypurin Isophane (AS)</i>		
.Alimentary tract and metabolism	92	
<i>Hypurin Neutral (AS)</i>		
.Alimentary tract and metabolism	92	
<i>Hysone 20 (AF)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	187	
<i>Hysone 4 (AF)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	187	
<i>Hytrin (AB)</i>		
.Repatriation Schedule	925	
I		
<i>Iallex (LN)</i>		
.Antiinfectives for systemic use.....	199, 200	
.Dental.....	548, 549	
IBANDRONIC ACID		
.Musculo-skeletal system	400	
.Section 100.....	708, 857	
<i>Ibilex 125 (AF)</i>		
.Antiinfectives for systemic use.....	199	
.Dental.....	548	
<i>Ibilex 250 (AF)</i>		
.Antiinfectives for systemic use.....	199, 200	
.Dental.....	548, 549	
<i>Ibilex 500 (AF)</i>		
.Antiinfectives for systemic use.....	200	
.Dental.....	548	
<i>Ibimicyn (TS)</i>		
.Antiinfectives for systemic use.....	196	
.Dental.....	545	
IBUPROFEN		
.Dental.....	554	
.Musculo-skeletal system	393, 394	
.Palliative Care.....	529	
ICATIBANT		
.Blood and blood forming organs.....	116	
<i>Idaprex 2 (SZ)</i>		
.Cardiovascular system	135	
<i>Idaprex 4 (SZ)</i>		

GENERIC/PROPRIETARY INDEX

.Cardiovascular system	135	.Cardiovascular system	122
<i>Idaprex 8 (SZ)</i>		<i>Indapamide Sandoz (SZ)</i>	
.Cardiovascular system	136	.Cardiovascular system	122
<i>Idaprex Combi 4/1.25 (SZ)</i>		<i>Indapamide-GA (GM)</i>	
.Cardiovascular system	141	.Cardiovascular system	122
IDARUBICIN HYDROCHLORIDE		<i>Indapamide-PS (FZ)</i>	
.Antineoplastic and immunomodulating agents	225	.Cardiovascular system	122
<i>Ikorel (SW)</i>		<i>Inderal (AP)</i>	
.Cardiovascular system	120	.Cardiovascular system	124, 125
ILOPROST TROMETAMOL		INDINAVIR	
.Section 100	594, 740	.Section 100.....	613, 759
IMATINIB		<i>Indocid (AS)</i>	
.Antineoplastic and immunomodulating agents ...	230, 232, 233, 234, 235, 236, 237, 238	.Dental.....	553
<i>Imdur 120 mg (AP)</i>		.Musculo-skeletal system.....	391
.Cardiovascular system	120	.Palliative Care.....	528, 529
<i>Imdur Durule (AP)</i>		INDOMETHACIN	
.Cardiovascular system	120	.Dental.....	553
<i>Imigran (GK)</i>		.Musculo-skeletal system.....	391
.Nervous system.....	422	.Palliative Care.....	528, 529
<i>Imigran FDT (GK)</i>		<i>Indopril 2 (QA)</i>	
.Nervous system.....	422	.Cardiovascular system	135
IMIPRAMINE HYDROCHLORIDE		<i>Indopril 4 (QA)</i>	
.Nervous system.....	458	.Cardiovascular system	135
IMIQUIMOD		<i>Indopril 8 (QA)</i>	
.Dermatologicals	173	.Cardiovascular system	136
.Repatriation Schedule.....	920	<i>Indopril Combi 4/1.25 (QA)</i>	
<i>ImmuCyst (SW)</i>		.Cardiovascular system	141
.Antineoplastic and immunomodulating agents	253	INFLIXIMAB	
<i>Imodium (JT)</i>		.Repatriation Schedule.....	927
.Alimentary tract and metabolism	87	.Section 100....	646, 650, 655, 661, 673, 677, 682, 794, 798, 803, 809, 821, 826, 830
<i>Imovane (SW)</i>		INSECT ALLERGEN EXTRACT—HONEY BEE VENOM	
.Repatriation Schedule.....	932	.Various	501
<i>Implanon NXT (MK)</i>		INSECT ALLERGEN EXTRACT—PAPER WASP VENOM	
.Genito urinary system and sex hormones	176	.Various	501
<i>Improvil 28 Day (FZ)</i>		INSECT ALLERGEN EXTRACT—YELLOW JACKET VENOM	
.Genito urinary system and sex hormones	176	.Various	501
<i>Imrest (AF)</i>		<i>Insig (QA)</i>	
.Repatriation Schedule.....	932	.Cardiovascular system	122
<i>Imtrate 60 mg (GM)</i>		<i>Inspra (PF)</i>	
.Cardiovascular system	120	.Cardiovascular system	123
<i>Imukin (BY)</i>		INSULIN ASPART	
.Section 100	624, 772	.Alimentary tract and metabolism	91
<i>Imulate (QA)</i>		INSULIN ASPART—INSULIN ASPART PROTAMINE SUSPENSION	
.Antineoplastic and immunomodulating agents ...	262, 263	.Alimentary tract and metabolism	92
.Section 100	634, 782	INSULIN DETEMIR	
<i>Imuran (AS)</i>		.Alimentary tract and metabolism	93
.Antineoplastic and immunomodulating agents	390	INSULIN GLARGINE	
<i>In a Wink Moisturising (IQ)</i>		.Alimentary tract and metabolism	93
.Optometrical.....	569	INSULIN GLULISINE	
.Sensory organs.....	496, 497	.Alimentary tract and metabolism	91
INDACATEROL		INSULIN ISOPHANE (N.P.H.)	
.Respiratory system	482	.Alimentary tract and metabolism	92
INDAPAMIDE HEMIHYDRATE		INSULIN LISPRO	

GENERIC/PROPRIETARY INDEX

.Alimentary tract and metabolism	92	.Repatriation Schedule	953
INSULIN LISPRO—INSULIN LISPRO PROTAMINE		<i>Iodosorb 66051360 (SN)</i>	
SUSPENSION		.Repatriation Schedule	953
.Alimentary tract and metabolism	92	<i>Iodosorb Ointment 66051230 (SN)</i>	
INSULIN NEUTRAL		.Repatriation Schedule	953
.Alimentary tract and metabolism	92	<i>Iodosorb Ointment 66051240 (SN)</i>	
INSULIN NEUTRAL—INSULIN ISOPHANE (N.P.H.), (MIXED)		.Repatriation Schedule	953
(Biphasic Isophane)		<i>Iodosorb Powder 66051070 (SN)</i>	
.Alimentary tract and metabolism	92	.Repatriation Schedule	953
<i>Intal CFC-Free (SW)</i>		<i>Ionil-T (GA)</i>	
.Respiratory system	486	.Repatriation Schedule	919
<i>Intal Forte CFC-Free (SW)</i>		<i>Iopidine 0.5% (AQ)</i>	
.Respiratory system	486	.Sensory organs	490
<i>Intal Spincaps (GM)</i>		<i>Ipratrin (AF)</i>	
.Respiratory system	486	.Respiratory system	486
<i>Integrilin (MK)</i>		<i>Ipratrin Adult (AF)</i>	
.Blood and blood forming organs	109	.Respiratory system	486
<i>Intelligence (JC)</i>		IPRATROPIUM BROMIDE	
.Section 100	617, 764	.Repatriation Schedule	935
INTERFERON ALFA-2a		.Respiratory system	486
.Antineoplastic and immunomodulating agents	251	<i>Ipravent (PF)</i>	
.Section 100	624, 771	.Respiratory system	486
INTERFERON ALFA-2b		IRBESARTAN	
.Antineoplastic and immunomodulating agents	252	.Cardiovascular system	142
.Section 100	624, 772	IRBESARTAN with HYDROCHLOROTHIAZIDE	
INTERFERON BETA-1a		.Cardiovascular system	144
.Antineoplastic and immunomodulating agents	252	<i>Ircal (PE)</i>	
INTERFERON BETA-1b		.Optometrical	570
.Antineoplastic and immunomodulating agents	252	.Sensory organs	498
INTERFERON GAMMA-1b		<i>Iressa (AP)</i>	
.Section 100	624, 772	.Antineoplastic and immunomodulating agents	230
<i>Intrasite Gel 7313 (SN)</i>		IRON POLYMALTOSE COMPLEX	
.Repatriation Schedule	952	.Blood and blood forming organs	114
<i>Intron A (MK)</i>		IRON SUCROSE	
.Section 100	624, 772	.Blood and blood forming organs	114
<i>Intron A Redipen (MK)</i>		<i>Iscover (BQ)</i>	
.Antineoplastic and immunomodulating agents	252	.Blood and blood forming organs	107, 108
.Section 100	624, 772	.Repatriation Schedule	914
<i>Invega (JC)</i>		<i>Isentress (MK)</i>	
.Nervous system	448, 449	.Section 100	619, 766
<i>Invega Sustenna (JC)</i>		<i>Isoleucine 1000 Amino Acid Supplement (VF)</i>	
.Nervous system	449	.Various	517
<i>Invirase (RO)</i>		<i>Isoleucine Amino Acid Supplement (VF)</i>	
.Section 100	613, 759	.Various	517
<i>Inza 250 (AF)</i>		ISOLEUCINE with CARBOHYDRATE	
.Dental	554	.Various	517
.Musculo-skeletal system	394	<i>Isomonit (SZ)</i>	
.Palliative Care	529	.Cardiovascular system	120
<i>Inza 500 (AF)</i>		ISONIAZID	
.Dental	554	.Anti-infectives for systemic use	214
.Musculo-skeletal system	394	<i>Isoptin (AB)</i>	
.Palliative Care	529	.Cardiovascular system	131
<i>Iodosorb 66051330 (SN)</i>		.Emergency Drug Supplies	65
.Repatriation Schedule	953	<i>Isoptin 180 SR (AB)</i>	
<i>Iodosorb 66051340 (SN)</i>		.Cardiovascular system	131

GENERIC/PROPRIETARY INDEX

<i>Isoptin SR (AB)</i>		<i>.Repatriation Schedule</i>	944
<i>.Cardiovascular system</i>	131	<i>Kaltostat 168210 (CC)</i>	
<i>Isopto Carpine (AQ)</i>		<i>.Repatriation Schedule</i>	945
<i>.Optometrical</i>	566	<i>Kaltostat 168212 (CC)</i>	
<i>.Sensory organs</i>	491	<i>.Repatriation Schedule</i>	945
<i>Isopto Homatropine (AQ)</i>		<i>Kapanol (GK)</i>	
<i>.Sensory organs</i>	493	<i>.Nervous system</i>	411
<i>Isordil Sublingual (QA)</i>		<i>Karicare Aptamil De-Lact (NU)</i>	
<i>.Cardiovascular system</i>	120	<i>.Various</i>	511, 512
ISOSORBIDE DINITRATE		<i>Karicare Aptamil Pepti-Junior Gold (NU)</i>	
<i>.Cardiovascular system</i>	120	<i>.Various</i>	511
ISOSORBIDE MONONITRATE		<i>Karlors CD (LN)</i>	
<i>.Cardiovascular system</i>	120	<i>.Antiinfectives for systemic use</i>	201
ISOTRETINOIN		<i>.Dental</i>	549
<i>.Dermatologicals</i>	171	<i>Karvea (SW)</i>	
ISPAGHULA HUSK		<i>.Cardiovascular system</i>	142, 143
<i>.Repatriation Schedule</i>	912	<i>Karvezide 150/12.5 (SW)</i>	
ITRACONAZOLE		<i>.Cardiovascular system</i>	144
<i>.Antiinfectives for systemic use</i>	212	<i>Karvezide 300/12.5 (SW)</i>	
IVERMECTIN		<i>.Cardiovascular system</i>	144
<i>.Antiparasitic products, insecticides and repellents</i>		<i>Karvezide 300/25 (SW)</i>	
.....	481	<i>.Cardiovascular system</i>	144
J			
<i>Janumet (MK)</i>		<i>Keflex (AS)</i>	
<i>.Alimentary tract and metabolism</i>	97	<i>.Antiinfectives for systemic use</i>	199, 200
<i>Januvia (MK)</i>		<i>.Dental</i>	548, 549
<i>.Alimentary tract and metabolism</i>	101	<i>Keflin Neutral (AS)</i>	
<i>Jelonet 7404 (SN)</i>		<i>.Antiinfectives for systemic use</i>	199
<i>.Repatriation Schedule</i>	948	<i>.Dental</i>	548
<i>Jezil (GN)</i>		<i>Keflor (AF)</i>	
<i>.Cardiovascular system</i>	161	<i>.Antiinfectives for systemic use</i>	202
<i>JJ 02013 (JJ)</i>		<i>.Dental</i>	549
<i>.Repatriation Schedule</i>	944	<i>Keflor CD (AF)</i>	
<i>JJ 12010 (JJ)</i>		<i>.Antiinfectives for systemic use</i>	201
<i>.Repatriation Schedule</i>	953	<i>.Dental</i>	549
<i>Jurnista (JC)</i>		<i>Kefzol (AS)</i>	
<i>.Nervous system</i>	409	<i>.Antiinfectives for systemic use</i>	201
K			
<i>Kaletra (VE)</i>		<i>Kenacomb (QA)</i>	
<i>.Section 100</i>	618, 765	<i>.Repatriation Schedule</i>	919
<i>Kalixocin (AF)</i>		<i>Kenacomb Otic (QA)</i>	
<i>.Antiinfectives for systemic use</i>	205	<i>.Sensory organs</i>	500
<i>Kalma 0.25 (AF)</i>		<i>Kenacort-A10 (QA)</i>	
<i>.Nervous system</i>	454	<i>.Dental</i>	543
<i>Kalma 0.5 (AF)</i>		<i>.Systemic hormonal preparations, excl. sex hormones and insulins</i>	189
<i>.Nervous system</i>	454	<i>Kepcet (GM)</i>	
<i>Kalma 1 (AF)</i>		<i>.Nervous system</i>	430
<i>.Nervous system</i>	454	<i>Keppra (UC)</i>	
<i>Kalma 2 (AF)</i>		<i>.Nervous system</i>	430, 431
<i>.Nervous system</i>	455	<i>Kerron 1000 (DO)</i>	
<i>Kaltostat 168117 (CC)</i>		<i>.Nervous system</i>	430
		<i>Kerron 250 (DO)</i>	
		<i>.Nervous system</i>	430
		<i>Kerron 500 (DO)</i>	
		<i>.Nervous system</i>	430
		<i>KetoCal (SB)</i>	

GENERIC/PROPRIETARY INDEX

.Various	517	.Palliative Care.....	523
KETOCONAZOLE		<i>Lamictal (GK)</i>	
.Antiinfectives for systemic use	211	.Nervous system.....	428, 429
.Dermatologicals	166	<i>Lamidus (RA)</i>	
.Repatriation Schedule	916	.Nervous system.....	428, 429
<i>Keto-Diabur- Test 5000 (RD)</i>		<i>Lamisil (NC)</i>	
.Various	503, 504	.Dermatologicals	166
<i>Keto-Diastix (BN)</i>		.Repatriation Schedule	916
.Various	503, 504	<i>Lamisil (Novartis Pharmaceuticals Australia Pty Limited) (NV)</i>	
KETOPROFEN		.Dermatologicals	167
.Dental.....	554	.Repatriation Schedule	917
.Musculo-skeletal system.....	394	<i>Lamisil DermGel (NC)</i>	
<i>Kevtam (AF)</i>		.Repatriation Schedule	916
.Nervous system.....	430	LAMIVUDINE	
<i>Kindergen (SB)</i>		.Section 100.....	615, 761, 762
.Various	518	<i>Lamivudine RBX (RA)</i>	
<i>Kinson (AF)</i>		.Section 100.....	615, 762
.Nervous system.....	433	LAMIVUDINE with ZIDOVUDINE	
<i>Kivexa (VI)</i>		.Section 100.....	618, 765
.Section 100	617, 764	<i>Lamogine (AF)</i>	
<i>Klacid (AB)</i>		.Nervous system.....	428, 429
.Antiinfectives for systemic use	205	LAMOTRIGINE	
.Section 100	611, 757	.Nervous system.....	428
<i>Kosteo (QA)</i>		<i>Lamotrigine generichealth (GQ)</i>	
.Alimentary tract and metabolism	102	.Nervous system.....	428, 429
.Musculo-skeletal system.....	405	<i>Lamotrigine Sandoz (SZ)</i>	
<i>Krypton 10 (AF)</i>		.Nervous system.....	428, 429
.Genito urinary system and sex hormones	174	<i>Lamotrigine-GA (GN)</i>	
.Nervous system.....	435	.Nervous system.....	428, 429
<i>Krypton 2.5 (AF)</i>		<i>Lamotrigine-PS (FZ)</i>	
.Genito urinary system and sex hormones	174	.Nervous system.....	428, 429
.Nervous system.....	435	<i>Lamotrast 100 (MI)</i>	
<i>Krypton 5 (AF)</i>		.Nervous system.....	429
.Genito urinary system and sex hormones	175	<i>Lamotrast 200 (MI)</i>	
.Nervous system.....	435	.Nervous system.....	429
<i>Kytril (HH)</i>		<i>Lamotrast 25 (MI)</i>	
.Alimentary tract and metabolism	79, 80	.Nervous system.....	428
L			
LABETALOL HYDROCHLORIDE		<i>Lamotrast 50 (MI)</i>	
.Cardiovascular system	129	.Nervous system.....	429
<i>Lac-Dol (GM)</i>		<i>Lanoxin (QA)</i>	
.Alimentary tract and metabolism	85	.Cardiovascular system	117
.Palliative Care	523, 524	<i>Lanoxin-PG (QA)</i>	
LACOSAMIDE		.Cardiovascular system	117
.Nervous system.....	428	LANREOTIDE ACETATE	
<i>Lacri-Lube (AG)</i>		.Section 100.....	608, 754
.Optometrical.....	570	LANSOPRAZOLE	
.Sensory organs.....	498	.Alimentary tract and metabolism	74
<i>Lactocur (SZ)</i>		LANTHANUM	
.Alimentary tract and metabolism	85	.Section 100.....	719, 868
.Palliative Care	523, 524	.Various	501
LACTULOSE		<i>Lantus (SW)</i>	
.Alimentary tract and metabolism	85	.Alimentary tract and metabolism	93
		<i>Lantus SoloStar (AV)</i>	
		.Alimentary tract and metabolism	93

GENERIC/PROPRIETARY INDEX

<i>Lanvis (AS)</i>		
.Antineoplastic and immunomodulating agents	224	
<i>Lanzek (EL)</i>		
.Nervous system.....	441, 442, 443	
<i>Lanzek Zydys (EL)</i>		
.Nervous system.....	443, 444	
<i>Lanzopran (RA)</i>		
.Alimentary tract and metabolism	74, 75	
LAPATINIB		
.Antineoplastic and immunomodulating agents	239	
<i>Largactil (SW)</i>		
.Emergency Drug Supplies	64	
.Nervous system.....	438	
<i>Lasix (SW)</i>		
.Cardiovascular system	122, 123	
.Emergency Drug Supplies	64	
<i>Lasix-M (SW)</i>		
.Cardiovascular system	122	
<i>Latanocom (FZ)</i>		
.Optometrical.....	568	
.Sensory organs.....	492	
LATANOPROST		
.Optometrical.....	568	
.Sensory organs.....	492	
<i>Latanoprost Pfizer (FZ)</i>		
.Optometrical.....	568	
.Sensory organs.....	492	
<i>Latanoprost Sandoz (SZ)</i>		
.Optometrical.....	568	
.Sensory organs.....	492	
LATANOPROST with TIMOLOL MALEATE		
.Optometrical.....	568	
.Sensory organs.....	492	
<i>Lax-Tab (AE)</i>		
.Alimentary tract and metabolism	85	
.Palliative Care	522, 523	
LEFLUNOMIDE		
.Antineoplastic and immunomodulating agents ...	261, 262	
LENALIDOMIDE		
.Section 100	700, 848	
<i>Lengout (LN)</i>		
.Musculo-skeletal system.....	397	
LENOGRASTIM		
.Section 100	622, 770	
<i>Lercadip (GM)</i>		
.Cardiovascular system	130	
<i>Lercan (QA)</i>		
.Cardiovascular system	130	
LERCANIDIPINE HYDROCHLORIDE		
.Cardiovascular system	130	
LERCANIDIPINE HYDROCHLORIDE with ENALAPRIL MALEATE		
.Cardiovascular system	141	
<i>Lercanidipine Sandoz (SZ)</i>		
.Cardiovascular system	130	
<i>Lescol (NV)</i>		
.Cardiovascular system	152	
<i>Lescol XL (NV)</i>		
.Cardiovascular system	152	
<i>Letara (FZ)</i>		
.Antineoplastic and immunomodulating agents	250	
LETROZOLE		
.Antineoplastic and immunomodulating agents	250	
<i>Letrozole Actavis (TA)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>Letrozole generichealth (GQ)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>Letrozole RBX (RA)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>Letrozole Sandoz (SZ)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>Letrozole-DRLA (RZ)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>Letrozole-GA (GM)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>Letrozole-Synthon (ZT)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>Leucovorin Calcium (Hospira Pty Limited) (HH)</i>		
.Various	502	
<i>Leucovorin Calcium (Pfizer Australia Pty Ltd) (PF)</i>		
.Various	502	
<i>Leukeran (AS)</i>		
.Antineoplastic and immunomodulating agents	222	
<i>Leukoflex 1124 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukoplast 01071-00 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukoplast 01072-00 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukoplast 01073-00 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukopor 2471 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukopor 2472 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukopor 2474 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukosilk 1021 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukosilk 1022 (BV)</i>		
.Repatriation Schedule	954	
<i>Leukosilk 1024 (BV)</i>		
.Repatriation Schedule	954	
LEUPRORELIN ACETATE		
.Antineoplastic and immunomodulating agents	246	
<i>Levecetam 1000 (RZ)</i>		
.Nervous system.....	430	
<i>Levecetam 250 (RZ)</i>		
.Nervous system.....	430	

GENERIC/PROPRIETARY INDEX

<i>Levecetam 500 (RZ)</i>		
.Nervous system.....	430	
<i>Levemir FlexPen (NF)</i>		
.Alimentary tract and metabolism	93	
<i>Levemir Penfill (NO)</i>		
.Alimentary tract and metabolism	93	
LEVETIRACETAM		
.Nervous system.....	429, 430	
<i>Levetiracetam generichealth (GQ)</i>		
.Nervous system.....	430	
<i>Levetiracetam SZ (SZ)</i>		
.Nervous system.....	430	
<i>Levitacord (RA)</i>		
.Nervous system.....	430	
<i>Levitam 1000 (QA)</i>		
.Nervous system.....	430	
<i>Levitam 250 (QA)</i>		
.Nervous system.....	430	
<i>Levitam 500 (QA)</i>		
.Nervous system.....	430	
<i>Levitra (BN)</i>		
.Repatriation Schedule	924	
<i>Levlen ED (SY)</i>		
.Genito urinary system and sex hormones	175	
<i>Levo/Carbidopa Sandoz (SZ)</i>		
.Nervous system.....	433	
LEVOCABASTINE HYDROCHLORIDE		
.Repatriation Schedule	935, 937	
LEVODOPA with BENSERAZIDE		
.Nervous system.....	433	
LEVODOPA with CARBIDOPA		
.Nervous system.....	433, 434	
.Section 100	709, 858	
LEVODOPA with CARBIDOPA and ENTACAPONE		
.Nervous system.....	434	
LEVONORGESTREL		
.Genito urinary system and sex hormones	174, 176	
LEVONORGESTREL with ETHINYLOESTRADIOL		
.Genito urinary system and sex hormones	175, 176	
<i>Lexam 10 (QA)</i>		
.Nervous system.....	459	
<i>Lexam 20 (QA)</i>		
.Nervous system.....	460	
<i>Lexapro (LU)</i>		
.Nervous system.....	460, 461	
<i>Lexotan (RO)</i>		
.Repatriation Schedule	932	
<i>Lezole (WQ)</i>		
.Antineoplastic and immunomodulating agents	250	
<i>Lifeline Attest (OI)</i>		
.Various	505, 506	
LIGNOCAINE HYDROCHLORIDE		
.Cardiovascular system	117	
.Dental.....	541	
LIGNOCAINE HYDROCHLORIDE with		
CARBOXYMETHYLCELLULOSE		
.Repatriation Schedule	918	
LINAGLIPTIN		
.Alimentary tract and metabolism	100	
<i>Lincocin (PF)</i>		
.Antiinfectives for systemic use.....	207	
.Dental.....	551	
LINCOMYCIN		
.Antiinfectives for systemic use.....	207	
.Dental.....	551	
<i>Link Medical Products Pty Ltd (LM)</i>		
.Antiinfectives for systemic use.....	214	
.Cardiovascular system	118	
.Dental.....	541, 561	
.Dermatologicals	172	
.Emergency Drug Supplies.....	64	
.Respiratory system.....	486	
<i>Lioresal 10 (NV)</i>		
.Musculo-skeletal system	396	
<i>Lioresal 25 (NV)</i>		
.Musculo-skeletal system	396	
<i>Lioresal Intrathecal (NV)</i>		
.Section 100.....	707, 856	
LIOTHYRONINE SODIUM		
.Systemic hormonal preparations, excl. sex hormones		
and insulins	189	
<i>Lipazil 600 mg (GM)</i>		
.Cardiovascular system	161	
<i>Lipex 10 (FR)</i>		
.Cardiovascular system	156, 159	
<i>Lipex 20 (FR)</i>		
.Cardiovascular system	157, 159	
<i>Lipex 40 (FR)</i>		
.Cardiovascular system	157, 160	
<i>Lipex 80 (FR)</i>		
.Cardiovascular system	158, 160	
<i>Lipidil (AB)</i>		
.Cardiovascular system	160, 161	
<i>Lipigem (AF)</i>		
.Cardiovascular system	161, 162	
<i>Lipistart (VF)</i>		
.Various	511	
<i>Lipitor (PF)</i>		
.Cardiovascular system	149, 150, 151, 152	
<i>Lipodox (ZF)</i>		
.Section 100.....	621, 768	
<i>Lipostat 10 (QA)</i>		
.Cardiovascular system	153, 154	
<i>Lipostat 20 (QA)</i>		
.Cardiovascular system	153, 154	
<i>Lipostat 40 (QA)</i>		
.Cardiovascular system	153, 155	
<i>Lipostat 80 (QA)</i>		
.Cardiovascular system	154, 155	

GENERIC/PROPRIETARY INDEX

<i>Liquifilm Forte (AG)</i>		
.Optometrical.....	570	
.Sensory organs.....	499	
<i>Liquifilm Tears (AG)</i>		
.Optometrical.....	571	
.Sensory organs.....	499	
<i>Liquigen (SB)</i>		
.Various	506	
LISINAPRIL		
.Cardiovascular system	134	
<i>Lisinopril 10 (CR)</i>		
.Cardiovascular system	134	
<i>Lisinopril 20 (CR)</i>		
.Cardiovascular system	134	
<i>Lisinopril 5 (CR)</i>		
.Cardiovascular system	134	
<i>Lisinopril generichealth (GQ)</i>		
.Cardiovascular system	134	
<i>Lisinopril Ranbaxy (RA)</i>		
.Cardiovascular system	134	
<i>Lisinopril Sandoz (SZ)</i>		
.Cardiovascular system	134, 135	
<i>Lisinopril-DRLA (RZ)</i>		
.Cardiovascular system	134	
<i>Lisinopril-GA (GN)</i>		
.Cardiovascular system	134	
<i>Lisinopril-PS (FZ)</i>		
.Cardiovascular system	134	
<i>Lisodur (AF)</i>		
.Cardiovascular system	134, 135	
<i>Lithicarb (AS)</i>		
.Nervous system.....	448, 465	
LITHIUM CARBONATE		
.Nervous system.....	448, 465	
<i>Livostin (JT)</i>		
.Repatriation Schedule.....	935, 937	
<i>Locasol (SB)</i>		
.Various	512	
<i>Loceryl (GA)</i>		
.Repatriation Schedule.....	916	
<i>Locilan 28 Day (FZ)</i>		
.Genito urinary system and sex hormones	176	
<i>Lodam 50 (ZP)</i>		
.Dental.....	557	
.Nervous system.....	418	
<i>Lodam SR 100 (ZP)</i>		
.Nervous system.....	419	
<i>Lodam SR 150 (ZP)</i>		
.Nervous system.....	419	
<i>Lodam SR 200 (ZP)</i>		
.Nervous system.....	419	
<i>Lofenoxal (HC)</i>		
.Alimentary tract and metabolism	87	
<i>Logicin Rapid Relief (QA)</i>		
.Repatriation Schedule.....	935	
<i>Logicin Sinus (QA)</i>		
.Repatriation Schedule	935	
<i>Logynon ED (SY)</i>		
.Genito urinary system and sex hormones.....	176	
<i>Lomotil (BI)</i>		
.Alimentary tract and metabolism	87	
<i>Loniten (PF)</i>		
.Cardiovascular system	122	
LOPERAMIDE HYDROCHLORIDE		
.Alimentary tract and metabolism	87	
<i>Lophlex (SB)</i>		
.Various	514	
<i>Lopid (PF)</i>		
.Cardiovascular system	161, 162	
LOPINAVIR with RITONAVIR		
.Section 100.....	618, 765	
<i>Lopresor 100 (NV)</i>		
.Cardiovascular system	127	
<i>Lopresor 50 (NV)</i>		
.Cardiovascular system	127	
<i>Lorano (SZ)</i>		
.Repatriation Schedule	936	
LORATADINE		
.Repatriation Schedule	936	
<i>Lorstat 10 (AF)</i>		
.Cardiovascular system	149, 151	
<i>Lorstat 20 (AF)</i>		
.Cardiovascular system	150, 151	
<i>Lorstat 40 (AF)</i>		
.Cardiovascular system	150, 151	
<i>Lorstat 80 (AF)</i>		
.Cardiovascular system	150, 152	
LOSARTAN		
.Cardiovascular system	143	
<i>Losec Tablets (AP)</i>		
.Alimentary tract and metabolism	75, 76	
<i>Lovan (AL)</i>		
.Nervous system.....	461	
<i>Lovan 20 Tab (AL)</i>		
.Nervous system.....	461	
<i>Lovir (GM)</i>		
.Anti-infectives for systemic use.....	215	
<i>LoxaLate (AF)</i>		
.Nervous system.....	459, 460	
<i>Loxip 500 (DO)</i>		
.Anti-infectives for systemic use.....	208	
<i>Loxip 750 (DO)</i>		
.Anti-infectives for systemic use.....	208	
LPV (VT)		
.Anti-infectives for systemic use.....	196, 197	
.Dental.....	545, 546	
LUBRICATING GEL		
.Repatriation Schedule	941	
<i>Lubri-Gel (PP)</i>		
.Repatriation Schedule	941	

GENERIC/PROPRIETARY INDEX

<i>Lucentis (NV)</i>		<i>Madopar 62.5 (RO)</i>	
.Sensory organs.....	493	.Nervous system.....	433
<i>Lucrin Depot 3 Month PDS (VE)</i>		<i>Madopar HBS (RO)</i>	
.Antineoplastic and immunomodulating agents	247	.Nervous system.....	433
<i>Lucrin Depot 4 Month PDS (VE)</i>		<i>Madopar Rapid 125 (RO)</i>	
.Antineoplastic and immunomodulating agents	247	.Nervous system.....	433
<i>Lucrin Depot 7.5mg PDS (VE)</i>		<i>Madopar Rapid 62.5 (RO)</i>	
.Antineoplastic and immunomodulating agents	246	.Nervous system.....	433
<i>Lumigan (AG)</i>		<i>Magicul 400 (AF)</i>	
.Optometrical.....	567	.Alimentary tract and metabolism	71
.Sensory organs.....	492	<i>Magicul 800 (AF)</i>	
<i>Lumin 10 (AF)</i>		.Alimentary tract and metabolism	71
.Nervous system.....	465	<i>Magmin (BB)</i>	
<i>Lumin 20 (AF)</i>		.Repatriation Schedule	913
.Nervous system.....	465	MAGNESIUM	
<i>Lunava 10 (ZP)</i>		.Alimentary tract and metabolism	103
.Antineoplastic and immunomodulating agents	262	.Repatriation Schedule	913
<i>Lunava 20 (ZP)</i>		<i>Mag-Sup (PP)</i>	
.Antineoplastic and immunomodulating agents	262	.Alimentary tract and metabolism	103
<i>Luvox (AB)</i>		.Repatriation Schedule	913
.Nervous system.....	461	<i>Malarone (GK)</i>	
<i>Lycinate (FM)</i>		.Antiparasitic products, insecticides and repellents	
.Cardiovascular system	119	480
.Dental.....	541	MANNITOL	
<i>Lyclear (JT)</i>		.Section 100.....	716, 865
.Antiparasitic products, insecticides and repellents		MARAVIROC	
.....	481	.Section 100.....	618, 766
<i>Lyof foam C 603025 (SS)</i>		<i>Marevan (FM)</i>	
.Repatriation Schedule.....	947	.Blood and blood forming organs.....	105
<i>Lyof foam Extra 603088 (XP)</i>		<i>Max Pharma Ceftriaxone (GQ)</i>	
.Repatriation Schedule.....	946	.Antiinfectives for systemic use.....	204
<i>Lyof foam Extra 603090 (XP)</i>		<i>Maxalt (MK)</i>	
.Repatriation Schedule.....	946	.Nervous system.....	421
<i>Lyof foam Flat 603092 (XP)</i>		<i>Maxamox (SZ)</i>	
.Repatriation Schedule.....	946	.Antiinfectives for systemic use.....	196
<i>Lyof foam Flat 603093 (XP)</i>		.Dental.....	545
.Repatriation Schedule.....	946	<i>Maxidex (AQ)</i>	
<i>Lyof foam Flat 603095 (XP)</i>		.Optometrical.....	565
.Repatriation Schedule.....	946	.Sensory organs.....	490
<i>Lyrica (PF)</i>		<i>Maxipime (BQ)</i>	
.Repatriation Schedule.....	932	.Antiinfectives for systemic use.....	204
M		<i>Maxolon (VT)</i>	
<i>Mabthera (RO)</i>		.Alimentary tract and metabolism	79
.Section 100	706, 854	.Dental.....	538
<i>Macrodantin (PF)</i>		.Emergency Drug Supplies.....	64
.Antiinfectives for systemic use	210	<i>Mayne Pharma Aspirin (YT)</i>	
MACROGOL 3350		.Blood and blood forming organs.....	106
.Alimentary tract and metabolism	85	<i>Mayne Pharma Doxycycline (YT)</i>	
.Palliative Care	524	.Antiinfectives for systemic use.....	193, 194
<i>Madopar (RO)</i>		.Dental.....	544
.Nervous system.....	433	<i>Mayne Pharma Erythromycin (YT)</i>	
<i>Madopar 125 (RO)</i>		.Antiinfectives for systemic use.....	205
.Nervous system.....	433	.Dental.....	550
		<i>MCT Oil (SB)</i>	
		.Various	506

GENERIC/PROPRIETARY INDEX

<i>MCT Pro-Cal (VF)</i>		
.Various	518	
MEBENDAZOLE		
.Repatriation Schedule	934	
MEBEVERINE HYDROCHLORIDE		
.Repatriation Schedule	911	
<i>MediHealth ClearLax (ON)</i>		
.Alimentary tract and metabolism	85	
.Palliative Care	524	
<i>Medipore 2961 (MM)</i>		
.Repatriation Schedule	954	
MEDROXYPROGESTERONE ACETATE		
.Antineoplastic and immunomodulating agents	245	
.Genito urinary system and sex hormones	176, 178	
<i>Medroxyprogesterone Sandoz (SZ)</i>		
.Genito urinary system and sex hormones	178	
MEFENAMIC ACID		
.Musculo-skeletal system	395	
<i>Mefix 310250 (MH)</i>		
.Repatriation Schedule	954	
<i>Megace (QA)</i>		
.Antineoplastic and immunomodulating agents	246	
<i>Megafol 0.5 (AF)</i>		
.Blood and blood forming organs	114	
<i>Megafol 5 (AF)</i>		
.Blood and blood forming organs	115	
MEGESTROL ACETATE		
.Antineoplastic and immunomodulating agents	246	
<i>Melizide (AF)</i>		
.Alimentary tract and metabolism	95	
<i>Melolin 36361357 (SN)</i>		
.Repatriation Schedule	952	
<i>Melolin 66974933 (SN)</i>		
.Repatriation Schedule	952	
<i>Melox 15 (GM)</i>		
.Musculo-skeletal system	393	
<i>Melox 7.5 (GM)</i>		
.Musculo-skeletal system	392	
<i>Meloxibell (GQ)</i>		
.Musculo-skeletal system	392, 393	
MELOXICAM		
.Musculo-skeletal system	392	
<i>Meloxicam Ranbaxy (RA)</i>		
.Musculo-skeletal system	392, 393	
<i>Meloxicam Sandoz (SZ)</i>		
.Musculo-skeletal system	392, 393	
<i>Meloxicam-GA (GM)</i>		
.Musculo-skeletal system	392, 393	
<i>Meloxicam-PS (FZ)</i>		
.Musculo-skeletal system	392, 393	
MELPHALAN		
.Antineoplastic and immunomodulating agents	222	
MEMANTINE HYDROCHLORIDE		
.Nervous system	474	
<i>Memanxa (QA)</i>		
.Nervous system	475	
<i>Mepilex 294100 (MH)</i>		
.Repatriation Schedule	948	
<i>Mepilex Border 295200 (MH)</i>		
.Repatriation Schedule	947	
<i>Mepilex Border 295300 (MH)</i>		
.Repatriation Schedule	947	
<i>Mepilex Lite 284000 (MH)</i>		
.Repatriation Schedule	947	
<i>Mepilex Lite 284100 (MH)</i>		
.Repatriation Schedule	948	
<i>Mepitac 298300 (MH)</i>		
.Repatriation Schedule	954	
<i>Mepitac 298400 (MH)</i>		
.Repatriation Schedule	954	
<i>Mepitel 290510 (MH)</i>		
.Repatriation Schedule	953	
<i>Mepitel 290710 (MH)</i>		
.Repatriation Schedule	953	
<i>Meprazol (SZ)</i>		
.Alimentary tract and metabolism	75, 76	
MERCAPTOPYRINE		
.Antineoplastic and immunomodulating agents	224	
<i>Merck Sharp & Dohme (Australia) Pty Ltd (MK)</i>		
.Genito urinary system and sex hormones	176, 177	
MESALAZINE		
.Alimentary tract and metabolism	88, 89	
<i>Mesasal (GK)</i>		
.Alimentary tract and metabolism	88	
MESNA		
.Various	502	
<i>Mestinon (VT)</i>		
.Nervous system	475	
<i>Mestinon Timespan (VT)</i>		
.Nervous system	475	
<i>Metalyse (BY)</i>		
.Blood and blood forming organs	110	
<i>Metamucil Natural Granular (PY)</i>		
.Repatriation Schedule	912	
<i>Metamucil Orange Smooth (PY)</i>		
.Repatriation Schedule	912	
<i>Metex XR (QA)</i>		
.Alimentary tract and metabolism	94	
<i>Metformin 500 (CR)</i>		
.Alimentary tract and metabolism	93	
<i>Metformin 850 (CR)</i>		
.Alimentary tract and metabolism	93	
<i>Metformin generichealth (GQ)</i>		
.Alimentary tract and metabolism	93	
<i>Metformin generichealth 1000 (GQ)</i>		
.Alimentary tract and metabolism	94	
METFORMIN HYDROCHLORIDE		
.Alimentary tract and metabolism	93	
METFORMIN HYDROCHLORIDE with GLIBENCLAMIDE		
.Alimentary tract and metabolism	96	

GENERIC/PROPRIETARY INDEX

<i>Metformin Pfizer (FZ)</i>	
.Alimentary tract and metabolism	93, 94
<i>Metformin Ranbaxy (RA)</i>	
.Alimentary tract and metabolism	93
<i>Metformin Ranbaxy 1000 (RA)</i>	
.Alimentary tract and metabolism	94
<i>Metformin Sandoz (SZ)</i>	
.Alimentary tract and metabolism	93, 94
<i>Metformin-GA (GM)</i>	
.Alimentary tract and metabolism	93, 94
<i>Methaccord (WQ)</i>	
.Antineoplastic and immunomodulating agents	223
METHADONE HYDROCHLORIDE	
.Nervous system.....	417
.Palliative Care	533
.Section 100	876
<i>Methoblastin (PF)</i>	
.Antineoplastic and immunomodulating agents ...	223, 224, 390
<i>Methopt (QA)</i>	
.Optometrical.....	569
.Sensory organs.....	496, 497
METHOTREXATE	
.Antineoplastic and immunomodulating agents ...	223, 224, 390
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	
.Section 100	580, 726
METHYL SALICYLATE	
.Repatriation Schedule.....	929
METHYLDOPA	
.Cardiovascular system	120
METHYLNALTREXONE	
.Palliative Care	525
METHYLPHENIDATE HYDROCHLORIDE	
.Nervous system.....	468
<i>Methylpred (AS)</i>	
.Systemic hormonal preparations, excl. sex hormones and insulins	188
METHYLPREDNISOLONE	
.Systemic hormonal preparations, excl. sex hormones and insulins	188
METHYLPREDNISOLONE ACEPONATE	
.Dermatologicals	170, 171
METHYLPREDNISOLONE ACETATE	
.Dental.....	543
.Systemic hormonal preparations, excl. sex hormones and insulins	188
METHYSERGIDE	
.Nervous system.....	421
METOCLOPRAMIDE HYDROCHLORIDE	
.Alimentary tract and metabolism	79
.Dental.....	538
<i>Metohexal (SZ)</i>	
.Cardiovascular system	127
METOPROLOL SUCCINATE	
.Cardiovascular system	126
METOPROLOL TARTRATE	
.Cardiovascular system	127
<i>Metrogyl 200 (AF)</i>	
.Antiinfectives for systemic use.....	209
.Antiparasitic products, insecticides and repellents	479
.Dental.....	552
<i>Metrogyl 400 (AF)</i>	
.Antiinfectives for systemic use.....	210
.Antiparasitic products, insecticides and repellents	479
.Dental.....	552
<i>Metrol 100 (QA)</i>	
.Cardiovascular system	127
<i>Metrol 50 (QA)</i>	
.Cardiovascular system	127
METRONIDAZOLE	
.Antiinfectives for systemic use.....	209, 210
.Antiparasitic products, insecticides and repellents	479
.Dental.....	552
METRONIDAZOLE BENZOATE	
.Antiinfectives for systemic use.....	210
.Antiparasitic products, insecticides and repellents	479
.Dental.....	552
<i>Metronide 200 (AV)</i>	
.Antiinfectives for systemic use.....	210
.Antiparasitic products, insecticides and repellents	479
.Dental.....	552
<i>Metronide 400 (AV)</i>	
.Antiinfectives for systemic use.....	210
.Antiparasitic products, insecticides and repellents	479
.Dental.....	552
<i>Mezavant (ZI)</i>	
.Alimentary tract and metabolism	89
<i>Miacalcic 100 (NV)</i>	
.Systemic hormonal preparations, excl. sex hormones and insulins	191
<i>Miacalcic 50 (NV)</i>	
.Systemic hormonal preparations, excl. sex hormones and insulins	191
MIANSERIN HYDROCHLORIDE	
.Nervous system.....	465
<i>Micardis (BY)</i>	
.Cardiovascular system	143
<i>Micardis Plus 40/12.5 mg (BY)</i>	
.Cardiovascular system	144
<i>Micardis Plus 80/12.5 mg (BY)</i>	
.Cardiovascular system	144
<i>Micardis Plus 80/25 mg (BY)</i>	
.Cardiovascular system	144

GENERIC/PROPRIETARY INDEX

<i>Micolette (AE)</i>		
.Alimentary tract and metabolism	86	
.Palliative Care	524, 525	
.Repatriation Schedule	912	
MICONAZOLE		
.Dermatologicals	166	
.Repatriation Schedule	916	
MICONAZOLE NITRATE		
.Dermatologicals	166	
.Repatriation Schedule	916	
<i>Microgynon 30 ED (BN)</i>		
.Genito urinary system and sex hormones	175	
<i>Microgynon 50 ED (BN)</i>		
.Genito urinary system and sex hormones	175	
<i>Microlax (JT)</i>		
.Alimentary tract and metabolism	86	
.Palliative Care	525	
.Repatriation Schedule	912	
<i>Microlut 28 (BN)</i>		
.Genito urinary system and sex hormones	176	
<i>Micronor (JC)</i>		
.Genito urinary system and sex hormones	176	
<i>Milivin OD 15 (DO)</i>		
.Nervous system	465	
<i>Milivin OD 30 (DO)</i>		
.Nervous system	465	
<i>Milivin OD 45 (DO)</i>		
.Nervous system	465	
MILK POWDER—LACTOSE FREE FORMULA		
.Various	511, 512	
MILK POWDER—LACTOSE MODIFIED		
.Various	512	
MILK POWDER—SYNTHETIC		
.Various	512	
MILK PROTEIN and FAT FORMULA with VITAMINS and MINERALS—CARBOHYDRATE FREE		
.Various	517	
<i>Minax 100 (AF)</i>		
.Cardiovascular system	127	
<i>Minax 50 (AF)</i>		
.Cardiovascular system	127	
<i>Minidiab (PF)</i>		
.Alimentary tract and metabolism	95	
<i>Minipress (PF)</i>		
.Cardiovascular system	121	
<i>Minirin (FP)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	185	
<i>Minirin Melt (FP)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	186	
<i>Minirin Nasal Spray (FP)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	185, 186	
<i>Minitran 10 (IA)</i>		
.Cardiovascular system	119	
<i>Minitran 15 (IA)</i>		
.Cardiovascular system	119	
<i>Minitran 5 (IA)</i>		
.Cardiovascular system	119	
MINOCYCLINE		
.Anti-infectives for systemic use	195	
<i>Minomycin-50 (QA)</i>		
.Anti-infectives for systemic use	195	
MINOXIDIL		
.Cardiovascular system	121	
<i>Mircera (RO)</i>		
.Section 100	580, 726	
<i>Mirena (BN)</i>		
.Genito urinary system and sex hormones	174	
MIRTAZAPINE		
.Nervous system	465	
<i>Mirtazapine GH (GQ)</i>		
.Nervous system	465, 466	
<i>Mirtazapine Sandoz (SZ)</i>		
.Nervous system	465, 466	
<i>Mirtazapine-DP (GM)</i>		
.Nervous system	465	
<i>Mirtazon (QA)</i>		
.Nervous system	465, 466	
MISOPROSTOL		
.Alimentary tract and metabolism	73	
<i>Mixtard 30/70 InnoLet (NI)</i>		
.Alimentary tract and metabolism	92	
<i>Mixtard 30/70 Penfill 3 mL (NO)</i>		
.Alimentary tract and metabolism	92	
<i>Mixtard 50/50 Penfill 3 mL (NO)</i>		
.Alimentary tract and metabolism	92	
<i>MMA/PA Anamix infant (SB)</i>		
.Various	514	
<i>MMA/PA cooler (VF)</i>		
.Various	514	
<i>MMA/PA express 15 (VF)</i>		
.Various	514	
<i>MMA/PA gel (VF)</i>		
.Various	514	
<i>Mobic (BY)</i>		
.Musculo-skeletal system	392, 393	
<i>Mobilis 10 (AF)</i>		
.Dental	554	
.Musculo-skeletal system	393	
<i>Mobilis 20 (AF)</i>		
.Dental	554	
.Musculo-skeletal system	393	
<i>Mobilis D-10 (AF)</i>		
.Dental	554	
.Musculo-skeletal system	393	
<i>Mobilis D-20 (AF)</i>		
.Dental	554	
.Musculo-skeletal system	393	

GENERIC/PROPRIETARY INDEX

MOCLOBEMIDE	
.Nervous system.....	463
<i>Moclobemide Sandoz (SZ)</i>	
.Nervous system.....	464
<i>Moclobemide-PS (FZ)</i>	
.Nervous system.....	464
MODAFINIL	
.Nervous system.....	469
<i>Modavigil (CS)</i>	
.Nervous system.....	469
<i>Modecate (BQ)</i>	
.Nervous system.....	438
<i>Moduretic (AS)</i>	
.Cardiovascular system	124
<i>Mogadon (VT)</i>	
.Dental.....	560
.Nervous system.....	425, 456, 457
.Palliative Care	536
<i>Mohexal (HX)</i>	
.Nervous system.....	464
MOMETASONE FUROATE	
.Dermatologicals	171
.Repatriation Schedule	919
<i>Momex SR 10 (QA)</i>	
.Nervous system.....	411
<i>Momex SR 100 (QA)</i>	
.Nervous system.....	411
<i>Momex SR 30 (QA)</i>	
.Nervous system.....	411
<i>Momex SR 60 (QA)</i>	
.Nervous system.....	411
<i>Monace 10 (AF)</i>	
.Cardiovascular system	133
<i>Monace 20 (AF)</i>	
.Cardiovascular system	134
<i>Monodur 120 mg (PM)</i>	
.Cardiovascular system	120
<i>Monodur 60 mg (PM)</i>	
.Cardiovascular system	120
<i>Monofeme 28 (FZ)</i>	
.Genito urinary system and sex hormones	175
<i>Monogen (SB)</i>	
.Various	511
<i>Monoplus 10/12.5 (BQ)</i>	
.Cardiovascular system	140
<i>Monoplus 20/12.5 (BQ)</i>	
.Cardiovascular system	140
<i>Monopril (BQ)</i>	
.Cardiovascular system	133, 134
MONTELUKAST SODIUM	
.Respiratory system	487, 488
MORPHINE HYDROCHLORIDE	
.Dental.....	556
.Nervous system.....	409
MORPHINE SULFATE	
.Dental.....	556, 557
.Nervous system.....	410, 411, 412
.Palliative Care.....	531
.Repatriation Schedule	931
MORPHINE TARTRATE	
.Nervous system.....	412
<i>Motilium (JC)</i>	
.Alimentary tract and metabolism	79
<i>Movalis 15 (QA)</i>	
.Musculo-skeletal system	393
<i>Movalis 7.5 (QA)</i>	
.Musculo-skeletal system	392
<i>Movicol (NE)</i>	
.Alimentary tract and metabolism	85
.Palliative Care.....	524
<i>Movox 100 (AF)</i>	
.Nervous system.....	461
<i>Movox 50 (AL)</i>	
.Nervous system.....	461
<i>Moxicam 15 (AF)</i>	
.Musculo-skeletal system	393
<i>Moxicam 7.5 (AF)</i>	
.Musculo-skeletal system	392
<i>Moxiclav Duo 500/125 (QA)</i>	
.Anti-infectives for systemic use.....	198
.Dental.....	547
<i>Moxiclav Duo Forte 875/125 (QA)</i>	
.Anti-infectives for systemic use.....	198
.Dental.....	547
MOXONIDINE	
.Cardiovascular system	121
<i>MS Contin (MF)</i>	
.Nervous system.....	411, 412
.Palliative Care.....	531, 532
.Repatriation Schedule	931
<i>MS Contin Suspension 100 mg (MF)</i>	
.Nervous system.....	411
<i>MS Contin Suspension 20 mg (MF)</i>	
.Nervous system.....	412
<i>MS Contin Suspension 200 mg (MF)</i>	
.Nervous system.....	412
<i>MS Contin Suspension 30 mg (MF)</i>	
.Nervous system.....	411
<i>MS Contin Suspension 60 mg (MF)</i>	
.Nervous system.....	411
<i>MS Mono (MF)</i>	
.Nervous system.....	412
<i>MSUD AID III (SB)</i>	
.Various	515
<i>MSUD Anamix infant (SB)</i>	
.Various	515
<i>MSUD Anamix Junior (SB)</i>	
.Various	515
<i>MSUD Anamix Junior LQ (SB)</i>	
.Various	515

GENERIC/PROPRIETARY INDEX

<i>MSUD Cooler (VF)</i>	
.Various	515
<i>MSUD express 15 (VF)</i>	
.Various	515
<i>MSUD express 20 (VF)</i>	
.Various	515
<i>MSUD gel (VF)</i>	
.Various	515
<i>MSUD Lophlex LQ 20 (SB)</i>	
.Various	515
<i>MSUD Maxamaid (SB)</i>	
.Various	515
<i>MSUD Maxamum (SB)</i>	
.Various	515
MUPIROCIN	
.Repatriation Schedule	918
.Respiratory system	482
<i>Murelax (FM)</i>	
.Dental.....	560
.Nervous system.....	455, 456
.Palliative Care	535
<i>Mycobutin (PF)</i>	
.Section 100	611, 757
MYCOPHENOLATE MOFETIL	
.Antineoplastic and immunomodulating agents ...	262, 263
.Section 100	633, 634, 782
<i>Mycophenolate Sandoz (SZ)</i>	
.Antineoplastic and immunomodulating agents ...	262, 263
.Section 100	634, 782
MYCOPHENOLATE SODIUM	
.Antineoplastic and immunomodulating agents	263
.Section 100	634, 782
<i>Mycostatin (FM)</i>	
.Alimentary tract and metabolism	71
.Dental.....	538
.Dermatologicals	166
.Repatriation Schedule	916
<i>Myfortic (NV)</i>	
.Antineoplastic and immunomodulating agents	263
.Section 100	634, 782
<i>MyGlucoHealth (EH)</i>	
.Various	505, 506
<i>Mylanta Double Strength (JT)</i>	
.Repatriation Schedule	911
<i>Mylanta P (JT)</i>	
.Alimentary tract and metabolism	71
<i>Myleran (AS)</i>	
.Antineoplastic and immunomodulating agents	222
<i>Myocrisin (SW)</i>	
.Musculo-skeletal system.....	396
<i>Mysoline (LM)</i>	
.Nervous system.....	423

N

NAFARELIN	
.Section 100.....	875
.Systemic hormonal preparations, excl. sex hormones and insulins	186
NALOXONE HYDROCHLORIDE	
.Dental.....	563
.Various	501
<i>Naloxone Min-I-Jet (CS)</i>	
.Dental.....	563
.Emergency Drug Supplies.....	65
.Various	501
<i>Naltrexone generichealth (GQ)</i>	
.Nervous system.....	478
NALTREXONE HYDROCHLORIDE	
.Nervous system.....	478
NANDROLONE DECANOATE	
.Alimentary tract and metabolism	103
NAPHAZOLINE HYDROCHLORIDE	
.Repatriation Schedule	937
<i>Naprosyn (RO)</i>	
.Dental.....	554
.Musculo-skeletal system	394
.Palliative Care.....	529, 530
<i>Naprosyn SR1000 (RO)</i>	
.Dental.....	554
.Musculo-skeletal system	394
.Palliative Care.....	529, 530
<i>Naprosyn SR750 (RO)</i>	
.Dental.....	554
.Musculo-skeletal system	394
.Palliative Care.....	529, 530
NAPROXEN	
.Dental.....	554
.Musculo-skeletal system	394
.Palliative Care.....	529
NAPROXEN SODIUM	
.Dental.....	555
.Musculo-skeletal system	394
.Palliative Care.....	530
<i>Naramig (GK)</i>	
.Special Pharmaceutical Benefits	68
NARATRIPTAN	
.Special Pharmaceutical Benefits	68
<i>Nardil (LM)</i>	
.Nervous system.....	463
NATALIZUMAB	
.Section 100.....	634, 783
<i>Natrilix (SE)</i>	
.Cardiovascular system	122
<i>Natrilix SR (SE)</i>	
.Cardiovascular system	122
<i>Navelbine (FB)</i>	
.Antineoplastic and immunomodulating agents	224

GENERIC/PROPRIETARY INDEX

<i>Navoban (NV)</i>		
.Alimentary tract and metabolism	83	
<i>Nebilet (CS)</i>		
.Cardiovascular system	127	
NEBIVOLOL		
.Cardiovascular system	127	
NEDOCROMIL SODIUM		
.Respiratory system	486	
<i>Nemdyn (HA)</i>		
.Sensory organs.....	500	
<i>Neo-B12 (HH)</i>		
.Blood and blood forming organs.....	114	
<i>Neocate Advance (SB)</i>		
.Variou.....	507, 508	
<i>Neocate Advance Tropical Flavour (SB)</i>		
.Variou.....	507, 508	
<i>Neocate Advance Vanilla (SB)</i>		
.Variou.....	507	
<i>Neocate Gold (SB)</i>		
.Variou.....	509, 510	
<i>Neocate LCP (SB)</i>		
.Variou.....	508	
<i>Neo-Mercazole (LM)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	190	
NEOMYCIN UNDECENOATE with BACITRACIN ZINC		
.Sensory organs.....	500	
<i>Neoral (NV)</i>		
.Antineoplastic and immunomodulating agents	389	
.Section 100	699, 847	
<i>Neoral 10 (NV)</i>		
.Antineoplastic and immunomodulating agents	389	
.Section 100	699, 847	
<i>Neoral 100 (NV)</i>		
.Antineoplastic and immunomodulating agents	389	
.Section 100	699, 847	
<i>Neoral 25 (NV)</i>		
.Antineoplastic and immunomodulating agents	389	
.Section 100	699, 847	
<i>Neoral 50 (NV)</i>		
.Antineoplastic and immunomodulating agents	389	
.Section 100	699, 847	
<i>NeoRecormon (RO)</i>		
.Section 100	580, 726	
<i>Neotigason (TA)</i>		
.Dermatologicals	169	
<i>Neulactil (SW)</i>		
.Nervous system.....	439	
<i>Neulasta (AN)</i>		
.Section 100	624, 771	
<i>Neupogen (AN)</i>		
.Section 100	622, 770	
<i>Neurontin (PF)</i>		
.Nervous system.....	427, 428	
.Repatriation Schedule.....	931, 932	
NEVIRAPINE		
.Section 100.....	617, 764	
<i>Nexavar (BN)</i>		
.Antineoplastic and immunomodulating agents	244	
<i>Nexcare Durable Cloth First Aid Tape 799 (MM)</i>		
.Repatriation Schedule	954	
<i>Nexcare Gentle Paper First Aid Tape 789 (MM)</i>		
.Repatriation Schedule	954	
<i>Nexcare Tegaderm Transparent H1624 (MM)</i>		
.Repatriation Schedule	945	
<i>Nexcare Tegaderm Transparent H1626 (MM)</i>		
.Repatriation Schedule	945	
<i>Nexium (AP)</i>		
.Alimentary tract and metabolism	73, 74	
<i>Nexium Hp7 (AP)</i>		
.Alimentary tract and metabolism	78	
<i>Nicabate CQ 14 (GC)</i>		
.Repatriation Schedule	933	
<i>Nicabate CQ 21 (GC)</i>		
.Repatriation Schedule	933	
<i>Nicabate P (GC)</i>		
.Nervous system.....	476	
NICORANDIL		
.Cardiovascular system	120	
<i>Nicorette Patch (JT)</i>		
.Nervous system.....	476	
.Repatriation Schedule	933	
NICOTINE		
.Nervous system.....	476, 477	
.Repatriation Schedule	933	
<i>Nicotinell Step 1 (NC)</i>		
.Nervous system.....	476, 477	
<i>Nicotinell Step 2 (NC)</i>		
.Nervous system.....	476	
<i>Nicotinell Step 3 (NC)</i>		
.Nervous system.....	476	
<i>Nidem (QA)</i>		
.Alimentary tract and metabolism	94	
NIFEDIPINE		
.Cardiovascular system	130	
<i>Nifehexal (SZ)</i>		
.Cardiovascular system	131	
NILOTINIB		
.Antineoplastic and immunomodulating agents ...	240, 242	
<i>Nilstat (QA)</i>		
.Alimentary tract and metabolism	71, 86	
.Dental.....	538, 539	
.Repatriation Schedule	921	
NILUTAMIDE		
.Antineoplastic and immunomodulating agents	249	
NITRAZEPAM		
.Dental.....	560	
.Nervous system.....	424, 456	
.Palliative Care.....	536	

GENERIC/PROPRIETARY INDEX

<i>Nitro-Dur 10 (MK)</i>		
.Cardiovascular system	119	
<i>Nitro-Dur 15 (MK)</i>		
.Cardiovascular system	119	
<i>Nitro-Dur 5 (MK)</i>		
.Cardiovascular system	119	
NITROFURANTOIN		
.Anti-infectives for systemic use	210	
<i>Nitrolingual Pumpspray (SW)</i>		
.Cardiovascular system	119	
.Emergency Drug Supplies	64	
<i>Nivestim (HH)</i>		
.Section 100	622, 770	
<i>Nizac (LN)</i>		
.Alimentary tract and metabolism	72	
NIZATIDINE		
.Alimentary tract and metabolism	72	
<i>Nizoral (JC)</i>		
.Anti-infectives for systemic use	211	
<i>Nizoral 1% (JT)</i>		
.Dermatologicals	166	
<i>Nizoral 2% (JT)</i>		
.Dermatologicals	166	
.Repatriation Schedule	916	
<i>Nizoral 2% Cream (JT)</i>		
.Dermatologicals	166	
<i>Nolvadex-D (AP)</i>		
.Antineoplastic and immunomodulating agents	247	
<i>Nordette 28 (PF)</i>		
.Genito urinary system and sex hormones	175	
<i>Nordip (AF)</i>		
.Cardiovascular system	129, 130	
<i>Norditropin FlexPro (NO)</i>		
.Section 100	872	
<i>Norditropin NordiFlex (NO)</i>		
.Section 100	872	
<i>Norditropin SimpleXx (NO)</i>		
.Section 100	873	
NORETHISTERONE		
.Genito urinary system and sex hormones	176, 179	
NORETHISTERONE with ETHINYLLOESTRADIOL		
.Genito urinary system and sex hormones	175, 176	
NORETHISTERONE with MESTRANOL		
.Genito urinary system and sex hormones	176	
NORFLOXACIN		
.Anti-infectives for systemic use	208	
<i>Norfloxacin Sandoz (SZ)</i>		
.Anti-infectives for systemic use	208	
<i>Norfloxacin-GA (GM)</i>		
.Anti-infectives for systemic use	208	
<i>Norfloxacin-PS (FZ)</i>		
.Anti-infectives for systemic use	208	
<i>Noriday 28 Day (PF)</i>		
.Genito urinary system and sex hormones	176	
<i>Norimin 28 Day (FZ)</i>		
.Genito urinary system and sex hormones.....	175	
<i>Norimin-1 28 Day (FZ)</i>		
.Genito urinary system and sex hormones.....	176	
<i>Norinyl-1/28 (PF)</i>		
.Genito urinary system and sex hormones.....	176	
<i>Normacol Plus (NE)</i>		
.Alimentary tract and metabolism	85	
.Palliative Care.....	523	
.Repatriation Schedule	912	
<i>Normison (QA)</i>		
.Dental.....	560	
.Nervous system.....	457	
.Palliative Care.....	536	
<i>Noroxin (MK)</i>		
.Anti-infectives for systemic use.....	209	
<i>Norprolac (FP)</i>		
.Genito urinary system and sex hormones.....	175	
<i>Norspan (MF)</i>		
.Nervous system.....	418	
NORTRIPTYLINE HYDROCHLORIDE		
.Nervous system.....	458	
<i>Norvapine (GN)</i>		
.Cardiovascular system	129, 130	
<i>Norvasc (PF)</i>		
.Cardiovascular system	129, 130	
<i>Norvir (VE)</i>		
.Section 100.....	613, 759	
<i>Noten (AF)</i>		
.Cardiovascular system	125	
<i>Novasone (FR)</i>		
.Dermatologicals	171	
<i>Novicrit (NV)</i>		
.Section 100.....	580, 726	
<i>NovoMix 30 FlexPen (NF)</i>		
.Alimentary tract and metabolism	92	
<i>NovoMix 30 Penfill 3 mL (NO)</i>		
.Alimentary tract and metabolism	92	
<i>NovoRapid (NO)</i>		
.Alimentary tract and metabolism	91	
<i>NovoRapid FlexPen (NF)</i>		
.Alimentary tract and metabolism	91	
<i>NovoRapid Penfill 3 mL (NO)</i>		
.Alimentary tract and metabolism	91	
<i>Noxafil (MK)</i>		
.Anti-infectives for systemic use.....	213	
<i>Nplate (AN)</i>		
.Section 100.....	579, 725	
<i>Nucolox (QA)</i>		
.Repatriation Schedule	912	
<i>Nuelin (IA)</i>		
.Respiratory system.....	487	
<i>Nuelin-SR 200 (IA)</i>		
.Respiratory system.....	487	
<i>Nuelin-SR 250 (IA)</i>		
.Respiratory system.....	487	

GENERIC/PROPRIETARY INDEX

<i>Nuelin-SR 300 (IA)</i>	
. Respiratory system	487
<i>Nufloxib (AF)</i>	
. Antiinfectives for systemic use	208
<i>Nu-Gel 2497 (JJ)</i>	
. Repatriation Schedule	952
<i>Nupentin 100 (AF)</i>	
. Nervous system	427
. Repatriation Schedule	931
<i>Nupentin 300 (AF)</i>	
. Nervous system	427
. Repatriation Schedule	931
<i>Nupentin 400 (AF)</i>	
. Nervous system	427
. Repatriation Schedule	931
<i>Nupentin Tabs (AF)</i>	
. Nervous system	427, 428
<i>NutropinAq (IS)</i>	
. Section 100	873
<i>Nyogel (NV)</i>	
. Optometrical	567
. Sensory organs	492
NYSTATIN	
. Alimentary tract and metabolism	71, 86
. Dental	538, 539
. Dermatologicals	166
. Repatriation Schedule	916, 921

O

<i>O.R.S. (AS)</i>	
. Alimentary tract and metabolism	87
OCTREOTIDE	
. Section 100	608, 609, 754, 755
<i>Octreotide MaxRx (GQ)</i>	
. Section 100	609, 755
<i>Ocufen (AG)</i>	
. Optometrical	566
. Sensory organs	490
<i>Ocuflox (AG)</i>	
. Optometrical	565
. Sensory organs	490
OESTRADIOL	
. Genito urinary system and sex hormones	177, 178
OESTRADIOL and OESTRADIOL with DYDROGESTERONE	
. Genito urinary system and sex hormones	179
OESTRADIOL and OESTRADIOL with NORETHISTERONE ACETATE	
. Genito urinary system and sex hormones	179
OESTRADIOL VALERATE	
. Genito urinary system and sex hormones	178
OESTRADIOL with NORETHISTERONE ACETATE	
. Genito urinary system and sex hormones	179
OESTRIOL	
. Genito urinary system and sex hormones	178

OFLOXACIN	
. Optometrical	565
. Sensory organs	490
OLANZAPINE	
. Nervous system	440, 441, 442, 443, 444, 445
<i>Olanzapine generichealth 10 (GQ)</i>	
. Nervous system	442
<i>Olanzapine generichealth 2.5 (GQ)</i>	
. Nervous system	440
<i>Olanzapine generichealth 5 (GQ)</i>	
. Nervous system	441
<i>Olanzapine generichealth 7.5 (GQ)</i>	
. Nervous system	442
<i>Olanzapine ODT generichealth 10 (GQ)</i>	
. Nervous system	444
<i>Olanzapine ODT generichealth 5 (GQ)</i>	
. Nervous system	443
<i>Olanzapine ODT-DRLA (RZ)</i>	
. Nervous system	443, 444
<i>Olanzapine RBX (RA)</i>	
. Nervous system	441, 442, 443
<i>Olanzapine Sandoz (SZ)</i>	
. Nervous system	441, 442, 443
<i>Olanzapine Sandoz ODT 10 (SZ)</i>	
. Nervous system	444
<i>Olanzapine Sandoz ODT 5 (SZ)</i>	
. Nervous system	443
<i>Olanzapine-DRLA (RZ)</i>	
. Nervous system	441, 442, 443
<i>Olanzapine-GA (GM)</i>	
. Nervous system	441, 442, 443
<i>Olanzapine-GA ODT (GM)</i>	
. Nervous system	443, 444
<i>Olanzapine-PS (FZ)</i>	
. Nervous system	441, 442, 443
<i>Olanzapine-Synthon (ZT)</i>	
. Nervous system	440, 441, 442
OLMESARTAN MEDOXOMIL	
. Cardiovascular system	143
OLMESARTAN MEDOXOMIL with HYDROCHLOROTHIAZIDE	
. Cardiovascular system	144
OLMESARTAN with AMLODIPINE	
. Cardiovascular system	145
<i>Olmetec (MK)</i>	
. Cardiovascular system	143
<i>Olmetec Plus (MK)</i>	
. Cardiovascular system	144
OLSALAZINE SODIUM	
. Alimentary tract and metabolism	90
OMALIZUMAB	
. Section 100	710, 859
<i>Omegapharm Pty Ltd (OE)</i>	
. Antiinfectives for systemic use	204
<i>Omepral (PM)</i>	

GENERIC/PROPRIETARY INDEX

.Alimentary tract and metabolism	75, 76		
OMEPRAZOLE			
.Alimentary tract and metabolism	75, 76		
OMEPRAZOLE and CLARITHROMYCIN and AMOXICILLIN			
.Alimentary tract and metabolism	79		
<i>Omeprazole generichealth (GQ)</i>			
.Alimentary tract and metabolism	75, 76		
<i>Omeprazole Ranbaxy (RA)</i>			
.Alimentary tract and metabolism	75, 76		
<i>Omeprazole Sandoz (HX)</i>			
.Alimentary tract and metabolism	75, 76		
<i>Omeprazole Sandoz (SZ)</i>			
.Alimentary tract and metabolism	75, 76		
<i>Omeprazole Winthrop (WA)</i>			
.Alimentary tract and metabolism	75, 76		
<i>Omeprazole-GA (GM)</i>			
.Alimentary tract and metabolism	75, 76		
<i>Omeprazole-PS (FZ)</i>			
.Alimentary tract and metabolism	75, 76		
<i>Omepro-GA (GM)</i>			
.Alimentary tract and metabolism	75, 76		
<i>Omnitest EZ (BR)</i>			
.Various	504, 505		
<i>Omnitrope (SZ)</i>			
.Section 100	873		
<i>Onbrez (NV)</i>			
.Respiratory system	482		
<i>On-Call Plus (PZ)</i>			
.Various	505		
<i>OncoTICE (MK)</i>			
.Antineoplastic and immunomodulating agents	253		
ONDANSETRON			
.Alimentary tract and metabolism	80, 81, 82		
<i>Ondansetron Alphapharm (AF)</i>			
.Alimentary tract and metabolism	80, 81, 82		
<i>Ondansetron ODT-DRLA (RZ)</i>			
.Alimentary tract and metabolism	81, 82		
<i>Ondansetron Tabs Pfizer (FZ)</i>			
.Alimentary tract and metabolism	81, 82		
<i>Ondansetron-Clarix (AE)</i>			
.Alimentary tract and metabolism	80, 81, 82		
<i>Ondansetron-DRLA (RZ)</i>			
.Alimentary tract and metabolism	80, 81, 82		
<i>Ondaz (SZ)</i>			
.Alimentary tract and metabolism	80, 81, 82		
<i>Ondaz Zydix (SZ)</i>			
.Alimentary tract and metabolism	81, 82		
<i>OneTouch Verio (JJ)</i>			
.Various	504, 505		
<i>Onglyza (BQ)</i>			
.Alimentary tract and metabolism	100		
<i>Onsetron (ZP)</i>			
.Alimentary tract and metabolism	81, 82		
<i>Onsetron 4 (ZP)</i>			
.Alimentary tract and metabolism	80, 82		
<i>Onsetron 8 (ZP)</i>			
.Alimentary tract and metabolism	80, 82		
<i>Onsetron ODT 4 (WQ)</i>			
.Alimentary tract and metabolism	81, 82		
<i>Onsetron ODT 8 (WQ)</i>			
.Alimentary tract and metabolism	81, 82		
<i>Op-Site Flexigrid 4629 (SN)</i>			
.Repatriation Schedule	945		
<i>Opticrom (SW)</i>			
.Optometrical	568		
.Sensory organs	493		
<i>Optium Omega (MS)</i>			
.Various	504, 505		
<i>Optive (AG)</i>			
.Optometrical	569		
.Sensory organs	496		
<i>Orabase (QA)</i>			
.Repatriation Schedule	917		
<i>Oratane (GM)</i>			
.Dermatologicals	172		
<i>Ordine 10 (MF)</i>			
.Dental	556		
.Nervous system	410		
<i>Ordine 2 (MF)</i>			
.Dental	556		
.Nervous system	410		
<i>Ordine 5 (MF)</i>			
.Dental	556		
.Nervous system	410		
<i>Orencia (BQ)</i>			
.Antineoplastic and immunomodulating agents ...	258,		
261			
.Section 100	633, 781		
<i>Orgalutran (MK)</i>			
.Section 100	875		
<i>Orion Laboratories Pty Ltd (ON)</i>			
.Section 100	875		
<i>Orion Temozolomide (ON)</i>			
.Antineoplastic and immunomodulating agents ...	222,		
223			
ORLISTAT			
.Repatriation Schedule	912		
<i>Oroxine (QA)</i>			
.Systemic hormonal preparations, excl. sex hormones			
and insulins	189, 190		
<i>Orphan Australia Pty Ltd (OA)</i>			
.Nervous system	478		
<i>Orudis (SW)</i>			
.Dental	554		
.Musculo-skeletal system	394		
<i>Orudis SR 200 (SW)</i>			
.Dental	554		
.Musculo-skeletal system	394		
<i>Oruvail SR (AV)</i>			
.Dental	554		

GENERIC/PROPRIETARY INDEX

.Musculo-skeletal system.....	394
<i>OsmoLax (KY)</i>	
.Alimentary tract and metabolism	85
.Palliative Care	524
<i>Ospolot (PL)</i>	
.Nervous system.....	431
<i>Ossmax 70mg (RA)</i>	
.Musculo-skeletal system.....	398
<i>Otocomb Otic (FM)</i>	
.Sensory organs.....	500
<i>Otodex (AV)</i>	
.Sensory organs.....	500
<i>Ovestin (MK)</i>	
.Genito urinary system and sex hormones	178
<i>Ovestin Ovula (MK)</i>	
.Genito urinary system and sex hormones	178
<i>Ovidrel (SG)</i>	
.Section 100	874
OXAZEPAM	
.Dental.....	560
.Nervous system.....	455
.Palliative Care	535
OXCARBAZEPINE	
.Nervous system.....	425
<i>Oxis Turbuhaler (AP)</i>	
.Respiratory system	482
OXPRENOLOL HYDROCHLORIDE	
.Cardiovascular system	124
OXYBUTYNIN	
.Genito urinary system and sex hormones	182
OXYBUTYNIN HYDROCHLORIDE	
.Genito urinary system and sex hormones	183
<i>Oxybutynin Sandoz (SZ)</i>	
.Genito urinary system and sex hormones	183
<i>Oxybutynin Winthrop (WA)</i>	
.Genito urinary system and sex hormones	183
OXYCODONE	
.Dental.....	557
.Nervous system.....	412
OXYCODONE HYDROCHLORIDE	
.Dental.....	557
.Nervous system.....	412, 413
OXYCODONE HYDROCHLORIDE with NALOXONE HYDROCHLORIDE	
.Nervous system.....	413
<i>OxyContin (MF)</i>	
.Nervous system.....	413
OXYMETAZOLINE HYDROCHLORIDE	
.Repatriation Schedule.....	935
<i>OxyNorm (MF)</i>	
.Dental.....	557
.Nervous system.....	413
<i>OxyNorm Liquid 5mg/5mL (MF)</i>	
.Dental.....	557
.Nervous system.....	413

<i>Oxytrol (HH)</i>	
.Genito urinary system and sex hormones.....	182
<i>Ozapace (RA)</i>	
.Cardiovascular system	135, 136
<i>Ozcef (RA)</i>	
.Antiinfectives for systemic use.....	201, 202
.Dental.....	549
<i>Oziclide MR (RA)</i>	
.Alimentary tract and metabolism	94
<i>Ozidal (RA)</i>	
.Nervous system.....	449, 451, 452, 453
<i>Ozin 10 (DO)</i>	
.Nervous system.....	443
<i>Ozin 2.5 (DO)</i>	
.Nervous system.....	441
<i>Ozin 5 (DO)</i>	
.Nervous system.....	441
<i>Ozin 7.5 (DO)</i>	
.Nervous system.....	442
<i>Ozlodip (RA)</i>	
.Cardiovascular system	129, 130
<i>Ozmep (ZP)</i>	
.Alimentary tract and metabolism	75, 76
<i>Ozole (RA)</i>	
.Antiinfectives for systemic use.....	211, 212
<i>Ozpan (RA)</i>	
.Alimentary tract and metabolism	77, 78
<i>Ozvir (RA)</i>	
.Antiinfectives for systemic use.....	215

P

<i>PAA (IQ)</i>	
.Optometrical.....	568
.Sensory organs.....	495
<i>Paediatric Seravit (SB)</i>	
.Various	518
PALIPERIDONE	
.Nervous system.....	448, 449
PALONOSETRON	
.Alimentary tract and metabolism	83
<i>Pamacid 20 (AF)</i>	
.Alimentary tract and metabolism	72
<i>Pamacid 40 (AF)</i>	
.Alimentary tract and metabolism	72
<i>Pamisol (HH)</i>	
.Musculo-skeletal system	399
.Section 100.....	707, 708, 856, 857
<i>Panadeine Forte (SW)</i>	
.Dental.....	556
.Nervous system.....	408
<i>Panadol (GC)</i>	
.Palliative Care.....	533
<i>Panadol Osteo (GC)</i>	
.Nervous system.....	421

GENERIC/PROPRIETARY INDEX

.Palliative Care	533	.Alimentary tract and metabolism	78
<i>Panafcort (AS)</i>		<i>Parlodel (NV)</i>	
.Systemic hormonal preparations, excl. sex hormones and insulins	188	.Genito urinary system and sex hormones.....	174
<i>Panafcortelone (AS)</i>		.Nervous system.....	435
.Systemic hormonal preparations, excl. sex hormones and insulins	188	<i>Parnate (GH)</i>	
<i>Panamax (SW)</i>		.Nervous system.....	463
.Dental.....	558	PAROXETINE	
.Nervous system.....	420	.Nervous system.....	462
<i>Panamax 240 Elixir (SW)</i>		<i>Paroxetine 20 (CR)</i>	
.Dental.....	558	.Nervous system.....	462
.Nervous system.....	420	<i>Paroxetine generichealth (GQ)</i>	
<i>Panamax Co. 40 (SW)</i>		.Nervous system.....	462
.Repatriation Schedule	931	<i>Paroxetine Sandoz (SZ)</i>	
PANCREATIC EXTRACT		.Nervous system.....	462
.Alimentary tract and metabolism	90, 91	<i>Paroxetine Synthron (ZT)</i>	
PANCRELIPASE		.Nervous system.....	462
.Alimentary tract and metabolism	91	<i>Paroxetine-GA (GN)</i>	
<i>Panthron (GN)</i>		.Nervous system.....	462
.Alimentary tract and metabolism	77	<i>Paxam 0.5 (AF)</i>	
<i>Panto (NZ)</i>		.Nervous system.....	424
.Alimentary tract and metabolism	77, 78	.Palliative Care.....	534
<i>Pantofast 20 (RZ)</i>		<i>Paxam 2 (AF)</i>	
.Alimentary tract and metabolism	78	.Nervous system.....	424
<i>Pantofast 40 (RZ)</i>		.Palliative Care.....	534
.Alimentary tract and metabolism	77	<i>Paxtine (AF)</i>	
<i>Pantoloc (NH)</i>		.Nervous system.....	462
.Alimentary tract and metabolism	77, 78	<i>Peg 7420 (BK)</i>	
<i>Pantoprazole generichealth (GQ)</i>		.Repatriation Schedule	943
.Alimentary tract and metabolism	77, 78	<i>Peg 7422 (BK)</i>	
<i>Pantoprazole Sandoz (SZ)</i>		.Repatriation Schedule	943
.Alimentary tract and metabolism	77, 78	<i>Peg 7423 (BK)</i>	
PANTOPRAZOLE SODIUM SESQUIHYDRATE		.Repatriation Schedule	943
.Alimentary tract and metabolism	77	<i>Peg 7425 (BK)</i>	
<i>Pantoprazole-GA (GM)</i>		.Repatriation Schedule	943
.Alimentary tract and metabolism	77, 78	<i>Pegasys (RO)</i>	
<i>Pantoprazole-PS (FZ)</i>		.Section 100.....	625, 773
.Alimentary tract and metabolism	77, 78	<i>Pegasys RBV (RO)</i>	
<i>Panzytrat 25000 (TM)</i>		.Section 100.....	626, 774
.Alimentary tract and metabolism	91	<i>Pegatron (MK)</i>	
PARACETAMOL		.Section 100.....	627, 628, 775, 776
.Dental.....	558	PEGFILGRASTIM	
.Nervous system.....	420, 421	.Section 100.....	623, 771
.Palliative Care	533	PEGINTERFERON ALFA-2a	
<i>Paracetamol Sandoz (SZ)</i>		.Section 100.....	625, 773
.Dental.....	558	<i>Pemzo (QA)</i>	
.Nervous system.....	420	.Alimentary tract and metabolism	75, 76
PARAFFIN		PENICILLAMINE	
.Optometrical.....	570	.Musculo-skeletal system	396
.Sensory organs.....	498	<i>Pentasa (FP)</i>	
<i>Paralgin (FM)</i>		.Alimentary tract and metabolism	88, 89
.Dental.....	558	<i>Penthrox (NQ)</i>	
.Nervous system.....	420	.Emergency Drug Supplies.....	65
<i>Pariet (JC)</i>		<i>Peppidine (MK)</i>	
		.Alimentary tract and metabolism	72
		<i>Pepzan (GM)</i>	

GENERIC/PROPRIETARY INDEX

.Alimentary tract and metabolism	72	.Dental.....	538, 541, 563
PERGOLIDE MESYLATE		.Emergency Drug Supplies.....	64
.Nervous system.....	435	.Respiratory system.....	483
PERHEXILINE MALEATE		.Various	519
.Cardiovascular system	120	<i>Pharmacor Amlodipine 10 (CR)</i>	
<i>Periactin (AS)</i>		.Cardiovascular system	130
.Nervous system.....	423	<i>Pharmacor Amlodipine 5 (CR)</i>	
PERICYAZINE		.Cardiovascular system	129
.Nervous system.....	439	<i>Pharmacor Cephalexin 250 (CR)</i>	
<i>Perindo (AF)</i>		.Antiinfectives for systemic use.....	199
.Cardiovascular system	135, 136	.Dental.....	548
<i>Perindo Combi 4/1.25 (AF)</i>		<i>Pharmacor Cephalexin 500 (CR)</i>	
.Cardiovascular system	141	.Antiinfectives for systemic use.....	200
PERINDOPRIL		.Dental.....	548
.Cardiovascular system	135, 136	<i>Pharmacor Citalo 20 (MI)</i>	
<i>Perindopril 2 (CR)</i>		.Nervous system.....	459
.Cardiovascular system	135	<i>Pharmacor Clopidogrel 75 (CR)</i>	
<i>Perindopril 4 (CR)</i>		.Blood and blood forming organs.....	107
.Cardiovascular system	135	<i>Pharmacor Escitalopram 10 (CR)</i>	
<i>Perindopril 8 (CR)</i>		.Nervous system.....	459
.Cardiovascular system	136	<i>Pharmacor Escitalopram 20 (CR)</i>	
<i>Perindopril generichealth (GQ)</i>		.Nervous system.....	460
.Cardiovascular system	135, 136	<i>Pharmacor Gabapentin 600 (CR)</i>	
PERINDOPRIL with AMLODIPINE		.Nervous system.....	428
.Cardiovascular system	141	<i>Pharmacor Gabapentin 800 (CR)</i>	
PERINDOPRIL with INDAPAMIDE HEMIHYDRATE		.Nervous system.....	427
.Cardiovascular system	140	<i>Pharmacor Gemfibrozil 600 (CR)</i>	
<i>Perindopril/ Indapamide GH 4/1.25 (GQ)</i>		.Cardiovascular system	161, 162
.Cardiovascular system	141	<i>Pharmacor Glimepiride 1 (CR)</i>	
<i>Perindopril-DP (GN)</i>		.Alimentary tract and metabolism	95
.Cardiovascular system	135, 136	<i>Pharmacor Glimepiride 2 (CR)</i>	
<i>Perindopril-GA (GM)</i>		.Alimentary tract and metabolism	95
.Cardiovascular system	135, 136	<i>Pharmacor Glimepiride 3 (CR)</i>	
<i>Permax (AS)</i>		.Alimentary tract and metabolism	95
.Nervous system.....	436	<i>Pharmacor Glimepiride 4 (CR)</i>	
PERMETHRIN		.Alimentary tract and metabolism	95
.Antiparasitic products, insecticides and repellents		<i>Pharmacor Meloxicam 15 (CR)</i>	
.....	481	.Musculo-skeletal system	393
<i>Persantin SR (BY)</i>		<i>Pharmacor Meloxicam 7.5 (CR)</i>	
.Blood and blood forming organs.....	108	.Musculo-skeletal system	392
<i>Petrus Bisacodyl Suppositories (PP)</i>		<i>Pharmacor Metformin 1000 (CR)</i>	
.Alimentary tract and metabolism	85	.Alimentary tract and metabolism	94
.Palliative Care	522, 523	<i>Pharmacor Mycophenolate 250 (CR)</i>	
<i>Petrus Pharmaceuticals Pty Ltd (PP)</i>		.Antineoplastic and immunomodulating agents	262
.Alimentary tract and metabolism	86	.Section 100.....	634, 782
.Palliative Care	525, 526	<i>Pharmacor Mycophenolate 500 (CR)</i>	
.Repatriation Schedule.....	912	.Antineoplastic and immunomodulating agents	263
<i>Pexsig (QA)</i>		.Section 100.....	634, 782
.Cardiovascular system	120	<i>Pharmacor Olanzapine 10 (CR)</i>	
<i>Pfizer Australia Pty Ltd (PF)</i>		.Nervous system.....	443
.Alimentary tract and metabolism	79	<i>Pharmacor Olanzapine 2.5 (CR)</i>	
.Antiinfectives for systemic use	207	.Nervous system.....	441
.Antineoplastic and immunomodulating agents	223	<i>Pharmacor Olanzapine 5 (CR)</i>	
.Blood and blood forming organs.....	106	.Nervous system.....	441
.Cardiovascular system	117	<i>Pharmacor Olanzapine 7.5 (CR)</i>	

GENERIC/PROPRIETARY INDEX

.Nervous system.....	442	<i>Phenex-2 (AB)</i>	
<i>Pharmacor Omeprazole 20 (CR)</i>		.Various	514
.Alimentary tract and metabolism	76	PHENOBARBITONE	
<i>Pharmacor Paroxo 20 (MI)</i>		.Nervous system.....	423
.Nervous system.....	462	PHENOBARBITONE SODIUM	
<i>Pharmacor Pioglitazone 15 (CR)</i>		.Nervous system.....	423
.Alimentary tract and metabolism	98	PHENOXYBENZAMINE HYDROCHLORIDE	
<i>Pharmacor Pioglitazone 30 (CR)</i>		.Cardiovascular system	124
.Alimentary tract and metabolism	99	.Genito urinary system and sex hormones.....	183
<i>Pharmacor Pioglitazone 45 (CR)</i>		<i>Phenoxymethyl- penicillin-AFT (AE)</i>	
.Alimentary tract and metabolism	99	.Antiinfectives for systemic use.....	197
<i>Pharmacor Pravastat 10 (CR)</i>		.Dental.....	546
.Cardiovascular system	153, 154	PHENOXYMETHYLPENICILLIN	
<i>Pharmacor Pravastat 20 (CR)</i>		.Antiinfectives for systemic use.....	196, 197
.Cardiovascular system	153, 154	.Dental.....	545
<i>Pharmacor Pravastat 40 (CR)</i>		<i>Phenylalanine Amino Acid Supplement (VF)</i>	
.Cardiovascular system	153, 155	.Various	517
<i>Pharmacor Prozine 5 (CR)</i>		PHENYLALANINE with CARBOHYDRATE	
.Alimentary tract and metabolism	84	.Various	517
.Dental.....	538	PHENYTOIN	
<i>Pharmacor Quinapril 10 (CR)</i>		.Nervous system.....	423
.Cardiovascular system	136	PHENYTOIN SODIUM	
<i>Pharmacor Quinapril 20 (CR)</i>		.Nervous system.....	424
.Cardiovascular system	136	<i>Phlexy-10 (SB)</i>	
<i>Pharmacor Quinapril 5 (CR)</i>		.Various	513
.Cardiovascular system	136	<i>Phlexy-10 Drink Mix (SB)</i>	
<i>Pharmacor Ramipril 1.25 (CR)</i>		.Various	513
.Cardiovascular system	137	PHOLCODINE	
<i>Pharmacor Ramipril 10 (CR)</i>		.Repatriation Schedule	936
.Cardiovascular system	139	<i>Phosphate Sandoz (NV)</i>	
<i>Pharmacor Ramipril 2.5 (CR)</i>		.Various	503
.Cardiovascular system	138	<i>Physeptone (QA)</i>	
<i>Pharmacor Ramipril 5 (CR)</i>		.Nervous system.....	417
.Cardiovascular system	138	<i>Physiotens (AB)</i>	
<i>Pharmacor Salbutamol 2.5 (CR)</i>		.Cardiovascular system	121
.Emergency Drug Supplies	65	<i>Piax (AF)</i>	
.Respiratory system	483	.Blood and blood forming organs.....	107
<i>Pharmacor Salbutamol 5 (CR)</i>		PILOCARPINE HYDROCHLORIDE	
.Emergency Drug Supplies	66	.Optometrical.....	566
.Respiratory system	483	.Sensory organs.....	491
<i>Pharmacor Simvastatin 10 (MI)</i>		PIMECROLIMUS	
.Cardiovascular system	156, 158	.Dermatologicals	172
<i>Pharmacor Simvastatin 20 (MI)</i>		PINDOLOL	
.Cardiovascular system	156, 159	.Cardiovascular system	124
<i>Pharmacor Simvastatin 40 (MI)</i>		PINE TAR with CADE OIL, COAL TAR SOLUTION, ARACHIS	
.Cardiovascular system	157, 159	OIL EXTRACT OF CRUDE COAL TAR and OLEYL	
<i>Pharmacor Simvastatin 80 (MI)</i>		ALCOHOL	
.Cardiovascular system	158, 160	.Repatriation Schedule	919
<i>Pharmacor Sumatriptan 50 (CR)</i>		PINE TAR with TRIETHANOLAMINE LAURYL SULFATE	
.Nervous system.....	422	.Repatriation Schedule	918
<i>Pharmacy Choice Paracetamol (YM)</i>		<i>Pinetarsol (EO)</i>	
.Dental.....	558	.Repatriation Schedule	918
.Nervous system.....	420	PIOGLITAZONE	
PHENELZINE SULFATE		.Alimentary tract and metabolism	97
.Nervous system.....	463	<i>Pioglitazone generichealth 15 (GQ)</i>	

GENERIC/PROPRIETARY INDEX

.Alimentary tract and metabolism	98	PNEUMOCOCCAL VACCINE, POLYVALENT	
<i>Pioglitazone generichealth 30 (GQ)</i>		.Antiinfectives for systemic use.....	220
.Alimentary tract and metabolism	99	<i>Pneumovax 23 (CS)</i>	
<i>Pioglitazone generichealth 45 (GQ)</i>		.Antiinfectives for systemic use.....	220
.Alimentary tract and metabolism	99	PODOPHYLLOTOXIN	
<i>Pioglitazone Sandoz (SZ)</i>		.Repatriation Schedule	918
.Alimentary tract and metabolism	98, 99	<i>Poly Gel (AQ)</i>	
<i>Pioglitazone-GA (GM)</i>		.Optometrical	569
.Alimentary tract and metabolism	98, 99	.Sensory organs	495
PIROXICAM		<i>Poly Visc (IQ)</i>	
.Dental.....	553	.Optometrical	570
.Musculo-skeletal system.....	393	.Sensory organs	498
<i>Pizaccord (RA)</i>		POLYETHYLENE GLYCOL 400	
.Alimentary tract and metabolism	98, 99	.Optometrical	570
PIZOTIFEN MALATE		.Sensory organs	498
.Nervous system.....	423	POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL	
<i>PKU Anamix infant (SB)</i>		.Optometrical	570
.Various	513	.Sensory organs	499
<i>PKU Anamix Junior (SB)</i>		POLY-L-LACTIC ACID	
.Various	514	.Various	503
<i>PKU Anamix Junior LQ (SB)</i>		<i>Polytar (GK)</i>	
.Various	515	.Repatriation Schedule	919
<i>PKU Cooler 10 (VF)</i>		<i>Poly-Tears (IQ)</i>	
.Various	514	.Optometrical	570
<i>PKU Cooler 15 (VF)</i>		.Sensory organs	497
.Various	514	POLYVINYL ALCOHOL	
<i>PKU Cooler 20 (VF)</i>		.Optometrical	570
.Various	514	.Sensory organs	499
<i>PKU express 15 (VF)</i>		<i>Polstan (PF)</i>	
.Various	514	.Musculo-skeletal system	395
<i>PKU express 20 (VF)</i>		POSACONAZOLE	
.Various	514	.Antiinfectives for systemic use.....	213
<i>PKU gel (VF)</i>		POTASSIUM CHLORIDE	
.Various	514	.Alimentary tract and metabolism	103
<i>PKU Lophlex LQ 10 (SB)</i>		POTASSIUM CHLORIDE with POTASSIUM BICARBONATE	
.Various	515	.Alimentary tract and metabolism	103
<i>PKU Lophlex LQ 20 (SB)</i>		POVIDONE-IODINE	
.Various	515	.Repatriation Schedule	919
<i>PKU squeeze (VF)</i>		<i>Pradaxa (BY)</i>	
.Various	514	.Blood and blood forming organs.....	111
<i>Placil (AF)</i>		<i>Pramin (AF)</i>	
.Nervous system.....	456, 458	.Alimentary tract and metabolism	79
<i>Plaquacide (OB)</i>		.Dental.....	538
.Repatriation Schedule	911	PRAMIPEXOLE HYDROCHLORIDE	
<i>Plaquenil (SW)</i>		.Nervous system.....	436, 437
.Musculo-skeletal system.....	395	<i>Prantal (MK)</i>	
<i>Plasma-Lyte 148 (BX)</i>		.Repatriation Schedule	919
.Blood and blood forming organs.....	115	PRASUGREL	
<i>Plavacor 75 (MI)</i>		.Blood and blood forming organs.....	109
.Blood and blood forming organs.....	107	<i>Pravachol (FM)</i>	
<i>Plavix (SW)</i>		.Cardiovascular system	153, 154, 155
.Blood and blood forming organs.....	107, 108	PRAVASTATIN	
.Repatriation Schedule	914	.Cardiovascular system	152, 154
<i>Plendil ER (AP)</i>		<i>Pravastatin Actavis 10 (TA)</i>	
.Cardiovascular system	130	.Cardiovascular system	153, 154

GENERIC/PROPRIETARY INDEX

<i>Pravastatin Actavis 20 (TA)</i>		
.Cardiovascular system	153, 154	
<i>Pravastatin Actavis 40 (TA)</i>		
.Cardiovascular system	153, 155	
<i>Pravastatin generichealth (GQ)</i>		
.Cardiovascular system	153, 154, 155	
<i>Pravastatin Sandoz (SZ)</i>		
.Cardiovascular system	153, 154, 155	
<i>Pravastatin Winthrop (WA)</i>		
.Cardiovascular system	153, 154, 155	
<i>Pravastatin-GA 10 (GM)</i>		
.Cardiovascular system	153, 154	
<i>Pravastatin-GA 20 (GM)</i>		
.Cardiovascular system	153, 154	
<i>Pravastatin-GA 40 (GM)</i>		
.Cardiovascular system	153, 155	
<i>Pravastatin-GA 80 (GM)</i>		
.Cardiovascular system	154, 155	
<i>Pravastatin-PS (FZ)</i>		
.Cardiovascular system	153, 154, 155	
PRAZIQUANTEL		
.Antiparasitic products, insecticides and repellents	480	
PRazosin		
.Cardiovascular system	121	
<i>PredMix (LN)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
<i>Prednefrin Forte (AG)</i>		
.Optometrical.....	566	
.Sensory organs.....	490	
PREDNISOLONE		
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
PREDNISOLONE ACETATE with PHENYLEPHRINE HYDROCHLORIDE		
.Optometrical.....	566	
.Sensory organs.....	490	
PREDNISOLONE SODIUM PHOSPHATE		
.Alimentary tract and metabolism	87, 88	
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
PREDNISON		
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
<i>Predsol (QA)</i>		
.Alimentary tract and metabolism	87, 88	
<i>Predsolone (LN)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
<i>Predstone (LN)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
PREGABALIN		
.Repatriation Schedule	932	
<i>Pregnyl (MK)</i>		
.Genito urinary system and sex hormones.....	181	
.Section 100.....	875	
<i>Presolol 100 (AF)</i>		
.Cardiovascular system	129	
<i>Presolol 200 (AF)</i>		
.Cardiovascular system	129	
<i>Prexaton (GM)</i>		
.Nervous system.....	475, 476	
<i>Prezista (JC)</i>		
.Section 100.....	612, 758, 759	
<i>Prilace 1.25 (QA)</i>		
.Cardiovascular system	137	
<i>Prilace 10 (QA)</i>		
.Cardiovascular system	139	
<i>Prilace 2.5 (QA)</i>		
.Cardiovascular system	137	
<i>Prilace 5 (QA)</i>		
.Cardiovascular system	138	
PRIMIDONE		
.Nervous system.....	423	
<i>Primolut N (BN)</i>		
.Genito urinary system and sex hormones.....	179	
<i>Primoteston Depot (BN)</i>		
.Genito urinary system and sex hormones.....	177	
<i>Prinivil 10 (MK)</i>		
.Cardiovascular system	134	
<i>Prinivil 20 (MK)</i>		
.Cardiovascular system	135	
<i>Prinivil 5 (MK)</i>		
.Cardiovascular system	134	
<i>Pristiq (PF)</i>		
.Nervous system.....	464	
<i>Pro-Banthine (QA)</i>		
.Genito urinary system and sex hormones.....	183	
PROBENECID		
.Musculo-skeletal system	397	
<i>Probitor (SZ)</i>		
.Alimentary tract and metabolism	76	
<i>Probitor Hp7 (SZ)</i>		
.Alimentary tract and metabolism	79	
PROCAINE PENICILLIN		
.Antiinfectives for systemic use.....	197	
.Dental.....	546	
<i>ProCalm (QA)</i>		
.Alimentary tract and metabolism	84	
.Dental.....	538	
PROCHLORPERAZINE		
.Alimentary tract and metabolism	84	
.Dental.....	538	
<i>Prochlorperazine GH (GQ)</i>		
.Alimentary tract and metabolism	84	
.Dental.....	538	
<i>Prochlorperazine-GA (GM)</i>		
.Alimentary tract and metabolism	84	

GENERIC/PROPRIETARY INDEX

.Dental.....	538	PROPRANOLOL HYDROCHLORIDE	
<i>Prochlorperazine-PS (FZ)</i>		.Cardiovascular system	124
.Alimentary tract and metabolism	84	PROPYLTHIOURACIL	
.Dental.....	538	.Systemic hormonal preparations, excl. sex hormones and insulins	190
<i>Pro-Cid (PL)</i>		<i>Proscar (MK)</i>	
.Musculo-skeletal system.....	397	.Repatriation Schedule	925
<i>Proctosedyl (SW)</i>		<i>Protaphane (NO)</i>	
.Repatriation Schedule	915	.Alimentary tract and metabolism	92
<i>Procur (GM)</i>		<i>Protaphane InnoLet (NI)</i>	
.Antineoplastic and immunomodulating agents	248	.Alimentary tract and metabolism	92
.Genito urinary system and sex hormones	181	<i>Protaphane Penfill 3 mL (NO)</i>	
<i>Procur 100 (GM)</i>		.Alimentary tract and metabolism	92
.Antineoplastic and immunomodulating agents	248	PROTEIN HYDROLYSATE FORMULA with MEDIUM CHAIN TRIGLYCERIDES	
.Genito urinary system and sex hormones	182	.Various	510
<i>Prodeine 15 (SW)</i>		<i>Protos 2 g (SE)</i>	
.Repatriation Schedule	931	.Musculo-skeletal system	406
<i>Prodeine Forte (AV)</i>		<i>Provera (PF)</i>	
.Dental.....	556	.Antineoplastic and immunomodulating agents ...	245, 246
.Nervous system.....	408	.Genito urinary system and sex hormones.....	178, 179
<i>Profloxin (HX)</i>		<i>Proxen SR 1000 (MD)</i>	
.Antiinfectives for systemic use	208	.Dental.....	554
<i>Profore 66050016 (SN)</i>		.Musculo-skeletal system	394
.Repatriation Schedule	942	.Palliative Care.....	529, 530
<i>Profore Lite 66050415 (SN)</i>		<i>Proxen SR 750 (MD)</i>	
.Repatriation Schedule	942	.Dental.....	554
PROGESTERONE		.Musculo-skeletal system	394
.Section 100	875	.Palliative Care.....	529, 530
<i>Progout 100 (AF)</i>		<i>Prozac 20 (LY)</i>	
.Musculo-skeletal system.....	397	.Nervous system.....	461
<i>Progout 300 (AF)</i>		<i>Prozac Tab (LY)</i>	
.Musculo-skeletal system.....	397	.Nervous system.....	461
<i>Prograf (JC)</i>		<i>ProZero (VF)</i>	
.Antineoplastic and immunomodulating agents	390	.Various	517
.Section 100	699, 848	<i>PS Olanzapine ODT (FZ)</i>	
<i>Prograf XL (JC)</i>		.Nervous system.....	443, 444
.Antineoplastic and immunomodulating agents	390	PSEUDOEPHEDRINE HYDROCHLORIDE	
.Section 100	700, 848	.Repatriation Schedule	935
<i>ProGuide 66000780 (SN)</i>		PSYLLIUM HYDROPHILIC MUCILLOID	
.Repatriation Schedule	942	.Repatriation Schedule	912
<i>ProGuide 66000781 (SN)</i>		PSYLLIUM HYDROPHILIC MUCILLOID with HIGH AMYLOSE MAIZE STARCH	
.Repatriation Schedule	942	.Repatriation Schedule	912
<i>ProGuide 66000782 (SN)</i>		<i>PTU (PL)</i>	
.Repatriation Schedule	942	.Systemic hormonal preparations, excl. sex hormones and insulins	190
<i>Progynova (BN)</i>		<i>Pulmicort Respules (AP)</i>	
.Genito urinary system and sex hormones	178	.Respiratory system.....	485
<i>Proladone (PL)</i>		<i>Pulmicort Turbuhaler (AP)</i>	
.Dental.....	557	.Respiratory system.....	485
.Nervous system.....	412	<i>Pulmozyme (RO)</i>	
<i>Prolia (AN)</i>		.Section 100.....	716, 865
.Musculo-skeletal system.....	406	<i>Puregon 300 IU/0.36 mL (MK)</i>	
PROMETHAZINE HYDROCHLORIDE			
.Dental.....	539		
.Respiratory system	488		
PROPANTHELINE BROMIDE			
.Genito urinary system and sex hormones	183		

GENERIC/PROPRIETARY INDEX

.Genito urinary system and sex hormones	180
.Section 100	874
<i>Puregon 600 IU/0.72 mL (MK)</i>	
.Genito urinary system and sex hormones	180
.Section 100	874
<i>Puregon 900 IU/1.08 mL (MK)</i>	
.Genito urinary system and sex hormones	180
.Section 100	874
<i>Purinethol (AS)</i>	
.Antineoplastic and immunomodulating agents	224
<i>PVA Forte (PE)</i>	
.Optometrical	570
.Sensory organs	499
<i>PVA Tears (PE)</i>	
.Optometrical	571
.Sensory organs	499
<i>Pyralin EN (FZ)</i>	
.Alimentary tract and metabolism	90
PYRANTEL EMBONATE	
.Antiparasitic products, insecticides and repellents	481
PYRIDOSTIGMINE BROMIDE	
.Nervous system	475
PYRIMETHAMINE	
.Antiparasitic products, insecticides and repellents	479

Q

<i>Qpril 10 (AF)</i>	
.Cardiovascular system	136
<i>Qpril 20 (AF)</i>	
.Cardiovascular system	136
<i>Qpril 5 (AF)</i>	
.Cardiovascular system	136
<i>Questran Lite (QA)</i>	
.Cardiovascular system	162
<i>Quetiaccord (WQ)</i>	
.Nervous system	446, 447
QUETIAPINE	
.Nervous system	445
<i>Quetiapine Actavis 100 (TA)</i>	
.Nervous system	446
<i>Quetiapine Actavis 200 (TA)</i>	
.Nervous system	446
<i>Quetiapine Actavis 25 (TA)</i>	
.Nervous system	446
<i>Quetiapine Actavis 300 (TA)</i>	
.Nervous system	447
<i>Quetiapine GH 100 (GQ)</i>	
.Nervous system	446
<i>Quetiapine GH 200 (GQ)</i>	
.Nervous system	446
<i>Quetiapine GH 25 (GQ)</i>	
.Nervous system	446

<i>Quetiapine GH 300 (GQ)</i>	
.Nervous system	447
<i>Quetiapine Pfizer (FZ)</i>	
.Nervous system	446, 447
<i>Quetiapine RBX (RA)</i>	
.Nervous system	446, 447
<i>Quetiapine Sandoz (SZ)</i>	
.Nervous system	446, 447
<i>Quetiapine-DRLA (RZ)</i>	
.Nervous system	446, 447
<i>Quetiapine-Synthon (ZT)</i>	
.Nervous system	446, 447
<i>Quilonum SR (GK)</i>	
.Nervous system	448, 465
QUINAGOLIDE HYDROCHLORIDE	
.Genito urinary system and sex hormones	175
QUINAPRIL	
.Cardiovascular system	136
<i>Quinapril generichealth (GQ)</i>	
.Cardiovascular system	136, 137
QUINAPRIL HYDROCHLORIDE with HYDROCHLOROTHIAZIDE	
.Cardiovascular system	141
<i>Quinapril Pfizer (FZ)</i>	
.Cardiovascular system	136, 137
<i>Quinapril Sandoz (SZ)</i>	
.Cardiovascular system	136, 137
<i>Quinapril-GA (GM)</i>	
.Cardiovascular system	137
<i>Quinate (AS)</i>	
.Antiparasitic products, insecticides and repellents	480
QUININE SULFATE	
.Antiparasitic products, insecticides and repellents	480
<i>Quipine (GM)</i>	
.Nervous system	446, 447
<i>QuitX (AF)</i>	
.Repatriation Schedule	933
<i>QV Bath Oil (EO)</i>	
.Repatriation Schedule	917
<i>Qvar 100 (IA)</i>	
.Respiratory system	485
<i>Qvar 100 Autohaler (IA)</i>	
.Respiratory system	485
<i>Qvar 50 (IA)</i>	
.Respiratory system	485
<i>Qvar 50 Autohaler (IA)</i>	
.Respiratory system	485

R

RABEPRAZOLE SODIUM	
.Alimentary tract and metabolism	78
<i>Ralovera (FZ)</i>	

GENERIC/PROPRIETARY INDEX

.Genito urinary system and sex hormones	178, 179
RALOXIFENE HYDROCHLORIDE	
.Genito urinary system and sex hormones	182
.Musculo-skeletal system.....	406
Ralozam (GM)	
.Nervous system.....	454, 455
RALTEGRAVIR	
.Section 100	619, 766
Ramace 1.25 mg (AV)	
.Cardiovascular system	137
Ramace 10 mg (AV)	
.Cardiovascular system	139
Ramace 2.5 mg (AV)	
.Cardiovascular system	137
Ramace 5 mg (AV)	
.Cardiovascular system	138
RAMIPRIL	
.Cardiovascular system	137, 138, 139
Ramipril generichealth (GQ)	
.Cardiovascular system	137, 138, 139
Ramipril Sandoz (SZ)	
.Cardiovascular system	137, 138, 139
Ramipril Tabs Pfizer (FZ)	
.Cardiovascular system	137, 138, 139
Ramipril Winthrop (WA)	
.Cardiovascular system	137, 138, 139
RAMIPRIL with FELODIPINE	
.Cardiovascular system	141
Ramipril-GA (GM)	
.Cardiovascular system	137, 138, 139
Ramipril-PS (FZ)	
.Cardiovascular system	139
Rancef (RA)	
.Antiinfectives for systemic use	199, 200
.Dental.....	548
Rani 2 (AF)	
.Alimentary tract and metabolism	72
RANIBIZUMAB	
.Sensory organs.....	493
RANITIDINE HYDROCHLORIDE	
.Alimentary tract and metabolism	72, 73
Ranitidine Sandoz (SZ)	
.Alimentary tract and metabolism	72
Ranitidine-PS (FZ)	
.Alimentary tract and metabolism	72
Ranmoxy (RA)	
.Antiinfectives for systemic use	195
.Dental.....	545
Ranoxyl (GM)	
.Alimentary tract and metabolism	72
Ransim (RA)	
.Cardiovascular system	156, 157, 158, 159, 160
Ranzepam (RA)	
.Dental.....	559
.Nervous system.....	455
.Palliative Care.....	534, 535
Rapamune (PF)	
.Antineoplastic and immunomodulating agents	263
.Section 100.....	635, 783
Rapilysin 10 U (TA)	
.Blood and blood forming organs.....	110
RASAGILINE	
.Nervous system.....	437
RBX Topiramate (RA)	
.Nervous system.....	431, 432
RCF (AB)	
.Various	517
Reandron 1000 (BN)	
.Genito urinary system and sex hormones.....	177
Reaptan 10/10 (RX)	
.Cardiovascular system	141
Reaptan 10/5 (RX)	
.Cardiovascular system	141
Reaptan 5/10 (RX)	
.Cardiovascular system	141
Reaptan 5/5 (RX)	
.Cardiovascular system	141
Rebif 44 (SG)	
.Antineoplastic and immunomodulating agents	252
REBOXETINE MESILATE	
.Nervous system.....	466
Redipred (AS)	
.Systemic hormonal preparations, excl. sex hormones and insulins	188
Refresh Liquigel (AG)	
.Optometrical	569
.Sensory organs.....	495, 496
Refresh Tears Plus (AG)	
.Optometrical	569
.Sensory organs.....	495, 496
Relistor (LM)	
.Palliative Care.....	525
Relpax (PF)	
.Nervous system.....	421
Remeron SolTab (FR)	
.Nervous system.....	465, 466
Remicade (JC)	
.Repatriation Schedule	928
.Section 100....	650, 655, 661, 673, 677, 682, 689, 798, 803, 809, 821, 825, 830, 837
Reminyl (JC)	
.Nervous system.....	471, 472
Renagel (GZ)	
.Section 100.....	720, 869
.Various	502
RenaStart (VF)	
.Various	518
Renitec (MK)	
.Cardiovascular system	133
Renitec 20 (MK)	

GENERIC/PROPRIETARY INDEX

.Cardiovascular system	133	RICINOLEIC ACID with ACETIC ACID and HYDROXYQUINOLINE SULFATE	
<i>Renitec M (MK)</i>		.Repatriation Schedule	921
.Cardiovascular system	133	<i>Ridaura (BZ)</i>	
<i>Renitec Plus 20/6 (MK)</i>		.Musculo-skeletal system	395
.Cardiovascular system	140	<i>Ridaura (GH)</i>	
<i>ReoPro (LY)</i>		.Musculo-skeletal system	395
.Blood and blood forming organs.....	106	RIFABUTIN	
<i>Repalyte New Formulation (SW)</i>		.Section 100.....	611, 757
.Alimentary tract and metabolism	87	<i>Rifadin (SW)</i>	
<i>Replicare Ultra 66000434 (SN)</i>		.Antiinfectives for systemic use.....	215
.Repatriation Schedule.....	950	RIFAMPICIN	
<i>Resdone 0.5 (CR)</i>		.Antiinfectives for systemic use.....	214, 215
.Nervous system.....	449, 451	RILPIVIRINE	
<i>Resdone 1 (CR)</i>		.Section 100.....	617, 764
.Nervous system.....	451, 452	<i>Rilutek (SW)</i>	
<i>Resdone 2 (CR)</i>		.Nervous system.....	478
.Nervous system.....	452, 453	RILUZOLE	
<i>Resdone 3 (CR)</i>		.Nervous system.....	478
.Nervous system.....	452	<i>Rimycin 150 (AF)</i>	
<i>Resdone 4 (CR)</i>		.Antiinfectives for systemic use.....	214, 215
.Nervous system.....	453	<i>Rimycin 300 (AF)</i>	
<i>Resolve Thrush (EO)</i>		.Antiinfectives for systemic use.....	214, 215
.Repatriation Schedule.....	916	<i>Risedro once a week (QA)</i>	
<i>Resonium-A (SW)</i>		.Musculo-skeletal system	400
.Repatriation Schedule	938	.Repatriation Schedule	929
<i>Resprim Forte (AF)</i>		<i>Risedronate Sandoz (SZ)</i>	
.Antiinfectives for systemic use	204	.Musculo-skeletal system	400
.Dental.....	550	RISEDRONATE SODIUM	
<i>restore O.R.S. (GM)</i>		.Musculo-skeletal system	400
.Alimentary tract and metabolism	87	.Repatriation Schedule	929
RETEPLASE (Recombinant plasminogen activator)		RISEDRONATE SODIUM and CALCIUM CARBONATE	
.Blood and blood forming organs.....	110	.Musculo-skeletal system	404
<i>Retrovir (GK)</i>		.Repatriation Schedule	929
.Section 100	616, 763	RISEDRONATE SODIUM and CALCIUM CARBONATE with COLECALCIFEROL	
<i>Revatio (PF)</i>		.Musculo-skeletal system	404
.Section 100	602, 748	.Repatriation Schedule	929
<i>ReVia (BQ)</i>		<i>Risedronate-GA (GM)</i>	
.Nervous system.....	478	.Musculo-skeletal system	400
<i>Revlimid (CJ)</i>		<i>Rispa (QA)</i>	
.Section 100	701, 849	.Nervous system.....	449, 451, 452, 453
<i>Revolade (GK)</i>		<i>Risperdal (JC)</i>	
.Section 100	576, 722	.Nervous system.....	450, 451, 452, 453
<i>Reyataz (BQ)</i>		<i>Risperdal Consta (JC)</i>	
.Section 100	612, 758	.Nervous system.....	454
<i>Riamet (NV)</i>		<i>Risperdal Quicklet (JC)</i>	
.Antiparasitic products, insecticides and repellents		.Nervous system.....	451, 452, 453, 454
.....	480	RISPERIDONE	
<i>Riamet 20mg/120mg Dispersible (NV)</i>		.Nervous system.....	449, 450, 451, 452, 453, 454
.Antiparasitic products, insecticides and repellents		<i>Risperidone Actavis 0.5 (TA)</i>	
.....	480	.Nervous system.....	449, 451
RIBAVIRIN and PEGINTERFERON ALFA-2a		<i>Risperidone Actavis 1 (TA)</i>	
.Section 100	625, 773	.Nervous system.....	451, 452
RIBAVIRIN and PEGINTERFERON ALFA-2b		<i>Risperidone Actavis 2 (TA)</i>	
.Section 100	626, 627, 774, 775		

GENERIC/PROPRIETARY INDEX

.Nervous system.....	452, 453	.Section 100.....	577, 723
<i>Risperidone Actavis 3 (TA)</i>		ROSIGLITAZONE	
.Nervous system.....	452	.Alimentary tract and metabolism	99
<i>Risperidone Actavis 4 (TA)</i>		ROSIGLITAZONE with METFORMIN	
.Nervous system.....	453	.Alimentary tract and metabolism	96
<i>Risperidone generichealth (GQ)</i>		ROSUVASTATIN	
.Nervous system.....	451, 452, 453	.Cardiovascular system	155, 156
<i>Risperidone Pfizer (FZ)</i>		<i>Roxar 150 (QA)</i>	
.Nervous system.....	450, 451, 452, 453, 454	.Antiinfectives for systemic use.....	206
<i>Risperidone Sandoz (SZ)</i>		.Dental.....	551
.Nervous system.....	450, 451, 452, 453, 454	<i>Roxar 300 (QA)</i>	
<i>Risperidone-DRLA (RZ)</i>		.Antiinfectives for systemic use.....	206
.Nervous system.....	449, 451, 452, 453	.Dental.....	551
<i>Risperidone-GA (GM)</i>		<i>Roxet 20 (DO)</i>	
.Nervous system.....	449, 451, 452, 453	.Nervous system.....	462
<i>Ritalin 10 (NV)</i>		<i>Roximycin (AF)</i>	
.Nervous system.....	468	.Antiinfectives for systemic use.....	206
<i>Ritalin LA (NV)</i>		.Dental.....	551
.Nervous system.....	468	<i>Roxin (QA)</i>	
<i>Rithmik 200 (QA)</i>		.Antiinfectives for systemic use.....	209
.Cardiovascular system	118	ROXITHROMYCIN	
RITONAVIR		.Antiinfectives for systemic use.....	206
.Section 100	613, 759	.Dental.....	550
RITUXIMAB		<i>Roxithromycin Sandoz (SZ)</i>	
.Section 100	701, 850	.Antiinfectives for systemic use.....	206
RIVAROXABAN		.Dental.....	551
.Blood and blood forming organs.....	112, 113	<i>Roxithromycin-GA (GM)</i>	
RIVASTIGMINE		.Antiinfectives for systemic use.....	206
.Nervous system.....	472	.Dental.....	551
RIVASTIGMINE HYDROGEN TARTRATE		<i>Roxithromycin-PS (FZ)</i>	
.Nervous system.....	473	.Antiinfectives for systemic use.....	206
<i>Rivotril (RO)</i>		.Dental.....	551
.Emergency Drug Supplies	64	<i>Rulide (SW)</i>	
.Nervous system.....	424	.Antiinfectives for systemic use.....	206
.Palliative Care	534	.Dental.....	551
<i>Rixadone (AF)</i>		<i>Rulide D (SW)</i>	
.Nervous system.....	450, 451, 452, 453, 454	.Antiinfectives for systemic use.....	206
RIZATRIPTAN		.Dental.....	550
.Nervous system.....	421	<i>Rynacrom (SW)</i>	
<i>Roaccutane (RO)</i>		.Repatriation Schedule	935
.Dermatologicals	172	<i>Rythmodan (SW)</i>	
<i>Rocaltrol (RO)</i>		.Cardiovascular system	117
.Alimentary tract and metabolism	102		
.Musculo-skeletal system.....	405		
<i>Rocephin (RO)</i>			
.Antiinfectives for systemic use	203		
<i>Rocta 10 (QA)</i>			
.Dermatologicals	172		
<i>Rocta 20 (QA)</i>			
.Dermatologicals	172		
<i>Roferon-A (RO)</i>			
.Antineoplastic and immunomodulating agents ...	251, 252		
.Section 100	624, 772		
ROMIPLOSTIM			

S

<i>S-26 LF (PF)</i>	
.Various	511, 512
<i>Sabril (SW)</i>	
.Nervous system.....	427
<i>Saizen (SG)</i>	
.Section 100.....	873
<i>Saizen 8 mg click.easy (SG)</i>	
.Section 100.....	873
<i>Salazopyrin (PF)</i>	
.Alimentary tract and metabolism	90

GENERIC/PROPRIETARY INDEX

<i>Salazopyrin-EN (PF)</i>		
.Alimentary tract and metabolism	90	
<i>Salbutamol Sandoz (SZ)</i>		
.Emergency Drug Supplies	65, 66	
.Respiratory system	483	
SALBUTAMOL SULFATE		
.Respiratory system	482, 483, 487	
<i>Salbutamol-GA (GM)</i>		
.Emergency Drug Supplies	65, 66	
.Respiratory system	483	
SALCATONIN		
.Systemic hormonal preparations, excl. sex hormones and insulins	191	
SALICYLIC ACID		
.Repatriation Schedule	920	
SALICYLIC ACID with COAL TAR SOLUTION		
.Repatriation Schedule	919	
SALICYLIC ACID with COAL TAR SOLUTION and PINE TAR		
.Repatriation Schedule	919	
SALICYLIC ACID with LACTIC ACID		
.Repatriation Schedule	920	
SALMETEROL XINAFOATE		
.Respiratory system	483	
<i>Salofalk (OA)</i>		
.Alimentary tract and metabolism	88, 89	
<i>Salpraz (AF)</i>		
.Alimentary tract and metabolism	77, 78	
<i>Sandimmun (NV)</i>		
.Section 100	699, 847	
<i>Sandomigran 0.5 (NV)</i>		
.Nervous system	423	
<i>Sandostatin 0.05 (NV)</i>		
.Section 100	609, 755	
<i>Sandostatin 0.1 (NV)</i>		
.Section 100	609, 755	
<i>Sandostatin 0.5 (NV)</i>		
.Section 100	609, 755	
<i>Sandostatin LAR (NV)</i>		
.Section 100	609, 755	
<i>Sandrena (AS)</i>		
.Genito urinary system and sex hormones	177	
<i>Saphris (LU)</i>		
.Nervous system	440	
SAQUINAVIR		
.Section 100	613, 759	
<i>Savacol Mouth and Throat Rinse (OM)</i>		
.Repatriation Schedule	911	
SAXAGLIPTIN		
.Alimentary tract and metabolism	100	
<i>Sculptrra (SW)</i>		
.Various	503	
<i>Seaze 100 (QA)</i>		
.Nervous system	429	
<i>Seaze 200 (QA)</i>		
.Nervous system	429	
<i>Seaze 25 (QA)</i>		
.Nervous system	428	
<i>Seaze 5 (QA)</i>		
.Nervous system	429	
<i>Seaze 50 (QA)</i>		
.Nervous system	429	
<i>Sebifin 250 (RA)</i>		
.Dermatologicals	167	
<i>SebiRinse (EO)</i>		
.Repatriation Schedule	920	
<i>Sebitar (EO)</i>		
.Repatriation Schedule	919	
<i>Sebivo (NV)</i>		
.Section 100	616, 762	
<i>Sebizole (GM)</i>		
.Repatriation Schedule	916	
SELEGILINE HYDROCHLORIDE		
.Nervous system	437	
SELENIUM SULFIDE		
.Repatriation Schedule	920	
<i>Selgene (AF)</i>		
.Nervous system	437	
<i>Selsun (DQ)</i>		
.Repatriation Schedule	920	
SENEGA and AMMONIA		
.Repatriation Schedule	935	
SENNA STANDARDISED		
.Repatriation Schedule	912	
<i>Senokot (RC)</i>		
.Repatriation Schedule	912	
<i>Sensipar (AN)</i>		
.Section 100	610, 756	
.Systemic hormonal preparations, excl. sex hormones and insulins	192	
<i>SensoCard (PX)</i>		
.Various	505, 506	
<i>Septtrin (QA)</i>		
.Anti-infectives for systemic use	204	
.Dental	550	
<i>Septtrin Forte (QA)</i>		
.Anti-infectives for systemic use	204	
.Dental	550	
<i>Sequase (PM)</i>		
.Nervous system	446, 447	
<i>Serenace (QA)</i>		
.Emergency Drug Supplies	64	
.Nervous system	439	
<i>Serepax (QA)</i>		
.Dental	560	
.Nervous system	455, 456	
.Palliative Care	535	
<i>Seretide Accuhaler 100/50 (GK)</i>		
.Respiratory system	484	
<i>Seretide Accuhaler 250/50 (GK)</i>		
.Respiratory system	484	

GENERIC/PROPRIETARY INDEX

<i>Seretide Accuhaler 500/50 (GK)</i>	
. Respiratory system	484
<i>Seretide MDI 125/25 (GK)</i>	
. Respiratory system	484
<i>Seretide MDI 250/25 (GK)</i>	
. Respiratory system	485
<i>Seretide MDI 50/25 (GK)</i>	
. Respiratory system	484
<i>Serevent Accuhaler (GK)</i>	
. Respiratory system	483
<i>Seronia 100 (QA)</i>	
. Nervous system.....	446
<i>Seronia 200 (QA)</i>	
. Nervous system.....	447
<i>Seronia 25 (QA)</i>	
. Nervous system.....	446
<i>Seronia 300 (QA)</i>	
. Nervous system.....	447
<i>Serophene (SG)</i>	
. Genito urinary system and sex hormones	181
<i>Seroquel (AP)</i>	
. Nervous system.....	446, 447
<i>Seroquel XR (AP)</i>	
. Nervous system.....	445, 447
<i>Sertra 100 (QA)</i>	
. Nervous system.....	463
<i>Sertra 50 (QA)</i>	
. Nervous system.....	462
<i>Sertracor 100 (MI)</i>	
. Nervous system.....	463
<i>Sertracor 50 (MI)</i>	
. Nervous system.....	462
SERTRALINE	
. Nervous system.....	462, 463
<i>Sertraline 100 (CR)</i>	
. Nervous system.....	463
<i>Sertraline 50 (CR)</i>	
. Nervous system.....	462
<i>Sertraline generichealth (GQ)</i>	
. Nervous system.....	462, 463
<i>Sertraline Pfizer (FZ)</i>	
. Nervous system.....	462, 463
<i>Sertraline Sandoz (SZ)</i>	
. Nervous system.....	462, 463
<i>Sertraline-DRLA (RZ)</i>	
. Nervous system.....	462, 463
<i>Sertraline-GA (GM)</i>	
. Nervous system.....	462, 463
<i>Setopress 3504 (SS)</i>	
. Repatriation Schedule.....	941
<i>Setopress 3505 (SS)</i>	
. Repatriation Schedule.....	941
<i>Setrona (RA)</i>	
. Nervous system.....	462, 463
SEVELAMER HYDROCHLORIDE	
. Section 100.....	719, 869
. Various	501
<i>Sevikar 20/5 (MK)</i>	
. Cardiovascular system	145
<i>Sevikar 40/10 (MK)</i>	
. Cardiovascular system	145
<i>Sevikar 40/5 (MK)</i>	
. Cardiovascular system	145
<i>Sevredol (MF)</i>	
. Nervous system.....	410
. Palliative Care.....	531
<i>Shilova 500 (DO)</i>	
. Antiinfectives for systemic use.....	219
<i>Sical (AF)</i>	
. Alimentary tract and metabolism	102
. Musculo-skeletal system	405
<i>Sifrol (BY)</i>	
. Nervous system.....	436, 437
<i>Sifrol ER (BY)</i>	
. Nervous system.....	437
<i>Sigma Methadone Syrup (QA)</i>	
. Palliative Care.....	533
. Section 100.....	876
<i>Sigmacort (QA)</i>	
. Dental.....	542
. Dermatologicals	169
<i>Sigmaxin (FM)</i>	
. Cardiovascular system	117
<i>Sigmaxin-PG (FM)</i>	
. Cardiovascular system	117
SILDENAFIL CITRATE	
. Repatriation Schedule	921
. Section 100.....	598, 744
<i>Silic 15 (EO)</i>	
. Repatriation Schedule	917
SILVER SULFADIAZINE	
. Dermatologicals	169
<i>Simipex 0.125 (QA)</i>	
. Nervous system.....	436
<i>Simipex 0.25 (QA)</i>	
. Nervous system.....	436
<i>Simipex 1 (QA)</i>	
. Nervous system.....	436
<i>Simplotan (FZ)</i>	
. Antiinfectives for systemic use.....	210
. Antiparasitic products, insecticides and repellents	479
<i>Simponi (JC)</i>	
. Antineoplastic and immunomodulating agents ...	364, 367, 370, 373, 377, 380
<i>Simvacor 10 (CR)</i>	
. Cardiovascular system	156, 158
<i>Simvacor 20 (CR)</i>	
. Cardiovascular system	156, 159
<i>Simvacor 40 (CR)</i>	

GENERIC/PROPRIETARY INDEX

.Cardiovascular system	157, 159
<i>Simvacor 80 (CR)</i>	
.Cardiovascular system	158, 160
<i>Simvahexal (HX)</i>	
.Cardiovascular system	156, 157, 158, 159
<i>Simvar 10 (QA)</i>	
.Cardiovascular system	156, 158
<i>Simvar 20 (QA)</i>	
.Cardiovascular system	157, 159
<i>Simvar 40 (QA)</i>	
.Cardiovascular system	157, 159
<i>Simvar 80 (QA)</i>	
.Cardiovascular system	158, 160
SIMVASTATIN	
.Cardiovascular system	156, 158
<i>Simvastatin generichealth (GQ)</i>	
.Cardiovascular system	156, 157, 158, 159, 160
<i>Simvastatin Pfizer (FZ)</i>	
.Cardiovascular system	156, 157, 158, 159, 160
<i>Simvastatin Sandoz (SZ)</i>	
.Cardiovascular system	156, 157, 158, 159, 160
<i>Simvastatin Winthrop (WA)</i>	
.Cardiovascular system	156, 157, 158, 159, 160
<i>Simvastatin-DP (GM)</i>	
.Cardiovascular system	156, 157, 158, 159, 160
<i>Simvastatin-DRLA (RZ)</i>	
.Cardiovascular system	156, 157, 158, 159, 160
<i>Simvastatin-GA 10 (GN)</i>	
.Cardiovascular system	156, 158
<i>Simvastatin-GA 20 (GN)</i>	
.Cardiovascular system	157, 159
<i>Simvastatin-GA 40 (GN)</i>	
.Cardiovascular system	157, 159
<i>Simvastatin-GA 80 (GN)</i>	
.Cardiovascular system	158, 160
<i>Simvastatin-Spirit 10 (ZP)</i>	
.Cardiovascular system	156, 159
<i>Simvastatin-Spirit 20 (ZP)</i>	
.Cardiovascular system	157, 159
<i>Simvastatin-Spirit 40 (ZP)</i>	
.Cardiovascular system	157, 160
<i>Simvastatin-Spirit 80 (ZP)</i>	
.Cardiovascular system	158, 160
<i>Sinemet (MK)</i>	
.Nervous system.....	433
<i>Sinemet 100/25 (MK)</i>	
.Nervous system.....	433
<i>Sinemet CR (MK)</i>	
.Nervous system.....	434
<i>Sinequan (PF)</i>	
.Nervous system.....	458
<i>Singulair (MK)</i>	
.Respiratory system	488
SIROLIMUS	
.Antineoplastic and immunomodulating agents	263
.Section 100.....	635, 783
SITAGLIPTIN	
.Alimentary tract and metabolism	100
SITAGLIPTIN with METFORMIN	
.Alimentary tract and metabolism	96
<i>Skelid (SW)</i>	
.Musculo-skeletal system.....	401
SKIN CLEANSER	
.Repatriation Schedule.....	920
SKIN EMOLLIENT	
.Repatriation Schedule.....	917
<i>Slow-K (NV)</i>	
.Alimentary tract and metabolism	103
<i>Sodibic (AS)</i>	
.Genito urinary system and sex hormones.....	183
SODIUM ACID PHOSPHATE	
.Various	503
SODIUM ALGINATE with CALCIUM CARBONATE and SODIUM BICARBONATE	
.Alimentary tract and metabolism	79
SODIUM AUROTHIOMALATE	
.Musculo-skeletal system.....	395
SODIUM BICARBONATE	
.Genito urinary system and sex hormones.....	183
SODIUM CHLORIDE	
.Blood and blood forming organs.....	115
.Dental.....	540, 563
.Repatriation Schedule.....	914
.Various	519
<i>Sodium Chloride 0.9% Freeflex (PK)</i>	
.Blood and blood forming organs.....	116
SODIUM CHLORIDE COMPOUND	
.Blood and blood forming organs.....	116
SODIUM CHLORIDE with GLUCOSE	
.Blood and blood forming organs.....	116
.Dental.....	540
SODIUM CITRO-TARTRATE	
.Repatriation Schedule.....	924
SODIUM CLODRONATE TETRAHYDRATE	
.Musculo-skeletal system.....	401
SODIUM CROMOGLYCATE	
.Optometrical.....	568
.Repatriation Schedule.....	935
.Respiratory system.....	486
.Sensory organs.....	493
SODIUM LACTATE COMPOUND	
.Blood and blood forming organs.....	116
SODIUM POLYSTYRENE SULFONATE	
.Repatriation Schedule.....	938
SODIUM VALPROATE	
.Nervous system.....	426
<i>Sodium Valproate Sandoz (SZ)</i>	
.Nervous system.....	426
<i>Soflax (GM)</i>	
.Repatriation Schedule.....	912

GENERIC/PROPRIETARY INDEX

<i>Sofradex (SW)</i>		
.Sensory organs.....	500	
<i>Soframycin (SW)</i>		
.Optometrical.....	571	
.Sensory organs.....	500	
<i>Solaraze 3% Gel (CS)</i>		
.Repatriation Schedule.....	920	
<i>Solavert (QA)</i>		
.Cardiovascular system	118, 125	
<i>Solian 100 (SW)</i>		
.Nervous system.....	447	
<i>Solian 200 (SW)</i>		
.Nervous system.....	448	
<i>Solian 400 (SW)</i>		
.Nervous system.....	448	
<i>Solian Solution (SW)</i>		
.Nervous system.....	448	
<i>Solone (VT)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
<i>SoloSite Gel 36361338 (SN)</i>		
.Repatriation Schedule.....	952	
<i>Solprin (RC)</i>		
.Blood and blood forming organs.....	106	
.Dental.....	558	
.Nervous system.....	420	
<i>Solu-Cortef (PF)</i>		
.Dental.....	543	
.Emergency Drug Supplies	64	
.Systemic hormonal preparations, excl. sex hormones and insulins	187, 188	
<i>Solugel 10336 (JJ)</i>		
.Repatriation Schedule.....	951	
<i>Solu-Medrol (PF)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	188	
<i>Somac (NQ)</i>		
.Alimentary tract and metabolism	77, 78	
SOMATROPIN (Recombinant human growth hormone)		
.Section 100	872	
<i>Somatuline Autogel (IS)</i>		
.Section 100	608, 754	
<i>Somatuline LA (IS)</i>		
.Section 100	608, 754	
<i>Sone (VT)</i>		
.Systemic hormonal preparations, excl. sex hormones and insulins	188, 189	
SORAFENIB		
.Antineoplastic and immunomodulating agents	244	
SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE		
.Alimentary tract and metabolism	86	
.Palliative Care	524, 525	
.Repatriation Schedule.....	912	
<i>Sorbsan 1410 (UM)</i>		
.Repatriation Schedule.....	945	
<i>Sorbsan 1411 (UM)</i>		
.Repatriation Schedule.....	944	
<i>Sotacor (FM)</i>		
.Cardiovascular system	118, 125	
SOTALOL HYDROCHLORIDE		
.Cardiovascular system	118, 125	
<i>Sotalol Sandoz (SZ)</i>		
.Cardiovascular system	118, 125	
SOY LECITHIN		
.Optometrical.....	571	
.Sensory organs.....	500	
SOY PROTEIN and FAT FORMULA with VITAMINS and MINERALS—CARBOHYDRATE FREE		
.Variou.....	517	
<i>Sozol (QA)</i>		
.Alimentary tract and metabolism	77	
<i>Span-K (AS)</i>		
.Alimentary tract and metabolism	103	
<i>Spiractin 100 (AF)</i>		
.Cardiovascular system	123	
<i>Spiractin 25 (AF)</i>		
.Cardiovascular system	123	
<i>Spiriva (BY)</i>		
.Respiratory system.....	486	
SPIRONOLACTONE		
.Cardiovascular system	123	
<i>Sporanox (JC)</i>		
.Antiinfectives for systemic use.....	213	
<i>Spren 100 (QA)</i>		
.Blood and blood forming organs.....	107	
<i>Sprycel (BQ)</i>		
.Antineoplastic and immunomodulating agents ...	227, 228, 229, 230	
<i>STADA Atorvastatin (TD)</i>		
.Cardiovascular system	149, 150, 151, 152	
<i>STADA Clopidogrel (TD)</i>		
.Blood and blood forming organs.....	107	
<i>STADA Olanzapine (TD)</i>		
.Nervous system.....	440, 441, 442	
<i>STADA Quetiapine (TD)</i>		
.Nervous system.....	446, 447	
<i>Stalevo 100/25/200mg (NV)</i>		
.Nervous system.....	434	
<i>Stalevo 125/31.25/200mg (NV)</i>		
.Nervous system.....	434	
<i>Stalevo 150/37.5/200mg (NV)</i>		
.Nervous system.....	434	
<i>Stalevo 200/50/200mg (NV)</i>		
.Nervous system.....	434	
<i>Stalevo 50/12.5/200mg (NV)</i>		
.Nervous system.....	434	
<i>Stalevo 75/18.75/200mg (NV)</i>		
.Nervous system.....	434	
<i>Staphylex 250 (AF)</i>		

GENERIC/PROPRIETARY INDEX

.Antiinfectives for systemic use	198	.Nervous system.....	431
.Dental.....	546	<i>Sumagran 50 (QA)</i>	
<i>Staphylex 500 (AF)</i>		.Nervous system.....	422
.Antiinfectives for systemic use	198	<i>Sumagran Aspen 50 (AS)</i>	
.Dental.....	546	.Nervous system.....	422
STAVUDINE		<i>Sumatab (AF)</i>	
.Section 100	615, 762	.Nervous system.....	422
<i>Stelara (JC)</i>		SUMATRIPTAN	
.Antineoplastic and immunomodulating agents ...	385, 389	.Nervous system.....	421, 422
<i>Stelax 10 (QA)</i>		<i>Sumatriptan generichealth (GQ)</i>	
.Musculo-skeletal system.....	396	.Nervous system.....	422
<i>Stelax 25 (QA)</i>		<i>Sumatriptan-GA (GM)</i>	
.Musculo-skeletal system.....	396	.Nervous system.....	422
<i>Stelazine (GH)</i>		SUNITINIB	
.Nervous system.....	438	.Antineoplastic and immunomodulating agents	244
<i>Stemetil (SW)</i>		SUNSCREENS	
.Alimentary tract and metabolism	84	.Repatriation Schedule	917
.Dental.....	539	<i>Sunsense Sensitive SPF 30+ (EO)</i>	
.Emergency Drug Supplies	64	.Repatriation Schedule	917
<i>Stemzine (AV)</i>		<i>SunSense Ultra SPF 30+ (EO)</i>	
.Alimentary tract and metabolism	84	.Repatriation Schedule	918
.Dental.....	539	<i>Surepress 650947 (CC)</i>	
STERCULIA with FRANGULA BARK		.Repatriation Schedule	941
.Alimentary tract and metabolism	85	<i>Surepress 650948 (CC)</i>	
.Palliative Care	523	.Repatriation Schedule	941
.Repatriation Schedule	912	<i>Surgam (SW)</i>	
<i>Steripaste 3610 (XP)</i>		.Musculo-skeletal system	394
.Repatriation Schedule	944	<i>Sutent (PF)</i>	
<i>Stieprox Liquid (GK)</i>		.Antineoplastic and immunomodulating agents ...	244, 245
.Repatriation Schedule	916	<i>Symbicort Turbuhaler 100/6 (AP)</i>	
<i>Stocrin (MK)</i>		.Respiratory system.....	484
.Section 100	616, 763	<i>Symbicort Turbuhaler 200/6 (AP)</i>	
<i>Strattera (LY)</i>		.Respiratory system.....	484
.Nervous system.....	467	<i>Symbicort Turbuhaler 400/12 (AP)</i>	
<i>Stromectol (MK)</i>		.Respiratory system.....	484
.Antiparasitic products, insecticides and repellents		<i>Symmetrel 100 (NV)</i>	
.....	481	.Nervous system.....	435
STRONTIUM RANELATE		<i>Synacthen Depot 1 mg/1 mL (NV)</i>	
.Musculo-skeletal system.....	406	.Systemic hormonal preparations, excl. sex hormones and insulins	185
<i>Suboxone (RC)</i>		<i>Synarel (PF)</i>	
.Section 100	876	.Section 100.....	875
<i>Suboxone Film 2/0.5 (RC)</i>		.Systemic hormonal preparations, excl. sex hormones and insulins	186
.Section 100	876	<i>Synthon Simvastatin (ZT)</i>	
<i>Suboxone Film 8/2 (RC)</i>		.Cardiovascular system	156, 157, 158, 159, 160
.Section 100	876	<i>Syquet (AF)</i>	
<i>Subutex (RC)</i>		.Nervous system.....	446, 447
.Section 100	876	<i>Systane (AQ)</i>	
SUCRALFATE		.Optometrical	570
.Alimentary tract and metabolism	79	.Sensory organs.....	499
SULFASALAZINE			
.Alimentary tract and metabolism	90		
<i>Sulprix (AF)</i>			
.Nervous system.....	448		
SULTHIAME			

GENERIC/PROPRIETARY INDEX

T

<i>Tacidine (AF)</i>		.Alimentary tract and metabolism 72
TACROLIMUS		.Antineoplastic and immunomodulating agents 390
		.Section 100 699, 848
<i>Tacrolimus Sandoz (SZ)</i>		.Antineoplastic and immunomodulating agents 390
		.Section 100 699, 700, 848
TADALAFIL		.Repatriation Schedule 921
		.Section 100 602, 748
<i>Talam (QA)</i>		.Nervous system..... 459
<i>Tamate (AF)</i>		.Nervous system..... 431, 432
<i>Tambocor (IA)</i>		.Cardiovascular system 117, 118
<i>Tamosin (QA)</i>		.Antineoplastic and immunomodulating agents 247
<i>Tamoxen 20 mg (GM)</i>		.Antineoplastic and immunomodulating agents 247
TAMOXIFEN CITRATE		.Antineoplastic and immunomodulating agents 247
<i>Tamoxifen Sandoz (SZ)</i>		.Antineoplastic and immunomodulating agents 247
<i>Tamsil (QA)</i>		.Dermatologicals 167
		.Repatriation Schedule 917
TAMSULOSIN HYDROCHLORIDE		.Repatriation Schedule 925
TAPES—NON-WOVEN RETENTION (POLYACRYLATE)		.Repatriation Schedule 954
TAPES—PLASTER ADHESIVE (WITH SILICONE)		.Repatriation Schedule 954
TAPES—PLASTER ADHESIVE ELASTIC		.Repatriation Schedule 954
TAPES—PLASTER ADHESIVE HYPOALLERGENIC		.Repatriation Schedule 954
<i>Tarceva (RO)</i>		.Antineoplastic and immunomodulating agents 230
<i>Targin 10/5mg (MF)</i>		.Nervous system..... 414
<i>Targin 20/10mg (MF)</i>		.Nervous system..... 414
<i>Targin 40/20mg (MF)</i>		.Nervous system..... 414
<i>Targin 5/2.5mg (MF)</i>		.Nervous system..... 414
<i>Tarka 2/180 (AB)</i>		.Cardiovascular system 142
<i>Tarka 4/240 (AB)</i>		.Cardiovascular system 142
<i>Tasigna (NV)</i>		.Antineoplastic and immunomodulating agents ... 242, 243
<i>Tazac (AS)</i>		.Alimentary tract and metabolism 72
<i>Tears Naturale (AQ)</i>		.Optometrical 570
		.Sensory organs 497
<i>tearsagain (RB)</i>		.Optometrical 571
		.Sensory organs 500
<i>Tegaderm Transparent 1628 (MM)</i>		.Repatriation Schedule 945
<i>Tegaderm Transparent Island 3582 (MM)</i>		.Repatriation Schedule 945
<i>Tegaderm Transparent Island 3586 (MM)</i>		.Repatriation Schedule 945
<i>Tegretol 100 (NV)</i>		.Dental 559
		.Nervous system 425
<i>Tegretol 200 (NV)</i>		.Dental 559
		.Nervous system 425
<i>Tegretol CR 200 (NV)</i>		.Dental 559
		.Nervous system 425
<i>Tegretol CR 400 (NV)</i>		.Dental 559
		.Nervous system 425
<i>Tegretol Liquid (NV)</i>		.Dental 559
		.Nervous system 425
TELBIVUDINE		.Section 100..... 615, 762
<i>Telfa 1970C (KE)</i>		.Repatriation Schedule 952
<i>Telfa 2140C (KE)</i>		.Repatriation Schedule 952
<i>Telfa 7650C (KE)</i>		.Repatriation Schedule 952
<i>Telfa 8252F (KE)</i>		.Repatriation Schedule 943
<i>Telfa 8253F (KE)</i>		.Repatriation Schedule 943
<i>Telfa 8254F (KE)</i>		.Repatriation Schedule 943
<i>Telfast (SW)</i>		.Repatriation Schedule 936
<i>Telfast 120 (SW)</i>		.Repatriation Schedule 936
TELMISARTAN		.Cardiovascular system 143
TELMISARTAN with AMLODIPINE		.Cardiovascular system 145
TELMISARTAN with HYDROCHLOROTHIAZIDE		.Cardiovascular system 144

GENERIC/PROPRIETARY INDEX

<i>Telzir (VI)</i>		
. Section 100	613, 759	
<i>Temaze (AF)</i>		
. Dental.....	560	
. Nervous system.....	457	
. Palliative Care	536	
TEMAZEPAM		
. Dental.....	560	
. Nervous system.....	457	
. Palliative Care	536	
<i>Temizole 100 (QA)</i>		
. Antineoplastic and immunomodulating agents ...	222, 223	
<i>Temizole 140 (QA)</i>		
. Antineoplastic and immunomodulating agents	223	
<i>Temizole 20 (QA)</i>		
. Antineoplastic and immunomodulating agents ...	222, 223	
<i>Temizole 250 (QA)</i>		
. Antineoplastic and immunomodulating agents	223	
<i>Temizole 5 (QA)</i>		
. Antineoplastic and immunomodulating agents ...	222, 223	
<i>Temodal (MK)</i>		
. Antineoplastic and immunomodulating agents ...	222, 223	
TEMOZOLOMIDE		
. Antineoplastic and immunomodulating agents ...	222, 223	
<i>Temtabs (FM)</i>		
. Dental.....	560	
. Nervous system.....	457	
. Palliative Care	536	
<i>TenderWet 24 Active (HR)</i>		
. Repatriation Schedule	948	
<i>TenderWet Active Cavity (HR)</i>		
. Repatriation Schedule	948	
TENECTEPLASE		
. Blood and blood forming organs.....	110	
TENOFOVIR		
. Section 100	616, 762	
TENOFOVIR with EMTRICITABINE		
. Section 100	618, 765	
TENOFOVIR with EMTRICITABINE and EFAVIRENZ		
. Section 100	618, 765	
TENOFOVIR with EMTRICITABINE and RILPIVIRINE		
. Section 100	618, 765	
<i>Tenopt (QA)</i>		
. Optometrical.....	567	
. Sensory organs.....	492	
<i>Tenormin (AP)</i>		
. Cardiovascular system	125	
<i>Tensig (QA)</i>		
. Cardiovascular system	125	
<i>Tensocrepe 36300501 (BV)</i>		
. Repatriation Schedule	943	
<i>Tensocrepe 36301001 (BV)</i>		
. Repatriation Schedule	943	
<i>Tensocrepe 36307501 (BV)</i>		
. Repatriation Schedule	943	
<i>Tensoress 71723-00 (BV)</i>		
. Repatriation Schedule	941	
<i>Tensoress 71723-01 (BV)</i>		
. Repatriation Schedule	941	
TERAZOSIN HYDROCHLORIDE		
. Repatriation Schedule	925	
<i>Terbihexal (HX)</i>		
. Dermatologicals	167	
TERBINAFINE		
. Dermatologicals	166, 167	
. Repatriation Schedule	916, 917	
<i>Terbinafine 250 (CR)</i>		
. Dermatologicals	167	
<i>Terbinafine Sandoz (SZ)</i>		
. Dermatologicals	167	
. Repatriation Schedule	917	
<i>Terbinafine-DP (GN)</i>		
. Repatriation Schedule	917	
<i>Terbinafine-DRLA (RZ)</i>		
. Dermatologicals	167	
<i>Terbinafine-GA (GM)</i>		
. Dermatologicals	167	
<i>Terbix 250 (MI)</i>		
. Dermatologicals	167	
TERBUTALINE SULFATE		
. Respiratory system.....	483, 487	
<i>Teril (AF)</i>		
. Dental.....	559	
. Nervous system.....	425	
TERIPARATIDE		
. Musculo-skeletal system	406	
. Systemic hormonal preparations, excl. sex hormones and insulins	190	
<i>Terry White Chemists Aciclovir (TW)</i>		
. Anti-infectives for systemic use.....	215	
<i>Terry White Chemists Alendronate 70mg (TW)</i>		
. Musculo-skeletal system	398	
<i>Terry White Chemists Allopurinol (TW)</i>		
. Musculo-skeletal system	397	
<i>Terry White Chemists Alprazolam (TW)</i>		
. Nervous system.....	454, 455	
<i>Terry White Chemists Amiodarone (TW)</i>		
. Cardiovascular system	118	
<i>Terry White Chemists Amlodipine (TW)</i>		
. Cardiovascular system	129, 130	
<i>Terry White Chemists Amoxycillin (TW)</i>		
. Anti-infectives for systemic use.....	195, 196	
. Dental.....	544, 545	
<i>Terry White Chemists Amoxycillin and Clavulanic Acid (TW)</i>		

GENERIC/PROPRIETARY INDEX

.Antiinfectives for systemic use	198	.Alimentary tract and metabolism	72
.Dental.....	547	<i>Terry White Chemists Fluoxetine (TW)</i>	
<i>Terry White Chemists Anastrozole (TW)</i>		.Nervous system.....	461
.Antineoplastic and immunomodulating agents	249	<i>Terry White Chemists Frusemide (TW)</i>	
<i>Terry White Chemists Atenolol (TW)</i>		.Cardiovascular system	122, 123
.Cardiovascular system	125	<i>Terry White Chemists Gemfibrozil (TW)</i>	
<i>Terry White Chemists Atorvastatin (TW)</i>		.Cardiovascular system	161, 162
.Cardiovascular system	150, 151, 152	<i>Terry White Chemists Glipizide (TW)</i>	
<i>Terry White Chemists Baclofen (TW)</i>		.Alimentary tract and metabolism	94
.Musculo-skeletal system.....	396	<i>Terry White Chemists Glipizide MR (TW)</i>	
<i>Terry White Chemists Bisoprolol (TW)</i>		.Alimentary tract and metabolism	94
.Cardiovascular system	126	<i>Terry White Chemists Hydroxychloroquine (TW)</i>	
<i>Terry White Chemists Carvedilol 12.5 mg (TW)</i>		.Musculo-skeletal system.....	395
.Cardiovascular system	128	<i>Terry White Chemists Indapamide (TW)</i>	
<i>Terry White Chemists Carvedilol 25 mg (TW)</i>		.Cardiovascular system	122
.Cardiovascular system	128	<i>Terry White Chemists Isosorbide Mononitrate (TW)</i>	
<i>Terry White Chemists Carvedilol 3.125 mg (TW)</i>		.Cardiovascular system	120
.Cardiovascular system	128	<i>Terry White Chemists Latanoprost (TW)</i>	
<i>Terry White Chemists Carvedilol 6.25 mg (TW)</i>		.Optometrical.....	568
.Cardiovascular system	128	.Sensory organs.....	492
<i>Terry White Chemists Cefaclor (TW)</i>		<i>Terry White Chemists Lercanidipine (TW)</i>	
.Antiinfectives for systemic use	202	.Cardiovascular system	130
.Dental.....	549	<i>Terry White Chemists Letrozole (TW)</i>	
<i>Terry White Chemists Cefaclor CD (TW)</i>		.Antineoplastic and immunomodulating agents	250
.Antiinfectives for systemic use	201	<i>Terry White Chemists Levetiracetam (TW)</i>	
.Dental.....	549	.Nervous system.....	430
<i>Terry White Chemists Cephalexin (TW)</i>		<i>Terry White Chemists Lisinopril (TW)</i>	
.Antiinfectives for systemic use	199, 200	.Cardiovascular system	134, 135
.Dental.....	548, 549	<i>Terry White Chemists Meloxicam (TW)</i>	
<i>Terry White Chemists Citalopram (TW)</i>		.Musculo-skeletal system.....	392, 393
.Nervous system.....	459	<i>Terry White Chemists Meloxicam 15 mg (TW)</i>	
<i>Terry White Chemists Clarithromycin (TW)</i>		.Musculo-skeletal system.....	393
.Antiinfectives for systemic use	205	<i>Terry White Chemists Meloxicam 7.5 mg (TW)</i>	
<i>Terry White Chemists Clomipramine (TW)</i>		.Musculo-skeletal system.....	392
.Nervous system.....	456, 458	<i>Terry White Chemists Metformin (TW)</i>	
<i>Terry White Chemists Clopidogrel (TW)</i>		.Alimentary tract and metabolism	93
.Blood and blood forming organs.....	107	<i>Terry White Chemists Metformin 1000 (TW)</i>	
<i>Terry White Chemists Diclofenac (TW)</i>		.Alimentary tract and metabolism	94
.Dental.....	553	<i>Terry White Chemists Metoprolol (TW)</i>	
.Musculo-skeletal system.....	391	.Cardiovascular system	127
.Palliative Care	527, 528	<i>Terry White Chemists Mirtazapine (TW)</i>	
<i>Terry White Chemists Diltiazem (TW)</i>		.Nervous system.....	465, 466
.Cardiovascular system	132	<i>Terry White Chemists Moclobemide (TW)</i>	
<i>Terry White Chemists Diltiazem CD (TW)</i>		.Nervous system.....	464
.Cardiovascular system	131, 132	<i>Terry White Chemists Norfloxacin (TW)</i>	
<i>Terry White Chemists Doxycycline (TW)</i>		.Antiinfectives for systemic use.....	209
.Antiinfectives for systemic use	193, 194	<i>Terry White Chemists Olanzapine (TW)</i>	
.Dental.....	544	.Nervous system.....	441, 442, 443
<i>Terry White Chemists Enalapril (TW)</i>		<i>Terry White Chemists Olanzapine ODT (TW)</i>	
.Cardiovascular system	133	.Nervous system.....	443, 444, 445
<i>Terry White Chemists Escitalopram (TW)</i>		<i>Terry White Chemists Omeprazole (TW)</i>	
.Nervous system.....	459, 460	.Alimentary tract and metabolism	75, 76
<i>Terry White Chemists Famciclovir (TW)</i>		<i>Terry White Chemists Pantoprazole (TW)</i>	
.Antiinfectives for systemic use	217, 218	.Alimentary tract and metabolism	77, 78
<i>Terry White Chemists Famotidine (TW)</i>		<i>Terry White Chemists Paracetamol (YS)</i>	

GENERIC/PROPRIETARY INDEX

.Dental.....	558	.Genito urinary system and sex hormones.....	177
.Nervous system.....	420	TESTOSTERONE UNDECANOATE	
<i>Terry White Chemists Paroxetine (TW)</i>		.Genito urinary system and sex hormones.....	177
.Nervous system.....	462	TETRABENAZINE	
<i>Terry White Chemists Perindopril (TW)</i>		.Nervous system.....	478
.Cardiovascular system	135, 136	TETRACOSACTRIN	
<i>Terry White Chemists Perindopril/ Indapamide 4/1.25 (TW)</i>		.Systemic hormonal preparations, excl. sex hormones and insulins	185
.Cardiovascular system	141	<i>TevaGrastim (AS)</i>	
<i>Terry White Chemists Pioglitazone (TW)</i>		.Section 100.....	622, 769
.Alimentary tract and metabolism	98, 99	<i>Teveten (AB)</i>	
<i>Terry White Chemists Piroxicam (TW)</i>		.Cardiovascular system	142
.Dental.....	554	<i>Teveten Plus 600/12.5 (AB)</i>	
.Musculo-skeletal system.....	393	.Cardiovascular system	144
<i>Terry White Chemists Pravastatin (TW)</i>		THALIDOMIDE	
.Cardiovascular system	153, 154, 155	.Section 100.....	706, 854
<i>Terry White Chemists Prazosin (TW)</i>		<i>Thalomid (CJ)</i>	
.Cardiovascular system	121	.Section 100.....	706, 855
<i>Terry White Chemists Quetiapine (TW)</i>		THEOPHYLLINE	
.Nervous system.....	446, 447	.Respiratory system.....	487
<i>Terry White Chemists Ramipril (TW)</i>		<i>TheraTears (CX)</i>	
.Cardiovascular system	137, 138, 139	.Optometrical.....	569
<i>Terry White Chemists Ranitidine (TW)</i>		.Sensory organs.....	496
.Alimentary tract and metabolism	72	THIAMINE HYDROCHLORIDE	
<i>Terry White Chemists Risedronate (TW)</i>		.Alimentary tract and metabolism	102
.Musculo-skeletal system.....	400	.Repatriation Schedule	913
.Repatriation Schedule	929	THIOGUANINE	
<i>Terry White Chemists Roxithromycin (TW)</i>		.Antineoplastic and immunomodulating agents	224
.Antiinfectives for systemic use	206	<i>Thioprine (AF)</i>	
.Dental.....	551	.Antineoplastic and immunomodulating agents	390
<i>Terry White Chemists Sertraline (TW)</i>		<i>Thyrogen (GZ)</i>	
.Nervous system.....	462, 463	.Systemic hormonal preparations, excl. sex hormones and insulins	185
<i>Terry White Chemists Simvastatin (TW)</i>		THYTROPIN ALFA	
.Cardiovascular system	156, 157, 158, 159, 160	.Systemic hormonal preparations, excl. sex hormones and insulins	185
<i>Terry White Chemists Sotalol (TW)</i>		THYROXINE SODIUM	
.Cardiovascular system	118, 125	.Systemic hormonal preparations, excl. sex hormones and insulins	189
<i>Terry White Chemists Sumatriptan (TW)</i>		TIAGABINE HYDROCHLORIDE	
.Nervous system.....	422	.Nervous system.....	426
<i>Terry White Chemists Tramadol (TW)</i>		TIAPROFENIC ACID	
.Dental.....	557	.Musculo-skeletal system	394
.Nervous system.....	418	TICAGRELOR	
<i>Terry White Chemists Tramadol SR (TW)</i>		.Blood and blood forming organs.....	109
.Nervous system.....	419	TICARCILLIN with CLAVULANIC ACID	
<i>Terry White Chemists Valaciclovir (TW)</i>		.Antiinfectives for systemic use.....	199
.Antiinfectives for systemic use	218, 219, 220	.Dental.....	547
<i>Terry White Chemists Venlafaxine XR (TW)</i>		TICLOPIDINE HYDROCHLORIDE	
.Nervous system.....	466, 467	.Blood and blood forming organs.....	109
<i>Tertroxin (QA)</i>		<i>Tielle MT2442 (JJ)</i>	
.Systemic hormonal preparations, excl. sex hormones and insulins	189	.Repatriation Schedule	949
<i>Testogel (BN)</i>		<i>Tielle MTL101E (JJ)</i>	
.Genito urinary system and sex hormones	177	.Repatriation Schedule	949
TESTOSTERONE		<i>Tilade CFC-Free (SW)</i>	
.Genito urinary system and sex hormones	176		
TESTOSTERONE ENANTHATE			

GENERIC/PROPRIETARY INDEX

.Respiratory system	486	<i>Toleraide 10 (PQ)</i>	
<i>Tilodene (AF)</i>		.Nervous system	458
.Blood and blood forming organs.....	110	<i>Toleraide 25 (PQ)</i>	
TILUDRONATE DISODIUM		.Nervous system	458
.Musculo-skeletal system.....	401	TOLNAFTATE	
<i>Timentin (GK)</i>		.Repatriation Schedule	916
.Antiinfectives for systemic use	199	<i>Tolvon (MK)</i>	
.Dental.....	547	.Nervous system	465
TIMOLOL MALEATE		<i>Topamax (JC)</i>	
.Optometrical.....	567	.Nervous system.....	431, 432
.Sensory organs.....	492	<i>Topamax Sprinkle (JC)</i>	
<i>Timoptol (FR)</i>		.Nervous system.....	432
.Optometrical.....	567	TOPIRAMATE	
.Sensory organs.....	492	.Nervous system.....	431, 432
<i>Timoptol XE (MK)</i>		<i>Topiramate Sandoz (SZ)</i>	
.Optometrical.....	567	.Nervous system.....	431, 432
.Sensory organs.....	492	<i>Topiramate-GA (GM)</i>	
<i>Tinaderm (MK)</i>		.Nervous system.....	431, 432
.Repatriation Schedule	916	<i>Toprol-XL 190 (AP)</i>	
<i>Tinasil (AF)</i>		.Cardiovascular system	126
.Dermatologicals	167	<i>Toprol-XL 23.75 (AP)</i>	
.Repatriation Schedule	917	.Cardiovascular system	126
<i>Tinexa (QA)</i>		<i>Toprol-XL 47.5 (AP)</i>	
.Genito urinary system and sex hormones	175	.Cardiovascular system	126
TINIDAZOLE		<i>Toprol-XL 95 (AP)</i>	
.Antiinfectives for systemic use	210	.Cardiovascular system	126
.Antiparasitic products, insecticides and repellents		TOREMIFENE CITRATE	
.....	479	.Antineoplastic and immunomodulating agents	248
TIOTROPIUM BROMIDE MONOHYDRATE		<i>Torlemo DT 100 (TA)</i>	
.Respiratory system	486	.Nervous system.....	429
TIPRANAVIR		<i>Torlemo DT 200 (TA)</i>	
.Section 100	613, 760	.Nervous system.....	429
TIROFIBAN HYDROCHLORIDE		<i>Torlemo DT 25 (TA)</i>	
.Blood and blood forming organs.....	110	.Nervous system.....	428
<i>Titralac (MM)</i>		<i>Torlemo DT 50 (TA)</i>	
.Repatriation Schedule	911	.Nervous system.....	429
<i>Tobi (NV)</i>		<i>Torvastat 10 (QA)</i>	
.Antiinfectives for systemic use	207	.Cardiovascular system	150, 151
<i>Tobra-Day (PL)</i>		<i>Torvastat 20 (QA)</i>	
.Antiinfectives for systemic use	207	.Cardiovascular system	150, 151
TOBRAMYCIN		<i>Torvastat 40 (QA)</i>	
.Antiinfectives for systemic use	207	.Cardiovascular system	150, 152
.Optometrical.....	565	<i>Torvastat 80 (QA)</i>	
.Sensory organs.....	489	.Cardiovascular system	150, 152
TOBRAMYCIN SULFATE		<i>Torzole 20 (TA)</i>	
.Antiinfectives for systemic use	207	.Alimentary tract and metabolism	78
<i>Tobrex (AQ)</i>		<i>Torzole 40 (TA)</i>	
.Optometrical.....	565	.Alimentary tract and metabolism	77, 78
.Sensory organs.....	489	<i>Tracleer (AT)</i>	
TOCILIZUMAB		.Section 100.....	590, 736
.Section 100	689, 694, 837, 842	<i>Trajenta (BY)</i>	
<i>Tofranil 10 (LM)</i>		.Alimentary tract and metabolism	100
.Nervous system.....	458	TRAMADOL HYDROCHLORIDE	
<i>Tofranil 25 (LM)</i>		.Dental.....	557, 558
.Nervous system.....	458	.Nervous system.....	418, 419, 420

GENERIC/PROPRIETARY INDEX

<i>Tramadol Sandoz (SZ)</i>		<i>.Sensory organs</i>492
.Dental.....	557	TRAVOPROST
.Nervous system.....	418	.Optometrical.....
<i>Tramadol Sandoz SR (SZ)</i>		.Sensory organs.....
.Nervous system.....	419	TRAVOPROST with TIMOLOL MALEATE
<i>Tramahexal (SZ)</i>		.Optometrical.....
.Dental.....	558	.Sensory organs.....
.Emergency Drug Supplies	65	TRIAMCINOLONE ACETONIDE
.Nervous system.....	420	.Dental.....
<i>Tramal (CS)</i>		.Dermatologicals
.Dental.....	557, 558	.Systemic hormonal preparations, excl. sex hormones
.Nervous system.....	418, 419	and insulins
<i>Tramal 100 (CS)</i>		TRIAMCINOLONE ACETONIDE with NEOMYCIN SULFATE,
.Dental.....	558	GRAMICIDIN and NYSTATIN
.Emergency Drug Supplies	65	.Repatriation Schedule
.Nervous system.....	420	.Sensory organs.....
<i>Tramal SR 100 (CS)</i>		<i>Triasyn 2.5/2.5 (SW)</i>
.Nervous system.....	419	.Cardiovascular system
<i>Tramal SR 150 (CS)</i>		<i>Triasyn 5.0/5.0 (SW)</i>
.Nervous system.....	419	.Cardiovascular system
<i>Tramal SR 200 (CS)</i>		<i>Tricortone (FM)</i>
.Nervous system.....	419	.Dermatologicals
<i>Tramal SR 50 (CS)</i>		<i>Trifeme 28 (FZ)</i>
.Nervous system.....	419	.Genito urinary system and sex hormones.....
<i>Tramedo (AF)</i>		TRIFLUOPERAZINE HYDROCHLORIDE
.Dental.....	557	.Nervous system.....
.Nervous system.....	418	TRIGLYCERIDES, LONG CHAIN with GLUCOSE POLYMER
<i>Tramedo SR 100 (AF)</i>		.Variou.....
.Nervous system.....	419	TRIGLYCERIDES, MEDIUM CHAIN
<i>Tramedo SR 150 (AF)</i>		.Variou.....
.Nervous system.....	419	TRIGLYCERIDES, MEDIUM CHAIN and LONG CHAIN with
<i>Tramedo SR 200 (AF)</i>		GLUCOSE POLYMER
.Nervous system.....	419	.Variou.....
<i>Tranalpha (AF)</i>		TRIGLYCERIDES—MEDIUM CHAIN, FORMULA
.Cardiovascular system	139, 140	.Variou.....
<i>Trandate (QA)</i>		<i>Trileptal (NV)</i>
.Cardiovascular system	129	.Nervous system.....
TRANDOLAPRIL		TRIMETHOPRIM
.Cardiovascular system	139	.Anti-infectives for systemic use.....
<i>Trandolapril generichealth (GQ)</i>		TRIMETHOPRIM with SULFAMETHOXAZOLE
.Cardiovascular system	139, 140	.Anti-infectives for systemic use.....
TRANDOLAPRIL with VERAPAMIL HYDROCHLORIDE		.Dental.....
.Cardiovascular system	142	<i>Triphasil 28 (PF)</i>
<i>Trandolapril-DP (GN)</i>		.Genito urinary system and sex hormones.....
.Cardiovascular system	139, 140	<i>Triprim (QA)</i>
TRANEXAMIC ACID		.Anti-infectives for systemic use.....
.Blood and blood forming organs.....	113	TRIPTORELIN
<i>Transiderm-Nitro 25 (NV)</i>		.Antineoplastic and immunomodulating agents
.Cardiovascular system	119	<i>Triquilar ED (BN)</i>
<i>Transiderm-Nitro 50 (NV)</i>		.Genito urinary system and sex hormones.....
.Cardiovascular system	119	<i>Tritace (SW)</i>
TRANLYCYPROMINE SULFATE		.Cardiovascular system
.Nervous system.....	463	<i>Tritace 1.25 mg (SW)</i>
<i>Travatan (AQ)</i>		.Cardiovascular system
.Optometrical.....	568	<i>Tritace 10 mg (SW)</i>

GENERIC/PROPRIETARY INDEX

.Cardiovascular system	139	.Repatriation Schedule	944
<i>Tritace 2.5 mg (SW)</i>		<i>Tubigrip 1482 (SS)</i>	
.Cardiovascular system	137	.Repatriation Schedule	943
<i>Tritace 5 mg (SW)</i>		<i>Tubigrip 1483 (SS)</i>	
.Cardiovascular system	138	.Repatriation Schedule	943
<i>Tritace Titration Pack (SW)</i>		<i>Tubigrip 1484 (SS)</i>	
.Cardiovascular system	139	.Repatriation Schedule	943
<i>Trizivir (VI)</i>		<i>Tubigrip 1486 (SS)</i>	
.Section 100	617, 765	.Repatriation Schedule	943
TROPISETRON HYDROCHLORIDE		<i>Tubigrip B 1520 (SS)</i>	
.Alimentary tract and metabolism	83	.Repatriation Schedule	943
<i>Trovas (RA)</i>		<i>Tubigrip C 1545 (SS)</i>	
.Cardiovascular system	150, 151, 152	.Repatriation Schedule	943
<i>TRUEbalance (NX)</i>		<i>Tubigrip D 1546 (SS)</i>	
.Various	504, 505	.Repatriation Schedule	943
<i>TRUEresult (NX)</i>		<i>Tubigrip E 1547 (SS)</i>	
.Various	504, 505	.Repatriation Schedule	943
<i>TrueTrack (NX)</i>		<i>Tubigrip F 1548 (SS)</i>	
.Various	505	.Repatriation Schedule	943
<i>Trusopt (MK)</i>		<i>Twynsta (BY)</i>	
.Optometrical	567	.Cardiovascular system	145
.Sensory organs	491	<i>Tykerb (GK)</i>	
<i>Truvada (GI)</i>		.Antineoplastic and immunomodulating agents	240
.Section 100	618, 765	<i>TYR Anamix infant (SB)</i>	
<i>Tryzan Caps 1.25 (AF)</i>		.Various	515
.Cardiovascular system	137	<i>TYR Anamix Junior (SB)</i>	
<i>Tryzan Caps 10 (AF)</i>		.Various	515
.Cardiovascular system	139	<i>TYR Anamix junior LQ (SB)</i>	
<i>Tryzan Caps 2.5 (AF)</i>		.Various	513
.Cardiovascular system	138	<i>TYR Cooler (VF)</i>	
<i>Tryzan Caps 5 (AF)</i>		.Various	515
.Cardiovascular system	138	<i>TYR express 15 (VF)</i>	
<i>Tryzan Tabs 1.25 (AF)</i>		.Various	515
.Cardiovascular system	137	<i>TYR gel (VF)</i>	
<i>Tryzan Tabs 10 (AF)</i>		.Various	515
.Cardiovascular system	139	<i>TYR Lophlex LQ 20 (SB)</i>	
<i>Tryzan Tabs 2.5 (AF)</i>		.Various	515
.Cardiovascular system	138	<i>Tyrosine Amino Acid Supplement (VF)</i>	
<i>Tryzan Tabs 5 (AF)</i>		.Various	518
.Cardiovascular system	138	TYROSINE with CARBOHYDRATE	
<i>Tubegauz 0501633 (SS)</i>		.Various	518
.Repatriation Schedule	943	<i>Tysabri (BD)</i>	
<i>Tubegauz 0501658 (SS)</i>		.Section 100	635, 783
.Repatriation Schedule	943		
<i>Tubifast 2434 (SS)</i>			
.Repatriation Schedule	943		
<i>Tubifast 2436 (SS)</i>			
.Repatriation Schedule	943		
<i>Tubifast 2438 (SS)</i>			
.Repatriation Schedule	943		
<i>Tubigrip 1479 (SS)</i>			
.Repatriation Schedule	943		
<i>Tubigrip 1480 (SS)</i>			
.Repatriation Schedule	944		
<i>Tubigrip 1481 (SS)</i>			

U

<i>Ulcaid (RA)</i>	
.Alimentary tract and metabolism	72, 73
<i>Ulcylte (AF)</i>	
.Alimentary tract and metabolism	79
<i>Uracol (GM)</i>	
.Repatriation Schedule	924
<i>Ural Sachets (QA)</i>	
.Repatriation Schedule	924
UREA	

GENERIC/PROPRIETARY INDEX

.Repatriation Schedule.....	917
<i>Urederm (VT)</i>	
.Repatriation Schedule.....	917
<i>Uremide (AF)</i>	
.Cardiovascular system	123
<i>Urex (FM)</i>	
.Cardiovascular system	123
<i>Urex-Forte (FM)</i>	
.Cardiovascular system	123
<i>Urex-M (FM)</i>	
.Cardiovascular system	122
<i>Uro-Carb (YN)</i>	
.Nervous system.....	475
<i>Uromitexan (BX)</i>	
.Various	503
URSODEOXYCHOLIC ACID	
.Alimentary tract and metabolism	84
<i>Ursofalk (OA)</i>	
.Alimentary tract and metabolism	84
USTEKINUMAB	
.Antineoplastic and immunomodulating agents ...	380, 385

V

<i>Vaclovir (AF)</i>	
.Antiinfectives for systemic use	218, 219, 220
<i>Vagifem (NO)</i>	
.Genito urinary system and sex hormones	178
VALACICLOVIR	
.Antiinfectives for systemic use	218, 219, 220
.Section 100	611, 758
<i>Valaciclovir Actavis 500 (TA)</i>	
.Antiinfectives for systemic use	219, 220
<i>Valaciclovir GA (GN)</i>	
.Antiinfectives for systemic use	218, 219, 220
<i>Valaciclovir generichealth (GQ)</i>	
.Antiinfectives for systemic use	219, 220
<i>Valaciclovir Pfizer (FZ)</i>	
.Antiinfectives for systemic use	218, 219, 220
<i>Valaciclovir RBX (RA)</i>	
.Antiinfectives for systemic use	219, 220
.Section 100	611, 758
<i>Valaciclovir Sandoz (SZ)</i>	
.Antiinfectives for systemic use	218, 219, 220
<i>Valaciclovir SZ (HX)</i>	
.Antiinfectives for systemic use	219, 220
<i>Valacor 500 (QR)</i>	
.Antiinfectives for systemic use	219, 220
<i>Valcyte (RO)</i>	
.Section 100	612, 758
VALGANCICLOVIR HYDROCHLORIDE	
.Section 100	612, 758
<i>Valine 1000 Amino Acid Supplement (VF)</i>	
.Various	518
<i>Valine Amino Acid Supplement (VF)</i>	
.Various	518
VALINE with CARBOHYDRATE	
.Various	518
<i>Valium (RO)</i>	
.Dental.....	559
.Nervous system.....	455
.Palliative Care.....	534, 535
<i>Valnir (QA)</i>	
.Antiinfectives for systemic use.....	218, 219, 220
<i>Valpam 2 (QA)</i>	
.Dental.....	559
.Nervous system.....	455
.Palliative Care.....	534, 535
<i>Valpam 5 (QA)</i>	
.Dental.....	559
.Nervous system.....	455
.Palliative Care.....	534, 535
<i>Valprease 200 (QA)</i>	
.Nervous system.....	426
<i>Valprease 500 (QA)</i>	
.Nervous system.....	426
<i>Valpro 200 (AF)</i>	
.Nervous system.....	426
<i>Valpro 500 (AF)</i>	
.Nervous system.....	426
<i>Valproate Winthrop EC 200 (WA)</i>	
.Nervous system.....	426
<i>Valproate Winthrop EC 500 (WA)</i>	
.Nervous system.....	426
VALSARTAN	
.Cardiovascular system	143, 144
VALSARTAN with HYDROCHLOROTHIAZIDE	
.Cardiovascular system	145
<i>Valtrex (GK)</i>	
.Antiinfectives for systemic use.....	218, 219, 220
.Section 100.....	611, 758
<i>Valvala (NV)</i>	
.Antiinfectives for systemic use.....	218, 219, 220
.Section 100.....	611, 758
<i>Vancocin (AS)</i>	
.Alimentary tract and metabolism	87
<i>Vancocin CP (AS)</i>	
.Antiinfectives for systemic use.....	209
.Dental.....	551
VANCOMYCIN	
.Alimentary tract and metabolism	87
.Antiinfectives for systemic use.....	209
.Dental.....	551
<i>Vancomycin Alphapharm (AF)</i>	
.Antiinfectives for systemic use.....	209
.Dental.....	551
<i>Vancomycin Sandoz (SZ)</i>	
.Antiinfectives for systemic use.....	209
.Dental.....	551

GENERIC/PROPRIETARY INDEX

VARDENAFIL	
.Repatriation Schedule	924
VARENICLINE	
.Nervous system	477
Vascalace 1.25 (DO)	
.Cardiovascular system	137
Vascalace 10 (DO)	
.Cardiovascular system	139
Vascalace 2.5 (DO)	
.Cardiovascular system	138
Vascalace 5 (DO)	
.Cardiovascular system	138
Vasocardol (AV)	
.Cardiovascular system	132
Vasocardol CD (AV)	
.Cardiovascular system	132
Vastin (NM)	
.Cardiovascular system	152
Vedilol 12.5 (QA)	
.Cardiovascular system	128
Vedilol 25 (QA)	
.Cardiovascular system	128
Vedilol 3.125 (QA)	
.Cardiovascular system	128
Vedilol 6.25 (QA)	
.Cardiovascular system	128
Venla RBX (RA)	
.Nervous system	466, 467
Venlafaxine generichealth XR (GQ)	
.Nervous system	466, 467
VENLAFAXINE HYDROCHLORIDE	
.Nervous system	466
Venlafaxine Sandoz XR (SZ)	
.Nervous system	466, 467
Venlexor XR (GM)	
.Nervous system	466, 467
Venofer (AS)	
.Blood and blood forming organs	114
Ventavis (BN)	
.Section 100	598, 744
Ventolin (GK)	
.Respiratory system	487
Ventolin CFC-free (GK)	
.Emergency Drug Supplies	65
.Respiratory system	482
Ventolin Nebules (GK)	
.Emergency Drug Supplies	65, 66
.Respiratory system	483
Ventolin Rotacaps (GK)	
.Respiratory system	482
Vepesid (BQ)	
.Antineoplastic and immunomodulating agents	225
Veracaps SR (QA)	
.Cardiovascular system	131
VERAPAMIL HYDROCHLORIDE	
.Cardiovascular system	131
Vermox (BI)	
.Repatriation Schedule	934
VERTEPORFIN	
.Sensory organs	494
Vexazone (AF)	
.Alimentary tract and metabolism	98, 99
Vfend (PF)	
.Anti-infectives for systemic use	213, 214
Viagra (PF)	
.Repatriation Schedule	921
Vibra-Tabs (PF)	
.Anti-infectives for systemic use	193
Vidaza (CJ)	
.Section 100	620, 621, 767, 768
Videx EC (BQ)	
.Section 100	614, 760
VIGABATRIN	
.Nervous system	426
VILDAGLIPTIN	
.Alimentary tract and metabolism	101
VILDAGLIPTIN with METFORMIN	
.Alimentary tract and metabolism	97
Vimpat (UC)	
.Nervous system	428
VINORELBINE	
.Antineoplastic and immunomodulating agents	224
Viramune (BY)	
.Section 100	617, 764
Viramune XR (BY)	
.Section 100	617, 764
Viread (GI)	
.Section 100	616, 763
Viscopaste 4948 (SN)	
.Repatriation Schedule	944
Viscotears (AQ)	
.Optometrical	568
.Sensory organs	495
Viscotears Gel PF (AQ)	
.Optometrical	568
.Sensory organs	495
Visken 15 (NV)	
.Cardiovascular system	124
Vistide (GI)	
.Section 100	611, 757
Vistil (AE)	
.Optometrical	571
.Sensory organs	499
Vistil Forte (AE)	
.Optometrical	571
.Sensory organs	499
Visudyne (NV)	
.Sensory organs	495
VITAMIN B GROUP COMPLEX	
.Repatriation Schedule	913

GENERIC/PROPRIETARY INDEX

VITAMINS, MINERALS and TRACE ELEMENTS with CARBOHYDRATE	
.Various	518
<i>Vitrasert (BU)</i>	
.Section 100	718, 867
<i>Volibris (GK)</i>	
.Section 100	585, 731
<i>Volirop 12.5 (DO)</i>	
.Cardiovascular system	128
<i>Volirop 25 (DO)</i>	
.Cardiovascular system	129
<i>Volirop 3.125 (DO)</i>	
.Cardiovascular system	128
<i>Volirop 6.25 (DO)</i>	
.Cardiovascular system	128
<i>Voltaren 100 (NV)</i>	
.Dental.....	553
.Musculo-skeletal system.....	391
.Palliative Care	527, 528
<i>Voltaren 25 (NV)</i>	
.Dental.....	553
.Musculo-skeletal system.....	391
.Palliative Care	527, 528
<i>Voltaren 50 (NV)</i>	
.Dental.....	553
.Musculo-skeletal system.....	391
.Palliative Care	527, 528
<i>Voluven 6% (PK)</i>	
.Blood and blood forming organs.....	115
VORICONAZOLE	
.Antifungives for systemic use	213, 214
<i>Voxam (SZ)</i>	
.Nervous system.....	461
<i>Vycin IV (WQ)</i>	
.Antifungives for systemic use	209
.Dental.....	551, 552
<i>Vytorin (MK)</i>	
.Cardiovascular system	163, 164

W

WARFARIN SODIUM	
.Blood and blood forming organs.....	105
<i>Wartec Cream (GK)</i>	
.Repatriation Schedule.....	918
<i>Waxsol (NE)</i>	
.Repatriation Schedule.....	937
<i>Wellvone (GK)</i>	
.Antiparasitic products, insecticides and repellents	479
WHEY PROTEIN FORMULA supplemented with AMINO ACIDS, LONG CHAIN POLYUNSATURATED FATTY ACIDS, VITAMINS and MINERALS, and low in PROTEIN, PHOSPHATE, POTASSIUM and LACTOSE	
.Various	518

WHEY PROTEIN FORMULA supplemented with AMINO ACIDS, VITAMINS and MINERALS, and low in PROTEIN, PHOSPHATE, POTASSIUM and LACTOSE	
.Various	518
WOOL ALCOHOLS	
.Repatriation Schedule.....	917

X

<i>Xalacom (PF)</i>	
.Optometrical.....	568
.Sensory organs.....	492
<i>Xalatan (PF)</i>	
.Optometrical.....	568
.Sensory organs.....	492
<i>Xanax (PF)</i>	
.Nervous system.....	454
<i>Xanax Tri-Score (PF)</i>	
.Nervous system.....	455
<i>Xarelto (BN)</i>	
.Blood and blood forming organs.....	112, 113
<i>Xatral SR (SW)</i>	
.Repatriation Schedule.....	925
<i>Xeloda (RO)</i>	
.Antineoplastic and immunomodulating agents	224
<i>Xenical (RO)</i>	
.Repatriation Schedule.....	913
<i>Xergic (AF)</i>	
.Repatriation Schedule.....	936
<i>Xgeva (AN)</i>	
.Musculo-skeletal system.....	405
<i>XLYS, LOW TRY Maxamaid (SB)</i>	
.Various	513
<i>XMET Maxamaid (SB)</i>	
.Various	514
<i>XMET Maxamum (SB)</i>	
.Various	514
<i>XMTVI Maxamaid (SB)</i>	
.Various	514
<i>XMTVI Maxamum (SB)</i>	
.Various	514
<i>Xolair (NV)</i>	
.Section 100.....	714, 863
<i>XP Maxamaid (SB)</i>	
.Various	514
<i>XP Maxamum (SB)</i>	
.Various	514
<i>XPhen, Tyr Maxamaid (SB)</i>	
.Various	515
<i>XPhen, Tyr Maxamum (SB)</i>	
.Various	515
<i>Xydep 100 (GN)</i>	
.Nervous system.....	463
<i>Xydep 50 (GN)</i>	
.Nervous system.....	462, 463

GENERIC/PROPRIETARY INDEX

<i>Xylocaine Viscous (AP)</i>	
.Repatriation Schedule	918
<i>Xylocard 500 (AP)</i>	
.Cardiovascular system	117

Y

<i>your pharmacy Clear Laxative (OY)</i>	
.Alimentary tract and metabolism	85
.Palliative Care	524

Z

<i>Z.S.C. (QA)</i>	
.Repatriation Schedule	920
<i>Zactin (AF)</i>	
.Nervous system.....	461
<i>Zactin Tablet (AF)</i>	
.Nervous system.....	461
<i>Zan-Extra 10/10 (AB)</i>	
.Cardiovascular system	141
<i>Zan-Extra 10/20 (AB)</i>	
.Cardiovascular system	141
<i>Zanidip (AB)</i>	
.Cardiovascular system	130
<i>Zantac (GK)</i>	
.Alimentary tract and metabolism	72, 73
<i>Zantac Syrup (GK)</i>	
.Alimentary tract and metabolism	73
<i>Zarontin (PF)</i>	
.Nervous system.....	424
<i>Zavedos (PF)</i>	
.Antineoplastic and immunomodulating agents	225
<i>Zedace (AF)</i>	
.Cardiovascular system	132
<i>Zedd 500 (QA)</i>	
.Repatriation Schedule	926
<i>Zeffix (GK)</i>	
.Section 100	615, 762
<i>Zeldox (PF)</i>	
.Nervous system.....	439
<i>Zelitrex (GM)</i>	
.Antiinfectives for systemic use	219, 220
.Section 100	612, 758
<i>Zentel (GK)</i>	
.Antiparasitic products, insecticides and repellents	481
<i>Zerit (BQ)</i>	
.Section 100	615, 762
<i>Zestril (AP)</i>	
.Cardiovascular system	134, 135
<i>Ziagen (VI)</i>	
.Section 100	613, 760
<i>ZIDOVUDINE</i>	
.Section 100	616, 763

<i>Zilarex (SZ)</i>	
.Repatriation Schedule	936
<i>Zilfojim 4 (DO)</i>	
.Alimentary tract and metabolism	82
<i>Zilfojim 8 (DO)</i>	
.Alimentary tract and metabolism	82
<i>Zimstat (AF)</i>	
.Cardiovascular system	156, 157, 158, 159, 160
<i>ZINC OXIDE</i>	
.Repatriation Schedule	915
<i>ZINC OXIDE with STARCH and CHLORPHENESIN</i>	
.Repatriation Schedule	920
<i>Zincaband 3604 (SS)</i>	
.Repatriation Schedule	944
<i>Zinnat (GK)</i>	
.Antiinfectives for systemic use.....	202
.Dental.....	549
<i>ZIPRASIDONE HYDROCHLORIDE</i>	
.Nervous system.....	439
<i>ZipZoc 66051550 (SN)</i>	
.Repatriation Schedule	944
<i>Zircol (AF)</i>	
.Cardiovascular system	130
<i>Zithromax (PF)</i>	
.Antiinfectives for systemic use.....	205
.Repatriation Schedule	926
.Section 100.....	611, 757
.Sensory organs.....	489
<i>Zitrocin (GM)</i>	
.Antiinfectives for systemic use.....	205
.Sensory organs.....	489
<i>Zocor (MK)</i>	
.Cardiovascular system	156, 157, 158, 159, 160
<i>Zofran (GK)</i>	
.Alimentary tract and metabolism	80, 81, 82
<i>Zofran syrup 50 mL (GK)</i>	
.Alimentary tract and metabolism	81, 82
<i>Zofran Zydis (GK)</i>	
.Alimentary tract and metabolism	81, 82, 83
<i>ZolaCos CP 10.8/50(28) (AP)</i>	
.Antineoplastic and immunomodulating agents	246
<i>ZolaCos CP 10.8/50(84) (AP)</i>	
.Antineoplastic and immunomodulating agents	246
<i>ZolaCos CP 3.6/50 (AP)</i>	
.Antineoplastic and immunomodulating agents	246
<i>Zoladex 10.8 Implant (AP)</i>	
.Antineoplastic and immunomodulating agents	246
<i>Zoladex Implant (AP)</i>	
.Antineoplastic and immunomodulating agents	246
<i>ZOLEDRONIC ACID</i>	
.Musculo-skeletal system	401, 402
.Section 100.....	708, 857
<i>ZOLMITRIPTAN</i>	
.Special Pharmaceutical Benefits	68, 69
<i>Zoloft (PF)</i>	

GENERIC/PROPRIETARY INDEX

.Nervous system.....	462, 463	.Nervous system.....	418
<i>Zomacton (FP)</i>		<i>Zydol SR 100 (QA)</i>	
.Section 100	873	.Nervous system.....	419
<i>Zometa (NV)</i>		<i>Zydol SR 150 (QA)</i>	
.Section 100	708, 857	.Nervous system.....	419
<i>Zomig (AP)</i>		<i>Zydol SR 200 (QA)</i>	
.Special Pharmaceutical Benefits	69	.Nervous system.....	419
<i>Zondan (GM)</i>		<i>Zylap 10 (QA)</i>	
.Alimentary tract and metabolism	80, 82	.Nervous system.....	443
<i>Zonegran (SA)</i>		<i>Zylap 2.5 (QA)</i>	
.Nervous system.....	432	.Nervous system.....	441
ZONISAMIDE		<i>Zylap 5 (QA)</i>	
.Nervous system.....	432	.Nervous system.....	441
ZOPICLONE		<i>Zylap 7.5 (QA)</i>	
.Repatriation Schedule	932	.Nervous system.....	442
<i>Zopral (AF)</i>		<i>Zylap ODT 10 (QA)</i>	
.Alimentary tract and metabolism	74, 75	.Nervous system.....	444
<i>Zoton FasTabs (PF)</i>		<i>Zylap ODT 5 (QA)</i>	
.Alimentary tract and metabolism	74, 75	.Nervous system.....	443
<i>Zovirax (GK)</i>		<i>Zyloprim (QA)</i>	
.Optometrical.....	565	.Musculo-skeletal system	397
.Sensory organs.....	489	<i>Zypine (AF)</i>	
<i>Zovirax 200 mg (GK)</i>		.Nervous system.....	441, 442, 443
.Antiinfectives for systemic use	215, 216	<i>Zypine ODT (AF)</i>	
<i>Zovirax 800 mg (GK)</i>		.Nervous system.....	443, 444
.Antiinfectives for systemic use	216	<i>Zyprexa (LY)</i>	
ZUCLOPENTHIXOL DECANOATE		.Nervous system.....	441, 442, 443
.Nervous system.....	440	<i>Zyprexa Relprevv (LY)</i>	
<i>Zumenon (AB)</i>		.Nervous system.....	445
.Genito urinary system and sex hormones	178	<i>Zyprexa Zydys (LY)</i>	
<i>Zyban (GK)</i>		.Nervous system.....	443, 444, 445
.Nervous system.....	476	<i>Zyrtec (JT)</i>	
<i>Zydol (QA)</i>		.Repatriation Schedule	936
.Dental.....	557		

THERAPEUTIC GROUP PREMIUM POLICY

PHARMACEUTICAL BENEFIT ITEMS WHICH HAVE A THERAPEUTIC GROUP PREMIUM WITH EFFECT FROM 1 August 2012

The Schedule of Pharmaceutical Benefits shows differences in price in some therapeutic groups where alternative drugs may have a therapeutic group premium.

The Therapeutic Group Premium Policy applies within narrowly defined therapeutic sub-groups where the drugs concerned are of similar safety and health outcomes.

The Australian Government, through the PBS, subsidises up to the price of the lowest priced drug in the group. This means that consumers may have to pay for more expensive drugs (those with a therapeutic group premium). This extra amount does not count towards their PBS safety net threshold.

Therapeutic group premiums apply where a prescriber has prescribed a drug within a therapeutic group that attracts a therapeutic group premium and has not sought an exemption from Medicare Australia on clinical grounds.

The exemption provisions are:

- adverse effects occurring with all of the base-priced drugs; or
- drug interactions occurring with all of the base-priced drugs; or
- drug interactions expected to occur with all of the base-priced drugs; or
- transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.

The premiums are not a Government charge but reflect the fact that the supplier(s) of the drug charge a price higher than the Government is willing to subsidise.

Under the Therapeutic Group Premium Policy drug substitution by pharmacists is not permitted.

For ease of prescribing and dispensing, and in the interests of your patients, the following list shows those PBS drugs that attract a therapeutic group premium.

Premium Priced Brand	Form and Strength	Max Qty	Therapeutic Group Premium \$
----------------------	-------------------	---------	------------------------------------

H₂-RECEPTOR ANTAGONISTS

<i>Zantac</i>	Effervescent tablet 150 mg (base)	60	3.16
<i>Zantac Syrup</i>	Syrup 150 mg (base) per 10 mL, 300 mL	2	2.20

The base-priced drugs in this therapeutic group are cimetidine, nizatidine and ranitidine hydrochloride (except ranitidine hydrochloride effervescent tablet 150 mg (base) and syrup 150 mg (base) per 10 mL, 300 mL).

ANGIOTENSIN II ANTAGONISTS

Atacand	Tablet 8 mg	30	2.95
Atacand	Tablet 16 mg	30	3.26
Atacand	Tablet 32 mg	30	2.87
Teveten	Tablet 400 mg (base)	56	3.48
Teveten	Tablet 600 mg (base)	28	2.00
Olmotec	Tablet 20 mg	30	1.00
Olmotec	Tablet 40 mg	30	1.00
Micardis	Tablet 40 mg	28	2.00
Micardis	Tablet 80 mg	28	1.99

The base-priced drugs in this therapeutic group are candesartan cilexetil (Tablet 4 mg), irbesartan, and valsartan.

BRAND PREMIUM POLICY

BRANDS OF PHARMACEUTICAL BENEFIT ITEMS WHICH HAVE A BRAND PREMIUM AND THAT MAY BE SUBSTITUTED WITH EFFECT FROM 1 August 2012

The Schedule of Pharmaceutical Benefits shows differences in price between some alternative brands of the same drug product.

Manufacturers can develop generic equivalents and apply to have them listed on the PBS. In doing this, manufacturers need to ensure that they comply with the relevant legislation applicable to patents. These brands are clinically equivalent and must undergo the same strict quality controls. Although these brands are designed to act on the body in exactly the same way, they are usually cheaper than the originator brands.

The Australian Government, through the PBS, subsidises up to the price of the lowest priced brand (except in those instances where the lowest priced brand has, as part of its price, a therapeutic group premium). This means that consumers may have to pay extra for more expensive brands (those with a brand premium). This extra amount does not count towards their PBS safety net threshold.

Brand substitution by pharmacists without reference to the prescriber is permitted for PBS prescriptions where:

- the patient agrees to the substitution;
- the brands are identified in the Schedule of Pharmaceutical Benefits as being interchangeable;
- the prescriber has not indicated on the prescription form that substitution is not to occur; and
- substitution is permitted under the relevant State or Territory legislation.

Prescription forms supplied by Medicare Australia contain a box to be ticked where brand substitution is not to take place.

Prescribers not using these prescription forms should endorse the prescription if brand substitution is not permitted. Where a stamp is used for this purpose, the prescriber will be required to initial the stamped statement.

For ease of prescribing and dispensing, and in the interests of your patients, the following list shows those PBS drugs that attract a brand premium and that can be substituted where permitted. They are listed alphabetically, by brand name, with the brand premium and benchmark brand(s) cited in the last column.

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
<i>Abbacillin-V</i>	Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL	2	1.90	<i>Cilicaine V</i>
<i>Accupril</i>	Tablet 5 mg (as hydrochloride)	30	1.95	<i>Acquin 5; Acquin Aspen 5; APO-Quinapril; Aquinafil; Pharmacor Quinapril 5; Qpril 5; Quinapril generichealth; Quinapril Pfizer; Quinapril Sandoz</i>
	Tablet 10 mg (as hydrochloride)	30	1.95	<i>Acquin 10; Acquin Aspen 10; APO-Quinapril; Aquinafil; Pharmacor Quinapril 10; Qpril 10; Quinapril generichealth; Quinapril Pfizer</i>
	Tablet 20 mg (as hydrochloride)	30	1.95	<i>Acquin 20; Acquin Aspen 20; APO-Quinapril; Aquinafil; Pharmacor Quinapril 20; Qpril 20; Quinapril-GA; Quinapril generichealth; Quinapril Pfizer; Quinapril Sandoz</i>
<i>Adalat 10</i>	Tablet 10 mg	60	0.95	<i>Adefin 10</i>
<i>Adalat 20</i>	Tablet 20 mg	60	1.76	<i>Adefin 20; GenRx Nifedipine; Nifehexal</i>
<i>Adalat Oros 30</i>	Tablet 30 mg (controlled release)	30	2.03	<i>Addos XR 30; Adefin XL 30; APO-Nifedipine XR</i>
<i>Adalat Oros 60</i>	Tablet 60 mg (controlled release)	30	2.24	<i>Addos XR 60; Adefin XL 60; APO-Nifedipine XR</i>
<i>Aldactone</i>	Tablet 25 mg	100	1.75	<i>Spiractin 25</i>
	Tablet 100 mg	100	2.40	<i>Spiractin 100</i>
<i>Aldomet</i>	Tablet 250 mg	100	2.70	<i>Hydopa</i>
<i>Alphagan</i>	Eye drops 2 mg per mL (0.2%), 5 mL	1	1.63	<i>Enidin</i>
<i>Amaryl</i>	Tablet 1 mg	30	2.81	<i>APO-Glimepiride; Aylide 1; Diapride 1; Dimirel; Glimepiride GA 1; Glimepiride Sandoz; Pharmacor Glimepiride 1</i>
	Tablet 2 mg	30	2.81	<i>APO-Glimepiride; Aylide 2; Diapride 2; Dimirel; Glimepiride GA 2; Glimepiride Sandoz; Pharmacor Glimepiride 2</i>
	Tablet 3 mg	30	2.80	<i>APO-Glimepiride; Aylide 3; Diapride 3; Dimirel; Glimepiride GA 3; Glimepiride Sandoz; Pharmacor Glimepiride 3</i>
	Tablet 4 mg	30	2.80	<i>APO-Glimepiride; Aylide 4; Diapride 4; Dimirel; Glimepiride GA 4; Glimepiride Sandoz; Pharmacor Glimepiride 4</i>
<i>Amoxil</i>	Capsule 250 mg	20	0.88	<i>Alphamox 250; Amoxycillin-GA; Amoxycillin Ranbaxy; Amoxycillin Sandoz; APO-Amoxycillin; Chem mart Amoxycillin; Cilamox; GenRx Amoxycillin; Terry White Chemists Amoxycillin</i>
	Capsule 500 mg	20	0.89	<i>Alphamox 500; Amoxycillin-GA; Amoxycillin generichealth 500; Amoxycillin Ranbaxy; Amoxycillin Sandoz; APO-Amoxycillin; Chem mart Amoxycillin; Cilamox; GenRx Amoxycillin; Terry White Chemists Amoxycillin</i>
	Powder for syrup 125 mg per 5 mL, 100 mL	1	0.89	<i>Alphamox 125; Amoxycillin Sandoz; Bgramin; Chem mart Amoxycillin; GenRx Amoxycillin; Ranmoxy; Terry White Chemists Amoxycillin</i>
<i>Amoxil Forte</i>	Powder for syrup 250 mg per 5 mL, 100 mL	1	0.87	<i>Alphamox 250; Amoxycillin Sandoz; Bgramin; Chem mart Amoxycillin; Cilamox; GenRx Amoxycillin; Ranmoxy; Terry White Chemists Amoxycillin</i>
<i>Anafranil 25</i>	Tablet 25 mg	50	3.06	<i>Chem mart Clomipramine; GenRx Clomipramine; Placil; Terry White Chemists Clomipramine</i>
<i>Anaprox 550</i>	Tablet 550 mg	50	2.17	<i>Crysanal</i>
<i>Androcur</i>	Tablet 50 mg	20	2.50	<i>Cyprohexal; Cyprone; Cyprostat; GenRx Cyproterone Acetate; Procur</i>
	Tablet 50 mg	100	2.62	<i>Cyprohexal; Cyprone; Cyprostat; GenRx Cyproterone Acetate; Procur</i>
<i>Androcur-100</i>	Tablet 100 mg	50	1.31	<i>Cyprocur 100; Cyprohexal; Cyprostat-100; GenRx Cyproterone Acetate; Procur 100</i>
<i>Anginine Stabilised</i>	Tablets 600 micrograms, 100	1	2.94	<i>Lycinate</i>
<i>Aristocort 0.02%</i>	Cream 200 micrograms per g (0.02%), 100 g	2	3.78	<i>Tricortone</i>

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
<i>Aropax</i>	Ointment 200 micrograms per g (0.02%), 100 g	2	3.78	<i>Tricortone</i>
	Tablet 20 mg (as hydrochloride)	30	0.80	<i>Chem mart Paroxetine; Extine 20; GenRx Paroxetine; Paroxetine 20; Paroxetine-GA; Paroxetine Sandoz; Paxtine; Roxet 20; Terry White Chemists Paroxetine</i>
<i>Astrix</i>	Tablet 100 mg	112	1.08	<i>Mayne Pharma Aspirin; Spren 100</i>
<i>Atrovent</i>	Nebuliser solution single dose units 250 micrograms (anhydrous) in 1 mL, 30	2	0.68	<i>Aeron 250; APO-Ipratropium; Ipratrin; Ipravent</i>
<i>Atrovent Adult</i>	Nebuliser solution single dose units 500 micrograms (anhydrous) in 1 mL, 30	2	0.58	<i>Aeron 500; APO-Ipratropium; Ipratrin Adult; Ipravent</i>
<i>Augmentin</i>	Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL	1	1.58	<i>Clamoxyl; Curam</i>
<i>Augmentin Duo</i>	Tablet 500 mg-125 mg	10	1.57	<i>Amoxycillin/ Clavulanic Acid 500/125 generichealth; APO-Amoxycillin/ Clavulanic Acid 500/125; Clamoxyl Duo; Curam Duo 500/125; GA-Amclav 500/125; Moxiclav Duo 500/125</i>
<i>Augmentin Duo 400</i>	Powder for syrup 400 mg-57 mg per 5 mL, 60 mL	1	1.58	<i>Clamoxyl Duo 400; Curam Duo</i>
<i>Augmentin Duo forte</i>	Tablet 875 mg-125 mg	10	1.56	<i>Amoxycillin/ Clavulanic Acid 875/125 generichealth; Chem mart Amoxycillin and Clavulanic Acid; Clamoxyl Duo forte; Clavycillin 875/125; Curam Duo Forte 875/125; GA-Amclav Forte 875/125; GenRx Amoxycillin and Clavulanic Acid; Moxiclav Duo Forte 875/125; Terry White Chemists Amoxycillin and Clavulanic Acid</i>
<i>Aurorix</i>	Tablet 150 mg	60	0.55	<i>Amira 150; Chem mart Moclobemide; Clobemix; GenRx Moclobemide; Moclobemide-PS; Moclobemide Sandoz; Mohexal; Terry White Chemists Moclobemide</i>
<i>Aurorix 300 mg</i>	Tablet 300 mg	60	1.10	<i>Amira 300; Chem mart Moclobemide; Clobemix; GenRx Moclobemide; Moclobemide-PS; Moclobemide Sandoz; Terry White Chemists Moclobemide</i>
<i>Avanza</i>	Tablet 30 mg	30	3.50	<i>Aurozapine 30; Axit 30; Chem mart Mirtazapine; GenRx Mirtazapine; Mirtazapine-DP; Mirtazapine GH; Mirtazapine Sandoz; Mirtazon; Terry White Chemists Mirtazapine</i>
	Tablet 45 mg	30	3.51	<i>APO-Mirtazapine; Aurozapine 45; Axit 45; Chem mart Mirtazapine; Mirtazapine GH; Mirtazapine Sandoz; Mirtazon; Terry White Chemists Mirtazapine</i>
<i>Azopt</i>	Eye drops 10 mg per mL (1%), 5 mL	1	1.18	<i>BrinzoQuin</i>
<i>Betaloc</i>	Tablet 50 mg	100	2.51	<i>Chem mart Metoprolol; GenRx Metoprolol; Metohexal; Metrol 50; Minax 50; Terry White Chemists Metoprolol</i>
	Tablet 100 mg	60	2.50	<i>Chem mart Metoprolol; GenRx Metoprolol; Metohexal; Metrol 100; Minax 100; Terry White Chemists Metoprolol</i>
<i>Betnovate 1/2</i>	Cream 500 micrograms (base) per g (0.05%), 15 g	1	2.94	<i>Cortival 1/2</i>
	Ointment 500 micrograms (base) per g (0.05%), 15 g	1	2.94	<i>Cortival 1/2</i>
<i>Betnovate 1/5</i>	Cream 200 micrograms (base) per g (0.02%), 100 g	2	6.88	<i>Cortival 1/5</i>
<i>Betoptic</i>	Eye drops, solution, 5 mg (base) per mL (0.5%), 5 mL	1	2.09	<i>BetoQuin</i>
<i>Brevinor</i>	Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets	4	7.68	<i>Norimin 28 Day</i>
<i>Brevinor-1</i>	Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets	4	7.68	<i>Norimin-1 28 Day</i>
<i>Capoten</i>	Tablet 25 mg	90	6.92	<i>Captopril Sandoz; GenRx Captopril; Zedace</i>
	Tablet 50 mg	90	5.38	<i>Captopril Sandoz; GenRx Captopril; Zedace</i>
<i>Carafate</i>	Tablet equivalent to 1 g anhydrous sucralfate	120	2.06	<i>Ulcyte</i>
<i>Ceclor</i>	Powder for oral suspension 125 mg per 5 mL, 100 mL	1	4.83	<i>Aclor 125; Cefaclor Sandoz; Chem mart</i>

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
	Powder for oral suspension 250 mg per 5 mL, 75 mL	1	5.08	Cefaclor; GenRx Cefaclor; Keflor; Ozcef; Terry White Chemists Cefaclor
Ceclor CD	Tablet 375 mg (sustained release)	10	6.16	Aclor 250; Cefaclor Sandoz; Chem mart Cefaclor; GenRx Cefaclor; Keflor; Ozcef; Terry White Chemists Cefaclor
Celestone-M	Cream 200 micrograms (base) per g (0.02%), 100 g	2	2.46	Cefaclor-GA; Cefaclor GH; Chem mart Cefaclor CD; GenRx Cefaclor CD; Karlor CD; Keflor CD; Ozcef; Terry White Chemists Cefaclor CD
	Ointment 200 micrograms (base) per g (0.02%), 100 g	2	2.46	Antroquoril
Ciloxan	Eye drops 3 mg per mL (0.3%), 5 mL	2	2.06	Antroquoril
Cipramil	Tablet 20 mg (base)	28	4.45	CiloQuin
				A-Citalopram; APO-Citalopram; Auro-Citalopram 20; Celapram; Celica; Chem mart Citalopram; Ciazil; Citalopram 20; Citalopram-GA; Citalopram generichealth; Citalopram Pfizer; Citalopram Sandoz; GenRx Citalopram; Pharmacor Citalo 20; Talam; Terry White Chemists Citalopram
Ciproxin 250	Tablet 250 mg	14	0.79	C-Flox 250; Cifran; Ciprofloxacin-DRLA; Ciprofloxacin Sandoz; Ciprol 250; GenRx Ciprofloxacin; Profloxin
Ciproxin 500	Tablet 500 mg	14	0.79	C-Flox 500; Cifran; Ciprofloxacin 500; Ciprofloxacin-BW; Ciprofloxacin-DRLA; Ciprofloxacin-GA; Ciprofloxacin-PS; Ciprofloxacin Sandoz; Ciprol 500; GenRx Ciprofloxacin; Loxip 500
Ciproxin 750	Tablet 750 mg	14	0.78	C-Flox 750; Cifran; Ciprofloxacin 750; Ciprofloxacin-BW; Ciprofloxacin-DRLA; Ciprofloxacin-GA; Ciprofloxacin-PS; Ciprofloxacin Sandoz; Ciprol 750; GenRx Ciprofloxacin; Loxip 750
Colgout	Tablet 500 micrograms	30	0.85	Lengout
Dalacin C	Capsule 150 mg	24	1.37	Cleacin
Daonil	Tablet 5 mg	100	1.44	Glimel
Depo-Medrol	Injection 40 mg in 1 mL	5	0.96	Depo-Nisolone
Depo-Provera	Injection 150 mg in 1 mL	1	3.20	Depo-Ralovera
Diabex	Tablet 500 mg	100	1.41	APO-Metformin 500; Chem mart Metformin; Diaformin; Formet 500; Formet Aspen 500; GenRx Metformin; Glucobete 500; Glucophage; Metformin 500; Metformin-GA; Metformin generichealth; Metformin Pfizer; Metformin Ranbaxy; Metformin Sandoz; Terry White Chemists Metformin
Diabex 1000	Tablet 1 g	90	1.43	APO-Metformin 1000; Chem mart Metformin 1000; Diaformin 1000; Formet 1000; Glucobete 1000; Metformin-GA; Metformin generichealth 1000; Metformin Pfizer; Metformin Ranbaxy 1000; Metformin Sandoz; Pharmacor Metformin 1000; Terry White Chemists Metformin 1000
Diabex 850	Tablet 850 mg	60	1.41	APO-Metformin 850; Chem mart Metformin; Diaformin 850; Formet 850; Formet Aspen 850; GenRx Metformin; Glucobete 850; Glucophage; Metformin 850; Metformin-GA; Metformin generichealth; Metformin Pfizer; Metformin Ranbaxy; Metformin Sandoz; Terry White Chemists Metformin
Diprosone	Cream 500 micrograms (base) per g (0.05%), 15 g	1	2.45	Eleuphrat
	Ointment 500 micrograms (base) per g (0.05%), 15 g	1	2.45	Eleuphrat
Doryx	Capsule 100 mg (as hydrochloride)	7	2.86	Mayne Pharma Doxycycline
	Capsule 50 mg (as hydrochloride)	25	2.91	Mayne Pharma Doxycycline
	Capsule 100 mg (as hydrochloride)	28	11.44	Mayne Pharma Doxycycline
	Capsule 100 mg (as hydrochloride)	21	3.89	Mayne Pharma Doxycycline

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
<i>Dulcolax</i>	Suppositories 10 mg, 10	3	1.50	<i>Petrus Bisacodyl Suppositories</i>
<i>Duphalac</i>	Mixture 3.34 g per 5 mL, 500 mL	1	1.20	<i>Actilax; Genlac; GenRx Lactulose; Lac-Dol; Lactocur</i>
	Mixture 3.34 g per 5 mL, 500 mL	3	3.60	<i>Actilax; Genlac; GenRx Lactulose; Lac-Dol; Lactocur</i>
<i>Duratears</i>	Compound eye ointment 3.5 g	2	2.54	<i>Poly Visc</i>
<i>E.E.S. 200</i>	Powder for oral liquid 200 mg (base) per 5 mL, 100 mL	1	2.71	<i>E-Mycin 200</i>
<i>E.E.S. 400 Filmstab</i>	Tablet 400 mg (base)	25	2.66	<i>E-Mycin</i>
<i>E.E.S. Granules</i>	Powder for oral liquid 400 mg (base) per 5 mL, 100 mL	1	2.73	<i>E-Mycin 400</i>
<i>Elocon</i>	Cream 1 mg per g (0.1%), 15 g	1	2.45	<i>Novasone</i>
	Ointment 1 mg per g (0.1%), 15 g	1	2.45	<i>Novasone</i>
	Lotion 1 mg per g (0.1% w/w), 30 mL	1	2.45	<i>Novasone</i>
<i>Epilim EC</i>	Tablet 200 mg (enteric coated)	200	2.00	<i>Sodium Valproate Sandoz; Valprease 200; Valpro 200; Valproate Winthrop EC 200</i>
	Tablet 500 mg (enteric coated)	200	2.00	<i>Sodium Valproate Sandoz; Valprease 500; Valpro 500; Valproate Winthrop EC 500</i>
<i>Eryc</i>	Capsule 250 mg	25	2.91	<i>Mayne Pharma Erythromycin</i>
<i>Fasigyn</i>	Tablet 500 mg	4	2.42	<i>Simplotan</i>
<i>Feldene</i>	Capsule 10 mg	50	2.52	<i>Chem mart Piroxicam; GenRx Piroxicam; Mobilis 10; Terry White Chemists Piroxicam</i>
	Capsule 20 mg	25	2.49	<i>Chem mart Piroxicam; GenRx Piroxicam; Mobilis 20; Terry White Chemists Piroxicam</i>
<i>Feldene-D</i>	Dispersible tablet 20 mg	25	2.95	<i>Mobilis D-20</i>
<i>Flagyl</i>	Tablet 400 mg	21	2.30	<i>Metrogyl 400; Metronide 400</i>
	Tablet 200 mg	21	2.30	<i>Metrogyl 200; Metronide 200</i>
<i>Fosamax Once Weekly</i>	Tablet equivalent to 70 mg alendronic acid	4	2.50	<i>Adronat; Alendrobell 70mg; Alendronate-GA; Alendronate Sandoz; Alendro Once Weekly; APO-Alendronate; Chem mart Alendronate 70mg; Densate 70; Ossmax 70mg; Terry White Chemists Alendronate 70mg</i>
<i>Fosamax Plus 70 mg/140 mcg</i>	Tablet equivalent to 70 mg alendronic acid with 140 micrograms colecalciferol	4	2.50	<i>Dronalen Plus</i>
<i>Genteal</i>	Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative)	1	1.95	<i>In a Wink Moisturising</i>
<i>Genteal gel</i>	Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g	1	1.95	<i>HPMC PAA</i>
<i>Glucophage</i>	Tablet 500 mg	100	0.87	<i>APO-Metformin 500; Chem mart Metformin; Diabex; Diaformin; Formet 500; Formet Aspen 500; GenRx Metformin; Glucobete 500; Metformin 500; Metformin-GA; Metformin generichealth; Metformin Pfizer; Metformin Ranbaxy; Metformin Sandoz; Terry White Chemists Metformin</i>
	Tablet 850 mg	60	0.87	<i>APO-Metformin 850; Chem mart Metformin; Diabex 850; Diaformin 850; Formet 850; Formet Aspen 850; GenRx Metformin; Glucobete 850; Metformin 850; Metformin-GA; Metformin generichealth; Metformin Pfizer; Metformin Ranbaxy; Metformin Sandoz; Terry White Chemists Metformin</i>
<i>Gopten</i>	Capsule 500 micrograms	28	1.39	<i>APO-Trandolapril; Dolapril 0.5; Tranalpha; Trandolapril-DP; Trandolapril generichealth</i>
	Capsule 1 mg	28	1.41	<i>APO-Trandolapril; Dolapril 1; Tranalpha; Trandolapril-DP; Trandolapril generichealth</i>
	Capsule 2 mg	28	3.00	<i>APO-Trandolapril; Dolapril 2; Tranalpha; Trandolapril-DP; Trandolapril generichealth</i>
	Capsule 4 mg	28	3.00	<i>APO-Trandolapril; Dolapril 4; Tranalpha; Trandolapril-DP; Trandolapril generichealth</i>

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
<i>Imdur 120 mg</i>	Tablet 120 mg (sustained release)	30	2.55	<i>Monodur 120 mg</i>
<i>Imdur Durule</i>	Tablet 60 mg (sustained release)	30	2.41	<i>Chem mart Isosorbide Mononitrate; Duride; GenRx Isosorbide Mononitrate; Imtrate 60 mg; Isomonit; Monodur 60 mg; Terry White Chemists Isosorbide Mononitrate</i>
<i>Imigran</i>	Tablet 50 mg (as succinate)	4	1.84	<i>APO-Sumatriptan; Chem mart Sumatriptan; Sumagran 50; Sumagran Aspen 50; Sumatab; Terry White Chemists Sumatriptan</i>
<i>Imodium</i>	Capsule 2 mg	12	0.89	<i>Gastro-Stop Loperamide</i>
<i>Indocid</i>	Capsule 25 mg	100	2.02	<i>Arthrexin</i>
<i>Isoptin</i>	Tablet 40 mg	100	0.73	<i>Anpec 40</i>
	Tablet 80 mg	100	0.71	<i>Anpec 80</i>
<i>Isoptin 180 SR</i>	Tablet 180 mg (sustained release)	30	3.50	<i>Cordilox 180 SR</i>
<i>Isoptin SR</i>	Tablet 240 mg (sustained release)	30	3.50	<i>Cordilox SR</i>
<i>Keflex</i>	Capsule 250 mg	20	3.94	<i>Cefalexin Sandoz; Cephalexin generichealth; Cephalexin-PS; Cephatrust 250; Chem mart Cephalexin; Cilex; GenRx Cephalexin; Ialex; Ibilex 250; Pharmacor Cephalexin 250; Rancef; Terry White Chemists Cephalexin</i>
	Capsule 500 mg	20	5.65	<i>Cefalexin Sandoz; Cephalexin generichealth; Cephalexin-PS; Cephatrust 500; Chem mart Cephalexin; Cilex; GenRx Cephalexin; Ialex; Ibilex 500; Pharmacor Cephalexin 500; Rancef; Terry White Chemists Cephalexin</i>
	Granules for syrup 125 mg per 5 mL, 100 mL	1	4.34	<i>APO-Cephalexin; Cefalexin Sandoz; Chem mart Cephalexin; Cilex; GenRx Cephalexin; Ialex; Ibilex 125; Terry White Chemists Cephalexin</i>
	Granules for syrup 250 mg per 5 mL, 100 mL	1	5.58	<i>APO-Cephalexin; Cefalexin Sandoz; Chem mart Cephalexin; Cilex; GenRx Cephalexin; Ialex; Ibilex 250; Terry White Chemists Cephalexin</i>
<i>Kenacomb Otic</i>	Ear drops 1 mg-2.5 mg (base)- 250 micrograms-100,000 units per g (0.1%-0.25%-0.025%-100,000 units per g), 7.5 mL	1	1.95	<i>Otocomb Otic</i>
	Ear ointment 1 mg-2.5 mg (base)- 250 micrograms-100,000 units per g (0.1%-0.25%-0.025%-100,000 units per g), 5 g	1	1.95	<i>Otocomb Otic</i>
<i>Klacid</i>	Tablet 250 mg	14	1.50	<i>APO-Clarithromycin; Chem mart Clarithromycin; Clarac; Clarihexal; Clarithro 250; GenRx Clarithromycin; Kalixocin; Terry White Chemists Clarithromycin</i>
<i>Lacri-Lube</i>	Pack containing 2 tubes compound eye ointment 3.5 g	1	2.12	<i>Ircal</i>
<i>Lamictal</i>	Tablet 5 mg	56	1.85	<i>Lamogine; Seaze 5</i>
	Tablet 25 mg	56	1.86	<i>APO-Lamotrigine; GenRx Lamotrigine; Lamidus; Lamogine; Lamotrigine-GA; Lamotrigine generichealth; Lamotrigine-PS; Lamotrigine Sandoz; Lamotrust 25; Seaze 25; Torlemo DT 25</i>
	Tablet 50 mg	56	2.14	<i>APO-Lamotrigine; GenRx Lamotrigine; Lamidus; Lamogine; Lamotrigine-GA; Lamotrigine generichealth; Lamotrigine-PS; Lamotrigine Sandoz; Lamotrust 50; Seaze 50; Torlemo DT 100</i>
	Tablet 100 mg	56	1.69	<i>APO-Lamotrigine; GenRx Lamotrigine; Lamidus; Lamogine; Lamotrigine-GA; Lamotrigine generichealth; Lamotrigine-PS; Lamotrigine Sandoz; Lamotrust 100; Seaze 100; Torlemo DT 100</i>
	Tablet 200 mg	56	1.85	<i>APO-Lamotrigine; GenRx Lamotrigine; Lamidus; Lamogine; Lamotrigine-GA; Lamotrigine generichealth; Lamotrigine-PS; Lamotrigine Sandoz;</i>

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
				Lamotrust 200; Seaze 200; Torlemo DT 200
Lanoxin	Tablet 250 micrograms	100	2.94	Sigmaxin
Lanoxin-PG	Tablet 62.5 micrograms	200	2.95	Sigmaxin-PG
Lasix	Tablet 40 mg	100	2.40	Chem mart Frusemide; Frusax; Frusemide-PS; Frusemide Sandoz; Frusid; GenRx Frusemide; Terry White Chemists Frusemide; Uremide
Lasix-M	Tablet 20 mg	100	1.92	Urex-M
Lexapro	Tablet 10 mg (as oxalate)	28	2.97	APO-Escitalopram; Chem mart Escitalopram; Escicor 10; Escitalopram-DRLA; Escitalopram GA; Escitalopram generichealth; Esipram; Esitalo; Lexam 10; LoxaLate; Pharmacor Escitalopram 10; Terry White Chemists Escitalopram
	Tablet 20 mg (as oxalate)	28	4.33	APO-Escitalopram; Chem mart Escitalopram; Escicor 20; Escitalopram-DRLA; Escitalopram GA; Escitalopram generichealth; Esipram; Esitalo; Lexam 20; LoxaLate; Pharmacor Escitalopram 20; Terry White Chemists Escitalopram
Lioresal 10	Tablet 10 mg	100	1.50	Chem mart Baclofen; Clofen 10; GenRx Baclofen; Stelax 10; Terry White Chemists Baclofen
Lioresal 25	Tablet 25 mg	100	1.29	Chem mart Baclofen; Clofen 25; GenRx Baclofen; Stelax 25; Terry White Chemists Baclofen
Lipex 10	Tablet 10 mg	30	3.33	APO-Simvastatin; Auro-Simvastatin 10; Chem mart Simvastatin; GenRx Simvastatin; Pharmacor Simvastatin 10; Ransim; Simvacor 10; Simvahexal; Simvar 10; Simvastatin-DP; Simvastatin-DRLA; Simvastatin-GA 10; Simvastatin generichealth; Simvastatin Pfizer; Simvastatin Sandoz; Simvastatin-Spirit 10; Simvastatin Winthrop; Synthon Simvastatin; Terry White Chemists Simvastatin; Zimstat; Zocor
Lipex 20	Tablet 20 mg	30	3.31	APO-Simvastatin; Auro-Simvastatin 20; Chem mart Simvastatin; GenRx Simvastatin; Pharmacor Simvastatin 20; Ransim; Simvacor 20; Simvahexal; Simvar 20; Simvastatin-DP; Simvastatin-DRLA; Simvastatin-GA 20; Simvastatin generichealth; Simvastatin Pfizer; Simvastatin Sandoz; Simvastatin-Spirit 20; Simvastatin Winthrop; Synthon Simvastatin; Terry White Chemists Simvastatin; Zimstat; Zocor
Lipex 40	Tablet 40 mg	30	3.32	APO-Simvastatin; Auro-Simvastatin 40; Chem mart Simvastatin; GenRx Simvastatin; Pharmacor Simvastatin 40; Ransim; Simvacor 40; Simvar 40; Simvastatin-DP; Simvastatin-DRLA; Simvastatin-GA 40; Simvastatin generichealth; Simvastatin Pfizer; Simvastatin Sandoz; Simvastatin-Spirit 40; Simvastatin Winthrop; Synthon Simvastatin; Terry White Chemists Simvastatin; Zimstat; Zocor
Lipex 80	Tablet 80 mg	30	3.32	APO-Simvastatin; Auro-Simvastatin 80; Chem mart Simvastatin; GenRx Simvastatin; Pharmacor Simvastatin 80; Ransim; Simvacor 80; Simvar 80; Simvastatin-DP; Simvastatin-DRLA; Simvastatin-GA 80; Simvastatin generichealth; Simvastatin Pfizer;

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
				<i>Simvastatin Sandoz; Simvastatin-Spirit 80; Simvastatin Winthrop; Synthon Simvastatin; Terry White Chemists Simvastatin; Zimstat; Zocor</i>
<i>Liquifilm Forte</i>	Eye drops 30 mg per mL (3%), 15 mL	1	5.59	<i>PVA Forte</i>
<i>Liquifilm Tears</i>	Eye drops 14 mg per mL (1.4%), 15 mL	1	1.60	<i>PVA Tears</i>
<i>Lomotil</i>	Tablet 2.5 mg-25 micrograms	20	1.72	<i>Lofenoxal</i>
<i>Lopid</i>	Tablet 600 mg	60	1.98	<i>Ausgem; Chem mart Gemfibrozil; Gemhexal; GenRx Gemfibrozil; Jezil; Lipazil 600 mg; Lipigem; Pharmacor Gemfibrozil 600; Terry White Chemists Gemfibrozil</i>
<i>LOSEC Tablets</i>	Tablet 20 mg (as magnesium)	30	2.23	<i>Acimax Tablets; Omepral; Omeprazole Sandoz</i>
<i>Luvox</i>	Tablet containing fluvoxamine maleate 50 mg	30	2.30	<i>APO-Fluvoxamine; Faverin 50; Fluvoxamine GA; Movox 50; Voxam</i>
	Tablet containing fluvoxamine maleate 100 mg	30	2.30	<i>APO-Fluvoxamine; Faverin 100; Fluvoxamine GA; Movox 100; Voxam</i>
<i>Maxamox</i>	Tablet 1 g	14	0.73	<i>Amoxycillin Sandoz</i>
<i>Microgynon 30 ED</i>	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	4	13.59	<i>Levlen ED</i>
<i>Minidiab</i>	Tablet 5 mg	100	3.83	<i>Melizide</i>
<i>Minomycin-50</i>	Tablet 50 mg	60	1.89	<i>Akamin 50</i>
<i>Mobic</i>	Tablet 7.5 mg	30	1.35	<i>Chem mart Meloxicam 7.5 mg; GenRx Meloxicam; Meloxicbell; Meloxicam-GA; Meloxicam-PS; Meloxicam Ranbaxy; Meloxicam Sandoz; Movalis 7.5; Moxicam 7.5; Pharmacor Meloxicam 7.5; Terry White Chemists Meloxicam 7.5 mg</i>
	Tablet 15 mg	30	1.34	<i>Chem mart Meloxicam 15 mg; GenRx Meloxicam; Meloxicbell; Meloxicam-GA; Meloxicam-PS; Meloxicam Ranbaxy; Meloxicam Sandoz; Movalis 15; Moxicam 15; Pharmacor Meloxicam 15; Terry White Chemists Meloxicam 15 mg</i>
<i>Mogadon</i>	Tablet 5 mg	50	2.90	<i>Alodorm</i>
	Tablet 5 mg	25	1.45	<i>Alodorm</i>
<i>Naprosyn</i>	Tablet 250 mg	100	2.24	<i>Inza 250</i>
	Tablet 500 mg	50	1.30	<i>Inza 500</i>
<i>Naprosyn SR1000</i>	Tablet 1 g (sustained release)	28	1.29	<i>Proxen SR 1000</i>
<i>Naprosyn SR750</i>	Tablet 750 mg (sustained release)	28	1.22	<i>Proxen SR 750</i>
<i>Natrilix</i>	Tablet 2.5 mg	90	2.04	<i>Chem mart Indapamide; Dapa-Tabs; GenRx Indapamide; Indapamide-GA; Indapamide-PS; Indapamide Sandoz; Insig; Terry White Chemists Indapamide</i>
<i>Neurontin</i>	Capsule 100 mg	100	1.95	<i>APO-Gabapentin; DBL Gabapentin; Gabatine 100; Nupentin 100</i>
	Capsule 300 mg	100	1.95	<i>DBL Gabapentin; Gabapentin 300; Gabapentin-GA; Gabapentin Sandoz; Gabatine 300; Gantin; GenRx Gabapentin; Nupentin 300</i>
	Capsule 400 mg	100	1.95	<i>DBL Gabapentin; Gabapentin 400; Gabapentin Sandoz; Gabatine 400; Gantin; GenRx Gabapentin; Nupentin 400</i>
	Tablet 600 mg	100	1.96	<i>Gabaran; Gabatine 600; GenRx Gabapentin; Nupentin Tabs; Pharmacor Gabapentin 600</i>
	Tablet 800 mg	100	1.95	<i>Gabaran; Gabatine 800; Gantin; GenRx Gabapentin; Nupentin Tabs; Pharmacor Gabapentin 800</i>
<i>Nordette 28</i>	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	4	13.55	<i>Monofeme 28</i>
<i>Noriday 28 Day</i>	Tablets 350 micrograms, 28	4	3.88	<i>Locilan 28 Day</i>
<i>Normison</i>	Tablet 10 mg	25	2.05	<i>APO-Temazepam; Temaze; Temtabs</i>
	Tablet 10 mg	50	4.10	<i>APO-Temazepam; Temaze; Temtabs</i>
<i>Noroxin</i>	Tablet 400 mg	14	3.91	<i>Chem mart Norfloxacin; GenRx Norfloxacin; Norfloxacin-GA;</i>

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
Norvasc	Tablet 5 mg (as besylate)	30	3.75	Norfloxacin-PS; Norfloxacin Sandoz; Nufloxib; Roxin; Terry White Chemists Norfloxacin
	Tablet 10 mg (as besylate)	30	5.50	Amlodipine-DRLA; Amlodipine-GA; Amlodipine generichealth; Amlodipine Pfizer; Amlodipine Sandoz; APO-Amlodipine; Auro-Amlodipine 5; Chem mart Amlodipine; Nordip; Norvapine; Ozlodip; Pharmacor Amlodipine 5; Terry White Chemists Amlodipine Amlodipine-DRLA; Amlodipine-GA; Amlodipine generichealth; Amlodipine Pfizer; Amlodipine Sandoz; APO-Amlodipine; Auro-Amlodipine 10; Chem mart Amlodipine; Nordip; Norvapine; Ozlodip; Pharmacor Amlodipine 10; Terry White Chemists Amlodipine
Oroxine	Tablet equivalent to 50 micrograms anhydrous thyroxine sodium	200	2.21	Eutroxsig
	Tablet equivalent to 75 micrograms anhydrous thyroxine sodium	200	2.27	Eutroxsig
	Tablet equivalent to 100 micrograms anhydrous thyroxine sodium	200	2.21	Eutroxsig
	Tablet equivalent to 200 micrograms anhydrous thyroxine sodium	200	2.21	Eutroxsig
Orudis SR 200 Panadeine Forte	Capsule 200 mg (sustained release)	28	2.21	Oruvail SR
	Tablet 30 mg-500 mg	20	2.80	APO- Paracetamol/Codeine 500/30; Codalgin Forte; Codapane Forte; Comfarol Forte; Prodeine Forte
	Tablet 30 mg-500 mg	60	8.40	APO- Paracetamol/Codeine 500/30; Codalgin Forte; Codapane Forte; Comfarol Forte; Prodeine Forte
Panafcort	Tablet 1 mg	100	0.61	Predsona
Panafcortelone	Tablet 1 mg	100	0.44	Predsolone
Pepcidine	Tablet 40 mg	30	3.84	Ausfam 40; Chem mart Famotidine; Famotidine Sandoz; GenRx Famotidine; Pamacid 40; Pepzan; Terry White Chemists Famotidine
Plendil ER	Tablet 2.5 mg (extended release)	30	4.06	Felodur ER 2.5 mg
	Tablet 5 mg (extended release)	30	4.07	Felodil XR 5; Felodur ER 5 mg
	Tablet 10 mg (extended release)	30	4.08	Felodil XR 10; Felodur ER 10 mg
Pravachol	Tablet containing pravastatin sodium 10 mg	30	4.00	APO-Pravastatin; Chem mart Pravastatin; Cholstat 10; GenRx Pravastatin; Lipostat 10; Pharmacor Pravastat 10; Pravastatin Actavis 10; Pravastatin-GA 10; Pravastatin generichealth; Pravastatin-PS; Pravastatin Sandoz; Pravastatin Winthrop; Terry White Chemists Pravastatin
	Tablet containing pravastatin sodium 20 mg	30	3.99	APO-Pravastatin; Chem mart Pravastatin; Cholstat 20; Cholvastin; GenRx Pravastatin; Lipostat 20; Pharmacor Pravastat 20; Pravastatin Actavis 20; Pravastatin-GA 20; Pravastatin generichealth; Pravastatin-PS; Pravastatin Sandoz; Pravastatin Winthrop; Terry White Chemists Pravastatin
	Tablet containing pravastatin sodium 40 mg	30	4.26	APO-Pravastatin; Chem mart Pravastatin; Cholstat 40; Cholvastin; GenRx Pravastatin; Lipostat 40; Pharmacor Pravastat 40; Pravastatin Actavis 40; Pravastatin-GA 40; Pravastatin generichealth; Pravastatin-PS; Pravastatin Sandoz; Pravastatin Winthrop; Terry White Chemists Pravastatin
	Tablet containing pravastatin sodium 80 mg	30	4.25	APO-Pravastatin; Chem mart Pravastatin; Lipostat 80; Pravastatin-

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
<i>Prinivil 10</i>	Tablet 10 mg	30	3.76	GA 80; Pravastatin generichealth; Pravastatin-PS; Pravastatin Sandoz; Terry White Chemists Pravastatin APO-Lisinopril; Chem mart Lisinopril; Fibsol 10; GenRx Lisinopril; Lisinopril 10; Lisinopril-DRLA; Lisinopril-GA; Lisinopril generichealth; Lisinopril-PS; Lisinopril Ranbaxy; Lisinopril Sandoz; Lisodur; Terry White Chemists Lisinopril; Zestril
<i>Prinivil 20</i>	Tablet 20 mg	30	3.75	APO-Lisinopril; Chem mart Lisinopril; Fibsol 20; GenRx Lisinopril; Lisinopril 20; Lisinopril-DRLA; Lisinopril-GA; Lisinopril generichealth; Lisinopril-PS; Lisinopril Ranbaxy; Lisinopril Sandoz; Lisodur; Terry White Chemists Lisinopril; Zestril
<i>Prinivil 5</i>	Tablet 5 mg	30	3.74	APO-Lisinopril; Chem mart Lisinopril; Fibsol 5; GenRx Lisinopril; Lisinopril 5; Lisinopril-DRLA; Lisinopril-GA; Lisinopril generichealth; Lisinopril-PS; Lisinopril Ranbaxy; Lisinopril Sandoz; Lisodur; Terry White Chemists Lisinopril; Zestril
<i>Provera</i>	Tablet 10 mg	100	1.95	Ralovera
	Tablet 5 mg	56	1.95	Ralovera
	Tablet 10 mg	30	1.95	Medroxyprogesterone Sandoz; Ralovera
<i>Prozac 20</i>	Capsule 20 mg (as hydrochloride)	28	3.53	Auscip; Chem mart Fluoxetine; Fluoxetine 20; Fluoxetine-GA; Fluoxetine generichealth; Fluoxetine-PS; Fluoxetine RBX; Fluoxetine Sandoz; GenRx Fluoxetine; Lovan; Terry White Chemists Fluoxetine; Zactin
<i>Prozac Tab</i>	Tablet, dispersible, 20 mg (as hydrochloride)	28	3.53	Lovan 20 Tab; Zactin Tablet
<i>Redipred</i>	Oral solution equivalent to 5 mg prednisolone per mL, 30 mL	1	2.36	PredMix
<i>Renitec</i>	Tablet containing enalapril maleate 10 mg	30	4.65	Acetec; Auspril; Chem mart Enalapril; Enalapril-GA; Enalapril generichealth; Enalapril-PS; Enalapril Sandoz; GenRx Enalapril; Terry White Chemists Enalapril
<i>Renitec 20</i>	Tablet containing enalapril maleate 20 mg	30	4.66	Acetec; Auspril; Chem mart Enalapril; Enalapril-GA; Enalapril generichealth; Enalapril-PS; Enalapril Sandoz; GenRx Enalapril; Terry White Chemists Enalapril
<i>Renitec M</i>	Tablet containing enalapril maleate 5 mg	30	4.66	Acetec; Auspril; Chem mart Enalapril; Enalapril-GA; Enalapril generichealth; Enalapril-PS; Enalapril Sandoz; GenRx Enalapril; Terry White Chemists Enalapril
<i>Rivotril</i>	Tablet 500 micrograms	100	1.71	Paxam 0.5
	Tablet 500 micrograms	200	3.42	Paxam 0.5
	Tablet 2 mg	100	1.93	Paxam 2
	Tablet 2 mg	200	3.86	Paxam 2
<i>Rulide</i>	Tablet 150 mg	10	2.61	APO-Roxithromycin; Biaxig; Chem mart Roxithromycin; Roxar 150; Roximycin; Roxithromycin-GA; Roxithromycin-PS; Roxithromycin Sandoz; Terry White Chemists Roxithromycin
	Tablet 300 mg	5	2.61	APO-Roxithromycin; Biaxig; Chem mart Roxithromycin; Roxar 300; Roximycin; Roxithromycin-GA; Roxithromycin-PS; Roxithromycin Sandoz; Terry White Chemists Roxithromycin
<i>Salazopyrin-EN</i>	Tablet 500 mg (enteric coated)	200	1.84	Pyralin EN
<i>Septtrin Forte</i>	Tablet 160 mg-800 mg	10	1.46	Bactrim DS; Resprim Forte
<i>Serepax</i>	Tablet 15 mg	25	2.69	Alepam 15
	Tablet 15 mg	50	5.38	Alepam 15
	Tablet 30 mg	25	2.69	Alepam 30; APO-Oxazepam; Murelax

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
<i>Sigmacort</i>	Tablet 30 mg	50	5.38	<i>Alepam 30; APO-Oxazepam; Murelax</i>
	Cream 10 mg per g (1%), 30 g	1	2.69	<i>Cortic-DS 1%</i>
	Cream 10 mg per g (1%), 50 g	1	2.70	<i>Cortic-DS 1%</i>
	Topical ointment 10 mg per g (1%), 30 g	1	2.69	<i>Cortic-DS 1%</i>
	Topical ointment 10 mg per g (1%), 50 g	1	2.70	<i>Cortic-DS 1%</i>
<i>Sinemet</i>	Tablet 250 mg-25 mg	100	2.92	<i>Levo/Carbidopa Sandoz</i>
<i>Sinemet 100/25</i>	Tablet 100 mg-25 mg	100	5.19	<i>Kinson</i>
<i>Slow-K</i>	Tablet 600 mg (sustained release)	200	2.94	<i>Duro-K</i>
<i>Sofradex</i>	Ear drops 500 micrograms-5 mg-50 micrograms per mL, 8 mL	1	1.91	<i>Otodex</i>
<i>Sotalcor</i>	Tablet 80 mg	60	4.99	<i>GenRx Sotalol; Solavert; Sotalol Sandoz</i>
	Tablet 160 mg	60	5.00	<i>Cardol; Chem mart Sotalol; GenRx Sotalol; Solavert; Sotalol Sandoz; Terry White Chemists Sotalol</i>
<i>Stemetil</i>	Tablet containing prochlorperazine maleate 5 mg	25	2.57	<i>APO-Prochlorperazine; Pharmacor Prozine 5; ProCalm; Prochlorperazine-GA; Prochlorperazine GH; Prochlorperazine-PS; Stemzine</i>
<i>Tazac</i>	Capsule 150 mg	60	5.32	<i>Nizac; Tacidine</i>
	Capsule 300 mg	30	5.32	<i>Nizac; Tacidine</i>
<i>Tears Naturale</i>	Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL	1	2.04	<i>Poly-Tears</i>
<i>Tenormin</i>	Tablet 50 mg	30	2.21	<i>APO-Atenolol; Atenolol-GA; Atenolol generichealth; Atenolol-PS; Atenolol Sandoz; Chem mart Atenolol; Noten; Tensig; Terry White Chemists Atenolol</i>
<i>Timoptol</i>	Eye drops 2.5 mg (base) per mL (0.25%), 5 mL	1	3.03	<i>Tenopt</i>
	Eye drops 5 mg (base) per mL (0.5%), 5 mL	1	3.03	<i>Tenopt</i>
<i>Tofranil 10</i>	Tablet 10 mg	50	2.79	<i>Tolerade 10</i>
<i>Tofranil 25</i>	Tablet 25 mg	50	2.79	<i>Tolerade 25</i>
<i>Tolvon</i>	Tablet 10 mg	50	3.30	<i>Lumin 10</i>
	Tablet 20 mg	50	3.30	<i>Lumin 20</i>
<i>Tramal</i>	Capsule 50 mg	20	2.41	<i>APO-Tramadol; Chem mart Tramadol; GA Tramadol 50mg; GenRx Tramadol; Lodam 50; Terry White Chemists Tramadol; Tramadol Sandoz; Tramedo; Zydol</i>
<i>Tramal SR 100</i>	Tablet 100 mg (twice daily sustained release)	20	4.50	<i>APO-Tramadol SR; Chem mart Tramadol SR; GA Tramadol SR 100mg; Lodam SR 100; Terry White Chemists Tramadol SR; Tramadol Sandoz SR; Tramedo SR 100; Zydol SR 100</i>
<i>Tramal SR 150</i>	Tablet 150 mg (twice daily sustained release)	20	5.37	<i>APO-Tramadol SR; Chem mart Tramadol SR; GA Tramadol SR 150mg; Lodam SR 150; Terry White Chemists Tramadol SR; Tramadol Sandoz SR; Tramedo SR 150; Zydol SR 150</i>
<i>Tramal SR 200</i>	Tablet 200 mg (twice daily sustained release)	20	6.09	<i>APO-Tramadol SR; Chem mart Tramadol SR; GA Tramadol SR 200mg; Lodam SR 200; Terry White Chemists Tramadol SR; Tramadol Sandoz SR; Tramedo SR 200; Zydol SR 200</i>
<i>Trandate</i>	Tablet 100 mg	100	3.13	<i>Presolol 100</i>
	Tablet 200 mg	100	3.14	<i>Presolol 200</i>
<i>Triphasil 28</i>	Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets	4	13.55	<i>Trifeme 28</i>
<i>Triprim</i>	Tablet 300 mg	7	1.89	<i>Alprim</i>
<i>Triquilar ED</i>	Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets	4	13.59	<i>Logynon ED</i>
<i>Valium</i>	Tablet 2 mg	50	0.82	<i>Antenex 2; APO-Diazepam; Ranzepam; Valpam 2</i>
	Tablet 5 mg	50	0.85	<i>Antenex 5; APO-Diazepam; Diazepam-GA; Ranzepam; Valpam 5</i>
<i>Vastin</i>	Capsule 20 mg (as sodium)	28	3.09	<i>Lescol</i>
	Capsule 40 mg (as sodium)	28	3.36	<i>Lescol</i>
<i>Ventolin CFC-free</i>	Oral pressurised inhalation 100 micrograms (base) per dose (200 doses), CFC-free formulation	2	2.32	<i>Airomir; APO-Salbutamol Inhaler; Asmol CFC-free</i>
<i>Ventolin Nebules</i>	Nebuliser solution single dose units 2.5 mg (base) in 2.5 mL, 30	2	1.34	<i>Asmol 2.5 uni-dose; Butamol 2.5; GenRx Salbutamol; Pharmacor Salbutamol 2.5; Salbutamol-GA;</i>

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
	Nebuliser solution single dose units 5 mg (base) in 2.5 mL, 30	2	1.36	Salbutamol Sandoz Asmol 5 uni-dose; Butamol 5; GenRx Salbutamol; Pharmacor Salbutamol 5; Salbutamol-GA; Salbutamol Sandoz Doxy-50; Doxylin 50
Vibra-Tabs	Tablet 50 mg (as hydrochloride)	25	1.95	PAA
Viscotears	Eye gel 2 mg per g (0.2%), 10 g	1	1.50	Barbloc 15
Visken 15	Tablet 15 mg	50	2.57	APO-Diclofenac; Chem mart
Voltaren 25	Tablet 25 mg (enteric coated)	100	2.32	Diclofenac; Clonac 25; Diclofenac-GA; Diclofenac Sandoz; Fenac 25; Terry White Chemists Diclofenac
Voltaren 50	Tablet 50 mg (enteric coated)	50	2.34	APO-Diclofenac; Chem mart Diclofenac; Clonac 50; Diclofenac-GA; Diclofenac Sandoz; Fenac; Terry White Chemists Diclofenac
Xanax	Tablet 250 micrograms	50	1.96	Alprax 0.25; Alprazolam Sandoz; Kalma 0.25
	Tablet 500 micrograms	50	1.95	Alprax 0.5; Alprazolam Sandoz; Kalma 0.5
	Tablet 1 mg	50	1.95	Alprax 1; Alprazolam Sandoz; Chem mart Alprazolam; GenRx Alprazolam; Kalma 1; Ralozam; Terry White Chemists Alprazolam
Xanax Tri-Score	Tablet 2 mg	50	1.96	Alprax 2; Alprazolam Sandoz; Chem mart Alprazolam; GenRx Alprazolam; Kalma 2; Ralozam; Terry White Chemists Alprazolam
Zanidip	Tablet 10 mg	28	2.66	APO-Lercanidipine; Chem mart Lercanidipine; Lercadip; Lercan; Lercanidipine Sandoz; Terry White Chemists Lercanidipine; Zircol
	Tablet 20 mg	28	2.64	APO-Lercanidipine; Chem mart Lercanidipine; Lercadip; Lercan; Lercanidipine Sandoz; Terry White Chemists Lercanidipine; Zircol
Zantac	Tablet 150 mg (base)	60	2.35	Ausran; Chem mart Ranitidine; GenRx Ranitidine; Rani 2; Ranitidine-PS; Ranitidine Sandoz; Ranoxyl; Terry White Chemists Ranitidine; Ulcaid
	Tablet 300 mg (base)	30	2.35	Ausran; Chem mart Ranitidine; GenRx Ranitidine; Rani 2; Ranitidine Sandoz; Terry White Chemists Ranitidine; Ulcaid
Zestril	Tablet 5 mg	30	1.47	APO-Lisinopril; Chem mart Lisinopril; Fibsol 5; GenRx Lisinopril; Lisinopril 5; Lisinopril-DRLA; Lisinopril-GA; Lisinopril generichealth; Lisinopril-PS; Lisinopril Ranbaxy; Lisinopril Sandoz; Lisodur; Prinivil 5; Terry White Chemists Lisinopril
	Tablet 10 mg	30	1.47	APO-Lisinopril; Chem mart Lisinopril; Fibsol 10; GenRx Lisinopril; Lisinopril 10; Lisinopril-DRLA; Lisinopril-GA; Lisinopril generichealth; Lisinopril-PS; Lisinopril Ranbaxy; Lisinopril Sandoz; Lisodur; Prinivil 10; Terry White Chemists Lisinopril
	Tablet 20 mg	30	1.47	APO-Lisinopril; Chem mart Lisinopril; Fibsol 20; GenRx Lisinopril; Lisinopril 20; Lisinopril-DRLA; Lisinopril-GA; Lisinopril generichealth; Lisinopril-PS; Lisinopril Ranbaxy; Lisinopril Sandoz; Lisodur; Prinivil 20; Terry White Chemists Lisinopril
Zocor	Tablet 5 mg	30	3.32	Simvahexal; Simvastatin Sandoz; Zimstat
	Tablet 10 mg	30	3.33	APO-Simvastatin; Auro-Simvastatin 10; Chem mart Simvastatin; GenRx Simvastatin; Lipex 10; Pharmacor Simvastatin 10; Ransim; Simvacor 10; Simvahexal; Simvar 10; Simvastatin-

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
	Tablet 20 mg	30	3.31	DP; Simvastatin-DRLA; Simvastatin-GA 10; Simvastatin generichealth; Simvastatin Pfizer; Simvastatin Sandoz; Simvastatin-Spirit 10; Simvastatin Winthrop; Synthon Simvastatin; Terry White Chemists Simvastatin; Zimstat
	Tablet 40 mg	30	3.32	APO-Simvastatin; Auro-Simvastatin 20; Chem mart Simvastatin; GenRx Simvastatin; Lipex 20; Pharmacor Simvastatin 20; Ransim; Simvacor 20; Simvahexal; Simvar 20; Simvastatin-DP; Simvastatin-DRLA; Simvastatin-GA 20; Simvastatin generichealth; Simvastatin Pfizer; Simvastatin Sandoz; Simvastatin-Spirit 20; Simvastatin Winthrop; Synthon Simvastatin; Terry White Chemists Simvastatin; Zimstat
	Tablet 80 mg	30	3.32	APO-Simvastatin; Auro-Simvastatin 40; Chem mart Simvastatin; GenRx Simvastatin; Lipex 40; Pharmacor Simvastatin 40; Ransim; Simvacor 40; Simvar 40; Simvastatin-DP; Simvastatin-DRLA; Simvastatin-GA 40; Simvastatin generichealth; Simvastatin Pfizer; Simvastatin Sandoz; Simvastatin-Spirit 40; Simvastatin Winthrop; Synthon Simvastatin; Terry White Chemists Simvastatin; Zimstat
	Tablet 50 mg (as hydrochloride)	30	1.95	APO-Simvastatin; Auro-Simvastatin 80; Chem mart Simvastatin; GenRx Simvastatin; Lipex 80; Pharmacor Simvastatin 80; Ransim; Simvacor 80; Simvar 80; Simvastatin-DP; Simvastatin-DRLA; Simvastatin-GA 80; Simvastatin generichealth; Simvastatin Pfizer; Simvastatin Sandoz; Simvastatin-Spirit 80; Simvastatin Winthrop; Synthon Simvastatin; Terry White Chemists Simvastatin; Zimstat
	Tablet 100 mg (as hydrochloride)	30	1.95	Auro-Sertraline 50; Chem mart Sertraline; Eleva 50; GenRx Sertraline; Sertra 50; Sertracor 50; Sertraline 50; Sertraline-DRLA; Sertraline-GA; Sertraline generichealth; Sertraline Pfizer; Sertraline Sandoz; Setrona; Terry White Chemists Sertraline; Xydep 50
	Tablet 200 mg	50	4.10	Auro-Sertraline 100; Chem mart Sertraline; Eleva 100; GenRx Sertraline; Sertra 100; Sertracor 100; Sertraline 100; Sertraline-DRLA; Sertraline-GA; Sertraline generichealth; Sertraline Pfizer; Sertraline Sandoz; Setrona; Terry White Chemists Sertraline; Xydep 100
	Tablet 200 mg	90	3.06	Acihexal; Acyclo-V 200; Lovir
	Tablet 800 mg	35	1.49	Aciclovir 200; Aciclovir GH; Acihexal; Acyclo-V 200; Chem mart Aciclovir; GenRx Aciclovir; Lovir; Ozvir; Terry White Chemists Aciclovir
	Tablet 150 mg (sustained release)	30	0.80	Aciclovir 800; Acihexal; Acyclo-V 800; GenRx Aciclovir
	Tablet 150 mg (sustained release)	90	0.81	Aciclovir 200; Aciclovir GH; Acihexal; Acyclo-V 200; Chem mart Aciclovir; GenRx Aciclovir; Lovir; Ozvir; Terry White Chemists Aciclovir
	Tablet 100 mg	200	2.85	Aciclovir 800; Acihexal; Acyclo-V 800; GenRx Aciclovir
	Tablet 300 mg	60	2.85	Allopurinol Sandoz; Allosig; Chem mart Allopurinol; GenRx Allopurinol; Terry White Chemists Allopurinol
				Allopurinol Sandoz; Allosig; Chem mart Allopurinol; GenRx Allopurinol;

Premium Priced Brand	Form and Strength	Max. Qty	Brand Premium \$	Benchmark Priced Brands
				<i>Pro gout 300; Terry White Chemists Allopurinol</i>